<SEC-DOCUMENT>0001213900-22-032864.txt : 20220614
<SEC-HEADER>0001213900-22-032864.hdr.sgml : 20220614
<ACCEPTANCE-DATETIME>20220614172717
ACCESSION NUMBER:		0001213900-22-032864
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		119
FILED AS OF DATE:		20220614
DATE AS OF CHANGE:		20220614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-255112
		FILM NUMBER:		221015914

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>ea158528-posam1_abvcbio.htm
<DESCRIPTION>POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 14 21:16:03 UTC 2022 -->
<html xmlns:abvc="http://metuboutique.com/20220331" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pf0="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
  <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><b>As filed with the Securities
and Exchange Commission on June 14, 2022</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registration No. 333-255112</b></span></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES AND EXCHANGE COMMISSION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington, D.C. 20549</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POST-EFFECTIVE AMENDMENT NO. 1 TO</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
S-1</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REGISTRATION STATEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNDER</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE SECURITIES ACT OF 1933</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><span style="font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>ABVC BIOPHARMA, INC.</b></span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact name of registrant as specified in its charter)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nevada</b></span></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5084</b></span></td> <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>26-0014658</b></span></td></tr> <tr style="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State or other jurisdiction of<br/> incorporation or organization)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Primary Standard Industrial<br/> Classification Code Number)</b></span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(I.R.S. Employer</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification Number)</b></span></p></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>44370 Old Warm Springs Blvd.,</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fremont, CA 94538</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(510) 668-0881</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr. Howard Doong</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Chief Executive Officer</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>44370 Old Warm Springs Blvd.,</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fremont, CA 94538</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(510)-668-0881- telephone</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Name, address, including zip code, and telephone number, including area code, of agent for service)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>With copies to:</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Louis Taubman, Esq.</b></span></td>
    <td style="width: 1%; text-align: center">&#160;</td>
    <td style="width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ross D. Carmel, Esq.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joan Wu, Esq.</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Jeffrey P. Wofford, Esq.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hunter Taubman Fischer &amp; Li LLC</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Carmel, Milazzo &amp; Feil</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>48 Wall Street, Suite 1100</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>55 West 39<sup>th </sup>Street, 18<sup>th</sup> Floor</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New York, New York 10005</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>New York, New York 10018</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(917) 512-0827- telephone</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Telephone: (212) 658-0458</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Louis Taubman, Esq.</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Approximate date of commencement of proposed sale of the securities to the public: </b>As soon as practicable after this registration statement is declared effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. &#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 21%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 25%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap; width: 19%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; white-space: nowrap"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></ix:nonNumeric></td></tr> </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.</b></span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information in this preliminary prospectus is not complete and may be changed. We may not sell or accept an offer to buy these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting any offer to buy these securities in any jurisdiction where such offer or sale is not permitted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SUBJECT TO COMPLETION, DATED JUNE 14, 2022</b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRELIMINARY PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="img_001.jpg" style="height: 90px; width: 200px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,255,000 Shares of Common Stock Underlying Previously Issued Warrants</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus relates to the offer and sale by ABVC Biopharma, Inc., a Nevada corporation of up to 2,255,000 shares of common stock underlying warrants previously issued by us that are issuable at a price of $6.25 per share from time to time upon exercise of outstanding warrants issued to investors and the underwriters in our public offering that was consummated in August 2021 (the &#8220;August 2021 Public Offering&#8221;), the issuance of which were previously registered on a Registration Statement on Form S-1 (File No. 333-255112).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are not selling any shares of our common stock in this offering and, as a result, we will not receive any proceeds from the sale of the common stock covered by this prospectus. All of the net proceeds from the sale of our common stock will go to the warrant holders. Upon exercise of the warrants, however, we will receive proceeds from the exercise of such warrants if exercised for cash and not on a cashless basis. Any proceeds received from the exercise of such warrants will be used for general working capital and other corporate purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Our common stock issued in the initial public offering are listed on
the Nasdaq Capital Market under the symbol &#8220;ABVC.&#8221; On June 13, 2022, the last reported sale price of our common stock on the
Nasdaq Capital Market was $1.07 per&#160; share. There is no established public trading market for the Warrants and we will not seek to
list them. We urge prospective purchasers of our common stock to obtain current information about the market prices of our common stock
issued in connection with our initial public offering in August 2021.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Investing in our securities involves a high
degree of risk. See &#8220;Risk Factors&#8221; starting on page 10 of this prospectus.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">See the &#8220;Plan of Distribution&#8221; section
of this prospectus beginning on page 94 for more information on this offering.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No underwriter or person has been engaged to facilitate the sale of Shares in this offering. All costs associated with the registration were borne by us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should read this prospectus, together with additional information described under the headings &#8220;Incorporation of Certain Information by Reference&#8221; and &#8220;Where You Can Find More Information&#8221;, carefully before you invest in any of our securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is June 14, 2021</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPLANATORY NOTE</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AmendmentDescription-c0_cont_1" name="dei:AmendmentDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Post-Effective Amendment No. 2 (this &#8220;Amendment&#8221;) to the Registration Statement on Form S-1, as amended (SEC File No. 333-255112) (the &#8220;Original Registration Statement&#8221;), of ABVC BioPharma, Inc. (the &#8220;Company&#8221;) is being filed pursuant to the undertakings in the Original Registration Statement to update and supplement the information contained in the Original Registration Statement, which was originally declared effective by the Securities and Exchange Commission on August 2, 2021.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_AmendmentDescription-c0_cont_2" id="_AmendmentDescription-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Original Registration Statement, as amended by this Amendment, pertains solely to the registration of 2,255,000 shares (the &#8220;Warrant Shares&#8221;) of common stock, par value $0.001 per share, underlying warrants (the &#8220;Offering Warrants&#8221;) previously issued by the Company to the investors and Representative. The Warrant Shares were initially registered on the Original Registration Statement.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_AmendmentDescription-c0_cont_3" id="_AmendmentDescription-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the convenience of the reader, this Amendment
sets forth the Original Registration Statement in its entirety, as amended by this Amendment. This Amendment is being filed to incorporate
certain information from the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March
31, 2022 and the registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, which was filed with the SEC on
May 16, 2022, and to update certain other information in the Registration Statement.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_AmendmentDescription-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No additional securities are being registered under this Post-Effective Amendment No. 1. All applicable registration fees were previously paid.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE OF CONTENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001"><b>PROSPECTUS CONVENTIONS</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002"><b>INDUSTRY AND MARKET DATA</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">i<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_003"><b>PROSPECTUS SUMMARY</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004"><b>THE OFFERING</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">8</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005"><b>RISK FACTORS</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006"><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007"><b>USE OF PROCEEDS</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008"><b>DIVIDEND POLICY</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_010"><b>DILUTION</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_011"><b>MARKET FOR OUR COMMON STOCK, DIVIDENDS AND RELATED SHAREHOLDER INFORMATION</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_012"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS&#160;OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_013"><b>BUSINESS</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_014"><b>MANAGEMENT</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">76</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_015"><b>EXECUTIVE COMPENSATION</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_016"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">84</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_017"><b>RELATED PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS OF THE COMBINED COMPANY</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION OF SECURITIES THAT WE ARE OFFERING</b></span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">89</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><b><a href="#planof">PLAN OF DISTRIBUTION</a></b></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">94</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_021"><b>LEGAL MATTERS</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_022"><b>EXPERTS</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_023"><b>WHERE YOU CAN FIND MORE INFORMATION</b></a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You should rely only on the information contained in this prospectus or in any free writing prospectus that we may specifically authorize to be delivered or made available to you. We and our Underwriter have not authorized anyone to provide you with any information other than that contained in this prospectus or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus may only be used where it is legal to offer and sell our securities. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of these securities in any jurisdiction where the offer is not permitted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless the context otherwise requires, the terms &#8220;ABVC,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this prospectus refer to ABVC BioPharma, Inc., and &#8220;this offering&#8221; refers to the offering contemplated in this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><!-- Field: Page; Sequence: 4; Options: NewSection --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS CONVENTIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except where the context otherwise requires and for purposes of this prospectus only:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;American BriVision Corporation&#8221; refers to a Delaware corporation and wholly-owned subsidiary of ABVC;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;APR&#8221; or &#8220;annual percentage rate&#8221; refers to the annual rate that is charged to borrowers, including a fixed interest rate and a transaction fee rate, expressed as a single percentage number that represents the actual yearly cost of borrowing over the life of a loan;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;BioKey&#8221; means BioKey, Inc. refers to a California corporation and wholly-owned subsidiary of ABVC;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;BioLite&#8221; means BioLite Holding, Inc. refers to a Nevada corporation and a wholly-owned subsidiary of ABVC;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The &#8220;Board&#8221; or &#8220;Board of Directors&#8221; refers to the board of directors of the Company;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;China&#8221;, &#8220;mainland China&#8221; and &#8220;P.R.C.&#8221; refer to the People&#8217;s Republic of China, excluding Taiwan, Hong Kong or Macau for purposes of this prospectus;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Common Stock&#8221; is the Common Stock of ABVC Biopharma, Inc., par value US$0.001 per share;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Merger Agreement&#8221; means the Agreement and Plan of Merger dated as of January 31, 2018, pursuant to which the Company, BioLite, BioKey, &#8220;BioLite Acquisition Corp.&#8221; a Nevada corporation, and BioKey Acquisition Corp.&#8221; a California corporation completed a business combination on February 8, 2019 where ABVC acquired BioLite and BioKey via the issuance of additional shares of Common Stock to the shareholders of BioLite and BioKey;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Series A Convertible Preferred Stock&#8221; is the Series A convertible preferred stock of ABVC Biopharma, Inc., par value US$0.001 per share;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; &#8220;our Company&#8221; or &#8220;ABVC&#8221; refers to ABVC Biopharma, Inc., a Nevada corporation, and all of the Subsidiaries as defined herein unless the context specifies;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;R.O.C.&#8221; or &#8220;Taiwan&#8221; refers to Taiwan, the Republic of China;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;Subsidiary&#8221; or &#8220;Subsidiaries,&#8221; refer to American BriVision Corporation, sometimes referred to as &#8220;BriVision&#8221;, BioLite Holding, Inc. or BioLite and BioKey, Inc. or BioKey;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All references to &#8220;NTD&#8221; and &#8220;New Taiwan Dollars&#8221; are to the legal currency of R.O.C.; and</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All references to &#8220;U.S. dollars&#8221;, &#8220;dollars&#8221;, and &#8220;$&#8221; are to the legal currency of the U.S.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus specifies certain NTD amounts and in parenthesis the approximate U.S. dollar amounts at the exchange rate on the date of this prospectus. The conversion rates regarding NTD and U.S. dollars are subject to change and, therefore, we can provide no assurance that U.S. dollar amounts specified in this prospectus will not change.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For clarification, this prospectus follows English naming convention of first name followed by last name, regardless of whether an individual&#8217;s name is Chinese or English.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus does not discuss any affiliates of the Company that are not controlled by the Company, such as BioFirst and BioFirst Australia.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDUSTRY AND MARKET DATA</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus includes information with respect to market and industry conditions and market share from third-party sources or based upon estimates using such sources when available. We have not, directly or indirectly, sponsored or participated in the publication of any of such materials. We believe that such information and estimates are reasonable and reliable. We also assume the information extracted from publications of third-party sources has been accurately reproduced. We understand that the Company would be liable for the information included in this prospectus if any part of the information was incorrect, misleading or imprecise to a material extent.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>
</div><div style="border: Black 1.5pt solid; padding: 0 5pt; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<a id="a_003"></a><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PROSPECTUS SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making your investment decision. Before investing in our securities, you should carefully read this entire prospectus, including our&#160;financial statements and the related notes and the information set forth under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in each case included elsewhere in this prospectus.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Company Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our Mission</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We devote our resources to building a sophisticated biotech company and becoming a pioneer in the biopharmaceutical industry. Dr. Howard Doong, our Chief Executive Officer, and Dr. Tsung-Shann Jiang, the founder and majority shareholder of the Company, understand the challenges and opportunities of the biotech industry and intend to provide therapeutic solutions to significant unmet medical needs and to improve health and quality of human life by developing innovative botanical drugs to treat central nervous system (&#8220;CNS&#8221;) and oncology/ hematology diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date hereof, the Company&#8217;s minimal revenue has come from the sale of CDMO services through BioKey. However, the Company&#8217;s focus is on developing a pipeline of products by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company&#8217;s scientists and other specialists known to the Company to identify drugs or medical devices that it believes demonstrate efficacy and safety based on the Company&#8217;s internal qualifications. Once a drug or medical device is shown to be a good candidate for further development and ultimately commercialization, ABVC licenses the drug or medical device from the original researchers and introduces the drug or medical device clinical trial plan to highly respected principal investigators in the United States, Australia and Taiwan. In almost all cases, ABVC has found that research institutions in each of those countries are eager to work with the Company to move forward with Phase II clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Institutions that have or are now conducting phase II clinical trials in partnership with ABVC include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1504, Major Depressive Disorder (MDD), Phase II completed. NCE drug Principal Investigators: Charles DeBattista M.D. and Alan F. Schatzberg, MD,&#160;Stanford University Medical Center, Cheng-Ta Li, MD, Ph.D &#8211;&#160;Taipei Veterans General Hospital</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1505, Adult Attention-Deficit Hyperactivity Disorder (ADHD), Phase II Part 1 completed. NCE drug Principal Investigators: Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D.,&#160;University of California San Francisco (UCSF), School of Medicine. Phase II, Part 2 is expected to begin in the 1<sup>st </sup>quarter of 2022 at UCSF and 5 locations in Taiwan.The Principal Investigators are Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D.,&#160;University of California San Francisco (UCSF), School of Medicine; Susan Shur-Fen Gau, M.D., National Taiwan University Hospital; Xinzhang Ni, M.D. Linkou Chang Gung Memorial Hospital; Wenjun Xhou, M.D., Kaohsiung Chang Gung Memorial Hospital; Ton-Ping Su, M.D., Cheng Hsin General Hospital, Cheng-Ta Li, M.D., Taipei Veterans General Hospital</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott Irwin, MD, Ph.D. &#8211;&#160;Cedars Sinai Medical Center (CSMC)</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1703, Advanced Inoperable or Metastatic Pancreatic Cancer, Phase II, NCE drug Principal Investigator: Andrew E. Hendifar, MD &#8211;&#160;Cedars Sinai Medical Center (CSMC)</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>
</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>
</div><div style="border: Black 1.5pt solid; padding: 0 5pt; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following trials are expected to begin in the second quarter of 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Device: ABV-1701, Vitargus&#174; in vitrectomy surgery, Phase II Study in Australia and Thailand, Principal Investigator: Duangnate Rojanaporn, M.D., Ramathibodi Hospital; Thuss Sanguansak, M.D., Srinagarind Hospital</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott Irwin, MD, Ph.D. &#8211;&#160;Cedars Sinai Medical Center (CSMC)</span></td> </tr>
  </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1505, Adult Attention-Deficit Hyperactivity Disorder (ADHD), Phase II Part 2 is in progress. Principal Investigators: Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D.,&#160;University of California San Francisco (UCSF), School of Medicine; Susan Shur-Fen Gau, M.D., National Taiwan University Hospital; Xinzhang Ni, M.D. Linkou Chang Gung Memorial Hospital; Wenjun Xhou, M.D., Kaohsiung Chang Gung Memorial Hospital; Ton-Ping Su, M.D., Cheng Hsin General Hospital, Cheng-Ta Li, M.D., Taipei Veterans General Hospital</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon successful completion of a Phase II trial, ABVC will seek a partner, typically a large pharmaceutical company, to complete a Phase III study and commercialize the drug or medical device upon approval by the US FDA, Taiwan TFDA and other country regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Structure</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC was incorporated under the laws of the State of Nevada on February 6, 2002 and has three wholly-owned Subsidiaries: BriVision, BioLite Holding, Inc. and BioKey, Inc. BriVision was incorporated in July 2015 in the State of Delaware and is in the business of developing pharmaceutical products in North America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Holding was incorporated under the laws of the State of Nevada on July 27, 2016, with 500,000,000 shares authorized, par value $0.0001. Its key Subsidiaries include BioLite BVI, Inc. (&#8220;BioLite BVI&#8221;) that was incorporated in the British Virgin Islands on September 13, 2016 and BioLite Inc. (&#8220;BioLite Taiwan&#8221;), a Taiwanese corporation that was founded in February 2006. BioLite Taiwan has been in the business of developing new drugs for over twelve years. Certain shareholders of BioLite Taiwan exchanged approximately 73% of equity securities in BioLite Taiwan for the Common Stock in BioLite Holding in accordance with a share purchase/ exchange agreement (the &#8220;Share Purchase/ Exchange Agreement&#8221;). As a result, BioLite Holding owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated in California on November 20, 2000, BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon closing of the Mergers on February 8, 2019, BioLite and BioKey became two wholly-owned subsidiaries of ABVC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following chart illustrates the corporate structure of ABVC:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img alt="" src="img_002.jpg" style="height: 254px; width: 550px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: Red"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>
</div><div style="border: Black 1.5pt solid; padding: 0 5pt; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective March 5, 2022, the Company&#8217;s Board for Directors approved amending the Company&#8217;s Bylaws to remove Section 2.8, which permitted cumulative voting for directors since cumulative voting is specifically prohibited by our Articles of Incorporation. Since it is not otherwise stated in our Articles of Incorporation or Bylaws, directors shall be elected by a plurality of the votes cast at the election, as provided in the Nevada Revised Statutes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Developments</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NASDAQ Listing</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2021, we closed a public offering (the &#8220;Offering&#8221;) of&#160;1,100,000&#160;units (the &#8220;Units&#8221;), with each Unit consisting of one share of our common stock (the &#8220;Common Stock&#8221;), one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $6.30&#160;per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $10.00&#160;per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;). The Units were priced at $6.25&#160;per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. The Offering was conducted on a firm commitment basis. The Common Stock was approved for listing on The Nasdaq Capital Market and commenced trading under the ticker symbol &#8220;ABVC&#8221; on August 3, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>1 </sup><b><i>J Cancer Res Clin Oncol (2009) 135:1215-1221</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key elements of our business strategy include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advancing to the pivotal trial phase of ABV-1701 Vitargus&#174; for the treatments of Retinal Detachment or Vitreous Hemorrhage, which we expect to generate revenues in the future.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Focusing on licensing ABV-1504 for the treatment of major depressive disorder, MDD, after the successful completion of its Phase II clinical trials.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing Phase II, Part 2 clinical trial for ABV-1505 for the treatment of attention deficit hyperactivity disorder, ADHD.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out licensing drug candidates and medical device candidates to major pharmaceutical companies for phase III and pivotal clinical trials, as applicable, and further marketing if approved by the FDA.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We plan to augment our core research and development capability and assets by conducting Phase I and II clinical trials for investigational new drugs and medical devices in the fields of CNS, Hematology/Oncology and Ophthalmology.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has extensive experiences across a wide range of new drug and medical device development and we have in-licensed new
drug and medical device candidates from large research institutes and universities in both the U.S. and Taiwan. Through an assertive
product development approach, we expect that we will build a substantial portfolio of Oncology/ Hematology, CNS and Ophthalmology products.
We primarily focus on Phase I and II research of new drug candidates and out license the post-Phase-II products to pharmaceutical companies;
we do not expect to devote substantial efforts and resources to building the disease-specific distribution channels.</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>
</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>
</div><div style="border: Black 1.5pt solid; padding: 0 5pt; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Material Risks and Challenges</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face substantial competition from a great many established and emerging pharmaceutical and biotech companies that develop, distribute or sell therapeutics to treat the same indications that our drug candidates are designed to treat. Our current and potential competitors include large pharmaceutical and biotechnology companies, and specialty pharmaceutical and generic drug companies. Many of our current and potential competitors have substantially greater financial, technical and human resources than we do and significantly more experience in the marketing, commercialization, discovery, development and regulatory approvals of products, which could place us at a significant competitive disadvantage or deny our marketing exclusivity rights. Typically, our competitors will most likely have more capital resources to support their products than we do. In addition, you should carefully consider the risks described under the &#8220;Risk Factors&#8221; section beginning on page 10 before investing in us. Some of these risks are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; ">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk associated with our profitability including, but not limited to:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never generated revenue and will continue to be unprofitable in the foreseeable future.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business, operations and plans and timelines could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></td> </tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk associated with clinical trials and the development of our products, including but not limited to:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical trials are expensive and time consuming, and their outcome is uncertain.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical trials could be delayed or unsuccessful, and we may not be able to obtain regulatory approval for any of our drug candidates when expected, or at all.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may experience delays in our clinical trials that could adversely affect our business and operations.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties to conduct our preclinical studies and clinical trials and if such third parties do not meet our deadlines or otherwise conduct the studies as required, we may be delayed in progressing, or ultimately may not be able to progress, our drug candidates to clinical trials.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to secure and maintain research institutions to conduct our future trials.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to secure co-developers or partners to further post-Phase II clinical trials and eventually commercialize our drug candidates.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may need to prioritize the development of our most promising candidates at the expense of the development of other products.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physicians, patients, third-party payors or others in the medical community may not be receptive to our products, and we may not generate any future revenue from the sale or licensing of our products.</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>


</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>
</div><div style="border: Black 1.5pt solid; padding: 0 5pt; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated with intellectual property including but not limited to:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be successful in obtaining or maintaining patent or other relating rights necessary to the development of our drug candidates in the pipeline;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intellectual property rights underlying our exclusive licensing rights may expire or be terminated due to lack of maintenance;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated with competition and manufacturing including, but not limited to:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face competition from entities that have developed or are developing products for our target disease indications, including companies developing novel treatments and technologies similar to ours; and</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend primarily upon a sole supplier of our key extract for three drug candidates and could incur significant costs and delays if we are unable to promptly find a replacement for such supplier if the supplier fails to deliver the extract pursuant to our orders.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated with government regulations including without limitation:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we do not obtain the necessary governmental approvals, we will be unable to sub-license or commercialize our pharmaceutical products; and</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we obtain regulatory approval for a drug candidate, our products may remain subject to regulatory scrutiny.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk associated with our Common Stock including without limitation:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market prices and trading volumes of the Common may be volatile and may be affected by economic conditions beyond our control; and,</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is only a limited trading market for our Common Stock and such market may never develop.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These and other risks described in this prospectus could materially and adversely impact our business, financial condition, operating results and cash flow, which could cause the trading price of our Common Stock to decline and could result in a loss of your investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Risk Factors</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The below is a summary of principal risks to our business and risks associated with this offering. It is only a summary. You should read the more detailed discussion of risks set forth below and elsewhere in this prospectus for a more complete discussion of the risks listed below and other risks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk associated with our competition, including, but not limited to:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many of our current and potential competitors have substantially greater financial, technical and human resources than we do, which could place us at a significant competitive disadvantage or deny our marketing exclusivity rights.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many of our current and potential competitors have significantly more experience in the marketing, commercialization, discovery, development and regulatory approvals of products, which could place us at a significant competitive disadvantage or deny our marketing exclusivity rights</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</div><div>
</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><div style="border: Black 1.5pt solid; padding: 0 5pt; width: 98%">
<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk associated with our profitability including, but not limited to:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never generated revenue and will continue to be unprofitable in the foreseeable future.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business, operations and plans and timelines could be adversely affected by the effects of health epidemics, including the recent COVID-19 pandemic.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk associated with clinical trials and the development of our products, including but not limited to:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical trials are expensive and time consuming, and their outcome is uncertain.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our clinical trials could be delayed or unsuccessful, and we may not be able to obtain regulatory approval for any of our drug candidates when expected, or at all.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may experience delays in our clinical trials that could adversely affect our business and operations.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We rely on third parties to conduct our preclinical studies and clinical trials and if such third parties do not meet our deadlines or otherwise conduct the studies as required, we may be delayed in progressing, or ultimately may not be able to progress, our drug candidates to clinical trials.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to secure and maintain research institutions to conduct our future trials.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to secure co-developers or partners to further post-Phase II clinical trials and eventually commercialize our drug candidates.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may need to prioritize the development of our most promising candidates at the expense of the development of other products.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physicians, patients, third-party payors or others in the medical community may not be receptive to our products, and we may not generate any future revenue from the sale or licensing of our products.</span></td> </tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated with intellectual property including but not limited to:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be successful in obtaining or maintaining patent or other relating rights necessary to the development of our drug candidates in the pipeline;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The intellectual property rights underlying our exclusive licensing rights may expire or be terminated due to lack of maintenance;</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated with competition and manufacturing including, but not limited to:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face competition from entities that have developed or are developing products for our target disease indications, including companies developing novel treatments and technologies similar to ours; and</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We depend primarily upon a sole supplier of our key extract for three drug candidates and could incur significant costs and delays if we are unable to promptly find a replacement for such supplier if the supplier fails to deliver the extract pursuant to our orders.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

</div><div>
</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>
</div><div style="border: Black 1.5pt solid; padding: 0 5pt; width: 98%"><p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks associated with government regulations including without limitation:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we do not obtain the necessary governmental approvals, we will be unable to sub-license or commercialize our pharmaceutical products; and</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we obtain regulatory approval for a drug candidate, our products may remain subject to regulatory scrutiny.</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk associated with our Common Stock including without limitation:</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market prices and trading volumes of the Common may be volatile and may be affected by economic conditions beyond our control; and,</span></td> </tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.5in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9675;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is only a limited trading market for our Common Stock and such market may never develop.</span></td> </tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These and other risks described in this prospectus could materially and adversely impact our business, financial condition, operating results and cash flow, which could cause the trading price of our Common Stock to decline and could result in a loss of your investment. In addition, you should carefully consider the risks described under &#8220;Risk Factors&#8221; beginning on page 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC was incorporated under the laws of the State of Nevada on February 6, 2002. BriVision was incorporated in the State of Delaware on July 21, 2015. BioLite was incorporated in the State of Nevada on July 27, 2016. BioKey was incorporated in the State of California on November 20, 2000. BriVision, BioLite and BioKey are three operating subsidiaries that are wholly owned by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s shareholders approved an amendment to the Company&#8217;s Articles of Incorporation to change the Company&#8217;s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &#8220;<b>Annual Meeting</b>&#8221;). The name change amendment to the Company&#8217;s Articles of Incorporation was filed with Nevada&#8217;s Secretary of State and became effective on March 8, 2021 and FINRA approved our application for the name change as of May 3, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Common Stock was approved for listing on The Nasdaq Capital Market and commenced trading under the ticker symbol &#8220;ABVC&#8221; on August 3, 2021. The Company&#8217;s CUSIP number is 0091F106.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our principal executive office is located at 44370 Old Warm Springs Blvd., Fremont, CA 94538. Our telephone number at our principal executive office is (510) 668-0881. Our corporate website of BriVision is http://www.abvcpharma.com<i>.</i> The information on our corporate website is not part of, and is not incorporated by reference into, this prospectus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>
</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>
</div><div style="border: Black 1.5pt solid; padding: 0 5pt; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<a id="a_004"></a><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 27%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities offered by us</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 70%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 2,255,000 shares of common stock issuable upon exercise of the outstanding warrants issued in our August 2021 public offering, consisting of (a) 1,100,000 shares underlying Series A warrant (the &#8220;Series A Warrants&#8221;) with an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, (b) 1,100,000 shares underlying Series B warrant with an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date and subject to certain adjustment and cashless exercise provisions as described herein and (c) 55,000 shares underlying the warrants issued to the Representative, with an exercise price equal to $6.25 per share, exercisable until the third anniversary of the issuance date. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; width: 27%"><span style="font-size: 10pt"><b>Common Stock outstanding prior to completion of this offering (1)</b></span></td>
    <td style="vertical-align: bottom; text-align: justify; width: 3%">&#160;</td>
    <td style="vertical-align: top; text-align: justify; width: 70%"><span style="font-size: 10pt">1,100,000</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Common Stock outstanding immediately after this offering (2)</b></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">32,307,329 shares (assuming full exercise of the warrants issued in our August 2021 offering)</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Nasdaq Trading Symbol</b></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Our Common Stock is currently quoted on the Nasdaq Capital Market under the symbol &#8220;ABVC&#8221;.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>No Listing for Purchase Warrants</b></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">There is no established public trading market for the Purchase Warrants and we will not seek to list them.</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Use of proceeds</b></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">We will receive approximately $6,875,000 of proceeds if all the currently outstanding warrants issued in the August 2021 public offering are exercised for cash, of which there is no guarantee. We currently intend to use these proceeds for general corporate purposes. See &#8220;Use of Proceeds.&#8221;</span></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt"><b>Risk factors</b></span></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><span style="font-size: 10pt">Investment in our securities involves a high
    degree of risk and could result in a loss of your entire investment. See &#8220;Risk Factors&#8221; beginning on page 10 to read
    about factors you should consider before buying our shares of common stock.</span></td></tr>
  </table>



<p style="margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify">The number of Common Stock to be outstanding before this offering
is based on 32,307,329 shares of Common Stock outstanding as of the date of this prospectus, and excludes:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">1,307,102</span> &#160;<span style="font-size: 10pt">shares of our Common Stock issuable upon the exercise of stock options outstanding; and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">4,878,442</span>&#160; <span style="font-size: 10pt">shares of our Common Stock underlying any outstanding warrants.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The number of Common Stock to be
outstanding after this offering is based on 32,307,329 shares of Common Stock outstanding as of June 13, 2022, and excludes:</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">1,307,102</span>&#160;&#160;<span style="font-size: 10pt">&#160;shares of our Common Stock issuable upon the exercise of stock options outstanding;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify">

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">7,038,442&#160;&#160; shares of our Common Stock underlying any outstanding
warrants;</p>


</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">600,020</span>&#160; <span style="font-size: 10pt">shares of our Common Stock issuable upon the exercise of the Purchase Warrants; and </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt">&#9679; </span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">92,000 shares of our Common Stock issuable upon the exercise of the Representative&#8217;s Warrants issued in this Offering; </span></td></tr>
  </table>



<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>
</div><div style="border: Black 1.5pt solid; padding: 0 5pt; width: 98%">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Except as otherwise indicated,
all information in this prospectus assumes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 24px">&#160;</td>
    <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">no exercise of the 1,307,102 shares of our Common Stock issuable upon the exercise of stock options outstanding.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUR AUGUST 2021 PUBLIC OFFERING</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2021, we closed our August 2021 public offering of 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;).&#160;<span>The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. Th</span>e Offering was conducted on a firm commitment basis. We also issued a Warrant to WallachBeth Capital, LLC, as underwriter, pursuant to which they may purchase up to 55,000 shares of Common Stock at an exercise price of $6.25 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date hereof, 2,255,000 shares of our common stock remain issuable upon exercise of the warrants issued in our offering of August 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>
</div><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RISK FACTORS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing in our securities includes a high degree of risk. Prior to making a decision about investing in our securities, you should consider carefully the specific factors discussed below, together with all of the other information contained in this prospectus. If any of the following risks actually occurs, our business, financial condition, results of operations and future prospects would likely be materially and adversely affected. This could cause the market price of our Common Stock to decline and could cause you to lose all or part of your investment.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to the Company&#8217;s Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Unfavorable global economic conditions, including as a result of health and safety concerns, could adversely affect our business, financial condition or results of operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our results of operations could be adversely affected by general conditions in the global economy, including conditions that are outside of our control, such as the impact of health and safety concerns from the current outbreak of the COVID-19 coronavirus (&#8220;COVID-19&#8221;). The spread of the COVID-19, which was declared a pandemic by the World Health Organization in March 2020, has caused different countries and cities to mandate curfews, including &#8220;shelter-in-place&#8221; and closures of most non-essential businesses as well as other measures to mitigate the spread of the virus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The negative impact of COVID-19 on our operations is ongoing and the extent of which remains uncertain and potentially wide-spread, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">our ability to successfully execute our long-term growth strategy during these uncertain times;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">our ability to recruit the necessary number of patients to complete future clinical trials; </span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">supply chain disruptions in projects ABV-1504, ABV-1505 and ABV-1601, resulting from reduced workforces, scarcity of raw materials, and scrutiny or embargoing of goods produced in infected areas;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to perform on-site due-diligence for project ABV-1505 (MDD Phase II completed new drug candidate) and ABV-1701 (Vitargus FIH completed medical device) with our potential partners/collaborators in US, Mainland China, and Japan;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to access capital sources, as well as the ability of our key customers, suppliers, and vendors to do the same in regard to their own obligations; and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of management and employee attention and resources from key business activities and risk management outside of COVID-19 response efforts, including maintenance of internal controls.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The COVID-19 pandemic remains highly volatile and continues to evolve on a daily basis and therefore, despite our efforts and developments to combat the virus, there can be no assurance that these measures will prove successful. The extent to which COVID-19 continues to impact the Company&#8217;s business, sales, and results of operations will depend on future developments, which are highly uncertain and cannot be predicted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The Company is a development stage biopharmaceutical company and is thus subject to the risks associated with new businesses in that industry.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acquired the sole licensing rights to develop and commercialize for therapeutic purposes six compounds from BioLite and the right to co-develop with BioFirst a medical device (collectively the &#8220;ABVC Pipeline Products&#8221;). As such, the Company is a clinical stage biopharmaceutical company with operations that generate unsubstantial revenues. The Company is establishing and implementing many important functions necessary to operate a business, including the clinical research and development of the ABVC Pipeline Products, further establishment of the Company&#8217;s managerial and administrative structure, accounting systems and internal financial controls</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite and BioKey are expected to continue to have limited revenue and remain unprofitable for an indefinite period of time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly, you should consider the Company&#8217;s prospects in light of the risks and uncertainties that a pharmaceutical company with a limited operating history and revenue faces. In particular, potential investors should consider that there are significant risks that the Company will not be able to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">implement or execute its current business plan, or generate profits;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract and maintain a skillful management team;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise sufficient funds in the capital markets or otherwise to effectuate its business plan;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine that the processes and technologies that it has developed are commercially viable; and/or</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">enter into contracts with commercial partners, such as licensors and suppliers.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If any of the above risks occurs, the Company&#8217;s business may fail, in which case you may lose the entire amount of your investment in the Company. The Company cannot assure that any of its efforts in business operations will be successful or result in the timely development of new products, or ultimately produce any material revenue and profits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a pre-profit biopharmaceutical company, the Company needs to transition from a company with a research and development focus to a company capable of supporting commercial activities. The Company may not be able to reach such transition point or make such a transition, which would have affect our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If the Company fails to raise additional capital, its ability to implement its business model and strategy could be compromised.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has limited capital resources and operations. The CDMO services provided by BioKey generates a limited amount of revenue that can only partially support the operations of the Company. To date, the Company&#8217;s operations have been&#160;funded partially from the proceeds from financings or loans from its shareholders. From time to time, we may seek additional financing to provide the capital required to expand research and development (&#8220;R&amp;D&#8221;) initiatives and/or working capital, as well as to repay outstanding loans if cash flow from operations is insufficient to do so.&#160;We cannot predict with certainty the timing or amount of any such capital requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company does not raise sufficient capital to fund its ongoing development activities, it is likely that it will be unable to carry out its business plans, including R&amp;D development and expansion of production facilities. Even if the Company obtains financing for near term operations and product development, the Company may require additional capital beyond the near term. Furthermore, additional capital may not be available in sufficient amounts or on reasonable terms, if at all, and our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. If the Company is unable to raise capital when needed, its business, financial condition and results of operations would be materially adversely affected, and it could be forced to reduce or discontinue our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The Company has no history in obtaining regulatory approval for, or commercializing, any new drug candidate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With limited operating history, the Company has never obtained regulatory approval for, or commercialized, any new drug candidate. It is possible that the FDA may refuse to accept our planned New Drug Application (or &#8220;NDA&#8221;) for any of the six drug products for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval of the new drug candidates or the medical device. Although our CDMO strategic business department has experience in obtaining abbreviated new drug application (or &#8220;ANDA&#8221;) approvals, the processes and timelines of obtaining an NDA approval and ANDA approval can differentiate substantially. If the FDA does not accept or approve our planned NDA for our product candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies, which may be costly. Depending on the FDA required studies, approval of any NDA or application that we submit may be significantly delayed, possibly for several years, or may require us to expend more resources than we have. Any delay in obtaining, or inability to obtain, regulatory approvals of any of our drug candidate will prevent us from sublicensing such product. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA. If any of these outcomes occurs, we may be forced to abandon our planned NDA for such drug candidate, which materially adversely affects our business and could potentially cause us to cease operations. We face similar regulatory risks in a foreign jurisdiction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our growth is dependent on our ability to successfully develop, acquire or license new drugs.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our growth is supported by continuous investment in time, resources and capital to identify and develop new products or new formulations for the market and market penetration. If we are unable to either develop new products on our own or acquire licenses for new products from other parties, our ability to grow revenues and market share will be adversely affected.&#160;In addition, we may not be able to recover our investment in the development of new drugs and medical devices, given that projects may be interrupted, unsuccessful, not as profitable as initially contemplated or we may not be able to obtain necessary financing for such development. Similarly, there is no assurance that we can successfully secure such rights from third parties on an economically feasible basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our current products have certain side effects. If the side effects associated with our current or future products are not identified prior to their marketing and sale, we may be required to withdraw such products from the market, perform lengthy additional clinical trials or change the labeling of our products, any of which could adversely impact our growth.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company researches and develops the following six drug products and one medical device: ABV-1501, ABV-1504, ABV-1505, ABV-1701, ABV-1702, ABV-1601 and ABV-1703. Each of these seven products may cause serious adverse effects to their users. For example, the API of ABV-1501, ABV-1702 and ABV-1703 is Maitake mushroom extract. Side effects, or adverse events, associated with Maitake mushroom extract include blood bilirubin increase, lymphocyte count decrease, neutrophil count decrease, platelet count decrease, white blood cell decrease, headache, and hyperglycemia. Serious adverse events (collectively, the &#8220;SAE&#8221;) associated with this compound include leukocytosis, platelet count decrease, eye disorders, abdominal pain, gastrointestinal disorders, aphonia, lung infection, muscle weakness right-sided, confusion, edema cerebral, stroke, dyspnea, wheezing, and pruritus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV-1504 and ABV-1505 have the same API, &#8220;Radix Polygala&#8221;, which is known as Polygala tenuifolia Willd or PDC-1421 Capsule (&#8220;Polygala tenuifolia Willd&#8221;). Side effects, or adverse events, associated with ABV-1504 and ABV-1505, coming from administration of the trial medicine or examination procedure such as the procedure of taking blood (fainting, pain and/or bruising), may lead to gastrointestinal disorders (abdominal fullness and constipation), nervous system disorders (drowsiness, sleepiness, and oral ulcer). In addition, long-term use may cause miscarriages.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The safety and preliminary efficacy findings from this study, combined with the unique properties of ABV-1701, are supportive of further investigation for its use following vitrectomy surgery in patients requiring vitreous replacement. However, new serious side effects of ABV-1701 may be uncovered as the clinical trials continue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The occurrence of any of those adverse events would harm our future sales of these medicines and substantially increase the costs and expenses of marketing these medicines, which in turn could cause our revenues and net income to decline.&#160;In addition, the reputation and sales of our future medicines could be adversely affected due to the severe side effects discovered.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We may be subject to product liability claims in the future, which could divert our resources, cause us to incur substantial liabilities and limit commercialization of any products that we may develop.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face an inherent business risk of exposure to product liability claims in the event that the uses of our products are alleged to have caused adverse side effects.&#160;Side effects or marketing or manufacturing problems pertaining to any of our products could result in product liability claims or adverse publicity.&#160;These risks will exist for those products in clinical development and with respect to those products that receive regulatory approval for commercial sale.&#160;Furthermore, although we have not historically experienced any problems associated with claims by users of our products, we do not currently maintain product liability insurance and&#160;there could be no assurance that we are able to acquire product liability insurance with terms that are commercially feasible.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face an inherent risk of product liability claims as a result of the clinical testing of our products and potentially commercially selling any products that we may develop. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidate. Regardless of the merits or eventual outcome, liability claims may result in:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased demand for our product candidates or products that we may develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury to our reputation and significant negative media attention;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical trial participants;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significant costs to defend resulting litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards to trial participants or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of revenue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced resources of our management to pursue our business strategy; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to commercialize any products that we may develop.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We currently have insurance policies to cover liabilities under the clinic trials but do not maintain general liability insurance; and even if we have a general liability insurance in the future, this insurance may not fully cover potential liabilities that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We would need to increase our insurance coverage if and when we begin selling any product candidate that receives marketing approval. In addition, insurance coverage is becoming increasingly expensive. If we are unable to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidate, which could adversely affect our business, financial condition, results of operations and prospects.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We have conducted, and may in the future conduct, clinical trials for certain of our product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have conducted and may in the future choose to conduct one or more of our clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any of our clinical trials that we determine to conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and delay or permanently halt our development of the product candidate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the conduct of clinical trials outside the United States could have a significant impact on us. Risks inherent in conducting international clinical trials include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign regulatory requirements that could restrict or limit our ability to conduct our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative burdens of conducting clinical trials under multiple foreign regulatory schema;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">foreign exchange fluctuations; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diminished protection of intellectual property in some countries.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA and comparable non-U.S. regulators, we may incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Comparable non-U.S. regulatory authorities impose similar restrictions. We may never receive such approvals. We must complete extensive preclinical development and clinical trials to demonstrate the safety and efficacy of our product candidate in humans before we will be able to obtain these approvals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. Any inability to successfully complete preclinical and clinical development could result in additional costs to us and impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if (1) we are required to conduct additional clinical trials or other testing of our product candidate beyond the trials and testing that we contemplate, (2) we are unable to successfully complete clinical trials of our product candidate or other testing, (3) the results of these trials or tests are unfavorable, uncertain or are only modestly favorable, or (4) there are unacceptable safety concerns associated with our product candidate, we, in addition to incurring additional costs, may:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be delayed in obtaining marketing approval for our product candidates;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not obtain marketing approval at all;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain approval for indications or patient populations that are not as broad as we intended or desired;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be subject to additional post-marketing testing or other requirements; or</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">be required to remove the product from the market after obtaining marketing approval.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third party payors and others in the medical community necessary for commercial success and the market opportunity for the product candidate may be smaller than we estimate.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never completed a new drug or new medical device FDA application process from Phase I to FDA approval and commercialization. Even if our products are approved by the appropriate regulatory authorities for marketing and sale, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third party payors and others in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The potential market opportunities for our products are difficult to estimate precisely. Our estimates of the potential market opportunities are predicated on many assumptions, including industry knowledge and publications, third party research reports and other surveys. While we believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source. If any of the assumptions proves to be inaccurate, the actual markets for our products could be smaller than our estimates of the potential market opportunities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We may seek to enter into collaborations with third parties for the development and commercialization of our product candidates. If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may seek third-party collaborators for development and commercialization of our products. Our likely collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies, non-profit organizations, government agencies, and biotechnology companies. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217;&#160;abilities to successfully perform the functions assigned to them in these arrangements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborations involving our products will pose the following risks to us:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not pursue development and commercialization of our product candidate or may elect not to continue or renew development or commercialization programs based on preclinical or clinical trial results, changes in the collaborators&#8217;&#160;strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidate if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management attention and resources; and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborative agreements may not lead to development or commercialization of our product candidate in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ABVC, through BioLite, may not be able to receive the full amounts available under the collaboration agreement by and between BioLite, Inc. and BioHopeKing, which could increase its burden to seek additional capital to fund the business operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February and December 2015, BioLite, Inc., a subsidiary of BioLite, entered into a total of three collaboration agreements with BioHopeKing to jointly develop ABV-1501 for TNBC (or BLI-1401-2 as used by BioLite internally) and ABV-1504 for MDD (or BLI-1005 as used by BioLite internally) in most Asian countries and BLI-1006, which has been later replaced with BLI-1008 for ADHD in Asia, excluding Japan. ABVC and BioLite are co-developing ABV-1501 for TNBC and ABV-1504 for MDD pursuant to the Collaboration Agreement and its Addendum entered by and between BriVision and BioLite Taiwan where ABVC and BriVision are responsible for the clinical trials of such two new drug candidates. In accordance with the terms of the BioHopeKing Collaboration Agreement for ABV-1501 or BLI-1401-2 and the Addendum thereto, BioLite shall receive payments of a total of $10 million in cash and equity of BioHopeKing or equity securities owned by it at various stages on a schedule dictated by BioLite&#8217;s achievements of certain milestones and twelve per cent (12%) of net sales of the drug products when ABV-1501 or BLI-1401-2 is approved for sale in the licensed territories. If BioLite fails to reach any of the milestones in a timely manner, it may not receive the rest of the payments from BioHopeKing. As a result of BioLite&#8217;s potential inability to receive the full payments under those collaboration agreements with BioHopeKing, ABVC may have to seek other sources of financing to fund its operation activities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ABVC and its Subsidiaries may not be successful in establishing and maintaining additional strategic partnerships, which could adversely affect ABVC&#8217;s ability to develop and commercialize products, negatively impacting its operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to ABVC&#8217;s current collaboration with BioHopeKing for selected Asian markets, a part of its strategy is to evaluate and, as deemed appropriate, enter into additional partnerships in the future with major biotechnology or pharmaceutical companies. ABVC&#8217;s products may prove to be difficult to effectively license out as planned. Various regulatory, commercial and manufacturing factors may impact ABVC&#8217;s ability to seek co-developers of or grow revenues from licensing out any of the six products in the pipeline, none of which has been fully licensed out. Specifically, ABVC may encounter difficulty by virtue of:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">its inability to effectively identify and align with commercial partners in the U.S. to collaborate the development of ABV-1504 for the treatment of Major Depressive Disorder, ABV-1505 to treat Attention-Deficit Hyperactivity Disease, ABV-1501 for the treatment of Triple Negative Breast Cancer, ABV-1703 to the treatment of Pancreatic Cancer, ABV-1601 to treat Depression in Cancer Patients and ABV-1702 to treat Myelodysplastic syndromes and ABV-1701 Vitargus for the treatments of Retinal Detachment or Vitreous Hemorrhage;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">its inability to secure appropriate contract research organizations (&#8220;CRO&#8221;s) to conduct data analysis, lab research and FDA communication; and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">its inability to effectively continue clinical studies on and secure positive research results of all of our investigational new drugs to attract additional commercial collaborators outside the U.S.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC faces significant competition in seeking appropriate partners for its therapeutic candidates, and the negotiation process is time-consuming and complex. In order for ABVC to successfully partner its autoimmune, CNS and hematology therapeutic candidates, as well as Vitargus, its medical device, potential partners must view these medicinal candidates as economically valuable in markets they determine to be attractive in light of the terms that ABVC is seeking and compared to other available products for licensing by other companies. Even if ABVC is successful in its efforts to establish new strategic partnerships, the terms that ABVC agrees upon may not be favorable, and it may not be able to maintain such strategic partnerships if, for example, development or approval of an autoimmune therapeutic is delayed or sales of an approved product are disappointing. Any delay in entering into new strategic partnership agreements related to any of ABVC&#8217;s therapeutic candidates could delay the development and commercialization of such candidates and reduce its competitiveness even if it reaches the market.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If ABVC fails to establish and maintain additional strategic partnerships or collaboration related to its therapeutic candidates that have not been fully licensed, it will bear all of the risk and costs related to the development of any such drug candidate, and it may need to seek additional financing, hire additional employees and otherwise develop expertise for which it has not budgeted. This could negatively affect the development of any incompletely partnered new drug candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ABVC&#8217;s licensors may choose to terminate any of the license agreements with ABVC. As a result, ABVC&#8217;s research and development of new drug candidates that contain the underlying API may be terminated abruptly. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If ABVC&#8217;s Subsidiary BioLite materially breaches any license agreements it has with Yukiguni Maitake Co. (&#8220;Yukiguni&#8221;), Medical and Pharmaceutical Industry Technology and Development Center (&#8220;MPITDC&#8221;) or Industrial Technology Research Institute (&#8220;ITRI&#8221;), or any of such license agreement terminates unexpectedly, BioLite may not be able to continue its research and development of the new drug candidate which contains the underlying API whose license has been terminated. Pursuant to the Yukiguni License Agreement, if BioLite fails to meet the milestone sales requirement or submit certain applications to the appropriate health authorities on a schedule prescribed therein, Yukiguni shall have the right to terminate the Yukiguni License Agreement. If the Yukiguni License Agreement is terminated involuntarily, BioLite will be forced to discontinue its new drug development of ABV-1703, ABV-1502 and ABV-1501 and terminate the collaboration agreements relating to the three new drug candidates. The termination of the right to use the underlying API will materially disrupt the operations of ABVC. Pursuant to the license agreement between BioLite Taiwan and ITRI, if BioLite Taiwan fails to complete the research submission milestones according to the schedule set forth therein without reasons or with reasons unstatisfied with ITRI, ITRI shall have the right to terminate the license agreement with BioLite Taiwan without refund to BioLite Taiwan. BioLite Taiwan and BioLite have submitted the IND for PDC-1421 and subsequently conducted Phase II clinical trials of two drug candidiates developed from PDC-1421 according to the schedule listed in the license agreement between BioLite Taiwan and MPITDC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ABVC&#8217;s Subsidiary BioLite depends on one supplier for the API of ABV-1703, ABV-1502 and ABV-1501 and any failure of such supplier to deliver sufficient quantities of the API that meets its quality standard could have a material adverse effect on its research of these three drug candidates. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently BioLite relies primarily on Yukiguni, a Japanese supplier, to provide Yukiguni Maitake Extract 404, the API which is contained in ABV-1703, ABV-1502 and ABV-1501, three of the six drug candidates in BioLite&#8217;s oncology/hematology portfolio. It has entered into the Yukiguni License Agreement, among other things, for the delivery of Yukiguni Maitake Extract 404,. BioLite agrees to fulfill its demand of the Yukiguni Maitake Extract 404 by purchasing first from Yukiguni respecting the therapeutic products and Yukiguni represents that it will provide sufficient quantities of such API that meets cGMP standards. If the supplies of Yukiguni Maitake Extract 404 were interrupted for any reason, BioLite&#8217;s research and development activities of these three drug candidates could be delayed. These delays could be extensive and expensive, especially in situations where a substitution is not readily available.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite is currently negotiating with another supplier of Yukiguni Maitake Extract 404 that is located in Canada. However, there can be no assurance that the negotiation will be successful. Failure to obtain adequate supplies of high quality Yukiguni Maitake Extract 404 in a timely manner could have a disruptive effect on ABVC and BioLite&#8217;s research and development activities of ABV-1703, ABV-1502 and ABV-1501, resulting in a material adverse effect on the Company&#8217;s business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ABVC may use hazardous chemicals and biological materials in its business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s research and development may involve the controlled use of hazardous materials, including chemicals and biological materials. ABVC cannot eliminate the risk of accidental contamination or discharge and any resulting injury from these materials. ABVC may be sued for any injury or contamination that results from its use or the use by third parties of these materials, and its liability may exceed any insurance coverage and its total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. Although ABVC makes its best efforts to comply with environmental laws and regulations despite the associated high costs and inconvenience, ABVC cannot guarantee that it will not mishandle any hazardous materials in the future. If it fails to comply with these requirements or any improper handling of hazardous materials occurs, it could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance. In addition, ABVC cannot predict the impact on its business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted and enforced.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The facilities where the samples of drug candidates are manufactured need to be maintained and monitored in compliance with the good manufacturing practice standards, the failure of such maintenance could contaminate the results of our clinical trials and adversely affect our operations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s Subsidiary BioKey operates a laboratory facility that is a certified good manufacturing practice facility (&#8220;cGMP&#8221;) and some of its contract clinical trial service providers use cGMP facilities to conduct clinical studies. ABVC cannot be certain that ABVC or its present or future contract manufacturers or suppliers will be able to comply with cGMPs regulations and other FDA regulatory requirements. Failure to comply with these requirements may result in, among other things, total or partial suspension of production activities, failure of the FDA to grant approval for marketing, and withdrawal, suspension, or revocation of marketing approvals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to Intellectual Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Pharmaceutical patents and patent applications involve highly complex legal and factual questions, which, if determined adversely to the Company, could negatively impact its respective licensors&#8217; patent position and interrupt its research activities. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patent positions of pharmaceutical companies and research institutions can be highly uncertain and involve complex legal and factual questions. The interpretation and breadth of claims allowed in some patents covering pharmaceutical compositions may be uncertain and difficult to determine, and are often affected materially by the facts and circumstances that pertain to the patented compositions and the related patent claims. The standards of the U.S. Patent and Trademark Office, or USPTO, are sometimes uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented. U.S. patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to re-examination proceedings, post-grant review and/or inter parties review in the USPTO. Foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such interference, re-examination, post-grant review, inter parties review and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide the Company with sufficient protection against competitive products or processes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, changes in or different interpretations of patent laws in the U.S. and foreign countries may permit others to use discoveries of the Company or to develop and commercialize their new drug candidates without providing any compensation thereto, or may limit the number of patents or claims the Company can obtain. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws and those countries may lack adequate rules and procedures for defending the intellectual property rights of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company fails to obtain and maintain patent protection and trade secret protection of its respective products, the Company could lose their competitive advantages and competition it faces would increase, reducing any potential revenues and adversely affecting its ability to attain or maintain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developments in patent law could have a negative impact on the Company&#8217;s Licensors&#8217; patent positions and the Company&#8217;s business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress or the USPTO may change the standards of patentability and any such changes could have a negative impact on the Company&#8217;s business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system, changes the way issued patents are challenged, and changes the way patent applications are disputed during the examination process. These changes may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions, became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect the Company, BioLite and BioKey&#8217;s ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America Invents Act will ultimately have on the cost of prosecuting the Company&#8217;s patent applications, its ability to obtain patents based on its discoveries and its ability to enforce or defend its patents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If the Company is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed, respectively. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to patent protection, because the Company operates in the highly technical field of discovery and development of therapies, it relies in part on trade secret protection in order to protect its proprietary technology and processes. However, trade secrets are difficult to protect. The Company has entered into confidentiality and non-disclosure agreements with its employees, consultants, outside scientific and commercial collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties any confidential information developed by the party or made known to the party by the Company during the course of the party&#8217;s relationship therewith. These agreements also generally provide that inventions conceived by the party in the course of rendering services to the Company will be ABVC&#8217;s exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to contractual measures, the Company tries to protect the confidential nature of its proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for the Company. The Company&#8217;s security measures may not prevent an employee or consultant from misappropriating its trade secrets and providing them to a competitor, and recourse it takes against such misconduct may not provide an adequate remedy to protect the Company&#8217;s interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secrets. Trade secrets may be independently developed by others in a manner that could prevent legal recourse by the Company. If the Company&#8217;s confidential or proprietary information, such as the trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, its competitive position could be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Third parties may assert that the Company&#8217;s employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company might employ individuals who were previously employed at universities or other biopharmaceutical companies, including its competitors or potential competitors. Although through certain non-disclosure covenants and employment agreements with its officers and employees, the Company tries to ensure that its employees and consultants do not use the proprietary information or know-how of others in the work for the Company, the Company may be subject to claims that it or its employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If the Company fails in defending any such claims, in addition to paying monetary damages, the Company may lose valuable intellectual property rights or personnel. Even if the Company is successful in defending against such claims, litigation could result in substantial costs and be a distraction to the Company&#8217;s management and other employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>ABVC&#8217;s ability to compete may decline if it does not adequately protect its proprietary rights or if it is barred by the intellectual property rights of others. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s commercial success depends on obtaining and maintaining proprietary rights to its drug candidates as well as successfully defending these rights against third-party challenges. ABVC obtains its rights to use and research certain proprietary information to further develop the drug candidates primarily from three institutions, MPITDC, ITRI and Yukiguni (collectively the &#8220;Licensors&#8221;). These three institutions own the intellectual property rights in the products that have been licensed to us and may prosecute new patents of the drug candidates that are invented or discovered within the licensed scope of use under the respective license agreements. ABVC will only be able to protect its new drug candidates from unauthorized use by third parties to the extent that its valid and enforceable patents, or effectively protected trade secrets and know-how, cover them.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s ability to obtain new patent protection for its new drug candidates is uncertain due to a number of factors, including that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC may not have been the first to make the inventions covered by pending patent applications or issued patents;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC may not have been the first to file patent applications for its new drug candidates;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others may independently develop identical, similar or alternative products or compositions and uses thereof;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s disclosures in patent applications may not be sufficient to meet the statutory requirements for patentability;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any or all of ABVC&#8217;s pending patent applications may not result in issued patents;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC may not seek or obtain patent protection in countries that may eventually provide a significant business opportunity;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any patents issued to ABVC may not provide a basis for commercially viable products, may not provide any competitive advantages, or may be successfully challenged by third parties;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s methods may not be patentable;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC&#8217;s licensors may successfully challenge that ABVC&#8217;s new patent application fall outside the licensed use of the products; or</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others may design around ABVC&#8217;s patent claims to produce competitive products which fall outside of the scope of its patents.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if ABVC has or obtains new patents covering its new drug candidates, ABVC may still be barred from making, using and selling them because of the patent rights of others. Others may have filed, and in the future may file, patent applications covering products that are similar or identical to ABVC. There are many issued U.S. and foreign patents relating to therapeutic products and some of these relate to ABVC&#8217;s new drug candidates. These could materially affect ABVC&#8217;s ability to develop its drug candidates. Because patent applications can take many years to issue, there may be currently pending applications unknown to ABVC that may later result in issued patents that its new drug candidates may infringe. These patent applications may have priority over patent applications filed by ABVC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The Company and its respective licensors may not be able to enforce their intellectual property rights throughout the world. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to pharmaceuticals and medical devices. This could make it difficult for the Company and its respective licensors to stop the infringement of some of the Licensors&#8217; patents, or the misappropriation of their other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, the Company and its licensors have chosen in the past and may choose in the future not to seek patent protection in certain countries, and as a result the Company will not have the benefit of patent protection in such countries. Moreover, the Company may choose in the future not to seek patent protection in certain countries, and as a result it will not have the benefit of patent protection in such countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceedings to enforce the Company&#8217;s and its licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert its efforts and attention from other aspects of the businesses. Accordingly, the efforts to protect the Company&#8217;s intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the U.S. and foreign countries may affect the Company&#8217;s ability to obtain adequate protection for its technology and the enforcement of intellectual property.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Regulatory Risks Relating to Biopharmaceutical Business</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The Company is subject to various government regulations.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The manufacture and sale of human therapeutic and diagnostic products in the U.S. and foreign jurisdictions are governed by a variety of statutes and regulations. These laws require approval of manufacturing facilities, controlled research and testing of products and government review and approval of a submission containing manufacturing, preclinical and clinical data in order to obtain marketing approval based on establishing the safety and efficacy of the product for each use sought, including adherence to current PIC/S Guide to Good Manufacturing Practice for Medicinal products during production and storage, and control of marketing activities, including advertising and labeling.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The products the Company is currently developing will require significant development, preclinical and clinical testing and investment of substantial funds prior to its commercialization. The process of obtaining required approvals can be costly and time-consuming, and there can be no assurance that future products will be successfully developed and will prove to be safe and effective in clinical trials or receive applicable regulatory approvals. Markets other than the U.S. have similar restrictions. Potential investors and shareholders should be aware of the risks, problems, delays, expenses and difficulties which we may encounter in view of the extensive regulatory environment which controls our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The Company cannot be certain that it will be able to obtain regulatory approval for, or successfully commercialize, any of its current or future product candidates. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company may not be able to develop any current or future product candidates. The Company&#8217;s new drug candidates will require substantial additional clinical development, testing, and regulatory approval before the commencement of commercialization. The clinical trials of the Company&#8217;s drug candidates are, and the manufacturing and marketing of our new drug candidates will be subject to extensive and rigorous review and regulation by numerous government authorities in the U.S. and in other countries where the Company intend to test and, if approved, market any new drug candidate. Before obtaining regulatory approvals for the commercial sale of any product candidate, the Company must demonstrate through pre-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This process can take many years and may include post-marketing studies and surveillance, which will require the expenditure of substantial resources. Of the large number of drugs in development in the U.S., only a small percentage successfully completes the FDA regulatory approval process and is commercialized. Accordingly, even if the Company is able to obtain the requisite financing to continue to fund its development and clinical programs, it cannot assure the investors that any of the product candidates will be successfully developed or commercialized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is not permitted to market a therapeutic product in the U.S. until it receives approval of an NDA or ANDA, for that product from the FDA, or in any foreign countries until they receive the requisite approval from such countries. Obtaining approval of an NDA is a complex, lengthy, expensive and uncertain process, and the FDA may delay, limit or deny approval of any product candidate for many reasons, including, among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unable to demonstrate that a product candidate is safe and effective to the satisfaction of the FDA;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the results of the Company&#8217;s clinical trials may not meet the level of statistical or clinical significance required by the FDA for marketing approval;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may not approve the formulation of any product candidate;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the CROs, that BioLite or the Company retains to conduct its clinical trials may take actions outside of its control that materially adversely impact its clinical trials;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in patient enrollment, variability in the number and types of patients available for clinical trials, and lower-than anticipated retention rates for patients in clinical trials;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may find the data from pre-clinical studies and clinical trials insufficient to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks, such as the risk of drug abuse by patients or the public in general;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may disagree with the interpretation of data from the Company&#8217;s pre-clinical studies and clinical trials;</span></td> </tr>
  </table><div>
</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may not accept data generated at the Company&#8217;s clinical trial sites;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if an NDA, if and when submitted, is reviewed by an advisory committee, the FDA may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of our application or may recommend that the FDA require, as a condition of approval, additional pre-clinical studies or clinical trials, limitations on approved labeling or distribution and use restrictions;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may require development of a Risk Evaluation and Mitigation Strategy, or REMS, as a condition of approval or post-approval; or</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the FDA may change its approval policies or adopt new regulations.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These same risks apply to applicable foreign regulatory agencies from which the Company, through BioLite, may seek approval for any of our new drug candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any of these factors, many of which are beyond the Company&#8217;s control, could jeopardize its ability to obtain regulatory approval for and successfully market any new drug candidate. As a result, any such setback in the Company&#8217;s pursuit of initial or additional regulatory approval would have a material adverse effect on its business and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company does not successfully complete pre-clinical and Phase I and II clinical development, it will be unable to receive full payments under their respective collaboration agreements, find future collaborators or partners to take the drug candidates to Phase III clinical trials. Even if the Company successfully completes all Phase I and II clinical trials, those results are not necessarily predictive of results of additional trials that may be needed before an NDA for Phase III trials may be submitted to the FDA. Although there are a large number of drugs in development in the U.S. and other countries, only a very small percentage result in commercialization, and even fewer achieve widespread physician and consumer acceptance following the regulatory approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the Company may encounter delays or drug candidate rejections based on new governmental regulations, future legislative or administrative actions, or changes in FDA policy or interpretation during the period of product development. If the Company obtains required regulatory approvals, such approvals may later be withdrawn. Delays or failures in obtaining regulatory approvals may result in:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying interpretations of data and commitments by the FDA and similar foreign regulatory agencies; and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diminishment of any competitive advantages that such drug candidates may have or attain.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore, if the Company fails to comply with applicable FDA and other regulatory requirements at any stage during this regulatory process, the Company may encounter or be subject to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays or termination in clinical trials or commercialization;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal by the FDA or similar foreign regulatory agencies to review pending applications or supplements to approved applications;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recalls or seizures;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension of manufacturing;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawals of previously approved marketing applications; and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines, civil penalties, and criminal prosecutions.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The Company faces substantial competition from companies with considerably more resources and experience than the Company has, which may result in others discovering, developing, receiving approval for, or commercializing products before or more successfully than the Company. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company competes with companies that research, develop, manufacture and market already-existing and new pharmaceutical products in the fields of CNS, hematology/oncology and autoimmune. The Company anticipates that it will face increased competition in the future as new companies enter the market with new drugs and/or technologies and/or their competitors improve their current products. One or more of their competitors may offer new drugs superior to the Company&#8217;s and render the Company&#8217;s drugs uneconomical. A lot of the Company&#8217;s current competitors, as well as many of its respective potential competitors, have greater name recognition, more substantial intellectual property portfolios, longer operating histories, significantly greater resources to invest in new drug development, more substantial experience in product marketing and new product development, greater regulatory expertise, more extensive manufacturing capabilities and the distribution channels to deliver products to customers. If the Company is not able to compete successfully, it may not generate sufficient revenue to become profitable. The Company&#8217;s ability to compete successfully will depend largely on its ability to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully commercialize its drug candidates with commercial partners;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discover and develop new drug candidates that are superior to other products in the market;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with its collaborators, obtain required regulatory approvals;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract and retain qualified personnel; and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain patent and/or other proprietary protection for its product candidates.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Established pharmaceutical companies devote significant financial resources to discovering, developing or licensing novel compounds that could make the Company&#8217;s products and product candidates obsolete. Our competitors may obtain patent protection, receive FDA approval, and commercialize medicines before we do. Other companies are or may become engaged in the discovery of compounds or botanical materials that may compete with the drug candidates the Company is developing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company competes with a large number of well-established pharmaceutical companies that may have more resources than the Company does in developing therapeutics in the fields of CNS, oncology/hematology and ophthalmology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any new drug candidate the Company is developing or commercializing that competes with a currently-approved product must demonstrate compelling advantages in efficacy, convenience, tolerability and/or safety in order to address price competition and be commercially successful. If the Company is not able to compete effectively against its current and future competitors, its business will not grow and its financial condition and operations will suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Relating to Doing Business Outside the United States</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because part of ABVC&#8217;s pharmaceutical research and development is conducted outside of the U.S., the Company is subject to the risks of doing business internationally, including periodic foreign economic downturns and political instability, which may adversely affect the Company&#8217;s revenue and cost of doing business in Taiwan.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC collaborates with partners whose primary place of business is in Taiwan, Republic of China and the Company has certain key employees in Taiwan. Foreign economic downturns may affect our results of operations in the future. Additionally, other facts relating to the operation of the Company&#8217;s business outside of the U.S. may have a material adverse effect on the Company&#8217;s business, financial condition and results of operations, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">international economic and political changes;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the imposition of governmental controls or changes in government regulations, including tax laws, regulations and treaties;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in, or impositions of, legislative or regulatory requirements regarding the pharmaceutical industry;</span></td> </tr>
  </table><div>
</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with U.S. and international laws involving international operations, including the Foreign Corrupt Practices Act and export control laws;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in achieving headcount reductions due to unionized labor and works councils;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on transfers of funds and assets between jurisdictions; and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China- Taiwan geo-political instability.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As the Company continues to operate its business globally, its success will depend in part, on its ability to anticipate and effectively manage these risks. The impact of any one or more of these factors could materially adversely affect the Company&#8217;s business, financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The Company may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and Chinese anti-corruption law.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to the FCPA, and other laws that prohibit improper payments or offers of payments to foreign governments, foreign government officials and political parties by U.S. persons as defined by the statute for purposes of obtaining or retaining businesses. The Company may have agreements with third parties who may make sales in mainland China and the U.S., during the process of which the Company may be exposed to corruption. Activities in Taiwan create the risk of unauthorized payments or offers of payments by an employee, consultant or agent of the Company, because these parties are not always subject to the Company&#8217;s control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although the Company believes to date it has complied in all material aspects with the provisions of the FCPA and Chinese anti-corruption law, the existing safeguards and any future improvements may prove to be less than effective and any of the Company&#8217;s employees, consultants or agents may engage in corruptive conduct for which the Company might be held responsible. Violations of the FCPA or Chinese anti-corruption law may result in severe criminal or civil sanctions against the Company and individuals and therefore could negatively affect the Company&#8217;s business, operating results and financial condition. In addition, the Taiwanese government may seek to hold the Company liable as a successor for FCPA violations committed by companies in which the Company invests or acquires.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>International operations expose the Company to currency exchange and repatriation risks, and the Company cannot predict the effect of future exchange rate fluctuations on its business and operating results.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has business operations in Taiwan and collaborative activities in the U.S. and Japan. Substantial amounts of revenues are received and expenses are incurred in New Taiwan Dollars and U.S. dollars. Thus, the Company has exposure to currency fluctuations. The Company cannot assure you that the effect of currency exchange fluctuations will not materially affect its revenues and net income in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We conduct our operations internationally and the effect of business, legal and political risks associated with international operations may seriously harm our business.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales to customers outside the United States accounted for 7% and 0% for the year ended December 31, 2021 and 2020, respectively. Our international sales and operations are subject to a wide range of risks, which may vary from country to country or region to region. These risks include the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">export and import duties, changes to import and export regulations, and restrictions on the transfer of funds;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">political and economic instability;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issues arising from cultural or language differences and labor unrest;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">longer payment cycles and greater difficulty in collecting accounts receivable;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with trade and technical standards in a variety of jurisdictions;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties in staffing and managing international operations, including the risks associated with fraud, theft and other illegal conduct;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with laws and regulations, including environmental, employment and tax laws, which vary from country to country and over time, increasing the costs of compliance and potential risks of&#160;non-compliance;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States and European countries;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operations may be affected by political tensions, trade disputes and similar matters, particularly between China and Taiwan or between China and the United States;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United States and foreign trade restrictions, including those that may limit the importation of technology or components to or from various countries or impose tariffs or quotas; and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of currency exchange controls or taxes that make it impracticable or costly to repatriate funds from foreign countries.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We cannot assure you that risks relating to our international operations will not seriously harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If the Company becomes directly subject to the recent scrutiny, criticism and negative publicity involving U.S.-listed Chinese companies, we may have to expend significant resources to investigate and resolve the matters. Any unfavorable results from the investigations could harm our business operations, this offering and our reputation.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently, U.S. public companies that have substantially all of their operations in China, have been subjects of intense scrutiny, criticism and negative publicity by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and negative publicity has centered on financial and accounting irregularities, lack of effective internal control over financial accountings, inadequate corporate governance and ineffective implementation thereof and, in many cases, allegations of fraud. As a result of enhanced scrutiny, criticism and negative publicity, the publicly traded stocks of many U.S. listed Chinese companies have sharply decreased in value and, in some cases, have become virtually worthless or illiquid. Many of these companies are now subject to shareholder lawsuits and SEC enforcement actions and are conducting internal and external investigations into the allegations. It is not clear what effects the sector-wide investigations will have on the Company. If the Company becomes a subject of any unfavorable allegations, whether such allegations are proven to be true or untrue, the Company will have to expend significant resources to investigate such allegations and defend the Company. If such allegations were not proven to be baseless, the Company would be severely hampered and the price of the stock of the Company could decline substantially. If such allegations were proven to be groundless, the investigation might have significantly distracted the attention of the Company&#8217;s management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to the Company&#8217;s Financial Condition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our existing indebtedness may adversely affect our ability to obtain additional funds and may increase our vulnerability to economic or business downturns. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to a number of risks associated with our indebtedness, including: 1) we must dedicate a portion of our cash flows from operations
to pay debt service costs, and therefore we have less funds available for operations and other purposes; 2) it may be more difficult
and expensive to obtain additional funds through financings, if available at all; 3) we are more vulnerable to economic downturns and
fluctuations in interest rates, less able to withstand competitive pressures and less flexible in reacting to changes in our industry
and general economic conditions; and 4) if we default under any of our existing credit facilities or if our creditors demand payment
of a portion or all of our indebtedness, we may not have sufficient funds to make such payments. As of March 31, 2022 and December 31,
2021, our outstanding current liabilities were approximately $3.7 million and $3.7 million, respectively, which consisted primarily of
short-term bank loans and accrued expenses. On April 5 and 20, 2020, we entered into certain exchange agreements separately with certain
U.S. and non-U.S. holders of certain convertible promissory notes in the aggregate amount of $1,446,780; pursuant to the exchange agreements,
we issued to the Holders an aggregate of 795,735 shares of Common Stock and warrants to purchase 795,735 shares of Common Stock. On November
9, 2020, we entered into an exchange agreement with a certain non-U.S. holder of certain convertible promissory notes in the amount of
$270,272; pursuant to the exchange agreements, we will issue to the holder an aggregate of 120,121 shares of Common Stock and warrants
to purchase 120,121 shares of Common Stock. We also agreed to issue an aggregate of 545,182 options of common stock to some of our employees
in lieu of their deferred salaries in an aggregate amount of $1,090,360.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure to maintain the effectiveness of our disclosure controls and procedures may lead to restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market prices for our Common Stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Sarbanes-Oxley Act of 2002 and the Securities and Exchange Commission (SEC) have requirements that we may fail to meet or we may fall out of compliance with, such as the internal controls auditor attestation required under Section 404 of the Sarbanes-Oxley Act of 2002, with which we are not currently required to comply as we are a smaller reporting company. If we fail to achieve and maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002. Moreover, effective internal controls, particularly those related to revenue recognition, are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our stock could drop significantly.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our articles of incorporation allow for our board to create new series of preferred stock without further approval by our shareholders, which could adversely affect the rights of the holders of our Common Stock. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Board of Directors has the authority to fix and determine the relative rights and preferences of preferred stock without shareholder approval. As a result, our Board of Directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of Common Stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our Common Stock. In addition, our Board of Directors could authorize the issuance of a series of preferred stock that has greater voting power than our Common Stock or that is convertible into our Common Stock, which could decrease the relative voting power of our Common Stock or result in dilution to our existing shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may create any additional series of preferred stock and issue such shares in the future although we do not have any present intention of doing so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We may not be able to secure financing needed for future operating needs on acceptable terms, or on any terms at all.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, we may seek additional financing to provide the capital required to expand our production facilities, Research and development (&#8220;R&amp;D&#8221;) initiatives and/or working capital, as well as to repay outstanding loans if cash flow from operations is insufficient to do so.&#160;We cannot predict with certainty the timing or amount of any such capital requirements.&#160;If such financing is not available on satisfactory terms, we may be unable to expand our business or to develop new business at the rate desired.&#160;If we are able to incur debt, we may be subject to certain restrictions imposed by the terms of the debt and the repayment of such debt may limit our cash flow and growth.&#160;If we are unable to incur debt, we may be forced to issue additional equity, which could have a dilutive effect on our current shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our internal computer systems, or those of our third-party contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Despite the implementation of security measures, our internal computer systems and those of our third-party contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we do not believe that we have experienced any such system failure, accident, or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a loss of clinical trial data for our new drug candidates which could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or other data or applications relating to our technology or new drug candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product candidates could be delayed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The elimination of personal liability against our directors and officers under Nevada law and the existence of indemnification rights held by our directors, officers and employees may result in substantial expenses. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC Bylaws eliminate the personal liability of our directors and officers to us and our shareholders for damages for breach of fiduciary duty as a director or officer to the extent permissible under Nevada law. Further, our Bylaws provide that we are obligated to indemnify each of our directors or officers to the fullest extent authorized by Nevada law and, subject to certain conditions, advance the expenses incurred by any director or officer in defending any action, suit or proceeding prior to its final disposition. Those indemnification obligations could expose us to substantial expenditures to cover the cost of settlement or damage awards against our directors or officers, which we may be unable to afford. Further, those provisions and resulting costs may discourage us or our shareholders from bringing a lawsuit against any of our current or former directors or officers for breaches of their fiduciary duties, even if such actions might otherwise benefit our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks Related to the Company&#8217;s Common Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The share price of our Common Stock is volatile and may be influenced by numerous factors, some of which are beyond our control. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is currently only a limited public market for our Common Stock, which is listed on the Nasdaq Capital Market, and there can be no assurance that a trading market will develop further or be maintained for our Common Stock in the future. The trading price of our Common Stock is likely to be highly volatile, and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere herein, these factors include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the new drug candidates we acquire for commercialization;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the product candidates we seek to pursue, and our ability to obtain rights to develop those product candidates;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated adverse results or delays in our pre-clinical studies and clinical trials;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our failure to get any of our new drug candidates approved;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated serious safety and environmental concerns related to the use and research activities of any of our new drug candidates;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overall performance of the equity markets and other factors that may be unrelated to our operating performance or the operating performance of our competitors, including changes in market valuations of similar companies;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions or trends in the healthcare, biotechnology and pharmaceutical industries;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">introduction of new products offered by us or our competitors;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain an adequate rate of growth and manage such growth;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuances of debt or equity securities by us;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales of our securities by us or our shareholders in the future, or the perception that such sales could occur;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">trading volume of our Common Stock;</span></td> </tr>
  </table><div>
</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffectiveness of our internal control over financial reporting or disclosure controls and procedures;</span></td> </tr>
  </table><div>
</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">general political and economic conditions in U.S. and other countries and territories where we conduct our business;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">effects of natural or man-made catastrophic events; and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse regulatory decisions;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions or departures of key scientific or management personnel;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in laws or regulations applicable to our product candidates, including without limitation clinical trial requirements for approvals;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes or other developments relating to patents and other proprietary rights and our ability to obtain protection for our products;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our dependence on third parties, including CROs and scientific and medical advisors;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet or exceed any financial guidance or expectations regarding development milestones that we may provide to the public;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual or anticipated variations in quarterly operating results;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure to meet or exceed the estimates and projections of the investment community;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, many of which are beyond our control.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, the stock market in general, and the stocks of small-cap healthcare, biotechnology and pharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our Common Stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in these &#8220;Risk Factors,&#8221; could have a dramatic and material adverse impact on the market price of our Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Insiders have substantial control over us, and they could delay or prevent a change in our corporate control even if our other shareholders wanted it to occur.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our executive officers, directors, and principal shareholders own, in the aggregate, approximately 70.8% of our outstanding Common Stock.&#160;As a result of their stockholdings, these shareholders are able to assert substantial control over matters requiring shareholder approval, including the election of directors and approval of significant corporate transactions.&#160;This could delay or prevent an outside party from acquiring or merging with us even if our other shareholders wanted it to occur.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The market price of our Common Stock may be volatile</i>&#160;and&#160;<i>there may not be sufficient liquidity in the market for our securities in order for investors to sell their securities.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of our Common Stock has been and will likely continue to be highly volatile, as is the stock market in general. Factors that may materially affect the market price of our Common Stock are beyond our control, these factors may materially adversely affect the market price of our Common Stock, regardless of our performance.&#160;In addition, the public stock markets have experienced extreme price and trading volume volatility.&#160;These broad market fluctuations may influence the market price of our Common Stock. There is currently only a limited public market for our Common Stock, which is listed on the Nasdaq Capital Market, and there can be no assurance that a trading market will develop further or be maintained in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies, including very recently in connection with the ongoing COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic, political, regulatory and other market conditions, may negatively affect the market price of shares of our common stock, regardless of our actual operating performance. The market price of shares of our common stock may decline and you may lose some or all of your investment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our shares.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never paid any cash dividends on our Common Stock and do not anticipate paying any cash dividends in the foreseeable future, and any return on investment may be limited to the value of our Common Stock. We plan to retain any future earnings to finance growth.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under applicable Nevada law, we, as a Nevada corporation, generally may not make a distribution if i) we would not be able to pay our debts as they become due in the usual course of business, or ii) our total assets would be less than the sum of our total liabilities plus the amount that would be needed, if we were to be dissolved at the time of distribution, to satisfy the preferential rights upon dissolution of shareholders whose preferential rights are superior to those receiving the distribution.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and any trading volume could decline.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any trading market for our Common Stock that may develop will depend in part on the research and reports that securities or industry analysts publish about us or our business. As of the date hereof, there is only 1 publish research report about our business. If securities or industry analysts provide additional coverage, and one or more of those analysts downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our Common Stock could decrease, which might cause our stock price and any trading volume to decline.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plan or otherwise, could result in dilution of the percentage ownership of our shareholders and could cause our stock price to fall. </i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that we will need significant additional capital in the future to continue our planned operations. To raise capital, we may sell Common Stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell Common Stock, convertible securities or other equity securities in more than one transaction, including issuance of equity securities pursuant to any future stock incentive plan to our officers, directors, employees and non-employee consultants for their services to us, investors in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales may result in material dilution to our existing shareholders, and new investors could gain rights, preferences and privileges senior to those of holders of our Common Stock. Further, any future sales of our Common Stock by us or resales of our Common Stock by our existing shareholders could cause the market price of our Common Stock to decline. Any future grants of options, warrants or other securities exercisable or convertible into our Common Stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect on the market price of our Common Stock. On October 29, 2021, we filed a registration statement on Form S-3, as amended on November 16, 2021, which was declared effective on November 29, 2021. As of the date hereof, we have not yet issued any shares through the Form S-3, but may in the future, which would further dilute your ownership.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our Common Stock may be subject to the &#8220;penny stock&#8221; rules of the Securities and Exchange Commission, which may make it more difficult for shareholders to sell our Common Stock.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The SEC has adopted Rule 15g-9 which establishes the definition of a &#8220;penny stock,&#8221; for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require that a broker or dealer approve a person&#8217;s account for transactions in penny stocks, and the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order to approve a person&#8217;s account for transactions in penny stocks, the broker or dealer must obtain financial information and investment experience objectives of the person, and make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form sets forth the basis on which the broker or dealer made the suitability determination, and that the broker or dealer received a signed, written agreement from the investor prior to the transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally, brokers may be less willing to execute transactions in securities subject to the &#8220;penny stock&#8221; rules. This may make it more difficult for investors to dispose of the Company&#8217;s Common Stock if and when such shares are eligible for sale and may cause a decline in the market value of its stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading and about the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our failure to meet the continued listing requirements of the Nasdaq Capital Market could result in a delisting of our Common Stock</i>.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to satisfy the continued listing requirements of the Nasdaq Capital Market, such as the corporate governance requirements or the minimum closing bid price requirement, the Nasdaq Capital Market may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a delisting, we anticipate that we would take actions to restore our compliance with the Nasdaq Capital Market or another national exchange&#8217;s listing requirements, but we can provide no assurance that any such action taken by us would allow our Common Stock to remain listed on the Nasdaq Capital Market, stabilize our market price, improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq Capital Market&#8217;s minimum bid price requirement, or prevent future non-compliance with the Nasdaq Capital Market or another national exchange&#8217;s listing requirements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance requirements as a result of our Common Stock being listed on the Nasdaq Capital Market.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance requirements of the Nasdaq Capital Market. As a public company, we will continue to incur significant legal, accounting and other expenses. We are subject to mandatory reporting requirements of the Exchange Act, which require, among other things, that we continue to file with the SEC annual, quarterly and current reports with respect to our business and financial condition, that we were not required to file as a voluntary reporting company (though we did file such reports with the SEC on a voluntary basis). We have incurred and will continue to incur costs associated with the preparation and filing of these SEC reports. Furthermore, we are subject to mandatory new corporate governance and other compliance requirements of the Nasdaq Capital Market. In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, the Dodd-Frank Wall Street Reform and Consumer Protection Act and the Nasdaq Capital Market or another national exchange have imposed various other requirements on public companies. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate) the way we operate our business. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have and will continue to increase our legal and financial compliance costs and will make some activities more time-consuming and costly.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if and when we cease to be a smaller reporting company and become subject to Section 404(b) of the Sarbanes-Oxley Act, we will
be required to furnish an attestation report on internal control over financial reporting issued by our independent registered public
accounting firm. To achieve compliance with Section 404 within the prescribed time period, we will continue to be engaged in a process
to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will
need to dedicate substantially greater internal resources, potentially engage outside consultants and adopt a detailed work plan to assess
and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate
through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal
control over financial reporting. Despite our efforts, there is a risk that our independent registered public accounting firm, when required,
will not be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required
by Section 404. This could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our
financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plan or otherwise, could result in dilution of the percentage ownership of our shareholders and could cause our stock price to fall.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We expect that we will need significant additional capital in the future to continue our planned operations. To raise capital, we may sell Common Stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell Common Stock, convertible securities or other equity securities in more than one transaction, including issuance of equity securities pursuant to any future stock incentive plan to our officers, directors, employees and non-employee consultants for their services to us, investors in a prior transaction may be materially diluted by subsequent sales. Additionally, any such sales may result in material dilution to our existing shareholders, and new investors could gain rights, preferences and privileges senior to those of holders of our Common Stock. Further, any future sales of our Common Stock by us or resales of our Common Stock by our existing shareholders could cause the market price of our Common Stock to decline. Any future grants of options, warrants or other securities exercisable or convertible into our Common Stock, or the exercise or conversion of such shares, and any sales of such shares in the market, could have an adverse effect on the market price of our Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<b><i>An active, liquid, and orderly market for our common stock or Purchase Warrants may not develop.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Common Stock trades on Nasdaq. If an active market for our Common Stock does not continue to develop or is not sustained, it may be difficult for investors to sell shares of our Common Stock without depressing the market price and investors may not be able to sell the shares of our Common Stock at all. An inactive market may also impair our ability to raise capital by selling our Common Stock and may impair our ability to acquire other businesses, applications, or technologies using our Common Stock as consideration, which, in turn, could materially adversely affect our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The Purchase Warrants may not have any value.</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Warrant has an exercise price of $6.30 per share and the Series B Warrant has an exercise price of $10.00 per share; all of the Purchase Warrants will expire on the fifth anniversary of the date they first become exercisable. In the event our Common Stock price does not exceed the exercise price of the Purchase Warrants during the period when the warrants are exercisable, the Purchase Warrants may not have any value.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus contains forward-looking statements that involve risks and uncertainties, including statements based on our current expectations, assumptions, estimates and projections about us, our industry and the regulatory environment in which we and companies integral to our ecosystem operate. The forward-looking statements are contained principally in the sections entitled &#8220;Prospectus Summary,&#8221; &#8220;Risk Factors,&#8221; &#8220;Use of Proceeds,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Business.&#8221; These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. In some cases, these forward-looking statements can be identified by words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;is/are likely to&#8221; or other similar expressions. The forward-looking statements included in this prospectus relate to, among others:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">risks and uncertainties associated with our research and development activities, including our clinical trials and preclinical studies;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the timing or likelihood of regulatory filings and approvals or of alternative regulatory pathways for our drug candidates;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential market opportunities for commercializing our drug candidates;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the potential market size and the size of the patient populations for our drug candidates, if approved for commercial use, and our ability to serve such markets;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">estimates of our expenses, future revenue, capital requirements and our needs for additional financing;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to develop, acquire and advance our product candidates into, and successfully complete, clinical trials and preclinical studies and obtain regulatory approvals;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the implementation of our business model and strategic plans for our business and drug candidates;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation, cost, timing, progress and results of future preclinical studies and clinical trials, and our research and development programs;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of future licensing arrangements, and whether we can enter into such arrangements at all;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing and receipt or payments of licensing and milestone revenues, if any;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates and our ability to operate our business without infringing the intellectual property rights of others;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory developments in the United States and foreign countries;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the performance of our third party suppliers and manufacturers;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain and establish collaborations or obtain additional funding;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of competing therapies that are currently or may become available;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to continue as a going concern;</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of the ongoing COVID-19 pandemic;</span> </td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left">&#9679;</td>
    <td style="text-align: justify"><p style="margin: 0pt 0">our financial performance; and</p></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments and projections relating to our competitors and our industry.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We caution you that the forward-looking statements highlighted above do not encompass all of the forward-looking statements made in this prospectus or in the documents incorporated by reference in this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are important factors that could cause actual results to vary materially from those described in this registration statement as anticipated, estimated or expected, including, but not limited to: the effects of the COVID-19 outbreak, including on the demand for our products&#894; the duration of the COVID-19 outbreak and severity of such outbreak in regions where we operate&#894; the pace of recovery following the COVID-19 outbreak&#894; our ability to implement cost containment and business recovery strategies&#894; the adverse effects of the COVID-19 outbreak on our business or the market price of our ordinary shares; competition in the industry in which we operate and the impact of such competition on pricing, revenues and margins, volatility in the securities market due to the general economic downturn; SEC regulations which affect trading in the securities of &#8220;penny stocks,&#8221; and other risks and uncertainties described herein and the risk factors set forth in Part I - Item 1A, &#8220;Risk Factors&#8221;, in our Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on March 16, 2021 and elsewhere in the documents incorporated by reference into this prospectus. Moreover, we operate in a very competitive and challenging environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this prospectus and in the documents incorporated by reference in this prospectus. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. Except as required by law, we assume no obligation to update any forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in any forward- looking statements, even if new information becomes available in the future. Depending on the market for our stock and other conditional tests, a specific safe harbor under the Private Securities Litigation Reform Act of 1995 may be available. Notwithstanding the above, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) expressly state that the safe harbor for forward-looking statements does not apply to companies that issue penny stock. Because we may from time to time be considered to be an issuer of penny stock, the safe harbor for forward-looking statements may not apply to us at certain times.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The forward-looking statements contained in this prospectus and in the documents incorporated by reference in this prospectus relate only to events as of the date on which the statements are made. We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated events. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, other strategic transactions or investments we may make.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>USE OF PROCEEDS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not selling any shares of our common stock
in this offering and, as a result, we will not receive any proceeds from the sale of the common stock covered by this prospectus. All
of the net proceeds from the sale of our common stock will go to the holders of the warrants issued in the August 2021 public offering.
Upon exercise of the warrants, however, we will receive proceeds from the exercise of such warrants if exercised for cash and not on a
cashless basis. We will receive approximately $6,875,000 of proceeds if all the currently outstanding warrants issued in the August 2021
public offering are exercised for cash. We currently intend to use these proceeds for general corporate purposes.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DIVIDEND POLICY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have never declared or paid any cash dividends on our capital stock, and we do not currently intend to pay any cash dividends on our capital stock in the foreseeable future. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. Any future determination to pay dividends will be made at the discretion of our Board, subject to applicable laws and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. Our future ability to pay cash dividends on our capital stock may also be limited by the terms of any debt instruments or preferred securities issued in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DILUTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If&#160;you invest in our securities, your interest may be immediately and substantially diluted to the extent of the difference between the price you pay per share and the pro forma net tangible book value per share of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our historical net
tangible book value as March 31, 2022 was $8,971,141</span><span style="font-size: 10pt">,
or $0.30 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Our pro forma net
tangible book value as of March 31, 2022 was $12,635,066, or $0.37 per share and includes the following transactions subsequent to March
31, 2022: (i) issuance of a total of 2,000,000 shares of common stock in a registered direct offering to certain investors, and (ii)
issuance of a total of 761,920 stock options.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">Assuming the exercise
of all of the remaining outstanding warrants issued in the August 2021 and May 2022 offering, which means the issuance of 2,600,020</span><span style="font-size: 9pt">&#160;</span>
<span style="font-size: 10pt">shares of common stock upon the exercise of such warrants, our pro forma as adjusted net tangible book value
would have been approximately $21,258,177, or $0.65 per share at March 31, 2022. This represents an immediate increase in net tangible
book value of thirty-five cents per share to our existing stockholders, and an immediate dilution of $1.73 dollar per share to investors
purchasing shares&#160;in an offering using this prospectus, assuming an exercise price per share of $6.3 per share for the warrant series
A and $2.45 for warrants issued in May 2021.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution in pro forma as adjusted net tangible book value per share represents the difference between the amount per share of common stock and the pro forma net tangible book value per share of our common stock immediately after this offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table illustrates the per share dilution to investors purchasing shares in an offering using this prospectus:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 76%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed price per share</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro forma net tangible book value per share as of March 31, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">0.37</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in pro forma net tangible book value per share</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.28</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro forma as adjusted net tangible book value per share after this offering</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.65</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution per share to new investors</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5.6</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The number of shares of common stock that will
be outstanding immediately after this offering is based on 30,307,329 shares of common stock outstanding as of March 31, 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MARKET FOR OUR COMMON STOCK, DIVIDENDS AND</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RELATED SHAREHOLDER INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b>. Since August 3, 2021,
our common stock, par value $.001 per share (the &#8220;Common Stock&#8221;), is quoted on the Nasdaq Capital Markets under the symbol
&#8220;ABVC&#8221;.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth the range of high and low bid quotations for our common stock. The quotations represent inter-dealer prices without retail markup, markdown or commission, and may not necessarily represent actual transactions.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Quarter Ended</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">High Bid<br/> ($)</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Low Bid <br/> ($)</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/22</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">3.72</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: center">2.18</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/21</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">3.52</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">3.36</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/30/21</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2.40</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2.26</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/30/21</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">5.05</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">5.00</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/21</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">4.50</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">4.40</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/20</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">5.50</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2.75</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/30/20</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">4.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2.60</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/30/20</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">3.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">1.05</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/20</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">5.05</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">1.80</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/31/19</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">7.18</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2.00</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/30/19</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">13.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">5.12</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/30/19</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">27.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">11.95</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/31/19</span></td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">37.80</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">26.10</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Holders</b>. As of June 13, 2022, we had approximately
751 shareholders of record of our common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividends</b>. Holders of our common stock
are entitled to receive such dividends as may be declared by our board of directors. No dividends on our common stock have ever been paid,
and we do not anticipate that dividends will be paid on our common stock in the foreseeable future.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securities authorized for issuance under equity incentive plans.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity Compensation Plan Information</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&#160;following table discloses information as of December 31, 2021, with respect to compensation plans (including individual compensation arrangements) under which our equity securities are authorized for issuance, aggregated as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Plan category</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> securities<br/> to be issued<br/> upon<br/> exercise of<br/> outstanding<br/> options,<br/> warrants<br/> and rights</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> average<br/> exercise<br/> price of<br/> outstanding<br/> options,<br/> warrants<br/> and rights</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares of<br/> common<br/> stock<br/> remaining<br/> available for<br/> future<br/> issuance<br/> under equity<br/> compensation<br/> plans</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Equity compensation plans approved by security holders</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1,825,184</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">2.70</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">2,979,264</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity compensation plans not approved by security holders</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,825,184</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">2.70</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,979,264</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See, Executive Compensation &#8211; Stock Option Plan for additional details about our option plan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS&#160;OF FINANCIAL CONDITION AND<br/> RESULTS OF OPERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The following discussion and analysis should be read together with our financial statements and the related notes appearing elsewhere in this prospectus. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. See &#8220;Cautionary Note Regarding Forward-Looking Statements and Industry Data&#8221; for a discussion of the uncertainties, risks and assumptions associated with these statements. Actual results and the timing of events could differ materially from those discussed in our forward-looking statements as a result of many factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this prospectus.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From its inception, the Company has not generated
substantial revenue from its medical device and new drug development. For the three months ended March 31, 2022 and 2021, and the year
ended December 31, 2021, the Company generated $25,660, $263,150 and $355,797 in revenue, respectively, mainly from the sale of Contract
Development &amp; Manufacturing Organization (&#8220;CDMO&#8221;) services.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC BioPharma Inc., which was incorporated in July 2015 in the State of Delaware, is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicines derived from plants have a long history of relieving or preventing many diseases and, typically, have exhibited fewer side effects than drugs developed from animals or chemical ingredients. Perhaps the most famous example is aspirin, which evolved from a compound found in the bark and leaves of the willow tree and was later marketed by Bayer starting in 1899. Aspirin has very few serious side effects and has proven to be one of the most successful drugs in medical history. Some 50 years later, scientists identified anticancer compounds in the rosy periwinkle, which Eli Lilly subsequently produced for the treatment of leukemia and Hodgkins disease. Other well-known examples of successful botanical drugs include the cancer-fighting Taxol, isolated from the Pacific yew tree.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company develops its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company&#8217;s scientists and other specialists known to the Company to identify drugs that it believes demonstrate efficacy and safety based on the Company&#8217;s internal qualifications. Once a drug is shown to be a good candidate for further development and ultimately commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly respected principal investigators in the United States, Australia and Taiwan. In almost all cases, we have found that research institutions in each of those countries are eager to work with the Company to move forward with Phase II clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, institutions conducting phase II clinical trials in partnership with ABVC include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Device: ABV-1701, Vitargus&#174; in vitrectomy surgery, Pivotal Study in Australia, Principal Investigator: Andrew Chang, MD, Ph.D., Sydney Eye Hospital, Australia</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1504, Major Depressive Disorder (MDD), Phase II, NCE drug Principal Investigators: Charles DeBattista M.D. and Alan F. Schatzberg, MD,&#160;Stanford University Medical Center, Cheng-Ta Li, MD, Ph.D &#8211;&#160;Taipei Veterans General Hospital</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1505, Adult Attention-Deficit Hyperactivity Disorder (ADHD), Phase II, NCE drug Principal Investigators: Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D.,&#160;University of California San Francisco (UCSF), School of Medicine</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott Irwin, MD, Ph.D. &#8211;&#160;Cedars Sinai Medical Center (CSMC)</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1703, Advanced Inoperable or Metastatic Pancreatic Cancer, Phase II, NCE drug Principal Investigator: Andrew E. Hendifar, MD &#8211;&#160;Cedars Sinai Medical Center (CSMC)</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>



</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1501, A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined with Docetaxel Monotherapy in Patients with Stage IV or Recurrent Breast Cancer Patients</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Device: ABV-2002, Class I/II through 510K for market launch, Corneal Storage Media, Technology Licensing in progress</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon successful completion of the Phase II trial,
the Company will seek a partner &#8211; a large pharmaceutical company &#8211; to complete a Phase III study, submit the New Drug Application
(NDA), and commercialize the drug upon approval by the FDA and Taiwan FDAs. The Company expects to seek its first commercialization partner
in 2022 for Vitargus, its vitreous substitute that helps to maintain a round shape and retinal location during vitrectomy surgery.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Another part of the Company&#8217;s business is conducted by BioKey, a wholly owned subsidiary, that is engaged in a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (phase I through phase III) and commercial manufacturing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2019, the Company, BioLite Holding, Inc. (&#8220;BioLite&#8221;), BioKey, Inc. (&#8220;BioKey&#8221;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of the Company (&#8220;Merger Sub 1&#8221;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of the Company (&#8220;Merger Sub 2&#8221;) (collectively referred to as the &#8220;Parties&#8221;) completed the business combination pursuant to that certain Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated January 31, 2018, pursuant to which the Company acquired BioLite and BioKey via issuing shares of the Company&#8217;s Common Stock to the shareholders of BioLite and BioKey. As a result, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company issued an aggregate of 104,558,777 shares of Common Stock (prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285), which became effective by operation of law on or about February 5, 2019.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite was incorporated under the laws of the State of Nevada on July 27, 2016, with 500,000,000 shares authorized, par value $0.0001. BioLite&#8217;s key subsidiaries include BioLite BVI, Inc. (&#8220;BioLite BVI&#8221;) that was incorporated in the British Virgin Islands on September 13, 2016 and BioLite, Inc. (&#8220;BioLite Taiwan&#8221;), a Taiwanese corporation that was founded in February 2006. BioLite Taiwan has been in the business of developing new drugs for over ten years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite and BioLite BVI are holding companies and have not carried out substantive business operations of their own.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2017, BioLite, BioLite BVI, BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &#8220;BioLite Share Purchase / Exchange Agreement&#8221;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite Share Purchase / Exchange Agreement sold their equity in BioLite Taiwan and used the proceeds from such sales to purchase shares of Common Stock of BioLite at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite owns, via BioLite BVI, approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioKey was incorporated on August 9, 2000 in the State of California. It is engaged primarily in research and development, manufacturing, and distribution of generic drugs and nutraceuticals with strategic partners. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (phase 1 through phase 3) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development processes with other biotechnology, pharmaceutical, and nutraceutical companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common Stock Reverse Split</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2019, the Board by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#8220;Reverse Split&#8221;) of both the authorized common stock of the Company and the issued and outstanding common stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company&#8217;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 3, 2019, the Company filed a certificate of amendment to the Company&#8217;s articles of incorporation (the &#8220;Amendment&#8221;) to effect the Reverse Split with the Secretary of State of the State of Nevada. The Reverse Split took effect on May 8, 2019.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Series A Convertible Preferred Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2019, the Company filed a certificate of designation (the &#8220;Series A COD&#8221;) of Series A Convertible Preferred Stock (the &#8220;Series A Stock&#8221;) with the Secretary of the State of Nevada.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Series A COD, the Company designated 3,500,000 shares of preferred stock as Series A Stock, par value of $0.001 per share. Subject to the laws of Nevada, the Company will pay cumulative dividends on the Series A Stock on each anniversary from the date of original issue for a period of four calendar years. The Series A Stock will rank senior to the outstanding common stock of the Company, par value $0.001 (the &#8220;Common Stock&#8221;) with respect to dividend rights, rights upon liquidation, dissolution or winding up in the amount of accrued but unpaid dividend. Holders of the Series A Stock will have the same voting rights as the Company&#8217;s Common Stock holders. Each share of Series A Stock is initially convertible at any time at the option of the holder into one share of Common Stock and automatically converts into one share of Common Stock on the four-year anniversary of its issuance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, no Series A Convertible
Preferred Stock has been issued by the Company.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Increasing the Authorized Shares</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2020, our board of directors approved and adopted an amendment to the Company&#8217;s Articles of Incorporation, to increase the authorized shares of the common stock, par value $0.001 per share, from 20,000,000 to 100,000,000, such that, after including the previously authorized 20,000,000 shares of preferred stock, par value $0.001 per share, the aggregate number of shares of stock that the Company has authority to issue is 120,000,000 shares. The amendment became effective on April 2, 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>NASDAQ Listing</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2021, we closed a public offering (the &#8220;Offering&#8221;) of&#160;1,100,000&#160;units (the &#8220;Units&#8221;), with each Unit consisting of one share of our common stock (the &#8220;Common Stock&#8221;), one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $6.30&#160;per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $10.00&#160;per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;). The Units were priced at $6.25&#160;per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. The Offering was conducted on a firm commitment basis. The Common Stock was approved for listing on The Nasdaq Capital Market and commenced trading under the ticker symbol &#8220;ABVC&#8221; on August 3, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Name Change and Cusip Number</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s shareholders approved an amendment to the Company&#8217;s Articles of Incorporation to change the Company&#8217;s corporate name to &#8220;ABVC BioPharma, Inc.&#8221; and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &#8220;<b>Annual Meeting</b>&#8221;). Nevada&#8217;s Secretary of State approved the name change on March 8, 2021, but since are still in the FINRA approval process for such name change, the new name is not yet effective. Stock certificates will remain valid and stockholders are not required to submit their stock certificates for exchange as a result of the name change. <i>New</i> stock certificates issued by the Company will be printed with the Company&#8217;s new name, ABVC BioPharma, Inc.; existing stock certificates will remain valid.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s cusip number is 0091F106. The Company&#8217;s stock symbol remains ABVC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Joint Venture Agreement</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 6, 2021 (the &#8220;<b>Completion Date</b>&#8221;), ABVC BioPharma, Inc. (the &#8220;<b>Company</b>&#8221;), Lucidaim Co., Ltd., a Japanese corporation (&#8220;<b>Lucidaim</b>,&#8221; together with the Company, the &#8220;<b>Shareholders</b>&#8221;), and BioLite Japan K.K., a Japanese corporation (&#8220;<b>Biolite JP&#8221;</b>) entered into a Joint Venture Agreement (the &#8220;<b>Agreement</b>&#8221;). Biolite JP is a private limited company (a Japanese&#160;<i>Kabushiki Kaisha</i>) incorporated on December 18, 2018 and at the date of the Agreement has 10,000 ordinary shares authorized, with 3,049 ordinary shares issued and outstanding (the &#8220;<b>Ordinary Shares</b>&#8221;). Immediately prior to the execution of the Agreement, Lucidaim owned 1,501 ordinary shares and the Company owned the 1,548 ordinary shares. The Shareholders entered into the joint venture to formally reduce to writing their desire to invest in and operate Biolite JP as a joint venture. The business of the joint venture shall be the research and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements carried on by Biolite JP and its subsidiaries in Japan, or any other territory or businesses as may from time to time be agreed by an amendment to the Agreement. The closing of the transaction is conditioned upon the approval and receipt of all necessary government approvals, which have been received.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Agreement and the related share transfer agreement, the Company shall transfer 54 of its Ordinary Shares to Lucidaim for no consideration, such that following the transfer, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). Also pursuant to the Agreement, there shall be 3 directors of Biolite JP, consisting of 1 director appointed by the Company and 2 appointed by Lucidiam. The Company shall appoint Eugene Jiang, the Company&#8217;s current Chairman and Chief Business Officer and Lucidaim shall appoint Michihito Onishi; the current director of Biolite JP, Toru Seo (who is also a director of BioLite Japan&#8217;s other shareholder), is considered the second Lucidaim director. The Agreement further provides that the Company and Biolite JP shall assign the research collaboration and license agreement between them to Biolite JP or prepare the same (the &#8220;<b>License Agreement</b>&#8221;). The aforementioned transactions occurred on the Completion Date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As per the Agreement, the Shareholders shall supervise and manage the business and operations of Biolite JP. The directors shall not be entitled to any renumeration for their services as a director and each Shareholder can remove and replace the director he/she/it appointed. If a Shareholder sells or disposes of all of its Ordinary Shares, the director such Shareholder appointed must tender his/her resignation. The Agreement also sets forth certain corporate actions that must be pre-approved by all Shareholders (the &#8220;<b>Reserved Matters</b>&#8221;). If the Shareholders are unable to make a decision on any Reserved Matter, then either Shareholder can submit a deadlock notice to the other shareholder, 5 days after which they must refer the matter to each Shareholder&#8217;s chairman and use good faith to resolve the dispute. If such dispute is not resolved within 10 days thereafter, then either Shareholder can offer to buy all of the other Shareholder&#8217;s Ordinary Shares for cash at a specified price; if there is not affirmative acceptance of the sale, the sale shall proceed as set forth in the sale offer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the Shareholders maintains a pre-emptive right to purchase such number of additional Ordinary Shares as would allow such Shareholder to maintain its ownership percentage in Biolite JP if Biolite JP issues any new Ordinary Shares. However, the Agreement provides that the Company shall lose its pre-emptive rights under certain conditions. The Shareholders also maintain a right of first refusal if the other Shareholder receives an offer to buy such shareholder&#8217;s Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement also requires Biolite JP to obtain a bank facility in the amount of JPY 30,460,000 (approximately USD272,000), for its initial working capital purposes. Pursuant to the Agreement, each Shareholder agrees to guarantee such bank facility if the bank requires a guarantee. Accordingly, the Company may be liable for the bank facility in an amount up to JPY 14,925,400 (approximately USD134,000), which represents 49% of the maximum bank facility. The Agreement further provides that Biolite JP shall issue annual dividends at the rate of at least 1.5% of Biolite JP&#8217;s profits, if it has sufficient cash to do so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Agreement, the Company and Biolite
JP agree to use their best efforts to execute the License Agreement by the end of December 2021; the parties continue to negotiate the
License Agreement. The Company agreed that any negotiation on behalf of Biolite JP regarding the terms of the License Agreement shall
be handled by the directors appointed by Lucidaim. If the Company and such Lucidaim directors do not reach agreement on the terms, Biolite
JP may at its sole discretion determine not to execute the License Agreement without any liability to the Company.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement contains non-solicitation and non-compete clauses for a period of 2 years after a Shareholder or its subsidiaries ceases to be a Shareholder, with such restrictive covenants limited to business within the ophthalmologic filed or central neurological field. Any rights to intellectual property that arise from Biolite JP&#8217;s activities, shall belong to Biolite JP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement contains standard indemnification terms, except that no indemnifying party shall have any liability for an individual liability unless it exceeds JPY 500,000 (approximately USD4,500) and until the aggregate amount of all liabilities exceeds JPY 2,000,000 (approximately USD18,000) and then only to the extent such liability exceed such limit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company paid $150,000 towards the setup of the joint venture and BioLite Japan&#8217;s other shareholder paid $150,000 after the Letter of Intent was signed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement shall continue for 10 years, unless earlier terminated and shall continue until terminated by: (i) either party by giving the other party at least 6 months written notice, until the end of the 10 years, after which the parties can terminate at any time or (ii) or by written agreement of all Shareholders, in which case it shall terminate automatically on the date upon which all Ordinary Shares are owned by one Shareholder. The Agreement also allows a Shareholder to terminate the agreement upon certain defaults committed by another Shareholder, as set forth in the Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This was a&#160;<i>related</i>&#160;<i>party</i>&#160;transaction and was conducted at arm&#8217;s length. In addition to the Company&#8217;s board of directors providing approval for the Company to enter into the Agreement, the Company&#8217;s audit committee approved the Company&#8217;s entry into the Agreement. The Board believes that this joint venture will enhance the Company&#8217;s ability to provide therapeutic solutions to significant unmet medical needs and to develop innovative botanical drugs to treat central nervous system (&#8220;CNS&#8221;) and oncology/ hematology diseases. The Company&#8217;s Board of Directors believes that the joint venture has the potential to provide the Company with access to additional early-stage product candidates that it would not otherwise have access to and to introduce the Company to early-stage opportunities, and therefore the Board believes the joint venture is in the best interest of the Company and its shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent PPP</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 14, 2020, the Company received a loan in the amount of $124,400 under the Paycheck Protection Program (&#8220;PPP&#8221;) administered by the United States Small Business Administration (the &#8220;SBA&#8221;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;Cares Act&#8221;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years after the date of the promissory note. On March 15, 2021 the US Government approved our application of the loan forgiveness program, so there will be no obligation to pay back this loan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 29, 2021, BioKey&#160;received a loan in the amount of $132,331 under the Paycheck Protection Program (&#8220;PPP&#8221;) administered by the United States Small Business Administration (the &#8220;SBA&#8221;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;Cares Act&#8221;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. In addition, on September 28, 2021, the US Government approved our application of the loan forgiveness program, so there will be no obligation to pay back this loan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2021, the Company received a loan in the amount of $104,167 under the Paycheck Protection Program (&#8220;PPP&#8221;) administered by the United States Small Business Administration (the &#8220;SBA&#8221;) from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;Cares Act&#8221;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. In addition, on November 15, 2021, the US Government approved our application of the loan forgiveness program, so there will be no obligation to pay back this loan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent Research Results</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 23, 2019, the Company announced its internal Phase II clinical study results of ABV-1504 for Major Depression Disorder (&#8220;MDD&#8221;). The clinical study results showed that PDC-1421, the active pharmaceutical ingredient of ABV-1504, met the pre-specified primary endpoint of the Phase II clinical trial and significantly improved the symptoms of MDD.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Phase II clinical study was a randomized, double-blind, placebo-controlled, multi-center trial, in which 60 adult patients with confirmed moderate to severe MDD were treated with PDC-1421 in either low dose (380 mg) or high dose (2 x 380 mg) compared with placebo administration, three times a day for six weeks. PDC-1421 high dose (2 x 380 mg) met the pre-specified primary endpoint by demonstrating a highly significant 13.2-point reduction in the Montgomery-&#197;sberg Depression Rating Scale (MADRS) total score by Intention-To-Treat (ITT) analysis, averaged over the 6-week treatment period (overall treatment effect) from baseline, as compared to 9.2-point reduction of the placebo group. By Per-Protocol (PP) analysis, PDC-1421 showed a dose dependent efficacy toward MDD in which high dose (2 x 380 mg) gave 13.4-point reduction in MADRS total score from baseline and low dose (380 mg) gave 10.4-point reduction as compared to a 8.6-point in the placebo group. The Company has decided to use the high dose formula in the Phase III clinical trial of ABV-1504.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 9, 2020 the Company issued a full clinical study report (CSR) of Vitargus&#174; First-in-Human Phase I Clinical Trial<i>.&#160;</i>The safety and preliminary efficacy findings from this study, combined with the unique properties of Vitargus&#174; (BFC-1401), are supportive of further development for its use during vitrectomy surgery in patients requiring vitreous replacement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The study was an open label, Phase I study undertaken at a single study center in Sydney, Australia. A total of 11&#160;participants were enrolled for the study in which each participant had been diagnosed with either (1) a complex or rhegmatogenous retinal detachment or chronic retinal detachment with failure of gas or silicone oil treatment or (2) a vitreous hemorrhage that requires vitrectomy surgery. The study found that Vitargus&#174; was well-tolerated as a vitreous substitute without any apparent toxicity to ocular tissues. Further, there was no indication of an increased overall safety risk with Vitargus&#174;.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 9, 2020 the Company issued a full clinical study report (CSR) of its ABV-1505 Phase II Part I clinical trial conducted at the University of California, San Francisco (UCSF) for the treatment of adult Attention-Deficit Hyperactivity Disorder (ADHD).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Phase II Part I clinical study for treating ADHD found that the PDC-1421 Capsule was safe, well tolerated and efficacious during its treatment and the follow-up period with six adult patients. For the primary endpoints, the percentages of improvement in Adult Attention-Deficit/Hyperactivity Disorder Rating Scale-Investigator Rated-IV (ADHD-RS-IV) score from baseline to 8 weeks treatment were 83.3% (N=5) in the Intention-To-Treat (ITT) population and 80.0% (N=4) in the Per-Protocol (PP) population. Both low and high doses of PDC-1421 Capsule met the primary end points by passing the required 40% population in ADHD-RS-IV test scores.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall, the results from this study, which demonstrate the therapeutic value of PDC-1421, support further clinical development of ABV-1505 for the treatment of adult ADHD.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 4, 2020, we executed an amendment to our collaboration agreement with BioFirst to add BFC-1403 Intraocular Irrigation Solution and BFC-1404 Corneal Storage Solution to our agreement. BFC-1404 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while BFC-1403 has broader utilization during a variety of ocular procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initially the Company will focus on BFC-1404, a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial keratoplasty (back layer cornea transplant). Designated ABV-2002 under the Company&#8217;s product identification system, the solution is comprised of a specific poly amino acid that protects ocular tissue from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early testing by BioFirst indicates that ABV-2002 may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can be manufactured at lower cost. Categorized as a Class I Medical Device which has the lowest risk to patients, the Company intends to submit a Premarket Notification 510(K) submission to the FDA before the end of 2021 to demonstrate the device is at least as safe and effective as current products on the market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Public Offering &amp; Financings</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On May 11, 2022, the Company entered into that
certain securities purchase agreement (the &#8220;SPA&#8221;), with a certain institutional investor (the &#8220;Purchaser&#8221;). Pursuant
to the SPA, the Company issued 2,000,000 shares (the &#8220;Shares&#8221;) of its Common Stock at a price of $2.11 per share and 5-year
warrants to purchase up to 2,000,000 shares of Common Stock, exercisable at a price of $2.45 per share (the &#8220;Warrants&#8221;) to
the Purchasers. WallachBeth Capital LLC and ViewTrade Securities, Inc. acted as co-placement agents for the offering of the Shares and
warrants. We paid to the co-placement agents an aggregate cash fee equal to 8% of the aggregate sales price of the securities sold and
issued them warrants to purchase up to 160,000 shares of Common Stock, on the same terms as the Warrants. The transaction contemplated
by the SPA was closed on May 16, 2022, as all the closing conditions were satisfied. The sale and offering of the Shares and Warrants
pursuant to the SPA was effected as a takedown off the Company&#8217;s shelf registration statement on Form S-3, as amended (File No.
333-260588), which became effective on November 29, 2021 (the &#8220;Registration Statement&#8221;). A final prospectus supplement to
the Registration Statement was filed with the Securities and Exchange Commission on May 16, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2021, the Company closed its public offering (the &#8220;Public Offering&#8221;) of 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of the Company&#8217;s common stock, one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. The Public Offering was conducted on a firm commitment basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Financing in November 2020</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 11, 2020, we conducted a closing with regard to certain securities purchase agreements (the &#8220;<b>SPAs</b>&#8221;) dated October 23, 2020, separately with two non-U.S. investors (the &#8220;<b>Investors</b>&#8221;). Each of the Investors agreed to purchase and the Company agreed to sell to each of the Investors 1,111,112 shares of the Company&#8217;s Common Stock, and warrants (the &#8220;<b>November Warrants</b>&#8221;) to purchase 1,111,112 shares of Common Stock, for a purchase price of $2,500,000. The November Warrants are exercisable upon issuance and will expire three years from the date of issuance. The initial exercise price of the November Warrants is $6.00, subject to stock, splits, stock dividend and other similar events. In addition, when the closing price of the Common Stock equals or exceeds $9.00 per share for twenty Trading Days (as defined in the SPAs) during any thirty-day period, the Company shall have the right to require the Investors to exercise all or any portion of the November Warrants for a cash exercise. The aggregate net proceeds were $5,000,000. The Company and the Investors further agreed to amend the terms of the SPA to permit the closing of the offering to occur on a rolling basis.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company paid the following fees to a FINRA member firm in connection with such offering: (i) a cash&#160;success fee of $175,000 and (ii) warrants to purchase a number of shares of Common Stock equal to 7% of the number of shares of Common Stock sold in the Offering, at an exercise price per share equal to $6.00 subject to adjustment (the &#8220;<b>Comp Warrants</b>&#8221;). The Comp Warrants are exercisable on a cashless basis, at the holder&#8217;s discretion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Financing in October 2020</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 23, 2020, we entered into a Securities Purchase Agreement (the &#8220;<b>October SPA</b>&#8221;) with one accredited investor. Pursuant to the October SPA, the Company sold and issued a convertible promissory note (the &#8220;<b>October Note</b>&#8221;) in the principal amount of $2,500,000 to the investor and received the payment from such investor on October 30, 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The October Note was issued on October 23, 2020 and the maturity date of the October Note is the twenty-four (24) month anniversary from the issuance date (the &#8220;<b>Maturity Date</b>&#8221;). Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the Company&#8217;s common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect to convert part or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding amount at any time, in whole or in part, without any penalty. On June 3, 2021, the parties to the October SPA signed Amendment No. 1 to Promissory Note (the &#8220;<b>Amendment</b>&#8221;). Pursuant to the Amendment, the October Note shall now also automatically convert into shares of the Company&#8217;s common stock immediately following the Company&#8217;s receipt of conditional approval to list its common stock on the NASDAQ stock market, if and when we receive such approval, which cannot be guaranteed, at a conversion price equal to the then current conversion price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the October Note and pursuant to the terms of an agreement entered into between the Company and a FINRA member firm, such firm shall receive (i) a cash success fee of $78,750 and (ii) upon conversion of the October Note, warrants equal to 7.0% of the number of shares of Common Stock received by the investor at the time of conversion (&#8220;<b>Note Warrants</b>&#8221;). The warrants are exercisable on a cashless basis, at the holder&#8217;s discretion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The issuance and sale of the Common Stock, the Investor Warrants, Comp Warrants, Note Warrants and the shares of Common Stock underlying the Investor Warrants, the Comp Warrants and the October Note were made in reliance on an exemption from registration contained in either&#160;Regulation D&#160;or&#160;Regulation S&#160;of the&#160;Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Financing in May 2020</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2020, the Company received capital contributions of approximately $1,602,040 in cash from 40 investors through private placements with the term of $2.25 per share and a free warrant attaches with each Common stock that was purchased. The exercise price of the warrant will be at $6.00 with a mandatory exercise price of $9.00.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of an agreement entered into between the Company and a FINRA member firm, such firm shall receive (i) a cash success fee of $60,831.65 (ii) a warrant to purchase 37,852 shares of Common Stock with an exercise price of $2.25 per share, and (iii) a warrant to purchase 37,852 shares of Common Stock with an exercise price of $6.00 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Financing in April 2020</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 21, 2020, the Company entered into three note agreements with existing note investors who executed the agreements in 2018. These three investors are Guoliang Yu and Yingfei Wei Family Trust, Keypoint Technology Ltd., and Yoshinobu Odaira. The new agreements bear the same term as other notes investors who executed the contract in 2019. On April 5, 2020, the Company entered into exchange agreements with such note holders. Pursuant to the exchange agreements, the Holders agreed to deliver the Notes to the Company for cancellation, of which the aggregate principal amount plus accrued interest expenses are $931,584, and the Company agreed to issue to the Holders an aggregate of 506,297 shares of the Company&#8217;s common stock and warrants to purchase 506,297 shares of the Company&#8217;s common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 28, 2019 and September 4, 2019, the Company issued convertible promissory notes in the aggregate principal amount plus accrued interest expenses are $515,196 to Kuo, Li Shen, Chang, Ping Shan, Lin, Shan Tyan, and Liu, Ching Hsuan. On April 20, 2020, the Company entered into separate exchange agreements with each note holder. Pursuant to the exchange agreements, the note holders agreed to cancel the notes and the Company agreed to issue to the holders an aggregate of 289,438 shares of the Company&#8217;s common stock and warrants to purchase 289,438 shares of the Company&#8217;s common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key elements of our business strategy include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advancing to the pivotal trial phase of ABV-1701 Vitargus&#174; for the treatments of Retinal Detachment or Vitreous Hemorrhage, which we expect to generate revenues in the future.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Focusing on licensing ABV-1504 for the treatment of major depressive disorder, MDD, after the successful completion of its Phase II clinical trials.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Completing Phase II, Part 2 clinical trial for ABV-1505 for the treatment of attention deficit hyperactivity disorder, ADHD.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out licensing drug candidates and medical device candidates to major pharmaceutical companies for phase III and pivotal clinical trials, as applicable, and further marketing if approved by the FDA.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We plan to augment our core research and development capability and assets by conducting Phase I and II clinical trials for investigational new drugs and medical devices in the fields of CNS, Hematology/Oncology and Ophthalmology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our management team has extensive experiences across a wide range of new drug and medical device development and we have in-licensed new drug and medical device candidates from large research institutes and universities in both the U.S. and Taiwan. Through an assertive product development approach, we expect that we will build a substantial portfolio of Oncology/ Hematology, CNS and Ophthalmology products. We primarily focus on Phase I and II research of new drug candidates and out license the post-Phase-II products to pharmaceutical companies; we do not expect to devote substantial efforts and resources to building the disease-specific distribution channels.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Objectives</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is operating its core business based on collaborative activities that can generate current and future revenues through research, development and/or commercialization joint venture agreements. The terms of these agreements typically include payment to the Company related to one or more of the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">nonrefundable upfront license fees,</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development and commercial milestones,</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">partial or complete reimbursement of research and development costs and</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">royalties on net sales of licensed products.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each type of payments results in revenue except for revenue from royalties on net sales of licensed products, which are classified as royalty revenues. To date, we have not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the joint venture partner.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Nonrefundable upfront payments</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related nonrefundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of nonrefundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Milestone payments</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration partners.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is nonrefundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) Multiple Element Arrangements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) Royalties and Profit Sharing Payments</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues Derived from Research and Development Activities Services &#8212; Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examples of collaborative agreements the Company has entered into are as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Collaborative agreements with BHK</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February and December of 2015, BioLite, Inc. entered into a total of three joint venture agreements with BioHopeKing to jointly develop
ABV-1501 for Triple Negative Breast Cancer (TNBC), ABV-1504 for MDD and ABV-1505 for ADHD. The agreements granted marketing rights to
BioHopeKing for certain Asian countries in return for a series of milestone payments totaling $10 million in cash and equity of BioHopeKing
or equity securities owned by BioHopeKing.</span></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The milestone payments are determined by a schedule of BioLite development achievements as shown below:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Milestone</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Payment</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Execution of BHK Co-Development Agreement</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,000,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Investigational New Drug (IND) Submission</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1,000,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Phase II Clinical Trial Complete</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">1,000,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Initiation of Phase III Clinical Trial</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">3,000,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1pt">New Drug Application (NDA) Submission</td>
    <td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">4,000,000</td>
    <td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">10,000,000</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December of 2015, BHK paid the initial cash payment of $1 million upon the execution of the BHK Agreement. The Company concluded that certain deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash payment as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The payment included compensation for past research efforts and contributions made by BioLite Taiwan before the BHK agreement was signed and does not relate to any future commitments made by BioLite Taiwan and BHK in the BHK Agreement.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2016, the Company received the second milestone payment of $1 million, and recognized collaboration revenue for the year ended December 31, 2016. As of December 31, 2021, the Company had completed the phase II clinical trial for ABV-1504 MDD on October 31, 2019, but has not yet completed the phase II clinical trial for ABV-1505 ADHD.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the milestone
payments, BioLite Taiwan is entitled to receive a royalty equal to 12% of BHK&#8217;s net sales related to ABV-1501, ABV-1504 and ABV-1505
Products. As of March 31, 2022, the Company has not earned royalties under the BHK Co-Development Agreement.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Co-Development agreement with Rgene Corporation, a related party</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 26, 2017, the Company entered into a co-development agreement (the &#8220;Rgene Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party under common control by the controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to the Rgene Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1703 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Rgene Agreement, Rgene is required to&#160;pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017 as compensation of BriVision&#8217;s past research efforts and contributions made by BriVision before the Rgene Agreement was executed. The payment does not relate to any future milestones attained by BriVision. In addition to $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene. All development costs shall be equally shared by both BriVision and Rgene.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2017, the Company delivered all research, technical data and development data to Rgene pursuant to the Rgene Agreement in return for a cash payment of $450,000 and 1,530,000 common shares of Rgene stock valued at $2,550,000, which in 2018 was accounted for using the equity method long-term investment. On December 31, 2018, the Company determined to fully write off this investment based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions, the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements and Rgene&#8217;s ability to remain in business. All research projects that were initiated will be managed and funded equally by the Company and Rgene.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and Rgene signed an amendment to the Rgene Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination Therapy and AB-1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions of the Rgene Agreement remain in full force and effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Collaborative agreement with BioFirst Corporation, a related party</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2017, the Company entered into a collaborative agreement (the &#8220;BioFirst Agreement&#8221;) with BioFirst Corporation, a corporation incorporated under the laws of Taiwan (&#8220;BioFirst&#8221;), pursuant to which BioFirst granted the Company global licensing rights to medical use of ABV-1701 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the Company is a Director and shareholders of BioFirst (See Note 12).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the BioFirst Agreement, the Company and BioFirst will co-develop and commercialize BFC-1401. The Company will pay BioFirst a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018 as payment in full for BioFirst&#8217;s past research efforts and contributions made by BioFirst before the BioFirst Agreement was executed. The Company is entitled to receive 50% of any future net licensing revenue or net profit associated with Vitargus&#174;. All development cost will be equally shared by both BriVision and BioFirst.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 25, 2017, BioFirst delivered all research, technical, data and development data to the Company. For the year ended September 30, 2017, the Company determined to fully expense the entire amount of $3,000,000 since the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended September 30, 2017.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2019, the Company entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued 428,571 shares of the Company&#8217;s common stock to BioFirst as payment for $3,000,000 owed by the Company to BioFirst in connection with the BioFirst Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2019, the Company entered into a second Stock Purchase Agreement with BioFirst whereby the Company issued 414,702 shares of the Company&#8217;s common stock to BioFirst as repayment in full for a loan in the amount of $2,902,911 provided to BriVision from BioFirst.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 4, 2020, the Company executed an amendment to the BioFirst Agreement with BioFirst to add ABV-2001 Intraocular Irrigation Solution and ABV-2002 Corneal Storage Solution to the agreement. ABV-2002 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while ABV-2001 has broader utilization during a variety of ocular procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initially the Company will focus on ABV-2002, a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial keratoplasty (back layer cornea transplant). ABV-2002 is a solution comprised of a specific poly amino acid that protects ocular tissue from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV-2002 can adjust osmolarity to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early testing by BioFirst indicates that ABV-2002 may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can be manufactured at lower cost. Categorized as a lower risk Class I Medical Device, the Company intends to submit a Premarket Notification 510(K) submission to the FDA before the end of 2021 to demonstrate the device is at least as safe and effective as current products on the market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Co-Development agreement with BioLite Japan K.K.</span></b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 6, 2021 (the &#8220;<b>Completion Date</b>&#8221;), the Company, Lucidaim Co., Ltd., a Japanese corporation (&#8220;<b>Lucidaim</b>,&#8221; together with the Company, the &#8220;<b>Shareholders</b>&#8221;), and BioLite Japan K.K., a Japanese corporation (&#8220;<b>Biolite&#8221;</b>) entered into a Joint Venture Agreement (the &#8220;<b>Agreement</b>&#8221;). Biolite is a private limited company (a Japanese&#160;<i>Kabushiki Kaisha</i>) incorporated on December 18, 2018 and at the date of the Agreement has 10,000 ordinary shares authorized, with 3,049 ordinary shares issued and outstanding (the &#8220;<b>Ordinary Shares</b>&#8221;). Immediately prior to the execution of the Agreement, Lucidaim owned 1,501 ordinary shares and the Company owned the 1,548 ordinary shares. The Shareholders entered into the joint venture to formally reduce to writing their desire to invest in and operate Biolite as a joint venture. The business of the joint venture shall be the research and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements carried on by Biolite and its subsidiaries in Japan, or any other territory or businesses as may from time to time be agreed by an amendment to the Agreement. The closing of the transaction is conditioned upon the approval and receipt of all necessary government approvals, which have been received.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Agreement and the related share transfer agreement, the Company shall transfer 54 of its Ordinary Shares to Lucidaim for no consideration, such that following the transfer, Lucidaim shall own 1,555 Ordinary Shares (51%) and the Company shall own 1,494 Ordinary Shares (49%). Also pursuant to the Agreement, there shall be 3 directors of Biolite, consisting of 1 director appointed by the Company and 2 appointed by Lucidiam. The Company shall appoint Eugene Jiang, the Company&#8217;s current Chairman and Chief Business Officer and Lucidaim shall appoint Michihito Onishi; the current director of Biolite, Toru Seo (who is also a director of BioLite Japan&#8217;s other shareholder), is considered the second Lucidaim director. The Agreement further provides that the Company and Biolite shall assign the research collaboration and license agreement between them to Biolite or prepare the same (the &#8220;<b>License Agreement</b>&#8221;). The aforementioned transactions occurred on the Completion Date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As per the Agreement, the Shareholders shall supervise and manage the business and operations of Biolite. The directors shall not be entitled to any renumeration for their services as a director and each Shareholder can remove and replace the director he/she/it appointed. If a Shareholder sells or disposes of all of its Ordinary Shares, the director such Shareholder appointed must tender his/her resignation. The Agreement also sets forth certain corporate actions that must be pre-approved by all Shareholders (the &#8220;<b>Reserved Matters</b>&#8221;). If the Shareholders are unable to make a decision on any Reserved Matter, then either Shareholder can submit a deadlock notice to the other shareholder, 5 days after which they must refer the matter to each Shareholder&#8217;s chairman and use good faith to resolve the dispute. If such dispute is not resolved within 10 days thereafter, then either Shareholder can offer to buy all of the other Shareholder&#8217;s Ordinary Shares for cash at a specified price; if there is not affirmative acceptance of the sale, the sale shall proceed as set forth in the sale offer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the Shareholders maintains a pre-emptive right to purchase such number of additional Ordinary Shares as would allow such Shareholder to maintain its ownership percentage in Biolite if Biolite issues any new Ordinary Shares. However, the Agreement provides that the Company shall lose its pre-emptive rights under certain conditions. The Shareholders also maintain a right of first refusal if the other Shareholder receives an offer to buy such shareholder&#8217;s Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement also requires Biolite to obtain a bank facility in the amount of JPY 30,460,000 (approximately USD272,000), for its initial working capital purposes. Pursuant to the Agreement, each Shareholder agrees to guarantee such bank facility if the bank requires a guarantee. Accordingly, the Company may be liable for the bank facility in an amount up to JPY 14,925,400 (approximately USD134,000), which represents 49% of the maximum bank facility. The Agreement further provides that Biolite shall issue annual dividends at the rate of at least 1.5% of Biolite&#8217;s profits, if it has sufficient cash to do so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Agreement, the Company and Biolite agree to use their best efforts to execute the License Agreement by the end of December 2021. The Company agreed that any negotiation on behalf of Biolite regarding the terms of the License Agreement shall be handled by the directors appointed by Lucidaim. If the Company and such Lucidaim directors do not reach agreement on the terms, Biolite may at its sole discretion determine not to execute the License Agreement without any liability to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement contains non-solicitation and non-compete clauses for a period of 2 years after a Shareholder or its subsidiaries ceases to be a Shareholder, with such restrictive covenants limited to business within the ophthalmologic filed or central neurological field. Any rights to intellectual property that arise from Biolite&#8217;s activities, shall belong to Biolite.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement contains standard indemnification terms, except that no indemnifying party shall have any liability for an individual liability unless it exceeds JPY 500,000 (approximately USD4,500) and until the aggregate amount of all liabilities exceeds JPY 2,000,000 (approximately USD18,000) and then only to the extent such liability exceed such limit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company paid $150,000 towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000 after the Letter of Intent was signed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement shall continue for 10 years, unless earlier terminated. The Agreement also allows a Shareholder to terminate the agreement upon certain defaults committed by another Shareholder, as set forth in the Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This was a&#160;related&#160;party&#160;transaction.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company received $4,244,452 in gross proceeds from the exercise of warrants issued in the Company&#8217;s August 3, 2021, public offering of securities. Investors exercised a total of 673,405 Series A warrants at a price of $6.30 per share, and 200 Series B warrants at a price of $10 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Agreement with BioLite, Inc.</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">The Company entered into a Collaborative Agreement
with BioLite, Inc., a company incorporated under the laws of Taiwan, and a subsidiary of the Company, (&#8220;BioLite&#8221;) on December
29, 2015, and then entered into two addendums to such agreement (as amended and revised, (the &#8220;Agreement&#8221;). The majority shareholder
of BioLite is one of the Company&#8217;s subsidiaries, the Company&#8217;s Chairman is a director of BioLite and Dr. Jiang, the Company&#8217;s
Chief Strategy Officer and a director, is the Chairman of BioLite.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant to the Agreement, the Company acquired
the sole licensing rights to develop and commercialize for therapeutic purposes six compounds from BioLite. In accordance with the terms
of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity
securities owned by it at various stages on a schedule dictated by BioLite&#8217;s achievements of certain milestones, as set forth in
the Agreement (the &#8220;Milestone Payments&#8221;) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501
is approved for sale in the licensed territories. If BioLite fails to reach any of the milestones in a timely manner, it may not receive
the rest of the payments from the Company. According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone
Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the &#8220;December 2021 Payment&#8221;)
and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company&#8217;s Board of Directors determined that the December
2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000,
that BioLite owes the Company as of December 31, 2021. On February 22, 2022, the parties entered into an amendment to the Agreement allowing
the Company to make all payments due under the Agreement via the forgiveness of debt, in equal value, owed by BioLite to the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">This was a related party transaction and was conducted
at arm&#8217;s length. In addition to the Company&#8217;s board of directors approving the modification of terms of the Agreement, the
Company&#8217;s audit committee approved them too. The Board believes it is in the Company&#8217;s best interest to cancel outstanding
debt and apply it to the December 2021 Payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Following such approval, the Company and BioLite
entered into an amendment to the Agreement reflecting the modified payment method.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BioKey Revenues</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to collaborative agreements, ABVC earns revenue through its wholly owned BioKey subsidiary which provides a wide range of Contract Development &amp; Manufacturing Organization (&#8220;CDMO&#8221;) services including API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (from Phase I through Phase III) and commercial manufacturing of pharmaceutical products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, BioKey provides a variety of regulatory services tailored to the needs of its customers, which include proofreading and regulatory review of submission documents related to formulation development, clinical trials, marketed products, generics, nutraceuticals and OTC products and training presentations. In addition to supporting ABVC&#8217;s new drug development, BioKey submits INDs, NDAs, ANDAs, and DMFs to the FDA, on ABVC&#8217;s behalf in compliance with new electronic submission guidelines of the FDA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Impact of COVID-19 Outbreak</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 30, 2020, the World Health Organization declared the coronavirus outbreak a &#8220;Public Health Emergency of International Concern&#8221; and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The coronavirus and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company operates. While the closures and limitations on movement, domestically and internationally, are expected to be temporary, if the outbreak continues on its current trajectory the duration of the supply chain disruption could reduce the availability, or result in delays, of materials or supplies to and from the Company, which in turn could materially interrupt the Company&#8217;s business operations. Given the speed and frequency of the continuously evolving developments with respect to this pandemic, the Company cannot reasonably estimate the magnitude of the impact to its consolidated results of operations. We have taken every precaution possible to ensure the safety of our employees.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due to the COVID-19 pandemic, our revenue for the fiscal 2020 and 2021 were significantly impacted. As we have not seen a stronger signal to indicate that overall global economies will be back to normal in the first half of fiscal 2022, our business&#8217;s overall revenue stream may be impacted further until the restrictions of COVID-19 can be released, after which we expect the Company can resume normal operations.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The&#160;COVID-19&#160;pandemic, including variants, has adversely affected, and is expected to continue to adversely affect, elements of our CDMO business sector. The COVID-19&#160;pandemic government imposed restrictions constrained researcher access to labs globally. These constraints limited scientific discovery capacity and we observed that demand in those labs fell well below historic levels. As constraints on social distancing were gradually lifted around the world recently, labs have been able to increase research activity. While we believe that underlying demand is still not yet at&#160;pre-COVID-19&#160;levels since lab operations remain below their normal capacity, we are hopeful that the vaccination programs that are underway combined with policy changes planned for the summer will further increase research activity and support a return to&#160;pre-COVID-19&#160;demand levels worldwide.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The global pandemic of COVID-19 continues to evolve rapidly, and we will continue to monitor the situation closely, including its potential effect on our plans and timelines.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally, it is reasonably possible that estimates made in the financial statements have been, or will be, materially and adversely impacted in the near term as a result of these conditions, including losses on inventory; impairment losses related to goodwill and other long-lived assets and current obligations.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary of Critical Accounting Policies</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Basis of Presentation</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;). All significant intercompany transactions and account balances have been eliminated.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Fiscal Year</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January
1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to
the twelve months ended September 30th of such year.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Use of Estimates</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Inventory</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Forward Stock Split</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Stock Reverse Split</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#8220;Reverse Split&#8221;) of both the authorized common stock of the Company (the &#8220;Common Stock&#8221;) and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company&#8217;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company&#8217;s articles of incorporation (the &#8220;Amendment&#8221;) to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-Q reflect this 1-for-18 reverse stock split.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Fair Value Measurements</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 820, &#8220;Fair Value Measurements&#8221; defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company&#8217;s long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Cash and Cash Equivalents</span>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2022 and December 31, 2021, the Company&#8217;s
cash and cash equivalents amounted to $2,717,936 and $5,828,548, respectively. Some of the Company&#8217;s cash deposits are held in financial
institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes
this financial institution is of high credit quality.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Restricted Cash Equivalents</span>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2022 and December 31, 2021, the Company&#8217;s restricted cash equivalents
amounted $714,652 and $736,667, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Revenue Recognition</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fiscal year 2018, the Company adopted Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#8217;s reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#8217;s review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company&#8217;s revenue during all periods presented.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Property and Equipment</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated&#160;Life<br/> in Years</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 83%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings and leasehold improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 ~ 50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 ~ 10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 ~ 6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Long-term Equity Investment</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable cost method investments when the equity method does not apply.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant judgment is required to identify whether an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#8217;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee&#8217;s industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#8217; revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Other-Than-Temporary Impairment</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#8217;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</span></td> </tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0.25in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable equity investments based on the Company&#8217;s assessment
of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee;
adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee;
additional funding requirements; and the investee&#8217;s ability to remain in business. A series of operating losses of an investee or
other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized
even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value
of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not
necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain
an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for
non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments
of equity investments were $0, $0 and $0 for the three months ended March 31, 2022 and 2021 and the year ended December 31, 2021, respectively.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Goodwill</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company completed the required testing of
goodwill for impairment as of March 31, 2022, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Research and Development Expenses</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for R&amp;D costs in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, Research and Development (&#8220;ASC 730&#8221;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Post-retirement and post-employment benefits</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#8217;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#8217; salaries to the employees&#8217;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $3,337 and $2,503 for the three months ended March 31, 2022 and 2021, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Stock-based Compensation</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2022 and 2021, respectively. Total
employee stock-based compensation expenses were $2,675,205 and $1,623,102 for the years ended December 31, 2021 and 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221; and FASB ASC Topic 505-50 &#8220;Equity-Based
Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $4,692,003 and $225,740 for the three months ended March 31, 2022 and 2021, respectively.
Total non-employee stock-based compensation expenses were $2,631,550 and $2,523,877 for the years ended December 31, 2021 and 2020, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Beneficial Conversion Feature</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Income Taxes</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the years ended December 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 22, 2017, the SEC issued Staff Accounting Bulletin (&#8220;SAB 118&#8221;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A valuation allowance is recorded to reduce the Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Loss Per Share of Common Stock</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company calculates net loss per share in accordance with ASC Topic 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Commitments and Contingencies</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted ASC Topic 450 &#8220;Contingencies&#8221; subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Foreign-currency Transactions</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Company&#8217;s subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#8217; Equity (Deficit).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Translation Adjustment</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounts of the Company&#8217;s subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#8220;NT$&#8221;). Such financial statements were translated into U.S. Dollars (&#8220;$&#8221; or &#8220;USD&#8221;) in accordance ASC 830, &#8220;Foreign Currency Matters&#8221;, with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, shareholder&#8217;s deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of shareholders&#8217; equity (deficit).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For contracts in an entity&#8217;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimates and Assumptions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
preparing our consolidated financial statements, we use estimates and assumptions that affect the reported amounts and disclosures. Our
estimates are often based on complex judgments, probabilities and assumptions that we believe to be reasonable, but that are inherently
uncertain and unpredictable. We are also subject to other risks and uncertainties that may cause actual results to differ from estimated
amounts.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations &#8212; Three Months
Ended March 31, 2022 Compared to Three Months Ended March 31, 2021.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table presents, for the three months
indicated, our consolidated statements of operations information.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">25,660</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">263,150</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,896</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,245</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23,764</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">261,905</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,191,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,167,595</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">359,404</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,315</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,692,003</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">225,740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,242,485</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,514,650</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,218,721</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,252,745</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40,175</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">52,529</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,213</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(130,229</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Rent income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,867</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Rent income &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,600</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Gain/Loss on foreign exchange changes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,563</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">951</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Gain/Loss on investment in equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,791</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Other (expense) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,410</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Government grant income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">124,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">44,239</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,398</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Loss before provision income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,174,482</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,246,347</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Provision for income tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(86,867</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(51,024</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,087,615</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,195,323</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss attributable to noncontrolling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(92,175</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(66,818</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss attributed to ABVC and subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,995,440</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,128,505</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113,339</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">36,140</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(6,108,779</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,092,365</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.20</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average number of common shares outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">29,683,402</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,420,526</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenues.</i></b>&#160;We generated $25,660
and $263,150 in revenues for the three months ended March 31, 2022 and 2021, respectively. The decrease in revenues was mainly due to
the impact of COVID-19 on our CDMO business sector.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Expenses.</i></b> Our operating
expenses have increased by $4,727,835, or 312%, to $6,242,485 for the three months ended March 31, 2022 from $1,514,650 for the three
months ended March 31, 2021. Such increase in operating expenses was mainly attributable to the increase in stock based compensation and
selling, general and administrative expenses by 4,489,746 which relates to costs in conjunction with our recent stock issuance, as well
as the increase in research and development expenses of $238,089 to continue developing our pipeline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other Income (Expense). </i></b>Our other
income was $44,239 and $6,398 for the three months ended March 31, 2022 and 2021, respectively. The change was principally caused by the
increase in rental income and decrease&#160;in interest expense, as well as the loss on investment in equity securities and government
grant income which occurred in the three months ended March 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest income (expense), net, was $21,962 for
the three months ended March 31, 2022, compared to $(77,700) for the three months ended March 31, 2021. The increase of $99,662, or approximately
128%, was primarily due to the repayment of convertible notes payable during the year ended 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Government grant income totaled $0 for the three
months ended March 31, 2022, compared to $124,400 for the three months ended March 31, 2021, which was recorded as receipt of the first
round of PPP loan forgiveness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Net Loss.</i></b>&#160;As a result of the
above factors, our net loss was $6,087,615 for the three months ended March 31, 2022 compared to $1,195,323 for the three months ended
March 31, 2021, representing an increase of $4,892,292, or 409%.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Results of Operations &#8212; Year Ended December 31, 2021 Compared to Year Ended December 31, 2020.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Revenues.&#160;</i></b>We generated $355,797 and $483,045 in revenues for the year ended December 31, 2021 and 2020, respectively. The decrease of $127,248, or approximately 26%, was primarily caused by the decrease in contract services due to continuous impacts from the COVID-19 pandemic.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Operating Expenses. </i></b>Our operating expenses were $12,056,679 in the year ended December 31, 2021, as compared to $8,970,105 in the year ended December 31, 2020. Such increase in operating expenses was mainly attributable to the increase in stock based compensation and selling, general and administrative expenses by $2,632,427 which relates to costs in conjunction with our public offering and our recent stock issuances, as well as increasing research and development expenses of $454,147 to continue to develop our pipeline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
Income (expense). </i></b>The other income was $495,141 in the year ended December 31, 2021 as compared to other expense of
$2,308,160 in the year ended December 31, 2020. The increase was principally caused by the increase in foreign currency exchange
income, government PPP forgiveness, and decrease in impairment loss and loss on investment in equity securities.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on impairment loss was $0 for the year ended December 31, 2021 as compared to $961,217 for the year ended December 31, 2020. The decrease of $961,217 was due to our re-assessment of valuation based on the latest market consensus and trading price.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss on investment in equity securities was $269,844 for the year ended December 31, 2021 as compared to $1,168,733 for the year ended December 31, 2020, representing a decrease of $898,889, or approximately 77%, which was mainly due to the investment in a related party, BioFirst, accounted for using the equity method accounting treatment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain (loss) on foreign currency exchange was $426,316 for the year ended December 31, 2021 as compared to ($3,275) for the year ended December 31, 2020. The increase of $429,591 was mainly due to the depreciation of the U.S. dollar against the NT dollar from the repayment by BioLite, in currency other than the functional currency of such subsidiaries. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Government grant income was $360,898&#160;for the year ended December 31, 2021 as compared to $0 for year ended December 31, 2020. The increase of $360,898 was due to the approval of PPP Forgiveness by the government.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Net Loss.</i></b>&#160;The net loss was $12,035,851 for the year ended December 31, 2021 compared to $10,593,584 for the year ended December 31, 2020. The Company&#8217;s net loss increased by $1,442,267 or approximately 14% during the year ended December 31, 2021 from 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Working Capital</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of<br/> March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of <br/> December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,987,931</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,625,120</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,663,698</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,692,312</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Working Capital</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,324,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,932,808</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash Flow from Operating Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the three months
ended March 31, 2022 and 2021, the net cash used in operating activities were $2,994,257 and $1,413,074, respectively. The increase in
the amount used in operating activities of $1,581,183 was primarily due to the increased amount due from related parties and non-cash
stock based compensation for nonemployees, and decreased accounts receivables, accrued expenses and other current liabilities, non-cash
government grant income and increase in net loss during the three months ended March 31, 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021 and 2020, the net cash used in operating activities were ($7,597,719) and ($4,563,919), respectively. The increase in the amount of $3,033,800 was primarily due to the increased net loss, account receivables, due from related parties, prepaid expenses, partially offset by the decrease of gain on sales of investment in equity securities, stock-based compensation, and investment loss; and by the increase of deferred tax during the year ended December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash Flow from Investing Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended March 31, 2022,
the net cash used in investing activities was $93,220, compared to the net cash used in investing activities of $281,952 for the three
months ended March 31, 2021.&#160;The decrease was due to the prepayment for equity investment during the three months ended March 31,
2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021 and 2020, the net cash used in investing activities was ($805,966) and the net cash generated was ($225,431), respectively. The increase in the amount of $580,535 was primarily due to the decrease in net proceeds from sale of investment occurred in 2020, and increase in purchase of investments, prepayment for equity investment and purchase of equipment during the year ended December 31, 2021, and partially offset by the decrease of loan to related parties during the year ended December 31, 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash Flow from Financing Activities</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the three months
ended March 31, 2022, the net cash provided by financing activities was $0, while the net cash provided by the three months ended March
31, 2021 was $42,226, respectively. The decrease in net cash provided by financing activities was primarily because there were no proceeds
from and repayment of any loans or convertible notes during the three months ended March 31, 2022.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2021 and 2020, the net cash provided by financing activities were $9,995,550 and $9,567,843, respectively.
The net cash provided by financing activities increased by $427,707, due to the issuance of common stock through up-list, partially offset
by the payment for up-list offering costs, repayment of convertible notes, repayment of short-term loans during the year ended December
31, 2021&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>BUSINESS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Industry Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The biotechnology industry focuses on developing breakthrough products and technologies to combat various types of diseases through efficient industrial manufacturing process. Biotechnology is an important business sector in the world&#8217;s economies&#160;and plays a key role in human health. Companies engaged in biotechnology&#160;generally require large amounts of capital investment for their research &amp; development activities and it may take up to tens of years to develop and commercialize a new drug or a new medical device. ABVC (&#8220;we&#8221; or the &#8220;Company&#8221;) is an early stage biotechnology company with a pipeline of six new drugs and one medical device under development, all of which are licensed&#160;from related parties of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Business Overview</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date hereof, the Company&#8217;s minimal revenue has come from the sale of CDMO services through BioKey. However, the Company&#8217;s focus is on developing a pipeline of products by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company&#8217;s scientists and other specialists known to the Company to identify drugs or medical devices that it believes demonstrate efficacy and safety based on the Company&#8217;s internal qualifications. Once a drug or medical device is shown to be a good candidate for further development and ultimately commercialization, ABVC licenses the drug or medical device from the original researchers and introduces the drug or medical device clinical trial plan to highly respected principal investigators in the United States, Australia and Taiwan. In almost all cases, ABVC has found that research institutions in each of those countries are eager to work with the Company to move forward with Phase II clinical trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Institutions that have or are now conducting phase II clinical trials in partnership with ABVC include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1504, Major Depressive Disorder (MDD), Phase II completed. NCE drug Principal Investigators: Charles DeBattista M.D. and Alan F. Schatzberg, MD,&#160;Stanford University Medical Center, Cheng-Ta Li, MD, Ph.D &#8211;&#160;Taipei Veterans General Hospital</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1505, Adult Attention-Deficit Hyperactivity Disorder (ADHD), Phase II Part 1 completed. NCE drug Principal Investigators: Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D.,&#160;University of California San Francisco (UCSF), School of Medicine. Phase II, Part 2 is expected to begin in the 1<sup>st </sup>quarter of 2022 at UCSF and 5 locations in Taiwan.The Principal Investigators are Keith McBurnett, Ph.D. and Linda Pfiffner, Ph.D.,&#160;University of California San Francisco (UCSF), School of Medicine; Susan Shur-Fen Gau, M.D., National Taiwan University Hospital; Xinzhang Ni, M.D. Linkou Chang Gung Memorial Hospital; Wenjun Xhou, M.D., Kaohsiung Chang Gung Memorial Hospital; Ton-Ping Su, M.D., Cheng Hsin General Hospital, Cheng-Ta Li, M.D., Taipei Veterans General Hospital</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott Irwin, MD, Ph.D. &#8211;&#160;Cedars Sinai Medical Center (CSMC)</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1703, Advanced Inoperable or Metastatic Pancreatic Cancer, Phase II, NCE drug Principal Investigator: Andrew E. Hendifar, MD &#8211;&#160;Cedars Sinai Medical Center (CSMC)</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following trials are expected to begin in the second quarter of 2022:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical Device: ABV-1701, Vitargus&#174; in vitrectomy surgery, Phase II Study in Australia and Thailand, Principal Investigator: Duangnate Rojanaporn, M.D., Ramathibodi Hospital; Thuss Sanguansak, M.D., Srinagarind Hospital</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug: ABV-1601, Major Depression in Cancer Patients, Phase I/II, NCE drug Principal Investigator: Scott Irwin, MD, Ph.D. &#8211;&#160;Cedars Sinai Medical Center (CSMC)</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug:
    ABV-1505, Adult Attention-Deficit Hyperactivity Disorder (ADHD), Phase II Part 2 is in progress. Principal Investigators: Keith
    McBurnett, Ph.D. and Linda Pfiffner, Ph.D.,&#160;University of California San Francisco (UCSF), School of Medicine; Susan Shur-Fen
    Gau, M.D., National Taiwan University Hospital; Xinzhang Ni, M.D. Linkou Chang Gung Memorial Hospital; Wenjun Xhou, M.D., Kaohsiung
    Chang Gung Memorial Hospital; Ton-Ping Su, M.D., Cheng Hsin General Hospital, Cheng-Ta Li, M.D., Taipei Veterans General
    Hospital</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon successful completion of a Phase II trial, ABVC will seek a partner, typically a large pharmaceutical company, to complete a Phase III study and commercialize the drug or medical device upon approval by the US FDA, Taiwan TFDA and other country regulatory authorities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>GMP Manufacturing</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC owns a certified GMP manufacturing facility, through BioKey, that is qualified to deliver small quantities of drugs for use by its clients in clinical trials from Phase I to Phase III. The GMP facility can manufacture direct API or blend fill-in capsules, manual and automated encapsulation, wet granulation or tray drying process, tablet compression and coating process, packaging solid dosage forms for ANDA and IND submission.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The BioKey facility consists of a GMP suite, product development area, analytical laboratory, food processing area, caged GMP storage area, receiving area and two warehouses. The facility was remodeled in December 2008 and received its first drug manufacturing license in June 2009. ABVC&#8217;s current drug manufacturing license allows it to manufacture drug products under IND for human clinical trials until the expiration of the license on December 2, 2024.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2022, BioKey will begin manufacturing a dietary supplement based on the maitake mushroom. The mushrooms, supplied by Shogun Maitake Canada, Co. Ltd., are grown in a controlled temperature and humid environment free of pesticides and chemicals. Initially, sales of the new supplement in the US and Canada will be targeted to high end grocery stores and worldwide via online distribution. While there are many mushroom-based supplements currently available to customers, BioKey believes its new line has a significant competitive advantage since the purity and consistency of the mushrooms themselves exceeds any maitake mushrooms currently available and the extraction process employed by BioKey delivers a particularly strong dose. The maitake mushroom is rich in bioactive polysaccharides, especially beta-glucans. These polysaccharides have well-documented immune-protecting and antitumor properties. BioKey has developed both a tablet and a liquid version of the supplement which are scheduled for commercial launch in the US and Canada in mid-2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beta-glucans in maitake mushrooms has been shown to reduce cholesterol, resulting in improved artery functionality and overall better cardiovascular health that lowers the risk of heart disease. Further, studies have shown that the beta-glucans in maitake mushroom have the effect of strengthening the immune system<sup>1</sup>. In a trial of postmenopausal breast cancer patients, oral administration of a maitake extract was shown to have immunomodulatory effects. In a different trial done at Memorial Sloan Kettering Cancer Center, maitake extracts were shown to enhance neutrophil and monocyte function in patients with myelodysplastic syndrome. It boosts production of lymphokines (protein mediators) and interleukins (secreted proteins) resulting in improved immune response.&#160;Further, beta-glucans, has been shown in clinical trials to lower blood glucose levels thereby helping to activate insulin receptors, while reducing insulin resistance in diabetes management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioKey has entered into a three-year distribution agreement with Define Biotech Co. Ltd., a Taiwan-based pharmaceutical marketing company that focuses on sales of drugs, dietary supplements and medical products in the Asia-Pacific region. The agreement grants Define Biotech the exclusive right to distribute this new dietary supplement in China and Taiwan in exchange for the commitment to purchase $3.0 million worth of the new product over the three-year period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our Pipeline</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>I.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Central Nervous System</b></span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-1504 to treat Major Depressive Disorder (&#8220;MDD&#8221;)</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. Prior to clinical trials, we conducted radioligand-binding assay tests on ABV-1504. Radioligand-binding assays are used to characterize the binding effects of a drug to its target receptor. In the case of ABV-1504, the receptors of radioligand-binding assays are norepinephrine, dopamine and serotonin. The radioligand-binding assay test on norepinephrine was conducted from May 3 to May 8, 2007 and the radioligand-binding assay test on dopamine and serotonin was administered from November 26 to December 5, 2007. The result of radioligand-binding assay to norepinephrine of ABV-1504was 2.102 &#956;g/ml of IC50, which indicated ABV-1504&#8217;s high inhibitory efficiency on norepinephrine. The results of radioligand-binding assay to dopamine and serotonin were not as good as to norepinephrine, which indicated lower inhibitory efficiency. Because research has shown that norepinephrine inhibitors can alleviate the level of depression, our research team saw ABV-1504&#8217;s potential to treat depression and decided to commence the clinical trial process of ABV-1504.&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2013, ABVC successfully completed the Phase I clinical trial of ABV-1504. The primary objective of the Phase I study was to assess the safety profile of ABV-1504. The safety endpoint was assessed based on the results of physical examinations, vital signs, laboratory data, electrocardiograms (&#8220;ECG&#8221;), Columbia-Suicide Severity Rating Scale evaluation and a number of adverse events during the study period. We began recruiting healthy people as subjects for the Phase I trial in Taiwan on October 30, 2012. For the Phase I trial, we screened 85 healthy volunteers at the Taipei Veterans General Hospital and eventually enrolled 30 people as trial subjects. We divided the subjects into four cohort groups and administered ABV-1504oral capsules of 380 mg, 1140 mg, 2280 mg, and 3800 mg to the subjects in each cohort group, respectively. BioLite visited the first subject the first time on November 13, 2012 and the last subject the last time on July 5, 2013. During the said period, no subject had a serious adverse event nor discontinued the trial due to any adverse events. ABVC did not observe any clinically significant findings in physical examinations, vital signs, electrocardiogram, laboratory measurements, and C-SSRS throughout the treatment period. However, ABVC observed the following mild adverse events: two subjects with flatulence and one subject with constipation in the single-dose 380mg cohort of seven subjects; one subject with somnolence and one subject with stomatitis ulcer in the single-dose 2,280 mg cohort. Comparatively, two subjects with somnolence and one subject with stomatitis ulcer were observed in the placebo group of seven subjects. ABVC did not observe any suicidal ideation or behavior throughout the trial period. ABV-1504&#8217;s Phase I clinical trial results reflected that the oral administration of ABV-1504 to healthy volunteers was safe and well-tolerated at the dose levels of from 380 mg to 3,800 mg.&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC received an IND approval to proceed with the Phase II clinical trial of ABV-1504 from the F.D.A. in March 2014 and an IND approval of its Phase II trial from the Taiwan F.D.A. in June 2014. For the Phase II trial, BioLite administered oral capsules to 72 MDD patients (the trial subjects) in a randomized, double-blind study with a placebo control group to assess ABV-1504&#8217;s efficacy and safety profile, primarily in accordance with the Montgomery-&#197;sberg Depression Rating Scale (&#8220;MADRS&#8221;). ABVC via BioLite began recruiting Phase II subjects in March 2015 at the following study sites, Taipei Veterans General Hospital, Linkou Chang Gung Memorial Hospital, Taipei City Hospital-Songde Branch, Tri-Service General Hospital, Wan Fang Hospital and started recruiting MDD patients at Stanford Depression Research Clinic. The first five sites are in Taiwan and the last one is in the United States. The primary endpoint of the Phase II trial is to see changes of the subjects&#8217; MADRS total scores from the baseline scores of the placebo subjects within the first six weeks. The secondary objectives of the Phase II trial are to evaluate the efficacy and safety profile of ABV-1504 on other rating scales with secondary endpoints of (i) demonstrating changes in MADRS total scores from baseline scores within the second to seventh weeks and (ii) showing changes in the total scores on Hamilton Rating Scale for Depression (HAM-D-17), Hamilton Rating Scale for Anxiety (HAM-A), Depression and Somatic Symptoms Scale (DSSS), Clinical Global Impression Scale (CGI) from the baseline scores in the second, fourth, sixth and seventh week. ABVC plans to measure the percentages of partial responders (subjects with a 25% to 50% decrease of total MADRS scores from the baseline score) and responders (subjects with 50% or more decrease of total MADRS scores from the baseline score) by the second, fourth, sixth and seventh week. Additionally, ABVC intends to monitor the subjects&#8217; performance in accordance with the Safety Assessments and Columbia-Suicide Severity Rating Scale from the screening stage to each subject&#8217;s last visit as well as to analyze the differences in the mean changes of MADRS, HAM-D-17, HAM-A, DSSS, CGI and Columbia-Suicide Severity Rating Scale scores of the subjects administered with ABV-1504 and the placebo group in the second, fourth, sixth and seventh week.</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 23, 2019, the Company announced the Phase II clinical study results of ABV-1504. The clinical study results showed that PDC-1421, the active pharmaceutical ingredient of ABV-1504, met the pre-specified primary endpoint of the Phase II clinical trial and significantly improved the symptoms of MDD. The Phase II clinical study was a randomized, double-blind, placebo-controlled, multi-center trial, in which sixty (60) adult patients with confirmed moderate to severe MDD were treated with PDC-1421 in either low dose (380 mg) or high dose (2 x 380 mg) compared with placebo administration, three times a day for six weeks. PDC-1421 high dose (2 x 380 mg) met the pre-specified primary endpoint by demonstrating a highly significant 13.2-point reduction in the Montgomery-&#197;sberg Depression Rating Scale (MADRS) total score by Intention-To-Treat (ITT) analysis, averaged over the 6-week treatment period (overall treatment effect) from baseline, as compared to 9.2-point reduction of the placebo group. By Per-Protocol (PP) analysis, PDC-1421 showed a dose dependent efficacy toward MDD in which high dose (2 x 380 mg) gave 13.4-point reduction in MADRS total score from baseline and low dose (380 mg) gave 10.4-point reduction as compared to a 8.6-point in the placebo group. Based on the trial results as set forth above, the Company has decided to use the high dose formula for ABV-1504&#8217;s Phase III clinical trial.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-1505 to treat Attention Deficit Hyperactivity Disorder (&#8220;ADHD&#8221;)</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We developed the ADHD indication from the same API of ABV-1504. Also, ABV-1505 shares similar pharmaceutical mechanism of action as ABV-1504 in as much as ABV-1505 shows the potential of increasing the level of norepinephrine in the human&#8217;s nervous system by inhibiting its reabsorption. Because of ABV-1505&#8217;s sufficient similarity with ABV-1504, in January 2016 the FDA approved our IND application to conduct ABV-1505&#8217;s Phase II clinical trial based on its preclinical research and the Phase I trial results of ABV-1504.</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the ADHD Phase II trial, ABVC plans to recruit a maximum of 105 ADHD patients as trial subjects in the United States and Taiwan, to whom ABVC intends to administer ABV-1505 oral capsules. ABVC has designed a randomized, double-blind dose escalation study with a placebo-controlled group to assess the efficacy and safety profile of ABV-1505, primarily against the ADHD Rating Scale-IV (&#8220;ADHD-RS-IV&#8221;). The primary endpoint of the Phase II trial is a 40% or higher improvement on the ADHD-RS-IV from the respective baseline scores within a period of up to eight weeks. The secondary objective is to determine the efficacy and safety profile of ABV-1505 on other rating scales with secondary endpoints of (i) improvements of the total ADHD symptom scores from the respective baseline scores on the Conners&#8217; Adult ADHD Rating Scale-Self Report: Short Version (&#8220;CAARS-S:S&#8221;) 18-Item for a treatment period of eight weeks at maximum; and (ii) achievement of scores of two or lower on both the Clinical Global Impression-ADHD- Severity (&#8220;CGI-ADHD-S&#8221;) and Clinical Global Impression-ADHD-Improvement (&#8220;CGI-ADHD-I&#8221;) from the subjects&#8217; respective baseline scores. The University of California San Francisco (&#8220;UCSF&#8221;) initiated the Phase II, Part 1 clinical trial entitled &#8220;A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD). Part I, on January 14, 2020. The Part 1 trial is a single center, open label, dose escalation evaluation with two dosage levels in six subjects. Six subjects were initially evaluated for safety and efficacy assessments at low-dose (1 capsule of PDC-1421, three times a day (TID)) for 28 days. A safety checkpoint was evaluated at day-28 for entering the high-dose (2 capsules TID). The subjects who passed the checkpoint were evaluated for safety and efficacy assessments at high-dose (2 capsules of PDC-1421 TID) for 28 days. On July 15, 2020, the last patient last visit (LPLV) marked the final step toward the completion of the ABV-1505 Phase II Part I clinical trial for the treatment of adult ADHD. On October 24, 2020, a full clinical study report (CSR) of ABV-1505 Phase II Part I clinical trial was issued. The study results showed that the PDC-1421 Capsule was safe, well tolerated and efficacious during its treatment and the follow-up period with six adult patients. For the primary endpoints, the percentages of improvement in ADHD-RS-IV score from baseline to 8 weeks treatment were 83.3% (N=5) in the ITT population and 80.0% (N=4) in the PP population. Both low and high doses of PDC-1421 Capsule met the primary end points by passing the required 40% population in ADHD-RS-IV test scores. Overall, the results from this study, which demonstrate the therapeutic value of PDC-1421, support further Phase II Part II clinical development of ABV-1505 for the treatment of adult ADHD.</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Phase II Part II study with its clinical protocol entitled &#8220;A Phase II Tolerability and Efficacy Study of PDC-1421 Treatment in Adult Patients with Attention-Deficit Hyperactivity Disorder (ADHD), Part II&#8221; is a randomized, double-blind, placebo-controlled, parallel three-groups with a maximum 99 subjects to be enrolled. This study will be conducted at the University of California, San Francisco, and five Taiwan medical centers beginning in April 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline;text-decoration: none">ABV-1601
    to treat Depression in Cancer Patients</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We developed a treatment for depression in cancer patient from the same active pharmaceutical ingredients as ABV-1504. ABV-1601 shares similar pharmaceutical mechanisms of action as ABV-1504 in that ABV-1601 shows the potential of increasing the level of norepinephrine in the human nervous system by inhibiting its reabsorption. Due to ABV-1601&#8217;s similarity with ABV-1504, the FDA approved our ABV-1601-001 clinical protocol under the same IND as for ABV-1504 (IND 112567) in December 2018.</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Phase II trial of ABV-1601, ABVC plans to recruit a maximum number of 54 cancer patients with depression, to whom ABVC intends to administer ABV-1601 oral capsules. ABVC is engaging the Principal Investigator at Cedars-Sinai Medical Center in the U.S. which designed a randomized, double-blind dose escalation study with a comparator-controlled group to assess the efficacy and safety profile of ABV-1601, primarily against Montgomery-&#197;sberg Depression Rating Scale (MADRS) total score. The primary endpoint of the Phase II trial is a change in MADRS, Hospital Anxiety and Depression Scale (HADS), subscales (HADS-A and HADS-D), and Clinical Global Impression Scale (CGI) total scores from baseline in patients taking PDC-1421 compared to the comparator. As of the date hereof, the Part I of Phase II clinical protocol, which is an open trial, has been approved by Cedars-Sinai Medical Center IRB Committee.&#160;This study was initiated in the first quarter of 2022.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>II.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Oncology</b></span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-1505 to treat Attention Deficit Hyperactivity Disorder (&#8220;ADHD&#8221;)</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC started the preparation for ABV-1702&#8217;s Phase II clinical trials after receiving its IND approval from the FDA in July 2016. ABVC plans to recruit fifty-two subjects in the United States who are diagnosed with either IPSS int-1, IPSS int-2 or high risk MDS or CMML and may take azacitidine as part of the subjects&#8217; prescription. Azacitidine is an FDA-approved drug used to treat MDS. ABVC intends to administer ABV-1702 in the oral liquid form along with azacitidine. The Phase II trial is divided into two parts, where Part 1 is to determine the safety and recommended dose level (&#8220;RDL&#8221;) of ABV-1702 in combination with azacitidine and Part 2 is to determine whether ABV-1702 under the established RDL reduces bactericidal and fungicidal infection in the subjects&#8217; respiratory systems. The primary endpoint of Part 1 Phase II trial is to assess the safety and RDL profile of ABV-1702 administered with azacitidine by measuring ABV-1702&#8217;s prohibited toxicity. The secondary endpoints of Phase II Part 1 are to determine the safety, time-to-first infection after first dose (Day 1) of the first azacitidine treatment cycle, reduction in treatment requirements and duration of infections, enhancement of immune responses, improvements of response rates, progression, and survival rates of the subjects under such ABV-1702 - azacitidine combination treatment. The primary endpoint of Part 2 of Phase II is to determine whether ABV-1702 under the established RDL reduces bactericidal and fungicidal infection risks in the subjects&#8217; respiratory systems in combination with azacitidine as compared to the control group with incidence of infections and incidence/frequency of inpatient hospitalization due to infections. The secondary endpoints of Part 2 of Phase II are to determine the safety, time-to-first infection after first dose (Day 1) of the first azacitidine treatment cycle, reduction in required dosage and duration of infection, enhancement of immune responses, improvement of response rate, progression, and survival rates of the subjects under the trial conditions. In April 2016, BioLite submitted a letter to the FDA in response to its queries with additional information about the proposed Phase II trial.&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company expects to begin Phase II clinical trials of ABV-1702 in the fourth quarter of 2022 and is actively looking for qualified principal investigators and an appropriate site for the study and therefore the timing cannot be guaranteed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-1505 to treat Attention Deficit Hyperactivity Disorder (&#8220;ADHD&#8221;)</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC developed a new indication for Pancreatic Cancer from Maitake Extract, which is named as ABV-1703 and out licensed it to Rgene for the preparation of its IND application with the FDA. On August 25, 2017, ABV-1703&#8217;s Phase II trial was approved by FDA. Pursuant to the ABVC-Rgene Co-development Agreement, ABVC is responsible for coordinating and conducting the clinical trials of ABV-1703 globally and Rgene is responsible for preparing the related FDA applications. As of the date hereof, we are engaging Cedars-Sinai Medical Center in the U.S. to conduct the Phase II clinical trial and plan to initiate the Phase II trial in the third quarter of 2022. We plan to submit ABV-1703&#8217;s Phase II clinical trial IND to the Taiwan FDA after we commence the clinical trials in the United States.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV- 1501 Triple Negative Breast Cancer - Combination therapy for Triple Negative Breast Cancer (&#8220;TNBC&#8221;)</span></span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABV- 1501 is developed from BLI-1401-2 whose active pharmaceutical ingredient is Yukiguni Maitake Extract 404. Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;) conducted the Phase I clinical trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom), which is very similar to Yukiguni Maitake Extract 404. The Phase I trial focused on Grifola frondosa extract&#8217;s immunological effects on breast cancer patients. The results of the Phase I trial showed that oral administration of a polysaccharide extract from Maitake mushroom is associated with both immunologically stimulatory and inhibitory measurable effects in peripheral blood. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our ABV-1501 Investigational New Drug (&#8220;IND&#8221;) application to the US FDA for the Phase II clinical trials referencing the MSKCC maitake research resulted in a Phase II IND approval in March of 2016 by the U.S. FDA.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently collaborating with BHK to file clinical trial application to the Taiwan FDA (&#8220;TFDA&#8221;) for conducting this combination
therapy trial in Taiwan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As an alternative route to Taiwan FDA approval, we are also working towards setting up a clinical site in the U.S. to obtain IRB approval of our IND application, which based on a recent adopted policy in Taiwan, the TFDA will then automatically approve. </span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our Collaborative Agreements</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">ABV-1701 Vitreous Substitute for Vitrectomy and Collaboration Agreement with BioFirst</span></span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2017, BriVision, one of our wholly-owned subsidiaries entered into a collaboration agreement (the &#8220;BioFirst Agreement&#8221;) with BioFirst, pursuant to which BioFirst granted BriVision the global license to co-develop BFC-1401 Vitreous Substitute for Vitrectomy (&#8220;BFC-1401&#8221;) for medical purposes. BioFirst is a related party to the Company because BioFirst and YuanGene Corporation (&#8220;YuanGene&#8221;), the Company&#8217;s controlling shareholder, are under common control, being both controlled by the controlling beneficiary shareholder of YuanGene.</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the BioFirst Agreement, we are to co-develop and commercialize BFC-1401 or ABV-1701 with BioFirst and are obligated to pay BioFirst $3,000,000 (the &#8220;Total Payment&#8221;) in cash or common stock of BriVision on or before September 30, 2018 in two installments. An upfront payment of $300,000, representing 10% of the Total Payment due under the Collaboration Agreement, was to be paid upon execution of the BioFirst Agreement. BriVision is entitled to receive 50% of the future net licensing income or net sales profit when ABV-1701 is sublicensed or commercialized. On June 30, 2019, the Company and BioFirst entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;), pursuant to which the Company will issue 428,571 shares of the Company&#8217;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst in connection with the BioFirst Collaborative Agreement. For more information about the BioFirst Agreement and Purchase Agreement, please refer to the current reports on Form 8-K filed on July 24, 2017 and July 12, 2019.</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 7, 2016, the application of Phase I clinical trial prepared and submitted by BioFirst was approved by the Human Research Ethics Committee, Australia (&#8220;HREC&#8221;), and on November 14, 2016, it was approved by the Therapeutic Goods Administration, Australia (&#8220;TGA&#8221;).</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We successfully finished the Phase I clinical trial of ABV-1701 at Sydney Retina Clinic and Day Surgery, a clinic located in Sydney, Australia. This was the only site for this Phase I clinical trial. The trial started on November 17, 2016, and was completed with positive results in July 2018. The Protocol Title is &#8220;A Phase I, single center, safety and tolerability study of Vitargus in the treatment of Retinal Detachment.&#8221;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The primary endpoint of this Phase I clinical trial was to evaluate the safety and tolerability of a single intravitreal dose of Vitargus in patients as a vitreous substitute during vitrectomy surgery for retinal detachment. Intravitreal is a route of administration of a drug or other substance, in which the substance is delivered into the eyes. The secondary endpoint of this Phase I clinical trial is to assess retinal attachment and Virtagus degradation at day 90 and to assess best corrected visual acuity (&#8220;BVCA&#8221;) after vitrectomy surgery. BVCA refers to the best possible vision a person can achieve. The primary and second endpoints are required by HREC for the purpose of evaluation of our Phase I clinical trial application. We enrolled an aggregate number of 10 patient subjects in this trial. On November 17, 2016, we received the approval from the Data and Safety Monitoring Board for the first subject, and nine more subjects were enrolled thereafter. In this trial, Vitargus was injected into the vitreous cavity of vitrectomised eyes, whose vitreous gel was removed from the vitreous cavity after a vitrectomy surgery. On August 24, 2020, a full clinical study report (CSR) of ABV-1701 Phase I clinical trial was issued. The study results showed that ABV-1701 (Vitargus) was well-tolerated as a vitreous substitute without any apparent toxicity to ocular tissues. Further, there was no indication of an increased overall safety risk with Vitargus. For efficacy, participants showed significant improvement in visual acuity. The optical properties of Vitargus allowed the patients to see well and facilitated visualisation of the fundus immediately following surgery. In addition, since Vitargus set as a stable semisolid gel adhering to the retina, it maintained its position without requiring the patient to remain face-down following surgery.</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are currently planning the pivotal study for ABV-1701 and the necessary step to obtain the Premarket Approval for this medical device. The pivotal study for ABV-1701 is designed to be a multi-nation and multi-site clinical trial involving several countries, including Australia, the U.S.A., Japan, Thailand, Taiwan, and the People&#8217;s Republic of China. The pivotal study will be initiated in Australia in the third quarter of 2021.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>II. Co-development Agreement with Rgene</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 26, 2017, American BriVision Corporation entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company. Pursuant to Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-17 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision&#8217;s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to the $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both BriVision and Rgene.</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By June 1, 2017, the Company had delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended September 30, 2017. During the year ended December 31, 2017, the Company received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully write off this investment based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene&#8217;s ability to remain in business. All projects that have been initiated will be managed and supported by the Company and Rgene.</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and Rgene signed an amendment to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions of the Co-Dev Agreement remain in full force and effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market Distribution Strategy</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We focus primarily on developing botanical drugs, which are intended for use in the diagnosis, cure, mitigation or treatment of disease in humans. Together with our strategic partners, we plan to market, distribute and sell our drug products internationally once those drug candidates comply with the local authorities regulating drugs and foods. Currently, many countries follow the International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (the &#8220;ICH&#8221;) guidelines that are published by European Medicines to provide guidance on quality and safety of pharmaceutical development and new drug commercialization in Japan, the United States and Europe. All of our drug candidates first go through the United States FDA process for new drug development first and then seek regulatory approval from regulators equivalent to the FDA in the jurisdictions where we plan to distribute those candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The new drug candidates are dependent on or are the subject of the following patents and patent applications.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent <br/> Starting <br/> Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent <br/> Expiration<br/> Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 30%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Territory</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent<br/> Owner<sup>(1)(2)</sup></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6911222</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/28/2005</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract, Part 1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7175861</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/13/2007</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract, Part 2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7179496</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/20/2007</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract, Part 3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7223425</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/29/2007</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract, Part 4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0001337647</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/31/2007</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Italy</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>

  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CH693499</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;9/15/2003</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Switzerland</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10220149</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;4/26/2007</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GB2383951</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;6/7/2006</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">United Kingdom</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4109907</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/6/2002</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/5/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FR2834643</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;7/18/2003</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I295576</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/11/2008</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/10/2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-depression Pharmaceutical Composition Containing Polygala Extract</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DE202007003503 U1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/23/2007</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/20/2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel Polygalatenosides and use thereof as an antidepressant agent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Germany</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7531519</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5/12/2009</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/20/2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel Polygalatenosides and use thereof as an antidepressant agent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4620652</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/20/2006</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11/19/2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel Polygalatenosides and use thereof as an antidepressant agent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I 314453</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/21/2006</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/20/2026</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel Polygalatenosides and use thereof as an antidepressant agent</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MPITDC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I389713</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/21/2013</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/13/2030</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute <b><sup>(3)</sup></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI</span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">17</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">granted</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">US 8197849 B2</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">6/12/2012</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">8/30/2030</span></td>
    <td>&#160;</td>
    <td style="text-align: center; font-size: 10pt; vertical-align: top"><span style="font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">The U.S.</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-size: 10pt">NHRI</span></td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU 2011/215775 B2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/17/2014</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/9/2031</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR 10-1428898</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/4/2014</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/9/2031</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Korea</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA 2786911 (C)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/6/2015</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/10/2031</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WO2011100469 A1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A<sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A<sup>(4)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PCT</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP 2534200</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/8/2015</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/9/2031</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">European Union (Germany, United Kingdom, France, Switzerland, Spain, Italy)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#29305;&#35377;&#31532;
    5885349&#34399;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/9/2011</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/9/2031</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZL 201180005494.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/24/2014</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/9/2031</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute<b><sup>(3)</sup></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK1178188</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/6/2015</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/21/2030</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-linked oxidized hyaluronic acid for use as a vitreous substitute<b><sup>(3)</sup></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong Kong<sup>&#160;(5)&#160;</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">26</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US 16/936,032</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2020 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;9/4/2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polygala extract for the treatment of major depressive disorder</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TW 109130285</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/4/2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polygala extract for the treatment of major depressive disorder</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US17/120,965</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/20/2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/20/2040</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polygala Extract for the Treatment of Attention Deficit Hyperactive Disorder</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TW 110106546</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/24/2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/24/2041</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Polygala Extract for the Treatment of Attention Deficit Hyperactive Disorder</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taiwan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;MPITDC&#8221; stands for Medical and Pharmaceutical Industry Technology and Development Center, Taiwan.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8220;NHRI&#8221; stands for National Health Research Institutes, Taiwan.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The patent name is translated into English and the original patent name is written as &#8220;&#20132;&#32852;&#27687;&#21270;&#36879;&#26126;&#36136;&#37240;&#20316;&#20026;&#30524;&#29699;&#29627;&#29827;&#20307;&#20043;&#26367;&#20195;&#29289;.&#8221;</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The starting date and expiration date of patents under PTC are subject to the laws of the specific participating jurisdiction where the patent application is filed. We have subsequently submitted such patent to the jurisdictions listed in No.22 herein above.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NHRI has obtained standard patent in Hong Kong based on the registration of the patent (listed as No.24 herein) granted by the State Intellectual Property Office, People&#8217;s Republic of China.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporate History and Structure</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC was incorporated under the laws of the State of Nevada on February 6, 2002 and has three wholly-owned Subsidiaries: BriVision, BioLite Holding, Inc. and BioKey, Inc. BriVision was incorporated in July 2015 in the State of Delaware and is in the business of developing pharmaceutical products in North America.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Holding was incorporated under the laws of the State of Nevada on July 27, 2016, with 500,000,000 shares authorized, par value $0.0001. Its key Subsidiaries include BioLite BVI, Inc. (&#8220;BioLite BVI&#8221;) that was incorporated in the British Virgin Islands on September 13, 2016 and BioLite Inc. (&#8220;BioLite Taiwan&#8221;), a Taiwanese corporation that was founded in February 2006. BioLite Taiwan has been in the business of developing new drugs for over twelve years. Certain shareholders of BioLite Taiwan exchanged approximately 73% of equity securities in BioLite Taiwan for the Common Stock in BioLite Holding in accordance with a share purchase/ exchange agreement (the &#8220;Share Purchase/ Exchange Agreement&#8221;). As a result, BioLite Holding owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated in California on November 20, 2000, BioKey has chosen to initially focus on developing generic drugs to ride the opportunity of the booming industry.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon closing of the Mergers on February 8, 2019, BioLite and BioKey became two wholly-owned subsidiaries of ABVC.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following chart illustrates the corporate structure of ABVC:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><img alt="" src="img_002.jpg" style="height: 254px; width: 550px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective March 5, 2022, the Company&#8217;s Board for Directors approved amending the Company&#8217;s Bylaws to remove Section 2.8, which permitted cumulative voting for directors since cumulative voting is specifically prohibited by our Articles of Incorporation. Since it is not otherwise stated in our Articles of Incorporation or Bylaws, directors shall be elected by a plurality of the votes cast at the election, as provided in the Nevada Revised Statutes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The healthcare industry is highly competitive and subject to significant and rapid technological change as researchers learn more about diseases and develop new technologies and treatments. Significant competitive factors in our industry include product efficacy and safety; quality and breadth of an organization&#8217;s technology; skill of an organization&#8217;s employees and its ability to recruit and retain key employees; timing and scope of regulatory approvals; the average selling price of products; the availability of raw materials and qualified manufacturing capacity; manufacturing costs; intellectual property and patent rights and their protection; and our capabilities of securing competent collaborators. Market acceptance of our current products and product candidates will depend on a number of factors, including: (i) potential advantages over existing or alternative therapies or tests, (ii) the actual or perceived safety of similar classes of products, (iii) the effectiveness of sales, marketing, and distribution capabilities, and (iv) the scope of any approval provided by the FDA or foreign regulatory authorities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since we are a small biopharmaceutical company compared to other companies that we may compete against, it is our intention to license our products to much larger pharmaceutical, specialty pharmaceutical and generic drug companies with the financial, technical and human resources to compete effectively in the markets we address.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We anticipate that our license partners will face intense and increasing competition when and as our new drug candidates enter the markets, as advanced technologies become available and as generic forms of currently branded products become available. Finally, the development of new treatment methods for the diseases we are targeting could render our products non-competitive or obsolete. There can be no assurance that any of our new drug candidates will be clinically superior or scientifically preferable to products developed or introduced by our competitors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following chart lists some, not all, of the biopharmaceutical companies that research, develop, commercialize, distribute or sell drugs that are in competition with our drug candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 29%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disease</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Drug Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pharmaceutical <br/> Companies</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Headquarters</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Major Depressive Disorder</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cymbalta oral</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eli Lilly and Co., Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lexapro oral</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forest Laboratories, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NJ</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pfizer Pharmaceuticals, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CT</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Attention-Deficit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adderall XR</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shire Development LLC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MA</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Hyperactivity Disease</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ritalin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novartis Pharmaceuticals Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NJ</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dexedrine</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">
        <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amedra Pharmaceuticals
LLC</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PA</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Myelodysplastic</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vidaza</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Celgene Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NJ</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Syndromes</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dacogen</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Astex Pharmaceuticals, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Triple Negative Breast Cancer</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avastin</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genentech, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Erbitux (Cetuximab)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ImClone Systems Incorporated</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NY</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pancreatic Cancer</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abraxane, Abraxis BioScience LLC</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Los Angeles</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novartis Pharma Stein AG</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stein</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Switzerland</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vitargus for the treatments</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alcon Laboratories, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fort Worth</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TX</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom">
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of Retinal Detachment or</b></span></p>
        <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Vitreous Hemorrhage</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arcadophta</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Toulouse</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">France</span></td></tr>
  </table><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>



</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government Regulations</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently, we are focusing on the research and development of six therapeutic candidates in the fields of CNS, oncology/hematology and autoimmune, for which regulatory approval must be received before we can commence marketing. In addition, our cGMP facility is subject to review by the FDA. Regulatory approval processes and FDA regulations for ABVC&#8217;s current and any future product candidates are discussed below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Approval Process for Pharmaceutical Products</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>FDA Approval Process for Pharmaceutical Products</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the U.S., pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act (the &#8220;FDC Act&#8221;), and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending NDAs, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. Pharmaceutical product development in the U.S. typically involves the performance of satisfactory nonclinical, also referred to as pre-clinical, laboratory and animal studies under the FDA&#8217;s Good Laboratory Practice, or GLP, regulation, the development and demonstration of manufacturing processes, which conform to FDA mandated current good manufacturing requirements, or cGMPs, including a quality system regulating manufacturing, the submission and acceptance of an IND application, which must become effective before human clinical trials may begin in the U.S., obtaining the approval of Institutional Review Boards, or IRBs, at each site where we plan to conduct a clinical trial to protect the welfare and rights of human subjects in clinical trials, adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought, and the submission to the FDA for review and approval of an NDA. Satisfaction of FDA requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-clinical tests generally include laboratory evaluation of a product candidate, its chemistry, formulation, stability and toxicity, as well as certain animal studies to assess its potential safety and efficacy. Results of these pre-clinical tests, together with chemistry, manufacturing controls and analytical data and the clinical trial protocol, which details the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, along with other requirements must be submitted to the FDA as part of an IND, which must become effective before human clinical trials can begin. The entire clinical trial and its protocol must be in compliance with what are referred to as good clinical practice, or GCP, requirements. The term, GCP, is used to refer to various FDA laws and regulations, as well as international scientific standards intended to protect the rights, health and safety of patients, define the roles of clinical trial sponsors and assure the integrity of clinical trial data.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the intended conduct of the trials and imposes what is referred to as a clinical hold. Pre-clinical studies generally take several years to complete, and there is no guarantee that an IND based on those studies will become effective, allowing clinical testing to begin. In addition to FDA review of an IND, each medical site that desires to participate in a proposed clinical trial must have the protocol reviewed and approved by an independent IRB or Ethics Committee, or EC. The IRB considers, among other things, ethical factors, and the selection and safety of human subjects. Clinical trials must be conducted in accordance with the FDA&#8217;s GCP requirements. The FDA and/or IRB may order the temporary, or permanent, discontinuation of a clinical trial or that a specific clinical trial site be halted at any time, or impose other sanctions for failure to comply with requirements under the appropriate entity jurisdiction.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In Phase I clinical trials, a product candidate is typically introduced either into healthy human subjects or patients with the medical condition for which the new drug is intended to be used. The main purpose of the trial is to assess a product candidate&#8217;s safety and the ability of the human body to tolerate the product candidate. Phase I clinical trials generally include less than 50 subjects or patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During Phase 2 trials, a product candidate is studied in an exploratory trial or trials in a limited number of patients with the disease or medical condition for which it is intended to be used in order to: (i) further identify any possible adverse side effects and safety risks, (ii) assess the preliminary or potential efficacy of the product candidate for specific target diseases or medical conditions, and (iii) assess dosage tolerance and determine the optimal dose for Phase III trials.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phase III trials are generally undertaken to demonstrate clinical efficacy and to further test for safety in an expanded patient population with the goal of evaluating the overall risk-benefit relationship of the product candidate. Phase III trials are generally designed to reach a specific goal or endpoint, the achievement of which is intended to demonstrate the candidate product&#8217;s clinical efficacy and adequate information for labeling of the approved drug.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the FDA&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs. Most applications for standard review drug products are reviewed within ten months; most applications for priority review drugs are reviewed within six months. Priority review can be applied to drugs that the FDA determines offer major advances in treatment, or provide a treatment where no adequate therapy exists. The review process for both standard and priority review may be extended by the FDA for three additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA may also refer applications for novel drug products, or drug products which present difficult questions of safety or efficacy, to an advisory committee&#160;&#8212;&#160;typically a panel that includes clinicians and other experts&#160;&#8212;&#160;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with cGMPs is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug outweigh the potential risks.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#8217;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Post-Approval Regulations</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if a product candidate receives regulatory approval, the approval is typically limited to specific clinical indications. Further, even after regulatory approval is obtained, subsequent discovery of previously unknown problems with a product may result in restrictions on its use or even complete withdrawal of the product from the market. Any FDA-approved products manufactured or distributed by us are subject to continuing regulation by the FDA, including record-keeping requirements and reporting of adverse events or experiences. Further, drug manufacturers and their subcontractors are required to register their establishments with the FDA and state agencies, and are subject to periodic inspections by the FDA and state agencies for compliance with cGMPs, which impose rigorous procedural and documentation requirements upon us and our contract manufacturers. ABVC cannot be certain that ABVC or its present or future contract manufacturers or suppliers will be able to comply with cGMPs regulations and other FDA regulatory requirements. Failure to comply with these requirements may result in, among other things, total or partial suspension of production activities, failure of the FDA to grant approval for marketing, and withdrawal, suspension, or revocation of marketing approvals.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the FDA approves one or more of our product candidates, ABVC must provide certain updated safety and efficacy information. Product changes, as well as certain changes in the manufacturing process or facilities where the manufacturing occurs or other post-approval changes may necessitate additional FDA review and approval. The labeling, advertising, promotion, marketing and distribution of a drug must be in compliance with FDA and Federal Trade Commission, or FTC, requirements which include, among others, standards and regulations for direct-to-consumer advertising, off-label promotion, industry sponsored scientific and educational activities, and promotional activities involving the Internet. The FDA and FTC have very broad enforcement authority, and failure to abide by these regulations can result in penalties, including the issuance of a warning letter directing us to correct deviations from regulatory standards and enforcement actions that can include seizures, fines, injunctions and criminal prosecution.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Foreign Regulatory Approval</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside of the U.S., ABVC&#8217;s ability to market our product candidates will be contingent also upon its receiving marketing authorizations from the appropriate foreign regulatory authorities, whether or not FDA approval has been obtained. The foreign regulatory approval process in most industrialized countries generally encompasses risks similar to those ABVC will encounter in the FDA approval process. The requirements governing conduct of clinical trials and marketing authorizations, and the time required to obtain requisite approvals, may vary widely from country to country and differ from those required for FDA approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC will be subject to additional regulations in other countries in which we market, sell and import our products, including Canada. ABVC or its distributors must receive all necessary approvals or clearance prior to marketing and/or importing our products in those markets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other Regulatory Matters</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing, sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the U.S., the Centers for Medicare &amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp;Health Administration, the Environmental Protection Agency and state and local governments. In the U.S., sales, marketing and scientific/educational programs must also comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Health Care Reform Law, as amended by the Health Care and Education Affordability Reconciliation Act, or ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive recordkeeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines, imprisonment or other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information regarding the safety or effectiveness of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date of this prospectus, ABVC, including its Subsidiaries, had 30 employees, located in the U.S. and Taiwan. The following table sets forth the number of our employees by function:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Functional Area</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Employees</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 88%; text-align: left">Senior management</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">5</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Research and development</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">12</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Public relations</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sales and Marketing</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Administration</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Accounting</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">6</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">30</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC believes that it maintains a good working relationship with its employees. ABVC offers its employees competitive benefits, including a pleasant and rewarding work environment, career-oriented training, and career growth opportunities. ABVC believes its employees are devoted to delivering superb services. ABVC did not experience any significant labor disputes.<b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal Proceedings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time ABVC and its Subsidiaries may become involved in legal proceedings and claims, or be threatened with other legal actions and claims, arising in the ordinary course of business relating to its intellectual property, product liability, regulatory compliance and/or marketing and advertising of its products. As of the date of this prospectus, ABVC and its Subsidiaries were not involved or threatened with any legal actions and regulatory proceedings.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environment</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC seeks to comply with all applicable statutory and administrative requirements concerning environmental quality. Expenditures for compliance with federal state and local environmental laws have not had, and are not expected to have, a material effect on ABVC&#8217;s capital expenditures, results of operations or competitive position.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Properties </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Subsidiary BioLite has its laboratories located in Hsinchu Biomedical Science Park, with an address of 20, Sec. 2, Shengyi Rd., 2nd Floor, Zhubei City, Hsinchu County 302, Taiwan (R.O.C.). On January 1, 2015, BioLite Taiwan entered into a lease agreement with the National Science Park Administrative Office (Hsinchu City) under which it rents two dormitory buildings in Hsinchu County, Taiwan for a period of five years. The aggregate leasing area amounts to approximately 678 square meters (equivalent to approximately 7,298 square feet) on the second floor of the building. The leased space counts for approximately 1.9% of the total space of the building. On January 1, 2020, BioLite Taiwan extended the contract for another five years. The new expiration date is on December 31, 2024. The rent increases by a small percentage each year during the term of the lease agreement. BioLite paid $60,296 and $64,506 in rental expense for the laboratory space for the years ended December 31, 2021 and 2020, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Another subsidiary BioKey is headquartered in Fremont, California. BioKey&#8217;s office lease will end on February 28, 2026 and the office occupies approximately 28,186 square feet. BioKey&#8217;s space consists of offices, research and production laboratories, and manufacturing facilities, which are GMP certified. BioKey has an option to extend the lease for its offices in Fremont for a period of five years commencing February 28, 2026, and BioKey may exercise this option for 5 more years. The total BioKey&#8217;s rental expenses were $331,482 and $403,776 for the years ended December 31, 2021 and 2020, respectively.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MANAGEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table lists the names, ages and
positions as of the date of the prospectus. At the Company&#8217;s recent annual shareholder meeting, Che Wei Hsu, Shuling Jiang and Kunag-Tseng
Chen were elected to our Board:</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang</span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="width: 59%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chihliang An</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer (&#8220;CFO&#8221;)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Tsang Ming Jiang</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">61</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Che Wei Hsu</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Norimi Sakamoto</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yen-Hsin Chou</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">33</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Tsung-Shann (T.S.) Jiang</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Strategy Officer (&#8220;CSTRO&#8221;) and Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Chang-Jen Jiang</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hsin-Hui Miao</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">55</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoshinobu Odaira</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuling Jiang</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kuang-Tseng Chen</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Howard Doong</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer (&#8220;CEO&#8221;)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Chi-Hsin (Richard) King</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer (&#8220;CSO&#8221;)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set forth below is certain biographical information regarding each of our directors and executive officers as of the date of this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Eugene Jiang, Chairman,</b>&#160;served as our CEO and President from the Company&#8217;s inception in July 2015 until he resigned on September 15, 2017. He remains the Chairman of the Board and the COB of the Company. Mr. Jiang also serves as our Chief Business Officer. From June 2015 until present, Mr. Jiang also serves as Director for&#160;BioLite&#160;Incorporation. He also serves as&#160;CEO for&#160;Genepro&#160;Investment Company since March 2010.&#160;Mr.&#160;Jiang obtained an EMBA degree from the University of&#160;Texas&#160;in Arrington in 2009 and in 2008, Mr. Jiang received a bachelor&#8217;s degree in Physical Education from Fu-Jen Catholic University.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr. Howard Doong, Ph. D. and M.D., CEO,</b>&#160;was appointed as the Company&#8217;s new CEO on September 15, 2017. In addition to the position at the Company, Dr. Doong also serves as the Chairman and the CEO of LifeCode Biotechnology Company (&#8220;LifeCode&#8221;), a Taiwan company in the biotechnology business, since 2017. At the same time, he also serves as the CSO of Wuhan Frasergen Genomic Medicine Company (&#8220;Wuhan Frasergen Genomic&#8221;), a Chinese company in the biotechnology business, since 2016. He served as the CSO of Cold Spring Biotech Corporation, a Taiwan corporation in the biotechnology business from 2014 to 2016. He served as the CEO of iKnowledge-Care Bioscience Corp, a Taiwan company in the biotechnology business from 2014 to 2015. He served as the director of Taipei Veteran General Hospital-LihPao Laboratory of Cancer Genomic Medicine from 2012 to 2013. He served as the Vice President and director of Quality Assurance, TrimGen Corporation, a Maryland corporation in the biotechnology business from 2006 to 2011. Before 2006, Dr. Doong was a professor at the University of Maryland School of Medicine and Biotechnology Institute, and a researcher at National Cancer Institute (NCI) of the National Institutes of Health (NIH). Dr. Doong received his Ph.D. degree from University of Chicago, the Department of Organismal Biology and Anatomy and the Department of Surgery. He received his M.D and Ph.D. degree from Harvard-MIT Division of Health Sciences and Technology. He received his M.S. degree from the University of New Hampshire, Genetics Program and B.S. degree from Fu-Jen Catholic University, Taiwan, Department of Biology.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Mr. Chihliang An, </b>38 years old, was the Managing Director of Investment Team at Yinyai Investment (Hong Kong) since September 2018 to June 2019. Prior to that, Mr. An served as a Senior Director of Sales and Operations at Goertek (USA) from March 2017 to August 2018 and a Director of Finance at BioKey, Inc., which is a wholly-owned subsidiary of the Company now, from March 2015 to February 2017. Mr. Chihliang An received a Bachelor of Art degree in Statistics from Tamkang University in Taiwan in 2003 and an MBA in Finance from University of Kentucky in 2007.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr. Chi-Hsin Richard King, CSO. </b>Effective September 15, 2017, the Board appointed Dr. Chi-Hsin Richard King as the CSO of the Company. Dr. Chi-Hsin Richard King, 69, retired since July 2017. He served as the consultant at TaiGen Biotechnology Co. Ltd (&#8220;TaiGen&#8221;), a Taiwan company in the biotechnology business, from August 2016 to July 2017, the Senior Vice President at TaiGen from July 2008 to August 2016 and as the Vice President at Research and Development of TaiGen from June 2005 to July 2008. Dr. King served as the Director at Albany Molecular Research Inc. (&#8220;AMRI&#8221;), a New York corporation, from January 2003 to June 2005, the Assistant Director at Medicinal Chemistry Department of AMRI from January 2000 to December 2002 and the Assistant Director at Chemical Development Department of AMRI from August 1997 to January 2000. Dr. King received the Ph. D. degree of organic chemistry from University of Utah in March 1980, and B.S. degree of chemistry from National Taiwan Normal University in July 1972.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr. T.S. Jiang, Chief Strategy Officer and Director,</b>&#160;was appointed as the Company&#8217;s Chief Strategy Officer on and elected as a director on our Board of Directors on February 8, 2019, the closing date of the Mergers. He has been the chairman of BioLite, Inc., a subsidiary of BioLite, Inc., since January 2010. Prior to BioLite, Dr. Jiang served as the president and/or chairman of multiple biotech companies in Taiwan, including PhytoHealth Corporation from 1998 to 2009 and AmCad BioMed Corporation from 2008 to 2009. In addition, Dr. Jiang is a director on various biotech associations, such as the Taiwan Bio Industry Organization (Taiwan) from 2006 to 2008 and the Chinese Herbs and Biotech Development Association in Taiwan from 2003 to 2006. Dr. Jiang was an assistant professor at University of Illinois from 1981 to 1987 and an associate professor at Rutgers, the State University of New Jersey from 1987 to 1990 and served as a professor at a few Taiwanese universities during a period from 1990 to 1993, such as National Taiwan University, National Cheng Kung University and Tunghai University. Dr. Jiang obtained his bachelor degree in Engineering and Chemical Engineering from National Taiwan University in Taiwan in 1976, masters and Ph.D. from Northwestern University in the U.S. in 1981 and Executive Master of Business Administration (&#8220;EMBA&#8221;) from National Taiwan University in Taiwan in 2007. As a successful entrepreneur, Dr. Jiang has developed and commercialized PG2 Lyo Injection, a new drug to treat cancer related fatigue. From 1998 to 2009, Dr. T. S. Jiang served as President of Phyto Health Corporation where he led a project team to develop PG2 Injectable. This product was extracted, isolated and purified from a type of Traditional Chinese Medicine. PG2 Injection was intended for cancer patients who had trouble recovering from severe fatigue. Dr. Jiang oversaw and managed the R&amp;D department, daily corporate operations and business of Phyto Health Corporation when he was the President. PG2 Lyo Injection received approval on its NDA from Taiwan Food and Drug Administration in 2010 and later was launched into the Taiwan market in 2012. We believe that Dr. Jiang provides leadership and technological guidance on our strategic development and operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr. Tsang Ming Jiang, Director</b>, was elected as a director on our Board of Directors on November 23, 2017. He has served as a technical director at the Industrial Technology Research Institute in Taiwan since January 2017. Prior to joining the Industrial Technology Research Institute as a technical director, Dr. Jiang worked at the Company as chief information officer from November 2016 to January 2017, Ericsson as engineering manager from 2013 to 2016 and the Industrial Technology Research Institute as deputy director from October 2011 to February 2013. In addition, Dr. Jiang worked at several other research institutes, including University of Alaska Fairbanks, National Taiwan University and Chung Cheng University, with his research interest in cloud computing and Internet security, especially in the areas of virtualization, software-defined data centers, SDN enabled networks and big data analytics. Dr. Jiang received his Bachelor of Science in electrical engineering in 1982 and Master of Science in electrical engineering in 1984, both from National Taiwan University, and his Ph.D. in electrical engineering and computer science from University of Illinois at Chicago in 1988. Dr. Tsang Ming Jiang is a brother of Dr. Tsung-Shann Jiang, who together with his wife collectively owns 80% of Lion Arts Promotion, Inc. which has approximately 69.3% of ownership interest in the Company through YuanGene Corporation, a wholly-owned subsidiary of Lion Arts Promotion, Inc.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Norimi Sakamoto, Director</b>, was elected
as a director on our Board of Directors on November 23, 2017. She currently serves with Shogun Maitake Canada Co., Ltd. as an executive
officer and business development manager from 2015, with Shogun Maitake Odaira Enterprise Ltd as an executive officer from 2017, with
Odaira Corporation Co., Ltd. as chief executive officer since 2014 and with MyLife Corporation as president and chief executive officer
since 2012. Ms. Sakamoto started her career in 1997 with Sumitomo Corporation Hokkaido Co., Ltd. in Japan. Ms. Sakamoto received her Bachelor
Degree of Arts in travel and tourism from Davis and Elkins College in 1993 and Master of Science in urban studies from the University
of New Orleans in 1995.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Yen-Hsin Chou, Director</b>, was elected as
a director on our Board of Directors on November 23, 2017. She has served as a clerk at Mega Securities Co., Ltd. since 2011. Ms. Chou&#8217;s
responsibilities primarily include selling various types of securities, including futures, funds and insurance, managing clients&#8217;
accounts and business development. Ms. Chou received a Bachelor Degree from Yuan Chi University School of Economics in 2011.&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr. Chang-Jen Jiang, Director,</b>&#160;was elected as a director on our Board of Directors on November 23, 2017. He has been an attending doctor at the department of pediatrics of Eugene Women and Children Clinic since 2008. Previously, Dr. Chang-Jen worked as an attending doctor at the department of pediatrics of Keelung Hospital, the Ministry of Health and Welfare in Taiwan from 1994 to 2008. Before his position at Keelung Hospital, he was a chief doctor at the department of pediatrics, hematology and oncology of Mackay Memorial Hospital in Taiwan for three years until 1994. Dr. Chang-Jen Jiang obtained his doctor of medicine degree (the Taiwanese equivalent degree of MD) from Taipei Medical University in Taiwan in 1982 and started his career in Mackay Memorial Hospital. We believe that the Company will benefit from Dr. Jiang&#8217;s knowledge in biology and experiences in medical practice.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Hsin-Hui Miao, Director,</b>&#160;was employed
by Yueh Shan Chi Cram School from Aug 2021 to May 2022; and was a teacher in a kindergarten division of Tunghai University from Aug 1988
to July 2021. Ms. Miao received a Bachelor of Education Degree from the Taichung University of Education in 1998.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Yoshinobu Odaira, Director,</b>&#160;was elected as a director on our Board of Directors on February 8, 2019. He is an entrepreneur and has founded a number of Japanese agricultural companies, including Yukiguni Maitake, our licensing partner. In 1983, Mr. Odaira established Yukiguni Maitake, which became a public company in Japan in 1994. In 2015, Bain Capital Private Equity purchased Yukiguni Maitake through a tender offer. In addition to his success with Yukiguni Maitake, Mr. Odaira served as the CEO of Yukiguni Shoji Co., Ltd. since 1988 and the CEO of Odaira Shoji Co., Ltd. from 1989. In 2015, Mr. Odaira founded two new companies, Shogun Maitake Canada Co., Ltd. in Canada and Odaira Kinoko Research Co., Ltd. in Japan. Yoshinobu Odaira graduated from the Ikazawa Junior High School in 1963. We believe that we will benefit from Mr. Odaira&#8217;s successful business experience.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Che Wei Hsu</b>&#160;has been employed as a
clerk in charge of foreign and domestic transactional business for Chunghwa Post Co., Ltd. since September 2016; she previously taught
in a Junior High School from 2006 through 2014. Ms. Hsu received a Bachelor Degree from Tunghai University School of Chinese Literature
in 2004.&#160;&#160;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Shuling Jiang</b>&#160;has served as a director
for various companies, including BioLite, Inc., BioFirst Corp, Lion Arts Promotion, Inc., since 2017 and started to serve as Managing
Director for Biokey, Inc. in March 2022. Ms. Jiang received a Bachelor Degree from National Taiwan Normal University School of Music in
1978 and a Master Degree from Northwestern University School of Music in 1983.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Kuang-Tseng Chen&#160;</b>founded the real
estate company Hao Ting Co., Ltd. in 2008 and has been working there since. Mr. Chen received a Bachelor Degree from National Taiwan University
School of Chemical Engineering in 1976.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family Relationships</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The only family relationships
among the executive officers and directors of the Company are: Dr. Tsang Ming Jiang, Dr. Tsung-Shann Jiang and Dr. Chang-Jen Jiang who
are brothers, Mr. Eugene Jiang who is Dr. Tsung-Shann Jiang&#8217;s son and the marital relationship between Yoshinobu Odaira and Norimi
Sakamoto and between Shuling Jiang and Dr. Jiang.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legal Proceedings</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Involvement in Certain Legal Proceedings</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the past ten years, none of our current directors, executive officers, promoters, control persons, or nominees has been:&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the subject of any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convicted in a criminal proceeding or is subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction or any Federal or State authority, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">found by a court of competent jurisdiction (in a civil action), the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of (a) any Federal or State securities or commodities law or regulation; (b) any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or (c) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>



</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless disclosed otherwise, we&#160;are currently not a party to any material legal or administrative proceedings and are not aware of any pending legal or administrative proceedings against us. We may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Director Independence</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NASDAQ Rules require that a majority of the
Board be independent. The Board consists of 11 directors, of which nine are non-management directors. Each year the Board reviews the
materiality of any relationship that each of our directors has with the Company, either directly or indirectly. No member of the Board
has any relationship or arrangement that would require disclosure under Item&#160;404&#160;of&#160;Regulation S-K. For additional information
see &#8220;Certain Relationships and Related-Party Transactions&#8221; herein. Based on this review, the Board has determined that the
following directors are &#8220;independent directors&#8221; as defined by the NASDAQ Rules: Messrs. Chen and Odaira and Mses. Sakamoto,
Chou and Hsu.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each director who is a member of the Audit and Finance Committee, Compensation Committee and Nominating and Corporate Governance Committee is an independent director.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Committees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><i>Audit Committee</i>.
The Audit Committee of the Board of Directors currently consists of Ms. Chou (Chair), Ms. Hsu and Ms. Miao. The functions of the Audit
Committee include the retention of our independent registered public accounting firm, reviewing and approving the planned scope, proposed
fee arrangements and results of the Company&#8217;s annual audit, reviewing the adequacy of the Company&#8217;s accounting and financial
controls and reviewing the independence of the Company&#8217;s independent registered public accounting firm. The Board has determined
that each of the committee members are an &#8220;independent director&#8221; under the listing standards of The NASDAQ Stock Market.
It is determined that Ms. Chou possesses accounting or related financial management experience that qualifies him as an &#8220;audit
committee financial expert&#8221; as defined by the rules and regulations of the SEC. The Audit Committee is governed by a written charter
approved by the Board of Directors, a copy of which is available on our website at www.abvcpharma.com. Information contained on our website
are not incorporated by reference into and do not form any part of this document. We have included the website address as a factual reference
and do not intend it to be an active link to the website.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation Committee</i>. The Compensation
Committee of the Board of Directors currently consists of Ms. Sakamoto (Chair), Ms. Hsu and Ms. Miao. The functions of the Compensation
Committee include the approval of the compensation offered to our executive officers and recommending to the full Board of Directors the
compensation to be offered to our directors, including our Chairman. The Board has determined that all committee members are &#8220;independent directors&#8221; under the listing standards of The NASDAQ Stock Market LLC. In addition, the members of the Compensation
Committee qualify as &#8220;non-employee directors&#8221; for purposes of Rule 16b-3 under the Exchange Act and as &#8220;outside directors&#8221;
for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended. The Compensation Committee is governed by a written charter
approved by the Board of Directors, a copy of which is available on our website at www.abvcpharma.com. Information contained on our website
are not incorporated by reference into and do not form any part of this document. We have included the website address as a factual reference
and do not intend it to be an active link to the website.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt"><i>Corporate Governance
and Nominating Committee</i>. The Corporate Governance and Nominating Committee of the Board of Directors consists of Mr. Yoshinobu Odaira
(Chair), Mr. Hsu and Ms. Miao, each of whom is an independent director under Nasdaq&#8217;s listing standards. The corporate governance
and nominating committee is responsible for overseeing the selection of persons to be nominated to serve on our board of directors. The
corporate governance and nominating committee considers persons identified by its members, management, shareholders, investment bankers
and others.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Guidelines for Selecting Director Nominees</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The guidelines for selecting nominees, which are specified in the Corporate Governance and Nominating Committee Charter, generally provide that persons to be nominated:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should have demonstrated notable or significant achievements in business, education or public service;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the shareholders.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The corporate governance and nominating committee will consider a number of qualifications relating to management and leadership experience, background and integrity and professionalism in evaluating a person&#8217;s candidacy for membership on the board of directors. The nominating committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The board of directors will also consider director candidates recommended for nomination by our shareholders during such times as they are seeking proposed nominees to stand for election at the next annual meeting of shareholders (or, if applicable, a special meeting of shareholders). Our shareholders that wish to nominate a director for election to the Board should follow the procedures set forth in our bylaws. The nominating committee does not distinguish among nominees recommended by shareholders and other persons.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board Leadership Structure and Role in Risk Oversight</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have two separate individuals serving as our CEO and Chairman. Our Board of Directors, or the Board, is primarily responsible for overseeing our risk management processes on behalf of our company. The Board receives and reviews periodic reports from management, auditors, legal counsel, and others, as considered appropriate regarding our company&#8217;s assessment of risks. In addition, the Board focuses on the most significant risks facing our company and our company&#8217;s general risk management strategy, and also ensures that risks undertaken by our company are consistent with the board&#8217;s appetite for risk. While the Board oversees our company&#8217;s risk management, management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our board leadership structure supports this approach.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code of Ethics</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We adopted a code of ethics, a copy of which is attached herein as Exhibit 14.1. The Code of Ethics applies to all of our employees, officers and directors. This Code constitutes a &#8220;code of ethics&#8221; as defined by the rules of the SEC. Copies of the code may be obtained free of charge from our website, www.abvcpharma.com. Any amendments to, or waivers from, a provision of our code of ethics that applies to any of our executive officers will be posted on our website in accordance with the rules of the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Indemnification</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither our Articles of Incorporation nor Bylaws prevent us from indemnifying our officers, directors and agents to the extent permitted under the Nevada Revised Statute (&#8220;NRS&#8221;). NRS Section 78.7502 provides that a corporation shall indemnify any director, officer, employee or agent of a corporation against expenses, including attorneys&#8217; fees, actually and reasonably incurred by him in connection with any the defense to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the Company pursuant to Nevada law, we are informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXECUTIVE COMPENSATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following tables set forth, for each of the last two completed fiscal years of us, the total compensation awarded to, earned by or paid to any person who was a principal executive officer during the preceding fiscal year and every other highest compensated executive officers earning more than $100,000 during the last fiscal year (together, the &#8220;Named Executive Officers&#8221;). The tables set forth below reflect the compensation of the Named Executive Officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: left">Name&#160;and&#160;Principal&#160;Position</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary<br/> ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus<br/> ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock<br/> Awards<br/> ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option<br/> Awards<br/> ($) (6)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-Equity<br/> Incentive<br/> Plan<br/> Compensation<br/> ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change in<br/> Pension<br/> Value&#160;and<br/> Nonqualified<br/> Deferred Compensation Earnings<br/> ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other<br/> Compensation<br/> ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> ($)</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 28%">Howard Doong (1)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: center">2021</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">200,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 5%; text-align: right">1,036,002</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2020</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">200,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">234,750</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">434,750</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Chihliang An (2)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">200,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">687,668</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2020</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">200,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">156,500</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">356,500</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tsung-Shann Jiang (3)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">200,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">262,700</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2020</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">200,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">106,749</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">306,749</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Richard Chi-Hsin King (4)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">200,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">861,834</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2020</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">200,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">234,750</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">434,750</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Eugene Jiang (5)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2021</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">200,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">262,700</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">2020</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">200,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">207,585</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">407,585</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0in"></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Doong was appointed as the CEO on September 15, 2017.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. An was appointed as the CFO on September 1, 2019.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Jiang was appointed as the CSTRO on September 1, 2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. King was appointed as the CSO on September 15, 2017</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang was appointed as CBO on September 1, 2019</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value of options granted during 2021 was $2.09, using the Black-Scholes option-pricing model. Accordingly, the Company recognized stock-based compensation expense of $2,675,205 for the years ended December 31, 2021.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Narrative Disclosure to Summary Compensation Table</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other than set out below, there are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. Our directors and executive officers may receive share options at the discretion of our board of directors in the future. We do not have any material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that share options may be granted at the discretion of our board of directors.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock Option Plan</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our board approved and adopted the Amended and Restated 2016 Equity Incentive Plan on September 12, 2020 (the &#8220;Plan&#8221;), a copy of which is attached hereto as exhibit 10.17.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Grants of Plan-Based Awards</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 21, 2020, the Company issued an aggregate of 545,182 options to purchase shares of Common Stock in lieu of unpaid salaries of certain employees (other than Officers and Directors) and unpaid consulting fees under the Plan, as amended; the total converted salaries was $1,090,361. The options are exercisable at $2.00 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 15, 2021, the Company&#8217;s Board of Directors approved and issued the following option awards pursuant to the Plan:&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000 options to each director, including the Chairman; such options are exercisable at $3.00 per share.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options for 400,001 shares, 233,334 shares, and 316,667 shares to the CEO, CFO and CSO, respectively; the options are exercisable at $3.00 per share.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 16, 2022, the Company&#8217;s Board of
Directors approved and issued the following option awards pursuant to the Plan:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options for 152,384 shares to each of the CEO, CFO, CSO, CSTRO, CBO respectively; the options are exercisable at $3.00 per share.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, we have granted options
under the Plan that can be exercised for an aggregate of 2,587,104 &#160;shares of Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding Equity Awards at Fiscal Year End</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes outstanding unexercised options, unvested stocks and equity incentive plan awards held by each of our named executive officers, as of December 31, 2021:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OUTSTANDING EQUITY AWARDS AT FISCAL&#160;YEAR-END</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td colspan="18" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OPTION AWARDS</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td colspan="12" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>STOCK AWARDS</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/>
Securities<br/>
Underlying<br/>
Unexercised<br/>
Options (#)<br/>
Exercisable</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number of<br/>
Securities<br/>
Underlying<br/>
Unexercised<br/>
Options (#)<br/>
Unexercisable</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/>
Incentive<br/>
Plan Awards:<br/>
Number of<br/>
Securities<br/>
Underlying<br/>
Unexercised<br/>
Unearned Options<br/>
(#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Options<br/>
Exercise<br/>
Prices<br/>
($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/>
Expiration<br/>
Date</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number&#160;of<br/>
Shares&#160;or<br/>
Units of<br/>
Stock That<br/>
Have Not<br/>
Vested<br/>
(#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market<br/>
Value&#160;of<br/>
Shares&#160;or<br/>
Units&#160;of<br/>
Stock That<br/>
Have Not<br/>
Vested<br/>
($)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/>
Incentive Plan<br/>
Awards:<br/>
Number&#160;of<br/>
Unearned<br/>
Shares, Units<br/>
or Other<br/>
Rights That<br/>
Have Not<br/>
Been Issued<br/>
(#)</b></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity<br/>
Incentive<br/>
Plan Awards:<br/>
Market&#160;or<br/>
Payout<br/>
Value of Unearned<br/>
Shares,<br/>
Units or<br/>
Other<br/>
Rights That<br/>
Have Not Been<br/>
Issued<br/>
($)</b></span></td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; width: 22%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Howard Doong<sup>(1)</sup></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">85,715</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10,715</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov 20, 2031</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">400,001</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct 15, 2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chihliang An<sup>(1)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54,762</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,524</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov 20, 2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">233,334</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct 15, 2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tsung-Shann&#160;Jiang<sup>(1)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,105</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov 20, 2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct 15, 2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Richard&#160;Chi-Hsin&#160;King<sup>(1)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">82,144</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,286</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov 20, 2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">316,667</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.0</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct 15, 2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang<sup>(1)</sup></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72,418</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,193</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nov 20, 2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30,000</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.00</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oct 15, 2031</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt"><b>(1)</b></span></td>
    <td style="font-size: 10pt; text-align: justify"><span style="font-size: 10pt">On April 16, 2022, this officer received 152,384 stock options. The stock options vested immediately and can be exercised at a price of $3 per share.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compensation of Directors</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
paid all directors, including the Chairman, 30,000 stock options for each person in fiscal year 2021. We will pay all directors, including
the Chairman, $3,500 per month for 12 months, starting from May 21, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pension, Retirement or Similar Benefit Plans</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers. We have no material bonus or profit sharing plans pursuant to which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may be granted at the discretion of the board of directors or a committee thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment Contracts</b>&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Howard Doong has entered into an employment agreements (&#8220;Doong Employment Agreement&#8221;) with the Company, pursuant to which he shall receive an annual base salary of $100,000. As of December 31, 2017, we paid Mr. Doong 20,833&#160;shares of the Company&#8217;s common stock at a per share price of $1.60 as opposed to cash compensation. Under Doong Employment Agreement, Dr. Doong is employed as our CEO and President of the Company. We may terminate the employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. In such case, the executive officer will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination, and the executive officer&#8217;s right to all other benefits will terminate, except as required by any applicable law. We may also terminate an executive officer&#8217;s employment without cause upon one-month advance written notice. In such case of termination by us, we are required to provide compensation to the executive officer, including severance pay equal to 12 months of base salary. The executive officer may terminate the employment at any time with a one-month advance written notice if there is any significant change in the executive officer&#8217;s duties and responsibilities or a material reduction in the executive officer&#8217;s annual salary. In such case, the executive officer will be entitled to receive compensation equivalent to 12 months of the executive officer&#8217;s base salary. On August 21, 2019, all of the Board members present at the Meeting, unanimously reelected Dr. Howard Doong as the Chief Executive Officer (&#8220;CEO&#8221;), which shall become effective on September 1, 2019 for a term of three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 21, 2019, all of the Board members present at the Meeting unanimously appointed Mr. Chihliang An as the Company&#8217;s Chief Financial Officer (&#8220;CFO&#8221;) effective from September 1, 2019 for a term of three years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Chi-Hsin Richard King has entered into an employment agreements (&#8220;King Employment Agreement&#8221;) with the Company, pursuant to which he shall receive an annual base salary of $50,000. As of December 31, 2017, we paid Mr. King 10,416 shares of the Company&#8217;s common stock at a per share price of $1.60 as opposed to cash compensation. Under King Employment Agreement, Dr. King is employed as the CSO of the Company. We may terminate the employment for cause, at any time, without notice or remuneration, for certain acts of the executive officer, such as conviction or plea of guilty to a felony or grossly negligent or dishonest acts to our detriment, or misconduct or a failure to perform agreed duties. In such case, the executive officer will not be entitled to receive payment of any severance benefits or other amounts by reason of the termination, and the executive officer&#8217;s right to all other benefits will terminate, except as required by any applicable law. We may also terminate an executive officer&#8217;s employment without cause upon one-month advance written notice. In such case of termination by us, we are required to provide compensation to the executive officer, including severance pay equal to 12 months of base salary. The executive officer may terminate the employment at any time with a one-month advance written notice if there is any significant change in the executive officer&#8217;s duties and responsibilities or a material reduction in the executive officer&#8217;s annual salary. In such case, the executive officer will be entitled to receive compensation equivalent to 12 months of the executive officer&#8217;s base salary. On August 21, 2019, all of the Board members present at the Meeting, unanimously reelected Dr. Richard King as the Chief Scientific Officer (&#8220;CSO&#8221;), which shall become effective on September 1, 2019 for a term of three years</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 21, 2019, all of the Board members present at the Meeting, except Eugene Jiang, appointed Mr. Eugene Jiang, the current Chairman of the Board, as the Chief Business Officer, effective since September 1, 2019 for a term of three years. Mr. Eugene Jiang excused himself from the discussion regarding his appointment as the Chief Business Officer of the Company during the Board meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 21, 2019, all of the Board members present at the Meeting, except Dr. Tsung-Shann Jiang, reelected Dr. Tsung-Shann Jiang as the Chief Strategy Officer, effective since September 1, 2019 for a term of three years. Dr. Tsung-Shann Jiang excused himself from the discussion regarding his appointment as the Chief Strategy Officer of the Company during the Board meeting.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth certain information regarding beneficial ownership of our common stock as of&#160;the date hereof (i) each person (or group of affiliated persons) who is known by us to own more than five percent (5%) of the outstanding shares of our Common Stock, (ii) each director, executive officer and director nominee, and (iii) all of our directors, executive officers and director nominees as a group.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. For purposes of this table, a person or group of persons is deemed to have &#8220;beneficial ownership&#8221;&#160;of any shares of common stock that such person has the right to acquire within 60 days of the date of the respective table. For purposes of computing the percentage of outstanding shares of our common stock held by each person or group of persons named above, any shares that such person or persons has the right to acquire within 60 days of the date of the respective table is deemed to be outstanding for such person, but is not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficial ownership.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise noted, the business address of each beneficial owner listed is&#160;44370 Old Warm Springs Blvd., Fremont, CA 94538. Except as otherwise indicated, the persons listed below have sole voting and investment power with respect to all shares of our common stock owned by them, except to the extent that power may be shared with a spouse.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of&#160;June 13, 2022, we had 32,307,329
shares of common stock issued and outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount and<br/> Nature of<br/> Beneficial<br/> Ownership</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent&#160;of <br/> Class</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Dr. Howard Doong</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">18,404</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Eugene Jiang (1)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">702,127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Chihliang An</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,334</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Chi-Hsin (Richard) King</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Yen-Hsin&#160;Chou</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,679</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Hsin-Hui Miao</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Dr. Tsang-Ming Jiang</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,067</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Norimi Sakamoto</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Dr. Tsung-Shann Jiang (2)(4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,142,451</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Dr. Chang-Jen Jiang (3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,545</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Yoshinobu Odaira</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">163,702</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Che Wei Hsu</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,012</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Shuling Jiang (5)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,908,805</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Kuang-Tseng Chen</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,556</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-size: 10pt">*</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">All officers and directors as a group (Fourteen (14) persons)</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">12,978,337</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">39.5</td><td style="font-weight: bold; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">YuanGene Corporation (4)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,296,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25.7</td><td style="text-align: left">%</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">less
than 1%.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene
Jiang held 673,189 shares of the Company&#8217;s common stock through his ownership in AsianGene, 3,743 shares of the Company&#8217;s
common stock through his ownership in BioFirst, 22 shares of the Company&#8217;s common stock through his ownership in Rgene, and the
rest of 25,173 shares through direct ownership.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&#160;Tsung-Shann
Jiang held 1,675,988 shares of common stock through his ownership in YuanGene Corporation, 853 shares of the Company&#8217;s common
stock through BioLite, 23,800 shares through Rgene Corporation, 24,610 shares through BioFirst, 136,295 shares through Lion Arts, 115,
shares through LionGene, 3,310 shares through Genepro Investment, and the rest of 2,161,742 shares through direct ownership.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Chang-Jen Jiang held 939 shares of common stock in the Company through his ownership in BioFirst, 6 shares of the Company&#8217;s common
stock through Rgene, and the rest of 4,600 shares through direct ownership.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YuanGene
Corporation is a company wholly-owned by Lion Arts, which is owned by Shu-Ling Chiang (80%) and Dr.&#160;Tsung-Shann Jiang (20%); however,
YuanGene appointed Eugene Jiang to have sole voting control over the shares held by YuanGene, the principal office address of which is
2<sup>nd</sup>&#160;floor, Building B, SNPF Plaza, Savalalo, Apia, Samoa.</span></td>
</tr></table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Jiang owns 213,120 shares through Keypoint Technology Ltd. (&#8220;Keypoint&#8221;), over which she has sole voting control and for which
Eugene Jiang&#8217;s mother is the chairman, 538,429 through her 80% of Lion Arts, 6,620,981 through Lion Arts&#8217; ownership of
YuanGene Corporation, 71,685 shares through BioFirst, 1,415 shares through BioLite, 381,193
shares through Liongene, 12,228 shares through Rgene, 3,310 shares through Genpro Investment, and 64,215 shares directly.</span></td>
</tr></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>



</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RELATED PARTY TRANSACTIONS OF DIRECTORS AND EXECUTIVE OFFICERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except as disclosed herein, no director, executive officer, shareholder holding at least 5% of shares of our common stock, or any family member thereof, had any material interest, direct or indirect, in any transaction, or proposed transaction since January 1, 2020, in which the amount involved in the transaction exceeds the lesser of $120,000 or one percent of the average of our total assets at the year-end for the last two completed fiscal years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Co-Development agreement with Rgene Corporation</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 10, 2020, the Company and Rgene signed an amendment to the Co-Dev Agreement dated May 26, 2017, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions of the Co-Dev Agreement remain in full force and effect.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Collaborative agreement with BioFirst Corporation</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 4, 2020, we executed an amendment to our collaboration agreement with BioFirst dated July 24, 2017, to add BFC-1403 Intraocular Irrigation Solution and BFC-1404 Corneal Storage Solution to our agreement. BFC-1404 is utilized during a corneal transplant procedure to replace a damaged or diseased cornea while BFC-1403 has broader utilization during a variety of ocular procedures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initially ABVC will focus on BFC-1404, a solution utilized to store a donor cornea prior to either penetrating keratoplasty (full thickness cornea transplant) or endothelial keratoplasty (back layer cornea transplant). Designated ABV-2002 under ABVC&#8217;s product identification system, the solution is comprised of a specific poly amino acid that protects ocular tissue from damage caused by external osmolarity exposure during pre-surgery storage. The specific polymer in ABV 2002 can adjust osmolarity to maintain a range of 330 to 390 mOsM thereby permitting hydration within the corneal stroma during the storage period. Stromal hydration results in (a) maintaining acceptable corneal transparency and (b) prevents donor cornea swelling. ABV-2002 also contains an abundant phenolic phytochemical found in plant cell walls that provides antioxidant antibacterial properties and neuroprotection.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early testing by BioFirst indicates that ABV-2002 may be more effective for protecting the cornea and retina during long-term storage than other storage media available today and can be manufactured at lower cost. Categorized as a Class I Medical Device that has the lowest risk to patients, ABVC intends to submit a Premarket Notification 510(K) submission to the FDA before the end of 2021 to demonstrate the device is at least as safe and effective as current products on the market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 11, 2018, the Company and BioFirst (Australia)
entered into a loan agreement for a total amount of $40,000 to meet its working capital needs. The advances bear 0% interest rate and
are due on demand prior to September 30, 2020. Afterwards, all outstanding load will bear interest rate at 12% per annum. On July 1, 2020,
the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation
based on co-development contract executed on July 24, 2017. The loan will be matured on September 30, 2021 with an interest rate of 6.5%
per annum. On September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project
needs. On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for
upcoming projects. The loan will mature on November 30, 2022 with an interest rate of 6.5% per annum. As of March 31, 2022 and December
31, 2021, the outstanding loan balance was $1,533,000 and $465,000; and accrued interest was $30,233 and $3,435, respectively.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Joint Venture Agreement</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 6, 2021 (the &#8220;<b>Completion Date</b>&#8221;), the Company, Lucidaim Co., Ltd., a Japanese corporation (&#8220;<b>Lucidaim</b>,&#8221; together with the Company, the &#8220;<b>Shareholders</b>&#8221;), and BioLite Japan K.K., a Japanese corporation (&#8220;<b>Biolite JP&#8221;</b>) entered into a Joint Venture Agreement (the &#8220;<b>Agreement</b>&#8221;). Biolite JP is a private limited company (a Japanese&#160;<i>Kabushiki Kaisha</i>) incorporated on December 18, 2018 and at the date of the Agreement has&#160;10,000&#160;ordinary shares authorized, with&#160;3,049&#160;ordinary shares issued and outstanding (the &#8220;<b>Ordinary Shares</b>&#8221;). Immediately prior to the execution of the Agreement, Lucidaim owned&#160;1,501&#160;Ordinary Shares and the Company owned 1,548&#160;Ordinary Shares. The Shareholders entered into the joint venture to formally reduce to writing their desire to invest in and operate Biolite JP as a joint venture. The business of the joint venture shall be the research and development of drugs, medical device and digital media, investment, fund running and consulting, distribution and marketing of supplements carried on by Biolite JP and its subsidiaries in Japan, or any other territory or businesses as may from time to time be agreed by an amendment to the Agreement. The closing of the transaction is conditioned upon the approval and receipt of all necessary government approvals, which have been received.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Agreement and the related share transfer agreement, the Company shall transfer&#160;54&#160;of its Ordinary Shares to Lucidaim for no consideration, such that following the transfer, Lucidaim shall own&#160;1,555&#160;Ordinary Shares (51%) and the Company shall own&#160;1,494&#160;Ordinary Shares (49%). Also pursuant to the Agreement, there shall be 3 directors of Biolite JP, consisting of 1 director appointed by the Company and 2 appointed by Lucidiam. The Company shall appoint Eugene Jiang, the Company&#8217;s current Chairman and Chief Business Officer and Lucidaim shall appoint Michihito Onishi; the current director of Biolite JP, Toru Seo (who is also a director of BioLite Japan&#8217;s other shareholder), is considered the second Lucidaim director. The Agreement further provides that the Company and Biolite JP shall assign the research collaboration and license agreement between them to Biolite JP or prepare the same (the &#8220;<b>License Agreement</b>&#8221;). The aforementioned transactions occurred on the Completion Date.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As per the Agreement, the Shareholders shall supervise and manage the business and operations of Biolite JP. The directors shall not be entitled to any renumeration for their services as a director and each Shareholder can remove and replace the director he/she/it appointed. If a Shareholder sells or disposes of all of its Ordinary Shares, the director such Shareholder appointed must tender his/her resignation. The Agreement also sets forth certain corporate actions that must be pre-approved by all Shareholders (the &#8220;<b>Reserved Matters</b>&#8221;). If the Shareholders are unable to make a decision on any Reserved Matter, then either Shareholder can submit a deadlock notice to the other shareholder, 5 days after which they must refer the matter to each Shareholder&#8217;s chairman and use good faith to resolve the dispute. If such dispute is not resolved within 10 days thereafter, then either Shareholder can offer to buy all of the other Shareholder&#8217;s Ordinary Shares for cash at a specified price; if there is not affirmative acceptance of the sale, the sale shall proceed as set forth in the sale offer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each of the Shareholders maintains a pre-emptive right to purchase such number of additional Ordinary Shares as would allow such Shareholder to maintain its ownership percentage in Biolite JP if Biolite JP issues any new Ordinary Shares. However, the Agreement provides that the Company shall lose its pre-emptive rights under certain conditions. The Shareholders also maintain a right of first refusal if the other Shareholder receives an offer to buy such shareholder&#8217;s Ordinary Shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement also requires Biolite JP to obtain a bank facility in the amount of JPY&#160;30,460,000&#160;(approximately USD272,000), for its initial working capital purposes. Pursuant to the Agreement, each Shareholder agrees to guarantee such bank facility if the bank requires a guarantee. Accordingly, the Company may be liable for the bank facility in an amount up to JPY&#160;14,925,400&#160;(approximately USD134,000), which represents&#160;49% of the maximum bank facility. The Agreement further provides that Biolite JP shall issue annual dividends at the rate of at least&#160;1.5% of Biolite JP&#8217;s profits, if it has sufficient cash to do so.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Agreement, the Company and Biolite JP agree to use their best efforts to execute the License Agreement by the end of December 2021, but since it was not yet executed, the parties continue such efforts. The Company agreed that any negotiation on behalf of Biolite JP regarding the terms of the License Agreement shall be handled by the directors appointed by Lucidaim. If the Company and such Lucidaim directors do not reach agreement on the terms, Biolite JP may at its sole discretion determine not to execute the License Agreement without any liability to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement contains non-solicitation and non-compete clauses for a period of 2 years after a Shareholder or its subsidiaries ceases to be a Shareholder, with such restrictive covenants limited to business within the ophthalmologic filed or central neurological field. Any rights to intellectual property that arise from Biolite JP&#8217;s activities, shall belong to Biolite JP.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement contains standard indemnification terms, except that no indemnifying party shall have any liability for an individual liability unless it exceeds JPY&#160;500,000&#160;(approximately USD4,500) and until the aggregate amount of all liabilities exceeds JPY&#160;2,000,000&#160;(approximately USD18,000) and then only to the extent such liability exceed such limit.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company paid $150,000&#160;towards the setup of the joint venture; BioLite Japan&#8217;s other shareholder also paid $150,000&#160;after the Letter of Intent was signed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Agreement shall continue for 10 years, unless earlier terminated. The Agreement also allows a Shareholder to terminate the agreement upon certain defaults committed by another Shareholder, as set forth in the Agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Agreement with BioLite, Inc.</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We entered into a Collaborative Agreement with BioLite, Inc., a company incorporated under the laws of Taiwan, and a subsidiary of the Company, (&#8220;BioLite&#8221;) on December 29, 2015, and then entered into two addendums to such agreement (as amended and revised, (the &#8220;Agreement&#8221;). The majority shareholder of BioLite is one of the Company&#8217;s subsidiaries, the Company&#8217;s Chairman is a director of BioLite and Dr. Jiang, the Company&#8217;s Chief Strategy Officer and a director, is the Chairman of BioLite.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Agreement, the Company acquired the sole licensing rights to develop and commercialize for therapeutic purposes six compounds
from BioLite. In accordance with the terms of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million
in cash and equity of the Company or equity securities owned by it at various stages on a schedule dictated by BioLite&#8217;s achievements
of certain milestones, as set forth in the Agreement (the &#8220;Milestone Payments&#8221;) and (ii) a royalty payment equal to 5% of
net sales of the drug products when ABV-1501 is approved for sale in the licensed territories. If BioLite fails to reach any of the milestones
in a timely manner, it may not receive the rest of the payments from the Company. According to the Agreement, after Phase II clinical
trials are completed, 15% of the Milestone Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021
(the &#8220;December 2021 Payment&#8221;) and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company&#8217;s Board
of Directors determined that the December 2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding
debt, in the amount of $5,000,000, that BioLite owes the Company as of December 31, 2021. On February 22, 2022, the parties entered into
an amendment to the Agreement allowing the Company to make all payments due under the Agreement via the forgiveness of debt, in equal
value, owed by BioLite to the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This was a related party transaction and was conducted at arm&#8217;s length. In addition to the Company&#8217;s board of directors approving the modification of terms of the Agreement, the Company&#8217;s audit committee approved them too. The Board believes it is in the Company&#8217;s best interest to cancel outstanding debt and apply it to the December 2021 Payment.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following such approval, the Company and BioLite entered into an amendment to the Agreement reflecting the modified payment method.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Other related party transactions</span></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due from related parties:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, and December 31, 2021, the Company has advanced an aggregate amount of $48,586 and $49,110 to Rgene for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum). As of March 31, 2022, and December 31, 2021, the outstanding loan balance was $32,541&#160;and $33,520; and accrued interest was $14,214&#160;and $13,701, respectively. On January 1, 2021, BioLite Taiwan entered into a consultant services agreement with Rgene, of which the amount due from Rgene was $1,831&#160;and $1,889 as of March 31, 2022 and December 31, 2021, respectively.&#160;&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2021, the Company and BioFirst entered into several loan agreements for a total amount of $465,000&#160;to meet its working capital needs. All the loans period was twelve months and all with an interest rate of 6.5% per annum. In 2022, the Company and BioFirst entered into several loan agreements for a total amount of $1,068,000&#160;to meet its working capital needs. All the loans period was twelve months and with an interest rate of&#160;6.5% per annum. As of March 31, 2022, and December 31, 2021, the outstanding loan balance was $1,533,000&#160;and $465,000; and accrued interest was $30,233&#160;and $3,435, respectively.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487&#160;to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of&#160;6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873&#160;to meet its new project needs. &#160;&#160;On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000&#160;to increase the cost for upcoming projects. The loan will be matured on&#160;November 30, 2022&#160;with an interest rate of&#160;6.5% per annum. In January 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $327,000&#160;to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of&#160;6.5% per annum. As of March 31, 2022 and December 31, 2021, the aggregate amount of outstanding loan and accrued interest was $830,118&#160;and $491,816, respectively.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font-size: 10pt; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 3).&#160;The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.&#160;As of March 31, 2022 and December 31, 2021, due from BHK was $121,153&#160;and $124,972, respectively.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose.&#160;The advances bear&#160;0% interest rate and are due on demand.&#160;As of March 31, 2022 and December 31, 2021, the outstanding advance balances was $675&#160;and $675, respectively.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 8, 2020, the Company and Lucidaim entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan.&#160;Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan&#8217;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate.&#160;As of March 31, 2022 and December 31, 2021, the outstanding advance balances was $150,000&#160;and $150,000, respectively.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">On October 31, 2020,&#160;the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021.&#160;As of March 31, 2022 and December 31, 2021, the outstanding loan balance was $1,610&#160;and $1,610, respectively.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Due to related parties:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, BioFirst has advanced funds to the Company for working capital purpose.&#160;The advances bear interest 1% per month (or equivalent to 12% per annum).&#160;As of March 31, 2022 and December 31, 2021, the aggregate amount of outstanding balance and accrued interest is $40,878.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, and December 31, 2021, BioFirst (Australia) has advanced the Company an aggregate amount of $190,913&#160;and $132,443, respectively for new project purpose.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -24.1pt"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, and December 31, 2021, AsiaGene has advanced the Company an aggregate amount of $24,017&#160;for working capital purpose. This advance bears&#160;0% interest rate and is due on demand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of March 31, 2022, and December 31, 2021, YuanGene has advanced the Company an aggregate amount of $9,205&#160;for working capital purpose. This advance bears&#160;0% interest rate and is due on demand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2022, and December 31, 2021, the outstanding balance due to the Jiangs amounted to $18,750. These loans bear interest rate of&#160;0% to&#160;1% per month, and are due on demand.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose.&#160;The advances bear interest rate of 12% per annum.&#160;As of March 31, 2022 and December 31, 2021, the outstanding principal and accrued interest was $162,634&#160;and $168,131, respectively. Interest expenses in connection with these loans were $5,312&#160;and $5,298&#160;for the three months ended March 31, 2022 and 2021, respectively.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Promoters and Certain Control Persons</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None of our management or other control persons were &#8220;promoters&#8221; (within the meaning of Rule&#160;405 under the Securities Act), and none of such persons took the initiative in the formation of our business or received any of our debt or equity securities or any of the proceeds from the sale of such securities in exchange for the contribution of property or services, during the last five years.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DESCRIPTION OF SECURITIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>General</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s authorized capital stock consists of:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100,000,000 shares of Common Stock, $0.001 par value per share; and</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,000,000 shares of preferred stock, $0.001 par value per share.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Common Stock may be issued for such consideration as may be fixed from time to time by our board of directors. Our board of directors may issue such shares of our Common Stock in one or more series, with such voting powers, shall be stated in the resolution or resolutions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<b>ommon Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date hereof, there are 32,307,329 shares of our Common Stock issued and outstanding. Holders of Common Stock are entitled to cast one vote for each share on all matters submitted to a vote of shareholders, including the election of directors. The holders of Common Stock are entitled to receive ratably such dividends, if any, as may be declared by the Board out of funds legally available therefore. Such holders do not have any preemptive or other rights to subscribe for additional shares. All holders of Common Stock are entitled to share ratably in any assets for distribution to shareholders upon the liquidation, dissolution or winding up of the Company, subject to prior distribution rights of preferred stock then outstanding. There are no conversions, redemptions or sinking fund provisions applicable to the Common Stock. All outstanding shares of Common Stock are fully paid and non-assessable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Preferred Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of the date hereof, there is no preferred stock outstanding, including the class of Series A Convertible Preferred Stock. Pursuant to the articles of incorporation of the Company, the Board of Directors is expressly granted the authority to&#160;issue preferred stock up to 20,000,000 shares and prescribe its designations. On June 28, 2019, the Company filed a certificate of designation (the &#8220;Series A COD&#8221;) of Series A Convertible Preferred Stock (the &#8220;Series A Stock&#8221;) with the Secretary of the State of Nevada, pursuant to which the Company designated 3,500,000 shares of preferred stock as Series A Stock, par value of $0.001 per share.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following description of the Series A Stock is not complete. The Company&#8217;s Board of Directors has the authority, without further action by the shareholders, to issue shares of preferred stock in one or more other series and to fix the rights, preferences, privileges and restrictions granted to or imposed upon the preferred stock. Any or all of these rights may be greater than the rights of the Company&#8217;s Common Stock. These descriptions are qualified in their entirety by reference to the Company&#8217;s Articles of Incorporation, as amended, and the certificate of designation relating to each such series.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Conversion Rights</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each share of Series A Stock is initially convertible at any time at the option of the holders into one share of Common Stock and automatically converts into one share of Common Stock (the &#8220;Conversion Ratio&#8221;) on its four-year anniversary of issuance and without the payment of additional consideration by the holder thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fractional shares shall be issued upon conversion of Series A Stock into Common Stock and no payment. In lieu of delivering fractional shares, we will pay to the holder, to the extent permitted by law, an amount in cash equal to the current fair market value of such fractional share as determined in good faith by our Board.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>No Maturity, Sinking Fund or Mandatory Redemption</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Stock has no maturity date and we are not required to redeem the Series A Stock at any time. However, we may choose to convert all the outstanding shares of the Series A Stock into our Common Stock at the same Conversion Ratio at any time, provided that we have prepaid and distributed all the dividend accrued and to be accrued at the end of the four-year period since issuance thereof. Accordingly, the Series A Stock will remain outstanding until automatically converted to Common Stock on the four-year anniversary of issuance, unless the holders of the Series A Convertible Preferred Stock or we choose to convert the Series A Stock into the Common Stock. The Series A Stock is also not subject to any sinking fund.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Voting Rights</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of shares of the Series A Stock vote on an as converted basis with the holders of our Common Stock.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders of shares of Series A Stock were entitled to receive a cash dividend at the per annum rate of an amount equal to the product of 5% multiplied by the public offering price per share of the shares that were to be sold pursuant to the registration statement on Form S-1 (File No. 333-228387) initially filed on November 14, 2018, but has since been withdrawn. Therefore, the Series A Stock is not eligible for dividends at this time.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Warrants and Options</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the date hereof, we have 1,307,102 and 7,038,442 options and
warrants, respectively of the Company outstanding. We are not registering shares of common stock underlying any warrants in this S1.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>August 2021 Follow-on Offering</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 2, 2021, we closed a firm commitment underwritten public offering pursuant to which we issued and sold 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;).&#160;<span>The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,00</span></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The following summary of certain terms and provisions of the warrants issued pursuant to the August 2021 public offering is not complete and is subject to, and qualified in its entirety by, the provisions of the warrant agent agreement between us and Vstock, as warrant agent, and the form of warrants, all of which are filed as exhibits to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the warrant agent agreement, including the annexes thereto, and form of Purchase Warrant.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series A Warrants </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Warrants entitle the registered holder to purchase one share of our common stock at a price equal to $6.30 per share, subject to adjustment as discussed below, terminating at 5:00 p.m., New York City time, on the fifth (5th) anniversary of the date of issuance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise price and number of shares of common stock issuable upon exercise of the Series A Warrants may be adjusted in certain circumstances, including in the event of a stock dividend, extra common dividend on or recapitalization, reorganization, merger or consolidation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the Warrant Agent, with the exercise form attached to the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to us, for the number of warrants being exercised. The Series A Warrant holders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their Series A Warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the Series A warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Series A Warrants will be exercisable for cash unless at the time of the exercise a prospectus or prospectus relating to common stock issuable upon exercise of the Series A Warrants is current and the common stock has been registered or qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. Under the terms of the Series A Warrant Agent Agreement, we have agreed to use our best efforts to maintain a current prospectus or prospectus relating to common stock issuable upon exercise of the Series A Warrants until the expiration of the Series A Warrants. Additionally, the market for the Series A Warrants may be limited if the prospectus or prospectus relating to the common stock issuable upon exercise of the Series A Warrants is not current or if the common stock is not qualified or exempt from qualification in the jurisdictions in which the holders of such Series A Warrants reside. In no event will the registered holders of a Series A Warrant be entitled to receive a net-cash settlement in lieu of physical settlement in shares of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fractional shares of common stock will be issued upon exercise of the Series A Warrants. If, upon exercise of the Series A Warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number the number of shares of common stock to be issued to the Warrant holder. If multiple Series A Warrants are exercised by the holder at the same time, we will aggregate the number of whole shares issuable upon exercise of all the Series A Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The price of the Series A Warrants has been arbitrarily established by us and the Underwriter after giving consideration to numerous factors, including but not limited to, the pricing of the Units in this offering. No particular weighting was given to any one aspect of those factors considered. We have not performed any method of valuation of the warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Warrant form contains a governing law and forum selection provision which provides that, subject to applicable law, any action, proceeding or claim against us or the warrant agent arising out of or relating in any way to the warrant agreement shall be brought and enforced in the state and federal courts sitting in the City of New York, Borough of Manhattan, and that each party irrevocably submits to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. Each party to the Series A Warrant irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under the warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Notwithstanding the foregoing, the exclusive forum provision described above shall not apply to suits brought to enforce a duty or liability created by the&#160;Exchange Act, any other claim for which the federal courts have exclusive jurisdiction or any complaint asserting a cause of action arising under the&#160;Securities Act&#160;against us or any of our directors, officers, other employees or agents. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the&#160;Exchange Act&#160;or the rules and regulations thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Series B Warrants </i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series B Warrants entitle each holder to purchase one share of our common stock at an exercise price of $10.00 per share, subject to adjustment as discussed below, terminating at 5:00 p.m., New York City time, on the fifth (5th) anniversary of the date of issuance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The exercise price and number of shares of common stock issuable upon exercise of the Series B Warrants may be adjusted in certain circumstances, including in the event of a stock dividend, extra common dividend on or recapitalization, reorganization, merger or consolidation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series B Warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the Warrant Agent, with the exercise form attached to the warrant certificate completed and executed as indicated, accompanied by full payment of the exercise price, by certified or official bank check payable to us, for the number of warrants being exercised. The Series B Warrant holders do not have the rights or privileges of holders of common stock and any voting rights until they exercise their Series B Warrants and receive shares of common stock. After the issuance of shares of common stock upon exercise of the Series B warrants, each holder will be entitled to one vote for each share held of record on all matters to be voted on by stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No Series B Warrants will be exercisable for cash unless at the time of the exercise a prospectus or prospectus relating to common stock issuable upon exercise of the Series B Warrants is current and the common stock has been registered or qualified or deemed to be exempt under the securities laws of the state of residence of the holder of the warrants. Under the terms of the Series B Warrant Agent Agreement, we have agreed to use our best efforts to maintain a current prospectus or prospectus relating to common stock issuable upon exercise of the Series B Warrants until the expiration of the Series B Warrants. Additionally, the market for the Series B Warrants may be limited if the prospectus or prospectus relating to the common stock issuable upon exercise of the Series B Warrants is not current or if the common stock is not qualified or exempt from qualification in the jurisdictions in which the holders of such Series B Warrants reside. In no event will the registered holders of a Series B Warrant be entitled to receive a net-cash settlement in lieu of physical settlement in shares of our common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No fractional shares of common stock will be issued upon exercise of the Series B Warrants. If, upon exercise of the Series B Warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round up to the nearest whole number the number of shares of common stock to be issued to the Warrant holder. If multiple Series B Warrants are exercised by the holder at the same time, we will aggregate the number of whole shares issuable upon exercise of all the Series B Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The price of the Series B Warrants has been arbitrarily established by us and the Underwriter after giving consideration to numerous factors, including but not limited to, the pricing of the Units in this offering. No particular weighting was given to any one aspect of those factors considered. We have not performed any method of valuation of the warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to maintain a current prospectus or prospectus relating to the common stock issuable upon the exercise of the Series B Warrants, such holders may exercise their Series B warrants on a &#8220;cashless&#8221; basis pursuant to a formula set forth in the terms of the Series B Warrants. Additionally, holders of Series B Warrants may exercise such warrants on a &#8220;cashless&#8221; basis upon the earlier of (i) 15 trading days from the issuance date of such warrant or (ii) the time when $10.0 million of volume is traded in our common stock, if the volume weighted average price (&#8220;VWAP&#8221;) of our common stock on any trading day on or after the date of issuance fails to exceed the then current exercise price of the Series B Warrant (subject to adjustment for any stock splits, stock dividends, stock combinations, recapitalizations and similar events). In such event, the aggregate number of shares of common stock issuable in such cashless exercise shall equal the product of (x) the aggregate number of shares of common stock that would be issuable upon exercise of the Series B Warrant in accordance with its terms if such exercise were by means of a cash exercise rather than a cashless exercise and (y) 1.00.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant Agent</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Series A Warrants and Series B Warrants will be issued in registered form under a warrant agent agreement (the &#8220;Warrant Agent Agreement&#8221;) between us and our warrant agent, VStock Transfer, LLC (the &#8220;Warrant Agent&#8221;). The Purchase Warrants will be issued in book-entry form and shall initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company, or DTC, and registered in the name of Cede &amp; Co., a nominee of DTC, or as otherwise directed by DTC. The material provisions of the warrants are set forth herein and a copy of the Warrant Agent Agreement has been filed as an exhibit to the Registration Statement on Form S-1, of which this prospectus forms a part. The Company and the Warrant Agent may amend or supplement the Warrant Agent Agreement without the consent of any holder for the purpose of curing any ambiguity, or curing, correcting or supplementing any defective provision contained therein or adding or changing any other provisions with respect to matters or questions arising under the Warrant Agent Agreement as the parties thereto may deem necessary or desirable and that the parties determine, in good faith, shall not adversely affect the interest of the Series A Warrant or Series B Warrant holders. All other amendments and supplements to the Warrant Agent Agreement shall require the vote or written consent of holders of at least 50.1% of each of the Series A Warrants and Series B Warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Representative&#8217;s Warrants</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We issued the Representative (or its designed affiliates) share purchase warrants (the &#8220;Representative&#8217;s Warrants&#8221;) to purchase up to 55,000 shares of Common Stock at an exercise price equal to $6.25 per share. The Representative&#8217;s Warrants are not exercisable for six (6) months after the effective date of the registration statement of which this prospectus forms a part and will expire five (5) years after such effective date. The Representative&#8217;s Warrants are not be redeemable. The Representative&#8217;s Warrants have &#8220;piggy back&#8221; registration rights for a period of five (5) years from the effective date of the registration of which this prospectus forms a part in accordance with FINRA Rule 5110(g)(8)(D). The Representative&#8217;s Warrants may not be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days following the effective date of the registration statement of which this prospectus forms a part, except that they may be assigned, in whole or in part, to any officer or partner of the Representative and to members of the underwriting syndicate or selling group and officers and partners thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Transfer Agent</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transfer agent and registrar for our Common Stock&#160;is:&#160;Vstock Transfer, LLC; Address: 18 Lafayette Place, Woodmere, NY 11598;&#160;Phone:&#160;(212) 828 &#8211; 8436;&#160;website: https://www.vstocktransfer.com/.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anti-Takeover Provisions</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nevada Revised Statutes</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Acquisition of Controlling Interest Statutes</span>. Nevada&#8217;s &#8220;acquisition of controlling interest&#8221; statutes contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These &#8220;control share&#8221; laws provide generally that any person that acquires a &#8220;controlling interest&#8221; in certain Nevada corporations may be denied certain voting rights, unless a majority of the disinterested shareholders of the corporation elects to restore such voting rights. These statutes provide that a person acquires a &#8220;controlling interest&#8221; whenever a person acquires shares of a subject corporation that, but for the application of these provisions of the Nevada Revised Statutes, would enable that person to exercise (1) one-fifth or more, but less than one-third, (2) one-third or more, but less than a majority or (3) a majority or more, of all of the voting power of the corporation in the election of directors. Once an acquirer crosses one of these thresholds, shares which it acquired in the transaction taking it over the threshold and within the 90 days immediately preceding the date when the acquiring person acquired or offered to acquire a controlling interest become &#8220;control shares&#8221; to which the voting restrictions described above apply. Our articles of incorporation and bylaws currently contain no provisions relating to these statutes, and unless our articles of incorporation or bylaws in effect on the tenth day after the acquisition of a controlling interest were to provide otherwise, these laws would apply to us if we were to (i) have 200 or more shareholders of record (at least 100 of which have addresses in the State of Nevada appearing on our stock ledger) and (ii) do business in the State of Nevada directly or through an affiliated corporation. If these laws were to apply to us, they might discourage companies or persons interested in acquiring a significant interest in or control of the Company, regardless of whether such acquisition may be in the interest of our shareholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Combinations with Interested Shareholders Statutes</span>. Nevada&#8217;s &#8220;combinations with interested shareholders&#8221; statutes prohibit certain business &#8220;combinations&#8221; between certain Nevada corporations and any person deemed to be an &#8220;interested shareholder&#8221; for two years after such person first becomes an &#8220;interested shareholder&#8221; unless (i) the corporation&#8217;s board of directors approves the combination (or the transaction by which such person becomes an &#8220;interested shareholder&#8221;) in advance, or (ii) the combination is approved by the board of directors and sixty percent of the corporation&#8217;s voting power not beneficially owned by the interested shareholder, its affiliates and associates. Furthermore, in the absence of prior approval certain restrictions may apply even after such two-year period. For purposes of these statutes, an &#8220;interested shareholder&#8221; is any person who is (x) the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the outstanding voting shares of the corporation, or (y) an affiliate or associate of the corporation and at any time within the two previous years was the beneficial owner, directly or indirectly, of ten percent or more of the voting power of the then outstanding shares of the corporation. The definition of the term &#8220;combination&#8221; is sufficiently broad to cover most significant transactions between the corporation and an &#8220;interested shareholder&#8221;. Subject to certain timing requirements set forth in the statutes, a corporation may elect not to be governed by these statutes. We have not included any such provision in our articles of incorporation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The effect of these statutes may be to potentially discourage parties interested in taking control of the Company from doing so if it cannot obtain the approval of our board of directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="planof"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PLAN OF DISTRIBUTION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuance of Shares Upon Exercise of Warrants</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The prices at which the shares of common stock covered by this prospectus may actually be disposed of may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale or at negotiated prices.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the warrants, the shares of common stock will be distributed to those holders who surrender the warrants and provide payment of the exercise price to us.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon receipt of proper notice by any of the holders of the warrants issued that such holder desires to exercise a warrant, we will, within the time allotted by the agreement governing the warrant, issue instructions to our transfer agent to issue to the holder shares of common stock, free of a restrictive legend. Warrant Shares that are held by affiliates will be issued free of legend but will be deemed control securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This section summarizes certain U.S. federal income tax considerations relating to the purchase, ownership and disposition of our Common Stock. This summary does not provide a complete analysis of all potential tax considerations. The information provided below is based upon provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury regulations promulgated thereunder and administrative rulings and judicial decisions, all as currently in effect. These authorities may change at any time, possibly on a retroactive basis, or the U.S. Internal Revenue Service (the &#8220;IRS&#8221;), might interpret the existing authorities differently. In either case, the tax considerations of purchasing, owning or disposing of Common Stock could differ from those described below.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This discussion is addressed only to U.S. holders (defined below) which hold our shares of Common Stock as a &#8220;capital asset&#8221; within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion does not address all of the U.S. federal income tax considerations that might be relevant to a beneficial owner in light of such beneficial owner&#8217;s particular circumstances or to beneficial owners subject to special treatment under the U.S. federal income tax laws, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a broker, dealer or trader in securities, currencies, commodities, or notional principal contracts;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a bank, financial institution or insurance company;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a regulated investment company, a real estate investment trust or grantor trust;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a tax-exempt entity or organization, including an individual retirement account or Roth IRA as defined in Section 408 or 408A of the Code, respectively;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person holding the Common Stock as part of a hedging, integrated, or conversion transaction or a straddle, or a person deemed to sell Common Stock under the constructive sale provisions of the Code;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trader in securities that has elected the mark-to-market method of tax accounting for securities;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an entity that is treated as a partnership or other pass-through entity for U.S. federal income tax purposes;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a person who is a partner or investor in a partnership or other pass-through entity that holds the Common Stock;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a U.S. person whose &#8220;functional currency&#8221; is not the U.S. dollar;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a controlled foreign corporation or passive foreign investment company;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a qualified foreign pension fund or an entity that is wholly owned by one or more qualified foreign pension funds; or</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a U.S. expatriate.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of this discussion, a &#8220;U.S. holder&#8221; is a beneficial owner of a share of Common Stock that is, for U.S. federal income tax purposes:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a citizen or resident of the United States;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States, any state thereof or the District of Columbia;</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust if (1) it is subject to the primary supervision of a court within the United States and one or more U.S. persons have the authority to control all substantial decisions of the trust or (2) it has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For purposes of this discussion, a &#8220;non-U.S. holder&#8221; is a beneficial owner of a share of Common Stock that is (i) a foreign corporation, (ii) a nonresident alien individual, or (iii) a foreign estate or trust that in each case is not subject to U.S. federal income tax on a net-income basis on income or gain from a share of Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a partnership holds shares of Common Stock, the tax treatment of a partner will generally depend upon the status of the partner and the activities of the partnership. A partnership holding shares of Common Stock or a partner therein should consult its own tax advisors as to the tax consequences of holding and disposing of shares of Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation, as well as any tax consequences of the purchase, ownership and disposition of our Common Stock arising under the U.S. federal estate or gift tax rules or under the laws of any U.S. state or local or any non-U.S. or other taxing jurisdiction or under any applicable tax treaty.</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Certain U.S. Federal Income Tax Considerations for U.S. Holders of Common Stock</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dividends on our Common Stock</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not expect to declare or pay any distributions on our Common Stock in the foreseeable future. If we do make any distributions on shares of our Common Stock, however, such distributions will be includible in the gross income of a U.S. holder as ordinary dividend income to the extent paid out of current or accumulated earnings and profits, as determined for U.S. federal income tax purposes. Any portion of a distribution in excess of current or accumulated earnings and profits would be treated as a return of the holder&#8217;s tax basis in its Common Stock and then as gain from the sale or exchange of the Common Stock. Under current law, if certain requirements are met, a preferential U.S. federal income tax rate will apply to any dividends paid to a holder of Common Stock who is a U.S. individual.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distributions to U.S. holders that are corporate stockholders, constituting dividends for U.S. federal income tax purposes, may qualify for the dividends received deduction, or DRD, which is generally available to corporate stockholders. No assurance can be given that we will have sufficient earnings and profits (as determined for U.S. federal income tax purposes) to cause any distributions to be eligible for a DRD. In addition, a DRD is available only if certain holding periods and other taxable income requirements are satisfied.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Sale of Common Stock</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A U.S. holder of Common Stock will generally recognize gain or loss on the taxable sale, exchange, or other taxable disposition of such stock in an amount equal to the difference between such U.S. holder&#8217;s amount realized on the sale and its adjusted tax basis in the Common Stock sold. A U.S. holder&#8217;s amount realized should equal the amount of cash and the fair market value of any property received in consideration of its stock. The gain or loss should be capital gain or loss and should be long-term capital gain or loss if the Common Stock is held for more than one year at the time of disposition. The deductibility of capital losses for U.S. federal income tax purposes is subject to limitations under the Code. Under current law, long-term capital gain recognized by an individual U.S. holder is generally eligible for a preferential U.S. federal income tax rate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Information Reporting and Backup Withholding</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information reporting requirements generally will apply to payments of dividends on shares of Common Stock and to the proceeds of a sale of Common Stock unless a U.S. holder is an exempt recipient, such as a corporation. Backup withholding will apply to those payments if a U.S. holder fails to provide its correct taxpayer identification number and certification of exempt status, or fails to report in full dividend income. Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against U.S. federal income tax liability, provided the required information is timely furnished to the IRS.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, the registrant has been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>LEGAL MATTERS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The validity of the securities being offered by this prospectus been passed upon for us by Hunter Taubman Fischer &amp; Li LLC. Carmel, Milazzo &amp; Feil LLP, New York, New York is acting as counsel for the representative of the underwriters with respect to the offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPERTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The consolidated financial statements of ABVC
BioPharma, Inc.as of December 31, 2021 and 2020 included elsewhere in this prospectus have been audited by KCCW Accountancy Corp., independent
registered public accounting firm, as set forth in their report appearing elsewhere herein, and are included in reliance upon such report
given on the authority of such firm as experts in accounting and auditing. T<span>he consolidated financial
statements for the three months ended March 31, 2022 incorporated herein are not audited.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WHERE YOU CAN FIND MORE INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a reporting company and file annual, quarterly and special reports, and other information with the SEC. Copies of the reports and other information may be read and copied at the SEC&#8217;s Public Reference Room at 100 F Street N.E., Washington, D.C. 20549. You can request copies of such documents by writing to the SEC and paying a fee for the copying cost. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a web site at <span style="text-decoration:underline">http://www.sec.gov </span>that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus is part of a registration statement on Form S-1 that we filed with the SEC. Certain information in the registration statement has been omitted from this prospectus in accordance with the rules and regulations of the SEC. We have also filed exhibits and schedules with the registration statement that are excluded from this prospectus. For further information you may:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">read a copy of the registration statement, including the exhibits and schedules, without charge at the SEC&#8217;s Public Reference Room; or</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain a copy from the SEC upon payment of the fees prescribed by the SEC.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We file periodic reports, proxy statements, and other information with the SEC. These periodic reports, proxy statements, and other information will be available for inspection and copying at the SEC&#8217;s public reference facilities and the website of the SEC referred to above. After the closing of this offering, you may access our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act with the SEC free of charge as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The information contained in, or that can be accessed through, our website is not incorporated by reference into this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the SEC&#160;such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by us of expenses incurred or paid by one of our directors, officers or controlling persons in the successful defense of any action, suit or proceeding) is asserted by that director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether that indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of that issue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>INDEX
TO FINANCIAL INFORMATION</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Consolidated Financial Statements and Notes
thereto and the report of KCCW Accountancy Corp, our independent registered public accounting firm, are set forth on pages F-1 through
F-[42] of this Report.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 90%; text-align: justify">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#fs_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2022 (UNAUDITED) AND DECEMBER 31, 2021 (AUDITED)</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#fs_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#fs_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; DEFICIT FOR THE THREE MONTHS ENDED MARCH 31, 2022 (UNAUDITED)</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#fs_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; DEFICIT FOR THE THREE MONTHS ENDED MARCH 31, 2021 (UNAUDITED)</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#fs_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#fs_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#b_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID 2738)</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-38</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#b_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2021 AND DECEMBER 31, 2020</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-40</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#b_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED DECEMBER 31, 2021 AND DECEMBER 31, 2020</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-41</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#b_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2021 AND DECEMBER 31, 2020</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-42</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#b_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&#8217; DEFICIT FOR THE YEARS ENDED DECEMBER 31, 2020 AND DECEMBER&#160;31, 2021</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-43</span></td></tr>
  <tr>
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: justify"><a href="#b_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-44</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 104; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="fs_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March&#160;31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Current Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">2,717,936</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">5,828,548</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Restricted cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">714,652</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">736,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">281,197</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">280,692</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accounts receivable &#8211; related parties, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" unitRef="usd">145,399</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" unitRef="usd">145,399</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">2,715,375</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">1,286,618</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">22,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">25,975</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Short-term Investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">95,553</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">108,147</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Prepayment for long-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentForLongtermInvestments" scale="0" unitRef="usd">663,798</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentForLongtermInvestments" scale="0" unitRef="usd">684,720</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Prepaid expense and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">631,321</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">528,354</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Total Current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">7,987,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,625,120</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">598,648</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">525,881</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,382,695</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,471,899</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Goodwill, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Long-term investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">904,254</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">932,755</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd">1,036,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd">981,912</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid expenses &#8211; noncurrent</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd">115,664</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd">119,309</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Security deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd">40,733</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd">41,157</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Total Assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">12,066,755</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">13,698,033</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Short-term bank loans</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd">1,609,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd">1,640,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,247,558</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,300,803</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Advance from customers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdvanceFromCustomers" scale="0" unitRef="usd">10,985</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdvanceFromCustomers" scale="0" unitRef="usd">10,985</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Operating lease liabilities &#8211; current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">349,008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">347,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Due to related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">446,397</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">393,424</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Total Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">3,663,698</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">3,692,312</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Tenant security deposit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDepositLiability" scale="0" unitRef="usd">7,980</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDepositLiability" scale="0" unitRef="usd">10,580</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liability &#8211; noncurrent portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">1,033,686</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">1,124,799</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">4,705,364</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">4,827,691</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Preferred stock, $<ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">20,000,000</ix:nonFraction></ix:nonFraction> authorized, <span style="-sec-ix-hidden: hidden-fact-4"><span style="-sec-ix-hidden: hidden-fact-5"><span style="-sec-ix-hidden: hidden-fact-6"><span style="-sec-ix-hidden: hidden-fact-7">nil</span></span></span></span> shares issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Common stock, $<ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction> authorized, <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">30,307,329</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">28,926,322</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2022 and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">30,307</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">28,926</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">62,578,549</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">58,113,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Stock subscription receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd">2,031,660</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd">2,257,400</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">44,476,640</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">38,481,200</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">426,321</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">539,660</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Treasury stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd">9,100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd">9,100,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">7,426,877</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,843,653</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Noncontrolling interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd">65,486</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" unitRef="usd">26,689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">7,361,391</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">8,870,342</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Liabilities and Equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">12,066,755</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">13,698,033</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fs_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">Revenues</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">25,660</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">263,150</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Cost of revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">1,896</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">1,245</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Gross profit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">23,764</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">261,905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Selling, general and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,191,078</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">1,167,595</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">359,404</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">121,315</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Stock-based compensation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">4,692,003</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">225,740</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">6,242,485</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">1,514,650</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">6,218,721</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">1,252,745</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Other income (expense)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:InterestIncomes" scale="0" unitRef="usd">40,175</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:InterestIncomes" scale="0" unitRef="usd">52,529</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">18,213</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">130,229</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Operating sublease income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:RentIncome" scale="0" unitRef="usd">24,124</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:RentIncome" scale="0" unitRef="usd">4,867</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Operating sublease income &#8211; related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingSubleaseIncomeRelatedParties" scale="0" unitRef="usd">1,600</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Gain/Loss on foreign exchange changes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:GainLossOnForeignExchangeChanges" scale="0" unitRef="usd">7,563</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:GainLossOnForeignExchangeChanges" scale="0" unitRef="usd">951</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Gain/Loss on investment in equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="0" sign="-" unitRef="usd">47,791</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Other (expense) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" sign="-" unitRef="usd">9,410</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">71</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Government grant income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">124,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd">44,239</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd">6,398</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Loss before provision income tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">6,174,482</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">1,246,347</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Provision for income tax</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">86,867</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">51,024</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">6,087,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">1,195,323</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss attributable to noncontrolling interests</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="0" sign="-" unitRef="usd">92,175</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="0" sign="-" unitRef="usd">66,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net loss attributed to ABVC and subsidiaries</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetLossAttributableToAbvcAndSubsidiaries" scale="0" sign="-" unitRef="usd">5,995,440</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetLossAttributableToAbvcAndSubsidiaries" scale="0" sign="-" unitRef="usd">1,128,505</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">113,339</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" unitRef="usd">36,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">6,108,779</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">1,092,365</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Net loss per share:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.20</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.05</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average number of common shares outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">29,683,402</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">24,420,526</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fs_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Cash flows from operating activities</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">6,087,615</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">1,195,323</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in">Depreciation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">5,411</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">2,928</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Stock based compensation for non employees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">4,692,003</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">225,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Gain/Loss on investment in equity securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" sign="-" unitRef="usd">47,791</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Government grant income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:GovernmentGrantIncome" scale="0" unitRef="usd">124,400</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Other non-cash income and expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" sign="-" unitRef="usd">9,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Deferred tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">86,867</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">51,024</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Decrease (increase) in accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">505</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">238,484</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Decrease (increase) in prepaid expenses and deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" scale="0" unitRef="usd">113,292</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" scale="0" unitRef="usd">187,723</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Decrease (increase) in due from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseDueFromOtherRelatedParties" scale="0" unitRef="usd">1,434,353</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseDueFromOtherRelatedParties" scale="0" unitRef="usd">18,229</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Increase (decrease) in inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" sign="-" unitRef="usd">2,537</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Increase (decrease) in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd">12,710</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Increase (decrease) in accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd">38,378</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" unitRef="usd">136,519</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 27pt">Increase (decrease) in due to related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" unitRef="usd">57,299</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" unitRef="usd">1,841</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">2,994,257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">1,413,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt">Purchase of equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">93,220</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Prepayment for equity investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="0" unitRef="usd">281,952</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">93,220</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">281,952</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">40,448</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Repayment of convertible notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd">250,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Proceeds from long-term loans</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" unitRef="usd">236,498</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Borrowings from related parties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:BorrowingsFromRelatedParties" scale="0" unitRef="usd">10,651</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Net proceeds from short-term borrowing from related parties</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" scale="0" unitRef="usd">4,629</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">42,226</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash and cash equivalents and restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd">45,150</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd">15,335</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net decrease in cash and cash equivalents and restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">3,132,627</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" sign="-" unitRef="usd">1,668,135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Cash and cash equivalents and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Beginning</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">6,565,215</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">5,001,371</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Ending</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">3,432,588</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">3,333,236</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flows</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Cash paid during the year for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Interest expense paid</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">43,842</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">21,666</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in">Income taxes paid</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fs_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217;
EQUITY (DEFICIT)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND
2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated<br/> Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Treasury Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Non</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of <br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subscription <br/> Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Paid-in <br/> Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/> Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Comprehensive<br/> Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">controlling<br/> Interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity<br/> (Deficit)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt; width: 22%">Balance at December&#160;31, 2020</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">24,420,526</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">24,420</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">3,160,360</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">40,751,807</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">25,642,387</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">564,860</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" sign="-" unitRef="shares">275,347</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">9,100,000</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">776,273</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">2,662,067</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c16" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" unitRef="usd">225,740</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" unitRef="usd">225,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c18" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">1,128,505</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c21" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">66,818</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">1,195,323</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cumulative transaction adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="0" format="ixt:num-dot-decimal" name="abvc:CumulativeTransactionAdjustments" scale="0" unitRef="usd">36,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:CumulativeTransactionAdjustments" scale="0" unitRef="usd">36,140</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at March 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">24,420,526</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c22" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">24,420</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c23" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,934,620</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">40,751,807</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c25" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">26,770,892</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c26" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">601,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" sign="-" unitRef="shares">275,347</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c27" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">9,100,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">843,091</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">1,728,624</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><div><a id="fs_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Common Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated<br/> Other</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Treasury Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Non</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amounts</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Subscription <br/> Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Paid-in<br/> Capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated<br/> Deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Comprehensive<br/> Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of <br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">controlling<br/> Interest</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total<br/> Equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt; width: 22%">Balance at December&#160;31, 2021</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">28,926,322</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">28,926</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,257,400</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">58,113,667</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">38,481,200</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">539,660</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" sign="-" unitRef="shares">275,347</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">9,100,000</ix:nonFraction></td><td style="width: 0.5%; text-align: left">)</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">26,689</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">8,870,342</ix:nonFraction></td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Issuance of common shares for consulting service</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,381,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">1,381</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">4,464,882</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">4,466,263</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c37" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" unitRef="usd">225,740</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" scale="0" unitRef="usd">225,740</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Net loss for the period</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">5,995,440</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">92,175</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">6,087,615</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Cumulative transaction adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="abvc:CumulativeTransactionAdjustments" scale="0" sign="-" unitRef="usd">113,339</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:CumulativeTransactionAdjustments" scale="0" sign="-" unitRef="usd">113,339</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Balance at March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">30,307,329</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c42" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">30,307</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,031,660</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">62,578,549</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">44,476,640</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">426,321</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" sign="-" unitRef="shares">275,347</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c47" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">9,100,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c48" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">65,486</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">7,361,391</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>The accompanying notes are an integral part
of these consolidated financial statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><div><a id="fs_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(UNAUDITED)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC BioPharma, Inc. (the &#8220;Company&#8221;),
formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#8217;s operating entity, American
BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology
to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. &#160;BriVision develops
its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision
believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization,
BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly
respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical
trials for the Company&#8217;s drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering
Cancer Center (&#8220;MSKCC&#8221;) and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July
21, 2015.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Name Change</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s shareholders approved an amendment
to the Company&#8217;s Articles of Incorporation to change the Company&#8217;s corporate name from American BriVision (Holding) Corporation
to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders
(the &#8220;Annual Meeting&#8221;). The name change amendment to the Company&#8217;s Articles of Incorporation was filed with Nevada&#8217;s
Secretary of State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became
effective as of May 3, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s stock symbol remains ABVC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Reverse Merger</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2016, a Share Exchange Agreement
(the &#8220;Share Exchange Agreement&#8221;) was entered into by and among the Company, BriVision, and Euro-Asia Investment &amp; Finance
Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&#8217;s Republic of China
(&#8220;Euro-Asia&#8221;), being the owners of record of <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">164,387,376</ix:nonFraction> (<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,336,000</ix:nonFraction> pre-stock split) shares of Common Stock of the Company,
and the owners of record of all of the issued share capital of BriVision (the &#8220;BriVision Stock&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Share Exchange Agreement, upon
surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered
in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision
as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision
Stock in the name of the Company, the Company issued <ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">166,273,921</ix:nonFraction> (<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,936,583</ix:nonFraction> pre-stock split) shares (the &#8220;Acquisition Stock&#8221;)
(subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s Common Stock to the BriVision Shareholders
(or their designees), and <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">163,159,952</ix:nonFraction> (<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">51,945,225</ix:nonFraction> pre-stock split) shares of the Company&#8217;s Common Stock owned by Euro-Asia were
cancelled and retired to treasury. The Acquisition Stock collectively represented <ix:nonFraction contextRef="c71" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageOfCommonSharesIssuedAndOutstanding" scale="-2" unitRef="pure">79.70</ix:nonFraction>% of the issued and outstanding Common Stock of
the Company immediately after the Closing, in exchange for the BriVision Stock, representing <ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfIssuedShareCapital" scale="-2" unitRef="pure">100</ix:nonFraction>% of the issued share capital of BriVision
in a reverse merger (the &#8220;Merger&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger, all of the issued and
outstanding common shares of BriVision were converted, <ix:nonNumeric contextRef="c72" name="us-gaap:StockholdersEquityNoteStockSplit">at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583
pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.</ix:nonNumeric> The holders of Company&#8217;s
Common Stock as of immediately prior to the Merger held an aggregate of <ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">205,519,223</ix:nonFraction> (<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">65,431,144</ix:nonFraction> pre-stock split) shares of Company&#8217;s
Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the &#8220;Share Exchange&#8221;), BriVision had
become a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following
the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of the Share Exchange, BriVision
became a wholly owned subsidiary of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Share Exchange, the Company has
abandoned prior business plan and is now pursuing BriVision&#8217;s historically proposed businesses, which focus on the development of
new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements
from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&#8220;POC&#8221;), out-license
to international pharmaceutical companies, and explore global markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounting Treatment of the Reverse Merger</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, the Share Exchange
represents a &#8220;reverse merger&#8221;&#160;rather than a business combination and&#160;BriVision&#160;is deemed the accounting acquirer
in the transaction. The&#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#160;is the acquirer
for financial reporting purposes and the&#160;Company&#160;is the acquired company. Consequently, the assets and liabilities and the operations
reflected in the historical financial statements prior to the Share Exchange will be those of&#160;BriVision&#160;and recorded at the
historical cost basis of&#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will
include the assets and liabilities of the Company and BriVision, and the historical operations of&#160;BriVision&#160;and operations of
the Combined Company from the closing date of the Share Exchange.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_14" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Merger</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_15" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company, BioLite Holding,
Inc. (&#8220;BioLite&#8221;), BioKey, Inc. (&#8220;BioKey&#8221;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent
(&#8220;Merger Sub 1&#8221;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#8220;Merger Sub 2&#8221;) (collectively
referred to as the &#8220;Parties&#8221;) completed the business combination pursuant to the Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the
shareholders of BioLite and BioKey.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_16" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Merger Agreement,
BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">104,558,777</ix:nonFraction> shares
(prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file
number 333-226285), which became effective by operation of law on or about February 5, 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_17" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite Holding, Inc. (the &#8220;BioLite Holding&#8221;)
was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the &#8220;BioLite BVI&#8221;), a wholly owned
subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are
holding companies and have not carried out substantive business operations of their own.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_18" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite, Inc., (the &#8220;BioLite Taiwan&#8221;)
was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new
botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite
Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_19" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2017, BioLite Holding, BioLite BVI,
BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &#8220;BioLite Share
Purchase / Exchange Agreement&#8221;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the
BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase
shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock
as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately
owns via BioLite BVI approximately <ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfCommonSharesIssuedAndOutstanding" scale="-2" unitRef="pure">73</ix:nonFraction>% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement
retain their equity ownership in BioLite Taiwan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_20" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioKey, Inc. was incorporated on August 9, 2000
in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation
development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials
(Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development
processes with other biotechnology, pharmaceutical, and nutraceutical companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_21" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounting Treatment of the Merger</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 805, &#8220;Business Combination&#8221;
to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang&#8217;s
common control, the transaction is accounted for as a restructuring transaction.&#160;All the assets and liabilities of BioLite Holding,
BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger.
The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding&#8217;s common shares as if the
restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions,
and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity
transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the
earnings (or losses) of the transferred net assets.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;).
All significant intercompany transactions and account balances have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&#8217;s financial statements are expressed in U.S. dollars.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_FiscalPeriod-c0_cont_1" escape="true" name="us-gaap:FiscalPeriod"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fiscal Year</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation id="_FiscalPeriod-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the period
beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January
1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" continuedAt="_InventoryPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inventory</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation id="_InventoryPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" continuedAt="_ForwardStockSplitsPolicyTextBlock-c0_cont_1" escape="true" name="abvc:ForwardStockSplitsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Forward Stock Split</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation id="_ForwardStockSplitsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $<ix:nonFraction contextRef="c76" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share, to <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesAuthorized" scale="0" unitRef="shares">360,000,000</ix:nonFraction>, which was effective on April 8, 2016.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:nonNumeric contextRef="c0" continuedAt="_StockReverseSplitPolicyTextBlock-c0_cont_1" escape="true" name="abvc:StockReverseSplitPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stock Reverse Split</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation id="_StockReverseSplitPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2019, the Board of Directors of the
Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#8220;Reverse
Split&#8221;) of both the authorized common stock of the Company (the &#8220;Common Stock&#8221;) and the issued and outstanding Common
Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the
Reverse Split without obtaining approval of the Company&#8217;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On
May 3, 2019, <ix:nonNumeric contextRef="c77" name="us-gaap:StockholdersEquityReverseStockSplit">the Company filed a certificate of amendment to the Company&#8217;s articles of incorporation (the &#8220;Amendment&#8221;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) informed
the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect
this 1-for-18 reverse stock split.</ix:nonNumeric>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair Value Measurements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the
assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&#8217;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short.
The carrying value of the Company&#8217;s long-term bank loan approximates fair value because the interest rates approximate market rates
that the Company could obtain for debt with similar terms and maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cash and Cash Equivalents</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2022 and December 31, 2021, the Company&#8217;s
cash and cash equivalents amounted $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">2,717,936</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">5,828,548</ix:nonFraction>, respectively. Some&#160;of the Company&#8217;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Restricted Cash Equivalents</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2022 and December 31, 2021, the Company&#8217;s restricted cash equivalents
amounted $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="0" unitRef="usd">714,652</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="0" unitRef="usd">736,667</ix:nonFraction>, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#8217;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#8217;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&#8217;s revenue during all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within
the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the
goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the
scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price
that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborative Revenues &#8212; </b>The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees,
development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales
of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed
products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_6" id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_7" id="_RevenueRecognitionPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing
activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s judgment.
Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited to,
the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated
duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on
a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_8" id="_RevenueRecognitionPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) Non-refundable upfront payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_9" id="_RevenueRecognitionPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and
it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_10" id="_RevenueRecognitionPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) Milestone payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_11" id="_RevenueRecognitionPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to receive milestone payments
under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial
events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into
two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration
partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative agreement with
collaboration partners.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_12" id="_RevenueRecognitionPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded
that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each
triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more
of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional
payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete
each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi)
a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone
payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in
the period in which the underlying triggering event occurs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_13" id="_RevenueRecognitionPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) Multiple Element Arrangements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_14" id="_RevenueRecognitionPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s),
delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an
item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_15" id="_RevenueRecognitionPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which is
typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance or objectively
measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over
the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service
is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue
under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount
of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance
method, as applicable, as of the period ending date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_16" id="_RevenueRecognitionPolicyTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable
relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical,
regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment
required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether
a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive
are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other
revenue recognition criteria are met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_17" id="_RevenueRecognitionPolicyTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iv) Royalties and Profit Sharing Payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_18" id="_RevenueRecognitionPolicyTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is
resolved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_19" id="_RevenueRecognitionPolicyTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues Derived from Research and Development
Activities Services &#8212; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception
of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request
that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_20" id="_RevenueRecognitionPolicyTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset
to research and development expenses as it satisfies the related performance obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_21" id="_RevenueRecognitionPolicyTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and Equipment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:nonNumeric contextRef="c0" escape="true" name="abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated&#160;Life<br/> in Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Buildings and leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c78" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> ~ <ix:nonNumeric contextRef="c79" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">50</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c80" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> ~ <ix:nonNumeric contextRef="c81" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office equipment</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c82" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric> ~ <ix:nonNumeric contextRef="c83" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">6</ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted Accounting Standards Codification
subtopic 360-10, Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable
intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events
and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring
losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated,
the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and
ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or
the fair value less costs to sell.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:nonNumeric contextRef="c0" continuedAt="_LongTermEquityInvestmentPolicy-c0_cont_1" escape="true" name="abvc:LongTermEquityInvestmentPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Long-term Equity Investment</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:continuation continuedAt="_LongTermEquityInvestmentPolicy-c0_cont_2" id="_LongTermEquityInvestmentPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company
does not have control over the investees as:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:continuation continuedAt="_LongTermEquityInvestmentPolicy-c0_cont_3" id="_LongTermEquityInvestmentPolicy-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation continuedAt="_LongTermEquityInvestmentPolicy-c0_cont_4" id="_LongTermEquityInvestmentPolicy-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Non-marketable cost method investments when the equity method does not apply.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:continuation id="_LongTermEquityInvestmentPolicy-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant judgment is required to identify whether
an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, and therefore the Company considers this
a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact
on the investee&#8217;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term
prospects of the investee, changes in general market conditions in the investee&#8217;s industry or geographic area, and the management
and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market
and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent
financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding
the investees&#8217; revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment
exists could change in the future due to new developments or changes in applied assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:nonNumeric contextRef="c0" continuedAt="_OtherThanTemporaryImpairmentPolicyTextBlock-c0_cont_1" escape="true" name="abvc:OtherThanTemporaryImpairmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Other-Than-Temporary Impairment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:continuation continuedAt="_OtherThanTemporaryImpairmentPolicyTextBlock-c0_cont_2" id="_OtherThanTemporaryImpairmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation continuedAt="_OtherThanTemporaryImpairmentPolicyTextBlock-c0_cont_3" id="_OtherThanTemporaryImpairmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#8217;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:continuation id="_OtherThanTemporaryImpairmentPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Non-marketable equity investments based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairment of equity investments were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:ImpairmentOfEquityInvestments" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:ImpairmentOfEquityInvestments" scale="0" unitRef="usd">0</ix:nonFraction> for the three months ended March 31, 2022 and 2021, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:nonNumeric contextRef="c0" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Goodwill</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing
goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that
the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our
best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share,
and general economic conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company completed the required testing of
goodwill for impairment as of March 31, 2022, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For CDMO business unit, the Company accounts for
R&amp;D costs in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, Research and Development (&#8220;ASC 730&#8221;).
Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development
projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities,
including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing
and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable
advance payment for goods and services that will be used in future research and development activities are expensed when the activity
has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into
agreements with third parties to provide research and development services, costs are expensed as services are performed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:nonNumeric contextRef="c0" continuedAt="_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy-c0_cont_1" escape="true" name="us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Post-retirement and post-employment benefits</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:continuation id="_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abvc:LabourPensionFundPercentage" scale="-2" unitRef="pure">6</ix:nonFraction>% of the worker&#8217;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfMonthlyContribution" scale="-2" unitRef="pure">6</ix:nonFraction>% of employees&#8217; salaries to the employees&#8217;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="0" unitRef="usd">3,337</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="0" unitRef="usd">2,503</ix:nonFraction> for the three months ended March 31, 2022 and 2021, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_71" id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:nonNumeric contextRef="c0" continuedAt="_CompensationRelatedCostsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Stock-based Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_72" id="_SignificantAccountingPoliciesTextBlock-c0_cont_71"><ix:continuation continuedAt="_CompensationRelatedCostsPolicyTextBlock-c0_cont_2" id="_CompensationRelatedCostsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;.
Total employee stock-based compensation expenses were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">0</ix:nonFraction> for the three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_73" id="_SignificantAccountingPoliciesTextBlock-c0_cont_72"><ix:continuation id="_CompensationRelatedCostsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221; and FASB ASC Topic 505-50 &#8220;Equity-Based
Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockBasedCompensationForNonemployees" scale="0" unitRef="usd">4,692,003</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockBasedCompensationForNonemployees" scale="0" unitRef="usd">225,740</ix:nonFraction> for the three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_74" id="_SignificantAccountingPoliciesTextBlock-c0_cont_73"><ix:nonNumeric contextRef="c0" continuedAt="_BeneficialConversionFeature-c0_cont_1" escape="true" name="abvc:BeneficialConversionFeature"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Beneficial Conversion Feature</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_75" id="_SignificantAccountingPoliciesTextBlock-c0_cont_74"><ix:continuation id="_BeneficialConversionFeature-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_76" id="_SignificantAccountingPoliciesTextBlock-c0_cont_75"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_77" id="_SignificantAccountingPoliciesTextBlock-c0_cont_76"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_78" id="_SignificantAccountingPoliciesTextBlock-c0_cont_77"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is&#160;&#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than <ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanFundedPercentage" scale="-2" unitRef="pure">50</ix:nonFraction> percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2022 and 2021. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_79" id="_SignificantAccountingPoliciesTextBlock-c0_cont_78"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&#8220;SAB 118&#8221;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC
740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is
able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company
cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of
the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable
estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act
may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that
may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine
the final impact.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_80" id="_SignificantAccountingPoliciesTextBlock-c0_cont_79"><ix:nonNumeric contextRef="c0" continuedAt="_ValuationOfDeferredTaxAssetsPolicyTextBlock-c0_cont_1" escape="true" name="abvc:ValuationOfDeferredTaxAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_81" id="_SignificantAccountingPoliciesTextBlock-c0_cont_80"><ix:continuation id="_ValuationOfDeferredTaxAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_82" id="_SignificantAccountingPoliciesTextBlock-c0_cont_81"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Loss Per Share of Common Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_83" id="_SignificantAccountingPoliciesTextBlock-c0_cont_82"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company calculates net loss per share in accordance
with ASC Topic 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted average
number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that
the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common
stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_84" id="_SignificantAccountingPoliciesTextBlock-c0_cont_83"><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commitments and Contingencies</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_85" id="_SignificantAccountingPoliciesTextBlock-c0_cont_84"><ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted ASC Topic 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies
are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates
that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount
of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency
is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably
possible that a material loss could be incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_86" id="_SignificantAccountingPoliciesTextBlock-c0_cont_85"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Foreign-currency Transactions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_87" id="_SignificantAccountingPoliciesTextBlock-c0_cont_86"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the transactions
occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into
New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion
or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange
rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares
of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#8217; Equity (Deficit).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_88" id="_SignificantAccountingPoliciesTextBlock-c0_cont_87"><ix:nonNumeric contextRef="c0" continuedAt="_TranslationAdjustmentPolicyTextBlock-c0_cont_1" escape="true" name="abvc:TranslationAdjustmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Translation Adjustment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_89" id="_SignificantAccountingPoliciesTextBlock-c0_cont_88"><ix:continuation id="_TranslationAdjustmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounts of the Company&#8217;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#8220;NT$&#8221;). Such financial statements
were translated into U.S. Dollars (&#8220;$&#8221; or &#8220;USD&#8221;) in accordance ASC 830, &#8220;Foreign Currency Matters&#8221;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&#8217;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#8217;
equity (deficit).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_90" id="_SignificantAccountingPoliciesTextBlock-c0_cont_89"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_91" id="_SignificantAccountingPoliciesTextBlock-c0_cont_90"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06, Debt
&#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity
(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). ASU
2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models.
Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not
clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will
reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings
per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For
contracts in an entity&#8217;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features
that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements
to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted,
and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted,
but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company
is currently evaluating the impact that the standard will have on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_91"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2">In May 2021, the FASB issued ASU 2021-04, Earnings
Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic
718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain
Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04 provides guidance
as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written
call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new
instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified
or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model
that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination,
debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for
all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should
apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early
adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an
interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period.</ix:continuation> The Company is
currently evaluating the impact that the standard will have on its consolidated financial statements.&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CollaborativeArrangementDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. COLLABORATIVE AGREEMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_2" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Collaborative agreements with BHK</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_3" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) On February 24, 2015, BioLite Taiwan and BioHopeKing
Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;), pursuant
to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination
Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for
medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The
BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia
excluding Japan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_4" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $<ix:nonFraction contextRef="c84" decimals="-6" format="ixt:num-dot-decimal" name="abvc:MilestonePayments" scale="6" unitRef="usd">10</ix:nonFraction> million based on the following schedule:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_5" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><ix:nonNumeric contextRef="c84" continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_1" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement"><span style="font-size: 10pt">&#9679;</span></ix:nonNumeric></td> <td style="text-align: justify"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_2" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_1"><span style="font-size: 10pt">Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_6" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_5"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_3" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_7" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_6"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_4" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">At the completion of first phase II clinical trial: $1 million, or 10% of total payment</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_8" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_7"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_5" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_9" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_6" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_5">&#160;</ix:continuation></td> <td style="width: 24px"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_7" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_6"><span style="font-size: 10pt">&#9679;</span></ix:continuation></td> <td style="text-align: justify"><ix:continuation id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c84_cont_7"><span style="font-size: 10pt">Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_10" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, BHK has paid a non-refundable
upfront cash payment of $<ix:nonFraction contextRef="c85" decimals="-6" format="ixt:num-dot-decimal" name="abvc:UpfrontCashPayment" scale="6" unitRef="usd">1</ix:nonFraction> million, or <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure">10</ix:nonFraction>% of $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="0" unitRef="usd">10,000,000</ix:nonFraction>, upon the signing of BHK Co-Development Agreement. The Company concluded that
the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and
recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015.
The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement
was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August
2016, the Company has received the second milestone payment of NT$<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abvc:MilestonePayments" scale="0" unitRef="twd">31,649,000</ix:nonFraction>, approximately equivalent to $<ix:nonFraction contextRef="c87" decimals="-6" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="6" unitRef="usd">1</ix:nonFraction> million, and recognized collaboration
revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical
trial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_11" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure">12</ix:nonFraction>% of BHK&#8217;s net sales related to BLI-1401-2 Products. As of March 31, 2022 and December
31, 2021, the Company has not earned the royalty under the BHK Co-Development Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_12" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#8220;BHK Collaborative Agreements&#8221;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#8220;Targeting Major Depressive Disorder&#8221; (BLI-1005 Products) and BLI-1006 for
&#8220;Targeting Inflammatory Bowel Disease&#8221; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights,
and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between
BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of
the Product in in Asia excluding Japan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_13" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c86" name="abvc:CollaborativeAgreementsDescription">In 2015, the Company recognized the cash receipt
in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK.</ix:nonNumeric> The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_14" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c88" name="abvc:CollaborativeAgreementsDescription">In addition to the total of NT$50 million, approximately
equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.</ix:nonNumeric> As of March
31, 2022 and December 31, 2021, the Company has not earned the royalty under the BHK Collaborative Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_15" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Co-Development agreement with Rgene Corporation,
a related party</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_16" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2017, BriVision entered into a co-development
agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party under common control
by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to Co-Dev Agreement, BriVision
and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer
Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to&#160;pay
the Company $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForParticipationLiabilities" scale="0" unitRef="usd">3,000,000</ix:nonFraction> in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision&#8217;s
past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future
commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to $<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionCashPayment" scale="0" unitRef="usd">3,000,000</ix:nonFraction>, the Company is entitled to receive <ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure">50</ix:nonFraction>% of
the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both
BriVision and Rgene.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_17" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2017, the Company has delivered all
research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd">3,000,000</ix:nonFraction>
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended December
31, 2017, the Company has received $<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" scale="0" unitRef="usd">450,000</ix:nonFraction> in cash. On December 24, 2018, <ix:nonNumeric contextRef="c92" name="abvc:CoDevAgreementDescription">the Company received the remaining balance of $2,550,000 in
the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for
an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year
ended December 31, 2018, the Company has recognized investment loss of $549.</ix:nonNumeric> On December 31, 2018, the Company determined to fully write
off this investment based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative
analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment,
changes in operating structure of Rgene, additional funding requirements, and Rgene&#8217;s ability to remain in business. All projects
that have been initiated will be managed and supported by the Company and Rgene.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_18" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Rgene signed an amendment to the
Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination
Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and
ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions
of the Co-Dev Agreement remain in full force and effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_19" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Collaborative agreement with BioFirst Corporation,
a related party</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_20" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, BriVision entered into a collaborative
agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst Corporation (&#8220;BioFirst&#8221;), pursuant to which BioFirst
granted the Company the global licensing right for medical use of the product (the &#8220;Product&#8221;): BFC-1401 Vitreous Substitute
for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the
Company is one of the directors and Common Stock shareholders of BioFirst (See Note 12).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_21" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $<ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="0" unitRef="usd">3,000,000</ix:nonFraction> in cash or stock
of the Company before September 30, 2018. The amount of $<ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForParticipationLiabilities" scale="0" unitRef="usd">3,000,000</ix:nonFraction> is in connection with the compensation for BioFirst&#8217;s past research
efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future
commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive <ix:nonFraction contextRef="c93" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure">50</ix:nonFraction>%
of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and
BioFirst.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_22" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">3,000,000</ix:nonFraction>
since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
immediately. Hence, the entire amount of $<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">3,000,000</ix:nonFraction> is fully expensed as research and development expense during the year ended December
31, 2017.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_23" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2019, BriVision entered into a Stock
Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst Corporation. Pursuant to the Purchase Agreement, the Company issued
<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">428,571</ix:nonFraction> shares of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" scale="0" unitRef="usd">3,000,000</ix:nonFraction> owed by the Company to BioFirst (the &#8220;Total
Payment&#8221;) in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the &#8220;Collaborative
Agreement&#8221;). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401
or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2019, BriVision entered into a second
Stock Purchase Agreement (&#8220;Purchase Agreement 2&#8221;) with BioFirst Corporation. Pursuant to Purchase Agreement 2, the Company
issued <ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">414,702</ix:nonFraction> shares of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" scale="0" unitRef="usd">2,902,911</ix:nonFraction> owed by the Company to BioFirst
in connection with a loan provided to BriVision from BioFirst.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InventoryDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. INVENTORY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_InventoryDisclosureTextBlock-c0_cont_2" id="_InventoryDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.9pt; text-align: justify; text-indent: -22.9pt"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_InventoryDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Finished goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">104,036</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">96,725</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Raw materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">69,287</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">84,620</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:AllowanceForInventoryValuationAndObsolescenceLoss" scale="0" sign="-" unitRef="usd">150,623</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:AllowanceForInventoryValuationAndObsolescenceLoss" scale="0" sign="-" unitRef="usd">155,370</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Inventory, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">22,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="0" unitRef="usd">25,975</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.9pt; text-align: justify; text-indent: -22.9pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. PROPERTY AND EQUIPMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">Property and
equipment as of March 31, 2022 and December 31, 2021 are summarized as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Land</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">387,866</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">400,091</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Buildings and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c100" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">2,230,968</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">2,235,061</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,102,943</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,013,376</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">186,149</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">191,824</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">3,907,926</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">3,840,352</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">3,309,278</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">3,314,471</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">598,648</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentOtherNet" scale="0" unitRef="usd">525,881</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="0" unitRef="usd">5,411</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="0" unitRef="usd">2,928</ix:nonFraction> for
three months ended March 31, 2022 and 2021, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LongTermInvestmentTextBlock-c0_cont_1" escape="true" name="abvc:LongTermInvestmentTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b>6. LONG-TERM INVESTMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_2" id="_LongTermInvestmentTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The ownership percentages of
each investee are listed as follows:</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 331.3pt">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_3" id="_LongTermInvestmentTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Accounting</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">treatments</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c112" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.17</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c113" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.17</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center"><ix:nonNumeric contextRef="c114" name="abvc:AccountingTreatmentDescription">Cost Method</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c115" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.70</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c116" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.70</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c117" name="abvc:AccountingTreatmentDescription">Cost Method</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c118" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">5.90</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c119" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">5.90</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c120" name="abvc:AccountingTreatmentDescription">Cost Method</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c108" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">15.99</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c109" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">15.99</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c106" name="abvc:AccountingTreatmentDescription">Equity Method</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rgene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c121" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">31.62</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c122" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">31.62</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center"><ix:nonNumeric contextRef="c110" name="abvc:AccountingTreatmentDescription">Equity Method</ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_4" id="_LongTermInvestmentTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The extent the investee relies
on the company for its business are summarized as follows:</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_5" id="_LongTermInvestmentTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="abvc:ScheduleOfExtentInvesteeReliesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left">Name of related party</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left">The extent the investee relies on the Company for its business </td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c114" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">No specific business relationship</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c117" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">No specific business relationship</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c120" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Collaborating with the Company to develop and commercialize drugs</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c106" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Collaborating with the Company to develop and commercialize drugs</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rgene Corporation</td><td>&#160;</td>
    <td style="text-align: left"><ix:nonNumeric contextRef="c110" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Collaborating with the Company to develop and commercialize drugs</ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>&#160;&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_6" id="_LongTermInvestmentTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Long-term investment mainly
consists of the following:</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_7" id="_LongTermInvestmentTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="abvc:ScheduleOfLongTermInvestmentTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-marketable Cost Method Investments, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c123" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">7,698</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">7,941</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Genepharm Biotech Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">23,503</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">24,244</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">BioHopeKing Corporation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">873,053</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">900,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Sub total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">904,254</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">932,755</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity Method Investments, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Rgene Corporation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd">904,254</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd">932,755</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_8" id="_LongTermInvestmentTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_9" id="_LongTermInvestmentTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2022 and December
31, 2021, the Company owns <ix:nonFraction contextRef="c106" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">15.99</ix:nonFraction>% and <ix:nonFraction contextRef="c107" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">15.99</ix:nonFraction>% common stock shares of BioFirst, respectively. The Company made prepayment for equity investment
in BioFirst to purchase additional <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:PurchaseAdditionalShares" scale="0" unitRef="shares">317,000</ix:nonFraction> shares to be issued by BioFirst in the aggregate amount of $<ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">663,798</ix:nonFraction> and $<ix:nonFraction contextRef="c109" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">684,720</ix:nonFraction>, recorded
as prepayment for long-term investments as of March 31, 2022 and December 31, 2021, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_10" id="_LongTermInvestmentTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summarized financial information for the Company&#8217;s
equity method investee, BioFirst, is as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_11" id="_LongTermInvestmentTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Balance Sheet</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_12" id="_LongTermInvestmentTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCondensedBalanceSheetTableTextBlock-c0_cont_1" escape="true" name="pf0:ScheduleOfCondensedBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">2,147,097</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">2,205,669</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">812,865</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">959,454</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">3,237,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">2,909,703</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">17,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">32,522</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOther" scale="0" sign="-" unitRef="usd">295,402</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOther" scale="0" unitRef="usd">222,898</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_13" id="_LongTermInvestmentTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Statement of Operations</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_14" id="_LongTermInvestmentTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCondensedIncomeStatementTableTextBlock-c0_cont_1" escape="true" name="pf0:ScheduleOfCondensedIncomeStatementTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetSales" scale="0" unitRef="usd">8,808</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetSales" scale="0" unitRef="usd">12,339</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="abvc:GrossProfits" scale="0" unitRef="usd">6,133</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="abvc:GrossProfits" scale="0" unitRef="usd">7,080</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="abvc:LongTermInvestmentNetLoss" scale="0" sign="-" unitRef="usd">498,940</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="abvc:LongTermInvestmentNetLoss" scale="0" sign="-" unitRef="usd">220,855</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share of losses from investments accounted for using the equity method</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c141" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" sign="-" unitRef="usd">47,791</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_15" id="_LongTermInvestmentTextBlock-c0_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(b)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_16" id="_LongTermInvestmentTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Both Rgene and the Company are under
common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant
influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2022 and December
31, 2021, the Company owns <ix:nonFraction contextRef="c110" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">31.62</ix:nonFraction>% and <ix:nonFraction contextRef="c111" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">31.62</ix:nonFraction>% Common Stock shares of Rgene, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_17" id="_LongTermInvestmentTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summarized financial information for the Company&#8217;s
equity method investee, Rgene, is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_18" id="_LongTermInvestmentTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Balance Sheets</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_19" id="_LongTermInvestmentTextBlock-c0_cont_18"><ix:continuation id="_ScheduleOfCondensedBalanceSheetTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">221,169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">73,452</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">355,420</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">374,423</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">2,164,077</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">1,934,786</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shareholders&#8217; Deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOther" scale="0" sign="-" unitRef="usd">1,587,488</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOther" scale="0" sign="-" unitRef="usd">1,486,911</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_20" id="_LongTermInvestmentTextBlock-c0_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Statement of Operations</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_21" id="_LongTermInvestmentTextBlock-c0_cont_20"><ix:continuation id="_ScheduleOfCondensedIncomeStatementTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net sales</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross Profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c139" decimals="0" format="ixt:num-dot-decimal" name="abvc:LongTermInvestmentNetLoss" scale="0" sign="-" unitRef="usd">149,480</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c142" decimals="0" format="ixt:num-dot-decimal" name="abvc:LongTermInvestmentNetLoss" scale="0" sign="-" unitRef="usd">95,395</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share of loss from investments accounted for using the equity method</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_22" id="_LongTermInvestmentTextBlock-c0_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Disposition of long-term investment</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_23" id="_LongTermInvestmentTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the three months ended March
31, 2022 and 2021, there is no disposition of long-term investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_24" id="_LongTermInvestmentTextBlock-c0_cont_23"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Losses on Equity Investments</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c0_cont_25" id="_LongTermInvestmentTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of losses on equity investments
for each period were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LongTermInvestmentTextBlock-c0_cont_25"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:EquityMethodInvestmentsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Share of equity method investee losses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:ShareOfEquityMethodInvesteeLosses" scale="0" sign="-" unitRef="usd">47,791</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_1" escape="true" name="abvc:ConvertibleNotesPayableDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. CONVERTIBLE NOTES PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_2" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 9, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &#8220;Yu and Wei Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAmount" scale="0" unitRef="usd">300,000</ix:nonFraction> to Guoliang
Yu and Yingfei Wei Family Trust (the &#8220;Yu and Wei&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">300,000</ix:nonFraction>. The Yu and Wei Note bears
interest at <ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">8</ix:nonFraction>% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019.
In the event that the Company raises gross proceeds from the sale of its common stock of at least $<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">5,000,000</ix:nonFraction> (an &#8220;Equity Offering&#8221;)
then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any
time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal
plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion
price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $<ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">2.00</ix:nonFraction> per share (the &#8220;Fixed Conversion Price&#8221;), subject
to adjustment or (ii) <ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="abvc:SharesOfferingPricePercentage" scale="-2" unitRef="pure">80</ix:nonFraction>% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering
of the Company in an amount exceeding $<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValueOutstanding" scale="0" unitRef="usd">500,000</ix:nonFraction> that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments
set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial
conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears
interest at <ix:nonFraction contextRef="c147" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#8220;Yu and Wei&#8221; Note, which is on January
20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#8220;Yu and Wei&#8221;. The aggregate principal amount
plus accrued interest expenses were $<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAndAccruedInterestExpense" scale="0" unitRef="usd">354,722</ix:nonFraction>, and the Company agreed to issue to the Holders an aggregate of <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">192,784</ix:nonFraction> shares of the Company&#8217;s
common stock, and warrants to purchase <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">192,784</ix:nonFraction> shares of the Company&#8217;s common stock. These common shares have been issued during
the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_3" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 27, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &#8220;Keypoint Note&#8221;) in the aggregate principal amount of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to Keypoint
Technology Ltd. (&#8220;Keypoint&#8221;), a related party, pursuant to which the Company received $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">250,000</ix:nonFraction>. The Keypoint Note bears interest
at <ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">8</ix:nonFraction>% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event
that the Company raises gross proceeds from the sale of its common stock of at least $<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">5,000,000</ix:nonFraction> (an &#8220;Equity Offering&#8221;) then
within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from
the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of <ix:nonNumeric contextRef="c151" name="us-gaap:ConversionOfStockDescription">the Company&#8217;s common stock at a conversion price (the &#8220;Conversion
Price&#8221;) equal to the lower of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80%
of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an
amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint
Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature
present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum.
The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the
Twelve (12) month anniversary of the issuance date of the new &#8220;Keypoint&#8221; Note, which is on January 20, 2021. On April 5, 2020,
the Company entered into an exchange agreement with &#8220;Keypoint&#8221;. The aggregate principal amount plus accrued interest expenses
were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#8217;s common stock, and
warrants to purchase 159,145 shares of the Company&#8217;s common stock.</ix:nonNumeric> These common shares have been issued during the year ended December
31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_4" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2018, the Company issued an eighteen-month
term unsecured convertible promissory notes (the &#8220;Odaira Note&#8221;) in the aggregate principal amount of $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to Yoshinobu
Odaira. (&#8220;Odaira&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">250,000</ix:nonFraction>. The Odaira Note bears interest at <ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">8</ix:nonFraction>% per annum. The Company
shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18)
month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds
from the sale of its common stock of at least $<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">5,000,000</ix:nonFraction> (an &#8220;Equity Offering&#8221;) then within five days of the closing for such
offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has
been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest,
if any, into shares of <ix:nonNumeric contextRef="c154" name="us-gaap:ConversionOfStockDescription">the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower
of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80% of the per share offering price (the
&#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs
when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20,
the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21,
2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount
in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date
of the new &#8220;Odaira&#8221; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with
&#8220;Odaira&#8221;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to
the Holders an aggregate of 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s
common stock.</ix:nonNumeric> These common shares have been issued during the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_5" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 30 and July 10, 2019, the Company issued
two (2) twelve-month term unsecured convertible promissory notes (the &#8220;KSL Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAmount" scale="0" unitRef="usd">250,000</ix:nonFraction>
to Kuo Sheng Lung (the &#8220;KSL&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">160,000</ix:nonFraction> and $<ix:nonFraction contextRef="c158" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">90,000</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="c157" name="us-gaap:SaleOfStockDescriptionOfTransaction">The KSL Note bears
interest at <ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020.</ix:nonNumeric> At any
time from the issuance date until the KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of <ix:nonNumeric contextRef="c157" name="us-gaap:ConversionOfStockDescription">the Company&#8217;s common stock at a conversion price (the &#8220;Conversion
Price&#8221;) equal to the lower of (i) $0.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70%
of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company
in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission
on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company
recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company
received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company
entered into an agreement with &#8220;KSL&#8221;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL
agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the
Company agreed to issue 120,121 shares of the Company&#8217;s common stock and warrants for a purchase price of $270,272.&#160;During
the year ended December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company&#8217;s common stock.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_6" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 10, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#8220;NEA Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to New Eastern Asia
(the &#8220;NEA&#8221;), a related party, pursuant to which the Company received $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">250,000</ix:nonFraction> on July 10, 2019. The NEA Note bears interest
at <ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof
until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;)
equal to the lower of (i) $<ix:nonFraction contextRef="c161" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">.50</ix:nonFraction> per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) <ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">70</ix:nonFraction>% of the per share
offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding
$<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="abvc:PublicEquityOfferingExceedAmount" scale="0" unitRef="usd">10,000,000</ix:nonFraction> as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the NEA Note. During the year ended December 31, 2020, the Company
issued <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:SharesIssued1" scale="0" unitRef="shares">111,112</ix:nonFraction> shares of common stock to repay the outstanding balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_7" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 28, 2019, <ix:nonNumeric contextRef="c163" name="us-gaap:ConversionOfStockDescription">the Company issued a twelve-month
term unsecured convertible promissory note (the &#8220;KLS Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAmount" scale="0" unitRef="usd">200,000</ix:nonFraction> to Kuo Li Shen (the
&#8220;KLS&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">200,000</ix:nonFraction> on August 28, 2019. The KLS Note bears interest at <ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum.
The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this
KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default
interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to
the lower of (i) $.<ix:nonNumeric contextRef="c166" continuedAt="_ConversionOfStockDescription-c166_cont_1" name="us-gaap:ConversionOfStockDescription">50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering
price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public
Offering&#8221;), as amended from time to time.</ix:nonNumeric></ix:nonNumeric><ix:continuation continuedAt="_ConversionOfStockDescription-c166_cont_2" id="_ConversionOfStockDescription-c166_cont_1"> In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value
of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with
KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate
of 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have
been issued during the year ended December 31, 2020</ix:continuation></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_8" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_7"><ix:continuation id="_ConversionOfStockDescription-c166_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 4, 2019, the Company issued 3 twelve-month
term unsecured convertible promissory note (the &#8220;C.L.L. Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAmount" scale="0" unitRef="usd">257,500</ix:nonFraction> to Chang Ping
Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &#8220;C.L.L.&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">257,500</ix:nonFraction> on September
4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at <ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The
Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until
this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;)
equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into
an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed
to issue to the Holders an aggregate of 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of
common stock. These common shares have been issued during the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_9" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 29, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#8220;Lee Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to Hwalin Lee (the
&#8220;Lee&#8221;), a related party, pursuant to which the Company received $<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">250,000</ix:nonFraction> on October 29, 2019. The Lee Note bears interest
at <ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof
until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;)
equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the Lee Note. In January 2021, the Company paid off the convertible
promissory note of $306,836, including principal and accrued and unpaid interest expense.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_10" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2020, the Company entered into
a Securities Purchase Agreement (the &#8220;October SPA&#8221;) with one accredited investor. <ix:nonNumeric contextRef="c171" name="us-gaap:ConversionOfStockDescription">Pursuant to the October SPA, the Company
sold and issued a convertible promissory note (the &#8220;October Note&#8221;) in the principal amount of $2,500,000 to the investor and
received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of
the October Note is the twenty-four (24) month anniversary from the issuance date (the &#8220;Maturity Date&#8221;). Upon the Maturity
Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest
under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the
Company&#8217;s common stock at a fixed conversion price of $2.25 per share.</ix:nonNumeric> The holder of the October Note may elect to convert part
or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding
amount at any time, in whole or in part, without any penalty.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_11" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 17, 2021, the parties to the October SPA
signed Amendment No. 1 to Promissory Note (the &#8220;Amendment&#8221;). Pursuant to the Amendment, the Note shall also be automatically
converted into shares of the Company&#8217;s common stock immediately following the Company&#8217;s receipt of conditional approval to
list its common stock on the NASDAQ stock market, if and when the Company receives such approval, at a conversion price equal to $<ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">2.25</ix:nonFraction>
per share.&#160;On July 21, 2021, The Company converted all convertible promissory note amounted $<ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConvertiblePromissoryNote" scale="0" unitRef="usd">2,500,000</ix:nonFraction> into <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">1,111,112</ix:nonFraction> shares of the
Company&#8217;s common stock and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_12" id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022 and December 31, 2021, the
aggregate carrying values of the convertible debentures were both $<ix:nonFraction contextRef="c175" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd">0</ix:nonFraction>; and accrued convertible interest were both $<ix:nonFraction contextRef="c176" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">0</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ConvertibleNotesPayableDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total interest expenses in connection with the
above convertible note payable were $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c7" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="0" unitRef="usd">66,897</ix:nonFraction> for the three months ended March 31, 2022 and 2021, respectively.&#160;&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BankLoansTextBlock-c0_cont_1" escape="true" name="abvc:BankLoansTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. BANK LOANS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_2" id="_BankLoansTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Short-term bank loan consists
of the following:</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_3" id="_BankLoansTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cathay United Bank</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c194" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">261,750</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">270,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CTBC Bank</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">698,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">720,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cathay Bank</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">650,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">650,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,609,750</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,640,000</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_4" id="_BankLoansTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cathay United Bank</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_5" id="_BankLoansTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2016, BioLite Taiwan and Cathay United
Bank entered into a one-year bank loan agreement (the &#8220;Cathay United Loan Agreement&#8221;) in an amount of NT$<ix:nonFraction contextRef="c177" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent
to $<ix:nonFraction contextRef="c178" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">261,750</ix:nonFraction>. The term started June 28, 2016 with maturity date at <ix:nonNumeric contextRef="c179" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">June 28, 2017</ix:nonNumeric>. The loan balance bears interest at a floating rate of
prime rate plus <ix:nonFraction contextRef="c178" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">1.15</ix:nonFraction>%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite
Taiwan extended the Cathay United Loan Agreement for <ix:nonNumeric contextRef="c180" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, which was due on September 6, 2018, with the principal amount of NT$<ix:nonFraction contextRef="c181" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>,
equivalent to $<ix:nonFraction contextRef="c182" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">261,750</ix:nonFraction>. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of
NT$<ix:nonFraction contextRef="c183" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c184" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">261,750</ix:nonFraction> for <ix:nonNumeric contextRef="c185" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the
Cathay United Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">261,750</ix:nonFraction> for <ix:nonNumeric contextRef="c188" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, which is due on September
6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c189" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>,
equivalent to $<ix:nonFraction contextRef="c190" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">261,750</ix:nonFraction> for <ix:nonNumeric contextRef="c191" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, which is due on September 6, 2021. On September 6, 2021, BioLite Taiwan extended the Cathay United
Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c192" decimals="0" format="ixt:num-dot-decimal" name="abvc:principalAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="abvc:principalAmount" scale="0" unitRef="usd">261,750</ix:nonFraction>&#160;for&#160;one year, which is due on September
6, 2022. As of March 31, 2022 and December 31, 2021, the effective interest rates per annum was <ix:nonFraction contextRef="c194" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">2.1</ix:nonFraction>%. The loan is collateralized by the
building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company&#8217;s chairman.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_6" id="_BankLoansTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $<ix:nonFraction contextRef="c195" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">1,386</ix:nonFraction> and $<ix:nonFraction contextRef="c196" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">1,383</ix:nonFraction> for the
three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_7" id="_BankLoansTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">CTBC Bank</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_8" id="_BankLoansTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2017 and July 19, 2017, BioLite Taiwan
and CTBC Bank entered into short-term saving secured bank loan agreements (the &#8220;CTBC Loan Agreements&#8221;) in an amount of NT$<ix:nonFraction contextRef="c197" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">10,000,000</ix:nonFraction>,
equivalent to $<ix:nonFraction contextRef="c198" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">349,000</ix:nonFraction>, and NT$<ix:nonFraction contextRef="c199" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">10,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c200" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">349,000</ix:nonFraction>, respectively. Both two loans with the same maturity date at <ix:nonNumeric contextRef="c202" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate"><ix:nonNumeric contextRef="c201" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">January
19, 2018</ix:nonNumeric></ix:nonNumeric>. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for <ix:nonNumeric contextRef="c203" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>. On January 18, 2019,
BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan
extended the CTBC Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c204" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">698,000</ix:nonFraction> for <ix:nonNumeric contextRef="c206" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due
on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>,
equivalent to $<ix:nonFraction contextRef="c208" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">698,000</ix:nonFraction> for <ix:nonNumeric contextRef="c209" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement
with the same principal amount of NT$<ix:nonFraction contextRef="c210" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c211" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">698,000</ix:nonFraction> for <ix:nonNumeric contextRef="c212" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due on January 15, 2021. On January 15,
2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">698,000</ix:nonFraction> for <ix:nonNumeric contextRef="c215" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six
months</ix:nonNumeric>, which is due on July 15, 2021. On July 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount
of NT$<ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">698,000</ix:nonFraction> for <ix:nonNumeric contextRef="c218" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due on January 14, 2022. On January 14, 2022, BioLite Taiwan extended
the CTBC Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="abvc:principalAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="abvc:principalAmount" scale="0" unitRef="usd">698,000</ix:nonFraction> for <ix:nonNumeric contextRef="c219" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due on July 14,
2022. The loan balances bear interest at a fixed rate of <ix:nonFraction contextRef="c220" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">1.68</ix:nonFraction>% per annum. The loan is secured by the money deposited in a savings account
with the CTBC Bank. This loan was also personal guaranteed by the Company&#8217;s chairman and BioFirst. During the year ended December
31, 2020, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_9" id="_BankLoansTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $<ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">2,958</ix:nonFraction> and $<ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">2,949</ix:nonFraction> for the
three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_10" id="_BankLoansTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cathay Bank</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_11" id="_BankLoansTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 21, 2019, the Company received a loan
in the amount of $<ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="abvc:ReceivedLoanAmount" scale="0" unitRef="usd">500,000</ix:nonFraction> from Cathay Bank (the &#8220;Bank&#8221;) pursuant to a business loan agreement (the &#8220;Loan Agreement&#8221;)
entered by and between the Company and Bank on January 8, 2019 and a promissory note (the &#8220;Note&#8221;) executed by the Company
on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $<ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">1,000,000</ix:nonFraction> with a maturity date
(the &#8220;Maturity Date&#8221;) of January 1, 2020. <ix:nonNumeric contextRef="c225" name="abvc:RegularInterestRateDescription">The Note executed in connection with the Loan Agreement bears an interest rate (the
&#8220;Regular Interest Rate&#8221;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the
&#8220;Index&#8221;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company
shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note
before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%)
plus the Regular Interest Rate.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_12" id="_BankLoansTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Note and Loan Agreement,
on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the &#8220;Guaranty&#8221;) to guaranty
the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $<ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="abvc:ExceedingAmount" scale="0" unitRef="usd">500,000</ix:nonFraction> each
until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of
BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey. On December 29, 2020, the Company
entered into a new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr.
George Lee to be removed as guarantees from the list of Guaranty.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c0_cont_13" id="_BankLoansTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, on January 8, 2019, each of the Company
and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the &#8220;Security Agreement&#8221;) to
secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each, a &#8220;Grantor&#8221;,
and collectively, the &#8220;Grantors&#8221;) granted security interest in the collaterals as defined therein, comprised of almost all
of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company extended the Loan Agreement
with the same term for seven months, which is due on October 31, 2020. On April 8, 2020 and October 3, 2020, the Company repaid an aggregated
principal amount of $<ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="abvc:ReceivedLoanAmount" scale="0" unitRef="usd"><ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="abvc:ReceivedLoanAmount" scale="0" unitRef="usd">350,000</ix:nonFraction></ix:nonFraction>. On December 3, 2020, the Company renewed the Loan Agreement with the principal amount of $<ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">650,000</ix:nonFraction> for ten
months, which is due on October 31, 2021. On October 31, 2021, the Company renewed the Loan Agreement with the principal amount of $<ix:nonFraction contextRef="c230" decimals="0" format="ixt:num-dot-decimal" name="abvc:principalAmount" scale="0" unitRef="usd">650,000</ix:nonFraction>
for twelve months, which is due on October 30, 2022. On September 30, 2021, the Cathay Bank has increased the line of credit to $<ix:nonFraction contextRef="c231" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">1,000,000</ix:nonFraction>
from $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">650,000</ix:nonFraction>. The outstanding loan balance was $<ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermLineOfCredit" scale="0" unitRef="usd">650,000</ix:nonFraction> as of March 31, 2022 and December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BankLoansTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $<ix:nonFraction contextRef="c233" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">6,090</ix:nonFraction> and $<ix:nonFraction contextRef="c234" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">3,927</ix:nonFraction> for the
three months ended March 31, 2022 and 2021, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_1" escape="true" name="abvc:PaycheckProtectionProgramLoanPayableTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_2" id="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 14, 2020, the Company received a loan
in the amount of $<ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanFromPaycheckProtectionProgram" scale="0" unitRef="usd">124,400</ix:nonFraction> under the Paycheck Protection Program (&#8220;PPP&#8221;) administered by the United States Small Business Administration
(the &#8220;SBA&#8221;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;Cares Act&#8221;),
PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest
on mortgages, rent, and utilities. However, at least <ix:nonFraction contextRef="c237" decimals="2" format="ixt:num-dot-decimal" name="abvc:ForgivenAmountPercentageUsedForPayroll" scale="-2" unitRef="pure">60</ix:nonFraction>% of the forgiven amount must have been used for payroll.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_3" id="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c238" name="us-gaap:DebtInstrumentPaymentTerms">The loan was granted pursuant to a promissory
note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of <ix:nonFraction contextRef="c239" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">1.00</ix:nonFraction>% per annum.</ix:nonNumeric> The
Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years
after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&#8217;s
accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments
to be due on the same day of each month after that. No collateral or personal guarantees are required.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_4" id="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 29, 2021, BioKey received a loan in
the amount of $<ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanFromPaycheckProtectionProgram" scale="0" unitRef="usd">132,331</ix:nonFraction> under the Paycheck Protection Program administered by the United States Small Business Administration from East
West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal
amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least <ix:nonFraction contextRef="c240" decimals="2" format="ixt:num-dot-decimal" name="abvc:ForgivenAmountPercentageUsedForPayroll" scale="-2" unitRef="pure">60</ix:nonFraction>%
of the forgiven amount must have been used for payroll. <ix:nonNumeric contextRef="c240" continuedAt="_PromissoryNoteDescription-c240_cont_1" name="abvc:PromissoryNoteDescription">The loan was granted pursuant to a promissory note dated January 27, 2021 issued
by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.&#160;</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_5" id="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_4"><ix:continuation id="_PromissoryNoteDescription-c240_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2021, the Company received a loan
in the amount of $<ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanFromPaycheckProtectionPrograms" scale="0" unitRef="usd">104,167</ix:nonFraction> under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay
Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal
amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least <ix:nonFraction contextRef="c241" decimals="2" format="ixt:num-dot-decimal" name="abvc:ForgivenAmountPercentageUsedForPayroll" scale="-2" unitRef="pure">60</ix:nonFraction>%
of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued
by the Company, which matures on February 6, 2026 and bears interest at a rate of <ix:nonFraction contextRef="c242" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">1.00</ix:nonFraction>% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_6" id="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>PPP loan Forgiveness&#160;</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_7" id="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 27, 2021, the Company submitted all
required documents, such as application form and use of funds,&#160;to East West Bank for the application of forgiveness. The PPP loan
from East West Bank of $<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAmout" scale="0" unitRef="usd">124,400</ix:nonFraction> and $<ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentDecreaseForgiveness" scale="0" unitRef="usd">132,331</ix:nonFraction> was forgiven by the SBA as a gesture of supporting the operation of the Company on March
15, 2021 and September 28, 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_8" id="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 23, 2021, the Company submitted the
required documents, such as application form and use of funds,&#160;to Cathay Bank for the application of forgiveness. The PPP loan from
Cathay Bank of $<ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentDecreaseForgiveness" scale="0" unitRef="usd">104,167</ix:nonFraction> was forgiven by the SBA as a gesture of supporting the operation of the Company on November 15, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PaycheckProtectionProgramLoanPayableTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, the Company recorded the forgiveness
of the PPP loans as government grant income in the aggregate amount of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:GovernmentGrantIncome" scale="0" unitRef="usd">360,898</ix:nonFraction> during the year ended December 31, 2021. As of March
31, 2022, there was no outstanding balance payable to the bank.&#160;</p></ix:continuation><div>


</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_MortgageNotesPayableDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:MortgageNotesPayableDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. NOTES PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_MortgageNotesPayableDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c246" name="abvc:UnsecuredLoanAgreementsDescription">In January, 2019, BioLite Taiwan entered an unsecured
loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working
capital purpose.</ix:nonNumeric> On September 11, 2021 the outstanding balance has been repaid in full. As of March 31, 2022 and December 31, 2021, the
balance due to this individual amounted to both $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd">0</ix:nonFraction></ix:nonFraction>.&#160;Interest expense were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">3,204</ix:nonFraction> for the three months ended March 31, 2022
and 2021, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_ShortTermDebtTextBlock-c0_cont_1" escape="true" name="us-gaap:ShortTermDebtTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11. SHORT-TERM LOAN</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_ShortTermDebtTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2020, the Company entered an unsecured
loan agreement with a third-party in the amount of $<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd">100,000</ix:nonFraction>. This loan bears the interest rate of <ix:nonFraction contextRef="c248" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtInterestRateIncrease" scale="-2" unitRef="pure">1.5</ix:nonFraction>% per annum and will be matured on
August 17, 2020. On August 18, 2020, the Company extended the contract for six months under the same term. On February 18, 2021, the Company
extended the contract for six months under the same term. On August 26, 2021, the loan with interest has been repaid in full. Accrued
interest expense were both $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">0</ix:nonFraction></ix:nonFraction> as of March 31, 2022 and December 31, 2021.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12. RELATED PARTIES TRANSACTIONS</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The related parties of the company with whom transactions
are reported in these financial statements are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Name of entity or Individual</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left">Relationship with the Company and its subsidiaries</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c280" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Entity controlled by controlling beneficiary shareholder of YuanGene</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c281" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Rgene Corporation (the &#8220;Rgene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c282" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">YuanGene Corporation (the &#8220;YuanGene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c283" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Controlling beneficiary shareholder of the Company</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">AsiaGene Corporation (the &#8220;AsiaGene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c284" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Eugene Jiang</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c285" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Former President and Chairman</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c286" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c287" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Shareholder of the Company</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Yoshinobu Odaira (the &#8220;Odaira&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c288" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Director of the Company</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c289" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c290" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Shareholder of the Company</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">LBG USA, Inc. (the &#8220;LBG USA&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c291" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">LionGene Corporation (the &#8220;LionGene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c292" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c293" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Shareholder of the Company</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">The Jiangs</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c294" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst <br/> &#160; <br/> Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. <br/> &#160; <br/> Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. <br/> &#160; <br/> Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company. <br/> &#160; <br/> Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Amkey Ventures, LLC (&#8220;Amkey&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c295" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">BioLite Japan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c296" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">Entity controlled by controlling beneficiary shareholder of ABVC</ix:nonNumeric></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">ABVC BioPharma (HK), Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left"><ix:nonNumeric contextRef="c297" name="abvc:RelatedPartyTransactionDescriptionOfTransactions">An entity 100% owned by Mr. Tsung-Shann Jiang</ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable - related parties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable due from related parties consisted
of the following as of the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_6" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="abvc:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">GenePharm Inc.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c298" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">142,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c299" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">142,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Rgene</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">2,374</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">2,374</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Amkey</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c300" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">145,399</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">145,399</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_7" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Due from related parties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_8" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount due from related parties consisted of the
following as of the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_9" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Rgene</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c137" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">48,586</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">49,110</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>BioFirst</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">1,563,233</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">468,435</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioFirst (Australia)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">830,118</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">491,816</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">121,153</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">124,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LBG USA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c303" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">675</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c304" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">675</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioLite Japan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Keypoint</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c305" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">1,610</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c306" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">1,610</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">2,715,375</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">1,286,618</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_10" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">As of March 31, 2022, and December 31, 2021, the Company has advanced an aggregate amount of $48,586 and $49,110 to Rgene for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum). As of March 31, 2022, and December 31, 2021, the outstanding loan balance was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" scale="0" unitRef="usd">32,541</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" scale="0" unitRef="usd">33,520</ix:nonFraction>; and accrued interest was $<ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">14,214</ix:nonFraction> and $<ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">13,701</ix:nonFraction>, respectively. On January 1, 2021, BioLite Taiwan entered into a consultant services agreement with Rgene, of which the amount due from Rgene was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromAffiliateNoncurrent" scale="0" unitRef="usd">1,831</ix:nonFraction> and $1,889 as of March 31, 2022 and December 31, 2021, respectively.&#160;&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_11" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">In 2021, the Company and BioFirst entered into several loan agreements for a total amount of $<ix:nonFraction contextRef="c251" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">465,000</ix:nonFraction> to meet its working capital needs. All the loans period was twelve months and all with an interest rate of 6.5% per annum. In 2022, the Company and BioFirst entered into several loan agreements for a total amount of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAgreementTotalAmount" scale="0" unitRef="usd">1,068,000</ix:nonFraction> to meet its working capital needs. All the loans period was twelve months and with an interest rate of <ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="abvc:InterestRate" scale="-2" unitRef="pure">6.5</ix:nonFraction>% per annum. As of March 31, 2022, and December 31, 2021, the outstanding loan balance was $<ix:nonFraction contextRef="c135" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">1,533,000</ix:nonFraction> and $<ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">465,000</ix:nonFraction>; and accrued interest was $<ix:nonFraction contextRef="c133" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">30,233</ix:nonFraction> and $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">3,435</ix:nonFraction>, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_12" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentAggregateAmount" scale="0" unitRef="usd">361,487</ix:nonFraction> to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of <ix:nonFraction contextRef="c253" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">6.5</ix:nonFraction>% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentAggregateAmount" scale="0" unitRef="usd">67,873</ix:nonFraction> to meet its new project needs. &#160;&#160;On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c255" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentAggregateAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to increase the cost for upcoming projects. The loan will be matured on <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">November 30, 2022</ix:nonNumeric> with an interest rate of <ix:nonFraction contextRef="c256" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">6.5</ix:nonFraction>% per annum. In January 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $<ix:nonFraction contextRef="c257" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAgreementTotalAmount" scale="0" unitRef="usd">327,000</ix:nonFraction> to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of <ix:nonFraction contextRef="c258" decimals="3" format="ixt:num-dot-decimal" name="abvc:InterestRate" scale="-2" unitRef="pure">6.5</ix:nonFraction>% per annum. As of March 31, 2022 and December 31, 2021, the aggregate amount of outstanding loan and accrued interest was $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">830,118</ix:nonFraction> and $<ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">491,816</ix:nonFraction>, respectively.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 3). <ix:nonNumeric contextRef="c261" name="us-gaap:DebtInstrumentInterestRateTerms">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.</ix:nonNumeric> As of March 31, 2022 and December 31, 2021, due from BHK was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromEmployeesNoncurrent" scale="0" unitRef="usd">121,153</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromEmployeesNoncurrent" scale="0" unitRef="usd">124,972</ix:nonFraction>, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_13" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. <ix:nonNumeric contextRef="c262" name="abvc:AdvancesBearInterestDescription">The advances bear <ix:nonFraction contextRef="c263" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0</ix:nonFraction>% interest rate and are due on demand.</ix:nonNumeric> As of March 31, 2022 and December 31, 2021, the outstanding advance balances was $<ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingAdvanceFromRelatedParty" scale="0" unitRef="usd">675</ix:nonFraction> and $<ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingAdvanceFromRelatedParty" scale="0" unitRef="usd">675</ix:nonFraction>, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_14" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(6)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On May 8, 2020, the Company and Lucidaim entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. <ix:nonNumeric contextRef="c266" name="us-gaap:DebtInstrumentInterestRateTerms">Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan&#8217;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate.</ix:nonNumeric> As of March 31, 2022 and December 31, 2021, the outstanding advance balances was $<ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingAdvanceFromRelatedParty" scale="0" unitRef="usd">150,000</ix:nonFraction> and $<ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingAdvanceFromRelatedParty" scale="0" unitRef="usd">150,000</ix:nonFraction>, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_15" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(7)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On October 31, 2020, <ix:nonNumeric contextRef="c269" name="abvc:LoanAgreementDescription">the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021.</ix:nonNumeric> As of March 31, 2022 and December 31, 2021, the outstanding loan balance was $<ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">1,610</ix:nonFraction> and $<ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">1,610</ix:nonFraction>, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_16" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Due to related parties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_17" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount due to related parties consisted of the
following as of the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_18" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_17"><ix:nonNumeric contextRef="c0" escape="true" name="abvc:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c129" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">40,878</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">40,878</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst (Australia)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c256" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">190,913</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">132,443</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>AsiaGene</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c249" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">24,017</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">24,017</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>YuanGene</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c276" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">9,205</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c307" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">9,205</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">The Jiangs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c308" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">18,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">18,750</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Due to shareholders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c310" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">162,634</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">168,131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">446,397</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">393,424</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_19" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Since 2019, BioFirst has advanced funds to the Company for working capital purpose. <ix:nonNumeric contextRef="c272" name="us-gaap:DebtInstrumentInterestRateTerms">The advances bear interest 1% per month (or equivalent to 12% per annum).</ix:nonNumeric> As of March 31, 2022 and December 31, 2021, the aggregate amount of outstanding balance and accrued interest is $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">40,878</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_20" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">As of March 31, 2022, and December 31, 2021, BioFirst (Australia) has advanced the Company an aggregate amount of $<ix:nonFraction contextRef="c259" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">190,913</ix:nonFraction> and $<ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">132,443</ix:nonFraction>, respectively for new project purpose.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_21" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_20"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">As of March 31, 2022, and December 31, 2021, AsiaGene has advanced the Company an aggregate amount of $<ix:nonFraction contextRef="c273" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">24,017</ix:nonFraction> for working capital purpose. This advance bears <ix:nonFraction contextRef="c249" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0</ix:nonFraction>% interest rate and is due on demand.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_22" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">As of March 31, 2022, and December 31, 2021, YuanGene has advanced the Company an aggregate amount of $<ix:nonFraction contextRef="c274" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd"><ix:nonFraction contextRef="c275" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">9,205</ix:nonFraction></ix:nonFraction> for working capital purpose. This advance bears <ix:nonFraction contextRef="c276" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0</ix:nonFraction>% interest rate and is due on demand.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_23" id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_22"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2022, and December 31, 2021, the outstanding balance due to the Jiangs amounted to $<ix:nonFraction contextRef="c277" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingAdvanceFromRelatedParty" scale="0" unitRef="usd">18,750</ix:nonFraction>. These loans bear interest rate of <ix:nonFraction contextRef="c277" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0</ix:nonFraction>% to <ix:nonFraction contextRef="c278" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">1</ix:nonFraction>% per month, and are due on demand.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_23"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(6)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. <ix:nonNumeric contextRef="c279" name="us-gaap:DebtInstrumentInterestRateTerms">The advances bear interest rate of 12% per annum.</ix:nonNumeric> As of March 31, 2022 and December 31, 2021, the outstanding principal and accrued interest was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingPrincipalAndAccruedInterest" scale="0" unitRef="usd">162,634</ix:nonFraction> and $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingPrincipalAndAccruedInterest" scale="0" unitRef="usd">168,131</ix:nonFraction>, respectively. Interest expenses in connection with these loans were $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseRelatedParty" scale="0" unitRef="usd">5,312</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseRelatedParty" scale="0" unitRef="usd">5,298</ix:nonFraction> for the three months ended March 31, 2022 and 2021, respectively.</span></td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24.1pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. EQUITY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2016, a Share Exchange Agreement
(&#8220;Share Exchange Agreement&#8221;) was entered into by and among the&#160;Company, BriVision, Euro-Asia Investment &amp; Finance
Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People&#8217;s Republic of China (&#8220;Euro-Asia&#8221;),
being the owners of record of <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">164,387,376</ix:nonFraction> (<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,336,000</ix:nonFraction> pre-stock split) shares of Common Stock of the Company, and the owners of record
of all of the issued share capital of BriVision (the&#160;&#8220;BriVision Stock&#8221;). Pursuant to the Share Exchange Agreement, upon
surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered
in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision
as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision
Stock in the name of the Company, the Company should issue <ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">166,273,921</ix:nonFraction>(<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,936,583</ix:nonFraction> pre-stock split) shares (the&#160;&#8220;Acquisition
Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s Common Stock to the BriVision
Shareholders (or their designees), and <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">163,159,952</ix:nonFraction> (<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">51,945,225</ix:nonFraction> pre-stock split) shares of the Company&#8217;s Common Stock owned by Euro-Asia
should be cancelled and retired to treasury. The Acquisition Stock collectively should represent <ix:nonFraction contextRef="c71" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">79.70</ix:nonFraction>% of the issued and outstanding
Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing <ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfIssuedShareCapital" scale="-2" unitRef="pure">100</ix:nonFraction>% of the issued share
capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision&#8217;s
Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of <ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">166,273,921</ix:nonFraction>(<ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,936,583</ix:nonFraction> pre-stock split) shares
of Company&#8217;s Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&#8217;s Common
Stock as of immediately prior to the Merger held an aggregate of <ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">205,519,223</ix:nonFraction> (<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">65,431,144</ix:nonFraction> pre-stock split) shares of Company&#8217;s Common
Stock,&#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&#160;&#8220;Share Exchange&#8221;), BriVision
became a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following
the closing.&#160;&#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 17, 2016, pursuant to the 2016 Equity
Incentive Plan (the &#8220;2016 Plan&#8221;), <ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">157,050</ix:nonFraction> (<ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">50,000</ix:nonFraction> pre-stock split) shares were granted to the employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#8220;Forward&#160;Stock&#160;Split&#8221;)
and increase the number of our authorized shares of Common Stock, par value $<ix:nonFraction contextRef="c76" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share, to <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockShareAuthorized" scale="0" unitRef="shares">360,000,000</ix:nonFraction>, which was effective on April
8, 2016.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2016, <ix:nonNumeric contextRef="c314" name="abvc:AgreementDescription">the Company and BioLite Taiwan
agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed
to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of
the Company&#8217;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.</ix:nonNumeric> On
August 26, 2016, <ix:nonNumeric contextRef="c315" name="abvc:AgreementDescription">the Company issued 1,468,750 shares (&#8220;Shares&#8221;) of the Company&#8217;s Common Stock, par value $0.001 (the
&#8220;Offering&#8221;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#8220;SPA&#8221;).
The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net
proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should
pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires
that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.</ix:nonNumeric> In February 2017,
<ix:nonNumeric contextRef="c316" name="abvc:AgreementDescription">the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#8217;s
Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring
transaction between the Company and BioLite on February 8, 2019, the Company&#8217;s Common Stock held by BioLite Taiwan was accounted
for treasury stocks in the statement of equity (deficit).</ix:nonNumeric> On February 8, 2019, after the Merger, the Company issued <ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">74,997,546</ix:nonFraction> shares
to the shareholders of BioLite and <ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">29,561,231</ix:nonFraction> shares to the shareholders of BioKey.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 3, 2019, <ix:nonNumeric contextRef="c77" name="abvc:FinancialAmendmentDescription">the Company filed a Certificate
of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial
Industry Regulatory Authority (&#8220;FINRA&#8221;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse
stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#8217;s
common stock were exchanged for 17,693,625 shares of the Company&#8217;s Common Stock.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c319" name="abvc:Consultingagreementdescription">On October 1, 2016, the Company entered into a
consulting agreement with Kazunori Kameyama (&#8220;Kameyama&#8221;) for the provision of services related to the clinical trials and
other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the
Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#8217;s
Common Stock at $1.00 per share for any amount exceeding $3,000.</ix:nonNumeric> The Company&#8217;s stocks shall be calculated and issued in December
every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued
<ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">24,694</ix:nonFraction> stock options to Kameyama related to unpaid consulting fees of $<ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="abvc:UnpaidConsultingFees" scale="0" unitRef="usd">49,388</ix:nonFraction> (see Note 14).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, BriVision entered into a collaborative
agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $<ix:nonFraction contextRef="c321" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd">3,000,000</ix:nonFraction> due to BioFirst.
On June 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue <ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">428,571</ix:nonFraction>
shares of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedValue" scale="0" unitRef="usd">3,000,000</ix:nonFraction> owed by the Company to BioFirst. These common shares
were issued during the year ended December 31, 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019, the Company
entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant
Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in
the U.S. stock exchange market, investor relations, and business development. <ix:nonNumeric contextRef="c0" name="us-gaap:IntercompanyAgreementsDescription">Pursuant to the agreements, the Company issued <ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">644,972</ix:nonFraction> shares
of the Company&#8217;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">4,514,800</ix:nonFraction> in aggregate,
and recorded as stock subscription receivable.</ix:nonNumeric> As of March 31, 2022 and December 31, 2021, stock subscription receivable was $<ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockSubscriptionReceivable" scale="0" unitRef="usd">2,031,660</ix:nonFraction>
and $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockSubscriptionReceivable" scale="0" unitRef="usd">2,257,400</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August, 2019, the Company entered into several
Conversion Agreements to all creditors that are listed under below table of &#8220;due to related parties&#8221; in consideration for
a total of $<ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">4,872,340</ix:nonFraction> owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements,
creditor agrees to convert the amount of debt into the Company&#8217;s common stock at a price of $<ix:nonFraction contextRef="c324" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">7.00</ix:nonFraction> per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDebtConversionsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of<br/> Debt<br/> Converted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares<br/> Issued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lion Arts Promotion Inc</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtConversionConvertedInstrumentAmount" scale="0" unitRef="usd">97,864</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">13,981</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">LionGene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtConversionConvertedInstrumentAmount" scale="0" unitRef="usd">428,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">61,157</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtConversionConvertedInstrumentAmount" scale="0" unitRef="usd">2,902,911</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">414,702</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">AsiaGene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtConversionConvertedInstrumentAmount" scale="0" unitRef="usd">160,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">22,858</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">YuanGene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c353" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtConversionConvertedInstrumentAmount" scale="0" unitRef="usd">92,690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c353" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">13,242</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">The Jiangs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c354" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtConversionConvertedInstrumentAmount" scale="0" unitRef="usd">1,190,776</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c354" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">170,111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtConversionConvertedInstrumentAmount" scale="0" unitRef="usd">4,872,340</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">696,051</ix:nonFraction></td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2020, the board of directors of the
Company approved and adopted an amendment to the Company&#8217;s Articles of Incorporation, to increase the authorized shares of its common
stock, par value $<ix:nonFraction contextRef="c325" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share, from <ix:nonFraction contextRef="c326" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">20,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction> shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company entered an agreement
with View Trade Securities Inc. (&#8220;ViewTrade&#8221;) to engage ViewTrade as the placement agent&#160;and the Company&#8217;s advisor/consultant
with respect to its ongoing capital events. <ix:nonNumeric contextRef="c328" name="abvc:PlacementAgentAgreementDescription">Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares
of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years
with cashless exercise provision.</ix:nonNumeric> As of December 31, 2020, the Company has issued <ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">60,000</ix:nonFraction> shares of common stock to ViewTrade for the consulting
fee with an estimated value of $<ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">135,000</ix:nonFraction>. The warrants were never issued and the parties mutually agreed to terminate the agreement on
November 19, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the termination agreement, the Company
issued <ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">50,000</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">5</ix:nonFraction> per share as a termination fee on June 29, 2021, of which <ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">6,000</ix:nonFraction>
shares were issued to WallachBeth Capital LLC (&#8220;WallachBeth&#8221;). In January 2021, WallachBeth entered into a consulting agreement
with the Company pursuant to which the Company engaged WallachBeth to conduct due diligence and research work with respect to the Company.
On June 29, 2021, WallachBeth was issued <ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="abvc:RestrictedCommonShares" scale="0" unitRef="shares">6,000</ix:nonFraction> shares of common stock as compensation for those services.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on November 19, 2020, the Company and ViewTrade
agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only. In addition to a retainer fee,
the Company agreed to issue <ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="abvc:WarrantIssued" scale="0" unitRef="shares">200,000</ix:nonFraction> warrants, with an exercise price of $<ix:nonFraction contextRef="c334" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">2.25</ix:nonFraction>, an industry standard cashless exercise provision, and a
term of <ix:nonNumeric contextRef="c334" format="ixt-sec:duryear" name="abvc:WarrantTerm">5</ix:nonNumeric> years from November 19, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year&#160;ended December 31, 2020,
the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company
agreed to pay the service fee by issuing <ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="abvc:UnrestrictedCommonShares" scale="0" unitRef="shares">50,000</ix:nonFraction> shares of unrestricted common shares, valued at the closing price of $<ix:nonFraction contextRef="c335" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">2.9</ix:nonFraction> per share on
the grant date. These shares have been issued during the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, the Company
received aggregated capital contributions of $<ix:nonFraction contextRef="c336" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="0" unitRef="usd">7,615,331</ix:nonFraction> in cash from <ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="abvc:NumberOfInvestors" scale="0" unitRef="pure">45</ix:nonFraction> investors through private placements of the sale of the Company&#8217;s
common stock for the purchase price of&#160;$<ix:nonFraction contextRef="c336" decimals="2" format="ixt:num-dot-decimal" name="abvc:SharesIssuedPricePerShares" scale="0" unitRef="usdPershares">2.25</ix:nonFraction> per share and a free warrant attached with each common stock purchased. In December
2020, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStock" scale="0" unitRef="shares">3,384,615</ix:nonFraction> shares of the Company&#8217;s common stock have been issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, the Company
entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed
to pay the service fee by issuing <ix:nonFraction contextRef="c338" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">521,887</ix:nonFraction> shares of unrestricted common shares, valued at the closing price from $<ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">2</ix:nonFraction> to $<ix:nonFraction contextRef="c340" decimals="2" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodShareBasedCompensationServicesforShares" scale="0" unitRef="shares">3.68</ix:nonFraction> per share
on the grant date. These shares have been issued in October and December 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company issued aggregated
common shares of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateCommonStockShares" scale="0" unitRef="shares">915,856</ix:nonFraction> to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests,
including the debt conversion to the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt">&#160;</td> <td style="width: 24px; padding-bottom: 8pt"><ix:nonNumeric contextRef="c341" continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_1" name="us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature"><span style="font-size: 10pt">a.</span></ix:nonNumeric></td> <td style="text-align: justify"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_2" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_1"><span style="font-size: 10pt">Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#8217;s common stock, and warrants to purchase 159,145 shares of the Company&#8217;s common stock.</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_3" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-bottom: 8pt">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_4" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-bottom: 8pt">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_5" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-bottom: 8pt">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_6" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-bottom: 8pt">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#8217;s common stock, and warrants to purchase 192,784 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_7" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_6">&#160;</ix:continuation></td> <td style="width: 24px; padding-bottom: 8pt"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_8" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_7"><span style="font-size: 10pt">f.</span></ix:continuation></td> <td style="text-align: justify"><ix:continuation id="_DebtInstrumentConvertibleTermsOfConversionFeature-c341_cont_8"><span style="font-size: 10pt">KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#8217;s common stock, and warrants to purchase 120,121 shares of the Company&#8217;s common stock.</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Note 7 for more details in connection with the above debt conversion.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2021, <ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,111,112</ix:nonFraction> shares of the Company&#8217;s
common stock and warrants were issued pursuant to the conversion of convertible promissory note of $<ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConvertiblePromissoryNoteValue" scale="0" unitRef="usd">2,500,000</ix:nonFraction> entered in October 2020
(see Note 7).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2021, <ix:nonNumeric contextRef="c343" name="abvc:DescriptionOfPublicOffering">the Company closed its public
offering (the &#8220;Public Offering&#8221;) of 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of the
Company&#8217;s common stock, one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise
price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series
B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at
an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public
Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering
pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission
(the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective
on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August
4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;). The Units
were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.</ix:nonNumeric> In August
2021, <ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" scale="0" unitRef="shares">2,354,145</ix:nonFraction> shares of the Company&#8217;s common stock were issued for gross proceeds of $<ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">6,875,000</ix:nonFraction>, before placement agent fees and
legal fees of $<ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="0" unitRef="usd">850,429</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2021, the Company received $<ix:nonFraction contextRef="c345" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd">4,244,452</ix:nonFraction>&#160;in
gross proceeds from the exercise of warrants issued in the Company&#8217;s August 3, 2021, public offering of securities. Investors exercised
a total of&#160;<ix:nonFraction contextRef="c346" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares">673,405</ix:nonFraction>&#160;Series A warrants at a price of $<ix:nonFraction contextRef="c346" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">6.30</ix:nonFraction>&#160;per share and&#160;<ix:nonFraction contextRef="c347" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares">200</ix:nonFraction>&#160;Series B warrants at a price of $<ix:nonFraction contextRef="c347" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">10</ix:nonFraction>&#160;per
share. Pursuant to these exercises, the Company issued an aggregate of <ix:nonFraction contextRef="c345" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateCommonStockShares" scale="0" unitRef="shares">673,605</ix:nonFraction> shares of Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c348" name="abvc:ConsultingAgreementDesciption"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29"><ix:nonNumeric contextRef="c0" continuedAt="_ConsultingAgreementDesciption-c0_cont_1" name="abvc:ConsultingAgreementDesciption"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2021, the Company entered into consulting
agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted
$1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant
date. These shares have been issued during the year ended December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30"><ix:continuation id="_ConsultingAgreementDesciption-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2022, the Company agreed to pay the
deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued
at $3.29 per share on the grant date. These shares have been issued as of March 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2022, the Company issued <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ExcessStockSharesIssued" scale="0" unitRef="shares">75,000</ix:nonFraction> common
shares to&#160;BarLew Holdings, LLC for consulting and advisory services amounted to $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="0" unitRef="usd">169,500</ix:nonFraction>, valued at $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="dei:EntityListingParValuePerShare" scale="0" unitRef="usdPershares">2.26</ix:nonFraction> per share.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockOptionsTextBlock-c0_cont_1" escape="true" name="abvc:StockOptionsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. STOCK OPTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c0_cont_2" id="_StockOptionsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2020, the Company issued an aggregate
of <ix:nonFraction contextRef="c355" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">545,182</ix:nonFraction> shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive
Plan, as amended, at a conversion price of $<ix:nonFraction contextRef="c355" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConversionPrice" scale="0" unitRef="usdPershares">2</ix:nonFraction> per share; the total amount of converted salaries and consulting fees was $<ix:nonFraction contextRef="c356" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConsultingFees" scale="0" unitRef="usd">1,090,361</ix:nonFraction>. On
November 21, 2020, the Company entered&#160;into&#160;acknowledgement&#160;agreements and stock option purchase agreements with these
employees and consultant; pursuant to which the Company granted stock options to purchase <ix:nonFraction contextRef="c357" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">545,182</ix:nonFraction> shares of the Company&#8217;s common
stock in lieu of common stock. The options were vested at the grant date and become exercisable for <ix:nonNumeric contextRef="c358" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">10</ix:nonNumeric> years from the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c0_cont_3" id="_StockOptionsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2021, the Company entered&#160;into
stock option agreements with 11 directors and 3 employees, pursuant to which the Company granted options to purchase an aggregate of <ix:nonFraction contextRef="c359" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,280,002</ix:nonFraction>
shares of common stock&#160;under the 2016 Equity Incentive Plan, as amended, at an exercise price of $<ix:nonFraction contextRef="c360" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConversionPrice" scale="0" unitRef="usdPershares">3</ix:nonFraction> per share. The options were vested
at the grant date and become exercisable for <ix:nonNumeric contextRef="c360" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">10</ix:nonNumeric> years from the grant date.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c0_cont_4" id="_StockOptionsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued and outstanding as of December
31, 2021, and their activities during the year then ended are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c0_cont_5" id="_StockOptionsTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Underlying<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per&#160;Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Contractual<br/> Life<br/> Remaining<br/> in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding as of January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c362" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares">545,182</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c362" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.00</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-size: 10pt">&#8239;-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c363" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">1,280,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c363" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.00</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" unitRef="shares">1,825,184</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c364" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.70</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c363" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.51</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" unitRef="usd">616,056</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,825,184</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c364" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.70</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c363" format="ixt-sec:duryear" name="abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">9.51</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">616,056</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares">1,825,184</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c364" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.70</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c363" format="ixt-sec:duryear" name="abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1">9.51</ix:nonNumeric></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" unitRef="usd">616,056</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c0_cont_6" id="_StockOptionsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of stock options granted for the
year ended December 31, 2021 was calculated using the Black-Scholes option-pricing model applying the following assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c0_cont_7" id="_StockOptionsTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Risk free interest rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.13</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">108.51</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockOptionsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average grant date fair value of
options granted during the years ended&#160;December 31, 2021 was $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">2.09</ix:nonFraction>. There are <ix:nonFraction contextRef="c361" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares">2,979,264</ix:nonFraction>&#160;options available for grant under the
2016 Equity Incentive Plan as of December 31, 2021. Compensation costs associated with the Company&#8217;s stock options are recognized,
based on the grant-date fair values of these options over vesting period. Accordingly, the Company recognized stock-based compensation
expense of $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">0</ix:nonFraction> for the three months ended March 31, 2022 and 2021, respectively. There were no options exercised during the three
months ended March 31, 2022. As of March 31, 2022, there were no unvested options.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>15. LOSS PER SHARE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss
by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31,
2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_3" id="_EarningsPerShareTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months<br/> Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss attributable to ABVC&#8217;s common stockholders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd">5,995,440</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd">1,128,505</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted-average shares outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:WeightedaverageSharesOutstandingBasic" scale="0" unitRef="usdPershares">29,683,402</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:WeightedaverageSharesOutstandingBasic" scale="0" unitRef="usdPershares">24,420,526</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Stock options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8211;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8211;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abvc:WeightedAverageNumberOfSharesDiluted" scale="0" unitRef="usdPershares">29,683,402</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="abvc:WeightedAverageNumberOfSharesDiluted" scale="0" unitRef="usdPershares">24,420,526</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">-Basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abvc:BasicLossPerShare" scale="0" sign="-" unitRef="usdPershares">0.20</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="abvc:BasicLossPerShare" scale="0" sign="-" unitRef="usdPershares">0.05</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">-Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.20</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.05</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted loss per share takes into account the
potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_1" escape="true" name="abvc:OperatingLeasesOfLesseeDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. LEASE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_2" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#8220;ASC 842&#8221;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_3" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company applied the following practical expedients in the transition
to the new standard and allowed under ASC 842:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_4" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_5" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_6" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_7" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_8" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_9" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities. ROU assets represent the
Company&#8217;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#8217;s obligation to make
lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#8217;s future minimum based payments used
to determine the Company&#8217;s lease liabilities mainly include minimum based rent payments. As most of Company&#8217;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_10" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized lease liabilities, with
corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_11" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no finance leases. The Company&#8217;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#8217;s operating leases have remaining lease terms of up to approximately five years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_12" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">1,382,695</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="0" unitRef="usd">1,471,899</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities (current)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">349,008</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">347,100</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease liabilities (noncurrent)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeaseLiabilitienoncurrent" scale="0" unitRef="usd">1,033,686</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeaseLiabilitienoncurrent" scale="0" unitRef="usd">1,124,799</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_13" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Supplemental Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_14" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides details of the Company&#8217;s
lease expenses:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_15" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_14"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd">85,857</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd">78,847</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_16" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other information related to leases is presented
below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_17" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_16"><ix:continuation continuedAt="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c0_cont_2" id="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="0" unitRef="usd">85,857</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="0" unitRef="usd">78,847</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_18" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_17"><ix:continuation id="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Weighted Average Remaining Lease Term:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c1" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.65</ix:nonNumeric> years </span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonNumeric contextRef="c7" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.90</ix:nonNumeric> years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted Average Discount Rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">1.37</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">1.39</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_19" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c0_cont_19"><ix:nonNumeric contextRef="c0" escape="true" name="abvc:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating<br/> leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022 (excluding three months ended March 31, 2022)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueCurrent" scale="0" unitRef="usd">266,024</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueInTwoYears" scale="0" unitRef="usd">359,279</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueInThreeYears" scale="0" unitRef="usd">374,283</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueInFourYears" scale="0" unitRef="usd">338,676</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueThereafter" scale="0" unitRef="usd">56,916</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDue" scale="0" unitRef="usd">1,395,178</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" scale="0" unitRef="usd">12,484</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" scale="0" unitRef="usd">1,382,694</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>17. BUSINESS COMBINATION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_2" id="_BusinessCombinationDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company consummated the
Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned
subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, &#8220;Business Combination&#8221; to record the merger
transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey&#8217;s
results of operations were included in the Company&#8217;s results beginning February 8, 2019. The purchase price has been allocated to
the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_3" id="_BusinessCombinationDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Purchase consideration:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Common Stock (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" id="ix_0_fact" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd">44,341,847</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Allocation of the purchase price:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" unitRef="usd">531,147</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="0" unitRef="usd">188,550</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="0" unitRef="usd">56,075</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="0" unitRef="usd">485,684</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Security deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="0" unitRef="usd">10,440</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" unitRef="usd">1,271,896</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="0" unitRef="usd">56,204</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="0" unitRef="usd">251,335</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" scale="0" sign="-" unitRef="usd">267,256</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tenant security deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="0" unitRef="usd">2,880</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="0" unitRef="usd">577,675</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" unitRef="usd">694,221</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Goodwill as a result of the Merger</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="0" unitRef="usd">43,647,626</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c0_cont_4" id="_BusinessCombinationDisclosureTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"></td> <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-size: 10pt"><ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares">29,561,231</ix:nonFraction> shares (<ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">1,642,291</ix:nonFraction> after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $<ix:nonFraction contextRef="c365" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">1.50</ix:nonFraction> per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_BusinessCombinationDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company has recorded
a <ix:nonFraction contextRef="c366" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfGoodwill" scale="-2" unitRef="pure">100</ix:nonFraction>% goodwill write-down of $<ix:nonFraction contextRef="c366" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" unitRef="usd">43,647,626</ix:nonFraction>. Goodwill was determined to have been impaired because of the current financial condition of
the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company&#8217;s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably
assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation
of the Merger.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>18. SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_2" id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 16, 2022, the Company entered&#160;into
stock option agreements with <ix:nonFraction contextRef="c368" decimals="0" format="ixt:num-dot-decimal" name="abvc:NumberOfDirectors" scale="0" unitRef="pure">5</ix:nonFraction> directors, pursuant to which the Company granted options to purchase an aggregate of <ix:nonFraction contextRef="c369" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="0" unitRef="shares">761,920</ix:nonFraction> shares of
common stock&#160;under the 2016 Equity Incentive Plan, as amended, at an exercise price of $<ix:nonFraction contextRef="c368" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">3</ix:nonFraction> per share. The options were vested at the
grant date and become exercisable for <ix:nonNumeric contextRef="c369" format="ixt-sec:duryear" name="abvc:GrantDateTerm">10</ix:nonNumeric> years from the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c0_cont_3" id="_SubsequentEventsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 11, 2022, the Company and certain investors
entered into certain securities purchase agreement relating to the offer and sale of <ix:nonFraction contextRef="c370" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">2,000,000</ix:nonFraction> shares of common stock, par value $<ix:nonFraction contextRef="c371" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital" scale="0" unitRef="usd">0.001</ix:nonFraction>
per share in a registered direct offering. Pursuant to the Offering, the Company will also issue 5-year warrants to purchase <ix:nonFraction contextRef="c371" decimals="0" format="ixt:num-dot-decimal" name="abvc:WarrantsPurchased" scale="0" unitRef="shares">2,000,000</ix:nonFraction>
shares of Common Stock, exercisable at a price of $<ix:nonFraction contextRef="c371" decimals="2" format="ixt:num-dot-decimal" name="abvc:ExercisableAtAPricePerShare" scale="0" unitRef="usdPershares">2.45</ix:nonFraction> per share to the Purchasers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events through
the date which the consolidated financial statements were available to be issued. All subsequent events requiring recognition as of March
31, 2022 have been incorporated into these consolidated financial statements and there are no other subsequent events that require disclosure
in accordance with FASB ASC Topic 855, &#8220;Subsequent Events.&#8221;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div><a id="b_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="img_003.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To the Board of Directors and Shareholders of</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC BioPharma, Inc. and Subsidiaries</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion on the Consolidated Financial Statements</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have audited the accompanying consolidated balance sheets of ABVC BioPharma, Inc. and subsidiaries (collectively &#8220;the Company&#8221;) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive income (loss), shareholders&#8217; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis for Opinion</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Critical Audit Matters</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition of Stock-Based Compensation Cost for Stock Options Issued</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As described in Note 14 to the consolidated financial statements, the Company granted stock options to its directors and employees and estimated total stock compensation expense related to the issuance of stock options of $2,675,205 for the year ended December 31, 2021. The stock compensation cost was valued at the grant date, and management evaluated the fair value of these stock options at the grant date and recognized based on the vesting schedule.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We identified the recognition of stock options as a critical audit matter due to the significant judgments made by management when developing underlying assumptions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are the primary procedures we performed to address this critical audit matter. We obtained an understanding and evaluated the design and implementation of certain controls relating to significant judgments and assumptions developed by management. We evaluated and tested sources of data and assumptions used by management. In addition, we tested the completeness and accuracy of the underlying assumptions used by management.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ KCCW Accountancy Corp.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have served as the Company&#8217;s auditor since 2019.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diamond Bar, California</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 31, 2022</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>KCCW Accountancy Corp.</b> 3333 S. Brea Canyon Road, Suite 206, CA 91765 USA</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +1 909 348 7228 &#9679; Fax: +1 909 895 4155</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="b_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED BALANCE SHEETS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">ASSETS</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Cash and cash equivalents</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">5,828,548</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">4,273,208</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Restricted cash and cash equivalents</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">736,667</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" unitRef="usd">728,163</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts receivable, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">280,692</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" unitRef="usd">159,712</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts receivable - related parties, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" unitRef="usd">145,399</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="0" unitRef="usd">143,435</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Due from related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">1,286,618</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedPartiesCurrent" scale="0" unitRef="usd">696,255</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Inventory, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">25,975</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Short-term investments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="0" unitRef="usd">108,147</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Prepayment for long-term investments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentForLongtermInvestments" scale="0" unitRef="usd">684,720</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Prepaid expense and other current assets</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">528,354</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" unitRef="usd">172,193</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total Current Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">9,625,120</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="0" unitRef="usd">6,172,966</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">525,881</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">514,834</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,471,899</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,772,747</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Goodwill, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Long-term investments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">932,755</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermInvestments" scale="0" unitRef="usd">1,190,727</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Deferred tax assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd">981,912</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="0" unitRef="usd">1,790,597</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Prepaid expenses &#8211; noncurrent</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd">119,309</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseNoncurrent" scale="0" unitRef="usd">119,315</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Security deposits</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd">41,157</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" unitRef="usd">45,519</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total Assets</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">13,698,033</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" unitRef="usd">11,606,705</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">LIABILITIES AND EQUITY</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" unitRef="usd">23,044</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Short-term bank loans</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd">1,640,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" unitRef="usd">1,629,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Short-term loan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherShortTermBorrowings" scale="0" unitRef="usd">100,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Notes payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableToBankCurrent" scale="0" unitRef="usd">106,800</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accrued expenses and other current liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">1,300,803</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" unitRef="usd">2,118,854</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Advance from customers</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdvanceFromCustomers" scale="0" unitRef="usd">10,985</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdvanceFromCustomers" scale="0" unitRef="usd">12,070</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Operating lease liabilities &#8211; current portion</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">347,100</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" unitRef="usd">316,178</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Due to related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">393,424</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">288,445</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Convertible notes payable &#8211; related parties, current portion</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayableCurrent" scale="0" unitRef="usd">250,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left">Total Current Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">3,692,312</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" unitRef="usd">4,844,391</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Paycheck Protection Program Loan Payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansPayable" scale="0" unitRef="usd">124,400</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Tenant security deposit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDepositLiability" scale="0" unitRef="usd">10,580</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDepositLiability" scale="0" unitRef="usd">19,280</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Operating lease liability &#8211; noncurrent portion</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">1,124,799</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">1,456,567</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Convertible notes payable &#8211; noncurrent portion</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="0" unitRef="usd">2,500,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">4,827,691</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" unitRef="usd">8,944,638</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares">20,000,000</ix:nonFraction></ix:nonFraction> authorized, <span style="-sec-ix-hidden: hidden-fact-21"><span style="-sec-ix-hidden: hidden-fact-22"><span style="-sec-ix-hidden: hidden-fact-23"><span style="-sec-ix-hidden: hidden-fact-24">nil</span></span></span></span> shares issued and outstanding</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Common stock, $<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares"><ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction></ix:nonFraction> authorized, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">28,926,322</ix:nonFraction></ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">24,420,526</ix:nonFraction></ix:nonFraction> shares issued and outstanding</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">28,926</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" unitRef="usd">24,420</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Additional paid-in capital</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">58,113,667</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" unitRef="usd">40,751,807</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Stock subscription receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd">2,257,400</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" unitRef="usd">3,160,360</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accumulated deficit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">38,481,200</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" sign="-" unitRef="usd">25,642,387</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Accumulated other comprehensive income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">539,660</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" unitRef="usd">564,860</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Treasury stock</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd">9,100,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockValue" scale="0" unitRef="usd">9,100,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Total Stockholders&#8217; equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">8,843,653</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" unitRef="usd">3,438,340</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Noncontrolling interest</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" unitRef="usd">26,689</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="0" sign="-" unitRef="usd">776,273</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total Equity</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">8,870,342</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">2,662,067</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 4pt">Total Liabilities and Equity</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">13,698,033</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" unitRef="usd">11,606,705</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="b_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; font-weight: bold; text-align: left">Revenues</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">355,797</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">483,045</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cost of revenues</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">5,086</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="0" unitRef="usd">18,716</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Gross profit</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">350,711</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">464,329</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Operating expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Selling, general and administrative expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">5,746,119</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" unitRef="usd">4,273,468</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Research and development expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">1,003,805</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" unitRef="usd">549,658</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Stock based compensation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">5,306,755</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">4,146,979</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">12,056,679</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" unitRef="usd">8,970,105</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Loss from operations</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">11,705,968</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="0" sign="-" unitRef="usd">8,505,776</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Other income (expense)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:InterestIncomes" scale="0" unitRef="usd">43,196</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:InterestIncomes" scale="0" unitRef="usd">71,045</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest expense</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">227,210</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="0" unitRef="usd">405,032</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Operating sublease income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:RentIncome" scale="0" unitRef="usd">134,576</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:RentIncome" scale="0" unitRef="usd">20,071</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Operating sublease income &#8211; related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingSubleaseIncomeRelatedParties" scale="0" unitRef="usd">4,800</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingSubleaseIncomeRelatedParties" scale="0" unitRef="usd">4,800</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Impairment loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GoodwillImpairmentLoss" scale="0" unitRef="usd">961,217</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Investment loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RealizedInvestmentGainsLosses" scale="0" sign="-" unitRef="usd">40,589</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Gain/Loss on foreign exchange changes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:GainLossOnForeignExchangeChanges" scale="0" unitRef="usd">426,316</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:GainLossOnForeignExchangeChanges" scale="0" sign="-" unitRef="usd">3,275</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Gain/Loss on investment in equity securities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="0" sign="-" unitRef="usd">269,844</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="0" sign="-" unitRef="usd">1,168,733</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Other income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">22,409</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" unitRef="usd">174,770</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Government grant income</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="0" unitRef="usd">360,898</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 1.5pt">Total other income (expenses)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" unitRef="usd">495,141</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="0" sign="-" unitRef="usd">2,308,160</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Loss before provision income tax</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">11,210,827</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" sign="-" unitRef="usd">10,813,936</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Provision for income tax expense (benefit)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" unitRef="usd">825,024</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">220,352</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">12,035,851</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="0" sign="-" unitRef="usd">10,593,584</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss attributable to noncontrolling interests</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="0" unitRef="usd">802,962</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="0" sign="-" unitRef="usd">802,420</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss attributed to ABVC and subsidiaries</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetLossAttributableToAbvcAndSubsidiaries" scale="0" sign="-" unitRef="usd">12,838,813</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetLossAttributableToAbvcAndSubsidiaries" scale="0" sign="-" unitRef="usd">9,791,164</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">25,200</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" sign="-" unitRef="usd">98,893</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Comprehensive loss</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">12,864,013</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="0" sign="-" unitRef="usd">9,890,057</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss per share:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Basic and diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.51</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.50</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average number of common shares outstanding:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Basic and diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">25,053,522</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">19,715,559</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="b_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from operating activities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net loss</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">12,035,851</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="0" sign="-" unitRef="usd">10,593,584</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Depreciation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">11,993</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="0" unitRef="usd">37,142</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Stock based compensation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">5,306,755</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" unitRef="usd">4,146,979</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Gain/Loss on investment in equity securities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" sign="-" unitRef="usd">269,844</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnrealizedGainLossOnInvestments" scale="0" sign="-" unitRef="usd">1,168,733</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Government grant income</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:GovernmentGrantIncome" scale="0" unitRef="usd">360,898</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Other non-cash income and expenses</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" unitRef="usd">15,360</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Investment loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:InvestmentLoss1" scale="0" unitRef="usd">1,001,806</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Deferred tax</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" unitRef="usd">824,199</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" sign="-" unitRef="usd">223,201</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Changes in operating assets and liabilities:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Decrease (increase) in accounts receivable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" unitRef="usd">120,980</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" sign="-" unitRef="usd">3,696</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Decrease (increase) in prepaid expenses and other current assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" unitRef="usd">357,276</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" scale="0" unitRef="usd">15,778</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Decrease (increase) in due from related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseDueFromOtherRelatedParties" scale="0" unitRef="usd">595,037</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseDueFromOtherRelatedParties" scale="0" sign="-" unitRef="usd">20,645</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Decrease (increase) in inventory</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" unitRef="usd">25,830</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Increase (decrease) in accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd">23,044</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" sign="-" unitRef="usd">951</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Increase (decrease) in accrued expenses and other current liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd">173,151</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" sign="-" unitRef="usd">359,822</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Increase (decrease) in advanced from others</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" sign="-" unitRef="usd">1,085</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" sign="-" unitRef="usd">1,015</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Increase (decrease) in due to related parties</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" sign="-" unitRef="usd">317,358</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" unitRef="usd">266,791</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.625in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">7,597,719</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" sign="-" unitRef="usd">4,563,919</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from investing activities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net proceeds from sale of investment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfInvestmentProjects" scale="0" unitRef="usd">147,804</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Purchase of investments</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireInvestments" scale="0" unitRef="usd">107,547</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Purchase of equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" unitRef="usd">17,503</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Loan to related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="0" unitRef="usd">373,235</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Prepayment for equity investment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireLongtermInvestments" scale="0" unitRef="usd">680,916</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.625in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">805,966</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" sign="-" unitRef="usd">225,431</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash flows from financing activities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Issuance of common stock</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">11,119,452</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">7,615,331</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Payment for offering costs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" unitRef="usd">850,429</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from convertible notes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" unitRef="usd">2,500,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Repayment of convertible notes</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="0" unitRef="usd">306,836</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Repayment of short-term loan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfSubordinatedShortTermDebt" scale="0" unitRef="usd">100,000</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Repayment of notes payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="0" unitRef="usd">107,400</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Repayment of short-term bank loan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfOtherShortTermDebt" scale="0" unitRef="usd">350,000</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from short-term loan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromBankDebt" scale="0" unitRef="usd">100,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from long-term loan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="0" unitRef="usd">236,498</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" scale="0" unitRef="usd">124,400</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from (repayments of) short term borrowings from third parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherShortTermDebt" scale="0" unitRef="usd">4,265</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherShortTermDebt" scale="0" sign="-" unitRef="usd">480,989</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Proceeds from borrowings from related parties</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="0" unitRef="usd">72,704</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Repayment of long-term bank loans</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">-</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="0" unitRef="usd">13,603</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.625in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">9,995,550</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" unitRef="usd">9,567,843</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash and cash equivalents and restricted cash</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" sign="-" unitRef="usd">28,021</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">62,435</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net increase in cash and cash equivalents and restricted cash</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">1,563,844</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" unitRef="usd">4,840,928</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Cash and cash equivalents and restricted cash</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Beginning</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">5,001,371</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">160,443</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Ending</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">6,565,215</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" unitRef="usd">5,001,371</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Supplemental disclosure of cash flows</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Cash paid during the year for:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Interest expense paid</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">333,873</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="0" unitRef="usd">208,556</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Income taxes paid</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">-</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">-</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left">Non-cash financing and investing activities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Common shares issued for debt conversion</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">2,693,548</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">1,717,051</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="b_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR THE YEAR ENDED DECEMBER 31, 2021 AND 2020</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Common
    Stock</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Additional</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<br/>
    Other</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Treasury
    Stock</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Non</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stockholders&#8217;</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number
    of<br/> shares</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amounts</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Subscription<br/>
    Receivable</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Paid-in<br/>
    Capital</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Accumulated<br/>
    Deficit</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Comprehensive<br/>
    Income</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Number&#160;of<br/>
    Shares</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Amount</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">controlling<br/>
    Interest</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Equity<br/>
    (Deficit)</span></td>
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 20%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December&#160;31, 2019</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">19,478,168</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c49" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">19,478</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c50" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">4,063,320</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c51" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">28,180,348</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c52" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">15,851,223</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c53" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">663,753</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" sign="-" unitRef="shares">275,347</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">9,100,000</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c55" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">26,147</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">124,817</ix:nonFraction></span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Capital
    contribution</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" scale="0" unitRef="shares">3,384,615</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" scale="0" unitRef="usd">3,385</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" scale="0" unitRef="usd">7,611,946</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-53; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-54; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-55; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" scale="0" unitRef="usd">7,615,331</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    based compensation for options granted</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">1,706,419</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-56; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-57; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-58; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">1,706,419</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    based compensation for services</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodShareBasedCompensationServicesforShares" scale="0" unitRef="shares">641,887</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" scale="0" unitRef="usd">642</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c61" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" scale="0" unitRef="usd">902,960</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" scale="0" unitRef="usd">1,536,958</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-59; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-60; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-61; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" scale="0" unitRef="usd">2,440,560</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Debt
    conversion</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares">915,856</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">915</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">1,716,136</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-62; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-63; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-64; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" unitRef="usd">1,717,051</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss for the year</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-65; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c58" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">9,791,164</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-66; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c60" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">802,420</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">10,593,584</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cumulative
    transaction adjustments</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-67; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-68; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c59" decimals="0" format="ixt:num-dot-decimal" name="abvc:CumulativeTransactionAdjustments" scale="0" sign="-" unitRef="usd">98,893</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: hidden-fact-69; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:CumulativeTransactionAdjustments" scale="0" sign="-" unitRef="usd">98,893</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December&#160;31, 2020</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">24,420,526</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c9" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">24,420</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">3,160,360</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">40,751,807</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c12" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">25,642,387</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c13" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">564,860</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" sign="-" unitRef="shares">275,347</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c14" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">9,100,000</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">776,273</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">2,662,067</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common shares for cash</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">3,027,750</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">3,028</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">10,265,995</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-70; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-71; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-72; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd">10,269,023</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common shares for consulting service</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">366,934</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">367</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">1,728,223</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-73; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-74; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-75; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" unitRef="usd">1,728,590</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Issuance
    of common shares for debt conversion</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares">1,111,112</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd">1,111</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd">2,692,437</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-76; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-77; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-78; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" scale="0" unitRef="usd">2,693,548</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    based compensation for services</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c67" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" scale="0" unitRef="usd">902,960</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-79; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-80; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-81; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-82; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" scale="0" unitRef="usd">902,960</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Stock
    based compensation for options granted</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">2,675,205</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-83; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-84; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-85; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" unitRef="usd">2,675,205</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Net
    loss for the year</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-86; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">12,838,813</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="-sec-ix-hidden: hidden-fact-87; font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c66" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" unitRef="usd">802,962</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">12,035,851</ix:nonFraction></span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cumulative
    transaction adjustments</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c65" decimals="0" format="ixt:num-dot-decimal" name="abvc:CumulativeTransactionAdjustments" scale="0" sign="-" unitRef="usd">25,200</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">-</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:CumulativeTransactionAdjustments" scale="0" sign="-" unitRef="usd">25,200</ix:nonFraction></span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">Balance
    at December 31, 2021</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">28,926,322</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c29" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">28,926</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c30" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">2,257,400</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c31" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">58,113,667</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">38,481,200</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c33" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">539,660</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" sign="-" unitRef="shares">275,347</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">(<ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" sign="-" unitRef="usd">9,100,000</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">)</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c35" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">26,689</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">$</span></td>
    <td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" unitRef="usd">8,870,342</ix:nonFraction></span></td>
    <td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The accompanying notes are an integral part of these consolidated financial statements.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><div><a id="b_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BIOPHARMA, INC. AND SUBSIDIARIES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><ix:nonNumeric contextRef="c372" continuedAt="_StockholdersEquityNoteStockSplit-c372_cont_1" name="us-gaap:StockholdersEquityNoteStockSplit"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_1"><ix:continuation continuedAt="_StockholdersEquityNoteStockSplit-c372_cont_2" id="_StockholdersEquityNoteStockSplit-c372_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC BioPharma, Inc. (the &#8220;Company&#8221;), formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#8217;s operating entity, American BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical trials for the Company&#8217;s drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;) and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July 21, 2015.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_2"><ix:continuation continuedAt="_StockholdersEquityNoteStockSplit-c372_cont_3" id="_StockholdersEquityNoteStockSplit-c372_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Name Change</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_3"><ix:continuation continuedAt="_StockholdersEquityNoteStockSplit-c372_cont_4" id="_StockholdersEquityNoteStockSplit-c372_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s shareholders approved an amendment to the Company&#8217;s Articles of Incorporation to change the Company&#8217;s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &#8220;Annual Meeting&#8221;). The name change amendment to the Company&#8217;s Articles of Incorporation was filed with Nevada&#8217;s Secretary of State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became effective as of May 3, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_4"><ix:continuation continuedAt="_StockholdersEquityNoteStockSplit-c372_cont_5" id="_StockholdersEquityNoteStockSplit-c372_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s stock symbol remains ABVC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_5"><ix:continuation continuedAt="_StockholdersEquityNoteStockSplit-c372_cont_6" id="_StockholdersEquityNoteStockSplit-c372_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Reverse Merger</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_6"><ix:continuation continuedAt="_StockholdersEquityNoteStockSplit-c372_cont_7" id="_StockholdersEquityNoteStockSplit-c372_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2016, a Share Exchange Agreement (the &#8220;Share Exchange Agreement&#8221;) was entered into by and among the Company, BriVision, and Euro-Asia Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&#8217;s Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of <ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">164,387,376</ix:nonFraction> (<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,336,000</ix:nonFraction> pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the &#8220;BriVision Stock&#8221;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_7"><ix:continuation continuedAt="_StockholdersEquityNoteStockSplit-c372_cont_8" id="_StockholdersEquityNoteStockSplit-c372_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued <ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">166,273,921</ix:nonFraction> (<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,936,583</ix:nonFraction> pre-stock split) shares (the &#8220;Acquisition Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s Common Stock to the BriVision Shareholders (or their designees), and <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">163,159,952</ix:nonFraction> (<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">51,945,225</ix:nonFraction> pre-stock split) shares of the Company&#8217;s Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented <ix:nonFraction contextRef="c71" decimals="4" format="ixt:num-dot-decimal" name="abvc:PercentageOfCommonSharesIssuedAndOutstanding" scale="-2" unitRef="pure">79.70</ix:nonFraction>% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing <ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfIssuedShareCapital" scale="-2" unitRef="pure">100</ix:nonFraction>% of the issued share capital of BriVision in a reverse merger (the &#8220;Merger&#8221;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:continuation id="_StockholdersEquityNoteStockSplit-c372_cont_8">Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of <ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">166,273,921</ix:nonFraction> (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.</ix:continuation> The holders of Company&#8217;s Common Stock as of immediately prior to the Merger held an aggregate of <ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">205,519,223</ix:nonFraction> (<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">65,431,144</ix:nonFraction> pre-stock split) shares of Company&#8217;s Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the &#8220;Share Exchange&#8221;), BriVision had become a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the consummation of the Share Exchange, BriVision became a wholly owned subsidiary of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the Share Exchange, the Company has abandoned prior business plan and is now pursuing BriVision&#8217;s historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&#8220;POC&#8221;), out-license to international pharmaceutical companies, and explore global markets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Accounting Treatment of the Reverse Merger</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For financial reporting purposes, the Share Exchange represents a &#8220;reverse merger&#8221;&#160;rather than a business combination and&#160;BriVision&#160;is deemed the accounting acquirer in the transaction. The&#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#160;is the acquirer for financial reporting purposes and the&#160;Company&#160;is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of&#160;BriVision&#160;and recorded at the historical cost basis of&#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of&#160;BriVision&#160;and operations of the Combined Company from the closing date of the Share Exchange.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_14" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Merger</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_15" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2019, the Company, BioLite Holding, Inc. (&#8220;BioLite&#8221;), BioKey, Inc. (&#8220;BioKey&#8221;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#8220;Merger Sub 1&#8221;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#8220;Merger Sub 2&#8221;) (collectively referred to as the &#8220;Parties&#8221;) completed the business combination pursuant to the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the shareholders of BioLite and BioKey.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_16" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of <ix:nonFraction contextRef="c74" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">104,558,777</ix:nonFraction> shares (prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285), which became effective by operation of law on or about February 5, 2019.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_17" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Holding, Inc. (the &#8220;BioLite Holding&#8221;) was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the &#8220;BioLite BVI&#8221;), a wholly owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are holding companies and have not carried out substantive business operations of their own.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_18" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite, Inc., (the &#8220;BioLite Taiwan&#8221;) was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_19" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2017, BioLite Holding, BioLite BVI, BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &#8220;BioLite Share Purchase / Exchange Agreement&#8221;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately owns via BioLite BVI approximately <ix:nonFraction contextRef="c75" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfCommonSharesIssuedAndOutstanding" scale="-2" unitRef="pure">73</ix:nonFraction>% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_20" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioKey, Inc. was incorporated on August 9, 2000 in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development processes with other biotechnology, pharmaceutical, and nutraceutical companies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_21" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Accounting Treatment of the Merger</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c5_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted ASC 805, &#8220;Business Combination&#8221; to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang&#8217;s common control, the transaction is accounted for as a restructuring transaction.&#160;All the assets and liabilities of BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding&#8217;s common shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the earnings (or losses) of the transferred net assets.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_2" id="_SignificantAccountingPoliciesTextBlock-c5_cont_1"><ix:nonNumeric contextRef="c5" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Basis of Presentation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_3" id="_SignificantAccountingPoliciesTextBlock-c5_cont_2"><ix:continuation continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c5_cont_2" id="_BasisOfAccountingPolicyPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;). All significant intercompany transactions and account balances have been eliminated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_4" id="_SignificantAccountingPoliciesTextBlock-c5_cont_3"><ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_5" id="_SignificantAccountingPoliciesTextBlock-c5_cont_4"><ix:nonNumeric contextRef="c5" continuedAt="_FiscalPeriod-c5_cont_1" escape="true" name="us-gaap:FiscalPeriod"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Fiscal Year</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_6" id="_SignificantAccountingPoliciesTextBlock-c5_cont_5"><ix:continuation id="_FiscalPeriod-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_7" id="_SignificantAccountingPoliciesTextBlock-c5_cont_6"><ix:nonNumeric contextRef="c5" continuedAt="_UseOfEstimates-c5_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_8" id="_SignificantAccountingPoliciesTextBlock-c5_cont_7"><ix:continuation id="_UseOfEstimates-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_9" id="_SignificantAccountingPoliciesTextBlock-c5_cont_8"><ix:nonNumeric contextRef="c5" continuedAt="_InventoryPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Inventory</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_10" id="_SignificantAccountingPoliciesTextBlock-c5_cont_9"><ix:continuation id="_InventoryPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_11" id="_SignificantAccountingPoliciesTextBlock-c5_cont_10"><ix:nonNumeric contextRef="c5" continuedAt="_ForwardStockSplitsPolicyTextBlock-c5_cont_1" escape="true" name="abvc:ForwardStockSplitsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Forward Stock Split</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_12" id="_SignificantAccountingPoliciesTextBlock-c5_cont_11"><ix:continuation id="_ForwardStockSplitsPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_13" id="_SignificantAccountingPoliciesTextBlock-c5_cont_12"><ix:nonNumeric contextRef="c5" continuedAt="_StockReverseSplitPolicyTextBlock-c5_cont_1" escape="true" name="abvc:StockReverseSplitPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Stock Reverse Split</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_14" id="_SignificantAccountingPoliciesTextBlock-c5_cont_13"><ix:continuation id="_StockReverseSplitPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#8220;Reverse Split&#8221;) of both the authorized common stock of the Company (the &#8220;Common Stock&#8221;) and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company&#8217;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company&#8217;s articles of incorporation (the &#8220;Amendment&#8221;) to effect the Reverse Split with the Secretary of State of Nevada. <ix:nonNumeric contextRef="c373" name="us-gaap:StockholdersEquityReverseStockSplit">The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_15" id="_SignificantAccountingPoliciesTextBlock-c5_cont_14"><ix:nonNumeric contextRef="c5" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Fair Value Measurements</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_16" id="_SignificantAccountingPoliciesTextBlock-c5_cont_15"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 820, &#8220;Fair Value Measurements&#8221; defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_17" id="_SignificantAccountingPoliciesTextBlock-c5_cont_16"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_18" id="_SignificantAccountingPoliciesTextBlock-c5_cont_17"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_19" id="_SignificantAccountingPoliciesTextBlock-c5_cont_18"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_20" id="_SignificantAccountingPoliciesTextBlock-c5_cont_19"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c5_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company&#8217;s long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_21" id="_SignificantAccountingPoliciesTextBlock-c5_cont_20"><ix:nonNumeric contextRef="c5" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Cash and Cash Equivalents</span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_22" id="_SignificantAccountingPoliciesTextBlock-c5_cont_21"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2021 and 2020, the Company&#8217;s cash and cash equivalents amounted $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">5,828,548</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="0" unitRef="usd">4,273,208</ix:nonFraction>, respectively. Some&#160;of the Company&#8217;s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_23" id="_SignificantAccountingPoliciesTextBlock-c5_cont_22"><ix:nonNumeric contextRef="c5" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c5_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Restricted Cash Equivalents</span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_24" id="_SignificantAccountingPoliciesTextBlock-c5_cont_23"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of December 31, 2021 and 2020, the Company&#8217;s restricted cash equivalents amounted $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="0" unitRef="usd">736,667</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="0" unitRef="usd">728,163</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_25" id="_SignificantAccountingPoliciesTextBlock-c5_cont_24"><ix:nonNumeric contextRef="c5" continuedAt="_ConcentrationRiskCreditRisk-c5_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_26" id="_SignificantAccountingPoliciesTextBlock-c5_cont_25"><ix:continuation id="_ConcentrationRiskCreditRisk-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_27" id="_SignificantAccountingPoliciesTextBlock-c5_cont_26"><ix:nonNumeric contextRef="c5" continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Revenue Recognition</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_28" id="_SignificantAccountingPoliciesTextBlock-c5_cont_27"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_2" id="_RevenueRecognitionPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fiscal year 2018, the Company adopted Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#8217;s reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#8217;s review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company&#8217;s revenue during all periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_29" id="_SignificantAccountingPoliciesTextBlock-c5_cont_28"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_3" id="_RevenueRecognitionPolicyTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_30" id="_SignificantAccountingPoliciesTextBlock-c5_cont_29"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_4" id="_RevenueRecognitionPolicyTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_31" id="_SignificantAccountingPoliciesTextBlock-c5_cont_30"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_5" id="_RevenueRecognitionPolicyTextBlock-c5_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative Revenues</b> &#8212; The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_32" id="_SignificantAccountingPoliciesTextBlock-c5_cont_31"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_6" id="_RevenueRecognitionPolicyTextBlock-c5_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_33" id="_SignificantAccountingPoliciesTextBlock-c5_cont_32"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_7" id="_RevenueRecognitionPolicyTextBlock-c5_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_34" id="_SignificantAccountingPoliciesTextBlock-c5_cont_33"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_8" id="_RevenueRecognitionPolicyTextBlock-c5_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Non-refundable upfront payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_35" id="_SignificantAccountingPoliciesTextBlock-c5_cont_34"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_9" id="_RevenueRecognitionPolicyTextBlock-c5_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_36" id="_SignificantAccountingPoliciesTextBlock-c5_cont_35"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_10" id="_RevenueRecognitionPolicyTextBlock-c5_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Milestone payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_37" id="_SignificantAccountingPoliciesTextBlock-c5_cont_36"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_11" id="_RevenueRecognitionPolicyTextBlock-c5_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_38" id="_SignificantAccountingPoliciesTextBlock-c5_cont_37"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_12" id="_RevenueRecognitionPolicyTextBlock-c5_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_39" id="_SignificantAccountingPoliciesTextBlock-c5_cont_38"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_13" id="_RevenueRecognitionPolicyTextBlock-c5_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) Multiple Element Arrangements</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_40" id="_SignificantAccountingPoliciesTextBlock-c5_cont_39"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_14" id="_RevenueRecognitionPolicyTextBlock-c5_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_41" id="_SignificantAccountingPoliciesTextBlock-c5_cont_40"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_15" id="_RevenueRecognitionPolicyTextBlock-c5_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_42" id="_SignificantAccountingPoliciesTextBlock-c5_cont_41"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_16" id="_RevenueRecognitionPolicyTextBlock-c5_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_43" id="_SignificantAccountingPoliciesTextBlock-c5_cont_42"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_17" id="_RevenueRecognitionPolicyTextBlock-c5_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) Royalties and Profit Sharing Payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_44" id="_SignificantAccountingPoliciesTextBlock-c5_cont_43"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_18" id="_RevenueRecognitionPolicyTextBlock-c5_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_45" id="_SignificantAccountingPoliciesTextBlock-c5_cont_44"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_19" id="_RevenueRecognitionPolicyTextBlock-c5_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues Derived from Research and Development Activities Services &#8212; Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_46" id="_SignificantAccountingPoliciesTextBlock-c5_cont_45"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_20" id="_RevenueRecognitionPolicyTextBlock-c5_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_47" id="_SignificantAccountingPoliciesTextBlock-c5_cont_46"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c5_cont_21" id="_RevenueRecognitionPolicyTextBlock-c5_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_48" id="_SignificantAccountingPoliciesTextBlock-c5_cont_47"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c5_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_49" id="_SignificantAccountingPoliciesTextBlock-c5_cont_48"><ix:nonNumeric contextRef="c5" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Property and Equipment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_50" id="_SignificantAccountingPoliciesTextBlock-c5_cont_49"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_51" id="_SignificantAccountingPoliciesTextBlock-c5_cont_50"><ix:nonNumeric contextRef="c5" escape="true" name="abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated&#160;Life<br/> in Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings and leasehold improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c374" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> ~ <ix:nonNumeric contextRef="c375" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">50</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c376" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric> ~ <ix:nonNumeric contextRef="c377" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c378" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric> ~ <ix:nonNumeric contextRef="c379" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">6</ix:nonNumeric></span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_52" id="_SignificantAccountingPoliciesTextBlock-c5_cont_51"><ix:nonNumeric contextRef="c5" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_53" id="_SignificantAccountingPoliciesTextBlock-c5_cont_52"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_54" id="_SignificantAccountingPoliciesTextBlock-c5_cont_53"><ix:nonNumeric contextRef="c5" continuedAt="_LongTermEquityInvestmentPolicy-c5_cont_1" escape="true" name="abvc:LongTermEquityInvestmentPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Long-term Equity Investment</span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_55" id="_SignificantAccountingPoliciesTextBlock-c5_cont_54"><ix:continuation continuedAt="_LongTermEquityInvestmentPolicy-c5_cont_2" id="_LongTermEquityInvestmentPolicy-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_56" id="_SignificantAccountingPoliciesTextBlock-c5_cont_55"><ix:continuation continuedAt="_LongTermEquityInvestmentPolicy-c5_cont_3" id="_LongTermEquityInvestmentPolicy-c5_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_57" id="_SignificantAccountingPoliciesTextBlock-c5_cont_56"><ix:continuation continuedAt="_LongTermEquityInvestmentPolicy-c5_cont_4" id="_LongTermEquityInvestmentPolicy-c5_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable cost method investments when the equity method does not apply.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_58" id="_SignificantAccountingPoliciesTextBlock-c5_cont_57"><ix:continuation id="_LongTermEquityInvestmentPolicy-c5_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant judgment is required to identify whether an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#8217;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee&#8217;s industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#8217; revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_59" id="_SignificantAccountingPoliciesTextBlock-c5_cont_58"><ix:nonNumeric contextRef="c5" continuedAt="_OtherThanTemporaryImpairmentPolicyTextBlock-c5_cont_1" escape="true" name="abvc:OtherThanTemporaryImpairmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Other-Than-Temporary Impairment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_60" id="_SignificantAccountingPoliciesTextBlock-c5_cont_59"><ix:continuation continuedAt="_OtherThanTemporaryImpairmentPolicyTextBlock-c5_cont_2" id="_OtherThanTemporaryImpairmentPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_61" id="_SignificantAccountingPoliciesTextBlock-c5_cont_60"><ix:continuation continuedAt="_OtherThanTemporaryImpairmentPolicyTextBlock-c5_cont_3" id="_OtherThanTemporaryImpairmentPolicyTextBlock-c5_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#8217;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_62" id="_SignificantAccountingPoliciesTextBlock-c5_cont_61"><ix:continuation id="_OtherThanTemporaryImpairmentPolicyTextBlock-c5_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable equity investments based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:ImpairmentOfEquityInvestments" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:ImpairmentOfEquityInvestments" scale="0" unitRef="usd">961,217</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_63" id="_SignificantAccountingPoliciesTextBlock-c5_cont_62"><ix:nonNumeric contextRef="c5" continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Goodwill</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_64" id="_SignificantAccountingPoliciesTextBlock-c5_cont_63"><ix:continuation continuedAt="_GoodwillAndIntangibleAssetsPolicyTextBlock-c5_cont_2" id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_65" id="_SignificantAccountingPoliciesTextBlock-c5_cont_64"><ix:continuation id="_GoodwillAndIntangibleAssetsPolicyTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company completed the required testing of goodwill for impairment as of December 31, 2021, and determined that goodwill was impaired because of the current financial condition of the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_66" id="_SignificantAccountingPoliciesTextBlock-c5_cont_65"><ix:nonNumeric contextRef="c5" continuedAt="_ResearchAndDevelopmentExpensePolicy-c5_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Research and Development Expenses</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_67" id="_SignificantAccountingPoliciesTextBlock-c5_cont_66"><ix:continuation continuedAt="_ResearchAndDevelopmentExpensePolicy-c5_cont_2" id="_ResearchAndDevelopmentExpensePolicy-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_68" id="_SignificantAccountingPoliciesTextBlock-c5_cont_67"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our CDMO business unit, the Company accounts for R&amp;D costs in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, Research and Development (&#8220;ASC 730&#8221;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_69" id="_SignificantAccountingPoliciesTextBlock-c5_cont_68"><ix:nonNumeric contextRef="c5" continuedAt="_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy-c5_cont_1" escape="true" name="us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Post-retirement and post-employment benefits</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_70" id="_SignificantAccountingPoliciesTextBlock-c5_cont_69"><ix:continuation id="_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#8217;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfMonthlyContribution" scale="-2" unitRef="pure">6</ix:nonFraction>% of employees&#8217; salaries to the employees&#8217; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" scale="0" unitRef="usd">11,375</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash" scale="0" unitRef="usd">13,961</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_71" id="_SignificantAccountingPoliciesTextBlock-c5_cont_70"><ix:nonNumeric contextRef="c5" continuedAt="_CompensationRelatedCostsPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Stock-based Compensation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_72" id="_SignificantAccountingPoliciesTextBlock-c5_cont_71"><ix:continuation continuedAt="_CompensationRelatedCostsPolicyTextBlock-c5_cont_2" id="_CompensationRelatedCostsPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;. Total employee stock-based compensation expenses were $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">2,675,205</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="0" unitRef="usd">1,623,102</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_73" id="_SignificantAccountingPoliciesTextBlock-c5_cont_72"><ix:continuation id="_CompensationRelatedCostsPolicyTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221; and FASB ASC Topic 505-50 &#8220;Equity-Based Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockBasedCompensationForNonemployees" scale="0" unitRef="usd">2,631,550</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockBasedCompensationForNonemployees" scale="0" unitRef="usd">2,523,877</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_74" id="_SignificantAccountingPoliciesTextBlock-c5_cont_73"><ix:nonNumeric contextRef="c5" continuedAt="_BeneficialConversionFeature-c5_cont_1" escape="true" name="abvc:BeneficialConversionFeature"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Beneficial Conversion Feature</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_75" id="_SignificantAccountingPoliciesTextBlock-c5_cont_74"><ix:continuation id="_BeneficialConversionFeature-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_76" id="_SignificantAccountingPoliciesTextBlock-c5_cont_75"><ix:nonNumeric contextRef="c5" continuedAt="_IncomeTaxPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Income Taxes</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_77" id="_SignificantAccountingPoliciesTextBlock-c5_cont_76"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c5_cont_2" id="_IncomeTaxPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_78" id="_SignificantAccountingPoliciesTextBlock-c5_cont_77"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c5_cont_3" id="_IncomeTaxPolicyTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the year ended December 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_79" id="_SignificantAccountingPoliciesTextBlock-c5_cont_78"><ix:continuation id="_IncomeTaxPolicyTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 22, 2017, the SEC issued Staff Accounting Bulletin (&#8220;SAB 118&#8221;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_80" id="_SignificantAccountingPoliciesTextBlock-c5_cont_79"><ix:nonNumeric contextRef="c5" continuedAt="_ValuationOfDeferredTaxAssetsPolicyTextBlock-c5_cont_1" escape="true" name="abvc:ValuationOfDeferredTaxAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_81" id="_SignificantAccountingPoliciesTextBlock-c5_cont_80"><ix:continuation id="_ValuationOfDeferredTaxAssetsPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A valuation allowance is recorded to reduce the Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_82" id="_SignificantAccountingPoliciesTextBlock-c5_cont_81"><ix:nonNumeric contextRef="c5" continuedAt="_EarningsPerSharePolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Loss Per Share of Common Stock</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_83" id="_SignificantAccountingPoliciesTextBlock-c5_cont_82"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company calculates net loss per share in accordance with ASC Topic 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_84" id="_SignificantAccountingPoliciesTextBlock-c5_cont_83"><ix:nonNumeric contextRef="c5" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Commitments and Contingencies</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_85" id="_SignificantAccountingPoliciesTextBlock-c5_cont_84"><ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted ASC Topic 450 &#8220;Contingencies&#8221; subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_86" id="_SignificantAccountingPoliciesTextBlock-c5_cont_85"><ix:nonNumeric contextRef="c5" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Foreign-currency Transactions</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_87" id="_SignificantAccountingPoliciesTextBlock-c5_cont_86"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Company&#8217;s subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#8217; Equity (Deficit).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_88" id="_SignificantAccountingPoliciesTextBlock-c5_cont_87"><ix:nonNumeric contextRef="c5" continuedAt="_TranslationAdjustmentPolicyTextBlock-c5_cont_1" escape="true" name="abvc:TranslationAdjustmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Translation Adjustment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_89" id="_SignificantAccountingPoliciesTextBlock-c5_cont_88"><ix:continuation id="_TranslationAdjustmentPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounts of the Company&#8217;s subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#8220;NT$&#8221;). Such financial statements were translated into U.S. Dollars (&#8220;$&#8221; or &#8220;USD&#8221;) in accordance ASC 830, &#8220;Foreign Currency Matters&#8221;, with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder&#8217;s deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#8217; equity (deficit).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_90" id="_SignificantAccountingPoliciesTextBlock-c5_cont_89"><ix:nonNumeric contextRef="c5" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c5_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c5_cont_91" id="_SignificantAccountingPoliciesTextBlock-c5_cont_90"><ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c5_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For contracts in an entity&#8217;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c5_cont_91"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_1" escape="true" name="us-gaap:CollaborativeArrangementDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. COLLABORATIVE AGREEMENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_2" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Collaborative agreements with BHK</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_3" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_4" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $<ix:nonFraction contextRef="c84" decimals="-6" format="ixt:num-dot-decimal" name="abvc:MilestonePayments" scale="6" unitRef="usd">10</ix:nonFraction> million based on the following schedule:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_5" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><ix:nonNumeric contextRef="c380" continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_1" name="us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_2" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment</span></ix:continuation></td></tr> </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_6" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_5"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_3" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_7" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_6"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_4" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the completion of first phase II clinical trial: $1 million, or 10% of total payment</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_8" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_7"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_5" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_9" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_6" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><ix:continuation continuedAt="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_7" id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:continuation id="_RelatedPartyTransactionTermsAndMannerOfSettlement-c380_cont_7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_10" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2015, BHK has paid a non-refundable upfront cash payment of $<ix:nonFraction contextRef="c85" decimals="-6" format="ixt:num-dot-decimal" name="abvc:UpfrontCashPayment" scale="6" unitRef="usd">1</ix:nonFraction> million, or <ix:nonFraction contextRef="c86" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure">10</ix:nonFraction>% of $<ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="0" unitRef="usd">10,000,000</ix:nonFraction>, upon the signing of BHK Co-Development Agreement. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August 2016, the Company has received the second milestone payment of NT$<ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="abvc:MilestonePayments" scale="0" unitRef="twd">31,649,000</ix:nonFraction>, approximately equivalent to $<ix:nonFraction contextRef="c87" decimals="-6" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="6" unitRef="usd">1</ix:nonFraction> million, and recognized collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical trial.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_11" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the milestone payments, BioLite Taiwan is entitled to receive royalty on <ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="abvc:MilestonePaymentsRoyaltyPercentage" scale="-2" unitRef="pure">12</ix:nonFraction>% of BHK&#8217;s net sales related to BLI-1401-2 Products. As of December 31, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Co-Development Agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_12" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) On December 9, 2015, BioLite Taiwan entered into another two collaborative agreements (the &#8220;BHK Collaborative Agreements&#8221;), pursuant to which it is collaborative with BHK to co-develop and commercialize BLI-1005 for &#8220;Targeting Major Depressive Disorder&#8221; (BLI-1005 Products) and BLI-1006 for &#8220;Targeting Inflammatory Bowel Disease&#8221; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_13" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c86" name="abvc:CollaborativeAgreementsDescription">In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK.</ix:nonNumeric> The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this BHK Collaborative Agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_14" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c381" name="abvc:CollaborativeAgreementsDescription">In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.</ix:nonNumeric> As of December 31, 2021 and 2020, the Company has not earned the royalty under the BHK Collaborative Agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_15" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Co-Development agreement with Rgene Corporation, a related party</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_16" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 26, 2017, BriVision entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to&#160;pay the Company $<ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForParticipationLiabilities" scale="0" unitRef="usd">3,000,000</ix:nonFraction> in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision&#8217;s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to $<ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionCashPayment" scale="0" unitRef="usd">3,000,000</ix:nonFraction>, the Company is entitled to receive <ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure">50</ix:nonFraction>% of the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both BriVision and Rgene.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_17" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" unitRef="usd">3,000,000</ix:nonFraction> in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended December 31, 2017, the Company has received $<ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" scale="0" unitRef="usd">450,000</ix:nonFraction> in cash. On December 24, 2018, <ix:nonNumeric contextRef="c92" name="abvc:CoDevAgreementDescription">the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.</ix:nonNumeric> On December 31, 2018, the Company determined to fully write off this investment based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene&#8217;s ability to remain in business. All projects that have been initiated will be managed and supported by the Company and Rgene.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_18" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and Rgene signed an amendment to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions of the Co-Dev Agreement remain in full force and effect.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_19" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Collaborative agreement with BioFirst Corporation, a related party</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_20" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2017, BriVision entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst Corporation (&#8220;BioFirst&#8221;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the &#8220;Product&#8221;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See Note 12).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_21" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $<ix:nonFraction contextRef="c382" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfStockValue" scale="0" unitRef="usd">3,000,000</ix:nonFraction> in cash or stock of the Company before September 30, 2018. The amount of $<ix:nonFraction contextRef="c382" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForParticipationLiabilities" scale="0" unitRef="usd">3,000,000</ix:nonFraction> is in connection with the compensation for BioFirst&#8217;s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive <ix:nonFraction contextRef="c382" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfPaymentsUnderCodevelopmentAgreement" scale="-2" unitRef="pure">50</ix:nonFraction>% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_22" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $<ix:nonFraction contextRef="c94" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" unitRef="usd">3,000,000</ix:nonFraction> since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount of $<ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="0" unitRef="usd">3,000,000</ix:nonFraction> is fully expensed as research and development expense during the year ended December 31, 2017.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c5_cont_23" id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2019, BriVision entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">428,571</ix:nonFraction> shares of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" scale="0" unitRef="usd">3,000,000</ix:nonFraction> owed by the Company to BioFirst (the &#8220;Total Payment&#8221;) in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the &#8220;Collaborative Agreement&#8221;). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CollaborativeArrangementDisclosureTextBlock-c5_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2019, BriVision entered into a second Stock Purchase Agreement (&#8220;Purchase Agreement 2&#8221;) with BioFirst. Pursuant to Purchase Agreement 2, the Company issued <ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">414,702</ix:nonFraction> shares of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent" scale="0" unitRef="usd">2,902,911</ix:nonFraction> owed by the Company to BioFirst in connection with a loan provided to BriVision from BioFirst.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_InventoryDisclosureTextBlock-c5_cont_1" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. INVENTORY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_InventoryDisclosureTextBlock-c5_cont_2" id="_InventoryDisclosureTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_InventoryDisclosureTextBlock-c5_cont_2"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Finished goods</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">96,725</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="0" unitRef="usd">100,967</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Work-in-process</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="0" unitRef="usd">22,038</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Raw materials</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">84,620</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="0" unitRef="usd">61,718</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:AllowanceForInventoryValuationAndObsolescenceLoss" scale="0" sign="-" unitRef="usd">155,370</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:AllowanceForInventoryValuationAndObsolescenceLoss" scale="0" sign="-" unitRef="usd">184,723</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Inventory, net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="0" unitRef="usd">25,975</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c5_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. PROPERTY AND EQUIPMENT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c5_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment as of December 31, 2021 and 2020 are summarized as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c5_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c5_cont_2"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Land</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c99" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">400,091</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c383" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">395,645</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Buildings and leasehold improvements</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">2,235,061</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c384" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">2,233,573</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Machinery and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c103" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">1,013,376</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c385" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">994,544</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">191,824</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c386" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">189,760</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">3,840,352</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" unitRef="usd">3,813,522</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">3,314,471</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" unitRef="usd">3,298,688</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Property and equipment, net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">525,881</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" unitRef="usd">514,834</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense were $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="0" unitRef="usd">11,993</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherDepreciationAndAmortization" scale="0" unitRef="usd">37,142</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_LongTermInvestmentTextBlock-c5_cont_1" escape="true" name="abvc:LongTermInvestmentTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. LONG-TERM INVESTMENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_2" id="_LongTermInvestmentTextBlock-c5_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_3" id="_LongTermInvestmentTextBlock-c5_cont_2"><ix:nonNumeric contextRef="c5" escape="true" name="abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership percentage</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting</b></span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of related party</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>treatments</b></span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c113" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.17</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c389" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.17</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><ix:nonNumeric contextRef="c390" name="abvc:AccountingTreatmentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></ix:nonNumeric></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c116" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.70</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c391" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0.70</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c392" name="abvc:AccountingTreatmentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></ix:nonNumeric></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c119" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">5.90</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c393" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">5.90</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c394" name="abvc:AccountingTreatmentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></ix:nonNumeric></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c109" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">15.99</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c395" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">15.99</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c107" name="abvc:AccountingTreatmentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></ix:nonNumeric></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c122" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">31.62</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c396" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">31.62</ix:nonFraction>%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><ix:nonNumeric contextRef="c111" name="abvc:AccountingTreatmentDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></ix:nonNumeric></td>
    <td>&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_4" id="_LongTermInvestmentTextBlock-c5_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The extent the investee relies on the company for its business are summarized as follows:</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_5" id="_LongTermInvestmentTextBlock-c5_cont_4"><ix:nonNumeric contextRef="c5" escape="true" name="abvc:ScheduleOfExtentInvesteeReliesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of related party</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The extent the investee relies on the Company for its business </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c390" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c392" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c394" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c107" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned from the investee and provides research and development support service</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:nonNumeric contextRef="c111" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</span></ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 161; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_6" id="_LongTermInvestmentTextBlock-c5_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term investment mainly consists of the following:</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_7" id="_LongTermInvestmentTextBlock-c5_cont_6"><ix:nonNumeric contextRef="c5" escape="true" name="abvc:ScheduleOfLongTermInvestmentTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-marketable Cost Method Investments, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">7,941</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c397" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">7,853</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Genepharm Biotech Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">24,244</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c398" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">23,974</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">BioHopeKing Corporation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">900,570</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c399" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">890,564</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Sub total</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">932,755</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:NonmarketableCostMethodInvestmentsNet" scale="0" unitRef="usd">922,391</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity Method Investments, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">BioFirst Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c400" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd">268,336</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Rgene Corporation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd">932,755</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestments" scale="0" unitRef="usd">1,190,727</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_8" id="_LongTermInvestmentTextBlock-c5_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_9" id="_LongTermInvestmentTextBlock-c5_cont_8"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2021 and 2020, the Company owns <ix:nonFraction contextRef="c107" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">15.99</ix:nonFraction>% and <ix:nonFraction contextRef="c387" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">15.99</ix:nonFraction>% common stock shares of BioFirst, respectively. During year ended December 31, 2021, the Company made prepayment for equity investment in BioFirst to purchase additional&#160;<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:PurchaseAdditionalShares" scale="0" unitRef="shares">317,000</ix:nonFraction>&#160;shares to be issued by BioFirst in the aggregate amount of $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:PrepaymentForLongtermInvestments" scale="0" unitRef="usd">684,720</ix:nonFraction>, recorded as prepayment for long-term investments as of December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_10" id="_LongTermInvestmentTextBlock-c5_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized financial information for the Company&#8217;s equity method investee, BioFirst, is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_11" id="_LongTermInvestmentTextBlock-c5_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Balance Sheet</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_12" id="_LongTermInvestmentTextBlock-c5_cont_11"><ix:nonNumeric contextRef="c5" continuedAt="_ScheduleOfCondensedBalanceSheetTableTextBlock-c5_cont_1" escape="true" name="pf0:ScheduleOfCondensedBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Current Assets</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">2,205,669</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c402" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">1,299,822</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Noncurrent Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">959,454</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c402" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">2,540,041</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">2,909,703</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c402" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">1,986,340</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Noncurrent Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">32,522</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c402" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">73,197</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Stockholders&#8217; Equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOther" scale="0" unitRef="usd">222,898</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c403" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOther" scale="0" unitRef="usd">1,780,326</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_13" id="_LongTermInvestmentTextBlock-c5_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Statement of operation</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_14" id="_LongTermInvestmentTextBlock-c5_cont_13"><ix:nonNumeric contextRef="c5" continuedAt="_ScheduleOfCondensedIncomeStatementTableTextBlock-c5_cont_1" escape="true" name="pf0:ScheduleOfCondensedIncomeStatementTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net sales</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">26,693</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c403" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">257,235</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross profit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">8,348</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c403" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" unitRef="usd">10,121</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetLoss1" scale="0" sign="-" unitRef="usd">2,276,892</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c403" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetLoss1" scale="0" sign="-" unitRef="usd">5,401,074</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share of losses from investments accounted for using the equity method</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="0" sign="-" unitRef="usd">269,844</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c403" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="0" sign="-" unitRef="usd">1,168,733</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_15" id="_LongTermInvestmentTextBlock-c5_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_16" id="_LongTermInvestmentTextBlock-c5_cont_15"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2021 and 2020, the Company owns <ix:nonFraction contextRef="c111" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">31.62</ix:nonFraction>% and <ix:nonFraction contextRef="c388" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" unitRef="pure">31.62</ix:nonFraction>% common stock shares of Rgene, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_17" id="_LongTermInvestmentTextBlock-c5_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized financial information for the Company&#8217;s equity method investee, Rgene, is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_18" id="_LongTermInvestmentTextBlock-c5_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Balance Sheets</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_19" id="_LongTermInvestmentTextBlock-c5_cont_18"><ix:continuation id="_ScheduleOfCondensedBalanceSheetTableTextBlock-c5_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Current Assets</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">73,452</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="0" unitRef="usd">123,958</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Noncurrent Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">374,423</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" unitRef="usd">412,342</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">1,934,786</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" unitRef="usd">1,392,756</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Noncurrent Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" unitRef="usd">38,953</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shareholders&#8217; Deficit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOther" scale="0" sign="-" unitRef="usd">1,486,911</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c405" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityOther" scale="0" sign="-" unitRef="usd">895,409</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_20" id="_LongTermInvestmentTextBlock-c5_cont_19"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Statement of operations</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_21" id="_LongTermInvestmentTextBlock-c5_cont_20"><ix:continuation id="_ScheduleOfCondensedIncomeStatementTableTextBlock-c5_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net sales</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c405" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="0" unitRef="usd">16,595</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross Profit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c405" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="0" sign="-" unitRef="usd">335,735</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c140" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetLoss1" scale="0" sign="-" unitRef="usd">576,514</ix:nonFraction></td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c405" decimals="0" format="ixt:num-dot-decimal" name="abvc:NetLoss1" scale="0" sign="-" unitRef="usd">641,636</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share of loss from investments accounted for using the equity method</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_22" id="_LongTermInvestmentTextBlock-c5_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposition of long-term investment</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_23" id="_LongTermInvestmentTextBlock-c5_cont_22"><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, <ix:nonNumeric contextRef="c387" name="us-gaap:SaleOfStockDescriptionOfTransaction">the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the year ended December 31, 2020.</ix:nonNumeric> During the year ended December 31, 2021, there is no disposition of long-term investment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_24" id="_LongTermInvestmentTextBlock-c5_cont_23"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses on Equity Investments</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LongTermInvestmentTextBlock-c5_cont_25" id="_LongTermInvestmentTextBlock-c5_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of losses on equity investments for each period were as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LongTermInvestmentTextBlock-c5_cont_25"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:EquityMethodInvestmentsTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%">Share of equity method investee losses</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 9%">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:ShareOfEquityMethodInvesteeLosses" scale="0" sign="-" unitRef="usd">269,844</ix:nonFraction></td>
    <td style="text-align: left; width: 1%">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="abvc:ShareOfEquityMethodInvesteeLosses" scale="0" sign="-" unitRef="usd">1,168,733</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_1" escape="true" name="abvc:ConvertibleNotesPayableDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. CONVERTIBLE NOTES PAYABLE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_2" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 9, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the &#8220;Yu and Wei Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c143" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">300,000</ix:nonFraction> to Guoliang Yu and Yingfei Wei Family Trust (the &#8220;Yu and Wei&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c144" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">300,000</ix:nonFraction>. The Yu and Wei Note bears interest at <ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">8</ix:nonFraction>% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $<ix:nonFraction contextRef="c145" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">5,000,000</ix:nonFraction> (an &#8220;Equity Offering&#8221;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $<ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">2.00</ix:nonFraction> per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) <ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="abvc:SharesOfferingPricePercentage" scale="-2" unitRef="pure">80</ix:nonFraction>% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an amount exceeding $<ix:nonFraction contextRef="c146" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValueOutstanding" scale="0" unitRef="usd">500,000</ix:nonFraction> that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at <ix:nonFraction contextRef="c147" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:InvestmentInterestRate" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#8220;Yu and Wei&#8221; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#8220;Yu and Wei&#8221;. The aggregate principal amount plus accrued interest expenses were $<ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregatePrincipalAndAccruedInterestExpense" scale="0" unitRef="usd">354,722</ix:nonFraction>, and the Company agreed to issue to the Holders an aggregate of <ix:nonFraction contextRef="c148" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">192,784</ix:nonFraction> shares of the Company&#8217;s common stock, and warrants to purchase <ix:nonFraction contextRef="c149" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares">192,784</ix:nonFraction> shares of the Company&#8217;s common stock. These common shares have been issued during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_3" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the &#8220;Keypoint Note&#8221;) in the aggregate principal amount of $<ix:nonFraction contextRef="c150" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to Keypoint Technology Ltd. (&#8220;Keypoint&#8221;), a related party, pursuant to which the Company received $<ix:nonFraction contextRef="c151" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">250,000</ix:nonFraction>. The Keypoint Note bears interest at <ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">8</ix:nonFraction>% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $<ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">5,000,000</ix:nonFraction> (an &#8220;Equity Offering&#8221;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of <ix:nonNumeric contextRef="c151" name="us-gaap:ConversionOfStockDescription">the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#8220;Keypoint&#8221; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#8220;Keypoint&#8221;. The aggregate principal amount plus accrued interest expenses were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#8217;s common stock, and warrants to purchase 159,145 shares of the Company&#8217;s common stock.</ix:nonNumeric> These common shares have been issued during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_4" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 25, 2018, the Company issued an eighteen-month term unsecured convertible promissory notes (the &#8220;Odaira Note&#8221;) in the aggregate principal amount of $<ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to Yoshinobu Odaira. (&#8220;Odaira&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c154" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">250,000</ix:nonFraction>. The Odaira Note bears interest at <ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">8</ix:nonFraction>% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds from the sale of its common stock of at least $<ix:nonFraction contextRef="c155" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssued1" scale="0" unitRef="usd">5,000,000</ix:nonFraction> (an &#8220;Equity Offering&#8221;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of <ix:nonNumeric contextRef="c154" name="us-gaap:ConversionOfStockDescription">the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21, 2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#8220;Odaira&#8221; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#8220;Odaira&#8221;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s common stock.</ix:nonNumeric> These common shares have been issued during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_5" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30 and July 10, 2019, the Company issued two (2) twelve-month term unsecured convertible promissory notes (the &#8220;KSL Note&#8221;)
in an aggregate principal amount of $<ix:nonFraction contextRef="c156" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to Kuo Sheng Lung (the &#8220;KSL&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">160,000</ix:nonFraction>
and $<ix:nonFraction contextRef="c162" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">90,000</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="c157" name="us-gaap:SaleOfStockDescriptionOfTransaction">The KSL Note bears interest at <ix:nonFraction contextRef="c157" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to KSL an amount in cash representing
all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note,
which is on May 29, 2020 and July 9, 2020.</ix:nonNumeric> At any time from the issuance date until the KSL Note has been satisfied, the KSL may convert
the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of <ix:nonNumeric contextRef="c157" name="us-gaap:ConversionOfStockDescription">the Company&#8217;s
common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $0.50 per share (the &#8220;Fixed Conversion
Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of
the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form
S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time
to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of the embedded beneficial conversion
feature present in the KSL Note. On May 13, 2020, the Company received an acknowledgement letter from KSL that they will not claim the
repayment of loan for 12 months. On November 9, 2020, the Company entered into an agreement with &#8220;KSL&#8221;. The aggregate principal
amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to
a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company&#8217;s common
stock and warrants for a purchase price of $270,272.&#160;During the year ended December 31, 2020, the Company issued to the Holders
an aggregate of 120,121 shares of the Company&#8217;s common stock.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_6" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 10, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#8220;NEA Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c159" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to New Eastern Asia (the &#8220;NEA&#8221;), a related party, pursuant to which the Company received $<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">250,000</ix:nonFraction> on July 10, 2019. The NEA Note bears interest at <ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $<ix:nonFraction contextRef="c1" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">.50</ix:nonFraction> per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, <ix:nonNumeric contextRef="c406" name="us-gaap:ConversionOfStockDescription">the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note. During the year ended December 31, 2020, the Company issued 111,112 shares of common stock to repay the outstanding balance.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_7" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 28, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#8220;KLS Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">200,000</ix:nonFraction> to Kuo Li Shen (the &#8220;KLS&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c165" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">200,000</ix:nonFraction> on August 28, 2019. The KLS Note bears interest at <ix:nonFraction contextRef="c165" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $<ix:nonFraction contextRef="c407" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">.50</ix:nonFraction> per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. <ix:nonNumeric contextRef="c408" name="us-gaap:ConversionOfStockDescription">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have been issued during the year ended December, 2020.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_8" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 4, 2019, the Company issued 3 twelve-month term unsecured convertible promissory note (the &#8220;C.L.L. Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c167" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">257,500</ix:nonFraction> to Chang Ping Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &#8220;C.L.L.&#8221;), pursuant to which the Company received $<ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">257,500</ix:nonFraction> on September 4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at <ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $<ix:nonFraction contextRef="c409" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">.50</ix:nonFraction> per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. <ix:nonNumeric contextRef="c168" continuedAt="_ConversionOfStockDescription-c168_cont_1" name="us-gaap:ConversionOfStockDescription">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of common stock. These common shares have been issued during the year ended December 31. 2020.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_9" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:continuation id="_ConversionOfStockDescription-c168_cont_1">On October 29, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#8220;Lee Note&#8221;) in an aggregate principal amount of $<ix:nonFraction contextRef="c169" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to Hwalin Lee (the &#8220;Lee&#8221;), a related party, pursuant to which the Company received $<ix:nonFraction contextRef="c170" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireNotesReceivable" scale="0" unitRef="usd">250,000</ix:nonFraction> on October 29, 2019. The Lee Note bears interest at <ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure">20</ix:nonFraction>% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) <span style="-sec-ix-hidden: hidden-fact-113">$.</span><ix:nonNumeric contextRef="c411" continuedAt="_ConversionOfStockDescription-c411_cont_1" name="us-gaap:ConversionOfStockDescription">50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time.</ix:nonNumeric></ix:continuation><ix:continuation id="_ConversionOfStockDescription-c411_cont_1"> In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note. In January 2021, the Company paid off the convertible promissory note of $306,836, including principal and accrued and unpaid interest expense.</ix:continuation>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_10" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 23, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;October SPA&#8221;) with one accredited investor. <ix:nonNumeric contextRef="c171" name="us-gaap:ConversionOfStockDescription">Pursuant to the October SPA, the Company sold and issued a convertible promissory note (the &#8220;October Note&#8221;) in the principal amount of $2,500,000 to the investor and received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of the October Note is the twenty-four (24) month anniversary from the issuance date (the &#8220;Maturity Date&#8221;). Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the Company&#8217;s common stock at a fixed conversion price of $2.25 per share.</ix:nonNumeric> The holder of the October Note may elect to convert part or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding amount at any time, in whole or in part, without any penalty.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_11" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 17, 2021, the parties to the October SPA signed Amendment No. 1 to Promissory Note (the &#8220;Amendment&#8221;). Pursuant to the Amendment, the Note shall also be automatically converted into shares of the Company&#8217;s common stock immediately following the Company&#8217;s receipt of conditional approval to list its common stock on the NASDAQ stock market, if and when the Company receives such approval, at a conversion price equal to $<ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">2.25</ix:nonFraction> per share.&#160;On July 21, 2021, The Company converted all convertible promissory note amounted $<ix:nonFraction contextRef="c173" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConvertiblePromissoryNote" scale="0" unitRef="usd">2,500,000</ix:nonFraction> into <ix:nonFraction contextRef="c174" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">1,111,112</ix:nonFraction> shares of the Company&#8217;s common stock and warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p></ix:continuation><div>

</div><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_12" id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, the aggregate carrying values of the convertible debentures were $<ix:nonFraction contextRef="c412" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c413" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="0" unitRef="usd">2,750,000</ix:nonFraction>, respectively; and accrued convertible interest was $<ix:nonFraction contextRef="c414" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c415" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">104,551</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_ConvertibleNotesPayableDisclosureTextBlock-c5_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total interest expenses in connection with the above convertible note payable were $<ix:nonFraction contextRef="c414" decimals="0" format="ixt:num-dot-decimal" name="abvc:TotalInterestExpenses" scale="0" unitRef="usd">193,548</ix:nonFraction> and $<ix:nonFraction contextRef="c415" decimals="0" format="ixt:num-dot-decimal" name="abvc:TotalInterestExpenses" scale="0" unitRef="usd">240,420</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_BankLoansTextBlock-c5_cont_1" escape="true" name="abvc:BankLoansTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. BANK LOANS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_2" id="_BankLoansTextBlock-c5_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term bank loan consists of the following:</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_3" id="_BankLoansTextBlock-c5_cont_2"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:ScheduleOfShortTermDebtTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cathay United Bank</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c235" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">270,000</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c456" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">267,000</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">CTBC Bank</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c236" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">720,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c457" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">712,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cathay Bank</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">650,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c458" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">650,000</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,640,000</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShortTermBorrowings" scale="0" unitRef="usd">1,629,000</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_4" id="_BankLoansTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Cathay United Bank</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_5" id="_BankLoansTextBlock-c5_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2016, BioLite Taiwan and Cathay United Bank entered into a one-year bank loan agreement (the &#8220;Cathay United Loan Agreement&#8221;) in an amount of NT$<ix:nonFraction contextRef="c416" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c417" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">270,000</ix:nonFraction>. The term started June 28, 2016 with maturity date at <ix:nonNumeric contextRef="c179" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">June 28, 2017</ix:nonNumeric>. The loan balance bears interest at a floating rate of prime rate plus <ix:nonFraction contextRef="c178" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">1.15</ix:nonFraction>%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite Taiwan extended the Cathay United Loan Agreement for <ix:nonNumeric contextRef="c180" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, which was due on September 6, 2018, with the principal amount of NT$<ix:nonFraction contextRef="c418" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c419" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">270,000</ix:nonFraction>. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c420" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c421" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">270,000</ix:nonFraction> for <ix:nonNumeric contextRef="c422" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c423" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c424" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">270,000</ix:nonFraction> for <ix:nonNumeric contextRef="c188" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, which is due on September 6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c425" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c426" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">270,000</ix:nonFraction> for <ix:nonNumeric contextRef="c191" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, which is due on September 6, 2021. On September 6, 2021, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c427" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">7,500,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c428" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">270,000</ix:nonFraction> for <ix:nonNumeric contextRef="c429" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>, which is due on September 6, 2022. As of December 31, 2021 and December 31, 2020, the effective interest rates per annum was <ix:nonFraction contextRef="c3" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure"><ix:nonFraction contextRef="c235" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">2.1</ix:nonFraction></ix:nonFraction>%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company&#8217;s chairman.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_6" id="_BankLoansTextBlock-c5_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expenses were $<ix:nonFraction contextRef="c430" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">5,639</ix:nonFraction> and $<ix:nonFraction contextRef="c431" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">5,280</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>



</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_7" id="_BankLoansTextBlock-c5_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">CTBC Bank</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_8" id="_BankLoansTextBlock-c5_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 12, 2017 and July 19, 2017, BioLite Taiwan and CTBC Bank entered into short-term saving secured bank loan agreements (the &#8220;CTBC Loan Agreements&#8221;) in an amount of NT$<ix:nonFraction contextRef="c432" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">10,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c433" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">360,000</ix:nonFraction>, and NT$<ix:nonFraction contextRef="c434" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">10,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c435" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">360,000</ix:nonFraction>, respectively. Both two loans with the same maturity date at <ix:nonNumeric contextRef="c203" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">January 19, 2018</ix:nonNumeric>. <ix:nonNumeric contextRef="c436" name="us-gaap:DebtInstrumentPaymentTerms">In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for <ix:nonNumeric contextRef="c203" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonNumeric>.</ix:nonNumeric> On January 18, 2019, BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c437" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c438" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">720,000</ix:nonFraction> for <ix:nonNumeric contextRef="c206" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c439" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c440" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">720,000</ix:nonFraction> for <ix:nonNumeric contextRef="c209" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c441" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c442" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">720,000</ix:nonFraction> for <ix:nonNumeric contextRef="c212" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due on January 15, 2021. On January 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c443" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c444" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">720,000</ix:nonFraction> for <ix:nonNumeric contextRef="c215" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due on July 15, 2021. On July 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$<ix:nonFraction contextRef="c445" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="twd">20,000,000</ix:nonFraction>, equivalent to $<ix:nonFraction contextRef="c446" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">720,000</ix:nonFraction> for <ix:nonNumeric contextRef="c218" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">six months</ix:nonNumeric>, which is due on January 14, 2022. The loan balances bear interest at a fixed rate of <ix:nonFraction contextRef="c236" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure">1.68</ix:nonFraction>% per annum. The loan is secured by the money deposited in a savings account with the CTBC Bank. This loan was also personal guaranteed by the Company&#8217;s chairman and BioFirst. During the year ended December 31, 2021, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_9" id="_BankLoansTextBlock-c5_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expenses were $<ix:nonFraction contextRef="c447" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">12,029</ix:nonFraction> and $<ix:nonFraction contextRef="c448" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">11,395</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_10" id="_BankLoansTextBlock-c5_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Cathay Bank</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_11" id="_BankLoansTextBlock-c5_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 21, 2019, the Company received a loan in the amount of $<ix:nonFraction contextRef="c223" decimals="0" format="ixt:num-dot-decimal" name="abvc:ReceivedLoanAmount" scale="0" unitRef="usd">500,000</ix:nonFraction> from Cathay Bank (the &#8220;Bank&#8221;) pursuant to a business loan agreement (the &#8220;Loan Agreement&#8221;) entered by and between the Company and Bank on January 8, 2019 and a promissory note (the &#8220;Note&#8221;) executed by the Company on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $<ix:nonFraction contextRef="c224" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">1,000,000</ix:nonFraction> with a maturity date (the &#8220;Maturity Date&#8221;) of January 1, 2020. <ix:nonNumeric contextRef="c225" name="abvc:RegularInterestRateDescription">The Note executed in connection with the Loan Agreement bears an interest rate (the &#8220;Regular Interest Rate&#8221;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the &#8220;Index&#8221;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_12" id="_BankLoansTextBlock-c5_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Note and Loan Agreement, on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the &#8220;Guaranty&#8221;) to guaranty the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $<ix:nonFraction contextRef="c226" decimals="0" format="ixt:num-dot-decimal" name="abvc:ExceedingAmount" scale="0" unitRef="usd">500,000</ix:nonFraction> each until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey. On December 29, 2020, the Company entered into a new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr. George Lee to be removed as guarantees from the list of Guaranty.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BankLoansTextBlock-c5_cont_13" id="_BankLoansTextBlock-c5_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, on January 8, 2019, each of the Company and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the &#8220;Security Agreement&#8221;) to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each, a &#8220;Grantor&#8221;, and collectively, the &#8220;Grantors&#8221;) granted security interest in the collaterals as defined therein, comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. <ix:nonNumeric contextRef="c449" name="abvc:RegularInterestRateDescription">On March 31, 2020, the Company extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020.</ix:nonNumeric> On April 8, 2020 and October 3, 2020, the Company repaid an aggregated principal amount of $<ix:nonFraction contextRef="c450" decimals="0" format="ixt:num-dot-decimal" name="abvc:ReceivedLoanAmount" scale="0" unitRef="usd"><ix:nonFraction contextRef="c227" decimals="0" format="ixt:num-dot-decimal" name="abvc:ReceivedLoanAmount" scale="0" unitRef="usd">350,000</ix:nonFraction></ix:nonFraction>. On December 3, 2020, The Company renewed the Loan Agreement with the principal amount of $<ix:nonFraction contextRef="c229" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">650,000</ix:nonFraction> for <ix:nonNumeric contextRef="c451" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">ten months</ix:nonNumeric>, which is due on October 31, 2021. On September 30, 2021, the Cathay Bank has increased the line of credit to $<ix:nonFraction contextRef="c452" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">1,000,000</ix:nonFraction> from $<ix:nonFraction contextRef="c453" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" unitRef="usd">650,000</ix:nonFraction>. The outstanding loan balance was $<ix:nonFraction contextRef="c232" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LongTermLineOfCredit" scale="0" unitRef="usd">650,000</ix:nonFraction> as of December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BankLoansTextBlock-c5_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expenses were $<ix:nonFraction contextRef="c454" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">18,143</ix:nonFraction> and $<ix:nonFraction contextRef="c455" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestAndDebtExpense" scale="0" unitRef="usd">53,992</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_1" escape="true" name="abvc:PaycheckProtectionProgramLoanPayableTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</b>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_2" id="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 14, 2020, the Company received a loan in the amount of $<ix:nonFraction contextRef="c237" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanFromPaycheckProtectionProgram" scale="0" unitRef="usd">124,400</ix:nonFraction> under the Paycheck Protection Program (&#8220;PPP&#8221;) administered by the United States Small Business Administration (the &#8220;SBA&#8221;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;Cares Act&#8221;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least <ix:nonFraction contextRef="c237" decimals="2" format="ixt:num-dot-decimal" name="abvc:ForgivenAmountPercentageUsedForPayroll" scale="-2" unitRef="pure">60</ix:nonFraction>% of the forgiven amount must have been used for payroll.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_3" id="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c238" name="us-gaap:DebtInstrumentPaymentTerms">The loan was granted pursuant to a promissory note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of <ix:nonFraction contextRef="c239" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">1.00</ix:nonFraction>% per annum.</ix:nonNumeric> The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&#8217;s accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments to be due on the same day of each month after that. No collateral or personal guarantees are required.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_4" id="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 29, 2021, BioKey received a loan in the amount of $<ix:nonFraction contextRef="c240" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanFromPaycheckProtectionProgram" scale="0" unitRef="usd">132,331</ix:nonFraction> under the Paycheck Protection Program administered by the United States Small Business Administration from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least <ix:nonNumeric contextRef="c240" name="us-gaap:DebtInstrumentDescription">60%</ix:nonNumeric> of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of <ix:nonFraction contextRef="c459" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">1.00</ix:nonFraction>% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. No collateral or personal guarantees are required.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_5" id="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2021, the Company received a loan in the amount of $<ix:nonFraction contextRef="c241" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanFromPaycheckProtectionPrograms" scale="0" unitRef="usd">104,167</ix:nonFraction> under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of <ix:nonFraction contextRef="c242" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure">1.00</ix:nonFraction>% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. No collateral or personal guarantees are required.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_6" id="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PPP loan Forgiveness</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_7" id="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 27, 2021, the Company submitted all required documents, such as application form and use of funds,&#160;to East West Bank for the application of forgiveness. The PPP loan from East West Bank of $<ix:nonFraction contextRef="c243" decimals="0" format="ixt:num-dot-decimal" name="abvc:LoanAmout" scale="0" unitRef="usd">124,400</ix:nonFraction> and $<ix:nonFraction contextRef="c244" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentDecreaseForgiveness" scale="0" unitRef="usd">132,331</ix:nonFraction> was forgiven by the SBA as a gesture of supporting the operation of the Company on March 15, 2021 and September 28, 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_8" id="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 23, 2021, the Company submitted the required documents, such as application form and use of funds,&#160;to Cathay Bank for the application of forgiveness. The PPP loan from Cathay Bank of $<ix:nonFraction contextRef="c245" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentDecreaseForgiveness" scale="0" unitRef="usd">104,167</ix:nonFraction> was forgiven by the SBA as a gesture of supporting the operation of the Company on November 15, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PaycheckProtectionProgramLoanPayableTextBlock-c5_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result, the Company recorded the forgiveness of the PPP loans as government grant income in the aggregate amount of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:GovernmentGrantIncome" scale="0" unitRef="usd">360,898</ix:nonFraction> during the year ended December 31, 2021&#160;</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_MortgageNotesPayableDisclosureTextBlock-c5_cont_1" escape="true" name="us-gaap:MortgageNotesPayableDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. NOTES PAYABLE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_MortgageNotesPayableDisclosureTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c246" name="abvc:UnsecuredLoanAgreementsDescription">In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working capital purpose.</ix:nonNumeric> On September 11, 2021 the outstanding balance has been repaid in full. As of December 31, 2021 and 2020, the balance due to this individual amounted to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNotesPayable" scale="0" unitRef="usd">106,800</ix:nonFraction>, respectively.&#160;Interest expense was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">8,592</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseOther" scale="0" unitRef="usd">12,204</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_ShortTermDebtTextBlock-c5_cont_1" escape="true" name="us-gaap:ShortTermDebtTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. SHORT-TERM LOAN</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_ShortTermDebtTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 18, 2020, the Company entered an unsecured loan agreement with a third-party in the amount of $<ix:nonFraction contextRef="c247" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:UnsecuredDebt" scale="0" unitRef="usd">100,000</ix:nonFraction>. This loan bears the interest rate of <ix:nonFraction contextRef="c248" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermDebtInterestRateIncrease" scale="-2" unitRef="pure">1.5</ix:nonFraction>% per annum and will be matured on <ix:nonNumeric contextRef="c248" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate">August 17, 2020</ix:nonNumeric>. On August 18, 2020, the Company extended the contract for six months under the same term. On February 18, 2021, the Company extended the contract for six months under the same term. On August 26, 2021, the loan with interest totaling $<ix:nonFraction contextRef="c460" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LoansReceivableWithFixedRatesOfInterest1" scale="0" unitRef="usd">102,272</ix:nonFraction> has been repaid in full. Accrued interest expense was $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="0" unitRef="usd">1,302</ix:nonFraction> as of December 31, 2021 and 2020, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. RELATED PARTIES TRANSACTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_2" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The related parties of the company with whom transactions are reported in these financial statements are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_3" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_2"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of entity or Individual</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c483" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c484" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c485" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YuanGene Corporation (the &#8220;YuanGene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c486" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlling beneficiary shareholder of the Company</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AsiaGene Corporation (the &#8220;AsiaGene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c487" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c488" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former President and Chairman</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c489" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c490" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoshinobu Odaira (the &#8220;Odaira&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c491" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director of the Company</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c492" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c493" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LBG USA, Inc. (the &#8220;LBG USA&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c494" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LionGene Corporation (the &#8220;LionGene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c495" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c496" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <ix:nonNumeric contextRef="c497" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and
a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director
of the Company.</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</span></p></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amkey Ventures, LLC (&#8220;Amkey&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c498" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</span></ix:nonNumeric></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><ix:nonNumeric contextRef="c499" name="abvc:RelatedPartyTransactionDescriptionOfTransactions"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></ix:nonNumeric></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_4" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Accounts receivable - related parties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_5" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable due from related parties consisted of the following as of the periods indicated:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_6" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_5"><ix:nonNumeric contextRef="c5" escape="true" name="abvc:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">GenePharm Inc.</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c299" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">142,225</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c500" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">142,225</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Rgene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">2,374</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Amkey</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c301" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">800</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c501" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">1,210</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">145,399</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableRelatedParties" scale="0" unitRef="usd">143,435</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_7" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Due from related parties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_8" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount due from related parties consisted of the following as of the periods indicated:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_9" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_8"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Rgene</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c138" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">49,110</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">42,911</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">AsiaGene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c502" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">4,241</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">468,435</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst (Australia)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">491,816</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c503" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">373,235</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioHopeKing Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c128" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">124,972</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c399" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">123,583</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">LBG USA</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c304" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">675</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c504" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">675</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioLite Japan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">150,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c474" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">150,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Keypoint</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c306" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">1,610</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c505" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">1,610</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">1,286,618</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueFromtheRelatedPartiesCurrent" scale="0" unitRef="usd">696,255</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>



</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_10" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, due from Rgene amounted to $<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentAggregateAmount" scale="0" unitRef="usd">49,110</ix:nonFraction> and $<ix:nonFraction contextRef="c401" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentAggregateAmount" scale="0" unitRef="usd">42,911</ix:nonFraction>,respectively. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date was December 31, 2020. As of December 31, 2021, and December 31, 2020, the outstanding loan balance was $<ix:nonFraction contextRef="c461" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">33,520</ix:nonFraction> and $<ix:nonFraction contextRef="c462" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">31,684</ix:nonFraction>; and accrued interest was $<ix:nonFraction contextRef="c132" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">13,701</ix:nonFraction> and $<ix:nonFraction contextRef="c401" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">11,227</ix:nonFraction>, respectively. On January 1, 2021, BioLite Taiwan entered into a consultant services agreement with Rgene, of which the amount due from Rgene was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" unitRef="usd">1,889</ix:nonFraction> for the year ended December 31, 2021.</span></td> </tr> </table></ix:continuation><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_11" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,560, to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity date was December 31, 2020. The loan has been repaid in full during the year of 2021. As of December 31, 2021 and 2020, the outstanding loan balance was $<ix:nonFraction contextRef="c463" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c464" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">3,560</ix:nonFraction>, and accrued interest was $<ix:nonFraction contextRef="c465" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">681</ix:nonFraction>, respectively.</span></td></tr> </table></ix:continuation><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_12" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 2, 2021, November 12, 2021 and December 20, 2021, <ix:nonNumeric contextRef="c136" name="us-gaap:DebtInstrumentInterestRateTerms">the Company and BioFirst entered into loan agreements for a total amount of $45,000, $140,000, and $280,000, respectively, to meet its working capital needs. The loan will be matured on November 1, 2022, November 11, 2022, and December 19, 2022, respectively, all with an interest rate of 6.5% per annum.</ix:nonNumeric> As of December 31, 2021, and December 31, 2020, the outstanding loan balance was $<ix:nonFraction contextRef="c136" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">465,000</ix:nonFraction> and $<ix:nonFraction contextRef="c403" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">0</ix:nonFraction>; and accrued interest was $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">3,435</ix:nonFraction> and $<ix:nonFraction contextRef="c402" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">0</ix:nonFraction>, respectively.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c252" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentAggregateAmount" scale="0" unitRef="usd">361,487</ix:nonFraction> to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of <ix:nonFraction contextRef="c253" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">6.5</ix:nonFraction>% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentAggregateAmount" scale="0" unitRef="usd">67,873</ix:nonFraction> to meet its new project needs. On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $<ix:nonFraction contextRef="c468" decimals="0" format="ixt:num-dot-decimal" name="abvc:DebtInstrumentAggregateAmount" scale="0" unitRef="usd">250,000</ix:nonFraction> to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of <ix:nonFraction contextRef="c468" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">6.5</ix:nonFraction>% per annum. As of December 31, 2021 and 2020, the aggregate amount of outstanding loan and accrued interest was $<ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">491,816</ix:nonFraction> and $<ix:nonFraction contextRef="c469" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">373,235</ix:nonFraction>, respectively.</span></td></tr> </table></ix:continuation><div>



</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_13" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 3). <ix:nonNumeric contextRef="c261" name="us-gaap:DebtInstrumentInterestRateTerms">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.</ix:nonNumeric> As of December 31, 2021 and 2020, due from BHK was $<ix:nonFraction contextRef="c470" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedParties" scale="0" unitRef="usd">124,972</ix:nonFraction> and $<ix:nonFraction contextRef="c471" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueFromOtherRelatedParties" scale="0" unitRef="usd">123,583</ix:nonFraction>, respectively.</span></td></tr> </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>



</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_14" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. <ix:nonNumeric contextRef="c472" name="abvc:AdvancesBearInterestDescription">The advances bear <ix:nonFraction contextRef="c263" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0</ix:nonFraction>% interest rate and are due on demand.</ix:nonNumeric> As of December 31, 2021 and 2020, the outstanding advance balances was $<ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingAdvanceFromRelatedParty" scale="0" unitRef="usd">675</ix:nonFraction> and $<ix:nonFraction contextRef="c473" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingAdvanceFromRelatedParty" scale="0" unitRef="usd">675</ix:nonFraction>, respectively.</span></td></tr> </table></ix:continuation><div>



</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_15" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 8, 2020, the Company and Lucidaim entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. <ix:nonNumeric contextRef="c266" name="us-gaap:DebtInstrumentInterestRateTerms">Based on the LOI, each party will advance an aggregated amount of $<ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">150,000</ix:nonFraction> to meet BioLite Japan&#8217;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate.</ix:nonNumeric> As of December 31, 2021 and 2020, the outstanding advance balances was $<ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingAdvanceFromRelatedParty" scale="0" unitRef="usd">150,000</ix:nonFraction> and $<ix:nonFraction contextRef="c474" decimals="0" format="ixt:num-dot-decimal" name="abvc:OutstandingAdvanceFromRelatedParty" scale="0" unitRef="usd">150,000</ix:nonFraction>, respectively.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 31, 2020, <ix:nonNumeric contextRef="c269" name="abvc:LoanAgreementDescription">the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021.</ix:nonNumeric> As of December 31, 2021 and 2020, the outstanding loan balance was $<ix:nonFraction contextRef="c475" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">1,610</ix:nonFraction> and $<ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="0" unitRef="usd">1,610</ix:nonFraction>, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_16" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Due to related parties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_17" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount due to related parties consisted of the following as of the periods indicated:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_18" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_17"><ix:nonNumeric contextRef="c5" escape="true" name="abvc:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst Corporation</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c130" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">40,878</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c400" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">23,647</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst (Australia)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c302" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">132,443</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">AsiaGene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c250" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">24,017</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">YuanGene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c307" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">9,205</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c506" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">9,205</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">The Jiangs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c309" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">18,750</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c507" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">16,627</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Due to shareholders</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c311" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">168,131</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c508" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">166,261</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Due to employee</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c510" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">72,705</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">393,424</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" scale="0" unitRef="usd">288,445</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_19" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, BioFirst has advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of December 31, 2021 and 2020, the aggregate amount of outstanding balance and accrued interest is $<ix:nonFraction contextRef="c134" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">40,878</ix:nonFraction> and $<ix:nonFraction contextRef="c402" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">23,647</ix:nonFraction>, respectively.</span></td> </tr> </table></ix:continuation><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_20" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, BioFirst (Australia) has advanced the Company an aggregate amount of $<ix:nonFraction contextRef="c260" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">132,443</ix:nonFraction> and $<ix:nonFraction contextRef="c469" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">0</ix:nonFraction>, respectively for new project purpose.</span></td> </tr> </table></ix:continuation><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_21" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_20"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, AsiaGene has advanced the Company an aggregate amount of $<ix:nonFraction contextRef="c463" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">24,017</ix:nonFraction> and $<ix:nonFraction contextRef="c464" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">0</ix:nonFraction>, respectively for working capital purpose. This advance bears <ix:nonFraction contextRef="c465" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0</ix:nonFraction>% interest rate and is due on demand.</span></td> </tr> </table></ix:continuation><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_22" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, YuanGene has advanced the Company an aggregate amount of $<ix:nonFraction contextRef="c476" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateWorkingcapital" scale="0" unitRef="usd">9,205</ix:nonFraction> for working capital purpose. This advance bears <ix:nonFraction contextRef="c477" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0</ix:nonFraction>% interest rate and is due on demand.</span></td> </tr> </table></ix:continuation><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_23" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_22"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2021 and 2020, the outstanding balance due to the Jiangs amounted to $<ix:nonFraction contextRef="c278" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">18,750</ix:nonFraction> and $<ix:nonFraction contextRef="c478" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" unitRef="usd">16,627</ix:nonFraction>, respectively. These loans bear interest rate of <ix:nonFraction contextRef="c479" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">0</ix:nonFraction>% to <ix:nonFraction contextRef="c480" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">1</ix:nonFraction>% per month, and are due on demand.</span></td> </tr> </table></ix:continuation><div>

</div><ix:continuation continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_24" id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_23"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate from <ix:nonFraction contextRef="c481" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageRateForeignDeposit" scale="-2" unitRef="pure">12</ix:nonFraction>% to <ix:nonFraction contextRef="c482" decimals="6" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageRateForeignDeposit" scale="-2" unitRef="pure">13.6224</ix:nonFraction>% per annum. As of December 31, 2021 and 2020, the outstanding principal and accrued interest was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">168,131</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:AccruedInterest" scale="0" unitRef="usd">166,261</ix:nonFraction>, respectively. Interest expenses in connection with these loans were $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseRelatedParty" scale="0" unitRef="usd">22,779</ix:nonFraction> and $<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseRelatedParty" scale="0" unitRef="usd">21,520</ix:nonFraction> for the year ended December 31, 2021 and 2020, respectively.</span></td> </tr> </table></ix:continuation><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c5_cont_24"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing January, 2020, the Company had advances from one employee for working capital purpose. The outstanding balance including accrued interest due to this employee amounted to $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="0" unitRef="usd">0</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="0" unitRef="usd">72,705</ix:nonFraction> as of December 31, 2021 and 2020, respectively. This loan bears interest rate of <ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">1.5</ix:nonFraction>% per annum, and the loan with interest has been repaid in full during the year ended December 31, 2021.</span></td> </tr> </table></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. EQUITY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2016, a Share Exchange Agreement (&#8220;Share Exchange Agreement&#8221;) was entered into by and among
the&#160;Company, BriVision, Euro-Asia Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong
Special Administrative Region of People&#8217;s Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of
<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">164,387,376</ix:nonFraction> (<ix:nonFraction contextRef="c68" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,336,000</ix:nonFraction> pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share
capital of BriVision (the &#8220;BriVision Stock&#8221;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision
Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each
BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new
holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock
in the name of the Company, the Company should issue <ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">166,273,921</ix:nonFraction>(<ix:nonFraction contextRef="c69" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,936,583</ix:nonFraction> pre-stock split) shares (the &#8220;Acquisition
Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s Common Stock to the
BriVision Shareholders (or their designees), and <ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">163,159,952</ix:nonFraction> (<ix:nonFraction contextRef="c70" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">51,945,225</ix:nonFraction> pre-stock split) shares of the Company&#8217;s Common Stock
owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent <ix:nonFraction contextRef="c71" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure">79.70</ix:nonFraction>% of the
issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing
<ix:nonFraction contextRef="c71" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfIssuedShareCapital" scale="-2" unitRef="pure">100</ix:nonFraction>% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and
outstanding shares of BriVision&#8217;s Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of
<ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">166,273,921</ix:nonFraction>(<ix:nonFraction contextRef="c312" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">52,936,583</ix:nonFraction> pre-stock split) shares of Company&#8217;s Common Stock and BriVision became a wholly owned subsidiary, of
the Company. The holders of Company&#8217;s Common Stock as of immediately prior to the Merger held an aggregate of <ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">205,519,223</ix:nonFraction>
(<ix:nonFraction contextRef="c73" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">65,431,144</ix:nonFraction> pre-stock split) shares of Company&#8217;s Common Stock,&#160;Because of the exchange of the BriVision Stock for the
Acquisition Stock (the &#8220;Share Exchange&#8221;), BriVision became a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of
the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity
instruments issued in connection with the share exchange agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), <ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">157,050</ix:nonFraction> (<ix:nonFraction contextRef="c313" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedBeforeStockSplit" scale="0" unitRef="shares">50,000</ix:nonFraction> pre-stock split) shares were granted to the employees.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#8220;Forward&#160;Stock&#160;Split&#8221;) and increase the number of our authorized shares of Common Stock, par value $<ix:nonFraction contextRef="c76" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share, to <ix:nonFraction contextRef="c76" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockShareAuthorized" scale="0" unitRef="shares">360,000,000</ix:nonFraction>, which was effective on April 8, 2016.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 6, 2016, <ix:nonNumeric contextRef="c314" name="abvc:AgreementDescription">the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company&#8217;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.</ix:nonNumeric> On August 26, 2016, <ix:nonNumeric contextRef="c315" name="abvc:AgreementDescription">the Company issued 1,468,750 shares (&#8220;Shares&#8221;) of the Company&#8217;s Common Stock, par value $0.001 (the &#8220;Offering&#8221;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#8220;SPA&#8221;). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.</ix:nonNumeric> In February 2017, <ix:nonNumeric contextRef="c316" name="abvc:AgreementDescription">the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#8217;s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company&#8217;s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).</ix:nonNumeric> On February 8, 2019, after the Merger, the Company issued <ix:nonFraction contextRef="c317" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">74,997,546</ix:nonFraction> shares to the shareholders of BioLite and <ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">29,561,231</ix:nonFraction> shares to the shareholders of BioKey.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 3, 2019, <ix:nonNumeric contextRef="c77" name="abvc:FinancialAmendmentDescription">the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (&#8220;FINRA&#8221;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#8217;s common stock were exchanged for 17,693,625 shares of the Company&#8217;s Common Stock.</ix:nonNumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c319" name="abvc:Consultingagreementdescription">On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (&#8220;Kameyama&#8221;) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#8217;s Common Stock at $1.00 per share for any amount exceeding $3,000.</ix:nonNumeric> The Company&#8217;s stocks shall be calculated and issued in December every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued <ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">24,694</ix:nonFraction> stock options to Kameyama related to unpaid consulting fees of $<ix:nonFraction contextRef="c320" decimals="0" format="ixt:num-dot-decimal" name="abvc:UnpaidConsultingFees" scale="0" unitRef="usd">49,388</ix:nonFraction> (see Note 14).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2017, BriVision entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $<ix:nonFraction contextRef="c321" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="0" unitRef="usd">3,000,000</ix:nonFraction> due to BioFirst. On September 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue <ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">428,571</ix:nonFraction> shares of the Company&#8217;s common stock to BioFirst in consideration for $<ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockIssuedValue" scale="0" unitRef="usd">3,000,000</ix:nonFraction> owed by the Company to BioFirst. These common shares were issued during the year ended December 31, 2019.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued <ix:nonFraction contextRef="c8" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">644,972</ix:nonFraction> shares of the Company&#8217;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">4,514,800</ix:nonFraction> in aggregate, and recorded as stock subscription receivable. As of December 31, 2021 and 2020, stock subscription receivable was $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockSubscriptionReceivable" scale="0" unitRef="usd">2,257,400</ix:nonFraction> and $<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:StockSubscriptionReceivable" scale="0" unitRef="usd">3,160,360</ix:nonFraction>, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August, 2019, the Company entered into several Conversion Agreements to all creditors that are listed under below table of &#8220;due to related parties&#8221; in consideration for a total of $<ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">4,872,340</ix:nonFraction> owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements, creditor agrees to convert the amount of debt into the Company&#8217;s common stock at a price of $<ix:nonFraction contextRef="c324" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">7.00</ix:nonFraction> per share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_10"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:ScheduleOfDebtConversionsTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of<br/> Debt<br/> Converted</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> Shares<br/> Issued</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Lion Arts Promotion Inc</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">97,864</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c349" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">13,981</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">LionGene Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">428,099</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c350" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">61,157</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">2,902,911</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c351" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">414,702</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">AsiaGene Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">160,000</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c352" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">22,858</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">YuanGene Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c353" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">92,690</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c353" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">13,242</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">The Jiangs</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c354" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">1,190,776</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c354" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">170,111</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="0" unitRef="usd">4,872,340</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c323" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" unitRef="shares">696,051</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2020, the board of directors of the Company approved and adopted an amendment to the Company&#8217;s Articles of Incorporation, to increase the authorized shares of its common stock, par value $<ix:nonFraction contextRef="c325" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares">0.001</ix:nonFraction> per share, from <ix:nonFraction contextRef="c326" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">20,000,000</ix:nonFraction> to <ix:nonFraction contextRef="c327" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">100,000,000</ix:nonFraction> shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 8, 2020, the Company entered an agreement with View Trade Securities Inc. (&#8220;ViewTrade&#8221;) to engage ViewTrade as the placement agent&#160;and the Company&#8217;s advisor/consultant with respect to its ongoing capital events. <ix:nonNumeric contextRef="c328" name="abvc:PlacementAgentAgreementDescription">Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision.</ix:nonNumeric> As of December 31, 2020, the Company has issued <ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">60,000</ix:nonFraction> shares of common stock to ViewTrade for the consulting fee with an estimated value of $<ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="0" unitRef="usd">135,000</ix:nonFraction>. The warrants were never issued and the parties mutually agreed to terminate the agreement on November 19, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the termination agreement, the Company issued <ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">50,000</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">5</ix:nonFraction> per share as a termination
fee on June 29, 2021, of which <ix:nonFraction contextRef="c332" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">6,000</ix:nonFraction> shares were issued to WallachBeth Capital LLC (&#8220;WallachBeth&#8221;). In January 2021, WallachBeth
entered into a consulting agreement with the Company pursuant to which the Company engaged WallachBeth to conduct due diligence and research
work with respect to the Company. On June 29, 2021, WallachBeth was issued <ix:nonFraction contextRef="c333" decimals="0" format="ixt:num-dot-decimal" name="abvc:RestrictedCommonShares" scale="0" unitRef="shares">6,000</ix:nonFraction> shares of common stock as compensation for those services.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also on November 19, 2020, the Company and ViewTrade agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only. In addition to a retainer fee, the Company agreed to issue <ix:nonFraction contextRef="c334" decimals="0" format="ixt:num-dot-decimal" name="abvc:WarrantIssued" scale="0" unitRef="shares">200,000</ix:nonFraction> warrants, with an exercise price of $<ix:nonFraction contextRef="c334" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">2.25</ix:nonFraction>, an industry standard cashless exercise provision, and a term of <ix:nonNumeric contextRef="c334" format="ixt-sec:duryear" name="abvc:WarrantTerm">5</ix:nonNumeric> years from November 19, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year&#160;ended December 31, 2020, the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company agreed to pay the service fee by issuing <ix:nonFraction contextRef="c335" decimals="0" format="ixt:num-dot-decimal" name="abvc:UnrestrictedCommonShares" scale="0" unitRef="shares">50,000</ix:nonFraction> shares of unrestricted common shares, valued at the closing price of $<ix:nonFraction contextRef="c335" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares">2.9</ix:nonFraction> per share on the grant date. These shares have been issued during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company received aggregated capital contributions of $<ix:nonFraction contextRef="c336" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromContributionsFromAffiliates" scale="0" unitRef="usd">7,615,331</ix:nonFraction> in cash from <ix:nonFraction contextRef="c337" decimals="0" format="ixt:num-dot-decimal" name="abvc:NumberOfInvestors" scale="0" unitRef="pure">45</ix:nonFraction> investors through private placements of the sale of the Company&#8217;s common stock for the purchase price of&#160;$<ix:nonFraction contextRef="c337" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">2.25</ix:nonFraction> per share and a free warrant attached with each common stock purchased. In December 2020, <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:IssuanceOfCommonStock" scale="0" unitRef="shares">3,384,615</ix:nonFraction> shares of the Company&#8217;s common stock have been issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee by issuing <ix:nonFraction contextRef="c338" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">521,887</ix:nonFraction> shares of unrestricted common shares, valued at the closing price from $<ix:nonFraction contextRef="c339" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">2</ix:nonFraction> to $<ix:nonFraction contextRef="c340" decimals="2" format="ixt:num-dot-decimal" name="abvc:StockIssuedDuringPeriodShareBasedCompensationServicesforShares" scale="0" unitRef="shares">3.68</ix:nonFraction> per share on the grant date. These shares have been issued in October and December 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued aggregated common shares of <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateCommonStockShares" scale="0" unitRef="shares">915,856</ix:nonFraction> to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests, including the debt conversion to the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><ix:nonNumeric contextRef="c511" continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_1" name="us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></ix:nonNumeric></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_2" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#8217;s common stock, and warrants to purchase 159,145 shares of the Company&#8217;s common stock.</span></ix:continuation></td></tr> </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_20"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_3" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_21"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_4" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_22"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_5" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_23"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_6" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#8217;s common stock, and warrants to purchase 192,784 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_25" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_24"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_7" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><ix:continuation continuedAt="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_8" id="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><ix:continuation id="_DebtInstrumentConvertibleTermsOfConversionFeature-c511_cont_8"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#8217;s common stock, and warrants to purchase 120,121 shares of the Company&#8217;s common stock.</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_26" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 7 for more details in connection with the above debt conversion.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_27" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2021, <ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,111,112</ix:nonFraction> shares of the Company&#8217;s common stock and warrants were issued pursuant to the conversion of convertible promissory note of $<ix:nonFraction contextRef="c342" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConvertiblePromissoryNoteValue" scale="0" unitRef="usd">2,500,000</ix:nonFraction> entered in October 2020 (see Note 7).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_28" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2021, <ix:nonNumeric contextRef="c343" name="abvc:DescriptionOfPublicOffering">the Company closed its public offering (the &#8220;Public Offering&#8221;) of 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of the Company&#8217;s common stock, one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.</ix:nonNumeric> In August 2021, <ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" scale="0" unitRef="shares">2,354,145</ix:nonFraction> shares of the Company&#8217;s common stock were issued for gross proceeds of $<ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" unitRef="usd">6,875,000</ix:nonFraction>, before placement agent fees and legal fees of $<ix:nonFraction contextRef="c344" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="0" unitRef="usd">850,429</ix:nonFraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_29" id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_28"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company received $<ix:nonFraction contextRef="c345" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="0" unitRef="usd">4,244,452</ix:nonFraction>&#160;in gross proceeds from the exercise of warrants issued in the Company&#8217;s August 3, 2021, public offering of securities. Investors exercised a total of&#160;<ix:nonFraction contextRef="c346" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares">673,405</ix:nonFraction>&#160;Series A warrants at a price of $<ix:nonFraction contextRef="c346" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">6.30</ix:nonFraction>&#160;per share and&#160;<ix:nonFraction contextRef="c347" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" unitRef="shares">200</ix:nonFraction>&#160;Series B warrants at a price of $<ix:nonFraction contextRef="c347" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">10</ix:nonFraction>&#160;per share. Pursuant to these exercises, the Company issued an aggregate of <ix:nonFraction contextRef="c345" decimals="0" format="ixt:num-dot-decimal" name="abvc:AggregateCommonStockShares" scale="0" unitRef="shares">673,605</ix:nonFraction> shares of Common Stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c5_cont_29"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $<ix:nonFraction contextRef="c512" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyShareholderServiceFeeExpense" scale="0" unitRef="usd">1,478,590</ix:nonFraction> by issuing <ix:nonFraction contextRef="c513" decimals="0" format="ixt:num-dot-decimal" name="abvc:UnrestrictedCommonShares" scale="0" unitRef="shares">316,934</ix:nonFraction> shares of unrestricted common shares, valued at the closing price from $<ix:nonFraction contextRef="c514" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">2.31</ix:nonFraction> to $<ix:nonFraction contextRef="c515" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares">6.3</ix:nonFraction> per share on the grant date. These shares have been issued during the year ended December 31, 2021.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_StockOptionsTextBlock-c5_cont_1" escape="true" name="abvc:StockOptionsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14. STOCK OPTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c5_cont_2" id="_StockOptionsTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 30, 2020, the Company issued an aggregate of <ix:nonFraction contextRef="c355" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">545,182</ix:nonFraction> shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive Plan, as amended, at a conversion price of $<ix:nonFraction contextRef="c355" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConversionPrice" scale="0" unitRef="usdPershares">2</ix:nonFraction> per share; the total amount of converted salaries and consulting fees was $<ix:nonFraction contextRef="c356" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConsultingFees" scale="0" unitRef="usd">1,090,361</ix:nonFraction>. On November 21, 2020, the Company entered&#160;into&#160;acknowledgement&#160;agreements and stock option purchase agreements with these employees and consultant; pursuant to which the Company granted stock options to purchase <ix:nonFraction contextRef="c357" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">545,182</ix:nonFraction> shares of the Company&#8217;s common stock in lieu of common stock. The options were vested at the grant date and become exercisable for <ix:nonNumeric contextRef="c358" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">10</ix:nonNumeric> years from the grant date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c5_cont_3" id="_StockOptionsTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 15, 2021, the Company entered&#160;into stock option agreements with 11 directors and 3 employees, pursuant to which the Company granted options to purchase an aggregate of <ix:nonFraction contextRef="c359" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,280,002</ix:nonFraction> shares of common stock&#160;under the 2016 Equity Incentive Plan, as amended, at an exercise price of $<ix:nonFraction contextRef="c360" decimals="0" format="ixt:num-dot-decimal" name="abvc:ConversionPrice" scale="0" unitRef="usdPershares">3</ix:nonFraction> per share. The options were vested at the grant date and become exercisable for <ix:nonNumeric contextRef="c360" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">10</ix:nonNumeric> years from the grant date.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c5_cont_4" id="_StockOptionsTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options issued and outstanding as of December 31, 2021, and their activities during the year then ended are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c5_cont_5" id="_StockOptionsTextBlock-c5_cont_4"><ix:nonNumeric contextRef="c517" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number&#160;of</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Underlying<br/> Shares</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price<br/> Per&#160;Share</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> in Years</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Outstanding as of January 1, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">545,182</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c362" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.00</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c363" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" unitRef="shares">1,280,002</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c363" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">3.00</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Forfeited</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Outstanding as of December 31, 2021</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c362" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,825,184</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c364" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.70</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c363" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.51</ix:nonNumeric></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">616,056</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Exercisable as of December 31, 2021</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares">1,825,184</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c364" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.70</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c363" format="ixt-sec:duryear" name="abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">9.51</ix:nonNumeric></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" unitRef="usd">616,056</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Vested and expected to vest</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" unitRef="shares">1,825,184</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td>
    <td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c364" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.70</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right"><ix:nonNumeric contextRef="c363" format="ixt-sec:duryear" name="abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1">9.51</ix:nonNumeric></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c364" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="0" unitRef="usd">616,056</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c5_cont_6" id="_StockOptionsTextBlock-c5_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of stock options granted for the year ended December 31, 2021 and 2020 was calculated using the Black-Scholes option-pricing model applying the following assumptions:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockOptionsTextBlock-c5_cont_7" id="_StockOptionsTextBlock-c5_cont_6"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.13</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.38</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term (in years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonNumeric contextRef="c6" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonNumeric></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">108.51</ix:nonFraction></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">89.01</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockOptionsTextBlock-c5_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted options to purchase&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">545,182</ix:nonFraction>&#160;and&#160;<ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">1,280,002</ix:nonFraction>&#160;shares of common stock to employees and certain consultants during the years ended&#160;December 31, 2021&#160;and&#160;2020,&#160;respectively.&#160;The weighted average grant date fair value of options granted during the years ended&#160;December 31, 2021&#160;and&#160;2020 was $<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">2.09</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">3.13</ix:nonFraction>, respectively. There are <ix:nonFraction contextRef="c516" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares">2,979,264</ix:nonFraction>&#160;options available for grant under the 2016 Equity Incentive Plan as of December 31, 2020. Compensation costs associated with the Company&#8217;s stock options are recognized, based on the grant-date fair values of these options over vesting period. Accordingly, the Company recognized stock-based compensation expense of <ix:nonNumeric contextRef="c5" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants">$2,675,205</ix:nonNumeric> and <ix:nonNumeric contextRef="c6" name="abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants">$1,706,419</ix:nonNumeric> for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021 and 2020, there were no unvested options. There were no options exercised during the years ended December 31, 2021 and 2020.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_EarningsPerShareTextBlock-c5_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15. LOSS PER SHARE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c5_cont_2" id="_EarningsPerShareTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year ended December 31, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c5_cont_3" id="_EarningsPerShareTextBlock-c5_cont_2"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/>
Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Numerator:</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net loss attributable to ABVC&#8217;s common stockholders</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd">12,838,813</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" sign="-" unitRef="usd">9,791,164</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding - Basic</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">25,053,522</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">19,715,559</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Stock options</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">&#160;</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">25,053,522</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares">19,715,559</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">-Basic</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.51</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares">0.50</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">-Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.51</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c6" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares">0.50</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_1" escape="true" name="abvc:OperatingLeasesOfLesseeDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16. LEASE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_2" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (&#8220;ASC 842&#8221;) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_3" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applied the following practical expedients in the transition to the new standard and allowed under ASC 842:</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_4" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_5" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_6" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_7" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_8" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_9" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities. ROU assets represent the Company&#8217;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company&#8217;s future minimum based payments used to determine the Company&#8217;s lease liabilities mainly include minimum based rent payments. As most of Company&#8217;s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_10" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_11" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no finance leases. The Company&#8217;s leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements. The Company&#8217;s operating leases have remaining lease terms of up to approximately five years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_12" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_11"><ix:nonNumeric contextRef="c5" escape="true" name="abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">ASSETS</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease right-of-use assets</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,471,899</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" unitRef="usd">1,772,747</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">LIABILITIES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease liabilities (current)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">347,100</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="0" unitRef="usd">316,178</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease liabilities (noncurrent)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeaseLiabilitienoncurrent" scale="0" unitRef="usd">1,124,799</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeaseLiabilitienoncurrent" scale="0" unitRef="usd">1,456,567</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_13" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Supplemental Information</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_14" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following provides details of the Company&#8217;s lease expenses:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_15" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_14"><ix:nonNumeric contextRef="c5" continuedAt="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c5_cont_1" escape="true" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd">335,208</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="0" unitRef="usd">337,282</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_16" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to leases is presented below:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_17" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_16"><ix:continuation continuedAt="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c5_cont_2" id="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c5_cont_1"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Cash paid for amounts included in the measurement of operating lease liabilities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="0" unitRef="usd">335,208</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="0" unitRef="usd">337,282</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_18" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_17"><ix:continuation id="_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock-c5_cont_2"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted Average Remaining Lease Term:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating leases</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.90</ix:nonNumeric> years</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.08</ix:nonNumeric> years</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted Average Discount Rate:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating leases</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">1.39</ix:nonFraction></td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">0.55</ix:nonFraction></td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_19" id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
minimum future annual payments under non-cancellable leases during the next five years and thereafter, at rates now in force, are as
follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OperatingLeasesOfLesseeDisclosuresTextBlock-c5_cont_19"><ix:nonNumeric contextRef="c5" escape="true" name="abvc:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating leases</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">2022</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueCurrent" scale="0" unitRef="usd">353,896</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueInTwoYears" scale="0" unitRef="usd">360,994</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">2024</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueInThreeYears" scale="0" unitRef="usd">375,938</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">2025</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueInFourYears" scale="0" unitRef="usd">338,676</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDueThereafter" scale="0" unitRef="usd">56,916</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments, undiscounted</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:OperatingLeasesFutureMinimumPaymentDue" scale="0" unitRef="usd">1,486,420</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" scale="0" unitRef="usd">14,521</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of future minimum lease payments</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="abvc:PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" scale="0" unitRef="usd">1,471,899</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_BusinessCombinationDisclosureTextBlock-c5_cont_1" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17. BUSINESS COMBINATION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c5_cont_2" id="_BusinessCombinationDisclosureTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2019, the Company consummated the Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, &#8220;Business Combination&#8221; to record the merger transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey&#8217;s results of operations were included in the Company&#8217;s results beginning February 8, 2019. The purchase price has been allocated to the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c5_cont_3" id="_BusinessCombinationDisclosureTextBlock-c5_cont_2"><ix:nonNumeric contextRef="c5" escape="true" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Purchase consideration:</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Common Stock (*)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" id="ix_1_fact" name="us-gaap:TreasuryStockCommonValue" scale="0" unitRef="usd">44,341,847</ix:nonFraction></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Allocation of the purchase price:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Cash and cash equivalents</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="0" unitRef="usd">531,147</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accounts receivable, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="0" unitRef="usd">188,550</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="0" unitRef="usd">56,075</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="0" unitRef="usd">485,684</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Security deposits</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="0" unitRef="usd">10,440</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Total assets acquired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" scale="0" unitRef="usd">1,271,896</ix:nonFraction></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="0" unitRef="usd">56,204</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accrued expenses and other current liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" scale="0" unitRef="usd">251,335</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease liability</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" scale="0" sign="-" unitRef="usd">267,256</ix:nonFraction></td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Tenant security deposit</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="0" unitRef="usd">2,880</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Total liabilities assumed</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="0" unitRef="usd">577,675</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Total net assets acquired</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="0" unitRef="usd">694,221</ix:nonFraction></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Goodwill as a result of the Merger</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c367" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="0" unitRef="usd">43,647,626</ix:nonFraction></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><ix:continuation continuedAt="_BusinessCombinationDisclosureTextBlock-c5_cont_4" id="_BusinessCombinationDisclosureTextBlock-c5_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitRef="shares">29,561,231</ix:nonFraction> shares (<ix:nonFraction contextRef="c318" decimals="0" format="ixt:num-dot-decimal" name="abvc:CommonStockIssuedAfterStockSplit" scale="0" unitRef="shares">1,642,291</ix:nonFraction> after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $<ix:nonFraction contextRef="c518" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares">1.50</ix:nonFraction> per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</span></td> </tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BusinessCombinationDisclosureTextBlock-c5_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2019, the Company has recorded a <ix:nonFraction contextRef="c366" decimals="2" format="ixt:num-dot-decimal" name="abvc:PercentageOfGoodwill" scale="-2" unitRef="pure">100</ix:nonFraction>% goodwill write-down of $<ix:nonFraction contextRef="c366" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" unitRef="usd">43,647,626</ix:nonFraction>. Goodwill was determined to have been impaired because of the current financial condition of the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company&#8217;s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation of the Merger.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c5" continuedAt="_SubsequentEventsTextBlock-c5_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18. SUBSEQUENT EVENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c5_cont_2" id="_SubsequentEventsTextBlock-c5_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company entered into a Collaborative Agreement with BioLite, Inc., a company incorporated under the laws of Taiwan, and a subsidiary of the Company, (&#8220;BioLite&#8221;) on December 29, 2015, and then entered into two addendums to such agreement (as amended and revised, (the &#8220;Agreement&#8221;)).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c5_cont_3" id="_SubsequentEventsTextBlock-c5_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Agreement, the Company acquired the sole licensing rights to develop and commercialize for therapeutic purposes six compounds from BioLite. <ix:nonNumeric contextRef="c5" name="abvc:TermsOfAgreementDescription">In accordance with the terms of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity securities owned by it at various stages on a schedule dictated by BioLite&#8217;s achievements of certain milestones, as set forth in the Agreement (the &#8220;Milestone Payments&#8221;) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501 is approved for sale in the licensed territories.</ix:nonNumeric> If BioLite fails to reach any of the milestones in a timely manner, it may not receive the rest of the payments from the Company. <ix:nonNumeric contextRef="c5" name="abvc:MilestonePaymentDescription">According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the &#8220;December 2021 Payment&#8221;) and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company&#8217;s Board of Directors determined that the December 2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000, that BioLite owes the Company as of December 31, 2021.</ix:nonNumeric> On February 22, 2022, the parties entered into an amendment to the Agreement allowing the Company to make all payments due under the Agreement via the forgiveness of debt, in equal value, owed by BioLite to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c5_cont_4" id="_SubsequentEventsTextBlock-c5_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This was a related party transaction and was conducted at arm&#8217;s length. In addition to the Company&#8217;s board of directors approving the modification of terms of the Agreement, the Company&#8217;s audit committee approved them too. The Board believes it is in the Company&#8217;s best interest to cancel outstanding debt and apply it to the December 2021 Payment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c5_cont_5" id="_SubsequentEventsTextBlock-c5_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following such approval, the Company and BioLite entered into an amendment to the Agreement reflecting the modified payment method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SubsequentEventsTextBlock-c5_cont_6" id="_SubsequentEventsTextBlock-c5_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also issued an aggregate of <ix:nonFraction contextRef="c258" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">1,306,007</ix:nonFraction> shares of common stock to consultants, who provided consulting services in January 2022; it issued an additional <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="abvc:AdditionalSharesOfCommonStock" scale="0" unitRef="shares">75,000</ix:nonFraction> shares to another consultant in March 2022, based on the 6-month consulting and advisory services agreement, with a monthly payment of USD $<ix:nonFraction contextRef="c519" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpenseInvestmentAdvisoryFees" scale="0" unitRef="usd">15,000</ix:nonFraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c5_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of December 31, 2021 have been incorporated into these financial statements and there are no other subsequent events that require disclosure in accordance with FASB ASC Topic 855, &#8220;Subsequent Events.&#8221;</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PART
II&#160;&#8212;&#160;INFORMATION NOT REQUIRED IN PROSPECTUS</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 13. <i>Other Expenses of Issuance and Distribution</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table sets forth all expenses to be paid by the Registrant, other than estimated placement agents&#8217; fees, in connection with our public offering. All amounts shown are estimates except for the SEC registration fee and the FINRA filing fee:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 88%; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">SEC registration fee</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">3,019.01</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">FINRA filing fee</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">5,985.47</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Legal fees and expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">95,000</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Accounting fees and expenses</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">19,250</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Transfer agent and registrar fees</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">$</span></td>
    <td style="text-align: right"><span style="font-size: 10pt">10,238</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt">Miscellaneous fees and expenses</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt; padding-left: 9pt; text-indent: -9pt"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">133,492.48</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; "><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All amounts are estimated, except the U.S. Securities and Exchange Commission registration fee, the NASDAQ listing fee and the FINRA filing fee.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; ">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <tr style="vertical-align: top; text-align: justify">
    <td style="width: 0in"></td>
    <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To be completed by amendment.</span></td> </tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 14. <i>Indemnification of Directors and Officers</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither our Articles of Incorporation nor Bylaws prevent us from indemnifying our officers, directors and agents to the extent permitted under the Nevada Revised Statute (&#8220;NRS&#8221;). NRS Section 78.7502 provides that a corporation shall indemnify any director, officer, employee or agent of a corporation against expenses, including attorneys&#8217; fees, actually and reasonably incurred by him in connection with any the defense to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue or matter therein.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS 78.7502(1) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys&#8217; fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS Section 78.7502(2) provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys&#8217; fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 182; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed hereby in the Securities Act and we will be governed by the final adjudication of such issue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Articles of Incorporation and Bylaws</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our articles of incorporation, as amended, do not include specific provisions relating to the indemnification of our directors or officers.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our bylaws provide that the Company may indemnify and advance litigation expenses to its directors, officers, employees and agents to the extent permitted by law, the Company&#8217;s Articles or Bylaws, and shall indemnify and advance litigation expenses to its directors, officers, employees and agents to the extent required by law, the Company&#8217;s Articles of Incorporation or Bylaws. The Company&#8217;s obligations of indemnification, if any, shall be conditioned on the Company receiving prompt notice of the claim and the opportunity to settle and defend the claim. The Company may, to the extent permitted by law, purchase and maintain insurance on behalf of an individual who is or was a director, officer, employee or agent of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 15. <i>Recent Sales of Unregistered Securities</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the last three years, the Company has not issued unregistered securities to any person, except as described below. None of these transactions involved any underwriters, underwriting discounts or commissions, except as specified below, or any public offering, and, unless otherwise indicated below, the Registrant believes that each transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof and/or Rule 506 of Regulation D promulgated thereunder, and/or Regulation S promulgated thereunder regarding offshore offers and sales. All recipients had adequate access, though their relationships with the Registrant, to information about the Registrant.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 21, 2020, the Company entered into three note agreements with existing note investors who executed the agreements in 2018. These three investors are Guoliang Yu and Yingfei Wei Family Trust, Keypoint Technology Ltd., and Yoshinobu Odaira. The new agreements bear the same term as other notes investors who executed the contract in 2019. On April 5, 2020, the Company entered into exchange agreements with such note holders. Pursuant to the exchange agreements, the Holders agreed to deliver the Notes to the Company for cancellation, of which the aggregate principal amount plus accrued interest expenses are $931,584, and the Company issued to the Holders an aggregate of 506,297 shares of the Company&#8217;s common stock, and warrants to purchase 506,297 shares of the Company&#8217;s common stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 5, 2020 and April 20, 2020, the Company entered into certain exchange agreements separately with certain U.S. and non-U.S. holders who are holders of certain convertible promissory notes issued by the Company in the aggregate amount of $1,446,780. Pursuant to the exchange agreements, the Company agreed to issue to the Holders an aggregate of 795,735 shares of the Company&#8217;s common stock, and warrants to purchase 795,735 shares of common stock. Each warrant is exercisable upon issuance and expires three years from the date of issuance. The initial exercise price of the warrant is $5.00, subject to stock, splits, stock dividend and other similar events. In addition, when the closing price of the common stock equals or exceeds $9.00 per share for twenty Trading Days (as defined in the exchange agreements) during any thirty-day period, the Company shall have the right to require the holders to exercise all or any portion of the note holders&#8217; warrants for a cash exercise. On September 30, 2020, the Company has issued such note holders&#8217; shares warrants to the holders and closed the transactions contemplated by the Exchange Agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2020, the Company received capital contributions of approximately $1,602,040 in cash from 40 investors through private placements of the sale of certain number of Common Stocks for the purchase price of $2.25 per share of Common Stock and a free warrant attaches with each Common stock that was purchased. The exercise price of the warrant is at $6.00 per common stock with a mandatory redemption at $9.00 per common stock pursuant to the terms and conditions of the warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 8, 2020, the Company entered an agreement with View Trade Securities Inc. (&#8220;<b>ViewTrade</b>&#8221;) to engage ViewTrade as the placement agent and the Company&#8217;s advisor with respect to its ongoing capital events. Pursuant to the agreement, the Company agreed to pay View Trade (&#8220;<b>ViewTrade Securities</b>&#8221;) 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision. As of December 31, 2021, the Company has issued 60,000 shares of common stock to ViewTrade for the advisory services with an estimated value of $135,000. The warrants were never issued and the parties mutually agreed to terminate the agreement on November 19, 2020. As a termination fee, the Company agreed to issue ViewTrade 50,000 restricted common shares of the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also on November 19, 2020, the Company and ViewTrade agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only. In addition to a retainer fee, the Company agreed to issue 200,000 warrants, with an exercise price of $2.25, an industry standard cashless exercise provision, and a term of 5 years from November 19, 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 30, 2020, the Company also issued to Ever Adventure inv. (Formosa) Consultant Co., Ltd. (or its designee), Jinwei International Co., Ltd. (or its designee), and Thalia Media Ltd. (or its designee) (the &#8220;<b>Consultants</b>&#8221;) 120,000 shares, 180,000 shares and 120,000 shares of common stock (collectively, &#8220;<b>Consultants&#8217; Shares</b>&#8221;), respectively, as their compensation as the Company&#8217;s investor relations and business development advisors. Each Consultant has entered into certain consulting agreement with the Company.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 30, 2020, the Company issued an aggregate of 795,735 shares of Common Stock to five previous note holders, who had converted their outstanding principals and accrued and unpaid interests during the nine months ended September 30, 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 8, 2020, the Company entered into an exchange agreement with a holder of convertible promissory notes issued by the Company in the aggregate amount of $270,272. Pursuant to the exchange agreements, the Company agreed to issue to the Holder an aggregate of 120,121 shares of the Company&#8217;s common stock, and warrants to purchase 120,121 shares of common stock. On December 31, 2021, the Company issued an aggregated of 120,121 shares of Common Stock to the note holder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 11, 2020, the Company conducted a closing with regard to certain securities purchase agreements (the &#8220;<b>SPAs</b>&#8221;) dated October 23, 2020, separately with two non-U.S. investors (the &#8220;<b>Investors</b>&#8221;). Each of the Investors agreed to purchase and the Company agreed to sell to each of the Investors 1,111,112 shares of the Company&#8217;s common stock, and warrants to purchase 1,111,112 shares of common stock, for a purchase price of $2,500,000. The warrants are exercisable upon issuance and expires three years from the date of issuance. The initial exercise price of the warrants is $6.00, subject to stock, splits, stock dividend and other similar events. In addition, when the closing price of the common stock equals or exceeds $9.00 per share for twenty Trading Days (as defined in the exchange agreements) during any thirty-day period, the Company shall have the right to require the investors to exercise all or any portion of the warrants for a cash exercise. The aggregate net proceeds of the Offering were $5,000,000. The Company and the investors further agreed to amend the terms of the SPA to permit the closing of the offering to occur on a rolling basis. In July 2021,&#160;1,111,112&#160;shares of the Company&#8217;s common stock and warrants were issued pursuant to the conversion of a $2,500,000 convertible promissory note.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During the year&#160;ended December 31, 2020, the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company agreed to pay the service fee by issuing&#160;50,000&#160;shares of unrestricted common shares, valued at the closing price of $2.9&#160;per share on the grant date. These shares were issued in 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company received aggregated capital contributions of $7,615,331&#160;in cash from&#160;45&#160;investors through private placements of the sale of the Company&#8217;s common stock for the purchase price of&#160;$2.25&#160;per share and a free warrant attached with each common stock purchased. In December 2020,&#160;3,384,615&#160;shares of the Company&#8217;s common stock have been issued.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed to pay the aggregate service fee by issuing a total of 521,887 shares of unrestricted common shares, valued at the closing price from $2 to $3.68 per share on the grant date. As of December 31, 2021, these shares have been issued.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued an aggregate of 915,856 shares of common stock to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2021,&#160;the Company closed its public offering (the &#8220;Public Offering&#8221;) of 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of the Company&#8217;s common stock, one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.&#160;The Public Offering was conducted on a firm commitment basis. In August 2021,&#160;2,354,145&#160;shares of the Company&#8217;s common stock were issued for gross proceeds of $6,875,000, before placement agent fees and legal fees of $850,429.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued 644,972 shares of the Company&#8217;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable. As of December 31, 2021 and 2020, stock subscription receivable was $2,257,400 and $3,160,360, respectively.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company paid the following fees to a FINRA member firm in connection&#160;with the private financing transaction that closed on November 11, 2020: (i) a cash success fee of $175,000 and (ii) warrants to purchase a number of shares of Common Stock equal to 7% of the number of shares of Common Stock sold in this offering, at an exercise price per share equal to $6.00 subject to adjustment (the &#8220;<b>Comp Warrants</b>&#8221;). The Comp Warrants are exercisable on a cashless basis, at the holder&#8217;s discretion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 29, 2021, we issued 6,000 shares of Common Stock to WallachBeth as compensation for consulting services.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company issued an aggregate of 316,934 shares of Common Stock to Consultants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also issued an aggregate of 1,306,007 shares of Common Stock to Consultants, who provided consulting services in January 2022; it issued an additional 75,000 shares to another consultant in March 2022, based on the 6-month consulting and advisory services agreement, with a monthly payment of USD $15,000.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company issued 55,000&#160;underwriter warrants to WallachBeth, pursuant to the Company&#8217;s engagement of WallachBeth as the Company&#8217;s exclusive placement agent and advisor in connection with the offering for the listing on The Nasdaq Capital Market.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company received $4,244,452&#160;in gross proceeds from the exercise of warrants issued in the Company&#8217;s August 3, 2021 public offering of securities. Investors exercised a total of&#160;673,405&#160;Series A warrants at a price of $6.30&#160;per share and&#160;200&#160;Series B warrants at a price of $10&#160;per share. Pursuant to these exercises, the Company issued an aggregate of 673,605 shares of Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In January 2022, the Company issued an aggregate
of 1,306,007 shares of Common Stock to Consultants, who provided consulting services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On January 1, 2022, the Company engaged BarLew
Holdings, LLC, a consultant (&#8220;Barlew&#8221;) for consulting and advisory services for six months, with a monthly payment of USD15,000,
as well as additional compensation of 75,000 shares of restricted common stock. In March 2022, the Company issued 75,000 shares to BarLew.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In March 2022, the Company issued 242,247 warrants
to a FINRA member firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In May 2022, the company issued 160,000 warrants
to FINRA member firms.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 16. <i>Exhibits and Financial Statement Schedules</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000101489716000457/exhibit101.htm">Share
    Exchange Agreement, dated February 8, 2016 (1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000113789202000063/fex301ai.txt">Articles
    of Incorporation of the Company (2)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000113789202000063/fex302bl.txt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws
    of the Company, as amended (3)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000161577416004635/s102891_4-1.htm">Certificate
    of Amendment to Articles of Incorporation filed on March 21, 2016 (4)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000161577416007154/s104086_ex3-4.htm">Certificate
of Amendment to Articles of Incorporation filed on December 30, 2015 (5)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020008785/ea120454ex3-1_americanbri.htm">Certificate
    of Amendment to Articles of Incorporation filed on March 30, 2020 (6)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020010040/ea121013ex4-1_american.htm">Form
    of Warrant (7)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea158528ex4-2_abvcbio.htm">Form of the Registrant&#8217;s Common Stock certificate (filed herewith)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390021040497/ea145252ex4-1_abvcbiopharma.htm"><span style="font-size: 10pt">Warrant
    issued to WallachBeth Capital, LLC (32)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390021021784/ea139269ex5-1_abvcbio.htm">Legal
    Opinion of Hunter Taubman Fischer &amp; Li LLC (27)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000101489716000457/exhibit102.htm">Collaboration
    Agreement dated December 29, 2015 (8)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000161577416005823/s103448_ex99-1.htm">Collaborative
Agreement and Milestone Payment Agreement dated May 6, 2016 (9)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390017000304/f10k2016ex10iii_american.htm">Employment
    Agreement with Kira Huang (10)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390017001707/f8k0217ex99i_americanbri.htm">Addendum
    to the Collaboration Agreement dated January 12, 2017 (11)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390017007869/f8k072417ex10i_americanbri.htm">Collaboration
    Agreement with BioFirst dated July 24, 2017 (12)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390017005978/f8k052617ex99i_american.htm"><span style="font-size: 10pt">Co-Development
    Agreement with Rgene dated May 26, 2017 (13)</span></a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390017009853/f8k091517ex10-1_americanbriv.htm">Employment
    Agreement with Dr. Howard Doong (14)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390017009853/f8k091517ex10-3_americanbriv.htm">Employment
    Agreement with Dr. Chi-Hsin Richard King (15)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/f10k2019ex10-9_americanbriv.htm">Employment
    Agreement with Chihliang An (25)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390019001553/f8k012119ex10-1_americanbri.htm">Business
    Loan Agreement entered by and between Cathay Bank and American BriVision (Holding) Corporation (16)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390019001553/f8k012119ex10-2_americanbri.htm">Promissory
    Note entered by American BriVision (Holding) Corporation (17)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390019001553/f8k012119ex10-3_americanbri.htm">Form
    of Commercial Security Agreement (18)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020009167/ea120625ex10-2_americanbri.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Exchange Agreement entered into by and between the Company and non-US persons (19)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">10.14</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020009167/ea120625ex10-1_americanbri.htm">Form of Exchange Agreement entered into by and between the Company and US persons (20)</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020010040/ea121013ex10-1_american.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Exchange Agreement entered into by and between the Company and non-US person (21)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/f10k2019ex10-15_americanbriv.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement entered into by and between the Company and U.S. investors (22)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020012685/f10k2019ex10-16_americanbriv.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
    of Securities Purchase Agreement entered into by and between the Company and non-U.S. investors (23)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390021015729/f10k2020ex10-17_americanbriv.htm">Amended
    and Restated American BriVision (Holding) Corporation 2016 Equity Incentive (28)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390021052090/ea148616ex10-1_abvcbiopharma.htm">Joint
    Venture Agreement between the Company, Lucidaim Co., Ltd. And BioLite Japan K.K.(26)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000161577416008325/s104643_ex14-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code
    of Ethics (24)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ea158528ex21-1_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of subsidiaries (filed herewith)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390021021784/ea139269ex5-1_abvcbio.htm">Consent
    of Hunter Taubman Fischer &amp; Li LLC (19) (Included in Exhibit 5.1) (27)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea158528ex23-2_abvcbio.htm">Consent of KCCW Accountancy Corp (filed herewith)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020038891/ea130363ex99-1_american.htm">Charter
    of the Audit Committee (29)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020038891/ea130363ex99-2_american.htm">Charter
    of the Compensation Committee (30)</a> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1173313/000121390020038891/ea130363ex99-3_american.htm">Charter
    of the Nominating and Corporate Governance Committee (31)</a> </span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document for the year ended December 31, 2022 (33).</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document. (33)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document. (33)</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document. (33)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document. (33)</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document. (33)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document for the three months ended March 31, 2022 and 2021 (34).</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document. (34)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document. (34)</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document. (34)</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document. (34)</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document (34).</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 90%"><a href="ea158528ex-fee_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif"><span style="font-size: 10pt">Filing Fees Exhibit (filed herewith)</span></span></a></td></tr>
</table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>



</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 15%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on February 16, 2016.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 3.01 to the Company&#8217;s Form SB-2 filed on June 28, 2002</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="margin: 0pt 0">Incorporated by reference to Exhibit 3.02 to the Company&#8217;s Form SB-2, filed on June 28, 2002.</p></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed on March 28, 2016.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 3.4 to the Company&#8217;s Form S-1, filed on September 13, 2016. (3.4)</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K, filed on April 7, 2020</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>



</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 4.1 the Company&#8217;s Current Report on Form 8-K, filed on April 24, 2020</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.2 the Company&#8217;s Current Report on Form 8-K, filed on February 16, 2016.</span></td></tr>
  </table><div>



</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(9)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K, filed on June 9, 2016.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(10)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K, filed on January 12, 2017.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K, filed on February 22, 2017.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(12)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on July 24, 2017.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 99.1 to the Company&#8217;s Current Report on Form 8-K, filed on May 30, 2017.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(14)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on September 20, 2017.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(15)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed on September 20, 2017.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(16)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on February 1, 2019.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on February 1, 2019.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K, filed on February 1, 2019.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(19)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed on April 14, 2020.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 34px; text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on April 14, 2020.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(21)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed April 24, 2020.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K, filed May 15, 2020.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(23)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.16 to the Company&#8217;s Annual Report on Form 10-K, filed May 15, 2020</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 14.1 to the Company&#8217;s Amendment No.1 to Form S-1, filed on November 14, 2016.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.9 to the Company&#8217;s Annual Report on Form 10-K, filed May 15, 2020.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed on October 8, 2021. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(27)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 5.1 to the Company&#8217;s Form S-1, filed April 15, 2021.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 10.17 to the Company&#8217;s Annual Report on Form 10-K, filed March 16, 2021.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 99.1 to the Company&#8217;s Form S-1, filed on November 24, 2020. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 99.2 to the Company&#8217;s Form S-1, filed on November 24, 2020. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(31) </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 99.3 to the Company&#8217;s Form S-1, filed on November 24, 2020. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K, filed on August 5, 2021.</span></td></tr>
  </table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt; width: 0.35in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Company&#8217;s Annual Report on Form 10-K, filed March 31, 2022.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(34)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated by reference to the Company&#8217;s Quarterly Report on Form 10-Q, filed May 16, 2022.</span></td></tr>
  </table><div>

</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Item 17. Undertakings</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) To include any prospectus required by section 10(a)(3) of the Securities Act of 1933, as amended;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) (&#167;230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned registrant hereby undertakes that:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing
of the registrant&#8217;s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where
applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section 15(d) of the Securities Exchange Act of
1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to
the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof.</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p><div>



</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Act of 1933, the registrant has duly caused this registration statement on Form S-1 to be signed on its behalf by the undersigned, thereunto
duly authorized in the City of Taipei on June 14, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC
    BioPharma, Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 35%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Howard Doong </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Howard
    Doong </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC
    BioPharma, Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Chihliang An</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chihliang
    An</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer </span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>POWER OF ATTORNEY</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>KNOW ALL MEN BY THESE PRESENTS</b>, that each person whose signature appears below constitutes and appoints Howard Doong as his or her true and lawful attorney-in-fact, with full power of substitution and resubstitution for him and in his or her name, place and stead, in any and all capacities to sign any and all amendments including post-effective amendments to this registration statement and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Pursuant to the requirements
of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on June 14,
2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top; width: 40%; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">Name </span></td>
    <td style="vertical-align: top; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 59%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">Title</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Howard Doong</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">President and Chief Executive Officer</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Howard Doong</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">(Principal Executive Officer)</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Chihliang An</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chief Financial Officer</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chihliang An</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">(Principal Financial and Accounting Officer)</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Eugene Jiang</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Chairman of the Board of Directors and</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Eugene Jiang</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top"><span style="font-size: 10pt">Chief Business Officer</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Tsang Ming Jiang</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Tsang Ming Jiang</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Che Wei Hsu</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Che Wei Hsu</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Yen-Hsin Chou</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Yen-Hsin Chou</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Norimi Sakamoto</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom"><span style="font-size: 10pt">Director</span></td>
    </tr>
  <tr>
    <td style="vertical-align: top"><span style="font-size: 10pt">Norimi Sakamoto</span></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top">&#160;</td>
    </tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p><div>



</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 40%"><span style="font-size: 10pt">/s/ Tsung-Shann Jiang</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 59%"><span style="font-size: 10pt">Chief Strategy Officer and Director</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Tsung-Shann Jiang</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Chang-Jen Jiang</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Chang-Jen Jiang</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Hsin-Hui Miao</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Hsin-Hui Miao</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">/s/ Yoshinobu Odaira</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    </tr>
  <tr style="vertical-align: top">
    <td><span style="font-size: 10pt">Yoshinobu Odaira</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Director</span></td>
    </tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shuling Jiang</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shuling Jiang</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kuang-Tseng Chen</span></td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kuang-Tseng Chen</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><div>



</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>

    </div><!-- Field: /Page --><div>




</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c1" id="hidden-fact-0" name="us-gaap:Goodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:Goodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-2" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-4" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-5" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-6" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-7" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-8" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-9" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-10" name="abvc:PrepaymentForLongtermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-11" name="us-gaap:Goodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-12" name="us-gaap:Goodwill" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-13" name="us-gaap:AccountsPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-14" name="us-gaap:OtherShortTermBorrowings" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-15" name="us-gaap:NotesPayableToBankCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-16" name="us-gaap:OtherNotesPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-17" name="us-gaap:LoansPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-18" name="us-gaap:ConvertibleLongTermNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-19" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-20" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-21" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-22" name="us-gaap:PreferredStockSharesIssued" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-23" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-24" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-25" name="abvc:OperatingSubleaseIncomeRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-26" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-27" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-28" name="us-gaap:GoodwillImpairmentLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-29" name="us-gaap:RealizedInvestmentGainsLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-30" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-31" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-32" name="abvc:GovernmentGrantIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-33" name="us-gaap:OtherNoncashIncomeExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-34" name="us-gaap:IncreaseDecreaseInInventories" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-35" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-36" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-37" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-38" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-39" name="us-gaap:RepaymentsOfConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-40" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-41" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-42" name="us-gaap:IncomeTaxesPaid" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-43" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-44" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-45" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-46" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-47" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-48" name="abvc:CumulativeTransactionAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c18" id="hidden-fact-49" name="abvc:CumulativeTransactionAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-50" name="abvc:CumulativeTransactionAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-51" name="abvc:CumulativeTransactionAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-52" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-53" name="abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-54" name="abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-55" name="abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-56" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-57" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-58" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-59" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-60" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-61" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-62" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-63" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-64" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-65" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-66" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-67" name="abvc:CumulativeTransactionAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-68" name="abvc:CumulativeTransactionAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-69" name="abvc:CumulativeTransactionAdjustments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-70" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-71" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-72" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-73" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-74" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-75" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-76" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-77" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-78" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-79" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-80" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-81" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-82" name="abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-83" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-84" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c66" id="hidden-fact-85" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-86" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c65" id="hidden-fact-87" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c129" id="hidden-fact-88" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c130" id="hidden-fact-89" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-90" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c132" id="hidden-fact-91" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" id="hidden-fact-92" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c138" id="hidden-fact-93" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c139" id="hidden-fact-94" name="abvc:NetSales" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c139" id="hidden-fact-95" name="abvc:GrossProfits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c139" id="hidden-fact-96" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c142" id="hidden-fact-97" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-98" name="abvc:ShareOfEquityMethodInvesteeLosses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c362" id="hidden-fact-99" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c363" id="hidden-fact-100" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c363" id="hidden-fact-101" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-102" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-103" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:footnote id="ix_0_footnote" xml:lang="en-US">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of assets acquired and liabilities assumed based on fair value-->
<ix:nonFraction contextRef="c2" id="hidden-fact-104" name="us-gaap:InventoryWorkInProcess" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-105" name="us-gaap:InventoryNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c130" id="hidden-fact-106" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c132" id="hidden-fact-107" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c401" id="hidden-fact-108" name="us-gaap:EquityMethodInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-109" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-110" name="us-gaap:GrossProfit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-111" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c405" id="hidden-fact-112" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c410" decimals="4" id="hidden-fact-113" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="pure">0.0050</ix:nonFraction>
<ix:nonFraction contextRef="c404" id="hidden-fact-114" name="us-gaap:AccountsReceivableRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c250" id="hidden-fact-115" name="abvc:DueFromtheRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c402" id="hidden-fact-116" name="abvc:DueFromtheRelatedPartiesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c503" id="hidden-fact-117" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c502" id="hidden-fact-118" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c509" id="hidden-fact-119" name="abvc:DueToRelatedPartyCurrentAndNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c363" id="hidden-fact-120" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c363" id="hidden-fact-121" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-122" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c6" id="hidden-fact-123" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">true</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentPeriodEndDate">2022-03-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentType">POS AM</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="abvc-20220331.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship fromRefs="ix_0_fact ix_0_fact ix_1_fact" toRefs="ix_0_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-02-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementFourMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:MergerAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-03-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-07-02</xbrli:startDate>
    <xbrli:endDate>2016-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2015-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-12-01</xbrli:startDate>
    <xbrli:endDate>2015-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-08-02</xbrli:startDate>
    <xbrli:endDate>2016-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-08-02</xbrli:startDate>
    <xbrli:endDate>2017-08-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-05-02</xbrli:startDate>
    <xbrli:endDate>2017-05-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-12-02</xbrli:startDate>
    <xbrli:endDate>2018-12-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-09-02</xbrli:startDate>
    <xbrli:endDate>2017-09-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-01-01</xbrli:startDate>
    <xbrli:endDate>2017-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-08-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-05-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-04-25</xbrli:startDate>
    <xbrli:endDate>2018-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-04-25</xbrli:startDate>
    <xbrli:endDate>2018-05-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-05-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-26</xbrli:startDate>
    <xbrli:endDate>2020-04-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-26</xbrli:startDate>
    <xbrli:endDate>2020-04-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-06-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-06-02</xbrli:startDate>
    <xbrli:endDate>2018-06-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-06-02</xbrli:startDate>
    <xbrli:endDate>2018-06-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-08-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-08-02</xbrli:startDate>
    <xbrli:endDate>2018-08-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-08-02</xbrli:startDate>
    <xbrli:endDate>2018-08-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-05-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2019-07-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-06-26</xbrli:startDate>
    <xbrli:endDate>2019-07-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-06-26</xbrli:startDate>
    <xbrli:endDate>2019-07-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-28</xbrli:startDate>
    <xbrli:endDate>2019-08-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-08-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-28</xbrli:startDate>
    <xbrli:endDate>2019-08-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-20</xbrli:startDate>
    <xbrli:endDate>2019-09-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-10-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2019-10-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-05-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-06-01</xbrli:startDate>
    <xbrli:endDate>2016-06-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-09-01</xbrli:startDate>
    <xbrli:endDate>2017-09-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-10-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-10-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-09-25</xbrli:startDate>
    <xbrli:endDate>2018-10-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2019-09-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-09-01</xbrli:startDate>
    <xbrli:endDate>2020-09-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-07-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-07-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-06-01</xbrli:startDate>
    <xbrli:endDate>2017-06-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-07-01</xbrli:startDate>
    <xbrli:endDate>2017-07-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-07-01</xbrli:startDate>
    <xbrli:endDate>2017-07-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2019-07-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-01-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-14</xbrli:startDate>
    <xbrli:endDate>2022-01-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-31</xbrli:startDate>
    <xbrli:endDate>2021-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-04</xbrli:startDate>
    <xbrli:endDate>2020-04-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:PAYCHECKPROTECTIONPROGRAMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-04</xbrli:startDate>
    <xbrli:endDate>2020-04-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-01-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-02-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:PAYCHECKPROTECTIONPROGRAMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:PAYCHECKPROTECTIONPROGRAMMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-02-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-02</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0TSgIZzBWwoovVOsFPEA4rNNrbY6CE8wmoa0q+lpRTxGk3c+CiJGsyWKrkLTTMjgQTYSxh3ggHe8DlX9qv/pk+ILYd8K5ojpQS7Wnderc/ZHXKbqwIYJ6fn4w3DUr83pinl1Bn8GkYHzTrlHXt0n08=] CSR-->
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-02-01</xbrli:startDate>
    <xbrli:endDate>2015-02-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LbgUsaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-02-27</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LbgUsaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LbgUsaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-05-01</xbrli:startDate>
    <xbrli:endDate>2020-05-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-01-01</xbrli:startDate>
    <xbrli:endDate>2018-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationtheBioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneCorporationtheYuanGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneCorporationtheAsiaGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:EugeneJiangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointTechnologyLtdtheKeypointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionArtsPromotionInctheLionArtsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YoshinobuOdairatheOdairaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmInctheGenePharmMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAInctheLBGUSAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionGeneCorporationtheLionGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KimhoConsultantsCoLtdtheKimhoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyVenturesLLCAmkeyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ABVCBioPharmaHKLimitedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToshareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToshareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-05-01</xbrli:startDate>
    <xbrli:endDate>2016-05-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-08-01</xbrli:startDate>
    <xbrli:endDate>2016-08-26</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-02-01</xbrli:startDate>
    <xbrli:endDate>2017-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">abvc:BioLiteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">abvc:BioKeyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-09-24</xbrli:startDate>
    <xbrli:endDate>2016-10-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KameyamaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-01</xbrli:startDate>
    <xbrli:endDate>2020-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-09-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-08-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ArticlesOfIncorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ArticlesOfIncorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ArticlesOfIncorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:WallachBethCapitalLLCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-01</xbrli:startDate>
    <xbrli:endDate>2020-11-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:NonRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-07-01</xbrli:startDate>
    <xbrli:endDate>2021-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abvc:SeriesAWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abvc:SeriesBWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-30</xbrli:startDate>
    <xbrli:endDate>2021-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LionArtsPromotionInctheLIONMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LionGeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c353">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:YuangeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c354">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c355">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-10-01</xbrli:startDate>
    <xbrli:endDate>2020-10-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c356">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-10-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c357">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-11-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c358">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-11-01</xbrli:startDate>
    <xbrli:endDate>2020-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c359">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-10-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c360">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-10-04</xbrli:startDate>
    <xbrli:endDate>2021-10-15</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c361">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c362">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c363">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c364">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c365">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">abvc:BioKeyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abvc:BusinessCombinationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-02-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c366">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c367">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-02-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c368">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-04-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c369">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-04-02</xbrli:startDate>
    <xbrli:endDate>2022-04-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c370">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-05-02</xbrli:startDate>
    <xbrli:endDate>2022-05-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c371">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-11</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c372">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-02-01</xbrli:startDate>
    <xbrli:endDate>2016-02-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c373">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-03-01</xbrli:startDate>
    <xbrli:endDate>2019-03-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c374">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c375">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c376">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c377">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c378">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c379">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c380">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-07-02</xbrli:startDate>
    <xbrli:endDate>2016-07-27</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c381">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c382">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c383">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c384">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c385">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c386">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c387">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c388">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c389">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c390">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c391">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c392">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c393">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c394">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c395">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c396">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c397">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c398">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c399">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c400">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c401">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c402">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c403">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c404">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c405">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c406">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-06-26</xbrli:startDate>
    <xbrli:endDate>2019-07-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c407">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-08-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c408">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c409">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c410">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-10-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c411">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-10-01</xbrli:startDate>
    <xbrli:endDate>2019-10-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c412">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c413">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c414">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c415">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c416">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c417">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2016-06-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c418">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c419">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c420">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-10-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c421">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-10-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c422">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-09-25</xbrli:startDate>
    <xbrli:endDate>2018-10-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c423">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c424">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c425">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c426">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c427">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c428">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-06</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c429">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-09-01</xbrli:startDate>
    <xbrli:endDate>2021-09-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c430">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c431">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c432">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c433">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c434">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-07-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c435">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-07-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c436">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-07-01</xbrli:startDate>
    <xbrli:endDate>2017-07-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c437">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c438">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-07-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c439">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c440">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-01-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c441">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c442">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c443">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c444">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c445">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c446">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-07-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c447">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c448">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c449">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c450">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-10-03</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c451">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-12-01</xbrli:startDate>
    <xbrli:endDate>2020-12-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c452">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c453">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c454">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c455">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c456">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c457">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c458">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c459">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c460">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c461">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c462">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c463">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c464">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c465">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c466">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c467">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c468">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c469">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c470">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c471">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c472">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-05-01</xbrli:startDate>
    <xbrli:endDate>2018-05-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c473">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LbgUsaIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c474">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c475">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c476">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c477">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c478">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c479">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c480">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c481">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c482">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c483">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationtheBioFirstMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c484">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c485">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c486">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneCorporationtheYuanGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c487">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneCorporationtheAsiaGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c488">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:EugeneJiangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c489">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointTechnologyLtdtheKeypointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c490">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionArtsPromotionInctheLionArtsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c491">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YoshinobuOdairatheOdairaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c492">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmInctheGenePharmMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c493">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c494">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAInctheLBGUSAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c495">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionGeneCorporationtheLionGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c496">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KimhoConsultantsCoLtdtheKimhoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c497">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c498">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyVenturesLLCAmkeyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c499">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c500">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c501">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c502">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c503">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c504">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c505">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c506">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c507">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c508">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToshareholdersMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c509">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c510">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToEmployeeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c511">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:NonRelatedPartiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c512">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-01</xbrli:startDate>
    <xbrli:endDate>2021-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c513">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c514">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c515">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c516">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c517">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c518">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">abvc:BioKeyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-02-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c519">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="twd">
  <xbrli:measure>iso4217:TWD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>2
<FILENAME>ea158528ex4-2_abvcbio.htm
<DESCRIPTION>FORM OF THE REGISTRANT'S COMMON STOCK CERTIFICATE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 4.2</B></P>

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><B><IMG SRC="ex4-2_001.jpg" ALT="">&nbsp;</B></P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><B></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ex4-2_002.jpg" ALT=""><B>&nbsp;</B></P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><B>&nbsp;</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: left; margin-top: 0; margin-bottom: 0"><B></B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ea158528ex21-1_abvcbio.htm
<DESCRIPTION>LIST OF SUBSIDIARIES
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 21.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex21-1_001.jpg" ALT="">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>4
<FILENAME>ea158528ex23-2_abvcbio.htm
<DESCRIPTION>CONSENT OF KCCW ACCOUNTANCY CORP (FILED HEREWITH)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.2</B></P>

<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR>
    <TD STYLE="width: 50%"><IMG SRC="image_001.gif" ALT="">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 50%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 8pt; text-align: center"><B><U>A</U></B><U>udit <B>&bull; T</B>ax <B>&bull;
    C</B>onsulting <B>&bull; F</B>inancial <B>A</B>dvisory</U> <I><BR>
Registered with Public Company Accounting Oversight Board (PCAOB)</I></P></TD></TR>
  </TABLE>
<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Consent of Independent Registered Public Accounting
Firm</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">We hereby consent
to the incorporation by reference in this Registration Statement on Form S-1 Amendment No. 1 of&nbsp;</FONT>ABVC Biopharma, Inc. <FONT STYLE="background-color: white">of
our report dated March 31, 2022 relating to the consolidated financial statements of&nbsp;</FONT>ABVC Biopharma, Inc.&nbsp;<FONT STYLE="background-color: white">and
its subsidiaries, which appear in such Registration Statement. We also consent to the reference to us under the&nbsp;</FONT>caption&nbsp;<FONT STYLE="background-color: white">&ldquo;Experts&rdquo;
in such Registration Statement.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 99%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ KCCW Accountancy Corp.</FONT></TD>
    <TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diamond Bar, California</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">June 14, 2022</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: right">______________________________________________________________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>KCCW Accountancy Corp.</B> 3333 S. Brea Canyon Road,
    Suite 206, CA 91765 USA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Tel: +1 909 348 7228 &bull; Fax: +1 909 895 4155</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">&nbsp;</P>
<P STYLE="margin: 0; text-align: right"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>ea158528ex-fee_abvcbio.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
107</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CALCULATION
OF FILING FEE TABLES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>ABVC
BioPharma, Inc. </U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Table
1: Newly Registered Securities</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="text-align: center; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security
    Type</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-top: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Security
    Class Title</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee
    Calculation or Carry Forward Rule</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Maximum
    Aggregate Offering Price (1)(2)(3)</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fee
    Rate</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    of Registration Fee(3)</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Units
    (4)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    7,187,500.00 </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0000927</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    666.28</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock included in the Units, par value $0.001 per share (5)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    to purchase common stock (5)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock issuable upon exercise of the Series A Warrants, which are included in the Units</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,625,000.00
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0000927</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">799.54</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock issuable upon exercise of the Series B Warrants, which are included in the Units</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(o)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,500,000.00
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0000927</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,066.05</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Representative&rsquo;s
    Warrants (6)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(g)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock underlying Representative&rsquo;s Warrants (6)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">457(g)</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">359,375.00
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0000927</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">33.14</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Offering Amounts</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,671,875&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0000927</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    2,565.01</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Fees Previously Paid </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    3,019.01</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Fee Offsets</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    0</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Fee Due</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$
    0(4)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
                                            solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under
                                            the Securities Act of 1933, as amended, based on an estimate of the proposed maximum aggregate
                                            offering price.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition, pursuant to Rule 416 under the Securities Act of 1933, this Registration Statement
                                            includes an indeterminate number of additional shares as may be issuable as a result of stock
                                            splits or stock dividends which occur during this continuous offering.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
                                            the price of additional shares of common stock and warrants to purchase common stock that
                                            the underwriters have the option to purchase to cover over-allotments, if any, within 45
                                            days after the date of this prospectus.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
                                            Unit includes (i) one share of common stock, (ii) one Series A Warrant and (iii) one Series
                                            B Warrant.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Included
                                            in the price of the units. No separate registration fee is required pursuant to Rule 457(g)
                                            under the Securities Act.</FONT></TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated
                                            solely for the purposes of calculating the registration fee pursuant to Rule&nbsp;457(g)&nbsp;under
                                            the&nbsp;Securities Act. We have calculated the proposed maximum aggregate offering price
                                            of the common stock underlying the underwriter&rsquo;s warrants by assuming that such warrants
                                            are exercisable at a price per share equal to 100% &nbsp;of the public offering price of
                                            the common stock in the Units sold in this offering, and that the number of shares of common
                                            stock underlying the underwriter&rsquo;s warrants equal to five percent (5%) of the number
                                            of the common stock in the Units offered in this offering.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>abvc-20220331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 14 21:16:00 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:abvc="http://metuboutique.com/20220331" targetNamespace="http://metuboutique.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20220331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20220331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20220331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abvc-20220331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet" id="abvc_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals" id="abvc_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement" id="abvc_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConsolidatedCashFlow" id="abvc_r_ConsolidatedCashFlow">
        <link:definition>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ShareholdersEquityType2or3" id="abvc_r_ShareholdersEquityType2or3">
        <link:definition>005 - Statement - Consolidated Statements of Stockholders&#8217; Equity (Deficit) (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusiness" id="abvc_r_OrganizationandDescriptionofBusiness">
        <link:definition>006 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies" id="abvc_r_SummaryofSignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/CollaborativeAgreements" id="abvc_r_CollaborativeAgreements">
        <link:definition>008 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/Inventory" id="abvc_r_Inventory">
        <link:definition>009 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PropertyandEquipment" id="abvc_r_PropertyandEquipment">
        <link:definition>010 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LongTermInvestments" id="abvc_r_LongTermInvestments">
        <link:definition>011 - Disclosure - Long-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConvertibleNotesPayable" id="abvc_r_ConvertibleNotesPayable">
        <link:definition>012 - Disclosure - Convertible Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BankLoans" id="abvc_r_BankLoans">
        <link:definition>013 - Disclosure - Bank Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable" id="abvc_r_PaycheckProtectionProgramLoanPayable">
        <link:definition>014 - Disclosure - Paycheck Protection Program Loan Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/NotesPayable" id="abvc_r_NotesPayable">
        <link:definition>015 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ShortTermLoan" id="abvc_r_ShortTermLoan">
        <link:definition>016 - Disclosure - Short-Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactions" id="abvc_r_RelatedPartiesTransactions">
        <link:definition>017 - Disclosure - Related Parties Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/Equity" id="abvc_r_Equity">
        <link:definition>018 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/StockOptions" id="abvc_r_StockOptions">
        <link:definition>019 - Disclosure - Stock Options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LossperShare" id="abvc_r_LossperShare">
        <link:definition>020 - Disclosure - Loss per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/Lease" id="abvc_r_Lease">
        <link:definition>021 - Disclosure - Lease</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BusinessCombination" id="abvc_r_BusinessCombination">
        <link:definition>022 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SubsequentEvents" id="abvc_r_SubsequentEvents">
        <link:definition>023 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/AccountingPoliciesByPolicy" id="abvc_r_AccountingPoliciesByPolicy">
        <link:definition>024 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables" id="abvc_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>025 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/InventoryTables" id="abvc_r_InventoryTables">
        <link:definition>026 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PropertyandEquipmentTables" id="abvc_r_PropertyandEquipmentTables">
        <link:definition>027 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LongTermInvestmentsTables" id="abvc_r_LongTermInvestmentsTables">
        <link:definition>028 - Disclosure - Long-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BankLoansTables" id="abvc_r_BankLoansTables">
        <link:definition>029 - Disclosure - Bank Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsTables" id="abvc_r_RelatedPartiesTransactionsTables">
        <link:definition>030 - Disclosure - Related Parties Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/EquityTables" id="abvc_r_EquityTables">
        <link:definition>031 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/StockOptionsTables" id="abvc_r_StockOptionsTables">
        <link:definition>032 - Disclosure - Stock Options (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LossperShareTables" id="abvc_r_LossperShareTables">
        <link:definition>033 - Disclosure - Loss per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LeaseTables" id="abvc_r_LeaseTables">
        <link:definition>034 - Disclosure - Lease (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BusinessCombinationTables" id="abvc_r_BusinessCombinationTables">
        <link:definition>035 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails" id="abvc_r_OrganizationandDescriptionofBusinessDetails">
        <link:definition>036 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails" id="abvc_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>037 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable" id="abvc_r_ScheduleofpropertyandequipmentusefullivesTable">
        <link:definition>038 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/CollaborativeAgreementsDetails" id="abvc_r_CollaborativeAgreementsDetails">
        <link:definition>039 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofinventoryTable" id="abvc_r_ScheduleofinventoryTable">
        <link:definition>040 - Disclosure - Inventory (Details) - Schedule of inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PropertyandEquipmentDetails" id="abvc_r_PropertyandEquipmentDetails">
        <link:definition>041 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable" id="abvc_r_ScheduleofpropertyandequipmentTable">
        <link:definition>042 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/LongTermInvestmentsDetails" id="abvc_r_LongTermInvestmentsDetails">
        <link:definition>043 - Disclosure - Long-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable" id="abvc_r_ScheduleofownershippercentagesofinvesteeTable">
        <link:definition>044 - Disclosure - Long-Term Investments (Details) - Schedule of ownership percentages of investee</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable" id="abvc_r_ScheduleofextenttheinvesteereliesTable">
        <link:definition>045 - Disclosure - Long-Term Investments (Details) - Schedule of extent the investee relies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleoflongterminvestmentTable" id="abvc_r_ScheduleoflongterminvestmentTable">
        <link:definition>046 - Disclosure - Long-Term Investments (Details) - Schedule of long-term investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofbalancesheetsTable" id="abvc_r_ScheduleofbalancesheetsTable">
        <link:definition>047 - Disclosure - Long-Term Investments (Details) - Schedule of balance sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofstatementsofoperationTable" id="abvc_r_ScheduleofstatementsofoperationTable">
        <link:definition>048 - Disclosure - Long-Term Investments (Details) - Schedule of statements of operation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofequityinvestmentsTable" id="abvc_r_ScheduleofequityinvestmentsTable">
        <link:definition>049 - Disclosure - Long-Term Investments (Details) - Schedule of equity investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ConvertibleNotesPayableDetails" id="abvc_r_ConvertibleNotesPayableDetails">
        <link:definition>050 - Disclosure - Convertible Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BankLoansDetails" id="abvc_r_BankLoansDetails">
        <link:definition>051 - Disclosure - Bank Loans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofshorttermbankloanTable" id="abvc_r_ScheduleofshorttermbankloanTable">
        <link:definition>052 - Disclosure - Bank Loans (Details) - Schedule of short-term bank loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails" id="abvc_r_PaycheckProtectionProgramLoanPayableDetails">
        <link:definition>053 - Disclosure - Paycheck Protection Program Loan Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/NotesPayableDetails" id="abvc_r_NotesPayableDetails">
        <link:definition>054 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ShortTermLoanDetails" id="abvc_r_ShortTermLoanDetails">
        <link:definition>055 - Disclosure - Short-Term Loan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails" id="abvc_r_RelatedPartiesTransactionsDetails">
        <link:definition>056 - Disclosure - Related Parties Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable" id="abvc_r_ScheduleofrelatedpartytransactionsTable">
        <link:definition>057 - Disclosure - Related Parties Transactions (Details) - Schedule of related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable" id="abvc_r_ScheduleofaccountsreceivableduefromrelatedpartiesTable">
        <link:definition>058 - Disclosure - Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable" id="abvc_r_ScheduleofamountduefromrelatedpartiesTable">
        <link:definition>059 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due from related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable" id="abvc_r_ScheduleofamountduetorelatedpartiesTable">
        <link:definition>060 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due to related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/EquityDetails" id="abvc_r_EquityDetails">
        <link:definition>061 - Disclosure - Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable" id="abvc_r_ScheduleofconvertedamountofdebtandsharesTable">
        <link:definition>062 - Disclosure - Equity (Details) - Schedule of converted amount of debt and shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/StockOptionsDetails" id="abvc_r_StockOptionsDetails">
        <link:definition>063 - Disclosure - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable" id="abvc_r_ScheduleofoptionsissuedandoutstandingTable">
        <link:definition>064 - Disclosure - Stock Options (Details) - Schedule of options issued and outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable" id="abvc_r_ScheduleoffairvalueofstockoptionsgrantedTable">
        <link:definition>065 - Disclosure - Stock Options (Details) - Schedule of fair value of stock options granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleoflosspershareTable" id="abvc_r_ScheduleoflosspershareTable">
        <link:definition>066 - Disclosure - Loss per Share (Details) - Schedule of loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable" id="abvc_r_ScheduleofoperatingleasearrangementsTable">
        <link:definition>067 - Disclosure - Lease (Details) - Schedule of operating lease arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable" id="abvc_r_ScheduleofsupplementalinformationrelatedtooperatingleasesTable">
        <link:definition>068 - Disclosure - Lease (Details) - Schedule of supplemental information related to operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable" id="abvc_r_ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable">
        <link:definition>069 - Disclosure - Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/BusinessCombinationDetails" id="abvc_r_BusinessCombinationDetails">
        <link:definition>070 - Disclosure - Business Combination (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable" id="abvc_r_ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable">
        <link:definition>071 - Disclosure - Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/SubsequentEventsDetails" id="abvc_r_SubsequentEventsDetails">
        <link:definition>072 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0TSgIZzBWwoovVOsFPEA4rNNrbY6CE8wmoa0q+lpRTxGk3c+CiJGsyWKrkLTTMjgQTYSxh3ggHe8DlX9qv/pk+ILYd8K5ojpQS7Wnderc/ZHXKbqwIYJ6fn4w3DUr83pk/Ae36rjZYf7IfdCX+CrVY=] CSR-->
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0" id="abvc_r_ScheduleofpropertyandequipmentusefullivesTable0">
        <link:definition>073 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofinventoryTable0" id="abvc_r_ScheduleofinventoryTable0">
        <link:definition>074 - Disclosure - Inventory (Details) - Schedule of inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0" id="abvc_r_ScheduleofpropertyandequipmentTable0">
        <link:definition>075 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0" id="abvc_r_ScheduleofownershippercentagesofinvesteeTable0">
        <link:definition>076 - Disclosure - Long-Term Investments (Details) - Schedule of ownership percentages of investee</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0" id="abvc_r_ScheduleofextenttheinvesteereliesTable0">
        <link:definition>077 - Disclosure - Long-Term Investments (Details) - Schedule of extent the investee relies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleoflongterminvestmentTable0" id="abvc_r_ScheduleoflongterminvestmentTable0">
        <link:definition>078 - Disclosure - Long-Term Investments (Details) - Schedule of long-term investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofbalancesheetsTable0" id="abvc_r_ScheduleofbalancesheetsTable0">
        <link:definition>079 - Disclosure - Long-Term Investments (Details) - Schedule of balance sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofstatementsofoperationTable0" id="abvc_r_ScheduleofstatementsofoperationTable0">
        <link:definition>080 - Disclosure - Long-Term Investments (Details) - Schedule of statements of operation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofequityinvestmentsTable0" id="abvc_r_ScheduleofequityinvestmentsTable0">
        <link:definition>081 - Disclosure - Long-Term Investments (Details) - Schedule of equity investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofshorttermbankloanTable0" id="abvc_r_ScheduleofshorttermbankloanTable0">
        <link:definition>082 - Disclosure - Bank Loans (Details) - Schedule of short-term bank loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0" id="abvc_r_ScheduleofrelatedpartytransactionsTable0">
        <link:definition>083 - Disclosure - Related Parties Transactions (Details) - Schedule of related party transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0" id="abvc_r_ScheduleofaccountsreceivableduefromrelatedpartiesTable0">
        <link:definition>084 - Disclosure - Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0" id="abvc_r_ScheduleofamountduefromrelatedpartiesTable0">
        <link:definition>085 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due from related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0" id="abvc_r_ScheduleofamountduetorelatedpartiesTable0">
        <link:definition>086 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due to related parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0" id="abvc_r_ScheduleofconvertedamountofdebtandsharesTable0">
        <link:definition>087 - Disclosure - Equity (Details) - Schedule of converted amount of debt and shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0" id="abvc_r_ScheduleofoptionsissuedandoutstandingTable0">
        <link:definition>088 - Disclosure - Stock Options (Details) - Schedule of options issued and outstanding</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0" id="abvc_r_ScheduleoffairvalueofstockoptionsgrantedTable0">
        <link:definition>089 - Disclosure - Stock Options (Details) - Schedule of fair value of stock options granted</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleoflosspershareTable0" id="abvc_r_ScheduleoflosspershareTable0">
        <link:definition>090 - Disclosure - Loss Per Share (Details) - Schedule of loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0" id="abvc_r_ScheduleofoperatingleasearrangementsTable0">
        <link:definition>091 - Disclosure - Lease (Details) - Schedule of operating lease arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0" id="abvc_r_ScheduleofsupplementalinformationrelatedtooperatingleasesTable0">
        <link:definition>092 - Disclosure - Lease (Details) - Schedule of supplemental information related to operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0" id="abvc_r_ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0">
        <link:definition>093 - Disclosure - Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0" id="abvc_r_ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0">
        <link:definition>094 - Disclosure - Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://metuboutique.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentUsefulLivesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfPropertyAndEquipmentUsefulLivesAbstract"/>
  <xs:element name="ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfInventoryAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="LongTermInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LongTermInvestmentAbstract"/>
  <xs:element name="ScheduleOfOwnershipPercentagesOfInvesteeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfOwnershipPercentagesOfInvesteeAbstract"/>
  <xs:element name="ScheduleOfExtentTheInvesteeReliesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfExtentTheInvesteeReliesAbstract"/>
  <xs:element name="ScheduleOfLongTermInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfLongTermInvestmentAbstract"/>
  <xs:element name="ScheduleOfBalanceSheetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfBalanceSheetsAbstract"/>
  <xs:element name="ScheduleOfStatementsOfOperationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfStatementsOfOperationAbstract"/>
  <xs:element name="ScheduleOfEquityInvestmentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfEquityInvestmentsAbstract"/>
  <xs:element name="ConvertibleNotesPayableDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConvertibleNotesPayableDisclosureAbstract"/>
  <xs:element name="BankLoansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BankLoansAbstract"/>
  <xs:element name="ScheduleOfShortTermBankLoanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfShortTermBankLoanAbstract"/>
  <xs:element name="PaycheckProtectionProgramLoanPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PaycheckProtectionProgramLoanPayableAbstract"/>
  <xs:element name="ScheduleOfRelatedPartyTransactionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfRelatedPartyTransactionsAbstract"/>
  <xs:element name="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfAmountDueFromRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfAmountDueFromRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfAmountDueToRelatedPartiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
  <xs:element name="ScheduleOfConvertedAmountOfDebtAndSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfConvertedAmountOfDebtAndSharesAbstract"/>
  <xs:element name="StockOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockOptionsAbstract"/>
  <xs:element name="ScheduleOfOptionsIssuedAndOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfOptionsIssuedAndOutstandingAbstract"/>
  <xs:element name="ScheduleOfFairValueOfStockOptionsGrantedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
  <xs:element name="ScheduleOfLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfLossPerShareAbstract"/>
  <xs:element name="ScheduleOfOperatingLeaseArrangementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfOperatingLeaseArrangementsAbstract"/>
  <xs:element name="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
  <xs:element name="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
  <xs:element name="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
  <xs:element name="NonMarketableCostMethodInvestmentsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NonMarketableCostMethodInvestmentsNetAbstract"/>
  <xs:element name="EquityMethodInvestmentsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_EquityMethodInvestmentsNetAbstract"/>
  <xs:element name="NumeratorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NumeratorAbstract"/>
  <xs:element name="DenominatorAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DenominatorAbstract"/>
  <xs:element name="WeightedAverageSharesOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageSharesOutstandingAbstract"/>
  <xs:element name="LossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LossPerShareAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageRemainingLeaseTermAbstract"/>
  <xs:element name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageDiscountRateAbstract"/>
  <xs:element name="PurchaseConsiderationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PurchaseConsiderationAbstract"/>
  <xs:element name="AllocationOfThePurchasePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AllocationOfThePurchasePriceAbstract"/>
  <xs:element name="NonMarketableCostMethodInvestmentsNetAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NonMarketableCostMethodInvestmentsNetAbstract0"/>
  <xs:element name="EquityMethodInvestmentsNetAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_EquityMethodInvestmentsNetAbstract0"/>
  <xs:element name="NumeratorAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NumeratorAbstract0"/>
  <xs:element name="DenominatorAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DenominatorAbstract0"/>
  <xs:element name="WeightedAverageSharesOutstandingAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageSharesOutstandingAbstract0"/>
  <xs:element name="LossPerShareAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LossPerShareAbstract0"/>
  <xs:element name="WeightedAverageRemainingLeaseTermAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageRemainingLeaseTermAbstract0"/>
  <xs:element name="WeightedAverageDiscountRateAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageDiscountRateAbstract0"/>
  <xs:element name="PurchaseConsiderationAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PurchaseConsiderationAbstract0"/>
  <xs:element name="AllocationOfThePurchasePriceAbstract0" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AllocationOfThePurchasePriceAbstract0"/>
  <xs:element name="PrepaymentForLongtermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_PrepaymentForLongtermInvestments"/>
  <xs:element name="AdvanceFromCustomers" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdvanceFromCustomers"/>
  <xs:element name="InterestIncomes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_InterestIncomes"/>
  <xs:element name="RentIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_RentIncome"/>
  <xs:element name="OperatingSubleaseIncomeRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingSubleaseIncomeRelatedParties"/>
  <xs:element name="GainLossOnForeignExchangeChanges" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_GainLossOnForeignExchangeChanges"/>
  <xs:element name="NetLossAttributableToAbvcAndSubsidiaries" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_NetLossAttributableToAbvcAndSubsidiaries"/>
  <xs:element name="GovernmentGrantIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_GovernmentGrantIncome"/>
  <xs:element name="InvestmentLoss1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_InvestmentLoss1"/>
  <xs:element name="BorrowingsFromRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_BorrowingsFromRelatedParties"/>
  <xs:element name="CumulativeTransactionAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_CumulativeTransactionAdjustments"/>
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution"/>
  <xs:element name="AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution"/>
  <xs:element name="StockIssuedDuringPeriodValueShareBasedCompensationServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices"/>
  <xs:element name="StockIssuedDuringPeriodShareBasedCompensationServicesforShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
  <xs:element name="CollaborativeAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_CollaborativeAgreementsTable"/>
  <xs:element name="CollaborativeAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CollaborativeAgreementsLineItems"/>
  <xs:element name="LongTermInvestmentTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LongTermInvestmentTextBlock"/>
  <xs:element name="ConvertibleNotesPayableDisclosureTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConvertibleNotesPayableDisclosureTextBlock"/>
  <xs:element name="BankLoansTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BankLoansTextBlock"/>
  <xs:element name="PaycheckProtectionProgramLoanPayableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PaycheckProtectionProgramLoanPayableTextBlock"/>
  <xs:element name="NotesPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_NotesPayableTable"/>
  <xs:element name="NotesPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NotesPayableLineItems"/>
  <xs:element name="StockOptionsTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockOptionsTextBlock"/>
  <xs:element name="OperatingLeasesOfLesseeDisclosuresTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock"/>
  <xs:element name="ForwardStockSplitsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ForwardStockSplitsPolicyTextBlock"/>
  <xs:element name="StockReverseSplitPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockReverseSplitPolicyTextBlock"/>
  <xs:element name="LongTermEquityInvestmentPolicy" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LongTermEquityInvestmentPolicy"/>
  <xs:element name="OtherThanTemporaryImpairmentPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OtherThanTemporaryImpairmentPolicyTextBlock"/>
  <xs:element name="BeneficialConversionFeature" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BeneficialConversionFeature"/>
  <xs:element name="ValuationOfDeferredTaxAssetsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
  <xs:element name="TranslationAdjustmentPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TranslationAdjustmentPolicyTextBlock"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
  <xs:element name="ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"/>
  <xs:element name="ScheduleOfExtentInvesteeReliesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock"/>
  <xs:element name="ScheduleOfLongTermInvestmentTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfLongTermInvestmentTableTextBlock"/>
  <xs:element name="ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"/>
  <xs:element name="ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"/>
  <xs:element name="StockOptionsTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_StockOptionsTablesTable"/>
  <xs:element name="StockOptionsTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockOptionsTablesLineItems"/>
  <xs:element name="ScheduleOfOperatingLeaseArrangementsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock"/>
  <xs:element name="ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems"/>
  <xs:element name="AllowanceForInventoryValuationAndObsolescenceLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AllowanceForInventoryValuationAndObsolescenceLoss"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
  <xs:element name="AccountingTreatmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AccountingTreatmentDescription"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
  <xs:element name="RelatedPartyTransactionDescriptionOfTransactions" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
  <xs:element name="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
  <xs:element name="NonmarketableCostMethodInvestmentsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_NonmarketableCostMethodInvestmentsNet"/>
  <xs:element name="NetSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_NetSales"/>
  <xs:element name="GrossProfits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_GrossProfits"/>
  <xs:element name="LongTermInvestmentNetLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_LongTermInvestmentNetLoss"/>
  <xs:element name="ShareOfEquityMethodInvesteeLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareOfEquityMethodInvesteeLosses"/>
  <xs:element name="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
  <xs:element name="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
  <xs:element name="DueFromtheRelatedPartiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_DueFromtheRelatedPartiesCurrent"/>
  <xs:element name="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
  <xs:element name="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
  <xs:element name="DueToRelatedPartyCurrentAndNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_DueToRelatedPartyCurrentAndNoncurrent"/>
  <xs:element name="DebtConversionConvertedInstrumentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_DebtConversionConvertedInstrumentAmount"/>
  <xs:element name="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
  <xs:element name="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1"/>
  <xs:element name="WeightedaverageSharesOutstandingBasic" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedaverageSharesOutstandingBasic"/>
  <xs:element name="WeightedAverageNumberOfSharesDiluted" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WeightedAverageNumberOfSharesDiluted"/>
  <xs:element name="BasicLossPerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BasicLossPerShare"/>
  <xs:element name="OperatingLeaseLiabilitienoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingLeaseLiabilitienoncurrent"/>
  <xs:element name="OperatingLeasesFutureMinimumPaymentDueCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent"/>
  <xs:element name="OperatingLeasesFutureMinimumPaymentDueInTwoYears" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears"/>
  <xs:element name="OperatingLeasesFutureMinimumPaymentDueInThreeYears" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears"/>
  <xs:element name="OperatingLeasesFutureMinimumPaymentDueInFourYears" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears"/>
  <xs:element name="OperatingLeasesFutureMinimumPaymentDueThereafter" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter"/>
  <xs:element name="OperatingLeasesFutureMinimumPaymentDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OperatingLeasesFutureMinimumPaymentDue"/>
  <xs:element name="InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction"/>
  <xs:element name="PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
  <xs:element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
  <xs:element name="NetLoss1" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_NetLoss1"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_OrganizationandDescriptionofBusinessDetailsTable"/>
  <xs:element name="OrganizationandDescriptionofBusinessDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_OrganizationandDescriptionofBusinessDetailsLineItems"/>
  <xs:element name="CommonStockIssuedAfterStockSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CommonStockIssuedAfterStockSplit"/>
  <xs:element name="CommonStockIssuedBeforeStockSplit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CommonStockIssuedBeforeStockSplit"/>
  <xs:element name="PercentageOfCommonSharesIssuedAndOutstanding" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfCommonSharesIssuedAndOutstanding"/>
  <xs:element name="PercentageOfIssuedShareCapital" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfIssuedShareCapital"/>
  <xs:element name="ImpairmentOfEquityInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ImpairmentOfEquityInvestments"/>
  <xs:element name="LabourPensionFundPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LabourPensionFundPercentage"/>
  <xs:element name="PercentageOfMonthlyContribution" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfMonthlyContribution"/>
  <xs:element name="StockBasedCompensationForNonemployees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockBasedCompensationForNonemployees"/>
  <xs:element name="CollaborativeAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_CollaborativeAgreementsDetailsTable"/>
  <xs:element name="CollaborativeAgreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CollaborativeAgreementsDetailsLineItems"/>
  <xs:element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_MilestonePayments"/>
  <xs:element name="UpfrontCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_UpfrontCashPayment"/>
  <xs:element name="PercentageOfPaymentsUnderCodevelopmentAgreement" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
  <xs:element name="IssuanceOfStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_IssuanceOfStockValue"/>
  <xs:element name="MilestonePaymentsRoyaltyPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_MilestonePaymentsRoyaltyPercentage"/>
  <xs:element name="CollaborativeAgreementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CollaborativeAgreementsDescription"/>
  <xs:element name="AdditionCashPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdditionCashPayment"/>
  <xs:element name="CoDevAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CoDevAgreementDescription"/>
  <xs:element name="LongTermInvestmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_LongTermInvestmentsDetailsTable"/>
  <xs:element name="LongTermInvestmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LongTermInvestmentsDetailsLineItems"/>
  <xs:element name="PurchaseAdditionalShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PurchaseAdditionalShares"/>
  <xs:element name="ConvertibleNotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_ConvertibleNotesPayableDetailsTable"/>
  <xs:element name="ConvertibleNotesPayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConvertibleNotesPayableDetailsLineItems"/>
  <xs:element name="AggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AggregatePrincipalAmount"/>
  <xs:element name="SharesOfferingPricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_SharesOfferingPricePercentage"/>
  <xs:element name="AggregatePrincipalAndAccruedInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AggregatePrincipalAndAccruedInterestExpense"/>
  <xs:element name="PublicEquityOfferingExceedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_PublicEquityOfferingExceedAmount"/>
  <xs:element name="SharesIssued1" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SharesIssued1"/>
  <xs:element name="ConvertiblePromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConvertiblePromissoryNote"/>
  <xs:element name="TotalInterestExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_TotalInterestExpenses"/>
  <xs:element name="TypeOfCurrencyDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TypeOfCurrencyDomain"/>
  <xs:element name="BankLoansDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_BankLoansDetailsTable"/>
  <xs:element name="BankLoansDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BankLoansDetailsLineItems"/>
  <xs:element name="principalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_principalAmount"/>
  <xs:element name="ReceivedLoanAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ReceivedLoanAmount"/>
  <xs:element name="RegularInterestRateDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RegularInterestRateDescription"/>
  <xs:element name="ExceedingAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ExceedingAmount"/>
  <xs:element name="PaycheckProtectionProgramLoanPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_PaycheckProtectionProgramLoanPayableDetailsTable"/>
  <xs:element name="PaycheckProtectionProgramLoanPayableDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems"/>
  <xs:element name="LoanFromPaycheckProtectionProgram" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_LoanFromPaycheckProtectionProgram"/>
  <xs:element name="ForgivenAmountPercentageUsedForPayroll" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ForgivenAmountPercentageUsedForPayroll"/>
  <xs:element name="PromissoryNoteDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PromissoryNoteDescription"/>
  <xs:element name="LoanFromPaycheckProtectionPrograms" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_LoanFromPaycheckProtectionPrograms"/>
  <xs:element name="LoanAmout" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_LoanAmout"/>
  <xs:element name="UnsecuredLoanAgreementsDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_UnsecuredLoanAgreementsDescription"/>
  <xs:element name="RelatedPartiesTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_RelatedPartiesTransactionsDetailsTable"/>
  <xs:element name="RelatedPartiesTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RelatedPartiesTransactionsDetailsLineItems"/>
  <xs:element name="AccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AccruedInterest"/>
  <xs:element name="AggregateWorkingcapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_AggregateWorkingcapital"/>
  <xs:element name="LoanAgreementTotalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_LoanAgreementTotalAmount"/>
  <xs:element name="InterestRate" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_InterestRate"/>
  <xs:element name="DebtInstrumentAggregateAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_DebtInstrumentAggregateAmount"/>
  <xs:element name="AdvancesBearInterestDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdvancesBearInterestDescription"/>
  <xs:element name="OutstandingAdvanceFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OutstandingAdvanceFromRelatedParty"/>
  <xs:element name="LoanAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LoanAgreementDescription"/>
  <xs:element name="OutstandingPrincipalAndAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_OutstandingPrincipalAndAccruedInterest"/>
  <xs:element name="EquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_EquityDetailsTable"/>
  <xs:element name="EquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_EquityDetailsLineItems"/>
  <xs:element name="CommonStockShareAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_CommonStockShareAuthorized"/>
  <xs:element name="AgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AgreementDescription"/>
  <xs:element name="FinancialAmendmentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_FinancialAmendmentDescription"/>
  <xs:element name="Consultingagreementdescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_Consultingagreementdescription"/>
  <xs:element name="UnpaidConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_UnpaidConsultingFees"/>
  <xs:element name="StockIssuedValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockIssuedValue"/>
  <xs:element name="StockSubscriptionReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockSubscriptionReceivable"/>
  <xs:element name="PlacementAgentAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PlacementAgentAgreementDescription"/>
  <xs:element name="RestrictedCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_RestrictedCommonShares"/>
  <xs:element name="WarrantIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WarrantIssued"/>
  <xs:element name="WarrantTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WarrantTerm"/>
  <xs:element name="UnrestrictedCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_UnrestrictedCommonShares"/>
  <xs:element name="NumberOfInvestors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_NumberOfInvestors"/>
  <xs:element name="SharesIssuedPricePerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SharesIssuedPricePerShares"/>
  <xs:element name="IssuanceOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_IssuanceOfCommonStock"/>
  <xs:element name="AggregateCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AggregateCommonStockShares"/>
  <xs:element name="ConvertiblePromissoryNoteValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConvertiblePromissoryNoteValue"/>
  <xs:element name="DescriptionOfPublicOffering" type="xbrli:stringItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_DescriptionOfPublicOffering"/>
  <xs:element name="ConsultingAgreementDesciption" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConsultingAgreementDesciption"/>
  <xs:element name="StockOptionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_StockOptionsDetailsTable"/>
  <xs:element name="StockOptionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockOptionsDetailsLineItems"/>
  <xs:element name="ConversionPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConversionPrice"/>
  <xs:element name="ConsultingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConsultingFees"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants"/>
  <xs:element name="BusinessCombinationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_BusinessCombinationDetailsTable"/>
  <xs:element name="BusinessCombinationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BusinessCombinationDetailsLineItems"/>
  <xs:element name="PercentageOfGoodwill" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PercentageOfGoodwill"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abvc_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SubsequentEventsDetailsLineItems"/>
  <xs:element name="NumberOfDirectors" type="xbrli:integerItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_NumberOfDirectors"/>
  <xs:element name="GrantDateTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_GrantDateTerm"/>
  <xs:element name="WarrantsPurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_WarrantsPurchased"/>
  <xs:element name="ExercisableAtAPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_ExercisableAtAPricePerShare"/>
  <xs:element name="TermsOfAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TermsOfAgreementDescription"/>
  <xs:element name="MilestonePaymentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_MilestonePaymentDescription"/>
  <xs:element name="AdditionalSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abvc_AdditionalSharesOfCommonStock"/>
  <xs:element name="TypeOfCurrencyAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="abvc_TypeOfCurrencyAxis"/>
  <xs:element name="ABVCBioPharmaHKLimitedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ABVCBioPharmaHKLimitedMember"/>
  <xs:element name="AmkeyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AmkeyMember"/>
  <xs:element name="AmkeyVenturesLLCAmkeyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AmkeyVenturesLLCAmkeyMember"/>
  <xs:element name="ArticlesOfIncorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ArticlesOfIncorporationMember"/>
  <xs:element name="AsiaGeneCorporationtheAsiaGeneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AsiaGeneCorporationtheAsiaGeneMember"/>
  <xs:element name="AsiaGeneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AsiaGeneMember"/>
  <xs:element name="AsiangeneCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_AsiangeneCorporationMember"/>
  <xs:element name="BHKCoDevelopmentAggreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BHKCoDevelopmentAggreementMember"/>
  <xs:element name="BHKCoDevelopmentAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BHKCoDevelopmentAgreementMember"/>
  <xs:element name="BioFirstAustraliaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstAustraliaMember"/>
  <xs:element name="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
  <xs:element name="BioFirstCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstCorporationMember"/>
  <xs:element name="BioFirstCorporationtheBioFirstMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstCorporationtheBioFirstMember"/>
  <xs:element name="BioFirstMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstMember"/>
  <xs:element name="BioFirstStockPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioFirstStockPurchaseAgreementMember"/>
  <xs:element name="BioHopeKingCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioHopeKingCorporationMember"/>
  <xs:element name="BioKeyMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioKeyMember"/>
  <xs:element name="BioLiteJapanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioLiteJapanMember"/>
  <xs:element name="BioLiteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioLiteMember"/>
  <xs:element name="BioLiteTaiwanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BioLiteTaiwanMember"/>
  <xs:element name="BraingenesisBiotechnologyCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BraingenesisBiotechnologyCoLtdMember"/>
  <xs:element name="BuildingsAndLeaseholdImprovementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BuildingsAndLeaseholdImprovementsMember"/>
  <xs:element name="BusinessCombinationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_BusinessCombinationMember"/>
  <xs:element name="CTBCBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CTBCBankMember"/>
  <xs:element name="CathayBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CathayBankMember"/>
  <xs:element name="CathayUnitedBankMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CathayUnitedBankMember"/>
  <xs:element name="CathayUnitedLoanAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CathayUnitedLoanAgreementMember"/>
  <xs:element name="CodevelopmentagreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CodevelopmentagreementMember"/>
  <xs:element name="ConsultingAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ConsultingAgreementMember"/>
  <xs:element name="DueToEmployeeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DueToEmployeeMember"/>
  <xs:element name="DueToshareholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DueToshareholdersMember"/>
  <xs:element name="EugeneJiangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_EugeneJiangMember"/>
  <xs:element name="EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
  <xs:element name="GenePharmIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_GenePharmIncMember"/>
  <xs:element name="GenePharmInctheGenePharmMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_GenePharmInctheGenePharmMember"/>
  <xs:element name="GenepharmBiotechCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_GenepharmBiotechCorporationMember"/>
  <xs:element name="JIANGSMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_JIANGSMember"/>
  <xs:element name="KameyamaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_KameyamaMember"/>
  <xs:element name="KeypointMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_KeypointMember"/>
  <xs:element name="KeypointTechnologyLtdtheKeypointMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_KeypointTechnologyLtdtheKeypointMember"/>
  <xs:element name="KimhoConsultantsCoLtdtheKimhoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_KimhoConsultantsCoLtdtheKimhoMember"/>
  <xs:element name="LBGUSAInctheLBGUSAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LBGUSAInctheLBGUSAMember"/>
  <xs:element name="LBGUSAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LBGUSAMember"/>
  <xs:element name="LbgUsaIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LbgUsaIncMember"/>
  <xs:element name="LionArtsPromotionInctheLIONMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LionArtsPromotionInctheLIONMember"/>
  <xs:element name="LionArtsPromotionInctheLionArtsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LionArtsPromotionInctheLionArtsMember"/>
  <xs:element name="LionGeneCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LionGeneCorporationMember"/>
  <xs:element name="LionGeneCorporationtheLionGeneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LionGeneCorporationtheLionGeneMember"/>
  <xs:element name="LoanAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_LoanAgreementMember"/>
  <xs:element name="MergerAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_MergerAgreementMember"/>
  <xs:element name="MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember"/>
  <xs:element name="NTMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NTMember"/>
  <xs:element name="NonRelatedPartiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_NonRelatedPartiesMember"/>
  <xs:element name="PAYCHECKPROTECTIONPROGRAMMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_PAYCHECKPROTECTIONPROGRAMMember"/>
  <xs:element name="RgeneCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RgeneCorporationMember"/>
  <xs:element name="RgeneCorporationtheRgeneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RgeneCorporationtheRgeneMember"/>
  <xs:element name="RgeneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_RgeneMember"/>
  <xs:element name="SecuritiesPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SecuritiesPurchaseAgreementMember"/>
  <xs:element name="SeriesAWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SeriesAWarrantsMember"/>
  <xs:element name="SeriesBWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_SeriesBWarrantsMember"/>
  <xs:element name="ShareExchangeAgreementFourMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareExchangeAgreementFourMember"/>
  <xs:element name="ShareExchangeAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareExchangeAgreementMember"/>
  <xs:element name="ShareExchangeAgreementOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareExchangeAgreementOneMember"/>
  <xs:element name="ShareExchangeAgreementThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareExchangeAgreementThreeMember"/>
  <xs:element name="ShareExchangeAgreementTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ShareExchangeAgreementTwoMember"/>
  <xs:element name="StockSubscriptionReceivableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_StockSubscriptionReceivableMember"/>
  <xs:element name="TheJiangsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TheJiangsMember"/>
  <xs:element name="TwoThousandSixteenEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
  <xs:element name="UnsecuredConvertiblePromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_UnsecuredConvertiblePromissoryNoteMember"/>
  <xs:element name="ViewTradeSecuritiesIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_ViewTradeSecuritiesIncMember"/>
  <xs:element name="WallachBethCapitalLLCMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_WallachBethCapitalLLCMember"/>
  <xs:element name="YoshinobuOdairatheOdairaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_YoshinobuOdairatheOdairaMember"/>
  <xs:element name="YuanGeneCorporationtheYuanGeneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_YuanGeneCorporationtheYuanGeneMember"/>
  <xs:element name="YuanGeneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_YuanGeneMember"/>
  <xs:element name="YuangeneCorporationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_YuangeneCorporationMember"/>
  <xs:element name="CashPaidDuringYearForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_CashPaidDuringYearForAbstract"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abvc_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>abvc-20220331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 14 21:16:00 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedBalanceSheet" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedIncomeStatement" roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedCashFlow" roleURI="http://metuboutique.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentForLongtermInvestments" xlink:href="abvc-20220331.xsd#abvc_PrepaymentForLongtermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="abvc_PrepaymentForLongtermInvestments" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_AdvanceFromCustomers" xlink:href="abvc-20220331.xsd#abvc_AdvanceFromCustomers"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="abvc_AdvanceFromCustomers" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherShortTermBorrowings" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDepositLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_SecurityDepositLiability" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LoansPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <loc xlink:type="locator" xlink:label="abvc_InterestIncomes" xlink:href="abvc-20220331.xsd#abvc_InterestIncomes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="abvc_InterestIncomes" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_RentIncome" xlink:href="abvc-20220331.xsd#abvc_RentIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="abvc_RentIncome" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingSubleaseIncomeRelatedParties" xlink:href="abvc-20220331.xsd#abvc_OperatingSubleaseIncomeRelatedParties"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0TSgIZzBWwoovVOsFPEA4rNNrbY6CE8wmoa0q+lpRTxGk3c+CiJGsyWKrkLTTMjgQTYSxh3ggHe8DlX9qv/pk+ILYd8K5ojpQS7Wnderc/ZHXKbqwIYJ6fn4w3DUr83pqu4eI8XtFwg/13XoMk1QqU=] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="abvc_OperatingSubleaseIncomeRelatedParties" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_GainLossOnForeignExchangeChanges" xlink:href="abvc-20220331.xsd#abvc_GainLossOnForeignExchangeChanges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="abvc_GainLossOnForeignExchangeChanges" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_NonoperatingIncomeExpense" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherIncome" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_InterestExpense" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="abvc_NetLossAttributableToAbvcAndSubsidiaries" xlink:href="abvc-20220331.xsd#abvc_NetLossAttributableToAbvcAndSubsidiaries"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="abvc_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="abvc_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="abvc_NetLossAttributableToAbvcAndSubsidiaries" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_InvestmentLoss1" xlink:href="abvc-20220331.xsd#abvc_InvestmentLoss1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="abvc_InvestmentLoss1" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="abvc_GovernmentGrantIncome" xlink:href="abvc-20220331.xsd#abvc_GovernmentGrantIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="abvc_GovernmentGrantIncome" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abvc_BorrowingsFromRelatedParties" xlink:href="abvc-20220331.xsd#abvc_BorrowingsFromRelatedParties"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="abvc_BorrowingsFromRelatedParties" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromBankDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromBankDebt" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSubordinatedShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfSubordinatedShortTermDebt" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>abvc-20220331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 14 21:16:00 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedBalanceSheet" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedIncomeStatement" roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedCashFlow" roleURI="http://metuboutique.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ShareholdersEquityType2or3" roleURI="http://metuboutique.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_OrganizationandDescriptionofBusiness" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SummaryofSignificantAccountingPolicies" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_CollaborativeAgreements" roleURI="http://metuboutique.com/role/CollaborativeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_Inventory" roleURI="http://metuboutique.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PropertyandEquipment" roleURI="http://metuboutique.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LongTermInvestments" roleURI="http://metuboutique.com/role/LongTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConvertibleNotesPayable" roleURI="http://metuboutique.com/role/ConvertibleNotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BankLoans" roleURI="http://metuboutique.com/role/BankLoans"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PaycheckProtectionProgramLoanPayable" roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_NotesPayable" roleURI="http://metuboutique.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ShortTermLoan" roleURI="http://metuboutique.com/role/ShortTermLoan"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_RelatedPartiesTransactions" roleURI="http://metuboutique.com/role/RelatedPartiesTransactions"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_Equity" roleURI="http://metuboutique.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_StockOptions" roleURI="http://metuboutique.com/role/StockOptions"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LossperShare" roleURI="http://metuboutique.com/role/LossperShare"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_Lease" roleURI="http://metuboutique.com/role/Lease"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BusinessCombination" roleURI="http://metuboutique.com/role/BusinessCombination"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SubsequentEvents" roleURI="http://metuboutique.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_AccountingPoliciesByPolicy" roleURI="http://metuboutique.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_InventoryTables" roleURI="http://metuboutique.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PropertyandEquipmentTables" roleURI="http://metuboutique.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LongTermInvestmentsTables" roleURI="http://metuboutique.com/role/LongTermInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BankLoansTables" roleURI="http://metuboutique.com/role/BankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_RelatedPartiesTransactionsTables" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_EquityTables" roleURI="http://metuboutique.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_StockOptionsTables" roleURI="http://metuboutique.com/role/StockOptionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LossperShareTables" roleURI="http://metuboutique.com/role/LossperShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LeaseTables" roleURI="http://metuboutique.com/role/LeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BusinessCombinationTables" roleURI="http://metuboutique.com/role/BusinessCombinationTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofpropertyandequipmentusefullivesTable" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofinventoryTable" roleURI="http://metuboutique.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofpropertyandequipmentTable" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofownershippercentagesofinvesteeTable" roleURI="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofextenttheinvesteereliesTable" roleURI="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoflongterminvestmentTable" roleURI="http://metuboutique.com/role/ScheduleoflongterminvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofbalancesheetsTable" roleURI="http://metuboutique.com/role/ScheduleofbalancesheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofstatementsofoperationTable" roleURI="http://metuboutique.com/role/ScheduleofstatementsofoperationTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofequityinvestmentsTable" roleURI="http://metuboutique.com/role/ScheduleofequityinvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofshorttermbankloanTable" roleURI="http://metuboutique.com/role/ScheduleofshorttermbankloanTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofrelatedpartytransactionsTable" roleURI="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofaccountsreceivableduefromrelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofamountduefromrelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofamountduetorelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofconvertedamountofdebtandsharesTable" roleURI="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofoptionsissuedandoutstandingTable" roleURI="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoffairvalueofstockoptionsgrantedTable" roleURI="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoflosspershareTable" roleURI="http://metuboutique.com/role/ScheduleoflosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofoperatingleasearrangementsTable" roleURI="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofsupplementalinformationrelatedtooperatingleasesTable" roleURI="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable" roleURI="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable" roleURI="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofpropertyandequipmentusefullivesTable0" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofinventoryTable0" roleURI="http://metuboutique.com/role/ScheduleofinventoryTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofpropertyandequipmentTable0" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofownershippercentagesofinvesteeTable0" roleURI="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofextenttheinvesteereliesTable0" roleURI="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoflongterminvestmentTable0" roleURI="http://metuboutique.com/role/ScheduleoflongterminvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofbalancesheetsTable0" roleURI="http://metuboutique.com/role/ScheduleofbalancesheetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofstatementsofoperationTable0" roleURI="http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofequityinvestmentsTable0" roleURI="http://metuboutique.com/role/ScheduleofequityinvestmentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofshorttermbankloanTable0" roleURI="http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofrelatedpartytransactionsTable0" roleURI="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofaccountsreceivableduefromrelatedpartiesTable0" roleURI="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofamountduefromrelatedpartiesTable0" roleURI="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofamountduetorelatedpartiesTable0" roleURI="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofconvertedamountofdebtandsharesTable0" roleURI="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofoptionsissuedandoutstandingTable0" roleURI="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoffairvalueofstockoptionsgrantedTable0" roleURI="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoflosspershareTable0" roleURI="http://metuboutique.com/role/ScheduleoflosspershareTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofoperatingleasearrangementsTable0" roleURI="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofsupplementalinformationrelatedtooperatingleasesTable0" roleURI="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0" roleURI="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0" roleURI="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_OrganizationandDescriptionofBusinessDetails" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_CollaborativeAgreementsDetails" roleURI="http://metuboutique.com/role/CollaborativeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PropertyandEquipmentDetails" roleURI="http://metuboutique.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LongTermInvestmentsDetails" roleURI="http://metuboutique.com/role/LongTermInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConvertibleNotesPayableDetails" roleURI="http://metuboutique.com/role/ConvertibleNotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BankLoansDetails" roleURI="http://metuboutique.com/role/BankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PaycheckProtectionProgramLoanPayableDetails" roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_NotesPayableDetails" roleURI="http://metuboutique.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ShortTermLoanDetails" roleURI="http://metuboutique.com/role/ShortTermLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_RelatedPartiesTransactionsDetails" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_EquityDetails" roleURI="http://metuboutique.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_StockOptionsDetails" roleURI="http://metuboutique.com/role/StockOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BusinessCombinationDetails" roleURI="http://metuboutique.com/role/BusinessCombinationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SubsequentEventsDetails" roleURI="http://metuboutique.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#DocumentAndEntityInformation" roleURI="http://metuboutique.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentForLongtermInvestments" xlink:href="abvc-20220331.xsd#abvc_PrepaymentForLongtermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="abvc_PrepaymentForLongtermInvestments" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_SecurityDeposit" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherShortTermBorrowings" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableToBankCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdvanceFromCustomers" xlink:href="abvc-20220331.xsd#abvc_AdvanceFromCustomers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="abvc_AdvanceFromCustomers" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherNotesPayableCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LoansPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDepositLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_SecurityDepositLiability" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_EquityAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_InterestIncomes" xlink:href="abvc-20220331.xsd#abvc_InterestIncomes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="abvc_InterestIncomes" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RentIncome" xlink:href="abvc-20220331.xsd#abvc_RentIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="abvc_RentIncome" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingSubleaseIncomeRelatedParties" xlink:href="abvc-20220331.xsd#abvc_OperatingSubleaseIncomeRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="abvc_OperatingSubleaseIncomeRelatedParties" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GainLossOnForeignExchangeChanges" xlink:href="abvc-20220331.xsd#abvc_GainLossOnForeignExchangeChanges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="abvc_GainLossOnForeignExchangeChanges" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncome" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NetLossAttributableToAbvcAndSubsidiaries" xlink:href="abvc-20220331.xsd#abvc_NetLossAttributableToAbvcAndSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProfitLoss" xlink:to="abvc_NetLossAttributableToAbvcAndSubsidiaries" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_EarningsPerShareAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GovernmentGrantIncome" xlink:href="abvc-20220331.xsd#abvc_GovernmentGrantIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="abvc_GovernmentGrantIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_InvestmentLoss1" xlink:href="abvc-20220331.xsd#abvc_InvestmentLoss1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="abvc_InvestmentLoss1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSubordinatedShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfSubordinatedShortTermDebt" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromBankDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromBankDebt" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BorrowingsFromRelatedParties" xlink:href="abvc-20220331.xsd#abvc_BorrowingsFromRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="abvc_BorrowingsFromRelatedParties" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubscriptionReceivableMember" xlink:href="abvc-20220331.xsd#abvc_StockSubscriptionReceivableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abvc_StockSubscriptionReceivableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" xlink:href="abvc-20220331.xsd#abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" xlink:href="abvc-20220331.xsd#abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices" xlink:href="abvc-20220331.xsd#abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:href="abvc-20220331.xsd#abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CumulativeTransactionAdjustments" xlink:href="abvc-20220331.xsd#abvc_CumulativeTransactionAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abvc_CumulativeTransactionAdjustments" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreements">
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsLineItems" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsTable" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_CollaborativeAgreementsLineItems" xlink:to="abvc_CollaborativeAgreementsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestments">
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentAbstract" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentTextBlock" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentAbstract" xlink:to="abvc_LongTermInvestmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConvertibleNotesPayable">
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDisclosureAbstract" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDisclosureTextBlock" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDisclosureAbstract" xlink:to="abvc_ConvertibleNotesPayableDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoans">
    <loc xlink:type="locator" xlink:label="abvc_BankLoansAbstract" xlink:href="abvc-20220331.xsd#abvc_BankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_BankLoansTextBlock" xlink:href="abvc-20220331.xsd#abvc_BankLoansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansAbstract" xlink:to="abvc_BankLoansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable">
    <loc xlink:type="locator" xlink:label="abvc_PaycheckProtectionProgramLoanPayableAbstract" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_PaycheckProtectionProgramLoanPayableTextBlock" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableAbstract" xlink:to="abvc_PaycheckProtectionProgramLoanPayableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="abvc_NotesPayableLineItems" xlink:href="abvc-20220331.xsd#abvc_NotesPayableLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_NotesPayableTable" xlink:href="abvc-20220331.xsd#abvc_NotesPayableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_NotesPayableLineItems" xlink:to="abvc_NotesPayableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageNotesPayableDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_NotesPayableLineItems" xlink:to="us-gaap_MortgageNotesPayableDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShortTermLoan">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptions">
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsAbstract" xlink:href="abvc-20220331.xsd#abvc_StockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsTextBlock" xlink:href="abvc-20220331.xsd#abvc_StockOptionsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsAbstract" xlink:to="abvc_StockOptionsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LossperShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Lease">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesOfLesseeDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombination">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FiscalPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ForwardStockSplitsPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_ForwardStockSplitsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_ForwardStockSplitsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockReverseSplitPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_StockReverseSplitPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_StockReverseSplitPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermEquityInvestmentPolicy" xlink:href="abvc-20220331.xsd#abvc_LongTermEquityInvestmentPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_LongTermEquityInvestmentPolicy" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_OtherThanTemporaryImpairmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BeneficialConversionFeature" xlink:href="abvc-20220331.xsd#abvc_BeneficialConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_BeneficialConversionFeature" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TranslationAdjustmentPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_TranslationAdjustmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_TranslationAdjustmentPolicyTextBlock" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestmentsTables">
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentAbstract" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentAbstract" xlink:to="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfExtentInvesteeReliesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentAbstract" xlink:to="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLongTermInvestmentTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLongTermInvestmentTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentAbstract" xlink:to="abvc_ScheduleOfLongTermInvestmentTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoansTables">
    <loc xlink:type="locator" xlink:label="abvc_BankLoansAbstract" xlink:href="abvc-20220331.xsd#abvc_BankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtConversionsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfDebtConversionsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptionsTables">
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsTablesLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsTablesTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_StockOptionsTablesLineItems" xlink:to="abvc_StockOptionsTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_StockOptionsTablesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LossperShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LeaseTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombinationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable">
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:to="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BuildingsAndLeaseholdImprovementsMember" xlink:href="abvc-20220331.xsd#abvc_BuildingsAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="abvc_BuildingsAndLeaseholdImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfInventoryAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:href="abvc-20220331.xsd#abvc_AllowanceForInventoryValuationAndObsolescenceLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="abvc_AllowanceForInventoryValuationAndObsolescenceLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryGross" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BuildingsAndLeaseholdImprovementsMember" xlink:href="abvc-20220331.xsd#abvc_BuildingsAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="abvc_BuildingsAndLeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable">
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AccountingTreatmentDescription" xlink:href="abvc-20220331.xsd#abvc_AccountingTreatmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="abvc_AccountingTreatmentDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable">
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvc-20220331.xsd#abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="abvc_RelatedPartyTransactionDescriptionOfTransactions" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflongterminvestmentTable">
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract" xlink:href="abvc-20220331.xsd#abvc_NonMarketableCostMethodInvestmentsNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvc_NonMarketableCostMethodInvestmentsNetAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NonmarketableCostMethodInvestmentsNet" xlink:href="abvc-20220331.xsd#abvc_NonmarketableCostMethodInvestmentsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="abvc_NonmarketableCostMethodInvestmentsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityMethodInvestmentsNetAbstract" xlink:href="abvc-20220331.xsd#abvc_EquityMethodInvestmentsNetAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvc_EquityMethodInvestmentsNetAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityMethodInvestmentsNetAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofbalancesheetsTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityOther" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofstatementsofoperationTable">
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NetSales" xlink:href="abvc-20220331.xsd#abvc_NetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="abvc_NetSales" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GrossProfits" xlink:href="abvc-20220331.xsd#abvc_GrossProfits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="abvc_GrossProfits" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentNetLoss" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentNetLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="abvc_LongTermInvestmentNetLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofequityinvestmentsTable">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfEquityInvestmentsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfEquityInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareOfEquityMethodInvesteeLosses" xlink:href="abvc-20220331.xsd#abvc_ShareOfEquityMethodInvesteeLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfEquityInvestmentsAbstract" xlink:to="abvc_ShareOfEquityMethodInvesteeLosses" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofshorttermbankloanTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayUnitedBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCBankMember" xlink:href="abvc-20220331.xsd#abvc_CTBCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CTBCBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayBankMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstCorporationtheBioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationtheRgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneCorporationtheRgeneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YuanGeneCorporationtheYuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneCorporationtheYuanGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_YuanGeneCorporationtheYuanGeneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiaGeneCorporationtheAsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneCorporationtheAsiaGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AsiaGeneCorporationtheAsiaGeneMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EugeneJiangMember" xlink:href="abvc-20220331.xsd#abvc_EugeneJiangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_EugeneJiangMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_KeypointTechnologyLtdtheKeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointTechnologyLtdtheKeypointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_KeypointTechnologyLtdtheKeypointMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtsPromotionInctheLionArtsMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLionArtsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LionArtsPromotionInctheLionArtsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YoshinobuOdairatheOdairaMember" xlink:href="abvc-20220331.xsd#abvc_YoshinobuOdairatheOdairaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_YoshinobuOdairatheOdairaMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmInctheGenePharmMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_GenePharmInctheGenePharmMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:href="abvc-20220331.xsd#abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LBGUSAInctheLBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAInctheLBGUSAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LBGUSAInctheLBGUSAMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionGeneCorporationtheLionGeneMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationtheLionGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LionGeneCorporationtheLionGeneMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_KimhoConsultantsCoLtdtheKimhoMember" xlink:href="abvc-20220331.xsd#abvc_KimhoConsultantsCoLtdtheKimhoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_KimhoConsultantsCoLtdtheKimhoMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_TheJiangsMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AmkeyVenturesLLCAmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyVenturesLLCAmkeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AmkeyVenturesLLCAmkeyMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioLiteJapanMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ABVCBioPharmaHKLimitedMember" xlink:href="abvc-20220331.xsd#abvc_ABVCBioPharmaHKLimitedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_ABVCBioPharmaHKLimitedMember" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvc-20220331.xsd#abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_RelatedPartyTransactionDescriptionOfTransactions" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmIncMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_GenePharmIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AmkeyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstAustraliaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LBGUSAMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioLiteJapanMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_KeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_KeypointMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DueFromtheRelatedPartiesCurrent" xlink:href="abvc-20220331.xsd#abvc_DueFromtheRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="abvc_DueFromtheRelatedPartiesCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstAustraliaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AsiaGeneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_YuanGeneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_TheJiangsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DueToshareholdersMember" xlink:href="abvc-20220331.xsd#abvc_DueToshareholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_DueToshareholdersMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DueToRelatedPartyCurrentAndNoncurrent" xlink:href="abvc-20220331.xsd#abvc_DueToRelatedPartyCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="abvc_DueToRelatedPartyCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtsPromotionInctheLIONMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLIONMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_LionArtsPromotionInctheLIONMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionGeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_LionGeneCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_BioFirstCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_AsiangeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_AsiangeneCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YuangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_YuangeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_YuangeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_TheJiangsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtConversionConvertedInstrumentAmount" xlink:href="abvc-20220331.xsd#abvc_DebtConversionConvertedInstrumentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="abvc_DebtConversionConvertedInstrumentAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable">
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflosspershareTable">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLossPerShareAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_NumeratorAbstract" xlink:href="abvc-20220331.xsd#abvc_NumeratorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="abvc_NumeratorAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DenominatorAbstract" xlink:href="abvc-20220331.xsd#abvc_DenominatorAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="abvc_DenominatorAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedaverageSharesOutstandingBasic" xlink:href="abvc-20220331.xsd#abvc_WeightedaverageSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_DenominatorAbstract" xlink:to="abvc_WeightedaverageSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_DenominatorAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageNumberOfSharesDiluted" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageNumberOfSharesDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_DenominatorAbstract" xlink:to="abvc_WeightedAverageNumberOfSharesDiluted" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LossPerShareAbstract" xlink:href="abvc-20220331.xsd#abvc_LossPerShareAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="abvc_LossPerShareAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BasicLossPerShare" xlink:href="abvc-20220331.xsd#abvc_BasicLossPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LossPerShareAbstract" xlink:to="abvc_BasicLossPerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOperatingLeaseArrangementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeaseLiabilitienoncurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeaseLiabilitienoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="abvc_OperatingLeaseLiabilitienoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageRemainingLeaseTermAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageDiscountRateAbstract" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageDiscountRateAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="abvc_WeightedAverageDiscountRateAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDue" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" xlink:href="abvc-20220331.xsd#abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" xlink:href="abvc-20220331.xsd#abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseConsiderationAbstract" xlink:href="abvc-20220331.xsd#abvc_PurchaseConsiderationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="abvc_PurchaseConsiderationAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PurchaseConsiderationAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AllocationOfThePurchasePriceAbstract" xlink:href="abvc-20220331.xsd#abvc_AllocationOfThePurchasePriceAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="abvc_AllocationOfThePurchasePriceAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0">
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:to="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BuildingsAndLeaseholdImprovementsMember" xlink:href="abvc-20220331.xsd#abvc_BuildingsAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="abvc_BuildingsAndLeaseholdImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofinventoryTable0">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfInventoryAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0TSgIZzBWwoovVOsFPEA4rNNrbY6CE8wmoa0q+lpRTxGk3c+CiJGsyWKrkLTTMjgQTYSxh3ggHe8DlX9qv/pk+ILYd8K5ojpQS7Wnderc/ZHXKbqwIYJ6fn4w3DUr83poSHBe99OKyfvLnfrbUoLIU=] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:href="abvc-20220331.xsd#abvc_AllowanceForInventoryValuationAndObsolescenceLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="abvc_AllowanceForInventoryValuationAndObsolescenceLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LandMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BuildingsAndLeaseholdImprovementsMember" xlink:href="abvc-20220331.xsd#abvc_BuildingsAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="abvc_BuildingsAndLeaseholdImprovementsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0">
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AccountingTreatmentDescription" xlink:href="abvc-20220331.xsd#abvc_AccountingTreatmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="abvc_AccountingTreatmentDescription" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0">
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvc-20220331.xsd#abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="abvc_RelatedPartyTransactionDescriptionOfTransactions" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflongterminvestmentTable0">
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_GenepharmBiotechCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract0" xlink:href="abvc-20220331.xsd#abvc_NonMarketableCostMethodInvestmentsNetAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvc_NonMarketableCostMethodInvestmentsNetAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NonmarketableCostMethodInvestmentsNet" xlink:href="abvc-20220331.xsd#abvc_NonmarketableCostMethodInvestmentsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_NonMarketableCostMethodInvestmentsNetAbstract0" xlink:to="abvc_NonmarketableCostMethodInvestmentsNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityMethodInvestmentsNetAbstract0" xlink:href="abvc-20220331.xsd#abvc_EquityMethodInvestmentsNetAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvc_EquityMethodInvestmentsNetAbstract0" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityMethodInvestmentsNetAbstract0" xlink:to="us-gaap_EquityMethodInvestments" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofbalancesheetsTable0">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityOther" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofstatementsofoperationTable0">
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NetLoss1" xlink:href="abvc-20220331.xsd#abvc_NetLoss1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="abvc_NetLoss1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofequityinvestmentsTable0">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfEquityInvestmentsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfEquityInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareOfEquityMethodInvesteeLosses" xlink:href="abvc-20220331.xsd#abvc_ShareOfEquityMethodInvesteeLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfEquityInvestmentsAbstract" xlink:to="abvc_ShareOfEquityMethodInvesteeLosses" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofshorttermbankloanTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayUnitedBankMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCBankMember" xlink:href="abvc-20220331.xsd#abvc_CTBCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CTBCBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayBankMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstCorporationtheBioFirstMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationtheRgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneCorporationtheRgeneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YuanGeneCorporationtheYuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneCorporationtheYuanGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_YuanGeneCorporationtheYuanGeneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiaGeneCorporationtheAsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneCorporationtheAsiaGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AsiaGeneCorporationtheAsiaGeneMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EugeneJiangMember" xlink:href="abvc-20220331.xsd#abvc_EugeneJiangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_EugeneJiangMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_KeypointTechnologyLtdtheKeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointTechnologyLtdtheKeypointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_KeypointTechnologyLtdtheKeypointMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtsPromotionInctheLionArtsMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLionArtsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LionArtsPromotionInctheLionArtsMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YoshinobuOdairatheOdairaMember" xlink:href="abvc-20220331.xsd#abvc_YoshinobuOdairatheOdairaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_YoshinobuOdairatheOdairaMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmInctheGenePharmMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_GenePharmInctheGenePharmMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:href="abvc-20220331.xsd#abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LBGUSAInctheLBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAInctheLBGUSAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LBGUSAInctheLBGUSAMember" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionGeneCorporationtheLionGeneMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationtheLionGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LionGeneCorporationtheLionGeneMember" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_KimhoConsultantsCoLtdtheKimhoMember" xlink:href="abvc-20220331.xsd#abvc_KimhoConsultantsCoLtdtheKimhoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_KimhoConsultantsCoLtdtheKimhoMember" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AmkeyVenturesLLCAmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyVenturesLLCAmkeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AmkeyVenturesLLCAmkeyMember" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioLiteJapanMember" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvc-20220331.xsd#abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abvc_RelatedPartyTransactionDescriptionOfTransactions" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0">
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmIncMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_GenePharmIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AmkeyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AsiaGeneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstAustraliaMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioHopeKingCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LBGUSAMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioLiteJapanMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_KeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_KeypointMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DueFromtheRelatedPartiesCurrent" xlink:href="abvc-20220331.xsd#abvc_DueFromtheRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="abvc_DueFromtheRelatedPartiesCurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0">
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstAustraliaMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AsiaGeneMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_YuanGeneMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_TheJiangsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DueToshareholdersMember" xlink:href="abvc-20220331.xsd#abvc_DueToshareholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_DueToshareholdersMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DueToEmployeeMember" xlink:href="abvc-20220331.xsd#abvc_DueToEmployeeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_DueToEmployeeMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DueToRelatedPartyCurrentAndNoncurrent" xlink:href="abvc-20220331.xsd#abvc_DueToRelatedPartyCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="abvc_DueToRelatedPartyCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtsPromotionInctheLIONMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLIONMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_LionArtsPromotionInctheLIONMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LionGeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_LionGeneCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_BioFirstCorporationMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_AsiangeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_AsiangeneCorporationMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YuangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_YuangeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_YuangeneCorporationMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_TheJiangsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0">
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflosspershareTable0">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLossPerShareAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_NumeratorAbstract0" xlink:href="abvc-20220331.xsd#abvc_NumeratorAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="abvc_NumeratorAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_NumeratorAbstract0" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DenominatorAbstract0" xlink:href="abvc-20220331.xsd#abvc_DenominatorAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="abvc_DenominatorAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_DenominatorAbstract0" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_DenominatorAbstract0" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_DenominatorAbstract0" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LossPerShareAbstract0" xlink:href="abvc-20220331.xsd#abvc_LossPerShareAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="abvc_LossPerShareAbstract0" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LossPerShareAbstract0" xlink:to="us-gaap_EarningsPerShareBasic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LossPerShareAbstract0" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOperatingLeaseArrangementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeaseLiabilitienoncurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeaseLiabilitienoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="abvc_OperatingLeaseLiabilitienoncurrent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract0" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageRemainingLeaseTermAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract0" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract0" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageDiscountRateAbstract0" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageDiscountRateAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="abvc_WeightedAverageDiscountRateAbstract0" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_WeightedAverageDiscountRateAbstract0" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueThereafter"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDue" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" xlink:href="abvc-20220331.xsd#abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" xlink:href="abvc-20220331.xsd#abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0">
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseConsiderationAbstract0" xlink:href="abvc-20220331.xsd#abvc_PurchaseConsiderationAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="abvc_PurchaseConsiderationAbstract0" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PurchaseConsiderationAbstract0" xlink:to="us-gaap_TreasuryStockCommonValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AllocationOfThePurchasePriceAbstract0" xlink:href="abvc-20220331.xsd#abvc_AllocationOfThePurchasePriceAbstract0"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="abvc_AllocationOfThePurchasePriceAbstract0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails">
    <loc xlink:type="locator" xlink:label="abvc_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_OrganizationandDescriptionofBusinessDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:href="abvc-20220331.xsd#abvc_OrganizationandDescriptionofBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvc_OrganizationandDescriptionofBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementOneMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementTwoMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementFourMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementFourMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_MergerAgreementMember" xlink:href="abvc-20220331.xsd#abvc_MergerAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_MergerAgreementMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementThreeMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementThreeMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockIssuedAfterStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedAfterStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvc_CommonStockIssuedAfterStockSplit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockIssuedBeforeStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedBeforeStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvc_CommonStockIssuedBeforeStockSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfCommonSharesIssuedAndOutstanding" xlink:href="abvc-20220331.xsd#abvc_PercentageOfCommonSharesIssuedAndOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvc_PercentageOfCommonSharesIssuedAndOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfIssuedShareCapital" xlink:href="abvc-20220331.xsd#abvc_PercentageOfIssuedShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvc_PercentageOfIssuedShareCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Cash" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ImpairmentOfEquityInvestments" xlink:href="abvc-20220331.xsd#abvc_ImpairmentOfEquityInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_ImpairmentOfEquityInvestments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LabourPensionFundPercentage" xlink:href="abvc-20220331.xsd#abvc_LabourPensionFundPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_LabourPensionFundPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfMonthlyContribution" xlink:href="abvc-20220331.xsd#abvc_PercentageOfMonthlyContribution"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_PercentageOfMonthlyContribution" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockBasedCompensationForNonemployees" xlink:href="abvc-20220331.xsd#abvc_StockBasedCompensationForNonemployees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abvc_StockBasedCompensationForNonemployees" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanFundedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedBenefitPlanFundedPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreementsDetails">
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_CollaborativeAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BHKCoDevelopmentAgreementMember" xlink:href="abvc-20220331.xsd#abvc_BHKCoDevelopmentAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_BHKCoDevelopmentAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CodevelopmentagreementMember" xlink:href="abvc-20220331.xsd#abvc_CodevelopmentagreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_CodevelopmentagreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstStockPurchaseAgreementMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstStockPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_BioFirstStockPurchaseAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteTaiwanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteTaiwanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioLiteTaiwanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestonePayments" xlink:href="abvc-20220331.xsd#abvc_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_MilestonePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_UpfrontCashPayment" xlink:href="abvc-20220331.xsd#abvc_UpfrontCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_UpfrontCashPayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:href="abvc-20220331.xsd#abvc_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfStockValue" xlink:href="abvc-20220331.xsd#abvc_IssuanceOfStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_IssuanceOfStockValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage" xlink:href="abvc-20220331.xsd#abvc_MilestonePaymentsRoyaltyPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_MilestonePaymentsRoyaltyPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsDescription" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_CollaborativeAgreementsDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_PaymentsForParticipationLiabilities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdditionCashPayment" xlink:href="abvc-20220331.xsd#abvc_AdditionCashPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_AdditionCashPayment" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CoDevAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_CoDevAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_CoDevAgreementDescription" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OtherDepreciationAndAmortization" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestmentsDetails">
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_LongTermInvestmentsDetailsLineItems" xlink:to="abvc_LongTermInvestmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_LongTermInvestmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioFirstCorporationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_RgeneCorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseAdditionalShares" xlink:href="abvc-20220331.xsd#abvc_PurchaseAdditionalShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsLineItems" xlink:to="abvc_PurchaseAdditionalShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentForLongtermInvestments" xlink:href="abvc-20220331.xsd#abvc_PrepaymentForLongtermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsLineItems" xlink:to="abvc_PrepaymentForLongtermInvestments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConvertibleNotesPayableDetails">
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDetailsTable" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvc_ConvertibleNotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_UnsecuredConvertiblePromissoryNoteMember" xlink:href="abvc-20220331.xsd#abvc_UnsecuredConvertiblePromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_UnsecuredConvertiblePromissoryNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SecuritiesPurchaseAgreementMember" xlink:href="abvc-20220331.xsd#abvc_SecuritiesPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_SecuritiesPurchaseAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregatePrincipalAmount" xlink:href="abvc-20220331.xsd#abvc_AggregatePrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvc_AggregatePrincipalAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_StockIssued1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SharesOfferingPricePercentage" xlink:href="abvc-20220331.xsd#abvc_SharesOfferingPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvc_SharesOfferingPricePercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_CommonStockValueOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregatePrincipalAndAccruedInterestExpense" xlink:href="abvc-20220331.xsd#abvc_AggregatePrincipalAndAccruedInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvc_AggregatePrincipalAndAccruedInterestExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PublicEquityOfferingExceedAmount" xlink:href="abvc-20220331.xsd#abvc_PublicEquityOfferingExceedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvc_PublicEquityOfferingExceedAmount" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SharesIssued1" xlink:href="abvc-20220331.xsd#abvc_SharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvc_SharesIssued1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertiblePromissoryNote" xlink:href="abvc-20220331.xsd#abvc_ConvertiblePromissoryNote"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvc_ConvertiblePromissoryNote" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TotalInterestExpenses" xlink:href="abvc-20220331.xsd#abvc_TotalInterestExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvc_TotalInterestExpenses" order="24" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoansDetails">
    <loc xlink:type="locator" xlink:label="abvc_BankLoansDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_BankLoansDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_BankLoansDetailsTable" xlink:href="abvc-20220331.xsd#abvc_BankLoansDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="abvc_BankLoansDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_BankLoansDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_BankLoansDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TypeOfCurrencyAxis" xlink:href="abvc-20220331.xsd#abvc_TypeOfCurrencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_BankLoansDetailsTable" xlink:to="abvc_TypeOfCurrencyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TypeOfCurrencyDomain" xlink:href="abvc-20220331.xsd#abvc_TypeOfCurrencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="abvc_TypeOfCurrencyAxis" xlink:to="abvc_TypeOfCurrencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TypeOfCurrencyDomain_0" xlink:href="abvc-20220331.xsd#abvc_TypeOfCurrencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="abvc_TypeOfCurrencyAxis" xlink:to="abvc_TypeOfCurrencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteTaiwanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteTaiwanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_BioLiteTaiwanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NTMember" xlink:href="abvc-20220331.xsd#abvc_NTMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_TypeOfCurrencyDomain" xlink:to="abvc_NTMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedLoanAgreementMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedLoanAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayUnitedLoanAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayUnitedBankMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCBankMember" xlink:href="abvc-20220331.xsd#abvc_CTBCBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CTBCBankMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementMember" xlink:href="abvc-20220331.xsd#abvc_LoanAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_LoanAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_CathayBankMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_principalAmount" xlink:href="abvc-20220331.xsd#abvc_principalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="abvc_principalAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ReceivedLoanAmount" xlink:href="abvc-20220331.xsd#abvc_ReceivedLoanAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="abvc_ReceivedLoanAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RegularInterestRateDescription" xlink:href="abvc-20220331.xsd#abvc_RegularInterestRateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="abvc_RegularInterestRateDescription" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ExceedingAmount" xlink:href="abvc-20220331.xsd#abvc_ExceedingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="abvc_ExceedingAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="us-gaap_LongTermLineOfCredit" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPaymentTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails">
    <loc xlink:type="locator" xlink:label="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_PaycheckProtectionProgramLoanPayableDetailsTable" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvc_PaycheckProtectionProgramLoanPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PAYCHECKPROTECTIONPROGRAMMember" xlink:href="abvc-20220331.xsd#abvc_PAYCHECKPROTECTIONPROGRAMMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_PAYCHECKPROTECTIONPROGRAMMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanFromPaycheckProtectionProgram" xlink:href="abvc-20220331.xsd#abvc_LoanFromPaycheckProtectionProgram"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvc_LoanFromPaycheckProtectionProgram" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ForgivenAmountPercentageUsedForPayroll" xlink:href="abvc-20220331.xsd#abvc_ForgivenAmountPercentageUsedForPayroll"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvc_ForgivenAmountPercentageUsedForPayroll" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPaymentTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PromissoryNoteDescription" xlink:href="abvc-20220331.xsd#abvc_PromissoryNoteDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvc_PromissoryNoteDescription" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanFromPaycheckProtectionPrograms" xlink:href="abvc-20220331.xsd#abvc_LoanFromPaycheckProtectionPrograms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvc_LoanFromPaycheckProtectionPrograms" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAmout" xlink:href="abvc-20220331.xsd#abvc_LoanAmout"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvc_LoanAmout" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GovernmentGrantIncome" xlink:href="abvc-20220331.xsd#abvc_GovernmentGrantIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvc_GovernmentGrantIncome" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="abvc_UnsecuredLoanAgreementsDescription" xlink:href="abvc-20220331.xsd#abvc_UnsecuredLoanAgreementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="abvc_UnsecuredLoanAgreementsDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_OtherNotesPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseOther" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShortTermLoanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_UnsecuredDebt" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableWithFixedRatesOfInterest1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LoansReceivableWithFixedRatesOfInterest1" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsDetails">
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_YuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abvc_YuanGeneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="abvc_BioFirstAustraliaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AsiaGeneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioFirstAustraliaMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BHKCoDevelopmentAggreementMember" xlink:href="abvc-20220331.xsd#abvc_BHKCoDevelopmentAggreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BHKCoDevelopmentAggreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LbgUsaIncMember" xlink:href="abvc-20220331.xsd#abvc_LbgUsaIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_LbgUsaIncMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_BioLiteJapanMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_KeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_KeypointMember" order="6" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_YuanGeneMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_JIANGSMember" xlink:href="abvc-20220331.xsd#abvc_JIANGSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_JIANGSMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_RgeneCorporationMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_AsiangeneCorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_AsiangeneCorporationMember" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AccruedInterest" xlink:href="abvc-20220331.xsd#abvc_AccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_AccruedInterest" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromAffiliateNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromAffiliateNoncurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregateWorkingcapital" xlink:href="abvc-20220331.xsd#abvc_AggregateWorkingcapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_AggregateWorkingcapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementTotalAmount" xlink:href="abvc-20220331.xsd#abvc_LoanAgreementTotalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_LoanAgreementTotalAmount" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_InterestRate" xlink:href="abvc-20220331.xsd#abvc_InterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_InterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentAggregateAmount" xlink:href="abvc-20220331.xsd#abvc_DebtInstrumentAggregateAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_DebtInstrumentAggregateAmount" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromEmployeesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromEmployeesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromEmployeesNoncurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdvancesBearInterestDescription" xlink:href="abvc-20220331.xsd#abvc_AdvancesBearInterestDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_AdvancesBearInterestDescription" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingAdvanceFromRelatedParty" xlink:href="abvc-20220331.xsd#abvc_OutstandingAdvanceFromRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_OutstandingAdvanceFromRelatedParty" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_LoanAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_LoanAgreementDescription" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingPrincipalAndAccruedInterest" xlink:href="abvc-20220331.xsd#abvc_OutstandingPrincipalAndAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_OutstandingPrincipalAndAccruedInterest" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_InterestExpenseRelatedParty" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromOtherRelatedParties" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageRateForeignDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageRateForeignDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_WeightedAverageRateForeignDeposit" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="22" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="abvc_EquityDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_EquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityDetailsTable" xlink:href="abvc-20220331.xsd#abvc_EquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_EquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="srt_RangeAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementOneMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementOneMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementTwoMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementTwoMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementThreeMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementThreeMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementFourMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementFourMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ShareExchangeAgreementFourMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CodevelopmentagreementMember" xlink:href="abvc-20220331.xsd#abvc_CodevelopmentagreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_CodevelopmentagreementMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultingAgreementMember" xlink:href="abvc-20220331.xsd#abvc_ConsultingAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abvc_ConsultingAgreementMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20220331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abvc_TwoThousandSixteenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SeriesAWarrantsMember" xlink:href="abvc-20220331.xsd#abvc_SeriesAWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abvc_SeriesAWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SeriesBWarrantsMember" xlink:href="abvc-20220331.xsd#abvc_SeriesBWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abvc_SeriesBWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abvc_BioLiteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioKeyMember" xlink:href="abvc-20220331.xsd#abvc_BioKeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abvc_BioKeyMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_KameyamaMember" xlink:href="abvc-20220331.xsd#abvc_KameyamaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_KameyamaMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ArticlesOfIncorporationMember" xlink:href="abvc-20220331.xsd#abvc_ArticlesOfIncorporationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_ArticlesOfIncorporationMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ViewTradeSecuritiesIncMember" xlink:href="abvc-20220331.xsd#abvc_ViewTradeSecuritiesIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_ViewTradeSecuritiesIncMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WallachBethCapitalLLCMember" xlink:href="abvc-20220331.xsd#abvc_WallachBethCapitalLLCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_WallachBethCapitalLLCMember" order="3" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_ConsultingAgreementMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NonRelatedPartiesMember" xlink:href="abvc-20220331.xsd#abvc_NonRelatedPartiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abvc_NonRelatedPartiesMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockIssuedAfterStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedAfterStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_CommonStockIssuedAfterStockSplit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockIssuedBeforeStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedBeforeStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_CommonStockIssuedBeforeStockSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfIssuedShareCapital" xlink:href="abvc-20220331.xsd#abvc_PercentageOfIssuedShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_PercentageOfIssuedShareCapital" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockShareAuthorized" xlink:href="abvc-20220331.xsd#abvc_CommonStockShareAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_CommonStockShareAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AgreementDescription" xlink:href="abvc-20220331.xsd#abvc_AgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_AgreementDescription" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_FinancialAmendmentDescription" xlink:href="abvc-20220331.xsd#abvc_FinancialAmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_FinancialAmendmentDescription" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_Consultingagreementdescription" xlink:href="abvc-20220331.xsd#abvc_Consultingagreementdescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_Consultingagreementdescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_UnpaidConsultingFees" xlink:href="abvc-20220331.xsd#abvc_UnpaidConsultingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_UnpaidConsultingFees" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedValue" xlink:href="abvc-20220331.xsd#abvc_StockIssuedValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_StockIssuedValue" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyAgreementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntercompanyAgreementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_IntercompanyAgreementsDescription" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubscriptionReceivable" xlink:href="abvc-20220331.xsd#abvc_StockSubscriptionReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_StockSubscriptionReceivable" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PlacementAgentAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_PlacementAgentAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_PlacementAgentAgreementDescription" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_RestrictedCommonShares" xlink:href="abvc-20220331.xsd#abvc_RestrictedCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_RestrictedCommonShares" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WarrantIssued" xlink:href="abvc-20220331.xsd#abvc_WarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_WarrantIssued" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WarrantTerm" xlink:href="abvc-20220331.xsd#abvc_WarrantTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_WarrantTerm" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_UnrestrictedCommonShares" xlink:href="abvc-20220331.xsd#abvc_UnrestrictedCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_UnrestrictedCommonShares" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NumberOfInvestors" xlink:href="abvc-20220331.xsd#abvc_NumberOfInvestors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_NumberOfInvestors" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_SharesIssuedPricePerShares" xlink:href="abvc-20220331.xsd#abvc_SharesIssuedPricePerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_SharesIssuedPricePerShares" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfCommonStock" xlink:href="abvc-20220331.xsd#abvc_IssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_IssuanceOfCommonStock" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:href="abvc-20220331.xsd#abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregateCommonStockShares" xlink:href="abvc-20220331.xsd#abvc_AggregateCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_AggregateCommonStockShares" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertiblePromissoryNoteValue" xlink:href="abvc-20220331.xsd#abvc_ConvertiblePromissoryNoteValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_ConvertiblePromissoryNoteValue" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_DescriptionOfPublicOffering" xlink:href="abvc-20220331.xsd#abvc_DescriptionOfPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_DescriptionOfPublicOffering" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_LegalFees" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultingAgreementDesciption" xlink:href="abvc-20220331.xsd#abvc_ConsultingAgreementDesciption"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_ConsultingAgreementDesciption" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityListingParValuePerShare" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingParValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="dei_EntityListingParValuePerShare" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyShareholderServiceFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyShareholderServiceFeeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_EquityDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyShareholderServiceFeeExpense" order="50" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptionsDetails">
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="abvc_StockOptionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_StockOptionsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20220331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abvc_TwoThousandSixteenEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConversionPrice" xlink:href="abvc-20220331.xsd#abvc_ConversionPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="abvc_ConversionPrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultingFees" xlink:href="abvc-20220331.xsd#abvc_ConsultingFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="abvc_ConsultingFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:href="abvc-20220331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombinationDetails">
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationDetailsTable" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_BusinessCombinationDetailsLineItems" xlink:to="abvc_BusinessCombinationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_BusinessCombinationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_BusinessCombinationDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationMember" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="abvc_BusinessCombinationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_BioKeyMember" xlink:href="abvc-20220331.xsd#abvc_BioKeyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abvc_BioKeyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BusinessCombinationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockIssuedAfterStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedAfterStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BusinessCombinationDetailsLineItems" xlink:to="abvc_CommonStockIssuedAfterStockSplit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BusinessCombinationDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfGoodwill" xlink:href="abvc-20220331.xsd#abvc_PercentageOfGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BusinessCombinationDetailsLineItems" xlink:to="abvc_PercentageOfGoodwill" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_BusinessCombinationDetailsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="abvc_SubsequentEventsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="abvc_SubsequentEventsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="abvc_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_NumberOfDirectors" xlink:href="abvc-20220331.xsd#abvc_NumberOfDirectors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="abvc_NumberOfDirectors" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_GrantDateTerm" xlink:href="abvc-20220331.xsd#abvc_GrantDateTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="abvc_GrantDateTerm" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_WarrantsPurchased" xlink:href="abvc-20220331.xsd#abvc_WarrantsPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="abvc_WarrantsPurchased" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_ExercisableAtAPricePerShare" xlink:href="abvc-20220331.xsd#abvc_ExercisableAtAPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="abvc_ExercisableAtAPricePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_TermsOfAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_TermsOfAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="abvc_TermsOfAgreementDescription" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestonePaymentDescription" xlink:href="abvc-20220331.xsd#abvc_MilestonePaymentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="abvc_MilestonePaymentDescription" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abvc_AdditionalSharesOfCommonStock" xlink:href="abvc-20220331.xsd#abvc_AdditionalSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="abvc_AdditionalSharesOfCommonStock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseInvestmentAdvisoryFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://metuboutique.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="10" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>abvc-20220331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 14 21:16:00 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrossProfit_lbl0" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before provision income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NetLossAttributableToAbvcAndSubsidiaries" xlink:href="abvc-20220331.xsd#abvc_NetLossAttributableToAbvcAndSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="abvc_NetLossAttributableToAbvcAndSubsidiaries_lbl" xml:lang="en-US">Net loss attributed to ABVC and subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="abvc_NetLossAttributableToAbvcAndSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfPropertyAndEquipmentUsefulLivesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfPropertyAndEquipmentUsefulLivesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfPropertyAndEquipmentUsefulLivesAbstract_lbl" xml:lang="en-US">Schedule of property and equipment useful lives [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfPropertyAndEquipmentUsefulLivesAbstract" xlink:to="abvc_ScheduleOfPropertyAndEquipmentUsefulLivesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfInventoryAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfInventoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfInventoryAbstract_lbl" xml:lang="en-US">Schedule of inventory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfInventoryAbstract" xlink:to="abvc_ScheduleOfInventoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of property and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="abvc_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentAbstract" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentAbstract_lbl" xml:lang="en-US">Long Term Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentAbstract" xlink:to="abvc_LongTermInvestmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOwnershipPercentagesOfInvesteeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfOwnershipPercentagesOfInvesteeAbstract_lbl" xml:lang="en-US">Schedule of ownership percentages of investee [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:to="abvc_ScheduleOfOwnershipPercentagesOfInvesteeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfExtentTheInvesteeReliesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfExtentTheInvesteeReliesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfExtentTheInvesteeReliesAbstract_lbl" xml:lang="en-US">Schedule of extent the investee relies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfExtentTheInvesteeReliesAbstract" xlink:to="abvc_ScheduleOfExtentTheInvesteeReliesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLongTermInvestmentAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLongTermInvestmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfLongTermInvestmentAbstract_lbl" xml:lang="en-US">Schedule of long-term investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfLongTermInvestmentAbstract" xlink:to="abvc_ScheduleOfLongTermInvestmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfBalanceSheetsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfBalanceSheetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfBalanceSheetsAbstract_lbl" xml:lang="en-US">Schedule of balance sheets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfBalanceSheetsAbstract" xlink:to="abvc_ScheduleOfBalanceSheetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfStatementsOfOperationAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfStatementsOfOperationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfStatementsOfOperationAbstract_lbl" xml:lang="en-US">Schedule of statements of operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfStatementsOfOperationAbstract" xlink:to="abvc_ScheduleOfStatementsOfOperationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfEquityInvestmentsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfEquityInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfEquityInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of equity investments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfEquityInvestmentsAbstract" xlink:to="abvc_ScheduleOfEquityInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDisclosureAbstract" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertibleNotesPayableDisclosureAbstract_lbl" xml:lang="en-US">Convertible Notes Payable Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayableDisclosureAbstract" xlink:to="abvc_ConvertibleNotesPayableDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BankLoansAbstract" xlink:href="abvc-20220331.xsd#abvc_BankLoansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BankLoansAbstract_lbl" xml:lang="en-US">Bank Loans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BankLoansAbstract" xlink:to="abvc_BankLoansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfShortTermBankLoanAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfShortTermBankLoanAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfShortTermBankLoanAbstract_lbl" xml:lang="en-US">Schedule of short-term bank loan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfShortTermBankLoanAbstract" xlink:to="abvc_ScheduleOfShortTermBankLoanAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PaycheckProtectionProgramLoanPayableAbstract" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PaycheckProtectionProgramLoanPayableAbstract_lbl" xml:lang="en-US">Paycheck Protection Program Loan Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PaycheckProtectionProgramLoanPayableAbstract" xlink:to="abvc_PaycheckProtectionProgramLoanPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfRelatedPartyTransactionsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfRelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfRelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Schedule of related party transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfRelatedPartyTransactionsAbstract" xlink:to="abvc_ScheduleOfRelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of accounts receivable due from related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:to="abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAmountDueFromRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfAmountDueFromRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of amount due from related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:to="abvc_ScheduleOfAmountDueFromRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract_lbl" xml:lang="en-US">Schedule of amount due to related parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:to="abvc_ScheduleOfAmountDueToRelatedPartiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfConvertedAmountOfDebtAndSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfConvertedAmountOfDebtAndSharesAbstract_lbl" xml:lang="en-US">Schedule of converted amount of debt and shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:to="abvc_ScheduleOfConvertedAmountOfDebtAndSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsAbstract" xlink:href="abvc-20220331.xsd#abvc_StockOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockOptionsAbstract_lbl" xml:lang="en-US">Stock Options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsAbstract" xlink:to="abvc_StockOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOptionsIssuedAndOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfOptionsIssuedAndOutstandingAbstract_lbl" xml:lang="en-US">Schedule of options issued and outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:to="abvc_ScheduleOfOptionsIssuedAndOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0" xml:lang="en-US">Number of Underlying Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract_lbl" xml:lang="en-US">Schedule of fair value of stock options granted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Net loss per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLossPerShareAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of loss per share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfLossPerShareAbstract" xlink:to="abvc_ScheduleOfLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOperatingLeaseArrangementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfOperatingLeaseArrangementsAbstract_lbl" xml:lang="en-US">Schedule of operating lease arrangements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="abvc_ScheduleOfOperatingLeaseArrangementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract_lbl" xml:lang="en-US">Schedule of supplemental information related to operating leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract_lbl" xml:lang="en-US">Schedule of minimum future annual payments under non-cancellable leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xml:lang="en-US">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract_lbl" xml:lang="en-US">Schedule of assets acquired and liabilities assumed based on fair value [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Underlying Shares, Outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Company granted stock option</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts receivable &#8211; related parties, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl" xml:lang="en-US">Due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PrepaymentForLongtermInvestments" xlink:href="abvc-20220331.xsd#abvc_PrepaymentForLongtermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PrepaymentForLongtermInvestments_lbl" xml:lang="en-US">Prepayment for long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentForLongtermInvestments" xlink:to="abvc_PrepaymentForLongtermInvestments_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_PrepaymentForLongtermInvestments_lbl0" xml:lang="en-US">Prepayment for long-term investments (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentForLongtermInvestments" xlink:to="abvc_PrepaymentForLongtermInvestments_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expense and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermInvestments_lbl" xml:lang="en-US">Long-term investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expenses &#8211; noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US">Short-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdvanceFromCustomers" xlink:href="abvc-20220331.xsd#abvc_AdvanceFromCustomers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdvanceFromCustomers_lbl" xml:lang="en-US">Advance from customers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvanceFromCustomers" xlink:to="abvc_AdvanceFromCustomers_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities &#8211; current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl0" xml:lang="en-US">Outstanding balance and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDepositLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDepositLiability_lbl" xml:lang="en-US">Tenant security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability &#8211; noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Non-current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Noncurrent Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value, 100,000,000 authorized, 30,307,329 and 28,926,322 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common stock, authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Noncontrolling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherShortTermBorrowings_lbl" xml:lang="en-US">Short-term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermBorrowings" xlink:to="us-gaap_OtherShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xml:lang="en-US">Notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl" xml:lang="en-US">Convertible notes payable &#8211; related parties, current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Paycheck Protection Program Loan Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible notes payable &#8211; noncurrent portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Stock based compensation for non employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_InterestIncomes" xlink:href="abvc-20220331.xsd#abvc_InterestIncomes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_InterestIncomes_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_InterestIncomes" xlink:to="abvc_InterestIncomes_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RentIncome" xlink:href="abvc-20220331.xsd#abvc_RentIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RentIncome_lbl" xml:lang="en-US">Operating sublease income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RentIncome" xlink:to="abvc_RentIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingSubleaseIncomeRelatedParties" xlink:href="abvc-20220331.xsd#abvc_OperatingSubleaseIncomeRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingSubleaseIncomeRelatedParties_lbl" xml:lang="en-US">Operating sublease income &#8211; related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingSubleaseIncomeRelatedParties" xlink:to="abvc_OperatingSubleaseIncomeRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_GainLossOnForeignExchangeChanges" xlink:href="abvc-20220331.xsd#abvc_GainLossOnForeignExchangeChanges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GainLossOnForeignExchangeChanges_lbl" xml:lang="en-US">Gain/Loss on foreign exchange changes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GainLossOnForeignExchangeChanges" xlink:to="abvc_GainLossOnForeignExchangeChanges_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl" xml:lang="en-US">Gain/Loss on investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl0" xml:lang="en-US">Share of losses from investments accounted for using the equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (expense) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Government grant income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl" xml:lang="en-US">Net loss attributable to noncontrolling interests</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">-Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl" xml:lang="en-US">Weighted average number of common shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted-average shares outstanding - Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl" xml:lang="en-US">Investment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (decrease) in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US">Increase (decrease) in due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Issuance of common stock for debt (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from long-term loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BorrowingsFromRelatedParties" xlink:href="abvc-20220331.xsd#abvc_BorrowingsFromRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BorrowingsFromRelatedParties_lbl" xml:lang="en-US">Borrowings from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BorrowingsFromRelatedParties" xlink:to="abvc_BorrowingsFromRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Net proceeds from short-term borrowing from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash and cash equivalents and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest expense paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income taxes paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_InvestmentLoss1" xlink:href="abvc-20220331.xsd#abvc_InvestmentLoss1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_InvestmentLoss1_lbl" xml:lang="en-US">Investment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_InvestmentLoss1" xlink:to="abvc_InvestmentLoss1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (decrease) in advanced from others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl" xml:lang="en-US">Net proceeds from sale of investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromBankDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromBankDebt_lbl" xml:lang="en-US">Proceeds from short-term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xml:lang="en-US">Proceeds from long-term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl" xml:lang="en-US">Proceeds from (repayments of) short term borrowings from third parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from borrowings from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CashPaidDuringYearForAbstract" xlink:href="abvc-20220331.xsd#abvc_CashPaidDuringYearForAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CashPaidDuringYearForAbstract_lbl" xml:lang="en-US">Cash paid during the year for:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPaidDuringYearForAbstract" xlink:to="abvc_CashPaidDuringYearForAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash financing and investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Common shares issued for debt conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Amount of Debt Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1" xml:lang="en-US">Due to related parties consideration (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Net loss for the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CumulativeTransactionAdjustments" xlink:href="abvc-20220331.xsd#abvc_CumulativeTransactionAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CumulativeTransactionAdjustments_lbl" xml:lang="en-US">Cumulative transaction adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CumulativeTransactionAdjustments" xlink:to="abvc_CumulativeTransactionAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common shares for consulting service</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Issuance of common shares for consulting service (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" xlink:href="abvc-20220331.xsd#abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution_lbl" xml:lang="en-US">Capital contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" xlink:to="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" xlink:href="abvc-20220331.xsd#abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution_lbl" xml:lang="en-US">Capital contribution (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" xlink:to="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Stock based compensation for options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices" xlink:href="abvc-20220331.xsd#abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices_lbl" xml:lang="en-US">Stock based compensation for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices" xlink:to="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:href="abvc-20220331.xsd#abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl" xml:lang="en-US">Stock based compensation for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:to="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl0" xml:lang="en-US">Price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:to="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Debt conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Debt conversion (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common shares for cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common shares for cash (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Issuance of common shares, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Issuance of common shares for debt conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Issuance of common shares for debt conversion (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US">Stock subscription receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xml:lang="en-US">Impairment loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xml:lang="en-US">Gain/Loss on investment in equity securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_GovernmentGrantIncome" xlink:href="abvc-20220331.xsd#abvc_GovernmentGrantIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abvc_GovernmentGrantIncome_lbl" xml:lang="en-US">Government grant income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GovernmentGrantIncome" xlink:to="abvc_GovernmentGrantIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GovernmentGrantIncome_lbl0" xml:lang="en-US">Government grant income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GovernmentGrantIncome" xlink:to="abvc_GovernmentGrantIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">Other non-cash income and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl" xml:lang="en-US">Decrease (increase) in prepaid expenses and deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_lbl" xml:lang="en-US">Decrease (increase) in due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (decrease) in inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xml:lang="en-US">Prepayment for equity investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayment of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Decrease (increase) in prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xml:lang="en-US">Purchase of investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl" xml:lang="en-US">Loan to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment for offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSubordinatedShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfSubordinatedShortTermDebt_lbl" xml:lang="en-US">Repayment of short-term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:to="us-gaap_RepaymentsOfSubordinatedShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt_lbl" xml:lang="en-US">Repayment of short-term bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayment of long-term bank loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubscriptionReceivableMember" xlink:href="abvc-20220331.xsd#abvc_StockSubscriptionReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockSubscriptionReceivableMember_lbl" xml:lang="en-US">Stock Subscription Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceivableMember" xlink:to="abvc_StockSubscriptionReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">COLLABORATIVE AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:href="abvc-20220331.xsd#abvc_AllowanceForInventoryValuationAndObsolescenceLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AllowanceForInventoryValuationAndObsolescenceLoss_lbl" xml:lang="en-US">Allowance for inventory valuation and obsolescence loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:to="abvc_AllowanceForInventoryValuationAndObsolescenceLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryGross_lbl" xml:lang="en-US">Inventory, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentTextBlock" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LongTermInvestmentTextBlock_lbl" xml:lang="en-US">LONG-TERM INVESTMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentTextBlock" xlink:to="abvc_LongTermInvestmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks_lbl" xml:lang="en-US">Schedule of ownership percentages of investee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:to="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Interest rate percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1" xml:lang="en-US">Percentage of common shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_AccountingTreatmentDescription" xlink:href="abvc-20220331.xsd#abvc_AccountingTreatmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AccountingTreatmentDescription_lbl" xml:lang="en-US">Accounting treatments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccountingTreatmentDescription" xlink:to="abvc_AccountingTreatmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfExtentInvesteeReliesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl" xml:lang="en-US">Schedule of extent the investee relies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:to="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvc-20220331.xsd#abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RelatedPartyTransactionDescriptionOfTransactions_lbl" xml:lang="en-US">Relationship with the Company and its subsidiaries, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartyTransactionDescriptionOfTransactions" xlink:to="abvc_RelatedPartyTransactionDescriptionOfTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfLongTermInvestmentTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLongTermInvestmentTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfLongTermInvestmentTableTextBlock_lbl" xml:lang="en-US">Schedule of long-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfLongTermInvestmentTableTextBlock" xlink:to="abvc_ScheduleOfLongTermInvestmentTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract" xlink:href="abvc-20220331.xsd#abvc_NonMarketableCostMethodInvestmentsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract_lbl" xml:lang="en-US">Non-marketable Cost Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="abvc_NonMarketableCostMethodInvestmentsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NonmarketableCostMethodInvestmentsNet" xlink:href="abvc-20220331.xsd#abvc_NonmarketableCostMethodInvestmentsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NonmarketableCostMethodInvestmentsNet_lbl" xml:lang="en-US">Sub total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonmarketableCostMethodInvestmentsNet" xlink:to="abvc_NonmarketableCostMethodInvestmentsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityMethodInvestmentsNetAbstract" xlink:href="abvc-20220331.xsd#abvc_EquityMethodInvestmentsNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_EquityMethodInvestmentsNetAbstract_lbl" xml:lang="en-US">Equity Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodInvestmentsNetAbstract" xlink:to="abvc_EquityMethodInvestmentsNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestments_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of balance sheets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Non-current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityOther_lbl" xml:lang="en-US">Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityOther_lbl0" xml:lang="en-US">Shareholders&#8217; Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of statements of operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NetSales" xlink:href="abvc-20220331.xsd#abvc_NetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NetSales_lbl" xml:lang="en-US">Net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetSales" xlink:to="abvc_NetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_GrossProfits" xlink:href="abvc-20220331.xsd#abvc_GrossProfits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GrossProfits_lbl" xml:lang="en-US">Gross profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GrossProfits" xlink:to="abvc_GrossProfits_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentNetLoss" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentNetLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LongTermInvestmentNetLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentNetLoss" xlink:to="abvc_LongTermInvestmentNetLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Share of losses from investments accounted for using the equity method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl" xml:lang="en-US">Schedule of equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareOfEquityMethodInvesteeLosses" xlink:href="abvc-20220331.xsd#abvc_ShareOfEquityMethodInvesteeLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareOfEquityMethodInvesteeLosses_lbl" xml:lang="en-US">Share of equity method investee losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareOfEquityMethodInvesteeLosses" xlink:to="abvc_ShareOfEquityMethodInvesteeLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDisclosureTextBlock" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConvertibleNotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">CONVERTIBLE NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayableDisclosureTextBlock" xlink:to="abvc_ConvertibleNotesPayableDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BankLoansTextBlock" xlink:href="abvc-20220331.xsd#abvc_BankLoansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BankLoansTextBlock_lbl" xml:lang="en-US">BANK LOANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BankLoansTextBlock" xlink:to="abvc_BankLoansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl" xml:lang="en-US">Schedule of short-term bank loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PaycheckProtectionProgramLoanPayableTextBlock" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PaycheckProtectionProgramLoanPayableTextBlock_lbl" xml:lang="en-US">PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PaycheckProtectionProgramLoanPayableTextBlock" xlink:to="abvc_PaycheckProtectionProgramLoanPayableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageNotesPayableDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MortgageNotesPayableDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:to="us-gaap_MortgageNotesPayableDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl" xml:lang="en-US">SHORT-TERM LOAN</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of related party transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accounts receivable due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:to="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xml:lang="en-US">Accounts receivable due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">Schedule of amount due from related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DueFromtheRelatedPartiesCurrent" xlink:href="abvc-20220331.xsd#abvc_DueFromtheRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DueFromtheRelatedPartiesCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueFromtheRelatedPartiesCurrent" xlink:to="abvc_DueFromtheRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl" xml:lang="en-US">Schedule of amount due to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:to="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DueToRelatedPartyCurrentAndNoncurrent" xlink:href="abvc-20220331.xsd#abvc_DueToRelatedPartyCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DueToRelatedPartyCurrentAndNoncurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueToRelatedPartyCurrentAndNoncurrent" xlink:to="abvc_DueToRelatedPartyCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtConversionsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl" xml:lang="en-US">Schedule of converted amount of debt and shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:to="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtConversionConvertedInstrumentAmount" xlink:href="abvc-20220331.xsd#abvc_DebtConversionConvertedInstrumentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DebtConversionConvertedInstrumentAmount_lbl" xml:lang="en-US">Amount of Debt Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtConversionConvertedInstrumentAmount" xlink:to="abvc_DebtConversionConvertedInstrumentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Number of Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsTextBlock" xlink:href="abvc-20220331.xsd#abvc_StockOptionsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockOptionsTextBlock_lbl" xml:lang="en-US">STOCK OPTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsTextBlock" xlink:to="abvc_StockOptionsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of options issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Underlying Shares, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Number of Underlying Shares, Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl1" xml:lang="en-US">Stock options aggregate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Underlying Shares, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Number of Underlying Shares, Forfeited (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Contractual Life Remaining in Years, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Outstanding as of December 31, 2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Number of Underlying Shares, Exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of Underlying Shares, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0" xml:lang="en-US">Number of Underlying Shares, Vested and expected to vest (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NumeratorAbstract" xlink:href="abvc-20220331.xsd#abvc_NumeratorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NumeratorAbstract_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumeratorAbstract" xlink:to="abvc_NumeratorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to ABVC&#8217;s common stockholders (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net loss attributable to ABVC&#8217;s common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_DenominatorAbstract" xlink:href="abvc-20220331.xsd#abvc_DenominatorAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DenominatorAbstract_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DenominatorAbstract" xlink:to="abvc_DenominatorAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageSharesOutstandingAbstract" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted-average shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageSharesOutstandingAbstract" xlink:to="abvc_WeightedAverageSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedaverageSharesOutstandingBasic" xlink:href="abvc-20220331.xsd#abvc_WeightedaverageSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedaverageSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average shares outstanding - Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedaverageSharesOutstandingBasic" xlink:to="abvc_WeightedaverageSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US">Stock options (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0" xml:lang="en-US">Stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageNumberOfSharesDiluted" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageNumberOfSharesDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageNumberOfSharesDiluted_lbl" xml:lang="en-US">Weighted-average shares outstanding - Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageNumberOfSharesDiluted" xlink:to="abvc_WeightedAverageNumberOfSharesDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LossPerShareAbstract" xlink:href="abvc-20220331.xsd#abvc_LossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LossPerShareAbstract_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LossPerShareAbstract" xlink:to="abvc_LossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BasicLossPerShare" xlink:href="abvc-20220331.xsd#abvc_BasicLossPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BasicLossPerShare_lbl" xml:lang="en-US">-Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BasicLossPerShare" xlink:to="abvc_BasicLossPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">-Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesOfLesseeDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock_lbl" xml:lang="en-US">LEASE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock" xlink:to="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:to="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xml:lang="en-US">LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities (current)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeaseLiabilitienoncurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeaseLiabilitienoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingLeaseLiabilitienoncurrent_lbl" xml:lang="en-US">Operating lease liabilities (noncurrent)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeaseLiabilitienoncurrent" xlink:to="abvc_OperatingLeaseLiabilitienoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xml:lang="en-US">Schedule of supplemental information related to operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageRemainingLeaseTermAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageDiscountRateAbstract" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted Average Discount Rate:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageDiscountRateAbstract" xlink:to="abvc_WeightedAverageDiscountRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of minimum future annual payments under non-cancellable leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:to="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl" xml:lang="en-US">2022 (excluding three months ended March 31, 2022)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl0" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDue" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDue_lbl" xml:lang="en-US">Total future minimum lease payments, undiscounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDue" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDue_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" xlink:href="abvc-20220331.xsd#abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction_lbl" xml:lang="en-US">Less: Imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" xlink:to="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" xlink:href="abvc-20220331.xsd#abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions_lbl" xml:lang="en-US">Present value of future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" xlink:to="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS COMBINATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xml:lang="en-US">Schedule of assets acquired and liabilities assumed based on fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseConsiderationAbstract" xlink:href="abvc-20220331.xsd#abvc_PurchaseConsiderationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PurchaseConsiderationAbstract_lbl" xml:lang="en-US">Purchase consideration:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseConsiderationAbstract" xlink:to="abvc_PurchaseConsiderationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AllocationOfThePurchasePriceAbstract" xlink:href="abvc-20220331.xsd#abvc_AllocationOfThePurchasePriceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AllocationOfThePurchasePriceAbstract_lbl" xml:lang="en-US">Allocation of the purchase price:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="abvc_AllocationOfThePurchasePriceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl" xml:lang="en-US">Accounts receivable, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl" xml:lang="en-US">Security deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl" xml:lang="en-US">Total assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Total net assets acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xml:lang="en-US">Goodwill as a result of the Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work-in-process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract0" xlink:href="abvc-20220331.xsd#abvc_NonMarketableCostMethodInvestmentsNetAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract0_lbl" xml:lang="en-US">Non-marketable Cost Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonMarketableCostMethodInvestmentsNetAbstract0" xlink:to="abvc_NonMarketableCostMethodInvestmentsNetAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityMethodInvestmentsNetAbstract0" xlink:href="abvc-20220331.xsd#abvc_EquityMethodInvestmentsNetAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_EquityMethodInvestmentsNetAbstract0_lbl" xml:lang="en-US">Equity Method Investments, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodInvestmentsNetAbstract0" xlink:to="abvc_EquityMethodInvestmentsNetAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NetLoss1" xlink:href="abvc-20220331.xsd#abvc_NetLoss1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NetLoss1_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetLoss1" xlink:to="abvc_NetLoss1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NumeratorAbstract0" xlink:href="abvc-20220331.xsd#abvc_NumeratorAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NumeratorAbstract0_lbl" xml:lang="en-US">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumeratorAbstract0" xlink:to="abvc_NumeratorAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DenominatorAbstract0" xlink:href="abvc-20220331.xsd#abvc_DenominatorAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DenominatorAbstract0_lbl" xml:lang="en-US">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DenominatorAbstract0" xlink:to="abvc_DenominatorAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageSharesOutstandingAbstract0" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageSharesOutstandingAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageSharesOutstandingAbstract0_lbl" xml:lang="en-US">Weighted-average shares outstanding:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageSharesOutstandingAbstract0" xlink:to="abvc_WeightedAverageSharesOutstandingAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average shares outstanding - Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LossPerShareAbstract0" xlink:href="abvc-20220331.xsd#abvc_LossPerShareAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LossPerShareAbstract0_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LossPerShareAbstract0" xlink:to="abvc_LossPerShareAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract0" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageRemainingLeaseTermAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract0_lbl" xml:lang="en-US">Weighted Average Remaining Lease Term:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract0" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WeightedAverageDiscountRateAbstract0" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageDiscountRateAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WeightedAverageDiscountRateAbstract0_lbl" xml:lang="en-US">Weighted Average Discount Rate:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageDiscountRateAbstract0" xlink:to="abvc_WeightedAverageDiscountRateAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseConsiderationAbstract0" xlink:href="abvc-20220331.xsd#abvc_PurchaseConsiderationAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PurchaseConsiderationAbstract0_lbl" xml:lang="en-US">Purchase consideration:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseConsiderationAbstract0" xlink:to="abvc_PurchaseConsiderationAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AllocationOfThePurchasePriceAbstract0" xlink:href="abvc-20220331.xsd#abvc_AllocationOfThePurchasePriceAbstract0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AllocationOfThePurchasePriceAbstract0_lbl" xml:lang="en-US">Allocation of the purchase price:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="abvc_AllocationOfThePurchasePriceAbstract0_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xml:lang="en-US">Tenant security deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl" xml:lang="en-US">Total liabilities assumed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BuildingsAndLeaseholdImprovementsMember" xlink:href="abvc-20220331.xsd#abvc_BuildingsAndLeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BuildingsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Buildings and leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BuildingsAndLeaseholdImprovementsMember" xlink:to="abvc_BuildingsAndLeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LandMember_lbl" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember_lbl" xml:lang="en-US">Braingenesis Biotechnology Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GenepharmBiotechCorporationMember_lbl" xml:lang="en-US">Genepharm Biotech Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenepharmBiotechCorporationMember" xlink:to="abvc_GenepharmBiotechCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioHopeKingCorporationMember_lbl" xml:lang="en-US">BioHopeKing Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioHopeKingCorporationMember" xlink:to="abvc_BioHopeKingCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstCorporationMember_lbl" xml:lang="en-US">BioFirst Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationMember" xlink:to="abvc_BioFirstCorporationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_BioFirstCorporationMember_lbl0" xml:lang="en-US">BioFirst [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationMember" xlink:to="abvc_BioFirstCorporationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RgeneCorporationMember_lbl" xml:lang="en-US">Rgene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationMember" xlink:to="abvc_RgeneCorporationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_RgeneCorporationMember_lbl0" xml:lang="en-US">Rgene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationMember" xlink:to="abvc_RgeneCorporationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstMember_lbl" xml:lang="en-US">BioFirst [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstMember" xlink:to="abvc_BioFirstMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RgeneMember_lbl" xml:lang="en-US">Rgene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneMember" xlink:to="abvc_RgeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CathayUnitedBankMember_lbl" xml:lang="en-US">Cathay United Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayUnitedBankMember" xlink:to="abvc_CathayUnitedBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CTBCBankMember" xlink:href="abvc-20220331.xsd#abvc_CTBCBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CTBCBankMember_lbl" xml:lang="en-US">CTBC Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CTBCBankMember" xlink:to="abvc_CTBCBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CathayBankMember_lbl" xml:lang="en-US">Cathay Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayBankMember" xlink:to="abvc_CathayBankMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstCorporationtheBioFirstMember_lbl" xml:lang="en-US">BioFirst Corporation (the &quot;BioFirst&quot;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationtheBioFirstMember" xlink:to="abvc_BioFirstCorporationtheBioFirstMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl" xml:lang="en-US">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:to="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RgeneCorporationtheRgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RgeneCorporationtheRgeneMember_lbl" xml:lang="en-US">Rgene Corporation (the &#8220;Rgene&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationtheRgeneMember" xlink:to="abvc_RgeneCorporationtheRgeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_YuanGeneCorporationtheYuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneCorporationtheYuanGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_YuanGeneCorporationtheYuanGeneMember_lbl" xml:lang="en-US">YuanGene Corporation (the &#8220;YuanGene&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YuanGeneCorporationtheYuanGeneMember" xlink:to="abvc_YuanGeneCorporationtheYuanGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiaGeneCorporationtheAsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneCorporationtheAsiaGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AsiaGeneCorporationtheAsiaGeneMember_lbl" xml:lang="en-US">AsiaGene Corporation (the &#8220;AsiaGene&#8221;)	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AsiaGeneCorporationtheAsiaGeneMember" xlink:to="abvc_AsiaGeneCorporationtheAsiaGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EugeneJiangMember" xlink:href="abvc-20220331.xsd#abvc_EugeneJiangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_EugeneJiangMember_lbl" xml:lang="en-US">Eugene Jiang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EugeneJiangMember" xlink:to="abvc_EugeneJiangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_KeypointTechnologyLtdtheKeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointTechnologyLtdtheKeypointMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_KeypointTechnologyLtdtheKeypointMember_lbl" xml:lang="en-US">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_KeypointTechnologyLtdtheKeypointMember" xlink:to="abvc_KeypointTechnologyLtdtheKeypointMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtsPromotionInctheLionArtsMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLionArtsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LionArtsPromotionInctheLionArtsMember_lbl" xml:lang="en-US">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionArtsPromotionInctheLionArtsMember" xlink:to="abvc_LionArtsPromotionInctheLionArtsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_YoshinobuOdairatheOdairaMember" xlink:href="abvc-20220331.xsd#abvc_YoshinobuOdairatheOdairaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_YoshinobuOdairatheOdairaMember_lbl" xml:lang="en-US">Yoshinobu Odaira (the &#8220;Odaira&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YoshinobuOdairatheOdairaMember" xlink:to="abvc_YoshinobuOdairatheOdairaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmInctheGenePharmMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GenePharmInctheGenePharmMember_lbl" xml:lang="en-US">GenePharm Inc. (the &#8220;GenePharm&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenePharmInctheGenePharmMember" xlink:to="abvc_GenePharmInctheGenePharmMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:href="abvc-20220331.xsd#abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember_lbl" xml:lang="en-US">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:to="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LBGUSAInctheLBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAInctheLBGUSAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LBGUSAInctheLBGUSAMember_lbl" xml:lang="en-US">LBG USA, Inc. (the &#8220;LBG USA&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LBGUSAInctheLBGUSAMember" xlink:to="abvc_LBGUSAInctheLBGUSAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LionGeneCorporationtheLionGeneMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationtheLionGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LionGeneCorporationtheLionGeneMember_lbl" xml:lang="en-US">LionGene Corporation (the &#8220;LionGene&#8221;)	[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionGeneCorporationtheLionGeneMember" xlink:to="abvc_LionGeneCorporationtheLionGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_KimhoConsultantsCoLtdtheKimhoMember" xlink:href="abvc-20220331.xsd#abvc_KimhoConsultantsCoLtdtheKimhoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_KimhoConsultantsCoLtdtheKimhoMember_lbl" xml:lang="en-US">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_KimhoConsultantsCoLtdtheKimhoMember" xlink:to="abvc_KimhoConsultantsCoLtdtheKimhoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TheJiangsMember_lbl" xml:lang="en-US">The Jiangs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TheJiangsMember" xlink:to="abvc_TheJiangsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AmkeyVenturesLLCAmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyVenturesLLCAmkeyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AmkeyVenturesLLCAmkeyMember_lbl" xml:lang="en-US">Amkey Ventures, LLC (&#8220;Amkey&#8221;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AmkeyVenturesLLCAmkeyMember" xlink:to="abvc_AmkeyVenturesLLCAmkeyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioLiteJapanMember_lbl" xml:lang="en-US">BioLite Japan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJapanMember" xlink:to="abvc_BioLiteJapanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ABVCBioPharmaHKLimitedMember" xlink:href="abvc-20220331.xsd#abvc_ABVCBioPharmaHKLimitedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ABVCBioPharmaHKLimitedMember_lbl" xml:lang="en-US">ABVC BioPharma (HK), Limited [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ABVCBioPharmaHKLimitedMember" xlink:to="abvc_ABVCBioPharmaHKLimitedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_GenePharmIncMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GenePharmIncMember_lbl" xml:lang="en-US">GenePharm Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenePharmIncMember" xlink:to="abvc_GenePharmIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AmkeyMember_lbl" xml:lang="en-US">Amkey [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AmkeyMember" xlink:to="abvc_AmkeyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstAustraliaMember_lbl" xml:lang="en-US">BioFirst (Australia) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstAustraliaMember" xlink:to="abvc_BioFirstAustraliaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LBGUSAMember_lbl" xml:lang="en-US">LBG USA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LBGUSAMember" xlink:to="abvc_LBGUSAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_KeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_KeypointMember_lbl" xml:lang="en-US">Keypoint [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_KeypointMember" xlink:to="abvc_KeypointMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AsiaGeneMember_lbl" xml:lang="en-US">AsiaGene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AsiaGeneMember" xlink:to="abvc_AsiaGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_YuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_YuanGeneMember_lbl" xml:lang="en-US">YuanGene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YuanGeneMember" xlink:to="abvc_YuanGeneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DueToshareholdersMember" xlink:href="abvc-20220331.xsd#abvc_DueToshareholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DueToshareholdersMember_lbl" xml:lang="en-US">Due to Shareholders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueToshareholdersMember" xlink:to="abvc_DueToshareholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LionArtsPromotionInctheLIONMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLIONMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LionArtsPromotionInctheLIONMember_lbl" xml:lang="en-US">Lion Arts Promotion Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionArtsPromotionInctheLIONMember" xlink:to="abvc_LionArtsPromotionInctheLIONMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LionGeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LionGeneCorporationMember_lbl" xml:lang="en-US">LionGene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionGeneCorporationMember" xlink:to="abvc_LionGeneCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AsiangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_AsiangeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AsiangeneCorporationMember_lbl" xml:lang="en-US">AsiaGene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AsiangeneCorporationMember" xlink:to="abvc_AsiangeneCorporationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_AsiangeneCorporationMember_lbl0" xml:lang="en-US">AsiaGene [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AsiangeneCorporationMember" xlink:to="abvc_AsiangeneCorporationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_YuangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_YuangeneCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_YuangeneCorporationMember_lbl" xml:lang="en-US">YuanGene Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YuangeneCorporationMember" xlink:to="abvc_YuangeneCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember_lbl" xml:lang="en-US">Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the &quot;Jiangs&quot;) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:to="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DueToEmployeeMember" xlink:href="abvc-20220331.xsd#abvc_DueToEmployeeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DueToEmployeeMember_lbl" xml:lang="en-US">Due to Employee [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueToEmployeeMember" xlink:to="abvc_DueToEmployeeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TypeOfCurrencyAxis" xlink:href="abvc-20220331.xsd#abvc_TypeOfCurrencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TypeOfCurrencyAxis_lbl" xml:lang="en-US">Type Of Currency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TypeOfCurrencyAxis" xlink:to="abvc_TypeOfCurrencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockIssuedAfterStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedAfterStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CommonStockIssuedAfterStockSplit_lbl" xml:lang="en-US">Common stock issued post-stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockIssuedAfterStockSplit" xlink:to="abvc_CommonStockIssuedAfterStockSplit_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_CommonStockIssuedAfterStockSplit_lbl0" xml:lang="en-US">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockIssuedAfterStockSplit" xlink:to="abvc_CommonStockIssuedAfterStockSplit_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockIssuedBeforeStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedBeforeStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CommonStockIssuedBeforeStockSplit_lbl" xml:lang="en-US">Common stock issued pre-stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockIssuedBeforeStockSplit" xlink:to="abvc_CommonStockIssuedBeforeStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfCommonSharesIssuedAndOutstanding" xlink:href="abvc-20220331.xsd#abvc_PercentageOfCommonSharesIssuedAndOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfCommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US">Percentage of common shares issued and outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfCommonSharesIssuedAndOutstanding" xlink:to="abvc_PercentageOfCommonSharesIssuedAndOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfIssuedShareCapital" xlink:href="abvc-20220331.xsd#abvc_PercentageOfIssuedShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfIssuedShareCapital_lbl" xml:lang="en-US">Percentage of issued share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfIssuedShareCapital" xlink:to="abvc_PercentageOfIssuedShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Common stock issued post-stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US">Reverse split ratio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ImpairmentOfEquityInvestments" xlink:href="abvc-20220331.xsd#abvc_ImpairmentOfEquityInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ImpairmentOfEquityInvestments_lbl" xml:lang="en-US">Impairment of equity investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ImpairmentOfEquityInvestments" xlink:to="abvc_ImpairmentOfEquityInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LabourPensionFundPercentage" xlink:href="abvc-20220331.xsd#abvc_LabourPensionFundPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LabourPensionFundPercentage_lbl" xml:lang="en-US">Labor pension fund percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LabourPensionFundPercentage" xlink:to="abvc_LabourPensionFundPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfMonthlyContribution" xlink:href="abvc-20220331.xsd#abvc_PercentageOfMonthlyContribution"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfMonthlyContribution_lbl" xml:lang="en-US">Percentage of monthly contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfMonthlyContribution" xlink:to="abvc_PercentageOfMonthlyContribution_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xml:lang="en-US">Employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0" xml:lang="en-US">Due to employee amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Employee stock-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Stock-based compensation expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_StockBasedCompensationForNonemployees" xlink:href="abvc-20220331.xsd#abvc_StockBasedCompensationForNonemployees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockBasedCompensationForNonemployees_lbl" xml:lang="en-US">Non-employee stock-based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockBasedCompensationForNonemployees" xlink:to="abvc_StockBasedCompensationForNonemployees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanFundedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanFundedPercentage_lbl" xml:lang="en-US">Benefit percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanFundedPercentage" xlink:to="us-gaap_DefinedBenefitPlanFundedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl" xml:lang="en-US">Employee benefits amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestonePayments" xlink:href="abvc-20220331.xsd#abvc_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_MilestonePayments_lbl" xml:lang="en-US">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePayments" xlink:to="abvc_MilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xml:lang="en-US">Description of payment settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_UpfrontCashPayment" xlink:href="abvc-20220331.xsd#abvc_UpfrontCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_UpfrontCashPayment_lbl" xml:lang="en-US">Upfront cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UpfrontCashPayment" xlink:to="abvc_UpfrontCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:href="abvc-20220331.xsd#abvc_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl" xml:lang="en-US">Percentage of payments under co-development agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:to="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfStockValue" xlink:href="abvc-20220331.xsd#abvc_IssuanceOfStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_IssuanceOfStockValue_lbl" xml:lang="en-US">Common stock newly issued, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfStockValue" xlink:to="abvc_IssuanceOfStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage" xlink:href="abvc-20220331.xsd#abvc_MilestonePaymentsRoyaltyPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage_lbl" xml:lang="en-US">Milestone payments royalty percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePaymentsRoyaltyPercentage" xlink:to="abvc_MilestonePaymentsRoyaltyPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsDescription" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CollaborativeAgreementsDescription_lbl" xml:lang="en-US">Collaborative agreements, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementsDescription" xlink:to="abvc_CollaborativeAgreementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForParticipationLiabilities_lbl" xml:lang="en-US">Company cash payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForParticipationLiabilities" xlink:to="us-gaap_PaymentsForParticipationLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdditionCashPayment" xlink:href="abvc-20220331.xsd#abvc_AdditionCashPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdditionCashPayment_lbl" xml:lang="en-US">Addition cash payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionCashPayment" xlink:to="abvc_AdditionCashPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Amount received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CoDevAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_CoDevAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CoDevAgreementDescription_lbl" xml:lang="en-US">Co-Dev agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CoDevAgreementDescription" xlink:to="abvc_CoDevAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Licensing rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Aggregated shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl" xml:lang="en-US">Percentage of common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0" xml:lang="en-US">Offering price, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_PurchaseAdditionalShares" xlink:href="abvc-20220331.xsd#abvc_PurchaseAdditionalShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PurchaseAdditionalShares_lbl" xml:lang="en-US">Purchase additional shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseAdditionalShares" xlink:to="abvc_PurchaseAdditionalShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl" xml:lang="en-US">Additional shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ExcessStockSharesIssued_lbl0" xml:lang="en-US">Common shares, issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xml:lang="en-US">Sale of common stock, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl0" xml:lang="en-US">Equity offering, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregatePrincipalAmount" xlink:href="abvc-20220331.xsd#abvc_AggregatePrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AggregatePrincipalAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregatePrincipalAmount" xlink:to="abvc_AggregatePrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_lbl" xml:lang="en-US">Convertible promissory note received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Share price per unit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Number of investors (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Common stock per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="abvc_SharesOfferingPricePercentage" xlink:href="abvc-20220331.xsd#abvc_SharesOfferingPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SharesOfferingPricePercentage_lbl" xml:lang="en-US">Shares offering price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesOfferingPricePercentage" xlink:to="abvc_SharesOfferingPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValueOutstanding_lbl" xml:lang="en-US">Outstanding amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValueOutstanding" xlink:to="us-gaap_CommonStockValueOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregatePrincipalAndAccruedInterestExpense" xlink:href="abvc-20220331.xsd#abvc_AggregatePrincipalAndAccruedInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AggregatePrincipalAndAccruedInterestExpense_lbl" xml:lang="en-US">Aggregate principal and accrued interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregatePrincipalAndAccruedInterestExpense" xlink:to="abvc_AggregatePrincipalAndAccruedInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Aggregate shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockDescription_lbl" xml:lang="en-US">Conversion price, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PublicEquityOfferingExceedAmount" xlink:href="abvc-20220331.xsd#abvc_PublicEquityOfferingExceedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PublicEquityOfferingExceedAmount_lbl" xml:lang="en-US">Public equity offering exceed amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PublicEquityOfferingExceedAmount" xlink:to="abvc_PublicEquityOfferingExceedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SharesIssued1" xlink:href="abvc-20220331.xsd#abvc_SharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SharesIssued1_lbl" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesIssued1" xlink:to="abvc_SharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Common stock price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertiblePromissoryNote" xlink:href="abvc-20220331.xsd#abvc_ConvertiblePromissoryNote"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConvertiblePromissoryNote_lbl" xml:lang="en-US">Convertible promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertiblePromissoryNote" xlink:to="abvc_ConvertiblePromissoryNote_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Convertible promissory note, shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debenture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued convertible interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Accrued interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_TotalInterestExpenses" xlink:href="abvc-20220331.xsd#abvc_TotalInterestExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TotalInterestExpenses_lbl" xml:lang="en-US">Total interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TotalInterestExpenses" xlink:to="abvc_TotalInterestExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt instrument term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_principalAmount" xlink:href="abvc-20220331.xsd#abvc_principalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_principalAmount_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_principalAmount" xlink:to="abvc_principalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ReceivedLoanAmount" xlink:href="abvc-20220331.xsd#abvc_ReceivedLoanAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ReceivedLoanAmount_lbl" xml:lang="en-US">Received loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ReceivedLoanAmount" xlink:to="abvc_ReceivedLoanAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RegularInterestRateDescription" xlink:href="abvc-20220331.xsd#abvc_RegularInterestRateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RegularInterestRateDescription_lbl" xml:lang="en-US">Regular interest rate, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RegularInterestRateDescription" xlink:to="abvc_RegularInterestRateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ExceedingAmount" xlink:href="abvc-20220331.xsd#abvc_ExceedingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ExceedingAmount_lbl" xml:lang="en-US">Exceeding amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ExceedingAmount" xlink:to="abvc_ExceedingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLineOfCredit_lbl" xml:lang="en-US">Outstanding loan balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPaymentTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl" xml:lang="en-US">Debt instrument payment term description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl0" xml:lang="en-US">Debt Instrument, Payment Terms of description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanFromPaycheckProtectionProgram" xlink:href="abvc-20220331.xsd#abvc_LoanFromPaycheckProtectionProgram"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LoanFromPaycheckProtectionProgram_lbl" xml:lang="en-US">Loan from paycheck protection program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanFromPaycheckProtectionProgram" xlink:to="abvc_LoanFromPaycheckProtectionProgram_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ForgivenAmountPercentageUsedForPayroll" xlink:href="abvc-20220331.xsd#abvc_ForgivenAmountPercentageUsedForPayroll"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ForgivenAmountPercentageUsedForPayroll_lbl" xml:lang="en-US">Forgiven amount percentage used for payroll</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ForgivenAmountPercentageUsedForPayroll" xlink:to="abvc_ForgivenAmountPercentageUsedForPayroll_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PromissoryNoteDescription" xlink:href="abvc-20220331.xsd#abvc_PromissoryNoteDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PromissoryNoteDescription_lbl" xml:lang="en-US">Promissory note description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PromissoryNoteDescription" xlink:to="abvc_PromissoryNoteDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanFromPaycheckProtectionPrograms" xlink:href="abvc-20220331.xsd#abvc_LoanFromPaycheckProtectionPrograms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LoanFromPaycheckProtectionPrograms_lbl" xml:lang="en-US">Loan from paycheck protection programs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanFromPaycheckProtectionPrograms" xlink:to="abvc_LoanFromPaycheckProtectionPrograms_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAmout" xlink:href="abvc-20220331.xsd#abvc_LoanAmout"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LoanAmout_lbl" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAmout" xlink:to="abvc_LoanAmout_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl" xml:lang="en-US">Loan forgiven</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_UnsecuredLoanAgreementsDescription" xlink:href="abvc-20220331.xsd#abvc_UnsecuredLoanAgreementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_UnsecuredLoanAgreementsDescription_lbl" xml:lang="en-US">Unsecured loan agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnsecuredLoanAgreementsDescription" xlink:to="abvc_UnsecuredLoanAgreementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNotesPayable_lbl" xml:lang="en-US">Balance due amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseOther_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnsecuredDebt_lbl" xml:lang="en-US">Unsecured loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtInterestRateIncrease" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableWithFixedRatesOfInterest1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1_lbl" xml:lang="en-US">Loan interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:to="us-gaap_LoansReceivableWithFixedRatesOfInterest1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl" xml:lang="en-US">Outstanding loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AccruedInterest" xlink:href="abvc-20220331.xsd#abvc_AccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AccruedInterest_lbl" xml:lang="en-US">Outstanding principal and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccruedInterest" xlink:to="abvc_AccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromAffiliateNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromAffiliateNoncurrent_lbl" xml:lang="en-US">Consultant services agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromAffiliateNoncurrent" xlink:to="us-gaap_DueFromAffiliateNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregateWorkingcapital" xlink:href="abvc-20220331.xsd#abvc_AggregateWorkingcapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AggregateWorkingcapital_lbl" xml:lang="en-US">Aggregate working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregateWorkingcapital" xlink:to="abvc_AggregateWorkingcapital_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementTotalAmount" xlink:href="abvc-20220331.xsd#abvc_LoanAgreementTotalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LoanAgreementTotalAmount_lbl" xml:lang="en-US">Loan agreement total amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementTotalAmount" xlink:to="abvc_LoanAgreementTotalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_InterestRate" xlink:href="abvc-20220331.xsd#abvc_InterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_InterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_InterestRate" xlink:to="abvc_InterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl" xml:lang="en-US">Balance of outstanding loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DebtInstrumentAggregateAmount" xlink:href="abvc-20220331.xsd#abvc_DebtInstrumentAggregateAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DebtInstrumentAggregateAmount_lbl" xml:lang="en-US">Due from Rgene amounted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentAggregateAmount" xlink:to="abvc_DebtInstrumentAggregateAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl" xml:lang="en-US">Loan agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromEmployeesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromEmployeesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromEmployeesNoncurrent_lbl" xml:lang="en-US">Due amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromEmployeesNoncurrent" xlink:to="us-gaap_DueFromEmployeesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdvancesBearInterestDescription" xlink:href="abvc-20220331.xsd#abvc_AdvancesBearInterestDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdvancesBearInterestDescription_lbl" xml:lang="en-US">Advances bear interest, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvancesBearInterestDescription" xlink:to="abvc_AdvancesBearInterestDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingAdvanceFromRelatedParty" xlink:href="abvc-20220331.xsd#abvc_OutstandingAdvanceFromRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OutstandingAdvanceFromRelatedParty_lbl" xml:lang="en-US">Outstanding advance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingAdvanceFromRelatedParty" xlink:to="abvc_OutstandingAdvanceFromRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_LoanAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LoanAgreementDescription_lbl" xml:lang="en-US">Loan agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementDescription" xlink:to="abvc_LoanAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OutstandingPrincipalAndAccruedInterest" xlink:href="abvc-20220331.xsd#abvc_OutstandingPrincipalAndAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OutstandingPrincipalAndAccruedInterest_lbl" xml:lang="en-US">Outstanding principal and accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingPrincipalAndAccruedInterest" xlink:to="abvc_OutstandingPrincipalAndAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl" xml:lang="en-US">Interest expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Due from rgene</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromOtherRelatedParties_lbl" xml:lang="en-US">Due from BHK</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedParties" xlink:to="us-gaap_DueFromOtherRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageRateForeignDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageRateForeignDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageRateForeignDeposit_lbl" xml:lang="en-US">Bear interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageRateForeignDeposit" xlink:to="us-gaap_WeightedAverageRateForeignDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CommonStockShareAuthorized" xlink:href="abvc-20220331.xsd#abvc_CommonStockShareAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CommonStockShareAuthorized_lbl" xml:lang="en-US">Ordinary shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockShareAuthorized" xlink:to="abvc_CommonStockShareAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AgreementDescription" xlink:href="abvc-20220331.xsd#abvc_AgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AgreementDescription_lbl" xml:lang="en-US">Agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AgreementDescription" xlink:to="abvc_AgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_FinancialAmendmentDescription" xlink:href="abvc-20220331.xsd#abvc_FinancialAmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_FinancialAmendmentDescription_lbl" xml:lang="en-US">Financial amendment, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_FinancialAmendmentDescription" xlink:to="abvc_FinancialAmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_Consultingagreementdescription" xlink:href="abvc-20220331.xsd#abvc_Consultingagreementdescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_Consultingagreementdescription_lbl" xml:lang="en-US">Consulting agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_Consultingagreementdescription" xlink:to="abvc_Consultingagreementdescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_UnpaidConsultingFees" xlink:href="abvc-20220331.xsd#abvc_UnpaidConsultingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_UnpaidConsultingFees_lbl" xml:lang="en-US">Unpaid consulting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnpaidConsultingFees" xlink:to="abvc_UnpaidConsultingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US">Due to related parties (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockIssuedValue" xlink:href="abvc-20220331.xsd#abvc_StockIssuedValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockIssuedValue_lbl" xml:lang="en-US">Issuance of common shares (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedValue" xlink:to="abvc_StockIssuedValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyAgreementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntercompanyAgreementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntercompanyAgreementsDescription_lbl" xml:lang="en-US">Consulting service, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntercompanyAgreementsDescription" xlink:to="us-gaap_IntercompanyAgreementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Consulting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockSubscriptionReceivable" xlink:href="abvc-20220331.xsd#abvc_StockSubscriptionReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockSubscriptionReceivable_lbl" xml:lang="en-US">Stock subscription receivable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceivable" xlink:to="abvc_StockSubscriptionReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PlacementAgentAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_PlacementAgentAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PlacementAgentAgreementDescription_lbl" xml:lang="en-US">Placement agent agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PlacementAgentAgreementDescription" xlink:to="abvc_PlacementAgentAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Shares per price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RestrictedCommonShares" xlink:href="abvc-20220331.xsd#abvc_RestrictedCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_RestrictedCommonShares_lbl" xml:lang="en-US">Restricted common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RestrictedCommonShares" xlink:to="abvc_RestrictedCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WarrantIssued" xlink:href="abvc-20220331.xsd#abvc_WarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WarrantIssued_lbl" xml:lang="en-US">Warrant issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantIssued" xlink:to="abvc_WarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WarrantTerm" xlink:href="abvc-20220331.xsd#abvc_WarrantTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WarrantTerm_lbl" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantTerm" xlink:to="abvc_WarrantTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_UnrestrictedCommonShares" xlink:href="abvc-20220331.xsd#abvc_UnrestrictedCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_UnrestrictedCommonShares_lbl" xml:lang="en-US">Unrestricted common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnrestrictedCommonShares" xlink:to="abvc_UnrestrictedCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl" xml:lang="en-US">Aggregated capital contributions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NumberOfInvestors" xlink:href="abvc-20220331.xsd#abvc_NumberOfInvestors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NumberOfInvestors_lbl" xml:lang="en-US">Number of investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumberOfInvestors" xlink:to="abvc_NumberOfInvestors_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SharesIssuedPricePerShares" xlink:href="abvc-20220331.xsd#abvc_SharesIssuedPricePerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SharesIssuedPricePerShares_lbl" xml:lang="en-US">Purchase price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesIssuedPricePerShares" xlink:to="abvc_SharesIssuedPricePerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_IssuanceOfCommonStock" xlink:href="abvc-20220331.xsd#abvc_IssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_IssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfCommonStock" xlink:to="abvc_IssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AggregateCommonStockShares" xlink:href="abvc-20220331.xsd#abvc_AggregateCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AggregateCommonStockShares_lbl" xml:lang="en-US">Aggregate common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregateCommonStockShares" xlink:to="abvc_AggregateCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl" xml:lang="en-US">Debt conversion, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertiblePromissoryNoteValue" xlink:href="abvc-20220331.xsd#abvc_ConvertiblePromissoryNoteValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConvertiblePromissoryNoteValue_lbl" xml:lang="en-US">Convertible promissory note value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertiblePromissoryNoteValue" xlink:to="abvc_ConvertiblePromissoryNoteValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_DescriptionOfPublicOffering" xlink:href="abvc-20220331.xsd#abvc_DescriptionOfPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_DescriptionOfPublicOffering_lbl" xml:lang="en-US">Description of public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DescriptionOfPublicOffering" xlink:to="abvc_DescriptionOfPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl" xml:lang="en-US">Common stock issued to professional investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Gross proceeds from exercise of warrants (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrants exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultingAgreementDesciption" xlink:href="abvc-20220331.xsd#abvc_ConsultingAgreementDesciption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConsultingAgreementDesciption_lbl" xml:lang="en-US">Consulting agreement desciption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultingAgreementDesciption" xlink:to="abvc_ConsultingAgreementDesciption_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Consulting and advisory services amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityListingParValuePerShare" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingParValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityListingParValuePerShare_lbl" xml:lang="en-US">Consulting and advisory services value per share (in Dollars per share)</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0TSgIZzBWwoovVOsFPEA4rNNrbY6CE8wmoa0q+lpRTxGk3c+CiJGsyWKrkLTTMjgQTYSxh3ggHe8DlX9qv/pk+ILYd8K5ojpQS7Wnderc/ZHXKbqwIYJ6fn4w3DUr83pkMmCOv+OqpC8KA0O7UaTaY=] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyShareholderServiceFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyShareholderServiceFeeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyShareholderServiceFeeExpense_lbl" xml:lang="en-US">Service fee amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyShareholderServiceFeeExpense" xlink:to="us-gaap_InvestmentCompanyShareholderServiceFeeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConversionPrice" xlink:href="abvc-20220331.xsd#abvc_ConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConversionPrice_lbl" xml:lang="en-US">Conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConversionPrice" xlink:to="abvc_ConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultingFees" xlink:href="abvc-20220331.xsd#abvc_ConsultingFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConsultingFees_lbl" xml:lang="en-US">Consulting fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultingFees" xlink:to="abvc_ConsultingFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options vested grant date exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">(in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Options available for grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:href="abvc-20220331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl" xml:lang="en-US">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PercentageOfGoodwill" xlink:href="abvc-20220331.xsd#abvc_PercentageOfGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PercentageOfGoodwill_lbl" xml:lang="en-US">Percentage of goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfGoodwill" xlink:to="abvc_PercentageOfGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Goodwill write-down value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NumberOfDirectors" xlink:href="abvc-20220331.xsd#abvc_NumberOfDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NumberOfDirectors_lbl" xml:lang="en-US">Number of directors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumberOfDirectors" xlink:to="abvc_NumberOfDirectors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Granted options to purchase an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_GrantDateTerm" xlink:href="abvc-20220331.xsd#abvc_GrantDateTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_GrantDateTerm_lbl" xml:lang="en-US">Grant date term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GrantDateTerm" xlink:to="abvc_GrantDateTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Purchase agreement relating to offer and sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl" xml:lang="en-US">Common stock, par value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WarrantsPurchased" xlink:href="abvc-20220331.xsd#abvc_WarrantsPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WarrantsPurchased_lbl" xml:lang="en-US">Warrants purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantsPurchased" xlink:to="abvc_WarrantsPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ExercisableAtAPricePerShare" xlink:href="abvc-20220331.xsd#abvc_ExercisableAtAPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ExercisableAtAPricePerShare_lbl" xml:lang="en-US">Exercisable price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ExercisableAtAPricePerShare" xlink:to="abvc_ExercisableAtAPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TermsOfAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_TermsOfAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TermsOfAgreementDescription_lbl" xml:lang="en-US">Terms of agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TermsOfAgreementDescription" xlink:to="abvc_TermsOfAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_MilestonePaymentDescription" xlink:href="abvc-20220331.xsd#abvc_MilestonePaymentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_MilestonePaymentDescription_lbl" xml:lang="en-US">Milestone payment, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePaymentDescription" xlink:to="abvc_MilestonePaymentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_AdditionalSharesOfCommonStock" xlink:href="abvc-20220331.xsd#abvc_AdditionalSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_AdditionalSharesOfCommonStock_lbl" xml:lang="en-US">Additional shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionalSharesOfCommonStock" xlink:to="abvc_AdditionalSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseInvestmentAdvisoryFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl" xml:lang="en-US">Consulting and advisory services (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:to="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiscalPeriod_lbl" xml:lang="en-US">Fiscal Year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiscalPeriod" xlink:to="us-gaap_FiscalPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ForwardStockSplitsPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_ForwardStockSplitsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ForwardStockSplitsPolicyTextBlock_lbl" xml:lang="en-US">Forward Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ForwardStockSplitsPolicyTextBlock" xlink:to="abvc_ForwardStockSplitsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockReverseSplitPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_StockReverseSplitPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_StockReverseSplitPolicyTextBlock_lbl" xml:lang="en-US">Stock Reverse Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockReverseSplitPolicyTextBlock" xlink:to="abvc_StockReverseSplitPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermEquityInvestmentPolicy" xlink:href="abvc-20220331.xsd#abvc_LongTermEquityInvestmentPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LongTermEquityInvestmentPolicy_lbl" xml:lang="en-US">Long-term Equity Investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermEquityInvestmentPolicy" xlink:to="abvc_LongTermEquityInvestmentPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_OtherThanTemporaryImpairmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl" xml:lang="en-US">Other-Than-Temporary Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:to="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl" xml:lang="en-US">Post-retirement and post-employment benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BeneficialConversionFeature" xlink:href="abvc-20220331.xsd#abvc_BeneficialConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BeneficialConversionFeature" xlink:to="abvc_BeneficialConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl" xml:lang="en-US">Valuation of Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:to="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss Per Share of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Foreign-currency Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TranslationAdjustmentPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_TranslationAdjustmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TranslationAdjustmentPolicyTextBlock_lbl" xml:lang="en-US">Translation Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TranslationAdjustmentPolicyTextBlock" xlink:to="abvc_TranslationAdjustmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareExchangeAgreementMember_lbl" xml:lang="en-US">Share Exchange Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementMember" xlink:to="abvc_ShareExchangeAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementOneMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareExchangeAgreementOneMember_lbl" xml:lang="en-US">Share Exchange Agreement One [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementOneMember" xlink:to="abvc_ShareExchangeAgreementOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementTwoMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareExchangeAgreementTwoMember_lbl" xml:lang="en-US">Share Exchange Agreement Two [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementTwoMember" xlink:to="abvc_ShareExchangeAgreementTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementFourMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementFourMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareExchangeAgreementFourMember_lbl" xml:lang="en-US">Share Exchange Agreement Four [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementFourMember" xlink:to="abvc_ShareExchangeAgreementFourMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_MergerAgreementMember" xlink:href="abvc-20220331.xsd#abvc_MergerAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_MergerAgreementMember_lbl" xml:lang="en-US">Merger Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MergerAgreementMember" xlink:to="abvc_MergerAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ShareExchangeAgreementThreeMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ShareExchangeAgreementThreeMember_lbl" xml:lang="en-US">Share Exchange Agreement Three [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementThreeMember" xlink:to="abvc_ShareExchangeAgreementThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BHKCoDevelopmentAgreementMember" xlink:href="abvc-20220331.xsd#abvc_BHKCoDevelopmentAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BHKCoDevelopmentAgreementMember_lbl" xml:lang="en-US">BHK Co-Development Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAgreementMember" xlink:to="abvc_BHKCoDevelopmentAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CodevelopmentagreementMember" xlink:href="abvc-20220331.xsd#abvc_CodevelopmentagreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CodevelopmentagreementMember_lbl" xml:lang="en-US">Co-Dev Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CodevelopmentagreementMember" xlink:to="abvc_CodevelopmentagreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US">Collaborative Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioFirstStockPurchaseAgreementMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstStockPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioFirstStockPurchaseAgreementMember_lbl" xml:lang="en-US">BioFirst Stock Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstStockPurchaseAgreementMember" xlink:to="abvc_BioFirstStockPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteTaiwanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteTaiwanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioLiteTaiwanMember_lbl" xml:lang="en-US">BioLite Taiwan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteTaiwanMember" xlink:to="abvc_BioLiteTaiwanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_UnsecuredConvertiblePromissoryNoteMember" xlink:href="abvc-20220331.xsd#abvc_UnsecuredConvertiblePromissoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_UnsecuredConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Unsecured Convertible Promissory Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnsecuredConvertiblePromissoryNoteMember" xlink:to="abvc_UnsecuredConvertiblePromissoryNoteMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_UnsecuredConvertiblePromissoryNoteMember_lbl0" xml:lang="en-US">Unsecured convertible promissory note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnsecuredConvertiblePromissoryNoteMember" xlink:to="abvc_UnsecuredConvertiblePromissoryNoteMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Conversion Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SecuritiesPurchaseAgreementMember" xlink:href="abvc-20220331.xsd#abvc_SecuritiesPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SecuritiesPurchaseAgreementMember" xlink:to="abvc_SecuritiesPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NTMember" xlink:href="abvc-20220331.xsd#abvc_NTMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NTMember_lbl" xml:lang="en-US">NT [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NTMember" xlink:to="abvc_NTMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CathayUnitedLoanAgreementMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedLoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_CathayUnitedLoanAgreementMember_lbl" xml:lang="en-US">Cathay United Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayUnitedLoanAgreementMember" xlink:to="abvc_CathayUnitedLoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LoanAgreementMember" xlink:href="abvc-20220331.xsd#abvc_LoanAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementMember" xlink:to="abvc_LoanAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PAYCHECKPROTECTIONPROGRAMMember" xlink:href="abvc-20220331.xsd#abvc_PAYCHECKPROTECTIONPROGRAMMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_PAYCHECKPROTECTIONPROGRAMMember_lbl" xml:lang="en-US">Paycheck Protection Program [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PAYCHECKPROTECTIONPROGRAMMember" xlink:to="abvc_PAYCHECKPROTECTIONPROGRAMMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_PAYCHECKPROTECTIONPROGRAMMember_lbl0" xml:lang="en-US">Paycheck protection program [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PAYCHECKPROTECTIONPROGRAMMember" xlink:to="abvc_PAYCHECKPROTECTIONPROGRAMMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_BHKCoDevelopmentAggreementMember" xlink:href="abvc-20220331.xsd#abvc_BHKCoDevelopmentAggreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BHKCoDevelopmentAggreementMember_lbl" xml:lang="en-US">BHK Co Development Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAggreementMember" xlink:to="abvc_BHKCoDevelopmentAggreementMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abvc_BHKCoDevelopmentAggreementMember_lbl0" xml:lang="en-US">BHK Co Development Aggreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAggreementMember" xlink:to="abvc_BHKCoDevelopmentAggreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abvc_LbgUsaIncMember" xlink:href="abvc-20220331.xsd#abvc_LbgUsaIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_LbgUsaIncMember_lbl" xml:lang="en-US">LBG USA, Inc.[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LbgUsaIncMember" xlink:to="abvc_LbgUsaIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_JIANGSMember" xlink:href="abvc-20220331.xsd#abvc_JIANGSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_JIANGSMember_lbl" xml:lang="en-US">Jiangs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_JIANGSMember" xlink:to="abvc_JIANGSMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20220331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2016 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:to="abvc_TwoThousandSixteenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioLiteMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioLiteMember_lbl" xml:lang="en-US">BioLite [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteMember" xlink:to="abvc_BioLiteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BioKeyMember" xlink:href="abvc-20220331.xsd#abvc_BioKeyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BioKeyMember_lbl" xml:lang="en-US">BioKey [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioKeyMember" xlink:to="abvc_BioKeyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_KameyamaMember" xlink:href="abvc-20220331.xsd#abvc_KameyamaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_KameyamaMember_lbl" xml:lang="en-US">Kameyama [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_KameyamaMember" xlink:to="abvc_KameyamaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ArticlesOfIncorporationMember" xlink:href="abvc-20220331.xsd#abvc_ArticlesOfIncorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ArticlesOfIncorporationMember_lbl" xml:lang="en-US">Articles of Incorporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ArticlesOfIncorporationMember" xlink:to="abvc_ArticlesOfIncorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ViewTradeSecuritiesIncMember" xlink:href="abvc-20220331.xsd#abvc_ViewTradeSecuritiesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ViewTradeSecuritiesIncMember_lbl" xml:lang="en-US">View Trade Securities Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ViewTradeSecuritiesIncMember" xlink:to="abvc_ViewTradeSecuritiesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_WallachBethCapitalLLCMember" xlink:href="abvc-20220331.xsd#abvc_WallachBethCapitalLLCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_WallachBethCapitalLLCMember_lbl" xml:lang="en-US">WallachBeth Capital LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WallachBethCapitalLLCMember" xlink:to="abvc_WallachBethCapitalLLCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConsultingAgreementMember" xlink:href="abvc-20220331.xsd#abvc_ConsultingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_ConsultingAgreementMember_lbl" xml:lang="en-US">Consulting Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultingAgreementMember" xlink:to="abvc_ConsultingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NonRelatedPartiesMember" xlink:href="abvc-20220331.xsd#abvc_NonRelatedPartiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_NonRelatedPartiesMember_lbl" xml:lang="en-US">Non Related Parties [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonRelatedPartiesMember" xlink:to="abvc_NonRelatedPartiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SeriesAWarrantsMember" xlink:href="abvc-20220331.xsd#abvc_SeriesAWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SeriesAWarrantsMember_lbl" xml:lang="en-US">Series A Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SeriesAWarrantsMember" xlink:to="abvc_SeriesAWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SeriesBWarrantsMember" xlink:href="abvc-20220331.xsd#abvc_SeriesBWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SeriesBWarrantsMember" xlink:to="abvc_SeriesBWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationMember" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abvc_BusinessCombinationMember_lbl" xml:lang="en-US">Business Combination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationMember" xlink:to="abvc_BusinessCombinationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsTable" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CollaborativeAgreementsTable_lbl" xml:lang="en-US">Collaborative Agreements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementsTable" xlink:to="abvc_CollaborativeAgreementsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsLineItems" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CollaborativeAgreementsLineItems_lbl" xml:lang="en-US">Collaborative Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementsLineItems" xlink:to="abvc_CollaborativeAgreementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NotesPayableTable" xlink:href="abvc-20220331.xsd#abvc_NotesPayableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NotesPayableTable_lbl" xml:lang="en-US">Notes Payable [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NotesPayableTable" xlink:to="abvc_NotesPayableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_NotesPayableLineItems" xlink:href="abvc-20220331.xsd#abvc_NotesPayableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NotesPayableLineItems_lbl" xml:lang="en-US">Notes Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NotesPayableLineItems" xlink:to="abvc_NotesPayableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsTablesTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockOptionsTablesTable_lbl" xml:lang="en-US">Stock Options (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsTablesTable" xlink:to="abvc_StockOptionsTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsTablesLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockOptionsTablesLineItems_lbl" xml:lang="en-US">Stock Options (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsTablesLineItems" xlink:to="abvc_StockOptionsTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:to="abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of ownership percentages of investee [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of extent the investee relies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of long-term investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems_lbl" xml:lang="en-US">Long-Term Investments (Details) - Schedule of long-term investment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Balance Sheet Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementTable_lbl" xml:lang="en-US">Condensed Income Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xml:lang="en-US">Condensed Income Statements, Captions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable_lbl" xml:lang="en-US">Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems_lbl" xml:lang="en-US">Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable_lbl" xml:lang="en-US">Related Parties Transactions (Details) - Schedule of amount due to related parties [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems_lbl" xml:lang="en-US">Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionTable_lbl" xml:lang="en-US">Debt Conversion [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_DebtConversionTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionLineItems_lbl" xml:lang="en-US">Debt Conversion [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable_lbl" xml:lang="en-US">Stock Options (Details) - Schedule of options issued and outstanding [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems_lbl" xml:lang="en-US">Stock Options (Details) - Schedule of options issued and outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:href="abvc-20220331.xsd#abvc_OrganizationandDescriptionofBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OrganizationandDescriptionofBusinessDetailsTable_lbl" xml:lang="en-US">Organization and Description of Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsTable" xlink:to="abvc_OrganizationandDescriptionofBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_OrganizationandDescriptionofBusinessDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OrganizationandDescriptionofBusinessDetailsLineItems_lbl" xml:lang="en-US">Organization and Description of Business (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="abvc_OrganizationandDescriptionofBusinessDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CollaborativeAgreementsDetailsTable_lbl" xml:lang="en-US">Collaborative Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementsDetailsTable" xlink:to="abvc_CollaborativeAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_CollaborativeAgreementsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CollaborativeAgreementsDetailsLineItems_lbl" xml:lang="en-US">Collaborative Agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementsDetailsLineItems" xlink:to="abvc_CollaborativeAgreementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsDetailsTable_lbl" xml:lang="en-US">Long-Term Investments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsDetailsTable" xlink:to="abvc_LongTermInvestmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_LongTermInvestmentsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentsDetailsLineItems_lbl" xml:lang="en-US">Long-Term Investments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentsDetailsLineItems" xlink:to="abvc_LongTermInvestmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDetailsTable" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertibleNotesPayableDetailsTable_lbl" xml:lang="en-US">Convertible Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayableDetailsTable" xlink:to="abvc_ConvertibleNotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertibleNotesPayableDetailsLineItems_lbl" xml:lang="en-US">Convertible Notes Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayableDetailsLineItems" xlink:to="abvc_ConvertibleNotesPayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_TypeOfCurrencyDomain" xlink:href="abvc-20220331.xsd#abvc_TypeOfCurrencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TypeOfCurrencyDomain_lbl" xml:lang="en-US">TypeOfCurrency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TypeOfCurrencyDomain" xlink:to="abvc_TypeOfCurrencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BankLoansDetailsTable" xlink:href="abvc-20220331.xsd#abvc_BankLoansDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BankLoansDetailsTable_lbl" xml:lang="en-US">Bank Loans (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BankLoansDetailsTable" xlink:to="abvc_BankLoansDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BankLoansDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_BankLoansDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BankLoansDetailsLineItems_lbl" xml:lang="en-US">Bank Loans (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BankLoansDetailsLineItems" xlink:to="abvc_BankLoansDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PaycheckProtectionProgramLoanPayableDetailsTable" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PaycheckProtectionProgramLoanPayableDetailsTable_lbl" xml:lang="en-US">Paycheck Protection Program Loan Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsTable" xlink:to="abvc_PaycheckProtectionProgramLoanPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems_lbl" xml:lang="en-US">Paycheck Protection Program Loan Payable (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsDetailsTable_lbl" xml:lang="en-US">Related Parties Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsDetailsTable" xlink:to="abvc_RelatedPartiesTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartiesTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Parties Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartiesTransactionsDetailsLineItems" xlink:to="abvc_RelatedPartiesTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title of Individual [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityDetailsTable" xlink:href="abvc-20220331.xsd#abvc_EquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EquityDetailsTable_lbl" xml:lang="en-US">Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityDetailsTable" xlink:to="abvc_EquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_EquityDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_EquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EquityDetailsLineItems_lbl" xml:lang="en-US">Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityDetailsLineItems" xlink:to="abvc_EquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockOptionsDetailsTable_lbl" xml:lang="en-US">Stock Options (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsDetailsTable" xlink:to="abvc_StockOptionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_StockOptionsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockOptionsDetailsLineItems_lbl" xml:lang="en-US">Stock Options (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsDetailsLineItems" xlink:to="abvc_StockOptionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationDetailsTable" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BusinessCombinationDetailsTable_lbl" xml:lang="en-US">Business Combination (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationDetailsTable" xlink:to="abvc_BusinessCombinationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_BusinessCombinationDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BusinessCombinationDetailsLineItems_lbl" xml:lang="en-US">Business Combination (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationDetailsLineItems" xlink:to="abvc_BusinessCombinationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SubsequentEventsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SubsequentEventsDetailsTable" xlink:to="abvc_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abvc_SubsequentEventsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SubsequentEventsDetailsLineItems" xlink:to="abvc_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AccruedInterest_lbl0" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccruedInterest" xlink:to="abvc_AccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AdditionalSharesOfCommonStock_lbl0" xml:lang="en-US">Additional shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionalSharesOfCommonStock" xlink:to="abvc_AdditionalSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution_lbl0" xml:lang="en-US">Amount of increase (decrease) in additional paid in capital contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" xlink:to="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution_lbl0" xml:lang="en-US">Shares of adjustments to additional paid in capital shares capital contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" xlink:to="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AdvanceFromCustomers_lbl0" xml:lang="en-US">Advance from customers.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvanceFromCustomers" xlink:to="abvc_AdvanceFromCustomers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AdvancesBearInterestDescription_lbl0" xml:lang="en-US">Advances bear interest description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvancesBearInterestDescription" xlink:to="abvc_AdvancesBearInterestDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AggregateCommonStockShares_lbl0" xml:lang="en-US">Aggregate Common Stock Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregateCommonStockShares" xlink:to="abvc_AggregateCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AggregatePrincipalAmount_lbl0" xml:lang="en-US">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregatePrincipalAmount" xlink:to="abvc_AggregatePrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AggregateWorkingcapital_lbl0" xml:lang="en-US">Aggregate working capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregateWorkingcapital" xlink:to="abvc_AggregateWorkingcapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AgreementDescription_lbl0" xml:lang="en-US">Agreement related description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AgreementDescription" xlink:to="abvc_AgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_AllowanceForInventoryValuationAndObsolescenceLoss_lbl0" xml:lang="en-US">Allowance for inventory valuation and obsolescence loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:to="abvc_AllowanceForInventoryValuationAndObsolescenceLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_BeneficialConversionFeature_lbl0" xml:lang="en-US">Disclosure of accounting policy for beneficial conversion feature.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BeneficialConversionFeature" xlink:to="abvc_BeneficialConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_CoDevAgreementDescription_lbl0" xml:lang="en-US">Co-Dev agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CoDevAgreementDescription" xlink:to="abvc_CoDevAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_CollaborativeAgreementsDescription_lbl0" xml:lang="en-US">Collaborative Agreements, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementsDescription" xlink:to="abvc_CollaborativeAgreementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_CommonStockIssuedAfterStockSplit_lbl1" xml:lang="en-US">Common stock issued after stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockIssuedAfterStockSplit" xlink:to="abvc_CommonStockIssuedAfterStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_CommonStockIssuedBeforeStockSplit_lbl0" xml:lang="en-US">Common stock issued before stock split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockIssuedBeforeStockSplit" xlink:to="abvc_CommonStockIssuedBeforeStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_CommonStockShareAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockShareAuthorized" xlink:to="abvc_CommonStockShareAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_Consultingagreementdescription_lbl0" xml:lang="en-US">Consulting agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_Consultingagreementdescription" xlink:to="abvc_Consultingagreementdescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConversionPrice_lbl0" xml:lang="en-US">Number of shares value is conversion price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConversionPrice" xlink:to="abvc_ConversionPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConvertibleNotesPayableDisclosureTextBlock_lbl0" xml:lang="en-US">Disclosure of convertible notes payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayableDisclosureTextBlock" xlink:to="abvc_ConvertibleNotesPayableDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConvertiblePromissoryNote_lbl0" xml:lang="en-US">The amount of convertible promissory note.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertiblePromissoryNote" xlink:to="abvc_ConvertiblePromissoryNote_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ConvertiblePromissoryNoteValue_lbl0" xml:lang="en-US">Convertible promissory note value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertiblePromissoryNoteValue" xlink:to="abvc_ConvertiblePromissoryNoteValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DebtConversionConvertedInstrumentAmount_lbl0" xml:lang="en-US">The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. &quot;Part noncash&quot; refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtConversionConvertedInstrumentAmount" xlink:to="abvc_DebtConversionConvertedInstrumentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DebtInstrumentAggregateAmount_lbl0" xml:lang="en-US">Face (par) amount of debt instrument at time of issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentAggregateAmount" xlink:to="abvc_DebtInstrumentAggregateAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DescriptionOfPublicOffering_lbl0" xml:lang="en-US">Description of public offering .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DescriptionOfPublicOffering" xlink:to="abvc_DescriptionOfPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DueFromtheRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due From Related Parties Current.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueFromtheRelatedPartiesCurrent" xlink:to="abvc_DueFromtheRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_DueToRelatedPartyCurrentAndNoncurrent_lbl0" xml:lang="en-US">Carrying amount as of the balance sheet date of obligations due all related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueToRelatedPartyCurrentAndNoncurrent" xlink:to="abvc_DueToRelatedPartyCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ExceedingAmount_lbl0" xml:lang="en-US">Exceeding amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ExceedingAmount" xlink:to="abvc_ExceedingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ForwardStockSplitsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for forward stock splits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ForwardStockSplitsPolicyTextBlock" xlink:to="abvc_ForwardStockSplitsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_GovernmentGrantIncome_lbl1" xml:lang="en-US">Amount of government grant income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GovernmentGrantIncome" xlink:to="abvc_GovernmentGrantIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ImpairmentOfEquityInvestments_lbl0" xml:lang="en-US">Impairment of equity investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ImpairmentOfEquityInvestments" xlink:to="abvc_ImpairmentOfEquityInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_InvestmentLoss1_lbl0" xml:lang="en-US">Investment loss.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_InvestmentLoss1" xlink:to="abvc_InvestmentLoss1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_IssuanceOfCommonStock_lbl0" xml:lang="en-US">Issuance of Common Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfCommonStock" xlink:to="abvc_IssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_LoanAgreementTotalAmount_lbl0" xml:lang="en-US">Loan agreement total amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementTotalAmount" xlink:to="abvc_LoanAgreementTotalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_LoanFromPaycheckProtectionPrograms_lbl0" xml:lang="en-US">Loan from pay check protection program.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanFromPaycheckProtectionPrograms" xlink:to="abvc_LoanFromPaycheckProtectionPrograms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_LongTermEquityInvestmentPolicy_lbl0" xml:lang="en-US">Disclosure of accounting policy for long-term equity investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermEquityInvestmentPolicy" xlink:to="abvc_LongTermEquityInvestmentPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_MilestonePaymentDescription_lbl0" xml:lang="en-US">Milestone payment, description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePaymentDescription" xlink:to="abvc_MilestonePaymentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_MilestonePayments_lbl0" xml:lang="en-US">Milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePayments" xlink:to="abvc_MilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage_lbl0" xml:lang="en-US">Milestone payments royalty percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePaymentsRoyaltyPercentage" xlink:to="abvc_MilestonePaymentsRoyaltyPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_NetLossAttributableToAbvcAndSubsidiaries_lbl0" xml:lang="en-US">Net loss attributable to ABVC and subsidiaries.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="abvc_NetLossAttributableToAbvcAndSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_OperatingLeaseLiabilitienoncurrent_lbl0" xml:lang="en-US">Present value of lessee&apos;s discounted obligation for lease payments from operating lease, classified as noncurrent.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeaseLiabilitienoncurrent" xlink:to="abvc_OperatingLeaseLiabilitienoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_OperatingSubleaseIncomeRelatedParties_lbl0" xml:lang="en-US">Operating sublease income  from related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingSubleaseIncomeRelatedParties" xlink:to="abvc_OperatingSubleaseIncomeRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for other than temporary impairment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:to="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_OutstandingAdvanceFromRelatedParty_lbl0" xml:lang="en-US">Amount of outstanding advance from related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingAdvanceFromRelatedParty" xlink:to="abvc_OutstandingAdvanceFromRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfCommonSharesIssuedAndOutstanding_lbl0" xml:lang="en-US">Percentage of common shares issued and outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfCommonSharesIssuedAndOutstanding" xlink:to="abvc_PercentageOfCommonSharesIssuedAndOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfIssuedShareCapital_lbl0" xml:lang="en-US">Percentage of issued share capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfIssuedShareCapital" xlink:to="abvc_PercentageOfIssuedShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfMonthlyContribution_lbl0" xml:lang="en-US">Percentage of monthly contribution.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfMonthlyContribution" xlink:to="abvc_PercentageOfMonthlyContribution_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl0" xml:lang="en-US">Percentage of payments under co-development agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:to="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PrepaymentForLongtermInvestments_lbl1" xml:lang="en-US">Prepayment for long-term investments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentForLongtermInvestments" xlink:to="abvc_PrepaymentForLongtermInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_PurchaseAdditionalShares_lbl0" xml:lang="en-US">Purchase additional shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseAdditionalShares" xlink:to="abvc_PurchaseAdditionalShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ReceivedLoanAmount_lbl0" xml:lang="en-US">Received loan amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ReceivedLoanAmount" xlink:to="abvc_ReceivedLoanAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_RegularInterestRateDescription_lbl0" xml:lang="en-US">Regular interest rate description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RegularInterestRateDescription" xlink:to="abvc_RegularInterestRateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_RelatedPartyTransactionDescriptionOfTransactions_lbl0" xml:lang="en-US">It represents related party descriptions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartyTransactionDescriptionOfTransactions" xlink:to="abvc_RelatedPartyTransactionDescriptionOfTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_RestrictedCommonShares_lbl0" xml:lang="en-US">Restricted Common Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RestrictedCommonShares" xlink:to="abvc_RestrictedCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl0" xml:lang="en-US">Schedule of extent the investee relies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:to="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl0" xml:lang="en-US">Schedule of operating lease arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:to="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of property and equipment estimated useful life.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl0" xml:lang="en-US">Tabular disclosure of related party transactions. Amount due to related party.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:to="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareOfEquityMethodInvesteeLosses_lbl0" xml:lang="en-US">Share of equity method investee losses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareOfEquityMethodInvesteeLosses" xlink:to="abvc_ShareOfEquityMethodInvesteeLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_SharesIssued1_lbl0" xml:lang="en-US">Shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesIssued1" xlink:to="abvc_SharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_SharesIssuedPricePerShares_lbl0" xml:lang="en-US">Share price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesIssuedPricePerShares" xlink:to="abvc_SharesIssuedPricePerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_SharesOfferingPricePercentage_lbl0" xml:lang="en-US">Shares offering price percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesOfferingPricePercentage" xlink:to="abvc_SharesOfferingPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockBasedCompensationForNonemployees_lbl0" xml:lang="en-US">Stock based compensation for nonemployees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockBasedCompensationForNonemployees" xlink:to="abvc_StockBasedCompensationForNonemployees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices_lbl0" xml:lang="en-US">Value, after forfeiture, of shares issued under share-based payment services arrangement. Excludes employee stock ownership plan (ESOP).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices" xlink:to="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockReverseSplitPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for Stock Reverse Split.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockReverseSplitPolicyTextBlock" xlink:to="abvc_StockReverseSplitPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_StockSubscriptionReceivable_lbl0" xml:lang="en-US">The amount of stock subscription receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceivable" xlink:to="abvc_StockSubscriptionReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_TermsOfAgreementDescription_lbl0" xml:lang="en-US">Description of agreement terms.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TermsOfAgreementDescription" xlink:to="abvc_TermsOfAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_TotalInterestExpenses_lbl0" xml:lang="en-US">Total interest expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TotalInterestExpenses" xlink:to="abvc_TotalInterestExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_TranslationAdjustmentPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for translation adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TranslationAdjustmentPolicyTextBlock" xlink:to="abvc_TranslationAdjustmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_UnsecuredLoanAgreementsDescription_lbl0" xml:lang="en-US">Description of unsecured loan agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnsecuredLoanAgreementsDescription" xlink:to="abvc_UnsecuredLoanAgreementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_UpfrontCashPayment_lbl0" xml:lang="en-US">The amount of upfront payments which are paid during the term of agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UpfrontCashPayment" xlink:to="abvc_UpfrontCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for valuation of deferred tax assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:to="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_WarrantIssued_lbl0" xml:lang="en-US">Warrant issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantIssued" xlink:to="abvc_WarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_WarrantTerm_lbl0" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantTerm" xlink:to="abvc_WarrantTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_WeightedAverageNumberOfSharesDiluted_lbl0" xml:lang="en-US">Weighted-average shares outstanding .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageNumberOfSharesDiluted" xlink:to="abvc_WeightedAverageNumberOfSharesDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_WeightedaverageSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted-average shares outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedaverageSharesOutstandingBasic" xlink:to="abvc_WeightedaverageSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abvc_ShareExchangeAgreementMember_lbl0" xml:lang="en-US">Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementMember" xlink:to="abvc_ShareExchangeAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AsiaGeneCorporationtheAsiaGeneMember_lbl0" xml:lang="en-US">AsiaGeneCorporationtheAsiaGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AsiaGeneCorporationtheAsiaGeneMember" xlink:to="abvc_AsiaGeneCorporationtheAsiaGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SharesIssued1_lbl1" xml:lang="en-US">SharesIssued1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesIssued1" xlink:to="abvc_SharesIssued1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LoanAgreementDescription_lbl0" xml:lang="en-US">LoanAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementDescription" xlink:to="abvc_LoanAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedaverageSharesOutstandingBasic_lbl1" xml:lang="en-US">WeightedaverageSharesOutstandingBasic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedaverageSharesOutstandingBasic" xlink:to="abvc_WeightedaverageSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UnsecuredConvertiblePromissoryNoteMember_lbl1" xml:lang="en-US">UnsecuredConvertiblePromissoryNoteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnsecuredConvertiblePromissoryNoteMember" xlink:to="abvc_UnsecuredConvertiblePromissoryNoteMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl1" xml:lang="en-US">StockIssuedDuringPeriodShareBasedCompensationServicesforShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:to="abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingSubleaseIncomeRelatedParties_lbl1" xml:lang="en-US">OperatingSubleaseIncomeRelatedParties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingSubleaseIncomeRelatedParties" xlink:to="abvc_OperatingSubleaseIncomeRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AggregateCommonStockShares_lbl1" xml:lang="en-US">AggregateCommonStockShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregateCommonStockShares" xlink:to="abvc_AggregateCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_MilestonePaymentDescription_lbl1" xml:lang="en-US">MilestonePaymentDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePaymentDescription" xlink:to="abvc_MilestonePaymentDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NetLoss1_lbl0" xml:lang="en-US">NetLoss1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetLoss1" xlink:to="abvc_NetLoss1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConsultingFees_lbl0" xml:lang="en-US">ConsultingFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultingFees" xlink:to="abvc_ConsultingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RgeneCorporationtheRgeneMember_lbl0" xml:lang="en-US">RgeneCorporationtheRgeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationtheRgeneMember" xlink:to="abvc_RgeneCorporationtheRgeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueShareBasedCompensationServices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices" xlink:to="abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DueFromtheRelatedPartiesCurrent_lbl1" xml:lang="en-US">DueFromtheRelatedPartiesCurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueFromtheRelatedPartiesCurrent" xlink:to="abvc_DueFromtheRelatedPartiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RentIncome_lbl0" xml:lang="en-US">RentIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RentIncome" xlink:to="abvc_RentIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfCommonSharesIssuedAndOutstanding_lbl1" xml:lang="en-US">PercentageOfCommonSharesIssuedAndOutstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfCommonSharesIssuedAndOutstanding" xlink:to="abvc_PercentageOfCommonSharesIssuedAndOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_MergerAgreementMember_lbl0" xml:lang="en-US">MergerAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MergerAgreementMember" xlink:to="abvc_MergerAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_KameyamaMember_lbl0" xml:lang="en-US">KameyamaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_KameyamaMember" xlink:to="abvc_KameyamaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CommonStockIssuedAfterStockSplit_lbl2" xml:lang="en-US">CommonStockIssuedAfterStockSplit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockIssuedAfterStockSplit" xlink:to="abvc_CommonStockIssuedAfterStockSplit_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GenePharmInctheGenePharmMember_lbl0" xml:lang="en-US">GenePharmInctheGenePharmMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenePharmInctheGenePharmMember" xlink:to="abvc_GenePharmInctheGenePharmMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WallachBethCapitalLLCMember_lbl0" xml:lang="en-US">WallachBethCapitalLLCMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WallachBethCapitalLLCMember" xlink:to="abvc_WallachBethCapitalLLCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DueToshareholdersMember_lbl0" xml:lang="en-US">DueToshareholdersMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueToshareholdersMember" xlink:to="abvc_DueToshareholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfGoodwill_lbl0" xml:lang="en-US">PercentageOfGoodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfGoodwill" xlink:to="abvc_PercentageOfGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TypeOfCurrencyAxis_lbl0" xml:lang="en-US">TypeOfCurrencyAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TypeOfCurrencyAxis" xlink:to="abvc_TypeOfCurrencyAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CathayUnitedLoanAgreementMember_lbl0" xml:lang="en-US">CathayUnitedLoanAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayUnitedLoanAgreementMember" xlink:to="abvc_CathayUnitedLoanAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract0_lbl0" xml:lang="en-US">NonMarketableCostMethodInvestmentsNetAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonMarketableCostMethodInvestmentsNetAbstract0" xlink:to="abvc_NonMarketableCostMethodInvestmentsNetAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CashPaidDuringYearForAbstract_lbl0" xml:lang="en-US">CashPaidDuringYearForAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CashPaidDuringYearForAbstract" xlink:to="abvc_CashPaidDuringYearForAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfOperatingLeaseArrangementsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:to="abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageSharesOutstandingAbstract0_lbl0" xml:lang="en-US">WeightedAverageSharesOutstandingAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageSharesOutstandingAbstract0" xlink:to="abvc_WeightedAverageSharesOutstandingAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LionGeneCorporationtheLionGeneMember_lbl0" xml:lang="en-US">LionGeneCorporationtheLionGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionGeneCorporationtheLionGeneMember" xlink:to="abvc_LionGeneCorporationtheLionGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EquityMethodInvestmentsNetAbstract0_lbl0" xml:lang="en-US">EquityMethodInvestmentsNetAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodInvestmentsNetAbstract0" xlink:to="abvc_EquityMethodInvestmentsNetAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfLongTermInvestmentTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfLongTermInvestmentTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfLongTermInvestmentTableTextBlock" xlink:to="abvc_ScheduleOfLongTermInvestmentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl1" xml:lang="en-US">OtherThanTemporaryImpairmentPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OtherThanTemporaryImpairmentPolicyTextBlock" xlink:to="abvc_OtherThanTemporaryImpairmentPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_YuangeneCorporationMember_lbl0" xml:lang="en-US">YuangeneCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YuangeneCorporationMember" xlink:to="abvc_YuangeneCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConsultingAgreementMember_lbl0" xml:lang="en-US">ConsultingAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultingAgreementMember" xlink:to="abvc_ConsultingAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AllocationOfThePurchasePriceAbstract_lbl0" xml:lang="en-US">AllocationOfThePurchasePriceAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AllocationOfThePurchasePriceAbstract" xlink:to="abvc_AllocationOfThePurchasePriceAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_KeypointMember_lbl0" xml:lang="en-US">KeypointMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_KeypointMember" xlink:to="abvc_KeypointMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DebtConversionConvertedInstrumentAmount_lbl1" xml:lang="en-US">DebtConversionConvertedInstrumentAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtConversionConvertedInstrumentAmount" xlink:to="abvc_DebtConversionConvertedInstrumentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioLiteTaiwanMember_lbl0" xml:lang="en-US">BioLiteTaiwanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteTaiwanMember" xlink:to="abvc_BioLiteTaiwanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GrossProfits_lbl0" xml:lang="en-US">GrossProfits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GrossProfits" xlink:to="abvc_GrossProfits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AllowanceForInventoryValuationAndObsolescenceLoss_lbl1" xml:lang="en-US">AllowanceForInventoryValuationAndObsolescenceLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AllowanceForInventoryValuationAndObsolescenceLoss" xlink:to="abvc_AllowanceForInventoryValuationAndObsolescenceLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl1" xml:lang="en-US">ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:to="abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AggregateWorkingcapital_lbl1" xml:lang="en-US">AggregateWorkingcapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregateWorkingcapital" xlink:to="abvc_AggregateWorkingcapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_KimhoConsultantsCoLtdtheKimhoMember_lbl0" xml:lang="en-US">KimhoConsultantsCoLtdtheKimhoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_KimhoConsultantsCoLtdtheKimhoMember" xlink:to="abvc_KimhoConsultantsCoLtdtheKimhoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CollaborativeAgreementsDescription_lbl1" xml:lang="en-US">CollaborativeAgreementsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CollaborativeAgreementsDescription" xlink:to="abvc_CollaborativeAgreementsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember_lbl0" xml:lang="en-US">MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:to="abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioHopeKingCorporationMember_lbl0" xml:lang="en-US">BioHopeKingCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioHopeKingCorporationMember" xlink:to="abvc_BioHopeKingCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DueToRelatedPartyCurrentAndNoncurrent_lbl1" xml:lang="en-US">DueToRelatedPartyCurrentAndNoncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueToRelatedPartyCurrentAndNoncurrent" xlink:to="abvc_DueToRelatedPartyCurrentAndNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PrepaymentForLongtermInvestments_lbl2" xml:lang="en-US">PrepaymentForLongtermInvestments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PrepaymentForLongtermInvestments" xlink:to="abvc_PrepaymentForLongtermInvestments_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OutstandingAdvanceFromRelatedParty_lbl1" xml:lang="en-US">OutstandingAdvanceFromRelatedParty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingAdvanceFromRelatedParty" xlink:to="abvc_OutstandingAdvanceFromRelatedParty_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl0" xml:lang="en-US">BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:to="abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks_lbl0" xml:lang="en-US">ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:to="abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NumberOfDirectors_lbl0" xml:lang="en-US">NumberOfDirectors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumberOfDirectors" xlink:to="abvc_NumberOfDirectors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NonRelatedPartiesMember_lbl0" xml:lang="en-US">NonRelatedPartiesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonRelatedPartiesMember" xlink:to="abvc_NonRelatedPartiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BasicLossPerShare_lbl0" xml:lang="en-US">BasicLossPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BasicLossPerShare" xlink:to="abvc_BasicLossPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AsiaGeneMember_lbl0" xml:lang="en-US">AsiaGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AsiaGeneMember" xlink:to="abvc_AsiaGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PurchaseConsiderationAbstract_lbl0" xml:lang="en-US">PurchaseConsiderationAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseConsiderationAbstract" xlink:to="abvc_PurchaseConsiderationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DenominatorAbstract_lbl0" xml:lang="en-US">DenominatorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DenominatorAbstract" xlink:to="abvc_DenominatorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl1" xml:lang="en-US">OperatingLeasesFutureMinimumPaymentDueCurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdvanceFromCustomers_lbl1" xml:lang="en-US">AdvanceFromCustomers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvanceFromCustomers" xlink:to="abvc_AdvanceFromCustomers_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_InterestIncomes_lbl0" xml:lang="en-US">InterestIncomes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_InterestIncomes" xlink:to="abvc_InterestIncomes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_InvestmentLoss1_lbl1" xml:lang="en-US">InvestmentLoss1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_InvestmentLoss1" xlink:to="abvc_InvestmentLoss1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DebtInstrumentAggregateAmount_lbl1" xml:lang="en-US">DebtInstrumentAggregateAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DebtInstrumentAggregateAmount" xlink:to="abvc_DebtInstrumentAggregateAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PublicEquityOfferingExceedAmount_lbl0" xml:lang="en-US">PublicEquityOfferingExceedAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PublicEquityOfferingExceedAmount" xlink:to="abvc_PublicEquityOfferingExceedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CTBCBankMember_lbl0" xml:lang="en-US">CTBCBankMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CTBCBankMember" xlink:to="abvc_CTBCBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GovernmentGrantIncome_lbl2" xml:lang="en-US">GovernmentGrantIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GovernmentGrantIncome" xlink:to="abvc_GovernmentGrantIncome_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NonmarketableCostMethodInvestmentsNet_lbl0" xml:lang="en-US">NonmarketableCostMethodInvestmentsNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonmarketableCostMethodInvestmentsNet" xlink:to="abvc_NonmarketableCostMethodInvestmentsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockSubscriptionReceivableMember_lbl0" xml:lang="en-US">StockSubscriptionReceivableMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceivableMember" xlink:to="abvc_StockSubscriptionReceivableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareExchangeAgreementMember_lbl1" xml:lang="en-US">ShareExchangeAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementMember" xlink:to="abvc_ShareExchangeAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockIssuedValue_lbl0" xml:lang="en-US">StockIssuedValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockIssuedValue" xlink:to="abvc_StockIssuedValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BraingenesisBiotechnologyCoLtdMember_lbl0" xml:lang="en-US">BraingenesisBiotechnologyCoLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BraingenesisBiotechnologyCoLtdMember" xlink:to="abvc_BraingenesisBiotechnologyCoLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CathayBankMember_lbl0" xml:lang="en-US">CathayBankMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayBankMember" xlink:to="abvc_CathayBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WarrantsPurchased_lbl0" xml:lang="en-US">WarrantsPurchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantsPurchased" xlink:to="abvc_WarrantsPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RelatedPartyTransactionDescriptionOfTransactions_lbl1" xml:lang="en-US">RelatedPartyTransactionDescriptionOfTransactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RelatedPartyTransactionDescriptionOfTransactions" xlink:to="abvc_RelatedPartyTransactionDescriptionOfTransactions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LossPerShareAbstract_lbl0" xml:lang="en-US">LossPerShareAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LossPerShareAbstract" xlink:to="abvc_LossPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BusinessCombinationMember_lbl0" xml:lang="en-US">BusinessCombinationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationMember" xlink:to="abvc_BusinessCombinationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter_lbl0" xml:lang="en-US">OperatingLeasesFutureMinimumPaymentDueThereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueThereafter_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LoanFromPaycheckProtectionProgram_lbl0" xml:lang="en-US">LoanFromPaycheckProtectionProgram</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanFromPaycheckProtectionProgram" xlink:to="abvc_LoanFromPaycheckProtectionProgram_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_IssuanceOfStockValue_lbl0" xml:lang="en-US">IssuanceOfStockValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfStockValue" xlink:to="abvc_IssuanceOfStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioKeyMember_lbl0" xml:lang="en-US">BioKeyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioKeyMember" xlink:to="abvc_BioKeyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_YuanGeneCorporationtheYuanGeneMember_lbl0" xml:lang="en-US">YuanGeneCorporationtheYuanGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YuanGeneCorporationtheYuanGeneMember" xlink:to="abvc_YuanGeneCorporationtheYuanGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UnsecuredLoanAgreementsDescription_lbl1" xml:lang="en-US">UnsecuredLoanAgreementsDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnsecuredLoanAgreementsDescription" xlink:to="abvc_UnsecuredLoanAgreementsDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_FinancialAmendmentDescription_lbl0" xml:lang="en-US">FinancialAmendmentDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_FinancialAmendmentDescription" xlink:to="abvc_FinancialAmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LBGUSAInctheLBGUSAMember_lbl0" xml:lang="en-US">LBGUSAInctheLBGUSAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LBGUSAInctheLBGUSAMember" xlink:to="abvc_LBGUSAInctheLBGUSAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:to="abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UpfrontCashPayment_lbl1" xml:lang="en-US">UpfrontCashPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UpfrontCashPayment" xlink:to="abvc_UpfrontCashPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PurchaseAdditionalShares_lbl1" xml:lang="en-US">PurchaseAdditionalShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseAdditionalShares" xlink:to="abvc_PurchaseAdditionalShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions_lbl0" xml:lang="en-US">PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" xlink:to="abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockBasedCompensationForNonemployees_lbl1" xml:lang="en-US">StockBasedCompensationForNonemployees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockBasedCompensationForNonemployees" xlink:to="abvc_StockBasedCompensationForNonemployees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ViewTradeSecuritiesIncMember_lbl0" xml:lang="en-US">ViewTradeSecuritiesIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ViewTradeSecuritiesIncMember" xlink:to="abvc_ViewTradeSecuritiesIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DenominatorAbstract0_lbl0" xml:lang="en-US">DenominatorAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DenominatorAbstract0" xlink:to="abvc_DenominatorAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_IssuanceOfCommonStock_lbl1" xml:lang="en-US">IssuanceOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_IssuanceOfCommonStock" xlink:to="abvc_IssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EquityMethodInvestmentsNetAbstract_lbl0" xml:lang="en-US">EquityMethodInvestmentsNetAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EquityMethodInvestmentsNetAbstract" xlink:to="abvc_EquityMethodInvestmentsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BuildingsAndLeaseholdImprovementsMember_lbl0" xml:lang="en-US">BuildingsAndLeaseholdImprovementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BuildingsAndLeaseholdImprovementsMember" xlink:to="abvc_BuildingsAndLeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_MilestonePayments_lbl1" xml:lang="en-US">MilestonePayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePayments" xlink:to="abvc_MilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WarrantTerm_lbl1" xml:lang="en-US">WarrantTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantTerm" xlink:to="abvc_WarrantTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears_lbl0" xml:lang="en-US">OperatingLeasesFutureMinimumPaymentDueInFourYears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AmkeyMember_lbl0" xml:lang="en-US">AmkeyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AmkeyMember" xlink:to="abvc_AmkeyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageDiscountRateAbstract_lbl0" xml:lang="en-US">WeightedAverageDiscountRateAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageDiscountRateAbstract" xlink:to="abvc_WeightedAverageDiscountRateAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EugeneJiangMember_lbl0" xml:lang="en-US">EugeneJiangMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EugeneJiangMember" xlink:to="abvc_EugeneJiangMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_KeypointTechnologyLtdtheKeypointMember_lbl0" xml:lang="en-US">KeypointTechnologyLtdtheKeypointMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_KeypointTechnologyLtdtheKeypointMember" xlink:to="abvc_KeypointTechnologyLtdtheKeypointMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BHKCoDevelopmentAgreementMember_lbl0" xml:lang="en-US">BHKCoDevelopmentAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAgreementMember" xlink:to="abvc_BHKCoDevelopmentAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LabourPensionFundPercentage_lbl0" xml:lang="en-US">LabourPensionFundPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LabourPensionFundPercentage" xlink:to="abvc_LabourPensionFundPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ExceedingAmount_lbl1" xml:lang="en-US">ExceedingAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ExceedingAmount" xlink:to="abvc_ExceedingAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstStockPurchaseAgreementMember_lbl0" xml:lang="en-US">BioFirstStockPurchaseAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstStockPurchaseAgreementMember" xlink:to="abvc_BioFirstStockPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockSubscriptionReceivable_lbl1" xml:lang="en-US">StockSubscriptionReceivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockSubscriptionReceivable" xlink:to="abvc_StockSubscriptionReceivable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentTextBlock_lbl0" xml:lang="en-US">LongTermInvestmentTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentTextBlock" xlink:to="abvc_LongTermInvestmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AmkeyVenturesLLCAmkeyMember_lbl0" xml:lang="en-US">AmkeyVenturesLLCAmkeyMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AmkeyVenturesLLCAmkeyMember" xlink:to="abvc_AmkeyVenturesLLCAmkeyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OutstandingPrincipalAndAccruedInterest_lbl0" xml:lang="en-US">OutstandingPrincipalAndAccruedInterest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OutstandingPrincipalAndAccruedInterest" xlink:to="abvc_OutstandingPrincipalAndAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstMember_lbl0" xml:lang="en-US">BioFirstMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstMember" xlink:to="abvc_BioFirstMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TermsOfAgreementDescription_lbl1" xml:lang="en-US">TermsOfAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TermsOfAgreementDescription" xlink:to="abvc_TermsOfAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareExchangeAgreementFourMember_lbl0" xml:lang="en-US">ShareExchangeAgreementFourMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementFourMember" xlink:to="abvc_ShareExchangeAgreementFourMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GenepharmBiotechCorporationMember_lbl0" xml:lang="en-US">GenepharmBiotechCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenepharmBiotechCorporationMember" xlink:to="abvc_GenepharmBiotechCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareExchangeAgreementTwoMember_lbl0" xml:lang="en-US">ShareExchangeAgreementTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementTwoMember" xlink:to="abvc_ShareExchangeAgreementTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LoanAgreementTotalAmount_lbl1" xml:lang="en-US">LoanAgreementTotalAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementTotalAmount" xlink:to="abvc_LoanAgreementTotalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RestrictedCommonShares_lbl1" xml:lang="en-US">RestrictedCommonShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RestrictedCommonShares" xlink:to="abvc_RestrictedCommonShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConsultingAgreementDesciption_lbl0" xml:lang="en-US">ConsultingAgreementDesciption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConsultingAgreementDesciption" xlink:to="abvc_ConsultingAgreementDesciption_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl0" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NumberOfInvestors_lbl0" xml:lang="en-US">NumberOfInvestors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumberOfInvestors" xlink:to="abvc_NumberOfInvestors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AgreementDescription_lbl1" xml:lang="en-US">AgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AgreementDescription" xlink:to="abvc_AgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GrantDateTerm_lbl0" xml:lang="en-US">GrantDateTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GrantDateTerm" xlink:to="abvc_GrantDateTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NumeratorAbstract0_lbl0" xml:lang="en-US">NumeratorAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumeratorAbstract0" xlink:to="abvc_NumeratorAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RgeneCorporationMember_lbl1" xml:lang="en-US">RgeneCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneCorporationMember" xlink:to="abvc_RgeneCorporationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BankLoansTextBlock_lbl0" xml:lang="en-US">BankLoansTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BankLoansTextBlock" xlink:to="abvc_BankLoansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GainLossOnForeignExchangeChanges_lbl0" xml:lang="en-US">GainLossOnForeignExchangeChanges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GainLossOnForeignExchangeChanges" xlink:to="abvc_GainLossOnForeignExchangeChanges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_YoshinobuOdairatheOdairaMember_lbl0" xml:lang="en-US">YoshinobuOdairatheOdairaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YoshinobuOdairatheOdairaMember" xlink:to="abvc_YoshinobuOdairatheOdairaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdditionalSharesOfCommonStock_lbl1" xml:lang="en-US">AdditionalSharesOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionalSharesOfCommonStock" xlink:to="abvc_AdditionalSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_JIANGSMember_lbl0" xml:lang="en-US">JIANGSMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_JIANGSMember" xlink:to="abvc_JIANGSMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LossPerShareAbstract0_lbl0" xml:lang="en-US">LossPerShareAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LossPerShareAbstract0" xlink:to="abvc_LossPerShareAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AggregatePrincipalAndAccruedInterestExpense_lbl0" xml:lang="en-US">AggregatePrincipalAndAccruedInterestExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregatePrincipalAndAccruedInterestExpense" xlink:to="abvc_AggregatePrincipalAndAccruedInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareExchangeAgreementOneMember_lbl0" xml:lang="en-US">ShareExchangeAgreementOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementOneMember" xlink:to="abvc_ShareExchangeAgreementOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction_lbl0" xml:lang="en-US">InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" xlink:to="abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LBGUSAMember_lbl0" xml:lang="en-US">LBGUSAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LBGUSAMember" xlink:to="abvc_LBGUSAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AccruedInterest_lbl1" xml:lang="en-US">AccruedInterest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccruedInterest" xlink:to="abvc_AccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BeneficialConversionFeature_lbl1" xml:lang="en-US">BeneficialConversionFeature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BeneficialConversionFeature" xlink:to="abvc_BeneficialConversionFeature_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PlacementAgentAgreementDescription_lbl0" xml:lang="en-US">PlacementAgentAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PlacementAgentAgreementDescription" xlink:to="abvc_PlacementAgentAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TheJiangsMember_lbl0" xml:lang="en-US">TheJiangsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TheJiangsMember" xlink:to="abvc_TheJiangsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareOfEquityMethodInvesteeLosses_lbl1" xml:lang="en-US">ShareOfEquityMethodInvesteeLosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareOfEquityMethodInvesteeLosses" xlink:to="abvc_ShareOfEquityMethodInvesteeLosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ABVCBioPharmaHKLimitedMember_lbl0" xml:lang="en-US">ABVCBioPharmaHKLimitedMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ABVCBioPharmaHKLimitedMember" xlink:to="abvc_ABVCBioPharmaHKLimitedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SharesOfferingPricePercentage_lbl1" xml:lang="en-US">SharesOfferingPricePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesOfferingPricePercentage" xlink:to="abvc_SharesOfferingPricePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ForgivenAmountPercentageUsedForPayroll_lbl0" xml:lang="en-US">ForgivenAmountPercentageUsedForPayroll</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ForgivenAmountPercentageUsedForPayroll" xlink:to="abvc_ForgivenAmountPercentageUsedForPayroll_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TranslationAdjustmentPolicyTextBlock_lbl1" xml:lang="en-US">TranslationAdjustmentPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TranslationAdjustmentPolicyTextBlock" xlink:to="abvc_TranslationAdjustmentPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ReceivedLoanAmount_lbl1" xml:lang="en-US">ReceivedLoanAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ReceivedLoanAmount" xlink:to="abvc_ReceivedLoanAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ForwardStockSplitsPolicyTextBlock_lbl1" xml:lang="en-US">ForwardStockSplitsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ForwardStockSplitsPolicyTextBlock" xlink:to="abvc_ForwardStockSplitsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PaycheckProtectionProgramLoanPayableTextBlock_lbl0" xml:lang="en-US">PaycheckProtectionProgramLoanPayableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PaycheckProtectionProgramLoanPayableTextBlock" xlink:to="abvc_PaycheckProtectionProgramLoanPayableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_lbl0" xml:lang="en-US">BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:to="abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RgeneMember_lbl0" xml:lang="en-US">RgeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RgeneMember" xlink:to="abvc_RgeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfExtentInvesteeReliesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:to="abvc_ScheduleOfExtentInvesteeReliesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_Consultingagreementdescription_lbl1" xml:lang="en-US">Consultingagreementdescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_Consultingagreementdescription" xlink:to="abvc_Consultingagreementdescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CodevelopmentagreementMember_lbl0" xml:lang="en-US">CodevelopmentagreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CodevelopmentagreementMember" xlink:to="abvc_CodevelopmentagreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SeriesAWarrantsMember_lbl0" xml:lang="en-US">SeriesAWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SeriesAWarrantsMember" xlink:to="abvc_SeriesAWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_MilestonePaymentsRoyaltyPercentage_lbl1" xml:lang="en-US">MilestonePaymentsRoyaltyPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_MilestonePaymentsRoyaltyPercentage" xlink:to="abvc_MilestonePaymentsRoyaltyPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDue_lbl0" xml:lang="en-US">OperatingLeasesFutureMinimumPaymentDue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDue" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NetLossAttributableToAbvcAndSubsidiaries_lbl1" xml:lang="en-US">NetLossAttributableToAbvcAndSubsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetLossAttributableToAbvcAndSubsidiaries" xlink:to="abvc_NetLossAttributableToAbvcAndSubsidiaries_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl1" xml:lang="en-US">ValuationOfDeferredTaxAssetsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:to="abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LionArtsPromotionInctheLIONMember_lbl0" xml:lang="en-US">LionArtsPromotionInctheLIONMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionArtsPromotionInctheLIONMember" xlink:to="abvc_LionArtsPromotionInctheLIONMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SharesIssuedPricePerShares_lbl1" xml:lang="en-US">SharesIssuedPricePerShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharesIssuedPricePerShares" xlink:to="abvc_SharesIssuedPricePerShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TwoThousandSixteenEquityIncentivePlanMember_lbl0" xml:lang="en-US">TwoThousandSixteenEquityIncentivePlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TwoThousandSixteenEquityIncentivePlanMember" xlink:to="abvc_TwoThousandSixteenEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AggregatePrincipalAmount_lbl1" xml:lang="en-US">AggregatePrincipalAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AggregatePrincipalAmount" xlink:to="abvc_AggregatePrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstCorporationMember_lbl1" xml:lang="en-US">BioFirstCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationMember" xlink:to="abvc_BioFirstCorporationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CathayUnitedBankMember_lbl0" xml:lang="en-US">CathayUnitedBankMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CathayUnitedBankMember" xlink:to="abvc_CathayUnitedBankMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdvancesBearInterestDescription_lbl1" xml:lang="en-US">AdvancesBearInterestDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdvancesBearInterestDescription" xlink:to="abvc_AdvancesBearInterestDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NTMember_lbl0" xml:lang="en-US">NTMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NTMember" xlink:to="abvc_NTMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioLiteMember_lbl0" xml:lang="en-US">BioLiteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteMember" xlink:to="abvc_BioLiteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfMonthlyContribution_lbl1" xml:lang="en-US">PercentageOfMonthlyContribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfMonthlyContribution" xlink:to="abvc_PercentageOfMonthlyContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LionGeneCorporationMember_lbl0" xml:lang="en-US">LionGeneCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionGeneCorporationMember" xlink:to="abvc_LionGeneCorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConversionPrice_lbl1" xml:lang="en-US">ConversionPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConversionPrice" xlink:to="abvc_ConversionPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstAustraliaMember_lbl0" xml:lang="en-US">BioFirstAustraliaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstAustraliaMember" xlink:to="abvc_BioFirstAustraliaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CoDevAgreementDescription_lbl1" xml:lang="en-US">CoDevAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CoDevAgreementDescription" xlink:to="abvc_CoDevAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_InterestRate_lbl0" xml:lang="en-US">InterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_InterestRate" xlink:to="abvc_InterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BHKCoDevelopmentAggreementMember_lbl1" xml:lang="en-US">BHKCoDevelopmentAggreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BHKCoDevelopmentAggreementMember" xlink:to="abvc_BHKCoDevelopmentAggreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AllocationOfThePurchasePriceAbstract0_lbl0" xml:lang="en-US">AllocationOfThePurchasePriceAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AllocationOfThePurchasePriceAbstract0" xlink:to="abvc_AllocationOfThePurchasePriceAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution_lbl1" xml:lang="en-US">AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" xlink:to="abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CumulativeTransactionAdjustments_lbl0" xml:lang="en-US">CumulativeTransactionAdjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CumulativeTransactionAdjustments" xlink:to="abvc_CumulativeTransactionAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UnpaidConsultingFees_lbl0" xml:lang="en-US">UnpaidConsultingFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnpaidConsultingFees" xlink:to="abvc_UnpaidConsultingFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:to="abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract0_lbl0" xml:lang="en-US">WeightedAverageRemainingLeaseTermAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract0" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BorrowingsFromRelatedParties_lbl0" xml:lang="en-US">BorrowingsFromRelatedParties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BorrowingsFromRelatedParties" xlink:to="abvc_BorrowingsFromRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NetSales_lbl0" xml:lang="en-US">NetSales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NetSales" xlink:to="abvc_NetSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PurchaseConsiderationAbstract0_lbl0" xml:lang="en-US">PurchaseConsiderationAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PurchaseConsiderationAbstract0" xlink:to="abvc_PurchaseConsiderationAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdditionCashPayment_lbl0" xml:lang="en-US">AdditionCashPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdditionCashPayment" xlink:to="abvc_AdditionCashPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermEquityInvestmentPolicy_lbl1" xml:lang="en-US">LongTermEquityInvestmentPolicy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermEquityInvestmentPolicy" xlink:to="abvc_LongTermEquityInvestmentPolicy_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PromissoryNoteDescription_lbl0" xml:lang="en-US">PromissoryNoteDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PromissoryNoteDescription" xlink:to="abvc_PromissoryNoteDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LionArtsPromotionInctheLionArtsMember_lbl0" xml:lang="en-US">LionArtsPromotionInctheLionArtsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LionArtsPromotionInctheLionArtsMember" xlink:to="abvc_LionArtsPromotionInctheLionArtsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NumeratorAbstract_lbl0" xml:lang="en-US">NumeratorAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NumeratorAbstract" xlink:to="abvc_NumeratorAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertiblePromissoryNoteValue_lbl1" xml:lang="en-US">ConvertiblePromissoryNoteValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertiblePromissoryNoteValue" xlink:to="abvc_ConvertiblePromissoryNoteValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ExercisableAtAPricePerShare_lbl0" xml:lang="en-US">ExercisableAtAPricePerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ExercisableAtAPricePerShare" xlink:to="abvc_ExercisableAtAPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockReverseSplitPolicyTextBlock_lbl1" xml:lang="en-US">StockReverseSplitPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockReverseSplitPolicyTextBlock" xlink:to="abvc_StockReverseSplitPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_NonMarketableCostMethodInvestmentsNetAbstract_lbl0" xml:lang="en-US">NonMarketableCostMethodInvestmentsNetAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="abvc_NonMarketableCostMethodInvestmentsNetAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PAYCHECKPROTECTIONPROGRAMMember_lbl1" xml:lang="en-US">PAYCHECKPROTECTIONPROGRAMMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PAYCHECKPROTECTIONPROGRAMMember" xlink:to="abvc_PAYCHECKPROTECTIONPROGRAMMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_GenePharmIncMember_lbl0" xml:lang="en-US">GenePharmIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_GenePharmIncMember" xlink:to="abvc_GenePharmIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AccountingTreatmentDescription_lbl0" xml:lang="en-US">AccountingTreatmentDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AccountingTreatmentDescription" xlink:to="abvc_AccountingTreatmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WarrantIssued_lbl1" xml:lang="en-US">WarrantIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WarrantIssued" xlink:to="abvc_WarrantIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingLeaseLiabilitienoncurrent_lbl1" xml:lang="en-US">OperatingLeaseLiabilitienoncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeaseLiabilitienoncurrent" xlink:to="abvc_OperatingLeaseLiabilitienoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SeriesBWarrantsMember_lbl0" xml:lang="en-US">SeriesBWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SeriesBWarrantsMember" xlink:to="abvc_SeriesBWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember_lbl0" xml:lang="en-US">EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:to="abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DueToEmployeeMember_lbl0" xml:lang="en-US">DueToEmployeeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DueToEmployeeMember" xlink:to="abvc_DueToEmployeeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl1" xml:lang="en-US">PercentageOfPaymentsUnderCodevelopmentAgreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:to="abvc_PercentageOfPaymentsUnderCodevelopmentAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SecuritiesPurchaseAgreementMember_lbl0" xml:lang="en-US">SecuritiesPurchaseAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SecuritiesPurchaseAgreementMember" xlink:to="abvc_SecuritiesPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageSharesOutstandingAbstract_lbl0" xml:lang="en-US">WeightedAverageSharesOutstandingAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageSharesOutstandingAbstract" xlink:to="abvc_WeightedAverageSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CommonStockIssuedBeforeStockSplit_lbl1" xml:lang="en-US">CommonStockIssuedBeforeStockSplit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockIssuedBeforeStockSplit" xlink:to="abvc_CommonStockIssuedBeforeStockSplit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution_lbl1" xml:lang="en-US">AdjustmentsToAdditionalPaidInCapitalInCapitalContribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" xlink:to="abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertiblePromissoryNote_lbl1" xml:lang="en-US">ConvertiblePromissoryNote</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertiblePromissoryNote" xlink:to="abvc_ConvertiblePromissoryNote_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears_lbl0" xml:lang="en-US">OperatingLeasesFutureMinimumPaymentDueInThreeYears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_AsiangeneCorporationMember_lbl1" xml:lang="en-US">AsiangeneCorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_AsiangeneCorporationMember" xlink:to="abvc_AsiangeneCorporationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LoanAgreementMember_lbl0" xml:lang="en-US">LoanAgreementMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAgreementMember" xlink:to="abvc_LoanAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" xlink:to="abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageNumberOfSharesDiluted_lbl1" xml:lang="en-US">WeightedAverageNumberOfSharesDiluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageNumberOfSharesDiluted" xlink:to="abvc_WeightedAverageNumberOfSharesDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_DescriptionOfPublicOffering_lbl1" xml:lang="en-US">DescriptionOfPublicOffering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_DescriptionOfPublicOffering" xlink:to="abvc_DescriptionOfPublicOffering_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ConvertibleNotesPayableDisclosureTextBlock_lbl1" xml:lang="en-US">ConvertibleNotesPayableDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ConvertibleNotesPayableDisclosureTextBlock" xlink:to="abvc_ConvertibleNotesPayableDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears_lbl0" xml:lang="en-US">OperatingLeasesFutureMinimumPaymentDueInTwoYears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:to="abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ImpairmentOfEquityInvestments_lbl1" xml:lang="en-US">ImpairmentOfEquityInvestments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ImpairmentOfEquityInvestments" xlink:to="abvc_ImpairmentOfEquityInvestments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_CommonStockShareAuthorized_lbl1" xml:lang="en-US">CommonStockShareAuthorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_CommonStockShareAuthorized" xlink:to="abvc_CommonStockShareAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageRemainingLeaseTermAbstract_lbl0" xml:lang="en-US">WeightedAverageRemainingLeaseTermAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageRemainingLeaseTermAbstract" xlink:to="abvc_WeightedAverageRemainingLeaseTermAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioFirstCorporationtheBioFirstMember_lbl0" xml:lang="en-US">BioFirstCorporationtheBioFirstMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioFirstCorporationtheBioFirstMember" xlink:to="abvc_BioFirstCorporationtheBioFirstMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_RegularInterestRateDescription_lbl1" xml:lang="en-US">RegularInterestRateDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_RegularInterestRateDescription" xlink:to="abvc_RegularInterestRateDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_BioLiteJapanMember_lbl0" xml:lang="en-US">BioLiteJapanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_BioLiteJapanMember" xlink:to="abvc_BioLiteJapanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_YuanGeneMember_lbl0" xml:lang="en-US">YuanGeneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_YuanGeneMember" xlink:to="abvc_YuanGeneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ArticlesOfIncorporationMember_lbl0" xml:lang="en-US">ArticlesOfIncorporationMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ArticlesOfIncorporationMember" xlink:to="abvc_ArticlesOfIncorporationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_PercentageOfIssuedShareCapital_lbl1" xml:lang="en-US">PercentageOfIssuedShareCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_PercentageOfIssuedShareCapital" xlink:to="abvc_PercentageOfIssuedShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_TotalInterestExpenses_lbl1" xml:lang="en-US">TotalInterestExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_TotalInterestExpenses" xlink:to="abvc_TotalInterestExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_principalAmount_lbl0" xml:lang="en-US">principalAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_principalAmount" xlink:to="abvc_principalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:to="abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LoanFromPaycheckProtectionPrograms_lbl1" xml:lang="en-US">LoanFromPaycheckProtectionPrograms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanFromPaycheckProtectionPrograms" xlink:to="abvc_LoanFromPaycheckProtectionPrograms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_UnrestrictedCommonShares_lbl0" xml:lang="en-US">UnrestrictedCommonShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_UnrestrictedCommonShares" xlink:to="abvc_UnrestrictedCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_StockOptionsTextBlock_lbl0" xml:lang="en-US">StockOptionsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_StockOptionsTextBlock" xlink:to="abvc_StockOptionsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LbgUsaIncMember_lbl0" xml:lang="en-US">LbgUsaIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LbgUsaIncMember" xlink:to="abvc_LbgUsaIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_ShareExchangeAgreementThreeMember_lbl0" xml:lang="en-US">ShareExchangeAgreementThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_ShareExchangeAgreementThreeMember" xlink:to="abvc_ShareExchangeAgreementThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock_lbl0" xml:lang="en-US">OperatingLeasesOfLesseeDisclosuresTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock" xlink:to="abvc_OperatingLeasesOfLesseeDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LoanAmout_lbl0" xml:lang="en-US">LoanAmout</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LoanAmout" xlink:to="abvc_LoanAmout_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_WeightedAverageDiscountRateAbstract0_lbl0" xml:lang="en-US">WeightedAverageDiscountRateAbstract0</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_WeightedAverageDiscountRateAbstract0" xlink:to="abvc_WeightedAverageDiscountRateAbstract0_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abvc_LongTermInvestmentNetLoss_lbl0" xml:lang="en-US">LongTermInvestmentNetLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abvc_LongTermInvestmentNetLoss" xlink:to="abvc_LongTermInvestmentNetLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl0" xml:lang="en-US">Proceeds from Contributions from Affiliates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl0" xml:lang="en-US">Business Combination Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable_lbl0" xml:lang="en-US">Payments to Acquire Notes Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease_lbl0" xml:lang="en-US">Short-Term Debt, Interest Rate Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtInterestRateIncrease" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Due to Other Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl0" xml:lang="en-US">Temporary Equity, Par Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl0" xml:lang="en-US">Loans Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl0" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDepositLiability_lbl0" xml:lang="en-US">Security Deposit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl2" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl2" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl0" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt_lbl0" xml:lang="en-US">Proceeds from Other Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherShortTermDebt" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Income Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Subscriptions Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl0" xml:lang="en-US">Payments to Fund Long-Term Loans to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermInvestments_lbl0" xml:lang="en-US">Long-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl0" xml:lang="en-US">Goodwill, Impairment Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl0" xml:lang="en-US">Schedule of Debt Conversions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:to="us-gaap_ScheduleOfDebtConversionsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealizedInvestmentGainsLosses_lbl0" xml:lang="en-US">Realized Investment Gains (Losses)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealizedInvestmentGainsLosses" xlink:to="us-gaap_RealizedInvestmentGainsLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet_lbl0" xml:lang="en-US">Other Operating Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl0" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyShareholderServiceFeeExpense_lbl0" xml:lang="en-US">Investment Company, Shareholder Service Fee Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyShareholderServiceFeeExpense" xlink:to="us-gaap_InvestmentCompanyShareholderServiceFeeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl0" xml:lang="en-US">Conversion of Stock, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl0" xml:lang="en-US">Collaborative Arrangement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonValue_lbl0" xml:lang="en-US">Treasury Stock, Common, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseOther_lbl0" xml:lang="en-US">Interest Expense, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseOther" xlink:to="us-gaap_InterestExpenseOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesAuthorized_lbl0" xml:lang="en-US">Excess Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesAuthorized" xlink:to="us-gaap_ExcessStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl0" xml:lang="en-US">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0" xml:lang="en-US">Proceeds from Issuance of Other Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl2" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl0" xml:lang="en-US">Treasury Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAbstract_lbl0" xml:lang="en-US">Liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromBankDebt_lbl0" xml:lang="en-US">Proceeds from Bank Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromBankDebt" xlink:to="us-gaap_ProceedsFromBankDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntercompanyAgreementsDescription_lbl0" xml:lang="en-US">Intercompany Agreements, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntercompanyAgreementsDescription" xlink:to="us-gaap_IntercompanyAgreementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl0" xml:lang="en-US">Accounts Receivable, Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherDepreciationAndAmortization_lbl0" xml:lang="en-US">Other Depreciation and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherDepreciationAndAmortization" xlink:to="us-gaap_OtherDepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseRelatedParty_lbl0" xml:lang="en-US">Interest Expense, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseRelatedParty" xlink:to="us-gaap_InterestExpenseRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0" xml:lang="en-US">Schedule of Short-Term Debt [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl0" xml:lang="en-US">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl0" xml:lang="en-US">Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl1" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0" xml:lang="en-US">Short-Term Bank Loans and Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl0" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl0" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebt_lbl0" xml:lang="en-US">Unsecured Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfSubordinatedShortTermDebt_lbl0" xml:lang="en-US">Repayments of Subordinated Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:to="us-gaap_RepaymentsOfSubordinatedShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl0" xml:lang="en-US">Payments to Acquire Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Stockholders&apos; Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandMember_lbl0" xml:lang="en-US">Land [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandMember" xlink:to="us-gaap_LandMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl0" xml:lang="en-US">Inventory, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl0" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl1" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingParValuePerShare_lbl0" xml:lang="en-US">Entity Listing, Par Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingParValuePerShare" xlink:to="dei_EntityListingParValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromAffiliateNoncurrent_lbl0" xml:lang="en-US">Due from Affiliate, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromAffiliateNoncurrent" xlink:to="us-gaap_DueFromAffiliateNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentInterestRate_lbl0" xml:lang="en-US">Investment Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentInterestRate" xlink:to="us-gaap_InvestmentInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl0" xml:lang="en-US">Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl0" xml:lang="en-US">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl0" xml:lang="en-US">Accounts Receivable, Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryGross_lbl0" xml:lang="en-US">Inventory, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayableCurrent_lbl0" xml:lang="en-US">Other Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayableCurrent" xlink:to="us-gaap_OtherNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Stock Splits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValueOutstanding_lbl0" xml:lang="en-US">Common Stock, Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValueOutstanding" xlink:to="us-gaap_CommonStockValueOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt_lbl0" xml:lang="en-US">Repayments of Other Short-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiability_lbl0" xml:lang="en-US">Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiscalPeriod_lbl0" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiscalPeriod" xlink:to="us-gaap_FiscalPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_lbl0" xml:lang="en-US">Interest and Debt Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl0" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl0" xml:lang="en-US">Payments to Acquire Long-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl0" xml:lang="en-US">Treasury Stock, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl0" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTextBlock_lbl0" xml:lang="en-US">Short-Term Debt [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTextBlock" xlink:to="us-gaap_ShortTermDebtTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl0" xml:lang="en-US">Noninterest Expense Investment Advisory Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:to="us-gaap_NoninterestExpenseInvestmentAdvisoryFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MortgageNotesPayableDisclosureTextBlock_lbl0" xml:lang="en-US">Mortgage Notes Payable Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:to="us-gaap_MortgageNotesPayableDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromEmployeesNoncurrent_lbl0" xml:lang="en-US">Due from Employees, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromEmployeesNoncurrent" xlink:to="us-gaap_DueFromEmployeesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl0" xml:lang="en-US">Machinery and Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl0" xml:lang="en-US">Repayments of Long-Term Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Terms of Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl0" xml:lang="en-US">Unrealized Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl0" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl0" xml:lang="en-US">Related Party Transaction, Terms and Manner of Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageRateForeignDeposit_lbl0" xml:lang="en-US">Weighted Average Rate, Interest-Bearing Foreign Deposits, Point in Time</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageRateForeignDeposit" xlink:to="us-gaap_WeightedAverageRateForeignDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl0" xml:lang="en-US">Proceeds from Sale of Investment Projects</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl1" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl0" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl0" xml:lang="en-US">Repayments of Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl1" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNotesPayable_lbl0" xml:lang="en-US">Other Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNotesPayable" xlink:to="us-gaap_OtherNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl0" xml:lang="en-US">Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due from Other Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanFundedPercentage_lbl0" xml:lang="en-US">Defined Benefit Plan, Funded Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanFundedPercentage" xlink:to="us-gaap_DefinedBenefitPlanFundedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness_lbl0" xml:lang="en-US">Debt Instrument, Decrease, Forgiveness</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0" xml:lang="en-US">Short-Term Debt, Average Outstanding Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock_lbl0" xml:lang="en-US">Equity Method Investments [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Other, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl0" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl1" xml:lang="en-US">Accrued Employee Benefits, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl1" xml:lang="en-US">Due to Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl0" xml:lang="en-US">Notes Payable to Bank, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl1" xml:lang="en-US">Gross Profit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl1" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherShortTermBorrowings_lbl0" xml:lang="en-US">Other Short-Term Borrowings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherShortTermBorrowings" xlink:to="us-gaap_OtherShortTermBorrowings_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl0" xml:lang="en-US">Principal Amount Outstanding of Loans Held-in-portfolio</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestments_lbl0" xml:lang="en-US">Equity Method Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="us-gaap_EquityMethodInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) in Due to Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl0" xml:lang="en-US">Professional and Contract Services Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Income Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_lbl0" xml:lang="en-US">Increase (Decrease) Due from Other Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLineOfCredit_lbl0" xml:lang="en-US">Long-Term Line of Credit, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLineOfCredit" xlink:to="us-gaap_LongTermLineOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl0" xml:lang="en-US">Stock Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromOtherRelatedParties_lbl0" xml:lang="en-US">Due from Other Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromOtherRelatedParties" xlink:to="us-gaap_DueFromOtherRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl0" xml:lang="en-US">Employee Benefit and Share-Based Payment Arrangement, Noncash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1_lbl0" xml:lang="en-US">Loans Receivable with Fixed Rates of Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:to="us-gaap_LoansReceivableWithFixedRatesOfInterest1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl0" xml:lang="en-US">Cost of Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPaymentTerms_lbl1" xml:lang="en-US">Debt Instrument, Payment Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="us-gaap_DebtInstrumentPaymentTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityOther_lbl1" xml:lang="en-US">Stockholders&apos; Equity, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityOther" xlink:to="us-gaap_StockholdersEquityOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl1" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForParticipationLiabilities_lbl0" xml:lang="en-US">Payments for Participation Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForParticipationLiabilities" xlink:to="us-gaap_PaymentsForParticipationLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable and Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExcessStockSharesIssued_lbl1" xml:lang="en-US">Excess Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExcessStockSharesIssued" xlink:to="us-gaap_ExcessStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity, Reverse Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateTerms_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateTerms" xlink:to="us-gaap_DebtInstrumentInterestRateTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl0" xml:lang="en-US">Debt Instrument, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>abvc-20220331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Jun 14 21:16:00 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedBalanceSheet" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedIncomeStatement" roleURI="http://metuboutique.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConsolidatedCashFlow" roleURI="http://metuboutique.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ShareholdersEquityType2or3" roleURI="http://metuboutique.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_OrganizationandDescriptionofBusiness" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusiness"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SummaryofSignificantAccountingPolicies" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_CollaborativeAgreements" roleURI="http://metuboutique.com/role/CollaborativeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_Inventory" roleURI="http://metuboutique.com/role/Inventory"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PropertyandEquipment" roleURI="http://metuboutique.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LongTermInvestments" roleURI="http://metuboutique.com/role/LongTermInvestments"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConvertibleNotesPayable" roleURI="http://metuboutique.com/role/ConvertibleNotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BankLoans" roleURI="http://metuboutique.com/role/BankLoans"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PaycheckProtectionProgramLoanPayable" roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_NotesPayable" roleURI="http://metuboutique.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ShortTermLoan" roleURI="http://metuboutique.com/role/ShortTermLoan"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_RelatedPartiesTransactions" roleURI="http://metuboutique.com/role/RelatedPartiesTransactions"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_Equity" roleURI="http://metuboutique.com/role/Equity"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_StockOptions" roleURI="http://metuboutique.com/role/StockOptions"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LossperShare" roleURI="http://metuboutique.com/role/LossperShare"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_Lease" roleURI="http://metuboutique.com/role/Lease"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BusinessCombination" roleURI="http://metuboutique.com/role/BusinessCombination"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SubsequentEvents" roleURI="http://metuboutique.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_AccountingPoliciesByPolicy" roleURI="http://metuboutique.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_InventoryTables" roleURI="http://metuboutique.com/role/InventoryTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PropertyandEquipmentTables" roleURI="http://metuboutique.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LongTermInvestmentsTables" roleURI="http://metuboutique.com/role/LongTermInvestmentsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BankLoansTables" roleURI="http://metuboutique.com/role/BankLoansTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_RelatedPartiesTransactionsTables" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_EquityTables" roleURI="http://metuboutique.com/role/EquityTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_StockOptionsTables" roleURI="http://metuboutique.com/role/StockOptionsTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LossperShareTables" roleURI="http://metuboutique.com/role/LossperShareTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LeaseTables" roleURI="http://metuboutique.com/role/LeaseTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BusinessCombinationTables" roleURI="http://metuboutique.com/role/BusinessCombinationTables"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofpropertyandequipmentusefullivesTable" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofinventoryTable" roleURI="http://metuboutique.com/role/ScheduleofinventoryTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofpropertyandequipmentTable" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofownershippercentagesofinvesteeTable" roleURI="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofextenttheinvesteereliesTable" roleURI="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoflongterminvestmentTable" roleURI="http://metuboutique.com/role/ScheduleoflongterminvestmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofbalancesheetsTable" roleURI="http://metuboutique.com/role/ScheduleofbalancesheetsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofstatementsofoperationTable" roleURI="http://metuboutique.com/role/ScheduleofstatementsofoperationTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofequityinvestmentsTable" roleURI="http://metuboutique.com/role/ScheduleofequityinvestmentsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofshorttermbankloanTable" roleURI="http://metuboutique.com/role/ScheduleofshorttermbankloanTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofrelatedpartytransactionsTable" roleURI="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofaccountsreceivableduefromrelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofamountduefromrelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofamountduetorelatedpartiesTable" roleURI="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofconvertedamountofdebtandsharesTable" roleURI="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofoptionsissuedandoutstandingTable" roleURI="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoffairvalueofstockoptionsgrantedTable" roleURI="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoflosspershareTable" roleURI="http://metuboutique.com/role/ScheduleoflosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofoperatingleasearrangementsTable" roleURI="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofsupplementalinformationrelatedtooperatingleasesTable" roleURI="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable" roleURI="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable" roleURI="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofpropertyandequipmentusefullivesTable0" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofinventoryTable0" roleURI="http://metuboutique.com/role/ScheduleofinventoryTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofpropertyandequipmentTable0" roleURI="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofownershippercentagesofinvesteeTable0" roleURI="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofextenttheinvesteereliesTable0" roleURI="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoflongterminvestmentTable0" roleURI="http://metuboutique.com/role/ScheduleoflongterminvestmentTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofbalancesheetsTable0" roleURI="http://metuboutique.com/role/ScheduleofbalancesheetsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofstatementsofoperationTable0" roleURI="http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofequityinvestmentsTable0" roleURI="http://metuboutique.com/role/ScheduleofequityinvestmentsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofshorttermbankloanTable0" roleURI="http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofrelatedpartytransactionsTable0" roleURI="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofaccountsreceivableduefromrelatedpartiesTable0" roleURI="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofamountduefromrelatedpartiesTable0" roleURI="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofamountduetorelatedpartiesTable0" roleURI="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofconvertedamountofdebtandsharesTable0" roleURI="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofoptionsissuedandoutstandingTable0" roleURI="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoffairvalueofstockoptionsgrantedTable0" roleURI="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleoflosspershareTable0" roleURI="http://metuboutique.com/role/ScheduleoflosspershareTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofoperatingleasearrangementsTable0" roleURI="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofsupplementalinformationrelatedtooperatingleasesTable0" roleURI="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0" roleURI="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0" roleURI="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_OrganizationandDescriptionofBusinessDetails" roleURI="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_CollaborativeAgreementsDetails" roleURI="http://metuboutique.com/role/CollaborativeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PropertyandEquipmentDetails" roleURI="http://metuboutique.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_LongTermInvestmentsDetails" roleURI="http://metuboutique.com/role/LongTermInvestmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ConvertibleNotesPayableDetails" roleURI="http://metuboutique.com/role/ConvertibleNotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BankLoansDetails" roleURI="http://metuboutique.com/role/BankLoansDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_PaycheckProtectionProgramLoanPayableDetails" roleURI="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_NotesPayableDetails" roleURI="http://metuboutique.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_ShortTermLoanDetails" roleURI="http://metuboutique.com/role/ShortTermLoanDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_RelatedPartiesTransactionsDetails" roleURI="http://metuboutique.com/role/RelatedPartiesTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_EquityDetails" roleURI="http://metuboutique.com/role/EquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_StockOptionsDetails" roleURI="http://metuboutique.com/role/StockOptionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_BusinessCombinationDetails" roleURI="http://metuboutique.com/role/BusinessCombinationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#abvc_r_SubsequentEventsDetails" roleURI="http://metuboutique.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abvc-20220331.xsd#DocumentAndEntityInformation" roleURI="http://metuboutique.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromOtherRelatedPartiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForLongtermInvestments" xlink:href="abvc-20220331.xsd#abvc_PrepaymentForLongtermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="PrepaymentForLongtermInvestments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_SecurityDeposit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBankLoansAndNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherShortTermBorrowings" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableToBankCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableToBankCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableToBankCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvanceFromCustomers" xlink:href="abvc-20220331.xsd#abvc_AdvanceFromCustomers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="AdvanceFromCustomers" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherNotesPayableCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LoansPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDepositLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDepositLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_SecurityDepositLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_EquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GoodwillImpairmentLoss" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_RealizedInvestmentGainsLosses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="InterestIncomes" xlink:href="abvc-20220331.xsd#abvc_InterestIncomes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="InterestIncomes" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="RentIncome" xlink:href="abvc-20220331.xsd#abvc_RentIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="RentIncome" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingSubleaseIncomeRelatedParties" xlink:href="abvc-20220331.xsd#abvc_OperatingSubleaseIncomeRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="OperatingSubleaseIncomeRelatedParties" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GainLossOnForeignExchangeChanges" xlink:href="abvc-20220331.xsd#abvc_GainLossOnForeignExchangeChanges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="GainLossOnForeignExchangeChanges" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncome" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherOperatingIncomeExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossAttributableToAbvcAndSubsidiaries" xlink:href="abvc-20220331.xsd#abvc_NetLossAttributableToAbvcAndSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="NetLossAttributableToAbvcAndSubsidiaries" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_EarningsPerShareAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentGrantIncome" xlink:href="abvc-20220331.xsd#abvc_GovernmentGrantIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GovernmentGrantIncome" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentLoss1" xlink:href="abvc-20220331.xsd#abvc_InvestmentLoss1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="InvestmentLoss1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseDueFromOtherRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseDueFromOtherRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfInvestmentProjects" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInvestmentProjects"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfInvestmentProjects" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToFundLongtermLoansToRelatedParties" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfSubordinatedShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSubordinatedShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfSubordinatedShortTermDebt" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfOtherShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfOtherShortTermDebt" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromBankDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromBankDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromBankDebt" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromOtherShortTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherShortTermDebt" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BorrowingsFromRelatedParties" xlink:href="abvc-20220331.xsd#abvc_BorrowingsFromRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="BorrowingsFromRelatedParties" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockSubscriptionReceivableMember" xlink:href="abvc-20220331.xsd#abvc_StockSubscriptionReceivableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="StockSubscriptionReceivableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="7.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" xlink:href="abvc-20220331.xsd#abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalInCapitalContribution" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" xlink:href="abvc-20220331.xsd#abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensationServices" xlink:href="abvc-20220331.xsd#abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueShareBasedCompensationServices" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:href="abvc-20220331.xsd#abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodShareBasedCompensationServicesforShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CumulativeTransactionAdjustments" xlink:href="abvc-20220331.xsd#abvc_CumulativeTransactionAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CumulativeTransactionAdjustments" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreements">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsTable" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsTable"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsLineItems" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CollaborativeAgreementsTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsTable" xlink:to="CollaborativeAgreementsLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsLineItems" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Inventory">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipment">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestments">
    <loc xlink:type="locator" xlink:label="LongTermInvestmentAbstract" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentTextBlock" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="LongTermInvestmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConvertibleNotesPayable">
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDisclosureAbstract" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDisclosureTextBlock" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDisclosureAbstract" xlink:to="ConvertibleNotesPayableDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoans">
    <loc xlink:type="locator" xlink:label="BankLoansAbstract" xlink:href="abvc-20220331.xsd#abvc_BankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="BankLoansTextBlock" xlink:href="abvc-20220331.xsd#abvc_BankLoansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansAbstract" xlink:to="BankLoansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable">
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableAbstract" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableTextBlock" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableAbstract" xlink:to="PaycheckProtectionProgramLoanPayableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/NotesPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableTable" xlink:href="abvc-20220331.xsd#abvc_NotesPayableTable"/>
    <loc xlink:type="locator" xlink:label="NotesPayableLineItems" xlink:href="abvc-20220331.xsd#abvc_NotesPayableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NotesPayableTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableTable" xlink:to="NotesPayableLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MortgageNotesPayableDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageNotesPayableDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableLineItems" xlink:to="us-gaap_MortgageNotesPayableDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShortTermLoan">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Equity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptions">
    <loc xlink:type="locator" xlink:label="StockOptionsAbstract" xlink:href="abvc-20220331.xsd#abvc_StockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsTextBlock" xlink:href="abvc-20220331.xsd#abvc_StockOptionsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="StockOptionsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LossperShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/Lease">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesOfLesseeDisclosuresTextBlock" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesOfLesseeDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="OperatingLeasesOfLesseeDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombination">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiscalPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FiscalPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForwardStockSplitsPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_ForwardStockSplitsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ForwardStockSplitsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockReverseSplitPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_StockReverseSplitPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="StockReverseSplitPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermEquityInvestmentPolicy" xlink:href="abvc-20220331.xsd#abvc_LongTermEquityInvestmentPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LongTermEquityInvestmentPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherThanTemporaryImpairmentPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_OtherThanTemporaryImpairmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OtherThanTemporaryImpairmentPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeneficialConversionFeature" xlink:href="abvc-20220331.xsd#abvc_BeneficialConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="BeneficialConversionFeature" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ValuationOfDeferredTaxAssetsPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ValuationOfDeferredTaxAssetsPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TranslationAdjustmentPolicyTextBlock" xlink:href="abvc-20220331.xsd#abvc_TranslationAdjustmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="TranslationAdjustmentPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/InventoryTables">
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipmentTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestmentsTables">
    <loc xlink:type="locator" xlink:label="LongTermInvestmentAbstract" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfExtentInvesteeReliesTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfExtentInvesteeReliesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="ScheduleOfExtentInvesteeReliesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermInvestmentTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLongTermInvestmentTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="ScheduleOfLongTermInvestmentTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="us-gaap_EquityMethodInvestmentsTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoansTables">
    <loc xlink:type="locator" xlink:label="BankLoansAbstract" xlink:href="abvc-20220331.xsd#abvc_BankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDebtConversionsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtConversionsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfDebtConversionsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptionsTables">
    <loc xlink:type="locator" xlink:label="StockOptionsAbstract" xlink:href="abvc-20220331.xsd#abvc_StockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsTablesTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsTablesTable"/>
    <loc xlink:type="locator" xlink:label="StockOptionsTablesLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="StockOptionsTablesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsTablesTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsTablesTable" xlink:to="StockOptionsTablesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsTablesLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LossperShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LeaseTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeaseArrangementsTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfOperatingLeaseArrangementsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombinationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentUsefulLivesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfPropertyAndEquipmentUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BuildingsAndLeaseholdImprovementsMember" xlink:href="abvc-20220331.xsd#abvc_BuildingsAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="BuildingsAndLeaseholdImprovementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofinventoryTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowanceForInventoryValuationAndObsolescenceLoss" xlink:href="abvc-20220331.xsd#abvc_AllowanceForInventoryValuationAndObsolescenceLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="AllowanceForInventoryValuationAndObsolescenceLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BuildingsAndLeaseholdImprovementsMember" xlink:href="abvc-20220331.xsd#abvc_BuildingsAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="BuildingsAndLeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentOtherNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentOtherNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOwnershipPercentagesOfInvesteeAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:to="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountingTreatmentDescription" xlink:href="abvc-20220331.xsd#abvc_AccountingTreatmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="AccountingTreatmentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfExtentTheInvesteeReliesAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:to="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvc-20220331.xsd#abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="RelatedPartyTransactionDescriptionOfTransactions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflongterminvestmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermInvestmentAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermInvestmentAbstract" xlink:to="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenepharmBiotechCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NonMarketableCostMethodInvestmentsNetAbstract" xlink:href="abvc-20220331.xsd#abvc_NonMarketableCostMethodInvestmentsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="NonMarketableCostMethodInvestmentsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonmarketableCostMethodInvestmentsNet" xlink:href="abvc-20220331.xsd#abvc_NonmarketableCostMethodInvestmentsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonMarketableCostMethodInvestmentsNetAbstract" xlink:to="NonmarketableCostMethodInvestmentsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentsNetAbstract" xlink:href="abvc-20220331.xsd#abvc_EquityMethodInvestmentsNetAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="EquityMethodInvestmentsNetAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsNetAbstract" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofbalancesheetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalanceSheetsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceSheetsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofstatementsofoperationTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStatementsOfOperationAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfStatementsOfOperationAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatementsOfOperationAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NetSales" xlink:href="abvc-20220331.xsd#abvc_NetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="NetSales" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrossProfits" xlink:href="abvc-20220331.xsd#abvc_GrossProfits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="GrossProfits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentNetLoss" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentNetLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="LongTermInvestmentNetLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofequityinvestmentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEquityInvestmentsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfEquityInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareOfEquityMethodInvesteeLosses" xlink:href="abvc-20220331.xsd#abvc_ShareOfEquityMethodInvesteeLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityInvestmentsAbstract" xlink:to="ShareOfEquityMethodInvesteeLosses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofshorttermbankloanTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermBankLoanAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfShortTermBankLoanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermBankLoanAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayUnitedBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CTBCBankMember" xlink:href="abvc-20220331.xsd#abvc_CTBCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CTBCBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CathayBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayBankMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyTransactionsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfRelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationtheBioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationtheRgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationtheRgeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuanGeneCorporationtheYuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneCorporationtheYuanGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YuanGeneCorporationtheYuanGeneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiaGeneCorporationtheAsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneCorporationtheAsiaGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiaGeneCorporationtheAsiaGeneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EugeneJiangMember" xlink:href="abvc-20220331.xsd#abvc_EugeneJiangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="EugeneJiangMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeypointTechnologyLtdtheKeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointTechnologyLtdtheKeypointMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KeypointTechnologyLtdtheKeypointMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionArtsPromotionInctheLionArtsMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLionArtsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LionArtsPromotionInctheLionArtsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YoshinobuOdairatheOdairaMember" xlink:href="abvc-20220331.xsd#abvc_YoshinobuOdairatheOdairaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YoshinobuOdairatheOdairaMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenePharmInctheGenePharmMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenePharmInctheGenePharmMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:href="abvc-20220331.xsd#abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LBGUSAInctheLBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAInctheLBGUSAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LBGUSAInctheLBGUSAMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionGeneCorporationtheLionGeneMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationtheLionGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LionGeneCorporationtheLionGeneMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KimhoConsultantsCoLtdtheKimhoMember" xlink:href="abvc-20220331.xsd#abvc_KimhoConsultantsCoLtdtheKimhoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KimhoConsultantsCoLtdtheKimhoMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TheJiangsMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmkeyVenturesLLCAmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyVenturesLLCAmkeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AmkeyVenturesLLCAmkeyMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ABVCBioPharmaHKLimitedMember" xlink:href="abvc-20220331.xsd#abvc_ABVCBioPharmaHKLimitedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ABVCBioPharmaHKLimitedMember" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvc-20220331.xsd#abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionDescriptionOfTransactions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:to="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GenePharmIncMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenePharmIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AmkeyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAmountDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LBGUSAMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KeypointMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DueFromtheRelatedPartiesCurrent" xlink:href="abvc-20220331.xsd#abvc_DueFromtheRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="DueFromtheRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:to="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiaGeneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YuanGeneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TheJiangsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToshareholdersMember" xlink:href="abvc-20220331.xsd#abvc_DueToshareholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DueToshareholdersMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DueToRelatedPartyCurrentAndNoncurrent" xlink:href="abvc-20220331.xsd#abvc_DueToRelatedPartyCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="DueToRelatedPartyCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfConvertedAmountOfDebtAndSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:to="us-gaap_DebtConversionTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LionArtsPromotionInctheLIONMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLIONMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="LionArtsPromotionInctheLIONMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionGeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="LionGeneCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BioFirstCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_AsiangeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AsiangeneCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_YuangeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="YuangeneCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="TheJiangsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_DebtConversionLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DebtConversionConvertedInstrumentAmount" xlink:href="abvc-20220331.xsd#abvc_DebtConversionConvertedInstrumentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="DebtConversionConvertedInstrumentAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOptionsIssuedAndOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:to="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShareAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NumeratorAbstract" xlink:href="abvc-20220331.xsd#abvc_NumeratorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="NumeratorAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DenominatorAbstract" xlink:href="abvc-20220331.xsd#abvc_DenominatorAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="DenominatorAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedaverageSharesOutstandingBasic" xlink:href="abvc-20220331.xsd#abvc_WeightedaverageSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract" xlink:to="WeightedaverageSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfSharesDiluted" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageNumberOfSharesDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract" xlink:to="WeightedAverageNumberOfSharesDiluted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossPerShareAbstract" xlink:href="abvc-20220331.xsd#abvc_LossPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="LossPerShareAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BasicLossPerShare" xlink:href="abvc-20220331.xsd#abvc_BasicLossPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAbstract" xlink:to="BasicLossPerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeaseArrangementsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOperatingLeaseArrangementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilitienoncurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeaseLiabilitienoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilitienoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageRemainingLeaseTermAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="WeightedAverageRemainingLeaseTermAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRateAbstract" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageDiscountRateAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="WeightedAverageDiscountRateAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentDueInTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentDueInThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentDueInFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="OperatingLeasesFutureMinimumPaymentDueThereafter" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDue" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="OperatingLeasesFutureMinimumPaymentDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" xlink:href="abvc-20220331.xsd#abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" xlink:href="abvc-20220331.xsd#abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="PurchaseConsiderationAbstract" xlink:href="abvc-20220331.xsd#abvc_PurchaseConsiderationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="PurchaseConsiderationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PurchaseConsiderationAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllocationOfThePurchasePriceAbstract" xlink:href="abvc-20220331.xsd#abvc_AllocationOfThePurchasePriceAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="AllocationOfThePurchasePriceAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentUsefulLivesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfPropertyAndEquipmentUsefulLivesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:href="abvc-20220331.xsd#abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentUsefulLivesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BuildingsAndLeaseholdImprovementsMember" xlink:href="abvc-20220331.xsd#abvc_BuildingsAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="BuildingsAndLeaseholdImprovementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrb+OcBO0cz/DPQtq8WT+vHGytpy5eqldqmljvYMs+ffK0hVJun/LoadZRO6MVQWNprQnn57cflcp0TSgIZzBWwoovVOsFPEA4rNNrbY6CE8wmoa0q+lpRTxGk3c+CiJGsyWKrkLTTMjgQTYSxh3ggHe8DlX9qv/pk+ILYd8K5ojpQS7Wnderc/ZHXKbqwIYJ6fn4w3DUr83poUbpImjiTkJyTHC2kdd4Bg=] CSR-->
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofinventoryTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfInventoryAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfInventoryAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryFinishedGoods" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryRawMaterials" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllowanceForInventoryValuationAndObsolescenceLoss" xlink:href="abvc-20220331.xsd#abvc_AllowanceForInventoryValuationAndObsolescenceLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="AllowanceForInventoryValuationAndObsolescenceLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInventoryAbstract" xlink:to="us-gaap_InventoryNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BuildingsAndLeaseholdImprovementsMember" xlink:href="abvc-20220331.xsd#abvc_BuildingsAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="BuildingsAndLeaseholdImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_MachineryAndEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOwnershipPercentagesOfInvesteeAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOwnershipPercentagesOfInvesteeAbstract" xlink:to="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable" xlink:to="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountingTreatmentDescription" xlink:href="abvc-20220331.xsd#abvc_AccountingTreatmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems" xlink:to="AccountingTreatmentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfExtentTheInvesteeReliesAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExtentTheInvesteeReliesAbstract" xlink:to="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="GenepharmBiotechCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioHopeKingCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable" xlink:to="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvc-20220331.xsd#abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems" xlink:to="RelatedPartyTransactionDescriptionOfTransactions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflongterminvestmentTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfLongTermInvestmentAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLongTermInvestmentAbstract" xlink:to="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BraingenesisBiotechnologyCoLtdMember" xlink:href="abvc-20220331.xsd#abvc_BraingenesisBiotechnologyCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BraingenesisBiotechnologyCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenepharmBiotechCorporationMember" xlink:href="abvc-20220331.xsd#abvc_GenepharmBiotechCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenepharmBiotechCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentTable" xlink:to="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NonMarketableCostMethodInvestmentsNetAbstract0" xlink:href="abvc-20220331.xsd#abvc_NonMarketableCostMethodInvestmentsNetAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="NonMarketableCostMethodInvestmentsNetAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonmarketableCostMethodInvestmentsNet" xlink:href="abvc-20220331.xsd#abvc_NonmarketableCostMethodInvestmentsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonMarketableCostMethodInvestmentsNetAbstract0" xlink:to="NonmarketableCostMethodInvestmentsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquityMethodInvestmentsNetAbstract0" xlink:href="abvc-20220331.xsd#abvc_EquityMethodInvestmentsNetAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems" xlink:to="EquityMethodInvestmentsNetAbstract0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityMethodInvestmentsNetAbstract0" xlink:to="us-gaap_EquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofbalancesheetsTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalanceSheetsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfBalanceSheetsAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceSheetsAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofstatementsofoperationTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfStatementsOfOperationAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfStatementsOfOperationAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedIncomeStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStatementsOfOperationAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_GrossProfit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLoss1" xlink:href="abvc-20220331.xsd#abvc_NetLoss1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="NetLoss1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiRealizedGainLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofequityinvestmentsTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfEquityInvestmentsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfEquityInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareOfEquityMethodInvesteeLosses" xlink:href="abvc-20220331.xsd#abvc_ShareOfEquityMethodInvesteeLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEquityInvestmentsAbstract" xlink:to="ShareOfEquityMethodInvesteeLosses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofshorttermbankloanTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfShortTermBankLoanAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfShortTermBankLoanAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShortTermBankLoanAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayUnitedBankMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CTBCBankMember" xlink:href="abvc-20220331.xsd#abvc_CTBCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CTBCBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CathayBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayBankMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfRelatedPartyTransactionsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfRelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationtheBioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationtheBioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationtheBioFirstMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationtheRgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationtheRgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationtheRgeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuanGeneCorporationtheYuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneCorporationtheYuanGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YuanGeneCorporationtheYuanGeneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiaGeneCorporationtheAsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneCorporationtheAsiaGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiaGeneCorporationtheAsiaGeneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EugeneJiangMember" xlink:href="abvc-20220331.xsd#abvc_EugeneJiangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="EugeneJiangMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeypointTechnologyLtdtheKeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointTechnologyLtdtheKeypointMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KeypointTechnologyLtdtheKeypointMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionArtsPromotionInctheLionArtsMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLionArtsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LionArtsPromotionInctheLionArtsMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YoshinobuOdairatheOdairaMember" xlink:href="abvc-20220331.xsd#abvc_YoshinobuOdairatheOdairaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YoshinobuOdairatheOdairaMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GenePharmInctheGenePharmMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmInctheGenePharmMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenePharmInctheGenePharmMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" xlink:href="abvc-20220331.xsd#abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LBGUSAInctheLBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAInctheLBGUSAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LBGUSAInctheLBGUSAMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionGeneCorporationtheLionGeneMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationtheLionGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LionGeneCorporationtheLionGeneMember" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KimhoConsultantsCoLtdtheKimhoMember" xlink:href="abvc-20220331.xsd#abvc_KimhoConsultantsCoLtdtheKimhoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KimhoConsultantsCoLtdtheKimhoMember" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmkeyVenturesLLCAmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyVenturesLLCAmkeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AmkeyVenturesLLCAmkeyMember" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanMember" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionDescriptionOfTransactions" xlink:href="abvc-20220331.xsd#abvc_RelatedPartyTransactionDescriptionOfTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionDescriptionOfTransactions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract" xlink:to="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="GenePharmIncMember" xlink:href="abvc-20220331.xsd#abvc_GenePharmIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="GenePharmIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmkeyMember" xlink:href="abvc-20220331.xsd#abvc_AmkeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AmkeyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable" xlink:to="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAmountDueFromRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueFromRelatedPartiesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RgeneMember" xlink:href="abvc-20220331.xsd#abvc_RgeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiaGeneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioHopeKingCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioHopeKingCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioHopeKingCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LBGUSAMember" xlink:href="abvc-20220331.xsd#abvc_LBGUSAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LBGUSAMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KeypointMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DueFromtheRelatedPartiesCurrent" xlink:href="abvc-20220331.xsd#abvc_DueFromtheRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="DueFromtheRelatedPartiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAmountDueToRelatedPartiesAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAmountDueToRelatedPartiesAbstract" xlink:to="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiaGeneMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YuanGeneMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="TheJiangsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToshareholdersMember" xlink:href="abvc-20220331.xsd#abvc_DueToshareholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DueToshareholdersMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DueToEmployeeMember" xlink:href="abvc-20220331.xsd#abvc_DueToEmployeeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="DueToEmployeeMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable" xlink:to="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="DueToRelatedPartyCurrentAndNoncurrent" xlink:href="abvc-20220331.xsd#abvc_DueToRelatedPartyCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems" xlink:to="DueToRelatedPartyCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfConvertedAmountOfDebtAndSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfConvertedAmountOfDebtAndSharesAbstract" xlink:to="us-gaap_DebtConversionTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LionArtsPromotionInctheLIONMember" xlink:href="abvc-20220331.xsd#abvc_LionArtsPromotionInctheLIONMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="LionArtsPromotionInctheLIONMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LionGeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_LionGeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="LionGeneCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BioFirstCorporationMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_AsiangeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="AsiangeneCorporationMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_YuangeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="YuangeneCorporationMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TheJiangsMember" xlink:href="abvc-20220331.xsd#abvc_TheJiangsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="TheJiangsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionTable" xlink:to="us-gaap_DebtConversionLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOptionsIssuedAndOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsIssuedAndOutstandingAbstract" xlink:to="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable" xlink:to="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" xlink:href="abvc-20220331.xsd#abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfStockOptionsGrantedAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleoflosspershareTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfLossPerShareAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="NumeratorAbstract0" xlink:href="abvc-20220331.xsd#abvc_NumeratorAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="NumeratorAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NumeratorAbstract0" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="DenominatorAbstract0" xlink:href="abvc-20220331.xsd#abvc_DenominatorAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="DenominatorAbstract0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract0" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract0" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DenominatorAbstract0" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossPerShareAbstract0" xlink:href="abvc-20220331.xsd#abvc_LossPerShareAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLossPerShareAbstract" xlink:to="LossPerShareAbstract0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAbstract0" xlink:to="us-gaap_EarningsPerShareBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAbstract0" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeaseArrangementsAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfOperatingLeaseArrangementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseArrangementsAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeaseLiabilitienoncurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeaseLiabilitienoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="OperatingLeaseLiabilitienoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeLeasePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageRemainingLeaseTermAbstract0" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageRemainingLeaseTermAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="WeightedAverageRemainingLeaseTermAbstract0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageRemainingLeaseTermAbstract0" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageDiscountRateAbstract0" xlink:href="abvc-20220331.xsd#abvc_WeightedAverageDiscountRateAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract" xlink:to="WeightedAverageDiscountRateAbstract0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageDiscountRateAbstract0" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueCurrent" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentDueCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueInTwoYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentDueInTwoYears" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueInThreeYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentDueInThreeYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract" xlink:to="OperatingLeasesFutureMinimumPaymentDueInFourYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDueThereafter" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="OperatingLeasesFutureMinimumPaymentDueThereafter" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OperatingLeasesFutureMinimumPaymentDue" xlink:href="abvc-20220331.xsd#abvc_OperatingLeasesFutureMinimumPaymentDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="OperatingLeasesFutureMinimumPaymentDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" xlink:href="abvc-20220331.xsd#abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" xlink:href="abvc-20220331.xsd#abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeasesFutureMinimumPaymentDueInFourYears" xlink:to="PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0">
    <loc xlink:type="locator" xlink:label="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:href="abvc-20220331.xsd#abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract"/>
    <loc xlink:type="locator" xlink:label="PurchaseConsiderationAbstract0" xlink:href="abvc-20220331.xsd#abvc_PurchaseConsiderationAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="PurchaseConsiderationAbstract0" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PurchaseConsiderationAbstract0" xlink:to="us-gaap_TreasuryStockCommonValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AllocationOfThePurchasePriceAbstract0" xlink:href="abvc-20220331.xsd#abvc_AllocationOfThePurchasePriceAbstract0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract" xlink:to="AllocationOfThePurchasePriceAbstract0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllocationOfThePurchasePriceAbstract0" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsTable" xlink:href="abvc-20220331.xsd#abvc_OrganizationandDescriptionofBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_OrganizationandDescriptionofBusinessDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandDescriptionofBusinessDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementOneMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementTwoMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementFourMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementFourMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MergerAgreementMember" xlink:href="abvc-20220331.xsd#abvc_MergerAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MergerAgreementMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementThreeMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementThreeMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsTable" xlink:to="OrganizationandDescriptionofBusinessDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedAfterStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedAfterStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="CommonStockIssuedAfterStockSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedBeforeStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedBeforeStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="CommonStockIssuedBeforeStockSplit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonSharesIssuedAndOutstanding" xlink:href="abvc-20220331.xsd#abvc_PercentageOfCommonSharesIssuedAndOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="PercentageOfCommonSharesIssuedAndOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfIssuedShareCapital" xlink:href="abvc-20220331.xsd#abvc_PercentageOfIssuedShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="PercentageOfIssuedShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionofBusinessDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ExcessStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityReverseStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_Cash" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImpairmentOfEquityInvestments" xlink:href="abvc-20220331.xsd#abvc_ImpairmentOfEquityInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ImpairmentOfEquityInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabourPensionFundPercentage" xlink:href="abvc-20220331.xsd#abvc_LabourPensionFundPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LabourPensionFundPercentage" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfMonthlyContribution" xlink:href="abvc-20220331.xsd#abvc_PercentageOfMonthlyContribution"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PercentageOfMonthlyContribution" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationForNonemployees" xlink:href="abvc-20220331.xsd#abvc_StockBasedCompensationForNonemployees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="StockBasedCompensationForNonemployees" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedBenefitPlanFundedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DefinedBenefitPlanFundedPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/CollaborativeAgreementsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CollaborativeAgreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BHKCoDevelopmentAgreementMember" xlink:href="abvc-20220331.xsd#abvc_BHKCoDevelopmentAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BHKCoDevelopmentAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CodevelopmentagreementMember" xlink:href="abvc-20220331.xsd#abvc_CodevelopmentagreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CodevelopmentagreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_CollaborativeArrangementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstStockPurchaseAgreementMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstStockPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BioFirstStockPurchaseAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioLiteTaiwanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioLiteTaiwanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsTable" xlink:to="CollaborativeAgreementsDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="abvc-20220331.xsd#abvc_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="MilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontCashPayment" xlink:href="abvc-20220331.xsd#abvc_UpfrontCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="UpfrontCashPayment" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfPaymentsUnderCodevelopmentAgreement" xlink:href="abvc-20220331.xsd#abvc_PercentageOfPaymentsUnderCodevelopmentAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="PercentageOfPaymentsUnderCodevelopmentAgreement" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfStockValue" xlink:href="abvc-20220331.xsd#abvc_IssuanceOfStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="IssuanceOfStockValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsRoyaltyPercentage" xlink:href="abvc-20220331.xsd#abvc_MilestonePaymentsRoyaltyPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="MilestonePaymentsRoyaltyPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollaborativeAgreementsDescription" xlink:href="abvc-20220331.xsd#abvc_CollaborativeAgreementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="CollaborativeAgreementsDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForParticipationLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForParticipationLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_PaymentsForParticipationLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionCashPayment" xlink:href="abvc-20220331.xsd#abvc_AdditionCashPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="AdditionCashPayment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CoDevAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_CoDevAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="CoDevAgreementDescription" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeAgreementsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PropertyandEquipmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_OtherDepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/LongTermInvestmentsDetails">
    <loc xlink:type="locator" xlink:label="LongTermInvestmentAbstract" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentAbstract"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LongTermInvestmentsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_LongTermInvestmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentAbstract" xlink:to="LongTermInvestmentsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioFirstCorporationMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioFirstCorporationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RgeneCorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsTable" xlink:to="LongTermInvestmentsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAdditionalShares" xlink:href="abvc-20220331.xsd#abvc_PurchaseAdditionalShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsLineItems" xlink:to="PurchaseAdditionalShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaymentForLongtermInvestments" xlink:href="abvc-20220331.xsd#abvc_PrepaymentForLongtermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsLineItems" xlink:to="PrepaymentForLongtermInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongTermInvestmentsDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ConvertibleNotesPayableDetails">
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDisclosureAbstract" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDetailsTable" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesPayableDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_ConvertibleNotesPayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDisclosureAbstract" xlink:to="ConvertibleNotesPayableDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="UnsecuredConvertiblePromissoryNoteMember" xlink:href="abvc-20220331.xsd#abvc_UnsecuredConvertiblePromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="UnsecuredConvertiblePromissoryNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementMember" xlink:href="abvc-20220331.xsd#abvc_SecuritiesPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="SecuritiesPurchaseAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsTable" xlink:to="ConvertibleNotesPayableDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="AggregatePrincipalAmount" xlink:href="abvc-20220331.xsd#abvc_AggregatePrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="AggregatePrincipalAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_PaymentsToAcquireNotesReceivable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_StockIssued1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesOfferingPricePercentage" xlink:href="abvc-20220331.xsd#abvc_SharesOfferingPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="SharesOfferingPricePercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_CommonStockValueOutstanding" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_InvestmentInterestRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePrincipalAndAccruedInterestExpense" xlink:href="abvc-20220331.xsd#abvc_AggregatePrincipalAndAccruedInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="AggregatePrincipalAndAccruedInterestExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicEquityOfferingExceedAmount" xlink:href="abvc-20220331.xsd#abvc_PublicEquityOfferingExceedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="PublicEquityOfferingExceedAmount" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssued1" xlink:href="abvc-20220331.xsd#abvc_SharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="SharesIssued1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNote" xlink:href="abvc-20220331.xsd#abvc_ConvertiblePromissoryNote"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="ConvertiblePromissoryNote" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleDebt" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalInterestExpenses" xlink:href="abvc-20220331.xsd#abvc_TotalInterestExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleNotesPayableDetailsLineItems" xlink:to="TotalInterestExpenses" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BankLoansDetails">
    <loc xlink:type="locator" xlink:label="BankLoansAbstract" xlink:href="abvc-20220331.xsd#abvc_BankLoansAbstract"/>
    <loc xlink:type="locator" xlink:label="BankLoansDetailsTable" xlink:href="abvc-20220331.xsd#abvc_BankLoansDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BankLoansDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_BankLoansDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansAbstract" xlink:to="BankLoansDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedLoanAgreementMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedLoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayUnitedLoanAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CathayUnitedBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayUnitedBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayUnitedBankMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CTBCBankMember" xlink:href="abvc-20220331.xsd#abvc_CTBCBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CTBCBankMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAgreementMember" xlink:href="abvc-20220331.xsd#abvc_LoanAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="LoanAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CathayBankMember" xlink:href="abvc-20220331.xsd#abvc_CathayBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="CathayBankMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioLiteTaiwanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteTaiwanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioLiteTaiwanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyAxis" xlink:href="abvc-20220331.xsd#abvc_TypeOfCurrencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsTable" xlink:to="TypeOfCurrencyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TypeOfCurrencyDomain" xlink:href="abvc-20220331.xsd#abvc_TypeOfCurrencyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="TypeOfCurrencyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NTMember" xlink:href="abvc-20220331.xsd#abvc_NTMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfCurrencyAxis" xlink:to="NTMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsTable" xlink:to="BankLoansDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="principalAmount" xlink:href="abvc-20220331.xsd#abvc_principalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="principalAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestAndDebtExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDebtExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_InterestAndDebtExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivedLoanAmount" xlink:href="abvc-20220331.xsd#abvc_ReceivedLoanAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="ReceivedLoanAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegularInterestRateDescription" xlink:href="abvc-20220331.xsd#abvc_RegularInterestRateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="RegularInterestRateDescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExceedingAmount" xlink:href="abvc-20220331.xsd#abvc_ExceedingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="ExceedingAmount" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermLineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLineOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_LongTermLineOfCredit" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPaymentTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BankLoansDetailsLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails">
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableAbstract" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableDetailsTable" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableAbstract" xlink:to="PaycheckProtectionProgramLoanPayableDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PAYCHECKPROTECTIONPROGRAMMember" xlink:href="abvc-20220331.xsd#abvc_PAYCHECKPROTECTIONPROGRAMMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PAYCHECKPROTECTIONPROGRAMMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsTable" xlink:to="PaycheckProtectionProgramLoanPayableDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="LoanFromPaycheckProtectionProgram" xlink:href="abvc-20220331.xsd#abvc_LoanFromPaycheckProtectionProgram"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="LoanFromPaycheckProtectionProgram" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForgivenAmountPercentageUsedForPayroll" xlink:href="abvc-20220331.xsd#abvc_ForgivenAmountPercentageUsedForPayroll"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="ForgivenAmountPercentageUsedForPayroll" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPaymentTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteDescription" xlink:href="abvc-20220331.xsd#abvc_PromissoryNoteDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="PromissoryNoteDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanFromPaycheckProtectionPrograms" xlink:href="abvc-20220331.xsd#abvc_LoanFromPaycheckProtectionPrograms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="LoanFromPaycheckProtectionPrograms" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAmout" xlink:href="abvc-20220331.xsd#abvc_LoanAmout"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="LoanAmout" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDecreaseForgiveness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDecreaseForgiveness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDecreaseForgiveness" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentGrantIncome" xlink:href="abvc-20220331.xsd#abvc_GovernmentGrantIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="GovernmentGrantIncome" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaycheckProtectionProgramLoanPayableDetailsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/NotesPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="UnsecuredLoanAgreementsDescription" xlink:href="abvc-20220331.xsd#abvc_UnsecuredLoanAgreementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="UnsecuredLoanAgreementsDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_OtherNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_InterestExpenseOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/ShortTermLoanDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnsecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnsecuredDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_UnsecuredDebt" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtInterestRateIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtInterestRateIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ShortTermDebtInterestRateIncrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LoansReceivableWithFixedRatesOfInterest1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansReceivableWithFixedRatesOfInterest1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LoansReceivableWithFixedRatesOfInterest1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/RelatedPartiesTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesTransactionsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_RelatedPartiesTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartiesTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="BioFirstAustraliaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AsiaGeneMember" xlink:href="abvc-20220331.xsd#abvc_AsiaGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiaGeneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstMember" xlink:href="abvc-20220331.xsd#abvc_BioFirstMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioFirstAustraliaMember_0" xlink:href="abvc-20220331.xsd#abvc_BioFirstAustraliaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioFirstAustraliaMember_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BHKCoDevelopmentAggreementMember" xlink:href="abvc-20220331.xsd#abvc_BHKCoDevelopmentAggreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BHKCoDevelopmentAggreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="LbgUsaIncMember" xlink:href="abvc-20220331.xsd#abvc_LbgUsaIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LbgUsaIncMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioLiteJapanMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteJapanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="BioLiteJapanMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KeypointMember" xlink:href="abvc-20220331.xsd#abvc_KeypointMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KeypointMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YuanGeneMember" xlink:href="abvc-20220331.xsd#abvc_YuanGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="YuanGeneMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="JIANGSMember" xlink:href="abvc-20220331.xsd#abvc_JIANGSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="JIANGSMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RgeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_RgeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RgeneCorporationMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AsiangeneCorporationMember" xlink:href="abvc-20220331.xsd#abvc_AsiangeneCorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AsiangeneCorporationMember" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="YuanGeneMember_0" xlink:href="abvc-20220331.xsd#abvc_YuanGeneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="YuanGeneMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsTable" xlink:to="RelatedPartiesTransactionsDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterest" xlink:href="abvc-20220331.xsd#abvc_AccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="AccruedInterest" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromAffiliateNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromAffiliateNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromAffiliateNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateWorkingcapital" xlink:href="abvc-20220331.xsd#abvc_AggregateWorkingcapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="AggregateWorkingcapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAgreementTotalAmount" xlink:href="abvc-20220331.xsd#abvc_LoanAgreementTotalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="LoanAgreementTotalAmount" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InterestRate" xlink:href="abvc-20220331.xsd#abvc_InterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="InterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShorttermDebtAverageOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShorttermDebtAverageOutstandingAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_ShorttermDebtAverageOutstandingAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentAggregateAmount" xlink:href="abvc-20220331.xsd#abvc_DebtInstrumentAggregateAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="DebtInstrumentAggregateAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateTerms" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromEmployeesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromEmployeesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromEmployeesNoncurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdvancesBearInterestDescription" xlink:href="abvc-20220331.xsd#abvc_AdvancesBearInterestDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="AdvancesBearInterestDescription" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingAdvanceFromRelatedParty" xlink:href="abvc-20220331.xsd#abvc_OutstandingAdvanceFromRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="OutstandingAdvanceFromRelatedParty" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_LoanAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="LoanAgreementDescription" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OutstandingPrincipalAndAccruedInterest" xlink:href="abvc-20220331.xsd#abvc_OutstandingPrincipalAndAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="OutstandingPrincipalAndAccruedInterest" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_InterestExpenseRelatedParty" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueFromOtherRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueFromOtherRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueFromOtherRelatedParties" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageRateForeignDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageRateForeignDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_WeightedAverageRateForeignDeposit" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesTransactionsDetailsLineItems" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/EquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsTable" xlink:href="abvc-20220331.xsd#abvc_EquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="EquityDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_EquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="EquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementOneMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementOneMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementTwoMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementTwoMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementThreeMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementThreeMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareExchangeAgreementFourMember" xlink:href="abvc-20220331.xsd#abvc_ShareExchangeAgreementFourMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ShareExchangeAgreementFourMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_CollaborativeArrangementMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CodevelopmentagreementMember" xlink:href="abvc-20220331.xsd#abvc_CodevelopmentagreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CodevelopmentagreementMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingAgreementMember" xlink:href="abvc-20220331.xsd#abvc_ConsultingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ConsultingAgreementMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioLiteMember" xlink:href="abvc-20220331.xsd#abvc_BioLiteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="BioLiteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioKeyMember" xlink:href="abvc-20220331.xsd#abvc_BioKeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="BioKeyMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="KameyamaMember" xlink:href="abvc-20220331.xsd#abvc_KameyamaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KameyamaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ArticlesOfIncorporationMember" xlink:href="abvc-20220331.xsd#abvc_ArticlesOfIncorporationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ArticlesOfIncorporationMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ViewTradeSecuritiesIncMember" xlink:href="abvc-20220331.xsd#abvc_ViewTradeSecuritiesIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ViewTradeSecuritiesIncMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WallachBethCapitalLLCMember" xlink:href="abvc-20220331.xsd#abvc_WallachBethCapitalLLCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="WallachBethCapitalLLCMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingAgreementMember_0" xlink:href="abvc-20220331.xsd#abvc_ConsultingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ConsultingAgreementMember_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRelatedPartiesMember" xlink:href="abvc-20220331.xsd#abvc_NonRelatedPartiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="NonRelatedPartiesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesAWarrantsMember" xlink:href="abvc-20220331.xsd#abvc_SeriesAWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesAWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBWarrantsMember" xlink:href="abvc-20220331.xsd#abvc_SeriesBWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="srt_RangeAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20220331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSixteenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsTable" xlink:to="EquityDetailsLineItems" order="8.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedAfterStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedAfterStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CommonStockIssuedAfterStockSplit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedBeforeStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedBeforeStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CommonStockIssuedBeforeStockSplit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfIssuedShareCapital" xlink:href="abvc-20220331.xsd#abvc_PercentageOfIssuedShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="PercentageOfIssuedShareCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockShareAuthorized" xlink:href="abvc-20220331.xsd#abvc_CommonStockShareAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="CommonStockShareAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementDescription" xlink:href="abvc-20220331.xsd#abvc_AgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AgreementDescription" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FinancialAmendmentDescription" xlink:href="abvc-20220331.xsd#abvc_FinancialAmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="FinancialAmendmentDescription" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Consultingagreementdescription" xlink:href="abvc-20220331.xsd#abvc_Consultingagreementdescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="Consultingagreementdescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidConsultingFees" xlink:href="abvc-20220331.xsd#abvc_UnpaidConsultingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="UnpaidConsultingFees" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedValue" xlink:href="abvc-20220331.xsd#abvc_StockIssuedValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockIssuedValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntercompanyAgreementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntercompanyAgreementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_IntercompanyAgreementsDescription" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProfessionalFees" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockSubscriptionReceivable" xlink:href="abvc-20220331.xsd#abvc_StockSubscriptionReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockSubscriptionReceivable" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="17.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PlacementAgentAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_PlacementAgentAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="PlacementAgentAgreementDescription" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="RestrictedCommonShares" xlink:href="abvc-20220331.xsd#abvc_RestrictedCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="RestrictedCommonShares" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantIssued" xlink:href="abvc-20220331.xsd#abvc_WarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantIssued" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantTerm" xlink:href="abvc-20220331.xsd#abvc_WarrantTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="WarrantTerm" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnrestrictedCommonShares" xlink:href="abvc-20220331.xsd#abvc_UnrestrictedCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="UnrestrictedCommonShares" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributionsFromAffiliates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfInvestors" xlink:href="abvc-20220331.xsd#abvc_NumberOfInvestors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="NumberOfInvestors" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesIssuedPricePerShares" xlink:href="abvc-20220331.xsd#abvc_SharesIssuedPricePerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="SharesIssuedPricePerShares" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStock" xlink:href="abvc-20220331.xsd#abvc_IssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="IssuanceOfCommonStock" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodShareBasedCompensationServicesforShares" xlink:href="abvc-20220331.xsd#abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="StockIssuedDuringPeriodShareBasedCompensationServicesforShares" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateCommonStockShares" xlink:href="abvc-20220331.xsd#abvc_AggregateCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="AggregateCommonStockShares" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNoteValue" xlink:href="abvc-20220331.xsd#abvc_ConvertiblePromissoryNoteValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ConvertiblePromissoryNoteValue" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfPublicOffering" xlink:href="abvc-20220331.xsd#abvc_DescriptionOfPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="DescriptionOfPublicOffering" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_LegalFees" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="42.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="43.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingAgreementDesciption" xlink:href="abvc-20220331.xsd#abvc_ConsultingAgreementDesciption"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="ConsultingAgreementDesciption" order="44.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExcessStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ExcessStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ExcessStockSharesIssued" order="45.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalAndContractServicesExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" order="46.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityListingParValuePerShare" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityListingParValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="dei_EntityListingParValuePerShare" order="47.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="48.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyShareholderServiceFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentCompanyShareholderServiceFeeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityDetailsLineItems" xlink:to="us-gaap_InvestmentCompanyShareholderServiceFeeExpense" order="49.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/StockOptionsDetails">
    <loc xlink:type="locator" xlink:label="StockOptionsAbstract" xlink:href="abvc-20220331.xsd#abvc_StockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockOptionsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_StockOptionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="StockOptionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSixteenEquityIncentivePlanMember" xlink:href="abvc-20220331.xsd#abvc_TwoThousandSixteenEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoThousandSixteenEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsTable" xlink:to="StockOptionsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPrice" xlink:href="abvc-20220331.xsd#abvc_ConversionPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="ConversionPrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConsultingFees" xlink:href="abvc-20220331.xsd#abvc_ConsultingFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="ConsultingFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" xlink:href="abvc-20220331.xsd#abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsDetailsLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/BusinessCombinationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationDetailsTable" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="BusinessCombinationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioKeyMember" xlink:href="abvc-20220331.xsd#abvc_BioKeyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="BioKeyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BusinessCombinationMember" xlink:href="abvc-20220331.xsd#abvc_BusinessCombinationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="BusinessCombinationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsTable" xlink:to="BusinessCombinationDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockSplits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockSplits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockSplits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedAfterStockSplit" xlink:href="abvc-20220331.xsd#abvc_CommonStockIssuedAfterStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="CommonStockIssuedAfterStockSplit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfGoodwill" xlink:href="abvc-20220331.xsd#abvc_PercentageOfGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="PercentageOfGoodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BusinessCombinationDetailsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="abvc-20220331.xsd#abvc_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="abvc-20220331.xsd#abvc_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="NumberOfDirectors" xlink:href="abvc-20220331.xsd#abvc_NumberOfDirectors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NumberOfDirectors" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantDateTerm" xlink:href="abvc-20220331.xsd#abvc_GrantDateTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="GrantDateTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsPurchased" xlink:href="abvc-20220331.xsd#abvc_WarrantsPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="WarrantsPurchased" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisableAtAPricePerShare" xlink:href="abvc-20220331.xsd#abvc_ExercisableAtAPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="ExercisableAtAPricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TermsOfAgreementDescription" xlink:href="abvc-20220331.xsd#abvc_TermsOfAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="TermsOfAgreementDescription" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentDescription" xlink:href="abvc-20220331.xsd#abvc_MilestonePaymentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="MilestonePaymentDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalSharesOfCommonStock" xlink:href="abvc-20220331.xsd#abvc_AdditionalSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="AdditionalSharesOfCommonStock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoninterestExpenseInvestmentAdvisoryFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseInvestmentAdvisoryFees" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://metuboutique.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="abvc-20220331.xsd#abvc_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !) *8# 2(  A$! Q$!_\0
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M:)I-G\-]4U34;^226*&RTS3-,BEO[N\NY(K>TL8WNKB2.!&<?V:K_P %3_\
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M<?LD^$M=^._Q,\7?%_Q=X9\&Z?X0\'6_B#7C=?%3]H/QSHN@Z1;:M/!?W[I
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MW&J>(->OO%\ESXK\<^++ME.N>-O&.I-+]KU36=6OC/=PZ5#(5LX)VBL[6.$
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M^/I=.\87OC[Q%X_6SO=&UW0/".CI'X*\-+I\\NLV$-O;0F[DN-1=$2,S.<D
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MJ,)I?B70_A/X2L-?TS&65[36AI]Y(H 0"U-E#)<60*(-K?*/Y=?^'[_[<?\
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M5^T3QW5A)I]W=6LJO-%'*PGV/OK^9;]GG]MK_@I=\;OV;?!O[1UU_P %%?\
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L$MI)I_B/0)-7TVVU!]%\06$Q,UEK>E-<&QU6TE)DMK^">%R60FBNBHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $A G # 2(  A$! Q$!_\0
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MG_\ !)G_ *,"^!?Y^,__ )Y%'_#D_P#X),_]&!? O\_&?_SR*_4"B@#\O_\
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M0** /R__ .')_P#P29_Z,"^!?Y^,_P#YY%'_  Y/_P""3/\ T8%\"_S\9_\
MSR*_4"B@#\O_ /AR?_P29_Z,"^!?Y^,__GD4?\.3_P#@DS_T8%\"_P _&?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB\4_!7XS_"32?%/QLMOA1=_\%0/V$-&^&_B'X9G]J[P6+#X$^.M(\!CXY_\
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MM^#GCSX-> ]$^.NLZ'\$-!^'+? P?#GPFVNGPMXT^)_Q8\8_\)EX)^,N@"-
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MS/\ PCOBOPY_S-7A3P=XQ\9^-/!9 &?^*. T-!\;?$;RO $'QB^(W[;&B?\
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M_P"P3I7_ *:HZZ"N?\.?\B]X;_[!.E?^FJ.N@H **** "BBB@ HHHH ****
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M7'_/<?Y_&H** +'G3^3Y'VBZ\C_GT[=?RZ4>=/YOG^?<_:/3CIU_+_/2J]%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+X9'@_Q?<^$OV3_C!I'BFRTDZUH6N%="UM_C7*RN'T2/.^, $[,%FRG]+-%
M&3IMJ+#3K"RZ_9++3K4]>L86,@9Y[<?_ *ZUJ** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^DG_  Z;_P""7/\ TCD_8@_\16^"_P#\P% 'N7_#;'[&W_1VG[,W_A]_A?\
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M=I^S-_X??X7_ /S44?\ #;'[&W_1VG[,W_A]_A?_ /-17AO_  Z;_P""7/\
MTCD_8@_\16^"_P#\P%'_  Z;_P""7/\ TCD_8@_\16^"_P#\P% 'N7_#;'[&
MW_1VG[,W_A]_A?\ _-11_P -L?L;?]':?LS?^'W^%_\ \U%>&_\ #IO_ ()<
M_P#2.3]B#_Q%;X+_ /S 4?\ #IO_ ()<_P#2.3]B#_Q%;X+_ /S 4 >Y?\-L
M?L;?]':?LS?^'W^%_P#\U%'_  VQ^QM_T=I^S-_X??X7_P#S45X;_P .F_\
M@ES_ -(Y/V(/_$5O@O\ _,!1_P .F_\ @ES_ -(Y/V(/_$5O@O\ _,!0![E_
MPVQ^QM_T=I^S-_X??X7_ /S44?\ #;'[&W_1VG[,W_A]_A?_ /-17AO_  Z;
M_P""7/\ TCD_8@_\16^"_P#\P%'_  Z;_P""7/\ TCD_8@_\16^"_P#\P% '
MN7_#;'[&W_1VG[,W_A]_A?\ _-11_P -L?L;?]':?LS?^'W^%_\ \U%>&_\
M#IO_ ()<_P#2.3]B#_Q%;X+_ /S 4?\ #IO_ ()<_P#2.3]B#_Q%;X+_ /S
M4 >Y?\-L?L;?]':?LS?^'W^%_P#\U%'_  VQ^QM_T=I^S-_X??X7_P#S45X;
M_P .F_\ @ES_ -(Y/V(/_$5O@O\ _,!1_P .F_\ @ES_ -(Y/V(/_$5O@O\
M_,!0![E_PVQ^QM_T=I^S-_X??X7_ /S44?\ #;'[&W_1VG[,W_A]_A?_ /-1
M7AO_  Z;_P""7/\ TCD_8@_\16^"_P#\P%'_  Z;_P""7/\ TCD_8@_\16^"
M_P#\P% 'R[_P5H_:W_99\5?\$PO^"@'AKPK^TO\ L]^(/$WB+]CS]HG0-$T#
M0OC1\-]5U+6M4UCX8>(D72]&T>W\322ZWK# GRH;>+[1ND+1HK2R(/6_V%/V
MP/V2- _8E_8[T'6OVI/V<])UG2?V6?V=](U73=5^-OPRT_4=/U;3/@UX',FE
MZKO\2DK,I=FD#(/EDV1K(&P?C3_@K/\ \$VO^"=?PV_X)D?MY^/?AW^PI^R#
MX%\;^"_V6?B_K_@_QAX/_9Q^#OASQ/X5\4:+X)UUM$U?P_K^A^$[?Q%HVN0M
M*C1W$$\;%DC64QGS-WV!\#_^"5?_  30U/X*_"+5M6_X)]?L5:GK.J?"SX>Z
MCJVJWO[,7P8O[_4M4;P9H*MJQE;PK(S,[@NQ#%\L@78,E@#[$_X;8_8V_P"C
MM/V9O_#[_"__ .:BC_AMC]C;_H[3]F;_ ,/O\+__ )J*\-_X=-_\$N?^D<G[
M$'_B*WP7_P#F H_X=-_\$N?^D<G[$'_B*WP7_P#F H ]R_X;8_8V_P"CM/V9
MO_#[_"__ .:BC_AMC]C;_H[3]F;_ ,/O\+__ )J*\-_X=-_\$N?^D<G[$'_B
M*WP7_P#F H_X=-_\$N?^D<G[$'_B*WP7_P#F H ]R_X;8_8V_P"CM/V9O_#[
M_"__ .:BC_AMC]C;_H[3]F;_ ,/O\+__ )J*\-_X=-_\$N?^D<G[$'_B*WP7
M_P#F H_X=-_\$N?^D<G[$'_B*WP7_P#F H ]R_X;8_8V_P"CM/V9O_#[_"__
M .:BC_AMC]C;_H[3]F;_ ,/O\+__ )J*\-_X=-_\$N?^D<G[$'_B*WP7_P#F
M H_X=-_\$N?^D<G[$'_B*WP7_P#F H ]R_X;8_8V_P"CM/V9O_#[_"__ .:B
MC_AMC]C;_H[3]F;_ ,/O\+__ )J*\-_X=-_\$N?^D<G[$'_B*WP7_P#F H_X
M=-_\$N?^D<G[$'_B*WP7_P#F H ]R_X;8_8V_P"CM/V9O_#[_"__ .:BC_AM
MC]C;_H[3]F;_ ,/O\+__ )J*\-_X=-_\$N?^D<G[$'_B*WP7_P#F H_X=-_\
M$N?^D<G[$'_B*WP7_P#F H ]R_X;8_8V_P"CM/V9O_#[_"__ .:BC_AMC]C;
M_H[3]F;_ ,/O\+__ )J*\-_X=-_\$N?^D<G[$'_B*WP7_P#F H_X=-_\$N?^
MD<G[$'_B*WP7_P#F H ]R_X;8_8V_P"CM/V9O_#[_"__ .:BC_AMC]C;_H[3
M]F;_ ,/O\+__ )J*\-_X=-_\$N?^D<G[$'_B*WP7_P#F H_X=-_\$N?^D<G[
M$'_B*WP7_P#F H ]R_X;8_8V_P"CM/V9O_#[_"__ .:BC_AMC]C;_H[3]F;_
M ,/O\+__ )J*\-_X=-_\$N?^D<G[$'_B*WP7_P#F H_X=-_\$N?^D<G[$'_B
M*WP7_P#F H ]R_X;8_8V_P"CM/V9O_#[_"__ .:BC_AMC]C;_H[3]F;_ ,/O
M\+__ )J*\-_X=-_\$N?^D<G[$'_B*WP7_P#F H_X=-_\$N?^D<G[$'_B*WP7
M_P#F H ]R_X;8_8V_P"CM/V9O_#[_"__ .:BC_AMC]C;_H[3]F;_ ,/O\+__
M )J*\-_X=-_\$N?^D<G[$'_B*WP7_P#F H_X=-_\$N?^D<G[$'_B*WP7_P#F
M H ]R_X;8_8V_P"CM/V9O_#[_"__ .:BC_AMC]C;_H[3]F;_ ,/O\+__ )J*
M\-_X=-_\$N?^D<G[$'_B*WP7_P#F H_X=-_\$N?^D<G[$'_B*WP7_P#F H ]
MR_X;8_8V_P"CM/V9O_#[_"__ .:BDC_;2_8\FEA@@_:O_9IFN+@9M8%^.OPS
M9I-JG[H7Q*[9]!LSV49X/AW_  Z;_P""7/\ TCD_8@_\16^"_P#\P%?EA_P6
MP_X)T_L!?![_ ()9_ME?$/X5?L0?LG?#3X@^%OA_X=O/#GCKP/\ L\?"+PMX
MFT'4)?B5X$B?4]#\0:!X6'B#1\HSI+Y,PW(2K(R%F< _I>HK$T#_ ) NC_\
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MQ<AFM/#N@+XS6Z3Q+>!,KX<_\$)?&?P8O/ 'PH\#?M&^';[]F6]U;]@3Q_\
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M/%?_  JSXFZAX'\6_L\_MCR>'M:UKQ9%HP^(<7B+1?C%\,/$OA^:3P<GF_\
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MG[.OQ7_8S^#6K_#KXP>!O$?@#Q=;K^U5EO[+UO1\OK&BE_@>X/B'PW_R-'A
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MC[)HOCC2+#6M.TW7]1T)VT'7VMXM=T'PW<,\/B#2M7@E)MHE:168!(GC6/\
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MOTHS_LG\C^/?W;]*_)W_ (;,_;1_Z-&^"_\ XE:_O_U17W_S@4?\-F?MH_\
M1HWP7_\ $K7]_P#JBOO_ )P*?^I7$7_/G_R>D'^N>0?\_'_X#(_6+/\ LG\C
M^/?W;]*,_P"R?R/X]_=OTK\G?^&S/VT?^C1O@O\ ^)6O[_\ 5%??_.!1_P -
MF?MH_P#1HWP7_P#$K7]_^J*^_P#G H_U*XB_Y\_^3T@_USR#_GX__ 9'ZQ9_
MV3^1_'O[M^E&?]D_D?Q[^[?I7Y._\-F?MH_]&C?!?_Q*U_?_ *HK[_YP*/\
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M?!?_ ,2M?W_ZHK[_ .<"C_ALS]M'_HT;X+_^)6O[_P#5%??_ #@4O]2^(O\
MGRO_  92_P P_P!<^'_^?C_\!D?K%G_9/Y'\>_NWZ49_V3^1_'O[M^E?D[_P
MV9^VC_T:-\%__$K7]_\ JBOO_G H_P"&S/VT?^C1O@O_ .)6O[_]45]_\X%/
M_4KB+_GS_P"3TA?ZY\/_ //S_P ED?K%G_9/Y'\>_NWZ49_V3^1_'O[M^E?D
M[_PV9^VC_P!&C?!?_P 2M?W_ .J*^_\ G H_X;,_;1_Z-&^"_P#XE:_O_P!4
M5]_\X%+_ %+XB_Y\K_P92'_KGD'\[_\  )?Y'ZQ9_P!D_D?Q[^[?I7X/_P#!
MP_\ M9?#S]FC_@FO\;_#_B#XKW7PF^*_QJ\,MX:^!MYIC^+=.UC7_$F@>+_!
M.N:SI'A_6O#MO)-H>M?\([Y[I*\MN=IE9=R>9&??O^&S/VT?^C1O@O\ ^)6O
M[_\ 5%??_.!7YU_\%/\ X=_M"_\ !3_]DCQ=^R[\2?V8/@]X5N-3U7PMXP\#
M_$FW_:/3Q'J'P[\=Z#K1W:[I6BI\-(Y9#+X;?7_"LH\T(Z>(F&T$DTUP7Q%=
M7I<M^O/3??H@7&?#_6=U_AE_7_#'[W?LS_M#?"']J;X->"_CE\"?&FG_ !*^
M&/C"SU$^&O&^D:1K.F:3X@.C:M/H&MOI"Z[H?AN<Q#Q#HNL0,SVL:^? 9%!B
MV+#]$9_V3^1_'O[M^E?BE\&_CA^TE\!/A/\ #OX)?"[]BSX)^'?AW\*?!'A;
MP'X&T&V_:M;-AX9T'1XM$T0#/P3QL<Q#=U+;I,L6=C7I?_#9G[:/_1HWP7_\
M2M?W_P"J*^_^<"C_ %+XB;M[).U[?O*6UWK;=7W^8/C/A]ZJ;2_PR_R/UBS_
M +)_(_CW]V_2C/\ LG\C^/?W;]*_)W_ALS]M'_HT;X+_ /B5K^__ %17W_S@
M4?\ #9G[:/\ T:-\%_\ Q*U_?_JBOO\ YP*7^I?$7_/E?^#*0?ZYY!_._P#P
M"7^1^L6?]D_D?Q[^[?I1G_9/Y'\>_NWZ5^3O_#9G[:/_ $:-\%__ !*U_?\
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M/]L@:Z? O_(]#P/KG_"-CPQ\0#X3P3XV_P"$3\8>,?\ A"\'WKQWP'^V9?\
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MY%66?]>X?E$^,/\ @H+_ ,F4_M/_ /9&O'/_ *:)Z^6M _Y 7A__ +%O2_\
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M/_VS_P P/6O[!UPZ'KG_  C?_",^/_\ A%/$1'ACQM_PB?C#QC_PA8Y'45]
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MQX;^"?Q ^$O@7XG_  T!\6?!/_A=GAK7O#'Q6UGP%KNN@Z)_PLCX1_\ "/\
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MV,_#F@_![]D+X-Z7XQU*WT_]D[XP?"_XT-XBO-&QJ?Q:\4>!O^$].N_VX/\
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MW_D599_U[A^43XP_X*"_\F4_M/\ _9&O'/\ Z:)Z^6M _P"0%X?_ .Q;TO\
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M9ZYH?_"2?\)/\/\ P]XK\.C_ (2CP1XI^+'@_P '_P#":>#,T_J^$_F?W_\
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M;X+>/_ '[1^H? ?X<?\ "SO&'@?X3_$C1M2\3#PO_8W]O?VU^/AS0]<[#_D
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M@Z[H9_L+P_G_ (1_IK?_ !2_]<U]DUZ.&>CN^G?S/-Q-KJVU_P +>044459
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MA_XDF/\ D4#_ ,RQ7C$O[*_[7GC#]CS4/V'_ !QKG[.%MX.\,?"#2_ACX/\
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M/0];!\4@_P#,>[X-?IO\$O <_P *O@K\'_A7?WW]HZA\.OA9\,/A_>7?_/\
MZIX&\&:!H6NC&.W]A\@=?H:]0HIX;"O"WWWOJF]_O[CQ&)^M=5>VNMO4****
MZFG9Z/9]'V?D<5UW7WK_ #/G#]KG/_#.?Q(^GA?/KG_A,]!_^O7[WVO^HC_W
M5_\ 017X(?M<Y_X9S^)'T\+Y]<_\)GH/_P!>OWOM?]1'_NK_ .@BO@>/_@R;
M_KW5_P#3M,^SX)_WG-?\4?\ VXF/'_?+?TKX6_X*3?\ )DOQ[_[%2P_]2K0:
M^Z6[_P"ZW]*^%O\ @I-_R9-\>QW_ .$4L/\ U*M!KX[(_P#D=Y3_ -A.'O\
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M\NZONM^Z[^H5\K_MM_\ )I/Q_P#^Q#_]S6@5]45\K_MM_P#)I/Q__P"Q#_\
M<UH%=&7)K%Y7HU:][IJVOIH89@U]4S/5=.J_S/H;X>_\$Y_VB/A7X)\*_#GP
M=^V+X=M?"O@_1_[$TBWO/V6]"U#45TX;OW;:RWQ*64.<?=$9SD<],=A_PQ%^
MU9_T>AX5_P#$3] ]_P#JIWM^H]:_5;'^T?S/X]O9OTHQ_M'\S^/;V;]*_&_]
M<N(_^@J=WN^6@[O_ ,%'ZE_J;P^O^72TV]Z>GI[Q^5/_  Q%^U7_ -'H^$__
M !%#P_\ _/.H_P"&(OVJ_P#H]'PG_P"(H>'_ /YYU?JIA?7^?M[?7]/>C"^O
M\_;V^OZ>]/\ UQXD_P"@JI_X#0_^5'1_JKD'_/K_ ,GE_F?E7_PQ%^U7_P!'
MH^$__$4/#_\ \\ZC_AB+]JO_ */1\)_^(H>'_P#YYU?JIA?7^?M[?7]/>C"^
MO\_;V^OZ>]'^N/$G_054_P# :'_RH/\ 5;(/^?7_ )/+_,_*O_AB+]JO_H]'
MPG_XBAX?_P#GG4?\,1?M5_\ 1Z/A/_Q%#P__ //.K]5,+Z_S]O;Z_I[T87U_
MG[>WU_3WH_UQXD_Z"JG_ (#0_P#E0?ZK9!_SZ_\ )Y?YGY5_\,1?M5_]'H^$
M_P#Q%#P__P#/.H_X8B_:K_Z/1\)_^(H>'_\ YYU?JIA?7^?M[?7]/>C"^O\
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MC#QGX02T\*Z[X6D9+H>);>&FN,>)$T_K,VDTVG&C9V:T=J::3M9VUUT:8_\
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M_P!'H^$__$4/#_\ \\ZOU4POK_/V]OK^GO1A?7^?M[?7]/>C_7'B3_H*J?\
M@-#_ .5!_JMD'_/K_P GE_F?E7_PQ%^U7_T>CX3_ /$4/#__ ,\ZC_AB+]JO
M_H]'PG_XBAX?_P#GG5^JF%]?Y^WM]?T]Z,+Z_P _;V^OZ>]'^N/$G_034_\
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MU7_T>CX3_P#$4/#_ /\ /.K]5,+Z_P _;V^OZ>]&%]?Y^WM]?T]Z/]<>)/\
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M?ZX\2?\ 054_\!H?_*@_U6R#_GU_Y/+_ #/RK_X8B_:K_P"CT?"?_B*'A_\
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M_P!<>(_^@FI_X!0_^4A_JMD'_/K_ ,GE_F?E7_PQ%^U7_P!'H^$__$4/#_\
M\\ZC_AB+]JO_ */1\)_^(H>'_P#YYU?JIA?7^?M[?7]/>C"^O\_;V^OZ>]'^
MN/$?_034_P# *'_RD/\ 5;(/^?7_ )/+_,_*O_AB+]JO_H]'PG_XBAX?_P#G
MG4?\,1?M5_\ 1Z/A/_Q%#P__ //.K]5,+Z_S]O;Z_I[T87U_G[>WU_3WI_ZX
M\2?]!53_ ,!H?_*@_P!5L@_Y]?\ D\O\S\J_^&(OVJ_^CT?"?_B*'A__ .>=
M1_PQ%^U7_P!'H^$__$4/#_\ \\ZOU4POK_/V]OK^GO1A?7^?M[?7]/>C_7'B
M3_H*J?\ @-#_ .5!_JMD'_/K_P GE_F?E7_PQ%^U7_T>CX3_ /$4/#__ ,\Z
MC_AB+]JO_H]'PG_XBAX?_P#GG5^JF%]?Y^WM]?T]Z,+Z_P _;V^OZ>]+_7'B
M/_H)J?\ @%#_ .4A_JMD'_/K_P GE_F?E7_PQ%^U7_T>CX3_ /$4/#__ ,\Z
MC_AB+]JO_H]'PG_XBAX?_P#GG5^JF%]?Y^WM]?T]Z,+Z_P _;V^OZ>]/_7'B
M3_H*J?\ @-#_ .5!_JKD'_/K_P GE_F?E7_PQ%^U9_T>?X5_\1.T#W_ZJ=[?
MJ/6N0^(7_!.C]HCXI^"O%7PZ\8_MB^';KPKXPT<Z)J]O9_LMZ#I^HMIO>-=9
M7XE-(6&/NF->V#G-?L+_ ,"/YG\>WLWZ48_VC^9_'M[-^E'^N7$?_03.ZV]V
MC=/R_=+].AS_ .IO#[O^Z6N_O3U_\F_.Y)11D#J<4F1UR,>N:^:NNZ^]?YGU
MMO+\/^ +1112NNZ^]?YBLNR^Y?Y!1111==U]Z_S"R[+[E_D%%%%%UW7WK_,+
M+LON7^0444477=?>O\PLNR^Y?Y!7XMZ-_P $WOB1H'[)W[1OPV\1^(OV?/CG
M\?OVN_VCO'?[1'[2&N?'3X9^-_%'P0\>-X@UM$\"_#<^&] ^(WA;QAH/ASX4
M?#SP[\+?#/@IH?&!CC?P).9(8HO$[FW_ &DKY;_:S_:"^$G[-OP#^(7Q3^-W
MQ/\ "7PF\%VVD7^A+XQ\:WQT[PYI_B;7].GT/0=(DU3;\LESKVP A=[2;E^3
M:2'==U]Z_P QV79?=_P#\L/#_P#P1Q:+]FC]FO\ 9Q^('QD\*^+K;]G7X8?$
MO0[#XJP_!O2W^*#^.-?UO6]:^!WA#1=9\2Z]XF\4>'_V6_V=?$>NGQ+X.^$R
M>,II_&3?#WX66WCCQK)X0\,>+;+QM^@?[ '[-WQ<_99_9[L?A5\:/C7JWQP\
M<Q^,_&GB6/7[G6OB+J^G>'-&US5GN=%\'>']<^+GBSQM\3-9\,^&D9D@D\7>
M+/$EV9]2D.][?R&;Y7_X(0_M*?#?]HC_ ()C?LIV?A+XP:+\6/B%\)O@;\+O
M!'QJ6U\2-XD\2>$/B1_PB<37&@^--6D>27_A(?*4^8'+R@*-SO@5^S%%_/\
M'_@A9=E]R_R"BBBE==U]Z_S%9=E]R_R"BBBBZ[K[U_F%EV7W+_(****+KNOO
M7^8679?<O\@HHHHNNZ^]?YA9=E]R_P @HHHHNNZ^]?YC"BBBGIY?@ 4444!8
M****!679?<O\@HHHH"R[+[E_D%%%% 679?<O\@HHHH"R[+[E_D%%%% 679?<
MO\@HHHH"R[+[E_D%%%% 679?<O\ (**** LNR^Y?Y!1110%EV7W+_(**** L
MNR^Y?Y!1110%EV7W+_(****!A1110 4444"LNR^Y?Y!1110%EV7W+_(****
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MK+8ZC_AXIXC_ .C)?VK_ /P7_!_W_P"JH?3_ ">#_AXIXB_Z,E_:P_\ !?\
M!_W_ .JH?3]?7CEZ*Y/]6>'?^A=6_P#!M3_,Z_\ 6'/_ /H8T_\ P"'^1U'_
M  \4\1?]&2_M8?\ @O\ @_[_ /54/I^OKP?\/%/$7_1DO[6'_@O^#_O_ -50
M^GZ^O'+T4?ZL\._]"ZM_X-J?YA_K#G__ $,:?_@N'^1U7_#Q?Q)_T9+^U?\
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MH<:_ZM<.6NLOJ6[^VG;\[!_;/$5VO[2A=;KD5U9V>EN_:_S6I]7?\/%/$?\
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M+0(VD*/D]L;N!C!KE_'O_(B>.?\ L0_%'_ICU^K?"'#UKK*YI[I^UGONGO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7X;?#/X$>._A1\,= T'0O&GCCX6?\+(_X2?Q ?"?Q&T,^)\GX/\ C'_A-/[
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MA\(O]KYK65DG)ZOIIS;*W;7OIJ8G$8QVPJBN]U']5'7[_+:Z-BBO'_&'QS\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\>?B;H_@WPW\,_'G@/0O^9U_Y&3_ (2CX?\ AWQ9X<_XJGP1_P +8\'^#O\
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MXX^*'Q(_X)]Z+X"\;VFC>#?&_B8> _ O@O\ 9D\!^.M%US7-?_XICP_\._\
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MVY\3O'G[4MI\5/!OAOQS^T/X#_:1\%_'S0? NB_\2#_BY^@?\CQX'\+^-_\
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M ?@R\N_^?_5/ W@O0-!XSSS_ &'[?F<UW%8W_#/O_!0C_GS_ &-/_"S^.O\
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MB@ HHHH **** "BBBI7Q2^7Y&JVAZK\I!1115%A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
I110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  K G # 2(  A$! Q$!_\0
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M7[.7P>^$\-E"0;2VU.U\.6=]J;A5^6.>5I<R)U# YQSG].\+<+A.*,=D"S?
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MC*,)U7;F;2LY::<S2];M)*[NMT'@?AG]MCX+^+/VP?B;^Q1I6J77_"V_A?\
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M6]%B$NMZ'X;>SU>0:WK>CPL)=5TC2C<ZCIT3"2]M[=&5CX5\2OVM/#/AJ_\
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M=IX3\1>&-#UC1M)O-0T^QM[[3XO$<D$&N->W>IV<9L+.X29XT#KN'7R/P?\
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M$G<^&,%SN*Q>'C'FDDW6P=OM\EDJ[]WW$W=Z0G%WM<GVLEO!\W6RE:_7[/\
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M[Z6>J:Z;;+^NI^9?_!<#3_@)XV^'GP)^'7QK_;"T?]DW4=.^)</Q6\(:M?\
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MV?6C7H1J)V<%44G&4HJSERNR35NJ/0@^>,)<LH\R3<9)*4?)V;L_\T?P0?\
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M<\4K;ZEX(UKQ??\ B34M%WQ=-I__  32^+>L^ M>TO4M#\$>"KB7P=\6-?\
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M"$FU[/XI+5M.*<F]$G8\JMD\)8IS55V:O9WZMZ>FY_GG_L$Z#K7PE_X)6?\
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MLIK[<4F4FAXS_P""A_[1^D>#O!OB+P7\/_AE\6+V]\!^+?'OCIO <7BC5(/
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MDJ$5HX@3]\DIN+%\  JO7-7:K1\16Y!.7V%B226+(SMN)))RQ)P3@=N@JS7
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-(/)& 3VQQ4M% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ex4-2_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-2_001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_X0 B17AI9@  34T *@    @  0$2  ,
M   !  $       #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R
M4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M            ]M8  0    #3+4A0("
M                                 !%C<')T   !4    #-D97-C   !
MA    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:
M   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV
M=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#
M "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $
M/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA
M<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M         !)S4D="($E%0S8Q.38V+3(N,0
M                                        6%E:(        /-1  $
M   !%LQ865H@                     %A96B        !OH@  ./4   .0
M6%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:
M                      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                        9&5S8P         L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                         '9I97<      !.D_@ 47RX $,\4  /MS  $
M$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                     H\    "<VEG(     !#4E0@8W5R=@        0
M    !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@
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M)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1
M9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K
M_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X
M=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\
M(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82
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M!0';+9[\?UJ=7J+F99BF9H<M/(H\O'JRDC.6([]",4B7$B21M([*N[H'W&3
MQP /Q-0S.@FDD23]WN\QBI*LG 7)'\0XIBY,TP94C99/+/E !IFQN SUZ'.?
MK]*KFLQ\S+"WDDLFU9&78VQ6(_BQD*1^/7UIMO?R2+'(TAW;=Y0':J*,C)'?
MI3=D;AV5U:3S$9@3P2 !MSTSS21VD=O&T9_=Q^6J*N,LH!).0.@Y HU#F98>
M1G556>3=@J0QV,<\@C/I2-<NWWIF#))DD [!VVD]^M5YY3"DDCKN./-,>=RN
MN1EE^GI2M&TZR+(ZD,OEGJJ*"N<*,\GIS[T:BN2M>31.JJSAI)-AW$-L..,?
M6B*\(>/,TFW)?'WF?MGV7^M-:#,\CQJK_.'4%MNU@,?-GMT_*HQ"H55C;=F)
M8SL^5B%)Y4Y[<\4M>H<S)HIY/)^:9MJ@#S ^=X!STZYZ"EDNR"W[R0('!8Y*
MM%NZ<8^[5<S,=Q++M$8E$@C'F$'.!UZYITL*@2*9/*95$:@DD#!#89O4\?G3
M3;'S,>NH23OMDD8,)&B55.W)4<LQ';O3_,>6)0)&,FXD\E4;(Q@']1445M'%
M.S-'Y/F;V89W%V88. .P]::B>0J?-GY-H)R8Y HYXZ@@"ES,7,RR9F2*7=.W
MR[0N,MY>WU(]>],GO)HG)63YCM)4MN7#' *_C5>*5G$;#8OR"7'W8XP>!D ?
M,3SQ[5*;<-(JKNE\N-5*CY7^4Y!P>H-/H.[)5D9V_P!=-C=M/)RY4Y( S[<^
MHH-Q)(TFV9=O.&+X\O/8K[=JA$:?)^\5I&\S/)VMO.2 WJ.WXU&TFV6-,*5<
M-EI0"\03KSWQZ\T7%S,M37;>8VV:7YD)*8VL<?Q+_A]*8=0D:-E\QW6,)C:0
MK2E@,?3K44*J#&TDC+@,RAN7;?QEO0>GL*/LOE^6S'9'&\;%@00X5>,=^>/R
MHU'<F:X81S?OVW94*P/R*0>F?7U-.6:1IFWLR_(0(T;>PW<YR/3&!^-5T0!-
MJN5C:3"D9RNXYVE3]<4U93."=H4[G&Q?E5BN,L3Z#BFI"YF32W4BD>7*2RQN
MZG/R2[1C!'8\Y/TH-]*RLWF,I 7>3R(R0, *.IYJ-H%FV*'WS?O"Q!V[@X(.
MPX^F*' @6;#*)5*NH.65=HP-QZ GO]:0[LM/<G_EFS?*%RK/L;@]3GL><^N*
M:EPV(]MQ(S9()*GRY,GH#_(U5NMUKM4*K;7";'&[:2#C!)Z9Y_&G(@E9=S,0
MT@R3DM(R-_"O8 CK2N[V%S/8D&H2*RCSI55]^=V"T>S.?KTJ1+MMJN[39"Y\
MM?F89[MC\_:JIA\\/(I1A^\4/O\ E7<<MN'4$<CBGRI&/,:-F9=BLPY5P%'#
MKZ_3N:-1J3)8YG#0_OM_0DAMWFX'9>WJ:5YV$BJ)9=I;;DG#(3TR.X/:JQE)
ME>-MLFP*-RKM>8OT&1TJ38L6Y6:-9MR*N,A 5Y"D^O7GCKTHUMN',.M[^9T5
MC)^\8,<-]U0IP2?\*D\]VB51)(6*M][Y0^>X)X&.U0F%0KQLS)NC9 J_.ZAC
MDMQZ5'=NT<32+Y9;9YF,[HY57 /'8BGKU%S,G>[989&-Q-E6#%E!9$P,8/J.
MYH:YF%QM65E8NL; _, 6Y!'MUJM(GG*^Z3;(L>TN1\L6X= H(RQ%32)BXW1A
M7V[&"L^Q@RC W ]L8/X=Z YB:UNVDCC.^7;G('WFD&3UQT^E->Z=HFQ-A7)7
M.XAP"?[N,[O?TJ%+6/$:AA*601E<%/,(;=P?8YI#*5D_UA$8C,ADV_/@'!7K
MUSQ1K8=V6+B\^^VZ9%&&(/RL@[D<\CVJ-+Z:2Z\LR-\C>6@!^^V"26QT''\Z
MB\A=\BLQ7Y#%M +^7NP?G/J>.!TIR'9/'(?+^9C(VUMQE8J1A0.@YZGUHU[A
MS,L&Z:6!O+FDW,X*N1F,X_AZ]/>A)G#LK23-\F%" OMY)R3C_.*JJK0^6%DZ
M'RHFVG^%<[''/4#KW^M%O(TZ+(%5>3( ,K'& >K>O2CF=[!S$TNH2+$TBR'<
MD8D7:3LD7..GK[5,)6W2;I9/O;&.22Q !^4=NO;T-5DMPPC16+CRRA5SM=QD
M'(R/K3Y,&+AU\SS2QZF,YXVDX]* YF6'NG,DFV50N P5FVE">#D=QWIHD9D3
MRY9&.S;\XQYG?.>QZ_I54!U953"LTAC_ 'OS&-OO'!]",T^WFCWQM^]97/F+
MP6=^V3CH/YT!SL3^TFB;;YTC((O._P!HKTX_$BK33L))-TD@(79\@)6,^I/<
M_P OQJG&BM;_ .LC9,>7OW<8#9QCKFBY5 TDFZ1?+;SC@E7C)."0".5P#^5&
MHN9EJ"\_>P[KC=NR=J-OW]NW0#K]::T[>9Q+)MW%0P;!!P3A@?Y^XJ%Y&=_*
MD"YWB(!/E$K$$\GTQ0&58MRO&TC2;P=I"' V[<_3BDI.V@^9CDU"2:(.9-I,
M9?<?N*,X' ZGCI4S7#.%7S&7*[2)/D+>X-5?(CMX9(=S)M3:N%WF, [@S8]^
MW%-EN/LZ2R*GW0LK;3NCE#'&<=B#FF+F9<6^P-WF2<2$[E!*#V^GO49NY8Y/
M+623YI"C9YVX /'J,9J%H5+R!MS9/E$GGMDHBC'&.,^]/F(\V1E:/=NWC>VP
MQD@*<C'(Z?B:!\S);.ZWRI\TWW?,6,$N2#T8GW["G)=;54&=F7=@')WM@]-N
M.O:J[(GF(J;F#1JNU@5W[>FT^OMT-->Z8LVYCY.Q"I4#S'#' 4^G-',T',RW
M-=%-V9)-NY=R[B&C#'&?<?\ UZ8ES,SC]XS.&*]U4!>I/^><TWRXRDGF$*VT
M1_+G9& 20"::(QYR^8O+J^40[\EB,GZ<<?6B[!OL/-PSQ+B2;J2'D!59,^XZ
M=>*0W#)#(S2S-@Y)B^98POUZ^_K543;%5@S,S1LV]5X8*!PZGHPXH@;SX]SM
M@LBY;'RQAQPJKW/U_*A2=PNRQ->S1MQ)AF9%^4[E(;."!VI\=X^0#)(R[FP
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M6!$=WEC.<Y]><BIYNH<S+,EVPDC^=X]H*GS?NOG'7G@C%(UZT4+,TDY7.\R
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MJ 22??I^=.ANV,"MYDW9MS<[@0>H[#O4*NIG$C-'*67)"?Q9&"S9X' Z4R-
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M%ORVMO@X_P!,@S]-XS4:V31@KAE951"2/EP&SG/XUG6W,9+4F,._S-S!9#M
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M1(RD ^8VXD8R?PYJ;RH_+E#?+MPA,:';'@EL9[X/6J 10;LE929&#M& QPO
MSDC^G%#01B-6W2?-(7WN#MD)&TYQT'ITZ4Z."-KE=VTK)O8I'\WF%A@D]@/\
M:BD^2-2LCA@K!6'4E!G##UZ_A0!HZ+%&B,(V5EX4;<X ' &311I%P)U;YR['
M#?0'I1752^$WCL4?&>38V^#C_3(#G'^V*;*=DOE^7%E<2NSN3&!C[V/4^E2>
M+F M+;=_S^P=>GWQ4;6K8VC=YFV.(@@_PODG/TS6-;XC*5[CC!(\4C *S?NR
M ?E:0JVXY';(Z410>6WRL=NV7+,-F"Q&, ^G]*58&%Q)\J[7D9N0/WV>F&[$
M  8I6'V@?*-O. \@$A!S@J!^%9:7)&R!HPHD52(E&5QM8 ?Q(<].]$:LYW*O
MWE+>7G<6]"S'[N:D-NQMT^7;N9UVX^X&' _E36M&,4G\2L4^7.&D5>N/K3 A
MNK-C#&))%VF 1.X^8!@0>?;CK3Q [/N8+EI6<1Y&Y5*A0<=^1G!]:8MVL$7F
MG*HI.YQB)X0.?G'3 QU->0_$C]H2UM/!NK>([;Q!H/A'P#H<1FU'QOJVU[89
M?:!9!B%F;Y@!.Q:+>42..Y)=8U=)7_K^OP[D5*D8+FE_7Z?-Z'K$%PK!4559
MIAYB8.(G _B9>HQW![U-;0M,RL&51L= X4*)0R\ >J@]^.U?"?BK]L'6I[A=
M1\._"SXI>)-..#_:OC+XD_\ "%O>1270@6X32XF!CA\W +S6T&Q=Q<*H<B*U
M_;3UK1-9W>*_@U\7_#CW4<US%=^"O'W_  FS6T4,HMY[B33UE!\B*4[78V\B
MYXQDBN1XVFGU^YV^^UK>=['D2SS#QE:5_7EG;_P+EY?G>Q]W)"S3J/NR,T32
M(5XB"=>>G/:I65O-?:\?EF4NSD!D?.,(Q_AQD?I7@'P3_; TWXL^#&\1^%=>
MT_XK>$--D\K4)]-@,&OZ P5B1=Z;A6E/#']VD4A&WRX)1\U6_BO^UKIO@;X;
M7'B[6M;T+X9>!)(FBAU[Q.A2\UD@!@;+3@!(=ZY*-(3)\@/V5T8,=XUJ;A[2
M^G?I]^UO.]O,[HXVBZ?M8R7+O>ZM;O?:WGL>W-*P#*L9ADA(5LCS-K'LJYZG
MVZ5.RLB-\JJ3(Q*C&Z,,N 2/U./Z5\&>)OVX[SQ)>QS>%_A%\4_&D$UM-JT.
MK>/?%0\(V^I6T'D1RW-KIOWKF-&N( 3#:#+3QKC=(NYWAG]KGQ-8ZDUSJGP;
M\26>F1J;AKWX<?$DZQ=P()_LZW":8_DI=QO-E4,:S>=M<1I)L*USQQU)][=[
M.WWVL<<<\P[=E=KORSM]_+;YWMYGW=;V[&R95=.!'&F\[3,J<'CMGFB6;R)6
MD90_EC)!79)&I/3(X([5XU\)/VB(_%?@NV\6Z'K%K\5/A_>$Q'6]'M"VL:<Z
M??2\M$4%]AX<0QQ31L54VQ&^1/5=%URS\9>'+?4-+U/3]6TJ]M@L=]9W*W,$
MC!@<ATR&7MD'\JZXRO'F1ZE.I&:O#7]?3NO-71>DC9XI(1M7=C(. (#U#,3R
M3[=?I4DZ-]L:159E\WS4V+N\P;%7;GH#D&G/'))&LGEMM\YI#&?O!<8!V^QY
M KC?'GQ>M_ DL.FVUM=^(?$U]&'LM$TR0+>7F3CS)0V%MX ?O3R%$7D LQ1'
M<GK9ER:BKRT.M\AXEA_>@2)#Y3A2K-$V0<XZ'TI\:L%QY<<GF#S!(&*QGW(Z
M9]>GTKY5^./[55KX'\82>&=3UC7/&OCR,PRW'@?X?7*:?;^'TE91%_:6J2/"
MUN&=U19)IK;SLKLMCG;7DC_M1>+H;ZZM6^"'PFEO(PT,MKJOCZ?4-5<_:4BE
M4W4EHRLT)DA>4[R((YH9I"D,L<C\U3%1A+EU;\DW^2:/*K9Q1IOELV_)-V];
M)I/R>OD?H"T4DT4C>8JM)"R1M)M1I&)R,CL!CZ\U+#"?M8D?=&GVC[1*SC;L
M(0*%R>#^'I7PMX5_X*!:3X9@ANO&>E_$'X'QWET]I#KM[JG_  FW@.YN$E,)
MMI+Y7DC@"312(RQM:E2KJSH5./IRP^,VN/:V-B_AF77-4U:(2Z1J&C3?:M U
M6 X_TG[4586J ,KE) [D.! ;LJ:NGB*=36#_ ,_NW-\+F="NKP>O:SO\TTFK
M^:5^ESTB-)+:VCC;8P4%L_PS<Y+!LC#<Y.33H69YD:-/ED^90/G:4#'5CT7G
M_"OC_P")/[=.CW/C34O#6C2>-/C-XNT>?.H:%\-BUAHN@.N[Y+W5O,0*R8(<
MF<*60[H(R"!Y?9_M6>)-8L(6'P5^ ND0ZA8KJ,1UGQJVH27%LL)NGNCJ$5FT
M+1QP&-Y9O,86ZR0&5D$L9;*6-I)V5WZ)O\4FOD<M3.J$9<L;RZ:)R_&*:OY7
MNNI^ASZ;YEG'#Y@:(0&)C&"Y7Y@<8'4<$9%.6%I/G*KYIF,PB)&\+LVCCIN[
MC/'-?&?PM_;1M;34["W\76?BSX#ZQJACAL+S6M8;Q)X2NYY4#P6<]Q*P:RN&
M1@PM9A8S'.T,6^4?2WACXKO<Z[_PC?BBU@\+^))F,5M \I>SU8]1+9W+A?.(
M .Z$JLT9!++Y9223>G6C4UC^OY.S7S6O0[<-C:=97C^OXW2:]&EY'9+F-4CV
MK/YDC1@[MC;P<D.!@<<_IC-30%C+ S2*8U;>)" B]"-JCKWZ^U%U"T5YNVM\
MLPF4*A;S#MVXSVYQ537-2L_!>@MJ&J7UEIFGV-L/M%[=2I'!9A>K2,Y "],D
MGM[UIU.MW6K)WM'5(]RKNB\E7W$!%5'W;\\9R!QBA(F/G>7M999&<-MW)(6Y
M /<,.GITKQ/XP_M%0^&/!<GB+7->7X:^ 8IH[>#5KJT,FKZ].[?)#I]E(CD%
MR-B!HI9IB6V0(NR5OF_QK^U5K$<<VH0_"70;72HX_-6[^+?C>674I$@DB:XF
M>P"W2Z>(?-6682/&;>$&65(HD8KE6KQI[W^2;_),\[$9G3I=WZ)M^MDF[=F[
M)]+GWY'-N.[9]G?>(\XWN[8Z+NZ?RX[XX<;;Y-H\O(D>1T0[F0,N.GL3DXK\
M_P#0/VK?$&C:_/#JWP!FCCA-[/=W?PH\8M#JB+%)#%-*VDXM;FX1'GMR'=61
MUFAD0/'*CM[M\"?VT])^)7A6^UCPMKTGQ$T/P\P_MW36T\Z?XR\+$??:XL55
M?M*C))6.*)\1,(Q=.=@QHXRE.7+=W[--7]$UK\KF>&SC#U7RMV?9IIZ;NTDF
MUW:3MU/HPVFR-OF16_=+&KMM\P)GJ.V<GCVILLSQS22>4TQSY9YVNF>@)'!7
MGKS7SG\?_P!LK3_A3::;/XNUR7P'%XB+#0_#>GZ?_:WCCQ0, (8[3:ZVJEMP
M*&.4@,F^6W?=&/#=:_:E\0:GK:+8_ G3[&WCCL;F+4OBSXV^UZBD$QF\N=M.
M'VN>TB(@N7:7*I%%#/*^R*-FJJF,I0=M6^R3;_"]OGNMBL3G%"D^35R[)-O[
MDFU\[7Z'W[Y#2-Y<C*JHR\E0(XB"#\IZLW'ZTRXL9)9IL*TV5D6%0,QMOW$G
M=[9 (]J^"_ O[4NM17,$EQ\(=,.G,$N9KGX2>+I[?4+<3H]Q$?[+>.V_M"0P
MI]H$49F<P2QR^4\<T9D^COA3^T=#XD\%V?B;2-<M?B9\/;[S(VU^PA9-2T:9
M-I,=_91(I;:2PD*112PDH)+<KYDR5"M"HTE?YII_<[?A<TPN:4:VD;W\TT_N
M:3MYJZ75GMDBJD\DB2*ZLJAG0!@@4'Y2.N#R::&"R,OEK&8&!W$EE!.,;5]\
M]NE5M!U6S\6Z1;ZEIU]8ZCIU]"SVU[;2I);W,;+\I1U)#J<9!!JS':R//&54
MY9HV=2,;-@(.3[\8K<[M7L2JOSR#</,_=LL;$>8X4@DD>I]*9]F4JZ;VC1XY
M$#GY6W.<\#V KC?$_P 3Y+G69O#_ (4AL]>\012LET))2-.TG)R7NIE!VR*H
M)6W7,KG:#Y<9:9/E_P")/[8=KKM_>+X0L/$7QPNK.6:UO-6&OGP]X-BEC61Y
M[*V\G<=3EC2-V,$$-[(%0@R[LBHJ5HP5Y?YO[EJSCQ6/I4%>?ZOY)*[;\DM.
MMC[1G61CMDCD557++MV[1ZJW;%-B5I$; C43(69 1CYNA=OY8K\[+K]J7Q!I
M5G?3-\(_V9=>T_2X+BZE@T/Q UC-%";=;I94NY;,0QB2VS/ VX&ZBBDEAWI&
M[+Z7\/OVYM)T+QE9>'_$DGC;X%^*M4N(X;72OB-(=9\-ZY-Y:DPVVJ-*WSE2
MI7;/&N75O)DW8;FCCJ=[2NO5-+[VDOQ..GGE"4^65X]-5):^LDE\KW\C[)DM
MBS1G=YT?[HB11G<Z9&"/?K3@&3RRLA:3:P:-'4LFYB<CMD=#["O*=>^/&N:1
M;:I;WGA^'PO>:#;M-KNNZ_>>1X?TB''RSK=?NQ>JW)5%\HJJ,)VM2T:O\T^(
MOVY[/XA6CWG@CP=X_P#CE8QSQ0OX@U#4U\'>"&9KA;<) 92J7:?:&5 'AG.6
M4>:_!.]:O"G\7Y/\%:YU8C,Z%#XWKVLV_N2<G\E;YGW1AB=GEH_FCS!*0RKQ
MU+CU^HYQ3[="[QF23Y5C9%DE.&E) Y*]AQGGOFOSLLOC_P"*-5>$)\)_V6;J
MW>(W,%C;7U['=/%<W9M+?R)TL61FNK@.EL\8(NS;S& R")B/6O@;^UC:^(_$
MNGZ&MUJ_PN\<:LK/IFA^*-:'B3POXP",T;)IVJ;W\PAD($<$D<B$%VM90I!R
MIXR$GU7JFK^6J2^]F.'S>E4ERV:]5)?FDO36[Z'UQ!;R1.C-F-<Q[]P ";1V
M.<'/;%+''MBCCW1R+N*@_>68\8SW5N?7G^7)>"_BS9^)-3;0[RU;P[XJLU9K
MG2+QRTB*.L]J<!;F DJ1-$, ':XCD5XU[+[/)N>3: ^]'"$C<V.I('&X@_H.
M:[#UHM25X_U_P?(JP.SB-HU>-Y&)5%P9)=IY^8DX&1WJ0P>;#&@F+J4DC<)@
MF/S""#CT'3BL3QCX[TGX=::KZSJ4>GK?;[>T61&:XOIG;<(H($!DF<#HD:LQ
MP<"O#/C?^T?_ ,(A)I</B^X\3:;K'B16/ASX:^$S'<>+M;4OM\R:>-\V\:[E
MW-#+##!\P>ZDW!5B4HQ5Y[&-;$0I1O-_I]_]7?0^DDM)&CW*N6\U9$C8<L%4
M+SC\_KBHWB:%QYB&8R-Y8,F5D4]<$CJ/3M7YVW?[1'C#Q->V,VF?#?\ 9GT4
M7DUM;&+Q=X@NO$FJJUTT\-O)<WL4#*XENH'M%(DDS=%;<,9<J+W@C]KS5M$C
MBU+4O@=>6NCK)"SZ_P#!?7C*R3-YH19M(*P2RLABG#QS1S&-H94DC#1LHY?K
MM-.UG]TO\OQ/)6?4;VE&27?EG_\ (Z?.Q^@0_P!?$TDRB)&#%B0%&,@A!UQG
M .>.!ZT363-'(I&&93&7/^K*E]V<^O48]<5X+\%?VM;?XC?#V'Q5X3U3_A;O
MA-Y%T\7GA^UCAU[2+DMQ;7UD_EJK$E%:7,.P.CM"D(>X'!_M#_MMZ/\ #7Q/
MJ'A?Q#JFN>(O%]C:M?7?@/X9NTDVDVPPWFZGJ9,1M@%"N6#V@56^Y*I#MM*O
M!1Y[Z/\ '_/Y7.ZIF6'A3]JWI^#OM9J]_E>_39V^N+FWD,EQM9GAFEW*PCW
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MOMWANRDM;]5B;3 8DTZ"SN5>Y<7=E:^6;QS"\\VTQRI]H]*^)/PIU#XKV_\
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M-I=BVB:E]L^P)I<0B2W=$@5[30#M7R/LB1N;O4[G8V [A1&5TM#@_P#!2/\
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M"O@'[=(UQ\</$=EX2\2BSN2TPT73D%QXA.^W+F1S$B0LKRSR"-W3$(/E#*\
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M9VVI_MR_L[_%WQ?-:Z7KSZ0D330!/$NB-9Z3XH1I('+R2VWG21VTL]EI[O\
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MOBA?0WUQI?P[F/A[0M/TA]NH^._$5[F!M*B(SYD*RF%2F"/M,+NV!9_-\O\
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MOV77]3T6U6SU?4KR3:]S:_:+>**6.WB^U7][/+!#;S3F6_A(BCLKI9>9\/\
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MM2;P]JD,K2:#JMXD>^V@NF5YK"4217D\<1@557RQ(V?U6G0H<D):*[?HW?\
M!67HO(RE@:.#PJH4IKW7)OIHVVG=Z)Q3CN]KJUU9\UX8^)VH^!;3_BDM8ET6
MW\1316GAC5!<7=E9W5OJ=O+KF@0BY9WUC5_)O1=6C'=#&/[3OH=JQ[@N1\?_
M -E_PS^W/+='P=HL/@?XPZM8S:[8:>MLFF'786M=+NXX;NQCFG>PNQ_:?EI=
M2/'YC6S>:N'CE7TCX?\ P#\>'QCH?B;PEH^NZMI_[A8-0L;A[2>\@MM:M-6L
MX[G4+P_VA*J1RZK8-;QVD0DCCP5C4QE8O#OP]U#]A?X0Q_$[Q''HMGX=^&NA
MO'8Z9:WL2PZOJBS16^EP00QR223CS[=E^UWLDKQPQ2*D2?-(L5,/"K!PQ"O#
M?7HM'=/ND]&1B,+]9H<F)AS4K<S;VBEK>+\KZ-/9=4;/@_5+_P#:Q^#OA7XA
M0P7FM7GCSP]!>7VF7%S>-'-X@LII+680Q/=>7&%NX)9"B6L^U54^4R[]W>:I
M_P $WO#?CCXA0I)XLUK_ (1?QY>1:_KG@BPM;--,\57-G&IMKJ:2-T2))VM5
MDFBA"K,8P46#:]?./_!*S_@IUX'_ &5/V;[OP7\17URUUK3]4O;[1=6M;#[3
M:;;W9,Z,BMN#BX\X[F0X64A2,LI]8U_]JKX?^,+Z^\;:=\6/ <6CQW;2S)<3
M"WO/-/\ :3Q2R))MO T;V^D,-ENXWI,%W"20J\-BL'7I1;DF]&TVDT^M[V\[
M]+-]#; YCE.*H0JRE&3:3DFTFFM[K1]7=;-/:QTEOX.D\ ^.)M=\4S7T \-O
M=>)_$EW:SM!)<?9$DGN;J1+>>VBV2VZ=!:*F_"B:4!O,^7_@W^S1;Z[)8_%S
MXPV-CK7CSXUB7Q+X;\+:C<1PZ;9)>7,,%I>W0G:.._/VB\L@FGB9 (2ID)=U
M1?6OV]/^"MOPQ^*_[)_C'P;X/FUS7O&OBC36\/K?O926=O:V$[*)F,DQ26;]
MSN52\8<F;D*'>JO[$)UC]KKX'>!==T6ZLIM>^'2Z+X*\1Z/)/#',!IM[:7D5
MYY$_^CWD<ME9JZ[UBGAEBNC',VT(N%66#Q6(C1A)3<5S);KFT7I=+6WG<YJE
M;+<9BUA</)5907.OM*^B\U)Q6RU23?RQ/'/Q#US]HNYU#1[,7M@=6N8-/TW3
MY[";'AI-7NI]*LEN-*FF\R&.+0]-OI6N=-N8S&NHWMP%!E+CF]6\:MXJCMM8
MT^XCL+'Q@J7%C=-<R7B7,FID:;HZK>1I'+>QVFC027BR.%U;3PP;%Q%Y\!['
MPK^Q[XZT_P %>&[6\T>XL?#%IH%N8[Q776M)TT/X>TVP-U9HLR7^GE8Y-8G4
MVLDV^55(+-M /V:O'GA/_A+-6^)$ECJ^JWFE^)_[*L_MZFPM=9\0K"L$,0N)
M8%29[&Q:!;7^TK:*X:>4XE:25HDZ+RYE&;L_/LMW\O\ ,WYJKE&%5\K??M9.
MZ6^B=M4DWII=(XS_ (*<_ GQ#/\ LU_!GQX;&.'Q'JDNN^%WTZW$;&SAU1;B
M^T.S#Q$Q 10EHP(V:)7N"L;+&$4>N_M?_!:[^#.K^$/!5O=6<?@ZWTZQ\(Z=
MJ/VY+9=-0VZV<]S+,P*V[0:Q::-.+EHBT;W"&+S[HVT=KZ]X(^*_@/XMPZU8
M>+M#GT'P]X7\8_\ ";:;)!</<PPW^FW#WK1RP-%YEE>95?,M5S'(K>9 7$K/
M)S?C7]H#PK\08-4\,^.O"]QI]EXNN+2]U[4FU<?VMHTQCFM[2X,D5N9!K"-!
M$\%E8(I@96<M$RE6Z?JE&$YU4[.5OPM>_K97]#I>#PD*E3$1G[U10UL[^XK:
MO=*6E[V3MS+:Z^<_#6NM\4;[1+74(]0T>Z\82V5[J$-K8B&YT^+7)4L=4U$6
MTY,>F16^OVEMJ,-Y>_:;YI9-X WOG2\4?$?PS^T1\'YKCXL:0OB+PWY,NH1:
MPEXUM<^'Y9M/N[FYBT[5KIRUPUK>:)J\/V.UM#:NDT/RF.$XI^&_AG=_'N\^
M('@71[#5'\8:=<WEAX@T>[\,!HXM7NPK7=RD)9-.DB_M2STN_A:[N99O+NKQ
M%0J(V;U#_ADGXE?$CQ=K%Y<6=SI^K:YN(EO_ !-')?6D=S-KJQ(=07)ABCEU
M?R(UT^)6&6C\\KN8<].,JBL[26OFF]K/IOY?<<U*-6K'EC'GB[IZ)IO9WZ='
M=6\]]3@OV6?@WXC_ &8OB7\1?@CK&J"^LH[6'XH^!]:E:[TNTO;:.X2POGN8
M%FMY%W*+<R0R,5C-H[@,KI(WN.C_ +&-C\2OA1-=+>:IX,AT.[EUKPMXB@@A
MN-2T>96N(H2A=G-Q#<-/=%XI[J=&CFC5)(FV%?DWQ#^W)H/P?_X*>^&O$5JK
M>(OA[\++2]\#S_V.BVO]KK,DXU"]MD#X*?;)?W8,K%XK>,^:S,'KZE\3_P#!
M3KX0_M:^(M%TC2_&5CX=LS?0)%%XIMWMK69&FLX[@$,1;$F"34,%IE9'BA*!
MMU88/$8!0>'C->ZW%)OIY:][I6ULE8RRW&9/R3PBJ1]QN"@W;3R;M=)W2=[V
M6Y/XA_8_MO@KX$T]=(:[\1V]P[ZU?>(=0@ADU2YU"\C,FI7LDBRPM'+=0OY0
M;[7 B"VC54E=0S^%_M._ JX_:/\ C%X?^&=UX@O-#^''P4\-V_C3Q[K-HMYJ
MCV,U_E;6*&"62X8SFTA4J21%&MQ<RN,)L?V;X6_\%4?A+^SQX<;1?$?BV3Q5
M<*B-?KX8L3=6GVOR(O/:.0E(%9K@S2EXY9-SRGY@%0'YA^!W[46G_M._\%"O
MBI9ZQ#;:#X?_ &CM2L;.P>^&X:=?:8HCT>.62%P\;R1(8P\$@>.XE@*LZJP=
MXRO@)*&&YE[S2<4^GGV3ERI^I&8XS*)\F#52+=1J/(FGMJDVGI%R48N[3UM>
MQZ9I_CZ/X9>#])\)_"_1E^'=GJTRK:/INI3.UYJ=X]KH$$4^NVTKB2[AO;G5
MYT2^M6C#6EM^[C^S@+R.I7MY#;7$WAFW99+OS]8T+2VL3%);(\K^'_"Y%G:$
MJZ01P7]U%J6C2).L4"S/&Y*"7U+6_P!F?XL:?K UBPTN"Y\3_P!GI>13Z?X@
MM8[B2XN+KQ5<V4;W$FV*^M9KVXM!Y5[#$\CD!I'=6!XOQ)\.U^'/Q,\&_#>:
MW\51^)-2O!)HFEZ9X?EB_L\V6FK9V]_%&?,MXIK>R6\U!6TBY\P376UH6=5C
M;>I&=-6>D=ET2O9*UOE_P^_14IUH+EE%Q5TDK<J3O9<NR>O1=+6ZL[SX"_ M
M_P!IOX:_%#PO8WEO-X-\2^%M1\.Z'<O<1RIKES'MCT6\5HF\IW$FFWE\988T
M@D>^\U!%-->0UY7_ ,$WO@Y=:S^Q3\0O'DS31W'BC5M/L;Z!U2(S>'-)LX(]
M557?"(-M[/D$X9K1=RS_ /'O)]+_  U_:S\/^$KCP!;^#/"*MH.B)?VFAW5C
MJHN+V\LXH8#(L!\A3<7CE1)=V-ROVG=.\J%I(CY>MK?QI\&_L_IX=\/>"/#-
MUXA\)Z/K":_I$0G*#4=1U">XOS!ID 1?M,Z?:PNZ4_9[=?)W&-D<UI]6HN<:
MTG=Q377JK?DW]YT+!X*=2GBI2UA&4>N\[6MULO>^\^4M-\:-9Q7%]XJ,<=I8
M- _B0O/=PQZ='))_PC_B.R>Y!FN8&N@;6_%I;EM0GD43W4RN46NR^%/Q"\2?
M#OQ;IOAN[OM3DU.0^7K>F-IPN6E*WP\/:BS:/;RI:1(RW&D7[F_EN&PSRA&.
M65OQRUOPK<?$[PSK[Z?KMK:^+M2N]$>Y\.&?4['3=7FA:UUFVMY;>V639>Z9
MMNMVEPJQO+5R7"EVJ[X@_9#^(EQX \1--H]K;Z-<1W6LSW,R6^G:9/=?98A=
M7TFGK<F>\N!>:-9W,<FI3HR'51'*JLLBIE:5VH.]OUUN_P!%\NMCEA&LI-4W
MSM=5UZW?5>3V5K=7;Q_XB_!NS\ Q6'[1'PBT>WTFZ^$]U::[XR\'V%^VH6,<
M L[5[Y[:Y1#!"I:ZNK:6S29P(U>2%@J-&OUB/@F]U\35;0@-4E5K.YTK57S<
M;HF"G2)&%S<7CJT41>5I3#"'5'W3*ZJE>+_\%!)=4_9-^ 7BK3]<DLD\8?&&
M[U7PEI%G%>+>2V7AQ_LSWTD@5$@MQO62);:VC4;IXW:69D85T_[*G_!9+X<^
M"_V7?!7@W7H?$FA^./#7AZRT"\U-+/[5:W<-K 88Y_.B9IHXY!'&TA2+<C,V
MS=A6.%*K@\-BIT9R4&TI-;)2NUZ)M-7Z?>88;$99A,7+"XB2I2DE-K97;Z=$
MY)1;VMOU9Z;I_P#P3H\*_##QCJGV'Q%XAUW2O!,5Q>>&O!FK"+^R_#46H@K?
M_8BY<3N$=D@2?S8X?,=-LK/O7S7XNV]]^S-\#/'/C2TLYH?$?A^U:STBWMR]
MK/<>)=2GCL+&]6..Y6+ B<S112640RF[$93)T-!_:[^&_P '-?T?Q8WQ0\)W
MMG-<2?8H])A>XU:[97BB#/#%FX5I(7N;B19XXDEN%4DJ.OBO_!5?_@J)X9_:
MG^&?A;PS\,;7Q!8ZEH/B:S\1:AK>JQP0^;/912_94$4;MO\ WTPD9CL \E<!
MPV4UQ6,P>'H2:DDTFTEWZ/\ RZ6\CHS#,LHPN'E4YXQDKM)--MO9I*[OL[[6
M278U/@C^S1X5_P"">5U9PZUH]MXR^,FDVD6L3LP23^P88(-6NYK73+&Z6%+Z
M9O[)\DW44C2AKP-%Y*C<]SQ%\2[R4KJ7B/4X]5;P:T\_B&6[:^OK?3YM#MX-
M3O8KN.4MJFEQS^(+N")KFU>>+9I-A$4,:A6[2Y^'MQ^VC\#IOB-X9_LN7PC\
M2-">&^T>:<,NC:O+=745_;SV3A8Y-MQ>JJ7,$D%PT<^=DORL9O%_[/7CWP'?
MW'BCQ5H-Q;SZ29;VV9)9]?ECV:A/K)AAEL6_M:"$ZA<:7 T3PS0116DF]@)$
M9W3P\*=-1H)*%KJW5=V^M]&][A1POL:2AAX6I-<R:6C6]Y/K=:R;=VM#S7PE
M?>(;'Q[9Z"J7^H:Y97D=JD-Q/&UQ?SV< O;^ZG>&2.WGCO/$5Q:0-J,/EQ7#
M1F*]\IUBN%N?M<?L03^)O^"D_P %_"MV\FL6?Q3L-#3Q%=LK(NJ3Z"7@UDL"
M 5#V=M%\V!S+R 3SZ!^R7\;?#?PA\!:3XRTGPWX@UBX\2I<IHRZV+>VO[C14
M-P+C4!;1Q"SFO+O4FN)+B.&2.YEMFM\-(%BC/LWPW^+7A.3PMIOB9O#6H/K7
MPL2ZT?P3-H4OV[3S:ZA"+8FQN)(V6&)/L:^8MT3]D )D"Q&-!I'"T:]+EF[J
MZ:].OX-Z]4S>."PV)PZA7E?6,]5LHM-J]K.\;KYV^TD?/W[5.I^(/!7QKUZZ
M\[[='=W5WK^B3F"XF35C!<G5K:!8(9U>YDDTV^U*W-G&R-<-I\(G:*Q6)7XC
M_A)9/A,MQK.BZE$T'AG3;N"SN+F[BCCCCT>*/Q#H:7=^L(4^?HE[>VITW2HR
MALY9XVD;;\ONMU\2K'X\> M#\&V?A72%UX6E_KWA*32]0DDCO]5^W3R%(D$;
MS7-E<!MEW<7<@M9S)DJX+8\O_9R\*W7QJ\*>%_%/PYT7QL='T?4].@MH]<L(
M-+N;2RL;N0I&E_=%+&,16-[K-MG2XFF1((MYC+-5UK.K[DOBU7?2U_7?[M J
M1O7_ ';YN97TZ6LY)=6[_AYW(_B!H?@G]HSP_!X2^(-KJEPNGW)T+P[XLV2I
MXBTZV@O+2.UN8+=S=:CJ<$EOK6E*RW6 RP2S?N99M[2_LP?#76O#/PX\4?"'
MQA-;R>*O@9XIBCL[VVC-Q;3Z/K=L]W9O )+NVC.YTNG"NDTB[Q&8QR#U'P[_
M &*O&>FZ)-9^))M"\&Z?IL4!\1W]UJ$GV2S6#2?#T\DTZJ6GU%BNCS2M]IDM
M[? VNLNX*/"?V7_^"K6C?#']O_XC?$WQ5HFKWO@'XB6=OID-I:)!]LLX-/\
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M+?5-2L_BE\4M5TB\AUB/0=-7XD:E%JD,\(A73Y=0D:X\H6]VZ73E84$L$;0
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MI\BE)6=G9/SMJD]]5:_F&'K4J$ISIQC"4TE*S:3L]6TFU=6;;CO?3F;.Y_9
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M+,MOXD;_ $<*K_\ "4ZMRV\C&?M62WH>H]:]%MYV10Q9C+Y?FNP W/ECG'L
M/U%/)C*[L0Y9\[B3R_LG3-"BK7M^!7U:C_(ON//IOV7?!L)D/D>)AY#%,_\
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MM]W&2W&1R:[)V8.9 W$DS#S >F!P-W89R/QIHO-LG[PJI0;PSA6^7/\ "?\
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M[26.2!^'/UH FEED$+;7W<87IY<A_N!?0CO049+S:%_=VTQ.!R(QY8(S^/\
M*GM*#+N'R;Y'C5EP"57L">F3FF/)'*W*Q-(JYQ-E6 ]\#G'KVH ^8_\ @J)%
M):_ [P[Y,33/'J4DAA#[3=$Z?=<'(.XDXX.>F>@KX[^)-O\ 9'^6:UUIO^$;
M\12?\)C';7D=QXND/A+72[N;G>6:V/[K=;R2V_S;8A'AX8_L3_@JBLMW\&_#
M*K(T+2:Q-MG*\P@Z;=8D'(V\G'.>ON,?%_Q3DM]=\*RRVMPMGI<G@/Q%';>&
MWN;J[NO"[_\ "*:YYD4Z2[989)\B7[-&J1(J Q,X<O7'BE[S^7ZGQ^9?[_\
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MG;GYMP#*?]KUJXDS1A_O*RNRE4 Q$O.WY>^>.:KPW2,V_='YIS\X3]X?^ ]
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M20K;R"1R"/XN#SBILUN+7J-0*P">6F!L79V9F&3FI')FD:1=Q:,;2(2/F(Z
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MR51L@'LV]RG!V/TW+"&58L97S/(2/^ 83<2?4XSUZD"I8G2]=YE5F9@!NC?
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MW!Q:5S2E9(@T>V-O.)C;S,DS;1SD]OR-#SK8W/F,K[E7 :9PYP>NT#GGN3U
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MOBYX;\)_&3X(_&SX"Q^*+O[+IVK>+-)$.FQ.&5#)-O\ *E\M690[JDFPLI;
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MGR$?B.QR#3(Y#%*85^7<2=NTR8 '\;9P!VX-02'=;X7=AEBD"9SLW$@@'T-
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MNBTU%DT94ZCTY;K2-W+E\]5IHGHN^^U_"OV[?BEJ^F_!.S^)EU<K<>)?@?\
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M[3TM=/D6XFO(WTX&S+0@//,H5VD0)(5V_*I7=5$:\R/@+]C+_@E=^UI\=_\
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M[2'Q4^$?BOXAB);U?"T/V9EM5CMHC;^?%/'(Z%[6*0AB%W*AVDJ#73?L5_\
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MS?$*VT"Q'B9M.V_94U5K6/[;Y8'R^49]Y7 Q@KBNKF2,6LB/&9 V96#OMD?
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M)>+M)T=@VN7%@SZ2[2^63J$0$]KC.0JB9(CGM@TI/4SK)NG)1WL_R/SA^/\
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MDIYG]C6$<*A7:(62O'Y:-'YDFI7: QR7WVG3^;\?_!C1? OAQO$?C&YT_1_
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MU%I)8[FTN))EB^SZ@P 2XBFM[BSFBG9PMQ;.6EB#I'7H'[+'Q,US6/V1-/\
MA5XRAU;P[XV^ /B?6+8Z;J4,D-T--O/!WB9K2)PW_/,_;PASM$5O%M+!P:]4
M_8B\4ZYI/QB\=6'CZ3Q&NH#1-6GU VE]J]O.-3L+VPM]2-J5NQ<SI=+-8WT8
MBL51WNI%1E+D.[XU?';Q#\4KZV_MK06L=R^(;9+^?PM<V5QY#>&O$5P+-;RY
MN'E:&-P2%$>W=QB$!8CT4,#0I2^L0]UM--)63\[='Z?<CHP.6X3"U%BJ'N2J
M)QE%:)ZJS:^R[VVNNEE<R]=NKA/$GP[T_6+Z34?$$6IZ/=:5C58+B#2]$F\2
M:44L%M$5)+6[:1()2\RS&9+><I.$4Q)^B7[-<4*?LZ?#E%V1P_\ "*Z2-LF=
MN%M(RH5AQD>E?G/#<J=#\)_V6;I?"]K\1;!=0R;5E@\3+K.GM,]L(QYXM_LO
MG*QNV+,_E>6 GS']%OV=9VLOV=/ *6_[N6/PSI"%$&$*FTB4$#G '/Y8SWKU
ML+IKY+\CZ+(7[\GKUW^7WJVS>K6^MSOG$;6T?+?>QO9<*VX]UZ@<U&9/,955
MI(XSYBR@,2 4ZX]J;'''.3\S%6F(W*1OEV-SGL%# Y'_ .LNDB6:9\O&N[<5
M$F1)%N #8'<?U-=5VV?4$EK^ZN%^7/ E$*X^3.<,2>23@CTZ^E"QA65-Z_>!
MVE#YFW=G:1Z9[T%(RZ?*T?F((0)>!*%SCZ'KC\>*B>?S74;YO(:$2;<\G)V[
M3^-"=MP)KLQ[F:105W [2.5R0,J?<XX]J8BM-)M=O,99'B3>05P!R2.^.:<5
MC?S5<-P K,@&U,'. .O![@4Z&-3.&+*WWFVQ\Y+<%B3T^E5Z@-;:T2MEEY\S
M?)R#G(Y Y48Z>PKR?]O/XQ:S^S=^PM\9OB!X7MX;KQ%X'\%ZIK>F!X_,MXY[
M6TEEB=T8C>D;*'89Y"D=37JSR;/+= ?E! <_?0JI)5AWR/3US4=];P:Q8S0W
MD<=W;3P8F2:(21O'(-I0H1A@PR""""#T[4*5F-;GQ_XO^!,G[)GA/1?&>E_M
M!?$2;6M2T#5TU"'Q-XGN=8M_B5<MHMU>(UI;SS^1IMS;R6IND.G11H((Y8C&
MRE&B\M_X)^0^+K_]FGX?_$;Q%I/[6$&H_P#"L8_$ESXD\4?$NRU3PKK%VVB;
MWG:R759[A5DDF,L0:V38RQLRQE !]4?#[_@FQ\$_A5JGVG1O!*PR1:1=^'[&
M/4]:U'4(-$T^Y79/:Z='/<21Z?%(F$9+18?E15^ZJ@5_AS_P3:^$?PCL]-AT
M+3_']KINDZ?)HEKI]S\1/$5[I,-F]NUF8/L4]^]N8A Y1 8SY>%9-KJI&G.C
M7F1\1_L1?'#XA?$7Q+^RCX:@UCX_>&?%WCKP1:^*_%^H^/O$=MJ'AWQSI#:.
M!?2:./M=Q*VH"[N+:XC2(0R6\3[YT$92)O??V*?A5XHF_;>^/&C:I\8/C)XA
MT#X+^(]%TO0=+UGQ!'=6NHQ7/ANRO9TO 8=\Q\ZZD<$LN"$&< @_1-Y^R7\/
M;KPG\+?#AT2:UTOX.7EE=^$4MM1NH9M"DT^V-M"$ECD$DD9MF:*2.5G2:-V6
M17!(.MI'[/'A&PU?XBZE;Z7J%EJ7Q:,4_B>>UU&XBN)Y$TZ/3HI$D67,$BVL
M,:!K<H05WYW?,3VB9/,F?#?_  5$_:D^*G[.'Q&^,'B*'7/BAX=TWX<>!=-\
M4?"[3= \,2ZCX9\23Q-<RZN=9NA;O&-@CAA>&:>$0V[I-#F:0,B^)OVN?BI\
M*_VN-+M=5UGXE3>*]>^,=YX(_P"$'N_"QM_!J^&)8-1_L2[@OS!L>9_L]I=/
M*EV9F=KR)H1'"?)^H?%'_!-7X0^/?$&AZCK&F>(-4;2]-T;2KFT;Q'J36WBB
M#2)?.TW^UX3.4U!K>8LX>Z#LY8B0R+\M:FA_L'_#GPU\<)/&T-KKTMVVL7FN
MPZ/<ZY<S:'INJ:A%)!>:A!I[.;=9KA)IU=]IQ]IN2H1IYF<YD.Z/@SPM^W;\
M;+'X=6]EX3\3?$[QM\3/%?PBUKQ'XCT?Q+\/?LD_@GQ+9WNBQWL6EVQLH/M+
MVL6I7^-/+W(9K2P!8_:"\_U'_P $Y/VD]6^*GQH^-7@\>./%/Q)\(^"K;0-9
M\,>)_$NC)IFJW]OJ5M=>?$_EVUK'<01SV+^7,(%.9)8RS>4N.N\$?\$ROA3X
M0\'W^AM#XOUJSU#PXWA*SEU?Q->WEQX9T-)4D33]/G,@EM462.!A(K>>6MK<
MO*_D1;?1O@!^S%X;_9ULO$#Z;=:_K6N^,KY=0\1>(?$%X;S5->FCMX[>$SRJ
M%5%CMXHXXXXTCC4*3MWN[,.2L+F3T/0U"YQ]XL &)Y=RPS@'L,?I3WPTGF-Y
M<?((W#<O&<%3^--GV+;.QW-\P<NB\+@#H"<D >E-96M7VQ-L9I0&QG:0V3D9
MS_GVQ6=R-D2&) 8TY4K\H9^=V?[PZ\MS4*29*_*RPM&TC(/53M(^G.:DA$;R
M*VUC\VX+U9\,0&)Z=>U,\A9#)\RJK(P7*MYP5F)88_EQ0(E$:DLC(6&TQ%5X
M501R .YQCGVHB.)5W%9&A.\X&UL[2-S>G4TVZV 22,K*,>;(AZ\ #<,?Q 8&
M*C$OFW,T;.9MLOE*I/R@[=W/X>E!2D.RLI4!0$639C'S(2-PP>Z]_H:;:3-/
M&C2']X4+M)C)5<XX'J>O.13@P2W8JS,S,'5POIT^4<[>V?2A8XMLBK&TGF1E
M2(1\JCD\$]2>>GI0"0Y8(HXXE"^6JAE9G8.IR>58^O?\*-T:6K.5E9MQD,NT
M*<XZ@'L!^@JO+<>7$\T;,LGE%@Y4X?!"G>,?>&?U]C3VA^RN?,W_ #$1DLO[
MR;Y1TSP -Q!/M2N@U'2;PRQJ?+!F\MRG <$ @CTZTMGL7R]JJ=P\U4'8= S$
MGD_6E=XQ>R?\LY5_>".2,[@0-NY<=> >F:&A0B*((RLJ")3*H_> <@$=1T/.
M*8N426W5@Z[GVN64)L(?&=V >XZ\TV\.Z6:15_A,CHWS*P YQZ-C%1M,;4;7
M:>./RS*4)Y&.-OT.,U/Y:(TD!4L^TQ,L?2,$9P.Y..:+A9C$3=*T7F>9Y<HC
MCWDML^4M\P[\4Y"KKF-92S-YHDQN8=@=N>%(! 'IFF[XTN?.5E8JWG-M&W?\
MF,OD8&%IH57E2./<NQC'GC?;L%+#/MUX]Z+]AI$ICC;<NWS(YE6+@^6JCT4]
MR22:@FG A:>-OWGE>8DA&TMS@AAW.:6*Z\WRYF+9$?F-*W\ )P !ZGUI\K1[
M(UW>6J#R<R?.K'/0E>C9%&Z)LQJJJEXV&8M_E 9^:8[0S$MGH!GZX-/=Q+*9
M%'E22C</D\PYQMRA'?%-\R%K9F<7'$C/YC)C=QM)"]UQQC%(DNV\\E9!&SRF
M.54/#?+NR/?;VI=!DGEJTL*HIA; C"MR"!SAE_#(-5T<,C?*WDF))!%G RQV
MD'VR*L6K*ODLJ[L+O0(0 N1C))ZDU&B1Q!57<QR%V*G[W@D@$YQ@'O3YEU"Q
M(Z*_G1,C2,R["0=I..?D'H,TD,D8E69MK;2=S%?+3YL99O4]?:F71C=]S*=B
ML)'4]!GC<I'H>HJ%?,NY661UD=)'C3S/NJ% );'<\CCI1=W$2[@=O#8#/&,L
M/,B95W8SW!'J13+5]]NLC,Q9HE9G4EG)8D +GCMUJ:-XY+:/;YGRL)A(P'S$
M@@%E7E003VHM8HT#*5,PD"A2@V(@7! 4D\\\CZT!RCF52N0JQA5$0)_>*P!S
M@X[@Y_.EF>*)=K;D,9+^9NP_S'D[?3)YS4,DGD0&2-@K,HD\P?+Y@?\ O#^]
M_A4NQ3(0%_=M(5 'WI"IY+'^[D']* &RA8Y$5OW:RF0.$X#!,]!^%.M;@1K&
M^Q=Q57 SM1"W0>[8XS2R;6+C=M:0,0I7<W(Y*$=<TDJH_"KL9H]@5^5;;SM;
M'.<9H %C2-4^5L(5RGE?-A?NACZ ]Z:[+(&?:NP 2N =RL">JGKG@_4U$DGV
M@A5W-#LCD2,L=IWG@$_7_(J?9')%)&W[PLOEL1A<8/.T>@-&@$<9\ZX9=R[H
MIFC4R?,(U !R/PJ2*83P+M4@Y$@;(=AD<%E]P?U%.C=1*)/W<I7YN%\M<L!\
MQ)]?3WJ,6XB2/;N;R]P3)PR, 2 3W&/Z4!L2&)$C9=JX<!0?]7]W) 7\3G\Z
MK2S;XO.C;EEC9).59E?INP?O<8S[TJ2YB63+-)Y:DR'[[%R0JIZ9P>2*E_<@
MJN%A55"[3AD;!R.1W4_SHW0$2VD,%Y)<K;PF5OW)=@ SI&S$;W/)4,SD+G&6
M)[U-/&MS$WRLOF D!5W;MPP2C=LCOVJ(WL,%[%;D3K)M><2,A'!;!SQ@<L.#
MSCZ&D?;!(N=R19<2(A.,H"<#Z]<4#N/EN%NE;:J[BA&%<21N5'*GW&.O6D3:
M)#R6C_="(.VY0'XY]<?K3K=O*\MFC7<J@; =L<6[L..6(IT2*@7&Z3RV'R;-
MK?+TW$\<"CH(%,>UMP,DDQ^_D>8^WH5'H#T&:D5XTW942*R[<,-D9SU'/4D]
M>/RJ(^7(LB[0J;P"H.=F\G#*?<D<=.M,@7-NKR2.S#>3*PW$!#@D#UH?D.XV
MY_<0LVUOE5IE)X970@')[\$<G-.1 KLNW<I98V&!F9BF[YB>P'I3@8]FTQF+
MRPV6)\S(898.!R">O>EEDCBMY,^9C/G>8,*WR@#*J?0"E?47*A6=9W,B@JS8
M(9$\U>,@$'@ANM.)7<J@+#( (E96!=,YQN'3!(]^:K2 Q2_+\K-,JL4&T,K#
M@Y_,U(DD8VLR* -SA=P"J%.,LW7.3GTYHU"[8CG:W*X7RY':+/!8''Y'K4T>
M+=Y%Q&^W$)+-L7ID@?3-$D*ON4B16;=\FWYL$Y(#=,&DNY(YA)(R;LQEBO#J
M^,Y /][M3 ?'&MHBL=S>3T+KMQP!ECW.!3<*SKE>(Y1QD\%@<,I].3D&H$C9
M;N16;S-LXCAW?P_)DG\LU.1%+#N42,S2;Q(.7&,D-CT[ >]"&16L_P"X63=N
MW1L[,#EN,* OIG@U-)&A,>Q5C-OD+L.X+D<AEXI4=3N7_6*ZB/#?(O/8=^<B
MJM\?XM\C-Y;/&X7YAL."K=OXN._6IZ"Z%?Q;XHTKP+X2U+6->U#3]%T72;=[
M^_U'4;M+2"QMXEW27$DKD)%'&@+%F8  ')'6O'-%_P""D_P$\1:%X#UBU^+'
M@>33_B=J+Z9X?G?4HX6U"9;47#1NK$-"RHT0/FA/GN+=/OSQ!_9/$?A^S\3>
M'-2TF^@F>SU*!["Y2&5X9)DEBQ(!*A#IPQ^9"&'4$$"O+[?]@CX.V.A> ]+M
M? NFV.G_  SU5];\)6EK+<K:>'[M[N.[:2T1) L7[V, * $$4DL(40RRQO:M
MU*5NIG2_\%)O@)IVE^(K^3XK^!3:^#=9M] U-H]41TL[^XA6:&%%3/GEXRYW
MQ;U4P7(+ V\XCWK3]M'X0WWC'6]!C^)'@MM2\.Z19:_J-N-6@,=O87K2FVG\
M[=Y;+((BP56+!6A8@+-$7PM>_P"";_P2\4>!/&WA34/ 5O)X?^)6M#7_ !18
MC4[P1:UJ1G:X%W<;9@3-YK!MX.<Q0]H80EWQ=^P]\+/&WC+QMXDU7PFEUK7Q
M)\+W'ACQ-=?VC=H^L:9/#;6SVDA64?NQ':QA-H#1%[ET*M=3M(/EZC]TO>%O
MVY/A'\0;[P=;:-\0/"M]>?$72VUKP_;Q7H/]KVPE2 D*0"C><ZPA) KM*LB!
M2\;JMKX'?M8_#']I#Q#JVG?#_P ?^%O&-[I+[KE=,OTNFAM]\D?GICB2+SHI
M(A-'NC,D;INW(P',S_\ !.KX.:=<>$;JR\&-#J'PST:^T'PK)9ZG<Q2Z):75
MO/%-:VBM,(@K1W+H!("HQ#T$,>SXH_85\9ZQ\'/%_@7X@^,[[Q%:_!_]E_X%
MZGX6U34;_P"%VJ>&[S0X_/T@0V=\C2W,M_?16^E3O=_8D>UMS"DBL5N5Q:2>
MH^5=#]#;G]J;X<6OQNA^&,GC3PJOQ"N$6XC\/MJD8U1\Q-,G[K.3(T,;RB/[
MYBC=PI121'X(_:I^&/Q%\7>+O#?A_P >^#=<UWP2)$\0V-KJ\$D^C")BDOGJ
MK'RUC='1V/"2(Z-AE('Q3XNT&^F^.7C3X5GP?XFO/B)KW[3/ASXC6=\VFW4E
MFF@6W]CW<NKK>M&+=(4L]/N=.*>;N$N(MN945OF_QS\'_&WQD_8.\ _#'P3X
M7\;1?$;X(? ;QKH'Q"T^/2KR.>34+M=.MY-*$K1;+J?49+:[N8EA9VE6&-_N
M3QLU>S0<B/UN^$7[17@+]H_P1>>(_A[XU\,^-=!L[AK674]%U.&]M[29%1VA
M>2-B%/ER1R ,<E)$<95E8V/"O[07@'QO\5=<\"Z#XS\'ZUXP\+X?5?#UCK-O
M-J6EK\F7N+=&,D>#(@^91@NF<;A7S;^SU^T!X"U;]L'XL?%G3WN--^%WC?3_
M  #X!TG5WT:>WM/$&O\ VK5$,2(8MYV+J6F6C2NJJDB-"S*T#*GQKXN\%^)_
MBC^R_P"&?A/X.\.^(KSX^?#>P^+\WC*.*%QJ6G2ZEIVO00^9.0H_XFFI7NF7
M5OM<B=8ED0NL+.J]F@Y4?J?X/_:F^&?Q/\">(O%GAWXC^!]<\+>%I)DUS6-*
M\06=UI^D-"F^;[3.LACMRD?S-O*X4[LXYKH/AM\4/#GQD\(Z9XC\(ZYH/B;P
M[JBD6&JZ)J,5]8W84D$1S1,R2J&5E)4G!4CL<?E=\;-4\,?&3XA1_$+X=V37
MGP#\%^&OA/I/C@VFCS)IZPV'BI[V>TG@,8^;3+/RI;N(J7M89"DBIEE'U!^S
MA\2M-U#PA^T9??#_ %#3],D^-GQ&UL_":Z"F.Q\3WT7A.P%Q=V3#"R0R7^G:
MI/YJD+-Y<LJLP<.S]F@Y3Z>\#_&KP7\4;SQ!_P (OXN\)>(I/"DK66M1Z7JU
MO>?V%=J2)(KH1N?)D #;DEP1Y9R!@TW2OVC?A[K?PBF^(&G^.O!-_P" %#O+
MXFAU^VETD*C^6S?;%D,"A7^3E^&XX/%?C[\3(_#OQ6_9K\*P_#'1[[4-(^'/
M[,FF^'/BA%HUJWG:3"FO^'I[C1K_ & D7T5E:^(GDM&W3*LEQF,?: 9/:O'/
MC'X>Z_\ ML3_ !8CU?PQ>?LR6_QE\,7.H:["L<_A0ZQ%X0UJV75&N5)MS&FH
MW'AZW-QQ&ES!"&</$=A[-!R(_39/'&CNVBRC5]+D_P"$D;9HS/<Q%=4S ]QB
MV"G]^3!&\GR9_=HS?=!-5Y?'N@SZ5)=-K6C_ &&'4/[&EG^VQ-#;7[3K;):[
M]V%F:X=(1$?G,CJF-QQ7PS^P?^P/X'_:$T/P+\6-6L[JSA^'/Q(\;:W\,/L$
M$%O8R>'[CQ%<SV#F%X3YEJ8@SV@&U8H;KS(=K&*5>WF_X(=?!B[^"5[\/UN/
M&-OH]SXQ_P"$Z5X;BP^V6UZ+9XH8T/V7:MG%.XO$MMIC68!2#;EK=H=D[!)1
M/K#4?'&BZ-#J[7FK:79KH%E'?ZL)+N.,V$+AV$UR2<Q0A8Y&W/M&U'.<*<:/
M]M6@U&WM/M%NMY<V[3P0QLIEFAC9%9UC)W,BM(@W@$#S%Y&X9^7_ ![_ ,$A
M?A?X_P#$GQJU.ZN/%D=Q\?K:&Q\1Q)=VT44$$4J2M'8J;<FU$I1C(RG<[2-(
M290DBS:)_P $K_ ?AGXM>&?'4?B+Q[?:MX7\ IX!C6YO;=K?4;66&>">\N(T
MA4/>S;XGDE7:";>,*JKN5DK!:)],6>MV>I:2MQ:R6]U:Y+++#,) P#;682*=
MI8,", \$8J2[59;E87VMMF:-\@?O %#\^OI7D_[#W[''A_\ 8.^ =K\//#FL
M>*O$FGVM_=71OO$5\+V_N7D?<QED"KNV]% '0 =J]>E=KC>R^8ID.[]V P;'
M'4_=) QZU+MLC.43YA_X*AW$:_ W0;JZEAA5;V25I&4GRLVDS':1]W !))SP
M.A)KXO\ C'HBPZ7K[:KH\NCZYJ?A'Q%=:UX4M=+.FV&F$^$M;AB%LVYENC=1
MAY#<I(?-8'<L+(Z#[0_X*F2?\68T...+SII=2FCBC5_W3NMI,PC<=U.WL"<@
M>]?$_C\6MGX1U:6T2&^TRW\ ^)=0MO$9M+NQD\7O)X7U4RWDAG9II6B;,7VB
M)O*92HB5%4*.*NXN;OY?D_T_JY\?F<O^%"VGZ_#NEOUM?97:W:%_:7_8.\;?
M\%"_VW_$&O:[>1?#3X1_#^VB\':!<:DL=M?:Q;:<S0SG3[*9U4+)>-,%GG9(
M2C0$&8+PY-)\&_L?_$?7=&^%_@73I+?PO)>P-JE\[:KXC\4"SD2)P6:SEVI=
M:ILL%M[<!?)MM1E"DL%'JOP'_:)OK_X]_P!GMKDWBRV\0:A%9W-EK'B8R"&\
MCNE\ZY%I>6$:+<IAYUMP8F58(4,43&)Y? _B)<ZAK/Q>U/7E_LN2\\4:S_PD
M/AJZU2XL+>WGEN3=6V@70_M""6"X2PTF.\U<M#=[B]T@DCC,@1>"6%I4Y2Q$
M%><F[M[^BO\ DNQY-2EAHN6,H1_>SD^:35VM]$^B6BLK=FV>=?MD_!O4O@#=
M2?&[X3ZE)\/=6TNY%CXST[0+BXLULI#<R62:U:J]O:[M,O;RWGB,?E& .J[
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M'+J=A;:,4T^WAM-2\/KX@L2DR3(S3SW:S/ CK<E%B#2"*$!C*WZ.?L[V\?\
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MS-@8#:8\\[2.X///O0 X01'S%9=RR(4*Q-NX;EB3[U'(YB5I58;A&9-RC:)
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ME'[/7A'4;2WUCX[?!O3)KJTAU*W&H>,]/A:6RGB$T%S&KS#='+&597'RE6#
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M1D:&.&^_:@\9W%Q#&3Y<HMM.U**WC (Z1BVMBH/W?(3I@"OO+3)%CFA;R_\
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M6;^9;Q7]U*RGAX^FTP_\)/I]O9:;XDTO4\S'[#<:3=6^L:% +(>7<ZA::/J
MANDTG1S&UK8QP,[3W&)5\QP(V\RC6A.,,5R+FDKZV;TT=GT2VT_%L\^CB*4U
M3S&G"/-*-[M)NVUD]U9Z7\NI]3?MQ^.->T;XK6NCZ]XAN-,M]+L=\$MI%,+^
M&6\N9[1VLK2,*TFHWD@GM=/"M)Y-N&G.]Q\O*?$7P;>?$#]FGPA\4-?^QW6N
M33>+IQJ4-X\KO/+X=\4Q36"H0=J6T<4""Y$SO,T+*<K''(_!?!^]\:>+?%/P
MN\/IIH;PSH5YJ.A:]X?VWQU7P]9C1YM2M39Y(U&":"RNTTYQ*98TN[V-5+RR
MHR]]\;/V@KKQ=\'M/\!OH7AWPSI>DMXD70[+1='OK6$6H\'^(BB*MQ%'&3$,
MH3&3YD@E#K RJLOIJ<9WE+2_YVOIZ;'L4ZT92E5G=<VR?>\?RV[_ )',^,--
M,7BKPG=75K#H5Y)K<$2Z=;:9/:PZU;#5K%$UR2;/V:\NGQY0,*!X4N LKL=H
MK](?V?\ 3E;X*^!U3]X%\-:3N7>%=2ELNW@]CN.?PK\Y/&4BR^*]"F\V/5KB
M/Q&DG]JAKHR:,#>VS+X?F\S?;*85/F(EI(AQ$IFA5SOE_1SX&R?V?\#_  3'
MMCE\GP_ID)C?ED8VL>,'\/TKJH[/Y?DCJR._M9M^?Z;]/S]>B[;8%2/:RM)^
M\!7)"G<V2 W9JC9F62-=R_,&"R2("\07K]?6FH 519)EVA@KL>%!0_=11[]\
M=!4T]N9I/,7YU4R;&5AMP_'/<8YKHUZ'U6K"!422!W:2-2XD7<=TDAVXR?08
MS1!$4A0LZLN%7SBW#*&+#CKN[4YD19/W,K2'RT5MK?,H3/S#UZ\CO43,K.,L
MH94#F8(-Q4X'ZG(H E>%1<;A)Y85S@J<,I<Y^8'J":;$6=&3:J_.R"-!M#D=
M<GL/I1)"CHRM(J3,%"(S9.02PR>Q[>W%21VWE29?,:L7?DC)+=OPHU#U&[([
MA5564M(Q;CC?D;3M)ZD 4-:(JR L%9&CQCYMNTY&[\S4)=<1LLBE5BR/XHGV
MX/3LP 'YGTIT)9D5\A/E$FT*%2(,#C=W8^U $<[M9(VYHV 92RRX9?F;JI]^
M!4FQ78[F^4ML+$?>*G.%7M@C^=+)9*\BI&TD@2"-&"L%(VDD'!]<\T\0*Y $
MBEU+[@"0,/D\-CJ/6EJGH'4)HEFDE967:&;YMX_=[@ 01[=?QJ.=X_F:,MM*
M[RH^1T"C&X9'(QQB@2,KQJ-C,Q.'D'SH%^]GU(^M-6V67_63-&K+)C<?G;<-
MNX]@,=!307'$NLDB[L[ H9T0!Y-QX&>*=(/+CEW;?-#(5!X3*]%W=SQU--BM
MF@EC9CM5BG)8%<(,+C'.#GG-.,)/"3,FYBJ2KU7<2=I!^OX\4 @6S59L2-\I
MC=% ^9@&()Z=A@?6DG+V^^1)!A59B -R2X(!/J#CC XYI8F$Z_*NW<6/E)\@
M;:V"6/IFAX%GBC5)-[D/NP-O#$$D9X[=* Z"[#*LGS[< +TX3<!\H4=\<_C3
MYK9;B<O\C!0K[6.TJRYP?IR:$54WLTBI(S@@<MLPNT D=R._O44A>)\+B1@X
MCPZC*$\J0>XH86L2Q6ZN%V8D9TV-P563!SP>V"3^=1I=2QG:7VHT?FY*@R(!
MU7/0GG'X=ZD@=7\MV9F57R6/WI"N1P/3--^Q=&\P;55H]Y^[M+9Z==W:D_(J
MW5#A"AMF\S]W^[*X/S;-W)+&FQ+Y<R.PV?/N;;\QD;;CC':G3!8FF<2.JY\T
ME3\R<8X'<<5"JO+-(K%1MD*?NQM:0XSC/;OS^E#U:)"2W*[!#)M?'EQR'.T'
M&0K+Q[<^@HBD$T:-\J*N65>%1%#8!.._M4I4,-X=?,$H;&2%.!MP&QUQ^M1"
MUCA+0R2!9/+V*" Q W;LD#MG I>06'&T2=HU5MS&)E8,-K$,02:?Y:[49F"R
M^;OROS(I*X.3]._K3)RT9E;=&5"^9M?+JW/4$]!STH>(R)(LCX!'EN<< $=
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MS+"[>ZMS-<I$D,;QRXB+21Y85'J'[+/BSPI^U#\</$6L? WXP^/K?QA\0/\
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MB^H";<A54+(V[9B0<QD<\GOCC\Z6#;^[9IF==V_<W63&1P.R^_M4DL32W6]
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M.Z+E25.3T]?3TJ1X66.-F4_*78KC<T9;.#C_ #UI*]]05R*[M&+-M5BS&7&
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MQ_V]X7M]1UR0;FN-0NXTC29"1F58C=6[3D1.D3*2CPD8<8P_CWC;X?PYG?\
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MEO'/_P L/.E^X/V0?ASH%KIVAWW@^)E^'/A/PY!X-\!(S<7VF0K&;C4HY/\
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MCU15U:Q''-(VV155=R ^46 6,$D;B>^1VJ5K-6VPK)N5416((RNTD]/0TB6
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MQXGU%;'>EI96G]M-,C)*LT4#2:'J#1RVP,T86VGE-I'$$6WM;>VO_9O^"?\
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M(%C)]EO/ -XEW?/P%N-%F9$U*%R2,HD8^U*,_P"NLX>V0?S^\1:3;_ WXO\
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M*&+'(5@<D$^M$I70F^PW:R;8XX]LNW"<Y=< <L>PQ3KE/(O9&9@GDLTGOM*
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MKM5C$^/0Y.X_H*$E8,L@9MLK.Y8,!YFT_*N?3 J?4!LX>,,RY40"9<>_1/\
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MI$N]J*0^^0?+C9B0^H],\CD"A"TTJQMOV_,#O.7 Q][V]/QJ%0;@F1F(\Y(
M<'&X[OF'Z<BJ] '-.TD.YF7]V5.X'=L.[GYNXQUIEK:M$[*RJ6#33*IY&<C:
M?YU,;B0LW,@VL5PAX0 G&1CN.II!<?,OE,K;OF)A; ;ZM2T"XV*Z943+,5;
M+MEU<XY#+V_I1YVY2ZR,L)&=Z_*D?<;1W)]^M-<-,R;OFW&6+=Q^\7;\I^I(
M%)"&5>-RO#%"@++GRP3\W'KC\:6H#YQ(?X,2,L4FP8X.?FQ_6G>8P&[HLDLG
M.[ 8Y^4$XX]C^%*)=K%9MJ-@@>9\ZX]01C/TKQ?]A/0OCAH_@/7(?CUK'A/5
M/$%QXCNY]&?0H&BA.F3$7$4+JSMAH3*]N%&=JVH/F2[_ #&J-GJ-*]SV=)=Y
M8R-LD3(7?'NDCSV![BC<UP#'C[RN6#-NQQQGT.3^5?E_^R#_ ,%/OBMXO_9!
M^&>G_$#6K<?%KQ'K7@'7].\00V%HD/BWPGKOBC3;"\V0B,1Q7%K]JEL)PD8*
M"2TG1@UP"KO%G_!1WX\> _B%X/N-$8^--)L?B5\5XM;\,VVF6_\ :'B'PYX>
MU+R(;2R*QAC=V]LTDD*@JUQ);I'([;R:T]F]RN5]3]-U3>_F/L/VCR4W'J_]
MX?CC]*E+,CR?,Q97)94/^J7/R_+T(QU]Z_.7]H#_ (*1^,]3\37L_@3QY=6_
M@O7OC9X=\*:+KGAOP7_PDVH#P_?> (=?9K:TC@EEN6EN6#[A&[I&[<!5&/KK
M]A;Q/K'Q#\!ZOJ6M>-O''CEH=7\BVN?%7PZN? M]9@0QLT2VMQ;6TDT9W@B8
M1E22R@DHP"]F')8]A$K%B(5'W=WR 1QG.>IZ^GYTK[I$W8)$F^-&/\:E<C/Y
M5^6_[%/_  5,^*'Q,U']G.\\0>-+7Q WQH\22Z7J^AZQ\-KWPOH]A:M!?2)/
MIVO2*EI>SJUO L<,9F-SYI50A!D3WS]A#]NGQU^T%\<O!/ASQ%-IMUI7B#P_
M\1M7N9$LEBD=]&\;0:1IP&TX4+92,'&,NV&)R*7LW;4/9GV7$&AA9NC1K'&S
M*,^7UW8/XT@N BGS-JAE.-X\Q2/4'^E>-?L_?'GQ%\2_VN/V@O!NI-I\?AWX
M:ZGH5GH;VT!CDVWFCP7D_FON(D;S9., 84@<]:\"^&G[;7Q>_:$\?W7PU\,R
M^#]$\4ZC\0O']L/$5_I$EY9Z'X:\-ZI!IZN+-;B(W-[+-?6<(9I$C \Z1E8Q
MK&Q[-[H.4^X@S 1X)W,5\H%L>8,\_+Z ?RIDIV(?+Z0B5!D\J>=HQUZ=*_/W
M]H3_ (*,?'#]FK7M1^'$.@^#_B!\4=!\;^$[.&YMK5])M/'>AZS#J,JPQQM<
M2_8=0W:1>0;F>2#<(I @60QQ_1/[,_[;%E^U/\>=6M_"MU8ZA\/IOAEX8\;Z
M-?\ V8C4'GU34-<MYXI\MA3&NFPH8BH>.03!B2,*>S8<A] /_HTVQ5)VX$:A
MBN1W('0G.:'N53A=S,^.(TVL<]R?3W]J^6]1_;]UBR_X*)Q_#7^Q])'PG^V1
M> [KQ'([K?0^-IM-?6HK-3N\DVHTU4!;;YANKF*,< UY'K/_  5T\6>'/@9^
MTUJ.J>$M#L?&_P +YO$VI>!89%G;3/&6AZ3KMUHOGOB3>+B&[MBEU$C+M%S:
M2 *MP%!R2Z"Y>I]_*6\OS)#N2.2,*>?E).& /<8]?>HHK=HX&6/<TT<,C@#G
MYBWRGZXKXJ\9_MT?'>QL?VB/'7AW0/A=K'P^_9]\4:AI5WH4ZZA;Z_K5AI^F
MV=_=R07*R26XN#'<2B*-K?8S1H&*[MP]H_:'_:\F\,_!7X8ZQ\.K2Q\0:O\
M&W6M+T+P>;\R6^GK]NMI;[[;<A,2&.&QM[B<Q*5:0QB,,A?>#V;#E9[@MTJ#
M>S-Y#8^8Y=6X_B'8Y[5%-(T2.T;2?-DHV2-S8P B= ,XZC!_'-?'.B_M^?%+
MXM>(+'X<^#_ _@G_ (6]:7?BVT\2+JNHW<&A^7X>GL(3);>7&T_^GG5=.:(N
M"+99IBWV@PJDW1?#?_@I0WQGC\)Z]X-\#>(O$GA_6OA+8?$?5-,T>%+S7+:X
MU2[@M])TV#,D<&Y_(UCSGD943[&KET0.:GV3':1]3S)Y5ZR[41(YTE(R%"KL
MY/YC\Z;%$YMX5;=LF3< 7*EW)R<GKT/':OD;X;?\%$O'OQE^#/P'_P"$7\ ^
M%I/BG\<;;6-3;3-6UJ:/1O#5EI3$7;R7,4,LLI\V2RMUV1[2]T9,[4V/A3?\
M%=]8\3_"&Z\?>$_AE'J6@> _AM9_$WXC6FJ>(C:W^DVD\NHQ3Z?8H(&2ZO(#
MH^HL6E:"-O(A12//+PU[-[BY6?;HN/+)7<Y?[H7;\Y] &_,YJ-GDN()E1=RH
MC[L-N(8-P/K@9)KQ#]M[]K?4OV3O@AH?C#PWX$\5?$[^U-5L-/>U\.6HN+FW
MT^203W=YY9=3B*PBN9$YQYJQ*^U&9U]PMYKB:W0O#+;2LBE[?S!NAX!P,95B
M#D9'!QUQ4--:CY21(O/NOX6CDFW^NY0H S_P+^5(MPRJK?-YFT-(<G<A[Y7T
M^E/,^]/D8.V,G8H3/^\:3>V59FW1K,JJQYX*D$?3=BC?8GT!)UD D\P&/^_C
M:N/0#N?>F31O) -W$DD)&6[D$$?S--M%DAB"[6\R&$<9R58L>GOBIEF9)&W;
MECS\K$^8K^YZ8-+H"U0GED322;OW<DN78#JH4 <^F1^M)YK*-LCM&S,=I #X
MZ#Y>./UZTR>:0!O+W_,#L;.,-R.%[CI^=#[8KIB65%@D$C;CC8I4?UJA7%C:
M1KI1M;>K?,F_)V'KN[9.,C%5]HVK]W*QK#CHW+C(]>@_*I$$D4$?RLH**W+;
M59V)+9]_2I'N> K-(LC<*BJ#*><=:!#I6DCN7#9'S810VTA< #;VZYJ,S27"
M?>+",G_6#:B$9P6P>3G'''8TLI:2.9%5F6.,L5)^ZV>.?IVI;=?,O1L&4DG,
MG!R"NSJ?Q-+J5=B#K'(6=H_..USV4@@_AD?EBDMX93"0J_-'#&I*\[3D[@#Z
M[3V]:(YI(TC9O-D;'SN&Y4]\@]A[=JDCF78&5]T:J0S_ '1[X ZG-*]R1-Q0
M94[48X+K\P/ID'O3?GD&8]V]B"A;[Q/J?08[4R:-Y J2+Y;31*[;L#)##.>V
M<&I)EWQR2=(Y)&)8YVOP ,D=J(AJ,EW+=-E8X_)D=@#R64J!E?QS3_*DC\I6
M4*1&@C#YVEN=PR.AX'/O0URT.U6\R/S&VKA0^3_LM[^_3'TIULA>9<+M8_ZQ
M0Y; VG&??.*%:X TQF'E9FW8)92V .W)ZGKGK4<D;-#*RJK1J%8!%."X?<2O
MX8ID,!D*[OXQ$A&[DD-\PJ;<QN&^\&W-_$5( /&WL1BB^FI2D+;QL9WV%9&S
M)(ISD*3C&:9;N;9FVJP5!SM8^9&>^[)Y%*+OSDW?>7:,[P%"#WQU/TIS1LP4
MX;;^\0%O0KQR>V11$+Z$,Q:1Q(NUE;);=DO(,8&T _+SCDU)/$=ZQLW[QQ&Q
M/]XJ3GGIFDM8W2-MJL?*6*/<ISP -P'_ -:D23['$\C91< ED^=6[# /.< "
MF22,C&+S O[N21W9CGC^Z2.XZ=/:HGN6A55S,N[H(OF5SWQ_=R?K3V#-]T,)
M2VY=S?.>1R1T ZC\J9+"MMJ2D858I7?!.-H9!T'?)I=- /F#_@J';^?\)?#O
MG2+;0G5%BN&CDPH1Y[8;3_MY*L&Z@*>E?%7Q3TOS_#OBJ.:RA\-W6K?#SQ"E
M_P"$[/2KJWB\)3/H%]&8HX)2#,DHC,GFVT<<,[/F-2<N?L__ (*LVPL?@3X=
M$D'VEHM0M0+9FV).HNK0NA/0.< *6X^;UKXW^,.H)I/@_P 2(]Y+J4EC\/\
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M#*?NI.XZ>GI^!J%[MK: "-(9%MV5F0 _+SR0<?>YR!W]:$C.45).+ZH_+O\
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ME-&I3>WZMWXS?>65+K'<Q*HQSMVC/X>_O7Y3_M,:;;Z3-Y-BJZQ#<2>+)O\
MA)'L+F*>YE7PWK0ET=Y9F87B6&U8HVMR(8QNBV)(CY_5R?\ >:I,RB-G48+(
M_EN!_=;V]^HKW:"LFO-?E_7D?1\.Z3K+_#^/-_P^EEV21'!,6N89!]]T=FDV
M[LJ&QL49^F>*D%Q&WF.WE\\.1(1GC!W*.IIL<RR[1NBDCCD$9"KM"D\?*W<C
MOZU#)(6;<VV1HXICDC[VQB 3ZG@5M*_0^GO8M-NN_)CF8R;U8(RKL*D#.Y1G
M..@_"HT#3-YG*><D(8J<?,6^;'OP/>G"22VD;RPS,H17?RMSL6_B/(^4>WX4
MK3(MK'+^Y7RSE6W;E!/<+US@\#WH3NBNNHJW3-!M'RQY9 K#Y  <8+=<\9J5
MKDQA5S)U 50WFL?S]*AFF._.QC\Z!B%V[E;@AA[?U%16JF"!L#<!YS,J]9=I
M(4>U5<.9CVFDAC;RW822+*/D.!(R@88#L?I2!C"C+NV[7CB7GY4) )/U)/!]
M33HYR[QQMY8V?,JA=@/&1L;..,GJ.>:;O:**1 8SP6"E=RC SEVSWQ^&10*X
MY9EN9#YF)"RD$,#&X4]B1U'>H66WGN;:=H+>22U)@@?R0K0!\!A$WWE! &<=
M0!VQ1<'SA&I5O+9H6"N"S('SE3GG' X-/%RPN5949YF20A@F=H5P-J\]3U/T
MI)NX^9D)A^R_+&BI%$MQM"C:JE6X.!W)).?<U4?P7HMLNM01Z+I<<>LS!M4
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M!]XG&0<]?\*3N.^A8N)6\J1V9@T</FJQ'S1'GKCU]/:FHN9_+"LJM<G( QN
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M)0B21K&LC-ES$[;F8CGYCT7@#%'4"2*=9;C>%\R1>#Y1\N3'HRD]/H:1KA9
MJNJ,BNJ;4!^3)Q@-ZYZ].":CN#YQ[M\T91OXBK<X/Y5(CK%*K;>FZ3'.V( D
M< =2<GGWJ7(97<[9UD95:2-9@3C&\HQ SV_B;V^:K+.+2291Q\VQV9=V\[0?
MF/9>2*1X!/N<HQ#/DE7'EN.3SW SV]11>7(=6D4KYB1O(KC@-M'.5[CFFM!
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MV?4.0^[FFAN=[?ZQ6^5R9"@Q[K38Y_-DCC9EPQV*P&W:<%LKW(Z"OS5_9_\
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M=LKV2QC\'Z9XVT/Q)M/]G^([*[AMYV$65!CDBAO+)RKDL5N VT!3GR_X9?\
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M3XF:EX3\/^&_BMK$FC^*+KPA>ZE9^!-1FT2VU"VN3;7 DOA&81&DH;=*6"J
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M6Y\J<KN&&8C]V/,VX!)+''UXJ;W&#.WF9<DX.0LGS*<9&5('IVIC2NJMC+=
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M8 P?9N?Y5UX?9^J_(]'AV[E53[Q_73R]""VG5%C;Y5VAI$4\1Q+NVY]2U3F
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M+9L"PS\A+QJ",?7GVJ5%:Y7RYV\X;VBVOC;\O4GU^A]*9K 4^,E5F,?^@O\
M-C.T^9'CCZU8,,:7:EN=V]O+0E\EL9;V'4?C7/47O7,I+4:P00JRY4.^YG==
MJ.&X/TXZ?040E3'(NYF.Y2'B&Y4"@%1SUXZU'YH2)I(V_@+!P-N[9_"P/>G
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MN5GJ%J3/&)9-RLT2[V'+98X"CL/K4P599%91Y:Q@*./,1@#D=.A!]:\3M?\
M@H[^S^MIIK'XS?#>1=<9/[/D378%BN4%[<V,<D;%\-$;NTG@$V?+:2/:&RR
M]9<?M1_#6U^.9^&<?Q \'Q_$8LB_\(T-7@74F+PF<)]F+;_-\@&?9C<8AYF-
MGS5.MM@Y6=\Q2#8K;OE8MO.-QW$Y)7^[SWJ,KYDZJ&;#%UE120"5]/J"*\E?
M]OWX"?\ ")3^)O\ A=7PG7P[;Z@ND2ZFWBZP%J;MH?M"VYF,VT/Y/[SRP=VP
M$D8!QS_C7_@I!\,]$^*.J>$]&UO1O$GB"TT'P_XI2.V\1:3;6]YI^M:DNG02
MV\]Q=1I(5S%*0/O+<VBQF22YBC=J+W!1;1[];2B%E+!25 VC(41AAP 3]XXI
MMO$NU?\ 6%48#:8RK?+T#'I@>U<58?M-_#/6_B)KW@W3_B%X!O/&/AJV>ZU;
M0(_$%I)J.G0Q ;Y+BV$GFPJH==S.H"AESC(J;X;_ !W\#_&E]8B\&^-/"OC)
M=#GAMK^/1=;M]0.GRR@%(Y_)=S&2OS!6P2,D< T:BY6=>^PG&-T>]04/;>P&
MY3Z<FH[+]XI:23<=TC!C_P LT7 X]Z\[M?VL/ ]A%XL;Q-KFA^"8?"^KW.DR
M76MZYIMM%<+;&S5[F/%RWEPB:]MHBLWER+)*@9%$D9?OK_7=-T&R^U:A>:?:
MV<[I;I*\RPPEYY%2-=[D O([HJJ#EF90 2:.4?*RSY<;0*OE,BABP8XD8[LY
MW#J-V?\ ]5.CCC0,NQF9B!O&%Y3IM!YX'_ZS7,R_%[PF/AZOC!?%7AU?"K1&
M:/7?[4@73RH;8NZYW>2REOESNZ\<X-:H\3Z3%>6<-QJ>GQ7FH)%]GC:ZC\Z[
M,@=E$2D\[ECD(('(1\<*<)WN'*[EV:;>&9&*L3&=Z\;PQQD^_!J4&-",Q_+O
M9@F[ ^5OO,?KVK-LO&F@ZQH<NL6FKZ3)I-LI$E\EY')9Q>42&S*K;1L;(()X
M[U:FU_2[>UMY&N[>..0+Y<TDR;)5D90I&3R'9D (ZEE'<9=K!RNY;FB66-E_
M>#S"?EVY)SUVGI@^OO3;E_,,ORA693\I8,K%1T..AQ43LT<2JQ:.';(9!GNF
M0<$]CR?3 J2U,,MNDB;9E:/='Y;@J58 Y4YY)'?ISZ4!RD2;7++\[+\@C5V)
M5=_3/TJ4(JLZJK'?CE2H("GC"_W037*ZU\8?#?A7XQ^&/A_=7TG_  E?BK2[
M[6=,LUMI&-U:Z<ULD[O(!LBVM>6X 8J7+\9PV.IEMP9]KQR;-X)4]4Z<J1U
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MU<#CS,*#SZ]OUHAN-B1NQAWB-6RQQ&F[H%Q_.IC"LA:3;(!*2?D4-U !(/\
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MW&J?\+8\6-XNEMS"(O[/#:3I^E^2""=Z[-/$FXX.92-IVY/@?P\_X)6'PO\
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M?Z+XJ_LK6$T+4)=2NULV,EKJKZ;<74=C)+%<&X%K]EGD8P.3+L,5</\ "O\
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MI'A;5%\7?#.TU:[TWX*WWA[PQ!?>(K'[5HNJ7VKZ[=OIMM?VMO&EA)';7=G
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MXQ;3YVM;. C59/"7B=]8"+;G?)"D_EB%[I!/D3Y:1#$Q_5.ZM?\ B922*&D
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MLCM&[$LK.Q##)SL^&/V/?A;X.^,FH>/]+\ ^$](\<:@MT\NL6^F1)>":[/\
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M>T/$?VL/A1KWCOXT?LWWFBZ7)=:=X)^)DVMZW*LB!;"U/AS6K59?F8%E,]W
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M#N(;6:9UU+SHX(6!&YHP%W;NK$$@#_:)[5\;^--(MU\.ZC8K);:U9W'@[Q'
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M,Y0_<OPJ\$ZE#J6H^)O$:QP>,O%L<$=_;HXEM]-MX5E>WTV-UY/D^=,[2_\
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M^Y5*LK$ 9#.Q&,@9Z#UH^R?Z.J[MWW\A#NV!OYXH2TT&$)9HY%7;N9 =F,*
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MPR-N((5A_6JZSM$WDLL*NJF7.3Y:^AQ[\<"IEM))XYA\V9(T #D!F923D@<
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M6X],#\<U/*S)(RL,L9."3MW#MAO;TIIE9OW/[\MC+(2.GNW7%+Y;21S,JJR
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MW5_T)_::M5U3X*:G*S0I-:WFEZBDK2_9]DEMJ-M/'N!S@AH@>F3C''%?G?\
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M2B"7'E3R(7B +%OD(Y.>,T_;1*YD?F/\!=0\6?L4_&'QY\5;R#5(_"_@;0/
MO@SXKZ.T$DO]G:.?"UD5U9(XP7$VE7<DDDH4-FTNKPX+Q1UJ?"O]B3X2^//@
ME_P3AU#Q%\.?".JZY\0M)T>P\47EQIT<D^NVMK\.=1E@M[AR,R1QO;6K*K9"
MM!&1RH-?IIJ'A'1[F/7&;1]+/_"2PN=7S:I_Q-=B+"OG\?O08<1D/GY%"].*
M;!\,?#5DGAR*/P[H4,7@N41>'533H0N@ 6CVP-FNW%N3;R2P?NMO[MV3[K$4
M_:)AS'YMI^QCIGC;]M#]H[2-(^ GP)^(?AKP?X@\.^'M*7Q?XYOO#T^AV</@
M_1#'8VT,&EWB_95#;@QD3YW<;#@,>5_:_P##5WHGB3]L_P ;+\%O"?C;0O#7
MC&ST>3QM<>*]0L-8\!6J>%-!#WD5K9VDMRUGIXG-W(;6=)BK3;4&TL?T4^(_
M[#7P-^.'C._U[QI\&?A'XR\1:D%^VZGKWA#3KS4+@(BQ()99(6=]D:H@R>%5
M1T KO-$^'OAWP]%J<6GZ#HUG#XDNA-JB6]A%"NIR_9H[7S)0H_>$6\$$)+@Y
MCB1/NJ!1SH#\U_CY\)5\=^,->U637-%_:BA^$?PO\/:?KDQ\7S>%O%'@BX%G
M/=MXKT.1HY+&2XU""07'VC[1$5>S6/[0P5T7E_B)^U!J]YK?QJ\0>'?'GC+2
M?"?C31?@=IVH^,[Z\33-6\-^']7GNX[[4W956.TN7MYV#RQK'Y+SF12GE*5_
M07QE^P-\#_B/I_AV#Q%\&?A7KT7A32H])T0:CX5L;E-*M(G_ '5K"&C(2W0G
M(B'R G(7-=_+\'_"$NM>++]O"^@M>>-+6'2O$,S:9!(=;MH$DCBBO"5S-$L<
MTJ*CY4+(P P<4>T0<Z/SS_;6MO#O["%A\7/"O@CPM\9/ATNK?!_QQ+I-X/%<
M>H>&_%DMEH<=VU_Y4NH37]O>VSMY8NA# \K3.)'DQ$1F1_M(?$#P'\5_V=_@
MKXH\4>)YO$'AUM9U.SUF74)([CQ]X8E\$:Q-87MSLP);FTNHQ;7!8$_:+:"Y
MPGVN)1]O^!_^">_P'^%NC^)--\.?!_X>Z';>,-*N-!UA;#1X1+J>FSKMEL=^
M RVK*<>2"(P.BC&:[3Q7\ /!'CSQ-X7UC6/">AZEJW@=+VP\/WLULK3:5;W=
MIY%S' W5%EA58W .&"#T!H]I$.9'Q#_P2G\"^,-1^ WP7\>>(/!GQB@;4OA[
M9Z[>>-M6^.VK:UIE[<3Z,KM=RZ+/?/#F9Y"ZH82L+%6 4H,8OP%BUSX#?LM_
ML.?%+2/'7Q7U_P 7?&:?PCHGBO1_$?CO5_$6G^*(=6THSW\ZVM]//';36^QK
MU9+81;5MW3B-R*^M_A'_ ,$WO@?\#?$VDZUX3^&FBZ%JGA^V$-C);3W 6V22
M%[9U"-*4VB%F3!'"GC&!6C\$O^"?'P3_ &<?%VFZQX,^'.@Z/K&BV3:;IE[*
MLMQ<Z7;%1&T5I+,\AMXV7"LL6T,.#D<4>TB',CPW_@KO\>_$EA/X/^$WP_\
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M2.[)NP?+:5P6YY'.W\.E0M(T*A&+JV3@ !\=OE)_KW-3+3<?D?,'_!5@0P?
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MG'ID].U.BC+3_N_+;+O*!G/5<*3]33 Y4JVV3C!<J?WB'OD'J*J*L(MZ"?\
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M<#,-Q48P ,*Y)QM QGO3)%EG"!LE5:/'^L7<P)]#W'-.5VN)HU8, Q8%7ZX
MZ^W.*:T7^EJ5^8P._0YV@@<'VIMM(R!0&;YHD?"_>8G()Y],#BIUN U"TOS'
M=AXT&1W.[!'X8J;>X+###:[ !/\ EFN>#M[YH6ZW#AEV]L*?,SDYX_K3?-9@
M^[.^$*_KL)/3/?CG';\J/)#5@28K)M5ED9><(/+4^['\^E+AOE;<QR6CWDX9
MQMXS^/%,%L3-@+\WF/(%SPV/NY]O:I%G>2.,.?O*"W=0W<>HP?6A7ZCOH,MU
M:*,'))AB12?O,/[WXU))<JX ?:%)X#X=&^A]:0RDNWS-M'.Y!A1Z?[QXQ@5'
M.C7 "LK1LP1]J]CDY_0T;;"0LUVQ#*N[S&!$7S8W_0>W?/04DF$O^F(XYBQY
MP%!3K_WU3R&1RV<*9'RQZKZ 'MG^E1M<MM8,ZK)C*K*-^![8Z_\ ZJ-@OK8^
M7/\ @JI$G_#/WAN.XD-NLFIS%VC)5S_Q*KTMMP#\W4CTQGM7QW\;;!]-U7[1
MJ%I)H_C;4O#VNW&M:"FCIIT5D?\ A"?$'V:6!U9UNOM \]GN_-9I'B*LD)B,
M8^RO^"I+-+\&O#4;1^<EQK=PKPR_-YJG2[XXZ?+TZ>A/7I7Q/\8=(_L[P;9_
M9[9=2TV\\(^)?L7BIM.GM;KQ?-)X0\0M*9C,6>Y:#8L:SC]U(C#RU55"GAQ7
MQZ;67]?@CXS-O]\]&OR73]=EJK7DK?47[?7P0C\9>(= \3?#^\T73XM'M[[4
M;C6=.N8F?29;MUF>XNHB"MUI5RDTWVG)+1 I,@*F3/B?A']IC0/AY^S;<1Z4
MGA?QA-X@ULW&CZCJ5Q';:9H)@^RBU$NKL'2\DLM49K*">T,_EI=6SON$<F+/
MPPBU#Q3^TK/-JUK!XHU#6"_]LQ26_AFQ9[6^/^E)(-T]RUL]J\CN$:1]L,B1
MO=2%G7P[QGIVC_!&1?!>GV/[GX8:=?>%+>W75K;2[S5UTIV75XTN;CS;J!M1
MTFZM]3+6-O 6N;8[&E<K*,Z]2S]JM+W76^RM^']:*V>(Q3YI8F"Y>:Z?7MM^
M75[=E;:^'GQ#\06_C/\ X3.^N+ZZUC4);.Y_M_4[%M$CF<W'V9 LM_YUYS="
M.U>WLXX3:7J6\2_Z%=Q?9W:/X[AG_;&^.7PET@W5NVCZ@GCSPM;VD1TN6*ZN
M=-L9M<L[.*Y)6PDENWCG5IP39QQWLC*Q#JVI\'O G_"8?%[0VNM2MOLGB;4'
MM[KQ#:+<Z+_;4$FFH[ZE_:^H-]NQJ7AJ-WG33XMS7FA^<UQ;D":OG;XD^"?B
M]\ _BUIO[8OB#P3K5GX'U[QE)XF:?[7']M72M0FD"6\\2R>=;&XLIC"C.!@R
MJK%'9!7GXC%5:5.#46US>]Y1L[O[VF>7BJ]?#4H2C&4DY^\TKVC;66ETK-KI
MNM3ZO_9"^*<7PO\ &%I8ZM:P7'A/X@6,7AK4XK1)8=,O9Q>K'/-96LRO/<QJ
M\Y6^U.^<R-+=LKR)<)!8/O>+?@3>?";Q=J&DS>>]F^MW=Q8ZE;23!=0>>&)%
MNX7;SGENI;6:5)9P^HZE=/</O>&!?)&%\8OAWI_P\\2ZYI=S=V-]HNN*@%_=
MW@L[/7K5HF6Q::["QR-91Q-+)]@TJ(116\7DM-&D;Q7O6Z!\9M<@\&VO@O5I
M)-J^&+NYTJ/4HX+!UET_4X+:[LY;/R95BAD&J:8UK:2VT\L<<+(L$,DGEP>E
M&-HN';8]6$4J;HS>L+V?Z?JNUMS4_96CU#PM\6/BMX%L([+3M8\<7NG_ !A\
M H65(]0U.QAM++6M.#^8XB)DM+9&B+EX[?4]QP0P7[S^'GC/3_B?X>L-8TMF
MGT[4]^Z.3/F0[24EAN(VYCGBE5HGC.&21'5@"I _/#Q!<MXUOAH.CZE9^&/%
MW@;4H-=\(:K<+- WA*]6W>*-;FT$UP;73YE+03Q7#6J);W9#P?:L;/I+]DO]
MHVS^+/\ PC/C?3[.;P_#\4)KGP_XF\,2,/-\.>,-/28W44A&&WM%:7,3.<"0
M6MHX'[TD[8>6G+_7])_A:W4]K+,39<DO3IWM^#=O2SZ,^CH8V;R]W$GE0P$Y
M&[(?YUV]>GM5V21O.9?XHR2 "0P7C&WL>G-1K.UQ$JJTBR,,D*@\S'IN_KUI
M3(\L,Q56;8H<#=NVMN['Z8KJ1[?F/DN&*93Y@OWB<1JO&>2/K2;Y#'&3N97D
M94)_NE&Q^O'/M1L9[D!55E>1Y O4.-O!/XTQ9W:-69GV.H#,1N4G'(9,< 'N
M*%?J'J7M 5ELEC)&8T4''3.**?I3 H_E[-H; "KM4?2BNNEI$VB[+0I7_P _
MB!DQN#6XR <'[W4'\J>9%BD\P]3^[!DX R>F!ZGO3;Y5;Q X9=P:% 5]M^./
MYU#"2T"N^0RM+EV&2BH<<>YZUA4;4S-[CKEBL3XSPC%0>J,N.A].:=Y:S6ZJ
MW,>5C*[N)-R@G<>I'7BG.JRG9C9Y9Y92)#SU# \\C!H++'$5\O=EMY9FVMP,
M948[ =#BH$.$RSMY@WKN&T-$-V<9.,=0>O:O-_CU;?V_J7PS\.M&?L>L^,[4
M7(CD):);*VNM5CW$=C/80@@\')!KOKH*"N&&Z62-=XZR*QS^)&.OO7 _'6\7
M1M0^'.O2,L-KX?\ &%O)<+OVB..\M[O2D)_O?OKZ(G/ Z]J+ZF%>WLWS;=?2
M^OX'YP^$O'L?Q5F^(_C#5%@U#6?BA\5=7MKRWE@CD>[T/1Y%L;.R6WF&R[2U
M@M[BY9;=A<6IE,^R<,+6[P_$_B^[\4?"CXC>0MY=Z];?#_Q!813/)-<:AIEW
M<:)/%Y;?:F_M2TE,QM(YX[E[NW28PP&<W-O>2M<LO#%Q\,O%WQT^&-Q<66G7
M'@?XG:EJT/VM+6\MX=(UF)-6L;DV5WBWN8[-;>_U!\20S">PLT1W^:(U=:UJ
M/X:)I>H:IIMQH$>CA+W2M(U.[N(7TZVM;6.7["PU1HFCN(;&XLM/F>UU,++?
M^)-1,GF['4>1&H[_ "U];N_XW/BZLFO?D[--[^3:=WZWW[_,]2A\*'6]3FU_
M3[B&QECC^R6;PSRM+YD4EHD,,,D3PN\!^T"&*UEDO$21X(TX5UE\Y_:0OF_9
M3_X*+_";XR3>%5\;_!'P'X6ATX3^'889AH,MRM[(]XUNI"V[&65IHY"%BDCP
M4D+*,:FFZE<>&+"S\ 6DFA:AJ%K"MEX1M]9G?['XJLA-);QM&61A-Y,CV]K=
MPA7=D6YE=)H9=.>WK_#[Q;KEO\0=-DL6\4PV]_JUG;Q7S6\>LE_MVJFSBFDD
M1F?>--TW4KN5G#*L^K7+R2.<(9K\LH\M[--/3HT[ZI[K\^AC6E%PY(NTDXRO
MOJG?5/1KKTT6Z.;\7?\ !5'X??%S_@H"-4LX=2\+_#SQAX?TW1=4UV\NO['N
M)=7L+Y[[3KZ>2 RF.T#.;.4MNW073F56BB"-@^/OAI;_  :\87VD^)M4TW0]
M0\-VUQIES?1#3[/4+<-:P7_BC5Q-;WFGRRR74DL6G03^1&7CEB4H=P+'B?\
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MD?8-F%14(!Z=31*5R>:^@!<R[G7S&4NK-_>"\J3[U)$P23=_%L4L[Y;.>P]
M,421[TD^5OG^\(V^4D]_:@S;V7YE'!563/89QTP14HD/+\@*P4*J\Y9MR#O]
M2:<902^?O?*Q;&-P)Q@CUJ"-M^UUC50R1X _AWD D?G^E2OR9%^7;)E26)WL
M!WSZCTI=">A&C8,@Y"JSYP-IPH'3\:D5A-M3Y=RC=@97'N#W_&B1E@D60_>)
M*@R=1D] .^?7VJ,D,'1?E"[U(/(1EP<C_"B* GWK'N7Y/FY.X9W8YY]/_K57
MG_?J5'F=8G /)&X\C],>PI8@KVH^7<K!,H6P&9AGD_C4S 2R[L'</E9DX; S
MP0>WH:: -VSYO[VXCTC XP!33^_+-AF5A@D/A#]1U[TUY $V%8UV,,[&R4R<
M @^O/I4>,W2%OF8&3<>F=IXS_GG%*3 F^T^?(H+;BV[:RKM(P/U'7K4,"JSO
MMQN8Q]%_U>Y>=OOU_.I8YC$C-PW #,_?(W8XZ 9Z^]*&95C9LH<C(=QMC/H#
MCG':GZC ,)(E7Y1&S<*V?FYQR?7O2^9Y4H3D;OE!?YG8>WM3&+27(VC;ATW*
M!\LJMD<CJ".O8U#:$1Q*^'(82.Q'5@I "C\_THUN(FE;$3;DR-KY7.0"/3ZT
M0G"*OWLA,J3@ GG)_+\:DD?$Z*?+W)T"G##Z>M->7.Z,JK'[Q#<LWN?2IV=V
M,<+@7&[#&0C^ZVUC]0?QIRW"L%5=K*C!1@?=SP.?7FJ]S^]C7YF"[H\'/.&[
M9_ 5,'(D5BJCAF_V44''3UJA\S(9)_+(8@,WER,21G)4\9]ZE-T;=GSA?+(4
ML5SN)&?P%)E6W;HSY>><. C$]<C.?J*)9=ZEOE\QE)#)QG;@\^HZ4:; EU'!
MO*VG[F!@9.Y1Z8'?\:;*^%9FP6#1J>V=Q Y%0PJ/-9HPJF0QX('W=PR:D$@(
M\O:BI)D[3GG!QG=TST(%!(V+)/W_ )=\C. .7"G &?QJPTN2D;8SC*@?*1QV
M/XTQW-NX[<;29/F8Y/3 ]?6H[@^9;LI7Y=K?+GA"OI]:-AWT)=[ R1A4^;)*
M\G/'\1['Z5!,ID8 %MK/&0&Y*@C)7Z<#]:?$[$;=JMDJ !P,E<Y;UQ_6GLX<
MLWS9^[\ORL ,\$?U]Z+W0A(78,LWR[B'Y X50W  Z9]Z&Q/EOE9<ALAL+G.1
MD=<TYGV(JX^52HVKU7)QU[U7F\P2F155ML<AQZLI(!)_*CI8=R::X+J64GYD
M9E8#:PV^OM1&XBNLJJC=(BGCL020*&8QF15V_*=C.XSN) /// .:YWXOS^)K
M+X5^(KCP3:Z+=>-(=-N&\/PZU.\>FS7PB;R$G:/]XL32;0Q7D DBG'<<=[GB
MG_!+B_C\,_LF1?#G[4UQ-\%/$.K_  X9)FWRI;:7>R1:=N;)P7TTV$H&3@2
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M1MG!7:0>.H/&:LQ%9@K*8RS/]X-P2>.GK7@G@_0X?V8_VF-)\(Z5]GL?A?\
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MXM>#M)<P7WQ!\)RS&2+4;! 5\R167[1''&<2-]JLBY:)HSY;\.M-DM?^$?\
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MJ;9&3*C+YC2?N\\*6QV4>@SG%5<?,-MXU\SR]S-^^,>6&=@ SQG]*=#.)X<
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M3;'S\XV[<=,GO3Y=;L;!I(PC?*NUSNR7(8^^?7/;M2F38S,$^;[@,IV9SC@
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MV6?]W\Z[0?8"FS*JQ'[P&UL<Y:,KSC/I[4EH@VV'R3;(Y%\M6X+ $_,^._'
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M>4P,!O<X/!'3%,FF\J%UVJ=HR5&<D=_F_O4]]4)@7^U;^%9ER, E <= P/\
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MO0[@?H1Q7NX:WO>J/J>'E[D_5+M:RVMLK=EHME=:N2*WC'DHL;(=BQ#</O@
MD*P[8YJ(R>8OWI/(:,.R;OO'..M+:$-+;S*&VN/.$?<Y'#$^_/ ]:=Y$8XSR
MN5^4$R*"P.,=.PYKI=]CWR2%(_-D5EWO&/+& %5<CE5YY.,9Y]*=$8X75O\
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M\-]-\.^'?B(NO^"-/N-0\/\ C>RUNTL=/U_6HM/<1WC6$L,>I1R P2PRVKI
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MD 9ZCI6;N"WL$Y#P87C?&"I/5/F"D9[]ORJ3 $S<<;BJKCC@ DGUZTXCS0>
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MNW>T$L^FRQPVL;.!:W-O,(+F8)&#]L&H>U?L8> =6U:RT_Q-K5G?6/B/X_\
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MM&OO$<^G^'=-&H3V&E6+PQW5ZRF1&D57N8%$, EN)"_[N%\-M.7N+EL83?\
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MDNA;D)''<E8TD5P$5@F]OM+_ (*IVLFL?L^Z7;V_F1.-1O%#1Y98B-%U(KN
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M$(=?NM#-]?>(+FWD9]2EM+6%9VDL[:Z6:!',H@39.ZSOND9?6?V1?V%OA/\
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M[D_X*%>+Y)]"5--LY+SQ.(;O1XUTF3;?Q29CB,;?:"#O8[5R 6;@ MQ4<_\
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M7_;W\=:1X/F\175O:V^FV][>V3R2:D$GM9K>"2XNHYX#HQFA,$$;R.9$554
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M1QQVY21G=%7;+#@YFCWGMUU3^X'GF&7?[GWM^9]Y*L>_S%9F\QSGC+.5./P
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MD:K>-$;%M:'1)OA[\0;'5(8(;7Q%X25W@^R0QVTTVFVWE2R0P1GRH-%T2%'
M,L[*TT-T#FQMKL17GO&NZ?X;^-?AR3Q1I\*6OBC7X[?6O$&DVUA+_I-RK7<$
M=S%&T1GFMVFL[QX4NX+E4Y=[:VE!9/44>=:JSC_7X'KTX>TIVE\4;W\UOIYK
M2_JK.V_/_L-ZC!X&O/C%)-):K=>%_CY;^-K[[.5N(GL/$&DV<*W0E5$!0?;9
MY6E5$79 Y 49 _0>%52:.*-5A9/]'!5MV,#@,.G0?AGWK\[(/$6D_ GQA/\
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M2[.WTV6PL@^KR*MZ(;+3#<M^_AO'-S>N4;]W&'C$5*?M>2<U=V25U?7:RW_
MC$U:=3$*G7J1YY/:]Y;Z)):WMY.Z[(V?AWH-S\1?&$/CQXV\-Z+=W5SXPO\
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M5V;=/[+Q>ZE,Z3Q?*;E)XK*.!66TO-KH8 4UO$]FFBZ6+:?1],CL;6S^Q_\
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MHH$6[$MHD%O;:>EQ%!+!*6F8# 5G]8TKQ!Y=K8ZQHNI6D^O36)<RV+&>2\:
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M>W,.Y;B"/#1D;1YF3SW[(>GW4OPTOOB)IKWVCR?%3Q!J&M:2_F3-]DTN&?\
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M]]W_ $BHX6])1;]Y.]TOM;NU^]W;;5Z:;\W\+'M=;M)O ?B2./4O#_C+2/\
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M)FBNKHBXU./2"\8FEO\ >19VEG=.IM?/N(X&?*OIM];20H\30P\GHO@[4OB
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MV6EOFT_(_/;3/B/X.U+QW=3P_$+P+>-=7,,["_U[3]*N;QV:V,[3HIC0-/\
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MO-4626[O+)(Y;;41%OFD:1+.:**ZF:$&:[+E"YFBTV&-FD::5>]^/S1_$8Z
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M8RDC*2,A+S1D]53R8W&1(CJ2#Z9I]I'91V]K#$([? B%N!M6.(*<84#Y ,
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M+<2"X7B3<SJ%$AY<9^8X[ #G/J:6CV'))JS(K:WCL[9;6,?9U5 D<,: ;4'
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MUG:_X2M?&>C/INI6-KJ%H\6]X95#1F02!T;V92-RL.58 @@C-:4<CCYG9VD
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M.IJR+CS)667:S*,8D'EL,=\CJ.^*>)F\]HUV*T@PRE3(3[L1P/I5.7$UEO\
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M;C^54YD8LVTJLAA-LBD9(??W]N_7I5PO)$(69=H92P!R%+$Y.2.AQC&:<)F
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M]-DT0RHJLX.UL@X/Y=:7LY+8.5E%Y56)H_+C:*(C,:@_+DXQGUH9=]Z@D7S
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M^-']DL#N\Q=V,$[>6&,8/TI^SET#D9GQ2J3N0KY7&2C>6BCU]S4=W:23Q,N
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K<3QLP;S%S@';@#'! _'-%2:?I1T]%42,P50H'8#K^?-%:TU)1LS:.B/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ex4-2_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex4-2_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /H NX# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]G803WDT$; 'J-%00G.,[@VS!4MOV8;:5+!G 97#*WSMN(P&8( D] !1110
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M\A?#_P"V+XC_ &C]8^":?%'_ (*(+H,'[-?_  5Q\.75G^UU8>+/V+/'FH?
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M4/"D.N_#;XE>&K^/6O!/B[7M+5[F, _D@?\ : _:SNOCKJ/[4-_^UIK/@/\
M:'UK_@D1XM;]D_XA^%_@+\*;6S_X*<:C\'_^"A'[6$7[,WA70_@G\0OAYXOU
M?7=:_:=^$NN_ 7Q]J_PF_9K_ .$.^+,%W\>_ ^L^']0\(Z?KVC^$YOI7Q?\
MM]_MQZ)X,_X*(_'#7/VQ?$'A+0?V??VZ_ O[)GC#X7Z=X,_9P\7>%_V)?@YK
MG@KX#?$+QC\<=>\:>!_V4?B1\5/%6HV/C^^^(O[,NA_$/Q)\-OBO\._#B:SX
ME^)>L_![QG<> I[;0/Z(K+]M_P#9,\1>-V\#1?$JPO?&?AS]JJ]_8[MK*_\
M WCZ"73_ -J6U^$5W\6+WX<Z;J>H>#[?3/[8?X/WFI^(8_%6E:A_PB&H:/)K
M6C6GB.>_M-3TZ+[$C4+@*H5%&T* !L'!5-H!  !. "NU=H*G@@ _F_\ %OQ_
M_;F\)>$_V7?$WP;_ &QO&?[7G@/]KWPS^TG^PGX$^,7A']GSX(Z1H?A3]KCQ
M3XY\4:[^R'^WG!X:T[X6"V^)7P<^''PL\%_$S2_C!XM\.>)-*_9O^*/A[P#X
M0^,_P[^&$FA^.Y;.]YC]I7]OKXH?#OXC_M&_!?0/VY];T;6/A3_P4!^"'P;L
M];G\._L[Z*WAOX:>-_\ @G+_ ,+3O/AS\6/BS/\ L\?$[PW\)8_'7QXL?$^J
M?";QXG[.OQF^)GQ3^/7AG3/V3O!/@MM*U;QKK/PO_IKP,Y[XQ^'6EH _AZUC
M_@I#\7-(^%?Q<_;(/[='Q'\+?'#XC?\ !O[^RO\ &/X>^'-7TKX<Z9\+_P#A
MLGPE\5/CC\.?VA&\&?"OQI^S[XOT73-4T;XP?#;0?!OB33[+3=-\/ZYXJ^-$
MGA=?$%K:>+/@!K/PW_1#7?VU?VB?&/[3?CVRT#]K75?AE\61^W?\*_AI\'OV
M0=(T+X0^._AS\8?^"57C[PQ\/?[>_;:^'.KGP7X@U2ZL=&\$>(?B9^U8W[4^
MI>,==^%'@/Q=\*K/]FGQGX7U9+]O!GC+^G)QD 8!R<8)PIR#PW7@]/NMR1@9
MP1\J7?[9_P"SG;?$;XB?"C_A-=8O?B#\)?BO\$/@I\1O#^D?#3XJZ\/!OQ$_
M:/T32_$OP6T_7=3T7P)J.BV.A^,M*US1YI/'BZB? 7ARZU.STOQ=XKT+5GCL
M  ?RJ_L_?\%4OVB]5_9>^"/B;QW_ ,%9?A:_QF_:A_80OOC/J=U\?] _9J\*
M?#KX"_&>Q_;C_9^_9QT+3HM1^ '[/-GXI^%_A_Q[H/CCXG^ M=\;?&+0/BKX
M;^%WB3PIXI^-VM>'AX%^$OQ+T6P_H6_X)Z_MM^ OC9\+/@=\//'/Q/U8?M,?
M$7P/\9/BII'P[^)7B/X9^(OB!XB^%OP[^/WC+X6OXO\ "WC?X/Z5I7PM^,?P
MGM+C3M-TKX6?&KP?I^GO\:_A9'X9^,LFDQ7?B75I8?T]Y;G!P<'<&!&3@[E/
M5E&%/.U2I((."@XF?P+X4/CV'XJ7&E"Y\:V/A&X\"Z?K=Y=:C=/H7A+4]:L]
M=US3/#]A>74ND>'5\2ZSI>@WWC'4-&L-,OO%\?A+P;#XMN]7M/ _@Y=  /Y]
M/VM_VHO^"AO[,'[3/QAL=#NOVC?C5\!_V?\ XJ_!G]MGQ7;_  ^^'OP&UF/Q
M3_P3S^,NF'X-?$7]ES1-3C^!5KK%]\;/@K^T;X-\8?&_X;VBZ]HOC#Q;^REH
MWQ*TSQU\:QXSTWP3>:S\1_MC?M)_'3]DC]I;XI_%;4?VY-)\)_M.? ']@C_@
MCCH7[3.F6$7[,6O^$?'VO_$S_@HU\:=#^/7@_P"(-AXB^$ UCPKX%^''PM^/
MI\2>%I/AU;_"3Q[8^!_%WPU\=>,_$VH07UOJ&M?V*V5U;WD1FMIH)XXYKJUD
M>VG2>-+RRN9;*^MV>([#-:7=O-:7$3*DMI<02VTR1S)+%%<  Z=J /Y _P!H
MG]O_ /:$\/:%_P %(?B)X/\ V^OBA\$_VAOV8/ W[</_  F/[,>J?LT0ZYX:
M\%:=\-_C=KU__P $\/B!H_CGXP_"75?@9\-]'^,7PKG\!6.@:O:2_$*\_;4\
M+_&RYLO!#V7Q$^%^F>//AO\ K_\ \$[_ (UW?Q<\:_\ !0?]GO4_VU-1_:]T
M'X3?%SX=I\)_BO'KGP:A^)EA\(_CQ^RY\(?B3<:C;>)OV?/AY\*_!%]H%G\6
M_$GQ:MOAQXN\/>&KN#0K+2H_!D'B;4-4\%W6D:+^OI .,]CD?7_)K"\4^(--
M\)^&]>\5ZS]N_LCPOHVJ^(=4.EZ-K7B+5!IVC:=<ZA>_V9X?\.6.J^(=<U V
MUO*+/1M!TK5-9U6X*6&EZ=>7MQ! X!_'-\)?^"D'[>_Q%\&>#] \4?MDR> ?
M%^C?L&_$B3X^^,?C'\ ])^&GPP^&O[:?PA_X*1?"GP%XX\$?&SQEX<_9V\-:
MY\"/$^A_LS^*]9^'?QXUO0]-F\+_ +./PSOV_:OF\$3Z?X5L_B!K.Q;?MB_M
M>^.G_91\.7?[9GQ=_8D\/^,/!=UJG[./BKQA\$_%/[>7B;]JOXR6_P"V)\?O
M"?Q.^&O@?XH?!^?X?_"W]I3PIX9^!7ASX':;^SYXD\9>#M5TWXU? /XO)^U%
M92KXMT6;QSX&_J7^$/[3_P &OCI;_"K5/A7K?B3Q5H7QM^!VD?M&?#/Q8OPU
M^*.D>#_$WPDUR7PW'I.M-XOU_P $Z1X5T#Q+?KXLT*Y'PU\3:OH?Q2%A<7.J
M2>"ETC2M0OK+Z%(') P=W'OTSV;&1D' X&>1U !_)3\%?VAO&WQ-_P""I_[%
M'_"ZOB?\5]=^.G@_]I?_ (*S_#K]H3]GC6/#CR>&OV5[1+J^T+]AZQL=#\._
M#?27\#^"_B]^S-XB\+^(/ OQ9UG7;SPG^T+]IU;Q8?&'C#6M!U&?PU]0_MR?
MM-?'OP!^TE^UOX \$_MK>,/A%X<T;6_^"0.H^!+?3M/_ &>=0/PR\/\ CO\
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MT35M<TVU\;Z]X>N_%$5CJ-MX2BUJ[TO4;>W]QCW!FW!N"0">%(W$C8-[D##
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M]@Z?_@FI\.=!:]?X*_M*:1XT\>Q>'OVK+CXJZ/IUOJ'AOX@6]AJGB'Q-X?\
MC)HWBCQ'H?C+X"?!;X=^&OCGX4LOA%I&J2?&#QQX3^Q;\=/VM=+_ &\_@QI/
MC?\ :*_:#^+'PR^+_P"U;_P5^^%WCBQ^*,>AW_PZM/@W\(/B)X=U7]AG7O#L
M'AKP#X6\*>#HO'VFW&N:O\-?&VD):)\5]'\0ZIX<\)W^J^!?#G@CPKX/_IO\
M(>(K#QAX9\/>+=+L]<T[3O$N@Z/K]AI_B?PUX@\%^)[&SUO3+35+6S\2^#?%
M6GZ/XF\*:]:V]S%#JGAKQ+I&E^(-!O$GTW5M/L[Z*XMTZ4C((/0\&@#^5C_@
MH7X+N[#]I7]L.74?''[6VAS>.?C5_P $9O'N@ZII$?Q>\5?#;P'\*/ /[8GP
M@U'XK_$7X/S:IX,\9_!?PMXO^$Q\&^(?'=MX=ACUO5M+:R^+WCV7P/J>B'Q[
M>Q97B#X[?M2H^G_!NU_:C_:C^'GP/\*_&#_@HQ\)?#G[3,7[-O[1G[4GQ8TG
MXZ>!/V@/ 6I?LB>']2L/@VOAGQ]\7=+/[/6J?%+5/@M)X_T'XF? 7XZ7UMI/
MAKQ=IOQI\2P>"].TS^KI551A0 .O'2EP,Y[XQ^!H _$;_@I996/B[X"?L Q?
M&/QQ\;OASX[U3]KG]C^[\2S_  YU'Q;\/->TF?\ MC1-7^+/B?XC:9\&M<^)
M?@SX?>%_AO86^H>(M;\=^(/&>K?#7X1:];:=;Z?\6W?4]+O_ !+^8<G[=G_!
M0*\_:/\ CNOP^\!_MSZ?X2\5?"G]I)-3^&6K_"+QY\4_B7X/UOX,_MW_  IL
M;_6_!,EW\#/"G[-_PT^/'AG]@SQ-\>M;^ ?P8^$7C/XG>"_B';:+^S;J?Q5U
M3]I'X]?%#PM:^/?Z]0H!R!00".@/IGIGM0!_+=\3?CI\6-3L_AK8_ _]K7]O
MCPE^QWX^OOVN/^$$_:5^)W[&W[4'Q5^*7@W]H&:Y^ _B'X#^ =!\%^$] ^%?
M[3WQ,^&7@G1M4_:2TSX,+^T+X:^)/@SXN?$_P]>?"KXA:=\8;#0?A/IUO^@_
M[9/C[XZ>']&_X)V:/\3]5^,G@O\ 9Z^(_C.Y\._\% ?B3\)[;Q1X%^*_@W5;
MC]F[QG??#32/$_B+]FGQ7X[UWX#?#;QC\?[33]+^(WC_ .$'Q0N=,\)^,;7P
M)X,L?C6O@;Q3K.I>)?V("KDG:OS#+=\D<#Z]3^/UI54#D!1VX7:?_P!5 '\V
MG[+,7Q>\?_MT?\$Z/%7[3/B?XS/\9/#?[#O[?^DW7C.[N_B1\,!\4O"D_P"U
MK\ 3^R3>?'+X&Z>)?A9\*/B1\=?V5_AUJOQZ^(_PVGM/"?CC7O&^@7ND_$/P
M+X6F^"?A#PUH_P 9?\%//A[XYF_:9_X*T0ZKJ?[2-KJ_QK\&_P#!#RX_9Y;2
MH?''BKX>)\/OA)^VQX:UGXUZA\,K+4_#OBSX/:!K?P?UC1/$7Q)_X1'Q-IUU
MJ>BOK?QL^),?A"^\+>(/BE?S_P!C6 >HS28 Z #\* /Y@/AO\?\ ]H'P_P#$
M;X;?#JY^/?[8%E:_#K_@J+_P4[_9RTAO'?P^\1>/)O%W[-'A#]D+XF^,_AYX
MN\?:MK'@![?XN0?#C]I37/@IX?\ V:]9U/QS8KX\3Q=I7@2X7QQX@T_5#X.^
MN?\ @F=\0?VJM;_98_:LGU35=8^+_P"T'X)O=,L/A5XK\7?$GXK>-?V</C/X
MUE_9/^$WB_P5X@^$^J_'+P=\-_C%\//"/BSQQKMOHOQ^^$7C76_%%[\'_C]!
M\7_".E>,])TJQM?"7A3]QZ8RJ2-P!!XP1D ]C[=QGWH _DX\*?M*?'"\_9N^
M"OQ LOC;_P %)VTSQ%XZ_9:L_P#@IAJOQ=_9B_:*FO/V</'</P'^,=S\8O"W
MPI\(^#/A]\%_VCXK;QI^U#'\%]*^-.B?LU>)[WX6_!GPM':3_#Z;PIX+\=ZE
MX=U_ROQ-J?[8_P =(_CC\%-/_;(_X*,>-]!\$_\ !&GQW\8?@YJ&B_"S5?V8
MO&W[0'[2O@CXH?M<^#_A[!XBT31O VK_ !3L/&7C/X*:[\$O%FE?"V?XB>$?
MC+\5O#&N^ OB9\3/!)\7VEAIWP^_L<"J#G W ;<A<':<'&?3@< XX%.H _B7
M_:-UOQ5XJ_X)>_M"?L[_  ]\>?M;ZEHUU_P1;_8MN/AQ\+M=T_XZ:#K]Y\;?
M#OQK^-WP_P#C7X$T33?%7@O0/%NKZAXLM;KP=I/BSX<:O)J">,O@OJ/PW?P7
MH)^"3>";B'[;3XM_'+X:?';]JCP-<_&G]L'X@_L*^ /V]?V0]#\6?$SPIK_Q
M&^+WQ%\-_LM_$/\ 8/\ $_B_Q)J_@#XH^%[+5_B9<?#F?]O"/X>^#/C!XI^%
M5SJOB7P7X0E\;Z&VH>%-)TCQ'?Z=_4;2$9^HZ'T.",_K0!_)U\<_VG_VK_A9
M^T;^QAX.^$?C'_@H#XM\&>"?$W_!-/2/B#\4_C3\*?BY._Q__9U^*_CKX@>"
M_CWXOD^ _P .?V=="\,^%]0_X0CX@^$IOCY\7/VD=;T3XU?#;XI>$?A5\/O
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M5]&^'GQ"\9V&GZG<1_SB?!CQ;\2_BS=?LC?"SX]_%[]JV<> /^"@W@/5;_\
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MK[2W\6>$_!^L&?0+3O@ #G SC&0,<4 ?Q^>-?CU^VAX'T'Q[X17XD_M6^/\
MP]\(OVY/^"B'P/\  WPTT77_ ([^$_VF_B9\(O"'CC]E34/@WXT^#7QVT[X2
M_$#P7\6OB_\ "D>,/'7ACX-_!S]I>]B^%?[1WACXD>)+6Y\3W^I?"73[[1.U
M/A?XO2?M2P_"*U_:'_X*%_LZ#XT_\%7OVUO!'QSO_"GBOXA2Z;H'P?\ 'WP
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M_ _AE_P4K_94^*.L^"=%M-?^)_@2+XG^"_''Q4^%/B3XR_L__';X)>!_B?\
M"+X;^'?#_BWQ;\4_"7Q$^)O@+PWX+B\'Z9X>\1V&NROXE\2:!XAF\//-XCB\
M.W'AN\TW6+L _!&]\;_\%1M>'[<WC_P7^T?^V]XG^)'[-7[$_P"QWXE^ GA*
M^_9IT#X5^%OCUX@\<_"CXD^&/VD_C=;_ ++]]X-U:\U[]H+PWX*\0:%^T?\
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M>.?B/X,?P)\0?#\'P[O?"EFOC'Q+X>M=,\%?$'_A)_#</B22X^&NL#6+N_\
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MQNNCR^&_VP]7LM.\5?#GP]XFFU+5?"'C&^\(:[XYM/"_C&+X)P?%6YT1[>X
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M'U/QYX?LO#FG_&GX<:W';7,?Q&?P]J6AF;0+K5??_P!K3X6_';P-^V)^S?\
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MCZA\![CP;^TGH'[17PR^&?@N[^)O[-?P:L_%OQ#\3_:OA;]@;XGZ1^W3X?\
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MK\5?BCI%IKGA'X8>%O@C>^(/VJOB)X"\%_!KX.:A\9OCQ\4O'OCCQEKWP?\
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M_P#@IE^PUIOQBTSX"77[1/@V3XI:QXH^%/@FRT*PT_Q7J^C?\)7\>]$@\1?
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M03X'U_6OA?\ %_XT:/I[>$/'OB$:C\,?V?\ 0+7Q1\9_%%C<^%?"NLV4]OX
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M7P6^)%CXMU7X8/X3?QYX=OM$\5>"O%OAK3O'GAU?%?@+Q-J'A/QYH7AK7YO
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MGX ^%EI?6&L1WGC&)M$UA]-^2/A]^VU\:/CO_P %&OC7^R]\&/#GA31O@_\
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MJUOP%J?@R;3-5M[FXNM$\1Z!XB_MB#7_  S^F]% 'YN_LP?LS?'/X1?MP_\
M!1?]H#QT?A7)\+/VN?%/[/\ XF^&D7A+QGXRUSX@Z!_PH_X+Z#\%[NT\<Z'K
M/PV\,>&;1O$UIH,/BBWD\/>*=<_LFZO9?#TZ:W':-KDNO^U5^S_\=_BK^U#_
M ,$\?C'\,K/X3W'@S]E7XX_%#XB_%*T\>^._&'A7Q1J7A[XE? GQ[^SRUO\
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MB=X0\+Z9\*O%-A%XEM/V@)_C7\2=1\>^ I/A;XN^#G_$W^-WA3XI>&/VE/\
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M[)GPW^,O[('A7P+\6_@WXZ^!'@OXJV7[#MGH?[46K^ ?''QG\%^/-!E_:?\
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M7\*_"_X,R^*V^)TM\VH?#;XL;/C#K7Q533(-9^(UNH^';>%?!^E*^IU]:44
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M4JFPH"%52[NY8U/10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?!/P^TKP;\2/V6OB3\=_&UY^S//-\0OA/XG^/-A=_!+P_P#$#Q79^(=7;?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P"'+_X)8_\ TR&@#]!Z*_/C_AL?]I+_ *1._M^_^'+_ ."6/_TR&C_AL?\
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M/[2/[3_Q@\ ?$_XE_ OX9^#_  5?Z#XE\0_'+XI:K\0OV:? GBBY'BJW\)_
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M^%II\,?A3\1?%_\ PG/C"[F\?_#GPKX7\8Z1J?BCQ'J_AS6M#U/5]8O+CO\
MQK^Q-^S3X_\ V;_AW^RCKO@"]M/@K\(=/^$-E\(M%\*^-?'_ ('\7?"JZ^ #
M^'W^#?B3X<?$SPAXGT'XG>#O&7PYE\,:%-X:\8Z'XML_$UNUD_GZI>0W^H0W
MH!^(?[5WQ3_;E_:V_8RO/V9/B+\-_A[;>(/V]OVR_A3^RK^SQ?\ B/X+_$/]
MEZ7QI^S[HWAV[_:'_:<\>?%+X#?&WXD?$OXQ_#SP58_##X)_&OP%X4U[7O\
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M^,O'6C_L\Z?\)?V/_P!KB^U_X5^!_@9\,[#5?VIO%/[2?[)/@KQE\>?C._Q
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M1=(N_@5\3/&?[$QU[XP>!=3^(\?CJS^*?Q0TG6?AKX5TO3KWP;JUGJOZG_M
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M@O\ !GX#^([G]MC3-%\#:OXG^('_  3^^/GQ,_9I\<:7K_PG^$F@?%YOC[\
M_P!K3PQJ%KIWAWQC\/?C_P"%O#O[0MG)\-/0E_:B_;0\8_"?]K77O#'QV_:<
MT#]H#P;\*_&=S^Q)\$-._9;\&>*T_:-\%WG_  327XE_!3]H?5SXC_9!^'&L
MS^*/'/[1J^+?%WB.ZN;3X0_#?P5\7_"_@W]C7Q7\'O!WQ#\6V/PY\9?TE_Y_
MS^5% '\TW[6?[7/[=.MZMX5\3?LC?%/XRW'A75OC/90Z8_@[X'>#/&?P_O\
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MT_6OA##?OW?[%'QL_:]'@_\ ;&^/7[;;?$+1]!^!OCGX^6=K\)]#M[7Q _\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX*K?]$;_ ."?G_B2_P"T?_\ 0IT ?H317Y[?\)#_ ,%5O^B-_P#!/S_Q)?\
M:/\ _H4Z/^$A_P""JW_1&_\ @GY_XDO^T?\ _0IT ?H317Y[?\)#_P %5O\
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M^-OPLTKX'_M!?M!V'Q_\2?L\_M.?LSZQ^UY\)_$E_P"(O@:GPM^.GA+XP?\
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MO[47A.31M2\%^&/B#:^%];?78M+T>Y\?:#K^@:%JFJ6UE'JES]L?%;]L73O
M_P 4O&7P2^&'P:^+/[1OQ3^%_P '[/XY?%;PG\)5\"6TW@3P7XGO/%VF_"W1
M[C4?B5XW\ Z1K_Q*^-VI_#SXBV7PQ\#^&]3U*Z8>"=6U;XAZCX"T;5_!6I^+
M?&?"'_!-[1_ _B3_ ()<:QHWQ;U6?2O^"9/P;^('P>T;3]5\'V-QJ7QDL/'/
MP$\*? Q?$&N:SI^MZ59^$M1TZ#PPOBJY2TT+Q%'JFH:A/:O)8(K7;>@?%O\
M9(^)-]\;/B'^T'^S1^T%:_L^_$_XT_!OPE\$/C%J7B7X-Z5\<=&U30OAC?\
MQ#U;X/\ Q$\":%JGBWP3!X+^,7PNO_BKX\&B:EKL_C[X3^)--UN.U^(?P8\9
MW6D^']0TH ^9=0_X+2? $>,?AK#X7^$_QC^('P1^+5M^Q9J?@?\ :/\ !FJ?
M!"Y\&ZOI'[??C#Q5\-?V?[C3/AAXA^,6@?M&:]K[_$WX??$+PGX]^'?A7X+^
M(?B9X#3P)XEU[5O!1T33+JZB^E/VKOVV?%W[+OCWX0>"=/\ V./VB/C[;?''
MQ=X;^&W@7QA\'?$?[.%OH-S\4]?TOXE>)Y_ =_IOQ6^//PV\86,OA[P5\+=>
M\<>(/%EQX9A\"6F@WMD(_%$NKPZW8:9\=Z%_P14^'?PY\>^!/B/\&/B+X=^'
M/C/]F_X/?LO?!_\ 8G\;S_!V'7_B'^S]HO[.C?%2/Q=;>+_%ME\0_#47QG\+
M_M5:7\>OC-X=_:4\$W.D^ =*\8Z=XC\*>(=!N/#OQ4^&WA7XFP_H?^T#^SMX
MH^-7B_\ 94\5Z)\2](\#']FS]HC2OCUJ>GW?P]F\8I\01:?"_P")GPCU3P;:
M32^.="7P3!J'A?XN>,KRSUR*T\1W6D>(+?PO?KI]Y8Z1J^E>( #Y]T+_ (*3
MZ-J7B'QI\,?$G[-?Q]^&G[17A[Q9^SEX=\.?LT^/;KX.6_Q5^)&A_M*KXDU+
MPWX]\#7_ (6^+7BCX8:]X1\">%?AU\</$_Q7NM(^(M_JO@32_P!GCXUS7>F7
ML'A/29_$7S/XO_X+I?!7P1K'QUTS7OV9OVG(=.^#;_MZIHOBBSC^!5_X=^+S
M?\$T=>M--_:TC\$P6'QHNO%_A@^$-#NE\5>$-1^+/A7X;Z!XX@2V\.Z5K<'C
M#5O#WAS5?T7\6?LVZQXB_;%^"/[5-IXV\,:=I_PC^!GQW^!=[X(N_AQ+J?B3
MQ5I'QY\7?!_QOJ^L0_$>'QUI5KX?N/#'B#X#^ (O#VFMX!UZS72-8^)FGWLE
MS<^--*U+P=\:Z3_P29\&Z#^SC_P43^#7A_QCX!TOXF?\%%O%W[5^H_$#]H6+
MX#:7#X^\._#O]K;Q5XT\2>(/AO?R6GCBPU_X@6OPT7XF_$6/X87NO^,K#2-
MU36=.UF]\'Z@UKK5EXE /3T_X*2>'K73O ^JZS\#?&]IIGQ!^/?@K]FKP[XA
M\._%3]F?XC^$5^*_Q&^$^I?$3P9X;\0^)OAE\;?&%AX2NKOQ?:Z9\"M0M/%
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M6G\%ZMHWC/48O@A^WC\)_P!H'Q=\"/"7@'0O&UOJ/QT^"/QY^,"VOBK3-/\
M#GB/X3ZU^S'\1/@1\*OC;\#/C;X/N-4N/$O@'XY?#[X@?M!>&_"?B?P1<6.I
M)H6N^&?'&GZEJ5I=:3IRZS@^$/V0OB?I7[.?[0GP,\2_%CX+F]^->A>,=!T3
M5_A)^RII/P5\#^!8?'/@^;PGKVKWWPWT/XK:U>>.O$MS#<&5M:U+QWI3S6FG
M:'I4END5EJ,^K>4?$[_@EQX0\;_&KQ[^TGX7^)VJ?#;XT_&S]G+Q-^SC\??^
M$?T/5[CX2?$?3?B5XH_9JG^,/Q&TKX:?\)Y8:A\.OBG\0OA;^SCHGP<F\<^%
MO'4/B73_  L_@;5+[6/$/B+X5^&;^Z )O$O_  5J_9[T']BGQ_\ MZ6?@WXO
M:_\ !;X1?%2_^'_Q<T33_""6?Q8^'WA>W^(VF>"[3XLZ[\,-4U"P\46_@W5O
M OBKX=_M#6&F7=O9^-1^SW\0_#?CZ7PNEV\F@#0_:*_X*H?!O]GSXG_M!_"G
M_A7?Q6^*.L_LS?L8?$/]MWXHZ[\/(? <GA"S\"?"K4/ EUX\^&&DZ]XE\<Z!
M#?\ QRT'X;?$GP5\9+WP%/#IL=M\./&7@#5KS7;*\^)'@C3]9H6?_!-@^!_'
M7QEO/@O\5=!\"_!;XY^.OV/_ !EXT^!'BSX9^(OBGH4+?LKII.C:O8Z%KWB+
MXQ6ATG_A;_PZ\#_"'X4ZU!+H5[X:\(_#_P"%7A[3/#WA.XO+N_OY_FNT_P""
M&_A?P3\-_&GP=^$W[3/Q#T_X>>*_V OVC?V$HS\7_"MK\7?'BVG[3WC+P WC
MOXQ:_P"-[3Q;\.I?%?C#PI\#/A+\)?V=/A;I%[HVGZ;X+^'7PC^%&F-=:UX7
M\":7X,8 _63X#?'6P^.V@^)M=TW1=.TNW\.^)T\+S'1?B7\+?B=8W-ZWAGPS
MXFNH3K/PL\9>++'1M3TP^)XM+U+1?$$NC:Q#=PKJ=A::CX8U'0M>U;Y6M_\
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MP2L?@!X,\*W5RWP2\.?#/PG\(KO5/&U]?>-_'FJ?%7X@^,?B!XV\8Z1JNO\
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M_'\./BF_QK@^ .I^!;G0KWS;P-_P5=MOC?:3>*?V;/V8?B?\</ OAO\ 9J\
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M'G[+%O\ M1?%3Q#\ /!/@;X=?"0^!/BWX'^%'Q&D\,^ /A=XT^*OB?P/XN^
MVNZ7X6\!WWP _::\$^&OB1HWPO\ !'[17AJ/6-2\.> _A9\-;N?P?K?Q)\-V
MGQ!C]+^*W_!,VS^.OQ&^(_COXL_'7Q)K\^O_  ;_ &E?@7\+_$NC?#GX>^&_
MC'\-_AW^U?J6NS_$/PKX@^*:6-_9?%;P5\-]&UY_#?[._@+Q5X"LO"O@&UM(
MO$OQ&TSXT_$6RT3QMI0!=M_^"AGB/Q%!\5=4\ ? /3O$GAO]FSPY\.U_:2\0
M:Y\=_ _P\T_1_C9X\^'7P^^++?LX_!/6O&VB:9X.^*?Q*\,^"_B/X,/B#7OB
M;XL_9[^&=OXB\<_#[PFOC\>(KWQ[;?#/'U+_ (*C>$?#%Q\;O _C;X<0>'?C
MA\%/B7\$=)C^&]M\0K#6-&^+/P'^/G[0W@#X#^%?VDO@QXW3PUIS>-?"NB77
MCZ)?B%X7?PSI.O> ?B)86'@3Q5-I?A_QY\,_B7XSQ_C'_P $G_#?Q+\,_';X
M9^%/C]\1OA?\&_VQO 6@>"_VR_ &D^'_  KXCE^)NO>&OAEI/PEB^,_PFO\
MQ!#/HGP&^-?C#P/X6\"^&?BCKFG^$O'7P]\<Z'\/_"MW;?#+P]X\77?'^O\
MN?QI_P""='P&_:(;PS=_%R3Q/KOB#P!^U3X;_:N^&GC/0KK2?"GC+P-K^CZW
MX'U/5OAQIGB/1M(COM1^%7Q TSP1;>%/B9X=U9[N\\5^']0-R=1TWQ3X;\">
M)_# !\K^%O\ @JWX\\9_\-8ZCX<_9R^%6N:-^R]<?MPZ5?:+HG[:/PXU/XPZ
MGJO[$GCGQ?X"UC4?&GP3?P%I_C+X;^!OB5K_ (2&F^&?$K/XOU;2KKQE\.KO
M7/"5OX0\9)XSL?5?A)_P4@N_%OPMT?XT?$?X9_"7P_\ #.[^-/P0^#7B;QS\
M%_VM_AC\?_#?PLO_ (_:5HL7@NX^*]]'X?\ AM=>%_$%CXX^(OP-\,>(?!FG
MZ;K^I:9X<^.'@_XC6ES?^$++Q-+I700?\$\-5M_!OQH^$UK^U#\4M'^#?QBU
M?]L+Q/>^%-"^'WP03Q;IGB']N#Q#\<O&/QBL;GXA:[\//$=YK7@7PYX\^,UG
MX\^$WAE-&TC6-!\1> /#MG\2?&/Q4\%8\&VF'\<_V#/'GQ5^!?A_]F+Q+\7M
M2^+OP@\5^,/V1-)^*:_$'1O /A*XTCX5?LN?$&V^+_BG6=#LOA7X#\*:IXU^
M*G[1EQX$^''P0\7_ &[Q-X0\%^!?"DD7Q)^'^BZ'JG@K4O!/Q3 /U(1<.3_$
M44'DGOGD$ ;@3EF"JS!E$@^5#4U11D]/0$CC&<D9SG!+!MRME5;(.Y5)!:6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH :_3TY'<CN,9P0<9[9 /1OE)KXU^)_[-_[0
M/COQ]XA\6>"_^"@?[2'P5\+ZNVE'2?AAX$^%W[%OB#PCX42QT+2M+O(M(U;X
MK_LN?$3XA7C:UJ=C?>)M2?Q%XQU@PZGK=W9:2-,T&STO2+'[,HH _/C_ (9"
M_:H_Z2J_M>_^&5_X)U__ $$]'_#(7[5'_257]KW_ ,,K_P $Z_\ Z">OT'HH
M _/C_AD+]JC_ *2J_M>_^&5_X)U__03T?\,A?M4?])5?VO?_  RO_!.O_P"@
MGK]!Z* /SX_X9"_:H_Z2J_M>_P#AE?\ @G7_ /03T?\ #(7[5'_257]KW_PR
MO_!.O_Z">OT'HH _/C_AD+]JC_I*K^U[_P"&5_X)U_\ T$]'_#(7[5'_ $E5
M_:]_\,K_ ,$Z_P#Z">OT'HH _/C_ (9"_:H_Z2J_M>_^&5_X)U__ $$]'_#(
M7[5'_257]KW_ ,,K_P $Z_\ Z">OT'HH _/C_AD+]JC_ *2J_M>_^&5_X)U_
M_03T?\,A?M4?])5?VO?_  RO_!.O_P"@GK]!Z* /SW;]D+]JC!_XVJ?M>G@_
M\T6_X)U@Y((&,?L4#G/3D?6JW_#'_P"U1]I>8?\ !5;]L'+0Q1K#)\%_^"=C
M1(8Y+F03Q_\ &$Z?Z1,+@)=MC#Q6=ELMK=U9KC]$:* /SPC_ &/_ -J?SYIO
M^'J_[81,RQE(G^"W_!./R8 J_O/LY3]AZ.Y*SNRL_P!JN)6#1 1C;DBQ_P ,
MA?M4?])5?VO?_#*_\$Z__H)Z_0>B@#\^/^&0OVJ>W_!57]KWW_XLK_P3KZ?A
M^Q/4$W['O[4SJF/^"JO[8"LDUO*&B^"W_!.E6;R)XYS"Q/[$K;8K@1FWG*^7
M+Y$L@AGMY2D\?Z'44 ?G;)^QS^U&^QU_X*M_MFQR"[2XF"?![_@G$ULUK%;1
M1+ID<+_L+N\5O<3&YN;V;?+>W#364-K-9VE@+>>27]C_ /:FGAF@/_!57]L&
M,3Q/&)K?X,_\$ZDGA:1"%N;5G_8GF5+A"?/MY9Q+''<0Q/)!*@:-OT.HH _.
M^3]C/]HUQJLG_#U']N-;G4/#.F>'K,#P!_P3T^Q:1<01Z6NL>)K2TA_86B,W
MB/5Y=/O[F"[N)A9:;-K=W'I]@EM;Z;;6.GK/['WQ[U>+['!_P4Z_;?\ #^G1
M0P6\0T#P3_P3XBUAC;6?A>"&[N=;UG]A?79;RXEN]$UG5+RX,,9N9/%6IVTD
M8MM.TJVL?OVB@#\WV_8:^//VG3G7_@JS_P %!H[:UMI8]4M9-"_X)]3G59C:
M216UZEW+^P@OV"XBN";V6"W5K&=T@#V-O%\C//[#7QR>*./_ (>L?\%%$D6.
M=9+A=._X)Y&28SOD/(DO_!/IH$DL8=D4*16UM!(&,EU%/=!IA^CM% 'YVV?[
M#OQOAC=+G_@JC_P4-U"4R%UN+C3/^"?4$B(413 %TW]@>PM619$9PQM_,RY!
M<C.;1_8B^,X'/_!4/_@H,P/'%G^P4",\!@5_84# J<'@@<88,A9&_0BB@#\\
M(_V(?C5'"J2?\%2/^"A,\@)W3O9?L!B1]Q.T*MM^P;:VP,:C_EG:@E06=99@
MDB*G[$/QJ\Z5S_P5)_X*%-&ZQ^5"UE^P&([<(I#^45_8-6Y;SV.]S=W-R^Y,
M1>6@93^AU% 'Y[_\,1?&C_I*+_P4&_\  /\ 8)_^@4H_X8B^-'_247_@H-_X
M!_L$_P#T"E?H110!^>__  Q%\:/^DHO_  4&_P# /]@G_P"@4H_X8B^-'_24
M7_@H-_X!_L$__0*5^A%% 'Y[_P##$7QH_P"DHO\ P4&_\ _V"?\ Z!2C_AB+
MXT?])1?^"@W_ (!_L$__ $"E?H110!^>_P#PQ%\:/^DHO_!0;_P#_8)_^@4H
M_P"&(OC1_P!)1?\ @H-_X!_L$_\ T"E?H110!^>__#$7QH_Z2B_\%!O_  #_
M &"?_H%*/^&(OC1_TE%_X*#?^ ?[!/\ ] I7Z$44 ?GO_P ,1?&C_I*+_P %
M!O\ P#_8)_\ H%*/^&(OC1_TE%_X*#?^ ?[!/_T"E?H110!^>_\ PQ%\:/\
MI*+_ ,%!O_ /]@G_ .@4H_X8B^-'_247_@H-_P" ?[!/_P! I7Z$44 ?GO\
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M?^ ?[!/_ - I7Z$44 ?GO_PQ%\:/^DHO_!0;_P  _P!@G_Z!2FM^Q'\: /\
ME*'_ ,%!3GCFT_8+ &0?F+)^PH",=<GCL<9W#]"J* /A_5_V1/BCJOAGP1H-
ME_P4(_;:\.:MX2LO$5IKGC?18_V/9/$_Q,;6O$M]X@TV^\=VNN_LAZWX.M]0
M\'V>H?\ ")>'YOA_X3\"1W/AFQTZ'Q7;^)=9L8=:'+_\,1?&C_I*+_P4&_\
M /\ 8)_^@4K]"** /SV/[$?QG7YO^'H?_!05B,E0UG^P2%W8.-W_ !@FW'I\
MK$-A@I(%;FJ?L>?%6^EF:Q_X**?MSZ$CZ)HFF+;:7_PQQ=11:GI-OHMOJ'BN
M&3Q!^Q]K%P^N>*9M+OKW7]/GN)O"5G<^)=<B\+>&O#5G;^&+7P_]VT4 ?!.B
M?L9_%C3;Q[G4O^"D'[=_BB!H&ACT_6O^&,+&TCE>XAE%^DGA+]C?POJ!N8XE
MFM889]2GL&M;AY9].GO8[>YAW=$_9,^(FF0Z*NH?MZ_MG^*6TRV\5QZA=:U=
M_LL6,GBB;7["VM=$O=87PK^RSX9L]/F^'\]O)JWA*/PC;>&+#5KV^O$^(EEX
M[T=-/TZR^V:* /A#2/V./B78ZMX<U#6?^"AO[='BW3=#FMKO4_#>LWW[)NB:
M5XOGL]0N-2LG\2:AX#_9-\'>+;*V6X_L^&]T_P )^(?#&EZK8:1;Z9K-C?:9
MJ7BJSUW;TS]D7Q=I<U[)#^VU^VA=6USJ_AFYM;'4_%WP4U./2?#OAS7M;U-_
M!-G/>? 2;4[C2?$FBZO;>"/$WBS6K_6?BG?>'_#VB:Y:?$.P^(9U;QYJGVI1
M0!\I^#/V<O'?A+XKP?$BZ_;#_:D\;>%H#>^7\"_&<G[.EW\)62^T1](C6>]T
M3]G?0?C+.NFWDA\1Z:9_B_<,NMPQK<27NAYT.7ZH0$8ZXVX&0=V >I+8?)R<
M[BQQ@DAB2TE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&U>*^\.ZN+#Q!H^K:;9_8M% 'Y^?\/,?V<O^B=_M^_\ BJ#_ (*E?_0<T?\
M#S']G+_HG?[?O_BJ#_@J5_\ 0<U^@=% 'Y^?\/,?V<O^B=_M^_\ BJ#_ (*E
M?_0<T?\ #S']G+_HG?[?O_BJ#_@J5_\ 0<U^@=% 'Y^?\/,?V<O^B=_M^_\
MBJ#_ (*E?_0<T?\ #S']G+_HG?[?O_BJ#_@J5_\ 0<U^@=% 'Y^?\/,?V<O^
MB=_M^_\ BJ#_ (*E?_0<T?\ #S']G+_HG?[?O_BJ#_@J5_\ 0<U^@=% 'Y^?
M\/,?V<O^B=_M^_\ BJ#_ (*E?_0<T?\ #S']G+_HG?[?O_BJ#_@J5_\ 0<U^
M@=% 'Y^?\/,?V<O^B=_M^_\ BJ#_ (*E?_0<T?\ #S']G+_HG?[?O_BJ#_@J
M5_\ 0<U^@=% 'Y^?\/,?V<O^B=_M^_\ BJ#_ (*E?_0<T?\ #S']G+_HG?[?
MO_BJ#_@J5_\ 0<U^@=% 'Y^?\/,?V<O^B=_M^_\ BJ#_ (*E?_0<T?\ #S']
MG+_HG?[?O_BJ#_@J5_\ 0<U^@=% 'Y^?\/,?V<O^B=_M^_\ BJ#_ (*E?_0<
MT?\ #S']G+_HG?[?O_BJ#_@J5_\ 0<U^@=% 'Y^?\/,?V<O^B=_M^_\ BJ#_
M (*E?_0<T?\ #S']G+_HG?[?O_BJ#_@J5_\ 0<U^@=% 'Y^?\/,?V<O^B=_M
M^_\ BJ#_ (*E?_0<T#_@IA^SD>!\//V_!_O?\$H/^"I6/I_R9R.:_0.B@#\]
MG_X*9?LZHT2K\./V_'$@),G_  ZD_P""HZ)&JYP6!_8YWD<8_=JY#%0V$)9:
MI_X*;_L\R7:0+\+_ /@H&;9K26X;44_X)4?\%./L8ECEAC%@T3_LB+J$M].)
M7FB6VM;BP6WM;A[N\B<103_HG10!^>LO_!2[]GE%,T?PU_;\FMTDCAG=/^"5
MG_!3I6MY9%>16EMIOV18+EX(XH99I+BT@N(X&1(KF:T::SCNL\?\%/OV?@8#
M)\)/^"AD(EU*ZLIC)_P2J_X*8*EE9VRW;0ZY<!/V3Y7?2M3>TA@T]+6.751+
MJNGC4])L(EU&XTW]&J* /SW@_P""D?P2OGU5=)^#W[?^J_V/X=U?Q+=.W_!,
MK_@H3X;6>WTA[;_B5:2OCC]F;PH=<\0WXO571]!T2+4=2OQ:WC>5B!)W(?\
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M^(#?M1?_ #N*_0:B@#\^?^'C/P\_Z-J_X*#?^(#?M1?_ #N*0_\ !1GX>?\
M1M7_  4''T_8&_:B/_O.#7Z#T4 ?'7PJ_;0\&?%[QUI'@#2?@I^V#X,U#68]
M1DA\0_%K]DCX\?"KP'9?V9IMUJ;IK'CCQKX*T;PWI4MW':-::9#?ZE;MJFJ3
M6>E6?FWMY;PR?8$>0<?-T/W@ >#@'Y0%&[EBHP0"I9%<MF6B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BHYE9D*JQ4GHR]0<$@_<?H<'@ Y
M'# ]?B/XC_ C]K_Q!\0O$'B7X<?MUWOPS\!ZBUN= ^&U[^S7\)/'=MX<5++3
M!?D^+M1N=*\2ZKYNI6FI7=C+?W,:V]CJQTV^74;ZT@UFX /N"BOS3L/V6?\
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M?QO>^%[/0TDTZUO!XD7XBWVM06-P\>H:9-?I/IV=:?L0_MZ)I_BJ*^_X+/\
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M.ZN)X86$4J1@VT$8 /T.HK\\KK]B_P#:!O)%E7_@JM_P4"LE$VGW!AM?!O\
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MR-]WT_ND<9]<8_6@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.?\ SG*/^'I7[$O_ $4CQ_\ ^(V_M.?_ #G* /T'HK\^/^'I7[$O_12/'_\
MXC;^TY_\YRC_ (>E?L2_]%(\?_\ B-O[3G_SG* /T'HK\^/^'I7[$O\ T4CQ
M_P#^(V_M.?\ SG*:W_!4C]B=L!?B3\0!\RAB/V;/VG#\I.TDY^#A55!(,CN"
MJQAF.T@,H!^A-%?F7J/_  5S_86TN35H9_&WQON7T6TL;VZFTK]BK]MS7[:Z
MAOKBQMHET*ZT3]GO4K;Q-=0S7\$E]IOAVYU+4M&MX=0OM5M[2UTG59[3J?\
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M4?\ P5)G22)PI$B2I^QP0R28!4@D.@27.'!(!^@U%?G_ /\ #RW]G7_HF_\
MP4 _\5/?\%3/_H.*/^'EO[.O_1-_^"@'_BI[_@J9_P#0<4 ?H!17Y_\ _#RW
M]G7_ *)O_P % /\ Q4]_P5,_^@XH_P"'EO[.O_1-_P#@H!_XJ>_X*F?_ $'%
M 'Z 45^?_P#P\M_9U_Z)O_P4 _\ %3W_  5,_P#H.*/^'EO[.O\ T3?_ (*
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M?G__ ,/+?V=?^B;_ /!0#_Q4]_P5,_\ H.*/^'EO[.O_ $3?_@H!_P"*GO\
M@J9_]!Q0!^@%%?G_ /\ #RW]G7_HF_\ P4 _\5/?\%3/_H.*/^'EO[.O_1-_
M^"@'_BI[_@J9_P#0<4 ?H!17Y_\ _#RW]G7_ *)O_P % /\ Q4]_P5,_^@XH
M_P"'EO[.O_1-_P#@H!_XJ>_X*F?_ $'% 'Z 45^?_P#P\M_9U_Z)O_P4 _\
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M  \M_9U_Z)O_ ,% /_%3W_!4S_Z#BC_AY;^SK_T3?_@H!_XJ>_X*F?\ T'%
M'Z 45^?_ /P\M_9U_P"B;_\ !0#_ ,5/?\%3/_H.*/\ AY;^SK_T3?\ X* ?
M^*GO^"IG_P!!Q0!^@%%?G_\ \/+?V=?^B;_\% /_ !4]_P %3/\ Z#BC_AY;
M^SK_ -$W_P""@'_BI[_@J9_]!Q0!^@%%?G__ ,/+?V=?^B;_ /!0#_Q4]_P5
M,_\ H.*/^'EO[.O_ $3?_@H!_P"*GO\ @J9_]!Q0!^@%%?G_ /\ #RW]G7_H
MF_\ P4 _\5/?\%3/_H.*/^'EO[.O_1-_^"@'_BI[_@J9_P#0<4 ?H!17Y_\
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MXOT3PUX%AOO''C+7]=_06@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "C SGOC'X444 %-V+Q\HXSC
MCUIU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOC[\._!WPX\3VWQ2^,'[3-I\1M9T'X:P^&P#^R4R1J S,%#=R>I''O3#/$V
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M_P"(?@SX:_!G4/B#^R#XD^+NA>![76?BE\0;_P" OACX36WC:P\&Z?\ $_X
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M@WP]X#\/_"'PL+W4_B'KGQ3\$?'7XA2>/_"VF?"7Q=;?TP?\$\?#?[37A/\
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M* 20,D#H,\U\T_M2?M1^"OV5/"OPT\5^-/#'C7Q=9?%#X_?!?]G;1-/\ ?\
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M%OJMY%J?A^\EU'49[_[QA5D4*QW%5P7RY+L6)9L.6903D[=QQG8/E16::B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/44K(HP?F8Y'!8D9#!@3DX&T@-D_W<=P" ?SJ?MJ_%Y/B7_P5,_9<^!?A/\
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MXKJPO8H;Z&&Y@AO=*O[;5=,OTCN T4=UI6IV5IJFGW87S[&_L[>]M62[MX'
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M@'P[X)\/W&A>!?"'B_Q?\9?BAXP_K;\I" "7P#\N7?CMCYB?PZ'%/9 0 -X
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MU37M+U?XG?M1^QK\39?AY_P0\\/?M$?M0_$/XD^.M'U7]D/XQ_M9_$36]/\
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M/B_7?V;-7N?'GQ'\9ZW\ ](T;Q1HO[-WA7PQ'\7/'%G;?''PXGB7^H#]M/\
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M0OAAJ'A?P/X9_7;RESD&7[P./-D ^4$=R,#!^[GD\C&VIOJ<#ZD'\\^G^.:
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MVF_^"LOB'X<_%OX\_M:?$[Q;X,NO"_AOP=J/PW^#<?C'P+J'AO3O%_@'X?\
MQA^,VC?$#X&?$GXSV$EYIOP^^#.C_"KPI>Z3;_M'77PX^(7]21A3.[YPWJ'=
M3C'3*\X]NA..^*8MO$I) <!B2P$LYW-Q\Q!;KUY]Z /Y&/ASXK\"?M<>$?\
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M%%% !1110 4444 %%%% !1110 4444 ,?)7CU_'C)R/E?++]Y0!RR@9QG/Y
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M%S7BK_@KA^U+X/TS]I3XU77P)^"-Y^S#\"/V^_B]^QEX(U/6_%WQ:\"_&/\
M:5\1Z+8:9\%_A!X$_9_\*P^"O'^F>/=7N_VP=2O;#XV?&BRD30?!7P?\&_$V
MP^'_ ,&?BCXS^'.LZK-]A_\ !/K_ ()Y:5\$_@Q^S_XC_:.T^\\<_M8^ ==^
M,/Q:\;:S=_%#QUXV^$_A_P#:-_:#\:>*/%GQN^)WP<^%][KL?PC\#W7BB_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT !CC)'R)D<\H#ZCKCW_ /K4GE1YSL3I_<'^>W_UZ>&4GA@3CH#GCZ _K2T
M1^6F/N)R<']V.GTQZ]SQ7.>+O"6B>-O"WB+P9K]M//X?\6:)JOAO7+>PU/5M
M!U";2-;L+C3-2CL->T"]TW7=#OFL[F86FL:)J.G:QIT_EW6EZA87\5O>0=/1
M0!^>4?\ P2^_9$8?O=+^/DK_ #;F7]M?]MQ.-V$VAOVBI)4 "E&CDD<;T^38
MJA!)_P .O/V0/^@-\?\ _P 3;_;=_P#HB*_0FB@#\]6_X)>?L@@971OC_NY
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M&>=02'&/?J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOW=E:ZQK6B1ZW\.-,N;2R^'4$]QJ/BNW\4P>'M7U6RTVY3X>:1XZO6T_3;X
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M .BUH _0FBOSV_X;H^)'_2-[_@H+_P"$M^RO_P#1:T?\-T?$C_I&]_P4%_\
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MZ_=QZA-J=JVI:)::(VG:1JJ7&JV]^VF6E]]6*, =>F/0<'C@< ^I4 -UZ;:
M'4444 %%%% !1110 4444 %%%% !1110 44USA2?3MR,\< %<L"6P.%8GH%)
M-> _$#]IGX(?"_Q]H/PP\;_$+3]'\;^(I/ $=KH<5CKFL2:/_P +9\>0_"?X
M1W?CF\T31M4TKX;:?\6?BE]I^'7PLU3Q[>>%](^(_CK3-9\+>";GQ!KVA:_I
M^F 'O[*&&#GKG@XIGE+ZM_WT:^9;#]L?]E[5/ D?Q/T[XZ?#>\^'\GP(U+]J
M >+H_$EG'HZ_L]Z-#)-J?Q@DEF8/%X%TT13+J&L.C):S1LCPF97$6IKO[5/[
M/?AOXI>#O@OX@^+'A/2OB5\0++PAJ'@SPW<WLRCQ!;_$6'X@2_#\:?K0L_\
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M^"?"_P#P4<^$_B6^\.Z=<_"[XY^&+KQI\6?BE\!?!,GBC0OAW::?XO\ C?\
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M-\>-2@T'X5^(?AEIO@/6O"7B[Q--\.OBY\8TT#1=?\0_$#PS!J.JK\(?@?\
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M^,'Q:?\ 9O\ BW\']=T;PI\3-9L8OAC=?%;]G?Q-X1M?@]X=^''BD_";PO\
M#;4/&GP)^('PW3P[XTM?V9_%FC?$>Z\67OCWX6_M,ZEXL34]5\$Q@'0? W_@
ML3^S/^T>/#FB_!_P!\?/%WQ0\2?#Y/C#;?!O3/!G@NZ\=:7\%;KX;?"KXN:7
M\5-=US3OB/>?"G2=,U/P'\=?@MJ=OX"N_B;!\9K:[^)_A30]6^&.FZ[>W.EV
M.C'_ ,%A/V.Y_!?Q%\=Z??>.M3T'X5Z3#X_\816&B>&7UNW_ &?M7_9-\8_M
MH>!?VGM,\./XO36]?^!GQ-^"/@C6'\&:CHNGW7CM_'2W7P]\0_#WPYXO\.^,
MM+\,VOB)^R'^RE^RG^R[\.]<N_&/QI^"/PV_8B_9R\<_"VV^+_PAEUP_%[1/
MV9=7\*^!M*^*'A[Q!-\+_A]KOBO5(+W1?A-\+_$&N?$/PCX0@^,/A?5?A9X?
M^(N@>/?"OB'3-=\0W<&I_L ?\$]?C):_$O\ 9GE\$PW^K_"?P+XA\")I^DMK
M7A[Q%^SW\,_VFOV/[+]C^Y\ _"WQ/9:=IVEV?@/Q)^S9X$T?0X_!_P!I\9:-
M%X@\)>%?&OB6PN/&WA;PEK&D 'UAX$_:?\/>,_\ A<NBZA\,?BOX"^*GP(T:
MU\3>.O@=XFTGP;KGQ0F\)>(5\;2?#7Q+X2'PM\<_$3P)XOT[XL1> ?%B> ;7
MP[XXOM>&I:=>>'?%NE>%/%MGJOA^U^3M(_X*Z?LN>(/AGX[^)WAGP[\8?$>G
M>!+32M9D\/:?X<\$VOB7Q#X)U[X(?LR_'WPK\0=$35?B#I/A[3_"GB?P7^V#
M\!+'2AXOU[PEK]KXK\67VC:OX?TC_A'/$5]I_P!(> O!/P>_9T^*L5CKOQ%\
M:>,_V@_VK+B&PC\:_$Z>7Q!XT^(-C\"/!6HW>D>%+&3PGX;\.?#OP5X/^'/A
M2^\0^(=+\*:!X;\'Z+J7BCQ/XZ\:S1>(?B)XZ\:>(-=\2\.?\$E?V)? W@KX
MO> _AK\-;WX9:1\9O"%QX)\2W/@[7+J'4-'T6X^//Q*_:39O"PUJ#6=(TVY;
MXF_%35IKEYM-U"WO?"GAOX>^ KR&Z\(_#CPOH]B 16?_  4\^&>GZ[\;[3XK
M? G]H/X!^"_@'\=/A1^SQX[^+GQ;/[/4'PZM_'_QNN/@M-\/;@MX$^/GCSQE
MH'AS5O#W[1/P;\::AKGC?P5X4C\/^&/%MY)XGATG6O 'Q-T3P3WWB[_@H'\,
M/#O[)-]^VMHWPR^-OC_X(:#<?%#4_&UQX4\-^"]+\4^ _AG\&-3^)5I\3?C5
MK_A_XA_$3P%-<_#OPUIWPMU[Q+;Q^$KGQ/\ $'QEHFH>&SX!\!>*=:UR#21P
MO[5/PC_9!^&>A^,?&GQYUGXC:?H_QS_;'^ W[2FM>%/".D>._BCKOQ2^//[-
MWPW^&%[\/_#'AWX4_#;P-X_\>^+_  EH/@7]D3P]\3_&G@[PGX5U!HM$^%_C
M7Q]XFU#3?"NF^);JP]XC_8Z^%-U^R9\3/V.]2U?Q[XE^#_QA\%?'SP)XNU/6
M_%\VK^.;SPI^TEJ?Q!U?QY96OC*:R\^62PB^).N:;X.U.ZANIM+TR#2([B34
M+JSFN;\ \TTW_@HK\(W^(O@GX,>+?AS\9OAS\;/&/Q2^&WPHNO@_XFT3P!K'
MC7P?X@^)WPR^(WQ5T;6?$TOPV^(_CWPI=>"M)\/?"KQA9^)?%W@WQ3XOT;3K
MZWL+J.XO/#.JZ=KERWX:?\%$_A3\8OV0/B'^VK\,/AQ\4_'?PO\  _@-OB9I
M7ASPI>?!'Q'\2/B'X,3X9^&_BS]I\)^'M'^-=[I7A_Q2GACQ&D=W\-/BSXB^
M&'Q4TK5=,FL]:\$Z9'J/A:?Q#KZC^Q#\%/B+\8+C]IQ]0^*>C?%'5?B_\+?C
M5IVO1ZA-X=N] U[X._"#QM\!O#?AG3O#WBCP@MWIG@;4?"/Q!\=77B7P?K5E
M?PZQK_BJ_P#$$-X@%BD.Y\)_V'_AW\(_V<M9_9<T7Q[\6]?^&.H?!'PY^SMH
ML?B?Q!X8_M;P3\(O!WPWD^%GA7P[X87PWX*\-:"=<T?PA-_9\WQ#\3^&_$OQ
M)\2):Z!#XS\6^)=-\)^$-.T$ X2P_P""G7[)NI>"?&_Q0MM?\61_#'P-JOP.
MM-1\>7_A*^TW2[K2/CIX6TGQPOBY]&OY;?QEX3\,?!WP-<>(?&'[1MS\1/#'
M@C4O@=X:^&WQ0UKQ_I>F:?X#\27%IH?$'_@I+^R_\,O&?QD^&?BK6O$MI\4?
M@G\:_P!EWX!Z]\/'T2WLO$?BSQU^V/\ \(_'^SY=?#V]UG4M)\/>*/#GC+^U
MO$4=YKR:[91>%O\ A6GQ/D\3KHEMX-O9IL3QK_P2L_8D\;^(/B_KFJ?!;P_;
MZ;\?/$'Q0^('QD\$6EII]S\/O&WQF^+?PXT[X0>)?CZ_@G6M*UK2- ^-5G\.
M%\5Z)I_C3P8GAUK[4OBE\6?%GBBP\3^,_'^N>()_"O"7[/7_  3P^//B?]FK
MQ"OBGXA_&+XJ?'[X.?#W]K;X _&#Q9??$BZ\<_$7X+?L_:O^PEXCL_'FL>)[
MOPAHOAR$QZUX7_9KN]1L_B79Z?\ $ME^,OQDTWPO!H=A\8?C%8:@ ?8_[+/[
M:'PZ_:TUOXP:+\/O"7C/01\$_%NJ_#WQ??>+M5^#[S)\0?"GCCXA?#/XA>"I
MO"/@3XL^//B-X+U7P!XX^&GB'1;VZ^*'@OP)H/CJTFL/%'P;UCXE^#9[OQ#8
M^:?$;_@I?^SM\/\ PCXZ\66VG_$'QM+\/OVIK7]CK7="TK1?#/P^D?XYWWPY
MT?XL:)I</C#X]>+_ (/?"O3O"OBSP7X@\,77P^\=^)/B-H7A?XF:_P"+O ?@
MWX;ZEXJ\8_$/P)X>\3>M? W]D;P_^S[#\0H?!/Q4^,-Y!\0=<^*/BI;'Q'K?
M@S4++P7XL^-'QB^)?QZ^)/BKPI:Z;\/]&M]6UW7/BC\5_%'B*VN?B1:>/K;0
M;2.T\,^&[/1O"L^KZ1JGR;\4OV!_V'?@#\&OB)K?C?X@WW[._P"S[=_!/X2?
M![]H*\O?%7PT\$_"+XA_#GX=:/\ &'X;0WOQWM_$O@B?PGXIU_XH:5^T1XDT
M#XF^+M;@AUCQ+J&D_#+6+"\T+Q9\/?!.M6(!].?M*?MP?"7]D_0O"WBOXR>'
M?B-HO@WQ/\/?BW\0G\4V?A[2IM.\.CX*_#R/XR^+_!&O:?=>)+#Q%'\1)?@Q
MH_Q7^+.@^'=#T/61J'A#X!_&*2>_L-=T7PYHGBKS[4O^"FG[+VB?&#3O@GK.
MI>)-.\7:[\2=!^%7AZ2:V\+[/$WB/Q'\>_'W[+VGW'A31K3Q;/XU\4Z=9?';
MX9?$+P7XN?PWX2OM3^'6F>&M1^)WQ"TOPK\(IK/X@7/NOQ0_9-^ WQO^'GPV
M^%GQ5^'MEXW\ ?!_QA\.O''@#PWXFO\ 5M<M=+\2?"B);/PC>:E+J-_>W/B:
M&'3);[1-7M/$]UKD?B;2=4U6U\1Q:PUVTL?SIJ7_  3<_9'^'TOPU^)'ACPQ
M\1O J_LM_!OX6> ?@_:?"[6?&NM>(? /A+]G+6/&7BSP7=^#K71K7Q=\5?&/
MCO4M$\>_%#X;^/H([WQ9K?[0'P[^)_Q$^&GQ%T#XAVGCJ^L;X BU'_@H_ILL
MUK:?#_\ 8S_;/^,%YK&C?$#5_"]K\//!WP.MSXL_X4W\7-)^"'QAM-$?X@_M
M ^ X;:X^&GQ!\2^!X+J_UYM%TKQYX:\40^.O@]J7Q(\%^#/B5KO@3$UO_@J5
M\-?#FK>%_#GB7]GC]HOPSXJ^(&O?%?1OACX5\477[,GA77_BA#\"OB;\-/@]
M\8M2\#V7B;]I728]0O?!?Q4^*WACP;8^ ]2GTSXL_%._34M6^"'P]^)WA<6G
MB"_]'\$?LY?L\?LN:?\ ##XM:;=_%.ZO?@_\./VN[#P:FK6_B_QO\2/%MA^U
M=\2?"/[7W[0$"_"WPQX6F^(OQ.^)^K^*O@K;>(?#7@+P9X3U#QU!:Z=KNA:#
MX0U+5Y$AL]"/]@?P!;-\,KW3OBY^T!I'B3X7>&?VD_!-EXXM_'NB7WCOQ/X*
M_:O^,/P^^-_QD\/^)?&.N^"=3UJUO+SQQ\+/ \OA7X@>"KCPA\5/!EGH<5UX
M?\>6.M75QJ\H!UOP)_;8^!_[1_B.U\+?"Z3Q'JFLQ1?%VT\86NJ:9INCW?PY
M\4?!GQ!\(]!\0>"_'FEWFKKK=CKGBC3?C1X'\<_#O5-'TO7?!/C_ .&%Y!X\
M\-^++SPSKW@V]\3\=XB_X*&? G0?#6B^,(M(^(?B#P_XD\5?&#X?Z7?Z9H7A
M^R^T?$/X,_MC?##]A35/!,MKXI\5^'[VTO\ Q;\?OBIH>E>$]?O(8/ B>%](
MU[Q9XP\5^$+ :*NN^G?#S]D+X*?#+XFZ/\:_#VBZQ/\ %W0O@W>_L^V'C_6O
M%7BFZU&?X,-\1KCXJ:#\/=8T.UU73O!^N:5X(\37EQ#X%U36/#-WXO\ "7A^
MYU;0M)\3PZ;XA\50:W\Q?%O]C+]DKX8^#=?UOXJ>,?B3H'PFUGX]^!/%.@>&
M[C6WU3PK\/?B;\;/VX?A!\?]0T'P?:Z?X1U3Q2WA[]H?]L'3/AOJGC:S\87W
MC.S\*V]]>:%X#U?X3> )=:L  :O@S_@J/^SK\2/#VC>.?ASX9^*OCOX:7/Q"
M^#_P6\6_$S0=#\$P^$/AO\<_CS:^#4^$GP>\6'6/B!I6NZUXB\<>)/BM\$_!
M]GXK^&?A_P ?_":PU#XW?#[Q!KGQ'TWX<-XK\;^%O5OV9?V]_P!GG]L;P./B
M7^SAJ^N_$[P&/A3X8^*W_"0:+H]N9(SXJU;XAZ''\-[SPU<ZC'XPTKXJZ/J7
MPR\0PZ]X2U30-.CL?M6A/#J5\NJQ!?)/%GPW_8^\3?M0>(?#=_XR\>1>,]7^
M)_P6^(WQ/^$OAN+Q1-\ M<_:3^'7@+2[[X ^)/B=KNG^#[_P'H'Q^\(_#WP)
M\*?&7@WX<7_Q+\.:M>:=X _9O^)6K> -9NM(^#OB.;O_  7\"_V2O^";WPL^
M)WQVTJRN_AS\//AG^RW\(_#/QI\9/:^(?%5_J'P>_8=^&?BW0_"'Q \7:-X5
MT:_UGQM\0?#?PIN)M \2>-;'P[JOCCQ=X0\&^ _#+S7^B>!/!VD60!R>A_\
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MGA[XDSZG9? /X.?M&^,K6_/Q&\=^"?!/@_3OAKX%_:%^".C>/?%OQ%\;^%/
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M"WCU/6O%^N:!X8CL4O\ 472+A?A__P %)?V:?BOX7\:>,OAK<^._%WAKP/\
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MX*^&/ASX@>(?$OA+P?9:=;R:7X^T+X7^+M \1>']0^&.EM>_>]% 'YI^$_\
M@G7IEC\2O!_Q[\:?%S6]=_:&TOQ1\)-9^(_Q0\&>%[7X>0?'KPW\-/A#\+O
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M^#/'?@KXT?&+0?&<&E?&+P)KQ?QHFO\ P_UGX?Z[X8\,7MG^E-% 'Y6>%_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4R3(4E<9&2-S;1G!V@MM;:"V 3M;@GY6SM+Z* ,?1I=8E
MANCK5E86-PNJ:O':1Z=JDVK0S:/#J$T>C7MQ-<:-H<EIJ%]IHMKO4-*CM[Z#
M2+V:?3DUK6A;KJ=UL444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ H(!&#R#110 U45.% 'TIU%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK\6^)OC-\9?%WBC5?BEJ,&D^"_%U_P"$;FX\.^+9_&6H> ="\*7FDP^+TO/
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MPL-,\'>&/!GAB?\ 8"B@"&(;0@)Y"L"I(R#E3C"[5 4$!1L^52H# $[IJ**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\ ?T3W?[0WP!LM)\>Z[>?''X06>B?"G78/#/Q1UBZ^)7@VWTOX;^)+G7/\
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MB!;=!:@HL7ANYN?#L>S;Y>@SRZ7%_P 2^62)L_P)\-/AU\+?#UGX1^&/P_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_001.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.gif
M1TE&.#EARP P /<  /______S/__F?__9O__,___ /_,___,S/_,F?_,9O_,
M,__, /^9__^9S/^9F?^99O^9,_^9 /]F__]FS/]FF?]F9O]F,_]F /\S__\S
MS/\SF?\S9O\S,_\S /\ __\ S/\ F?\ 9O\ ,_\  ,S__\S_S,S_F<S_9LS_
M,\S_ ,S,_\S,S,S,F<S,9LS,,\S, ,R9_\R9S,R9F<R99LR9,\R9 ,QF_\QF
MS,QFF<QF9LQF,\QF ,PS_\PSS,PSF<PS9LPS,\PS ,P _\P S,P F<P 9LP
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M,S.9 #-F_S-FS#-FF3-F9C-F,S-F #,S_S,SS#,SF3,S9C,S,S,S #, _S,
MS#, F3, 9C, ,S,   #__P#_S #_F0#_9@#_,P#_  #,_P#,S #,F0#,9@#,
M,P#,  "9_P"9S "9F0"99@"9,P"9  !F_P!FS !FF0!F9@!F,P!F   S_P S
MS  SF0 S9@ S,P S    _P  S   F0  9@  ,P
M
M
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?(_JMIX '3. "&_C "$ZP@A?,X 8[^,$0CG"# P( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ex21-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex21-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $A G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OF_]L/_ )-*_:F_[-Q^./\ ZK+Q'7TA7S?^V'_R:5^U-_V;C\<?_59>(Z /
MR@_X)LY_X=V_L(=/^3/OV<L_3_A6.@8Q[],_C7V?7QA_P39S_P .[?V$.G_)
MGW[.6?I_PK'0,8]^F?QK[/H (9C"?W!_3C^?''X<X]CS\WC;PY9^,M'^'/\
MPD>FVWCC7O#>I^-=&\)_;/\ B9W_ (7T+6M T'7=:_[%WPGXCUS0^>?^0_CF
MN@K\G_C]\2/''PE_:6_;P\<>!_#FM^+?C!I7_!/?]G/1?V8_#^E6?]I:GK_B
MCQU\:/CYX#/]AC_H7?\ A=.N>!_%'C?)QX+\%^E 'Z?^&_B%X5^)&EW&N>#O
M'&A^/]'TO6-4\,7FK>$_$FC>)-,L/%&A:T=!UW1AKGAX'_BHO"7B/_D=_"O3
MWZ5D?\+:^&4UAXYOO^%F^ +G3_A+K'_"%_$B[_X3'1O[,^&GB@X_XHKQP/\
MFG_B+&N:'_Q2WBSG_B?]>./RV_X)R?#+XM_LI_%[XH?LR^/_ (*V_P +?A]X
M\^#_ ,+_ (T?#>[\*_$8_%GP/?\ Q1\"Z)X?^!'[2&M:YXWT#PSX0\,^'_$7
MQ8\0Z)X&^*!\+$ @Z_XG\;GYL@?"?[1/P-^+?P_\$?ML?&_X6?#3QMXCT_\
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M?BC/3((Q@5OU^>OP U+7-8_;I_:#U6Y!,.J?L2_L)7OQ4)L_[,/_  N37/\
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M^"07_!-G_@GE\2_^"7G["?C[XB?L)_LA?$+QOXV_9D^&FN^+_&_B[]F_X/\
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M (BM\%__ )@* /<O^&V/V-O^CM/V9O\ P^_PO_\ FHH_X;8_8V_Z.T_9F_\
M#[_"_P#^:BO#?^'3?_!+G_I')^Q!_P"(K?!?_P"8"C_ATW_P2Y_Z1R?L0?\
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M'[&W_1VG[,W_ (??X7__ #44?\-L?L;?]':?LS?^'W^%_P#\U%>&_P##IO\
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M[E_PVQ^QM_T=I^S-_P"'W^%__P U%'_#;'[&W_1VG[,W_A]_A?\ _-17AO\
MPZ;_ ."7/_2.3]B#_P 16^"__P P%'_#IO\ X)<_](Y/V(/_ !%;X+__ # 4
M >Y?\-L?L;?]':?LS?\ A]_A?_\ -11_PVQ^QM_T=I^S-_X??X7_ /S45X;_
M ,.F_P#@ES_TCD_8@_\ $5O@O_\ ,!1_PZ;_ ."7/_2.3]B#_P 16^"__P P
M% 'N7_#;'[&W_1VG[,W_ (??X7__ #44?\-L?L;?]':?LS?^'W^%_P#\U%>&
M_P##IO\ X)<_](Y/V(/_ !%;X+__ # 4?\.F_P#@ES_TCD_8@_\ $5O@O_\
M,!0![E_PVQ^QM_T=I^S-_P"'W^%__P U%'_#;'[&W_1VG[,W_A]_A?\ _-17
MAO\ PZ;_ ."7/_2.3]B#_P 16^"__P P%'_#IO\ X)<_](Y/V(/_ !%;X+__
M # 4 >Y?\-L?L;?]':?LS?\ A]_A?_\ -121_MI?L>32PP0?M7_LTS7%P,VL
M"?'7X9,TFU3]T+XD=LY/ V9[*">#X=_PZ;_X)<_](Y/V(/\ Q%;X+_\ S 5^
M67_!:W_@G1^P%\'_ /@EK^V5\0OA5^P_^R=\-/B#X6^'WA^\\.>.O!'[._PB
M\+>)M!U"7XD>!8VU/0_$&@>%AX@T?*,Z2^3,-R$JR,A9G /Z7**PO#O_ " M
M%_[ VD?^DR5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7Y::]_P5'_99M="_;;3QEHGQ@\,Z?^Q3XC^'/@/XV>'?&GPBU[2_
M$GBO4OCKIL2_";1OA9X.0R^)/'%Q\66UG0] \&17=IX8>\D\0^'P0EM-)))^
MI=?SL^/_ /@E-^U9\7_'?_!2?Q5X]^-7[/OAJW_;6\=?LO?&/X;W/@SP)\1[
MR_\ AQ\4?V'-:^'?_"AHO&(\0^)4A\1> O&'AWX7QVWQFB;8?.UV1? ,D2NA
M8 ]>\-_\%<_V%/@5\'M"\)_#?X*?''P=%\'-/^,>B>/_ -E_X?\ P)TG3O'?
M[*'P_P#V4K7P*OQRUWXG^#/#7B2/PCX:\ _"C0_'?@607/A#Q-XR7QE#XB\/
MK\/H/%[3%E]@TK_@K]^Q_K7C7XN>"/#EU\2?$FL_"^U\+1^&#H/@235Y/CWJ
MGB'6] \&:7X2^")3Q#_;GC;Q/)XK\::!X<">*;;PA;[M;/C)9/\ A ?#?BOQ
MC9_"'B'_ ((Q?M,WNN_&/XS:%^TI\$M,_:/_ &O?#G[8WPQ_:CO;[X0^,]2^
M%.B?##]L+1?A'H%V_P $O#I^(L>OQ>/?@_H/P1\/?\(5=>*I)(?&SZ_XE;QR
M\*O$+CUWXZ_\$>M0\9V-_?\ PA^(O@/X2^-OAUX!^ _PT_9^\0:'X4UWP+XH
MUS3?A=H_AWP]\4_%_P"T)\5OA#KW@CXG^)_B'\5/A[HO_"H_!7B/PAXL\*7G
MP6^$$^OP>"%CE\8>,T8 _>RWE,T,,[03P%@,V]P%5K; .2P&>1V.XY!X*C@7
MJ\>^"?@OQ1\,/@W\(OAWX\\?:U\6/&O@3X=>!/!WC'XG^(B&UCXB^*_#WA_1
M-$UWQMKK'*IK?BW78Y_$4P 9O,N'567YF;V&@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *X_Q-X@A\+^'=8\036.MZI::+I-]J
MES8>&](U3Q-XDOTTJ(E],T30]&$VOZWK4[(((88(Y6EF**V!(Q3L*XWQ9_PE
MG_"+>)O^$+_L#_A._P"R;W_A#_\ A*?[3_X1C_A(_P"SG_L7^W_[&_XG/_"/
M?VSN^V^1_I7V?SOLOS^10!^3_B7_ (*8_L;_ !K_ &4O GBS7?@O\9/CGX/_
M &M_&OQX^ 'A#]D^?X-:=XH^,'Q7U#X*R_$+2?CCX?UCX5^)?$J^%O\ A'?"
M7A[X:>-O$GBQO$_BN$?84M+,QGQKK]OX.JUHO_!9+]AB35_A%H'@&7XAZ]\,
M/&_AO]F1E^+W@_X<&3X(?!D_M5AH_P!G/P3\4M9,\&O?#WQ-XNCCMDC\-R>$
M9%\#[M"A\=OX-@F9Z^0?@]_P2F_;'^$?PV_9F;1/CM^S(O[0O[(W[0'[5GQ?
M^%6L/\./B9??"/Q?X5_;=T?Q^GQ7T+QSHK>)(/%:>(/!WB+XFSS^!-?\,^+D
M,UIX=T!?&8NH_$MX$ROAS_P0D\9_!F\\ _"CP-^T;X=OOV9K[5OV!O'WQPL/
M$'PVU4_&GQ%\3OV [J/6O#1\#>(M&\40^%M!\!?%KQ!H6A2^,;3Q9X<\6R>#
M8RZ^"?WOER* ?HU^S]_P54_9J_:87P=9?"S3_BW?^)?'7Q4'PTT'P-JOA/2-
M(\=II,7@/P]\5A\:-5T5_$[C1?@P_P /O&?@KQ1)XINYS,#XG\->##X53Q[X
MBM_!9_4&OY\/B/\ \$??BUK'Q"\/_&#X,?'SP=^S9\1-6^.VJ>,/B)-\$/!G
MBSX5>&-&^#\?B_0/$/@GP;X*T;X<>*?"*Z]XB\-G1M>\1^-#\5X?%'@?XS>/
M/BKXL\9>/O!8;PSX#7PG_0?0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '#>-?%B>!/"6O^++K0O&'B&V\-Z.VJ2:%X(\.
M:KXT\4ZP(@RG3/#_ (>T99]>UW6WV*J0Q0DR>8LC 8D:/\>?BQ_P5+_82^+/
M['OPG^(GCGX-?%3X\_"3]KCP#\8OB!:_L]3_  1TCXA^,]3^$7[/>KN_QL^(
MOQ)^&VO^(1X6@\"?#*\TG07N;F7Q1>O=R:SX=7P);>+G>*.W_7[Q_'X^D\$>
M*(_A5+X6A^(:Z1JB>#3X_BUL>!AXE\M/[)/B)="*^(O[$CDP9#X><3E!(8V,
MB[&_G,^'?_!&O]L'X=?LZ_LV_#?P_P#M&?L]:;\7OV<_A-^V#^RROBO_ (59
M\3=0\#>+/V>_VQG\/ZSK?BM-&'Q#B\1:+\8?ACXET":7P>GF_P#"'^*8RL=]
MY4<JF@#] +S_ (+$?L6V'CO2_"UEK/Q$U/X9W#>$M '[16D?#JXU#]GRQ\=^
M.?@*W[1_@CX,/XM\T>((OB)XC^"T-EXIB\-IX0FADN=?T/P:WBJ#QW+'X1KT
M?]G#_@IW^SU^U8?AAIWPKT?XK+XU^(VO^.;)?ASXD\)Z99>)/!/A?P'H>AZ_
MK7Q*^),GA_7O%?AOPW\/;B'Q=X'\.>$_$:>*)5\6>-/'?AOPA#%Y\?C"3PK\
M*?"S_@BWXM^$GQ'^&_@_PU\:O#-Y^R!\/_VBO@1^UY+X'U?P)JR_'+6?C'\"
M_P!FGPY^SAHW@W_A.1XFF\(#X1>*F\&:'\2O%XD\(2>,)&#^"H7:T9[D;.A_
M\$BOBIX*^,7P&^-'PF^/7A/X)ZEIOQ37Q]^T7X/^"'A'Q;\*/AWKWAK1OB)H
M'B/P3\*?ACX(^'GBCPGX0/@+PI\.-'\9? \^&_BMX8\81R_\+<^*'QP95^-7
MB7[1* ?O_1110 4444 %%%% !1110 4444 1YS_">?8\Y].?=L?A^!G_ &3[
M\'OU[^[?F*_&3X;_ /!0W]JSXJ> _"WQ#\'?LE_"O_A%O&&C_P!N:,=6_:@D
MT_5?[,Z9.CGX*&3(!QCS .1[5W'_  V9^VC_ -&C?!C_ ,2M?WX_Y(K[Y_\
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M!Z4?\-F?MH_]&C?!C_Q*U_?_ *HI[_H/2I_U-S__ )\1_P#!M(7^N61]Y_\
M@,O\C]8L^H^O!]\_Q?[W^2<&?4'W^]^/\7^]_DG'Y._\-F?MH_\ 1HWP7_\
M$K7]_P#JBOO_ )P*/^&S/VT?^C1O@O\ ^)6O[_\ 5%??_.!5?ZF<0_\ 0/\
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M[Y[^[_Y%?DY_PV9^VC_T:/\ !C_Q*UO?_JBGOQ]!Z4?\-F?MH_\ 1H_P8_\
M$K6]_P#JBGOQ]!Z57^IG$'_0/_Y4HB_USR/^=_\ @+_R/UCSZJ??K[Y[^[_Y
M%&?53[]??/?W?_(K\G/^&S/VT?\ HT?X,?\ B5K>_P#U13WX^@]*/^&S/VT?
M^C1_@Q_XE:WO_P!44]^/H/2C_4SB#_H'_P#*E$/]<\C_ )W_ . O_(_6//JI
M]^OOGO[O_D49_P!D_D?Q[^[_ *>E?DY_PV9^VC_T:/\ !C_Q*UO?_JBGOQ]!
MZ4?\-F?MH_\ 1HWP8_\ $K7]_P#JBGO^@]*/]3.(/^@?_P J40_USR/^=_\
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M#X@Z1JWBRZ\8_"4:?XZ^*_QH\>> _'.B^-]=\0>'/^$HT#/AW1/!/BCP4/\
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M!S*8XY,/X?\ [:_[)GQ7^)&G_"+X>?'OP%XJ^).O#Q-9Z/X2TP:T/[>U+P0
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M\CT+6?!?C'64_P"$H$7_  D/PP\1:%JW_"'.T9D;^UO$(5E"L&\C$O&_6O\
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M?&7_  @VMKHO@CP_\2%\4>(/$/A/Q'HFM?\ %,?%8?!_QBPSXW5AGCM?BO\
M\% OA-\(O$'Q+TG4OA]\=_'?A/X!1^%+;]IKXU_##X:Z-XD^$GP*U+7M$T'7
M\^.-;_X27_A)-?/A;P]KFB>)_&L?PH\(^,I/!O@W72/'8..?$?$O_!,_5/'<
MG[4NH^./C[IJ^(/VG/@3JWP,U6Y^&7[/G@[X2Z9_9?B#QB/''_"ROBIX+\/^
M)1X:^,'QC\(_V)_PC*^*#_PB!'@[_A)CG/-=M\5OV!/$GCW6?VDM$\&?M*:W
M\+O@7^V7J.DZI^TS\*;7X5>#/$GB37M2C\&:%X%\;M\+/BCX@\2_\6@;XJ?#
MSP5HOAGQIGPAXR4%O^*%7PAC!3EFFO*[[=7MT[[:OS?WHY<H^U&WR7J^G]>A
MU/Q!_P""C'P7^'/C?XF^%M2\!?'S7?#'P4\5?#'PG\:?C!X2^'.AZC\(/AK%
M\;]&\"Z_X(UO7?'#>)5&O^'F'C/10(O"OA'QA+X/X7QNC>!F /WO+%Y<@A7H
M0&X[C //Z=?J>:_/_P"(G[!&A>./AM^VI\,[;XBZCX;T;]L3Q1\'?$&+3PW_
M &E_PJ?2OA3X-^$_@30M(T0KXD4^(#CX88/8C7@?6OOYY=[I*#NVJJ9[_*JC
MD'/L>?H371A7C$V\7)VOU;M:_K;MM_PW-B88*W^R02?I?MY7[_)^6KJ***[)
M2ERR]Z7POJ^S\SB48W7NQW71=_0*^6?VV?\ DTOX_?\ 8A_^YG0*^IJ^6?VV
M?^32_C]_V(?_ +F= KIR]MXO+M7:[YKR??M?7R,<?%?5,QT2[62Z?+]2/]B'
M_DT?]G__ +$,_P#I[\05]55\J_L0_P#)H_[/_P#V(9_]/?B"OJJC,;_7,QO;
M9??Y!E]_JF6W_E?WVU"BBBN5;+T7Y'1+XI?XI?FSX _;I_9J\9_M":S^S#KG
MASX/? +X_:/\$OBIX\\9^,?@Y^T'XE_X1OP-XOTKQU\,M>\"Z$#CX<?%S/B'
MPGXEUM?%//@_@C/I7@_P9_X)_P#Q6\!V'[-]EKFN_#CPEX7^'?[6G[4'[05[
M\*/AEK/C+_A!_P!GGX7?'7]G[Q]\)M"^"_[.NN>(/#9_X2'_ (1/Q+XX'BKD
M^#O!?_$_\3'P&<"OT8U[XM6.C_'/X7_ &QT.YUOQ1\1?!_Q0^(.L:O:7G]FZ
M;X#\!^!?[ T$:UKG_0P#Q9XC\<:'X7\$9Y_Y&?/->??LX?M:?#G]IS7OCAH7
M@?2O$FBW'P2\>'P5>7GBRTT;^R_'GA?_ (G^@Z%\3O QX_X2#X=^+/$?@?QQ
MX7]O^$!\45Y<L-A?K3;;V?Y=_P"MO([5B<8L*K-[Z;[7M^3T^?=W^.?@/^QY
M^TWX<C_8*^$OQ;F_9_TSX+?\$Z?$A\3^ _B!\,/$?C+4OB7\=]4T/X:>/?A/
MX%&M>!O$/AOPCX8^#NWPYXW'B;XVX\8^,?\ A-/&6@$5Y]X0_9%_;2A_8*\<
M?L%>*? _[/&FZ/\ \(?X[T7P?\8]*^._C+Q'J>O:KKW[07_"V]$_MSP,/@IX
M1'A_'AW7-="G_A,?&.1H .%/RCZP\0?\%#?@YX:\=_MJ_#35?#'CZ'Q3^Q-\
M-M5^+GB475EI TWXR^&-"^&>A^._'2_!+7&\1@>(/$OA3_A-_ WAKQN/%)\(
MC;XC\+9(?<$^E[SX_?!;3?%'A?P!KOQ4\ >&_B3XRT?2_$VC_#W5_$FC:;XF
MO]+UW1?[>T'_ (D?O_Q/.._]@=32CA\$F_>^%[:=/-[[>?G<Z'B,;\,H)MZW
MMMS>]I965W*[73;2UCX7_:$_8L^-/QFU[_@HOX LO$?@#1/@M^WA\-OA?]C\
M;7?B7QE_PG/PU^*'PH\%Z!X#T+1=<\#_ /",_P#",:_\._%@T/0_^*I_X2_P
M?XT_X0O/)&W/J'[(O[.OC_X;^//''Q4^+?PY\)>$OB!KWPW\+_#&S\6:3^UI
M^TM^U%XFU[POH6M:_KW]B_\ &0'AKPC_ ,*_^'?_  D>N?\ "3^"/"_A,?\
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M&U'Q#T76O$NSPF7)='D# .$2GX;_ &4OVM?@=J8\1?!:V_9W^)&L_$_]@_\
M9T_9*^*NE_&/QAXS\-Z;\-O%'P,\%Z]H2^,_ ^N:!\./%Z_$#X=>*3XWUT^-
M?A:!X.(.A'<Q^4+];_"O]M+X$?$+P;^SOKGB/Q]X ^%WCC]I;P'X7\:> _A/
MXL\>:-_PG-__ ,)T?^)%HNAX_P"1@]NO_":8Z=Z[#XS_ +0=E\)/%'PX^'.A
M?#GQO\8_C!\6O^$HO? ?PG^'UWX-TW4QX8\"C0?^$Z\9ZYXX^('B3PEX8^'_
M (=\)_VYHG_%4>+&Y\::]X8\#=152P^":>*NN6[]VZ=[W=K-[?*VWRZ?K6,<
MOJSWLE?E5K1C%=M-(I76OGJ?G!XF_P""7OQ ;X3>(?@QX.^(_A&YL--_80_9
M+_9D^''BSQ98ZP/[>^*'[*7QJU_XMG_A.-" POP[\6?\23PN .GTKHOBK^R/
M^UY^T3=_MG>-?B98?L]> /&/[2OP*_9C^$WA#PIX)\?>,O&^DZ#J?P-^,_CO
MQWKG_";>,_$'PT\(_P!OO_PCVM'_ (0QSX2(D4IX% 3RSXU?[]E_:B^"WAN+
MX;6'Q;\<>'/@#\0/BA9#_A&_A/\ &[Q)X.\-?$S^U3K7]@_V+_8?_"28Q_PD
M8/A?_A*>?!GC3@]15CQ)^U%^S+X/\1^*/!OBOX_?!WPWXP\!_P"F^//#WB'Q
MWHVFZGX#_P")UH&A?\5S@?\ %/D>(_''@?\ Y&S_ *&#PP!4_5\$_M?EI?Y_
M(7UC&ZZ-\R:;UUN[OIU:O_6GQQ\<OV*?BM\3_AG_ ,%%O!OAS5_ .G:_^UW^
MTY\&_C+\-;O5[W6=.&G>%?A2WP$9AXV_XIL@>(=WPMUX^"5_XK 9/AHD<EJ_
M/#3_ !#XI\.?MU_%?6;[14^)BZG_ ,%/]8\:^#?V4;WQ?^T!X)^)-AJFLIH/
M@5/VL="^%7AKPP_P+\0>'_#'AU-:^)<7Q3\6>+1%XS\':$OCF9X?'&YU_<Z'
M]J[]F6;X:3_&*']H7X.?\*GM/$A\%WGQ"_X3W1O^$9L/'AS_ ,47_;F?^1BZ
M?\4MZG)]:V+S]J+]GK38?AO!??M"_"ZVMOBU9Z7>_"L?\)YHW_%S-+UW6O[!
M_MKP1@_\5#CQ'P/\>:PKY?A.9.,]4XNZ:;LFG;>ZO;\;[BP]?%W?/%RO?>^N
MC2UWTZ:Z)+9!^SW\2/'_ ,3_  OX@\8_$#X?_P#"MM/_ .%J?%#1?A7I%W_;
M(\3>+/@WH7C3^P? OQ.\<:'X@Q_PC_B+Q8=#_P"$H'A; _YE@\<U\4_LB?L4
M?%/X#ZO_ ,$_]4\8ZKX!U(_LK?!3]L;X?^/+OP]?:SJ.I7_BCXY_$WP'X\\"
M_P#"$(?#62Q\.:)K9\;,&&P*PVMNROOWCS_@H%^QWX#^'/B#XMWOQ^^&_B3P
M/X6\>> _ACXDU;P1XDT;Q+_8/B?QUK?]@Z%_;@^F?%'MX,T#Q.>W/?C]ISX.
M:;:_%'Q'XJ^('@#PE\/_ (8W?PO^V?$'5OB3X-_X1G7A\5O!>@>// Q'/_"3
MZ!_PEAUT?\(1X7\6#'C4'_B@NU>A_L?+&,F_LKFE**Z6MOJ^WGL8_P"UIMI/
M6_1[,_.KX%_L3?M9_LN6G[//C?X9+^SS\1_B7X#_ &??CQ^S'X[\%?$#QAXQ
M\-^!+#PM\5OVF?$/QW\#>,_!'C;P_P##;Q<6;PJ=<C\+>-OA@/"7@T>,41A_
MPFLFY-GZG> S\5(=8\4:5X_T/X6Z=X/TK1_ 5E\-]5^'MYK(U/7M4_X0S_BO
M/[<\#^(,_P#"O_#H\1_\B/\ \(GXP\8_\46,9].'\2_M:?LK^#_"7@_Q_P"*
MOVC/@GX;\$>/-'U36O ?BS5OB1HVF^&?%NEZ%_Q(=>UK0]=X_P"$@/A,9_X3
M;//L!G&QH'QLT/6/CIX@^!XL?](M?@GX#^.O@3Q9::QHNI>&?B7X#UW6M?\
M >N_V'_V*?B/0]#/<X\?>&#TSAT*&$P_^ZRU=WK);MZVNVKWO?2_I>Y.(CBL
M3;W4DMY*.Z6U]%?3\-^EO:****[#B"N7\>_\B)XY_P"Q#\4?^F/7ZZBN7\>_
M\B)XY_[$/Q1_Z8]?K>7PR_PO\F8+=>J_,^U?V%/^3+OV5/\ LW;X,_\ JO\
M0*^M_P#EI_G^[7R1^PI_R9=^RI_V;M\&?_5?Z!7UO_RT_P _W:_ \P_Y&F9_
M]?Z__IZH?M66?\BO+O\ #'\D?%__  4&_P"3*?VGO^R-^.?_ $SW%?+>@?\
M("\/_P#8MZ7_ .F0U]2?\%!O^3*?VGO^R-^.?_3/<5\MZ!_R O#_ /V+>E_^
MF0U^D\#_ /(HG_V/8_\ IMGPG&O_ ",J?^!_^DHT****^ME\4O\ %+\V?+A1
M7C_Q@^,-C\)8OA?!_8=SXD\0?%KXP> _@OX/\/6EY_9OV_5/'7]OZ[KNM?\
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MX=\7?#+_ (7(->UKP4%\3^*^!X-_X20> @%W5POPH_9%_:0^$/PZ_97UR_\
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MO^))S\+_ /BCA_PF9/CG&!S^Q5%<W]F8=_%&3UNM)/\ 3<G^TL3WC]Z/R_\
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M &/?VM/B-\5_BYXQE^#OPN\)3>)/@Q_P4D^$ZW?P]_X4'X(\,^+%_:-\%?\
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M?373Y'Y5?\,1?M5_]'H^$_\ Q%#P_P#_ #SJ/^&(OVJ_^CT?"?\ XBAX?_\
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MA/\ \10\/_\ SSJ_53 ]1^O_ ,3]?\CDP/7^?M_L_7]/3E_ZW\1_]!-3_P
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MO_H]'PG_ .(H>'__ )YU?JI@>H_7_P")^O\ D<F!Z_S]O]GZ_IZ<G^MW$?\
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M_P#Q%#P__P#/.K]5,#U'Z_\ Q/U_R.3 ]1^O_P 3]?\ (Y7^MW$?_055_P#
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MZ,+Z_P _;V^OZ>]'^MW$?_054_\  :/_ ,K'_JKD/_/M_P#@<O\ ,_(CQ?\
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M48_X;1\)\<?\FH>'^W'_ $4ZC_AB+]JO_H]'PG_XBAX?_P#GG5^JF!ZC]?\
MXGZ_Y')@>H_7_P")^O\ D<^__K=Q'_T%5?\ P&C_ /*SQ/\ 5;(?^?;_ / Y
M?YGY5_\ #$7[5?\ T>CX3_\ $4/#_P#\\ZC_ (8B_:K_ .CT?"?_ (BAX?\
M_GG5^JF!ZC]?_B?K_D<F!ZC]?_B?K_D<G^MW$?\ T%5?_ :/_P K#_5;(?\
MGV__  .7^9^5?_#$7[5?_1Z/A/\ \10\/_\ SSJ/^&(OVJ_^CT?"?_B*'A__
M .>=7ZJ8'J/U_P#B?K_D<F!ZC]?_ (GZ_P"1R?ZW<1_]!57_ ,!H_P#RL?\
MJOD/\C_\&3_S/RK_ .&(OVJ_^CT?"?\ XBAX?_\ GG4?\,1?M5_]'H^$_P#Q
M%#P__P#/.K]5,#U'Z_\ Q/U_R.3 ]1^O_P 3]?\ (Y/];N(_^@JK_P" T?\
MY6'^J^0_R/\ \&3_ ,S\J_\ AB+]JO\ Z/1\)_\ B*'A_P#^>=1_PQ%^U7_T
M>CX3_P#$4/#_ /\ /.K]5,#U'Z__ !/U_P CDP/4?K_\3]?\CD_UNXC_ .@J
MK_X#1_\ E8O]5LA_Y]O_ ,#E_F?E7_PQ%^U7_P!'H^$__$4/#_\ \\ZC_AB+
M]JO_ */1\)_^(H>'_P#YYU?JI@>H_7_XGZ_Y')@>H_7_ .)^O^1R?ZW<1_\
M055_\!H__*Q_ZKY#_(__  9/_,_*O_AB+]JO_H]'PG_XBAX?_P#GG4?\,1?M
M5_\ 1Z/A/_Q%#P__ //.K]5,#U'Z_P#Q/U_R.3 ]1^O_ ,3]?\CD_P!;N(_^
M@JK_ . T?_E8?ZKY#_(__!D_\S\J_P#AB+]JO_H]'PG_ .(H>'__ )YU'_#$
M7[5?_1Z/A/\ \10\/_\ SSJ_53 ]1^O_ ,3]?\CDP/4?K_\ $_7_ ".3_6[B
M/_H*J_\ @-'_ .5A_JOD/\C_ /!D_P#,_*O_ (8B_:K_ .CT?"?_ (BAX?\
M_GG4?\,1?M5_]'H^$_\ Q%#P_P#_ #SJ_53 ]1^O_P 3]?\ (Y,#U'Z__$_7
M_(Y/];N(_P#H*J_^ T?_ )6'^J^0_P C_P#!D_\ ,_*O_AB+]JO_ */1\)_^
M(H>'_P#YYU'_  Q%^U7_ -'H^$__ !%#P_\ _/.K]5,#U'Z__$_7_(Y,#U_G
M[?[/U_3TY/\ 6[B/_H*J_P#@-'_Y6'^J^0_R/_P9/_,_*O\ X8B_:K_Z/1\)
M_P#B*'A__P">=1_PQ%^U7_T>CX3_ /$4/#__ ,\ZOU4POK_/V]OK^GO1A?7^
M?M[?7]/>C_6[B/\ Z"JG_@-'_P"5A_JMD/\ S[?_ ('+_,_*G_AB/]JW_H\[
MPK_XB?H ]?\ JIWL>/\ $5R/Q!_X)U?M$_%+P7XJ^'7C#]L3PY=>%?%^CG1-
M8M[/]EW0=/U!M-/6,:PGQ*:0MQ]TQKVVD'-?L+[EC]?F_P /3=_G-+CU8^_)
M_'M[-^E/_6_B'_H*G=/32DG\K4T[:]UT['/_ *G9"^;]W>^_O3U];O\ .^A)
M102!U('UI,CU'YU\W==U]Z/K+"T44477=?>A679?<@HHHHNNZ^]!9=E]R"BB
MBCFC_,OO7^8679?<@HHHHNNZ^]!9=E]R"OQ;T;_@F]\2- _9._:-^&WB/Q%^
MSY\<_C]^UW^T;X[_ &B/VD-<^.GPS\;^*/@AX\;Q!K:)X%^&Y\-Z!\1O"WC#
M0?#GPH^'GAWX6^&?!30^,#'&_@2<R0Q1>)W,'[25\M?M9_M!?"3]FWX!_$+X
MI_&[XG^$OA-X+MM'O]"7QCXUOCIWAS3_ !-K^GSZ'H.D2:IM^62YU[8%(7>T
MFY?DVD@NNZ^\++LON/RQ\/\ _!'%HOV:/V:OV<?B!\9/"OBZV_9V^&'Q+T.P
M^*L/P;TM_B@_CC7];UO6O@=X0T76?$NO>)_%'A_]EO\ 9U\1ZZ?$O@_X3)XR
MFG\9-\/?A9;^./&LGA#PQXMLO&WZ!_L ?LW?%S]EG]GNQ^%7QH^->K?'#QS'
MXS\:>)8]?N=:^(NKZ=X<T;7-6>YT7P;X?UWXN>+/&WQ,UGPSX:1F2"3Q=XL\
M27;3ZE(=[V_D,WRO_P $(?VE/AO^T1_P3&_93L_"7Q@T7XL?$+X3? WX7>"/
MC4MKXD;Q)XD\(?$C_A$XFN=!\::M(\DO_"0^4I\P.7E 4;G? K]F*+KNOO7^
M8679?<@HHHHNNZ^]!9=E]R"BBBBZ[K[T%EV7W(****+KNOO0679?<@HHHHNN
MZ^]!9=E]R"BBBCFC_-'[U_F,****8!1110 4444"LNR^Y!1110%EV7W(****
M LNR^Y!1110%EV7W(**** LNR^Y!1110%EV7W(**** LNR^Y!1110%EV7W(*
M*** LNR^Y!1110%EV7W(**** LNR^Y!1110,**** "BBB@5EV7W(**** LNR
M^Y!1110%EV7W(**** LNR^Y!1110%EV7W(**** LNR^Y!1110%EV7W(****
MLNR^Y!1110%EV7W(**** LNR^Y!1110%EV7W(****!GY-^%/^"H$/CSPSHGC
M'P?^Q_\ M/\ B7PIXELQJ&C:_:67PB%A?:?R X?_ (6CPI&X;2I/)PV"0>C_
M .'BGB0=/V)?VK1]=-^$!_G\4CZ\_P!*^+OV(?\ DT?]G_\ [$,_^GOQ!7U5
M7[/B>$.'<-B91^HUFE?:O/\ %MZ>>WD?C6&XHS[$X9/Z]&+[\B5^]G9'3_\
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M6VW\%6=KW[)M+7[NHO[8XBZYAH[[Q2Z7ZI=/OVWT/J__ (>*^)/^C)?VK?\
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M6_W6/5_^'BGB/_HR;]J__P %_P '_P#YZ%'_  \4\1_]&3?M7_\ @O\ @_\
M_/0KF**K_5GA_P#Z ,1_X.J$_P"L.??]!]+_ , 1T_\ P\4\1_\ 1DW[5_\
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Y[?V(?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4/CQX6^(/PK\/>$[/1M-\,G2_P#A2_@'0?'6M?\ "#^'O^1?_P"*CT/7"?\
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M^$M+T+_D.ZUKFAY_X2?P_P#\(G_A7E_C#]L#X'Z;\)?C1\6_AEXX\$_'ZV^
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MYQ7W11750R^AAKN\[Z]6U?IU9SXC,%B5LETNE_DD%%%%=5GV?W,Y KE_'O\
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MBWT7:U]^WS_(P?AAX/G^'OPO^%_PYOK_ /M+4/ ?PW\!^#+R[_Y_]4\"^"]
MT'C///\ 8?H/S.:[BL7_ (9^_P""A'_/E^QK_P"%G\=/_G?T?\,_?\%"/^?+
M]C7_ ,+/XZ?_ #OZZ5G>11LEFMDK:<E3I_W"//\ [,SAZ_V;OOK_ ,$VJ*Q?
M^&?O^"A'_/E^QK_X6?QT_P#G?T?\,_?\%"/^?+]C7_PL_CI_\[^NK_6+(O\
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635033222632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This Post-Effective Amendment No. 2 (this &#8220;Amendment&#8221;) to the Registration Statement on Form S-1, as amended (SEC File No. 333-255112) (the &#8220;Original Registration Statement&#8221;), of ABVC BioPharma, Inc. (the &#8220;Company&#8221;) is being filed pursuant to the undertakings in the Original Registration Statement to update and supplement the information contained in the Original Registration Statement, which was originally declared effective by the Securities and Exchange Commission on August 2, 2021.The Original Registration Statement, as amended by this Amendment, pertains solely to the registration of 2,255,000 shares (the &#8220;Warrant Shares&#8221;) of common stock, par value $0.001 per share, underlying warrants (the &#8220;Offering Warrants&#8221;) previously issued by the Company to the investors and Representative. The Warrant Shares were initially registered on the Original Registration Statement.For the convenience of the reader, this Amendment
sets forth the Original Registration Statement in its entirety, as amended by this Amendment. This Amendment is being filed to incorporate
certain information from the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March
31, 2022 and the registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, which was filed with the SEC on
May 16, 2022, and to update certain other information in the Registration Statement.No additional securities are being registered under this Post-Effective Amendment No. 1. All applicable registration fees were previously paid.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027669592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,717,936<span></span>
</td>
<td class="nump">$ 5,828,548<span></span>
</td>
<td class="nump">$ 4,273,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">714,652<span></span>
</td>
<td class="nump">736,667<span></span>
</td>
<td class="nump">728,163<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">281,197<span></span>
</td>
<td class="nump">280,692<span></span>
</td>
<td class="nump">159,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable &#8211; related parties, net</a></td>
<td class="nump">145,399<span></span>
</td>
<td class="nump">145,399<span></span>
</td>
<td class="nump">143,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedPartiesCurrent', window );">Due from related parties</a></td>
<td class="nump">2,715,375<span></span>
</td>
<td class="nump">1,286,618<span></span>
</td>
<td class="nump">696,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">22,700<span></span>
</td>
<td class="nump">25,975<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term Investment</a></td>
<td class="nump">95,553<span></span>
</td>
<td class="nump">108,147<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PrepaymentForLongtermInvestments', window );">Prepayment for long-term investments</a></td>
<td class="nump">663,798<span></span>
</td>
<td class="nump">684,720<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expense and other current assets</a></td>
<td class="nump">631,321<span></span>
</td>
<td class="nump">528,354<span></span>
</td>
<td class="nump">172,193<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">7,987,931<span></span>
</td>
<td class="nump">9,625,120<span></span>
</td>
<td class="nump">6,172,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">598,648<span></span>
</td>
<td class="nump">525,881<span></span>
</td>
<td class="nump">514,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,382,695<span></span>
</td>
<td class="nump">1,471,899<span></span>
</td>
<td class="nump">1,772,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">904,254<span></span>
</td>
<td class="nump">932,755<span></span>
</td>
<td class="nump">1,190,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">1,036,830<span></span>
</td>
<td class="nump">981,912<span></span>
</td>
<td class="nump">1,790,597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expenses &#8211; noncurrent</a></td>
<td class="nump">115,664<span></span>
</td>
<td class="nump">119,309<span></span>
</td>
<td class="nump">119,315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">40,733<span></span>
</td>
<td class="nump">41,157<span></span>
</td>
<td class="nump">45,519<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">12,066,755<span></span>
</td>
<td class="nump">13,698,033<span></span>
</td>
<td class="nump">11,606,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term bank loans</a></td>
<td class="nump">1,609,750<span></span>
</td>
<td class="nump">1,640,000<span></span>
</td>
<td class="nump">1,629,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableToBankCurrent', window );">Notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">106,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,247,558<span></span>
</td>
<td class="nump">1,300,803<span></span>
</td>
<td class="nump">2,118,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AdvanceFromCustomers', window );">Advance from customers</a></td>
<td class="nump">10,985<span></span>
</td>
<td class="nump">10,985<span></span>
</td>
<td class="nump">12,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current portion</a></td>
<td class="nump">349,008<span></span>
</td>
<td class="nump">347,100<span></span>
</td>
<td class="nump">316,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">446,397<span></span>
</td>
<td class="nump">393,424<span></span>
</td>
<td class="nump">288,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayableCurrent', window );">Convertible notes payable &#8211; related parties, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">3,663,698<span></span>
</td>
<td class="nump">3,692,312<span></span>
</td>
<td class="nump">4,844,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Paycheck Protection Program Loan Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">124,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Tenant security deposit</a></td>
<td class="nump">7,980<span></span>
</td>
<td class="nump">10,580<span></span>
</td>
<td class="nump">19,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability &#8211; noncurrent portion</a></td>
<td class="nump">1,033,686<span></span>
</td>
<td class="nump">1,124,799<span></span>
</td>
<td class="nump">1,456,567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes payable &#8211; noncurrent portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">4,705,364<span></span>
</td>
<td class="nump">4,827,691<span></span>
</td>
<td class="nump">8,944,638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 100,000,000 authorized, 30,307,329 and 28,926,322 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">30,307<span></span>
</td>
<td class="nump">28,926<span></span>
</td>
<td class="nump">24,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">62,578,549<span></span>
</td>
<td class="nump">58,113,667<span></span>
</td>
<td class="nump">40,751,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Stock subscription receivable</a></td>
<td class="num">(2,031,660)<span></span>
</td>
<td class="num">(2,257,400)<span></span>
</td>
<td class="num">(3,160,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(44,476,640)<span></span>
</td>
<td class="num">(38,481,200)<span></span>
</td>
<td class="num">(25,642,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">426,321<span></span>
</td>
<td class="nump">539,660<span></span>
</td>
<td class="nump">564,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="num">(9,100,000)<span></span>
</td>
<td class="num">(9,100,000)<span></span>
</td>
<td class="num">(9,100,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">7,426,877<span></span>
</td>
<td class="nump">8,843,653<span></span>
</td>
<td class="nump">3,438,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="num">(65,486)<span></span>
</td>
<td class="nump">26,689<span></span>
</td>
<td class="num">(776,273)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Equity</a></td>
<td class="nump">7,361,391<span></span>
</td>
<td class="nump">8,870,342<span></span>
</td>
<td class="nump">2,662,067<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Equity</a></td>
<td class="nump">$ 12,066,755<span></span>
</td>
<td class="nump">$ 13,698,033<span></span>
</td>
<td class="nump">$ 11,606,705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AdvanceFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance from customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AdvanceFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PrepaymentForLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment for long-term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PrepaymentForLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOtherRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromOtherRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1),20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028900008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">30,307,329<span></span>
</td>
<td class="nump">28,926,322<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">30,307,329<span></span>
</td>
<td class="nump">28,926,322<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635025152104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 25,660<span></span>
</td>
<td class="nump">$ 263,150<span></span>
</td>
<td class="nump">$ 355,797<span></span>
</td>
<td class="nump">$ 483,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenues</a></td>
<td class="nump">1,896<span></span>
</td>
<td class="nump">1,245<span></span>
</td>
<td class="nump">5,086<span></span>
</td>
<td class="nump">18,716<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">23,764<span></span>
</td>
<td class="nump">261,905<span></span>
</td>
<td class="nump">350,711<span></span>
</td>
<td class="nump">464,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">1,191,078<span></span>
</td>
<td class="nump">1,167,595<span></span>
</td>
<td class="nump">5,746,119<span></span>
</td>
<td class="nump">4,273,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">359,404<span></span>
</td>
<td class="nump">121,315<span></span>
</td>
<td class="nump">1,003,805<span></span>
</td>
<td class="nump">549,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,692,003<span></span>
</td>
<td class="nump">225,740<span></span>
</td>
<td class="nump">5,306,755<span></span>
</td>
<td class="nump">4,146,979<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,242,485<span></span>
</td>
<td class="nump">1,514,650<span></span>
</td>
<td class="nump">12,056,679<span></span>
</td>
<td class="nump">8,970,105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,218,721)<span></span>
</td>
<td class="num">(1,252,745)<span></span>
</td>
<td class="num">(11,705,968)<span></span>
</td>
<td class="num">(8,505,776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(961,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Investment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(40,589)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_InterestIncomes', window );">Interest income</a></td>
<td class="nump">40,175<span></span>
</td>
<td class="nump">52,529<span></span>
</td>
<td class="nump">43,196<span></span>
</td>
<td class="nump">71,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(18,213)<span></span>
</td>
<td class="num">(130,229)<span></span>
</td>
<td class="num">(227,210)<span></span>
</td>
<td class="num">(405,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RentIncome', window );">Operating sublease income</a></td>
<td class="nump">24,124<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
<td class="nump">134,576<span></span>
</td>
<td class="nump">20,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingSubleaseIncomeRelatedParties', window );">Operating sublease income &#8211; related parties</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_GainLossOnForeignExchangeChanges', window );">Gain/Loss on foreign exchange changes</a></td>
<td class="nump">7,563<span></span>
</td>
<td class="nump">951<span></span>
</td>
<td class="nump">426,316<span></span>
</td>
<td class="num">(3,275)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Gain/Loss on investment in equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(47,791)<span></span>
</td>
<td class="num">(269,844)<span></span>
</td>
<td class="num">(1,168,733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(9,410)<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="nump">22,409<span></span>
</td>
<td class="nump">174,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Government grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">124,400<span></span>
</td>
<td class="nump">360,898<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Total other income</a></td>
<td class="nump">44,239<span></span>
</td>
<td class="nump">6,398<span></span>
</td>
<td class="nump">495,141<span></span>
</td>
<td class="num">(2,308,160)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision income tax</a></td>
<td class="num">(6,174,482)<span></span>
</td>
<td class="num">(1,246,347)<span></span>
</td>
<td class="num">(11,210,827)<span></span>
</td>
<td class="num">(10,813,936)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income tax</a></td>
<td class="num">(86,867)<span></span>
</td>
<td class="num">(51,024)<span></span>
</td>
<td class="nump">825,024<span></span>
</td>
<td class="num">(220,352)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(6,087,615)<span></span>
</td>
<td class="num">(1,195,323)<span></span>
</td>
<td class="num">(12,035,851)<span></span>
</td>
<td class="num">(10,593,584)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Net loss attributable to noncontrolling interests</a></td>
<td class="num">(92,175)<span></span>
</td>
<td class="num">(66,818)<span></span>
</td>
<td class="nump">802,962<span></span>
</td>
<td class="num">(802,420)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NetLossAttributableToAbvcAndSubsidiaries', window );">Net loss attributed to ABVC and subsidiaries</a></td>
<td class="num">(5,995,440)<span></span>
</td>
<td class="num">(1,128,505)<span></span>
</td>
<td class="num">(12,838,813)<span></span>
</td>
<td class="num">(9,791,164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(113,339)<span></span>
</td>
<td class="nump">36,140<span></span>
</td>
<td class="num">(25,200)<span></span>
</td>
<td class="num">(98,893)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (6,108,779)<span></span>
</td>
<td class="num">$ (1,092,365)<span></span>
</td>
<td class="num">$ (12,864,013)<span></span>
</td>
<td class="num">$ (9,890,057)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic and diluted (in Shares)</a></td>
<td class="nump">29,683,402<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
<td class="nump">25,053,522<span></span>
</td>
<td class="nump">19,715,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_GainLossOnForeignExchangeChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_GainLossOnForeignExchangeChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_InterestIncomes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_InterestIncomes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NetLossAttributableToAbvcAndSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss attributable to ABVC and subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NetLossAttributableToAbvcAndSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingSubleaseIncomeRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating sublease income  from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingSubleaseIncomeRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026740600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,087,615)<span></span>
</td>
<td class="num">$ (1,195,323)<span></span>
</td>
<td class="num">$ (12,035,851)<span></span>
</td>
<td class="num">$ (10,593,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">5,411<span></span>
</td>
<td class="nump">2,928<span></span>
</td>
<td class="nump">11,993<span></span>
</td>
<td class="nump">37,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation for non employees</a></td>
<td class="nump">4,692,003<span></span>
</td>
<td class="nump">225,740<span></span>
</td>
<td class="nump">5,306,755<span></span>
</td>
<td class="nump">4,146,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Gain/Loss on investment in equity securities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">47,791<span></span>
</td>
<td class="nump">269,844<span></span>
</td>
<td class="nump">1,168,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_GovernmentGrantIncome', window );">Government grant income</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(124,400)<span></span>
</td>
<td class="num">(360,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income and expenses</a></td>
<td class="nump">9,503<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,360)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_InvestmentLoss1', window );">Investment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,001,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax</a></td>
<td class="num">(86,867)<span></span>
</td>
<td class="num">(51,024)<span></span>
</td>
<td class="nump">824,199<span></span>
</td>
<td class="num">(223,201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable</a></td>
<td class="num">(505)<span></span>
</td>
<td class="num">(238,484)<span></span>
</td>
<td class="num">(120,980)<span></span>
</td>
<td class="nump">3,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Decrease (increase) in prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(357,276)<span></span>
</td>
<td class="num">(15,778)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets', window );">Decrease (increase) in prepaid expenses and deposits</a></td>
<td class="num">(113,292)<span></span>
</td>
<td class="num">(187,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties', window );">Decrease (increase) in due from related parties</a></td>
<td class="num">(1,434,353)<span></span>
</td>
<td class="num">(18,229)<span></span>
</td>
<td class="num">(595,037)<span></span>
</td>
<td class="nump">20,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase (decrease) in inventory</a></td>
<td class="nump">2,537<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(25,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase (decrease) in accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(12,710)<span></span>
</td>
<td class="num">(23,044)<span></span>
</td>
<td class="num">(951)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Increase (decrease) in accrued expenses and other current liabilities</a></td>
<td class="num">(38,378)<span></span>
</td>
<td class="nump">136,519<span></span>
</td>
<td class="num">(173,151)<span></span>
</td>
<td class="num">(359,822)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Increase (decrease) in advanced from others</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,085)<span></span>
</td>
<td class="num">(1,015)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Increase (decrease) in due to related parties</a></td>
<td class="nump">57,299<span></span>
</td>
<td class="nump">1,841<span></span>
</td>
<td class="num">(317,358)<span></span>
</td>
<td class="nump">266,791<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(2,994,257)<span></span>
</td>
<td class="num">(1,413,074)<span></span>
</td>
<td class="num">(7,597,719)<span></span>
</td>
<td class="num">(4,563,919)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInvestmentProjects', window );">Net proceeds from sale of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchase of investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of equipment</a></td>
<td class="num">(93,220)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(17,503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Loan to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(373,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Prepayment for equity investment</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(281,952)<span></span>
</td>
<td class="num">(680,916)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(93,220)<span></span>
</td>
<td class="num">(281,952)<span></span>
</td>
<td class="num">(805,966)<span></span>
</td>
<td class="num">(225,431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">40,448<span></span>
</td>
<td class="nump">11,119,452<span></span>
</td>
<td class="nump">7,615,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment for offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(850,429)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(250,000)<span></span>
</td>
<td class="num">(306,836)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfSubordinatedShortTermDebt', window );">Repayment of short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherShortTermDebt', window );">Repayment of short-term bank loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromBankDebt', window );">Proceeds from short-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from long-term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,498<span></span>
</td>
<td class="nump">124,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherShortTermDebt', window );">Proceeds from (repayments of) short term borrowings from third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,265<span></span>
</td>
<td class="num">(480,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from borrowings from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,704<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term bank loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,603)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term loans</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">236,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BorrowingsFromRelatedParties', window );">Borrowings from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Net proceeds from short-term borrowing from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,226<span></span>
</td>
<td class="nump">9,995,550<span></span>
</td>
<td class="nump">9,567,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents and restricted cash</a></td>
<td class="num">(45,150)<span></span>
</td>
<td class="num">(15,335)<span></span>
</td>
<td class="num">(28,021)<span></span>
</td>
<td class="nump">62,435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="num">(3,132,627)<span></span>
</td>
<td class="num">(1,668,135)<span></span>
</td>
<td class="nump">1,563,844<span></span>
</td>
<td class="nump">4,840,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Beginning</a></td>
<td class="nump">6,565,215<span></span>
</td>
<td class="nump">5,001,371<span></span>
</td>
<td class="nump">5,001,371<span></span>
</td>
<td class="nump">160,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Ending</a></td>
<td class="nump">3,432,588<span></span>
</td>
<td class="nump">3,333,236<span></span>
</td>
<td class="nump">6,565,215<span></span>
</td>
<td class="nump">5,001,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest expense paid</a></td>
<td class="nump">43,842<span></span>
</td>
<td class="nump">21,666<span></span>
</td>
<td class="nump">333,873<span></span>
</td>
<td class="nump">208,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes paid</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash financing and investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Common shares issued for debt conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,693,548<span></span>
</td>
<td class="nump">$ 1,717,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BorrowingsFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BorrowingsFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_GovernmentGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of government grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_GovernmentGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_InvestmentLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_InvestmentLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseDueFromOtherRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables due from related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseDueFromOtherRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables, and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromBankDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from bank borrowing during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromBankDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from short-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInvestmentProjects">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfInvestmentProjects</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSubordinatedShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSubordinatedShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027516024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity (Deficit) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Stock Subscription Receivable</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non controlling Interest</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 19,478<span></span>
</td>
<td class="num">$ (4,063,320)<span></span>
</td>
<td class="nump">$ 28,180,348<span></span>
</td>
<td class="num">$ (15,851,223)<span></span>
</td>
<td class="nump">$ 663,753<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="nump">$ 26,147<span></span>
</td>
<td class="num">$ (124,817)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">19,478,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution', window );">Capital contribution</a></td>
<td class="nump">$ 3,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,611,946<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,615,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution', window );">Capital contribution (in Shares)</a></td>
<td class="nump">3,384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation for options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,706,419<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,706,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices', window );">Stock based compensation for services</a></td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">902,960<span></span>
</td>
<td class="nump">1,536,958<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,440,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares', window );">Stock based compensation for services (in Shares)</a></td>
<td class="nump">641,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Debt conversion</a></td>
<td class="nump">$ 915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,716,136<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,717,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Debt conversion (in Shares)</a></td>
<td class="nump">915,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(9,791,164)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(802,420)<span></span>
</td>
<td class="num">(10,593,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CumulativeTransactionAdjustments', window );">Cumulative transaction adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(98,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(98,893)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 24,420<span></span>
</td>
<td class="num">(3,160,360)<span></span>
</td>
<td class="nump">40,751,807<span></span>
</td>
<td class="num">(25,642,387)<span></span>
</td>
<td class="nump">564,860<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="num">(776,273)<span></span>
</td>
<td class="nump">2,662,067<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,740<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">225,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,128,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,818)<span></span>
</td>
<td class="num">(1,195,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CumulativeTransactionAdjustments', window );">Cumulative transaction adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,140<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">36,140<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 24,420<span></span>
</td>
<td class="num">(2,934,620)<span></span>
</td>
<td class="nump">40,751,807<span></span>
</td>
<td class="num">(26,770,892)<span></span>
</td>
<td class="nump">601,000<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="num">(843,091)<span></span>
</td>
<td class="nump">1,728,624<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 24,420<span></span>
</td>
<td class="num">(3,160,360)<span></span>
</td>
<td class="nump">40,751,807<span></span>
</td>
<td class="num">(25,642,387)<span></span>
</td>
<td class="nump">564,860<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="num">(776,273)<span></span>
</td>
<td class="nump">2,662,067<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">24,420,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common shares for cash</a></td>
<td class="nump">$ 3,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,265,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,269,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares for cash (in Shares)</a></td>
<td class="nump">3,027,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Issuance of common shares for debt conversion</a></td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,692,437<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,693,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Issuance of common shares for debt conversion (in Shares)</a></td>
<td class="nump">1,111,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common shares for consulting service</a></td>
<td class="nump">$ 367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,728,223<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,728,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common shares for consulting service (in Shares)</a></td>
<td class="nump">366,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock based compensation for options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,675,205<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,675,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices', window );">Stock based compensation for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">902,960<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">902,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,838,813)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">802,962<span></span>
</td>
<td class="num">(12,035,851)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CumulativeTransactionAdjustments', window );">Cumulative transaction adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,200)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 28,926<span></span>
</td>
<td class="num">(2,257,400)<span></span>
</td>
<td class="nump">58,113,667<span></span>
</td>
<td class="num">(38,481,200)<span></span>
</td>
<td class="nump">539,660<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="nump">26,689<span></span>
</td>
<td class="nump">8,870,342<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">28,926,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common shares for consulting service</a></td>
<td class="nump">$ 1,381<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,464,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,466,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common shares for consulting service (in Shares)</a></td>
<td class="nump">1,381,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss for the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,995,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92,175)<span></span>
</td>
<td class="num">(6,087,615)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CumulativeTransactionAdjustments', window );">Cumulative transaction adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,339)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 30,307<span></span>
</td>
<td class="num">$ (2,031,660)<span></span>
</td>
<td class="nump">$ 62,578,549<span></span>
</td>
<td class="num">$ (44,476,640)<span></span>
</td>
<td class="nump">$ 426,321<span></span>
</td>
<td class="num">$ (9,100,000)<span></span>
</td>
<td class="num">$ (65,486)<span></span>
</td>
<td class="nump">$ 7,361,391<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="nump">30,307,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(275,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares of adjustments to additional paid in capital shares capital contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CumulativeTransactionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CumulativeTransactionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment services arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635029677352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ABVC BioPharma, Inc. (the &#8220;Company&#8221;),
formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#8217;s operating entity, American
BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology
to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. &#160;BriVision develops
its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision
believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization,
BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly
respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical
trials for the Company&#8217;s drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering
Cancer Center (&#8220;MSKCC&#8221;) and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July
21, 2015.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Name Change</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s shareholders approved an amendment
to the Company&#8217;s Articles of Incorporation to change the Company&#8217;s corporate name from American BriVision (Holding) Corporation
to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders
(the &#8220;Annual Meeting&#8221;). The name change amendment to the Company&#8217;s Articles of Incorporation was filed with Nevada&#8217;s
Secretary of State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became
effective as of May 3, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s stock symbol remains ABVC.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Reverse Merger</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2016, a Share Exchange Agreement
(the &#8220;Share Exchange Agreement&#8221;) was entered into by and among the Company, BriVision, and Euro-Asia Investment &amp; Finance
Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&#8217;s Republic of China
(&#8220;Euro-Asia&#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company,
and the owners of record of all of the issued share capital of BriVision (the &#8220;BriVision Stock&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Share Exchange Agreement, upon
surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered
in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision
as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision
Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the &#8220;Acquisition Stock&#8221;)
(subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s Common Stock to the BriVision Shareholders
(or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s Common Stock owned by Euro-Asia were
cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of
the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision
in a reverse merger (the &#8220;Merger&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Merger, all of the issued and
outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583
pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company&#8217;s
Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&#8217;s
Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the &#8220;Share Exchange&#8221;), BriVision had
become a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following
the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of the Share Exchange, BriVision
became a wholly owned subsidiary of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following the Share Exchange, the Company has
abandoned prior business plan and is now pursuing BriVision&#8217;s historically proposed businesses, which focus on the development of
new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements
from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&#8220;POC&#8221;), out-license
to international pharmaceutical companies, and explore global markets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounting Treatment of the Reverse Merger</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For financial reporting purposes, the Share Exchange
represents a &#8220;reverse merger&#8221;&#160;rather than a business combination and&#160;BriVision&#160;is deemed the accounting acquirer
in the transaction. The&#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#160;is the acquirer
for financial reporting purposes and the&#160;Company&#160;is the acquired company. Consequently, the assets and liabilities and the operations
reflected in the historical financial statements prior to the Share Exchange will be those of&#160;BriVision&#160;and recorded at the
historical cost basis of&#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will
include the assets and liabilities of the Company and BriVision, and the historical operations of&#160;BriVision&#160;and operations of
the Combined Company from the closing date of the Share Exchange.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Merger</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company, BioLite Holding,
Inc. (&#8220;BioLite&#8221;), BioKey, Inc. (&#8220;BioKey&#8221;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent
(&#8220;Merger Sub 1&#8221;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#8220;Merger Sub 2&#8221;) (collectively
referred to as the &#8220;Parties&#8221;) completed the business combination pursuant to the Agreement and Plan of Merger (the &#8220;Merger
Agreement&#8221;) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the
shareholders of BioLite and BioKey.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Merger Agreement,
BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares
(prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file
number 333-226285), which became effective by operation of law on or about February 5, 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite Holding, Inc. (the &#8220;BioLite Holding&#8221;)
was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the &#8220;BioLite BVI&#8221;), a wholly owned
subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are
holding companies and have not carried out substantive business operations of their own.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioLite, Inc., (the &#8220;BioLite Taiwan&#8221;)
was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new
botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite
Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2017, BioLite Holding, BioLite BVI,
BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &#8220;BioLite Share
Purchase / Exchange Agreement&#8221;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the
BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase
shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock
as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately
owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement
retain their equity ownership in BioLite Taiwan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BioKey, Inc. was incorporated on August 9, 2000
in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation
development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials
(Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development
processes with other biotechnology, pharmaceutical, and nutraceutical companies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounting Treatment of the Merger</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted ASC 805, &#8220;Business Combination&#8221;
to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang&#8217;s
common control, the transaction is accounted for as a restructuring transaction.&#160;All the assets and liabilities of BioLite Holding,
BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger.
The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding&#8217;s common shares as if the
restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions,
and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity
transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the
earnings (or losses) of the transferred net assets.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABVC BioPharma, Inc. (the &#8220;Company&#8221;), formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#8217;s operating entity, American BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical trials for the Company&#8217;s drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;) and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July 21, 2015.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Name Change</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s shareholders approved an amendment to the Company&#8217;s Articles of Incorporation to change the Company&#8217;s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &#8220;Annual Meeting&#8221;). The name change amendment to the Company&#8217;s Articles of Incorporation was filed with Nevada&#8217;s Secretary of State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became effective as of May 3, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s stock symbol remains ABVC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Reverse Merger</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2016, a Share Exchange Agreement (the &#8220;Share Exchange Agreement&#8221;) was entered into by and among the Company, BriVision, and Euro-Asia Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&#8217;s Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the &#8220;BriVision Stock&#8221;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the &#8220;Acquisition Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the &#8220;Merger&#8221;).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company&#8217;s Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&#8217;s Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the &#8220;Share Exchange&#8221;), BriVision had become a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the consummation of the Share Exchange, BriVision became a wholly owned subsidiary of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following the Share Exchange, the Company has abandoned prior business plan and is now pursuing BriVision&#8217;s historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&#8220;POC&#8221;), out-license to international pharmaceutical companies, and explore global markets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Accounting Treatment of the Reverse Merger</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For financial reporting purposes, the Share Exchange represents a &#8220;reverse merger&#8221;&#160;rather than a business combination and&#160;BriVision&#160;is deemed the accounting acquirer in the transaction. The&#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#160;is the acquirer for financial reporting purposes and the&#160;Company&#160;is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of&#160;BriVision&#160;and recorded at the historical cost basis of&#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of&#160;BriVision&#160;and operations of the Combined Company from the closing date of the Share Exchange.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Merger</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2019, the Company, BioLite Holding, Inc. (&#8220;BioLite&#8221;), BioKey, Inc. (&#8220;BioKey&#8221;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#8220;Merger Sub 1&#8221;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#8220;Merger Sub 2&#8221;) (collectively referred to as the &#8220;Parties&#8221;) completed the business combination pursuant to the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the shareholders of BioLite and BioKey.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares (prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285), which became effective by operation of law on or about February 5, 2019.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Holding, Inc. (the &#8220;BioLite Holding&#8221;) was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the &#8220;BioLite BVI&#8221;), a wholly owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are holding companies and have not carried out substantive business operations of their own.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite, Inc., (the &#8220;BioLite Taiwan&#8221;) was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2017, BioLite Holding, BioLite BVI, BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &#8220;BioLite Share Purchase / Exchange Agreement&#8221;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioKey, Inc. was incorporated on August 9, 2000 in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development processes with other biotechnology, pharmaceutical, and nutraceutical companies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Accounting Treatment of the Merger</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted ASC 805, &#8220;Business Combination&#8221; to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang&#8217;s common control, the transaction is accounted for as a restructuring transaction.&#160;All the assets and liabilities of BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding&#8217;s common shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the earnings (or losses) of the transferred net assets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032642104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;).
All significant intercompany transactions and account balances have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&#8217;s financial statements are expressed in U.S. dollars.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fiscal Year</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the period
beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January
1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inventory</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Forward Stock Split</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stock Reverse Split</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2019, the Board of Directors of the
Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#8220;Reverse
Split&#8221;) of both the authorized common stock of the Company (the &#8220;Common Stock&#8221;) and the issued and outstanding Common
Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the
Reverse Split without obtaining approval of the Company&#8217;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On
May 3, 2019, the Company filed a certificate of amendment to the Company&#8217;s articles of incorporation (the &#8220;Amendment&#8221;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) informed
the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect
this 1-for-18 reverse stock split.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair Value Measurements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the
assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&#8217;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short.
The carrying value of the Company&#8217;s long-term bank loan approximates fair value because the interest rates approximate market rates
that the Company could obtain for debt with similar terms and maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cash and Cash Equivalents</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2022 and December 31, 2021, the Company&#8217;s
cash and cash equivalents amounted $2,717,936 and $5,828,548, respectively. Some&#160;of the Company&#8217;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Restricted Cash Equivalents</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2022 and December 31, 2021, the Company&#8217;s restricted cash equivalents
amounted $714,652 and $736,667, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#8217;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#8217;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&#8217;s revenue during all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within
the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the
goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the
scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price
that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborative Revenues &#8212; </b>The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees,
development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales
of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed
products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing
activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s judgment.
Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited to,
the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated
duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on
a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) Non-refundable upfront payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and
it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) Milestone payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to receive milestone payments
under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial
events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into
two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration
partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative agreement with
collaboration partners.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded
that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each
triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more
of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional
payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete
each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi)
a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone
payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in
the period in which the underlying triggering event occurs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) Multiple Element Arrangements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s),
delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an
item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which is
typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance or objectively
measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over
the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service
is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue
under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount
of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance
method, as applicable, as of the period ending date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable
relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical,
regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment
required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether
a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive
are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other
revenue recognition criteria are met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iv) Royalties and Profit Sharing Payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is
resolved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues Derived from Research and Development
Activities Services &#8212; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception
of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request
that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset
to research and development expenses as it satisfies the related performance obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and Equipment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated&#160;Life<br/> in Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Buildings and leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">5 ~ 50</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5 ~ 10</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office equipment</td><td>&#160;</td>
    <td style="text-align: center">3 ~ 6</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted Accounting Standards Codification
subtopic 360-10, Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable
intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events
and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring
losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated,
the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and
ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or
the fair value less costs to sell.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Long-term Equity Investment</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company
does not have control over the investees as:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Non-marketable cost method investments when the equity method does not apply.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant judgment is required to identify whether
an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, and therefore the Company considers this
a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact
on the investee&#8217;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term
prospects of the investee, changes in general market conditions in the investee&#8217;s industry or geographic area, and the management
and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market
and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent
financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding
the investees&#8217; revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment
exists could change in the future due to new developments or changes in applied assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Other-Than-Temporary Impairment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#8217;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Non-marketable equity investments based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairment of equity investments were $0 and $0 for the three months ended March 31, 2022 and 2021, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Goodwill</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing
goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that
the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our
best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share,
and general economic conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company completed the required testing of
goodwill for impairment as of March 31, 2022, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For CDMO business unit, the Company accounts for
R&amp;D costs in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, Research and Development (&#8220;ASC 730&#8221;).
Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development
projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities,
including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing
and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable
advance payment for goods and services that will be used in future research and development activities are expensed when the activity
has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into
agreements with third parties to provide research and development services, costs are expensed as services are performed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Post-retirement and post-employment benefits</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#8217;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#8217; salaries to the employees&#8217;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $3,337 and $2,503 for the three months ended March 31, 2022 and 2021, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Stock-based Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221; and FASB ASC Topic 505-50 &#8220;Equity-Based
Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $4,692,003 and $225,740 for the three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Beneficial Conversion Feature</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is&#160;&#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2022 and 2021. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&#8220;SAB 118&#8221;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC
740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is
able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company
cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of
the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable
estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act
may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that
may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine
the final impact.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Loss Per Share of Common Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company calculates net loss per share in accordance
with ASC Topic 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted average
number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that
the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common
stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commitments and Contingencies</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted ASC Topic 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies
are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates
that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount
of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency
is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably
possible that a material loss could be incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Foreign-currency Transactions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the transactions
occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into
New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion
or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange
rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares
of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#8217; Equity (Deficit).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Translation Adjustment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounts of the Company&#8217;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#8220;NT$&#8221;). Such financial statements
were translated into U.S. Dollars (&#8220;$&#8221; or &#8220;USD&#8221;) in accordance ASC 830, &#8220;Foreign Currency Matters&#8221;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&#8217;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#8217;
equity (deficit).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06, Debt
&#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity
(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). ASU
2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models.
Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not
clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will
reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings
per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For
contracts in an entity&#8217;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features
that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements
to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted,
and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted,
but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company
is currently evaluating the impact that the standard will have on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU 2021-04, Earnings
Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic
718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain
Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04 provides guidance
as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written
call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new
instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified
or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model
that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination,
debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for
all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should
apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early
adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an
interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is
currently evaluating the impact that the standard will have on its consolidated financial statements.&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Basis of Presentation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;). All significant intercompany transactions and account balances have been eliminated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Fiscal Year</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Inventory</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Forward Stock Split</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Stock Reverse Split</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#8220;Reverse Split&#8221;) of both the authorized common stock of the Company (the &#8220;Common Stock&#8221;) and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company&#8217;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company&#8217;s articles of incorporation (the &#8220;Amendment&#8221;) to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Fair Value Measurements</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 820, &#8220;Fair Value Measurements&#8221; defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company&#8217;s long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Cash and Cash Equivalents</span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2021 and 2020, the Company&#8217;s cash and cash equivalents amounted $5,828,548 and $4,273,208, respectively. Some&#160;of the Company&#8217;s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Restricted Cash Equivalents</span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of December 31, 2021 and 2020, the Company&#8217;s restricted cash equivalents amounted $736,667 and $728,163, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Revenue Recognition</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fiscal year 2018, the Company adopted Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#8217;s reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#8217;s review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company&#8217;s revenue during all periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative Revenues</b> &#8212; The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Non-refundable upfront payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Milestone payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) Multiple Element Arrangements</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) Royalties and Profit Sharing Payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues Derived from Research and Development Activities Services &#8212; Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Property and Equipment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated&#160;Life<br/> in Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings and leasehold improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 ~ 50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 ~ 10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 ~ 6</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Long-term Equity Investment</span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable cost method investments when the equity method does not apply.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant judgment is required to identify whether an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#8217;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee&#8217;s industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#8217; revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Other-Than-Temporary Impairment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#8217;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable equity investments based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $961,217 for the year ended December 31, 2021 and 2020, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Goodwill</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company completed the required testing of goodwill for impairment as of December 31, 2021, and determined that goodwill was impaired because of the current financial condition of the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Research and Development Expenses</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our CDMO business unit, the Company accounts for R&amp;D costs in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, Research and Development (&#8220;ASC 730&#8221;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Post-retirement and post-employment benefits</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#8217;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#8217; salaries to the employees&#8217; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $11,375 and $13,961 for the year ended December 31, 2021 and 2020, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Stock-based Compensation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;. Total employee stock-based compensation expenses were $2,675,205 and $1,623,102 for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221; and FASB ASC Topic 505-50 &#8220;Equity-Based Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $2,631,550 and $2,523,877 for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Beneficial Conversion Feature</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Income Taxes</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the year ended December 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 22, 2017, the SEC issued Staff Accounting Bulletin (&#8220;SAB 118&#8221;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A valuation allowance is recorded to reduce the Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Loss Per Share of Common Stock</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company calculates net loss per share in accordance with ASC Topic 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Commitments and Contingencies</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted ASC Topic 450 &#8220;Contingencies&#8221; subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Foreign-currency Transactions</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Company&#8217;s subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#8217; Equity (Deficit).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Translation Adjustment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounts of the Company&#8217;s subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#8220;NT$&#8221;). Such financial statements were translated into U.S. Dollars (&#8220;$&#8221; or &#8220;USD&#8221;) in accordance ASC 830, &#8220;Foreign Currency Matters&#8221;, with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder&#8217;s deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#8217; equity (deficit).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For contracts in an entity&#8217;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032650904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CollaborativeAgreementsLineItems', window );"><strong>Collaborative Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATIVE AGREEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>3. COLLABORATIVE AGREEMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Collaborative agreements with BHK</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(i) On February 24, 2015, BioLite Taiwan and BioHopeKing
Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;), pursuant
to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination
Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for
medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The
BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia
excluding Japan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">At the completion of first phase II clinical trial: $1 million, or 10% of total payment</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2015, BHK has paid a non-refundable
upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that
the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and
recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015.
The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement
was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August
2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized collaboration
revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical
trial.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on 12% of BHK&#8217;s net sales related to BLI-1401-2 Products. As of March 31, 2022 and December
31, 2021, the Company has not earned the royalty under the BHK Co-Development Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#8220;BHK Collaborative Agreements&#8221;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#8220;Targeting Major Depressive Disorder&#8221; (BLI-1005 Products) and BLI-1006 for
&#8220;Targeting Inflammatory Bowel Disease&#8221; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights,
and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between
BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of
the Product in in Asia excluding Japan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2015, the Company recognized the cash receipt
in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the total of NT$50 million, approximately
equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March
31, 2022 and December 31, 2021, the Company has not earned the royalty under the BHK Collaborative Agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Co-Development agreement with Rgene Corporation,
a related party</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 26, 2017, BriVision entered into a co-development
agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party under common control
by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to Co-Dev Agreement, BriVision
and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer
Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to&#160;pay
the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision&#8217;s
past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future
commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to $3,000,000, the Company is entitled to receive 50% of
the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both
BriVision and Rgene.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 1, 2017, the Company has delivered all
research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended December
31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in
the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for
an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year
ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully write
off this investment based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative
analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment,
changes in operating structure of Rgene, additional funding requirements, and Rgene&#8217;s ability to remain in business. All projects
that have been initiated will be managed and supported by the Company and Rgene.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company and Rgene signed an amendment to the
Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination
Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and
ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions
of the Co-Dev Agreement remain in full force and effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span style="text-decoration:underline">Collaborative agreement with BioFirst Corporation,
a related party</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, BriVision entered into a collaborative
agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst Corporation (&#8220;BioFirst&#8221;), pursuant to which BioFirst
granted the Company the global licensing right for medical use of the product (the &#8220;Product&#8221;): BFC-1401 Vitreous Substitute
for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the
Company is one of the directors and Common Stock shareholders of BioFirst (See Note 12).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock
of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst&#8217;s past research
efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future
commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50%
of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and
BioFirst.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000
since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended December
31, 2017.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 30, 2019, BriVision entered into a Stock
Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst Corporation. Pursuant to the Purchase Agreement, the Company issued
428,571 shares of the Company&#8217;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst (the &#8220;Total
Payment&#8221;) in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the &#8220;Collaborative
Agreement&#8221;). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401
or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2019, BriVision entered into a second
Stock Purchase Agreement (&#8220;Purchase Agreement 2&#8221;) with BioFirst Corporation. Pursuant to Purchase Agreement 2, the Company
issued 414,702 shares of the Company&#8217;s common stock to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst
in connection with a loan provided to BriVision from BioFirst.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3. COLLABORATIVE AGREEMENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Collaborative agreements with BHK</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment</span></td></tr> </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the completion of first phase II clinical trial: $1 million, or 10% of total payment</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2015, BHK has paid a non-refundable upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical trial.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the milestone payments, BioLite Taiwan is entitled to receive royalty on 12% of BHK&#8217;s net sales related to BLI-1401-2 Products. As of December 31, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Co-Development Agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) On December 9, 2015, BioLite Taiwan entered into another two collaborative agreements (the &#8220;BHK Collaborative Agreements&#8221;), pursuant to which it is collaborative with BHK to co-develop and commercialize BLI-1005 for &#8220;Targeting Major Depressive Disorder&#8221; (BLI-1005 Products) and BLI-1006 for &#8220;Targeting Inflammatory Bowel Disease&#8221; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this BHK Collaborative Agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of December 31, 2021 and 2020, the Company has not earned the royalty under the BHK Collaborative Agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Co-Development agreement with Rgene Corporation, a related party</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 26, 2017, BriVision entered into a co-development agreement (the &#8220;Co-Dev Agreement&#8221;) with Rgene Corporation (the &#8220;Rgene&#8221;), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to&#160;pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision&#8217;s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both BriVision and Rgene.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully write off this investment based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene&#8217;s ability to remain in business. All projects that have been initiated will be managed and supported by the Company and Rgene.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company and Rgene signed an amendment to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions of the Co-Dev Agreement remain in full force and effect.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration:underline">Collaborative agreement with BioFirst Corporation, a related party</span></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2017, BriVision entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst Corporation (&#8220;BioFirst&#8221;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the &#8220;Product&#8221;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See Note 12).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst&#8217;s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended December 31, 2017.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 30, 2019, BriVision entered into a Stock Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued 428,571 shares of the Company&#8217;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst (the &#8220;Total Payment&#8221;) in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the &#8220;Collaborative Agreement&#8221;). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2019, BriVision entered into a second Stock Purchase Agreement (&#8220;Purchase Agreement 2&#8221;) with BioFirst. Pursuant to Purchase Agreement 2, the Company issued 414,702 shares of the Company&#8217;s common stock to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst in connection with a loan provided to BriVision from BioFirst.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CollaborativeAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CollaborativeAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032642104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. INVENTORY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Inventory consists of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.9pt; text-align: justify; text-indent: -22.9pt"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Finished goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">104,036</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96,725</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Raw materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,620</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(150,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,370</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Inventory, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,975</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4. INVENTORY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Finished goods</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">96,725</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">100,967</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Work-in-process</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,038</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Raw materials</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">84,620</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">61,718</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(155,370</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(184,723</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Inventory, net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">25,975</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032597416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. PROPERTY AND EQUIPMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">Property and
equipment as of March 31, 2022 and December 31, 2021 are summarized as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Land</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">387,866</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">400,091</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Buildings and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,230,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,235,061</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,102,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,013,376</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">186,149</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">191,824</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,907,926</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,352</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,309,278</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,314,471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">598,648</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">525,881</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expenses were $5,411 and $2,928 for
three months ended March 31, 2022 and 2021, respectively.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5. PROPERTY AND EQUIPMENT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment as of December 31, 2021 and 2020 are summarized as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Land</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">400,091</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">395,645</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Buildings and leasehold improvements</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,235,061</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,233,573</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Machinery and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,013,376</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">994,544</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">191,824</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">189,760</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,840,352</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,813,522</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(3,314,471</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(3,298,688</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Property and equipment, net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">525,881</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">514,834</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense were $11,993 and $37,142 for the year ended December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635134635832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentAbstract', window );"><strong>Long Term Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentTextBlock', window );">LONG-TERM INVESTMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b>6. LONG-TERM INVESTMENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The ownership percentages of
each investee are listed as follows:</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 331.3pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Accounting</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">treatments</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Equity Method</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rgene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Equity Method</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(2)</span></td><td style="text-align: justify"><span style="font-size: 10pt">The extent the investee relies
on the company for its business are summarized as follows:</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left">Name of related party</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left">The extent the investee relies on the Company for its business </td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td>&#160;</td>
    <td style="text-align: left">No specific business relationship</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td>
    <td style="text-align: left">No specific business relationship</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td>
    <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rgene Corporation</td><td>&#160;</td>
    <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>&#160;&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(3)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Long-term investment mainly
consists of the following:</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-marketable Cost Method Investments, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,698</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,941</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Genepharm Biotech Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,244</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">BioHopeKing Corporation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">873,053</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">900,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Sub total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">904,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">932,755</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity Method Investments, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Rgene Corporation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">904,254</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">932,755</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2022 and December
31, 2021, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. The Company made prepayment for equity investment
in BioFirst to purchase additional 317,000 shares to be issued by BioFirst in the aggregate amount of $663,798 and $684,720, recorded
as prepayment for long-term investments as of March 31, 2022 and December 31, 2021, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summarized financial information for the Company&#8217;s
equity method investee, BioFirst, is as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Balance Sheet</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,147,097</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,205,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">812,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">959,454</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,237,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,909,703</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,522</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(295,402</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,898</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Statement of Operations</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,339</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,080</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(498,940</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(220,855</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share of losses from investments accounted for using the equity method</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,791</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(b)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Both Rgene and the Company are under
common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant
influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s
proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of March 31, 2022 and December
31, 2021, the Company owns 31.62% and 31.62% Common Stock shares of Rgene, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summarized financial information for the Company&#8217;s
equity method investee, Rgene, is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Balance Sheets</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">221,169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,452</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">374,423</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,164,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,934,786</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shareholders&#8217; Deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,587,488</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,486,911</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Statement of Operations</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net sales</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross Profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(149,480</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(95,395</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share of loss from investments accounted for using the equity method</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(4)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Disposition of long-term investment</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">During the three months ended March
31, 2022 and 2021, there is no disposition of long-term investment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(5)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Losses on Equity Investments</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The components of losses on equity investments
for each period were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Share of equity method investee losses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(47,791</td><td style="width: 1%; text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6. LONG-TERM INVESTMENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ownership percentages of each investee are listed as follows:</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership percentage</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting</b></span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of related party</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>treatments</b></span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.90%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.90%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.99%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.99%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.62%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.62%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td>
    <td>&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The extent the investee relies on the company for its business are summarized as follows:</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of related party</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The extent the investee relies on the Company for its business </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned from the investee and provides research and development support service</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-term investment mainly consists of the following:</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-marketable Cost Method Investments, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">7,941</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">7,853</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Genepharm Biotech Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">24,244</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,974</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">BioHopeKing Corporation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">900,570</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">890,564</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Sub total</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">932,755</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">922,391</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity Method Investments, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">BioFirst Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">268,336</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Rgene Corporation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">932,755</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,190,727</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;):</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2021 and 2020, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. During year ended December 31, 2021, the Company made prepayment for equity investment in BioFirst to purchase additional&#160;317,000&#160;shares to be issued by BioFirst in the aggregate amount of $684,720, recorded as prepayment for long-term investments as of December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized financial information for the Company&#8217;s equity method investee, BioFirst, is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Balance Sheet</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Current Assets</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">2,205,669</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,299,822</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Noncurrent Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">959,454</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,540,041</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,909,703</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,986,340</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Noncurrent Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">32,522</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">73,197</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Stockholders&#8217; Equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">222,898</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,780,326</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Statement of operation</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net sales</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">26,693</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">257,235</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross profit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,348</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">10,121</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,276,892</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(5,401,074</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share of losses from investments accounted for using the equity method</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(269,844</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,168,733</td>
    <td style="text-align: left">)</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#8212;Equity Method and Joint Ventures (&#8220;ASC 323&#8221;). Equity method adjustments include the Company&#8217;s proportionate share of investee&#8217;s income or loss and other adjustments required by the equity method. As of December 31, 2021 and 2020, the Company owns 31.62% and 31.62% common stock shares of Rgene, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summarized financial information for the Company&#8217;s equity method investee, Rgene, is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Balance Sheets</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Current Assets</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">73,452</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">123,958</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Noncurrent Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">374,423</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">412,342</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,934,786</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,392,756</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Noncurrent Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">38,953</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shareholders&#8217; Deficit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,486,911</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(895,409</td>
    <td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Statement of operations</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net sales</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">16,595</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross Profit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(335,735</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(576,514</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(641,636</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share of loss from investments accounted for using the equity method</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disposition of long-term investment</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the year ended December 31, 2020. During the year ended December 31, 2021, there is no disposition of long-term investment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Losses on Equity Investments</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of losses on equity investments for each period were as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%">Share of equity method investee losses</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 9%">(269,844</td>
    <td style="text-align: left; width: 1%">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,168,733</td>
    <td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermInvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermInvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635029814856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertibleNotesPayableDisclosureAbstract', window );"><strong>Convertible Notes Payable Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertibleNotesPayableDisclosureTextBlock', window );">CONVERTIBLE NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>7. CONVERTIBLE NOTES PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 9, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &#8220;Yu and Wei Note&#8221;) in an aggregate principal amount of $300,000 to Guoliang
Yu and Yingfei Wei Family Trust (the &#8220;Yu and Wei&#8221;), pursuant to which the Company received $300,000. The Yu and Wei Note bears
interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019.
In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#8220;Equity Offering&#8221;)
then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any
time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal
plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion
price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject
to adjustment or (ii) 80% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering
of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments
set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial
conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears
interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#8220;Yu and Wei&#8221; Note, which is on January
20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#8220;Yu and Wei&#8221;. The aggregate principal amount
plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company&#8217;s
common stock, and warrants to purchase 192,784 shares of the Company&#8217;s common stock. These common shares have been issued during
the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 27, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &#8220;Keypoint Note&#8221;) in the aggregate principal amount of $250,000 to Keypoint
Technology Ltd. (&#8220;Keypoint&#8221;), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest
at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event
that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#8220;Equity Offering&#8221;) then
within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from
the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion
Price&#8221;) equal to the lower of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80%
of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an
amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint
Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature
present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum.
The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the
Twelve (12) month anniversary of the issuance date of the new &#8220;Keypoint&#8221; Note, which is on January 20, 2021. On April 5, 2020,
the Company entered into an exchange agreement with &#8220;Keypoint&#8221;. The aggregate principal amount plus accrued interest expenses
were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#8217;s common stock, and
warrants to purchase 159,145 shares of the Company&#8217;s common stock. These common shares have been issued during the year ended December
31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 25, 2018, the Company issued an eighteen-month
term unsecured convertible promissory notes (the &#8220;Odaira Note&#8221;) in the aggregate principal amount of $250,000 to Yoshinobu
Odaira. (&#8220;Odaira&#8221;), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company
shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18)
month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds
from the sale of its common stock of at least $5,000,000 (an &#8220;Equity Offering&#8221;) then within five days of the closing for such
offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has
been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest,
if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower
of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80% of the per share offering price (the
&#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs
when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20,
the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21,
2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount
in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date
of the new &#8220;Odaira&#8221; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with
&#8220;Odaira&#8221;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to
the Holders an aggregate of 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s
common stock. These common shares have been issued during the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 30 and July 10, 2019, the Company issued
two (2) twelve-month term unsecured convertible promissory notes (the &#8220;KSL Note&#8221;) in an aggregate principal amount of $250,000
to Kuo Sheng Lung (the &#8220;KSL&#8221;), pursuant to which the Company received $160,000 and $90,000, respectively. The KSL Note bears
interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020. At any
time from the issuance date until the KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion
Price&#8221;) equal to the lower of (i) $0.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70%
of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company
in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission
on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company
recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company
received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company
entered into an agreement with &#8220;KSL&#8221;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL
agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the
Company agreed to issue 120,121 shares of the Company&#8217;s common stock and warrants for a purchase price of $270,272.&#160;During
the year ended December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company&#8217;s common stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 10, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#8220;NEA Note&#8221;) in an aggregate principal amount of $250,000 to New Eastern Asia
(the &#8220;NEA&#8221;), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest
at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof
until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;)
equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the NEA Note. During the year ended December 31, 2020, the Company
issued 111,112 shares of common stock to repay the outstanding balance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 28, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#8220;KLS Note&#8221;) in an aggregate principal amount of $200,000 to Kuo Li Shen (the
&#8220;KLS&#8221;), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum.
The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this
KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default
interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to
the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering
price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public
Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value
of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with
KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate
of 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have
been issued during the year ended December 31, 2020</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 4, 2019, the Company issued 3 twelve-month
term unsecured convertible promissory note (the &#8220;C.L.L. Note&#8221;) in an aggregate principal amount of $257,500 to Chang Ping
Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &#8220;C.L.L.&#8221;), pursuant to which the Company received $257,500 on September
4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The
Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until
this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;)
equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into
an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed
to issue to the Holders an aggregate of 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of
common stock. These common shares have been issued during the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 29, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#8220;Lee Note&#8221;) in an aggregate principal amount of $250,000 to Hwalin Lee (the
&#8220;Lee&#8221;), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest
at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof
until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;)
equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the Lee Note. In January 2021, the Company paid off the convertible
promissory note of $306,836, including principal and accrued and unpaid interest expense.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2020, the Company entered into
a Securities Purchase Agreement (the &#8220;October SPA&#8221;) with one accredited investor. Pursuant to the October SPA, the Company
sold and issued a convertible promissory note (the &#8220;October Note&#8221;) in the principal amount of $2,500,000 to the investor and
received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of
the October Note is the twenty-four (24) month anniversary from the issuance date (the &#8220;Maturity Date&#8221;). Upon the Maturity
Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest
under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the
Company&#8217;s common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect to convert part
or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding
amount at any time, in whole or in part, without any penalty.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 17, 2021, the parties to the October SPA
signed Amendment No. 1 to Promissory Note (the &#8220;Amendment&#8221;). Pursuant to the Amendment, the Note shall also be automatically
converted into shares of the Company&#8217;s common stock immediately following the Company&#8217;s receipt of conditional approval to
list its common stock on the NASDAQ stock market, if and when the Company receives such approval, at a conversion price equal to $2.25
per share.&#160;On July 21, 2021, The Company converted all convertible promissory note amounted $2,500,000 into 1,111,112 shares of the
Company&#8217;s common stock and warrants.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022 and December 31, 2021, the
aggregate carrying values of the convertible debentures were both $0; and accrued convertible interest were both $0.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total interest expenses in connection with the
above convertible note payable were $0 and $66,897 for the three months ended March 31, 2022 and 2021, respectively.&#160;&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7. CONVERTIBLE NOTES PAYABLE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 9, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the &#8220;Yu and Wei Note&#8221;) in an aggregate principal amount of $300,000 to Guoliang Yu and Yingfei Wei Family Trust (the &#8220;Yu and Wei&#8221;), pursuant to which the Company received $300,000. The Yu and Wei Note bears interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#8220;Equity Offering&#8221;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#8220;Yu and Wei&#8221; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#8220;Yu and Wei&#8221;. The aggregate principal amount plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company&#8217;s common stock, and warrants to purchase 192,784 shares of the Company&#8217;s common stock. These common shares have been issued during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 27, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the &#8220;Keypoint Note&#8221;) in the aggregate principal amount of $250,000 to Keypoint Technology Ltd. (&#8220;Keypoint&#8221;), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#8220;Equity Offering&#8221;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#8220;Keypoint&#8221; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#8220;Keypoint&#8221;. The aggregate principal amount plus accrued interest expenses were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#8217;s common stock, and warrants to purchase 159,145 shares of the Company&#8217;s common stock. These common shares have been issued during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 25, 2018, the Company issued an eighteen-month term unsecured convertible promissory notes (the &#8220;Odaira Note&#8221;) in the aggregate principal amount of $250,000 to Yoshinobu Odaira. (&#8220;Odaira&#8221;), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#8220;Equity Offering&#8221;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21, 2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#8220;Odaira&#8221; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#8220;Odaira&#8221;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s common stock. These common shares have been issued during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 30 and July 10, 2019, the Company issued two (2) twelve-month term unsecured convertible promissory notes (the &#8220;KSL Note&#8221;)
in an aggregate principal amount of $250,000 to Kuo Sheng Lung (the &#8220;KSL&#8221;), pursuant to which the Company received $160,000
and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to KSL an amount in cash representing
all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note,
which is on May 29, 2020 and July 9, 2020. At any time from the issuance date until the KSL Note has been satisfied, the KSL may convert
the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s
common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $0.50 per share (the &#8220;Fixed Conversion
Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of
the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form
S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time
to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of the embedded beneficial conversion
feature present in the KSL Note. On May 13, 2020, the Company received an acknowledgement letter from KSL that they will not claim the
repayment of loan for 12 months. On November 9, 2020, the Company entered into an agreement with &#8220;KSL&#8221;. The aggregate principal
amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to
a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company&#8217;s common
stock and warrants for a purchase price of $270,272.&#160;During the year ended December 31, 2020, the Company issued to the Holders
an aggregate of 120,121 shares of the Company&#8217;s common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 10, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#8220;NEA Note&#8221;) in an aggregate principal amount of $250,000 to New Eastern Asia (the &#8220;NEA&#8221;), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note. During the year ended December 31, 2020, the Company issued 111,112 shares of common stock to repay the outstanding balance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 28, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#8220;KLS Note&#8221;) in an aggregate principal amount of $200,000 to Kuo Li Shen (the &#8220;KLS&#8221;), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum. The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have been issued during the year ended December, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 4, 2019, the Company issued 3 twelve-month term unsecured convertible promissory note (the &#8220;C.L.L. Note&#8221;) in an aggregate principal amount of $257,500 to Chang Ping Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &#8220;C.L.L.&#8221;), pursuant to which the Company received $257,500 on September 4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of common stock. These common shares have been issued during the year ended December 31. 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 29, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#8220;Lee Note&#8221;) in an aggregate principal amount of $250,000 to Hwalin Lee (the &#8220;Lee&#8221;), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) <span style="-sec-ix-hidden: hidden-fact-113">$.</span>50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note. In January 2021, the Company paid off the convertible promissory note of $306,836, including principal and accrued and unpaid interest expense.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 23, 2020, the Company entered into a Securities Purchase Agreement (the &#8220;October SPA&#8221;) with one accredited investor. Pursuant to the October SPA, the Company sold and issued a convertible promissory note (the &#8220;October Note&#8221;) in the principal amount of $2,500,000 to the investor and received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of the October Note is the twenty-four (24) month anniversary from the issuance date (the &#8220;Maturity Date&#8221;). Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the Company&#8217;s common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect to convert part or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding amount at any time, in whole or in part, without any penalty.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 17, 2021, the parties to the October SPA signed Amendment No. 1 to Promissory Note (the &#8220;Amendment&#8221;). Pursuant to the Amendment, the Note shall also be automatically converted into shares of the Company&#8217;s common stock immediately following the Company&#8217;s receipt of conditional approval to list its common stock on the NASDAQ stock market, if and when the Company receives such approval, at a conversion price equal to $2.25 per share.&#160;On July 21, 2021, The Company converted all convertible promissory note amounted $2,500,000 into 1,111,112 shares of the Company&#8217;s common stock and warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, the aggregate carrying values of the convertible debentures were $0 and $2,750,000, respectively; and accrued convertible interest was $0 and $104,551, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total interest expenses in connection with the above convertible note payable were $193,548 and $240,420 for the year ended December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConvertibleNotesPayableDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConvertibleNotesPayableDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConvertibleNotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConvertibleNotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032661144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansAbstract', window );"><strong>Bank Loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansTextBlock', window );">BANK LOANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>8. BANK LOANS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">(1)</span></td><td style="text-align: justify"><span style="font-size: 10pt">Short-term bank loan consists
of the following:</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cathay United Bank</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">261,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">270,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CTBC Bank</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">698,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">720,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cathay Bank</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,609,750</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,640,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Cathay United Bank</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 28, 2016, BioLite Taiwan and Cathay United
Bank entered into a one-year bank loan agreement (the &#8220;Cathay United Loan Agreement&#8221;) in an amount of NT$7,500,000, equivalent
to $261,750. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of
prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite
Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000,
equivalent to $261,750. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of
NT$7,500,000, equivalent to $261,750 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the
Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $261,750 for one year, which is due on September
6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000,
equivalent to $261,750 for one year, which is due on September 6, 2021. On September 6, 2021, BioLite Taiwan extended the Cathay United
Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $261,750&#160;for&#160;one year, which is due on September
6, 2022. As of March 31, 2022 and December 31, 2021, the effective interest rates per annum was 2.1%. The loan is collateralized by the
building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company&#8217;s chairman.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $1,386 and $1,383 for the
three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">CTBC Bank</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2017 and July 19, 2017, BioLite Taiwan
and CTBC Bank entered into short-term saving secured bank loan agreements (the &#8220;CTBC Loan Agreements&#8221;) in an amount of NT$10,000,000,
equivalent to $349,000, and NT$10,000,000, equivalent to $349,000, respectively. Both two loans with the same maturity date at January
19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019,
BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan
extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $698,000 for six months, which is due
on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000,
equivalent to $698,000 for six months, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement
with the same principal amount of NT$20,000,000, equivalent to $698,000 for six months, which is due on January 15, 2021. On January 15,
2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $698,000 for six
months, which is due on July 15, 2021. On July 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount
of NT$20,000,000, equivalent to $698,000 for six months, which is due on January 14, 2022. On January 14, 2022, BioLite Taiwan extended
the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $698,000 for six months, which is due on July 14,
2022. The loan balances bear interest at a fixed rate of 1.68% per annum. The loan is secured by the money deposited in a savings account
with the CTBC Bank. This loan was also personal guaranteed by the Company&#8217;s chairman and BioFirst. During the year ended December
31, 2020, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $2,958 and $2,949 for the
three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cathay Bank</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 21, 2019, the Company received a loan
in the amount of $500,000 from Cathay Bank (the &#8220;Bank&#8221;) pursuant to a business loan agreement (the &#8220;Loan Agreement&#8221;)
entered by and between the Company and Bank on January 8, 2019 and a promissory note (the &#8220;Note&#8221;) executed by the Company
on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date
(the &#8220;Maturity Date&#8221;) of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the
&#8220;Regular Interest Rate&#8221;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the
&#8220;Index&#8221;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company
shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note
before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%)
plus the Regular Interest Rate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Note and Loan Agreement,
on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the &#8220;Guaranty&#8221;) to guaranty
the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each
until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of
BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey. On December 29, 2020, the Company
entered into a new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr.
George Lee to be removed as guarantees from the list of Guaranty.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, on January 8, 2019, each of the Company
and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the &#8220;Security Agreement&#8221;) to
secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each, a &#8220;Grantor&#8221;,
and collectively, the &#8220;Grantors&#8221;) granted security interest in the collaterals as defined therein, comprised of almost all
of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company extended the Loan Agreement
with the same term for seven months, which is due on October 31, 2020. On April 8, 2020 and October 3, 2020, the Company repaid an aggregated
principal amount of $350,000. On December 3, 2020, the Company renewed the Loan Agreement with the principal amount of $650,000 for ten
months, which is due on October 31, 2021. On October 31, 2021, the Company renewed the Loan Agreement with the principal amount of $650,000
for twelve months, which is due on October 30, 2022. On September 30, 2021, the Cathay Bank has increased the line of credit to $1,000,000
from $650,000. The outstanding loan balance was $650,000 as of March 31, 2022 and December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interest expenses were $6,090 and $3,927 for the
three months ended March 31, 2022 and 2021, respectively.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8. BANK LOANS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term bank loan consists of the following:</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cathay United Bank</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">270,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">267,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">CTBC Bank</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">720,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">712,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cathay Bank</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,640,000</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,629,000</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Cathay United Bank</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2016, BioLite Taiwan and Cathay United Bank entered into a one-year bank loan agreement (the &#8220;Cathay United Loan Agreement&#8221;) in an amount of NT$7,500,000, equivalent to $270,000. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000, equivalent to $270,000. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $270,000 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $270,000 for one year, which is due on September 6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $270,000 for one year, which is due on September 6, 2021. On September 6, 2021, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $270,000 for one year, which is due on September 6, 2022. As of December 31, 2021 and December 31, 2020, the effective interest rates per annum was 2.1%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company&#8217;s chairman.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expenses were $5,639 and $5,280 for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">CTBC Bank</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 12, 2017 and July 19, 2017, BioLite Taiwan and CTBC Bank entered into short-term saving secured bank loan agreements (the &#8220;CTBC Loan Agreements&#8221;) in an amount of NT$10,000,000, equivalent to $360,000, and NT$10,000,000, equivalent to $360,000, respectively. Both two loans with the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019, BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on January 15, 2021. On January 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on July 15, 2021. On July 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on January 14, 2022. The loan balances bear interest at a fixed rate of 1.68% per annum. The loan is secured by the money deposited in a savings account with the CTBC Bank. This loan was also personal guaranteed by the Company&#8217;s chairman and BioFirst. During the year ended December 31, 2021, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expenses were $12,029 and $11,395 for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Cathay Bank</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 21, 2019, the Company received a loan in the amount of $500,000 from Cathay Bank (the &#8220;Bank&#8221;) pursuant to a business loan agreement (the &#8220;Loan Agreement&#8221;) entered by and between the Company and Bank on January 8, 2019 and a promissory note (the &#8220;Note&#8221;) executed by the Company on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date (the &#8220;Maturity Date&#8221;) of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the &#8220;Regular Interest Rate&#8221;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the &#8220;Index&#8221;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Note and Loan Agreement, on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the &#8220;Guaranty&#8221;) to guaranty the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey. On December 29, 2020, the Company entered into a new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr. George Lee to be removed as guarantees from the list of Guaranty.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition, on January 8, 2019, each of the Company and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the &#8220;Security Agreement&#8221;) to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each, a &#8220;Grantor&#8221;, and collectively, the &#8220;Grantors&#8221;) granted security interest in the collaterals as defined therein, comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020. On April 8, 2020 and October 3, 2020, the Company repaid an aggregated principal amount of $350,000. On December 3, 2020, The Company renewed the Loan Agreement with the principal amount of $650,000 for ten months, which is due on October 31, 2021. On September 30, 2021, the Cathay Bank has increased the line of credit to $1,000,000 from $650,000. The outstanding loan balance was $650,000 as of December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest expenses were $18,143 and $53,992 for the year ended December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BankLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BankLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BankLoansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BankLoansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032650776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program Loan Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PaycheckProtectionProgramLoanPayableAbstract', window );"><strong>Paycheck Protection Program Loan Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PaycheckProtectionProgramLoanPayableTextBlock', window );">PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 14, 2020, the Company received a loan
in the amount of $124,400 under the Paycheck Protection Program (&#8220;PPP&#8221;) administered by the United States Small Business Administration
(the &#8220;SBA&#8221;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;Cares Act&#8221;),
PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest
on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The loan was granted pursuant to a promissory
note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The
Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years
after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&#8217;s
accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments
to be due on the same day of each month after that. No collateral or personal guarantees are required.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 29, 2021, BioKey received a loan in
the amount of $132,331 under the Paycheck Protection Program administered by the United States Small Business Administration from East
West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal
amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60%
of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated January 27, 2021 issued
by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 7, 2021, the Company received a loan
in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay
Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal
amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60%
of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued
by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>PPP loan Forgiveness&#160;</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 27, 2021, the Company submitted all
required documents, such as application form and use of funds,&#160;to East West Bank for the application of forgiveness. The PPP loan
from East West Bank of $124,400 and $132,331 was forgiven by the SBA as a gesture of supporting the operation of the Company on March
15, 2021 and September 28, 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 23, 2021, the Company submitted the
required documents, such as application form and use of funds,&#160;to Cathay Bank for the application of forgiveness. The PPP loan from
Cathay Bank of $104,167 was forgiven by the SBA as a gesture of supporting the operation of the Company on November 15, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result, the Company recorded the forgiveness
of the PPP loans as government grant income in the aggregate amount of $360,898 during the year ended December 31, 2021. As of March
31, 2022, there was no outstanding balance payable to the bank.&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE</b>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 14, 2020, the Company received a loan in the amount of $124,400 under the Paycheck Protection Program (&#8220;PPP&#8221;) administered by the United States Small Business Administration (the &#8220;SBA&#8221;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;Cares Act&#8221;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The loan was granted pursuant to a promissory note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&#8217;s accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments to be due on the same day of each month after that. No collateral or personal guarantees are required.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 29, 2021, BioKey received a loan in the amount of $132,331 under the Paycheck Protection Program administered by the United States Small Business Administration from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. No collateral or personal guarantees are required.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 7, 2021, the Company received a loan in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. No collateral or personal guarantees are required.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PPP loan Forgiveness</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 27, 2021, the Company submitted all required documents, such as application form and use of funds,&#160;to East West Bank for the application of forgiveness. The PPP loan from East West Bank of $124,400 and $132,331 was forgiven by the SBA as a gesture of supporting the operation of the Company on March 15, 2021 and September 28, 2021, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 23, 2021, the Company submitted the required documents, such as application form and use of funds,&#160;to Cathay Bank for the application of forgiveness. The PPP loan from Cathay Bank of $104,167 was forgiven by the SBA as a gesture of supporting the operation of the Company on November 15, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a result, the Company recorded the forgiveness of the PPP loans as government grant income in the aggregate amount of $360,898 during the year ended December 31, 2021&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PaycheckProtectionProgramLoanPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PaycheckProtectionProgramLoanPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PaycheckProtectionProgramLoanPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PaycheckProtectionProgramLoanPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032658488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NotesPayableLineItems', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MortgageNotesPayableDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. NOTES PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January, 2019, BioLite Taiwan entered an unsecured
loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working
capital purpose. On September 11, 2021 the outstanding balance has been repaid in full. As of March 31, 2022 and December 31, 2021, the
balance due to this individual amounted to both $0.&#160;Interest expense were $0 and $3,204 for the three months ended March 31, 2022
and 2021, respectively.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10. NOTES PAYABLE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working capital purpose. On September 11, 2021 the outstanding balance has been repaid in full. As of December 31, 2021 and 2020, the balance due to this individual amounted to $0 and $106,800, respectively.&#160;Interest expense was $8,592 and $12,204 for the year ended December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NotesPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NotesPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageNotesPayableDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for mortgage notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageNotesPayableDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032746936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Loan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTextBlock', window );">SHORT-TERM LOAN</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>11. SHORT-TERM LOAN</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 18, 2020, the Company entered an unsecured
loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on
August 17, 2020. On August 18, 2020, the Company extended the contract for six months under the same term. On February 18, 2021, the Company
extended the contract for six months under the same term. On August 26, 2021, the loan with interest has been repaid in full. Accrued
interest expense were both $0 as of March 31, 2022 and December 31, 2021.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11. SHORT-TERM LOAN</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 18, 2020, the Company entered an unsecured loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on August 17, 2020. On August 18, 2020, the Company extended the contract for six months under the same term. On February 18, 2021, the Company extended the contract for six months under the same term. On August 26, 2021, the loan with interest totaling $102,272 has been repaid in full. Accrued interest expense was $0 and $1,302 as of December 31, 2021 and 2020, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032652872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>12. RELATED PARTIES TRANSACTIONS</b>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The related parties of the company with whom transactions
are reported in these financial statements are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Name of entity or Individual</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left">Relationship with the Company and its subsidiaries</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Rgene Corporation (the &#8220;Rgene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">YuanGene Corporation (the &#8220;YuanGene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Controlling beneficiary shareholder of the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">AsiaGene Corporation (the &#8220;AsiaGene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Eugene Jiang</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Former President and Chairman</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Yoshinobu Odaira (the &#8220;Odaira&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Director of the Company</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">LBG USA, Inc. (the &#8220;LBG USA&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">LionGene Corporation (the &#8220;LionGene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">The Jiangs</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst <br/> &#160; <br/> Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. <br/> &#160; <br/> Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. <br/> &#160; <br/> Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company. <br/> &#160; <br/> Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Amkey Ventures, LLC (&#8220;Amkey&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">BioLite Japan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Entity controlled by controlling beneficiary shareholder of ABVC</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">ABVC BioPharma (HK), Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">An entity 100% owned by Mr. Tsung-Shann Jiang</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Accounts receivable - related parties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Accounts receivable due from related parties consisted
of the following as of the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">GenePharm Inc.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Rgene</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,374</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,374</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Amkey</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">145,399</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">145,399</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Due from related parties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount due from related parties consisted of the
following as of the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Rgene</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48,586</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49,110</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>BioFirst</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,563,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">468,435</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioFirst (Australia)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">830,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">491,816</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LBG USA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioLite Japan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Keypoint</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,610</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,610</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,715,375</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,286,618</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">As of March 31, 2022, and December 31, 2021, the Company has advanced an aggregate amount of $48,586 and $49,110 to Rgene for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum). As of March 31, 2022, and December 31, 2021, the outstanding loan balance was $32,541 and $33,520; and accrued interest was $14,214 and $13,701, respectively. On January 1, 2021, BioLite Taiwan entered into a consultant services agreement with Rgene, of which the amount due from Rgene was $1,831 and $1,889 as of March 31, 2022 and December 31, 2021, respectively.&#160;&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">In 2021, the Company and BioFirst entered into several loan agreements for a total amount of $465,000 to meet its working capital needs. All the loans period was twelve months and all with an interest rate of 6.5% per annum. In 2022, the Company and BioFirst entered into several loan agreements for a total amount of $1,068,000 to meet its working capital needs. All the loans period was twelve months and with an interest rate of 6.5% per annum. As of March 31, 2022, and December 31, 2021, the outstanding loan balance was $1,533,000 and $465,000; and accrued interest was $30,233 and $3,435, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. &#160;&#160;On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In January 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $327,000 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. As of March 31, 2022 and December 31, 2021, the aggregate amount of outstanding loan and accrued interest was $830,118 and $491,816, respectively.</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2022 and December 31, 2021, due from BHK was $121,153 and $124,972, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of March 31, 2022 and December 31, 2021, the outstanding advance balances was $675 and $675, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(6)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On May 8, 2020, the Company and Lucidaim entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan&#8217;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate. As of March 31, 2022 and December 31, 2021, the outstanding advance balances was $150,000 and $150,000, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(7)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">On October 31, 2020, the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. As of March 31, 2022 and December 31, 2021, the outstanding loan balance was $1,610 and $1,610, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Due to related parties</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount due to related parties consisted of the
following as of the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,878</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,878</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst (Australia)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,443</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>AsiaGene</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>YuanGene</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">The Jiangs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Due to shareholders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162,634</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">168,131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">446,397</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">393,424</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Since 2019, BioFirst has advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of March 31, 2022 and December 31, 2021, the aggregate amount of outstanding balance and accrued interest is $40,878.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="text-align: justify; width: 24px"><span style="font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">As of March 31, 2022, and December 31, 2021, BioFirst (Australia) has advanced the Company an aggregate amount of $190,913 and $132,443, respectively for new project purpose.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">As of March 31, 2022, and December 31, 2021, AsiaGene has advanced the Company an aggregate amount of $24,017 for working capital purpose. This advance bears 0% interest rate and is due on demand.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">As of March 31, 2022, and December 31, 2021, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on demand.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2022, and December 31, 2021, the outstanding balance due to the Jiangs amounted to $18,750. These loans bear interest rate of 0% to 1% per month, and are due on demand.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">(6)</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate of 12% per annum. As of March 31, 2022 and December 31, 2021, the outstanding principal and accrued interest was $162,634 and $168,131, respectively. Interest expenses in connection with these loans were $5,312 and $5,298 for the three months ended March 31, 2022 and 2021, respectively.</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12. RELATED PARTIES TRANSACTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The related parties of the company with whom transactions are reported in these financial statements are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of entity or Individual</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YuanGene Corporation (the &#8220;YuanGene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlling beneficiary shareholder of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AsiaGene Corporation (the &#8220;AsiaGene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former President and Chairman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoshinobu Odaira (the &#8220;Odaira&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LBG USA, Inc. (the &#8220;LBG USA&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LionGene Corporation (the &#8220;LionGene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and
a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director
of the Company.</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amkey Ventures, LLC (&#8220;Amkey&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Accounts receivable - related parties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable due from related parties consisted of the following as of the periods indicated:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">GenePharm Inc.</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">142,225</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">142,225</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Rgene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,374</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Amkey</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">800</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,210</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">145,399</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">143,435</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Due from related parties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount due from related parties consisted of the following as of the periods indicated:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Rgene</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">49,110</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">42,911</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">AsiaGene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,241</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">468,435</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst (Australia)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">491,816</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">373,235</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioHopeKing Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">124,972</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">123,583</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">LBG USA</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">675</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">675</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioLite Japan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">150,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">150,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Keypoint</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,610</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,610</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,286,618</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,255</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, due from Rgene amounted to $49,110 and $42,911,respectively. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date was December 31, 2020. As of December 31, 2021, and December 31, 2020, the outstanding loan balance was $33,520 and $31,684; and accrued interest was $13,701 and $11,227, respectively. On January 1, 2021, BioLite Taiwan entered into a consultant services agreement with Rgene, of which the amount due from Rgene was $1,889 for the year ended December 31, 2021.</span></td> </tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,560, to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity date was December 31, 2020. The loan has been repaid in full during the year of 2021. As of December 31, 2021 and 2020, the outstanding loan balance was $0 and $3,560, and accrued interest was $0 and $681, respectively.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 2, 2021, November 12, 2021 and December 20, 2021, the Company and BioFirst entered into loan agreements for a total amount of $45,000, $140,000, and $280,000, respectively, to meet its working capital needs. The loan will be matured on November 1, 2022, November 11, 2022, and December 19, 2022, respectively, all with an interest rate of 6.5% per annum. As of December 31, 2021, and December 31, 2020, the outstanding loan balance was $465,000 and $0; and accrued interest was $3,435 and $0, respectively.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. As of December 31, 2021 and 2020, the aggregate amount of outstanding loan and accrued interest was $491,816 and $373,235, respectively.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#8220;BHK&#8221;) entered into a co-development agreement, (the &#8220;BHK Co-Development Agreement&#8221;, see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2021 and 2020, due from BHK was $124,972 and $123,583, respectively.</span></td></tr> </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2021 and 2020, the outstanding advance balances was $675 and $675, respectively.</span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 8, 2020, the Company and Lucidaim entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan&#8217;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate. As of December 31, 2021 and 2020, the outstanding advance balances was $150,000 and $150,000, respectively.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 31, 2020, the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. As of December 31, 2021 and 2020, the outstanding loan balance was $1,610 and $1,610, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Due to related parties</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount due to related parties consisted of the following as of the periods indicated:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst Corporation</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">40,878</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">23,647</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst (Australia)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">132,443</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">AsiaGene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">24,017</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">YuanGene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">9,205</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">9,205</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">The Jiangs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">18,750</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">16,627</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Due to shareholders</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">168,131</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">166,261</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Due to employee</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">72,705</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">393,424</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">288,445</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, BioFirst has advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of December 31, 2021 and 2020, the aggregate amount of outstanding balance and accrued interest is $40,878 and $23,647, respectively.</span></td> </tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, BioFirst (Australia) has advanced the Company an aggregate amount of $132,443 and $0, respectively for new project purpose.</span></td> </tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, AsiaGene has advanced the Company an aggregate amount of $24,017 and $0, respectively for working capital purpose. This advance bears 0% interest rate and is due on demand.</span></td> </tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on demand.</span></td> </tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2021 and 2020, the outstanding balance due to the Jiangs amounted to $18,750 and $16,627, respectively. These loans bear interest rate of 0% to 1% per month, and are due on demand.</span></td> </tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since 2018, the Company&#8217;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate from 12% to 13.6224% per annum. As of December 31, 2021 and 2020, the outstanding principal and accrued interest was $168,131 and $166,261, respectively. Interest expenses in connection with these loans were $22,779 and $21,520 for the year ended December 31, 2021 and 2020, respectively.</span></td> </tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commencing January, 2020, the Company had advances from one employee for working capital purpose. The outstanding balance including accrued interest due to this employee amounted to $0 and $72,705 as of December 31, 2021 and 2020, respectively. This loan bears interest rate of 1.5% per annum, and the loan with interest has been repaid in full during the year ended December 31, 2021.</span></td> </tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032675160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. EQUITY</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2016, a Share Exchange Agreement
(&#8220;Share Exchange Agreement&#8221;) was entered into by and among the&#160;Company, BriVision, Euro-Asia Investment &amp; Finance
Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People&#8217;s Republic of China (&#8220;Euro-Asia&#8221;),
being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record
of all of the issued share capital of BriVision (the&#160;&#8220;BriVision Stock&#8221;). Pursuant to the Share Exchange Agreement, upon
surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered
in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision
as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision
Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&#160;&#8220;Acquisition
Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s Common Stock to the BriVision
Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s Common Stock owned by Euro-Asia
should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding
Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share
capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision&#8217;s
Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares
of Company&#8217;s Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&#8217;s Common
Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&#8217;s Common
Stock,&#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&#160;&#8220;Share Exchange&#8221;), BriVision
became a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of the Company and there was a change of control of the Company following
the closing.&#160;&#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 17, 2016, pursuant to the 2016 Equity
Incentive Plan (the &#8220;2016 Plan&#8221;), 157,050 (50,000 pre-stock split) shares were granted to the employees.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#8220;Forward&#160;Stock&#160;Split&#8221;)
and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April
8, 2016.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 6, 2016, the Company and BioLite Taiwan
agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed
to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of
the Company&#8217;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On
August 26, 2016, the Company issued 1,468,750 shares (&#8220;Shares&#8221;) of the Company&#8217;s Common Stock, par value $0.001 (the
&#8220;Offering&#8221;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#8220;SPA&#8221;).
The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net
proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should
pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires
that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017,
the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#8217;s
Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring
transaction between the Company and BioLite on February 8, 2019, the Company&#8217;s Common Stock held by BioLite Taiwan was accounted
for treasury stocks in the statement of equity (deficit). On February 8, 2019, after the Merger, the Company issued 74,997,546 shares
to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 3, 2019, the Company filed a Certificate
of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial
Industry Regulatory Authority (&#8220;FINRA&#8221;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse
stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#8217;s
common stock were exchanged for 17,693,625 shares of the Company&#8217;s Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 1, 2016, the Company entered into a
consulting agreement with Kazunori Kameyama (&#8220;Kameyama&#8221;) for the provision of services related to the clinical trials and
other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the
Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#8217;s
Common Stock at $1.00 per share for any amount exceeding $3,000. The Company&#8217;s stocks shall be calculated and issued in December
every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued
24,694 stock options to Kameyama related to unpaid consulting fees of $49,388 (see Note 14).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 24, 2017, BriVision entered into a collaborative
agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst.
On June 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571
shares of the Company&#8217;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. These common shares
were issued during the year ended December 31, 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2019, the Company
entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant
Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in
the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued 644,972 shares
of the Company&#8217;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate,
and recorded as stock subscription receivable. As of March 31, 2022 and December 31, 2021, stock subscription receivable was $2,031,660
and $2,257,400, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August, 2019, the Company entered into several
Conversion Agreements to all creditors that are listed under below table of &#8220;due to related parties&#8221; in consideration for
a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements,
creditor agrees to convert the amount of debt into the Company&#8217;s common stock at a price of $7.00 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of<br/> Debt<br/> Converted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares<br/> Issued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lion Arts Promotion Inc</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">97,864</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,981</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">LionGene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">428,099</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,157</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,902,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">414,702</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">AsiaGene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,858</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">YuanGene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,690</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,242</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">The Jiangs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,190,776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,872,340</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,051</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2020, the board of directors of the
Company approved and adopted an amendment to the Company&#8217;s Articles of Incorporation, to increase the authorized shares of its common
stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company entered an agreement
with View Trade Securities Inc. (&#8220;ViewTrade&#8221;) to engage ViewTrade as the placement agent&#160;and the Company&#8217;s advisor/consultant
with respect to its ongoing capital events. Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares
of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years
with cashless exercise provision. As of December 31, 2020, the Company has issued 60,000 shares of common stock to ViewTrade for the consulting
fee with an estimated value of $135,000. The warrants were never issued and the parties mutually agreed to terminate the agreement on
November 19, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the termination agreement, the Company
issued 50,000 shares of the Company&#8217;s common stock at a price of $5 per share as a termination fee on June 29, 2021, of which 6,000
shares were issued to WallachBeth Capital LLC (&#8220;WallachBeth&#8221;). In January 2021, WallachBeth entered into a consulting agreement
with the Company pursuant to which the Company engaged WallachBeth to conduct due diligence and research work with respect to the Company.
On June 29, 2021, WallachBeth was issued 6,000 shares of common stock as compensation for those services.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Also on November 19, 2020, the Company and ViewTrade
agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only. In addition to a retainer fee,
the Company agreed to issue 200,000 warrants, with an exercise price of $2.25, an industry standard cashless exercise provision, and a
term of 5 years from November 19, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year&#160;ended December 31, 2020,
the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company
agreed to pay the service fee by issuing 50,000 shares of unrestricted common shares, valued at the closing price of $2.9 per share on
the grant date. These shares have been issued during the year ended December 31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, the Company
received aggregated capital contributions of $7,615,331 in cash from 45 investors through private placements of the sale of the Company&#8217;s
common stock for the purchase price of&#160;$2.25 per share and a free warrant attached with each common stock purchased. In December
2020, 3,384,615 shares of the Company&#8217;s common stock have been issued.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the year ended December 31, 2020, the Company
entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed
to pay the service fee by issuing 521,887 shares of unrestricted common shares, valued at the closing price from $2 to $3.68 per share
on the grant date. These shares have been issued in October and December 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of March 31, 2022, the Company issued aggregated
common shares of 915,856 to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests,
including the debt conversion to the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt">&#160;</td> <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#8217;s common stock, and warrants to purchase 159,145 shares of the Company&#8217;s common stock.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-bottom: 8pt">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-bottom: 8pt">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-bottom: 8pt">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px; padding-bottom: 8pt">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#8217;s common stock, and warrants to purchase 192,784 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; padding-bottom: 8pt">&#160;</td> <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">f.</span></td> <td style="text-align: justify"><span style="font-size: 10pt">KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#8217;s common stock, and warrants to purchase 120,121 shares of the Company&#8217;s common stock.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">See Note 7 for more details in connection with the above debt conversion.&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2021, 1,111,112 shares of the Company&#8217;s
common stock and warrants were issued pursuant to the conversion of convertible promissory note of $2,500,000 entered in October 2020
(see Note 7).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 5, 2021, the Company closed its public
offering (the &#8220;Public Offering&#8221;) of 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of the
Company&#8217;s common stock, one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise
price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series
B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at
an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public
Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering
pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission
(the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective
on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August
4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;). The Units
were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. In August
2021, 2,354,145 shares of the Company&#8217;s common stock were issued for gross proceeds of $6,875,000, before placement agent fees and
legal fees of $850,429.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2021, the Company received $4,244,452&#160;in
gross proceeds from the exercise of warrants issued in the Company&#8217;s August 3, 2021, public offering of securities. Investors exercised
a total of&#160;673,405&#160;Series A warrants at a price of $6.30&#160;per share and&#160;200&#160;Series B warrants at a price of $10&#160;per
share. Pursuant to these exercises, the Company issued an aggregate of 673,605 shares of Common Stock.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In November 2021, the Company entered into consulting
agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted
$1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant
date. These shares have been issued during the year ended December 31, 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In January 2022, the Company agreed to pay the
deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued
at $3.29 per share on the grant date. These shares have been issued as of March 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In March 2022, the Company issued 75,000 common
shares to&#160;BarLew Holdings, LLC for consulting and advisory services amounted to $169,500, valued at $2.26 per share.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13. EQUITY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 8, 2016, a Share Exchange Agreement (&#8220;Share Exchange Agreement&#8221;) was entered into by and among
the&#160;Company, BriVision, Euro-Asia Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong
Special Administrative Region of People&#8217;s Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of
164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share
capital of BriVision (the &#8220;BriVision Stock&#8221;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision
Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each
BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new
holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock
in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the &#8220;Acquisition
Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s Common Stock to the
BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s Common Stock
owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the
issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing
100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and
outstanding shares of BriVision&#8217;s Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of
166,273,921(52,936,583 pre-stock split) shares of Company&#8217;s Common Stock and BriVision became a wholly owned subsidiary, of
the Company. The holders of Company&#8217;s Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223
(65,431,144 pre-stock split) shares of Company&#8217;s Common Stock,&#160;Because of the exchange of the BriVision Stock for the
Acquisition Stock (the &#8220;Share Exchange&#8221;), BriVision became a wholly owned subsidiary (the &#8220;Subsidiary&#8221;) of
the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity
instruments issued in connection with the share exchange agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;), 157,050 (50,000 pre-stock split) shares were granted to the employees.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#8220;Forward&#160;Stock&#160;Split&#8221;) and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 6, 2016, the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company&#8217;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On August 26, 2016, the Company issued 1,468,750 shares (&#8220;Shares&#8221;) of the Company&#8217;s Common Stock, par value $0.001 (the &#8220;Offering&#8221;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#8220;SPA&#8221;). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#8217;s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company&#8217;s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit). On February 8, 2019, after the Merger, the Company issued 74,997,546 shares to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 3, 2019, the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (&#8220;FINRA&#8221;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#8217;s common stock were exchanged for 17,693,625 shares of the Company&#8217;s Common Stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (&#8220;Kameyama&#8221;) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#8217;s Common Stock at $1.00 per share for any amount exceeding $3,000. The Company&#8217;s stocks shall be calculated and issued in December every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued 24,694 stock options to Kameyama related to unpaid consulting fees of $49,388 (see Note 14).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 24, 2017, BriVision entered into a collaborative agreement (the &#8220;BioFirst Collaborative Agreement&#8221;) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On September 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares of the Company&#8217;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. These common shares were issued during the year ended December 31, 2019.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued 644,972 shares of the Company&#8217;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable. As of December 31, 2021 and 2020, stock subscription receivable was $2,257,400 and $3,160,360, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August, 2019, the Company entered into several Conversion Agreements to all creditors that are listed under below table of &#8220;due to related parties&#8221; in consideration for a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements, creditor agrees to convert the amount of debt into the Company&#8217;s common stock at a price of $7.00 per share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of<br/> Debt<br/> Converted</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> Shares<br/> Issued</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Lion Arts Promotion Inc</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">97,864</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">13,981</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">LionGene Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">428,099</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">61,157</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,902,911</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">414,702</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">AsiaGene Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">160,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,858</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">YuanGene Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">92,690</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">13,242</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">The Jiangs</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,190,776</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">170,111</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,872,340</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,051</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2020, the board of directors of the Company approved and adopted an amendment to the Company&#8217;s Articles of Incorporation, to increase the authorized shares of its common stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 8, 2020, the Company entered an agreement with View Trade Securities Inc. (&#8220;ViewTrade&#8221;) to engage ViewTrade as the placement agent&#160;and the Company&#8217;s advisor/consultant with respect to its ongoing capital events. Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision. As of December 31, 2020, the Company has issued 60,000 shares of common stock to ViewTrade for the consulting fee with an estimated value of $135,000. The warrants were never issued and the parties mutually agreed to terminate the agreement on November 19, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the termination agreement, the Company issued 50,000 shares of the Company&#8217;s common stock at a price of $5 per share as a termination
fee on June 29, 2021, of which 6,000 shares were issued to WallachBeth Capital LLC (&#8220;WallachBeth&#8221;). In January 2021, WallachBeth
entered into a consulting agreement with the Company pursuant to which the Company engaged WallachBeth to conduct due diligence and research
work with respect to the Company. On June 29, 2021, WallachBeth was issued 6,000 shares of common stock as compensation for those services.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also on November 19, 2020, the Company and ViewTrade agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only. In addition to a retainer fee, the Company agreed to issue 200,000 warrants, with an exercise price of $2.25, an industry standard cashless exercise provision, and a term of 5 years from November 19, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year&#160;ended December 31, 2020, the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company agreed to pay the service fee by issuing 50,000 shares of unrestricted common shares, valued at the closing price of $2.9 per share on the grant date. These shares have been issued during the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company received aggregated capital contributions of $7,615,331 in cash from 45 investors through private placements of the sale of the Company&#8217;s common stock for the purchase price of&#160;$2.25 per share and a free warrant attached with each common stock purchased. In December 2020, 3,384,615 shares of the Company&#8217;s common stock have been issued.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee by issuing 521,887 shares of unrestricted common shares, valued at the closing price from $2 to $3.68 per share on the grant date. These shares have been issued in October and December 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2020, the Company issued aggregated common shares of 915,856 to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests, including the debt conversion to the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#8217;s common stock, and warrants to purchase 159,145 shares of the Company&#8217;s common stock.</span></td></tr> </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#8217;s common stock, and warrants to purchase 192,784 shares of the Company&#8217;s common stock.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#8217;s common stock, and warrants to purchase 120,121 shares of the Company&#8217;s common stock.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See Note 7 for more details in connection with the above debt conversion.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2021, 1,111,112 shares of the Company&#8217;s common stock and warrants were issued pursuant to the conversion of convertible promissory note of $2,500,000 entered in October 2020 (see Note 7).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 5, 2021, the Company closed its public offering (the &#8220;Public Offering&#8221;) of 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of the Company&#8217;s common stock, one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. In August 2021, 2,354,145 shares of the Company&#8217;s common stock were issued for gross proceeds of $6,875,000, before placement agent fees and legal fees of $850,429.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company received $4,244,452&#160;in gross proceeds from the exercise of warrants issued in the Company&#8217;s August 3, 2021, public offering of securities. Investors exercised a total of&#160;673,405&#160;Series A warrants at a price of $6.30&#160;per share and&#160;200&#160;Series B warrants at a price of $10&#160;per share. Pursuant to these exercises, the Company issued an aggregate of 673,605 shares of Common Stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant date. These shares have been issued during the year ended December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032663176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockOptionsTextBlock', window );">STOCK OPTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>14. STOCK OPTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 30, 2020, the Company issued an aggregate
of 545,182 shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive
Plan, as amended, at a conversion price of $2 per share; the total amount of converted salaries and consulting fees was $1,090,361. On
November 21, 2020, the Company entered&#160;into&#160;acknowledgement&#160;agreements and stock option purchase agreements with these
employees and consultant; pursuant to which the Company granted stock options to purchase 545,182 shares of the Company&#8217;s common
stock in lieu of common stock. The options were vested at the grant date and become exercisable for 10 years from the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 15, 2021, the Company entered&#160;into
stock option agreements with 11 directors and 3 employees, pursuant to which the Company granted options to purchase an aggregate of 1,280,002
shares of common stock&#160;under the 2016 Equity Incentive Plan, as amended, at an exercise price of $3 per share. The options were vested
at the grant date and become exercisable for 10 years from the grant date.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Options issued and outstanding as of December
31, 2021, and their activities during the year then ended are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Underlying<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per&#160;Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Contractual<br/> Life<br/> Remaining<br/> in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding as of January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">545,182</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-size: 10pt">&#8239;-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,280,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.51</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.51</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.51</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of stock options granted for the
year ended December 31, 2021 was calculated using the Black-Scholes option-pricing model applying the following assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Risk free interest rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.13</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108.51</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The weighted average grant date fair value of
options granted during the years ended&#160;December 31, 2021 was $2.09. There are 2,979,264&#160;options available for grant under the
2016 Equity Incentive Plan as of December 31, 2021. Compensation costs associated with the Company&#8217;s stock options are recognized,
based on the grant-date fair values of these options over vesting period. Accordingly, the Company recognized stock-based compensation
expense of $0 and $0 for the three months ended March 31, 2022 and 2021, respectively. There were no options exercised during the three
months ended March 31, 2022. As of March 31, 2022, there were no unvested options.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14. STOCK OPTIONS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 30, 2020, the Company issued an aggregate of 545,182 shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive Plan, as amended, at a conversion price of $2 per share; the total amount of converted salaries and consulting fees was $1,090,361. On November 21, 2020, the Company entered&#160;into&#160;acknowledgement&#160;agreements and stock option purchase agreements with these employees and consultant; pursuant to which the Company granted stock options to purchase 545,182 shares of the Company&#8217;s common stock in lieu of common stock. The options were vested at the grant date and become exercisable for 10 years from the grant date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On October 15, 2021, the Company entered&#160;into stock option agreements with 11 directors and 3 employees, pursuant to which the Company granted options to purchase an aggregate of 1,280,002 shares of common stock&#160;under the 2016 Equity Incentive Plan, as amended, at an exercise price of $3 per share. The options were vested at the grant date and become exercisable for 10 years from the grant date.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options issued and outstanding as of December 31, 2021, and their activities during the year then ended are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number&#160;of</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Underlying<br/> Shares</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price<br/> Per&#160;Share</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> in Years</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Outstanding as of January 1, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">545,182</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">2.00</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,280,002</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Forfeited</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Outstanding as of December 31, 2021</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">2.70</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">9.51</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">616,056</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Exercisable as of December 31, 2021</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">2.70</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">9.51</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">616,056</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Vested and expected to vest</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td>
    <td style="padding-bottom: 4pt; text-align: right">2.70</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">9.51</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">616,056</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of stock options granted for the year ended December 31, 2021 and 2020 was calculated using the Black-Scholes option-pricing model applying the following assumptions:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1.13</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">0.38</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term (in years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5.00</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">108.51</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">89.01</td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company granted options to purchase&#160;545,182&#160;and&#160;1,280,002&#160;shares of common stock to employees and certain consultants during the years ended&#160;December 31, 2021&#160;and&#160;2020,&#160;respectively.&#160;The weighted average grant date fair value of options granted during the years ended&#160;December 31, 2021&#160;and&#160;2020 was $2.09&#160;and $3.13, respectively. There are 2,979,264&#160;options available for grant under the 2016 Equity Incentive Plan as of December 31, 2020. Compensation costs associated with the Company&#8217;s stock options are recognized, based on the grant-date fair values of these options over vesting period. Accordingly, the Company recognized stock-based compensation expense of $2,675,205 and $1,706,419 for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021 and 2020, there were no unvested options. There were no options exercised during the years ended December 31, 2021 and 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockOptionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockOptionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032650776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>15. LOSS PER SHARE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Basic loss per share is computed by dividing net
loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss
by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31,
2022 and 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months<br/> Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss attributable to ABVC&#8217;s common stockholders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,995,440</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,128,505</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted-average shares outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">29,683,402</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,420,526</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Stock options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8211;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8211;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">29,683,402</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,420,526</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">-Basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.20</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">-Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.20</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diluted loss per share takes into account the
potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15. LOSS PER SHARE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year ended December 31, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/>
Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Numerator:</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net loss attributable to ABVC&#8217;s common stockholders</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(12,838,813</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(9,791,164</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding - Basic</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">25,053,522</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">19,715,559</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Stock options</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">&#160;</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">25,053,522</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">19,715,559</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">-Basic</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(0.51</td>
    <td style="padding-bottom: 4pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(0.50</td>
    <td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">-Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(0.51</td>
    <td style="padding-bottom: 4pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(0.50</td>
    <td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635029814728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesOfLesseeDisclosuresTextBlock', window );">LEASE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>16. LEASE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#8220;ASC 842&#8221;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company applied the following practical expedients in the transition
to the new standard and allowed under ASC 842:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities. ROU assets represent the
Company&#8217;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#8217;s obligation to make
lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#8217;s future minimum based payments used
to determine the Company&#8217;s lease liabilities mainly include minimum based rent payments. As most of Company&#8217;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognized lease liabilities, with
corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no finance leases. The Company&#8217;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#8217;s operating leases have remaining lease terms of up to approximately five years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,382,695</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,471,899</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities (current)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349,008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347,100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease liabilities (noncurrent)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,033,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,124,799</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Supplemental Information</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following provides details of the Company&#8217;s
lease expenses:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">85,857</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78,847</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other information related to leases is presented
below:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">85,857</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78,847</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Weighted Average Remaining Lease Term:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2.65 years </span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2.90 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted Average Discount Rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.37</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.39</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating<br/> leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022 (excluding three months ended March 31, 2022)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">266,024</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">359,279</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">374,283</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">338,676</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,916</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,395,178</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,484</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,382,694</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16. LEASE</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (&#8220;ASC 842&#8221;) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applied the following practical expedients in the transition to the new standard and allowed under ASC 842:</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use (&#8220;ROU&#8221;) assets and lease liabilities. ROU assets represent the Company&#8217;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company&#8217;s future minimum based payments used to determine the Company&#8217;s lease liabilities mainly include minimum based rent payments. As most of Company&#8217;s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has no finance leases. The Company&#8217;s leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements. The Company&#8217;s operating leases have remaining lease terms of up to approximately five years.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">ASSETS</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease right-of-use assets</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,471,899</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,772,747</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">LIABILITIES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease liabilities (current)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">347,100</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">316,178</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease liabilities (noncurrent)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,124,799</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,456,567</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Supplemental Information</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following provides details of the Company&#8217;s lease expenses:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">335,208</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">337,282</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other information related to leases is presented below:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Cash paid for amounts included in the measurement of operating lease liabilities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">335,208</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">337,282</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted Average Remaining Lease Term:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating leases</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.90 years</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.08 years</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted Average Discount Rate:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating leases</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.39</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0.55</td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
minimum future annual payments under non-cancellable leases during the next five years and thereafter, at rates now in force, are as
follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating leases</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">2022</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">353,896</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">360,994</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">2024</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">375,938</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">2025</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">338,676</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">56,916</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments, undiscounted</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,486,420</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">14,521</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of future minimum lease payments</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,471,899</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesOfLesseeDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesOfLesseeDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032669304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>17. BUSINESS COMBINATION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company consummated the
Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned
subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, &#8220;Business Combination&#8221; to record the merger
transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey&#8217;s
results of operations were included in the Company&#8217;s results beginning February 8, 2019. The purchase price has been allocated to
the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Purchase consideration:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Common Stock (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,341,847</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Allocation of the purchase price:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">531,147</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,550</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,075</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">485,684</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Security deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,271,896</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,204</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(251,335</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(267,256</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tenant security deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(577,675</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">694,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Goodwill as a result of the Merger</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,647,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"/> <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-size: 10pt">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 8, 2019, the Company has recorded
a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of
the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company&#8217;s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably
assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation
of the Merger.</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17. BUSINESS COMBINATION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2019, the Company consummated the Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, &#8220;Business Combination&#8221; to record the merger transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey&#8217;s results of operations were included in the Company&#8217;s results beginning February 8, 2019. The purchase price has been allocated to the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Purchase consideration:</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Common Stock (*)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">44,341,847</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Allocation of the purchase price:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Cash and cash equivalents</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">531,147</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accounts receivable, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">188,550</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">56,075</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">485,684</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Security deposits</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">10,440</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Total assets acquired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,271,896</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(56,204</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accrued expenses and other current liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(251,335</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease liability</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(267,256</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Tenant security deposit</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(2,880</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Total liabilities assumed</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(577,675</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Total net assets acquired</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">694,221</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Goodwill as a result of the Merger</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">43,647,626</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"> <tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"/> <td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</span></td> </tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 8, 2019, the Company has recorded a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company&#8217;s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation of the Merger.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032775480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>18. SUBSEQUENT EVENTS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 16, 2022, the Company entered&#160;into
stock option agreements with 5 directors, pursuant to which the Company granted options to purchase an aggregate of 761,920 shares of
common stock&#160;under the 2016 Equity Incentive Plan, as amended, at an exercise price of $3 per share. The options were vested at the
grant date and become exercisable for 10 years from the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 11, 2022, the Company and certain investors
entered into certain securities purchase agreement relating to the offer and sale of 2,000,000 shares of common stock, par value $0.001
per share in a registered direct offering. Pursuant to the Offering, the Company will also issue 5-year warrants to purchase 2,000,000
shares of Common Stock, exercisable at a price of $2.45 per share to the Purchasers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has evaluated subsequent events through
the date which the consolidated financial statements were available to be issued. All subsequent events requiring recognition as of March
31, 2022 have been incorporated into these consolidated financial statements and there are no other subsequent events that require disclosure
in accordance with FASB ASC Topic 855, &#8220;Subsequent Events.&#8221;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18. SUBSEQUENT EVENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company entered into a Collaborative Agreement with BioLite, Inc., a company incorporated under the laws of Taiwan, and a subsidiary of the Company, (&#8220;BioLite&#8221;) on December 29, 2015, and then entered into two addendums to such agreement (as amended and revised, (the &#8220;Agreement&#8221;)).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Agreement, the Company acquired the sole licensing rights to develop and commercialize for therapeutic purposes six compounds from BioLite. In accordance with the terms of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity securities owned by it at various stages on a schedule dictated by BioLite&#8217;s achievements of certain milestones, as set forth in the Agreement (the &#8220;Milestone Payments&#8221;) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501 is approved for sale in the licensed territories. If BioLite fails to reach any of the milestones in a timely manner, it may not receive the rest of the payments from the Company. According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the &#8220;December 2021 Payment&#8221;) and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company&#8217;s Board of Directors determined that the December 2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000, that BioLite owes the Company as of December 31, 2021. On February 22, 2022, the parties entered into an amendment to the Agreement allowing the Company to make all payments due under the Agreement via the forgiveness of debt, in equal value, owed by BioLite to the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This was a related party transaction and was conducted at arm&#8217;s length. In addition to the Company&#8217;s board of directors approving the modification of terms of the Agreement, the Company&#8217;s audit committee approved them too. The Board believes it is in the Company&#8217;s best interest to cancel outstanding debt and apply it to the December 2021 Payment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following such approval, the Company and BioLite entered into an amendment to the Agreement reflecting the modified payment method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company also issued an aggregate of 1,306,007 shares of common stock to consultants, who provided consulting services in January 2022; it issued an additional 75,000 shares to another consultant in March 2022, based on the 6-month consulting and advisory services agreement, with a monthly payment of USD $15,000.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of December 31, 2021 have been incorporated into these financial statements and there are no other subsequent events that require disclosure in accordance with FASB ASC Topic 855, &#8220;Subsequent Events.&#8221;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026841976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Basis of Presentation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;).
All significant intercompany transactions and account balances have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&#8217;s financial statements are expressed in U.S. dollars.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Basis of Presentation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#8220;U.S. GAAP&#8221;). All significant intercompany transactions and account balances have been eliminated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#8217;s financial statements are expressed in U.S. dollars.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Year</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fiscal Year</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company changed its fiscal year from the period
beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January
1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Fiscal Year</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Use of Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Use of Estimates</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Inventory</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Inventory</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ForwardStockSplitsPolicyTextBlock', window );">Forward Stock Split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Forward Stock Split</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Forward Stock Split</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockReverseSplitPolicyTextBlock', window );">Stock Reverse Split</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Stock Reverse Split</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 12, 2019, the Board of Directors of the
Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#8220;Reverse
Split&#8221;) of both the authorized common stock of the Company (the &#8220;Common Stock&#8221;) and the issued and outstanding Common
Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the
Reverse Split without obtaining approval of the Company&#8217;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On
May 3, 2019, the Company filed a certificate of amendment to the Company&#8217;s articles of incorporation (the &#8220;Amendment&#8221;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) informed
the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect
this 1-for-18 reverse stock split.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Stock Reverse Split</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#8220;Reverse Split&#8221;) of both the authorized common stock of the Company (the &#8220;Common Stock&#8221;) and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company&#8217;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company&#8217;s articles of incorporation (the &#8220;Amendment&#8221;) to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Fair Value Measurements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">FASB ASC 820, &#8220;Fair Value Measurements&#8221;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the
assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px; padding-bottom: 8pt"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="padding-bottom: 8pt; text-align: justify"><span style="font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&#8217;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short.
The carrying value of the Company&#8217;s long-term bank loan approximates fair value because the interest rates approximate market rates
that the Company could obtain for debt with similar terms and maturities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Fair Value Measurements</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FASB ASC 820, &#8220;Fair Value Measurements&#8221; defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company&#8217;s short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company&#8217;s long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Cash and Cash Equivalents</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2022 and December 31, 2021, the Company&#8217;s
cash and cash equivalents amounted $2,717,936 and $5,828,548, respectively. Some&#160;of the Company&#8217;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Cash and Cash Equivalents</span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2021 and 2020, the Company&#8217;s cash and cash equivalents amounted $5,828,548 and $4,273,208, respectively. Some&#160;of the Company&#8217;s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Restricted Cash Equivalents</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2022 and December 31, 2021, the Company&#8217;s restricted cash equivalents
amounted $714,652 and $736,667, respectively.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Restricted Cash Equivalents</span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of December 31, 2021 and 2020, the Company&#8217;s restricted cash equivalents amounted $736,667 and $728,163, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Concentration of Credit Risk</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation&#8217;s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Revenue Recognition</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#8217;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#8217;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&#8217;s revenue during all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within
the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the
goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the
scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price
that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Collaborative Revenues &#8212; </b>The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees,
development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales
of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed
products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing
activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s judgment.
Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited to,
the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated
duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on
a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(i) Non-refundable upfront payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a license to the Company&#8217;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and
it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(ii) Milestone payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company is eligible to receive milestone payments
under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial
events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into
two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration
partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative agreement with
collaboration partners.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded
that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each
triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more
of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional
payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete
each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi)
a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone
payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in
the period in which the underlying triggering event occurs.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iii) Multiple Element Arrangements</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s),
delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an
item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which is
typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance or objectively
measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over
the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service
is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue
under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount
of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance
method, as applicable, as of the period ending date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable
relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical,
regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment
required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether
a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive
are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other
revenue recognition criteria are met.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(iv) Royalties and Profit Sharing Payments</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is
resolved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues Derived from Research and Development
Activities Services &#8212; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception
of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request
that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset
to research and development expenses as it satisfies the related performance obligations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Revenue Recognition</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fiscal year 2018, the Company adopted Accounting Standards Codification (&#8220;ASC&#8221;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#8217;s reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#8217;s review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company&#8217;s revenue during all periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Collaborative Revenues</b> &#8212; The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&amp;D personnel costs, discount rates and probabilities of technical and regulatory success.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company&#8217;s deliverables requires the use of management&#8217;s judgment. Significant factors considered in management&#8217;s evaluation of the estimated performance periods include, but are not limited to, the Company&#8217;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i) Non-refundable upfront payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii) Milestone payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company&#8217;s obligations under the collaborative agreement with collaboration partners.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii) Multiple Element Arrangements</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company&#8217;s contractual or estimated performance period for the undelivered elements, which is typically the term of the Company&#8217;s research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#8217;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv) Royalties and Profit Sharing Payments</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenues Derived from Research and Development Activities Services &#8212; Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company&#8217;s transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Property and Equipment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Property and Equipment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted Accounting Standards Codification
subtopic 360-10, Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable
intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events
and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring
losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated,
the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and
ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or
the fair value less costs to sell.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Impairment of Long-Lived Assets</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (&#8220;ASC 360-10&#8221;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermEquityInvestmentPolicy', window );">Long-term Equity Investment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Long-term Equity Investment</span>&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company
does not have control over the investees as:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Non-marketable cost method investments when the equity method does not apply.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant judgment is required to identify whether
an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, and therefore the Company considers this
a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact
on the investee&#8217;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term
prospects of the investee, changes in general market conditions in the investee&#8217;s industry or geographic area, and the management
and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market
and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent
financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding
the investees&#8217; revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment
exists could change in the future due to new developments or changes in applied assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Long-term Equity Investment</span>&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable cost method investments when the equity method does not apply.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant judgment is required to identify whether an impairment exists in the valuation of the Company&#8217;s non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#8217;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee&#8217;s industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#8217; revenue, costs, and discount rates. The Company&#8217;s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OtherThanTemporaryImpairmentPolicyTextBlock', window );">Other-Than-Temporary Impairment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Other-Than-Temporary Impairment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 24px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#8217;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">Non-marketable equity investments based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairment of equity investments were $0 and $0 for the three months ended March 31, 2022 and 2021, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Other-Than-Temporary Impairment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#8217;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.</span></td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-marketable equity investments based on the Company&#8217;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#8217;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $961,217 for the year ended December 31, 2021 and 2020, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Goodwill</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing
goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that
the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our
best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share,
and general economic conditions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company completed the required testing of
goodwill for impairment as of March 31, 2022, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Goodwill</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company completed the required testing of goodwill for impairment as of December 31, 2021, and determined that goodwill was impaired because of the current financial condition of the Company and the Company&#8217;s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Research and Development Expenses</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For CDMO business unit, the Company accounts for
R&amp;D costs in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, Research and Development (&#8220;ASC 730&#8221;).
Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development
projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities,
including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing
and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable
advance payment for goods and services that will be used in future research and development activities are expensed when the activity
has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into
agreements with third parties to provide research and development services, costs are expensed as services are performed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Research and Development Expenses</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For our CDMO business unit, the Company accounts for R&amp;D costs in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 730, Research and Development (&#8220;ASC 730&#8221;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy', window );">Post-retirement and post-employment benefits</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Post-retirement and post-employment benefits</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&#8217;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#8217;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#8217; salaries to the employees&#8217;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $3,337 and $2,503 for the three months ended March 31, 2022 and 2021, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Post-retirement and post-employment benefits</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company&#8217;s subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#8220;Act&#8221;) in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#8217;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#8217; salaries to the employees&#8217; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $11,375 and $13,961 for the year ended December 31, 2021 and 2020, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Stock-based Compensation</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221; and FASB ASC Topic 505-50 &#8220;Equity-Based
Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $4,692,003 and $225,740 for the three months ended March 31, 2022 and 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Stock-based Compensation</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221;. Total employee stock-based compensation expenses were $2,675,205 and $1,623,102 for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 &#8220;Compensation-Stock Compensation&#8221; and FASB ASC Topic 505-50 &#8220;Equity-Based Payments to Non-Employees&#8221; which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $2,631,550 and $2,523,877 for the year ended December 31, 2021 and 2020, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BeneficialConversionFeature', window );">Beneficial Conversion Feature</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Beneficial Conversion Feature</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Beneficial Conversion Feature</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Income Taxes</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under ASC 740, a tax position is recognized as
a benefit only if it is&#160;&#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2022 and 2021. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&#8220;SAB 118&#8221;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC
740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is
able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company
cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of
the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable
estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act
may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that
may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine
the final impact.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Income Taxes</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 740, a tax position is recognized as a benefit only if it is &#8220;more likely than not&#8221;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the year ended December 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 22, 2017, the SEC issued Staff Accounting Bulletin (&#8220;SAB 118&#8221;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock', window );">Valuation of Deferred Tax Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A valuation allowance is recorded to reduce the
Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Valuation of Deferred Tax Assets</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A valuation allowance is recorded to reduce the Company&#8217;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#8217;s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share of Common Stock</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Loss Per Share of Common Stock</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company calculates net loss per share in accordance
with ASC Topic 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted average
number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that
the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common
stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Loss Per Share of Common Stock</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company calculates net loss per share in accordance with ASC Topic 260, &#8220;Earnings per Share&#8221;. Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Commitments and Contingencies</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has adopted ASC Topic 450 &#8220;Contingencies&#8221;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies
are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates
that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount
of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency
is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably
possible that a material loss could be incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Commitments and Contingencies</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has adopted ASC Topic 450 &#8220;Contingencies&#8221; subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign-currency Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Foreign-currency Transactions</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the Company&#8217;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the transactions
occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into
New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion
or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange
rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares
of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#8217; Equity (Deficit).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Foreign-currency Transactions</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Company&#8217;s subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars (&#8220;NTD&#8221;) at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#8217; Equity (Deficit).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_TranslationAdjustmentPolicyTextBlock', window );">Translation Adjustment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Translation Adjustment</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accounts of the Company&#8217;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#8220;NT$&#8221;). Such financial statements
were translated into U.S. Dollars (&#8220;$&#8221; or &#8220;USD&#8221;) in accordance ASC 830, &#8220;Foreign Currency Matters&#8221;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&#8217;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#8217;
equity (deficit).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Translation Adjustment</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accounts of the Company&#8217;s subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#8220;NT$&#8221;). Such financial statements were translated into U.S. Dollars (&#8220;$&#8221; or &#8220;USD&#8221;) in accordance ASC 830, &#8220;Foreign Currency Matters&#8221;, with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder&#8217;s deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#8217; equity (deficit).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2020, the FASB issued ASU 2020-06, Debt
&#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity
(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). ASU
2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models.
Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not
clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will
reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings
per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For
contracts in an entity&#8217;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features
that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements
to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted,
and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted,
but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company
is currently evaluating the impact that the standard will have on its consolidated financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>In May 2021, the FASB issued ASU 2021-04, Earnings
Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic
718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain
Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04 provides guidance
as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written
call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new
instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified
or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model
that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination,
debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for
all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should
apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early
adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an
interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period.<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For contracts in an entity&#8217;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt &#8212; Modifications and Extinguishments (Subtopic 470-50), Compensation &#8212; Stock Compensation (Topic 718), and Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#8220;ASU 2021-04&#8221;). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ForwardStockSplitsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for forward stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ForwardStockSplitsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermEquityInvestmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-term equity investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermEquityInvestmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OtherThanTemporaryImpairmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other than temporary impairment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OtherThanTemporaryImpairmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockReverseSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Stock Reverse Split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockReverseSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_TranslationAdjustmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_TranslationAdjustmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for valuation of deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235144<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235172<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235116<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635116158200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of property and equipment useful lives</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated&#160;Life<br/> in Years</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Buildings and leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">5 ~ 50</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: center">5 ~ 10</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Office equipment</td><td>&#160;</td>
    <td style="text-align: center">3 ~ 6</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated&#160;Life<br/> in Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Buildings and leasehold improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 ~ 50</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 ~ 10</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 ~ 6</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635029748616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Finished goods</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">104,036</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96,725</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Raw materials</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">69,287</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">84,620</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(150,623</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,370</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Inventory, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,975</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Finished goods</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">96,725</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">100,967</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Work-in-process</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,038</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Raw materials</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">84,620</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">61,718</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Allowance for inventory valuation and obsolescence loss</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(155,370</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(184,723</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Inventory, net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">25,975</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-105">-</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026825512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Land</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">387,866</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">400,091</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Buildings and leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,230,968</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,235,061</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Machinery and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,102,943</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,013,376</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Office equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">186,149</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">191,824</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,907,926</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,840,352</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,309,278</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,314,471</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">598,648</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">525,881</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Land</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">400,091</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">395,645</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Buildings and leasehold improvements</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,235,061</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,233,573</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Machinery and equipment</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,013,376</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">994,544</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Office equipment</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">191,824</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">189,760</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,840,352</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3,813,522</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(3,314,471</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(3,298,688</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Property and equipment, net</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">525,881</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">514,834</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026004216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentAbstract', window );"><strong>Long Term Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks', window );">Schedule of ownership percentages of investee</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Ownership percentage</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Accounting</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Name of related party</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">treatments</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.17</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.70</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Cost Method</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15.99</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Equity Method</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rgene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">31.62</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: center">Equity Method</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="3" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ownership percentage</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December&#160;31,</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accounting</b></span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of related party</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>treatments</b></span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.17%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.70%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.90%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.90%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost Method</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.99%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.99%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td>
    <td>&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.62%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.62%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Method</span></td>
    <td>&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfExtentInvesteeReliesTableTextBlock', window );">Schedule of extent the investee relies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left">Name of related party</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left">The extent the investee relies on the Company for its business </td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Braingenesis Biotechnology Co., Ltd.</td><td>&#160;</td>
    <td style="text-align: left">No specific business relationship</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Genepharm Biotech Corporation</td><td>&#160;</td>
    <td style="text-align: left">No specific business relationship</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td>
    <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Rgene Corporation</td><td>&#160;</td>
    <td style="text-align: left">Collaborating with the Company to develop and commercialize drugs</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><b>&#160;&#160;</b></p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of related party</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>The extent the investee relies on the Company for its business </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Braingenesis Biotechnology Co., Ltd.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Genepharm Biotech Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No specific business relationship</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioHopeKing Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loaned from the investee and provides research and development support service</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaborating with the Company to develop and commercialize drugs</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfLongTermInvestmentTableTextBlock', window );">Schedule of long-term investment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-marketable Cost Method Investments, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Braingenesis Biotechnology Co., Ltd.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,698</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">7,941</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Genepharm Biotech Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,503</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,244</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">BioHopeKing Corporation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">873,053</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">900,570</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Sub total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">904,254</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">932,755</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Equity Method Investments, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-88">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-89">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Rgene Corporation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 0.25in">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">904,254</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">932,755</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Non-marketable Cost Method Investments, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Braingenesis Biotechnology Co., Ltd.</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">7,941</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">7,853</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Genepharm Biotech Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">24,244</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">23,974</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">BioHopeKing Corporation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">900,570</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">890,564</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Sub total</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">932,755</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">922,391</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Equity Method Investments, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left">BioFirst Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">268,336</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Rgene Corporation</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-107">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-108">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">932,755</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,190,727</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pf0_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of balance sheets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,147,097</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,205,669</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">812,865</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">959,454</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,237,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,909,703</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,522</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(295,402</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,898</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Current Assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">221,169</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">73,452</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">355,420</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">374,423</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,164,077</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,934,786</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Noncurrent Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shareholders&#8217; Deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,587,488</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,486,911</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Current Assets</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">2,205,669</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,299,822</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Noncurrent Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">959,454</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,540,041</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,909,703</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,986,340</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Noncurrent Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">32,522</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">73,197</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Stockholders&#8217; Equity</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">222,898</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,780,326</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Current Assets</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">73,452</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">123,958</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Noncurrent Assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">374,423</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">412,342</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Current Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,934,786</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,392,756</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Noncurrent Liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">-</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">38,953</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Shareholders&#8217; Deficit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,486,911</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(895,409</td>
    <td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pf0_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Schedule of statements of operation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net sales</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">8,808</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,339</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,133</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,080</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(498,940</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(220,855</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share of losses from investments accounted for using the equity method</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,791</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net sales</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Gross Profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(149,480</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(95,395</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share of loss from investments accounted for using the equity method</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97">-</div></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net sales</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">26,693</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">257,235</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross profit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">8,348</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">10,121</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(2,276,892</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(5,401,074</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share of losses from investments accounted for using the equity method</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(269,844</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(1,168,733</td>
    <td style="text-align: left">)</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net sales</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-109">-</div></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">16,595</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Gross Profit</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(335,735</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net loss</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(576,514</td>
    <td style="text-align: left">)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(641,636</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Share of loss from investments accounted for using the equity method</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of equity investments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(Unaudited)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Share of equity method investee losses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(47,791</td><td style="width: 1%; text-align: left">)</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%">Share of equity method investee losses</td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td>
    <td style="text-align: right; width: 9%">(269,844</td>
    <td style="text-align: left; width: 1%">)</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">(1,168,733</td>
    <td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfExtentInvesteeReliesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of extent the investee relies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfExtentInvesteeReliesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfLongTermInvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfLongTermInvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pf0_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pf0_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pf0_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pf0_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pf0_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pf0_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635029931800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansAbstract', window );"><strong>Bank Loans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of short-term bank loan</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cathay United Bank</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">261,750</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">270,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CTBC Bank</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">698,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">720,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cathay Bank</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,609,750</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,640,000</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Cathay United Bank</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">270,000</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">267,000</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left">CTBC Bank</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">720,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">712,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cathay Bank</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">650,000</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,640,000</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,629,000</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BankLoansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BankLoansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026018952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Name of entity or Individual</td><td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left">Relationship with the Company and its subsidiaries</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Rgene Corporation (the &#8220;Rgene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">YuanGene Corporation (the &#8220;YuanGene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Controlling beneficiary shareholder of the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">AsiaGene Corporation (the &#8220;AsiaGene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Eugene Jiang</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Former President and Chairman</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Yoshinobu Odaira (the &#8220;Odaira&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Director of the Company</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">LBG USA, Inc. (the &#8220;LBG USA&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">LionGene Corporation (the &#8220;LionGene&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Shareholder of the Company</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">The Jiangs</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst <br/> &#160; <br/> Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. <br/> &#160; <br/> Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. <br/> &#160; <br/> Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company. <br/> &#160; <br/> Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Amkey Ventures, LLC (&#8220;Amkey&#8221;)</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">BioLite Japan</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">Entity controlled by controlling beneficiary shareholder of ABVC</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">ABVC BioPharma (HK), Limited</td><td>&#160;</td>
    <td style="vertical-align: top; text-align: left">An entity 100% owned by Mr. Tsung-Shann Jiang</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name of entity or Individual</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Relationship with the Company and its subsidiaries</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst Corporation (the &#8220;BioFirst&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene Corporation (the &#8220;Rgene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">YuanGene Corporation (the &#8220;YuanGene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controlling beneficiary shareholder of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AsiaGene Corporation (the &#8220;AsiaGene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eugene Jiang</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Former President and Chairman</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yoshinobu Odaira (the &#8220;Odaira&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GenePharm Inc. (the &#8220;GenePharm&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LBG USA, Inc. (the &#8220;LBG USA&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LionGene Corporation (the &#8220;LionGene&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder of the Company</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms.
Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and
a member of board of directors of BioLite Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director
of the Company.</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amkey Ventures, LLC (&#8220;Amkey&#8221;)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BioLite Japan</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entity controlled by controlling beneficiary shareholder of ABVC</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock', window );">Schedule of accounts receivable due from related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">GenePharm Inc.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">142,225</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Rgene</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,374</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,374</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Amkey</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">800</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">145,399</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">145,399</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">GenePharm Inc.</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">142,225</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">142,225</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Rgene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,374</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Amkey</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">800</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,210</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">145,399</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">143,435</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of amount due from related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Rgene</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48,586</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49,110</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>BioFirst</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,563,233</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">468,435</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BioFirst (Australia)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">830,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">491,816</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioHopeKing Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">121,153</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124,972</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">LBG USA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioLite Japan</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Keypoint</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,610</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,610</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,715,375</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,286,618</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Rgene</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">49,110</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">42,911</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">AsiaGene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115">-</div></td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">4,241</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">468,435</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst (Australia)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">491,816</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">373,235</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioHopeKing Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">124,972</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">123,583</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">LBG USA</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">675</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">675</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioLite Japan</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">150,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">150,000</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Keypoint</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,610</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,610</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,286,618</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,255</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty', window );">Schedule of amount due to related parties</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">BioFirst Corporation</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,878</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">40,878</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">BioFirst (Australia)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190,913</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,443</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>AsiaGene</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,017</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>YuanGene</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,205</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">The Jiangs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,750</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Due to shareholders</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162,634</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">168,131</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">446,397</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">393,424</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst Corporation</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">40,878</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">23,647</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst (Australia)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">132,443</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">AsiaGene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">24,017</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118">-</div></td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">YuanGene</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">9,205</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">9,205</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">The Jiangs</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">18,750</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">16,627</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Due to shareholders</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">168,131</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">166,261</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Due to employee</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">72,705</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">393,424</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">288,445</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Amount due to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635034365912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtConversionsTextBlock', window );">Schedule of converted amount of debt and shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of<br/> Debt<br/> Converted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Shares<br/> Issued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lion Arts Promotion Inc</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">97,864</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">13,981</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">LionGene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">428,099</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61,157</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">BioFirst Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,902,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">414,702</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">AsiaGene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">160,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,858</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">YuanGene Corporation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,690</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,242</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">The Jiangs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,190,776</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">170,111</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,872,340</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,051</td><td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount of<br/> Debt<br/> Converted</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number&#160;of<br/> Shares<br/> Issued</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Lion Arts Promotion Inc</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">97,864</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">13,981</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">LionGene Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">428,099</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">61,157</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">BioFirst Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">2,902,911</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">414,702</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">AsiaGene Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">160,000</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">22,858</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">YuanGene Corporation</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">92,690</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">13,242</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">The Jiangs</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">1,190,776</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">170,111</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in">Total</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,872,340</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">696,051</td>
    <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtConversionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. The information may be presented entirely or partially in this block of text or in the associated elements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtConversionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027370184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockOptionsTablesLineItems', window );"><strong>Stock Options (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of options issued and outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Underlying<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Exercise<br/> Price<br/> Per&#160;Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-<br/> Average<br/> Contractual<br/> Life<br/> Remaining<br/> in Years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate<br/> Intrinsic<br/> Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%">Outstanding as of January 1, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">545,182</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.00</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-99; font-size: 10pt">&#8239;-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,280,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.00</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Outstanding as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.51</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Exercisable as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.51</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Vested and expected to vest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">2.70</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">9.51</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">616,056</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of stock options granted</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Risk free interest rate</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.13</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">108.51</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<br/> December&#160;31</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Risk free interest rate</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">1.13</td>
    <td style="width: 1%; text-align: left">%</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">0.38</td>
    <td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected term (in years)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">5.00</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0</td>
    <td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected volatility</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">108.51</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">89.01</td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockOptionsTablesLineItems', window );"><strong>Stock Options (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of options issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Average</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Contractual</td>
    <td style="font-weight: bold">&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number&#160;of</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Life</td>
    <td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Aggregate</td>
    <td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Underlying<br/> Shares</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Price<br/> Per&#160;Share</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Remaining<br/> in Years</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic<br/> Value</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Outstanding as of January 1, 2021</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">545,182</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">2.00</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Granted</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,280,002</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">3.00</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Forfeited</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-121">-</div></td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Outstanding as of December 31, 2021</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">2.70</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">9.51</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">616,056</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Exercisable as of December 31, 2021</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">2.70</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">9.51</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">616,056</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Vested and expected to vest</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,825,184</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td>
    <td style="padding-bottom: 4pt; text-align: right">2.70</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: right">9.51</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">616,056</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockOptionsTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockOptionsTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635032006440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months<br/> Ended</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31,<br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss attributable to ABVC&#8217;s common stockholders</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(5,995,440</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,128,505</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Denominator:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Weighted-average shares outstanding:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">29,683,402</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,420,526</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Stock options</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-102">&#8211;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-103">&#8211;</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Weighted-average shares outstanding - Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">29,683,402</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">24,420,526</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">-Basic</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.20</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">-Diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.20</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.05</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the<br/>
Year Ended</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Numerator:</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Net loss attributable to ABVC&#8217;s common stockholders</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(12,838,813</td>
    <td style="width: 1%; text-align: left">)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">(9,791,164</td>
    <td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Denominator:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding - Basic</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">25,053,522</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">19,715,559</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Stock options</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-122">&#160;</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-123">&#160;</div></td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Weighted-average shares outstanding - Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">25,053,522</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: right">19,715,559</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Loss per share</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">-Basic</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(0.51</td>
    <td style="padding-bottom: 4pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(0.50</td>
    <td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">-Diluted</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(0.51</td>
    <td style="padding-bottom: 4pt; text-align: left">)</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">(0.50</td>
    <td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635031964872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock', window );">Schedule of operating lease arrangements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease right-of-use assets</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,382,695</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,471,899</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold">LIABILITIES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities (current)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">349,008</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">347,100</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease liabilities (noncurrent)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,033,686</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,124,799</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">ASSETS</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease right-of-use assets</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,471,899</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">1,772,747</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">LIABILITIES</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease liabilities (current)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">347,100</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">316,178</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease liabilities (noncurrent)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,124,799</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,456,567</td>
    <td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of supplemental information related to operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">85,857</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78,847</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended <br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">85,857</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">78,847</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, <br/> 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, <br/> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Weighted Average Remaining Lease Term:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2.65 years </span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><span style="font-size: 10pt">2.90 years</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted Average Discount Rate:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating leases</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.37</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.39</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease expenses</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">335,208</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">337,282</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Cash paid for amounts included in the measurement of operating lease liabilities</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">335,208</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">337,282</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2021</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31,<br/> 2020</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted Average Remaining Lease Term:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating leases</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.90 years</span></td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.08 years</span></td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted Average Discount Rate:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating leases</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1.39</td>
    <td style="text-align: left">%</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">0.55</td>
    <td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock', window );">Schedule of minimum future annual payments under non-cancellable leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating<br/> leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022 (excluding three months ended March 31, 2022)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">266,024</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">359,279</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">374,283</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">338,676</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">56,916</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total future minimum lease payments, undiscounted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,395,178</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,484</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Present value of future minimum lease payments</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,382,694</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
    <td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Operating leases</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">2022</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">353,896</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">2023</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">360,994</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">2024</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">375,938</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">2025</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">338,676</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">56,916</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total future minimum lease payments, undiscounted</span></td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,486,420</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Imputed interest</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">14,521</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Present value of future minimum lease payments</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">1,471,899</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635034392376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of assets acquired and liabilities assumed based on fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>Purchase consideration:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Common Stock (*)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">44,341,847</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Allocation of the purchase price:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">531,147</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188,550</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">56,075</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">485,684</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Security deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,440</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Total assets acquired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,271,896</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(56,204</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(251,335</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(267,256</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Tenant security deposit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,880</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total liabilities assumed</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(577,675</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total net assets acquired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">694,221</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Goodwill as a result of the Merger</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">43,647,626</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Purchase consideration:</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Common Stock (*)</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td>
    <td style="width: 9%; text-align: right">44,341,847</td>
    <td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Allocation of the purchase price:</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Cash and cash equivalents</td>
    <td>&#160;</td>
    <td style="text-align: left">$</td>
    <td style="text-align: right">531,147</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accounts receivable, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">188,550</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Property and equipment, net</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">56,075</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease right-of-use assets</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">485,684</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Security deposits</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">10,440</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Total assets acquired</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">1,271,896</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accounts payable</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(56,204</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Accrued expenses and other current liabilities</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(251,335</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Operating lease liability</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: right">(267,256</td>
    <td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Tenant security deposit</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(2,880</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Total liabilities assumed</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">(577,675</td>
    <td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Total net assets acquired</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">694,221</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Goodwill as a result of the Merger</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td>
    <td style="border-bottom: Black 4pt double; text-align: right">43,647,626</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="margin-top: 0; margin-bottom: 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028658504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - shares<br></strong></div></th>
<th class="th"><div>Feb. 08, 2019</div></th>
<th class="th"><div>Feb. 08, 2016</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfCommonSharesIssuedAndOutstanding', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583
pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1. ORGANIZATION AND DESCRIPTION OF BUSINESS&#160;ABVC BioPharma, Inc. (the &#8220;Company&#8221;), formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#8217;s operating entity, American BriVision Corporation (&#8220;BriVision&#8221;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical trials for the Company&#8217;s drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering Cancer Center (&#8220;MSKCC&#8221;) and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July 21, 2015.&#160;Name Change&#160;The Company&#8217;s shareholders approved an amendment to the Company&#8217;s Articles of Incorporation to change the Company&#8217;s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &#8220;Annual Meeting&#8221;). The name change amendment to the Company&#8217;s Articles of Incorporation was filed with Nevada&#8217;s Secretary of State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became effective as of May 3, 2021.&#160;The Company&#8217;s stock symbol remains ABVC.&#160;Reverse Merger&#160;On February 8, 2016, a Share Exchange Agreement (the &#8220;Share Exchange Agreement&#8221;) was entered into by and among the Company, BriVision, and Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&#8217;s Republic of China (&#8220;Euro-Asia&#8221;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the &#8220;BriVision Stock&#8221;).&#160;Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the &#8220;Acquisition Stock&#8221;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#8217;s Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#8217;s Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the &#8220;Merger&#8221;).&#160;Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementMember', window );">Share Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,387,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementOneMember', window );">Share Exchange Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementTwoMember', window );">Share Exchange Agreement Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,159,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,945,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfCommonSharesIssuedAndOutstanding', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfIssuedShareCapital', window );">Percentage of issued share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementFourMember', window );">Share Exchange Agreement Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,519,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,431,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_MergerAgreementMember', window );">Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="nump">104,558,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementThreeMember', window );">Share Exchange Agreement Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OrganizationandDescriptionofBusinessDetailsLineItems', window );"><strong>Organization and Description of Business (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CommonStockIssuedAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CommonStockIssuedAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CommonStockIssuedBeforeStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued before stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CommonStockIssuedBeforeStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OrganizationandDescriptionofBusinessDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OrganizationandDescriptionofBusinessDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfCommonSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfCommonSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfIssuedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfIssuedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635025244056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 03, 2019</div></th>
<th class="th"><div>Mar. 03, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 21, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Common Stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Common Stock authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse split ratio</a></td>
<td class="text">the Company filed a certificate of amendment to the Company&#8217;s articles of incorporation (the &#8220;Amendment&#8221;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) informed
the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect
this 1-for-18 reverse stock split.<span></span>
</td>
<td class="text">The Financial Industry Regulatory Authority (&#8220;FINRA&#8221;) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,717,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,828,548<span></span>
</td>
<td class="nump">$ 4,273,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">714,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">736,667<span></span>
</td>
<td class="nump">728,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ImpairmentOfEquityInvestments', window );">Impairment of equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">961,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LabourPensionFundPercentage', window );">Labor pension fund percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfMonthlyContribution', window );">Percentage of monthly contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,337<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">72,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Employee stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,675,205<span></span>
</td>
<td class="nump">1,623,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockBasedCompensationForNonemployees', window );">Non-employee stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,692,003<span></span>
</td>
<td class="nump">$ 225,740<span></span>
</td>
<td class="nump">2,631,550<span></span>
</td>
<td class="nump">2,523,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedPercentage', window );">Benefit percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash', window );">Employee benefits amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,375<span></span>
</td>
<td class="nump">$ 13,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ImpairmentOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of equity investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ImpairmentOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LabourPensionFundPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LabourPensionFundPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfMonthlyContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of monthly contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfMonthlyContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockBasedCompensationForNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation for nonemployees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockBasedCompensationForNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of plan assets to benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027626456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635021754760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 24, 2018</div></th>
<th class="th">
<div>Sep. 25, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 26, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jul. 27, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_MilestonePaymentsRoyaltyPercentage', window );">Milestone payments royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CoDevAgreementDescription', window );">Co-Dev agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company received the remaining balance of $2,550,000 in
the form of newly issued shares of Rgene&#8217;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for
an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year
ended December 31, 2018, the Company has recognized investment loss of $549.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,306,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember', window );">BHK Co-Development Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,649,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Description of payment settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#9679;Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment

    &#160;
    &#9679;
    Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment
  &#160;

    &#160;
    &#9679;
    At the completion of first phase II clinical trial: $1 million, or 10% of total payment
  &#160;

    &#160;
    &#9679;
    At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment
  &#160;&#160;&#9679;Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UpfrontCashPayment', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfPaymentsUnderCodevelopmentAgreement', window );">Percentage of payments under co-development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfStockValue', window );">Common stock newly issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CollaborativeAgreementsDescription', window );">Collaborative agreements, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In 2015, the Company recognized the cash receipt
in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK.<span></span>
</td>
<td class="text">In addition to the total of NT$50 million, approximately
equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.<span></span>
</td>
<td class="text">In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember', window );">BHK Co-Development Agreement [Member] | BioLite Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Description of payment settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#9679;Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment

    &#160;
    &#9679;
    Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment
  &#160;

    &#160;
    &#9679;
    At the completion of first phase II clinical trial: $1 million, or 10% of total payment
  &#160;

    &#160;
    &#9679;
    At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment
  &#160;&#160;&#9679;Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember', window );">Co-Dev Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfPaymentsUnderCodevelopmentAgreement', window );">Percentage of payments under co-development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForParticipationLiabilities', window );">Company cash payments</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AdditionCashPayment', window );">Addition cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfPaymentsUnderCodevelopmentAgreement', window );">Percentage of payments under co-development agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfStockValue', window );">Common stock newly issued, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForParticipationLiabilities', window );">Company cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Licensing rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_BioFirstStockPurchaseAgreementMember', window );">BioFirst Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CollaborativeAgreementsDetailsLineItems', window );"><strong>Collaborative Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent', window );">Amount received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,902,911<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414,702<span></span>
</td>
<td class="nump">428,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AdditionCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AdditionCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CoDevAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Co-Dev agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CoDevAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CollaborativeAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CollaborativeAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CollaborativeAgreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CollaborativeAgreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_IssuanceOfStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_IssuanceOfStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_MilestonePaymentsRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments royalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_MilestonePaymentsRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfPaymentsUnderCodevelopmentAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of payments under co-development agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfPaymentsUnderCodevelopmentAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_UpfrontCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments which are paid during the term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_UpfrontCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount payable to related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForParticipationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments related to participation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473203&amp;loc=d3e55336-107963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForParticipationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_BHKCoDevelopmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_BioFirstStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_BioFirstStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635025232552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Schedule of inventory - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfInventoryAbstract', window );"><strong>Schedule of inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 104,036<span></span>
</td>
<td class="nump">$ 96,725<span></span>
</td>
<td class="nump">$ 100,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">69,287<span></span>
</td>
<td class="nump">84,620<span></span>
</td>
<td class="nump">61,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AllowanceForInventoryValuationAndObsolescenceLoss', window );">Allowance for inventory valuation and obsolescence loss</a></td>
<td class="num">(150,623)<span></span>
</td>
<td class="num">(155,370)<span></span>
</td>
<td class="num">$ (184,723)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, net</a></td>
<td class="nump">$ 22,700<span></span>
</td>
<td class="nump">$ 25,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AllowanceForInventoryValuationAndObsolescenceLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for inventory valuation and obsolescence loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AllowanceForInventoryValuationAndObsolescenceLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635029891832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation expenses</a></td>
<td class="nump">$ 5,411<span></span>
</td>
<td class="nump">$ 2,928<span></span>
</td>
<td class="nump">$ 11,993<span></span>
</td>
<td class="nump">$ 37,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028600184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of property and equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,907,926<span></span>
</td>
<td class="nump">$ 3,840,352<span></span>
</td>
<td class="nump">$ 3,813,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(3,309,278)<span></span>
</td>
<td class="num">(3,314,471)<span></span>
</td>
<td class="num">(3,298,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOtherNet', window );">Property and equipment, net</a></td>
<td class="nump">598,648<span></span>
</td>
<td class="nump">525,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">387,866<span></span>
</td>
<td class="nump">400,091<span></span>
</td>
<td class="nump">395,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,230,968<span></span>
</td>
<td class="nump">2,235,061<span></span>
</td>
<td class="nump">2,233,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,102,943<span></span>
</td>
<td class="nump">1,013,376<span></span>
</td>
<td class="nump">994,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 186,149<span></span>
</td>
<td class="nump">$ 191,824<span></span>
</td>
<td class="nump">$ 189,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOtherNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOtherNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026540248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsLineItems', window );"><strong>Long-Term Investments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of common stock shares</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchaseAdditionalShares', window );">Purchase additional shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,000<span></span>
</td>
<td class="nump">317,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Additional shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PrepaymentForLongtermInvestments', window );">Prepayment for long-term investments (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 663,798<span></span>
</td>
<td class="nump">$ 684,720<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsLineItems', window );"><strong>Long-Term Investments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.99%<span></span>
</td>
<td class="nump">15.99%<span></span>
</td>
<td class="nump">15.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Additional shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">663,798<span></span>
</td>
<td class="nump">684,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Sale of common stock, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the year ended December 31, 2020.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsLineItems', window );"><strong>Long-Term Investments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Percentage of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermInvestmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermInvestmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PrepaymentForLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment for long-term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PrepaymentForLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026634392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.17%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">15.99%<span></span>
</td>
<td class="nump">15.99%<span></span>
</td>
<td class="nump">15.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">31.62%<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AccountingTreatmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AccountingTreatmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027780760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
<td class="text">Loaned from the investee and provides research and development support service<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartyTransactionDescriptionOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents related party descriptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartyTransactionDescriptionOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028558280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of long-term investment - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">$ 904,254<span></span>
</td>
<td class="nump">$ 932,755<span></span>
</td>
<td class="nump">$ 922,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total</a></td>
<td class="nump">904,254<span></span>
</td>
<td class="nump">932,755<span></span>
</td>
<td class="nump">1,190,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">7,698<span></span>
</td>
<td class="nump">7,941<span></span>
</td>
<td class="nump">7,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">23,503<span></span>
</td>
<td class="nump">24,244<span></span>
</td>
<td class="nump">23,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">873,053<span></span>
</td>
<td class="nump">900,570<span></span>
</td>
<td class="nump">890,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">268,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_EquityMethodInvestmentsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_EquityMethodInvestmentsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NonMarketableCostMethodInvestmentsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NonmarketableCostMethodInvestmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NonmarketableCostMethodInvestmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026846536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of balance sheets - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Current Assets</a></td>
<td class="nump">$ 2,147,097<span></span>
</td>
<td class="nump">$ 2,205,669<span></span>
</td>
<td class="nump">$ 1,299,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non-current Assets</a></td>
<td class="nump">812,865<span></span>
</td>
<td class="nump">959,454<span></span>
</td>
<td class="nump">2,540,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="nump">3,237,623<span></span>
</td>
<td class="nump">2,909,703<span></span>
</td>
<td class="nump">1,986,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current Liabilities</a></td>
<td class="nump">17,741<span></span>
</td>
<td class="nump">32,522<span></span>
</td>
<td class="nump">73,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders&#8217; Equity</a></td>
<td class="num">(295,402)<span></span>
</td>
<td class="nump">222,898<span></span>
</td>
<td class="nump">1,780,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Current Assets</a></td>
<td class="nump">221,169<span></span>
</td>
<td class="nump">73,452<span></span>
</td>
<td class="nump">123,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Non-current Assets</a></td>
<td class="nump">355,420<span></span>
</td>
<td class="nump">374,423<span></span>
</td>
<td class="nump">412,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="nump">2,164,077<span></span>
</td>
<td class="nump">1,934,786<span></span>
</td>
<td class="nump">1,392,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">38,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Stockholders&#8217; Equity</a></td>
<td class="num">$ (1,587,488)<span></span>
</td>
<td class="num">$ (1,486,911)<span></span>
</td>
<td class="num">$ (895,409)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028666488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of statements of operation - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NetSales', window );">Net sales</a></td>
<td class="nump">$ 8,808<span></span>
</td>
<td class="nump">$ 12,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_GrossProfits', window );">Gross profit</a></td>
<td class="nump">6,133<span></span>
</td>
<td class="nump">7,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentNetLoss', window );">Net loss</a></td>
<td class="num">(498,940)<span></span>
</td>
<td class="num">(220,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of losses from investments accounted for using the equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,791)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NetSales', window );">Net sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_GrossProfits', window );">Gross profit</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentNetLoss', window );">Net loss</a></td>
<td class="num">(149,480)<span></span>
</td>
<td class="num">(95,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share of losses from investments accounted for using the equity method</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_GrossProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_GrossProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermInvestmentNetLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermInvestmentNetLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028938184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of equity investments - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfEquityInvestmentsAbstract', window );"><strong>Schedule of equity investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareOfEquityMethodInvesteeLosses', window );">Share of equity method investee losses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (47,791)<span></span>
</td>
<td class="num">$ (269,844)<span></span>
</td>
<td class="num">$ (1,168,733)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfEquityInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfEquityInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareOfEquityMethodInvesteeLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of equity method investee losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareOfEquityMethodInvesteeLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635019052552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 05, 2020</div></th>
<th class="th"><div>Aug. 28, 2019</div></th>
<th class="th"><div>Jul. 10, 2019</div></th>
<th class="th"><div>Jul. 21, 2021</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
<th class="th"><div>Oct. 29, 2019</div></th>
<th class="th"><div>Sep. 04, 2019</div></th>
<th class="th"><div>Aug. 28, 2019</div></th>
<th class="th"><div>Jul. 10, 2019</div></th>
<th class="th"><div>May 30, 2019</div></th>
<th class="th"><div>Aug. 25, 2018</div></th>
<th class="th"><div>Jun. 27, 2018</div></th>
<th class="th"><div>May 09, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>May 17, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 07, 2021</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
<th class="th"><div>Jan. 21, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Jan. 21, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertibleNotesPayableDetailsLineItems', window );"><strong>Convertible Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Convertible promissory note received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per unit (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharesOfferingPricePercentage', window );">Shares offering price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Outstanding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregatePrincipalAndAccruedInterestExpense', window );">Aggregate principal and accrued interest expense</a></td>
<td class="nump">$ 354,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Aggregate shares of common stock (in Shares)</a></td>
<td class="nump">192,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion price, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering
price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public
Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value
of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with
KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate
of 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have
been issued during the year ended December 31, 2020On September 4, 2019, the Company issued 3 twelve-month
term unsecured convertible promissory note (the &#8220;C.L.L. Note&#8221;) in an aggregate principal amount of $257,500 to Chang Ping
Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &#8220;C.L.L.&#8221;), pursuant to which the Company received $257,500 on September
4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The
Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until
this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;)
equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into
an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed
to issue to the Holders an aggregate of 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of
common stock. These common shares have been issued during the year ended December 31, 2020.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note. In January 2021, the Company paid off the convertible promissory note of $306,836, including principal and accrued and unpaid interest expense.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have been issued during the year ended December, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Offering price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PublicEquityOfferingExceedAmount', window );">Public equity offering exceed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharesIssued1', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertiblePromissoryNote', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Convertible promissory note, shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued convertible interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertibleNotesPayableDetailsLineItems', window );"><strong>Convertible Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Aggregate shares of common stock (in Shares)</a></td>
<td class="nump">192,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertibleNotesPayableDetailsLineItems', window );"><strong>Convertible Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price per unit (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_UnsecuredConvertiblePromissoryNoteMember', window );">Unsecured convertible promissory note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertibleNotesPayableDetailsLineItems', window );"><strong>Convertible Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregatePrincipalAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 257,500<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Convertible promissory note received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 257,500<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion price, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of common stock. These common shares have been issued during the year ended December 31. 2020.On October 29, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#8220;Lee Note&#8221;) in an aggregate principal amount of $250,000 to Hwalin Lee (the &#8220;Lee&#8221;), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company&#8217;s common stock at a conversion price (the &#8220;Conversion
Price&#8221;) equal to the lower of (i) $0.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70%
of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company
in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission
on November 14, 2018 (the &#8220;Public Offering&#8221;), as amended from time to time. In accordance with FASB ASC 470-20, the Company
recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company
received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company
entered into an agreement with &#8220;KSL&#8221;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL
agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the
Company agreed to issue 120,121 shares of the Company&#8217;s common stock and warrants for a purchase price of $270,272.&#160;During
the year ended December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company&#8217;s common stock.<span></span>
</td>
<td class="text">the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to the lower
of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80% of the per share offering price (the
&#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs
when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20,
the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21,
2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount
in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date
of the new &#8220;Odaira&#8221; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with
&#8220;Odaira&#8221;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to
the Holders an aggregate of 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s
common stock.<span></span>
</td>
<td class="text">the Company&#8217;s common stock at a conversion price (the &#8220;Conversion
Price&#8221;) equal to the lower of (i) $2.00 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment or (ii) 80%
of the per share offering price (the &#8220;Alternative Conversion Price&#8221;) of any completed equity offering of the Company in an
amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint
Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature
present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum.
The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the
Twelve (12) month anniversary of the issuance date of the new &#8220;Keypoint&#8221; Note, which is on January 20, 2021. On April 5, 2020,
the Company entered into an exchange agreement with &#8220;Keypoint&#8221;. The aggregate principal amount plus accrued interest expenses
were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#8217;s common stock, and
warrants to purchase 159,145 shares of the Company&#8217;s common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Equity offering, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The KSL Note bears
interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debenture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued convertible interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 257,500<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_TotalInterestExpenses', window );">Total interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,548<span></span>
</td>
<td class="nump">$ 240,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Conversion Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertibleNotesPayableDetailsLineItems', window );"><strong>Convertible Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion price, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company issued a twelve-month
term unsecured convertible promissory note (the &#8220;KLS Note&#8221;) in an aggregate principal amount of $200,000 to Kuo Li Shen (the
&#8220;KLS&#8221;), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum.
The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this
KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default
interest, if any, into shares of the Company&#8217;s common stock at a conversion price (the &#8220;Conversion Price&#8221;) equal to
the lower of (i) $.50 per share (the &#8220;Fixed Conversion Price&#8221;), subject to adjustment, or (ii) 70% of the per share offering
price (the &#8220;Alternative Conversion Price&#8221;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#8220;Public
Offering&#8221;), as amended from time to time.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note. During the year ended December 31, 2020, the Company issued 111,112 shares of common stock to repay the outstanding balance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertibleNotesPayableDetailsLineItems', window );"><strong>Convertible Notes Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Conversion price, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the October SPA, the Company
sold and issued a convertible promissory note (the &#8220;October Note&#8221;) in the principal amount of $2,500,000 to the investor and
received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of
the October Note is the twenty-four (24) month anniversary from the issuance date (the &#8220;Maturity Date&#8221;). Upon the Maturity
Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest
under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the
Company&#8217;s common stock at a fixed conversion price of $2.25 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate principal amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AggregatePrincipalAndAccruedInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AggregatePrincipalAndAccruedInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConvertibleNotesPayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConvertibleNotesPayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConvertiblePromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConvertiblePromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PublicEquityOfferingExceedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PublicEquityOfferingExceedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharesOfferingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares offering price percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharesOfferingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_TotalInterestExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total interest expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_TotalInterestExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_UnsecuredConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_UnsecuredConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635013901448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Loans (Details)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 14, 2022 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 15, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2020 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 08, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 12, 2017</div></th>
<th class="th">
<div>Jun. 12, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 17, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 18, 2020</div></th>
<th class="th">
<div>Jan. 19, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 18, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 21, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2021 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2021 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jan. 15, 2021 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Oct. 03, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2020 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jul. 17, 2020 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Apr. 08, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 19, 2020 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2019 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jul. 18, 2019 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Sep. 06, 2017 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jul. 19, 2017 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jun. 12, 2017 </div>
<div>TWD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2016 </div>
<div>TWD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 17,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_principalAmount', window );">Principal amount</a></td>
<td class="nump">$ 698,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="nump">$ 261,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ReceivedLoanAmount', window );">Received loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedLoanAgreementMember', window );">Cathay United Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,750<span></span>
</td>
<td class="nump">$ 261,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 28,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedLoanAgreementMember', window );">Cathay United Loan Agreement [Member] | NT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedLoanAgreementMember', window );">Cathay United Loan Agreement [Member] | BioLite Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedLoanAgreementMember', window );">Cathay United Loan Agreement [Member] | BioLite Taiwan [Member] | NT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember', window );">Cathay United Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,386<span></span>
</td>
<td class="nump">$ 1,383<span></span>
</td>
<td class="nump">$ 5,639<span></span>
</td>
<td class="nump">$ 5,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember', window );">CTBC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 698,000<span></span>
</td>
<td class="nump">$ 698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,000<span></span>
</td>
<td class="nump">$ 698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 698,000<span></span>
</td>
<td class="nump">$ 698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 19,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Bears interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,958<span></span>
</td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">$ 12,029<span></span>
</td>
<td class="nump">11,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt instrument payment term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember', window );">CTBC Bank [Member] | NT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember', window );">CTBC Bank [Member] | BioLite Taiwan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="nump">$ 720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember', window );">CTBC Bank [Member] | BioLite Taiwan [Member] | NT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ReceivedLoanAmount', window );">Received loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RegularInterestRateDescription', window );">Regular interest rate, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Note executed in connection with the Loan Agreement bears an interest rate (the
&#8220;Regular Interest Rate&#8221;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the
&#8220;Index&#8221;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company
shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note
before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%)
plus the Regular Interest Rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On March 31, 2020, the Company extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ExceedingAmount', window );">Exceeding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayBankMember', window );">Cathay Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BankLoansDetailsLineItems', window );"><strong>Bank Loans (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,090<span></span>
</td>
<td class="nump">$ 3,927<span></span>
</td>
<td class="nump">$ 18,143<span></span>
</td>
<td class="nump">$ 53,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ReceivedLoanAmount', window );">Received loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLineOfCredit', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BankLoansDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BankLoansDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ExceedingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exceeding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ExceedingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ReceivedLoanAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Received loan amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ReceivedLoanAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RegularInterestRateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regular interest rate description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RegularInterestRateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_principalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_principalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1336-112600<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1314-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_TypeOfCurrencyAxis=abvc_NTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_TypeOfCurrencyAxis=abvc_NTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteTaiwanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioLiteTaiwanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027625208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Bank Loans (Details) - Schedule of short-term bank loan - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 1,609,750<span></span>
</td>
<td class="nump">$ 1,640,000<span></span>
</td>
<td class="nump">$ 1,629,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember', window );">Cathay United Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">261,750<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember', window );">CTBC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">698,000<span></span>
</td>
<td class="nump">720,000<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayBankMember', window );">Cathay Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026611784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Paycheck Protection Program Loan Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 07, 2021</div></th>
<th class="th"><div>Apr. 14, 2020</div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
<th class="th"><div>Sep. 28, 2021</div></th>
<th class="th"><div>Jan. 29, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 15, 2021</div></th>
<th class="th"><div>Oct. 29, 2019</div></th>
<th class="th"><div>Sep. 04, 2019</div></th>
<th class="th"><div>Aug. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems', window );"><strong>Paycheck Protection Program Loan Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LoanFromPaycheckProtectionProgram', window );">Loan from paycheck protection program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ForgivenAmountPercentageUsedForPayroll', window );">Forgiven amount percentage used for payroll</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PromissoryNoteDescription', window );">Promissory note description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The loan was granted pursuant to a promissory note dated January 27, 2021 issued
by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.&#160;On February 7, 2021, the Company received a loan
in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay
Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal
amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60%
of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued
by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LoanFromPaycheckProtectionPrograms', window );">Loan from paycheck protection programs</a></td>
<td class="nump">$ 104,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LoanAmout', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_GovernmentGrantIncome', window );">Government grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 124,400<span></span>
</td>
<td class="nump">$ 360,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt Instrument, Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_PAYCHECKPROTECTIONPROGRAMMember', window );">Paycheck protection program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems', window );"><strong>Paycheck Protection Program Loan Payable (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPaymentTerms', window );">Debt Instrument, Payment Terms of description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The loan was granted pursuant to a promissory
note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDecreaseForgiveness', window );">Loan forgiven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,167<span></span>
</td>
<td class="nump">$ 132,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ForgivenAmountPercentageUsedForPayroll">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ForgivenAmountPercentageUsedForPayroll</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_GovernmentGrantIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of government grant income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_GovernmentGrantIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LoanAmout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LoanAmout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LoanFromPaycheckProtectionProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LoanFromPaycheckProtectionProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LoanFromPaycheckProtectionPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan from pay check protection program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LoanFromPaycheckProtectionPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PromissoryNoteDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PromissoryNoteDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDecreaseForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDecreaseForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_PAYCHECKPROTECTIONPROGRAMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_PAYCHECKPROTECTIONPROGRAMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635029343688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnsecuredLoanAgreementsDescription', window );">Unsecured loan agreement, description</a></td>
<td class="text">In January, 2019, BioLite Taiwan entered an unsecured
loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working
capital purpose.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNotesPayable', window );">Balance due amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 106,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,204<span></span>
</td>
<td class="nump">$ 8,592<span></span>
</td>
<td class="nump">$ 12,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_UnsecuredLoanAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of unsecured loan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_UnsecuredLoanAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term notes payable classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635021689736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Loan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 18, 2020</div></th>
<th class="th"><div>Jul. 19, 2017</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtInterestRateIncrease', window );">Interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Aug. 17,  2020<span></span>
</td>
<td class="text">Jan. 19,  2018<span></span>
</td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableWithFixedRatesOfInterest1', window );">Loan interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 102,272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableWithFixedRatesOfInterest1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loan with fixed rate of interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableWithFixedRatesOfInterest1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtInterestRateIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage increase in the stated interest rate on a short-term debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtInterestRateIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635017874632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 02, 2021</div></th>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>May 11, 2018</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Feb. 18, 2020</div></th>
<th class="th"><div>Jul. 19, 2017</div></th>
<th class="th"><div>Feb. 24, 2015</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 01, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 07, 2021</div></th>
<th class="th"><div>Jul. 01, 2020</div></th>
<th class="th"><div>Feb. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio', window );">Outstanding loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccruedInterest', window );">Outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,131<span></span>
</td>
<td class="nump">$ 166,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromAffiliateNoncurrent', window );">Consultant services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LoanAgreementTotalAmount', window );">Loan agreement total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,068,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_InterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentAggregateAmount', window );">Due from Rgene amounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 17,  2020<span></span>
</td>
<td class="text">Jan. 19,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The advances bear interest rate of 12% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromEmployeesNoncurrent', window );">Due amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingPrincipalAndAccruedInterest', window );">Outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162,634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Interest expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,312<span></span>
</td>
<td class="nump">$ 5,298<span></span>
</td>
<td class="nump">22,779<span></span>
</td>
<td class="nump">21,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Due from rgene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Outstanding balance and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,424<span></span>
</td>
<td class="nump">288,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Due to employee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,337<span></span>
</td>
<td class="nump">$ 2,503<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageRateForeignDeposit', window );">Bear interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageRateForeignDeposit', window );">Bear interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.6224%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_YuanGeneMember', window );">YuanGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember', window );">AsiaGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccruedInterest', window );">Outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccruedInterest', window );">Outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,435<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="nump">$ 465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Balance of outstanding loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,533,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company and BioFirst entered into loan agreements for a total amount of $45,000, $140,000, and $280,000, respectively, to meet its working capital needs. The loan will be matured on November 1, 2022, November 11, 2022, and December 19, 2022, respectively, all with an interest rate of 6.5% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The advances bear interest 1% per month (or equivalent to 12% per annum).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Outstanding balance and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,878<span></span>
</td>
<td class="nump">23,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,443<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Balance of outstanding loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 830,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,816<span></span>
</td>
<td class="nump">373,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentAggregateAmount', window );">Due from Rgene amounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,873<span></span>
</td>
<td class="nump">$ 361,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AdvancesBearInterestDescription', window );">Advances bear interest, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The advances bear 0% interest rate and are due on demand.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The advances bear 0% interest rate and are due on demand.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BHKCoDevelopmentAggreementMember', window );">BHK Co Development Aggreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromOtherRelatedParties', window );">Due from BHK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,972<span></span>
</td>
<td class="nump">123,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LbgUsaIncMember', window );">LBG USA, Inc.[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingAdvanceFromRelatedParty', window );">Outstanding advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateTerms', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan&#8217;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingAdvanceFromRelatedParty', window );">Outstanding advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointMember', window );">Keypoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Balance of outstanding loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LoanAgreementDescription', window );">Loan agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneMember', window );">YuanGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_JIANGSMember', window );">Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OutstandingAdvanceFromRelatedParty', window );">Outstanding advance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Outstanding balance and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="nump">$ 16,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_JIANGSMember', window );">Jiangs [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_JIANGSMember', window );">Jiangs [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccruedInterest', window );">Outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,701<span></span>
</td>
<td class="nump">$ 11,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Balance of outstanding loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,520<span></span>
</td>
<td class="nump">31,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentAggregateAmount', window );">Due from Rgene amounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,110<span></span>
</td>
<td class="nump">42,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiangeneCorporationMember', window );">AsiaGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccruedInterest', window );">Outstanding principal and accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregateWorkingcapital', window );">Aggregate working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,017<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShorttermDebtAverageOutstandingAmount', window );">Balance of outstanding loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsLineItems', window );"><strong>Related Parties Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtInstrumentAggregateAmount', window );">Due from Rgene amounted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Interest rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AdvancesBearInterestDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances bear interest description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AdvancesBearInterestDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AggregateWorkingcapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate working capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AggregateWorkingcapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtInstrumentAggregateAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtInstrumentAggregateAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_InterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_InterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LoanAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LoanAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LoanAgreementTotalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan agreement total amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LoanAgreementTotalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OutstandingAdvanceFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding advance from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OutstandingAdvanceFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OutstandingPrincipalAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OutstandingPrincipalAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartiesTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartiesTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromAffiliateNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=d3e56071-112765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromAffiliateNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromEmployeesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from an Entity employee, not to include stockholders or officers, which are usually due after 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39599-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromEmployeesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromOtherRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable from related parties classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromOtherRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=d3e107314-111719<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShorttermDebtAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShorttermDebtAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageRateForeignDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate calculated at point in time for foreign deposit liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageRateForeignDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_YuanGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_YuanGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BHKCoDevelopmentAggreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BHKCoDevelopmentAggreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LbgUsaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LbgUsaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_KeypointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_JIANGSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_JIANGSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiangeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AsiangeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635021652888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of related party transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationtheBioFirstMember', window );">BioFirst Corporation (the "BioFirst") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember', window );">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationtheRgeneMember', window );">Rgene Corporation (the &#8220;Rgene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneCorporationtheYuanGeneMember', window );">YuanGene Corporation (the &#8220;YuanGene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Controlling beneficiary shareholder of the Company<span></span>
</td>
<td class="text">Controlling beneficiary shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneCorporationtheAsiaGeneMember', window );">AsiaGene Corporation (the &#8220;AsiaGene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_EugeneJiangMember', window );">Eugene Jiang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Former President and Chairman<span></span>
</td>
<td class="text">Former President and Chairman<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointTechnologyLtdtheKeypointMember', window );">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.<span></span>
</td>
<td class="text">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionArtsPromotionInctheLionArtsMember', window );">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company<span></span>
</td>
<td class="text">Shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_YoshinobuOdairatheOdairaMember', window );">Yoshinobu Odaira (the &#8220;Odaira&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Director of the Company<span></span>
</td>
<td class="text">Director of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmInctheGenePharmMember', window );">GenePharm Inc. (the &#8220;GenePharm&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.<span></span>
</td>
<td class="text">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember', window );">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company<span></span>
</td>
<td class="text">Shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAInctheLBGUSAMember', window );">LBG USA, Inc. (the &#8220;LBG USA&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionGeneCorporationtheLionGeneMember', window );">LionGene Corporation (the &#8220;LionGene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_KimhoConsultantsCoLtdtheKimhoMember', window );">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company<span></span>
</td>
<td class="text">Shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst  &#160;  Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.  &#160;  Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.  &#160;  Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director of the Company.  &#160;  Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyVenturesLLCAmkeyMember', window );">Amkey Ventures, LLC (&#8220;Amkey&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc<span></span>
</td>
<td class="text">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of ABVC<span></span>
</td>
<td class="text">Entity controlled by controlling beneficiary shareholder of ABVC<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ABVCBioPharmaHKLimitedMember', window );">ABVC BioPharma (HK), Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">An entity 100% owned by Mr. Tsung-Shann Jiang<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartyTransactionDescriptionOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents related party descriptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartyTransactionDescriptionOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationtheBioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationtheBioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationtheRgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationtheRgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneCorporationtheYuanGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneCorporationtheYuanGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneCorporationtheAsiaGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneCorporationtheAsiaGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_EugeneJiangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_EugeneJiangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointTechnologyLtdtheKeypointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_KeypointTechnologyLtdtheKeypointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionArtsPromotionInctheLionArtsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LionArtsPromotionInctheLionArtsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_YoshinobuOdairatheOdairaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_YoshinobuOdairatheOdairaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmInctheGenePharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmInctheGenePharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAInctheLBGUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAInctheLBGUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionGeneCorporationtheLionGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LionGeneCorporationtheLionGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_KimhoConsultantsCoLtdtheKimhoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_KimhoConsultantsCoLtdtheKimhoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyVenturesLLCAmkeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyVenturesLLCAmkeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_ABVCBioPharmaHKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_ABVCBioPharmaHKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027490136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">$ 145,399<span></span>
</td>
<td class="nump">$ 145,399<span></span>
</td>
<td class="nump">$ 143,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmIncMember', window );">GenePharm Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">142,225<span></span>
</td>
<td class="nump">142,225<span></span>
</td>
<td class="nump">142,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">2,374<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyMember', window );">Amkey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635033198200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of amount due from related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,715,375<span></span>
</td>
<td class="nump">$ 1,286,618<span></span>
</td>
<td class="nump">$ 696,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">48,586<span></span>
</td>
<td class="nump">49,110<span></span>
</td>
<td class="nump">42,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">1,563,233<span></span>
</td>
<td class="nump">468,435<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">830,118<span></span>
</td>
<td class="nump">491,816<span></span>
</td>
<td class="nump">373,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">121,153<span></span>
</td>
<td class="nump">124,972<span></span>
</td>
<td class="nump">123,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAMember', window );">LBG USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointMember', window );">Keypoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DueFromtheRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due From Related Parties Current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DueFromtheRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_KeypointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027802312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 446,397<span></span>
</td>
<td class="nump">$ 393,424<span></span>
</td>
<td class="nump">$ 288,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">40,878<span></span>
</td>
<td class="nump">40,878<span></span>
</td>
<td class="nump">23,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">190,913<span></span>
</td>
<td class="nump">132,443<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember', window );">AsiaGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">24,017<span></span>
</td>
<td class="nump">24,017<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneMember', window );">YuanGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">9,205<span></span>
</td>
<td class="nump">9,205<span></span>
</td>
<td class="nump">9,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">16,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_DueToshareholdersMember', window );">Due to Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 162,634<span></span>
</td>
<td class="nump">$ 168,131<span></span>
</td>
<td class="nump">$ 166,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DueToRelatedPartyCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DueToRelatedPartyCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_DueToshareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_DueToshareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635005418968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="10">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th"><div>May 03, 2019</div></th>
<th class="th">
<div>Feb. 08, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 01, 2016</div></th>
<th class="th"><div>May 06, 2016</div></th>
<th class="th">
<div>Feb. 08, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 19, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Aug. 26, 2016</div></th>
<th class="th">
<div>Feb. 17, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th"><div>Aug. 05, 2021</div></th>
<th class="th">
<div>Jun. 29, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 17, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 12, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 09, 2018 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 25, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 21, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockShareAuthorized', window );">Ordinary shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AgreementDescription', window );">Agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company and BioLite Taiwan
agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed
to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of
the Company&#8217;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#8217;s
Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring
transaction between the Company and BioLite on February 8, 2019, the Company&#8217;s Common Stock held by BioLite Taiwan was accounted
for treasury stocks in the statement of equity (deficit).<span></span>
</td>
<td class="text">the Company issued 1,468,750 shares (&#8220;Shares&#8221;) of the Company&#8217;s Common Stock, par value $0.001 (the
&#8220;Offering&#8221;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#8220;SPA&#8221;).
The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net
proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should
pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires
that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_FinancialAmendmentDescription', window );">Financial amendment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company filed a Certificate
of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial
Industry Regulatory Authority (&#8220;FINRA&#8221;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse
stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#8217;s
common stock were exchanged for 17,693,625 shares of the Company&#8217;s Common Stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntercompanyAgreementsDescription', window );">Consulting service, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the agreements, the Company issued 644,972 shares
of the Company&#8217;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate,
and recorded as stock subscription receivable.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,307,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,926,322<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">644,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Consulting fees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,514,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,514,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockSubscriptionReceivable', window );">Stock subscription receivable (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,031,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,257,400<span></span>
</td>
<td class="nump">$ 3,160,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Due to related parties consideration (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,872,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,693,548<span></span>
</td>
<td class="nump">$ 1,717,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Shares per price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,306,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WarrantIssued', window );">Warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WarrantTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_IssuanceOfCommonStock', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AggregateCommonStockShares', window );">Aggregate common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConvertiblePromissoryNoteValue', window );">Convertible promissory note value (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DescriptionOfPublicOffering', window );">Description of public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company closed its public
offering (the &#8220;Public Offering&#8221;) of 1,100,000 units (the &#8220;Units&#8221;), with each Unit consisting of one share of the
Company&#8217;s common stock, one Series A warrant (the &#8220;Series A Warrants&#8221;) to purchase one share of common stock at an exercise
price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#8220;Series
B Warrants,&#8221; and together with the Series A Warrants, the &#8220;Public Warrants&#8221;) to purchase one share of common stock at
an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public
Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering
pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission
(the &#8220;SEC&#8221;) on April 8, 2021 (as amended, the &#8220;Original Registration Statement&#8221;), that the SEC declared effective
on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August
4, 2021 (the &#8220;S-1MEF,&#8221; together with the Original Registration Statement, the &#8220;Registration Statement&#8221;). The Units
were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock for debt (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 40,448<span></span>
</td>
<td class="nump">$ 11,119,452<span></span>
</td>
<td class="nump">$ 7,615,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Gross proceeds from exercise of warrants (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,244,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConsultingAgreementDesciption', window );">Consulting agreement desciption</a></td>
<td class="text">In November 2021, the Company entered into consulting
agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted
$1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant
date. These shares have been issued during the year ended December 31, 2021.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In November 2021, the Company entered into consulting
agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted
$1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant
date. These shares have been issued during the year ended December 31, 2021.&#160;In January 2022, the Company agreed to pay the
deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued
at $3.29 per share on the grant date. These shares have been issued as of March 31, 2022.&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExcessStockSharesIssued', window );">Common shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Consulting and advisory services amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 169,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingParValuePerShare', window );">Consulting and advisory services value per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of investors (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Aggregated capital contributions (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,615,331<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NumberOfInvestors', window );">Number of investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharesIssuedPricePerShares', window );">Purchase price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of investors (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares', window );">Common stock issued to professional investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,354,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common stock for debt (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abvc_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised</a></td>
<td class="nump">673,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abvc_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants exercised</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_KameyamaMember', window );">Kameyama [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnpaidConsultingFees', window );">Unpaid consulting fees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ArticlesOfIncorporationMember', window );">Articles of Incorporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ArticlesOfIncorporationMember', window );">Articles of Incorporation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ArticlesOfIncorporationMember', window );">Articles of Incorporation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ViewTradeSecuritiesIncMember', window );">View Trade Securities Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Consulting fees (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PlacementAgentAgreementDescription', window );">Placement agent agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares
of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years
with cashless exercise provision.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RestrictedCommonShares', window );">Restricted common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_WallachBethCapitalLLCMember', window );">WallachBeth Capital LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Common stock price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_UnrestrictedCommonShares', window );">Unrestricted common shares</a></td>
<td class="nump">316,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">316,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyShareholderServiceFeeExpense', window );">Service fee amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,478,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_NonRelatedPartiesMember', window );">Non Related Parties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature', window );">Debt conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#8217;s common stock, and warrants to purchase 159,145 shares of the Company&#8217;s common stock.

    &#160;
    b.
    Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s common stock.
  &#160;

    &#160;
    c.
    C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of the Company&#8217;s common stock.
  &#160;

    &#160;
    d.
    KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of the Company&#8217;s common stock.
  &#160;

    &#160;
    e.
    Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#8217;s common stock, and warrants to purchase 192,784 shares of the Company&#8217;s common stock.
  &#160;&#160;f.KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#8217;s common stock, and warrants to purchase 120,121 shares of the Company&#8217;s common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#8217;s common stock, and warrants to purchase 159,145 shares of the Company&#8217;s common stock.

    &#160;
    b.
    Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#8217;s common stock, and warrants to purchase 154,368 shares of the Company&#8217;s common stock.
  &#160;

    &#160;
    c.
    C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#8217;s common stock, and warrants to purchase 162,908 shares of the Company&#8217;s common stock.
  &#160;

    &#160;
    d.
    KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#8217;s common stock, and warrants to purchase 126,530 shares of the Company&#8217;s common stock.
  &#160;

    &#160;
    e.
    Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#8217;s common stock, and warrants to purchase 192,784 shares of the Company&#8217;s common stock.
  &#160;&#160;f.KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#8217;s common stock, and warrants to purchase 120,121 shares of the Company&#8217;s common stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvc_BioLiteMember', window );">BioLite [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,997,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvc_BioKeyMember', window );">BioKey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,642,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,561,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Number of investors (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementMember', window );">Share Exchange Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,387,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,336,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementOneMember', window );">Share Exchange Agreement One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementTwoMember', window );">Share Exchange Agreement Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">163,159,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,945,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of common shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfIssuedShareCapital', window );">Percentage of issued share capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementThreeMember', window );">Share Exchange Agreement Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,273,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,936,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementFourMember', window );">Share Exchange Agreement Four [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Common stock issued post-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,519,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedBeforeStockSplit', window );">Common stock issued pre-stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,431,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common shares, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_Consultingagreementdescription', window );">Consulting agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On October 1, 2016, the Company entered into a
consulting agreement with Kazunori Kameyama (&#8220;Kameyama&#8221;) for the provision of services related to the clinical trials and
other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the
Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#8217;s
Common Stock at $1.00 per share for any amount exceeding $3,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedValue', window );">Issuance of common shares (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember', window );">Co-Dev Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Due to related parties (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ConsultingAgreementMember', window );">Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_ConsultingAgreementMember', window );">Consulting Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityDetailsLineItems', window );"><strong>Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AggregateCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Common Stock Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AggregateCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement related description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CommonStockIssuedAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CommonStockIssuedAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CommonStockIssuedBeforeStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued before stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CommonStockIssuedBeforeStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CommonStockShareAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CommonStockShareAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConsultingAgreementDesciption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConsultingAgreementDesciption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_Consultingagreementdescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consulting agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_Consultingagreementdescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConvertiblePromissoryNoteValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConvertiblePromissoryNoteValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DescriptionOfPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of public offering .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DescriptionOfPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_EquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_EquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_FinancialAmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_FinancialAmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_IssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Common Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_IssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NumberOfInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NumberOfInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfIssuedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issued share capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfIssuedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PlacementAgentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PlacementAgentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RestrictedCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restricted Common Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RestrictedCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharesIssuedPricePerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharesIssuedPricePerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockIssuedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockIssuedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockSubscriptionReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of stock subscription receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockSubscriptionReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_UnpaidConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_UnpaidConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_UnrestrictedCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_UnrestrictedCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of conversion terms for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of excess stock shares of an entity that have been sold or granted to shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntercompanyAgreementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of product support, consulting, business, or other advisory service agreements entered into between the managing member or general partner and the LLC or LP, affiliate of the managing member or general partner, or affiliate of the LLC or LP. Includes a description of the key provisions of such agreements and the amount of compensation for such services during the accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntercompanyAgreementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyShareholderServiceFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for shareholder services. Includes, but is not limited to, fee and expense for transfer and dividend disbursing agent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyShareholderServiceFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abvc_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abvc_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abvc_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abvc_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_KameyamaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_KameyamaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_ArticlesOfIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_ArticlesOfIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_ViewTradeSecuritiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_ViewTradeSecuritiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_WallachBethCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_WallachBethCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_NonRelatedPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_NonRelatedPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvc_BioLiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvc_BioLiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvc_BioKeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvc_BioKeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ShareExchangeAgreementFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_CodevelopmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_ConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_ConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635033187784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of converted amount of debt and shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtConversionConvertedInstrumentAmount', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 4,872,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">696,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_LionArtsPromotionInctheLIONMember', window );">Lion Arts Promotion Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtConversionConvertedInstrumentAmount', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 97,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">13,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_LionGeneCorporationMember', window );">LionGene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtConversionConvertedInstrumentAmount', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 428,099<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">61,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtConversionConvertedInstrumentAmount', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 2,902,911<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">414,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_AsiangeneCorporationMember', window );">AsiaGene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtConversionConvertedInstrumentAmount', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">22,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_YuangeneCorporationMember', window );">YuanGene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtConversionConvertedInstrumentAmount', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 92,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">13,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DebtConversionConvertedInstrumentAmount', window );">Amount of Debt Converted | $</a></td>
<td class="nump">$ 1,190,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued | shares</a></td>
<td class="nump">170,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DebtConversionConvertedInstrumentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DebtConversionConvertedInstrumentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_LionArtsPromotionInctheLIONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_LionArtsPromotionInctheLIONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_LionGeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_LionGeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_AsiangeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_AsiangeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_YuangeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_YuangeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026635608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 15, 2021</div></th>
<th class="th"><div>Nov. 21, 2020</div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockOptionsDetailsLineItems', window );"><strong>Stock Options (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConversionPrice', window );">Conversion price (in Dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ConsultingFees', window );">Consulting fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,090,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Company granted stock option</a></td>
<td class="nump">1,280,002<span></span>
</td>
<td class="nump">545,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,182<span></span>
</td>
<td class="nump">1,280,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested grant date exercisable</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">(in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Stock-based compensation expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,675,205<span></span>
</td>
<td class="nump">$ 1,623,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$2,675,205<span></span>
</td>
<td class="text">$1,706,419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember', window );">2016 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockOptionsDetailsLineItems', window );"><strong>Stock Options (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Options available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,979,264<span></span>
</td>
<td class="nump">2,979,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares value is conversion price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockOptionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockOptionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abvc_TwoThousandSixteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027801176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details) - Schedule of options issued and outstanding - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems', window );"><strong>Stock Options (Details) - Schedule of options issued and outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Underlying Shares, Outstanding | shares</a></td>
<td class="nump">545,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding | $ / shares</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Underlying Shares, Exercisable | shares</a></td>
<td class="nump">1,825,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable | $ / shares</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm', window );">Weighted-Average Contractual Life Remaining in Years, Exercisable</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Underlying Shares, Vested and expected to vest | shares</a></td>
<td class="nump">1,825,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Vested and expected to vest | $ / shares</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest | $</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Underlying Shares, Granted | shares</a></td>
<td class="nump">1,280,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted | $ / shares</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Underlying Shares, Forfeited | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Forfeited | $ / shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Underlying Shares, Outstanding | shares</a></td>
<td class="nump">1,825,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding | $ / shares</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Contractual Life Remaining in Years, Outstanding</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635033182024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details) - Schedule of fair value of stock options granted<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract', window );"><strong>Schedule of fair value of stock options granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.13%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">108.51%<span></span>
</td>
<td class="nump">89.01%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635025318168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss per Share (Details) - Schedule of loss per share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ABVC&#8217;s common stockholders (in Dollars)</a></td>
<td class="num">$ (5,995,440)<span></span>
</td>
<td class="num">$ (1,128,505)<span></span>
</td>
<td class="num">$ (12,838,813)<span></span>
</td>
<td class="num">$ (9,791,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WeightedaverageSharesOutstandingBasic', window );">Weighted-average shares outstanding - Basic</a></td>
<td class="nump">$ 29,683,402<span></span>
</td>
<td class="nump">$ 24,420,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock options (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WeightedAverageNumberOfSharesDiluted', window );">Weighted-average shares outstanding - Diluted</a></td>
<td class="nump">$ 29,683,402<span></span>
</td>
<td class="nump">$ 24,420,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LossPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BasicLossPerShare', window );">-Basic</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">-Diluted</a></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BasicLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BasicLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WeightedAverageNumberOfSharesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average shares outstanding .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WeightedAverageNumberOfSharesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WeightedaverageSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WeightedaverageSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028677752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Details) - Schedule of operating lease arrangements - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,382,695<span></span>
</td>
<td class="nump">$ 1,471,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities (current)</a></td>
<td class="nump">349,008<span></span>
</td>
<td class="nump">347,100<span></span>
</td>
<td class="nump">$ 316,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeaseLiabilitienoncurrent', window );">Operating lease liabilities (noncurrent)</a></td>
<td class="nump">$ 1,033,686<span></span>
</td>
<td class="nump">$ 1,124,799<span></span>
</td>
<td class="nump">$ 1,456,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeaseLiabilitienoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeaseLiabilitienoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635005397608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Details) - Schedule of supplemental information related to operating leases - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract', window );"><strong>Schedule of supplemental information related to operating leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses</a></td>
<td class="nump">$ 85,857<span></span>
</td>
<td class="nump">$ 78,847<span></span>
</td>
<td class="nump">$ 335,208<span></span>
</td>
<td class="nump">$ 337,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 85,857<span></span>
</td>
<td class="nump">$ 78,847<span></span>
</td>
<td class="nump">$ 335,208<span></span>
</td>
<td class="nump">$ 337,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026814776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract', window );"><strong>Schedule of minimum future annual payments under non-cancellable leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueCurrent', window );">2022 (excluding three months ended March 31, 2022)</a></td>
<td class="nump">$ 266,024<span></span>
</td>
<td class="nump">$ 353,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears', window );">2023</a></td>
<td class="nump">359,279<span></span>
</td>
<td class="nump">360,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears', window );">2024</a></td>
<td class="nump">374,283<span></span>
</td>
<td class="nump">375,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears', window );">2025</a></td>
<td class="nump">338,676<span></span>
</td>
<td class="nump">338,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueThereafter', window );">Thereafter</a></td>
<td class="nump">56,916<span></span>
</td>
<td class="nump">56,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">1,395,178<span></span>
</td>
<td class="nump">1,486,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction', window );">Less: Imputed interest</a></td>
<td class="nump">12,484<span></span>
</td>
<td class="nump">14,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 1,382,694<span></span>
</td>
<td class="nump">$ 1,471,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635025308152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Feb. 08, 2019</div></th>
<th class="th"><div>May 09, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BusinessCombinationDetailsLineItems', window );"><strong>Business Combination (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PercentageOfGoodwill', window );">Percentage of goodwill</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Goodwill write-down value (in Dollars)</a></td>
<td class="nump">$ 43,647,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvc_BioKeyMember', window );">BioKey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BusinessCombinationDetailsLineItems', window );"><strong>Business Combination (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits', window );">Common stock issued</a></td>
<td class="nump">29,561,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_CommonStockIssuedAfterStockSplit', window );">Reverse stock split</a></td>
<td class="nump">1,642,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock per share (in Dollars per share)</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abvc_BioKeyMember', window );">BioKey [Member] | Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BusinessCombinationDetailsLineItems', window );"><strong>Business Combination (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock per share (in Dollars per share)</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BusinessCombinationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BusinessCombinationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_CommonStockIssuedAfterStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued after stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_CommonStockIssuedAfterStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PercentageOfGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PercentageOfGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of a stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abvc_BioKeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abvc_BioKeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=abvc_BusinessCombinationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=abvc_BusinessCombinationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635033185304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value<br></strong></div></th>
<th class="th" colspan="2">
<div>Feb. 08, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchaseConsiderationAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Common Stock</a></td>
<td class="nump">$ 44,341,847<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AllocationOfThePurchasePriceAbstract', window );"><strong>Allocation of the purchase price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">531,147<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">188,550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">56,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">485,684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Security deposits</a></td>
<td class="nump">10,440<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">1,271,896<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(56,204)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(251,335)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(267,256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Tenant security deposit</a></td>
<td class="num">(2,880)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="num">(577,675)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net assets acquired</a></td>
<td class="nump">694,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Goodwill as a result of the Merger</a></td>
<td class="nump">$ 43,647,626<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AllocationOfThePurchasePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AllocationOfThePurchasePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PurchaseConsiderationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PurchaseConsiderationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635005346552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 11, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 16, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_TermsOfAgreementDescription', window );">Terms of agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In accordance with the terms of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity securities owned by it at various stages on a schedule dictated by BioLite&#8217;s achievements of certain milestones, as set forth in the Agreement (the &#8220;Milestone Payments&#8221;) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501 is approved for sale in the licensed territories.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_MilestonePaymentDescription', window );">Milestone payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the &#8220;December 2021 Payment&#8221;) and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company&#8217;s Board of Directors determined that the December 2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000, that BioLite owes the Company as of December 31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Aggregated shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,306,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AdditionalSharesOfCommonStock', window );">Additional shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoninterestExpenseInvestmentAdvisoryFees', window );">Consulting and advisory services (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NumberOfDirectors', window );">Number of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Granted options to purchase an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_GrantDateTerm', window );">Grant date term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Purchase agreement relating to offer and sale of shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital', window );">Common stock, par value (in Dollars) | $</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WarrantsPurchased', window );">Warrants purchased</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ExercisableAtAPricePerShare', window );">Exercisable price per share (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AdditionalSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AdditionalSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ExercisableAtAPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ExercisableAtAPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_GrantDateTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_GrantDateTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_MilestonePaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_MilestonePaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_TermsOfAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of agreement terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_TermsOfAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WarrantsPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WarrantsPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseInvestmentAdvisoryFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This represents the company's cost incurred during an accounting period for managing the money in a fund, which will be billed back to the client and is a component of noninterest expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseInvestmentAdvisoryFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109244457&amp;loc=d3e16649-113920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026516056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635029296056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory (Details) - Schedule of inventory - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfInventoryAbstract', window );"><strong>Schedule of inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">$ 104,036<span></span>
</td>
<td class="nump">$ 96,725<span></span>
</td>
<td class="nump">$ 100,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">69,287<span></span>
</td>
<td class="nump">84,620<span></span>
</td>
<td class="nump">61,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AllowanceForInventoryValuationAndObsolescenceLoss', window );">Allowance for inventory valuation and obsolescence loss</a></td>
<td class="num">(150,623)<span></span>
</td>
<td class="num">(155,370)<span></span>
</td>
<td class="num">(184,723)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">$ 22,700<span></span>
</td>
<td class="nump">$ 25,975<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AllowanceForInventoryValuationAndObsolescenceLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for inventory valuation and obsolescence loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AllowanceForInventoryValuationAndObsolescenceLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635013831352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - Schedule of property and equipment - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,907,926<span></span>
</td>
<td class="nump">$ 3,840,352<span></span>
</td>
<td class="nump">$ 3,813,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(3,309,278)<span></span>
</td>
<td class="num">(3,314,471)<span></span>
</td>
<td class="num">(3,298,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">598,648<span></span>
</td>
<td class="nump">525,881<span></span>
</td>
<td class="nump">514,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">387,866<span></span>
</td>
<td class="nump">400,091<span></span>
</td>
<td class="nump">395,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember', window );">Buildings and leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,230,968<span></span>
</td>
<td class="nump">2,235,061<span></span>
</td>
<td class="nump">2,233,573<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,102,943<span></span>
</td>
<td class="nump">1,013,376<span></span>
</td>
<td class="nump">994,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 186,149<span></span>
</td>
<td class="nump">$ 191,824<span></span>
</td>
<td class="nump">$ 189,760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abvc_BuildingsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635013867400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.17%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">Cost Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">15.99%<span></span>
</td>
<td class="nump">15.99%<span></span>
</td>
<td class="nump">15.99%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">31.62%<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
<td class="nump">31.62%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AccountingTreatmentDescription', window );">Accounting treatments</a></td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">Equity Method<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AccountingTreatmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AccountingTreatmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635030135976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">No specific business relationship<span></span>
</td>
<td class="text">No specific business relationship<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
<td class="text">Loaned from the investee and provides research and development support service<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems', window );"><strong>Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
<td class="text">Collaborating with the Company to develop and commercialize drugs<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartyTransactionDescriptionOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents related party descriptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartyTransactionDescriptionOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026639064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of long-term investment - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract0', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">$ 904,254<span></span>
</td>
<td class="nump">$ 932,755<span></span>
</td>
<td class="nump">$ 922,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract0', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total</a></td>
<td class="nump">904,254<span></span>
</td>
<td class="nump">932,755<span></span>
</td>
<td class="nump">1,190,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember', window );">Braingenesis Biotechnology Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract0', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">7,698<span></span>
</td>
<td class="nump">7,941<span></span>
</td>
<td class="nump">7,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember', window );">Genepharm Biotech Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract0', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">23,503<span></span>
</td>
<td class="nump">24,244<span></span>
</td>
<td class="nump">23,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract0', window );"><strong>Non-marketable Cost Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NonmarketableCostMethodInvestmentsNet', window );">Sub total</a></td>
<td class="nump">873,053<span></span>
</td>
<td class="nump">900,570<span></span>
</td>
<td class="nump">890,564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract0', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">268,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember', window );">Rgene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_EquityMethodInvestmentsNetAbstract0', window );"><strong>Equity Method Investments, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_EquityMethodInvestmentsNetAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_EquityMethodInvestmentsNetAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NonMarketableCostMethodInvestmentsNetAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NonMarketableCostMethodInvestmentsNetAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NonmarketableCostMethodInvestmentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NonmarketableCostMethodInvestmentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BraingenesisBiotechnologyCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_GenepharmBiotechCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027492280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of balance sheets - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Current Assets</a></td>
<td class="nump">$ 2,147,097<span></span>
</td>
<td class="nump">$ 2,205,669<span></span>
</td>
<td class="nump">$ 1,299,822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Noncurrent Assets</a></td>
<td class="nump">812,865<span></span>
</td>
<td class="nump">959,454<span></span>
</td>
<td class="nump">2,540,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="nump">3,237,623<span></span>
</td>
<td class="nump">2,909,703<span></span>
</td>
<td class="nump">1,986,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent Liabilities</a></td>
<td class="nump">17,741<span></span>
</td>
<td class="nump">32,522<span></span>
</td>
<td class="nump">73,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Shareholders&#8217; Deficit</a></td>
<td class="num">(295,402)<span></span>
</td>
<td class="nump">222,898<span></span>
</td>
<td class="nump">1,780,326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Condensed Balance Sheet Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Current Assets</a></td>
<td class="nump">221,169<span></span>
</td>
<td class="nump">73,452<span></span>
</td>
<td class="nump">123,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Noncurrent Assets</a></td>
<td class="nump">355,420<span></span>
</td>
<td class="nump">374,423<span></span>
</td>
<td class="nump">412,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Current Liabilities</a></td>
<td class="nump">2,164,077<span></span>
</td>
<td class="nump">1,934,786<span></span>
</td>
<td class="nump">1,392,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">38,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Shareholders&#8217; Deficit</a></td>
<td class="num">$ (1,587,488)<span></span>
</td>
<td class="num">$ (1,486,911)<span></span>
</td>
<td class="num">$ (895,409)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635027626584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of statements of operation - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="nump">$ 26,693<span></span>
</td>
<td class="nump">$ 257,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">8,348<span></span>
</td>
<td class="nump">10,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NetLoss1', window );">Net loss</a></td>
<td class="num">(2,276,892)<span></span>
</td>
<td class="num">(5,401,074)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Share of losses from investments accounted for using the equity method</a></td>
<td class="num">(269,844)<span></span>
</td>
<td class="num">(1,168,733)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Net sales</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">16,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(335,735)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NetLoss1', window );">Net loss</a></td>
<td class="num">(576,514)<span></span>
</td>
<td class="num">(641,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Share of losses from investments accounted for using the equity method</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NetLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NetLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028598856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Investments (Details) - Schedule of equity investments - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfEquityInvestmentsAbstract', window );"><strong>Schedule of equity investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ShareOfEquityMethodInvesteeLosses', window );">Share of equity method investee losses</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (47,791)<span></span>
</td>
<td class="num">$ (269,844)<span></span>
</td>
<td class="num">$ (1,168,733)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfEquityInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfEquityInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ShareOfEquityMethodInvesteeLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share of equity method investee losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ShareOfEquityMethodInvesteeLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026602744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Bank Loans (Details) - Schedule of short-term bank loan - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 1,609,750<span></span>
</td>
<td class="nump">$ 1,640,000<span></span>
</td>
<td class="nump">$ 1,629,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember', window );">Cathay United Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">261,750<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember', window );">CTBC Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">698,000<span></span>
</td>
<td class="nump">720,000<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayBankMember', window );">Cathay Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Total</a></td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayUnitedBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CTBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=abvc_CathayBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=abvc_CathayBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635005315768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of related party transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationtheBioFirstMember', window );">BioFirst Corporation (the "BioFirst") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember', window );">BioFirst (Australia) Pty Ltd. (the &#8220;BioFirst (Australia)&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationtheRgeneMember', window );">Rgene Corporation (the &#8220;Rgene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneCorporationtheYuanGeneMember', window );">YuanGene Corporation (the &#8220;YuanGene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Controlling beneficiary shareholder of the Company<span></span>
</td>
<td class="text">Controlling beneficiary shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneCorporationtheAsiaGeneMember', window );">AsiaGene Corporation (the &#8220;AsiaGene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_EugeneJiangMember', window );">Eugene Jiang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Former President and Chairman<span></span>
</td>
<td class="text">Former President and Chairman<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointTechnologyLtdtheKeypointMember', window );">Keypoint Technology Ltd. (the &#8220;Keypoint&#8217;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.<span></span>
</td>
<td class="text">The Chairman of Keypoint is Eugene Jiang&#8217;s mother.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionArtsPromotionInctheLionArtsMember', window );">Lion Arts Promotion Inc. (the &#8220;Lion Arts&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company<span></span>
</td>
<td class="text">Shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_YoshinobuOdairatheOdairaMember', window );">Yoshinobu Odaira (the &#8220;Odaira&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Director of the Company<span></span>
</td>
<td class="text">Director of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmInctheGenePharmMember', window );">GenePharm Inc. (the &#8220;GenePharm&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.<span></span>
</td>
<td class="text">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember', window );">Euro-Asia Investment &amp; Finance Corp Ltd. (the &#8220;Euro-Asia&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company<span></span>
</td>
<td class="text">Shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAInctheLBGUSAMember', window );">LBG USA, Inc. (the &#8220;LBG USA&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionGeneCorporationtheLionGeneMember', window );">LionGene Corporation (the &#8220;LionGene&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
<td class="text">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_KimhoConsultantsCoLtdtheKimhoMember', window );">Kimho Consultants Co., Ltd. (the &#8220;Kimho&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Shareholder of the Company<span></span>
</td>
<td class="text">Shareholder of the Company<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember', window );">Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the "Jiangs") [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst &#160; Ms.
Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#8217;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. &#160; Mr. Eugene Jiang is Mr. and Ms. Jiang&#8217;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and
a member of board of directors of BioLite Inc. &#160; Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#8217;s sibling and the director
of the Company. &#160; Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#8217;s sibling.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyVenturesLLCAmkeyMember', window );">Amkey Ventures, LLC (&#8220;Amkey&#8221;) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc<span></span>
</td>
<td class="text">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartyTransactionDescriptionOfTransactions', window );">Relationship with the Company and its subsidiaries, description</a></td>
<td class="text">Entity controlled by controlling beneficiary shareholder of ABVC<span></span>
</td>
<td class="text">Entity controlled by controlling beneficiary shareholder of ABVC<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartyTransactionDescriptionOfTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents related party descriptions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartyTransactionDescriptionOfTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationtheBioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationtheBioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationtheRgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneCorporationtheRgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneCorporationtheYuanGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneCorporationtheYuanGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneCorporationtheAsiaGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneCorporationtheAsiaGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_EugeneJiangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_EugeneJiangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointTechnologyLtdtheKeypointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_KeypointTechnologyLtdtheKeypointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionArtsPromotionInctheLionArtsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LionArtsPromotionInctheLionArtsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_YoshinobuOdairatheOdairaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_YoshinobuOdairatheOdairaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmInctheGenePharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmInctheGenePharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAInctheLBGUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAInctheLBGUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LionGeneCorporationtheLionGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LionGeneCorporationtheLionGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_KimhoConsultantsCoLtdtheKimhoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_KimhoConsultantsCoLtdtheKimhoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyVenturesLLCAmkeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyVenturesLLCAmkeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028460744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">$ 145,399<span></span>
</td>
<td class="nump">$ 145,399<span></span>
</td>
<td class="nump">$ 143,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmIncMember', window );">GenePharm Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">142,225<span></span>
</td>
<td class="nump">142,225<span></span>
</td>
<td class="nump">142,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">2,374<span></span>
</td>
<td class="nump">2,374<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyMember', window );">Amkey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable due from related parties</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_GenePharmIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AmkeyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635025255912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of amount due from related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,715,375<span></span>
</td>
<td class="nump">$ 1,286,618<span></span>
</td>
<td class="nump">$ 696,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember', window );">Rgene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">48,586<span></span>
</td>
<td class="nump">49,110<span></span>
</td>
<td class="nump">42,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember', window );">AsiaGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember', window );">BioFirst [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">1,563,233<span></span>
</td>
<td class="nump">468,435<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">830,118<span></span>
</td>
<td class="nump">491,816<span></span>
</td>
<td class="nump">373,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember', window );">BioHopeKing Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">121,153<span></span>
</td>
<td class="nump">124,972<span></span>
</td>
<td class="nump">123,583<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAMember', window );">LBG USA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">675<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember', window );">BioLite Japan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointMember', window );">Keypoint [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueFromtheRelatedPartiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DueFromtheRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Due From Related Parties Current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DueFromtheRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_RgeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioHopeKingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_LBGUSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioLiteJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_KeypointMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_KeypointMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635028487800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 446,397<span></span>
</td>
<td class="nump">$ 393,424<span></span>
</td>
<td class="nump">$ 288,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">40,878<span></span>
</td>
<td class="nump">40,878<span></span>
</td>
<td class="nump">23,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember', window );">BioFirst (Australia) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">190,913<span></span>
</td>
<td class="nump">132,443<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember', window );">AsiaGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">24,017<span></span>
</td>
<td class="nump">24,017<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneMember', window );">YuanGene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">9,205<span></span>
</td>
<td class="nump">9,205<span></span>
</td>
<td class="nump">9,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">16,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_DueToshareholdersMember', window );">Due to Shareholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="nump">$ 162,634<span></span>
</td>
<td class="nump">168,131<span></span>
</td>
<td class="nump">166,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=abvc_DueToEmployeeMember', window );">Due to Employee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems', window );"><strong>Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DueToRelatedPartyCurrentAndNoncurrent', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 72,705<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DueToRelatedPartyCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DueToRelatedPartyCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_BioFirstAustraliaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_AsiaGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_YuanGeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_DueToshareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_DueToshareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abvc_DueToEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abvc_DueToEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635005330696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Details) - Schedule of converted amount of debt and shares - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted</a></td>
<td class="nump">$ 4,872,340<span></span>
</td>
<td class="nump">$ 2,693,548<span></span>
</td>
<td class="nump">$ 1,717,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued</a></td>
<td class="nump">696,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_LionArtsPromotionInctheLIONMember', window );">Lion Arts Promotion Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted</a></td>
<td class="nump">$ 97,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued</a></td>
<td class="nump">13,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_LionGeneCorporationMember', window );">LionGene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted</a></td>
<td class="nump">$ 428,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued</a></td>
<td class="nump">61,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_BioFirstCorporationMember', window );">BioFirst Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted</a></td>
<td class="nump">$ 2,902,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued</a></td>
<td class="nump">414,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_AsiangeneCorporationMember', window );">AsiaGene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted</a></td>
<td class="nump">$ 160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued</a></td>
<td class="nump">22,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_YuangeneCorporationMember', window );">YuanGene Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted</a></td>
<td class="nump">$ 92,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued</a></td>
<td class="nump">13,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abvc_TheJiangsMember', window );">The Jiangs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionLineItems', window );"><strong>Debt Conversion [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Amount of Debt Converted</a></td>
<td class="nump">$ 1,190,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Number of Shares Issued</a></td>
<td class="nump">170,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_LionArtsPromotionInctheLIONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_LionArtsPromotionInctheLIONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_LionGeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_LionGeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_BioFirstCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_BioFirstCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_AsiangeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_AsiangeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_YuangeneCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_YuangeneCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abvc_TheJiangsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abvc_TheJiangsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026540232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details) - Schedule of options issued and outstanding - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems', window );"><strong>Stock Options (Details) - Schedule of options issued and outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Underlying Shares, Outstanding (in Shares) | shares</a></td>
<td class="nump">545,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Underlying Shares, Granted (in Shares) | shares</a></td>
<td class="nump">1,280,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Granted</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Underlying Shares, Forfeited (in Shares) | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Forfeited</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Underlying Shares, Outstanding (in Shares) | shares</a></td>
<td class="nump">1,825,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Outstanding</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding as of December 31, 2021</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Underlying Shares, Exercisable (in Shares) | shares</a></td>
<td class="nump">1,825,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm', window );">Weighted-Average Contractual Life Remaining in Years, Exercisable</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable (in Dollars) | $</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Underlying Shares, Vested and expected to vest (in Shares) | shares</a></td>
<td class="nump">1,825,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Vested and expected to vest</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest</a></td>
<td class="text">9 years 6 months 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest (in Dollars) | $</a></td>
<td class="nump">$ 616,056<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635026066568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details) - Schedule of fair value of stock options granted<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract', window );"><strong>Schedule of fair value of stock options granted [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.13%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">108.51%<span></span>
</td>
<td class="nump">89.01%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635021602072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - Schedule of loss per share - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_NumeratorAbstract0', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ABVC&#8217;s common stockholders</a></td>
<td class="num">$ (5,995,440)<span></span>
</td>
<td class="num">$ (1,128,505)<span></span>
</td>
<td class="num">$ (12,838,813)<span></span>
</td>
<td class="num">$ (9,791,164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_DenominatorAbstract0', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - Basic</a></td>
<td class="nump">29,683,402<span></span>
</td>
<td class="nump">24,420,526<span></span>
</td>
<td class="nump">25,053,522<span></span>
</td>
<td class="nump">19,715,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,053,522<span></span>
</td>
<td class="nump">19,715,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_LossPerShareAbstract0', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">-Basic</a></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">-Diluted</a></td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_DenominatorAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_DenominatorAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_LossPerShareAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_LossPerShareAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_NumeratorAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_NumeratorAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635033185000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease (Details) - Schedule of operating lease arrangements - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 1,382,695<span></span>
</td>
<td class="nump">$ 1,471,899<span></span>
</td>
<td class="nump">$ 1,772,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities (current)</a></td>
<td class="nump">349,008<span></span>
</td>
<td class="nump">347,100<span></span>
</td>
<td class="nump">316,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeaseLiabilitienoncurrent', window );">Operating lease liabilities (noncurrent)</a></td>
<td class="nump">$ 1,033,686<span></span>
</td>
<td class="nump">$ 1,124,799<span></span>
</td>
<td class="nump">$ 1,456,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeaseLiabilitienoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeaseLiabilitienoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635029659288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease (Details) - Schedule of supplemental information related to operating leases - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract', window );"><strong>Schedule of supplemental information related to operating leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expenses</a></td>
<td class="nump">$ 85,857<span></span>
</td>
<td class="nump">$ 78,847<span></span>
</td>
<td class="nump">$ 335,208<span></span>
</td>
<td class="nump">$ 337,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities</a></td>
<td class="nump">$ 85,857<span></span>
</td>
<td class="nump">$ 78,847<span></span>
</td>
<td class="nump">$ 335,208<span></span>
</td>
<td class="nump">$ 337,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WeightedAverageRemainingLeaseTermAbstract0', window );"><strong>Weighted Average Remaining Lease Term:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">2 years 7 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">3 years 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_WeightedAverageDiscountRateAbstract0', window );"><strong>Weighted Average Discount Rate:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">1.37%<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WeightedAverageDiscountRateAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WeightedAverageDiscountRateAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_WeightedAverageRemainingLeaseTermAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_WeightedAverageRemainingLeaseTermAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635021715048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract', window );"><strong>Schedule of minimum future annual payments under non-cancellable leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueCurrent', window );">2022</a></td>
<td class="nump">$ 266,024<span></span>
</td>
<td class="nump">$ 353,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears', window );">2023</a></td>
<td class="nump">359,279<span></span>
</td>
<td class="nump">360,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears', window );">2024</a></td>
<td class="nump">374,283<span></span>
</td>
<td class="nump">375,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears', window );">2025</a></td>
<td class="nump">338,676<span></span>
</td>
<td class="nump">338,676<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDueThereafter', window );">Thereafter</a></td>
<td class="nump">56,916<span></span>
</td>
<td class="nump">56,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_OperatingLeasesFutureMinimumPaymentDue', window );">Total future minimum lease payments, undiscounted</a></td>
<td class="nump">1,395,178<span></span>
</td>
<td class="nump">1,486,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction', window );">Less: Imputed interest</a></td>
<td class="nump">12,484<span></span>
</td>
<td class="nump">14,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions', window );">Present value of future minimum lease payments</a></td>
<td class="nump">$ 1,382,694<span></span>
</td>
<td class="nump">$ 1,471,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_OperatingLeasesFutureMinimumPaymentDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_OperatingLeasesFutureMinimumPaymentDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140635013857272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value<br></strong></div></th>
<th class="th" colspan="2">
<div>Feb. 08, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_PurchaseConsiderationAbstract0', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Common Stock</a></td>
<td class="nump">$ 44,341,847<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_AllocationOfThePurchasePriceAbstract0', window );"><strong>Allocation of the purchase price:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">531,147<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">188,550<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">56,075<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">485,684<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Security deposits</a></td>
<td class="nump">10,440<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Total assets acquired</a></td>
<td class="nump">1,271,896<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(56,204)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(251,335)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(267,256)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Tenant security deposit</a></td>
<td class="num">(2,880)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Total liabilities assumed</a></td>
<td class="num">(577,675)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net assets acquired</a></td>
<td class="nump">694,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Goodwill as a result of the Merger</a></td>
<td class="nump">$ 43,647,626<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_AllocationOfThePurchasePriceAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_AllocationOfThePurchasePriceAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abvc_PurchaseConsiderationAbstract0">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abvc_PurchaseConsiderationAbstract0</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abvc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>ea158528-posam1_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abvc="http://metuboutique.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pf0="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abvc-20220331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abvc:StockSubscriptionReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-08</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-08</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-08</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-08</instant>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-08</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-08</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-08</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2016-03-21</instant>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-02</startDate>
            <endDate>2016-07-27</endDate>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-02</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-02</startDate>
            <endDate>2017-08-15</endDate>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-02</startDate>
            <endDate>2017-05-26</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2018-12-02</startDate>
            <endDate>2018-12-24</endDate>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-02</startDate>
            <endDate>2017-09-25</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-05</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-09</instant>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-25</startDate>
            <endDate>2018-05-09</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2018-04-25</startDate>
            <endDate>2018-05-09</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2018-05-09</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2020-01-21</instant>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2020-03-26</startDate>
            <endDate>2020-04-05</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-26</startDate>
            <endDate>2020-04-05</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-27</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-02</startDate>
            <endDate>2018-06-27</endDate>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2018-06-02</startDate>
            <endDate>2018-06-27</endDate>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-25</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-02</startDate>
            <endDate>2018-08-25</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2018-08-02</startDate>
            <endDate>2018-08-25</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-30</endDate>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-10</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-10</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-07-10</endDate>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-10</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-07-10</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-28</startDate>
            <endDate>2019-08-28</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-28</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-28</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2019-08-28</startDate>
            <endDate>2019-08-28</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-04</instant>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-20</startDate>
            <endDate>2019-09-04</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-29</instant>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-23</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-05-17</instant>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-21</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-07-21</instant>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-28</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-28</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-28</endDate>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-01</startDate>
            <endDate>2017-09-06</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-06</instant>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-06</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-25</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-06</instant>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-06</instant>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-06</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-06</instant>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-06</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-06</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-06</endDate>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-06</endDate>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-12</instant>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-12</instant>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-19</instant>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-19</instant>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-12</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-19</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-19</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-18</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-18</instant>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-18</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-19</instant>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-19</instant>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-19</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-17</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-15</instant>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-15</instant>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-15</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-15</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2022-01-14</startDate>
            <endDate>2022-01-14</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-21</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2019-01-21</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-21</endDate>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-08</endDate>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-08</instant>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2020-10-03</instant>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-03</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:PAYCHECKPROTECTIONPROGRAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-04-14</endDate>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2020-04-14</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-29</endDate>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-07</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-02-07</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-03-15</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:PAYCHECKPROTECTIONPROGRAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:PAYCHECKPROTECTIONPROGRAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2020-02-18</instant>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-18</endDate>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-02</endDate>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-02-01</startDate>
            <endDate>2015-02-24</endDate>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LbgUsaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-27</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LbgUsaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LbgUsaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationtheBioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneCorporationtheYuanGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneCorporationtheAsiaGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:EugeneJiangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointTechnologyLtdtheKeypointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionArtsPromotionInctheLionArtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YoshinobuOdairatheOdairaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmInctheGenePharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAInctheLBGUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionGeneCorporationtheLionGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KimhoConsultantsCoLtdtheKimhoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyVenturesLLCAmkeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ABVCBioPharmaHKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToshareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToshareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ShareExchangeAgreementThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-08</endDate>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-17</endDate>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-06</endDate>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-26</endDate>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">abvc:BioLiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-08</endDate>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">abvc:BioKeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-08</endDate>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-24</startDate>
            <endDate>2016-10-01</endDate>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KameyamaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-21</endDate>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:CodevelopmentagreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-25</instant>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ArticlesOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-12</instant>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ArticlesOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-12</instant>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ArticlesOfIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-12</instant>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-08</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:WallachBethCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ViewTradeSecuritiesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-19</endDate>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:NonRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abvc:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abvc:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-11-30</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LionArtsPromotionInctheLIONMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:LionGeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="c353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:YuangeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="c354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="c355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-30</endDate>
        </period>
    </context>
    <context id="c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2020-10-30</instant>
        </period>
    </context>
    <context id="c357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2020-11-21</instant>
        </period>
    </context>
    <context id="c358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-21</endDate>
        </period>
    </context>
    <context id="c359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-10-15</instant>
        </period>
    </context>
    <context id="c360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2021-10-15</endDate>
        </period>
    </context>
    <context id="c361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">abvc:BioKeyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">abvc:BusinessCombinationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-08</instant>
        </period>
    </context>
    <context id="c366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-08</endDate>
        </period>
    </context>
    <context id="c367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2019-02-08</instant>
        </period>
    </context>
    <context id="c368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-16</instant>
        </period>
    </context>
    <context id="c369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-02</startDate>
            <endDate>2022-04-16</endDate>
        </period>
    </context>
    <context id="c370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-02</startDate>
            <endDate>2022-05-11</endDate>
        </period>
    </context>
    <context id="c371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-11</instant>
        </period>
    </context>
    <context id="c372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-02-01</startDate>
            <endDate>2016-02-08</endDate>
        </period>
    </context>
    <context id="c373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-03</endDate>
        </period>
    </context>
    <context id="c374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-02</startDate>
            <endDate>2016-07-27</endDate>
        </period>
    </context>
    <context id="c381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abvc:BHKCoDevelopmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abvc:BuildingsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BraingenesisBiotechnologyCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenepharmBiotechCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioHopeKingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-07-10</endDate>
        </period>
    </context>
    <context id="c407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2019-08-28</instant>
        </period>
    </context>
    <context id="c408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-28</endDate>
        </period>
    </context>
    <context id="c409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2019-09-04</instant>
        </period>
    </context>
    <context id="c410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2019-10-29</instant>
        </period>
    </context>
    <context id="c411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <context id="c412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:UnsecuredConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-28</instant>
        </period>
    </context>
    <context id="c417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-28</instant>
        </period>
    </context>
    <context id="c418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-06</instant>
        </period>
    </context>
    <context id="c419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-06</instant>
        </period>
    </context>
    <context id="c420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="c421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="c422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-25</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="c423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-06</instant>
        </period>
    </context>
    <context id="c424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-06</instant>
        </period>
    </context>
    <context id="c425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-06</instant>
        </period>
    </context>
    <context id="c426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-06</instant>
        </period>
    </context>
    <context id="c427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-06</instant>
        </period>
    </context>
    <context id="c428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-06</instant>
        </period>
    </context>
    <context id="c429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-06</endDate>
        </period>
    </context>
    <context id="c430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-12</instant>
        </period>
    </context>
    <context id="c433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-12</instant>
        </period>
    </context>
    <context id="c434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-19</instant>
        </period>
    </context>
    <context id="c435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-19</instant>
        </period>
    </context>
    <context id="c436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-12</endDate>
        </period>
    </context>
    <context id="c437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-18</instant>
        </period>
    </context>
    <context id="c438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-18</instant>
        </period>
    </context>
    <context id="c439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-19</instant>
        </period>
    </context>
    <context id="c440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-19</instant>
        </period>
    </context>
    <context id="c441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="c442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="c443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-15</instant>
        </period>
    </context>
    <context id="c444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-15</instant>
        </period>
    </context>
    <context id="c445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abvc:TypeOfCurrencyAxis">abvc:NTMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="c446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:BioLiteTaiwanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-15</instant>
        </period>
    </context>
    <context id="c447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:LoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-03</instant>
        </period>
    </context>
    <context id="c451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="c452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayUnitedBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CTBCBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:CathayBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-01-29</instant>
        </period>
    </context>
    <context id="c460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-08-26</instant>
        </period>
    </context>
    <context id="c461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiangeneCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <instant>2021-09-07</instant>
        </period>
    </context>
    <context id="c468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-01</instant>
        </period>
    </context>
    <context id="c469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BHKCoDevelopmentAggreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-11</endDate>
        </period>
    </context>
    <context id="c473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LbgUsaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:JIANGSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstCorporationtheBioFirstMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:RgeneCorporationtheRgeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneCorporationtheYuanGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneCorporationtheAsiaGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:EugeneJiangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointTechnologyLtdtheKeypointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionArtsPromotionInctheLionArtsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YoshinobuOdairatheOdairaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmInctheGenePharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAInctheLBGUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LionGeneCorporationtheLionGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KimhoConsultantsCoLtdtheKimhoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyVenturesLLCAmkeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioLiteJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:GenePharmIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AmkeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:AsiaGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:BioFirstAustraliaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:LBGUSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:KeypointMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:YuanGeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:TheJiangsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToshareholdersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:DueToEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:NonRelatedPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="c513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abvc:ConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-30</instant>
        </period>
    </context>
    <context id="c516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abvc:TwoThousandSixteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:TitleOfIndividualAxis">abvc:BioKeyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-08</instant>
        </period>
    </context>
    <context id="c519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="twd">
        <measure>iso4217:TWD</measure>
    </unit>
    <dei:EntityRegistrantName contextRef="c0">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:AmendmentDescription contextRef="c0">This Post-Effective Amendment No. 2 (this &#x201c;Amendment&#x201d;) to the Registration Statement on Form S-1, as amended (SEC File No. 333-255112) (the &#x201c;Original Registration Statement&#x201d;), of ABVC BioPharma, Inc. (the &#x201c;Company&#x201d;) is being filed pursuant to the undertakings in the Original Registration Statement to update and supplement the information contained in the Original Registration Statement, which was originally declared effective by the Securities and Exchange Commission on August 2, 2021.The Original Registration Statement, as amended by this Amendment, pertains solely to the registration of 2,255,000 shares (the &#x201c;Warrant Shares&#x201d;) of common stock, par value $0.001 per share, underlying warrants (the &#x201c;Offering Warrants&#x201d;) previously issued by the Company to the investors and Representative. The Warrant Shares were initially registered on the Original Registration Statement.For the convenience of the reader, this Amendment
sets forth the Original Registration Statement in its entirety, as amended by this Amendment. This Amendment is being filed to incorporate
certain information from the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March
31, 2022 and the registrant&#x2019;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, which was filed with the SEC on
May 16, 2022, and to update certain other information in the Registration Statement.No additional securities are being registered under this Post-Effective Amendment No. 1. All applicable registration fees were previously paid.</dei:AmendmentDescription>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" unitRef="usd">2717936</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">5828548</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c1" decimals="0" unitRef="usd">714652</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">736667</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c1" decimals="0" unitRef="usd">281197</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" unitRef="usd">280692</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="c1" decimals="0" unitRef="usd">145399</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">145399</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c1" decimals="0" unitRef="usd">2715375</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">1286618</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:InventoryNet contextRef="c1" decimals="0" unitRef="usd">22700</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" unitRef="usd">25975</us-gaap:InventoryNet>
    <us-gaap:ShortTermInvestments contextRef="c1" decimals="0" unitRef="usd">95553</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="0" unitRef="usd">108147</us-gaap:ShortTermInvestments>
    <abvc:PrepaymentForLongtermInvestments contextRef="c1" decimals="0" unitRef="usd">663798</abvc:PrepaymentForLongtermInvestments>
    <abvc:PrepaymentForLongtermInvestments contextRef="c2" decimals="0" unitRef="usd">684720</abvc:PrepaymentForLongtermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="0" unitRef="usd">631321</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" unitRef="usd">528354</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="0" unitRef="usd">7987931</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" unitRef="usd">9625120</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c1" decimals="0" unitRef="usd">598648</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">525881</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c1" decimals="0" unitRef="usd">1382695</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" unitRef="usd">1471899</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments contextRef="c1" decimals="0" unitRef="usd">904254</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="0" unitRef="usd">932755</us-gaap:LongTermInvestments>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c1" decimals="0" unitRef="usd">1036830</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c2" decimals="0" unitRef="usd">981912</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c1" decimals="0" unitRef="usd">115664</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c2" decimals="0" unitRef="usd">119309</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:SecurityDeposit contextRef="c1" decimals="0" unitRef="usd">40733</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="c2" decimals="0" unitRef="usd">41157</us-gaap:SecurityDeposit>
    <us-gaap:Assets contextRef="c1" decimals="0" unitRef="usd">12066755</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="0" unitRef="usd">13698033</us-gaap:Assets>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c1" decimals="0" unitRef="usd">1609750</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c2" decimals="0" unitRef="usd">1640000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">1247558</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">1300803</us-gaap:AccruedLiabilitiesCurrent>
    <abvc:AdvanceFromCustomers contextRef="c1" decimals="0" unitRef="usd">10985</abvc:AdvanceFromCustomers>
    <abvc:AdvanceFromCustomers contextRef="c2" decimals="0" unitRef="usd">10985</abvc:AdvanceFromCustomers>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c1" decimals="0" unitRef="usd">349008</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" unitRef="usd">347100</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c1" decimals="0" unitRef="usd">446397</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">393424</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="0" unitRef="usd">3663698</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">3692312</us-gaap:LiabilitiesCurrent>
    <us-gaap:SecurityDepositLiability contextRef="c1" decimals="0" unitRef="usd">7980</us-gaap:SecurityDepositLiability>
    <us-gaap:SecurityDepositLiability contextRef="c2" decimals="0" unitRef="usd">10580</us-gaap:SecurityDepositLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c1" decimals="0" unitRef="usd">1033686</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" unitRef="usd">1124799</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c1" decimals="0" unitRef="usd">4705364</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c2" decimals="0" unitRef="usd">4827691</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c1" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c1" decimals="0" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c1" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c1" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c1" decimals="0" unitRef="shares">30307329</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c1" decimals="0" unitRef="shares">30307329</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">28926322</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">28926322</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c1" decimals="0" unitRef="usd">30307</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" unitRef="usd">28926</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="0" unitRef="usd">62578549</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" unitRef="usd">58113667</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c1" decimals="0" unitRef="usd">2031660</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c2" decimals="0" unitRef="usd">2257400</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="0" unitRef="usd">-44476640</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" unitRef="usd">-38481200</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c1" decimals="0" unitRef="usd">426321</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" unitRef="usd">539660</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue contextRef="c1" decimals="0" unitRef="usd">9100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c2" decimals="0" unitRef="usd">9100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="0" unitRef="usd">7426877</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">8843653</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c1" decimals="0" unitRef="usd">-65486</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c2" decimals="0" unitRef="usd">26689</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" unitRef="usd">7361391</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" unitRef="usd">8870342</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="0" unitRef="usd">12066755</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" unitRef="usd">13698033</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="0" unitRef="usd">25660</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="0" unitRef="usd">263150</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c0" decimals="0" unitRef="usd">1896</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c4" decimals="0" unitRef="usd">1245</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c0" decimals="0" unitRef="usd">23764</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c4" decimals="0" unitRef="usd">261905</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c0" decimals="0" unitRef="usd">1191078</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c4" decimals="0" unitRef="usd">1167595</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="0" unitRef="usd">359404</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="0" unitRef="usd">121315</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">4692003</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="0" unitRef="usd">225740</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="0" unitRef="usd">6242485</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c4" decimals="0" unitRef="usd">1514650</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-6218721</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-1252745</us-gaap:OperatingIncomeLoss>
    <abvc:InterestIncomes contextRef="c0" decimals="0" unitRef="usd">40175</abvc:InterestIncomes>
    <abvc:InterestIncomes contextRef="c4" decimals="0" unitRef="usd">52529</abvc:InterestIncomes>
    <us-gaap:InterestExpense contextRef="c0" decimals="0" unitRef="usd">18213</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c4" decimals="0" unitRef="usd">130229</us-gaap:InterestExpense>
    <abvc:RentIncome contextRef="c0" decimals="0" unitRef="usd">24124</abvc:RentIncome>
    <abvc:RentIncome contextRef="c4" decimals="0" unitRef="usd">4867</abvc:RentIncome>
    <abvc:OperatingSubleaseIncomeRelatedParties contextRef="c4" decimals="0" unitRef="usd">1600</abvc:OperatingSubleaseIncomeRelatedParties>
    <abvc:GainLossOnForeignExchangeChanges contextRef="c0" decimals="0" unitRef="usd">7563</abvc:GainLossOnForeignExchangeChanges>
    <abvc:GainLossOnForeignExchangeChanges contextRef="c4" decimals="0" unitRef="usd">951</abvc:GainLossOnForeignExchangeChanges>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c4" decimals="0" unitRef="usd">-47791</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="0" unitRef="usd">-9410</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="0" unitRef="usd">71</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OtherIncome contextRef="c4" decimals="0" unitRef="usd">124400</us-gaap:OtherIncome>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c0" decimals="0" unitRef="usd">44239</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c4" decimals="0" unitRef="usd">6398</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-6174482</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="0" unitRef="usd">-1246347</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">-86867</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">-51024</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c0" decimals="0" unitRef="usd">-6087615</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="0" unitRef="usd">-1195323</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c0" decimals="0" unitRef="usd">-92175</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c4" decimals="0" unitRef="usd">-66818</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <abvc:NetLossAttributableToAbvcAndSubsidiaries contextRef="c0" decimals="0" unitRef="usd">-5995440</abvc:NetLossAttributableToAbvcAndSubsidiaries>
    <abvc:NetLossAttributableToAbvcAndSubsidiaries contextRef="c4" decimals="0" unitRef="usd">-1128505</abvc:NetLossAttributableToAbvcAndSubsidiaries>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c0" decimals="0" unitRef="usd">-113339</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c4" decimals="0" unitRef="usd">36140</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c0" decimals="0" unitRef="usd">-6108779</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c4" decimals="0" unitRef="usd">-1092365</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">-0.2</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="shares">29683402</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="0" unitRef="shares">24420526</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="0" unitRef="usd">-6087615</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="0" unitRef="usd">-1195323</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="0" unitRef="usd">5411</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c4" decimals="0" unitRef="usd">2928</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">4692003</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="0" unitRef="usd">225740</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c4" decimals="0" unitRef="usd">-47791</us-gaap:UnrealizedGainLossOnInvestments>
    <abvc:GovernmentGrantIncome contextRef="c4" decimals="0" unitRef="usd">124400</abvc:GovernmentGrantIncome>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="0" unitRef="usd">-9503</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c0" decimals="0" unitRef="usd">-86867</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c4" decimals="0" unitRef="usd">-51024</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c0" decimals="0" unitRef="usd">505</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c4" decimals="0" unitRef="usd">238484</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets contextRef="c0" decimals="0" unitRef="usd">113292</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets contextRef="c4" decimals="0" unitRef="usd">187723</us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties contextRef="c0" decimals="0" unitRef="usd">1434353</us-gaap:IncreaseDecreaseDueFromOtherRelatedParties>
    <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties contextRef="c4" decimals="0" unitRef="usd">18229</us-gaap:IncreaseDecreaseDueFromOtherRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c0" decimals="0" unitRef="usd">-2537</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c4" decimals="0" unitRef="usd">-12710</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c0" decimals="0" unitRef="usd">-38378</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c4" decimals="0" unitRef="usd">136519</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c0" decimals="0" unitRef="usd">57299</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c4" decimals="0" unitRef="usd">1841</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="0" unitRef="usd">-2994257</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="0" unitRef="usd">-1413074</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="0" unitRef="usd">93220</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c4" decimals="0" unitRef="usd">281952</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="0" unitRef="usd">-93220</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="0" unitRef="usd">-281952</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c4" decimals="0" unitRef="usd">40448</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c4" decimals="0" unitRef="usd">250000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c4" decimals="0" unitRef="usd">236498</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <abvc:BorrowingsFromRelatedParties contextRef="c4" decimals="0" unitRef="usd">10651</abvc:BorrowingsFromRelatedParties>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt contextRef="c4" decimals="0" unitRef="usd">4629</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="0" unitRef="usd">42226</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c0" decimals="0" unitRef="usd">-45150</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c4" decimals="0" unitRef="usd">-15335</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="0" unitRef="usd">-3132627</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="0" unitRef="usd">-1668135</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" unitRef="usd">6565215</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">5001371</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="0" unitRef="usd">3432588</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c7" decimals="0" unitRef="usd">3333236</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="0" unitRef="usd">43842</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c4" decimals="0" unitRef="usd">21666</us-gaap:InterestPaidNet>
    <us-gaap:SharesOutstanding contextRef="c9" decimals="0" unitRef="shares">24420526</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c9" decimals="0" unitRef="usd">24420</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c10" decimals="0" unitRef="usd">-3160360</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" unitRef="usd">40751807</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="0" unitRef="usd">-25642387</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="0" unitRef="usd">564860</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c14" decimals="0" unitRef="shares">-275347</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="0" unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="0" unitRef="usd">-776273</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" unitRef="usd">2662067</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c16" decimals="0" unitRef="usd">225740</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c4" decimals="0" unitRef="usd">225740</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c18" decimals="0" unitRef="usd">-1128505</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c21" decimals="0" unitRef="usd">-66818</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c4" decimals="0" unitRef="usd">-1195323</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <abvc:CumulativeTransactionAdjustments contextRef="c19" decimals="0" unitRef="usd">36140</abvc:CumulativeTransactionAdjustments>
    <abvc:CumulativeTransactionAdjustments contextRef="c4" decimals="0" unitRef="usd">36140</abvc:CumulativeTransactionAdjustments>
    <us-gaap:SharesOutstanding contextRef="c22" decimals="0" unitRef="shares">24420526</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c22" decimals="0" unitRef="usd">24420</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c23" decimals="0" unitRef="usd">-2934620</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c24" decimals="0" unitRef="usd">40751807</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c25" decimals="0" unitRef="usd">-26770892</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c26" decimals="0" unitRef="usd">601000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c27" decimals="0" unitRef="shares">-275347</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c27" decimals="0" unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c28" decimals="0" unitRef="usd">-843091</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c7" decimals="0" unitRef="usd">1728624</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c29" decimals="0" unitRef="shares">28926322</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c29" decimals="0" unitRef="usd">28926</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c30" decimals="0" unitRef="usd">-2257400</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c31" decimals="0" unitRef="usd">58113667</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c32" decimals="0" unitRef="usd">-38481200</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c33" decimals="0" unitRef="usd">539660</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c34" decimals="0" unitRef="shares">-275347</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c34" decimals="0" unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c35" decimals="0" unitRef="usd">26689</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" unitRef="usd">8870342</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c36" decimals="0" unitRef="shares">1381007</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c36" decimals="0" unitRef="usd">1381</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c38" decimals="0" unitRef="usd">4464882</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c0" decimals="0" unitRef="usd">4466263</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c37" decimals="0" unitRef="usd">225740</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross contextRef="c0" decimals="0" unitRef="usd">225740</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c39" decimals="0" unitRef="usd">-5995440</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c40" decimals="0" unitRef="usd">-92175</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c0" decimals="0" unitRef="usd">-6087615</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <abvc:CumulativeTransactionAdjustments contextRef="c41" decimals="0" unitRef="usd">-113339</abvc:CumulativeTransactionAdjustments>
    <abvc:CumulativeTransactionAdjustments contextRef="c0" decimals="0" unitRef="usd">-113339</abvc:CumulativeTransactionAdjustments>
    <us-gaap:SharesOutstanding contextRef="c42" decimals="0" unitRef="shares">30307329</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c42" decimals="0" unitRef="usd">30307</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c43" decimals="0" unitRef="usd">-2031660</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c44" decimals="0" unitRef="usd">62578549</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c45" decimals="0" unitRef="usd">-44476640</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c46" decimals="0" unitRef="usd">426321</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c47" decimals="0" unitRef="shares">-275347</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c47" decimals="0" unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="0" unitRef="usd">-65486</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="0" unitRef="usd">7361391</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;ABVC BioPharma, Inc. (the &#x201c;Company&#x201d;),
formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#x2019;s operating entity, American
BriVision Corporation (&#x201c;BriVision&#x201d;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology
to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. &#160;BriVision develops
its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific
region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision
believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization,
BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly
respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical
trials for the Company&#x2019;s drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering
Cancer Center (&#x201c;MSKCC&#x201d;) and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July
21, 2015.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Name Change&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s shareholders approved an amendment
to the Company&#x2019;s Articles of Incorporation to change the Company&#x2019;s corporate name from American BriVision (Holding) Corporation
to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders
(the &#x201c;Annual Meeting&#x201d;). The name change amendment to the Company&#x2019;s Articles of Incorporation was filed with Nevada&#x2019;s
Secretary of State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became
effective as of May 3, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s stock symbol remains ABVC.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Reverse Merger&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 8, 2016, a Share Exchange Agreement
(the &#x201c;Share Exchange Agreement&#x201d;) was entered into by and among the Company, BriVision, and Euro-Asia Investment &amp;amp; Finance
Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&#x2019;s Republic of China
(&#x201c;Euro-Asia&#x201d;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company,
and the owners of record of all of the issued share capital of BriVision (the &#x201c;BriVision Stock&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Share Exchange Agreement, upon
surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered
in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision
as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision
Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the &#x201c;Acquisition Stock&#x201d;)
(subject to adjustment for fractionalized shares as set forth below) of the Company&#x2019;s Common Stock to the BriVision Shareholders
(or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#x2019;s Common Stock owned by Euro-Asia were
cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of
the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision
in a reverse merger (the &#x201c;Merger&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the Merger, all of the issued and
outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583
pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company&#x2019;s
Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&#x2019;s
Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the &#x201c;Share Exchange&#x201d;), BriVision had
become a wholly owned subsidiary (the &#x201c;Subsidiary&#x201d;) of the Company and there was a change of control of the Company following
the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon the consummation of the Share Exchange, BriVision
became a wholly owned subsidiary of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Following the Share Exchange, the Company has
abandoned prior business plan and is now pursuing BriVision&#x2019;s historically proposed businesses, which focus on the development of
new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements
from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&#x201c;POC&#x201d;), out-license
to international pharmaceutical companies, and explore global markets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Accounting Treatment of the Reverse Merger&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For financial reporting purposes, the Share Exchange
represents a &#x201c;reverse merger&#x201d;&#160;rather than a business combination and&#160;BriVision&#160;is deemed the accounting acquirer
in the transaction. The&#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#160;is the acquirer
for financial reporting purposes and the&#160;Company&#160;is the acquired company. Consequently, the assets and liabilities and the operations
reflected in the historical financial statements prior to the Share Exchange will be those of&#160;BriVision&#160;and recorded at the
historical cost basis of&#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will
include the assets and liabilities of the Company and BriVision, and the historical operations of&#160;BriVision&#160;and operations of
the Combined Company from the closing date of the Share Exchange.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Merger&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 8, 2019, the Company, BioLite Holding,
Inc. (&#x201c;BioLite&#x201d;), BioKey, Inc. (&#x201c;BioKey&#x201d;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent
(&#x201c;Merger Sub 1&#x201d;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#x201c;Merger Sub 2&#x201d;) (collectively
referred to as the &#x201c;Parties&#x201d;) completed the business combination pursuant to the Agreement and Plan of Merger (the &#x201c;Merger
Agreement&#x201d;) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the
shareholders of BioLite and BioKey.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the Merger Agreement,
BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares
(prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file
number 333-226285), which became effective by operation of law on or about February 5, 2019.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;BioLite Holding, Inc. (the &#x201c;BioLite Holding&#x201d;)
was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the &#x201c;BioLite BVI&#x201d;), a wholly owned
subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are
holding companies and have not carried out substantive business operations of their own.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;BioLite, Inc., (the &#x201c;BioLite Taiwan&#x201d;)
was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new
botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite
Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2017, BioLite Holding, BioLite BVI,
BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &#x201c;BioLite Share
Purchase / Exchange Agreement&#x201d;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the
BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase
shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock
as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately
owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement
retain their equity ownership in BioLite Taiwan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;BioKey, Inc. was incorporated on August 9, 2000
in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation
development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials
(Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development
processes with other biotechnology, pharmaceutical, and nutraceutical companies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Accounting Treatment of the Merger&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company adopted ASC 805, &#x201c;Business Combination&#x201d;
to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang&#x2019;s
common control, the transaction is accounted for as a restructuring transaction.&#160;All the assets and liabilities of BioLite Holding,
BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger.
The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding&#x2019;s common shares as if the
restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions,
and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity
transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the
earnings (or losses) of the transferred net assets.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c68" decimals="0" unitRef="shares">164387376</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c68" decimals="0" unitRef="shares">52336000</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c69" decimals="0" unitRef="shares">166273921</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c69" decimals="0" unitRef="shares">52936583</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c70" decimals="0" unitRef="shares">163159952</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c70" decimals="0" unitRef="shares">51945225</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:PercentageOfCommonSharesIssuedAndOutstanding contextRef="c71" decimals="4" unitRef="pure">0.797</abvc:PercentageOfCommonSharesIssuedAndOutstanding>
    <abvc:PercentageOfIssuedShareCapital contextRef="c71" decimals="2" unitRef="pure">1</abvc:PercentageOfIssuedShareCapital>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="c72">at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583
pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.</us-gaap:StockholdersEquityNoteStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c73" decimals="0" unitRef="shares">205519223</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c73" decimals="0" unitRef="shares">65431144</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c74" decimals="0" unitRef="shares">104558777</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:PercentageOfCommonSharesIssuedAndOutstanding contextRef="c75" decimals="2" unitRef="pure">0.73</abvc:PercentageOfCommonSharesIssuedAndOutstanding>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;).
All significant intercompany transactions and account balances have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&#x2019;s financial statements are expressed in U.S. dollars.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company changed its fiscal year from the period
beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January
1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Forward Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Stock Reverse Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 12, 2019, the Board of Directors of the
Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#x201c;Reverse
Split&#x201d;) of both the authorized common stock of the Company (the &#x201c;Common Stock&#x201d;) and the issued and outstanding Common
Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the
Reverse Split without obtaining approval of the Company&#x2019;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On
May 3, 2019, the Company filed a certificate of amendment to the Company&#x2019;s articles of incorporation (the &#x201c;Amendment&#x201d;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;) informed
the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect
this 1-for-18 reverse stock split.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;FASB ASC 820, &#x201c;Fair Value Measurements&#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the
assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short.
The carrying value of the Company&#x2019;s long-term bank loan approximates fair value because the interest rates approximate market rates
that the Company could obtain for debt with similar terms and maturities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2022 and December 31, 2021, the Company&#x2019;s
cash and cash equivalents amounted $2,717,936 and $5,828,548, respectively. Some&#160;of the Company&#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Restricted Cash Equivalents&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2022 and December 31, 2021, the Company&#x2019;s restricted cash equivalents
amounted $714,652 and $736,667, respectively.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&#x2019;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#x2019;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#x2019;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&#x2019;s revenue during all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within
the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the
goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the
scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price
that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Collaborative Revenues &#x2014; &lt;/b&gt;The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees,
development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales
of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed
products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing
activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s judgment.
Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited to,
the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated
duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on
a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(i) Non-refundable upfront payments&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If a license to the Company&#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and
it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;(ii) Milestone payments&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is eligible to receive milestone payments
under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial
events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into
two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement with collaboration
partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative agreement with
collaboration partners.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded
that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each
triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more
of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional
payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete
each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi)
a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone
payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in
the period in which the underlying triggering event occurs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(iii) Multiple Element Arrangements&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s),
delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an
item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which is
typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance or objectively
measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over
the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service
is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue
under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount
of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance
method, as applicable, as of the period ending date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable
relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical,
regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment
required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether
a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive
are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other
revenue recognition criteria are met.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(iv) Royalties and Profit Sharing Payments&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is
resolved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues Derived from Research and Development
Activities Services &#x2014; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception
of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request
that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset
to research and development expenses as it satisfies the related performance obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated&#160;Life&lt;br/&gt; in Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Buildings and leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;5 ~ 50&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5 ~ 10&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3 ~ 6&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has adopted Accounting Standards Codification
subtopic 360-10, Property, Plant and Equipment (&#x201c;ASC 360-10&#x201d;). ASC 360-10 requires that long-lived assets and certain identifiable
intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events
and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring
losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated,
the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and
ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or
the fair value less costs to sell.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Long-term Equity Investment&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company
does not have control over the investees as:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Non-marketable cost method investments when the equity method does not apply.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Significant judgment is required to identify whether
an impairment exists in the valuation of the Company&#x2019;s non-marketable equity investments, and therefore the Company considers this
a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact
on the investee&#x2019;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term
prospects of the investee, changes in general market conditions in the investee&#x2019;s industry or geographic area, and the management
and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market
and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent
financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding
the investees&#x2019; revenue, costs, and discount rates. The Company&#x2019;s assessment of these factors in determining whether an impairment
exists could change in the future due to new developments or changes in applied assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Other-Than-Temporary Impairment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#x2019;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Non-marketable equity investments based on the Company&#x2019;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#x2019;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairment of equity investments were $0 and $0 for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing
goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that
the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our
best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share,
and general economic conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company completed the required testing of
goodwill for impairment as of March 31, 2022, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&#x2019;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For CDMO business unit, the Company accounts for
R&amp;amp;D costs in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730, Research and Development (&#x201c;ASC 730&#x201d;).
Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development
projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities,
including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing
and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable
advance payment for goods and services that will be used in future research and development activities are expensed when the activity
has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into
agreements with third parties to provide research and development services, costs are expensed as services are performed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Post-retirement and post-employment benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#x201c;Act&#x201d;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#x2019;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#x2019; salaries to the employees&#x2019;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $3,337 and $2,503 for the three months ended March 31, 2022 and 2021, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d; and FASB ASC Topic 505-50 &#x201c;Equity-Based
Payments to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $4,692,003 and $225,740 for the three months ended March 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Beneficial Conversion Feature&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 740, a tax position is recognized as
a benefit only if it is&#160;&#x201c;more likely than not&#x201d;&#160;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2022 and 2021. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&#x201c;SAB 118&#x201d;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC
740 is complete. To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but it is
able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company
cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of
the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable
estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act
may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that
may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine
the final impact.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Valuation of Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A valuation allowance is recorded to reduce the
Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Loss Per Share of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company calculates net loss per share in accordance
with ASC Topic 260, &#x201c;Earnings per Share&#x201d;. Basic loss per share is computed by dividing the net loss by the weighted average
number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that
the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common
stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has adopted ASC Topic 450 &#x201c;Contingencies&#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies
are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates
that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount
of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency
is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably
possible that a material loss could be incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Foreign-currency Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the Company&#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the transactions
occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into
New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion
or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange
rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares
of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#x2019; Equity (Deficit).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Translation Adjustment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accounts of the Company&#x2019;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#x201c;NT$&#x201d;). Such financial statements
were translated into U.S. Dollars (&#x201c;$&#x201d; or &#x201c;USD&#x201d;) in accordance ASC 830, &#x201c;Foreign Currency Matters&#x201d;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&#x2019;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#x2019;
equity (deficit).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2020, the FASB issued ASU 2020-06, Debt
&#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity
(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;). ASU
2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models.
Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not
clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will
reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings
per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For
contracts in an entity&#x2019;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features
that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements
to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted,
and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted,
but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company
is currently evaluating the impact that the standard will have on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings
Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation (Topic
718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain
Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04 provides guidance
as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written
call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new
instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified
or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model
that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination,
debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for
all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should
apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early
adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an
interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is
currently evaluating the impact that the standard will have on its consolidated financial statements.&#160;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements
have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;).
All significant intercompany transactions and account balances have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;This basis of accounting involves the application
of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
The Company&#x2019;s financial statements are expressed in U.S. dollars.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company changed its fiscal year from the period
beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January
1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FiscalPeriod>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The preparation of financial statements in conformity
with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated
financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from
those results.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:InventoryPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Inventory consists of raw materials, work-in-process,
finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis.
Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine
whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory
obsolescence.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <abvc:ForwardStockSplitsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Forward Stock Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number
of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</abvc:ForwardStockSplitsPolicyTextBlock>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="c76" decimals="3" unitRef="usdPershares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:ExcessStockSharesAuthorized contextRef="c76" decimals="0" unitRef="shares">360000000</us-gaap:ExcessStockSharesAuthorized>
    <abvc:StockReverseSplitPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Stock Reverse Split&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 12, 2019, the Board of Directors of the
Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#x201c;Reverse
Split&#x201d;) of both the authorized common stock of the Company (the &#x201c;Common Stock&#x201d;) and the issued and outstanding Common
Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the
Reverse Split without obtaining approval of the Company&#x2019;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On
May 3, 2019, the Company filed a certificate of amendment to the Company&#x2019;s articles of incorporation (the &#x201c;Amendment&#x201d;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;) informed
the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect
this 1-for-18 reverse stock split.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</abvc:StockReverseSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c77">the Company filed a certificate of amendment to the Company&#x2019;s articles of incorporation (the &#x201c;Amendment&#x201d;)
to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;) informed
the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect
this 1-for-18 reverse stock split.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;FASB ASC 820, &#x201c;Fair Value Measurements&#x201d;
defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments
to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit
price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases
the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing
the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the
assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent
of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes
the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The carrying values of certain assets and liabilities
of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid
expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their
relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loan, convertible notes payable, and accrued interest
approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short.
The carrying value of the Company&#x2019;s long-term bank loan approximates fair value because the interest rates approximate market rates
that the Company could obtain for debt with similar terms and maturities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company considers highly liquid investments
with maturities of three months or less, when purchased, to be cash equivalents. As of March 31, 2022 and December 31, 2021, the Company&#x2019;s
cash and cash equivalents amounted $2,717,936 and $5,828,548, respectively. Some&#160;of the Company&#x2019;s cash deposits are held in
financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company
believes this financial institution is of high credit quality.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash contextRef="c1" decimals="0" unitRef="usd">2717936</us-gaap:Cash>
    <us-gaap:Cash contextRef="c2" decimals="0" unitRef="usd">5828548</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Restricted Cash Equivalents&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Restricted cash equivalents primarily consist
of cash held in a reserve bank account in Taiwan. As of March 31, 2022 and December 31, 2021, the Company&#x2019;s restricted cash equivalents
amounted $714,652 and $736,667, respectively.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c1" decimals="0" unitRef="usd">714652</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c2" decimals="0" unitRef="usd">736667</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s financial instruments that
are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary
cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation
and the U.S. Federal Deposit Insurance Corporation&#x2019;s insurance limits. The Company does not enter into financial instruments for
hedging, trading or speculative purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the fiscal year 2018, the Company adopted
Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified
retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment
to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#x2019;s
reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and
continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#x2019;s review of existing
collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant
change on the Company&#x2019;s revenue during all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to ASC 606, the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within
the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step
model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the
goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the
scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations,
and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price
that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following are examples of when the Company
recognizes revenue based on the types of payments the Company receives.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;Collaborative Revenues &#x2014; &lt;/b&gt;The Company
recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms
of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees,
development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales
of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed
products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized
upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As part of the accounting for these arrangements,
the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the
stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone
selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for
R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company had multiple deliverables under the
collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing
activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s judgment.
Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited to,
the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated
duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on
a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing
of future revenue recognition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(i) Non-refundable upfront payments&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If a license to the Company&#x2019;s intellectual
property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue
from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to
the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and
the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely
for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and
it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative
agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;(ii) Milestone payments&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company is eligible to receive milestone payments
under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial
events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into
two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement with collaboration
partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative agreement with
collaboration partners.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The former category of milestone payments consists
of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded
that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each
triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more
of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional
payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete
each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi)
a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone
payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in
the period in which the underlying triggering event occurs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(iii) Multiple Element Arrangements&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates multiple element arrangements
to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of
accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations
and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects
of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has
value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s),
delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an
item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization
capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also
considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining
element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can
provide the undelivered element(s).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognizes arrangement consideration
allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of
accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the
combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which is
typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance or objectively
measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over
the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service
is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue
under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount
of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance
method, as applicable, as of the period ending date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At the inception of an arrangement that includes
milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent
nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s
performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting
from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable
relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical,
regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment
required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether
a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive
are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other
revenue recognition criteria are met.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;(iv) Royalties and Profit Sharing Payments&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the collaborative agreement with the collaboration
partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company
recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company
considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is
resolved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Revenues Derived from Research and Development
Activities Services &#x2014; Revenues related to research and development and regulatory activities are recognized when the related services
or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception
of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request
that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K
submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines
an option is a material right, the Company will consider the option a separate performance obligation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If the Company is entitled to reimbursement from
its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate
performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement
of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance
with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset
to research and development expenses as it satisfies the related performance obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company then determines the transaction price
by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under
the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone
payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by the Company
based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred.
The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because
the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company
should include additional payments in the transaction price.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company receives payments from its customers
based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt
or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these
arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company
does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period
between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Property and equipment is carried at cost net
of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related
asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or
loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining
lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment
under capital leases, generally based on the following useful lives:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Estimated&#160;Life&lt;br/&gt; in Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Buildings and leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;5 ~ 50&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;5 ~ 10&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;3 ~ 6&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c78">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c79">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c80">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c81">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c82">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c83">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has adopted Accounting Standards Codification
subtopic 360-10, Property, Plant and Equipment (&#x201c;ASC 360-10&#x201d;). ASC 360-10 requires that long-lived assets and certain identifiable
intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events
and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring
losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated,
the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and
ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or
the fair value less costs to sell.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <abvc:LongTermEquityInvestmentPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Long-term Equity Investment&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company acquires the equity investments to
promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company
does not have control over the investees as:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Non-marketable cost method investments when the equity method does not apply.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Significant judgment is required to identify whether
an impairment exists in the valuation of the Company&#x2019;s non-marketable equity investments, and therefore the Company considers this
a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact
on the investee&#x2019;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term
prospects of the investee, changes in general market conditions in the investee&#x2019;s industry or geographic area, and the management
and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market
and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent
financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding
the investees&#x2019; revenue, costs, and discount rates. The Company&#x2019;s assessment of these factors in determining whether an impairment
exists could change in the future due to new developments or changes in applied assumptions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</abvc:LongTermEquityInvestmentPolicy>
    <abvc:OtherThanTemporaryImpairmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Other-Than-Temporary Impairment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s long-term equity investments
are subject to a periodic impairment review. Impairments affect earnings as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#x2019;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Non-marketable equity investments based on the Company&#x2019;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#x2019;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairment of equity investments were $0 and $0 for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</abvc:OtherThanTemporaryImpairmentPolicyTextBlock>
    <abvc:ImpairmentOfEquityInvestments contextRef="c0" decimals="0" unitRef="usd">0</abvc:ImpairmentOfEquityInvestments>
    <abvc:ImpairmentOfEquityInvestments contextRef="c4" decimals="0" unitRef="usd">0</abvc:ImpairmentOfEquityInvestments>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company evaluates goodwill for impairment
annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing
goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that
the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment
is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step
impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined
to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step
is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value.
The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our
best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share,
and general economic conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company completed the required testing of
goodwill for impairment as of March 31, 2022, and determined that goodwill was impaired because of the current financial condition of
the Company and the Company&#x2019;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably
assured.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for the cost of using licensing
rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses
the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
when incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For CDMO business unit, the Company accounts for
R&amp;amp;D costs in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730, Research and Development (&#x201c;ASC 730&#x201d;).
Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development
projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities,
including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing
and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable
advance payment for goods and services that will be used in future research and development activities are expensed when the activity
has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into
agreements with third parties to provide research and development services, costs are expensed as services are performed.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Post-retirement and post-employment benefits&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company&#x2019;s subsidiaries in Taiwan adopted
the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#x201c;Act&#x201d;) in Taiwan. Such labor regulations
require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#x2019;s
monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#x2019; salaries to the employees&#x2019;
pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee
benefits, which were expensed as incurred, were $3,337 and $2,503 for the three months ended March 31, 2022 and 2021, respectively. Other
than the above, the Company does not provide any other post-retirement or post-employment benefits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy>
    <abvc:LabourPensionFundPercentage contextRef="c0" decimals="2" unitRef="pure">0.06</abvc:LabourPensionFundPercentage>
    <abvc:PercentageOfMonthlyContribution contextRef="c1" decimals="2" unitRef="pure">0.06</abvc:PercentageOfMonthlyContribution>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c1" decimals="0" unitRef="usd">3337</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c7" decimals="0" unitRef="usd">2503</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company measures expense associated with all
employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements
on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d;.
Total employee stock-based compensation expenses were $0 and $0 for the three months ended March 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounted for stock-based compensation
to non-employees in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d; and FASB ASC Topic 505-50 &#x201c;Equity-Based
Payments to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the
earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total
non-employee stock-based compensation expenses were $4,692,003 and $225,740 for the three months ended March 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c4" decimals="0" unitRef="usd">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <abvc:StockBasedCompensationForNonemployees contextRef="c0" decimals="0" unitRef="usd">4692003</abvc:StockBasedCompensationForNonemployees>
    <abvc:StockBasedCompensationForNonemployees contextRef="c4" decimals="0" unitRef="usd">225740</abvc:StockBasedCompensationForNonemployees>
    <abvc:BeneficialConversionFeature contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Beneficial Conversion Feature&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;From time to time, the Company may issue convertible
notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note
is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated
proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related
warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding
amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective
interest method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</abvc:BeneficialConversionFeature>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 40.2pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company accounts for income taxes using the
asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization
of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary
differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax
purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company
is able to realize their benefits, or future deductibility is uncertain.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under ASC 740, a tax position is recognized as
a benefit only if it is&#160;&#x201c;more likely than not&#x201d;&#160;that the tax position would be sustained in a tax examination, with
a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether
it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or
litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not
threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount
of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to
meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met.
Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent
financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income
tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred
for the three months ended March 31, 2022 and 2021. GAAP also provides guidance on de-recognition, classification, interest and penalties,
accounting in interim periods, disclosures and transition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 22, 2017, the SEC issued Staff Accounting
Bulletin (&#x201c;SAB 118&#x201d;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement
period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740.
In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC
740 is complete. To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but it is
able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company
cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of
the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable
estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act
may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that
may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine
the final impact.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DefinedBenefitPlanFundedPercentage contextRef="c1" decimals="2" unitRef="pure">0.50</us-gaap:DefinedBenefitPlanFundedPercentage>
    <abvc:ValuationOfDeferredTaxAssetsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Valuation of Deferred Tax Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;A valuation allowance is recorded to reduce the
Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation
allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning
strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance
against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s
projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with
the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets.
As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate
and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in
the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction.
In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results
in the period such determination was made.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</abvc:ValuationOfDeferredTaxAssetsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Loss Per Share of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company calculates net loss per share in accordance
with ASC Topic 260, &#x201c;Earnings per Share&#x201d;. Basic loss per share is computed by dividing the net loss by the weighted average
number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that
the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common
stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive
potential shares if their effect is anti-dilutive.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has adopted ASC Topic 450 &#x201c;Contingencies&#x201d;
subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies
are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates
that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount
of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency
is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably
possible that a material loss could be incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Foreign-currency Transactions&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;For the Company&#x2019;s subsidiaries in Taiwan,
the foreign-currency transactions are recorded in New Taiwan dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the transactions
occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into
New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion
or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange
rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares
of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#x2019; Equity (Deficit).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <abvc:TranslationAdjustmentPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Translation Adjustment&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accounts of the Company&#x2019;s subsidiaries
in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#x201c;NT$&#x201d;). Such financial statements
were translated into U.S. Dollars (&#x201c;$&#x201d; or &#x201c;USD&#x201d;) in accordance ASC 830, &#x201c;Foreign Currency Matters&#x201d;,
with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange
rate, stockholder&#x2019;s deficit are translated at the historical rates and income statement items are translated at an average exchange
rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#x2019;
equity (deficit).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</abvc:TranslationAdjustmentPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2020, the FASB issued ASU 2020-06, Debt
&#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity
(Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;). ASU
2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models.
Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not
clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will
reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings
per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For
contracts in an entity&#x2019;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features
that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements
to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted,
and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted,
but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company
is currently evaluating the impact that the standard will have on its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;In May 2021, the FASB issued ASU 2021-04, Earnings
Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation (Topic
718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain
Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04 provides guidance
as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written
call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new
instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified
or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model
that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination,
debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for
all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should
apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early
adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an
interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;3. COLLABORATIVE AGREEMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreements with BHK&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;(i) On February 24, 2015, BioLite Taiwan and BioHopeKing
Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;), pursuant
to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination
Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for
medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The
BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia
excluding Japan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 27, 2016, BioLite Taiwan and BHK agreed
to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;At the completion of first phase II clinical trial: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In December 2015, BHK has paid a non-refundable
upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that
the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and
recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015.
The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement
was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August
2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized collaboration
revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical
trial.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition to the milestone payments, BioLite
Taiwan is entitled to receive royalty on 12% of BHK&#x2019;s net sales related to BLI-1401-2 Products. As of March 31, 2022 and December
31, 2021, the Company has not earned the royalty under the BHK Co-Development Agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;(ii) On December 9, 2015, BioLite Taiwan entered
into another two collaborative agreements (the &#x201c;BHK Collaborative Agreements&#x201d;), pursuant to which it is collaborative with
BHK to co-develop and commercialize BLI-1005 for &#x201c;Targeting Major Depressive Disorder&#x201d; (BLI-1005 Products) and BLI-1006 for
&#x201c;Targeting Inflammatory Bowel Disease&#x201d; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights,
and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between
BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of
the Product in in Asia excluding Japan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In 2015, the Company recognized the cash receipt
in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items
have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data
and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by
BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan
and BHK in this BHK Collaborative Agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition to the total of NT$50 million, approximately
equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of March
31, 2022 and December 31, 2021, the Company has not earned the royalty under the BHK Collaborative Agreements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Co-Development agreement with Rgene Corporation,
a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 26, 2017, BriVision entered into a co-development
agreement (the &#x201c;Co-Dev Agreement&#x201d;) with Rgene Corporation (the &#x201c;Rgene&#x201d;), a related party under common control
by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to Co-Dev Agreement, BriVision
and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer
Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to&#160;pay
the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision&#x2019;s
past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future
commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to $3,000,000, the Company is entitled to receive 50% of
the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both
BriVision and Rgene.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 1, 2017, the Company has delivered all
research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control
by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000
in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended December
31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in
the form of newly issued shares of Rgene&#x2019;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for
an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year
ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully write
off this investment based on the Company&#x2019;s assessment of the severity and duration of the impairment, and qualitative and quantitative
analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment,
changes in operating structure of Rgene, additional funding requirements, and Rgene&#x2019;s ability to remain in business. All projects
that have been initiated will be managed and supported by the Company and Rgene.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company and Rgene signed an amendment to the
Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination
Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and
ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions
of the Co-Dev Agreement remain in full force and effect.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreement with BioFirst Corporation,
a related party&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 24, 2017, BriVision entered into a collaborative
agreement (the &#x201c;BioFirst Collaborative Agreement&#x201d;) with BioFirst Corporation (&#x201c;BioFirst&#x201d;), pursuant to which BioFirst
granted the Company the global licensing right for medical use of the product (the &#x201c;Product&#x201d;): BFC-1401 Vitreous Substitute
for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the
Company is one of the directors and Common Stock shareholders of BioFirst (See Note 12).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the BioFirst Collaborative Agreement,
the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock
of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst&#x2019;s past research
efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future
commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50%
of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and
BioFirst.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000
since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future
uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses
immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended December
31, 2017.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 30, 2019, BriVision entered into a Stock
Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with BioFirst Corporation. Pursuant to the Purchase Agreement, the Company issued
428,571 shares of the Company&#x2019;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst (the &#x201c;Total
Payment&#x201d;) in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the &#x201c;Collaborative
Agreement&#x201d;). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401
or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 5, 2019, BriVision entered into a second
Stock Purchase Agreement (&#x201c;Purchase Agreement 2&#x201d;) with BioFirst Corporation. Pursuant to Purchase Agreement 2, the Company
issued 414,702 shares of the Company&#x2019;s common stock to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst
in connection with a loan provided to BriVision from BioFirst.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <abvc:MilestonePayments contextRef="c84" decimals="-6" unitRef="usd">10000000</abvc:MilestonePayments>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c84">&#x25cf;Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment

    &#160;
    &#x25cf;
    Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment
  &#160;

    &#160;
    &#x25cf;
    At the completion of first phase II clinical trial: $1 million, or 10% of total payment
  &#160;

    &#160;
    &#x25cf;
    At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment
  &#160;&#160;&#x25cf;Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <abvc:UpfrontCashPayment contextRef="c85" decimals="-6" unitRef="usd">1000000</abvc:UpfrontCashPayment>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement contextRef="c86" decimals="2" unitRef="pure">0.10</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <abvc:IssuanceOfStockValue contextRef="c86" decimals="0" unitRef="usd">10000000</abvc:IssuanceOfStockValue>
    <abvc:MilestonePayments contextRef="c87" decimals="0" unitRef="twd">31649000</abvc:MilestonePayments>
    <abvc:IssuanceOfStockValue contextRef="c87" decimals="-6" unitRef="usd">1000000</abvc:IssuanceOfStockValue>
    <abvc:MilestonePaymentsRoyaltyPercentage contextRef="c0" decimals="2" unitRef="pure">0.12</abvc:MilestonePaymentsRoyaltyPercentage>
    <abvc:CollaborativeAgreementsDescription contextRef="c86">In 2015, the Company recognized the cash receipt
in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development
data was delivered to BHK.</abvc:CollaborativeAgreementsDescription>
    <abvc:CollaborativeAgreementsDescription contextRef="c88">In addition to the total of NT$50 million, approximately
equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.</abvc:CollaborativeAgreementsDescription>
    <us-gaap:PaymentsForParticipationLiabilities contextRef="c89" decimals="0" unitRef="usd">3000000</us-gaap:PaymentsForParticipationLiabilities>
    <abvc:AdditionCashPayment contextRef="c90" decimals="0" unitRef="usd">3000000</abvc:AdditionCashPayment>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement contextRef="c90" decimals="2" unitRef="pure">0.50</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c91" decimals="0" unitRef="usd">3000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="c91" decimals="0" unitRef="usd">450000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <abvc:CoDevAgreementDescription contextRef="c92">the Company received the remaining balance of $2,550,000 in
the form of newly issued shares of Rgene&#x2019;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for
an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year
ended December 31, 2018, the Company has recognized investment loss of $549.</abvc:CoDevAgreementDescription>
    <abvc:IssuanceOfStockValue contextRef="c93" decimals="0" unitRef="usd">3000000</abvc:IssuanceOfStockValue>
    <us-gaap:PaymentsForParticipationLiabilities contextRef="c93" decimals="0" unitRef="usd">3000000</us-gaap:PaymentsForParticipationLiabilities>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement contextRef="c93" decimals="2" unitRef="pure">0.50</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c94" decimals="0" unitRef="usd">3000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c95" decimals="0" unitRef="usd">3000000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SharesIssued contextRef="c96" decimals="0" unitRef="shares">428571</us-gaap:SharesIssued>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="c96" decimals="0" unitRef="usd">3000000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SharesIssued contextRef="c97" decimals="0" unitRef="shares">414702</us-gaap:SharesIssued>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="c97" decimals="0" unitRef="usd">2902911</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;4. INVENTORY&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Inventory consists of the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.9pt; text-align: justify; text-indent: -22.9pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;104,036&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for inventory valuation and obsolescence loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(150,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,370&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Inventory, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;22,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,975&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Finished goods&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;104,036&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96,725&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;84,620&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for inventory valuation and obsolescence loss&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(150,623&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,370&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Inventory, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;22,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,975&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="c1" decimals="0" unitRef="usd">104036</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c2" decimals="0" unitRef="usd">96725</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials contextRef="c1" decimals="0" unitRef="usd">69287</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c2" decimals="0" unitRef="usd">84620</us-gaap:InventoryRawMaterials>
    <abvc:AllowanceForInventoryValuationAndObsolescenceLoss contextRef="c1" decimals="0" unitRef="usd">-150623</abvc:AllowanceForInventoryValuationAndObsolescenceLoss>
    <abvc:AllowanceForInventoryValuationAndObsolescenceLoss contextRef="c2" decimals="0" unitRef="usd">-155370</abvc:AllowanceForInventoryValuationAndObsolescenceLoss>
    <us-gaap:InventoryGross contextRef="c1" decimals="0" unitRef="usd">22700</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c2" decimals="0" unitRef="usd">25975</us-gaap:InventoryGross>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;5. PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;Property and
equipment as of March 31, 2022 and December 31, 2021 are summarized as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Land&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;387,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;400,091&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Buildings and leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,230,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,235,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,013,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;186,149&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;191,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,907,926&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,309,278&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,314,471&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;598,648&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;525,881&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expenses were $5,411 and $2,928 for
three months ended March 31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Land&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;387,866&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;400,091&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Buildings and leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,230,968&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,235,061&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Machinery and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,102,943&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,013,376&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;186,149&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;191,824&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,907,926&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,840,352&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,309,278&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,314,471&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;598,648&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;525,881&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-align: justify; text-indent: -23.75pt"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c98" decimals="0" unitRef="usd">387866</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c99" decimals="0" unitRef="usd">400091</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c100" decimals="0" unitRef="usd">2230968</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c101" decimals="0" unitRef="usd">2235061</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c102" decimals="0" unitRef="usd">1102943</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c103" decimals="0" unitRef="usd">1013376</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c104" decimals="0" unitRef="usd">186149</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c105" decimals="0" unitRef="usd">191824</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c1" decimals="0" unitRef="usd">3907926</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" unitRef="usd">3840352</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c1" decimals="0" unitRef="usd">3309278</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" unitRef="usd">3314471</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c1" decimals="0" unitRef="usd">598648</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:PropertyPlantAndEquipmentOtherNet contextRef="c2" decimals="0" unitRef="usd">525881</us-gaap:PropertyPlantAndEquipmentOtherNet>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c0" decimals="0" unitRef="usd">5411</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c4" decimals="0" unitRef="usd">2928</us-gaap:OtherDepreciationAndAmortization>
    <abvc:LongTermInvestmentTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"&gt;&lt;b&gt;6. LONG-TERM INVESTMENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The ownership percentages of
each investee are listed as follows:&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: 331.3pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Ownership percentage&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Accounting&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name of related party&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;treatments&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15.99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15.99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Equity Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Rgene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31.62&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31.62&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Equity Method&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;The extent the investee relies
on the company for its business are summarized as follows:&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left"&gt;Name of related party&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left"&gt;The extent the investee relies on the Company for its business &lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;No specific business relationship&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;No specific business relationship&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Rgene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Long-term investment mainly
consists of the following:&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-marketable Cost Method Investments, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;873,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;900,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Sub total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;904,254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;932,755&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equity Method Investments, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Rgene Corporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;904,254&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;932,755&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;):&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company holds an equity interest
in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s
proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of March 31, 2022 and December
31, 2021, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. The Company made prepayment for equity investment
in BioFirst to purchase additional 317,000 shares to be issued by BioFirst in the aggregate amount of $663,798 and $684,720, recorded
as prepayment for long-term investments as of March 31, 2022 and December 31, 2021, respectively.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Summarized financial information for the Company&#x2019;s
equity method investee, BioFirst, is as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Balance Sheet&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,147,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,205,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-current Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;812,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;959,454&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,237,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,909,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-current Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,522&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stockholders&#x2019; Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(295,402&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222,898&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Statement of Operations&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,808&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(498,940&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(220,855&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share of losses from investments accounted for using the equity method&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47,791&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Both Rgene and the Company are under
common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant
influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed
in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s
proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of March 31, 2022 and December
31, 2021, the Company owns 31.62% and 31.62% Common Stock shares of Rgene, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Summarized financial information for the Company&#x2019;s
equity method investee, Rgene, is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;Balance Sheets&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;221,169&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;73,452&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Noncurrent Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;374,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,164,077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,934,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Noncurrent Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Shareholders&#x2019; Deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,587,488&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,486,911&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;Statement of Operations&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gross Profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(149,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(95,395&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share of loss from investments accounted for using the equity method&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Disposition of long-term investment&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;During the three months ended March
31, 2022 and 2021, there is no disposition of long-term investment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Losses on Equity Investments&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The components of losses on equity investments
for each period were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Share of equity method investee losses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(47,791&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvc:LongTermInvestmentTextBlock>
    <abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Ownership percentage&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Accounting&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Name of related party&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;treatments&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.17&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%; text-align: center"&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.70&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Cost Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15.99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15.99&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Equity Method&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Rgene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31.62&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;31.62&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Equity Method&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c112" decimals="4" unitRef="pure">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c113" decimals="4" unitRef="pure">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c114">Cost Method</abvc:AccountingTreatmentDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c115" decimals="4" unitRef="pure">0.007</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c116" decimals="4" unitRef="pure">0.007</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c117">Cost Method</abvc:AccountingTreatmentDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c118" decimals="4" unitRef="pure">0.059</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c119" decimals="4" unitRef="pure">0.059</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c120">Cost Method</abvc:AccountingTreatmentDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c108" decimals="4" unitRef="pure">0.1599</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c109" decimals="4" unitRef="pure">0.1599</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c106">Equity Method</abvc:AccountingTreatmentDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c121" decimals="4" unitRef="pure">0.3162</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c122" decimals="4" unitRef="pure">0.3162</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c110">Equity Method</abvc:AccountingTreatmentDescription>
    <abvc:ScheduleOfExtentInvesteeReliesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left"&gt;Name of related party&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left"&gt;The extent the investee relies on the Company for its business &lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;No specific business relationship&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;No specific business relationship&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Rgene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&lt;b&gt;&#160;&#160;&lt;/b&gt;&lt;/p&gt;</abvc:ScheduleOfExtentInvesteeReliesTableTextBlock>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c114">No specific business relationship</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c117">No specific business relationship</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c120">Collaborating with the Company to develop and commercialize drugs</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c106">Collaborating with the Company to develop and commercialize drugs</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c110">Collaborating with the Company to develop and commercialize drugs</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:ScheduleOfLongTermInvestmentTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-marketable Cost Method Investments, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 9pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,698&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,941&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Genepharm Biotech Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,244&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;873,053&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;900,570&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.25in"&gt;Sub total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;904,254&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;932,755&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Equity Method Investments, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-88"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-89"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Rgene Corporation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-90"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-91"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;904,254&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;932,755&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;</abvc:ScheduleOfLongTermInvestmentTableTextBlock>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c123" decimals="0" unitRef="usd">7698</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c124" decimals="0" unitRef="usd">7941</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c125" decimals="0" unitRef="usd">23503</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c126" decimals="0" unitRef="usd">24244</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c127" decimals="0" unitRef="usd">873053</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c128" decimals="0" unitRef="usd">900570</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c1" decimals="0" unitRef="usd">904254</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c2" decimals="0" unitRef="usd">932755</abvc:NonmarketableCostMethodInvestmentsNet>
    <us-gaap:EquityMethodInvestments contextRef="c1" decimals="0" unitRef="usd">904254</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c2" decimals="0" unitRef="usd">932755</us-gaap:EquityMethodInvestments>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c106" decimals="4" unitRef="pure">0.1599</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c107" decimals="4" unitRef="pure">0.1599</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <abvc:PurchaseAdditionalShares contextRef="c0" decimals="0" unitRef="shares">317000</abvc:PurchaseAdditionalShares>
    <us-gaap:ExcessStockSharesIssued contextRef="c108" decimals="0" unitRef="shares">663798</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ExcessStockSharesIssued contextRef="c109" decimals="0" unitRef="shares">684720</us-gaap:ExcessStockSharesIssued>
    <pf0:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,147,097&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,205,669&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-current Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;812,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;959,454&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,237,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,909,703&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Non-current Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;17,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,522&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stockholders&#x2019; Equity&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(295,402&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;222,898&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Current Assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;221,169&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;73,452&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Noncurrent Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;355,420&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;374,423&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Current Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,164,077&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,934,786&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Noncurrent Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-92"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-93"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Shareholders&#x2019; Deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,587,488&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,486,911&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</pf0:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:OtherAssetsCurrent contextRef="c133" decimals="0" unitRef="usd">2147097</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c134" decimals="0" unitRef="usd">2205669</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c133" decimals="0" unitRef="usd">812865</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c134" decimals="0" unitRef="usd">959454</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c133" decimals="0" unitRef="usd">3237623</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c134" decimals="0" unitRef="usd">2909703</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c133" decimals="0" unitRef="usd">17741</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c134" decimals="0" unitRef="usd">32522</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityOther contextRef="c135" decimals="0" unitRef="usd">-295402</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c136" decimals="0" unitRef="usd">222898</us-gaap:StockholdersEquityOther>
    <pf0:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net sales&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;8,808&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12,339&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,133&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,080&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(498,940&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(220,855&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share of losses from investments accounted for using the equity method&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47,791&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net sales&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-94"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Gross Profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-95"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(149,480&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(95,395&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Share of loss from investments accounted for using the equity method&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-96"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-97"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</pf0:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <abvc:NetSales contextRef="c135" decimals="0" unitRef="usd">8808</abvc:NetSales>
    <abvc:NetSales contextRef="c141" decimals="0" unitRef="usd">12339</abvc:NetSales>
    <abvc:GrossProfits contextRef="c135" decimals="0" unitRef="usd">6133</abvc:GrossProfits>
    <abvc:GrossProfits contextRef="c141" decimals="0" unitRef="usd">7080</abvc:GrossProfits>
    <abvc:LongTermInvestmentNetLoss contextRef="c135" decimals="0" unitRef="usd">-498940</abvc:LongTermInvestmentNetLoss>
    <abvc:LongTermInvestmentNetLoss contextRef="c141" decimals="0" unitRef="usd">-220855</abvc:LongTermInvestmentNetLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c141" decimals="0" unitRef="usd">-47791</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c110" decimals="4" unitRef="pure">0.3162</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c111" decimals="4" unitRef="pure">0.3162</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:OtherAssetsCurrent contextRef="c137" decimals="0" unitRef="usd">221169</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c138" decimals="0" unitRef="usd">73452</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c137" decimals="0" unitRef="usd">355420</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c138" decimals="0" unitRef="usd">374423</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c137" decimals="0" unitRef="usd">2164077</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c138" decimals="0" unitRef="usd">1934786</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:StockholdersEquityOther contextRef="c139" decimals="0" unitRef="usd">-1587488</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c140" decimals="0" unitRef="usd">-1486911</us-gaap:StockholdersEquityOther>
    <abvc:LongTermInvestmentNetLoss contextRef="c139" decimals="0" unitRef="usd">-149480</abvc:LongTermInvestmentNetLoss>
    <abvc:LongTermInvestmentNetLoss contextRef="c142" decimals="0" unitRef="usd">-95395</abvc:LongTermInvestmentNetLoss>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Share of equity method investee losses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-98"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(47,791&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <abvc:ShareOfEquityMethodInvesteeLosses contextRef="c4" decimals="0" unitRef="usd">-47791</abvc:ShareOfEquityMethodInvesteeLosses>
    <abvc:ConvertibleNotesPayableDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;7. CONVERTIBLE NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 9, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &#x201c;Yu and Wei Note&#x201d;) in an aggregate principal amount of $300,000 to Guoliang
Yu and Yingfei Wei Family Trust (the &#x201c;Yu and Wei&#x201d;), pursuant to which the Company received $300,000. The Yu and Wei Note bears
interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019.
In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;)
then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any
time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal
plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion
price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject
to adjustment or (ii) 80% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering
of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments
set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial
conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears
interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued
and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Yu and Wei&#x201d; Note, which is on January
20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Yu and Wei&#x201d;. The aggregate principal amount
plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company&#x2019;s
common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock. These common shares have been issued during
the year ended December 31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 27, 2018, the Company issued an eighteen-month
term unsecured convertible promissory note (the &#x201c;Keypoint Note&#x201d;) in the aggregate principal amount of $250,000 to Keypoint
Technology Ltd. (&#x201c;Keypoint&#x201d;), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest
at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event
that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;) then
within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from
the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion
Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80%
of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an
amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint
Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature
present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum.
The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the
Twelve (12) month anniversary of the issuance date of the new &#x201c;Keypoint&#x201d; Note, which is on January 20, 2021. On April 5, 2020,
the Company entered into an exchange agreement with &#x201c;Keypoint&#x201d;. The aggregate principal amount plus accrued interest expenses
were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#x2019;s common stock, and
warrants to purchase 159,145 shares of the Company&#x2019;s common stock. These common shares have been issued during the year ended December
31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 25, 2018, the Company issued an eighteen-month
term unsecured convertible promissory notes (the &#x201c;Odaira Note&#x201d;) in the aggregate principal amount of $250,000 to Yoshinobu
Odaira. (&#x201c;Odaira&#x201d;), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company
shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18)
month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds
from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;) then within five days of the closing for such
offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has
been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest,
if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower
of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the
&#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs
when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20,
the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21,
2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount
in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date
of the new &#x201c;Odaira&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with
&#x201c;Odaira&#x201d;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to
the Holders an aggregate of 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s
common stock. These common shares have been issued during the year ended December 31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 30 and July 10, 2019, the Company issued
two (2) twelve-month term unsecured convertible promissory notes (the &#x201c;KSL Note&#x201d;) in an aggregate principal amount of $250,000
to Kuo Sheng Lung (the &#x201c;KSL&#x201d;), pursuant to which the Company received $160,000 and $90,000, respectively. The KSL Note bears
interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020. At any
time from the issuance date until the KSL Note has been satisfied, the KSL may convert the unpaid and outstanding principal plus any accrued
and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion
Price&#x201d;) equal to the lower of (i) $0.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70%
of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company
in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission
on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company
recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company
received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company
entered into an agreement with &#x201c;KSL&#x201d;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL
agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the
Company agreed to issue 120,121 shares of the Company&#x2019;s common stock and warrants for a purchase price of $270,272.&#160;During
the year ended December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company&#x2019;s common stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 10, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#x201c;NEA Note&#x201d;) in an aggregate principal amount of $250,000 to New Eastern Asia
(the &#x201c;NEA&#x201d;), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest
at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof
until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;)
equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the NEA Note. During the year ended December 31, 2020, the Company
issued 111,112 shares of common stock to repay the outstanding balance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 28, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#x201c;KLS Note&#x201d;) in an aggregate principal amount of $200,000 to Kuo Li Shen (the
&#x201c;KLS&#x201d;), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum.
The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this
KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default
interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to
the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering
price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public
Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value
of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with
KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate
of 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have
been issued during the year ended December 31, 2020&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 4, 2019, the Company issued 3 twelve-month
term unsecured convertible promissory note (the &#x201c;C.L.L. Note&#x201d;) in an aggregate principal amount of $257,500 to Chang Ping
Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &#x201c;C.L.L.&#x201d;), pursuant to which the Company received $257,500 on September
4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The
Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until
this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;)
equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into
an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed
to issue to the Holders an aggregate of 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of
common stock. These common shares have been issued during the year ended December 31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 29, 2019, the Company issued a twelve-month
term unsecured convertible promissory note (the &#x201c;Lee Note&#x201d;) in an aggregate principal amount of $250,000 to Hwalin Lee (the
&#x201c;Lee&#x201d;), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest
at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest
on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof
until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;)
equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the Lee Note. In January 2021, the Company paid off the convertible
promissory note of $306,836, including principal and accrued and unpaid interest expense.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 23, 2020, the Company entered into
a Securities Purchase Agreement (the &#x201c;October SPA&#x201d;) with one accredited investor. Pursuant to the October SPA, the Company
sold and issued a convertible promissory note (the &#x201c;October Note&#x201d;) in the principal amount of $2,500,000 to the investor and
received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of
the October Note is the twenty-four (24) month anniversary from the issuance date (the &#x201c;Maturity Date&#x201d;). Upon the Maturity
Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest
under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the
Company&#x2019;s common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect to convert part
or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding
amount at any time, in whole or in part, without any penalty.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 17, 2021, the parties to the October SPA
signed Amendment No. 1 to Promissory Note (the &#x201c;Amendment&#x201d;). Pursuant to the Amendment, the Note shall also be automatically
converted into shares of the Company&#x2019;s common stock immediately following the Company&#x2019;s receipt of conditional approval to
list its common stock on the NASDAQ stock market, if and when the Company receives such approval, at a conversion price equal to $2.25
per share.&#160;On July 21, 2021, The Company converted all convertible promissory note amounted $2,500,000 into 1,111,112 shares of the
Company&#x2019;s common stock and warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022 and December 31, 2021, the
aggregate carrying values of the convertible debentures were both $0; and accrued convertible interest were both $0.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Total interest expenses in connection with the
above convertible note payable were $0 and $66,897 for the three months ended March 31, 2022 and 2021, respectively.&#160;&#160;&lt;/p&gt;</abvc:ConvertibleNotesPayableDisclosureTextBlock>
    <abvc:AggregatePrincipalAmount contextRef="c143" decimals="0" unitRef="usd">300000</abvc:AggregatePrincipalAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c144" decimals="0" unitRef="usd">300000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c144" decimals="2" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockIssued1 contextRef="c145" decimals="0" unitRef="usd">5000000</us-gaap:StockIssued1>
    <us-gaap:SharesIssuedPricePerShare contextRef="c146" decimals="2" unitRef="usdPershares">2</us-gaap:SharesIssuedPricePerShare>
    <abvc:SharesOfferingPricePercentage contextRef="c146" decimals="2" unitRef="pure">0.80</abvc:SharesOfferingPricePercentage>
    <us-gaap:CommonStockValueOutstanding contextRef="c146" decimals="0" unitRef="usd">500000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:InvestmentInterestRate contextRef="c147" decimals="2" unitRef="pure">0.20</us-gaap:InvestmentInterestRate>
    <abvc:AggregatePrincipalAndAccruedInterestExpense contextRef="c148" decimals="0" unitRef="usd">354722</abvc:AggregatePrincipalAndAccruedInterestExpense>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c148" decimals="0" unitRef="shares">192784</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c149" decimals="0" unitRef="shares">192784</us-gaap:ConversionOfStockSharesConverted1>
    <abvc:AggregatePrincipalAmount contextRef="c150" decimals="0" unitRef="usd">250000</abvc:AggregatePrincipalAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c151" decimals="0" unitRef="usd">250000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c151" decimals="2" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockIssued1 contextRef="c152" decimals="0" unitRef="usd">5000000</us-gaap:StockIssued1>
    <us-gaap:ConversionOfStockDescription contextRef="c151">the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion
Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80%
of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an
amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint
Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature
present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum.
The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the
Twelve (12) month anniversary of the issuance date of the new &#x201c;Keypoint&#x201d; Note, which is on January 20, 2021. On April 5, 2020,
the Company entered into an exchange agreement with &#x201c;Keypoint&#x201d;. The aggregate principal amount plus accrued interest expenses
were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#x2019;s common stock, and
warrants to purchase 159,145 shares of the Company&#x2019;s common stock.</us-gaap:ConversionOfStockDescription>
    <abvc:AggregatePrincipalAmount contextRef="c153" decimals="0" unitRef="usd">250000</abvc:AggregatePrincipalAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c154" decimals="0" unitRef="usd">250000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c154" decimals="2" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockIssued1 contextRef="c155" decimals="0" unitRef="usd">5000000</us-gaap:StockIssued1>
    <us-gaap:ConversionOfStockDescription contextRef="c154">the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower
of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the
&#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs
when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20,
the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21,
2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount
in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date
of the new &#x201c;Odaira&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with
&#x201c;Odaira&#x201d;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to
the Holders an aggregate of 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s
common stock.</us-gaap:ConversionOfStockDescription>
    <abvc:AggregatePrincipalAmount contextRef="c156" decimals="0" unitRef="usd">250000</abvc:AggregatePrincipalAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c157" decimals="0" unitRef="usd">160000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c158" decimals="0" unitRef="usd">90000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="c157">The KSL Note bears
interest at 20% per annum. The Company shall pay to KSL an amount in cash representing all outstanding principal and accrued and unpaid
interest on the Twelve (12) month anniversary of the issuance date of the KSL Note, which is on May 29, 2020 and July 9, 2020.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c157" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ConversionOfStockDescription contextRef="c157">the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion
Price&#x201d;) equal to the lower of (i) $0.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70%
of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company
in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission
on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company
recognized none of the intrinsic value of the embedded beneficial conversion feature present in the KSL Note. On May 13, 2020, the Company
received an acknowledgement letter from KSL that they will not claim the repayment of loan for 12 months. On November 9, 2020, the Company
entered into an agreement with &#x201c;KSL&#x201d;. The aggregate principal amount plus accrued interest expenses are $270,272, and KSL
agreed to use the full amount to purchase certain securities pursuant to a securities purchase agreement; KSL agreed to purchase and the
Company agreed to issue 120,121 shares of the Company&#x2019;s common stock and warrants for a purchase price of $270,272.&#160;During
the year ended December 31, 2020, the Company issued to the Holders an aggregate of 120,121 shares of the Company&#x2019;s common stock.</us-gaap:ConversionOfStockDescription>
    <abvc:AggregatePrincipalAmount contextRef="c159" decimals="0" unitRef="usd">250000</abvc:AggregatePrincipalAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c160" decimals="0" unitRef="usd">250000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c160" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:SharesIssuedPricePerShare contextRef="c161" decimals="2" unitRef="usdPershares">0.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c162" decimals="2" unitRef="pure">0.70</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <abvc:PublicEquityOfferingExceedAmount contextRef="c162" decimals="0" unitRef="usd">10000000</abvc:PublicEquityOfferingExceedAmount>
    <abvc:SharesIssued1 contextRef="c5" decimals="0" unitRef="shares">111112</abvc:SharesIssued1>
    <us-gaap:ConversionOfStockDescription contextRef="c163">the Company issued a twelve-month
term unsecured convertible promissory note (the &#x201c;KLS Note&#x201d;) in an aggregate principal amount of $200,000 to Kuo Li Shen (the
&#x201c;KLS&#x201d;), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum.
The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this
KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default
interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to
the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering
price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public
Offering&#x201d;), as amended from time to time.</us-gaap:ConversionOfStockDescription>
    <abvc:AggregatePrincipalAmount contextRef="c164" decimals="0" unitRef="usd">200000</abvc:AggregatePrincipalAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c165" decimals="0" unitRef="usd">200000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c165" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ConversionOfStockDescription contextRef="c166">50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering
price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000
as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public
Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value
of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with
KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate
of 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have
been issued during the year ended December 31, 2020On September 4, 2019, the Company issued 3 twelve-month
term unsecured convertible promissory note (the &#x201c;C.L.L. Note&#x201d;) in an aggregate principal amount of $257,500 to Chang Ping
Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &#x201c;C.L.L.&#x201d;), pursuant to which the Company received $257,500 on September
4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The
Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve
(12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until
this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest
and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;)
equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share
offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding
$10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018
(the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of
the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into
an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed
to issue to the Holders an aggregate of 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of
common stock. These common shares have been issued during the year ended December 31, 2020.&#160;</us-gaap:ConversionOfStockDescription>
    <abvc:AggregatePrincipalAmount contextRef="c167" decimals="0" unitRef="usd">257500</abvc:AggregatePrincipalAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c168" decimals="0" unitRef="usd">257500</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c168" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <abvc:AggregatePrincipalAmount contextRef="c169" decimals="0" unitRef="usd">250000</abvc:AggregatePrincipalAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c170" decimals="0" unitRef="usd">250000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c170" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ConversionOfStockDescription contextRef="c171">Pursuant to the October SPA, the Company
sold and issued a convertible promissory note (the &#x201c;October Note&#x201d;) in the principal amount of $2,500,000 to the investor and
received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of
the October Note is the twenty-four (24) month anniversary from the issuance date (the &#x201c;Maturity Date&#x201d;). Upon the Maturity
Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest
under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the
Company&#x2019;s common stock at a fixed conversion price of $2.25 per share.</us-gaap:ConversionOfStockDescription>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c172" decimals="2" unitRef="usdPershares">2.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:ConvertiblePromissoryNote contextRef="c173" decimals="0" unitRef="usd">2500000</abvc:ConvertiblePromissoryNote>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c174" decimals="0" unitRef="shares">1111112</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertibleDebt contextRef="c175" decimals="0" unitRef="usd">0</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c176" decimals="0" unitRef="usd">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:ConvertibleNotesPayable contextRef="c1" decimals="0" unitRef="usd">0</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ConvertibleNotesPayable contextRef="c7" decimals="0" unitRef="usd">66897</us-gaap:ConvertibleNotesPayable>
    <abvc:BankLoansTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;8. BANK LOANS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Short-term bank loan consists
of the following:&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cathay United Bank&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;261,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;270,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;CTBC Bank&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;698,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;720,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cathay Bank&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;650,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;650,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,609,750&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,640,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Cathay United Bank&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 28, 2016, BioLite Taiwan and Cathay United
Bank entered into a one-year bank loan agreement (the &#x201c;Cathay United Loan Agreement&#x201d;) in an amount of NT$7,500,000, equivalent
to $261,750. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of
prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite
Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000,
equivalent to $261,750. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of
NT$7,500,000, equivalent to $261,750 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the
Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $261,750 for one year, which is due on September
6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000,
equivalent to $261,750 for one year, which is due on September 6, 2021. On September 6, 2021, BioLite Taiwan extended the Cathay United
Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $261,750&#160;for&#160;one year, which is due on September
6, 2022. As of March 31, 2022 and December 31, 2021, the effective interest rates per annum was 2.1%. The loan is collateralized by the
building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company&#x2019;s chairman.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Interest expenses were $1,386 and $1,383 for the
three months ended March 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;CTBC Bank&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 12, 2017 and July 19, 2017, BioLite Taiwan
and CTBC Bank entered into short-term saving secured bank loan agreements (the &#x201c;CTBC Loan Agreements&#x201d;) in an amount of NT$10,000,000,
equivalent to $349,000, and NT$10,000,000, equivalent to $349,000, respectively. Both two loans with the same maturity date at January
19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019,
BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan
extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $698,000 for six months, which is due
on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000,
equivalent to $698,000 for six months, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement
with the same principal amount of NT$20,000,000, equivalent to $698,000 for six months, which is due on January 15, 2021. On January 15,
2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $698,000 for six
months, which is due on July 15, 2021. On July 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount
of NT$20,000,000, equivalent to $698,000 for six months, which is due on January 14, 2022. On January 14, 2022, BioLite Taiwan extended
the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $698,000 for six months, which is due on July 14,
2022. The loan balances bear interest at a fixed rate of 1.68% per annum. The loan is secured by the money deposited in a savings account
with the CTBC Bank. This loan was also personal guaranteed by the Company&#x2019;s chairman and BioFirst. During the year ended December
31, 2020, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Interest expenses were $2,958 and $2,949 for the
three months ended March 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Cathay Bank&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 21, 2019, the Company received a loan
in the amount of $500,000 from Cathay Bank (the &#x201c;Bank&#x201d;) pursuant to a business loan agreement (the &#x201c;Loan Agreement&#x201d;)
entered by and between the Company and Bank on January 8, 2019 and a promissory note (the &#x201c;Note&#x201d;) executed by the Company
on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date
(the &#x201c;Maturity Date&#x201d;) of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the
&#x201c;Regular Interest Rate&#x201d;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the
&#x201c;Index&#x201d;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company
shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note
before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%)
plus the Regular Interest Rate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the Note and Loan Agreement,
on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the &#x201c;Guaranty&#x201d;) to guaranty
the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each
until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of
BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey. On December 29, 2020, the Company
entered into a new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr.
George Lee to be removed as guarantees from the list of Guaranty.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, on January 8, 2019, each of the Company
and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the &#x201c;Security Agreement&#x201d;) to
secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each, a &#x201c;Grantor&#x201d;,
and collectively, the &#x201c;Grantors&#x201d;) granted security interest in the collaterals as defined therein, comprised of almost all
of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company extended the Loan Agreement
with the same term for seven months, which is due on October 31, 2020. On April 8, 2020 and October 3, 2020, the Company repaid an aggregated
principal amount of $350,000. On December 3, 2020, the Company renewed the Loan Agreement with the principal amount of $650,000 for ten
months, which is due on October 31, 2021. On October 31, 2021, the Company renewed the Loan Agreement with the principal amount of $650,000
for twelve months, which is due on October 30, 2022. On September 30, 2021, the Cathay Bank has increased the line of credit to $1,000,000
from $650,000. The outstanding loan balance was $650,000 as of March 31, 2022 and December 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Interest expenses were $6,090 and $3,927 for the
three months ended March 31, 2022 and 2021, respectively.&lt;/p&gt;</abvc:BankLoansTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cathay United Bank&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;261,750&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;270,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;CTBC Bank&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;698,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;720,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Cathay Bank&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;650,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;650,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,609,750&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,640,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c194" decimals="0" unitRef="usd">261750</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c235" decimals="0" unitRef="usd">270000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c220" decimals="0" unitRef="usd">698000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c236" decimals="0" unitRef="usd">720000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c231" decimals="0" unitRef="usd">650000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c232" decimals="0" unitRef="usd">650000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c1" decimals="0" unitRef="usd">1609750</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="0" unitRef="usd">1640000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c177" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c178" decimals="0" unitRef="usd">261750</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c179">2017-06-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c178" decimals="4" unitRef="pure">0.0115</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c180">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c181" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c182" decimals="0" unitRef="usd">261750</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c183" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c184" decimals="0" unitRef="usd">261750</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c185">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c186" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c187" decimals="0" unitRef="usd">261750</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c188">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c189" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c190" decimals="0" unitRef="usd">261750</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c191">P1Y</us-gaap:DebtInstrumentTerm>
    <abvc:principalAmount contextRef="c192" decimals="0" unitRef="twd">7500000</abvc:principalAmount>
    <abvc:principalAmount contextRef="c193" decimals="0" unitRef="usd">261750</abvc:principalAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c194" decimals="3" unitRef="pure">0.021</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestAndDebtExpense contextRef="c195" decimals="0" unitRef="usd">1386</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c196" decimals="0" unitRef="usd">1383</us-gaap:InterestAndDebtExpense>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c197" decimals="0" unitRef="twd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c198" decimals="0" unitRef="usd">349000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c199" decimals="0" unitRef="twd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c200" decimals="0" unitRef="usd">349000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c202">2018-01-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c201">2018-01-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentTerm contextRef="c203">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c204" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c205" decimals="0" unitRef="usd">698000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c206">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c207" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c208" decimals="0" unitRef="usd">698000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c209">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c210" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c211" decimals="0" unitRef="usd">698000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c212">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c213" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c214" decimals="0" unitRef="usd">698000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c215">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c216" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c217" decimals="0" unitRef="usd">698000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c218">P6M</us-gaap:DebtInstrumentTerm>
    <abvc:principalAmount contextRef="c219" decimals="0" unitRef="twd">20000000</abvc:principalAmount>
    <abvc:principalAmount contextRef="c219" decimals="0" unitRef="usd">698000</abvc:principalAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c219">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c220" decimals="4" unitRef="pure">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestAndDebtExpense contextRef="c221" decimals="0" unitRef="usd">2958</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c222" decimals="0" unitRef="usd">2949</us-gaap:InterestAndDebtExpense>
    <abvc:ReceivedLoanAmount contextRef="c223" decimals="0" unitRef="usd">500000</abvc:ReceivedLoanAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c224" decimals="0" unitRef="usd">1000000</us-gaap:DebtInstrumentFaceAmount>
    <abvc:RegularInterestRateDescription contextRef="c225">The Note executed in connection with the Loan Agreement bears an interest rate (the
&#x201c;Regular Interest Rate&#x201d;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the
&#x201c;Index&#x201d;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company
shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note
before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%)
plus the Regular Interest Rate.</abvc:RegularInterestRateDescription>
    <abvc:ExceedingAmount contextRef="c226" decimals="0" unitRef="usd">500000</abvc:ExceedingAmount>
    <abvc:ReceivedLoanAmount contextRef="c227" decimals="0" unitRef="usd">350000</abvc:ReceivedLoanAmount>
    <abvc:ReceivedLoanAmount contextRef="c228" decimals="0" unitRef="usd">350000</abvc:ReceivedLoanAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c229" decimals="0" unitRef="usd">650000</us-gaap:DebtInstrumentFaceAmount>
    <abvc:principalAmount contextRef="c230" decimals="0" unitRef="usd">650000</abvc:principalAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c231" decimals="0" unitRef="usd">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c1" decimals="0" unitRef="usd">650000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermLineOfCredit contextRef="c232" decimals="0" unitRef="usd">650000</us-gaap:LongTermLineOfCredit>
    <us-gaap:InterestAndDebtExpense contextRef="c233" decimals="0" unitRef="usd">6090</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c234" decimals="0" unitRef="usd">3927</us-gaap:InterestAndDebtExpense>
    <abvc:PaycheckProtectionProgramLoanPayableTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 14, 2020, the Company received a loan
in the amount of $124,400 under the Paycheck Protection Program (&#x201c;PPP&#x201d;) administered by the United States Small Business Administration
(the &#x201c;SBA&#x201d;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;Cares Act&#x201d;),
PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest
on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The loan was granted pursuant to a promissory
note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The
Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years
after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&#x2019;s
accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments
to be due on the same day of each month after that. No collateral or personal guarantees are required.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 29, 2021, BioKey received a loan in
the amount of $132,331 under the Paycheck Protection Program administered by the United States Small Business Administration from East
West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal
amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60%
of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated January 27, 2021 issued
by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 7, 2021, the Company received a loan
in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay
Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal
amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60%
of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued
by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;PPP loan Forgiveness&#160;&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 27, 2021, the Company submitted all
required documents, such as application form and use of funds,&#160;to East West Bank for the application of forgiveness. The PPP loan
from East West Bank of $124,400 and $132,331 was forgiven by the SBA as a gesture of supporting the operation of the Company on March
15, 2021 and September 28, 2021, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On September 23, 2021, the Company submitted the
required documents, such as application form and use of funds,&#160;to Cathay Bank for the application of forgiveness. The PPP loan from
Cathay Bank of $104,167 was forgiven by the SBA as a gesture of supporting the operation of the Company on November 15, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As a result, the Company recorded the forgiveness
of the PPP loans as government grant income in the aggregate amount of $360,898 during the year ended December 31, 2021. As of March
31, 2022, there was no outstanding balance payable to the bank.&#160;&lt;/p&gt;</abvc:PaycheckProtectionProgramLoanPayableTextBlock>
    <abvc:LoanFromPaycheckProtectionProgram contextRef="c237" decimals="0" unitRef="usd">124400</abvc:LoanFromPaycheckProtectionProgram>
    <abvc:ForgivenAmountPercentageUsedForPayroll contextRef="c237" decimals="2" unitRef="pure">0.60</abvc:ForgivenAmountPercentageUsedForPayroll>
    <us-gaap:DebtInstrumentPaymentTerms contextRef="c238">The loan was granted pursuant to a promissory
note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum.</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c239" decimals="4" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <abvc:LoanFromPaycheckProtectionProgram contextRef="c240" decimals="0" unitRef="usd">132331</abvc:LoanFromPaycheckProtectionProgram>
    <abvc:ForgivenAmountPercentageUsedForPayroll contextRef="c240" decimals="2" unitRef="pure">0.60</abvc:ForgivenAmountPercentageUsedForPayroll>
    <abvc:PromissoryNoteDescription contextRef="c240">The loan was granted pursuant to a promissory note dated January 27, 2021 issued
by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.&#160;On February 7, 2021, the Company received a loan
in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay
Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal
amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60%
of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued
by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal
in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory
note. No collateral or personal guarantees are required.&#160;</abvc:PromissoryNoteDescription>
    <abvc:LoanFromPaycheckProtectionPrograms contextRef="c241" decimals="0" unitRef="usd">104167</abvc:LoanFromPaycheckProtectionPrograms>
    <abvc:ForgivenAmountPercentageUsedForPayroll contextRef="c241" decimals="2" unitRef="pure">0.60</abvc:ForgivenAmountPercentageUsedForPayroll>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c242" decimals="4" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <abvc:LoanAmout contextRef="c243" decimals="0" unitRef="usd">124400</abvc:LoanAmout>
    <us-gaap:DebtInstrumentDecreaseForgiveness contextRef="c244" decimals="0" unitRef="usd">132331</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:DebtInstrumentDecreaseForgiveness contextRef="c245" decimals="0" unitRef="usd">104167</us-gaap:DebtInstrumentDecreaseForgiveness>
    <abvc:GovernmentGrantIncome contextRef="c5" decimals="0" unitRef="usd">360898</abvc:GovernmentGrantIncome>
    <us-gaap:MortgageNotesPayableDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;10. NOTES PAYABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January, 2019, BioLite Taiwan entered an unsecured
loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working
capital purpose. On September 11, 2021 the outstanding balance has been repaid in full. As of March 31, 2022 and December 31, 2021, the
balance due to this individual amounted to both $0.&#160;Interest expense were $0 and $3,204 for the three months ended March 31, 2022
and 2021, respectively.&lt;/p&gt;</us-gaap:MortgageNotesPayableDisclosureTextBlock>
    <abvc:UnsecuredLoanAgreementsDescription contextRef="c246">In January, 2019, BioLite Taiwan entered an unsecured
loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working
capital purpose.</abvc:UnsecuredLoanAgreementsDescription>
    <us-gaap:OtherNotesPayable contextRef="c1" decimals="0" unitRef="usd">0</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable contextRef="c2" decimals="0" unitRef="usd">0</us-gaap:OtherNotesPayable>
    <us-gaap:InterestExpenseOther contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c4" decimals="0" unitRef="usd">3204</us-gaap:InterestExpenseOther>
    <us-gaap:ShortTermDebtTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;11. SHORT-TERM LOAN&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 18, 2020, the Company entered an unsecured
loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on
August 17, 2020. On August 18, 2020, the Company extended the contract for six months under the same term. On February 18, 2021, the Company
extended the contract for six months under the same term. On August 26, 2021, the loan with interest has been repaid in full. Accrued
interest expense were both $0 as of March 31, 2022 and December 31, 2021.&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:UnsecuredDebt contextRef="c247" decimals="0" unitRef="usd">100000</us-gaap:UnsecuredDebt>
    <us-gaap:ShortTermDebtInterestRateIncrease contextRef="c248" decimals="3" unitRef="pure">0.015</us-gaap:ShortTermDebtInterestRateIncrease>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c5" decimals="0" unitRef="usd">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;12. RELATED PARTIES TRANSACTIONS&lt;/b&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The related parties of the company with whom transactions
are reported in these financial statements are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Name of entity or Individual&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left"&gt;Relationship with the Company and its subsidiaries&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;YuanGene Corporation (the &#x201c;YuanGene&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Controlling beneficiary shareholder of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;AsiaGene Corporation (the &#x201c;AsiaGene&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Eugene Jiang&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Former President and Chairman&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Keypoint Technology Ltd. (the &#x201c;Keypoint&#x2019;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;The Chairman of Keypoint is Eugene Jiang&#x2019;s mother.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Lion Arts Promotion Inc. (the &#x201c;Lion Arts&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Yoshinobu Odaira (the &#x201c;Odaira&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Director of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;GenePharm Inc. (the &#x201c;GenePharm&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Euro-Asia Investment &amp;amp; Finance Corp Ltd. (the &#x201c;Euro-Asia&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;LBG USA, Inc. (the &#x201c;LBG USA&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;LionGene Corporation (the &#x201c;LionGene&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Kimho Consultants Co., Ltd. (the &#x201c;Kimho&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;The Jiangs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst &lt;br/&gt; &#160; &lt;br/&gt; Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. &lt;br/&gt; &#160; &lt;br/&gt; Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. &lt;br/&gt; &#160; &lt;br/&gt; Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company. &lt;br/&gt; &#160; &lt;br/&gt; Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Amkey Ventures, LLC (&#x201c;Amkey&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;BioLite Japan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;ABVC BioPharma (HK), Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;An entity 100% owned by Mr. Tsung-Shann Jiang&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable - related parties&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Accounts receivable due from related parties consisted
of the following as of the periods indicated:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;GenePharm Inc.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Rgene&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Amkey&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;145,399&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;145,399&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Due from related parties&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Amount due from related parties consisted of the
following as of the periods indicated:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Rgene&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48,586&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;BioFirst&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,563,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;468,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BioFirst (Australia)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;830,118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;491,816&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;124,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;LBG USA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioLite Japan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Keypoint&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,610&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,610&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,715,375&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,286,618&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As of March 31, 2022, and December 31, 2021, the Company has advanced an aggregate amount of $48,586 and $49,110 to Rgene for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum). As of March 31, 2022, and December 31, 2021, the outstanding loan balance was $32,541 and $33,520; and accrued interest was $14,214 and $13,701, respectively. On January 1, 2021, BioLite Taiwan entered into a consultant services agreement with Rgene, of which the amount due from Rgene was $1,831 and $1,889 as of March 31, 2022 and December 31, 2021, respectively.&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;In 2021, the Company and BioFirst entered into several loan agreements for a total amount of $465,000 to meet its working capital needs. All the loans period was twelve months and all with an interest rate of 6.5% per annum. In 2022, the Company and BioFirst entered into several loan agreements for a total amount of $1,068,000 to meet its working capital needs. All the loans period was twelve months and with an interest rate of 6.5% per annum. As of March 31, 2022, and December 31, 2021, the outstanding loan balance was $1,533,000 and $465,000; and accrued interest was $30,233 and $3,435, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. &#160;&#160;On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. In January 2022, the Company entered into several loan agreements with BioFirst (Australia) for a total amount of $327,000 to increase the cost for upcoming projects. All the loans period was twelve months with an interest rate of 6.5% per annum. As of March 31, 2022 and December 31, 2021, the aggregate amount of outstanding loan and accrued interest was $830,118 and $491,816, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;, see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of March 31, 2022 and December 31, 2021, due from BHK was $121,153 and $124,972, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of March 31, 2022 and December 31, 2021, the outstanding advance balances was $675 and $675, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On May 8, 2020, the Company and Lucidaim entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan&#x2019;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate. As of March 31, 2022 and December 31, 2021, the outstanding advance balances was $150,000 and $150,000, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(7)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;On October 31, 2020, the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. As of March 31, 2022 and December 31, 2021, the outstanding loan balance was $1,610 and $1,610, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="text-decoration:underline"&gt;Due to related parties&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Amount due to related parties consisted of the
following as of the periods indicated:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;BioFirst Corporation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioFirst (Australia)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;AsiaGene&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;YuanGene&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;The Jiangs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Due to shareholders&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162,634&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;168,131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;446,397&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;393,424&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Since 2019, BioFirst has advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of March 31, 2022 and December 31, 2021, the aggregate amount of outstanding balance and accrued interest is $40,878.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="text-align: justify; width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As of March 31, 2022, and December 31, 2021, BioFirst (Australia) has advanced the Company an aggregate amount of $190,913 and $132,443, respectively for new project purpose.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As of March 31, 2022, and December 31, 2021, AsiaGene has advanced the Company an aggregate amount of $24,017 for working capital purpose. This advance bears 0% interest rate and is due on demand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;As of March 31, 2022, and December 31, 2021, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on demand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of March 31, 2022, and December 31, 2021, the outstanding balance due to the Jiangs amounted to $18,750. These loans bear interest rate of 0% to 1% per month, and are due on demand.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Since 2018, the Company&#x2019;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate of 12% per annum. As of March 31, 2022 and December 31, 2021, the outstanding principal and accrued interest was $162,634 and $168,131, respectively. Interest expenses in connection with these loans were $5,312 and $5,298 for the three months ended March 31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 30%; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Name of entity or Individual&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; border-bottom: Black 1.5pt solid; width: 69%; font-weight: bold; text-align: left"&gt;Relationship with the Company and its subsidiaries&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;YuanGene Corporation (the &#x201c;YuanGene&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Controlling beneficiary shareholder of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;AsiaGene Corporation (the &#x201c;AsiaGene&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Eugene Jiang&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Former President and Chairman&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Keypoint Technology Ltd. (the &#x201c;Keypoint&#x2019;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;The Chairman of Keypoint is Eugene Jiang&#x2019;s mother.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Lion Arts Promotion Inc. (the &#x201c;Lion Arts&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Yoshinobu Odaira (the &#x201c;Odaira&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Director of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;GenePharm Inc. (the &#x201c;GenePharm&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Euro-Asia Investment &amp;amp; Finance Corp Ltd. (the &#x201c;Euro-Asia&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;LBG USA, Inc. (the &#x201c;LBG USA&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;LionGene Corporation (the &#x201c;LionGene&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Kimho Consultants Co., Ltd. (the &#x201c;Kimho&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Shareholder of the Company&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;The Jiangs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst &lt;br/&gt; &#160; &lt;br/&gt; Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. &lt;br/&gt; &#160; &lt;br/&gt; Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc. &lt;br/&gt; &#160; &lt;br/&gt; Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company. &lt;br/&gt; &#160; &lt;br/&gt; Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Amkey Ventures, LLC (&#x201c;Amkey&#x201d;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;BioLite Japan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;ABVC BioPharma (HK), Limited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="vertical-align: top; text-align: left"&gt;An entity 100% owned by Mr. Tsung-Shann Jiang&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c280">Entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c281">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c282">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c283">Controlling beneficiary shareholder of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c284">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c285">Former President and Chairman</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c286">The Chairman of Keypoint is Eugene Jiang&#x2019;s mother.</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c287">Shareholder of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c288">Director of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c289">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c290">Shareholder of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c291">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c292">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c293">Shareholder of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c294">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst  &#160;  Ms. Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.  &#160;  Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and a member of board of directors of BioLite Inc.  &#160;  Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director of the Company.  &#160;  Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c295">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c296">Entity controlled by controlling beneficiary shareholder of ABVC</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c297">An entity 100% owned by Mr. Tsung-Shann Jiang</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;GenePharm Inc.&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;142,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Rgene&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,374&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Amkey&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;145,399&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;145,399&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</abvc:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c298" decimals="0" unitRef="usd">142225</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c299" decimals="0" unitRef="usd">142225</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c137" decimals="0" unitRef="usd">2374</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c138" decimals="0" unitRef="usd">2374</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c300" decimals="0" unitRef="usd">800</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c301" decimals="0" unitRef="usd">800</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c1" decimals="0" unitRef="usd">145399</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c2" decimals="0" unitRef="usd">145399</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Rgene&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48,586&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49,110&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;BioFirst&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,563,233&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;468,435&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BioFirst (Australia)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;830,118&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;491,816&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioHopeKing Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;121,153&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;124,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;LBG USA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;675&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioLite Japan&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Keypoint&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,610&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,610&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;2,715,375&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,286,618&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c137" decimals="0" unitRef="usd">48586</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c138" decimals="0" unitRef="usd">49110</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c133" decimals="0" unitRef="usd">1563233</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c134" decimals="0" unitRef="usd">468435</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c256" decimals="0" unitRef="usd">830118</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c302" decimals="0" unitRef="usd">491816</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c127" decimals="0" unitRef="usd">121153</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c128" decimals="0" unitRef="usd">124972</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c303" decimals="0" unitRef="usd">675</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c304" decimals="0" unitRef="usd">675</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c267" decimals="0" unitRef="usd">150000</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c268" decimals="0" unitRef="usd">150000</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c305" decimals="0" unitRef="usd">1610</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c306" decimals="0" unitRef="usd">1610</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c1" decimals="0" unitRef="usd">2715375</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">1286618</abvc:DueFromtheRelatedPartiesCurrent>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio contextRef="c1" decimals="0" unitRef="usd">32541</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio contextRef="c2" decimals="0" unitRef="usd">33520</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <abvc:AccruedInterest contextRef="c249" decimals="0" unitRef="usd">14214</abvc:AccruedInterest>
    <abvc:AccruedInterest contextRef="c250" decimals="0" unitRef="usd">13701</abvc:AccruedInterest>
    <us-gaap:DueFromAffiliateNoncurrent contextRef="c1" decimals="0" unitRef="usd">1831</us-gaap:DueFromAffiliateNoncurrent>
    <abvc:AggregateWorkingcapital contextRef="c251" decimals="0" unitRef="usd">465000</abvc:AggregateWorkingcapital>
    <abvc:LoanAgreementTotalAmount contextRef="c0" decimals="0" unitRef="usd">1068000</abvc:LoanAgreementTotalAmount>
    <abvc:InterestRate contextRef="c1" decimals="3" unitRef="pure">0.065</abvc:InterestRate>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c135" decimals="0" unitRef="usd">1533000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c136" decimals="0" unitRef="usd">465000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <abvc:AccruedInterest contextRef="c133" decimals="0" unitRef="usd">30233</abvc:AccruedInterest>
    <abvc:AccruedInterest contextRef="c134" decimals="0" unitRef="usd">3435</abvc:AccruedInterest>
    <abvc:DebtInstrumentAggregateAmount contextRef="c252" decimals="0" unitRef="usd">361487</abvc:DebtInstrumentAggregateAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c253" decimals="3" unitRef="pure">0.065</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:DebtInstrumentAggregateAmount contextRef="c254" decimals="0" unitRef="usd">67873</abvc:DebtInstrumentAggregateAmount>
    <abvc:DebtInstrumentAggregateAmount contextRef="c255" decimals="0" unitRef="usd">250000</abvc:DebtInstrumentAggregateAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c0">2022-11-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c256" decimals="3" unitRef="pure">0.065</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:LoanAgreementTotalAmount contextRef="c257" decimals="0" unitRef="usd">327000</abvc:LoanAgreementTotalAmount>
    <abvc:InterestRate contextRef="c258" decimals="3" unitRef="pure">0.065</abvc:InterestRate>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c259" decimals="0" unitRef="usd">830118</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c260" decimals="0" unitRef="usd">491816</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="c261">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DueFromEmployeesNoncurrent contextRef="c1" decimals="0" unitRef="usd">121153</us-gaap:DueFromEmployeesNoncurrent>
    <us-gaap:DueFromEmployeesNoncurrent contextRef="c2" decimals="0" unitRef="usd">124972</us-gaap:DueFromEmployeesNoncurrent>
    <abvc:AdvancesBearInterestDescription contextRef="c262">The advances bear 0% interest rate and are due on demand.</abvc:AdvancesBearInterestDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c263" decimals="2" unitRef="pure">0</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:OutstandingAdvanceFromRelatedParty contextRef="c264" decimals="0" unitRef="usd">675</abvc:OutstandingAdvanceFromRelatedParty>
    <abvc:OutstandingAdvanceFromRelatedParty contextRef="c265" decimals="0" unitRef="usd">675</abvc:OutstandingAdvanceFromRelatedParty>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="c266">Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan&#x2019;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate.</us-gaap:DebtInstrumentInterestRateTerms>
    <abvc:OutstandingAdvanceFromRelatedParty contextRef="c267" decimals="0" unitRef="usd">150000</abvc:OutstandingAdvanceFromRelatedParty>
    <abvc:OutstandingAdvanceFromRelatedParty contextRef="c268" decimals="0" unitRef="usd">150000</abvc:OutstandingAdvanceFromRelatedParty>
    <abvc:LoanAgreementDescription contextRef="c269">the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021.</abvc:LoanAgreementDescription>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c270" decimals="0" unitRef="usd">1610</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c271" decimals="0" unitRef="usd">1610</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <abvc:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;March 31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;BioFirst Corporation&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;40,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;BioFirst (Australia)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190,913&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,443&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;AsiaGene&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,017&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;YuanGene&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,205&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;The Jiangs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,750&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Due to shareholders&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162,634&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;168,131&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;446,397&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;393,424&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c129" decimals="0" unitRef="usd">40878</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c130" decimals="0" unitRef="usd">40878</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c256" decimals="0" unitRef="usd">190913</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c302" decimals="0" unitRef="usd">132443</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c249" decimals="0" unitRef="usd">24017</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c250" decimals="0" unitRef="usd">24017</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c276" decimals="0" unitRef="usd">9205</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c307" decimals="0" unitRef="usd">9205</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c308" decimals="0" unitRef="usd">18750</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c309" decimals="0" unitRef="usd">18750</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c310" decimals="0" unitRef="usd">162634</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c311" decimals="0" unitRef="usd">168131</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c1" decimals="0" unitRef="usd">446397</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c2" decimals="0" unitRef="usd">393424</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="c272">The advances bear interest 1% per month (or equivalent to 12% per annum).</us-gaap:DebtInstrumentInterestRateTerms>
    <abvc:AccruedInterest contextRef="c1" decimals="0" unitRef="usd">40878</abvc:AccruedInterest>
    <abvc:AggregateWorkingcapital contextRef="c259" decimals="0" unitRef="usd">190913</abvc:AggregateWorkingcapital>
    <abvc:AggregateWorkingcapital contextRef="c260" decimals="0" unitRef="usd">132443</abvc:AggregateWorkingcapital>
    <abvc:AggregateWorkingcapital contextRef="c273" decimals="0" unitRef="usd">24017</abvc:AggregateWorkingcapital>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c249" decimals="2" unitRef="pure">0</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AggregateWorkingcapital contextRef="c274" decimals="0" unitRef="usd">9205</abvc:AggregateWorkingcapital>
    <abvc:AggregateWorkingcapital contextRef="c275" decimals="0" unitRef="usd">9205</abvc:AggregateWorkingcapital>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c276" decimals="2" unitRef="pure">0</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:OutstandingAdvanceFromRelatedParty contextRef="c277" decimals="0" unitRef="usd">18750</abvc:OutstandingAdvanceFromRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c277" decimals="2" unitRef="pure">0</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c278" decimals="2" unitRef="pure">0.01</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="c279">The advances bear interest rate of 12% per annum.</us-gaap:DebtInstrumentInterestRateTerms>
    <abvc:OutstandingPrincipalAndAccruedInterest contextRef="c2" decimals="0" unitRef="usd">162634</abvc:OutstandingPrincipalAndAccruedInterest>
    <abvc:OutstandingPrincipalAndAccruedInterest contextRef="c1" decimals="0" unitRef="usd">168131</abvc:OutstandingPrincipalAndAccruedInterest>
    <us-gaap:InterestExpenseRelatedParty contextRef="c0" decimals="0" unitRef="usd">5312</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty contextRef="c4" decimals="0" unitRef="usd">5298</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;13. EQUITY&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 8, 2016, a Share Exchange Agreement
(&#x201c;Share Exchange Agreement&#x201d;) was entered into by and among the&#160;Company, BriVision, Euro-Asia Investment &amp;amp; Finance
Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People&#x2019;s Republic of China (&#x201c;Euro-Asia&#x201d;),
being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record
of all of the issued share capital of BriVision (the&#160;&#x201c;BriVision Stock&#x201d;). Pursuant to the Share Exchange Agreement, upon
surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered
in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision
as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision
Stock in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the&#160;&#x201c;Acquisition
Stock&#x201d;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#x2019;s Common Stock to the BriVision
Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#x2019;s Common Stock owned by Euro-Asia
should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding
Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share
capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision&#x2019;s
Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares
of Company&#x2019;s Common Stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company&#x2019;s Common
Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&#x2019;s Common
Stock,&#160;Because of the exchange of the BriVision Stock for the Acquisition Stock (the&#160;&#x201c;Share Exchange&#x201d;), BriVision
became a wholly owned subsidiary (the &#x201c;Subsidiary&#x201d;) of the Company and there was a change of control of the Company following
the closing.&#160;&#160;There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 17, 2016, pursuant to the 2016 Equity
Incentive Plan (the &#x201c;2016 Plan&#x201d;), 157,050 (50,000 pre-stock split) shares were granted to the employees.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 21, 2016, the Board of Directors of the
Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#x201c;Forward&#160;Stock&#160;Split&#x201d;)
and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April
8, 2016.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 6, 2016, the Company and BioLite Taiwan
agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed
to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of
the Company&#x2019;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On
August 26, 2016, the Company issued 1,468,750 shares (&#x201c;Shares&#x201d;) of the Company&#x2019;s Common Stock, par value $0.001 (the
&#x201c;Offering&#x201d;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#x201c;SPA&#x201d;).
The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;),
pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net
proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should
pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires
that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017,
the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#x2019;s
Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring
transaction between the Company and BioLite on February 8, 2019, the Company&#x2019;s Common Stock held by BioLite Taiwan was accounted
for treasury stocks in the statement of equity (deficit). On February 8, 2019, after the Merger, the Company issued 74,997,546 shares
to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 3, 2019, the Company filed a Certificate
of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial
Industry Regulatory Authority (&#x201c;FINRA&#x201d;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse
stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#x2019;s
common stock were exchanged for 17,693,625 shares of the Company&#x2019;s Common Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 1, 2016, the Company entered into a
consulting agreement with Kazunori Kameyama (&#x201c;Kameyama&#x201d;) for the provision of services related to the clinical trials and
other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the
Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#x2019;s
Common Stock at $1.00 per share for any amount exceeding $3,000. The Company&#x2019;s stocks shall be calculated and issued in December
every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued
24,694 stock options to Kameyama related to unpaid consulting fees of $49,388 (see Note 14).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 24, 2017, BriVision entered into a collaborative
agreement (the &#x201c;BioFirst Collaborative Agreement&#x201d;) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered
all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst.
On June 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571
shares of the Company&#x2019;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. These common shares
were issued during the year ended December 31, 2019.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2019, the Company
entered into service agreements with Euro-Asia Investment &amp;amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant
Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in
the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued 644,972 shares
of the Company&#x2019;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate,
and recorded as stock subscription receivable. As of March 31, 2022 and December 31, 2021, stock subscription receivable was $2,031,660
and $2,257,400, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August, 2019, the Company entered into several
Conversion Agreements to all creditors that are listed under below table of &#x201c;due to related parties&#x201d; in consideration for
a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements,
creditor agrees to convert the amount of debt into the Company&#x2019;s common stock at a price of $7.00 per share.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount of&lt;br/&gt; Debt&lt;br/&gt; Converted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Lion Arts Promotion Inc&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;97,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,981&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;LionGene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;428,099&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,157&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,902,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;AsiaGene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;YuanGene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;The Jiangs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,190,776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170,111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,872,340&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;696,051&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 12, 2020, the board of directors of the
Company approved and adopted an amendment to the Company&#x2019;s Articles of Incorporation, to increase the authorized shares of its common
stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 8, 2020, the Company entered an agreement
with View Trade Securities Inc. (&#x201c;ViewTrade&#x201d;) to engage ViewTrade as the placement agent&#160;and the Company&#x2019;s advisor/consultant
with respect to its ongoing capital events. Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares
of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years
with cashless exercise provision. As of December 31, 2020, the Company has issued 60,000 shares of common stock to ViewTrade for the consulting
fee with an estimated value of $135,000. The warrants were never issued and the parties mutually agreed to terminate the agreement on
November 19, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the termination agreement, the Company
issued 50,000 shares of the Company&#x2019;s common stock at a price of $5 per share as a termination fee on June 29, 2021, of which 6,000
shares were issued to WallachBeth Capital LLC (&#x201c;WallachBeth&#x201d;). In January 2021, WallachBeth entered into a consulting agreement
with the Company pursuant to which the Company engaged WallachBeth to conduct due diligence and research work with respect to the Company.
On June 29, 2021, WallachBeth was issued 6,000 shares of common stock as compensation for those services.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Also on November 19, 2020, the Company and ViewTrade
agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only. In addition to a retainer fee,
the Company agreed to issue 200,000 warrants, with an exercise price of $2.25, an industry standard cashless exercise provision, and a
term of 5 years from November 19, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year&#160;ended December 31, 2020,
the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company
agreed to pay the service fee by issuing 50,000 shares of unrestricted common shares, valued at the closing price of $2.9 per share on
the grant date. These shares have been issued during the year ended December 31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2020, the Company
received aggregated capital contributions of $7,615,331 in cash from 45 investors through private placements of the sale of the Company&#x2019;s
common stock for the purchase price of&#160;$2.25 per share and a free warrant attached with each common stock purchased. In December
2020, 3,384,615 shares of the Company&#x2019;s common stock have been issued.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;During the year ended December 31, 2020, the Company
entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed
to pay the service fee by issuing 521,887 shares of unrestricted common shares, valued at the closing price from $2 to $3.68 per share
on the grant date. These shares have been issued in October and December 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of March 31, 2022, the Company issued aggregated
common shares of 915,856 to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests,
including the debt conversion to the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#x2019;s common stock, and warrants to purchase 120,121 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;See Note 7 for more details in connection with the above debt conversion.&#160;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2021, 1,111,112 shares of the Company&#x2019;s
common stock and warrants were issued pursuant to the conversion of convertible promissory note of $2,500,000 entered in October 2020
(see Note 7).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 5, 2021, the Company closed its public
offering (the &#x201c;Public Offering&#x201d;) of 1,100,000 units (the &#x201c;Units&#x201d;), with each Unit consisting of one share of the
Company&#x2019;s common stock, one Series A warrant (the &#x201c;Series A Warrants&#x201d;) to purchase one share of common stock at an exercise
price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#x201c;Series
B Warrants,&#x201d; and together with the Series A Warrants, the &#x201c;Public Warrants&#x201d;) to purchase one share of common stock at
an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public
Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering
pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) on April 8, 2021 (as amended, the &#x201c;Original Registration Statement&#x201d;), that the SEC declared effective
on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August
4, 2021 (the &#x201c;S-1MEF,&#x201d; together with the Original Registration Statement, the &#x201c;Registration Statement&#x201d;). The Units
were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. In August
2021, 2,354,145 shares of the Company&#x2019;s common stock were issued for gross proceeds of $6,875,000, before placement agent fees and
legal fees of $850,429.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2021, the Company received $4,244,452&#160;in
gross proceeds from the exercise of warrants issued in the Company&#x2019;s August 3, 2021, public offering of securities. Investors exercised
a total of&#160;673,405&#160;Series A warrants at a price of $6.30&#160;per share and&#160;200&#160;Series B warrants at a price of $10&#160;per
share. Pursuant to these exercises, the Company issued an aggregate of 673,605 shares of Common Stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In November 2021, the Company entered into consulting
agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted
$1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant
date. These shares have been issued during the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In January 2022, the Company agreed to pay the
deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued
at $3.29 per share on the grant date. These shares have been issued as of March 31, 2022.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In March 2022, the Company issued 75,000 common
shares to&#160;BarLew Holdings, LLC for consulting and advisory services amounted to $169,500, valued at $2.26 per share.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c68" decimals="0" unitRef="shares">164387376</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c68" decimals="0" unitRef="shares">52336000</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c69" decimals="0" unitRef="shares">166273921</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c69" decimals="0" unitRef="shares">52936583</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c70" decimals="0" unitRef="shares">163159952</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c70" decimals="0" unitRef="shares">51945225</abvc:CommonStockIssuedBeforeStockSplit>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c71" decimals="4" unitRef="pure">0.797</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:PercentageOfIssuedShareCapital contextRef="c71" decimals="2" unitRef="pure">1</abvc:PercentageOfIssuedShareCapital>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c312" decimals="0" unitRef="shares">166273921</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c312" decimals="0" unitRef="shares">52936583</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c73" decimals="0" unitRef="shares">205519223</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c73" decimals="0" unitRef="shares">65431144</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c313" decimals="0" unitRef="shares">157050</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c313" decimals="0" unitRef="shares">50000</abvc:CommonStockIssuedBeforeStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c76" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <abvc:CommonStockShareAuthorized contextRef="c76" decimals="0" unitRef="shares">360000000</abvc:CommonStockShareAuthorized>
    <abvc:AgreementDescription contextRef="c314">the Company and BioLite Taiwan
agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed
to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of
the Company&#x2019;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.</abvc:AgreementDescription>
    <abvc:AgreementDescription contextRef="c315">the Company issued 1,468,750 shares (&#x201c;Shares&#x201d;) of the Company&#x2019;s Common Stock, par value $0.001 (the
&#x201c;Offering&#x201d;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#x201c;SPA&#x201d;).
The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;),
pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net
proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should
pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires
that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.</abvc:AgreementDescription>
    <abvc:AgreementDescription contextRef="c316">the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#x2019;s
Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring
transaction between the Company and BioLite on February 8, 2019, the Company&#x2019;s Common Stock held by BioLite Taiwan was accounted
for treasury stocks in the statement of equity (deficit).</abvc:AgreementDescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c317" decimals="0" unitRef="shares">74997546</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c318" decimals="0" unitRef="shares">29561231</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:FinancialAmendmentDescription contextRef="c77">the Company filed a Certificate
of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial
Industry Regulatory Authority (&#x201c;FINRA&#x201d;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse
stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#x2019;s
common stock were exchanged for 17,693,625 shares of the Company&#x2019;s Common Stock.</abvc:FinancialAmendmentDescription>
    <abvc:Consultingagreementdescription contextRef="c319">On October 1, 2016, the Company entered into a
consulting agreement with Kazunori Kameyama (&#x201c;Kameyama&#x201d;) for the provision of services related to the clinical trials and
other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the
Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#x2019;s
Common Stock at $1.00 per share for any amount exceeding $3,000.</abvc:Consultingagreementdescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c320" decimals="0" unitRef="shares">24694</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:UnpaidConsultingFees contextRef="c320" decimals="0" unitRef="usd">49388</abvc:UnpaidConsultingFees>
    <us-gaap:ContractWithCustomerLiability contextRef="c321" decimals="0" unitRef="usd">3000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c322" decimals="0" unitRef="shares">428571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:StockIssuedValue contextRef="c322" decimals="0" unitRef="usd">3000000</abvc:StockIssuedValue>
    <us-gaap:IntercompanyAgreementsDescription contextRef="c0">Pursuant to the agreements, the Company issued 644,972 shares
of the Company&#x2019;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate,
and recorded as stock subscription receivable.</us-gaap:IntercompanyAgreementsDescription>
    <us-gaap:CommonStockSharesIssued contextRef="c8" decimals="0" unitRef="shares">644972</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProfessionalFees contextRef="c0" decimals="0" unitRef="usd">4514800</us-gaap:ProfessionalFees>
    <abvc:StockSubscriptionReceivable contextRef="c1" decimals="0" unitRef="usd">2031660</abvc:StockSubscriptionReceivable>
    <abvc:StockSubscriptionReceivable contextRef="c2" decimals="0" unitRef="usd">2257400</abvc:StockSubscriptionReceivable>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c323" decimals="0" unitRef="usd">4872340</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c324" decimals="2" unitRef="usdPershares">7</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ScheduleOfDebtConversionsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount of&lt;br/&gt; Debt&lt;br/&gt; Converted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Shares&lt;br/&gt; Issued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;Lion Arts Promotion Inc&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;97,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;13,981&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;LionGene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;428,099&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;61,157&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;BioFirst Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,902,911&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;414,702&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;AsiaGene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;160,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,858&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -9pt; padding-left: 9pt"&gt;YuanGene Corporation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,690&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"&gt;The Jiangs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,190,776&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170,111&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 0.25in"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,872,340&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;696,051&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfDebtConversionsTextBlock>
    <abvc:DebtConversionConvertedInstrumentAmount contextRef="c349" decimals="0" unitRef="usd">97864</abvc:DebtConversionConvertedInstrumentAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c349" decimals="0" unitRef="shares">13981</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <abvc:DebtConversionConvertedInstrumentAmount contextRef="c350" decimals="0" unitRef="usd">428099</abvc:DebtConversionConvertedInstrumentAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c350" decimals="0" unitRef="shares">61157</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <abvc:DebtConversionConvertedInstrumentAmount contextRef="c351" decimals="0" unitRef="usd">2902911</abvc:DebtConversionConvertedInstrumentAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c351" decimals="0" unitRef="shares">414702</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <abvc:DebtConversionConvertedInstrumentAmount contextRef="c352" decimals="0" unitRef="usd">160000</abvc:DebtConversionConvertedInstrumentAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c352" decimals="0" unitRef="shares">22858</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <abvc:DebtConversionConvertedInstrumentAmount contextRef="c353" decimals="0" unitRef="usd">92690</abvc:DebtConversionConvertedInstrumentAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c353" decimals="0" unitRef="shares">13242</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <abvc:DebtConversionConvertedInstrumentAmount contextRef="c354" decimals="0" unitRef="usd">1190776</abvc:DebtConversionConvertedInstrumentAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c354" decimals="0" unitRef="shares">170111</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <abvc:DebtConversionConvertedInstrumentAmount contextRef="c323" decimals="0" unitRef="usd">4872340</abvc:DebtConversionConvertedInstrumentAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c323" decimals="0" unitRef="shares">696051</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c325" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c326" decimals="0" unitRef="shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c327" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <abvc:PlacementAgentAgreementDescription contextRef="c328">Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares
of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years
with cashless exercise provision.</abvc:PlacementAgentAgreementDescription>
    <us-gaap:CommonStockSharesIssued contextRef="c329" decimals="0" unitRef="shares">60000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProfessionalFees contextRef="c330" decimals="0" unitRef="usd">135000</us-gaap:ProfessionalFees>
    <us-gaap:CommonStockSharesIssued contextRef="c331" decimals="0" unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice contextRef="c331" decimals="0" unitRef="usdPershares">5</us-gaap:SharePrice>
    <us-gaap:SharesIssued contextRef="c332" decimals="0" unitRef="shares">6000</us-gaap:SharesIssued>
    <abvc:RestrictedCommonShares contextRef="c333" decimals="0" unitRef="shares">6000</abvc:RestrictedCommonShares>
    <abvc:WarrantIssued contextRef="c334" decimals="0" unitRef="shares">200000</abvc:WarrantIssued>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c334" decimals="2" unitRef="usdPershares">2.25</us-gaap:WarrantExercisePriceDecrease>
    <abvc:WarrantTerm contextRef="c334">P5Y</abvc:WarrantTerm>
    <abvc:UnrestrictedCommonShares contextRef="c335" decimals="0" unitRef="shares">50000</abvc:UnrestrictedCommonShares>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c335" decimals="1" unitRef="usdPershares">2.9</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c336" decimals="0" unitRef="usd">7615331</us-gaap:ProceedsFromContributionsFromAffiliates>
    <abvc:NumberOfInvestors contextRef="c337" decimals="0" unitRef="pure">45</abvc:NumberOfInvestors>
    <abvc:SharesIssuedPricePerShares contextRef="c336" decimals="2" unitRef="usdPershares">2.25</abvc:SharesIssuedPricePerShares>
    <abvc:IssuanceOfCommonStock contextRef="c3" decimals="0" unitRef="shares">3384615</abvc:IssuanceOfCommonStock>
    <us-gaap:SharesIssued contextRef="c338" decimals="0" unitRef="shares">521887</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockPricePerShare contextRef="c339" decimals="0" unitRef="usdPershares">2</us-gaap:SaleOfStockPricePerShare>
    <abvc:StockIssuedDuringPeriodShareBasedCompensationServicesforShares contextRef="c340" decimals="2" unitRef="shares">3.68</abvc:StockIssuedDuringPeriodShareBasedCompensationServicesforShares>
    <abvc:AggregateCommonStockShares contextRef="c0" decimals="0" unitRef="shares">915856</abvc:AggregateCommonStockShares>
    <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="c341">a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&#x2019;s common stock.

    &#160;
    b.
    Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s common stock.
  &#160;

    &#160;
    c.
    C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of the Company&#x2019;s common stock.
  &#160;

    &#160;
    d.
    KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of the Company&#x2019;s common stock.
  &#160;

    &#160;
    e.
    Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock.
  &#160;&#160;f.KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#x2019;s common stock, and warrants to purchase 120,121 shares of the Company&#x2019;s common stock.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c342" decimals="0" unitRef="shares">1111112</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:ConvertiblePromissoryNoteValue contextRef="c342" decimals="0" unitRef="usd">2500000</abvc:ConvertiblePromissoryNoteValue>
    <abvc:DescriptionOfPublicOffering contextRef="c343">the Company closed its public
offering (the &#x201c;Public Offering&#x201d;) of 1,100,000 units (the &#x201c;Units&#x201d;), with each Unit consisting of one share of the
Company&#x2019;s common stock, one Series A warrant (the &#x201c;Series A Warrants&#x201d;) to purchase one share of common stock at an exercise
price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#x201c;Series
B Warrants,&#x201d; and together with the Series A Warrants, the &#x201c;Public Warrants&#x201d;) to purchase one share of common stock at
an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public
Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering
pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission
(the &#x201c;SEC&#x201d;) on April 8, 2021 (as amended, the &#x201c;Original Registration Statement&#x201d;), that the SEC declared effective
on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August
4, 2021 (the &#x201c;S-1MEF,&#x201d; together with the Original Registration Statement, the &#x201c;Registration Statement&#x201d;). The Units
were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.</abvc:DescriptionOfPublicOffering>
    <us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares contextRef="c344" decimals="0" unitRef="shares">2354145</us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c344" decimals="0" unitRef="usd">6875000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:LegalFees contextRef="c344" decimals="0" unitRef="usd">850429</us-gaap:LegalFees>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c345" decimals="0" unitRef="usd">4244452</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c346" decimals="0" unitRef="shares">673405</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c346" decimals="2" unitRef="usdPershares">6.3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c347" decimals="0" unitRef="shares">200</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c347" decimals="0" unitRef="usdPershares">10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <abvc:AggregateCommonStockShares contextRef="c345" decimals="0" unitRef="shares">673605</abvc:AggregateCommonStockShares>
    <abvc:ConsultingAgreementDesciption contextRef="c348">In November 2021, the Company entered into consulting
agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted
$1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant
date. These shares have been issued during the year ended December 31, 2021.&#160;</abvc:ConsultingAgreementDesciption>
    <abvc:ConsultingAgreementDesciption contextRef="c0">In November 2021, the Company entered into consulting
agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted
$1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant
date. These shares have been issued during the year ended December 31, 2021.&#160;In January 2022, the Company agreed to pay the
deferred service fees related to Public Offering amounted $4,296,763 by issuing 1,306,007 shares of unrestricted common shares, valued
at $3.29 per share on the grant date. These shares have been issued as of March 31, 2022.&#160;</abvc:ConsultingAgreementDesciption>
    <us-gaap:ExcessStockSharesIssued contextRef="c1" decimals="0" unitRef="shares">75000</us-gaap:ExcessStockSharesIssued>
    <us-gaap:ProfessionalAndContractServicesExpense contextRef="c0" decimals="0" unitRef="usd">169500</us-gaap:ProfessionalAndContractServicesExpense>
    <dei:EntityListingParValuePerShare contextRef="c0" decimals="2" unitRef="usdPershares">2.26</dei:EntityListingParValuePerShare>
    <abvc:StockOptionsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;14. STOCK OPTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 30, 2020, the Company issued an aggregate
of 545,182 shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive
Plan, as amended, at a conversion price of $2 per share; the total amount of converted salaries and consulting fees was $1,090,361. On
November 21, 2020, the Company entered&#160;into&#160;acknowledgement&#160;agreements and stock option purchase agreements with these
employees and consultant; pursuant to which the Company granted stock options to purchase 545,182 shares of the Company&#x2019;s common
stock in lieu of common stock. The options were vested at the grant date and become exercisable for 10 years from the grant date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On October 15, 2021, the Company entered&#160;into
stock option agreements with 11 directors and 3 employees, pursuant to which the Company granted options to purchase an aggregate of 1,280,002
shares of common stock&#160;under the 2016 Equity Incentive Plan, as amended, at an exercise price of $3 per share. The options were vested
at the grant date and become exercisable for 10 years from the grant date.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Options issued and outstanding as of December
31, 2021, and their activities during the year then ended are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Underlying&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;br/&gt; Per&#160;Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; Remaining&lt;br/&gt; in Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding as of January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;545,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-99; font-size: 10pt"&gt;&#x202f;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,280,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of stock options granted for the
year ended December 31, 2021 was calculated using the Black-Scholes option-pricing model applying the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108.51&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The weighted average grant date fair value of
options granted during the years ended&#160;December 31, 2021 was $2.09. There are 2,979,264&#160;options available for grant under the
2016 Equity Incentive Plan as of December 31, 2021. Compensation costs associated with the Company&#x2019;s stock options are recognized,
based on the grant-date fair values of these options over vesting period. Accordingly, the Company recognized stock-based compensation
expense of $0 and $0 for the three months ended March 31, 2022 and 2021, respectively. There were no options exercised during the three
months ended March 31, 2022. As of March 31, 2022, there were no unvested options.&lt;/p&gt;</abvc:StockOptionsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c355" decimals="0" unitRef="shares">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <abvc:ConversionPrice contextRef="c355" decimals="0" unitRef="usdPershares">2</abvc:ConversionPrice>
    <abvc:ConsultingFees contextRef="c356" decimals="0" unitRef="usd">1090361</abvc:ConsultingFees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c357" decimals="0" unitRef="shares">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c358">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c359" decimals="0" unitRef="shares">1280002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <abvc:ConversionPrice contextRef="c360" decimals="0" unitRef="usdPershares">3</abvc:ConversionPrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c360">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of&lt;br/&gt; Underlying&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;br/&gt; Per&#160;Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;br/&gt; Remaining&lt;br/&gt; in Years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding as of January 1, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;545,182&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-99; font-size: 10pt"&gt;&#x202f;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,280,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-100"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-101"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Outstanding as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Exercisable as of December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Vested and expected to vest&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="c362" decimals="0" unitRef="shares">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c362" decimals="2" unitRef="usdPershares">2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c363" decimals="0" unitRef="shares">1280002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c363" decimals="2" unitRef="usdPershares">3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="c364" decimals="0" unitRef="shares">1825184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c364" decimals="2" unitRef="usdPershares">2.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c363">P9Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c364" decimals="0" unitRef="usd">616056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c364" decimals="0" unitRef="shares">1825184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c364" decimals="2" unitRef="usdPershares">2.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm contextRef="c363">P9Y6M3D</abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c364" decimals="0" unitRef="usd">616056</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c364" decimals="0" unitRef="shares">1825184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c364" decimals="2" unitRef="usdPershares">2.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1 contextRef="c363">P9Y6M3D</abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c364" decimals="0" unitRef="usd">616056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Year ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;108.51&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c5" decimals="4" unitRef="pure">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c5" decimals="4" unitRef="pure">1.0851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c5" decimals="2" unitRef="usdPershares">2.09</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c361" decimals="0" unitRef="shares">2979264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="0" unitRef="usd">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c4" decimals="0" unitRef="usd">0</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;15. LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Basic loss per share is computed by dividing net
loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss
by the weighted-average number of common shares and dilutive potential common shares outstanding during the three months ended March 31,
2022 and 2021.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Three Months&lt;br/&gt; Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net loss attributable to ABVC&#x2019;s common stockholders&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,995,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,128,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted-average shares outstanding:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,683,402&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,420,526&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,683,402&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,420,526&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;-Basic&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.20&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.05&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;-Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.20&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.05&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Diluted loss per share takes into account the
potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the Three Months&lt;br/&gt; Ended&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31,&lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net loss attributable to ABVC&#x2019;s common stockholders&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(5,995,440&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(1,128,505&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Denominator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Weighted-average shares outstanding:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,683,402&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,420,526&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Stock options&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-102"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-103"&gt;&#x2013;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29,683,402&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;24,420,526&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Loss per share&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;-Basic&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.20&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.05&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;-Diluted&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.20&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.05&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c0" decimals="0" unitRef="usd">-5995440</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c4" decimals="0" unitRef="usd">-1128505</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <abvc:WeightedaverageSharesOutstandingBasic contextRef="c0" decimals="0" unitRef="usdPershares">29683402</abvc:WeightedaverageSharesOutstandingBasic>
    <abvc:WeightedaverageSharesOutstandingBasic contextRef="c4" decimals="0" unitRef="usdPershares">24420526</abvc:WeightedaverageSharesOutstandingBasic>
    <abvc:WeightedAverageNumberOfSharesDiluted contextRef="c0" decimals="0" unitRef="usdPershares">29683402</abvc:WeightedAverageNumberOfSharesDiluted>
    <abvc:WeightedAverageNumberOfSharesDiluted contextRef="c4" decimals="0" unitRef="usdPershares">24420526</abvc:WeightedAverageNumberOfSharesDiluted>
    <abvc:BasicLossPerShare contextRef="c0" decimals="2" unitRef="usdPershares">-0.2</abvc:BasicLossPerShare>
    <abvc:BasicLossPerShare contextRef="c4" decimals="2" unitRef="usdPershares">-0.05</abvc:BasicLossPerShare>
    <us-gaap:EarningsPerShareDiluted contextRef="c0" decimals="2" unitRef="usdPershares">-0.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="c4" decimals="2" unitRef="usdPershares">-0.05</us-gaap:EarningsPerShareDiluted>
    <abvc:OperatingLeasesOfLesseeDisclosuresTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;16. LEASE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company adopted FASB Accounting Standards
Codification, Topic 842, Leases (&#x201c;ASC 842&#x201d;) using the modified retrospective approach, electing the practical expedient that
allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company applied the following practical expedients in the transition
to the new standard and allowed under ASC 842:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The new leasing standard requires recognition
of leases on the consolidated balance sheets as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities. ROU assets represent the
Company&#x2019;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#x2019;s obligation to make
lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present
value and future minimum lease payments over the lease term at commencement date. The Company&#x2019;s future minimum based payments used
to determine the Company&#x2019;s lease liabilities mainly include minimum based rent payments. As most of Company&#x2019;s leases do not
provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement
date in determining the present value of lease payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company recognized lease liabilities, with
corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months.
The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized
lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line
basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance,
property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which
the variable lease payments are based occur.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has no finance leases. The Company&#x2019;s
leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements.
The Company&#x2019;s operating leases have remaining lease terms of up to approximately five years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,382,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,471,899&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;LIABILITIES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities (current)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities (noncurrent)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,033,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,124,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;i&gt;Supplemental Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following provides details of the Company&#x2019;s
lease expenses:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85,857&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other information related to leases is presented
below:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85,857&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted Average Remaining Lease Term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.65 years &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.90 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted Average Discount Rate:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.37&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.39&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The minimum future annual payments under non-cancellable
leases during the next five years and thereafter, at rates now in force, are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating&lt;br/&gt; leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2022 (excluding three months ended March 31, 2022)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;266,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;359,279&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;374,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56,916&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,395,178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,484&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,382,694&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvc:OperatingLeasesOfLesseeDisclosuresTextBlock>
    <abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold"&gt;ASSETS&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,382,695&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,471,899&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold"&gt;LIABILITIES&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities (current)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;349,008&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;347,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities (noncurrent)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,033,686&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,124,799&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="0" unitRef="usd">1382695</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c5" decimals="0" unitRef="usd">1471899</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseLiability contextRef="c1" decimals="0" unitRef="usd">349008</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" unitRef="usd">347100</us-gaap:OperatingLeaseLiability>
    <abvc:OperatingLeaseLiabilitienoncurrent contextRef="c1" decimals="0" unitRef="usd">1033686</abvc:OperatingLeaseLiabilitienoncurrent>
    <abvc:OperatingLeaseLiabilitienoncurrent contextRef="c2" decimals="0" unitRef="usd">1124799</abvc:OperatingLeaseLiabilitienoncurrent>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended&lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85,857&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three Months Ended &lt;br/&gt; March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;85,857&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;78,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, &lt;br/&gt; 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, &lt;br/&gt; 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Weighted Average Remaining Lease Term:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.65 years &lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;2.90 years&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted Average Discount Rate:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.37&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.39&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="0" unitRef="usd">85857</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c4" decimals="0" unitRef="usd">78847</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c0" decimals="0" unitRef="usd">85857</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c4" decimals="0" unitRef="usd">78847</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c1">P2Y7M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c7">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c1" decimals="4" unitRef="pure">0.0137</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c7" decimals="4" unitRef="pure">0.0139</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abvc:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating&lt;br/&gt; leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2022 (excluding three months ended March 31, 2022)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;266,024&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;359,279&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;374,283&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;338,676&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56,916&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments, undiscounted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,395,178&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,484&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,382,694&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvc:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock>
    <abvc:OperatingLeasesFutureMinimumPaymentDueCurrent contextRef="c1" decimals="0" unitRef="usd">266024</abvc:OperatingLeasesFutureMinimumPaymentDueCurrent>
    <abvc:OperatingLeasesFutureMinimumPaymentDueInTwoYears contextRef="c1" decimals="0" unitRef="usd">359279</abvc:OperatingLeasesFutureMinimumPaymentDueInTwoYears>
    <abvc:OperatingLeasesFutureMinimumPaymentDueInThreeYears contextRef="c1" decimals="0" unitRef="usd">374283</abvc:OperatingLeasesFutureMinimumPaymentDueInThreeYears>
    <abvc:OperatingLeasesFutureMinimumPaymentDueInFourYears contextRef="c1" decimals="0" unitRef="usd">338676</abvc:OperatingLeasesFutureMinimumPaymentDueInFourYears>
    <abvc:OperatingLeasesFutureMinimumPaymentDueThereafter contextRef="c1" decimals="0" unitRef="usd">56916</abvc:OperatingLeasesFutureMinimumPaymentDueThereafter>
    <abvc:OperatingLeasesFutureMinimumPaymentDue contextRef="c1" decimals="0" unitRef="usd">1395178</abvc:OperatingLeasesFutureMinimumPaymentDue>
    <abvc:InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction contextRef="c1" decimals="0" unitRef="usd">12484</abvc:InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction>
    <abvc:PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions contextRef="c1" decimals="0" unitRef="usd">1382694</abvc:PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;17. BUSINESS COMBINATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 8, 2019, the Company consummated the
Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned
subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, &#x201c;Business Combination&#x201d; to record the merger
transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey&#x2019;s
results of operations were included in the Company&#x2019;s results beginning February 8, 2019. The purchase price has been allocated to
the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Purchase consideration:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Common Stock (*)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,341,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Allocation of the purchase price:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;531,147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;485,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Security deposits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,440&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,271,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,204&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(251,335&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(267,256&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tenant security deposit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,880&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities assumed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(577,675&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;694,221&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Goodwill as a result of the Merger&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43,647,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0px"/&gt; &lt;td style="width: 24px; padding-bottom: 8pt"&gt;&lt;span style="font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 8, 2019, the Company has recorded
a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of
the Company and the Company&#x2019;s inability to generate future operating income without substantial sales volume increases, which are
highly uncertain. Furthermore, the Company&#x2019;s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably
assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation
of the Merger.&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Purchase consideration:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Common Stock (*)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;44,341,847&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;Allocation of the purchase price:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;531,147&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;56,075&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;485,684&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Security deposits&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,440&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Total assets acquired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,271,896&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(56,204&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accrued expenses and other current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(251,335&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(267,256&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Tenant security deposit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,880&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total liabilities assumed&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(577,675&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total net assets acquired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;694,221&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Goodwill as a result of the Merger&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43,647,626&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:TreasuryStockCommonValue contextRef="c367" decimals="0" id="ix_0_fact" unitRef="usd">44341847</us-gaap:TreasuryStockCommonValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c367" decimals="0" unitRef="usd">531147</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c367" decimals="0" unitRef="usd">188550</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c367" decimals="0" unitRef="usd">56075</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets contextRef="c367" decimals="0" unitRef="usd">485684</abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c367" decimals="0" unitRef="usd">10440</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c367" decimals="0" unitRef="usd">1271896</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c367" decimals="0" unitRef="usd">56204</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther contextRef="c367" decimals="0" unitRef="usd">251335</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability contextRef="c367" decimals="0" unitRef="usd">-267256</abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="c367" decimals="0" unitRef="usd">2880</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c367" decimals="0" unitRef="usd">577675</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c367" decimals="0" unitRef="usd">694221</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c367" decimals="0" unitRef="usd">43647626</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits contextRef="c318" decimals="0" unitRef="shares">29561231</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c318" decimals="0" unitRef="shares">1642291</abvc:CommonStockIssuedAfterStockSplit>
    <us-gaap:SharesIssuedPricePerShare contextRef="c365" decimals="2" unitRef="usdPershares">1.5</us-gaap:SharesIssuedPricePerShare>
    <abvc:PercentageOfGoodwill contextRef="c366" decimals="2" unitRef="pure">1</abvc:PercentageOfGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c366" decimals="0" unitRef="usd">43647626</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;18. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On April 16, 2022, the Company entered&#160;into
stock option agreements with 5 directors, pursuant to which the Company granted options to purchase an aggregate of 761,920 shares of
common stock&#160;under the 2016 Equity Incentive Plan, as amended, at an exercise price of $3 per share. The options were vested at the
grant date and become exercisable for 10 years from the grant date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On May 11, 2022, the Company and certain investors
entered into certain securities purchase agreement relating to the offer and sale of 2,000,000 shares of common stock, par value $0.001
per share in a registered direct offering. Pursuant to the Offering, the Company will also issue 5-year warrants to purchase 2,000,000
shares of Common Stock, exercisable at a price of $2.45 per share to the Purchasers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has evaluated subsequent events through
the date which the consolidated financial statements were available to be issued. All subsequent events requiring recognition as of March
31, 2022 have been incorporated into these consolidated financial statements and there are no other subsequent events that require disclosure
in accordance with FASB ASC Topic 855, &#x201c;Subsequent Events.&#x201d;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <abvc:NumberOfDirectors contextRef="c368" decimals="0" unitRef="pure">5</abvc:NumberOfDirectors>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c369" decimals="0" unitRef="shares">761920</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c368" decimals="0" unitRef="usdPershares">3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <abvc:GrantDateTerm contextRef="c369">P10Y</abvc:GrantDateTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c370" decimals="0" unitRef="shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital contextRef="c371" decimals="3" unitRef="usd">0.001</us-gaap:TemporaryEquityValueExcludingAdditionalPaidInCapital>
    <abvc:WarrantsPurchased contextRef="c371" decimals="0" unitRef="shares">2000000</abvc:WarrantsPurchased>
    <abvc:ExercisableAtAPricePerShare contextRef="c371" decimals="2" unitRef="usdPershares">2.45</abvc:ExercisableAtAPricePerShare>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">5828548</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">4273208</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="0" unitRef="usd">736667</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="0" unitRef="usd">728163</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="0" unitRef="usd">280692</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c3" decimals="0" unitRef="usd">159712</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">145399</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="c3" decimals="0" unitRef="usd">143435</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">1286618</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:DueFromOtherRelatedPartiesCurrent contextRef="c3" decimals="0" unitRef="usd">696255</us-gaap:DueFromOtherRelatedPartiesCurrent>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" unitRef="usd">25975</us-gaap:InventoryNet>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="0" unitRef="usd">108147</us-gaap:ShortTermInvestments>
    <abvc:PrepaymentForLongtermInvestments contextRef="c2" decimals="0" unitRef="usd">684720</abvc:PrepaymentForLongtermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="0" unitRef="usd">528354</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="0" unitRef="usd">172193</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="0" unitRef="usd">9625120</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="0" unitRef="usd">6172966</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">525881</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">514834</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" unitRef="usd">1471899</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" unitRef="usd">1772747</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LongTermInvestments contextRef="c2" decimals="0" unitRef="usd">932755</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c3" decimals="0" unitRef="usd">1190727</us-gaap:LongTermInvestments>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c2" decimals="0" unitRef="usd">981912</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c3" decimals="0" unitRef="usd">1790597</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c2" decimals="0" unitRef="usd">119309</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="c3" decimals="0" unitRef="usd">119315</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:SecurityDeposit contextRef="c2" decimals="0" unitRef="usd">41157</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="c3" decimals="0" unitRef="usd">45519</us-gaap:SecurityDeposit>
    <us-gaap:Assets contextRef="c2" decimals="0" unitRef="usd">13698033</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="0" unitRef="usd">11606705</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="0" unitRef="usd">23044</us-gaap:AccountsPayableCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c2" decimals="0" unitRef="usd">1640000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable contextRef="c3" decimals="0" unitRef="usd">1629000</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:OtherShortTermBorrowings contextRef="c3" decimals="0" unitRef="usd">100000</us-gaap:OtherShortTermBorrowings>
    <us-gaap:NotesPayableToBankCurrent contextRef="c3" decimals="0" unitRef="usd">106800</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">1300803</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">2118854</us-gaap:AccruedLiabilitiesCurrent>
    <abvc:AdvanceFromCustomers contextRef="c2" decimals="0" unitRef="usd">10985</abvc:AdvanceFromCustomers>
    <abvc:AdvanceFromCustomers contextRef="c3" decimals="0" unitRef="usd">12070</abvc:AdvanceFromCustomers>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="0" unitRef="usd">347100</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="0" unitRef="usd">316178</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">393424</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c3" decimals="0" unitRef="usd">288445</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:OtherNotesPayableCurrent contextRef="c3" decimals="0" unitRef="usd">250000</us-gaap:OtherNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="0" unitRef="usd">3692312</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="0" unitRef="usd">4844391</us-gaap:LiabilitiesCurrent>
    <us-gaap:LoansPayable contextRef="c3" decimals="0" unitRef="usd">124400</us-gaap:LoansPayable>
    <us-gaap:SecurityDepositLiability contextRef="c2" decimals="0" unitRef="usd">10580</us-gaap:SecurityDepositLiability>
    <us-gaap:SecurityDepositLiability contextRef="c3" decimals="0" unitRef="usd">19280</us-gaap:SecurityDepositLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="0" unitRef="usd">1124799</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="0" unitRef="usd">1456567</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c3" decimals="0" unitRef="usd">2500000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:Liabilities contextRef="c2" decimals="0" unitRef="usd">4827691</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c3" decimals="0" unitRef="usd">8944638</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">28926322</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">28926322</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">24420526</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">24420526</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="0" unitRef="usd">28926</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="0" unitRef="usd">24420</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="0" unitRef="usd">58113667</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="0" unitRef="usd">40751807</us-gaap:AdditionalPaidInCapital>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c2" decimals="0" unitRef="usd">2257400</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable contextRef="c3" decimals="0" unitRef="usd">3160360</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="0" unitRef="usd">-38481200</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="0" unitRef="usd">-25642387</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="0" unitRef="usd">539660</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="0" unitRef="usd">564860</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockValue contextRef="c2" decimals="0" unitRef="usd">9100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c3" decimals="0" unitRef="usd">9100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="0" unitRef="usd">8843653</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="0" unitRef="usd">3438340</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c2" decimals="0" unitRef="usd">26689</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c3" decimals="0" unitRef="usd">-776273</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" unitRef="usd">8870342</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" unitRef="usd">2662067</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="0" unitRef="usd">13698033</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="0" unitRef="usd">11606705</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c5" decimals="0" unitRef="usd">355797</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c6" decimals="0" unitRef="usd">483045</us-gaap:Revenues>
    <us-gaap:CostOfRevenue contextRef="c5" decimals="0" unitRef="usd">5086</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue contextRef="c6" decimals="0" unitRef="usd">18716</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit contextRef="c5" decimals="0" unitRef="usd">350711</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c6" decimals="0" unitRef="usd">464329</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c5" decimals="0" unitRef="usd">5746119</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c6" decimals="0" unitRef="usd">4273468</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="0" unitRef="usd">1003805</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c6" decimals="0" unitRef="usd">549658</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">5306755</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="0" unitRef="usd">4146979</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingExpenses contextRef="c5" decimals="0" unitRef="usd">12056679</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c6" decimals="0" unitRef="usd">8970105</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-11705968</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c6" decimals="0" unitRef="usd">-8505776</us-gaap:OperatingIncomeLoss>
    <abvc:InterestIncomes contextRef="c5" decimals="0" unitRef="usd">43196</abvc:InterestIncomes>
    <abvc:InterestIncomes contextRef="c6" decimals="0" unitRef="usd">71045</abvc:InterestIncomes>
    <us-gaap:InterestExpense contextRef="c5" decimals="0" unitRef="usd">227210</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c6" decimals="0" unitRef="usd">405032</us-gaap:InterestExpense>
    <abvc:RentIncome contextRef="c5" decimals="0" unitRef="usd">134576</abvc:RentIncome>
    <abvc:RentIncome contextRef="c6" decimals="0" unitRef="usd">20071</abvc:RentIncome>
    <abvc:OperatingSubleaseIncomeRelatedParties contextRef="c5" decimals="0" unitRef="usd">4800</abvc:OperatingSubleaseIncomeRelatedParties>
    <abvc:OperatingSubleaseIncomeRelatedParties contextRef="c6" decimals="0" unitRef="usd">4800</abvc:OperatingSubleaseIncomeRelatedParties>
    <us-gaap:GoodwillImpairmentLoss contextRef="c6" decimals="0" unitRef="usd">961217</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c6" decimals="0" unitRef="usd">-40589</us-gaap:RealizedInvestmentGainsLosses>
    <abvc:GainLossOnForeignExchangeChanges contextRef="c5" decimals="0" unitRef="usd">426316</abvc:GainLossOnForeignExchangeChanges>
    <abvc:GainLossOnForeignExchangeChanges contextRef="c6" decimals="0" unitRef="usd">-3275</abvc:GainLossOnForeignExchangeChanges>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c5" decimals="0" unitRef="usd">-269844</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c6" decimals="0" unitRef="usd">-1168733</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="0" unitRef="usd">22409</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c6" decimals="0" unitRef="usd">174770</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OtherIncome contextRef="c5" decimals="0" unitRef="usd">360898</us-gaap:OtherIncome>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c5" decimals="0" unitRef="usd">495141</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c6" decimals="0" unitRef="usd">-2308160</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">-11210827</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c6" decimals="0" unitRef="usd">-10813936</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">825024</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c6" decimals="0" unitRef="usd">-220352</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c5" decimals="0" unitRef="usd">-12035851</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c6" decimals="0" unitRef="usd">-10593584</us-gaap:ProfitLoss>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c5" decimals="0" unitRef="usd">802962</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c6" decimals="0" unitRef="usd">-802420</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <abvc:NetLossAttributableToAbvcAndSubsidiaries contextRef="c5" decimals="0" unitRef="usd">-12838813</abvc:NetLossAttributableToAbvcAndSubsidiaries>
    <abvc:NetLossAttributableToAbvcAndSubsidiaries contextRef="c6" decimals="0" unitRef="usd">-9791164</abvc:NetLossAttributableToAbvcAndSubsidiaries>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c5" decimals="0" unitRef="usd">-25200</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c6" decimals="0" unitRef="usd">-98893</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c5" decimals="0" unitRef="usd">-12864013</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c6" decimals="0" unitRef="usd">-9890057</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c6" decimals="2" unitRef="usdPershares">-0.5</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">25053522</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c6" decimals="0" unitRef="shares">19715559</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="0" unitRef="usd">-12035851</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c6" decimals="0" unitRef="usd">-10593584</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c5" decimals="0" unitRef="usd">11993</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c6" decimals="0" unitRef="usd">37142</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">5306755</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c6" decimals="0" unitRef="usd">4146979</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c5" decimals="0" unitRef="usd">-269844</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c6" decimals="0" unitRef="usd">-1168733</us-gaap:UnrealizedGainLossOnInvestments>
    <abvc:GovernmentGrantIncome contextRef="c5" decimals="0" unitRef="usd">360898</abvc:GovernmentGrantIncome>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c6" decimals="0" unitRef="usd">15360</us-gaap:OtherNoncashIncomeExpense>
    <abvc:InvestmentLoss1 contextRef="c6" decimals="0" unitRef="usd">1001806</abvc:InvestmentLoss1>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c5" decimals="0" unitRef="usd">824199</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c6" decimals="0" unitRef="usd">-223201</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c5" decimals="0" unitRef="usd">120980</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c6" decimals="0" unitRef="usd">-3696</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c5" decimals="0" unitRef="usd">357276</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther contextRef="c6" decimals="0" unitRef="usd">15778</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties contextRef="c5" decimals="0" unitRef="usd">595037</us-gaap:IncreaseDecreaseDueFromOtherRelatedParties>
    <us-gaap:IncreaseDecreaseDueFromOtherRelatedParties contextRef="c6" decimals="0" unitRef="usd">-20645</us-gaap:IncreaseDecreaseDueFromOtherRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c5" decimals="0" unitRef="usd">25830</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c5" decimals="0" unitRef="usd">-23044</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c6" decimals="0" unitRef="usd">-951</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c5" decimals="0" unitRef="usd">-173151</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="c6" decimals="0" unitRef="usd">-359822</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c5" decimals="0" unitRef="usd">-1085</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="c6" decimals="0" unitRef="usd">-1015</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c5" decimals="0" unitRef="usd">-317358</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties contextRef="c6" decimals="0" unitRef="usd">266791</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="0" unitRef="usd">-7597719</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c6" decimals="0" unitRef="usd">-4563919</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfInvestmentProjects contextRef="c6" decimals="0" unitRef="usd">147804</us-gaap:ProceedsFromSaleOfInvestmentProjects>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c5" decimals="0" unitRef="usd">107547</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="0" unitRef="usd">17503</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties contextRef="c6" decimals="0" unitRef="usd">373235</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c5" decimals="0" unitRef="usd">680916</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="0" unitRef="usd">-805966</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c6" decimals="0" unitRef="usd">-225431</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c5" decimals="0" unitRef="usd">11119452</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c6" decimals="0" unitRef="usd">7615331</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c5" decimals="0" unitRef="usd">850429</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c6" decimals="0" unitRef="usd">2500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt contextRef="c5" decimals="0" unitRef="usd">306836</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfSubordinatedShortTermDebt contextRef="c5" decimals="0" unitRef="usd">100000</us-gaap:RepaymentsOfSubordinatedShortTermDebt>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c5" decimals="0" unitRef="usd">107400</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfOtherShortTermDebt contextRef="c6" decimals="0" unitRef="usd">350000</us-gaap:RepaymentsOfOtherShortTermDebt>
    <us-gaap:ProceedsFromBankDebt contextRef="c6" decimals="0" unitRef="usd">100000</us-gaap:ProceedsFromBankDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c5" decimals="0" unitRef="usd">236498</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt contextRef="c6" decimals="0" unitRef="usd">124400</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt contextRef="c5" decimals="0" unitRef="usd">4265</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromOtherShortTermDebt contextRef="c6" decimals="0" unitRef="usd">-480989</us-gaap:ProceedsFromOtherShortTermDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c6" decimals="0" unitRef="usd">72704</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c6" decimals="0" unitRef="usd">13603</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="0" unitRef="usd">9995550</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c6" decimals="0" unitRef="usd">9567843</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="0" unitRef="usd">-28021</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c6" decimals="0" unitRef="usd">62435</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="0" unitRef="usd">1563844</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c6" decimals="0" unitRef="usd">4840928</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">5001371</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c8" decimals="0" unitRef="usd">160443</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="0" unitRef="usd">6565215</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c3" decimals="0" unitRef="usd">5001371</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="0" unitRef="usd">333873</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c6" decimals="0" unitRef="usd">208556</us-gaap:InterestPaidNet>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c5" decimals="0" unitRef="usd">2693548</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c6" decimals="0" unitRef="usd">1717051</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:SharesOutstanding contextRef="c49" decimals="0" unitRef="shares">19478168</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c49" decimals="0" unitRef="usd">19478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c50" decimals="0" unitRef="usd">-4063320</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c51" decimals="0" unitRef="usd">28180348</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c52" decimals="0" unitRef="usd">-15851223</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c53" decimals="0" unitRef="usd">663753</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c54" decimals="0" unitRef="shares">-275347</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c54" decimals="0" unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c55" decimals="0" unitRef="usd">26147</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c8" decimals="0" unitRef="usd">-124817</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <abvc:AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution contextRef="c56" decimals="0" unitRef="shares">3384615</abvc:AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution>
    <abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution contextRef="c56" decimals="0" unitRef="usd">3385</abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution>
    <abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution contextRef="c57" decimals="0" unitRef="usd">7611946</abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution>
    <abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution contextRef="c6" decimals="0" unitRef="usd">7615331</abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c57" decimals="0" unitRef="usd">1706419</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c6" decimals="0" unitRef="usd">1706419</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <abvc:StockIssuedDuringPeriodShareBasedCompensationServicesforShares contextRef="c56" decimals="0" unitRef="shares">641887</abvc:StockIssuedDuringPeriodShareBasedCompensationServicesforShares>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices contextRef="c56" decimals="0" unitRef="usd">642</abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices contextRef="c61" decimals="0" unitRef="usd">902960</abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices contextRef="c57" decimals="0" unitRef="usd">1536958</abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices contextRef="c6" decimals="0" unitRef="usd">2440560</abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c56" decimals="0" unitRef="shares">915856</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c56" decimals="0" unitRef="usd">915</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c57" decimals="0" unitRef="usd">1716136</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c6" decimals="0" unitRef="usd">1717051</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c58" decimals="0" unitRef="usd">-9791164</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c60" decimals="0" unitRef="usd">-802420</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c6" decimals="0" unitRef="usd">-10593584</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <abvc:CumulativeTransactionAdjustments contextRef="c59" decimals="0" unitRef="usd">-98893</abvc:CumulativeTransactionAdjustments>
    <abvc:CumulativeTransactionAdjustments contextRef="c6" decimals="0" unitRef="usd">-98893</abvc:CumulativeTransactionAdjustments>
    <us-gaap:SharesOutstanding contextRef="c9" decimals="0" unitRef="shares">24420526</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c9" decimals="0" unitRef="usd">24420</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c10" decimals="0" unitRef="usd">-3160360</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c11" decimals="0" unitRef="usd">40751807</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c12" decimals="0" unitRef="usd">-25642387</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c13" decimals="0" unitRef="usd">564860</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c14" decimals="0" unitRef="shares">-275347</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c14" decimals="0" unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c15" decimals="0" unitRef="usd">-776273</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c3" decimals="0" unitRef="usd">2662067</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c62" decimals="0" unitRef="shares">3027750</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c62" decimals="0" unitRef="usd">3028</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c63" decimals="0" unitRef="usd">10265995</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="0" unitRef="usd">10269023</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c62" decimals="0" unitRef="shares">366934</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c62" decimals="0" unitRef="usd">367</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c63" decimals="0" unitRef="usd">1728223</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="c5" decimals="0" unitRef="usd">1728590</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits contextRef="c62" decimals="0" unitRef="shares">1111112</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c62" decimals="0" unitRef="usd">1111</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c63" decimals="0" unitRef="usd">2692437</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits contextRef="c5" decimals="0" unitRef="usd">2693548</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices contextRef="c67" decimals="0" unitRef="usd">902960</abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices contextRef="c5" decimals="0" unitRef="usd">902960</abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c63" decimals="0" unitRef="usd">2675205</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c5" decimals="0" unitRef="usd">2675205</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c64" decimals="0" unitRef="usd">-12838813</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c66" decimals="0" unitRef="usd">802962</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c5" decimals="0" unitRef="usd">-12035851</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <abvc:CumulativeTransactionAdjustments contextRef="c65" decimals="0" unitRef="usd">-25200</abvc:CumulativeTransactionAdjustments>
    <abvc:CumulativeTransactionAdjustments contextRef="c5" decimals="0" unitRef="usd">-25200</abvc:CumulativeTransactionAdjustments>
    <us-gaap:SharesOutstanding contextRef="c29" decimals="0" unitRef="shares">28926322</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c29" decimals="0" unitRef="usd">28926</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c30" decimals="0" unitRef="usd">-2257400</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c31" decimals="0" unitRef="usd">58113667</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c32" decimals="0" unitRef="usd">-38481200</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c33" decimals="0" unitRef="usd">539660</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c34" decimals="0" unitRef="shares">-275347</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c34" decimals="0" unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c35" decimals="0" unitRef="usd">26689</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="0" unitRef="usd">8870342</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ABVC BioPharma, Inc. (the &#x201c;Company&#x201d;), formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#x2019;s operating entity, American BriVision Corporation (&#x201c;BriVision&#x201d;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical trials for the Company&#x2019;s drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering Cancer Center (&#x201c;MSKCC&#x201d;) and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July 21, 2015.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Name Change&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s shareholders approved an amendment to the Company&#x2019;s Articles of Incorporation to change the Company&#x2019;s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &#x201c;Annual Meeting&#x201d;). The name change amendment to the Company&#x2019;s Articles of Incorporation was filed with Nevada&#x2019;s Secretary of State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became effective as of May 3, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s stock symbol remains ABVC.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Reverse Merger&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 8, 2016, a Share Exchange Agreement (the &#x201c;Share Exchange Agreement&#x201d;) was entered into by and among the Company, BriVision, and Euro-Asia Investment &amp;amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&#x2019;s Republic of China (&#x201c;Euro-Asia&#x201d;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the &#x201c;BriVision Stock&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the &#x201c;Acquisition Stock&#x201d;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#x2019;s Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#x2019;s Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the &#x201c;Merger&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company. The holders of Company&#x2019;s Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company&#x2019;s Common Stock. Because of the exchange of the BriVision Stock for the Acquisition Stock (the &#x201c;Share Exchange&#x201d;), BriVision had become a wholly owned subsidiary (the &#x201c;Subsidiary&#x201d;) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the consummation of the Share Exchange, BriVision became a wholly owned subsidiary of the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following the Share Exchange, the Company has abandoned prior business plan and is now pursuing BriVision&#x2019;s historically proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (&#x201c;POC&#x201d;), out-license to international pharmaceutical companies, and explore global markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Accounting Treatment of the Reverse Merger&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For financial reporting purposes, the Share Exchange represents a &#x201c;reverse merger&#x201d;&#160;rather than a business combination and&#160;BriVision&#160;is deemed the accounting acquirer in the transaction. The&#160;Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision&#160;is the acquirer for financial reporting purposes and the&#160;Company&#160;is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of&#160;BriVision&#160;and recorded at the historical cost basis of&#160;BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of&#160;BriVision&#160;and operations of the Combined Company from the closing date of the Share Exchange.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Merger&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 8, 2019, the Company, BioLite Holding, Inc. (&#x201c;BioLite&#x201d;), BioKey, Inc. (&#x201c;BioKey&#x201d;), BioLite Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#x201c;Merger Sub 1&#x201d;), and BioKey Acquisition Corp., a direct wholly-owned subsidiary of Parent (&#x201c;Merger Sub 2&#x201d;) (collectively referred to as the &#x201c;Parties&#x201d;) completed the business combination pursuant to the Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;) dated as of January 31, 2018 where ABVC acquired BioLite and BioKey via issuing additional Common Stock of ABVC to the shareholders of BioLite and BioKey.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. ABVC issued an aggregate of 104,558,777 shares (prior to the reverse stock split in 2019) to the shareholders of both BioLite and BioKey under a registration statement on Form S-4 (file number 333-226285), which became effective by operation of law on or about February 5, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Holding, Inc. (the &#x201c;BioLite Holding&#x201d;) was incorporated under the laws of the State of Nevada on July 27, 2016. BioLite BVI, Inc. (the &#x201c;BioLite BVI&#x201d;), a wholly owned subsidiary of BioLite Holding, was incorporated in the British Virgin Islands on September 13, 2016. BioLite Holding and BioLite BVI are holding companies and have not carried out substantive business operations of their own.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite, Inc., (the &#x201c;BioLite Taiwan&#x201d;) was incorporated on February 13, 2006 under the laws of Taiwan. BioLite is in the business of developing and commercialization of new botanical drugs with application in central nervous system, autoimmunity, inflammation, hematology, and oncology. In addition, BioLite Taiwan distributes dietary supplements made from extracts of Chinese herbs and Maitake mushroom.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In January 2017, BioLite Holding, BioLite BVI, BioLite Taiwan, and certain shareholders of BioLite Taiwan entered into a share purchase / exchange agreement (the &#x201c;BioLite Share Purchase / Exchange Agreement&#x201d;). Pursuant to the BioLite Share Purchase / Exchange Agreement, the shareholder participants to the BioLite Share Purchase / Exchange Agreement have sold their equity in BioLite Taiwan and were using the proceeds from such sales to purchase shares of Common Stock of BioLite Holding at the same price per share, resulting in their owning the same number of shares of Common Stock as they owned in the BioLite Taiwan. Upon closing of the Share Purchase/ Exchange Agreement in August 2017, BioLite Holding ultimately owns via BioLite BVI approximately 73% of BioLite Taiwan. The other shareholders who did not enter this Share Purchase/ Exchange Agreement retain their equity ownership in BioLite Taiwan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioKey, Inc. was incorporated on August 9, 2000 in the State of California. BioKey provides a wide range of services, including, API characterization, pre-formulation studies, formulation development, analytical method development, stability studies, IND/NDA/ANDA/510K submissions, and manufacturing clinical trial materials (Phase I through phase III) and commercial manufacturing. It also licenses out its technologies and initiates joint research and development processes with other biotechnology, pharmaceutical, and nutraceutical companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Accounting Treatment of the Merger&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company adopted ASC 805, &#x201c;Business Combination&#x201d; to record the merger transactions of BioKey. Since the Company and BioLite Holding are the entities under Dr. Tsung-Shann Jiang&#x2019;s common control, the transaction is accounted for as a restructuring transaction.&#160;All the assets and liabilities of BioLite Holding, BioLite BVI, and BioLite Taiwan were transferred to the Company at their respective carrying amounts on the closing date of the Merger. The Company has recast prior period financial statements to reflect the conveyance of BioLite Holding&#x2019;s common shares as if the restructuring transaction had occurred as of the earliest date of the financial statements. All material intercompany accounts, transactions, and profits have been eliminated in consolidation. The nature of and effects on earnings per share (EPS) of nonrecurring intra-entity transactions involving long-term assets and liabilities is not required to be eliminated and EPS amounts have been recast to include the earnings (or losses) of the transferred net assets.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="c372">1. ORGANIZATION AND DESCRIPTION OF BUSINESS&#160;ABVC BioPharma, Inc. (the &#x201c;Company&#x201d;), formerly known as American BriVision (Holding) Corporation, a Nevada corporation, through the Company&#x2019;s operating entity, American BriVision Corporation (&#x201c;BriVision&#x201d;), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology to fulfill unmet medical needs and focuses on the development of new drugs and medical devices derived from plants. BriVision develops its pipeline by carefully tracking new medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Pre-clinical, disease animal model and Phase I safety studies are examined closely by the Company to identify drugs that BriVision believes demonstrate efficacy and safety. Once a drug appears to be a good candidate for development and ultimately commercialization, BriVision licenses the drug or medical device from the original researchers and begins to introduce the drugs clinical plan to highly respected principal investigators in the United States, Australia and Taiwan to conduct a Phase II clinical trial. At present, clinical trials for the Company&#x2019;s drugs and medical devices are being conducted at such world-famous institutions as Memorial Sloan Kettering Cancer Center (&#x201c;MSKCC&#x201d;) and MD Anderson Cancer Center. BriVision had no predecessor operations prior to its formation on July 21, 2015.&#160;Name Change&#160;The Company&#x2019;s shareholders approved an amendment to the Company&#x2019;s Articles of Incorporation to change the Company&#x2019;s corporate name from American BriVision (Holding) Corporation to ABVC BioPharma, Inc. and approved and adopted the Certificate of Amendment to affect same at the 2020 annual meeting of shareholders (the &#x201c;Annual Meeting&#x201d;). The name change amendment to the Company&#x2019;s Articles of Incorporation was filed with Nevada&#x2019;s Secretary of State and became effective on March 8, 2021 and FINRA processed our request to change our name on April 30, 2021, which became effective as of May 3, 2021.&#160;The Company&#x2019;s stock symbol remains ABVC.&#160;Reverse Merger&#160;On February 8, 2016, a Share Exchange Agreement (the &#x201c;Share Exchange Agreement&#x201d;) was entered into by and among the Company, BriVision, and Euro-Asia Investment &amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of the People&#x2019;s Republic of China (&#x201c;Euro-Asia&#x201d;), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share capital of BriVision (the &#x201c;BriVision Stock&#x201d;).&#160;Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company issued 166,273,921 (52,936,583 pre-stock split) shares (the &#x201c;Acquisition Stock&#x201d;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#x2019;s Common Stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#x2019;s Common Stock owned by Euro-Asia were cancelled and retired to treasury. The Acquisition Stock collectively represented 79.70% of the issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger (the &#x201c;Merger&#x201d;).&#160;Pursuant to the Merger, all of the issued and outstanding common shares of BriVision were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921 (52,936,583 pre-stock split) common shares of the Company and BriVision had become a wholly owned subsidiary of the Company.</us-gaap:StockholdersEquityNoteStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c68" decimals="0" unitRef="shares">164387376</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c68" decimals="0" unitRef="shares">52336000</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c69" decimals="0" unitRef="shares">166273921</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c69" decimals="0" unitRef="shares">52936583</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c70" decimals="0" unitRef="shares">163159952</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c70" decimals="0" unitRef="shares">51945225</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:PercentageOfCommonSharesIssuedAndOutstanding contextRef="c71" decimals="4" unitRef="pure">0.797</abvc:PercentageOfCommonSharesIssuedAndOutstanding>
    <abvc:PercentageOfIssuedShareCapital contextRef="c71" decimals="2" unitRef="pure">1</abvc:PercentageOfIssuedShareCapital>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c312" decimals="0" unitRef="shares">166273921</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c73" decimals="0" unitRef="shares">205519223</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c73" decimals="0" unitRef="shares">65431144</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c74" decimals="0" unitRef="shares">104558777</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:PercentageOfCommonSharesIssuedAndOutstanding contextRef="c75" decimals="2" unitRef="pure">0.73</abvc:PercentageOfCommonSharesIssuedAndOutstanding>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;). All significant intercompany transactions and account balances have been eliminated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#x2019;s financial statements are expressed in U.S. dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Forward Stock Split&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Stock Reverse Split&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#x201c;Reverse Split&#x201d;) of both the authorized common stock of the Company (the &#x201c;Common Stock&#x201d;) and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company&#x2019;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company&#x2019;s articles of incorporation (the &#x201c;Amendment&#x201d;) to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB ASC 820, &#x201c;Fair Value Measurements&#x201d; defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company&#x2019;s long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2021 and 2020, the Company&#x2019;s cash and cash equivalents amounted $5,828,548 and $4,273,208, respectively. Some&#160;of the Company&#x2019;s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Restricted Cash Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of December 31, 2021 and 2020, the Company&#x2019;s restricted cash equivalents amounted $736,667 and $728,163, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation&#x2019;s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the fiscal year 2018, the Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#x2019;s reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#x2019;s review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company&#x2019;s revenue during all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Collaborative Revenues&lt;/b&gt; &#x2014; The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s judgment. Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited to, the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i) Non-refundable upfront payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii) Milestone payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative agreement with collaboration partners.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii) Multiple Element Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which is typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv) Royalties and Profit Sharing Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues Derived from Research and Development Activities Services &#x2014; Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&#160;Life&lt;br/&gt; in Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 ~ 50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 ~ 10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 ~ 6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (&#x201c;ASC 360-10&#x201d;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Long-term Equity Investment&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable cost method investments when the equity method does not apply.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant judgment is required to identify whether an impairment exists in the valuation of the Company&#x2019;s non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#x2019;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee&#x2019;s industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#x2019; revenue, costs, and discount rates. The Company&#x2019;s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Other-Than-Temporary Impairment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#x2019;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable equity investments based on the Company&#x2019;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#x2019;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $961,217 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company completed the required testing of goodwill for impairment as of December 31, 2021, and determined that goodwill was impaired because of the current financial condition of the Company and the Company&#x2019;s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For our CDMO business unit, the Company accounts for R&amp;amp;D costs in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730, Research and Development (&#x201c;ASC 730&#x201d;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Post-retirement and post-employment benefits&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#x201c;Act&#x201d;) in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#x2019;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#x2019; salaries to the employees&#x2019; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $11,375 and $13,961 for the year ended December 31, 2021 and 2020, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d;. Total employee stock-based compensation expenses were $2,675,205 and $1,623,102 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d; and FASB ASC Topic 505-50 &#x201c;Equity-Based Payments to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $2,631,550 and $2,523,877 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Beneficial Conversion Feature&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under ASC 740, a tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the year ended December 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On December 22, 2017, the SEC issued Staff Accounting Bulletin (&#x201c;SAB 118&#x201d;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Valuation of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A valuation allowance is recorded to reduce the Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Loss Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company calculates net loss per share in accordance with ASC Topic 260, &#x201c;Earnings per Share&#x201d;. Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has adopted ASC Topic 450 &#x201c;Contingencies&#x201d; subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Foreign-currency Transactions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the Company&#x2019;s subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#x2019; Equity (Deficit).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Translation Adjustment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accounts of the Company&#x2019;s subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#x201c;NT$&#x201d;). Such financial statements were translated into U.S. Dollars (&#x201c;$&#x201d; or &#x201c;USD&#x201d;) in accordance ASC 830, &#x201c;Foreign Currency Matters&#x201d;, with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder&#x2019;s deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In August 2020, the FASB issued ASU 2020-06, Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For contracts in an entity&#x2019;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation (Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accompanying consolidated financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the &#x201c;U.S. GAAP&#x201d;). All significant intercompany transactions and account balances have been eliminated.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company&#x2019;s financial statements are expressed in U.S. dollars.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Fiscal Year&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company changed its fiscal year from the period beginning on October 1st and ending on September 30th to the period beginning on January 1st and ending on December 31st, beginning January 1, 2018. All references herein to a fiscal year prior to December 31, 2017 refer to the twelve months ended September 30th of such year.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FiscalPeriod>
    <us-gaap:UseOfEstimates contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:InventoryPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Inventory&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory consists of raw materials, work-in-process, finished goods, and merchandise. Inventories are stated at the lower of cost or market and valued on a moving weighted average cost basis. Market is determined based on net realizable value. The Company periodically reviews the age and turnover of its inventory to determine whether any inventory has become obsolete or has declined in value, and incurs a charge to operations for known and anticipated inventory obsolescence.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <abvc:ForwardStockSplitsPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Forward Stock Split&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</abvc:ForwardStockSplitsPolicyTextBlock>
    <abvc:StockReverseSplitPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Stock Reverse Split&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 12, 2019, the Board of Directors of the Company by unanimous written consent in lieu of a meeting approved to i) effect a stock reverse split at the ratio of 1-for-18 (the &#x201c;Reverse Split&#x201d;) of both the authorized common stock of the Company (the &#x201c;Common Stock&#x201d;) and the issued and outstanding Common Stock and ii) to amend the articles of incorporation of the Company to reflect the Reverse Split. The Board approved and authorized the Reverse Split without obtaining approval of the Company&#x2019;s shareholders pursuant to Section 78.207 of Nevada Revised Statutes. On May 3, 2019, the Company filed a certificate of amendment to the Company&#x2019;s articles of incorporation (the &#x201c;Amendment&#x201d;) to effect the Reverse Split with the Secretary of State of Nevada. The Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</abvc:StockReverseSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="c373">The Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;) informed the Company that the Reverse Split was effective on May 8, 2019. All shares and related financial information in this Form 10-K reflect this 1-for-18 reverse stock split.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Fair Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;FASB ASC 820, &#x201c;Fair Value Measurements&#x201d; defines fair value for certain financial and nonfinancial assets and liabilities that are recorded at fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. It requires that an entity measure its financial instruments to base fair value on exit price, maximize the use of observable units and minimize the use of unobservable inputs to determine the exit price. It establishes a hierarchy which prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy increases the consistency and comparability of fair value measurements and related disclosures by maximizing the use of observable inputs and minimizing the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the assets or liabilities based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy prioritizes the inputs into three broad levels based on the reliability of the inputs as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 - Inputs are quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Valuation of these instruments does not require a high degree of judgment as the valuations are based on quoted prices in active markets that are readily and regularly available.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable as of the measurement date, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 - Valuations based on inputs that are unobservable and not corroborated by market data. The fair value for such assets and liabilities is generally determined using pricing models, discounted cash flow methodologies, or similar techniques that incorporate the assumptions a market participant would use in pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The carrying values of certain assets and liabilities of the Company, such as cash and cash equivalents, restricted cash, accounts receivable, due from related parties, inventory, prepaid expenses and other current assets, accounts payable, accrued liabilities, and due to related parties approximate fair value due to their relatively short maturities. The carrying value of the Company&#x2019;s short-term bank loan, convertible notes payable, and accrued interest approximates their fair value as the terms of the borrowing are consistent with current market rates and the duration to maturity is short. The carrying value of the Company&#x2019;s long-term bank loan approximates fair value because the interest rates approximate market rates that the Company could obtain for debt with similar terms and maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Cash and Cash Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of December 31, 2021 and 2020, the Company&#x2019;s cash and cash equivalents amounted $5,828,548 and $4,273,208, respectively. Some&#160;of the Company&#x2019;s cash deposits are held in financial institutions located in Taiwan where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:Cash contextRef="c2" decimals="0" unitRef="usd">5828548</us-gaap:Cash>
    <us-gaap:Cash contextRef="c3" decimals="0" unitRef="usd">4273208</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Restricted Cash Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Restricted cash equivalents primarily consist of cash held in a reserve bank account in Taiwan. As of December 31, 2021 and 2020, the Company&#x2019;s restricted cash equivalents amounted $736,667 and $728,163, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c2" decimals="0" unitRef="usd">736667</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="c3" decimals="0" unitRef="usd">728163</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of Taiwan Central Deposit Insurance Corporation and the U.S. Federal Deposit Insurance Corporation&#x2019;s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the fiscal year 2018, the Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;), Topic 606 (ASC 606), Revenue from Contracts with Customers, using the modified retrospective method to all contracts that were not completed as of January 1, 2018, and applying the new revenue standard as an adjustment to the opening balance of accumulated deficit at the beginning of 2018 for the cumulative effect. The results for the Company&#x2019;s reporting periods beginning on and after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported under the accounting standards in effect for the prior period. Based on the Company&#x2019;s review of existing collaborative agreements as of January 1, 2018, the Company concluded that the adoption of the new guidance did not have a significant change on the Company&#x2019;s revenue during all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines is within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. At inception of the contract, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following are examples of when the Company recognizes revenue based on the types of payments the Company receives.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Collaborative Revenues&lt;/b&gt; &#x2014; The Company recognizes collaborative revenues generated through collaborative research, development and/or commercialization agreements. The terms of these agreements typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, partial or complete reimbursement of research and development costs, and royalties on net sales of licensed products. Each type of payments results in collaborative revenues except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. To date, the Company has not received any royalty revenues. Revenue is recognized upon satisfaction of a performance obligation by transferring control of a good or service to the collaboration partners.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As part of the accounting for these arrangements, the Company applies judgment to determine whether the performance obligations are distinct, and develop assumptions in determining the stand-alone selling price for each distinct performance obligation identified in the collaboration agreements. To determine the stand-alone selling price, the Company relies on assumptions which may include forecasted revenues, development timelines, reimbursement rates for R&amp;amp;D personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company had multiple deliverables under the collaborative agreements, including deliverables relating to grants of technology licenses, regulatory and clinical development, and marketing activities. Estimation of the performance periods of the Company&#x2019;s deliverables requires the use of management&#x2019;s judgment. Significant factors considered in management&#x2019;s evaluation of the estimated performance periods include, but are not limited to, the Company&#x2019;s experience in conducting clinical development, regulatory and manufacturing activities. The Company reviews the estimated duration of its performance periods under its collaborative agreements on an annually basis, and makes any appropriate adjustments on a prospective basis. Future changes in estimates of the performance period under its collaborative agreements could impact the timing of future revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i) Non-refundable upfront payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in an arrangement, the Company recognizes revenue from the related non-refundable upfront payments based on the relative standalone selling price prescribed to the license compared to the total selling price of the arrangement. The revenue is recognized when the license is transferred to the collaboration partners and the collaboration partners are able to use and benefit from the license. To date, the receipt of non-refundable upfront fees was solely for the compensation of past research efforts and contributions made by the Company before the collaborative agreements entered into and it does not relate to any future obligations and commitments made between the Company and the collaboration partners in the collaborative agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii) Milestone payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company is eligible to receive milestone payments under the collaborative agreement with collaboration partners based on achievement of specified development, regulatory and commercial events. Management evaluated the nature of the events triggering these contingent payments, and concluded that these events fall into two categories: (a) events which involve the performance of the Company&#x2019;s obligations under the collaborative agreement with collaboration partners, and (b) events which do not involve the performance of the Company&#x2019;s obligations under the collaborative agreement with collaboration partners.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The former category of milestone payments consists of those triggered by development and regulatory activities in the territories specified in the collaborative agreements. Management concluded that each of these payments constitute substantive milestone payments. This conclusion was based primarily on the facts that (i) each triggering event represents a specific outcome that can be achieved only through successful performance by the Company of one or more of its deliverables, (ii) achievement of each triggering event was subject to inherent risk and uncertainty and would result in additional payments becoming due to the Company, (iii) each of the milestone payments is non-refundable, (iv) substantial effort is required to complete each milestone, (v) the amount of each milestone payment is reasonable in relation to the value created in achieving the milestone, (vi) a substantial amount of time is expected to pass between the upfront payment and the potential milestone payments, and (vii) the milestone payments relate solely to past performance. Based on the foregoing, the Company recognizes any revenue from these milestone payments in the period in which the underlying triggering event occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii) Multiple Element Arrangements&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company evaluates multiple element arrangements to determine (1) the deliverables included in the arrangement and (2) whether the individual deliverables represent separate units of accounting or whether they must be accounted for as a combined unit of accounting. This evaluation involves subjective determinations and requires management to make judgments about the individual deliverables and whether such deliverables are separate from other aspects of the contractual relationship. Deliverables are considered separate units of accounting provided that: (i) the delivered item(s) has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially within its control. In assessing whether an item under a collaboration has standalone value, the Company considers factors such as the research, manufacturing, and commercialization capabilities of the collaboration partner and the availability of the associated expertise in the general marketplace. The Company also considers whether its collaboration partners can use the other deliverable(s) for their intended purpose without the receipt of the remaining element(s), whether the value of the deliverable is dependent on the undelivered item(s), and whether there are other vendors that can provide the undelivered element(s).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company recognizes arrangement consideration allocated to each unit of accounting when all of the revenue recognition criteria in ASC 606 are satisfied for that particular unit of accounting. In the event that a deliverable does not represent a separate unit of accounting, the Company recognizes revenue from the combined unit of accounting over the Company&#x2019;s contractual or estimated performance period for the undelivered elements, which is typically the term of the Company&#x2019;s research and development obligations. If there is no discernible pattern of performance or objectively measurable performance measures do not exist, then the Company recognizes revenue under the arrangement on a straight-line basis over the period the Company is expected to complete its performance obligations. Conversely, if the pattern of performance in which the service is provided to the customer can be determined and objectively measurable performance measures exist, then the Company recognizes revenue under the arrangement using the proportional performance method. Revenue recognized is limited to the lesser of the cumulative amount of payments received or the cumulative amount of revenue earned, as determined using the straight-line method or proportional performance method, as applicable, as of the period ending date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the inception of an arrangement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether: (1) the consideration is commensurate with either the Company&#x2019;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from its performance to achieve the milestone, (2) the consideration relates solely to past performance and (3) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone and the level of effort and investment required to achieve the particular milestone in making this assessment. There is considerable judgment involved in determining whether a milestone satisfies all of the criteria required to conclude that a milestone is substantive. Milestones that are not considered substantive are recognized as earned if there are no remaining performance obligations or over the remaining period of performance, assuming all other revenue recognition criteria are met.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv) Royalties and Profit Sharing Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under the collaborative agreement with the collaboration partners, the Company is entitled to receive royalties on sales of products, which is at certain percentage of the net sales. The Company recognizes revenue from these events based on the revenue recognition criteria set forth in ASC 606. Based on those criteria, the Company considers these payments to be contingent revenues, and recognizes them as revenue in the period in which the applicable contingency is resolved.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues Derived from Research and Development Activities Services &#x2014; Revenues related to research and development and regulatory activities are recognized when the related services or activities are performed, in accordance with the contract terms. The Company typically has only one performance obligation at the inception of a contract, which is to perform research and development services. The Company may also provide its customers with an option to request that the Company provides additional goods or services in the future, such as active pharmaceutical ingredient, API, or IND/NDA/ANDA/510K submissions. The Company evaluates whether these options are material rights at the inception of the contract. If the Company determines an option is a material right, the Company will consider the option a separate performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If the Company is entitled to reimbursement from its customers for specified research and development expenses, the Company accounts for the related services that it provides as separate performance obligations if it determines that these services represent a material right. The Company also determines whether the reimbursement of research and development expenses should be accounted for as revenues or an offset to research and development expenses in accordance with provisions of gross or net revenue presentation. The Company recognizes the corresponding revenues or records the corresponding offset to research and development expenses as it satisfies the related performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company then determines the transaction price by reviewing the amount of consideration the Company is eligible to earn under the contracts, including any variable consideration. Under the outstanding contracts, consideration typically includes fixed consideration and variable consideration in the form of potential milestone payments. At the start of an agreement, the Company&#x2019;s transaction price usually consists of the payments made to or by the Company based on the number of full-time equivalent researchers assigned to the project and the related research and development expenses incurred. The Company does not typically include any payments that the Company may receive in the future in its initial transaction price because the payments are not probable. The Company would reassess the total transaction price at each reporting period to determine if the Company should include additional payments in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company receives payments from its customers based on billing schedules established in each contract. Upfront payments and fees may be recorded as advance from customers upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the right of the Company to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customers and the transfer of the promised goods or services to the customers will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment is carried at cost net of accumulated depreciation. Repairs and maintenance are expensed as incurred. Expenditures that improve the functionality of the related asset or extend the useful life are capitalized. When property and equipment is retired or otherwise disposed of, the related gain or loss is included in operating income. Leasehold improvements are depreciated on the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Depreciation is calculated on the straight-line method, including property and equipment under capital leases, generally based on the following useful lives:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; width: 84%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&#160;Life&lt;br/&gt; in Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Buildings and leasehold improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 ~ 50&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 ~ 10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 ~ 6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c374">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c375">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c376">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c377">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c378">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c379">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has adopted Accounting Standards Codification subtopic 360-10, Property, Plant and Equipment (&#x201c;ASC 360-10&#x201d;). ASC 360-10 requires that long-lived assets and certain identifiable intangibles held and used by the Company be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company evaluates its long-lived assets for impairment annually or more often if events and circumstances warrant. Events relating to recoverability may include significant unfavorable changes in business conditions, recurring losses, or a forecasted inability to achieve break-even operating results over an extended period. Should impairment in value be indicated, the carrying value of intangible assets will be adjusted, based on estimates of future discounted cash flows resulting from the use and ultimate disposition of the asset. ASC 360-10 also requires assets to be disposed of be reported at the lower of the carrying amount or the fair value less costs to sell.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <abvc:LongTermEquityInvestmentPolicy contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Long-term Equity Investment&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company acquires the equity investments to promote business and strategic objectives. The Company accounts for non-marketable equity and other equity investments for which the Company does not have control over the investees as:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity method investments when the Company has the ability to exercise significant influence, but not control, over the investee. Its proportionate share of the income or loss is recognized monthly and is recorded in gains (losses) on equity investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable cost method investments when the equity method does not apply.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Significant judgment is required to identify whether an impairment exists in the valuation of the Company&#x2019;s non-marketable equity investments, and therefore the Company considers this a critical accounting estimate. Its yearly analysis considers both qualitative and quantitative factors that may have a significant impact on the investee&#x2019;s fair value. Qualitative analysis of its investments involves understanding the financial performance and near-term prospects of the investee, changes in general market conditions in the investee&#x2019;s industry or geographic area, and the management and governance structure of the investee. Quantitative assessments of the fair value of its investments are developed using the market and income approaches. The market approach includes the use of comparable financial metrics of private and public companies and recent financing rounds. The income approach includes the use of a discounted cash flow model, which requires significant estimates regarding the investees&#x2019; revenue, costs, and discount rates. The Company&#x2019;s assessment of these factors in determining whether an impairment exists could change in the future due to new developments or changes in applied assumptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</abvc:LongTermEquityInvestmentPolicy>
    <abvc:OtherThanTemporaryImpairmentPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Other-Than-Temporary Impairment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s long-term equity investments are subject to a periodic impairment review. Impairments affect earnings as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Marketable equity securities include the consideration of general market conditions, the duration and extent to which the fair value is below cost, and our ability and intent to hold the investment for a sufficient period of time to allow for recovery of value in the foreseeable future. The Company also considers specific adverse conditions related to the financial health of, and the business outlook for, the investee, which may include industry and sector performance, changes in technology, operational and financing cash flow factors, and changes in the investee&#x2019;s credit rating. The Company records other-than-temporary impairments on marketable equity securities and marketable equity method investments in gains (losses) on equity investments.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Non-marketable equity investments based on the Company&#x2019;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee; adverse changes in market conditions and the regulatory or economic environment; changes in operating structure or management of the investee; additional funding requirements; and the investee&#x2019;s ability to remain in business. A series of operating losses of an investee or other factors may indicate that a decrease in value of the investment has occurred that is other than temporary and that shall be recognized even though the decrease in value is in excess of what would otherwise be recognized by application of the equity method. A loss in value of an investment that is other than a temporary decline shall be recognized. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. The Company records other-than-temporary impairments for non-marketable cost method investments and equity method investments in gains (losses) on equity investments. Other-than-temporary impairments of equity investments were $0 and $961,217 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</abvc:OtherThanTemporaryImpairmentPolicyTextBlock>
    <abvc:ImpairmentOfEquityInvestments contextRef="c5" decimals="0" unitRef="usd">0</abvc:ImpairmentOfEquityInvestments>
    <abvc:ImpairmentOfEquityInvestments contextRef="c6" decimals="0" unitRef="usd">961217</abvc:ImpairmentOfEquityInvestments>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company evaluates goodwill for impairment annually or more frequently when an event occurs or circumstances change that indicate the carrying value may not be recoverable. In testing goodwill for impairment, the Company may elect to utilize a qualitative assessment to evaluate whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If the qualitative assessment indicates that goodwill impairment is more likely than not, the Company performs a two-step impairment test. The Company tests goodwill for impairment under the two-step impairment test by first comparing the book value of net assets to the fair value of the reporting units. If the fair value is determined to be less than the book value or qualitative factors indicate that it is more likely than not that goodwill is impaired, a second step is performed to compute the amount of impairment as the difference between the estimated fair value of goodwill and the carrying value. The Company estimates the fair value of the reporting units using discounted cash flows. Forecasts of future cash flows are based on our best estimate of future net sales and operating expenses, based primarily on expected category expansion, pricing, market segment share, and general economic conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company completed the required testing of goodwill for impairment as of December 31, 2021, and determined that goodwill was impaired because of the current financial condition of the Company and the Company&#x2019;s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company anticipates future cash flows indicate that the recoverability of goodwill is not reasonably assured.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Research and Development Expenses&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For our CDMO business unit, the Company accounts for R&amp;amp;D costs in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 730, Research and Development (&#x201c;ASC 730&#x201d;). Research and development expenses are charged to expense as incurred unless there is an alternative future use in other research and development projects or otherwise. Research and development expenses are comprised of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services. Non-refundable advance payment for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. In instances where the Company enters into agreements with third parties to provide research and development services, costs are expensed as services are performed.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Post-retirement and post-employment benefits&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company&#x2019;s subsidiaries in Taiwan adopted the government mandated defined contribution plan pursuant to the Labor Pension Act (the &#x201c;Act&#x201d;) in Taiwan. Such labor regulations require that the rate of contribution made by an employer to the Labor Pension Fund per month shall not be less than 6% of the worker&#x2019;s monthly salaries. Pursuant to the Act, the Company makes monthly contribution equal to 6% of employees&#x2019; salaries to the employees&#x2019; pension fund. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $11,375 and $13,961 for the year ended December 31, 2021 and 2020, respectively. Other than the above, the Company does not provide any other post-retirement or post-employment benefits.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy>
    <abvc:PercentageOfMonthlyContribution contextRef="c2" decimals="2" unitRef="pure">0.06</abvc:PercentageOfMonthlyContribution>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash contextRef="c5" decimals="0" unitRef="usd">11375</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash contextRef="c6" decimals="0" unitRef="usd">13961</us-gaap:EmployeeBenefitsAndShareBasedCompensationNoncash>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Stock-based Compensation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company measures expense associated with all employee stock-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d;. Total employee stock-based compensation expenses were $2,675,205 and $1,623,102 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company accounted for stock-based compensation to non-employees in accordance with FASB ASC Topic 718 &#x201c;Compensation-Stock Compensation&#x201d; and FASB ASC Topic 505-50 &#x201c;Equity-Based Payments to Non-Employees&#x201d; which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Total non-employee stock-based compensation expenses were $2,631,550 and $2,523,877 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c5" decimals="0" unitRef="usd">2675205</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c6" decimals="0" unitRef="usd">1623102</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <abvc:StockBasedCompensationForNonemployees contextRef="c5" decimals="0" unitRef="usd">2631550</abvc:StockBasedCompensationForNonemployees>
    <abvc:StockBasedCompensationForNonemployees contextRef="c6" decimals="0" unitRef="usd">2523877</abvc:StockBasedCompensationForNonemployees>
    <abvc:BeneficialConversionFeature contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Beneficial Conversion Feature&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From time to time, the Company may issue convertible notes that may contain an imbedded beneficial conversion feature. A beneficial conversion feature exists on the date a convertible note is issued when the fair value of the underlying common stock to which the note is convertible into is in excess of the remaining unallocated proceeds of the note after first considering the allocation of a portion of the note proceeds to the fair value of the warrants, if related warrants have been granted. The intrinsic value of the beneficial conversion feature is recorded as a debt discount with a corresponding amount to additional paid in capital. The debt discount is amortized to interest expense over the life of the note using the effective interest method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</abvc:BeneficialConversionFeature>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Under ASC 740, a tax position is recognized as a benefit only if it is &#x201c;more likely than not&#x201d;&#160;that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred for the year ended December 31, 2021 and 2020. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On December 22, 2017, the SEC issued Staff Accounting Bulletin (&#x201c;SAB 118&#x201d;), which provides guidance on accounting for tax effects of the Tax Act. SAB 118 provides a measurement period that should not extend beyond one year from the Tax Act enactment date for companies to complete the accounting under ASC 740. In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#x2019;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Tax Act. While the Company is able to make reasonable estimates of the impact of the reduction in corporate rate and the deemed repatriation transition tax, the final impact of the Tax Act may differ from these estimates, due to, among other things, changes in our interpretations and assumptions, additional guidance that may be issued by the I.R.S., and actions the Company may take. The Company is continuing to gather additional information to determine the final impact.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <abvc:ValuationOfDeferredTaxAssetsPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Valuation of Deferred Tax Assets&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A valuation allowance is recorded to reduce the Company&#x2019;s deferred tax assets to the amount that is more likely than not to be realized. In assessing the need for the valuation allowance, management considers, among other things, projections of future taxable income and ongoing prudent and feasible tax planning strategies. If the Company determines that sufficient negative evidence exists, then it will consider recording a valuation allowance against a portion or all of the deferred tax assets in that jurisdiction. If, after recording a valuation allowance, the Company&#x2019;s projections of future taxable income and other positive evidence considered in evaluating the need for a valuation allowance prove, with the benefit of hindsight, to be inaccurate, it could prove to be more difficult to support the realization of its deferred tax assets. As a result, an additional valuation allowance could be required, which would have an adverse impact on its effective income tax rate and results. Conversely, if, after recording a valuation allowance, the Company determines that sufficient positive evidence exists in the jurisdiction in which the valuation allowance was recorded, it may reverse a portion or all of the valuation allowance in that jurisdiction. In such situations, the adjustment made to the deferred tax asset would have a favorable impact on its effective income tax rate and results in the period such determination was made.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</abvc:ValuationOfDeferredTaxAssetsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Loss Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company calculates net loss per share in accordance with ASC Topic 260, &#x201c;Earnings per Share&#x201d;. Basic loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. Diluted earnings per share excludes all dilutive potential shares if their effect is anti-dilutive.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has adopted ASC Topic 450 &#x201c;Contingencies&#x201d; subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Foreign-currency Transactions&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For the Company&#x2019;s subsidiaries in Taiwan, the foreign-currency transactions are recorded in New Taiwan dollars (&#x201c;NTD&#x201d;) at the rates of exchange in effect when the transactions occur. Gains or losses resulting from the application of different foreign exchange rates when cash in foreign currency is converted into New Taiwan dollars, or when foreign-currency receivables or payables are settled, are credited or charged to income in the year of conversion or settlement. On the balance sheet dates, the balances of foreign-currency assets and liabilities are restated at the prevailing exchange rates and the resulting differences are charged to current income except for those foreign currencies denominated investments in shares of stock where such differences are accounted for as translation adjustments under the Statements of Stockholders&#x2019; Equity (Deficit).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <abvc:TranslationAdjustmentPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Translation Adjustment&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The accounts of the Company&#x2019;s subsidiaries in Taiwan were maintained, and their financial statements were expressed, in New Taiwan Dollar (&#x201c;NT$&#x201d;). Such financial statements were translated into U.S. Dollars (&#x201c;$&#x201d; or &#x201c;USD&#x201d;) in accordance ASC 830, &#x201c;Foreign Currency Matters&#x201d;, with the NT$ as the functional currency. According to the Statement, all assets and liabilities are translated at the current exchange rate, stockholder&#x2019;s deficit are translated at the historical rates and income statement items are translated at an average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income (loss) as a component of stockholders&#x2019; equity (deficit).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</abvc:TranslationAdjustmentPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In August 2020, the FASB issued ASU 2020-06, Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 simplifies the accounting for convertible debt by eliminating the beneficial conversion and cash conversion accounting models. Upon adoption of ASU 2020-06, convertible debt, unless issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract, will no longer be allocated between debt and equity components. This modification will reduce the issue discount and result in less non-cash interest expense in financial statements. ASU 2020-06 also updates the earnings per share calculation and requires entities to assume share settlement when the convertible debt can be settled in cash or shares. For contracts in an entity&#x2019;s own equity, the type of contracts primarily affected by ASU 2020-06 are freestanding and embedded features that are accounted for as derivatives under the current guidance due to a failure to meet the settlement assessment by removing the requirements to (i) consider whether the contract would be settled in registered shares, (ii) consider whether collateral is required to be posted, and (iii) assess shareholder rights. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and only if adopted as of the beginning of such fiscal year. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt &#x2014; Modifications and Extinguishments (Subtopic 470-50), Compensation &#x2014; Stock Compensation (Topic 718), and Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (&#x201c;ASU 2021-04&#x201d;). ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. An entity should apply the guidance provided in ASU 2021-04 prospectively to modifications or exchanges occurring on or after the effective date. Early adoption is permitted for all entities, including adoption in an interim period. If an entity elects to early adopt ASU 2021-04 in an interim period, the guidance should be applied as of the beginning of the fiscal year that includes that interim period. The Company is currently evaluating the impact that the standard will have on its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3. COLLABORATIVE AGREEMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreements with BHK&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i) On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;), pursuant to which it is collaborative with BHK to develop and commercialize BLI-1401-2 (Botanical Drug) Triple Negative Breast Cancer (TNBC) Combination Therapy (BLI-1401-2 Products) in Asian countries excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 27, 2016, BioLite Taiwan and BHK agreed to amend the payment terms of the milestone payment in an aggregate amount of $10 million based on the following schedule:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the completion of first phase II clinical trial: $1 million, or 10% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2015, BHK has paid a non-refundable upfront cash payment of $1 million, or 10% of $10,000,000, upon the signing of BHK Co-Development Agreement. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this cash receipt as collaboration revenue when all research, technical, and development data was delivered to BHK in 2015. The receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this collaborative agreement was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this collaborative agreement. In August 2016, the Company has received the second milestone payment of NT$31,649,000, approximately equivalent to $1 million, and recognized collaboration revenue for the year ended December 31, 2016. As of the date of this report, the Company has not completed the first phase II clinical trial.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In addition to the milestone payments, BioLite Taiwan is entitled to receive royalty on 12% of BHK&#x2019;s net sales related to BLI-1401-2 Products. As of December 31, 2021 and December 31, 2020, the Company has not earned the royalty under the BHK Co-Development Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii) On December 9, 2015, BioLite Taiwan entered into another two collaborative agreements (the &#x201c;BHK Collaborative Agreements&#x201d;), pursuant to which it is collaborative with BHK to co-develop and commercialize BLI-1005 for &#x201c;Targeting Major Depressive Disorder&#x201d; (BLI-1005 Products) and BLI-1006 for &#x201c;Targeting Inflammatory Bowel Disease&#x201d; (BLI-1006 Products) in Asia excluding Japan for all related intellectual property rights, and has developed it for medicinal use in collaboration with outside researchers. The development costs shall be shared 50/50 between BHK and the Company. The BHK Co-Development Agreement will remain in effect for fifteen years from the date of first commercial sale of the Product in in Asia excluding Japan.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK. The Company concluded that the deliverables are considered separate units of accounting as the delivered items have value to the customer on a standalone basis and recognized this payment as collaboration revenue when all research, technical, data and development data was delivered to BHK. The cash receipt is for the compensation of past research efforts and contributions made by BioLite Taiwan before this BHK Collaborative Agreements was signed and it does not relate to any future commitments made by BioLite Taiwan and BHK in this BHK Collaborative Agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit. As of December 31, 2021 and 2020, the Company has not earned the royalty under the BHK Collaborative Agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Co-Development agreement with Rgene Corporation, a related party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 26, 2017, BriVision entered into a co-development agreement (the &#x201c;Co-Dev Agreement&#x201d;) with Rgene Corporation (the &#x201c;Rgene&#x201d;), a related party under common control by controlling beneficiary shareholder of YuanGene Corporation and the Company (See Note 12). Pursuant to Co-Dev Agreement, BriVision and Rgene agreed to co-develop and commercialize ABV-1507 HER2/neu Positive Breast Cancer Combination Therapy, ABV-1511 Pancreatic Cancer Combination Therapy and ABV-1527 Ovary Cancer Combination Therapy. Under the terms of the Co-Dev Agreement, Rgene is required to&#160;pay the Company $3,000,000 in cash or stock of Rgene with equivalent value by August 15, 2017. The payment is for the compensation of BriVision&#x2019;s past research efforts and contributions made by BriVision before the Co-Dev Agreement was signed and it does not relate to any future commitments made by BriVision and Rgene in this Co-Dev Agreement. In addition to $3,000,000, the Company is entitled to receive 50% of the future net licensing income or net sales profit earned by Rgene, if any, and any development costs shall be equally shared by both BriVision and Rgene.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 1, 2017, the Company has delivered all research, technical, data and development data to Rgene. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation and the Company, the Company has recorded the full amount of $3,000,000 in connection with the Co-Dev Agreement as additional paid-in capital during the year ended December 31, 2017. During the year ended December 31, 2017, the Company has received $450,000 in cash. On December 24, 2018, the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene&#x2019;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549. On December 31, 2018, the Company determined to fully write off this investment based on the Company&#x2019;s assessment of the severity and duration of the impairment, and qualitative and quantitative analysis of the operating performance of the investee, adverse changes in market conditions and the regulatory or economic environment, changes in operating structure of Rgene, additional funding requirements, and Rgene&#x2019;s ability to remain in business. All projects that have been initiated will be managed and supported by the Company and Rgene.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company and Rgene signed an amendment to the Co-Dev Agreement on November 10, 2020, pursuant to which both parties agreed to delete AB-1507 HER2/neu Positive Breast Cancer Combination Therapy and AB 1527 Ovary Cancer Combination Therapy and add ABV-1519 EGFR Positive Non-Small Cell Lung Cancer Combination Therapy and ABV-1526 Large Intestine / Colon / Rectal Cancer Combination Therapy to the products to be co-developed and commercialized. Other provisions of the Co-Dev Agreement remain in full force and effect.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span style="text-decoration:underline"&gt;Collaborative agreement with BioFirst Corporation, a related party&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 24, 2017, BriVision entered into a collaborative agreement (the &#x201c;BioFirst Collaborative Agreement&#x201d;) with BioFirst Corporation (&#x201c;BioFirst&#x201d;), pursuant to which BioFirst granted the Company the global licensing right for medical use of the product (the &#x201c;Product&#x201d;): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company because a controlling beneficiary shareholder of YuanGene Corporation and the Company is one of the directors and Common Stock shareholders of BioFirst (See Note 12).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to the BioFirst Collaborative Agreement, the Company will co-develop and commercialize the Product with BioFirst and pay BioFirst in a total amount of $3,000,000 in cash or stock of the Company before September 30, 2018. The amount of $3,000,000 is in connection with the compensation for BioFirst&#x2019;s past research efforts and contributions made by BioFirst before the BioFirst Collaborative Agreement was signed and it does not relate to any future commitments made by BioFirst and BriVision in this BioFirst Collaborative Agreement. In addition, the Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both BriVision and BioFirst.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision. The Company determined to fully expense the entire amount of $3,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount of $3,000,000 is fully expensed as research and development expense during the year ended December 31, 2017.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 30, 2019, BriVision entered into a Stock Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with BioFirst. Pursuant to the Purchase Agreement, the Company issued 428,571 shares of the Company&#x2019;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst (the &#x201c;Total Payment&#x201d;) in connection with a certain collaborative agreement between the Company and BioFirst dated July 24, 2017 (the &#x201c;Collaborative Agreement&#x201d;). Pursuant to the Collaborative Agreement, BioFirst granted the Company the global licensing right to co-develop BFC-1401 or ABV-1701 Vitreous Substitute for Vitrectomy for medical purposes in consideration for the Total Payment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 5, 2019, BriVision entered into a second Stock Purchase Agreement (&#x201c;Purchase Agreement 2&#x201d;) with BioFirst. Pursuant to Purchase Agreement 2, the Company issued 414,702 shares of the Company&#x2019;s common stock to BioFirst in consideration for $2,902,911 owed by the Company to BioFirst in connection with a loan provided to BriVision from BioFirst.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <abvc:MilestonePayments contextRef="c84" decimals="-6" unitRef="usd">10000000</abvc:MilestonePayments>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="c380">&#x25cf;Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment

    &#160;
    &#x25cf;
    Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment
  &#160;

    &#160;
    &#x25cf;
    At the completion of first phase II clinical trial: $1 million, or 10% of total payment
  &#160;

    &#160;
    &#x25cf;
    At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment
  &#160;&#160;&#x25cf;Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <abvc:UpfrontCashPayment contextRef="c85" decimals="-6" unitRef="usd">1000000</abvc:UpfrontCashPayment>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement contextRef="c86" decimals="2" unitRef="pure">0.10</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <abvc:IssuanceOfStockValue contextRef="c86" decimals="0" unitRef="usd">10000000</abvc:IssuanceOfStockValue>
    <abvc:MilestonePayments contextRef="c87" decimals="0" unitRef="twd">31649000</abvc:MilestonePayments>
    <abvc:IssuanceOfStockValue contextRef="c87" decimals="-6" unitRef="usd">1000000</abvc:IssuanceOfStockValue>
    <abvc:MilestonePaymentsRoyaltyPercentage contextRef="c5" decimals="2" unitRef="pure">0.12</abvc:MilestonePaymentsRoyaltyPercentage>
    <abvc:CollaborativeAgreementsDescription contextRef="c86">In 2015, the Company recognized the cash receipt in a total of NT$50 million, approximately equivalent to $1.6 million, as collaboration revenue when all research, technical, and development data was delivered to BHK.</abvc:CollaborativeAgreementsDescription>
    <abvc:CollaborativeAgreementsDescription contextRef="c381">In addition to the total of NT$50 million, approximately equivalent to $1.60 million, BioLite Taiwan is entitled to receive 50% of the future net licensing income or net sales profit.</abvc:CollaborativeAgreementsDescription>
    <us-gaap:PaymentsForParticipationLiabilities contextRef="c89" decimals="0" unitRef="usd">3000000</us-gaap:PaymentsForParticipationLiabilities>
    <abvc:AdditionCashPayment contextRef="c90" decimals="0" unitRef="usd">3000000</abvc:AdditionCashPayment>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement contextRef="c90" decimals="2" unitRef="pure">0.50</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c91" decimals="0" unitRef="usd">3000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="c91" decimals="0" unitRef="usd">450000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <abvc:CoDevAgreementDescription contextRef="c92">the Company received the remaining balance of $2,550,000 in the form of newly issued shares of Rgene&#x2019;s Common Stock, at the price of NT$50 (approximately equivalent to $1.60 per share), for an aggregate number of 1,530,000 shares, which accounted for equity method long-term investment as of December 31, 2018. During the year ended December 31, 2018, the Company has recognized investment loss of $549.</abvc:CoDevAgreementDescription>
    <abvc:IssuanceOfStockValue contextRef="c382" decimals="0" unitRef="usd">3000000</abvc:IssuanceOfStockValue>
    <us-gaap:PaymentsForParticipationLiabilities contextRef="c382" decimals="0" unitRef="usd">3000000</us-gaap:PaymentsForParticipationLiabilities>
    <abvc:PercentageOfPaymentsUnderCodevelopmentAgreement contextRef="c382" decimals="2" unitRef="pure">0.50</abvc:PercentageOfPaymentsUnderCodevelopmentAgreement>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c94" decimals="0" unitRef="usd">3000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c95" decimals="0" unitRef="usd">3000000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:SharesIssued contextRef="c96" decimals="0" unitRef="shares">428571</us-gaap:SharesIssued>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="c96" decimals="0" unitRef="usd">3000000</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SharesIssued contextRef="c97" decimals="0" unitRef="shares">414702</us-gaap:SharesIssued>
    <us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent contextRef="c97" decimals="0" unitRef="usd">2902911</us-gaap:DueToOtherRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4. INVENTORY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Finished goods&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;96,725&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;100,967&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Work-in-process&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,038&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Raw materials&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;84,620&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;61,718&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Allowance for inventory valuation and obsolescence loss&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,370&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(184,723&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Inventory, net&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,975&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Finished goods&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;96,725&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;100,967&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Work-in-process&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-104"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,038&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Raw materials&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;84,620&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;61,718&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Allowance for inventory valuation and obsolescence loss&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(155,370&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(184,723&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Inventory, net&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,975&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-105"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="c2" decimals="0" unitRef="usd">96725</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c3" decimals="0" unitRef="usd">100967</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess contextRef="c3" decimals="0" unitRef="usd">22038</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials contextRef="c2" decimals="0" unitRef="usd">84620</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c3" decimals="0" unitRef="usd">61718</us-gaap:InventoryRawMaterials>
    <abvc:AllowanceForInventoryValuationAndObsolescenceLoss contextRef="c2" decimals="0" unitRef="usd">-155370</abvc:AllowanceForInventoryValuationAndObsolescenceLoss>
    <abvc:AllowanceForInventoryValuationAndObsolescenceLoss contextRef="c3" decimals="0" unitRef="usd">-184723</abvc:AllowanceForInventoryValuationAndObsolescenceLoss>
    <us-gaap:InventoryNet contextRef="c2" decimals="0" unitRef="usd">25975</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5. PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property and equipment as of December 31, 2021 and 2020 are summarized as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Land&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;400,091&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;395,645&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Buildings and leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,235,061&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,233,573&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Machinery and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,013,376&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;994,544&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;191,824&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;189,760&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,840,352&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,813,522&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,314,471&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,298,688&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;525,881&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;514,834&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation expense were $11,993 and $37,142 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Land&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;400,091&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;395,645&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Buildings and leasehold improvements&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,235,061&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,233,573&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Machinery and equipment&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,013,376&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;994,544&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Office equipment&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;191,824&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;189,760&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,840,352&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3,813,522&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,314,471&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,298,688&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;525,881&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;514,834&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c99" decimals="0" unitRef="usd">400091</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c383" decimals="0" unitRef="usd">395645</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c101" decimals="0" unitRef="usd">2235061</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c384" decimals="0" unitRef="usd">2233573</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c103" decimals="0" unitRef="usd">1013376</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c385" decimals="0" unitRef="usd">994544</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c105" decimals="0" unitRef="usd">191824</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c386" decimals="0" unitRef="usd">189760</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="0" unitRef="usd">3840352</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="0" unitRef="usd">3813522</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="0" unitRef="usd">3314471</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="0" unitRef="usd">3298688</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="0" unitRef="usd">525881</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="0" unitRef="usd">514834</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c5" decimals="0" unitRef="usd">11993</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c6" decimals="0" unitRef="usd">37142</us-gaap:OtherDepreciationAndAmortization>
    <abvc:LongTermInvestmentTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6. LONG-TERM INVESTMENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The ownership percentages of each investee are listed as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership percentage&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accounting&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of related party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;treatments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.70%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.70%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.90%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.90%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.99%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.99%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31.62%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31.62%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The extent the investee relies on the company for its business are summarized as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of related party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The extent the investee relies on the Company for its business &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loaned from the investee and provides research and development support service&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-term investment mainly consists of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Non-marketable Cost Method Investments, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;7,941&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;7,853&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Genepharm Biotech Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;24,244&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;23,974&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;BioHopeKing Corporation&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;900,570&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;890,564&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;Sub total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;932,755&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;922,391&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Equity Method Investments, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;BioFirst Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;268,336&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Rgene Corporation&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;932,755&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,190,727&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(a)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;):&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company holds an equity interest in BioFirst Corporation, accounting for its equity interest using the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of December 31, 2021 and 2020, the Company owns 15.99% and 15.99% common stock shares of BioFirst, respectively. During year ended December 31, 2021, the Company made prepayment for equity investment in BioFirst to purchase additional&#160;317,000&#160;shares to be issued by BioFirst in the aggregate amount of $684,720, recorded as prepayment for long-term investments as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summarized financial information for the Company&#x2019;s equity method investee, BioFirst, is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Balance Sheet&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Current Assets&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2,205,669&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,299,822&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Noncurrent Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;959,454&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,540,041&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Current Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,909,703&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,986,340&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Noncurrent Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;32,522&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;73,197&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Stockholders&#x2019; Equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;222,898&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,780,326&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Statement of operation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net sales&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;26,693&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;257,235&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Gross profit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,348&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;10,121&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,276,892&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,401,074&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Share of losses from investments accounted for using the equity method&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(269,844&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,168,733&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(b)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Both Rgene and the Company are under common control by Dr. Tsung-Shann Jiang, the CEO and chairman of the BioLite Inc. Since Dr. Tsung-Shann Jiang is able to exercise significant influence, but not control, over the Rgene, the Company determined to use the equity method to accounts for its equity investment as prescribed in ASC 323, Investments&#x2014;Equity Method and Joint Ventures (&#x201c;ASC 323&#x201d;). Equity method adjustments include the Company&#x2019;s proportionate share of investee&#x2019;s income or loss and other adjustments required by the equity method. As of December 31, 2021 and 2020, the Company owns 31.62% and 31.62% common stock shares of Rgene, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Summarized financial information for the Company&#x2019;s equity method investee, Rgene, is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Balance Sheets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Current Assets&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;73,452&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;123,958&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Noncurrent Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;374,423&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;412,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Current Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,934,786&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,392,756&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Noncurrent Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;38,953&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Shareholders&#x2019; Deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,486,911&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(895,409&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Statement of operations&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net sales&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;16,595&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Gross Profit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(335,735&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(576,514&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(641,636&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Share of loss from investments accounted for using the equity method&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Disposition of long-term investment&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2020, the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the year ended December 31, 2020. During the year ended December 31, 2021, there is no disposition of long-term investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Losses on Equity Investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The components of losses on equity investments for each period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%"&gt;Share of equity method investee losses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;(269,844&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,168,733&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvc:LongTermInvestmentTextBlock>
    <abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Ownership percentage&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December&#160;31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accounting&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of related party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;treatments&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 68%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.17%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.70%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.70%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.90%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.90%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cost Method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.99%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.99%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31.62%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31.62%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equity Method&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c113" decimals="4" unitRef="pure">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c389" decimals="4" unitRef="pure">0.0017</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c390">Cost Method</abvc:AccountingTreatmentDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c116" decimals="4" unitRef="pure">0.007</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c391" decimals="4" unitRef="pure">0.007</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c392">Cost Method</abvc:AccountingTreatmentDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c119" decimals="4" unitRef="pure">0.059</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c393" decimals="4" unitRef="pure">0.059</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c394">Cost Method</abvc:AccountingTreatmentDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c109" decimals="4" unitRef="pure">0.1599</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c395" decimals="4" unitRef="pure">0.1599</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c107">Equity Method</abvc:AccountingTreatmentDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c122" decimals="4" unitRef="pure">0.3162</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c396" decimals="4" unitRef="pure">0.3162</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AccountingTreatmentDescription contextRef="c111">Equity Method</abvc:AccountingTreatmentDescription>
    <abvc:ScheduleOfExtentInvesteeReliesTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of related party&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 49%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;The extent the investee relies on the Company for its business &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Genepharm Biotech Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;No specific business relationship&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioHopeKing Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Loaned from the investee and provides research and development support service&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Collaborating with the Company to develop and commercialize drugs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</abvc:ScheduleOfExtentInvesteeReliesTableTextBlock>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c390">No specific business relationship</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c392">No specific business relationship</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c394">Collaborating with the Company to develop and commercialize drugs</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c107">Loaned from the investee and provides research and development support service</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c111">Collaborating with the Company to develop and commercialize drugs</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:ScheduleOfLongTermInvestmentTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Non-marketable Cost Method Investments, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left"&gt;Braingenesis Biotechnology Co., Ltd.&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;7,941&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;7,853&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;Genepharm Biotech Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;24,244&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;23,974&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;BioHopeKing Corporation&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;900,570&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;890,564&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left"&gt;Sub total&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;932,755&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;922,391&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Equity Method Investments, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left"&gt;BioFirst Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-106"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;268,336&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"&gt;Rgene Corporation&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-107"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-108"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.375in; text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;932,755&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,190,727&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfLongTermInvestmentTableTextBlock>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c124" decimals="0" unitRef="usd">7941</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c397" decimals="0" unitRef="usd">7853</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c126" decimals="0" unitRef="usd">24244</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c398" decimals="0" unitRef="usd">23974</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c128" decimals="0" unitRef="usd">900570</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c399" decimals="0" unitRef="usd">890564</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c2" decimals="0" unitRef="usd">932755</abvc:NonmarketableCostMethodInvestmentsNet>
    <abvc:NonmarketableCostMethodInvestmentsNet contextRef="c3" decimals="0" unitRef="usd">922391</abvc:NonmarketableCostMethodInvestmentsNet>
    <us-gaap:EquityMethodInvestments contextRef="c400" decimals="0" unitRef="usd">268336</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c2" decimals="0" unitRef="usd">932755</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c3" decimals="0" unitRef="usd">1190727</us-gaap:EquityMethodInvestments>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c107" decimals="4" unitRef="pure">0.1599</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c387" decimals="4" unitRef="pure">0.1599</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <abvc:PurchaseAdditionalShares contextRef="c5" decimals="0" unitRef="shares">317000</abvc:PurchaseAdditionalShares>
    <abvc:PrepaymentForLongtermInvestments contextRef="c2" decimals="0" unitRef="usd">684720</abvc:PrepaymentForLongtermInvestments>
    <pf0:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"&gt;Current Assets&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2,205,669&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,299,822&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Noncurrent Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;959,454&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,540,041&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Current Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,909,703&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,986,340&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Noncurrent Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;32,522&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;73,197&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"&gt;Stockholders&#x2019; Equity&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;222,898&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,780,326&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Current Assets&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;73,452&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;123,958&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Noncurrent Assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;374,423&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;412,342&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Current Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,934,786&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,392,756&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Noncurrent Liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;-&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;38,953&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Shareholders&#x2019; Deficit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,486,911&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(895,409&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;</pf0:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:OtherAssetsCurrent contextRef="c134" decimals="0" unitRef="usd">2205669</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c402" decimals="0" unitRef="usd">1299822</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c134" decimals="0" unitRef="usd">959454</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c402" decimals="0" unitRef="usd">2540041</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c134" decimals="0" unitRef="usd">2909703</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c402" decimals="0" unitRef="usd">1986340</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c134" decimals="0" unitRef="usd">32522</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c402" decimals="0" unitRef="usd">73197</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityOther contextRef="c136" decimals="0" unitRef="usd">222898</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c403" decimals="0" unitRef="usd">1780326</us-gaap:StockholdersEquityOther>
    <pf0:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net sales&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;26,693&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;257,235&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Gross profit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;8,348&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;10,121&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(2,276,892&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(5,401,074&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Share of losses from investments accounted for using the equity method&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(269,844&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,168,733&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Net sales&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-109"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;16,595&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Gross Profit&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-110"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(335,735&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Net loss&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(576,514&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(641,636&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;Share of loss from investments accounted for using the equity method&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-111"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-112"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</pf0:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:Revenues contextRef="c136" decimals="0" unitRef="usd">26693</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c403" decimals="0" unitRef="usd">257235</us-gaap:Revenues>
    <us-gaap:GrossProfit contextRef="c136" decimals="0" unitRef="usd">8348</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c403" decimals="0" unitRef="usd">10121</us-gaap:GrossProfit>
    <abvc:NetLoss1 contextRef="c136" decimals="0" unitRef="usd">-2276892</abvc:NetLoss1>
    <abvc:NetLoss1 contextRef="c403" decimals="0" unitRef="usd">-5401074</abvc:NetLoss1>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c136" decimals="0" unitRef="usd">-269844</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c403" decimals="0" unitRef="usd">-1168733</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c111" decimals="4" unitRef="pure">0.3162</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger contextRef="c388" decimals="4" unitRef="pure">0.3162</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:OtherAssetsCurrent contextRef="c138" decimals="0" unitRef="usd">73452</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c404" decimals="0" unitRef="usd">123958</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c138" decimals="0" unitRef="usd">374423</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c404" decimals="0" unitRef="usd">412342</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c138" decimals="0" unitRef="usd">1934786</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c404" decimals="0" unitRef="usd">1392756</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c404" decimals="0" unitRef="usd">38953</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityOther contextRef="c140" decimals="0" unitRef="usd">-1486911</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c405" decimals="0" unitRef="usd">-895409</us-gaap:StockholdersEquityOther>
    <us-gaap:Revenues contextRef="c405" decimals="0" unitRef="usd">16595</us-gaap:Revenues>
    <us-gaap:GrossProfit contextRef="c405" decimals="0" unitRef="usd">-335735</us-gaap:GrossProfit>
    <abvc:NetLoss1 contextRef="c140" decimals="0" unitRef="usd">-576514</abvc:NetLoss1>
    <abvc:NetLoss1 contextRef="c405" decimals="0" unitRef="usd">-641636</abvc:NetLoss1>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="c387">the Company sold 218,000 shares of common stock of BioHopeKing Corporation at price of NT$24, equivalent $0.85, to several individuals, and the percentage of ownership decreased to 5.90% as of December 31, 2020. As a result of the transactions, the Company recognized investment loss of $40,589 and impairment loss of $961,217 for the year ended December 31, 2020.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%"&gt;Share of equity method investee losses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 9%"&gt;(269,844&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(1,168,733&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <abvc:ShareOfEquityMethodInvesteeLosses contextRef="c5" decimals="0" unitRef="usd">-269844</abvc:ShareOfEquityMethodInvesteeLosses>
    <abvc:ShareOfEquityMethodInvesteeLosses contextRef="c6" decimals="0" unitRef="usd">-1168733</abvc:ShareOfEquityMethodInvesteeLosses>
    <abvc:ConvertibleNotesPayableDisclosureTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7. CONVERTIBLE NOTES PAYABLE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 9, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the &#x201c;Yu and Wei Note&#x201d;) in an aggregate principal amount of $300,000 to Guoliang Yu and Yingfei Wei Family Trust (the &#x201c;Yu and Wei&#x201d;), pursuant to which the Company received $300,000. The Yu and Wei Note bears interest at 8% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Yu and Wei Note, which is on November 8, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Yu and Wei Note. At any time from the date hereof until this Yu and Wei Note has been satisfied, the Yu and Wei may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Yu and Wei Note is outstanding, subject to adjustments set forth in the Yu and Wei Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Yu and Wei Note. On January 21, 2020, Yu and Wei entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Yu and Wei an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Yu and Wei&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Yu and Wei&#x201d;. The aggregate principal amount plus accrued interest expenses were $354,722, and the Company agreed to issue to the Holders an aggregate of 192,784 shares of the Company&#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock. These common shares have been issued during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 27, 2018, the Company issued an eighteen-month term unsecured convertible promissory note (the &#x201c;Keypoint Note&#x201d;) in the aggregate principal amount of $250,000 to Keypoint Technology Ltd. (&#x201c;Keypoint&#x201d;), a related party, pursuant to which the Company received $250,000. The Keypoint Note bears interest at 8% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Keypoint Note, which is on December 26, 2019. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Keypoint Note. At any time from the date hereof until this Keypoint Note has been satisfied, Keypoint may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Keypoint&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Keypoint&#x201d;. The aggregate principal amount plus accrued interest expenses were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&#x2019;s common stock. These common shares have been issued during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 25, 2018, the Company issued an eighteen-month term unsecured convertible promissory notes (the &#x201c;Odaira Note&#x201d;) in the aggregate principal amount of $250,000 to Yoshinobu Odaira. (&#x201c;Odaira&#x201d;), pursuant to which the Company received $250,000. The Odaira Note bears interest at 8% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Eighteenth (18) month anniversary of the issuance date of the Odaira Note, which is on February 24, 2020. In the event that the Company raises gross proceeds from the sale of its common stock of at least $5,000,000 (an &#x201c;Equity Offering&#x201d;) then within five days of the closing for such offering, the Company must repay the outstanding amount of this Odaira Note. At any time from the date hereof until this Odaira Note has been satisfied, Odaira may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21, 2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Odaira&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Odaira&#x201d;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s common stock. These common shares have been issued during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 30 and July 10, 2019, the Company issued two (2) twelve-month term unsecured convertible promissory notes (the &#x201c;KSL Note&#x201d;)
in an aggregate principal amount of $250,000 to Kuo Sheng Lung (the &#x201c;KSL&#x201d;), pursuant to which the Company received $160,000
and $90,000, respectively. The KSL Note bears interest at 20% per annum. The Company shall pay to KSL an amount in cash representing
all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note,
which is on May 29, 2020 and July 9, 2020. At any time from the issuance date until the KSL Note has been satisfied, the KSL may convert
the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s
common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $0.50 per share (the &#x201c;Fixed Conversion
Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of
the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form
S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time
to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of the embedded beneficial conversion
feature present in the KSL Note. On May 13, 2020, the Company received an acknowledgement letter from KSL that they will not claim the
repayment of loan for 12 months. On November 9, 2020, the Company entered into an agreement with &#x201c;KSL&#x201d;. The aggregate principal
amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to
a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company&#x2019;s common
stock and warrants for a purchase price of $270,272.&#160;During the year ended December 31, 2020, the Company issued to the Holders
an aggregate of 120,121 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 10, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#x201c;NEA Note&#x201d;) in an aggregate principal amount of $250,000 to New Eastern Asia (the &#x201c;NEA&#x201d;), a related party, pursuant to which the Company received $250,000 on July 10, 2019. The NEA Note bears interest at 20% per annum. The Company shall pay to the NEA an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the NEA Note, which is on July 9, 2020. At any time from the date hereof until this NEA Note has been satisfied, the NEA may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note. During the year ended December 31, 2020, the Company issued 111,112 shares of common stock to repay the outstanding balance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 28, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#x201c;KLS Note&#x201d;) in an aggregate principal amount of $200,000 to Kuo Li Shen (the &#x201c;KLS&#x201d;), pursuant to which the Company received $200,000 on August 28, 2019. The KLS Note bears interest at 20% per annum. The Company shall pay to the KLS an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KLS Note, which is on August 27, 2020. At any time from the date hereof until this KLS Note has been satisfied, the KLS may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have been issued during the year ended December, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On September 4, 2019, the Company issued 3 twelve-month term unsecured convertible promissory note (the &#x201c;C.L.L. Note&#x201d;) in an aggregate principal amount of $257,500 to Chang Ping Shan, Lin Shan Tyan, and Liu Ching Hsuan (together the &#x201c;C.L.L.&#x201d;), pursuant to which the Company received $257,500 on September 4, 2019. Chang Ping Shan and Liu Ching Hsuan are related parties to the Company. The C.L.L. Note bears interest at 20% per annum. The Company shall pay to the C.L.L. an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the C.L.L. Note, which is on September 3, 2020. At any time from the date hereof until this C.L.L. Note has been satisfied, the C.L.L. may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of common stock. These common shares have been issued during the year ended December 31. 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 29, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#x201c;Lee Note&#x201d;) in an aggregate principal amount of $250,000 to Hwalin Lee (the &#x201c;Lee&#x201d;), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) &lt;span style="-sec-ix-hidden: hidden-fact-113"&gt;$.&lt;/span&gt;50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note. In January 2021, the Company paid off the convertible promissory note of $306,836, including principal and accrued and unpaid interest expense.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 23, 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;October SPA&#x201d;) with one accredited investor. Pursuant to the October SPA, the Company sold and issued a convertible promissory note (the &#x201c;October Note&#x201d;) in the principal amount of $2,500,000 to the investor and received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of the October Note is the twenty-four (24) month anniversary from the issuance date (the &#x201c;Maturity Date&#x201d;). Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the Company&#x2019;s common stock at a fixed conversion price of $2.25 per share. The holder of the October Note may elect to convert part or all of the outstanding balance of the October Note from the issuance date until the Maturity Date. The Company may prepay the outstanding amount at any time, in whole or in part, without any penalty.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 17, 2021, the parties to the October SPA signed Amendment No. 1 to Promissory Note (the &#x201c;Amendment&#x201d;). Pursuant to the Amendment, the Note shall also be automatically converted into shares of the Company&#x2019;s common stock immediately following the Company&#x2019;s receipt of conditional approval to list its common stock on the NASDAQ stock market, if and when the Company receives such approval, at a conversion price equal to $2.25 per share.&#160;On July 21, 2021, The Company converted all convertible promissory note amounted $2,500,000 into 1,111,112 shares of the Company&#x2019;s common stock and warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"/&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2021 and 2020, the aggregate carrying values of the convertible debentures were $0 and $2,750,000, respectively; and accrued convertible interest was $0 and $104,551, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total interest expenses in connection with the above convertible note payable were $193,548 and $240,420 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</abvc:ConvertibleNotesPayableDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c143" decimals="0" unitRef="usd">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c144" decimals="0" unitRef="usd">300000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c144" decimals="2" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockIssued1 contextRef="c145" decimals="0" unitRef="usd">5000000</us-gaap:StockIssued1>
    <us-gaap:SharesIssuedPricePerShare contextRef="c146" decimals="2" unitRef="usdPershares">2</us-gaap:SharesIssuedPricePerShare>
    <abvc:SharesOfferingPricePercentage contextRef="c146" decimals="2" unitRef="pure">0.80</abvc:SharesOfferingPricePercentage>
    <us-gaap:CommonStockValueOutstanding contextRef="c146" decimals="0" unitRef="usd">500000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:InvestmentInterestRate contextRef="c147" decimals="2" unitRef="pure">0.20</us-gaap:InvestmentInterestRate>
    <abvc:AggregatePrincipalAndAccruedInterestExpense contextRef="c148" decimals="0" unitRef="usd">354722</abvc:AggregatePrincipalAndAccruedInterestExpense>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c148" decimals="0" unitRef="shares">192784</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c149" decimals="0" unitRef="shares">192784</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c150" decimals="0" unitRef="usd">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c151" decimals="0" unitRef="usd">250000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c151" decimals="2" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockIssued1 contextRef="c152" decimals="0" unitRef="usd">5000000</us-gaap:StockIssued1>
    <us-gaap:ConversionOfStockDescription contextRef="c151">the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Keypoint Note is outstanding, subject to adjustments set forth in the Keypoint Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Keypoint Note. On January 21, 2020, Keypoint entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Keypoint an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Keypoint&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Keypoint&#x201d;. The aggregate principal amount plus accrued interest expenses were $292,826, and the Company agreed to issue to the Holders an aggregate of 159,145 shares of the Company&#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&#x2019;s common stock.</us-gaap:ConversionOfStockDescription>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c153" decimals="0" unitRef="usd">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c154" decimals="0" unitRef="usd">250000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c154" decimals="2" unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockIssued1 contextRef="c155" decimals="0" unitRef="usd">5000000</us-gaap:StockIssued1>
    <us-gaap:ConversionOfStockDescription contextRef="c154">the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $2.00 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment or (ii) 80% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of any completed equity offering of the Company in an amount exceeding $500,000 that occurs when any part of the Odaira Note is outstanding, subject to adjustments set forth in the Odaira Note. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Odaira Note. On January 21, 2020, Odaira entered into a new agreement that the new Note bears interest at 20% per annum. The Company shall pay to the Odaira an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the new &#x201c;Odaira&#x201d; Note, which is on January 20, 2021. On April 5, 2020, the Company entered into an exchange agreement with &#x201c;Odaira&#x201d;. The aggregate principal amount plus accrued interest expenses were $284,036, and the Company agreed to issue to the Holders an aggregate of 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s common stock.</us-gaap:ConversionOfStockDescription>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c156" decimals="0" unitRef="usd">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c157" decimals="0" unitRef="usd">160000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c162" decimals="0" unitRef="usd">90000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="c157">The KSL Note bears interest at 20% per annum. The Company shall pay to KSL an amount in cash representing
all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the KSL Note,
which is on May 29, 2020 and July 9, 2020.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c157" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ConversionOfStockDescription contextRef="c157">the Company&#x2019;s
common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $0.50 per share (the &#x201c;Fixed Conversion
Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of
the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form
S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time
to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of the embedded beneficial conversion
feature present in the KSL Note. On May 13, 2020, the Company received an acknowledgement letter from KSL that they will not claim the
repayment of loan for 12 months. On November 9, 2020, the Company entered into an agreement with &#x201c;KSL&#x201d;. The aggregate principal
amount plus accrued interest expenses are $270,272, and KSL agreed to use the full amount to purchase certain securities pursuant to
a securities purchase agreement; KSL agreed to purchase and the Company agreed to issue 120,121 shares of the Company&#x2019;s common
stock and warrants for a purchase price of $270,272.&#160;During the year ended December 31, 2020, the Company issued to the Holders
an aggregate of 120,121 shares of the Company&#x2019;s common stock.</us-gaap:ConversionOfStockDescription>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c159" decimals="0" unitRef="usd">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c160" decimals="0" unitRef="usd">250000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c160" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c1" decimals="4" unitRef="pure">0.0050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConversionOfStockDescription contextRef="c406">the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the NEA Note. During the year ended December 31, 2020, the Company issued 111,112 shares of common stock to repay the outstanding balance.</us-gaap:ConversionOfStockDescription>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c164" decimals="0" unitRef="usd">200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c165" decimals="0" unitRef="usd">200000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c165" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c407" decimals="4" unitRef="pure">0.0050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConversionOfStockDescription contextRef="c408">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the KLS Note. On April 20, 2020, the Company entered into an exchange agreement with KLS. The aggregate principal amount plus accrued interest expenses were $225,222, and the Company agreed to issue to the Holders an aggregate of 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of common stock. These common shares have been issued during the year ended December, 2020.</us-gaap:ConversionOfStockDescription>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c167" decimals="0" unitRef="usd">257500</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c168" decimals="0" unitRef="usd">257500</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c168" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c409" decimals="4" unitRef="pure">0.0050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConversionOfStockDescription contextRef="c168">In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the C.L.L. Note. On April 20, 2020, the Company entered into an exchange agreement with C.L.L.. The aggregate principal amount plus accrued interest expenses were $289,974, and the Company agreed to issue to the Holders an aggregate of 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of common stock. These common shares have been issued during the year ended December 31. 2020.On October 29, 2019, the Company issued a twelve-month term unsecured convertible promissory note (the &#x201c;Lee Note&#x201d;) in an aggregate principal amount of $250,000 to Hwalin Lee (the &#x201c;Lee&#x201d;), a related party, pursuant to which the Company received $250,000 on October 29, 2019. The Lee Note bears interest at 20% per annum. The Company shall pay to the Lee an amount in cash representing all outstanding principal and accrued and unpaid interest on the Twelve (12) month anniversary of the issuance date of the Lee Note, which is on October 28, 2020. At any time from the date hereof until this Lee Note has been satisfied, the Lee may convert the unpaid and outstanding principal plus any accrued and unpaid interest and or default interest, if any, into shares of the Company&#x2019;s common stock at a conversion price (the &#x201c;Conversion Price&#x201d;) equal to the lower of (i) $.50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time.</us-gaap:ConversionOfStockDescription>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c169" decimals="0" unitRef="usd">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c170" decimals="0" unitRef="usd">250000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod contextRef="c170" decimals="2" unitRef="pure">0.20</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ConversionOfStockDescription contextRef="c411">50 per share (the &#x201c;Fixed Conversion Price&#x201d;), subject to adjustment, or (ii) 70% of the per share offering price (the &#x201c;Alternative Conversion Price&#x201d;) of the completed public equity offering of the Company in an amount exceeding $10,000,000 as stated on the registration statement on a Form S-1 filed with the Securities and Exchange Commission on November 14, 2018 (the &#x201c;Public Offering&#x201d;), as amended from time to time. In accordance with FASB ASC 470-20, the Company recognized none of the intrinsic value of embedded beneficial conversion feature present in the Lee Note. In January 2021, the Company paid off the convertible promissory note of $306,836, including principal and accrued and unpaid interest expense.</us-gaap:ConversionOfStockDescription>
    <us-gaap:ConversionOfStockDescription contextRef="c171">Pursuant to the October SPA, the Company sold and issued a convertible promissory note (the &#x201c;October Note&#x201d;) in the principal amount of $2,500,000 to the investor and received the payment from such investor on October 30, 2020. The October Note was issued on October 23, 2020 and the maturity date of the October Note is the twenty-four (24) month anniversary from the issuance date (the &#x201c;Maturity Date&#x201d;). Upon the Maturity Date, the Company shall pay to the holder, in cash, an amount representing all outstanding principal amount and accrued and unpaid interest under the October Note. The October Note bears an interest rate of ten percent (10%) per annum and may be convertible into shares of the Company&#x2019;s common stock at a fixed conversion price of $2.25 per share.</us-gaap:ConversionOfStockDescription>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c172" decimals="2" unitRef="usdPershares">2.25</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abvc:ConvertiblePromissoryNote contextRef="c173" decimals="0" unitRef="usd">2500000</abvc:ConvertiblePromissoryNote>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c174" decimals="0" unitRef="shares">1111112</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConvertibleDebt contextRef="c412" decimals="0" unitRef="usd">0</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt contextRef="c413" decimals="0" unitRef="usd">2750000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c414" decimals="0" unitRef="usd">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c415" decimals="0" unitRef="usd">104551</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <abvc:TotalInterestExpenses contextRef="c414" decimals="0" unitRef="usd">193548</abvc:TotalInterestExpenses>
    <abvc:TotalInterestExpenses contextRef="c415" decimals="0" unitRef="usd">240420</abvc:TotalInterestExpenses>
    <abvc:BankLoansTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8. BANK LOANS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term bank loan consists of the following:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Cathay United Bank&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;270,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;267,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;CTBC Bank&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;720,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;712,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Cathay Bank&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;650,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;650,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,640,000&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,629,000&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Cathay United Bank&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 28, 2016, BioLite Taiwan and Cathay United Bank entered into a one-year bank loan agreement (the &#x201c;Cathay United Loan Agreement&#x201d;) in an amount of NT$7,500,000, equivalent to $270,000. The term started June 28, 2016 with maturity date at June 28, 2017. The loan balance bears interest at a floating rate of prime rate plus 1.15%. The prime rate is based on term deposit saving interest rate of Cathay United Bank. On September 6, 2017, BioLite Taiwan extended the Cathay United Loan Agreement for one year, which was due on September 6, 2018, with the principal amount of NT$7,500,000, equivalent to $270,000. On October 1, 2018, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $270,000 for one year, which was due on September 6, 2019. On September 6, 2019, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $270,000 for one year, which is due on September 6, 2020. On September 6, 2020, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $270,000 for one year, which is due on September 6, 2021. On September 6, 2021, BioLite Taiwan extended the Cathay United Loan Agreement with the same principal amount of NT$7,500,000, equivalent to $270,000 for one year, which is due on September 6, 2022. As of December 31, 2021 and December 31, 2020, the effective interest rates per annum was 2.1%. The loan is collateralized by the building and improvement of BioLite Taiwan, and is also personal guaranteed by the Company&#x2019;s chairman.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest expenses were $5,639 and $5,280 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;CTBC Bank&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 12, 2017 and July 19, 2017, BioLite Taiwan and CTBC Bank entered into short-term saving secured bank loan agreements (the &#x201c;CTBC Loan Agreements&#x201d;) in an amount of NT$10,000,000, equivalent to $360,000, and NT$10,000,000, equivalent to $360,000, respectively. Both two loans with the same maturity date at January 19, 2018. In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year. On January 18, 2019, BioLite Taiwan and CTBC Bank agreed to extend the loan with a new maturity date, which was July 18, 2019. On July 18, 2019, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on January 17, 2020. On January 19, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on July 19, 2020. On July 17, 2020, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on January 15, 2021. On January 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on July 15, 2021. On July 15, 2021, BioLite Taiwan extended the CTBC Loan Agreement with the same principal amount of NT$20,000,000, equivalent to $720,000 for six months, which is due on January 14, 2022. The loan balances bear interest at a fixed rate of 1.68% per annum. The loan is secured by the money deposited in a savings account with the CTBC Bank. This loan was also personal guaranteed by the Company&#x2019;s chairman and BioFirst. During the year ended December 31, 2021, BioLite Taiwan has opened a TCD account with CTBC bank to guarantee the loan going forward.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest expenses were $12,029 and $11,395 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Cathay Bank&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 21, 2019, the Company received a loan in the amount of $500,000 from Cathay Bank (the &#x201c;Bank&#x201d;) pursuant to a business loan agreement (the &#x201c;Loan Agreement&#x201d;) entered by and between the Company and Bank on January 8, 2019 and a promissory note (the &#x201c;Note&#x201d;) executed by the Company on the same day. The Loan Agreement provides for a revolving line of credit in the principal amount of $1,000,000 with a maturity date (the &#x201c;Maturity Date&#x201d;) of January 1, 2020. The Note executed in connection with the Loan Agreement bears an interest rate (the &#x201c;Regular Interest Rate&#x201d;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the &#x201c;Index&#x201d;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In connection with the Note and Loan Agreement, on January 8, 2019, each of Dr. Tsung Shann Jiang and Dr. George Lee, executed a commercial guaranty (the &#x201c;Guaranty&#x201d;) to guaranty the loans for the Company pursuant to the Loan Agreement and Note, severally and individually, in the amount not exceeding $500,000 each until the entire Note plus interest are fully paid and satisfied. Dr. Tsung Shann Jiang is the Chairman and Chief Executive Officer of BioLite Holding, Inc. and Dr. George Lee serves as the Chairman of the board of directors of BioKey. On December 29, 2020, the Company entered into a new loan extension agreement and assignment of deposit account with the Bank, which allowed Dr. Tsung Shann Jiang and Dr. George Lee to be removed as guarantees from the list of Guaranty.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In addition, on January 8, 2019, each of the Company and BioKey, a wholly-owned subsidiary of the Company, signed a commercial security agreement (the &#x201c;Security Agreement&#x201d;) to secure the loans under the Loan Agreement and the Note. Pursuant to the Security Agreements, each of the Company and BioKey (each, a &#x201c;Grantor&#x201d;, and collectively, the &#x201c;Grantors&#x201d;) granted security interest in the collaterals as defined therein, comprised of almost all of the assets of each Grantor, to secure such loans for the benefit of the Bank. On March 31, 2020, the Company extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020. On April 8, 2020 and October 3, 2020, the Company repaid an aggregated principal amount of $350,000. On December 3, 2020, The Company renewed the Loan Agreement with the principal amount of $650,000 for ten months, which is due on October 31, 2021. On September 30, 2021, the Cathay Bank has increased the line of credit to $1,000,000 from $650,000. The outstanding loan balance was $650,000 as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest expenses were $18,143 and $53,992 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</abvc:BankLoansTextBlock>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"&gt;Cathay United Bank&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;270,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;267,000&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left"&gt;CTBC Bank&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;720,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;712,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"&gt;Cathay Bank&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;650,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;650,000&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="vertical-align: top; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;Total&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,640,000&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,629,000&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:ShortTermBorrowings contextRef="c235" decimals="0" unitRef="usd">270000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c456" decimals="0" unitRef="usd">267000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c236" decimals="0" unitRef="usd">720000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c457" decimals="0" unitRef="usd">712000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c232" decimals="0" unitRef="usd">650000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c458" decimals="0" unitRef="usd">650000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c2" decimals="0" unitRef="usd">1640000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings contextRef="c3" decimals="0" unitRef="usd">1629000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c416" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c417" decimals="0" unitRef="usd">270000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c179">2017-06-28</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c178" decimals="4" unitRef="pure">0.0115</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c180">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c418" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c419" decimals="0" unitRef="usd">270000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c420" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c421" decimals="0" unitRef="usd">270000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c422">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c423" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c424" decimals="0" unitRef="usd">270000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c188">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c425" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c426" decimals="0" unitRef="usd">270000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c191">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c427" decimals="0" unitRef="twd">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c428" decimals="0" unitRef="usd">270000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c429">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c3" decimals="3" unitRef="pure">0.021</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c235" decimals="3" unitRef="pure">0.021</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestAndDebtExpense contextRef="c430" decimals="0" unitRef="usd">5639</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c431" decimals="0" unitRef="usd">5280</us-gaap:InterestAndDebtExpense>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c432" decimals="0" unitRef="twd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c433" decimals="0" unitRef="usd">360000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c434" decimals="0" unitRef="twd">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c435" decimals="0" unitRef="usd">360000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c203">2018-01-19</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentPaymentTerms contextRef="c436">In February 2018, BioLite Taiwan combined two loans and extended the loan contract with CTBC for one year.</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentTerm contextRef="c203">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c437" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c438" decimals="0" unitRef="usd">720000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c206">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c439" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c440" decimals="0" unitRef="usd">720000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c209">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c441" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c442" decimals="0" unitRef="usd">720000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c212">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c443" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c444" decimals="0" unitRef="usd">720000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c215">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c445" decimals="0" unitRef="twd">20000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c446" decimals="0" unitRef="usd">720000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c218">P6M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c236" decimals="4" unitRef="pure">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestAndDebtExpense contextRef="c447" decimals="0" unitRef="usd">12029</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c448" decimals="0" unitRef="usd">11395</us-gaap:InterestAndDebtExpense>
    <abvc:ReceivedLoanAmount contextRef="c223" decimals="0" unitRef="usd">500000</abvc:ReceivedLoanAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c224" decimals="0" unitRef="usd">1000000</us-gaap:DebtInstrumentFaceAmount>
    <abvc:RegularInterestRateDescription contextRef="c225">The Note executed in connection with the Loan Agreement bears an interest rate (the &#x201c;Regular Interest Rate&#x201d;) equal to the sum of one percent (1%) and the prime rate as published in the Wall Street Journal (the &#x201c;Index&#x201d;) and the accrued interest shall become payable each month from February 1, 2019. Pursuant to the Note, the Company shall pay the entire outstanding principal plus accrued unpaid interest on the Maturity Date and may prepay portion or all of the Note before the Maturity Date without penalty. If the Company defaults on the Note, the default interest rate shall become five percent (5%) plus the Regular Interest Rate.</abvc:RegularInterestRateDescription>
    <abvc:ExceedingAmount contextRef="c226" decimals="0" unitRef="usd">500000</abvc:ExceedingAmount>
    <abvc:RegularInterestRateDescription contextRef="c449">On March 31, 2020, the Company extended the Loan Agreement with the same term for seven months, which is due on October 31, 2020.</abvc:RegularInterestRateDescription>
    <abvc:ReceivedLoanAmount contextRef="c450" decimals="0" unitRef="usd">350000</abvc:ReceivedLoanAmount>
    <abvc:ReceivedLoanAmount contextRef="c227" decimals="0" unitRef="usd">350000</abvc:ReceivedLoanAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c229" decimals="0" unitRef="usd">650000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm contextRef="c451">P10M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c452" decimals="0" unitRef="usd">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c453" decimals="0" unitRef="usd">650000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermLineOfCredit contextRef="c232" decimals="0" unitRef="usd">650000</us-gaap:LongTermLineOfCredit>
    <us-gaap:InterestAndDebtExpense contextRef="c454" decimals="0" unitRef="usd">18143</us-gaap:InterestAndDebtExpense>
    <us-gaap:InterestAndDebtExpense contextRef="c455" decimals="0" unitRef="usd">53992</us-gaap:InterestAndDebtExpense>
    <abvc:PaycheckProtectionProgramLoanPayableTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9. PAYCHECK PROTECTION PROGRAM LOAN PAYABLE&lt;/b&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 14, 2020, the Company received a loan in the amount of $124,400 under the Paycheck Protection Program (&#x201c;PPP&#x201d;) administered by the United States Small Business Administration (the &#x201c;SBA&#x201d;) from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;Cares Act&#x201d;), PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The loan was granted pursuant to a promissory note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is two years after the date of the promissory note. In addition, the Company will pay regular monthly payments in an amount equal to one month&#x2019;s accrued interest commencing on the date that is seven months after the date of the promissory note, with all subsequent interest payments to be due on the same day of each month after that. No collateral or personal guarantees are required.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 29, 2021, BioKey received a loan in the amount of $132,331 under the Paycheck Protection Program administered by the United States Small Business Administration from East West Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated January 27, 2021 issued by the Company, which matures on January 28, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. No collateral or personal guarantees are required.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 7, 2021, the Company received a loan in the amount of $104,167 under the Paycheck Protection Program administered by the United States Small Business Administration from Cathay Bank. According to the Coronavirus Aid, Relief, and Economic Security Act, PPP loan provides for forgiveness of up to the full principal amount and accrued interest if the funds are used for payroll costs, interest on mortgages, rent, and utilities. However, at least 60% of the forgiven amount must have been used for payroll. The loan was granted pursuant to a promissory note dated February 7, 2021 issued by the Company, which matures on February 6, 2026 and bears interest at a rate of 1.00% per annum. The Company will pay the principal in one payment of all outstanding principal plus all accrued unpaid interest on that date that is five years after the date of the promissory note. No collateral or personal guarantees are required.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;PPP loan Forgiveness&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 27, 2021, the Company submitted all required documents, such as application form and use of funds,&#160;to East West Bank for the application of forgiveness. The PPP loan from East West Bank of $124,400 and $132,331 was forgiven by the SBA as a gesture of supporting the operation of the Company on March 15, 2021 and September 28, 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On September 23, 2021, the Company submitted the required documents, such as application form and use of funds,&#160;to Cathay Bank for the application of forgiveness. The PPP loan from Cathay Bank of $104,167 was forgiven by the SBA as a gesture of supporting the operation of the Company on November 15, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As a result, the Company recorded the forgiveness of the PPP loans as government grant income in the aggregate amount of $360,898 during the year ended December 31, 2021&#160;&lt;/span&gt;&lt;/p&gt;</abvc:PaycheckProtectionProgramLoanPayableTextBlock>
    <abvc:LoanFromPaycheckProtectionProgram contextRef="c237" decimals="0" unitRef="usd">124400</abvc:LoanFromPaycheckProtectionProgram>
    <abvc:ForgivenAmountPercentageUsedForPayroll contextRef="c237" decimals="2" unitRef="pure">0.60</abvc:ForgivenAmountPercentageUsedForPayroll>
    <us-gaap:DebtInstrumentPaymentTerms contextRef="c238">The loan was granted pursuant to a promissory note dated April 14, 2020 issued by the Company, which matures on April 13, 2022 and bears interest at a rate of 1.00% per annum.</us-gaap:DebtInstrumentPaymentTerms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c239" decimals="4" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <abvc:LoanFromPaycheckProtectionProgram contextRef="c240" decimals="0" unitRef="usd">132331</abvc:LoanFromPaycheckProtectionProgram>
    <us-gaap:DebtInstrumentDescription contextRef="c240">60%</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c459" decimals="4" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <abvc:LoanFromPaycheckProtectionPrograms contextRef="c241" decimals="0" unitRef="usd">104167</abvc:LoanFromPaycheckProtectionPrograms>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c242" decimals="4" unitRef="pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <abvc:LoanAmout contextRef="c243" decimals="0" unitRef="usd">124400</abvc:LoanAmout>
    <us-gaap:DebtInstrumentDecreaseForgiveness contextRef="c244" decimals="0" unitRef="usd">132331</us-gaap:DebtInstrumentDecreaseForgiveness>
    <us-gaap:DebtInstrumentDecreaseForgiveness contextRef="c245" decimals="0" unitRef="usd">104167</us-gaap:DebtInstrumentDecreaseForgiveness>
    <abvc:GovernmentGrantIncome contextRef="c5" decimals="0" unitRef="usd">360898</abvc:GovernmentGrantIncome>
    <us-gaap:MortgageNotesPayableDisclosureTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10. NOTES PAYABLE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working capital purpose. On September 11, 2021 the outstanding balance has been repaid in full. As of December 31, 2021 and 2020, the balance due to this individual amounted to $0 and $106,800, respectively.&#160;Interest expense was $8,592 and $12,204 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:MortgageNotesPayableDisclosureTextBlock>
    <abvc:UnsecuredLoanAgreementsDescription contextRef="c246">In January, 2019, BioLite Taiwan entered an unsecured loan agreement with one individual bearing interest at fixed rates at 12% per annum of NT$3,000,000, equivalent to $106,800, for working capital purpose.</abvc:UnsecuredLoanAgreementsDescription>
    <us-gaap:OtherNotesPayable contextRef="c2" decimals="0" unitRef="usd">0</us-gaap:OtherNotesPayable>
    <us-gaap:OtherNotesPayable contextRef="c3" decimals="0" unitRef="usd">106800</us-gaap:OtherNotesPayable>
    <us-gaap:InterestExpenseOther contextRef="c5" decimals="0" unitRef="usd">8592</us-gaap:InterestExpenseOther>
    <us-gaap:InterestExpenseOther contextRef="c6" decimals="0" unitRef="usd">12204</us-gaap:InterestExpenseOther>
    <us-gaap:ShortTermDebtTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11. SHORT-TERM LOAN&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 18, 2020, the Company entered an unsecured loan agreement with a third-party in the amount of $100,000. This loan bears the interest rate of 1.5% per annum and will be matured on August 17, 2020. On August 18, 2020, the Company extended the contract for six months under the same term. On February 18, 2021, the Company extended the contract for six months under the same term. On August 26, 2021, the loan with interest totaling $102,272 has been repaid in full. Accrued interest expense was $0 and $1,302 as of December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:UnsecuredDebt contextRef="c247" decimals="0" unitRef="usd">100000</us-gaap:UnsecuredDebt>
    <us-gaap:ShortTermDebtInterestRateIncrease contextRef="c248" decimals="3" unitRef="pure">0.015</us-gaap:ShortTermDebtInterestRateIncrease>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c248">2020-08-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LoansReceivableWithFixedRatesOfInterest1 contextRef="c460" decimals="0" unitRef="usd">102272</us-gaap:LoansReceivableWithFixedRatesOfInterest1>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c5" decimals="0" unitRef="usd">0</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="c6" decimals="0" unitRef="usd">1302</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12. RELATED PARTIES TRANSACTIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The related parties of the company with whom transactions are reported in these financial statements are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of entity or Individual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company and its subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;YuanGene Corporation (the &#x201c;YuanGene&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Controlling beneficiary shareholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AsiaGene Corporation (the &#x201c;AsiaGene&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Eugene Jiang&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Former President and Chairman&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Keypoint Technology Ltd. (the &#x201c;Keypoint&#x2019;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Chairman of Keypoint is Eugene Jiang&#x2019;s mother.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lion Arts Promotion Inc. (the &#x201c;Lion Arts&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Yoshinobu Odaira (the &#x201c;Odaira&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GenePharm Inc. (the &#x201c;GenePharm&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Euro-Asia Investment &amp;amp; Finance Corp Ltd. (the &#x201c;Euro-Asia&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LBG USA, Inc. (the &#x201c;LBG USA&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LionGene Corporation (the &#x201c;LionGene&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Kimho Consultants Co., Ltd. (the &#x201c;Kimho&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ms.
Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and
a member of board of directors of BioLite Inc.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director
of the Company.&lt;/span&gt;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amkey Ventures, LLC (&#x201c;Amkey&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable - related parties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounts receivable due from related parties consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;GenePharm Inc.&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;142,225&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;142,225&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Rgene&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,374&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Amkey&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;800&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,210&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;145,399&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;143,435&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Due from related parties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amount due from related parties consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Rgene&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;49,110&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;42,911&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;AsiaGene&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,241&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;468,435&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst (Australia)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;491,816&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;373,235&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioHopeKing Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;124,972&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;123,583&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;LBG USA&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;675&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;675&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioLite Japan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;150,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;150,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Keypoint&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,610&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,610&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,286,618&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;696,255&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0in"/&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2021 and 2020, due from Rgene amounted to $49,110 and $42,911,respectively. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the maturity date was December 31, 2020. As of December 31, 2021, and December 31, 2020, the outstanding loan balance was $33,520 and $31,684; and accrued interest was $13,701 and $11,227, respectively. On January 1, 2021, BioLite Taiwan entered into a consultant services agreement with Rgene, of which the amount due from Rgene was $1,889 for the year ended December 31, 2021.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 27, 2019, the Company entered into loan agreements with AsiaGene for NT $100,000, equivalent to $3,560, to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the loan maturity date was December 31, 2020. The loan has been repaid in full during the year of 2021. As of December 31, 2021 and 2020, the outstanding loan balance was $0 and $3,560, and accrued interest was $0 and $681, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On November 2, 2021, November 12, 2021 and December 20, 2021, the Company and BioFirst entered into loan agreements for a total amount of $45,000, $140,000, and $280,000, respectively, to meet its working capital needs. The loan will be matured on November 1, 2022, November 11, 2022, and December 19, 2022, respectively, all with an interest rate of 6.5% per annum. As of December 31, 2021, and December 31, 2020, the outstanding loan balance was $465,000 and $0; and accrued interest was $3,435 and $0, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 1, 2020, the Company entered into a loan agreement with BioFirst (Australia) for $361,487 to properly record R&amp;amp;D cost and tax refund allocation based on co-development contract executed on July 24, 2017. The loan was originally set to be mature on September 30, 2021 with an interest rate of 6.5% per annum, but on September 7, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $67,873 to meet its new project needs. On December 1, 2021, the Company entered into a loan agreement with BioFirst (Australia) for $250,000 to increase the cost for upcoming projects. The loan will be matured on November 30, 2022 with an interest rate of 6.5% per annum. As of December 31, 2021 and 2020, the aggregate amount of outstanding loan and accrued interest was $491,816 and $373,235, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 24, 2015, BioLite Taiwan and BioHopeKing Corporation (the &#x201c;BHK&#x201d;) entered into a co-development agreement, (the &#x201c;BHK Co-Development Agreement&#x201d;, see Note 3). The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK. As of December 31, 2021 and 2020, due from BHK was $124,972 and $123,583, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 27, 2019, the Company has advanced funds to LBG USA for working capital purpose. The advances bear 0% interest rate and are due on demand. As of December 31, 2021 and 2020, the outstanding advance balances was $675 and $675, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 8, 2020, the Company and Lucidaim entered into a Letter of Intent (LOI) in regard to a potential joint venture of BioLite Japan. Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan&#x2019;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate. As of December 31, 2021 and 2020, the outstanding advance balances was $150,000 and $150,000, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(8)&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 31, 2020, the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021. As of December 31, 2021 and 2020, the outstanding loan balance was $1,610 and $1,610, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration:underline"&gt;Due to related parties&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amount due to related parties consisted of the following as of the periods indicated:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst Corporation&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;40,878&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;23,647&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst (Australia)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;132,443&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;AsiaGene&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;24,017&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;YuanGene&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;9,205&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;9,205&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;The Jiangs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;18,750&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;16,627&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Due to shareholders&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;168,131&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;166,261&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Due to employee&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72,705&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;393,424&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;288,445&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0in"/&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2019, BioFirst has advanced funds to the Company for working capital purpose. The advances bear interest 1% per month (or equivalent to 12% per annum). As of December 31, 2021 and 2020, the aggregate amount of outstanding balance and accrued interest is $40,878 and $23,647, respectively.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0in"/&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2021 and 2020, BioFirst (Australia) has advanced the Company an aggregate amount of $132,443 and $0, respectively for new project purpose.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0in"/&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2021 and 2020, AsiaGene has advanced the Company an aggregate amount of $24,017 and $0, respectively for working capital purpose. This advance bears 0% interest rate and is due on demand.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0in"/&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As of December 31, 2021 and 2020, YuanGene has advanced the Company an aggregate amount of $9,205 for working capital purpose. This advance bears 0% interest rate and is due on demand.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0in"/&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2019, the Jiangs advanced funds to the Company for working capital purpose. As of December 31, 2021 and 2020, the outstanding balance due to the Jiangs amounted to $18,750 and $16,627, respectively. These loans bear interest rate of 0% to 1% per month, and are due on demand.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0in"/&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(6)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Since 2018, the Company&#x2019;s shareholders have advanced funds to the Company for working capital purpose. The advances bear interest rate from 12% to 13.6224% per annum. As of December 31, 2021 and 2020, the outstanding principal and accrued interest was $168,131 and $166,261, respectively. Interest expenses in connection with these loans were $22,779 and $21,520 for the year ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0in"/&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(7)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commencing January, 2020, the Company had advances from one employee for working capital purpose. The outstanding balance including accrued interest due to this employee amounted to $0 and $72,705 as of December 31, 2021 and 2020, respectively. This loan bears interest rate of 1.5% per annum, and the loan with interest has been repaid in full during the year ended December 31, 2021.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%;"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 30%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Name of entity or Individual&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 68%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Relationship with the Company and its subsidiaries&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst Corporation (the &#x201c;BioFirst&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioFirst (Australia) Pty Ltd. (the &#x201c;BioFirst (Australia)&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Rgene Corporation (the &#x201c;Rgene&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;YuanGene Corporation (the &#x201c;YuanGene&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Controlling beneficiary shareholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;AsiaGene Corporation (the &#x201c;AsiaGene&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Eugene Jiang&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Former President and Chairman&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Keypoint Technology Ltd. (the &#x201c;Keypoint&#x2019;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Chairman of Keypoint is Eugene Jiang&#x2019;s mother.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lion Arts Promotion Inc. (the &#x201c;Lion Arts&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Yoshinobu Odaira (the &#x201c;Odaira&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Director of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;GenePharm Inc. (the &#x201c;GenePharm&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Euro-Asia Investment &amp;amp; Finance Corp Ltd. (the &#x201c;Euro-Asia&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LBG USA, Inc. (the &#x201c;LBG USA&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;LionGene Corporation (the &#x201c;LionGene&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Kimho Consultants Co., Ltd. (the &#x201c;Kimho&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shareholder of the Company&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ms.
Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and
a member of board of directors of BioLite Inc.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director
of the Company.&lt;/span&gt;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; "&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amkey Ventures, LLC (&#x201c;Amkey&#x201d;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;BioLite Japan&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entity controlled by controlling beneficiary shareholder of ABVC&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c483">Entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c484">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c485">Shareholder of the Company; entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c486">Controlling beneficiary shareholder of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c487">Shareholder; entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c488">Former President and Chairman</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c489">The Chairman of Keypoint is Eugene Jiang&#x2019;s mother.</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c490">Shareholder of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c491">Director of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c492">Dr. George Lee, Board Director of Biokey, is the Chairman of GenePharm.</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c493">Shareholder of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c494">100% owned by BioFirst; Entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c495">Shareholder of the Company; Entity controlled by controlling beneficiary shareholder of YuanGene</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c496">Shareholder of the Company</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c497">Mr. Tsung-Shann Jiang, the controlling beneficiary shareholder of the Company and Rgene, the Chairman and CEO of the BioLite Holding Inc. and BioLite Inc. and the President and a member of board of directors of BioFirst &#160; Ms.
Shu-Ling Jiang, Mr. Tsung-Shann Jiang&#x2019;s wife, is the Chairman of Keypoint; and a member of board of directors of BioLite Inc. &#160; Mr. Eugene Jiang is Mr. and Ms. Jiang&#x2019;s son. Mr. Eugene Jiang is the chairman, and majority shareholder of the Company and
a member of board of directors of BioLite Inc. &#160; Mr. Chang-Jen Jiang is Mr. Tsung-Shann Jiang&#x2019;s sibling and the director
of the Company. &#160; Ms. Mei-Ling Jiang is Ms. Shu-Ling Jiang&#x2019;s sibling.</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c498">An entity controlled by Dr. George Lee, who serves as one of the board directors of BioKey, Inc</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:RelatedPartyTransactionDescriptionOfTransactions contextRef="c499">Entity controlled by controlling beneficiary shareholder of ABVC</abvc:RelatedPartyTransactionDescriptionOfTransactions>
    <abvc:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;GenePharm Inc.&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;142,225&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;142,225&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Rgene&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,374&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-114"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Amkey&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;800&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,210&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;145,399&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;143,435&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c299" decimals="0" unitRef="usd">142225</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c500" decimals="0" unitRef="usd">142225</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c138" decimals="0" unitRef="usd">2374</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c301" decimals="0" unitRef="usd">800</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c501" decimals="0" unitRef="usd">1210</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c2" decimals="0" unitRef="usd">145399</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties contextRef="c3" decimals="0" unitRef="usd">143435</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Rgene&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;49,110&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;42,911&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;AsiaGene&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-115"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;4,241&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;468,435&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-116"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst (Australia)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;491,816&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;373,235&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioHopeKing Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;124,972&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;123,583&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;LBG USA&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;675&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;675&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioLite Japan&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;150,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;150,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Keypoint&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,610&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,610&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,286,618&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;696,255&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c138" decimals="0" unitRef="usd">49110</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c404" decimals="0" unitRef="usd">42911</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c502" decimals="0" unitRef="usd">4241</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c134" decimals="0" unitRef="usd">468435</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c302" decimals="0" unitRef="usd">491816</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c503" decimals="0" unitRef="usd">373235</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c128" decimals="0" unitRef="usd">124972</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c399" decimals="0" unitRef="usd">123583</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c304" decimals="0" unitRef="usd">675</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c504" decimals="0" unitRef="usd">675</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c268" decimals="0" unitRef="usd">150000</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c474" decimals="0" unitRef="usd">150000</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c306" decimals="0" unitRef="usd">1610</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c505" decimals="0" unitRef="usd">1610</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">1286618</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DueFromtheRelatedPartiesCurrent contextRef="c3" decimals="0" unitRef="usd">696255</abvc:DueFromtheRelatedPartiesCurrent>
    <abvc:DebtInstrumentAggregateAmount contextRef="c132" decimals="0" unitRef="usd">49110</abvc:DebtInstrumentAggregateAmount>
    <abvc:DebtInstrumentAggregateAmount contextRef="c401" decimals="0" unitRef="usd">42911</abvc:DebtInstrumentAggregateAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c461" decimals="0" unitRef="usd">33520</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c462" decimals="0" unitRef="usd">31684</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <abvc:AccruedInterest contextRef="c132" decimals="0" unitRef="usd">13701</abvc:AccruedInterest>
    <abvc:AccruedInterest contextRef="c401" decimals="0" unitRef="usd">11227</abvc:AccruedInterest>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="c2" decimals="0" unitRef="usd">1889</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c463" decimals="0" unitRef="usd">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c464" decimals="0" unitRef="usd">3560</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <abvc:AccruedInterest contextRef="c465" decimals="0" unitRef="usd">0</abvc:AccruedInterest>
    <abvc:AccruedInterest contextRef="c466" decimals="0" unitRef="usd">681</abvc:AccruedInterest>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="c136">the Company and BioFirst entered into loan agreements for a total amount of $45,000, $140,000, and $280,000, respectively, to meet its working capital needs. The loan will be matured on November 1, 2022, November 11, 2022, and December 19, 2022, respectively, all with an interest rate of 6.5% per annum.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c136" decimals="0" unitRef="usd">465000</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c403" decimals="0" unitRef="usd">0</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <abvc:AccruedInterest contextRef="c134" decimals="0" unitRef="usd">3435</abvc:AccruedInterest>
    <abvc:AccruedInterest contextRef="c402" decimals="0" unitRef="usd">0</abvc:AccruedInterest>
    <abvc:DebtInstrumentAggregateAmount contextRef="c252" decimals="0" unitRef="usd">361487</abvc:DebtInstrumentAggregateAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c253" decimals="3" unitRef="pure">0.065</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:DebtInstrumentAggregateAmount contextRef="c467" decimals="0" unitRef="usd">67873</abvc:DebtInstrumentAggregateAmount>
    <abvc:DebtInstrumentAggregateAmount contextRef="c468" decimals="0" unitRef="usd">250000</abvc:DebtInstrumentAggregateAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c468" decimals="3" unitRef="pure">0.065</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c260" decimals="0" unitRef="usd">491816</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c469" decimals="0" unitRef="usd">373235</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="c261">The development costs shall be shared 50/50 between BHK and the Company. Under the term of the agreement, BioLite issued relevant development cost to BHK.</us-gaap:DebtInstrumentInterestRateTerms>
    <us-gaap:DueFromOtherRelatedParties contextRef="c470" decimals="0" unitRef="usd">124972</us-gaap:DueFromOtherRelatedParties>
    <us-gaap:DueFromOtherRelatedParties contextRef="c471" decimals="0" unitRef="usd">123583</us-gaap:DueFromOtherRelatedParties>
    <abvc:AdvancesBearInterestDescription contextRef="c472">The advances bear 0% interest rate and are due on demand.</abvc:AdvancesBearInterestDescription>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c263" decimals="2" unitRef="pure">0</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:OutstandingAdvanceFromRelatedParty contextRef="c265" decimals="0" unitRef="usd">675</abvc:OutstandingAdvanceFromRelatedParty>
    <abvc:OutstandingAdvanceFromRelatedParty contextRef="c473" decimals="0" unitRef="usd">675</abvc:OutstandingAdvanceFromRelatedParty>
    <us-gaap:DebtInstrumentInterestRateTerms contextRef="c266">Based on the LOI, each party will advance an aggregated amount of $150,000 to meet BioLite Japan&#x2019;s working capital needs, which the Company advanced an amount of $150,000 and the advance bear 0% interest rate.</us-gaap:DebtInstrumentInterestRateTerms>
    <abvc:AggregateWorkingcapital contextRef="c266" decimals="0" unitRef="usd">150000</abvc:AggregateWorkingcapital>
    <abvc:OutstandingAdvanceFromRelatedParty contextRef="c268" decimals="0" unitRef="usd">150000</abvc:OutstandingAdvanceFromRelatedParty>
    <abvc:OutstandingAdvanceFromRelatedParty contextRef="c474" decimals="0" unitRef="usd">150000</abvc:OutstandingAdvanceFromRelatedParty>
    <abvc:LoanAgreementDescription contextRef="c269">the Company has advanced an aggregate amount of $1,610 to Keypoint for working capital purpose. Under the terms of the loan agreement, the loan bears interest at 6.5% per annum and the loan will be matured on October 30, 2021.</abvc:LoanAgreementDescription>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c475" decimals="0" unitRef="usd">1610</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <us-gaap:ShorttermDebtAverageOutstandingAmount contextRef="c271" decimals="0" unitRef="usd">1610</us-gaap:ShorttermDebtAverageOutstandingAmount>
    <abvc:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst Corporation&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;40,878&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;23,647&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst (Australia)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;132,443&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-117"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;AsiaGene&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;24,017&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-118"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;YuanGene&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;9,205&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;9,205&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;The Jiangs&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;18,750&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;16,627&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Due to shareholders&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;168,131&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;166,261&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Due to employee&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-119"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72,705&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;393,424&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;288,445&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c130" decimals="0" unitRef="usd">40878</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c400" decimals="0" unitRef="usd">23647</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c302" decimals="0" unitRef="usd">132443</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c250" decimals="0" unitRef="usd">24017</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c307" decimals="0" unitRef="usd">9205</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c506" decimals="0" unitRef="usd">9205</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c309" decimals="0" unitRef="usd">18750</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c507" decimals="0" unitRef="usd">16627</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c311" decimals="0" unitRef="usd">168131</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c508" decimals="0" unitRef="usd">166261</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c510" decimals="0" unitRef="usd">72705</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c2" decimals="0" unitRef="usd">393424</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">288445</abvc:DueToRelatedPartyCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c134" decimals="0" unitRef="usd">40878</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c402" decimals="0" unitRef="usd">23647</us-gaap:DueToRelatedPartiesCurrent>
    <abvc:AggregateWorkingcapital contextRef="c260" decimals="0" unitRef="usd">132443</abvc:AggregateWorkingcapital>
    <abvc:AggregateWorkingcapital contextRef="c469" decimals="0" unitRef="usd">0</abvc:AggregateWorkingcapital>
    <abvc:AggregateWorkingcapital contextRef="c463" decimals="0" unitRef="usd">24017</abvc:AggregateWorkingcapital>
    <abvc:AggregateWorkingcapital contextRef="c464" decimals="0" unitRef="usd">0</abvc:AggregateWorkingcapital>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c465" decimals="2" unitRef="pure">0</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:AggregateWorkingcapital contextRef="c476" decimals="0" unitRef="usd">9205</abvc:AggregateWorkingcapital>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c477" decimals="2" unitRef="pure">0</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c278" decimals="0" unitRef="usd">18750</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent contextRef="c478" decimals="0" unitRef="usd">16627</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c479" decimals="2" unitRef="pure">0</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c480" decimals="2" unitRef="pure">0.01</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:WeightedAverageRateForeignDeposit contextRef="c481" decimals="2" unitRef="pure">0.12</us-gaap:WeightedAverageRateForeignDeposit>
    <us-gaap:WeightedAverageRateForeignDeposit contextRef="c482" decimals="6" unitRef="pure">0.136224</us-gaap:WeightedAverageRateForeignDeposit>
    <abvc:AccruedInterest contextRef="c2" decimals="0" unitRef="usd">168131</abvc:AccruedInterest>
    <abvc:AccruedInterest contextRef="c3" decimals="0" unitRef="usd">166261</abvc:AccruedInterest>
    <us-gaap:InterestExpenseRelatedParty contextRef="c5" decimals="0" unitRef="usd">22779</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:InterestExpenseRelatedParty contextRef="c6" decimals="0" unitRef="usd">21520</us-gaap:InterestExpenseRelatedParty>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c2" decimals="0" unitRef="usd">0</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent contextRef="c3" decimals="0" unitRef="usd">72705</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c2" decimals="3" unitRef="pure">0.015</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13. EQUITY&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 8, 2016, a Share Exchange Agreement (&#x201c;Share Exchange Agreement&#x201d;) was entered into by and among
the&#160;Company, BriVision, Euro-Asia Investment &amp;amp; Finance Corp. Limited, a company incorporated under the laws of Hong Kong
Special Administrative Region of People&#x2019;s Republic of China (&#x201c;Euro-Asia&#x201d;), being the owners of record of
164,387,376 (52,336,000 pre-stock split) shares of Common Stock of the Company, and the owners of record of all of the issued share
capital of BriVision (the &#x201c;BriVision Stock&#x201d;). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision
Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each
BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new
holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock
in the name of the Company, the Company should issue 166,273,921(52,936,583 pre-stock split) shares (the &#x201c;Acquisition
Stock&#x201d;) (subject to adjustment for fractionalized shares as set forth below) of the Company&#x2019;s Common Stock to the
BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company&#x2019;s Common Stock
owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the
issued and outstanding Common Stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing
100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and
outstanding shares of BriVision&#x2019;s Common Stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of
166,273,921(52,936,583 pre-stock split) shares of Company&#x2019;s Common Stock and BriVision became a wholly owned subsidiary, of
the Company. The holders of Company&#x2019;s Common Stock as of immediately prior to the Merger held an aggregate of 205,519,223
(65,431,144 pre-stock split) shares of Company&#x2019;s Common Stock,&#160;Because of the exchange of the BriVision Stock for the
Acquisition Stock (the &#x201c;Share Exchange&#x201d;), BriVision became a wholly owned subsidiary (the &#x201c;Subsidiary&#x201d;) of
the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity
instruments issued in connection with the share exchange agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the &#x201c;2016 Plan&#x201d;), 157,050 (50,000 pre-stock split) shares were granted to the employees.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3:141 (the &#x201c;Forward&#160;Stock&#160;Split&#x201d;) and increase the number of our authorized shares of Common Stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 6, 2016, the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company&#x2019;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On August 26, 2016, the Company issued 1,468,750 shares (&#x201c;Shares&#x201d;) of the Company&#x2019;s Common Stock, par value $0.001 (the &#x201c;Offering&#x201d;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#x201c;SPA&#x201d;). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#x2019;s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company&#x2019;s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit). On February 8, 2019, after the Merger, the Company issued 74,997,546 shares to the shareholders of BioLite and 29,561,231 shares to the shareholders of BioKey.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 3, 2019, the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#x2019;s common stock were exchanged for 17,693,625 shares of the Company&#x2019;s Common Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (&#x201c;Kameyama&#x201d;) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#x2019;s Common Stock at $1.00 per share for any amount exceeding $3,000. The Company&#x2019;s stocks shall be calculated and issued in December every year. On November 21, 2020, the Company entered into an agreement with Kameyama, pursuant to which the Company granted and issued 24,694 stock options to Kameyama related to unpaid consulting fees of $49,388 (see Note 14).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 24, 2017, BriVision entered into a collaborative agreement (the &#x201c;BioFirst Collaborative Agreement&#x201d;) with BioFirst (See Note 3). On September 25, 2017, BioFirst has delivered all research, technical, data and development data to BriVision, and the Company has recorded the full amount of $3,000,000 due to BioFirst. On September 30, 2019, the Company entered into a Stock Purchase Agreement with BioFirst, pursuant to which the Company agreed to issue 428,571 shares of the Company&#x2019;s common stock to BioFirst in consideration for $3,000,000 owed by the Company to BioFirst. These common shares were issued during the year ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2019, the Company entered into service agreements with Euro-Asia Investment &amp;amp; Finance Corp Ltd. (a related party), Ever Adventure inv. (Formosa) Consultant Co., Ltd., New Eastern Asia (a related party), and Kimho Consultants Co., Ltd. (a related party) for the maintenance of the listing in the U.S. stock exchange market, investor relations, and business development. Pursuant to the agreements, the Company issued 644,972 shares of the Company&#x2019;s common stock for the consulting service from July 2019 to July 2024 for the service fee of $4,514,800 in aggregate, and recorded as stock subscription receivable. As of December 31, 2021 and 2020, stock subscription receivable was $2,257,400 and $3,160,360, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In August, 2019, the Company entered into several Conversion Agreements to all creditors that are listed under below table of &#x201c;due to related parties&#x201d; in consideration for a total of $4,872,340 owed by the Company to various creditors based on outstanding loan agreements. Under the Conversion Agreements, creditor agrees to convert the amount of debt into the Company&#x2019;s common stock at a price of $7.00 per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount of&lt;br/&gt; Debt&lt;br/&gt; Converted&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&#160;of&lt;br/&gt; Shares&lt;br/&gt; Issued&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Lion Arts Promotion Inc&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;97,864&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;13,981&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;LionGene Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;428,099&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;61,157&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,902,911&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;414,702&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;AsiaGene Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;160,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,858&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;YuanGene Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;92,690&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;13,242&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;The Jiangs&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,190,776&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170,111&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,872,340&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;696,051&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 12, 2020, the board of directors of the Company approved and adopted an amendment to the Company&#x2019;s Articles of Incorporation, to increase the authorized shares of its common stock, par value $0.001 per share, from 20,000,000 to 100,000,000 shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 8, 2020, the Company entered an agreement with View Trade Securities Inc. (&#x201c;ViewTrade&#x201d;) to engage ViewTrade as the placement agent&#160;and the Company&#x2019;s advisor/consultant with respect to its ongoing capital events. Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision. As of December 31, 2020, the Company has issued 60,000 shares of common stock to ViewTrade for the consulting fee with an estimated value of $135,000. The warrants were never issued and the parties mutually agreed to terminate the agreement on November 19, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the termination agreement, the Company issued 50,000 shares of the Company&#x2019;s common stock at a price of $5 per share as a termination
fee on June 29, 2021, of which 6,000 shares were issued to WallachBeth Capital LLC (&#x201c;WallachBeth&#x201d;). In January 2021, WallachBeth
entered into a consulting agreement with the Company pursuant to which the Company engaged WallachBeth to conduct due diligence and research
work with respect to the Company. On June 29, 2021, WallachBeth was issued 6,000 shares of common stock as compensation for those services.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also on November 19, 2020, the Company and ViewTrade agreed to a new Advisory agreement under which ViewTrade was engaged to provide advisory services only. In addition to a retainer fee, the Company agreed to issue 200,000 warrants, with an exercise price of $2.25, an industry standard cashless exercise provision, and a term of 5 years from November 19, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year&#160;ended December 31, 2020, the Company entered into a consulting agreement with a service provider for consulting and advisory services, pursuant to which the Company agreed to pay the service fee by issuing 50,000 shares of unrestricted common shares, valued at the closing price of $2.9 per share on the grant date. These shares have been issued during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2020, the Company received aggregated capital contributions of $7,615,331 in cash from 45 investors through private placements of the sale of the Company&#x2019;s common stock for the purchase price of&#160;$2.25 per share and a free warrant attached with each common stock purchased. In December 2020, 3,384,615 shares of the Company&#x2019;s common stock have been issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2020, the Company entered into consulting agreements with four service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee by issuing 521,887 shares of unrestricted common shares, valued at the closing price from $2 to $3.68 per share on the grant date. These shares have been issued in October and December 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2020, the Company issued aggregated common shares of 915,856 to six previous note holders, who had converted their outstanding principals and accrued and unpaid interests, including the debt conversion to the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#x2019;s common stock, and warrants to purchase 120,121 shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See Note 7 for more details in connection with the above debt conversion.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In July 2021, 1,111,112 shares of the Company&#x2019;s common stock and warrants were issued pursuant to the conversion of convertible promissory note of $2,500,000 entered in October 2020 (see Note 7).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 5, 2021, the Company closed its public offering (the &#x201c;Public Offering&#x201d;) of 1,100,000 units (the &#x201c;Units&#x201d;), with each Unit consisting of one share of the Company&#x2019;s common stock, one Series A warrant (the &#x201c;Series A Warrants&#x201d;) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#x201c;Series B Warrants,&#x201d; and together with the Series A Warrants, the &#x201c;Public Warrants&#x201d;) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on April 8, 2021 (as amended, the &#x201c;Original Registration Statement&#x201d;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#x201c;S-1MEF,&#x201d; together with the Original Registration Statement, the &#x201c;Registration Statement&#x201d;). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000. In August 2021, 2,354,145 shares of the Company&#x2019;s common stock were issued for gross proceeds of $6,875,000, before placement agent fees and legal fees of $850,429.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In November 2021, the Company received $4,244,452&#160;in gross proceeds from the exercise of warrants issued in the Company&#x2019;s August 3, 2021, public offering of securities. Investors exercised a total of&#160;673,405&#160;Series A warrants at a price of $6.30&#160;per share and&#160;200&#160;Series B warrants at a price of $10&#160;per share. Pursuant to these exercises, the Company issued an aggregate of 673,605 shares of Common Stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In November 2021, the Company entered into consulting agreements with service providers for consulting and advisory services, pursuant to which the Company agreed to pay the service fee amounted $1,478,590 by issuing 316,934 shares of unrestricted common shares, valued at the closing price from $2.31 to $6.3 per share on the grant date. These shares have been issued during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c68" decimals="0" unitRef="shares">164387376</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c68" decimals="0" unitRef="shares">52336000</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c69" decimals="0" unitRef="shares">166273921</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c69" decimals="0" unitRef="shares">52936583</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c70" decimals="0" unitRef="shares">163159952</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c70" decimals="0" unitRef="shares">51945225</abvc:CommonStockIssuedBeforeStockSplit>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c71" decimals="4" unitRef="pure">0.797</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <abvc:PercentageOfIssuedShareCapital contextRef="c71" decimals="2" unitRef="pure">1</abvc:PercentageOfIssuedShareCapital>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c312" decimals="0" unitRef="shares">166273921</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c312" decimals="0" unitRef="shares">52936583</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c73" decimals="0" unitRef="shares">205519223</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c73" decimals="0" unitRef="shares">65431144</abvc:CommonStockIssuedBeforeStockSplit>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c313" decimals="0" unitRef="shares">157050</abvc:CommonStockIssuedAfterStockSplit>
    <abvc:CommonStockIssuedBeforeStockSplit contextRef="c313" decimals="0" unitRef="shares">50000</abvc:CommonStockIssuedBeforeStockSplit>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c76" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <abvc:CommonStockShareAuthorized contextRef="c76" decimals="0" unitRef="shares">360000000</abvc:CommonStockShareAuthorized>
    <abvc:AgreementDescription contextRef="c314">the Company and BioLite Taiwan agreed to amend the BioLite Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby the Company has agreed to issue shares of Common Stock of the Company, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of the Company&#x2019;s first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016.</abvc:AgreementDescription>
    <abvc:AgreementDescription contextRef="c315">the Company issued 1,468,750 shares (&#x201c;Shares&#x201d;) of the Company&#x2019;s Common Stock, par value $0.001 (the &#x201c;Offering&#x201d;) to BioLite Taiwan pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the &#x201c;SPA&#x201d;). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), pursuant to Regulation S of the Securities Act promulgated thereunder. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. Pursuant to the BioLite Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of the Company with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016.</abvc:AgreementDescription>
    <abvc:AgreementDescription contextRef="c316">the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of the Company&#x2019;s Common Stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. Upon the consummation of the restructuring transaction between the Company and BioLite on February 8, 2019, the Company&#x2019;s Common Stock held by BioLite Taiwan was accounted for treasury stocks in the statement of equity (deficit).</abvc:AgreementDescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c317" decimals="0" unitRef="shares">74997546</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c318" decimals="0" unitRef="shares">29561231</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:FinancialAmendmentDescription contextRef="c77">the Company filed a Certificate of Amendment with the Secretary of State of Nevada, which was effective May 8, 2019 upon its receipt of the written notice from Financial Industry Regulatory Authority (&#x201c;FINRA&#x201d;). Pursuant to the Certificate of Amendment, the Company effectuated a 1-for-18 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 318,485,252 outstanding shares of the Company&#x2019;s common stock were exchanged for 17,693,625 shares of the Company&#x2019;s Common Stock.</abvc:FinancialAmendmentDescription>
    <abvc:Consultingagreementdescription contextRef="c319">On October 1, 2016, the Company entered into a consulting agreement with Kazunori Kameyama (&#x201c;Kameyama&#x201d;) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company&#x2019;s Common Stock at $1.00 per share for any amount exceeding $3,000.</abvc:Consultingagreementdescription>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c320" decimals="0" unitRef="shares">24694</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:UnpaidConsultingFees contextRef="c320" decimals="0" unitRef="usd">49388</abvc:UnpaidConsultingFees>
    <us-gaap:ContractWithCustomerLiability contextRef="c321" decimals="0" unitRef="usd">3000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c322" decimals="0" unitRef="shares">428571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:StockIssuedValue contextRef="c322" decimals="0" unitRef="usd">3000000</abvc:StockIssuedValue>
    <us-gaap:CommonStockSharesIssued contextRef="c8" decimals="0" unitRef="shares">644972</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProfessionalFees contextRef="c5" decimals="0" unitRef="usd">4514800</us-gaap:ProfessionalFees>
    <abvc:StockSubscriptionReceivable contextRef="c2" decimals="0" unitRef="usd">2257400</abvc:StockSubscriptionReceivable>
    <abvc:StockSubscriptionReceivable contextRef="c3" decimals="0" unitRef="usd">3160360</abvc:StockSubscriptionReceivable>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c323" decimals="0" unitRef="usd">4872340</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c324" decimals="2" unitRef="usdPershares">7</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ScheduleOfDebtConversionsTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Amount of&lt;br/&gt; Debt&lt;br/&gt; Converted&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number&#160;of&lt;br/&gt; Shares&lt;br/&gt; Issued&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Lion Arts Promotion Inc&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;97,864&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;13,981&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;LionGene Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;428,099&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;61,157&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;BioFirst Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;2,902,911&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;414,702&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;AsiaGene Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;160,000&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;22,858&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;YuanGene Corporation&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;92,690&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;13,242&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;The Jiangs&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,190,776&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;170,111&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.25in; text-indent: -0.125in"&gt;Total&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;4,872,340&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;696,051&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDebtConversionsTextBlock>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c349" decimals="0" unitRef="usd">97864</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c349" decimals="0" unitRef="shares">13981</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c350" decimals="0" unitRef="usd">428099</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c350" decimals="0" unitRef="shares">61157</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c351" decimals="0" unitRef="usd">2902911</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c351" decimals="0" unitRef="shares">414702</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c352" decimals="0" unitRef="usd">160000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c352" decimals="0" unitRef="shares">22858</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c353" decimals="0" unitRef="usd">92690</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c353" decimals="0" unitRef="shares">13242</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c354" decimals="0" unitRef="usd">1190776</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c354" decimals="0" unitRef="shares">170111</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c323" decimals="0" unitRef="usd">4872340</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="c323" decimals="0" unitRef="shares">696051</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c325" decimals="3" unitRef="usdPershares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c326" decimals="0" unitRef="shares">20000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c327" decimals="0" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <abvc:PlacementAgentAgreementDescription contextRef="c328">Pursuant to the agreement, the Company agreed to pay View Trade 60,000 restricted common shares of the Company and 60,000 warrants to purchase common shares of the Company at an exercise price of $6 per share for a period of 5 years with cashless exercise provision.</abvc:PlacementAgentAgreementDescription>
    <us-gaap:CommonStockSharesIssued contextRef="c329" decimals="0" unitRef="shares">60000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ProfessionalFees contextRef="c330" decimals="0" unitRef="usd">135000</us-gaap:ProfessionalFees>
    <us-gaap:CommonStockSharesIssued contextRef="c331" decimals="0" unitRef="shares">50000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharePrice contextRef="c331" decimals="0" unitRef="usdPershares">5</us-gaap:SharePrice>
    <us-gaap:SharesIssued contextRef="c332" decimals="0" unitRef="shares">6000</us-gaap:SharesIssued>
    <abvc:RestrictedCommonShares contextRef="c333" decimals="0" unitRef="shares">6000</abvc:RestrictedCommonShares>
    <abvc:WarrantIssued contextRef="c334" decimals="0" unitRef="shares">200000</abvc:WarrantIssued>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c334" decimals="2" unitRef="usdPershares">2.25</us-gaap:WarrantExercisePriceDecrease>
    <abvc:WarrantTerm contextRef="c334">P5Y</abvc:WarrantTerm>
    <abvc:UnrestrictedCommonShares contextRef="c335" decimals="0" unitRef="shares">50000</abvc:UnrestrictedCommonShares>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="c335" decimals="1" unitRef="usdPershares">2.9</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromContributionsFromAffiliates contextRef="c336" decimals="0" unitRef="usd">7615331</us-gaap:ProceedsFromContributionsFromAffiliates>
    <abvc:NumberOfInvestors contextRef="c337" decimals="0" unitRef="pure">45</abvc:NumberOfInvestors>
    <us-gaap:SharesIssuedPricePerShare contextRef="c337" decimals="2" unitRef="usdPershares">2.25</us-gaap:SharesIssuedPricePerShare>
    <abvc:IssuanceOfCommonStock contextRef="c3" decimals="0" unitRef="shares">3384615</abvc:IssuanceOfCommonStock>
    <us-gaap:SharesIssued contextRef="c338" decimals="0" unitRef="shares">521887</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockPricePerShare contextRef="c339" decimals="0" unitRef="usdPershares">2</us-gaap:SaleOfStockPricePerShare>
    <abvc:StockIssuedDuringPeriodShareBasedCompensationServicesforShares contextRef="c340" decimals="2" unitRef="shares">3.68</abvc:StockIssuedDuringPeriodShareBasedCompensationServicesforShares>
    <abvc:AggregateCommonStockShares contextRef="c5" decimals="0" unitRef="shares">915856</abvc:AggregateCommonStockShares>
    <us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="c511">a.Keypoint converted the aggregated amount of $292,826 at the conversion price of $1.84 on April 5, 2020, in exchange for 159,145 shares of the Company&#x2019;s common stock, and warrants to purchase 159,145 shares of the Company&#x2019;s common stock.

    &#160;
    b.
    Odaira converted the aggregated amount of $284,036 at the conversion price of $1.84 on April 5, 2020, in exchange for 154,368 shares of the Company&#x2019;s common stock, and warrants to purchase 154,368 shares of the Company&#x2019;s common stock.
  &#160;

    &#160;
    c.
    C.L.L. converted the aggregated amount of $289,974 at the conversion price of $1.78 on April 20, 2020, in exchange for 162,908 shares of the Company&#x2019;s common stock, and warrants to purchase 162,908 shares of the Company&#x2019;s common stock.
  &#160;

    &#160;
    d.
    KLS converted the aggregated amount of $225,222 at the conversion price of $1.78 on April 20, 2020, in exchange for 126,530 shares of the Company&#x2019;s common stock, and warrants to purchase 126,530 shares of the Company&#x2019;s common stock.
  &#160;

    &#160;
    e.
    Yu and Wei converted the aggregated amount of $354,722 at the conversion price of $1.84 on April 5, 2020, in exchange for 192,784 shares of the Company&#x2019;s common stock, and warrants to purchase 192,784 shares of the Company&#x2019;s common stock.
  &#160;&#160;f.KSL converted the aggregated amount of $270,272 at the conversion price of $2.25 on November 9, 2020, in exchange for 120,121 shares of the Company&#x2019;s common stock, and warrants to purchase 120,121 shares of the Company&#x2019;s common stock.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c342" decimals="0" unitRef="shares">1111112</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abvc:ConvertiblePromissoryNoteValue contextRef="c342" decimals="0" unitRef="usd">2500000</abvc:ConvertiblePromissoryNoteValue>
    <abvc:DescriptionOfPublicOffering contextRef="c343">the Company closed its public offering (the &#x201c;Public Offering&#x201d;) of 1,100,000 units (the &#x201c;Units&#x201d;), with each Unit consisting of one share of the Company&#x2019;s common stock, one Series A warrant (the &#x201c;Series A Warrants&#x201d;) to purchase one share of common stock at an exercise price equal to $6.30 per share, exercisable until the fifth anniversary of the issuance date, and one Series B warrant (the &#x201c;Series B Warrants,&#x201d; and together with the Series A Warrants, the &#x201c;Public Warrants&#x201d;) to purchase one share of common stock at an exercise price equal to $10.00 per share, exercisable until the fifth anniversary of the issuance date; the exercise price of the Public Warrants are subject to certain adjustment and cashless exercise provisions as described therein. The Company completed the Public Offering pursuant to its registration statement on Form S-1 (File No. 333-255112), originally filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on April 8, 2021 (as amended, the &#x201c;Original Registration Statement&#x201d;), that the SEC declared effective on August 2, 2021 and the registration statement on Form S-1 (File No. 333-258404) that was filed and automatically effective on August 4, 2021 (the &#x201c;S-1MEF,&#x201d; together with the Original Registration Statement, the &#x201c;Registration Statement&#x201d;). The Units were priced at $6.25 per Unit, before underwriting discounts and offering expenses, resulting in gross proceeds of $6,875,000.</abvc:DescriptionOfPublicOffering>
    <us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares contextRef="c344" decimals="0" unitRef="shares">2354145</us-gaap:StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c344" decimals="0" unitRef="usd">6875000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:LegalFees contextRef="c344" decimals="0" unitRef="usd">850429</us-gaap:LegalFees>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c345" decimals="0" unitRef="usd">4244452</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c346" decimals="0" unitRef="shares">673405</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c346" decimals="2" unitRef="usdPershares">6.3</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="c347" decimals="0" unitRef="shares">200</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c347" decimals="0" unitRef="usdPershares">10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <abvc:AggregateCommonStockShares contextRef="c345" decimals="0" unitRef="shares">673605</abvc:AggregateCommonStockShares>
    <us-gaap:InvestmentCompanyShareholderServiceFeeExpense contextRef="c512" decimals="0" unitRef="usd">1478590</us-gaap:InvestmentCompanyShareholderServiceFeeExpense>
    <abvc:UnrestrictedCommonShares contextRef="c513" decimals="0" unitRef="shares">316934</abvc:UnrestrictedCommonShares>
    <us-gaap:SaleOfStockPricePerShare contextRef="c514" decimals="2" unitRef="usdPershares">2.31</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="c515" decimals="1" unitRef="usdPershares">6.3</us-gaap:SaleOfStockPricePerShare>
    <abvc:StockOptionsTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14. STOCK OPTIONS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 30, 2020, the Company issued an aggregate of 545,182 shares of common stock in lieu of unpaid salaries of certain employees and unpaid consulting fees under the 2016 Equity Incentive Plan, as amended, at a conversion price of $2 per share; the total amount of converted salaries and consulting fees was $1,090,361. On November 21, 2020, the Company entered&#160;into&#160;acknowledgement&#160;agreements and stock option purchase agreements with these employees and consultant; pursuant to which the Company granted stock options to purchase 545,182 shares of the Company&#x2019;s common stock in lieu of common stock. The options were vested at the grant date and become exercisable for 10 years from the grant date.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On October 15, 2021, the Company entered&#160;into stock option agreements with 11 directors and 3 employees, pursuant to which the Company granted options to purchase an aggregate of 1,280,002 shares of common stock&#160;under the 2016 Equity Incentive Plan, as amended, at an exercise price of $3 per share. The options were vested at the grant date and become exercisable for 10 years from the grant date.&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Options issued and outstanding as of December 31, 2021, and their activities during the year then ended are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted-&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted-&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&#160;of&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Aggregate&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Underlying&lt;br/&gt; Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;br/&gt; Per&#160;Share&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining&lt;br/&gt; in Years&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Intrinsic&lt;br/&gt; Value&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Outstanding as of January 1, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;545,182&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,280,002&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Forfeited&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Outstanding as of December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Exercisable as of December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Vested and expected to vest&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The fair value of stock options granted for the year ended December 31, 2021 and 2020 was calculated using the Black-Scholes option-pricing model applying the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1.13&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;0.38&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;108.51&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;89.01&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company granted options to purchase&#160;545,182&#160;and&#160;1,280,002&#160;shares of common stock to employees and certain consultants during the years ended&#160;December 31, 2021&#160;and&#160;2020,&#160;respectively.&#160;The weighted average grant date fair value of options granted during the years ended&#160;December 31, 2021&#160;and&#160;2020 was $2.09&#160;and $3.13, respectively. There are 2,979,264&#160;options available for grant under the 2016 Equity Incentive Plan as of December 31, 2020. Compensation costs associated with the Company&#x2019;s stock options are recognized, based on the grant-date fair values of these options over vesting period. Accordingly, the Company recognized stock-based compensation expense of $2,675,205 and $1,706,419 for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021 and 2020, there were no unvested options. There were no options exercised during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;</abvc:StockOptionsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c355" decimals="0" unitRef="shares">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <abvc:ConversionPrice contextRef="c355" decimals="0" unitRef="usdPershares">2</abvc:ConversionPrice>
    <abvc:ConsultingFees contextRef="c356" decimals="0" unitRef="usd">1090361</abvc:ConsultingFees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c357" decimals="0" unitRef="shares">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c358">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c359" decimals="0" unitRef="shares">1280002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <abvc:ConversionPrice contextRef="c360" decimals="0" unitRef="usdPershares">3</abvc:ConversionPrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c360">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c517">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted-&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted-&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Average&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Contractual&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number&#160;of&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Life&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Aggregate&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Underlying&lt;br/&gt; Shares&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Price&lt;br/&gt; Per&#160;Share&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Remaining&lt;br/&gt; in Years&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Intrinsic&lt;br/&gt; Value&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Outstanding as of January 1, 2021&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;545,182&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;2.00&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Granted&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,280,002&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;3.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Forfeited&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-120"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-121"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Outstanding as of December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Exercisable as of December 31, 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Vested and expected to vest&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,825,184&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;2.70&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: right"&gt;9.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;616,056&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c364" decimals="0" unitRef="shares">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c362" decimals="2" unitRef="usdPershares">2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="c363" decimals="0" unitRef="shares">1280002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c363" decimals="2" unitRef="usdPershares">3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c362" decimals="0" unitRef="shares">1825184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c364" decimals="2" unitRef="usdPershares">2.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c363">P9Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="c364" decimals="0" unitRef="usdPershares">616056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c364" decimals="0" unitRef="shares">1825184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="c364" decimals="2" unitRef="usdPershares">2.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm contextRef="c363">P9Y6M3D</abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c364" decimals="0" unitRef="usd">616056</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c364" decimals="0" unitRef="shares">1825184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="c364" decimals="2" unitRef="usdPershares">2.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1 contextRef="c363">P9Y6M3D</abvc:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="c364" decimals="0" unitRef="usd">616056</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended&lt;br/&gt; December&#160;31&lt;/td&gt;
    &lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Risk free interest rate&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1.13&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;0.38&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;5.00&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;108.51&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;89.01&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c5" decimals="4" unitRef="pure">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c6" decimals="4" unitRef="pure">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c6">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c5" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c6" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c5" decimals="4" unitRef="pure">1.0851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c6" decimals="4" unitRef="pure">0.8901</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="0" unitRef="shares">545182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="0" unitRef="shares">1280002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c5" decimals="2" unitRef="usdPershares">2.09</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c6" decimals="2" unitRef="usdPershares">3.13</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c516" decimals="0" unitRef="shares">2979264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants contextRef="c5">$2,675,205</abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
    <abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants contextRef="c6">$1,706,419</abvc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants>
    <us-gaap:EarningsPerShareTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;15. LOSS PER SHARE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted loss per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the&lt;br/&gt;
Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Net loss attributable to ABVC&#x2019;s common stockholders&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(12,838,813&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(9,791,164&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average shares outstanding:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,053,522&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,715,559&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Stock options&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,053,522&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,715,559&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;-Basic&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.50&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;-Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.50&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Diluted loss per share takes into account the potential dilution that could occur if securities or other contracts to issue Common Stock were exercised and converted into Common Stock.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;For the&lt;br/&gt;
Year Ended&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Numerator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Net loss attributable to ABVC&#x2019;s common stockholders&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(12,838,813&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;(9,791,164&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Denominator:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average shares outstanding:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average shares outstanding - Basic&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,053,522&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,715,559&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Stock options&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-122"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-123"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted-average shares outstanding - Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;25,053,522&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,715,559&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Loss per share&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;-Basic&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.50&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;-Diluted&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.51&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(0.50&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c5" decimals="0" unitRef="usd">-12838813</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c6" decimals="0" unitRef="usd">-9791164</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c5" decimals="0" unitRef="shares">25053522</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c6" decimals="0" unitRef="shares">19715559</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c5" decimals="0" unitRef="shares">25053522</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c6" decimals="0" unitRef="shares">19715559</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic contextRef="c5" decimals="2" unitRef="usdPershares">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c6" decimals="2" unitRef="usdPershares">-0.5</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted contextRef="c5" decimals="2" unitRef="usdPershares">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted contextRef="c6" decimals="2" unitRef="usdPershares">-0.5</us-gaap:EarningsPerShareDiluted>
    <abvc:OperatingLeasesOfLesseeDisclosuresTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16. LEASE&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company adopted FASB Accounting Standards Codification, Topic 842, Leases (&#x201c;ASC 842&#x201d;) using the modified retrospective approach, electing the practical expedient that allows the Company not to restate its comparative periods prior to the adoption of the standard on January 1, 2019.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company applied the following practical expedients in the transition to the new standard and allowed under ASC 842:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reassessment of expired or existing contracts: The Company elected not to reassess, at the application date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and the accounting for initial direct costs for any existing leases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of hindsight: The Company elected to use hindsight in determining the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing impairment of right-to-use assets.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reassessment of existing or expired land easements: The Company elected not to evaluate existing or expired land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient. Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Separation of lease and non- lease components: Lease agreements that contain both lease and non-lease components are generally accounted for separately.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Short-term lease recognition exemption: The Company also elected the short-term lease recognition exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use (&#x201c;ROU&#x201d;) assets and lease liabilities. ROU assets represent the Company&#x2019;s right to use underlying assets for the lease terms and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The Company&#x2019;s future minimum based payments used to determine the Company&#x2019;s lease liabilities mainly include minimum based rent payments. As most of Company&#x2019;s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company recognized lease liabilities, with corresponding ROU assets, based on the present value of unpaid lease payments for existing operating leases longer than twelve months. The ROU assets were adjusted per ASC 842 transition guidance for existing lease-related balances of accrued and prepaid rent, unamortized lease incentives provided by lessors, and restructuring liabilities. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in Selling, general and administrative expenses. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has no finance leases. The Company&#x2019;s leases primarily include various office and laboratory spaces, copy machine, and vehicles under various operating lease arrangements. The Company&#x2019;s operating leases have remaining lease terms of up to approximately five years.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;ASSETS&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,471,899&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,772,747&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;LIABILITIES&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease liabilities (current)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;347,100&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;316,178&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease liabilities (noncurrent)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,124,799&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,456,567&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Supplemental Information&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The following provides details of the Company&#x2019;s lease expenses:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;335,208&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;337,282&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Other information related to leases is presented below:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;335,208&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;337,282&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted Average Remaining Lease Term:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.90 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.08 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted Average Discount Rate:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.39&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.55&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
minimum future annual payments under non-cancellable leases during the next five years and thereafter, at rates now in force, are as
follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating leases&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;2022&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;353,896&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;360,994&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;375,938&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;338,676&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56,916&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,486,420&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,521&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,471,899&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvc:OperatingLeasesOfLesseeDisclosuresTextBlock>
    <abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;ASSETS&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,471,899&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;1,772,747&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;LIABILITIES&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease liabilities (current)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;347,100&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;316,178&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease liabilities (noncurrent)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,124,799&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,456,567&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;</abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="0" unitRef="usd">1471899</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="0" unitRef="usd">1772747</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="0" unitRef="usd">347100</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c3" decimals="0" unitRef="usd">316178</us-gaap:OperatingLeaseLiability>
    <abvc:OperatingLeaseLiabilitienoncurrent contextRef="c2" decimals="0" unitRef="usd">1124799</abvc:OperatingLeaseLiabilitienoncurrent>
    <abvc:OperatingLeaseLiabilitienoncurrent contextRef="c3" decimals="0" unitRef="usd">1456567</abvc:OperatingLeaseLiabilitienoncurrent>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease expenses&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;335,208&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;337,282&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year Ended&lt;br/&gt; December&#160;31,&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Cash paid for amounts included in the measurement of operating lease liabilities&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;335,208&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;337,282&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2021&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31,&lt;br/&gt; 2020&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted Average Remaining Lease Term:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating leases&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.90 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.08 years&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Weighted Average Discount Rate:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating leases&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1.39&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;0.55&lt;/td&gt;
    &lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c5" decimals="0" unitRef="usd">335208</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c6" decimals="0" unitRef="usd">337282</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c5" decimals="0" unitRef="usd">335208</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments contextRef="c6" decimals="0" unitRef="usd">337282</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P2Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P3Y29D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="4" unitRef="pure">0.0139</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="4" unitRef="pure">0.0055</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <abvc:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Operating leases&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;2022&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;353,896&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;2023&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;360,994&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;2024&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;375,938&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;2025&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;338,676&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;56,916&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total future minimum lease payments, undiscounted&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,486,420&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,521&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,471,899&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abvc:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock>
    <abvc:OperatingLeasesFutureMinimumPaymentDueCurrent contextRef="c2" decimals="0" unitRef="usd">353896</abvc:OperatingLeasesFutureMinimumPaymentDueCurrent>
    <abvc:OperatingLeasesFutureMinimumPaymentDueInTwoYears contextRef="c2" decimals="0" unitRef="usd">360994</abvc:OperatingLeasesFutureMinimumPaymentDueInTwoYears>
    <abvc:OperatingLeasesFutureMinimumPaymentDueInThreeYears contextRef="c2" decimals="0" unitRef="usd">375938</abvc:OperatingLeasesFutureMinimumPaymentDueInThreeYears>
    <abvc:OperatingLeasesFutureMinimumPaymentDueInFourYears contextRef="c2" decimals="0" unitRef="usd">338676</abvc:OperatingLeasesFutureMinimumPaymentDueInFourYears>
    <abvc:OperatingLeasesFutureMinimumPaymentDueThereafter contextRef="c2" decimals="0" unitRef="usd">56916</abvc:OperatingLeasesFutureMinimumPaymentDueThereafter>
    <abvc:OperatingLeasesFutureMinimumPaymentDue contextRef="c2" decimals="0" unitRef="usd">1486420</abvc:OperatingLeasesFutureMinimumPaymentDue>
    <abvc:InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction contextRef="c2" decimals="0" unitRef="usd">14521</abvc:InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction>
    <abvc:PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions contextRef="c2" decimals="0" unitRef="usd">1471899</abvc:PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17. BUSINESS COMBINATION&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 8, 2019, the Company consummated the Merger transactions of BioLite and BioKey (See Note 1). Pursuant to the terms of the Merger Agreement, BioLite and BioKey became two wholly-owned subsidiaries of the Company on February 8, 2019. The Company adopted ASC 805, &#x201c;Business Combination&#x201d; to record the merger transactions of BioKey. The acquisition was accounted for as a business combination under the purchase method of accounting. BioKey&#x2019;s results of operations were included in the Company&#x2019;s results beginning February 8, 2019. The purchase price has been allocated to the assets acquired and the liabilities assumed based on their fair value at the acquisition date as summarized in the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Purchase consideration:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Common Stock (*)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;44,341,847&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Allocation of the purchase price:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Cash and cash equivalents&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;531,147&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Accounts receivable, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;188,550&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;56,075&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;485,684&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Security deposits&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,440&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Total assets acquired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,271,896&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Accounts payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(56,204&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Accrued expenses and other current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(251,335&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease liability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(267,256&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Tenant security deposit&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,880&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Total liabilities assumed&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(577,675&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Total net assets acquired&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;694,221&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Goodwill as a result of the Merger&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43,647,626&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt; &lt;tr style="vertical-align: top; text-align: justify"&gt; &lt;td style="width: 0in"/&gt; &lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;*&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On February 8, 2019, the Company has recorded a 100% goodwill write-down of $43,647,626. Goodwill was determined to have been impaired because of the current financial condition of the Company and the Company&#x2019;s inability to generate future operating income without substantial sales volume increases, which are highly uncertain. Furthermore, the Company&#x2019;s anticipated future cash flows indicate that the recoverability of goodwill is not reasonably assured. The goodwill write-down was reflected as a decrease in additional paid-in capital in the statement of equity upon the consummation of the Merger.&lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c5">&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Purchase consideration:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Common Stock (*)&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="width: 9%; text-align: right"&gt;44,341,847&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Allocation of the purchase price:&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Cash and cash equivalents&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right"&gt;531,147&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Accounts receivable, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;188,550&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Property and equipment, net&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;56,075&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease right-of-use assets&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;485,684&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Security deposits&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;10,440&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Total assets acquired&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;1,271,896&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Accounts payable&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(56,204&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Accrued expenses and other current liabilities&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(251,335&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"&gt;Operating lease liability&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;(267,256&lt;/td&gt;
    &lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Tenant security deposit&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,880&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Total liabilities assumed&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(577,675&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Total net assets acquired&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;694,221&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in"&gt;Goodwill as a result of the Merger&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;43,647,626&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:TreasuryStockCommonValue contextRef="c367" decimals="0" id="ix_1_fact" unitRef="usd">44341847</us-gaap:TreasuryStockCommonValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c367" decimals="0" unitRef="usd">531147</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c367" decimals="0" unitRef="usd">188550</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c367" decimals="0" unitRef="usd">56075</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets contextRef="c367" decimals="0" unitRef="usd">485684</abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c367" decimals="0" unitRef="usd">10440</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets contextRef="c367" decimals="0" unitRef="usd">1271896</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c367" decimals="0" unitRef="usd">56204</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther contextRef="c367" decimals="0" unitRef="usd">251335</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability contextRef="c367" decimals="0" unitRef="usd">-267256</abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="c367" decimals="0" unitRef="usd">2880</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c367" decimals="0" unitRef="usd">577675</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c367" decimals="0" unitRef="usd">694221</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c367" decimals="0" unitRef="usd">43647626</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:StockIssuedDuringPeriodSharesStockSplits contextRef="c318" decimals="0" unitRef="shares">29561231</us-gaap:StockIssuedDuringPeriodSharesStockSplits>
    <abvc:CommonStockIssuedAfterStockSplit contextRef="c318" decimals="0" unitRef="shares">1642291</abvc:CommonStockIssuedAfterStockSplit>
    <us-gaap:SharesIssuedPricePerShare contextRef="c518" decimals="2" unitRef="usdPershares">1.5</us-gaap:SharesIssuedPricePerShare>
    <abvc:PercentageOfGoodwill contextRef="c366" decimals="2" unitRef="pure">1</abvc:PercentageOfGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c366" decimals="0" unitRef="usd">43647626</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:SubsequentEventsTextBlock contextRef="c5">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;18. SUBSEQUENT EVENTS&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company entered into a Collaborative Agreement with BioLite, Inc., a company incorporated under the laws of Taiwan, and a subsidiary of the Company, (&#x201c;BioLite&#x201d;) on December 29, 2015, and then entered into two addendums to such agreement (as amended and revised, (the &#x201c;Agreement&#x201d;)).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant to the Agreement, the Company acquired the sole licensing rights to develop and commercialize for therapeutic purposes six compounds from BioLite. In accordance with the terms of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity securities owned by it at various stages on a schedule dictated by BioLite&#x2019;s achievements of certain milestones, as set forth in the Agreement (the &#x201c;Milestone Payments&#x201d;) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501 is approved for sale in the licensed territories. If BioLite fails to reach any of the milestones in a timely manner, it may not receive the rest of the payments from the Company. According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the &#x201c;December 2021 Payment&#x201d;) and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company&#x2019;s Board of Directors determined that the December 2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000, that BioLite owes the Company as of December 31, 2021. On February 22, 2022, the parties entered into an amendment to the Agreement allowing the Company to make all payments due under the Agreement via the forgiveness of debt, in equal value, owed by BioLite to the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This was a related party transaction and was conducted at arm&#x2019;s length. In addition to the Company&#x2019;s board of directors approving the modification of terms of the Agreement, the Company&#x2019;s audit committee approved them too. The Board believes it is in the Company&#x2019;s best interest to cancel outstanding debt and apply it to the December 2021 Payment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following such approval, the Company and BioLite entered into an amendment to the Agreement reflecting the modified payment method.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company also issued an aggregate of 1,306,007 shares of common stock to consultants, who provided consulting services in January 2022; it issued an additional 75,000 shares to another consultant in March 2022, based on the 6-month consulting and advisory services agreement, with a monthly payment of USD $15,000.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company has evaluated subsequent events through the date which the financial statements were available to be issued. All subsequent events requiring recognition as of December 31, 2021 have been incorporated into these financial statements and there are no other subsequent events that require disclosure in accordance with FASB ASC Topic 855, &#x201c;Subsequent Events.&#x201d;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <abvc:TermsOfAgreementDescription contextRef="c5">In accordance with the terms of the Agreement, the Company shall pay BioLite (i) milestone payments of up to $100 million in cash and equity of the Company or equity securities owned by it at various stages on a schedule dictated by BioLite&#x2019;s achievements of certain milestones, as set forth in the Agreement (the &#x201c;Milestone Payments&#x201d;) and (ii) a royalty payment equal to 5% of net sales of the drug products when ABV-1501 is approved for sale in the licensed territories.</abvc:TermsOfAgreementDescription>
    <abvc:MilestonePaymentDescription contextRef="c5">According to the Agreement, after Phase II clinical trials are completed, 15% of the Milestone Payment becomes due and shall be paid in two stages: (i) 5% no later than December 31, 2021 (the &#x201c;December 2021 Payment&#x201d;) and (ii) 10% no later than December 31, 2022. On February 12, 2022, the Company&#x2019;s Board of Directors determined that the December 2021 Payment, which is equal to $5,000,000, shall be paid via the cancellation of certain outstanding debt, in the amount of $5,000,000, that BioLite owes the Company as of December 31, 2021.</abvc:MilestonePaymentDescription>
    <us-gaap:SharesIssued contextRef="c258" decimals="0" unitRef="shares">1306007</us-gaap:SharesIssued>
    <abvc:AdditionalSharesOfCommonStock contextRef="c1" decimals="0" unitRef="shares">75000</abvc:AdditionalSharesOfCommonStock>
    <us-gaap:NoninterestExpenseInvestmentAdvisoryFees contextRef="c519" decimals="0" unitRef="usd">15000</us-gaap:NoninterestExpenseInvestmentAdvisoryFees>
    <us-gaap:Goodwill
      contextRef="c1"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c1"
      id="hidden-fact-4"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      id="hidden-fact-5"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c1"
      id="hidden-fact-6"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      id="hidden-fact-7"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="c3"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c3"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:PrepaymentForLongtermInvestments
      contextRef="c3"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="c2"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="c3"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableCurrent
      contextRef="c2"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherShortTermBorrowings
      contextRef="c2"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="c2"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNotesPayableCurrent
      contextRef="c2"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="c2"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="c2"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c3"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      id="hidden-fact-21"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c3"
      id="hidden-fact-22"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      id="hidden-fact-23"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c3"
      id="hidden-fact-24"
      unitRef="shares"
      xsi:nil="true"/>
    <abvc:OperatingSubleaseIncomeRelatedParties
      contextRef="c0"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="c0"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c0"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c5"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="c5"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c6"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="c0"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:GovernmentGrantIncome
      contextRef="c0"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="c4"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c4"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c0"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c4"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="c0"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c0"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="c0"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="c0"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c0"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaid
      contextRef="c4"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c17"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c18"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c19"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c21"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:CumulativeTransactionAdjustments
      contextRef="c17"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:CumulativeTransactionAdjustments
      contextRef="c18"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:CumulativeTransactionAdjustments
      contextRef="c20"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:CumulativeTransactionAdjustments
      contextRef="c21"
      id="hidden-fact-51"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c37"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution
      contextRef="c58"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution
      contextRef="c59"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:AdjustmentsToAdditionalPaidInCapitalInCapitalContribution
      contextRef="c60"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c58"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c59"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c60"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices
      contextRef="c58"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices
      contextRef="c59"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices
      contextRef="c60"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c58"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c59"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c60"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c57"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c59"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:CumulativeTransactionAdjustments
      contextRef="c57"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:CumulativeTransactionAdjustments
      contextRef="c58"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:CumulativeTransactionAdjustments
      contextRef="c60"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c64"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c65"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c66"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c64"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c65"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c66"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c64"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c65"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="c66"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices
      contextRef="c63"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices
      contextRef="c64"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices
      contextRef="c65"
      id="hidden-fact-81"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:StockIssuedDuringPeriodValueShareBasedCompensationServices
      contextRef="c66"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c64"
      id="hidden-fact-83"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c65"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c66"
      id="hidden-fact-85"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c63"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c65"
      id="hidden-fact-87"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c129"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c130"
      id="hidden-fact-89"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c131"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c132"
      id="hidden-fact-91"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c137"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c138"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:NetSales
      contextRef="c139"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:GrossProfits
      contextRef="c139"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="c139"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="c142"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:ShareOfEquityMethodInvesteeLosses
      contextRef="c0"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c362"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c363"
      id="hidden-fact-100"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c363"
      id="hidden-fact-101"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c0"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c4"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryWorkInProcess
      contextRef="c2"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="c3"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c130"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c132"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquityMethodInvestments
      contextRef="c401"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c140"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="c140"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="c140"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="c405"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c410"
      decimals="4"
      id="hidden-fact-113"
      unitRef="pure">0.0050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="c404"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:DueFromtheRelatedPartiesCurrent
      contextRef="c250"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:DueFromtheRelatedPartiesCurrent
      contextRef="c402"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent
      contextRef="c503"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent
      contextRef="c502"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <abvc:DueToRelatedPartyCurrentAndNoncurrent
      contextRef="c509"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c363"
      id="hidden-fact-120"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c363"
      id="hidden-fact-121"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c5"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c6"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">true</dei:AmendmentFlag>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentType contextRef="c0">POS AM</dei:DocumentType>
    <dei:EntityCentralIndexKey contextRef="c0">0001173313</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#ix_0_fact"
          xlink:label="ix_0_fact"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#ix_1_fact"
          xlink:label="ix_1_fact"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">29,561,231 shares (1,642,291 after stock reverse split) of common stock of the Company was issued to BioKey in connection with the Merger. Those shares were valued at $1.50 per share, based on the bid-and-ask share price of common stock of the Company on the final day of trading, February 8, 2019.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_0_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="ix_1_fact"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>114
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M )O(+&=BTQ GHQ;(Q0J61".&O%"ZL&E?&5003V78(^W0P(5[]P8?*UKD,:V
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M.@,LDK+L-LN!%H7MOY9"8S=G;U/LT$&: 'R_$D(_#DQ+5_?\TW]02P,$%
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MU(JLY=0*1VE"J875U RA*(D)@;%*#UBE?JS$,V]J#<]3DVF09/AP"!9O1Q?
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M[[/J6_ZZE.V$6(V7Y%G9_/9>6UE_XB7[LLHWK;*R8)-N#W_C/UM'G"@@8E'
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ML!W306ZJ<U(K_QD7QXT7@1NO.*]6FLSG"H>$<N. $Y"TU4H(DP>!+T*LUTJ
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M4K(,:2/[_%;$1UHZ(PR*M4$]_(M5CAHE"@20BEYJ(7CF.4-"^6(!5@R."Z2
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MS\.!RKH""L>C'P)D %Q+!9K;=]7<M/4-O(>;*G8[0!N"9<:/=7L EWL</XE
M+?_8 _CJNP6PWINRV9>\FRO@\_!35\*O5RV<X1\ @=MKW$S1->5Z04^57T!H
M]/)*W?;TX\0[ -%]!S=RF.'%GC,($%#'+U[UD]=)R\#R@!0]WR0!>-W6=='U
MA_G;JE_!"W^#W>1NS7QU7317^,* Z](S=_C,IFNW!)D=7%V[SI;E5=4T" C
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M$V4\BJ)-!_B%2D"&G]W2#I$8W'Y$;X'_ZYT.!2\OD7[<@UMW/M 3AJ#F\:;
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MC92*'DE6#L'>7ETCRR,O#W+@A,;  *0UV&VC83_::N)21\_8Q"5DL^0KSEQ
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M#&<V#"=D ]I%JZY:!G&O<.)4!/H]4<?0#I@;&[VM0C(<2$UKOJFJ'^69^T_
MGU7UZ\(&8IF#PKA!U1"-X?O^C %7TF1;8CN(Y<NR*3>5NRCY,$LO"D<RE$ W
MV)'(GX'NID3U#!0JS->L[S+S+ ",8$&CU5V!SGM0$<A9"08XV.J]YO$/ .:]
MAOE!PBWOHLM?EBCR4@C$-$+N*XZ/M 00.)P+.]=DM+1$UT(SD6K!"2; ]-1?
MA[LHA]LR5K4L(#(#ZK%N<%-F7C<@.^U=!>)@0(PSW/2,#XT&V%HE5Z9F[7;T
M5A8\'3-PD=#.]&:-'D !0@\XO8 Y]<#7F"CO8^((KK)#+V&&*(V'>Q=RW$4*
M<4)BWA2#)*,3,[]A';2KKJY*]0CVI4]4UQ,N%$,2+TEOJVS0E8&7G@VW8,G!
M)Z\H8QL,Z.(;?8AU**DQ&>N8T[+;X\>_ NA, <V'^'J9;&?=$F[^/]]5-GW]
M:F5TZ+(1N)'S?(QGEE;/ 6&RW_CR.,;N=<]$(PS"76D#R+2K)*L^8-H4X41*
MM<,M0P<VS$A_M[23:,_DER]#8L(D%4D>&J]*99S(SI@X7%2!-[@)OEX4K_CM
MS"$R73!Z(MFGADX*.>,*$X8IAYY>ENP*H;PUNRF&ZZ[=7UVK&KW9UQ%&)%P1
M,]<:2M78 G?,1!_R&N>"V4U"W@2OT9Z)A>^7?R>?!GHJ,.362) %+W7?2++
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MC'>#/2A['Q_%_,3K(H0(64"3CB2"W#E&J:>.]'V3OW0BXGDJP-=,J]\0GH\
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M+2=K%S/5KY@7CC]=<<6\M<>[I7YJW+W37'OQHLL[/RK,RDL]K2#4V$IP1S1
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MH@EV3F[-4@-TG5T:!CQ&/"I>\?&ND'OX?YB4,$K*<CPUFB(TX:U2\W[B^OQ
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M,3@X+OJK6I(G4%,9&C#"X+UC<X6-CFAL.RTYZ84^O!61>89K#75SVC@RC25
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M+7T31S/Z*67(HA ^]'(J@$(HO "^'T? &NT;7"#[,>[W_P502P,$%     @
M9(O.5 Y*W__T @  3@<  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
MO57?3]LP$'[O7W&*>  ID%]MTU9M)2A,XP&&8("F:0]N<FTL$KNSW1;^^YV=
M$KJM=),F[:4Y._=]=]]7YSQ<2_6D"T0#SU4I],@KC%D,@D!G!59,G\@%"GHS
MDZIBAI9J'NB%0I8[4%4&<1AV@XIQX8V';N]&C8=R:4HN\$:!7E854R]G6,KU
MR(N\UXU;/B^,W0C&PP6;XQV:^\6-HE70L.2\0J&Y%*!P-O).H\&D;?-=P@/'
MM=Z*P2J92OED%Y?YR MM0UAB9BP#H\<*)UB6EHC:^+[A])J2%K@=O[)_<-I)
MRY1IG,CRD>>F&'D]#W*<L65I;N7Z(V[T="Q?)DOM?F%=YR:Q!]E2&UEMP-1!
MQ47]9,\;'[8 O? =0+P!Q'\+2#: Q FM.W.RSIEAXZ&2:U VF]ALX+QQ:%+#
MA?T7[XRBMYQP9GPI5BB,5"_#P!"=W0RR#?2LAL;O0!.XDL(4&BY$COD._&0_
M/HKW$ 2DHQ$3OXHYB_<R7C%U DGD0QS&\:Z&]L//,6O@T9YVDL;;Q/$E?_(6
MSKG.2JF7"N'KZ50;1:?WVYX*[:9"VU5HOU?A^N'B^O.GVR^[_KV]4#L=!GK!
M,AQY]/EK5"OTQNT3:"CAK?U,TE>KC08Y U,@S&1)7S\7\T&++,\*9QJYA]44
ME5VT#N\%6^;<8'[4^L %IP.:PUS*7,,!1&';#Y,N1?VNG\:=UBU;TYDVJ#@K
M-73[?MQ+H=?VNW'8.K6EF,AL506\Z6G%RB6K)X'(04ZU+%%G:!/):0V'42<D
M@@2.;-CQDS2$HU:CR0=!(_( XMA/P] &';^?=F#7J?DO1F[;][.7O_E7N^:,
M#/U^-VT]TJ0\YN)XH62&I/W8R@J3WB_&UHY"-_+3J/<OQF[<I) H4^OQ#F-K
M/P^HF5T'/=@:616JN9ODF@Q:"E-/KV:WN2Q.W8P,WM+KFX:.X)P+#27."!J>
MI!T/5#V]ZX61"S< I]+0.'5A01<>*IM [V=2FM>%+=!<H>,?4$L#!!0    (
M &2+SE2VE\L+M@,  &,)   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;*U636_;.!"]ZU<00@X-0%@2)=E28!O(UV(+-*TW;5HL%GN@I;$E5!)=DJJ3
M_?4[I&3%63AJ#GNQA]2\-YSAXY#SO9#?50&@R6-=-6KA%EKO+CQ/90747$W$
M#AK\LA&RYAJ'<NNIG02>6U!=><SWIU[-R\9=SNW<2B[GHM55V<!*$M76-9=/
M5U")_<(-W,/$?;DMM)GPEO,=W\)GT ^[E<21-[#D90V-*D5#)&P6[F5P<1T9
M?^OPM82].K*)R60MQ'<S>)\O7-\L""K(M&'@^/<3KJ&J#!$NXT?/Z0XA#?#8
M/K#_9G/'7-9<P;6HOI6Y+A9NXI(<-KRM]+W8_PY]/K'ART2E["_9=[X11LQ:
MI47=@W%<ETWWSQ_[.AP!$O\5 .L![*V L >$-M%N93:M&Z[Y<B[%GDCCC6S&
ML+6Q:,RF;,PN?M82OY:(T\N51$%(_41XDY/;'VVYPRW2<T\CM_'PLI[GJN-A
MK_"$Y$XTNE#DMLDA/X&_'L<';(3 PZ2&S-@ALRLVRGC'Y82$ 27,9^S4@L;A
M-Y -\&!D.>%0Z-#RA;\H-"6KBC?Z9;W)7Y=KI25J^N^14-$0*K*AHM="W7]:
MW=Y_^9-<?KPAMW\\O%_=W7[\<FI/QWGB"3E-18Y5X\"0!5=$; @6/BN&RMM$
ML9A0KT$.!25<0M\YRG\@-\B-J+"EJ OG&7\,<]X]-+S-2PWYN?/!D)Z1,)G1
M9#I%*_)]ZJ>!<]6655XV6V7#5H 'O!!53LIZ)\5/,*M4A%$6^C2=)M:*J3\-
M,&A68/JR.PC/*04T\!E-HQ M/PAI.)LZGS:;,H-CIV1*@R@E01K0A$5.2%-_
M1E,V)2%-(I^&,7,^@%(7V+6RMFXKCEE@L\&^FY7<MK-W2.VGE,T2<FX'042C
M64#.G1<G=(A)28,M_HS$:4*G46(L%M,D";!H1[3PB.U>@2)[P(*?Q30* DMT
MADFQ!(LN'5U( %)WIP_,Z3NUA6;7*/9MM0/;>:NGR:E#]7\HBOQ742?DTZW(
M']/1"]0+*?7RZ45CA)3&6,7X[?*QHK%62.-9."*?7C0D32,:1]$)\72B01&E
M=#;UG4$R1CP(CMF;Q'/0BQDP(XHD^;5X>LF@A? DC$Z*I]=.$- T#3OQA#/4
M.S/J(;H \@1<]LIY?:M&Q=/U.>_H'JM!;NWUKD@FVD9W5]HP.[P@+NW%Z3V[
M=\\/5/"V;!3NX0:A_F06NT1V5WHWT&)G;\6UT'C'6K/ 5Q!(XX#?-T+HP\ $
M&-Y5RW\!4$L#!!0    ( &2+SE1J?]TAD H   XJ   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$R+GAM;.U:6U/;2!9^UZ_H8F'+5 FC^R4AJ0*2R60F(:F8
MR=;6UC[(=MO61E9[NF4(\^OW.RW)ED V)A,F/,P#Z.+NT]WG\IUSOM+)M9!?
MU(SS@GV=9[EZL3<KBL6SXV,UFO%YHOIBP7/\,A%RGA1XE--CM9 \&>M)\^S8
ML:S@>)ZD^=[+$_WNHWQY(I9%EN;\HV1J.9\G\N:,9^+ZQ9Z]5[_XE$YG!;TX
M?GFR2*9\P(O?%A\EGHY74L;IG.<J%3F3?/)B[]1^=N[1>#W@<\JO5>.>T4F&
M0GRAA[?C%WL6;8AG?%20A 27*W[.LXP$81N_5S+W5DO2Q.9]+?TG?7:<99@H
M?BZR?Z7C8O9B+]IC8SY)EEGQ25S_S*OS^"1O)#*E_[/K<JSK[+'14A5B7DW&
M#N9I7EZ3KY4>&A,B:\,$IYK@[#K!K2:X^J#ESO2Q7B5%\O)$BFLF:32DT8W6
MC9Z-TZ0Y67%02/R:8E[Q\IW(IT>77,[9V_R*JP(&*M3)<0'1-.!X5(DY*\4X
M&\2X[+W(BYEBK_,Q'W?,/]\^WW:V"#C&F58'<^J#G3E;);Y/9)^YMLD<RW&Z
M-K1]^BL^6DVWMVS'7>G9U?+<+7IFM_3,_G,Z5(6$)_]WRPK>:@5/K^!M6N'#
MQ9NCR]>?WK.W%Y]?#R[?O[ZX''19<KN8H,\Z)1D]^Y!=SC@3USF7:I8NV(++
M$8Z!8%=,3 R>C&8LU:?CG"62LRS%[9@EBDU$!KQ0SXP/';,-V I32=M0.Y\/
MN=0/IZ.16.9%FD^-BV2.E2? C2PAD8M$%C?:M-I K ""E;YKG$E@UY3G7*6*
MG:6BX*-9+C(QO6'GHF^R=\6XSZR^';*#^G(N5,'>\V(FQL8;S%S,$ABJFHM?
MY4+(1*..U0\M/4]?FO,P^F=@ZZ]8NS7#[\<TM+K<FO%3*O'<'&YC8(R!]?7U
M[\L4)ZVF?*)SM<:[=C]P,*Z^ML?WG-)F_&M!_E;@=F4@J#+ERH ,>CT2\T62
MW\!0DJ6%8L.E@F,HI>U80GSZQRU;=AME^WJL6N]\PWJ[F>]",+7@HW22CM8[
MU=N 3LB[[C'C_?,WF1/I(DN&^@F_7*?%K'6<0B"'7"$W+EB2CTFK<[AYFF10
M'AO+Y51UF_W/B[WK&G]>9L\]9#I!% 1<Z1JXJ#S(;HP1E(40I^C7HDO/P&K/
M-H2TT?LM3Y;C%-YR:%R(_ AN]847R3#CS=!HYB*3Y;S8S2OV66@&<:2OL6??
MXP..:_J6RQS/=#QOH[VCT#4MWV6Q99E^:!F#Y1":*Y(,;S#3]UCL.F;H^T8K
M\CI.T&7V(W;483AZ>ZG7V%^MLK]:IY<<LDYA/3+!/_\1.8[UO!Z@'^WGA\]T
M6-:FGXELC,C.&2_WG.8P,+9KI'FG:!/55@W%JXB]-9=1&$VU&U2_S$M-P,^J
MV>KNW)5' 5=0A:J13(=\3/LX'9PS%S9J:I).8SO/VYHFY_U%8!OL,\8L(83U
M*BU4,FHE]&MTK':6C/^WK"1C*Z-L.>;-"-&KA<^5L9 "FB!% .:8FA$DPN-K
M9*O'D0Q!B"A9)@@YL3$!>;*UD*2S2Z#E\.:NLOKL5 ?3.GITBB-)=1@9=5%B
MMJ(965F52>- #Z]N*:KA&B@C1U_*G6OYM9%-;(> D$KI[*;?<I)Y G7 )HOD
M1EN(;'?';BV/@:472VP<536.C"@GC64X1FA:EE4OCU%#I 6EEJ425M/3,C,D
MTZGD4])T,B>OH?WN!X%KA@AM.MI^$'EFZ%BT^9&0*!>-TGN:.\TZ8$N1EVW7
M+EMKMZV9P3H%3M(\R0DH(;ILHRCZ:-$NYVD'0^TS9L,$J6IF57:69!#/V8!J
M^EUP]'PI)1W[5"F.,^XSQ[0]J#P.];UC^680Q!IN1^VAD>V84>"SV(]-S_=6
MDMZER3#-8#^8RS4=%[#J "G-V(K-T');HIIC8>C0LQ%RIN\XQH"<CJ &!5^E
MCCH >T[LFY[EL$/F.-@#+#LH8')M/ECH XK#,A<;ES.)XJ'9'!BKLJ^=3M#R
MJB3CI('(C"S* SB?Z\;&&TGQB#">I 4+3-MUD2&LR-)S=*SVO#A"SK"PH1Z0
MPXQ\GQT:@SK4:0P$3Z2XY4\EL)%3P/R;$/ (XJ&9V(;(WO"0W47\)G3K7VO(
M8F= D&H"^6DSY&EO2RA$&E64(QT7$ATD@NH5FI]+M40,X QYSGY)DWQ:(<;K
M#V7"GR4IG#>ODS<<\ATT";Q%YS-(R04[I6A_I82-0.9?J61 N*MTFE,UE6A(
MF&1+CODF:JN"Y:*H=V8R<<7+,-%':D/8F%.\HA;3.6.I^-_)Y$<F$]U1E,FD
MNCTOW6QP*YE4IGQDO*Q6V0:6ZMO0$J>W@YBJ1A<HZ!"ZW<))UP=:.19S0P]7
MMQ,G ;J!9UIAR&PS=I&@HJ IJ3F4ZCL-+;? \15'! &A>K;I1Z'I11'!D8V;
MP(QMH,?W!<DC^JNP\6.)C;2S-2;:'M)"I#$1<.W&=R#QVP'QR.AYA^Q5JA9"
MZ3JA%-G1:KQ:REI(H4\Y+T_)Z92E;QLMWUZYLZ0J _##QO<OTS=Z/O4Z&N8Q
MK(KM!ESHVHBZ9)'KQW56$/E="%*&+I>($8&54ISYFO;3[)YWMME*Y=VA46^C
M-.@JTW117H_$_+!O9WY:==>#R1^;_EG?1/X<5/\?1OT<5/]W)7X.JO^[T3X'
M]64GTN>@OCR4\F%_4SY/@?)Y)Q(J=32$MK1&4E E7*5C3CM47"<U>ENMHW%1
M+1=41S#%Y54ZXC^"_V%;^)^-@?TXM$^,MH.ND>_>1_MHOH?8GSC<3/M4= ^+
M8EP#KTG[E#0,B]&WN+']C;2/$T3H3(+[R)]J+30RIHV=A$[XF/0/>R+T#WM2
M%3O[ZROV.VQ$7=A8CT'Z5!76#7"FJJHZV)#FLCLQ0^RO8H9NDT'L8630G;-^
M>^^RH4#;F>O9C)D=%$]%ZVAL<.+8A(]W="X5LX/QOF>9EF=OZ%TJ9H=Z%S0;
MKF=MZEU*;H=:)3L.MU$\-:]CHQ.R3-<)VLV+J)L7X]_D=ZOZMRSI6GV*$YA!
M[-*-'YJ.Z[?I'."HAU4LTT;9O.Y=H* PP :(8NH1UV2C-_.^'Z?3<P+H'(E$
M=V@VX#QTW4?B=]B3XG?8$^-W_LX6#\D6=UF=#=GBN[(Z&Y%Q)U;G ;A84CB:
M^46!YT==9$Y)XC"/R&'/Z03$%86#.S>F(FP+F>-&6,F]C]%9DSB]2)/?\6T^
M1ZSYG'LQD5I].S#]V+]-X/1<UP<6$5>S1D,?6.C;&JP"SS8#-_C!5,Z68N.6
MURIHE#EVU"P4L$#+:\OBIK.03PI$)/HC&G-QN8_J7Q_@"GK$CO:M?N2;A#H*
MK9#4SCQ.T7DMDPP%?(W(:\)"VVE%9(SY2'+4-!JWRDZ_NZBP=*PF%$W+K*@1
MN9!)KA+].9MJ'YIJ&0#N'WS<U)^V$]4\2.5^%.OMI9@ F&_]' <H">QP%8S;
ME-W?T2I/@%)C]U)JG6&S,WW62.G[K:3>]7'6<>.3._3-4_TEHF(Z9,JO[U9O
M5Q\[GNIO_([7P\LO)=\G<IH"FC,^P52K'_I[3)9?'Y8/A5CH#_B&HBC$7-_.
M.&IP20/P^T2@S:T>:('5)Z O_P]02P,$%     @ 9(O.5.[2K3SC$0  ")D
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M>+1[HA<#G# !?(*9^V"; ]!='** PIIGNG;:;:]V@"3J &63,^8X@#E<E \
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M8@'X?6B#$M07;&!F.]]$]R[_#U!+ P04    " !DB\Y40I5=&>4+  "^/@
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6S-6UESVS@2?N>O0'F=K:2*
MD43*MJ3$296/R4PRN2KV[#QL[0,D0A)J2$)#@)8UOWZ[&SPE2E%BV=*+38%
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M"?A\K) R\ALR4!Z\.OH74$L#!!0    ( &2+SE30B.<F30,   4)   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;,U6WV_3,!!^[U]QBL9;U?QH!]O4
M5FK+$$.#5=L (<2#FUP;"\<.MK-N_SUG)PT==!$\@'C8ZK/]??[N?+[+>*OT
M5Y,C6K@OA#23(+>V/ M#D^98,#-0)4I:62M=,$NFWH2FU,@R#RI$F$31\[!@
M7 ;3L9];ZNE8559PB4L-IBH*IA_F*-1V$L3!;N*:;W+K)L+IN&0;O$'[OEQJ
MLL*6)>,%2L.5!(WK23"+SQ8CM]]O^,!Q:_;&X#Q9*?75&1?9)(B<(!286L?
MZ.<.%RB$(R(9WQK.H#W2 ??'._97WG?R9<4,+I3XR#.;3X*3 #)<LTK8:[5]
MC8T_QXXO5<+X_["M]R;' :25L:IHP*2@X++^9?=-'/8 )]$3@*0!)+\+&#:
MH7>T5N;=>LDLFXZUVH)VNXG-#7QL/)J\X=+=XHW5M,H)9Z?OE$4#2_; 5@+'
MH25*MQ"F#7Q>PY,GX$-XJZ3-#9S+#+,#^$4W/DXZ"$+RI74HV3DT3SH9WS(]
M@&'<AR1*DD."NN$O,6WA<8><81O?H><;_DY\X?-L9:RFU/W203UJJ4>>>O04
M]=7M^0TL9Y]F\\OS0U?7#8^C 3RB@ L);YBLZ#$[]^/3/LRYNN06X9;Q+9.
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MMX'6UXIJ:V.X ]HOG^EW4$L#!!0    ( &2+SE1RI3P010,  )4)   9
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M9E(3E9DMX$='X<<[-LJT.73T=1>V7@/JC5E=[73M_0=;\BQLUS4(J.0X<P2
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ME?_GGQ4>K GC_IH)OIK@[SHA4!," E2>C,!ZR4O^_&F>+5F.HV$U_$"XH=D
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MXID=->F:2%D*5*@9V*I<6J,2UJHA)['#9?H]/PR&3P 33SQ7VD,8QV] 8]X
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M+\!O.>@TLR3 VN2C!AHX^<C@>RO:@2\ FJJP6(A%%"BVH&SJZ8_G)OAQ/NF
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M'6V$@U)TQ^X$W@4!AWV ((ULAPSP_/XF'DM7.4L"W(Q<I0:RE]$!9GTFQQ^
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MOD7XA:@4YH)'(;AU@3N)D8B(VM%SAY2Y-S9CLP)JP' ;049<[Z6E;#H/\_@
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MC!\_ZP<;.*^EJR2N5FR<F.GL61WLB)S.')*OW8*ED6U,JE2!N2Y6.SQV68!
M^)8RDP:AV$7..F5D<M]2<*4-!@,%J..%>:*7F4-,WLF40W/;QR*Q>I,%5/]^
M%Q-6FA$D_U9+_B/A_=L/51@2](Y!HL1<)<A NG2M/+Y6B(" 2I)E?#+ OB#E
MOL 56_(AK2?'-H72R%]+##K;5LVK76*I<),AE)0Z43&[=B[0^Q%9)TDW#"^7
M.7K!F5-O6JA^LV%59I"A>W9TVX8:R;LJ[TO2JX E-H/)\TI.75]V\]L!LEU<
M'A"Y+09VQ>AYHI8N.%%6*CY*S['(Q7U:19-B&!=&IQN1:,I;W!?%IG:V32--
M],[KMDX4H8WS8VZGXQK_2EN/TLL%^:(L2B2@DIJ6=7@U^NE;N0L%<,*D^#[B
M'.*-:6L7;NS?X>TT:7@C]C'MN75)EP<QW+>/3D&8>BJ+DC+>Y6Y(HUI$%RYP
M.6Y)5!L.,K80:\H6#]N<6]PM$!(JYKCI*LP@WG';O4Q)%-3!8#.C4@YB5,,P
M#ECVYMH8UW$0Z3;R*G.'.\[36Z$2,4_D+I9>S"W2_C971YGS6U/I-H:VRT?+
M^7OH^9SB7H2:2HLU+28)F^#R#X;+1FR9X487[T;)HMTP[(0F JVS)4<18ENL
M97(KZVKBD=:MR.:]2<3_Q@,6!<JFV6KO,LL2RP>5C<5>F_+,R*1=62RIC"7:
ME-)U<F@/ZT]1XJ,Q(L6Z2D!5>8G.Q#?8EE(_R@&!O.ZY$FI3-4'4R)HRPLAF
MN>WZLYNTU UA0])V".VA0"F?R/8B"@J@,PD70#HK>.@(]4 "4OOAN)J80Q"W
MP02)EGZ]-;F^-:8((J[<:=.FG'%Q^1G+#H?? 3]2.)(VV(MRIF&W1%#ZE"%H
M7G$/A;B3517B5G3C\%K";@E"HZM7==?MNG[7J/&^@,&QE-R4+[A[)?:1,E&9
MT@X3N1UDO5+1RJ/UMP]80(*K"(ZBTFSG!79TF.NP4&Q14VH/5"ZO"ET\E*0H
MJ55M2# V31A8V#V["HJ9K!$ C6<2/M!AG$0ZOT?T(FQ=I8N:6XFZ)TU/U;#9
MB1AA# 'ADMH[5%/WTFLE;@EL\M6&C]NS*&%SVGKX&'?'%0MM65 TW$MA4 0>
MT*,5'['QK"W3.>J&-][%]?6KFVMO-Z"W]N<J:;_'DU@X#?SQ;,37P\G G\YF
MWNNKBQ=7KZ]NKE[M\VF7\R?H)\K'IQ .9WZ_/\7_B3_H]X]387/6$ [\?ACZ
MX^D8KP;!T)_,9G!=XMFI+LQ7K>)[LW,TY#2W5'&Q*-OZQ'DP()H /T'78 NY
M-2WQ:,3!@XH]Q9N\^!ZF(W\ZFN#%9.I/AQ-XRRG4WASJ&H9NJSRL;%V(4<J<
M1GR_(?]2V!5PH>-^/J46U=8A'-<YF"+WTNU=9/6QEF)/[X?BYA<>T*&,"ZQ;
M8HG5O0E,UWK?8&">[ )D(>B.1RXD\7+6=Y?[W%XJR_TVO$>(#K 9=,,)_(7^
M9OA'GJZ[@ZH5$5E68CQL>A#.1FKT(ZH)">_*=?;'KL2[F<!=T<J;^C2,17*!
MJ<;G==KRJ;ZLN8AI$U'FDTA;A9MM*>R<]43>D4N<$/*GVQ=!DC]A S$M?HK8
M!^.QWP^&1!Q".)KYP61&-T,()T,_F(9T,X(PG/KCR9C*1Z4@C,;^;(!/-&7#
MT9:/ML6X@AF5P-R>C?S!9.J]QDWP!*[2O'1M#[+%G1#/!OYP.O3>[78*Q_O*
M3=$8PJ&QX)>;G<%CF9W!__/L#+[-SK[-SK[-SK[-SK[-SC[3[ P>R>QL[P#R
MU69G^V>]KS([@\<R.X-',CN#QS$[@R\T.X/',3N#1S,[@T<W.X-'-CN#QS([
M@R\P.ZM#]^O.S@YJ]IEG9^W)Q_\T/JM&9GP]F03^9#CYI/$9C\U0@3$?V/_
M^*P>FJ$JH[$_&D\^\_AL9PYVXOT#$=R,K08TX=B?][7&9F$X\H/^E*\F?C -
M_O#@#*K!V4')?\+ ;$_C(^'RZ5.S>E0&81=E??K4C,9E_>YHY*9FWJ=,S9JF
MX#--S;S]J5DEP@W/$-A1B&DSKL9AX[X_FPWK<=C(GX73/V,<-IR._2&&S$/C
ML*$_"@:?,@ZKB\"A3])ZK4\)4VF6_(4EC2E0*_=58?.T^8CS@K]=[&V6NR]
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MLF?^.V3OYGC]-?=2&-QX%FRU@&B_.QEU:K;=OCA=^H^,<^V<SOWC2@I<*7P
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MS/5_@V 2O62E:@]FH-XKXU#>3G]CP T ;J2TP6F"A.P0C+8'+(5K47["7P@
M:JR" C?6Q*%^B>XK)ZTM%8V$*H"9NB+?7T302$S(J>A [42ZC -1X=39SJI
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M8NEL<CH?A::W??"FXO=S"^.]*?AKIB1TFB9@?&F,;Q]H@^X-[^5O4$L#!!0
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M:'Z-]--Y\H9?!55UI6'!H,/"@^BJH3$*^*G2:9[].UWDF@</%$0Y82 !/#[
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MX11:_>$39G(>, 7SR.2IL\[ ^7DX B?083F%I) PI&T P9\S>P1*H[]JS^D
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MAQ%I4A,!$,N&R\G>S=<NY&;D&@4*L;Z<<-4!'ZBIRI:2 )1=45,"S+1K%SE
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M,O-)W;\1C3^AU9>J3+M_=%_/#:(Q2C?:J+P1AA7DLJA'_J6)PXY XNT1((T
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MAL(,FE.]O_%M%/X%S^TG8X7LH5Y\)JV?UE^E1_9C;']-7GS2AK2<,ZY01F?
MZO0B.!9E\9FXF&BQL%]:)T)KD=MA2@EX9PA@?2:$KB9&0?VM_N1O4$L#!!0
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M2;Y?9UOT<N^OA;:+#3K];(V*9IM!L\*"_K(432(U$X/'3M@T$H1W/,=.#_Q
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M<0@-DC>7CF8@6:7/[2LFX1:@Q13N:92K"?!_PYC<#]0"W<UO]A]02P,$%
M  @ 9(O.5+=7E*MV P    H  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL[59+;]LX$+[[5Q!"#\Y"C23JV< VD+C=QR&H46>WAT4/M#2VB%"B2E)Q
M\N]W2-EJFG6,[6DOO=A\S/?-?#/4D+.]5/>Z!C#DL1&MGGNU,=U5$.BRAH;I
M2]E!BSM;J1IF<*IV@>X4L,J!&A'0,,R"AO'66\S<VDHM9K(W@K>P4D3W3</4
MTPT(N9][D7=<^,1WM;$+P6+6L1VLP?S9K13.@I&EX@VTFLN6*-C.O>OH:IE8
M>V?P%X>]?C8F5LE&RGL[^:.:>Z$-" 24QC(P_'N )0AAB3",KP=.;W1I@<_'
M1_9?G7;4LF$:EE)\YI6IYU[AD0JVK!?FD]S_#@<]J>4KI=#NE^P'VYQZI.RU
MD<T!C!$TO!W^V>,A#\\ 1?@*@!X ]+\"X@,@=D*'R)RL]\RPQ4S)/5'6&MGL
MP.7&H5$-;VT5UT;A+D><6=ST&E>T)DO9;'C+7&ZG=VPC0%_, H,NK&%0'NAN
M!CKZ"EU,;F5K:DT^M!54)_#+\_B(GB$(4-LHD!X%WM"SC+=,79(X\@D-*3T5
MT'GX>RA'>'0FG'C,=^SXXA_(MR9_7V^T47BDOYQQD8PN$N<B><7%&K_TJA=
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M9C2//E,*R5"M7A:1>H)N<DNO665U>-)%#'X07"-[,BNP#26ENE@F:UA(?O+
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MMR=Z--DML6SGBT+8!8:8-%&+-VO>UV6\4DC5GNX X[&;CB2-FH6<X46B>.-
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MP!!TVOJ5#/VFZ8YK^PU1(J80];H#%+5V/Q-R%T;E]H<S$V6,2NW'N>"QT+0
MSZ=*F>4%_1:G_K'6U?\ 4$L#!!0    ( &2+SE3*6@-,104  ,\2   9
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M<+.WPXS1&5/& +Y/I=0O#^9ZW_R&-?H'4$L#!!0    ( &2+SE0\B"Y5,0,
M "D0   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;-58T4[;,!3]%2M/
MF[21.*$MH+82%*8A40U1;7M >S#)36/AV,5V*$C[^-E.25K4&M9.FOK2Q([/
MR;GWV+V][<^%O%<%@$9/)>-J$!1:ST["4*4%E$0=B!EP\R07LB3:#.4T5#,)
M)'.@DH5Q%'7#DE >#/MN[EH.^Z+2C'*XEDA594GD\QDP,1\$.'B9N*'30MN)
M<-B?D2E,0'^?74LS"AN6C); %14<2<@'P2D^&<61!;@5/RC,U=(]LJ'<"7%O
M!Y?9((BL(F"0:DM!S.411L"893(Z'A:D0?-."UR^?V'_XH(WP=P1!2/!?M),
M%X/@*$ 9Y*1B^D;,O\(BH([E2P53[A/-%VNC *65TJ)<@(V"DO+Z2IX6B5@"
M&)[U@'@!B%\#NAL R0*0N$!K92ZL<Z+)L"_%'$F[VK#9&Y<;AS;14&YMG&AI
MGE*#T\-);1\2.9K0*:<Y30G7Z#1-1<4UY5-T+1A-*2CTX1PTH4Q]1)_1Q&RG
MK&)@<3-I-I74SXCP#,%#16?&9HTJ!7G%$#,NJ7ZHC5;[QC!=Z#JK=<4;="5H
M++@N%+K@&61K\",_'L<>@M DJ<E4_)*IL]C+.";R "7X$XJC.%XGR \_A[2!
M8X^<I#$N<7R'&_C.*LHRXX]R:6=@MG(A6(9H:?QX!&N!0K=C*.] _D*_T9AR
M6E9E,^61<-A(.'02DO^Z=]#ME7DONM10*I_J3J.ZXTW<A=+4''_(T!7-8=W.
M].,[Z!F(7+>E1UL 5T+H-B%T_ZWWY.F]WO<:";T]\OZH47VTH_=^?"?:;/XV
MR)4@CIL@CKU48Y(69DJ^3MQVAQU';:6(]LARO%3A\(ZFOT'@.?';(%?#B-LP
MXIUM?_\YQVV=P<D^V=X6)WRXJ^U^ NPY[%M!5P-IZQ7VUXUON4DY['[0V^J"
MN_OD>%N2<&]7Q_T$B<?P+9"K8;0U"OM+A=?OOSCA;3W!QWOD=]P6I#C:T>\W
M"+J;_=X&68<1+C5C)<BIZU$5<KFL^[)FMNF#3UWW%[;+ZR;:M!Q3RI7YA9<;
M:'30,U\4LNY+ZX$6,]?:W0EM&D5W6YA>'J1=8)[G0NB7@7U!\^_ \ ]02P,$
M%     @ 9(O.5%\QN^/T!P  *"4  !D   !X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL[5I;;]NX$G[/KR#<;)$"KBU2EB]M$L")FZW3) V2=O=AL0^,3-M$
M=5N*BIN#\^//D)(E.9$HI6<WBP6V*!)=.-_,<"[\R.AP$XIO\9HQB;[[7A ?
M==921N_Z_=A=,Y_&O3!B ;Q9AL*G$F[%JA]'@M&%%O*]/K&L8=^G/.@<'^IG
MU^+X,$RDQP-V+5"<^#X5#R?,"S=''=S9/KCAJ[54#_K'AQ%=L5LFOT;7 N[Z
M.<J"^RR(>1@@P99'G2E^]]D>* $]XA?.-G'I&BE7[L+PF[J9+XXZEK*(><R5
M"H+"KWMVRCQ/(8$=?V2@G5RG$BQ?;]'/M//@S!V-V6GH_<H7<GW4&7?0@BUI
MXLF;</.190XY"L\-O5C_1)MT['#006X2R]#/A,$"GP?I;_H]FXB2 ,$U B03
M((\$QE:-@)T)V&TU##*!P6.!.@U.)N"TU3#,!(9M!4:9P*BMT^-,8-Q68)()
M3-H*8&L;.:NU2![LUM'&VW#CQ_&NC0;>!AP_B?BH3F0;<OPDYK4BVZ"G"=]/
M,UZ7RXQ*>GPHP@T2:CS@J0M=<UH>JH0'JCW<2@%O.<C)8R@KC]Z%@JHJ1=.5
M8 R*7\;H8,8DY5[\YK O08\:W7<SS),4D]1@3I-5#V&GBXB%1U]O9^A@OPKE
MU(PR8VX/D8%&&5>(S\SBMRP"\48C/IA1+ND#(L,FD+,6\V%CC3*L1_GY&2A?
M?JU#^6A&.4\\F)91DRWS%K');''J4<Z;)E=L40BI1_G4VA:"ZU$NVGMDB/1E
MP^S2H/ H7E/!X@J0JQ:!MM+,G62FU&)];@JW,LAJQ.I#V\A[!\E[!]'@]@_W
M#O3;!<B@N61^_+M!HYUKM+7&05W&<(]!4P3(B#ZDND3X0#WY@"(F7'@ E*8J
M$<VPF/0LZZ>JU'N^W(Y?@]RO@1'H-'P[8_>(;J>P"PPG=@6/%(6J:IUF.+EF
MZ#3T(QH\ (5S&81G@=1#P11CY,$**)5' Y>A<(GV2==QK*YE68@'>VJ88IWJ
M3< VW@/B<9R ?)HVZO'-B@7L]:LQP:/WL5+D \^[E:'[K8NHU(HBP5/PJR_[
MCH4.:!2)\#L'.L< D?V1\'OJ@:-(AF@?]X:6BE^JXDU7Z=^C0!U7,!\K$$%!
MXM_!>\##7<=.;4WMZ:+-FKMKH)ENF 02[ 1AK0!RPF=R'2Z0%P:KMY*!3SRX
MA_Q1,XRH=@7*GFGHK/3'/31+A)H@Y<4#HV*/!0M ?3*PB\JSO 8XF.EP%?#_
MP.B2'B^,M:9]9S#I&5+%R5/%,<;V-@U#%I0##C.OG[Q!_T6U7>(RQ1QJ3+5C
MN#_&MC6TK-%A_[["F&%NS-!HS,G'3RC-7=AG1-K?O V@WR[UC)GJ?I3K&;U0
MIQGG&L?/ZS15"W8*X91FU<;#P02R,Y_6=$U^.A!;Z;_J^9_D5DZ,5LZ*+J%R
M+#,5Q4Q*C]58_=$,^?K59#B:O/\: :3*\)BO=,, >'5KBO@[*&5@J9X'YG01
ME"&V?M)RH:3>UK@]A. _0J]?X:'U/KO4*O5UKG?)12S17!<2AR8 F !R!?O-
MF4A6Z&!^-7L#F]H['RI![S.#!3KAX06'=O&%\@WTCPV8 HW4@YP1B*IK8,BJ
MXR@G5,,0"UWI(3J;3=$-NX>]IWH@5/L0SW(I]\;DVS3MC2[T#(]M8Y;Z&4$#
M@>R=(Q?BP5W EH)3[Z]0#_B2TSQE,L5S=;.K'.8AA@;HKL$*>\<*VV3%]N=N
M&N6!FT:1!SJT_H.KV;0<1% TV%$TJ%!D*&YL%;L>RYCE7Z.E""%W71JO#14^
MSV J*K>Z<'%IWX6-%ESG?*54N3%*8+41D")O%Z4*RWE!I8EF/=AJX"BXH'N8
M-+ 4O=+':J7?X09=!*MY4D6\SC)(TP1F;M0.K)OJ@C1B,TW;73WRR8R;6-:\
M 7<>Z/W/+A,HL0!=["K!- >+Y!XLUC1+YIP:Y>G>1)%*(V-(D-PE?4QWSX*$
M 15B@6YTV\H%TYB[UC7=U1VRE%5[NAMN "QKD<IBW1M[E5NYQKF@BP77Y@"*
M<KV5HWM57# ?^JBA\QC!. YKFS8UH[;(R;J$6C42F0C@BPR(%S#0(%;]G ?0
M<IGJ)^IY#,IB(*CADLLJ3S_]19Y6LMZ_R]/=2BJV*=B\L6C%]X"(/O*F!1/$
M!?_%S@MQ05S07&SFN3_$LQHP_R5:_Q*M?RS1*C9N>-3F9.-9NT)<;-+P^*5Z
M0;'EPN8-TI]%W#XTZ'&:B!LIV"XQL]TM-RFSW:IC@A/RE.[:)@Y&"KI+S#1T
MNETR&QCWAPRGO0FETTHS?=V:H#.<+]YR94S$(>.KCHO)4SYJMJ.@H\1,(*:^
M.JG*#^8JE=M/SFL&CD%WL8"3IH/&G8(1@@:KUG5)BC6:O-0:38HUFIC7TS^K
M+L\;]%3594H<?T!PU]>BJY*FKOKLG=AY!FE*Z,R-YH&[9A?MFI@/U=KVH7-2
M<;)6;6OSP%U;BS9/S.WW(B?50GUA4&7F+(-HK=TN.K9M[M@W&2-XO&E#['L$
M9E4%^,)^9O.VB^9MFYLWT+TSS9[T(3^Z3L RQ6:>M:K;1:.V7^SO2J4_+/V_
M3?DJ0RC/+YE89(+Q;E)^KAAH#D31OFUS^_ZAP_^K#'1G-<&#D44>VUTQCHR=
M$7YD=K_TN8'ZANB2BA4/8N2Q)0A:O1%X+M+/<M(;&4;Z"X2[4,K0UY=K1J$O
MJP'P?AF&<GNC/FK(/XXZ_A]02P,$%     @ 9(O.5&2K2DJ> @  2P<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULC55-;^(P$/TK5K2'5BK-=T*K
M$*DEJK:'E:JB[AY6>S#) %8=F[4-Z?[[M9TT"A!0+\0?[[V9-S;CK.'B76X
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MM5] 7#F ?;Z6TCP-W)&Y_Z9:_ M02P,$%     @ 9(O.5'FDZF%'!   ' \
M !D   !X;"]W;W)K<VAE971S+W-H965T-#0N>&ULO5=M;^(X$/XK5M1*78DE
M+T" "I!:8+6]VYZJ=O?NP^H^N,E K"9VUC:PO5]_8R<-+TU#A>[V"\2.G\?/
M3,8SGM%&R">5 &CR,TNY&CN)UOFEZZHH@8RJMLB!XYN%D!G5.)1+5^42:&Q!
M6>H&GA>Z&67<F8SLW)V<C,1*IXS#G21JE654/E]#*C9CQW=>)N[9,M%FPIV,
M<KJ$!]#?\CN)([=BB5D&7#'!B83%V+GR+^=^SP#LBC\9;-3.,S&F/ KQ9 8W
M\=CQC")((=*&@N+?&J:0IH8)=?PH29UJ3P/<?7YA_V2-1V,>J8*I2/]BL4[&
MSL A,2SH*M7W8O,92H.LP$BDROZ23;&VYSDD6BDMLA*,"C+&BW_ZLW3$#@!Y
MZ@%!"0C>"^B4@,XA('P#T"T!W0/ X"T;>B7 FNX6MEO'S:BFDY$4&R+-:F0S
M#];[%HW^8MP$RH.6^)8A3D^^"+[\^!5D1F[X&I3&&-"*7,Q 4Y:J#^0C^?8P
M(Q=G'T:NQNT,R(U*ZNN".GB#VB>W@NM$D3F/(:[!3YOQG6/XV9']@P8"%_U4
M.2MX<=9UT,CXVRIM$]]KD<#SAW4&-<-OJ6R3CF_@05!G3S-\!E$%]VO@\_?#
MO09G=*K(Z5B^SHF1\_T+ LB-ADS]W;!=M]JN:[?KOK'='<@(=\#D1<2"1"++
M,,W@\8B>B$JH!%47H,V4?:_M>><-VGJ5MEZSMI6,$LQ6A,8Q,_F/IJ4H<L$X
M>;"/=2=H6O"&EM?D]/6DX_<]#[_/>C<PCB[;DQU6LL-&V5>OU#*E5A ?$QV^
M4M/OO2FF7XGI-_M00DZ?31 1+'\D-=&E372QW>A"83.1IE36*RNVZ.TH"\-.
M?S@X<&?-LD&W'QQX?=XHV%3P2Y73",8.EF@%<@W.A#1$TZ#RQ*#1$]=,?&)2
M:?+]%K)'D$VG9UAQ#G_%8?6];5GQ_O/C.CW"Z??:P^%Y;2$X$3@_ ;COD)TZ
MZ_\OAZVD#8_%=-VZ_:#>%QYLA0>-PA]H^NH;MO NIB+)<F-1K5^;.74"9"JR
MG/)GHD0:D\ ?M#"%O+CF,&1PC*?B,UZ/?V=\B5"9"TF+FZ8FN621E?C'U[.@
MVR+P8\76J!I3R9G7'O1:1 NB8 T2G<]XS-8L7M%4M0CE,3%:\KUH%1L.4B4L
M1RLCO'TK_$K(@+'@G1-JU6$QM6>S*JAM<J4(Q:NSPANJ66%HM:1<47LCQLUV
MC980B25G_R#S-K]ATE.6_:SKM7J#H97'$,#D_NMAZ+<"OV\3I6%]!BH)F$M.
MC;"FZ-W6>K_3^,'NEX#YX1T)R=_6<[_[2U+2MDC[1ZKT22FIF;/CM\.@/B6=
M")R? "P<XNYT 1G(I6V_%!JZXKJXXU:S58MW91N;@_F9:?UL=[&E*?I&O,$N
M&5<DA052>NT^:I5%*U8,M,AMK_$H-'8N]C'!]A6D68#O%T+HEX'9H&J()_\"
M4$L#!!0    ( &2+SE0B4"T:G@,   T3   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;,U876^;2!3]*R.DE;I2:YBQXR25;2DV[39JHHV2[NY#M0\$
MKLVHP-"9<=W\^[TS$+ K,K:1M<J+S<"<<S\X^. [V0CY3:4 FOS,LT)-O53K
M\KWOJSB%/%(#44*!5Y9"YI'&I5SYJI00)1:49SX+@K&?1[SP9A-[[D[.)F*M
M,U[ G21JG>>1?)I#)C93CWK/)^[Y*M7FA#^;E-$*'D#_5=Y)7/D-2\)S*!07
M!9&PG'I7]'W(F '8'7]SV*BM8V)*>13BFUE<)U,O,!E!!K$V%!%^_8 %9)EA
MPCR^UZ1>$], MX^?V3_:XK&8QTC!0F3_\$2G4^_"(PDLHW6F[\7F$]0%G1F^
M6&3*?I)-O3?P2+Q66N0U&#/(>5%]1S_K1FP!D*<;P&H ^Q4P?@$PK '#7P&C
M%P"C&C"RG:E*L7T((QW-)E)LB#2[D<T<V&9:-);/"W/?'[3$JQQQ>G8CBM6[
M+R!S<EW\ *7QEFI%WH2@(YZIW\D[\H!22]89$+$D8E. 5"DO20DRQJTH#64N
M< L&F/@:DS+4?EPG,*\28"\D,"2WHM"I(A^*!)(._,*-I\Q!X&,WFI:PYY;,
MF9/Q-I(#,J1O"0L8ZTK(#0\A;N"T QX>#@\<U0R;&SRT?*,7^.82'_X5%*"X
M(G,N-,1I(3*Q>B(+,7A+;G0R(%]O(7\$^:\CWJB)-[+QAO^/H,C7&PQ KC7D
MRI7>69/>F;,=?W8$[!*MFR48T//?NJ31#Q8>#=NI?=S4/G;R7,6Q6!<:Y4 T
M>D1U:[J*=],LA-+D%G0J.A_7GN"=BLZ;BLZ=;'^@KLLT0K'5RD9-RU+(R'K*
M :J^: )=O$957S;I79Y$U6Z68' >=*JZ'RP\&K93.PU:"PM.H^L]/'N$W1>]
M6]66,5/W#S<7G_#U[K,IZTA54]8&8:]1U[1U+^JVKT.5O8?F;'#9+>V>N/!X
MW&X#6CNEHQ.)V\VS3]P]T;M5M2Y,W9:&XO[()7(>J^S6Z^CX52J[M2[J]JZ#
ME>VFH2BURVYI]P2&/8"[/6A=E5Z<2-QNG@_?UUP_N>3=&[];66O(U.UN]^:5
M^UAUL];R6/ :U<U:]V)N]SI4W7MHAG0P9IWJ[@L,>P!W>]":*V.G4?<>GKWJ
M[H^O*O.WY@<YR)6=PRABLZ]&"<W99M9S92<<?KN]&A3AG^<5+Q3)8(E0?,=#
M'Y#5[*5::%'::<2CT%KD]C"%* %I-N#UI< 7^7IA C03L-E_4$L#!!0    (
M &2+SE1NVVA_?0,  -\/   9    >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM
M;,U7VV[C-A#]E8&>ND#6LN3$3A:V@;73[09-BB#9M@^+/M#26"*6%Y6D[*1?
MWR&MR$[K*$VQ,?)BB9<S9WAX9'+&:VV^V1+1P9T4RDZBTKGJ0QS;K$3);$]7
MJ&ADJ8UDCIJFB&UED.4!)$6<]OO#6#*NHNDX]%V;Z5C73G"%UP9L+24S]S,4
M>CV)DNBAXX87I?,=\71<L0)OT?U:71MJQ6V4G$M4EFL%!I>3Z&/R89Z,/"#,
M^(WCVNZ\@U_*0NMOOG&13Z*^SP@%9LZ'8/18X1R%\)$HCS^;H%'+Z8&[[P_1
M/X7%TV(6S.)<B]]Y[LI)=!I!CDM6"W>CUY^Q6=")CY=I8<,OK)NY_0BRVCHM
M&S!E(+G:/-E=(\0.8#A\ I V@/0?@-'9$X!! QB$A6XR"\LZ9XY-QT:OP?C9
M%,V_!&T"FE;#E=_&6V=HE!/.32^U*MY_02/A0JW0.MHA9^&'<W2,"_L.WL,M
M.2>O!8)> MXY&@=7(O P'9'V4G"TX]A1-CYFG#7,LPUS^@3S *ZT<J6%'U6.
M^1[\O!N?I!T!8I*AU2)]T&*6=D:\8J8'@^0(TGZ:[DNH&WZ.60M/.M(9M%LS
M"/&.GX@W,_05%JC0<@LSKAUFI=)"%_<PU[TCN'1Y#[Y>H5R@^:.#[[CE.PY\
M@U>V GR]I,APX5#:KKQ.VKQ..G6X0<'\)V]+7M'7X<I .M>R8NH>F,J!4YZV
M7EB><V8H@R/ZD&UF>.5A^YS93?B+!EMAQI<\@T5M:=1:O[8VBWW>^*XA'^DT
M;'4:=G+\1%:I2D;[UYB%-#*5-H'COQAEU!*-WI113MN\3@]ME&["_V64[QKR
MD4YGK4YGW7\L7'^F>\#/]._R4HLD_>VYTG]3)DEV3KSDT#9YAI'N&((M@LPD
M^;\HG:;X*[I158$]TU*BR3@3_"^$W-3%OM-U?EC.QUJG6ZW3YZSVB1OK7NRS
M[2&9#-Z6S[;':7)\<)]U,[Z.S[HY+S53F,/2:/E85D]1&;WBM";2V"(S="3Y
MWB8)OU.T_(I\04\T*YYAE_#;^T+RS(7!7YI>[+CM,9L,WY;CMN=R,CJXX[H9
M7\=Q!^7<:!WOE% TOPB5I25TK=RFFFI[V^KU8ZC9XNWT3>E+943!E06!2X+V
M>R-RJ]E4DYN&TU4HR!;:47D77DNJP-'X"32^U'1]:QJ>H*WIIW\#4$L#!!0
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MB&I/KR:*;^PNM^!*[YEVF.GW(!!&H*^O.%=O$[-Q-F]6T2M02P,$%     @
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MDO0&_#[GZ C[H*_8BDOTT=]02P,$%     @ 9(O.5!/K3^Y! P  1PD  !D
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MV"]J]P<V\8P<7Z:$\?^PJW534LXJ8U71@,F#@LOZRYZ;/!P KJ(3@*0!)$<
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M9=5MHVH(NM&'W9(*>73JUU1>T( I _E]1:G8-Y2#YLHW^@=02P,$%     @
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M=0_(T,-5]C@!#CH$R$%0(WYJ%Y^%S\"AE;2CD3X;EH902$.JD?[-+OTI3"<
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M!CT,4=?&2ZCRFX>"/E=J="'D^T&/*W7-H#$9@)(LH9TM6_3,!7IJ<W4=/]+
MT+$D2&AGR.UY<A?&8A&-GR5$34-<@@._[UNU'0ZPB]R^<]5VB%+7]0R#E,0*
M[1PGO%MF@"6K.'MFUG7KJZ9B[/>GE*],*>0YRMI6=3G]$:M-?)YQF 8LN1C:
MR7@6I5&R3L#O,Y;<L=R63T-)L##88QZ/)(LB.P.=*)"N(XD!)1!-'"NK(\E>
MR,XWL_#[6.>BK1IIGT42DCR![#PQTKEV)1!/"$*NU;T2^I$=^O^U#M,/(H4<
MXU\)L,C;IW\EOB([OKY[X&G.@TA#Q)&*0-EYN(IX&:+#>*16%@$RH0&2\(=V
M*"P&4N,!5<[0*I(0A>P0]:Z(PM%AEAB%]HE16&(4ML/+CZ5;C?(.M[L(NOV-
M"$=-%K'O&&ID+ $-VP%MESEZT>CJ<)];;8YJC9  B.WY] Z3]&) U= DQ5M[
M2 /H&&7OHYP;-6*28HEPV-WG))48B.U)Y@].4D_='7$0[F<]6,U3L8N]7N*C
M:67(H;&$6OQR4'N"5:AUB6?<P\$2;+$=(4^:))I7G5EO"U);Q& U!>1E(E9V
MG69833I[%C>NM:6=W4%)L,9VL-ZM8)\-:"MYP7Z:):LP?:YF7[O*6#7]JFF8
M51Z3?1;@/N/U>V<+3_CXE>L=<A\<@E?0=>I/0N4K1)MO?#JO6'5?(7X^%%5
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M:7MZ' \?OW?8.4'H1K;0[6QQ,-#*5C,LG7A>0EK2"2E-_+/BT\GVQM@968-
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M+1+#DFU2/1.[+U EU#-\D4A5\4MV5:QCD6BCM. 5&!7P)"N?[+$J1 /@^J\
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MLNSRRHD6>='W+(3&+JH8KK$S!FD"\/U2"/T\,:U4W6L'OP%02P,$%     @
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M6!"09WHE;EL%[N\5496F14(%)#R-00SRD+3%FCAGZB%I2S_!IWE8\_R]K)/
M[;R%SH_B0NSBCHM'<3H@[MAH[TQ=Y8RLAY<UT_E*8:6)SM5(1Q#5V%EM%"_,
M(/; E1[KS#+1HSJ($J#OKSA73YMRMFN&_]E?4$L#!!0    ( &6+SE3GO$*(
M?A<  'M_   9    >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;.U=;7/;.)+^
MKE_!\F:WDBI&)L#WF215CNULG#BQ-QI[;G;K/M 4;'%'(C4D9<=;^^.O 8($
M2)$@Y+/VJJZ2F4KT C2 [L:#Q@.P]>8ARW\O%H24QO?5,BW>'BS*<OW3X6$1
M+\@J*J;9FJ3PS6V6KZ(2WN9WA\4Z)]&<55HM#[%E>8>K*$D/WKUAGUWF[]YD
MFW*9I.0R-XK-:A7EC^_),GMX>X .Z@^^)7>+DGYP^.[-.KHC,U)>K2]S>'?8
M2)DG*Y(6298:.;E]>W"$?CHZ1;9/J[ RUPEY**37!AW,39;]3M^<S=\>6+1/
M9$GBD@J)X)][<DR62RH+>O('%WO0M$HKRJ]KZ1_8\&$X-U%!CK/EK\F\7+P]
M" Z,.;F--LOR6_;PD? AN51>G"T+]K?QP,M:!T:\*<ILQ2M##U9)6OT;?>>J
MT*F >06L6\'F%6S="@ZOX'0JV$,57%[!U6W!XQ4\W0H^K^!W*N"A"@&O$'3'
MX ]4"'F%L-O"4 5DU9:SM*LTQNY:>[A*;6[4M?>@-5!M<-2U^' KM<G1ELW1
M4)7:Z$C;ZJ@V.]*V.ZH-C[0MCVK3HZ[MAUNIC8^VK#\T?%Q;'W>M/SQQ:^OC
MKO4'G1(WD[UK_<'AX]KZ6'N^X]KZ6'O&X]KZN&M]VGY_E=KZN&O]X59JZV-M
MZ^/:^KAK_>&.U=;'VM:W:^O;7>L/CL6NK6]7"TZU0K#EY20JHW=O\NS!R&EY
MD$=?L#6*U8=5)4GI@CHK<_@V@7KEN],_-DGY:+P\(664+(M7;PY+D$J_.XRY
MA/>5!#P@X6MV/S5LRS2PA=$+X] H%E%.BNKO'G'':G&?-LNI805,G-53_41=
M_4OT:%@VK8W"GMJGZMH?R$W=. HUQO)!+>XB+D$<8N*\GNI_U1B+-UC[H_Y8
MO,$1G.U@W*O9B?'RQ2L-O7Q22SW:W(%4U)(Z*.NSAK_HRCK7&"VN9%ECLKYH
MR$)A)4M#95_5XF9D71L"A6-=N]!6?R-+]+!'WJ6&I^'*T_R>ZG_3Z X>]O-O
M&JTC?\3/9V-3+6^\".O[^2_Z4FO?[)%RI99R0N(M*1I]N]:7:NE+_75D-D:I
MT..@D/_2< C+K0;<4_VW,42 /N!0>T'Z^S@*5^XE2^N1<W2DX0T(:R/"T<C"
M*UD0A<-21M9;ML@P9:% /;R1E9<A%'8K%!AV]J.1)9AI"?,U4ZVE0XAUFH '
M-P$/9O)MS8#'^,<YE##.2K(J_ELAWV[DVTR^,R#_DN0Q2<OHCAC9K1%GJU66
M\C$825%LR-R(TKF1;<JBA!=)>M>'".HVT-2U_JSHJ]/TU5'*.>:]*[/X=]-8
M1[EQ'RTWQ'B9I,9)MEQ&>6&L25YU_Y7Q;T/I(+.J,9\U1HF<^W?6U+)@!M_+
M0],J=:U5ZNATK%A++6ZC%E>IEHL<S!+EC[79HDVYR/+D7V3>Z\^5,$_J@^U9
MU9_^?GA-/SQE/X[N<D)6X$RF,2=%G"=KRD#UQ9%J.>6"&&#J=90^,M][GV3G
M24F,7Z+D(4HG$6UF;I29$4%C\ **UT6.J1?<9'E$22]#ZE"YR+/-W<* -Z"H
M)(7:M-Z79$G G6!"74:/M*1<YV%!<G+S:,C]642@7]:!"8A@$Z16.TP?[J S
MZJ#TO533-**2O5_G2<SFV@LT]2SAKZ9QF^4P7A /\N\B&$VZ6=W UU#6];#I
M6A9O"F05U/U+^&HBM?&7/P48^3\7QFV2%R6,$J8LZ(/Q@"!DS8>XWN3%)H(7
M0TJ8&K\LB P"40I=?H!& 1_62U*"^F'*P<)%&.Q-^V(P?1OG9)645&:Y2$"[
MJVQ3]:TVZD-2+HP7GFN9X**TX3@J%LPS7KAF(#ZF,BEE2\>:DH?E8PU@PD ]
MRIK(1NNQ$I[J&@F;(:PG5F.FJ7&USJINQ5G**.#:%/0S*%'FF[C<Y "JDS*/
MTB*J.-L;4CX0DAI#$P&*0!29;^B<YYL_LV]H;7]<D.7< '=N3R=FUBB.J=+!
MJ>GPRIQ$Q8;B":U7U*H%9RK9S* #('Q9FI/;)$[*5WTN\#=]%^"&0J;C!:;O
MUAHT7M*A8.OG&7O+WJ"?7PU8TFA;4JP/+QC(&B^ASH0+O+B])53OC4C)W[AB
MY&D2&3')80&N=7FYR6.  @EBC'E$71ABP0U,O7I[P-HTZD%<'M7-32=TALTX
M7N?$(-_):ET:MWFVXLYQEX![5 Z34VWGK)G&BV<D!L<I$ZA_%#.3H-"V&3(P
M6(2^M-IN%:^[84[D07XC=QN.%K.!9M;0O\WR+JIF*\#C!EK**[Q8USJIYDXS
M9VI1M<K!V!7V5=524DY ; R06M2(5+M%HXZF+I47K:'\]P1F$X$Y_@*;=H4!
M4VJ6%K*-+@OO\^0Z88<MQ2+;+.<3P$@P=ID!<%88;3'1+>2!*5+T('R%4]14
MX'74(RKGHW.++M!W=:=6#=Q&\2(A]V1>*2)J7(G;NP!L!SCRINZ?65.L4QS$
M30!$NB+4<+-< FH8JVA.C$T-.M4J</;UQ"@V-RN88G2<#XLD7K!)SSXL.99#
M& L?]X!Y*Q+PFTC 5T[MLWK-Z(:4YG X]MG?BDL0^X/[HY*@Z4N@[,L'B(W2
M. '5L7FA$Y^<J"6V/!2,"1&R<0SPD  4@D].8-!'=5.54_"9E$,,#[ *W\\H
MEM(77\E]-(],R2P$7)V=V1ETJ\/AO3)J M,_)S&!CM>^]Y!3$Z9&FI5TTK$)
MTXQX<I;. 8V@23ZU,WAY5$6'%+PY-GPX^_I-(-/6))*&9LA#:RTYO-L;A@R1
M@5[#0O(:!=#=>Y(79%)-F&*]3%C7Z4CZ=Q?28AVWPGT.X@VJB_C,1H'I!*Z)
M73P@J6_9EZ4;#X1A,.!7>@=]HJL@[*&]T#8][*H%M58=U>0)&X<-1W8Y$"LL
M2S8"DM^#6<?\=:86V#5H S1%VX3<()[CF*&/^:@G Z-NJ8]%#768T^IZY9&?
M-@#4S(^A"_P-=IIJ35E2A5R.Z2+'#"K(;2(M<T)=!?P?X)3Z3<$;!QQKE%--
MC_OH9DE4ID"6.&ZP=MARMO;%O:R=M;VYLFS+MW'8V5;VE,1!B#T;X\[6LJ^D
MXV#+Q5Z[Y&\])=W6MJ[F:;;+@='!YOU(BZ3#&:3KNF#+0MZ8L^UXK\HJD:[4
M&0?,'W2[?:51L-UM0;$@K.SV3.5'>H/ 6WW#EHT\;VL0>-N8V/6=[FBO>R2"
M/,OVAD8K"!^D9F-.("B!:9B3)0-KNH^DX1V=NPD$<U4 J#'H"]Y.RR"!CVUG
M:]#;!3%@J^L$W4%O%T0^\BUW@"%!@CE"^M315H#Z-/[H@C<I]]9O#^COO$@H
MCWR*W8'1",('J1F?-BHI^9X9VN9[D-7E>[B=M(M>:Q5MCT[02$B],>3;(FJ)
MRE)/L\]OO!G9/D.:%X$M4D>VLY$5X%?4$\;:EF=9_D#3(HY%ZK#SURC/Z2H^
MV/87+J %+BJ+B(@$J2.(T^\DCY-F:_<T>WSAC>A-!BR6:*Q>HFN]E"1?]34[
M4MTU'@D,1$75B_4/J]>_OGT/G:-]QUU<5"M4L /'0T,*D4X,U,O94<--M8*T
MX3-UO+TH>3ZL-&Y[TL]ZRH7(#=Q.''(U7JX],K%T8?72!?'%/=V-T&694A$P
M%>B6!C8_9/LH8&C=^HQ[EB-7,4^P6&6P>I4Y$6$Z(UPW-\LDAE<5>=%WLC@B
M4 [/XV56T,TZ;)TJP9-:<(OIN:P:W2*X*$-D<CK#V*14C%SMBG[2\$*<RXA@
M3TJ_J(*#@@5V((=R%S*U,U%M#DQ6? :=H1P2;'&KV=HFI_B7?"H7,BO7T$JM
M5EN>'964DB4<I"852)$_-K#G!P$OO*G=HG!Y01;<;=(R67*VY+:DK'*:T!TK
MWZ?3+QH"G#)\9K5?%2-ZKQC1Y'TS(I,/B54OLSM"V3.9'.AHH-J9M4WZ9.U,
M).T87>T@NJ]^+O7\S#[JM,4+5J.8U*-@5![$W/\D,=N9U@1K-/_GIB@9=T)U
M11FW)2D*66AVSSB[@NX!JYWQ3<U')FE%IC63ICFP$%UHYD:+_:S(%8EUE?CN
MU*!WH8W9:V2\_)" 7KYF4\.V[=?8=1'",%\@_KI+TFBYK"DAF?>I&50ZGE-.
M,C#:H.+D)BW/.3T64S8UCD"%RXH%PM"X8'=;#G+!6Z<\CQC K!Z F-:,4&2]
M.CT&U<6 D]#7AG*:T!8Y@\V;C/@)VQ-4$SB6\ZIJDA);G"H#>1"P9O0L)&;Z
M$H17T_K$J0<L:^8U^G+ZH9E(VY-H1 LMC:D55?D0@\0)HX:8(\\IT ":8)=-
M%_JU:=R0VRRG$P6V3I2,HQ Y3PIVGE)9O$%I\GU-TH*2H+ .\VTR./Q=GH%[
M-Q0X)4 \,_#929**Q,!BNX#5VX6AL(01,'-R4VKM<=6-T"<I?BK644S>'JQA
M?"2_)P?OC+Y+2%Q0:]]H.=W-X%5/,4H'AX[;94AZ2OH01]GVP+81BZT(5F]%
M_MJV#2.S&B ";3[48*:AP#.\O1]QL./(XVEW4^Q*L'I7(O$NXA2!(N,@9?A>
M+;'?FF<IS.Y[PLX[Z?3L,, I1.#L-(&B>=.CB: ;JZE:LWT,QV'6%,P-)>J0
M0<0<,)[&=KPT3!H9K"NZO'4^VMP*H$<X75:Q.E0F\\D+9#I^8+JA18]"Z=I%
M6[219X:V(Q&]FY0=SR8Q73HZ1Q@LTIS7)\4T+*,RJK6.><@+/+51'7K(!V'5
MN<P==9D)72X9SA3-4?LB A"\H2>_G(J=L[-A5HEN4HSJ7.^$Q)4-ZDMVT[_\
M"7G6S[V3]H>9_[^9&<SS*4K9X3^]M6BJ]3.9$UA^J,$D114-^P<%.T%1HT3*
MP^/0,WW/EI6(3-OR8&WR=U+CA"Z=]A2' WHR=/04L<:JH\KZTF:O[[=A5# L
M6,VP'+=[/DSSXVVBQ7>']X^"9\':1S^]LZ.^'*.U7(?;RZ<7ND.=M 7?8H\=
MB8QTLMJ)_V_IU1GO1H<N&N 0;,'1V&J.YFMS7R=)[^E!?%X\L8='Q_;VD<3
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M)(&4;CF^B/T7J/7T#5\LN+)?LJ_V#GL.B;<*15Z#=00Y*ZH_/=1Y. ,$@RN
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M&L',8Z;F<.#:0+W?,29/"^V@F^P7_P)02P,$%     @ 98O.5),%T9N\ @
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MEVEJ+V3W#[Q^UO2QWQ FM?E"4[WK1,\NZJ>B[BB^LY?GFBM]%=OF5K^N( Q
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M9*:L >ZOI31/$WM VWC/_@502P,$%     @ 98O.5*?B6:L@ P  ;PD  !D
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M_,D!F>NGH1LG>QD8[((D"CS'G$,ZY) >S>$!I+PF]\VR13Y2(:4 J4R@Z2&
M%R3['6RP"D)].IH@7>?O]'".8LZ0"NM)5K1NN_/Q:-6-D\ Y.%M</_&B=#\#
MDV$0NTF:[B5A;TU#_2F"Q^"B8A)9"E0Z5S&Z$)OIOEDHONP&Y)PK'+?=;8E?
M1""T ;XO.%?O"SUSAV^LR1]02P,$%     @ 98O.5'32PX72 @  2 D  !D
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MZHJ77Z!VJ&_X$LZD_:*R6AOJQ<E6*I[58&U!1O/J3^[K0!P <'@$X-< _V]
M< 00U  ;.;>RS+HU)XK$8\%+),QJS68:-C86K;VAN=G&:R7T+-4X%4^W4H](
MB68\6]*<V-B>S$$1RN0I.D,WUW-T\NYT["JM9C!N4C-/*V;_"/,G6/:0-_R
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MPMY\2Z[T/6J;&_W4 6$6Z/D5Y^JQ8R[3YO$4_P%02P,$%     @ 98O.5""
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M8"E H54?.XVKX(P=WZ7TC)LW$((.0C *X2Z.184147%BP/";#*:D -V'(+A
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MB)4FFQM#,]"BK)ONC=#8PM>/*=ZR0)H7<'TKA#X.3(#NWK;Z'U!+ P04
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M LSWE1#Z>V+OB?9_1/H?4$L#!!0    ( &6+SE3L>:.=?@,  (8-   9
M>&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;+U776_;-A3]*X2PAQ9((G[I*[ -
M+/&&%6@PHT&WAV(/C$3;1"71):FX_?<C94569$9SA[0OMBB=<WG//>(E-=M+
M]5EO.3?@:U76>AYLC=E=AZ'.M[QB^DKN>&V?K*6JF+%#M0GU3G%6M*2J##&$
M<5@Q40>+67MOI18SV9A2U'RE@&ZJBJEO-[R4^WF @J<;'\1F:]R-<#';L0V_
MY^;C;J7L*.RC%*+BM1:R!HJOY\&OZ'J)$D=H$7\)OM>#:^"D/$CYV0W>%?,
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M'TI<.8!]OI;2/ W<R;K_]%K\"U!+ P04    " !EB\Y4(E M&IX#   -$P
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M''Z[O1H4X9_G%2\4R6")4'S'0Q^0U>RE6FA1VFG$H]!:Y/8PA2@!:3;@]:7
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ML5G0B8^7:6'#+ZR;N?T(LMHZ+1LP92"YVCS972/$#F X? *0-H#T'X#1V1.
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MA0G0[]><J\>!6:!OQ^?_ E!+ P04    " !EB\Y4^%6AN8L"  #I!@  &0
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MW @DMT5!Q<L,&-]-'>R\G;C-UYDR)]QHLJ%KF(.ZW]P(/7.;E#0OH)0Y+Y&
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M.(;J322'A),+Q6?FG.V *\5C\W-*,#BH)\#XF'.57F@#V5'MBW\!4$L#!!0
M   ( &6+SE01@L/=TP(  '<+   9    >&PO=V]R:W-H965T<R]S:&5E=#@U
M+GAM;-5676^;,!3]*Q;:0RNM!0SYJA*DMFA;I56*DG5[J/;@P$V"BC&SG:3]
M][L&2DF6,O9037T)MKGG^-Q[''/'.R$?U!I DT>>9FIBK;7.+VQ;16O@3)V+
M'#)\LQ22,XU3N;)5+H'%!8BG-G6<OLU9DEG!N%B;RF L-CI-,IA*HC:<,_ET
M!:G832S7>EZ8):NU-@MV,,[9"N:@[_*IQ)E=L\0)ATPE(B,2EA/KTKT(76H
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M2.4GMO^#5@F---^*I<+\1_MR;A!8:%4(R;(*K"+(DKS\)-^K0AP!%,]Y %0
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MX=HG:/<[D6J,NI1LS <&ZW>@W?!@%[R.30F-/4&_/?VUI>A#0O*->)%^C>'
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ME>,G\ \TY:3(=.&N8]SIUWTY;)^U_5[0=Y<-F.T*LVW%_&;>'(P^7BY1T$X
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M;BJ/"M:VM>U T%KW;3LJ9!>H+S/Y*4"8 LC[>TK%RT %Z#\NEO\#4$L#!!0
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MKO0I9YMK?7&!,  ]7W&NWCKFJ!NNPNPO4$L#!!0    ( &6+SE3'9K!U40,
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MJ/ 25&"""H^C>7$8A3VHBV8'4%$'%9V%^K:D, IR2;D)+3J*&82)VR>[9'4
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MRJ_[4OFB8GGX8_/A3]D7_P%02P,$%     @ 98O.5/HPA&BY @  Y#<  !H
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M?,D7R[_!;G\"4$L! A0#%     @ 9(O.5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !DB\Y4;] M
MI^\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " !DB\Y4F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &2+SE0\9M;,<P4   <0
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " !DB\Y4<V0W0W4)  #=*P  &               @(&W#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 9(O.5&])[@H9
M P  _PL  !@              ("!8A<  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( &2+SE3U.)SZ6P@  %LC   8              "
M@;$:  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !DB\Y4
MS/IM^& *  "C,   &               @(%"(P  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ 9(O.5(/R (CS"   M34  !@
M     ("!V"T  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M &2+SE0]166HQA(  %5:   8              " @0$W  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " !DB\Y4*C=IK&U,  "F" $ &
M            @(']20  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ 9(O.5$GA;0]+$   F%L  !@              ("!H)8  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &2+SE0.2M__] (  $X'
M   9              " @2&G  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ 9(O.5+:7RPNV P  8PD  !D              ("!3*H
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !DB\Y4:G_=
M(9 *   .*@  &0              @($YK@  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( &2+SE3NTJT\XQ$   B9   9
M  " @0"Y  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M9(O.5$*571GE"P  OCX  !D              ("!&LL  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " !DB\Y4CH?%^?\&  "$)0  &0
M            @($VUP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( &2+SE30B.<F30,   4)   9              " @6S>  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 9(O.5'*E/!!% P
ME0D  !D              ("!\.$  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " !DB\Y4:<-[+84.  #Q3   &0              @(%L
MY0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &2+SE0@
MBJ:Y1!D  (.'   9              " @2CT  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ 9(O.5..,:G[&!@  5QH  !D
M     ("!HPT! 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &2+SE3DJ;%4LT,  'B$ 0 9              "
M@8HR 0!X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 9(O.
M5+__?.)_ @  < 8  !D              ("!='8! 'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " !DB\Y4^Z-A=^,"  #_!@  &0
M        @($J>0$ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( &2+SE3,:3^P.P,  .H'   9              " @41\ 0!X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 9(O.5#W@S!HK!P  D1H
M !D              ("!MG\! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " !DB\Y4FX.][Y,"  "1!@  &0              @($8AP$
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &2+SE1.J$F'
M P<  +<?   9              " @>*) 0!X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ 9(O.5'.Z2&[: @  >@<  !D
M ("!')$! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !D
MB\Y4-UD24*<#  "1"P  &0              @($ME $ >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &2+SE29>+(I,0,  )@(   9
M          " @0N8 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#
M%     @ 9(O.5*>PX1&/!   !0X  !D              ("!<YL! 'AL+W=O
M<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !DB\Y4MU>4JW8#
M"@  &0              @($YH $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM
M;%!+ 0(4 Q0    ( &2+SE1<O$BFG H  +@E   9              " @>:C
M 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 9(O.5,I:
M TQ%!0  SQ(  !D              ("!N:X! 'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6Q02P$"% ,4    " !DB\Y4/(@N53$#   I$   &0
M    @($UM $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M &2+SE1?,;OC] <  "@E   9              " @9VW 0!X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ 9(O.5&2K2DJ> @  2P<  !D
M             ("!R+\! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " !DB\Y4/Y<^B6P"  "-!@  &0              @(&=P@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( &2+SE3.^\TE> ,
M %\-   9              " @4#% 0!X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ 9(O.5'FDZF%'!   ' \  !D              ("!
M[\@! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !DB\Y4
M(E M&IX#   -$P  &0              @(%MS0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( &2+SE1NVVA_?0,  -\/   9
M      " @4+1 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ 9(O.5)6?4Q"6 P  N X  !D              ("!]M0! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !DB\Y44QV:QQL$  #)#@
M&0              @('#V $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( &2+SE1(>A%A5 ,  !D+   9              " @17= 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 9(O.5/A5H;F+
M @  Z08  !D              ("!H. ! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    " !DB\Y4J1ME@P,0  "H80  &0
M@(%BXP$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( &2+
MSE3*.+M8@PH   1"   9              " @9SS 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ 9(O.5/3BV7"Q @  90D  !D
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M=#4W+GAM;%!+ 0(4 Q0    ( &2+SE0)E\ G'0<  /TN   9
M  " @34: @!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @
M9(O.5!&"P]W3 @  =PL  !D              ("!B2$" 'AL+W=O<FMS:&5E
M=',O<VAE970U.2YX;6Q02P$"% ,4    " !EB\Y4 [2E3=,#  "#$   &0
M            @(&3) ( >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4
M Q0    ( &6+SE1%H(6I<P,   @0   9              " @9TH @!X;"]W
M;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ 98O.5.>\0HA^%P
M>W\  !D              ("!1RP" 'AL+W=O<FMS:&5E=',O<VAE970V,BYX
M;6Q02P$"% ,4    " !EB\Y4X&HN4*P#   *$   &0              @('\
M0P( >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( &6+SE0+
MV93DI@,  '\-   9              " @=]' @!X;"]W;W)K<VAE971S+W-H
M965T-C0N>&UL4$L! A0#%     @ 98O.5$#_!D\$!   :A$  !D
M     ("!O$L" 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &6+SE2GXEFK( ,  &\)   9              "
M@>Y< @!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ 98O.
M5'32PX72 @  2 D  !D              ("!16 " 'AL+W=O<FMS:&5E=',O
M<VAE970W,2YX;6Q02P$"% ,4    " !EB\Y4((#\G9 $  ###0  &0
M        @(%.8P( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0
M   ( &6+SE2C2M5FN04  )X1   9              " @15H @!X;"]W;W)K
M<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ 98O.5#R(+E4Q P  *1
M !D              ("!!6X" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q0
M2P$"% ,4    " !EB\Y4?<&II-8"  !3"   &0              @(%M<0(
M>&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( &6+SE3L>:.=
M?@,  (8-   9              " @7IT @!X;"]W;W)K<VAE971S+W-H965T
M-S8N>&UL4$L! A0#%     @ 98O.5")0+1J> P  #1,  !D
M ("!+W@" 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " !E
MB\Y4;MMH?WT#  #?#P  &0              @($$? ( >&PO=V]R:W-H965T
M<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( &6+SE25GU,0E@,  +@.   9
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M970X,RYX;6Q02P$"% ,4    " !EB\Y4D_X1R L'  "V+0  &0
M    @($LD0( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0    (
M &6+SE01@L/=TP(  '<+   9              " @6Z8 @!X;"]W;W)K<VAE
M971S+W-H965T.#4N>&UL4$L! A0#%     @ 98O.5+$V23[_ P  %!(  !D
M             ("!>)L" 'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6Q02P$"
M% ,4    " !EB\Y4)_[7OJH#  ##$0  &0              @(&NGP( >&PO
M=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( &6+SE1>$(4UZ@,
M #41   9              " @8^C @!X;"]W;W)K<VAE971S+W-H965T.#@N
M>&UL4$L! A0#%     @ 98O.5-4]LRC] P  HQ   !D              ("!
ML*<" 'AL+W=O<FMS:&5E=',O<VAE970X.2YX;6Q02P$"% ,4    " !EB\Y4
M<JUX1I@"  "S!P  &0              @('DJP( >&PO=V]R:W-H965T<R]S
M:&5E=#DP+GAM;%!+ 0(4 Q0    ( &6+SE1LM8*UB ,  &@,   9
M      " @;.N @!X;"]W;W)K<VAE971S+W-H965T.3$N>&UL4$L! A0#%
M  @ 98O.5+ U,"R* @  %@<  !D              ("!<K(" 'AL+W=O<FMS
M:&5E=',O<VAE970Y,BYX;6Q02P$"% ,4    " !EB\Y4QV:P=5$#  "$"P
M&0              @($SM0( >&PO=V]R:W-H965T<R]S:&5E=#DS+GAM;%!+
M 0(4 Q0    ( &6+SE1"W(NB! ,  $$)   9              " @;NX @!X
M;"]W;W)K<VAE971S+W-H965T.30N>&UL4$L! A0#%     @ 98O.5"" _)V0
M!   PPT  !D              ("!]KL" 'AL+W=O<FMS:&5E=',O<VAE970Y
M-2YX;6Q02P$"% ,4    " !EB\Y410O&^"H#   ,$P  #0
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:+GAM;%!+!08     9P!G $@<  "]T (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>520</ContextCount>
  <ElementCount>463</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>105</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders??? Equity (Deficit) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity (Deficit) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Long-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LongTermInvestments</Role>
      <ShortName>Long-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Convertible Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/ConvertibleNotesPayable</Role>
      <ShortName>Convertible Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Bank Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BankLoans</Role>
      <ShortName>Bank Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Paycheck Protection Program Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable</Role>
      <ShortName>Paycheck Protection Program Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Short-Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ShortTermLoan</Role>
      <ShortName>Short-Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Related Parties Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactions</Role>
      <ShortName>Related Parties Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LossperShare</Role>
      <ShortName>Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/Lease</Role>
      <ShortName>Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Inventory</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PropertyandEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Long-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LongTermInvestmentsTables</Role>
      <ShortName>Long-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Bank Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BankLoansTables</Role>
      <ShortName>Bank Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BankLoans</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Related Parties Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactionsTables</Role>
      <ShortName>Related Parties Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Equity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/StockOptionsTables</Role>
      <ShortName>Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LossperShareTables</Role>
      <ShortName>Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LossperShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Lease (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LeaseTables</Role>
      <ShortName>Lease (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/Lease</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BusinessCombination</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/CollaborativeAgreements</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Inventory (Details) - Schedule of inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofinventoryTable</Role>
      <ShortName>Inventory (Details) - Schedule of inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/InventoryTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofpropertyandequipmentTable</Role>
      <ShortName>Property and Equipment (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Long-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/LongTermInvestmentsDetails</Role>
      <ShortName>Long-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Long-Term Investments (Details) - Schedule of ownership percentages of investee</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of ownership percentages of investee</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Long-Term Investments (Details) - Schedule of extent the investee relies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of extent the investee relies</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Long-Term Investments (Details) - Schedule of long-term investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleoflongterminvestmentTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of long-term investment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Long-Term Investments (Details) - Schedule of balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofbalancesheetsTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of balance sheets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Long-Term Investments (Details) - Schedule of statements of operation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofstatementsofoperationTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of statements of operation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Long-Term Investments (Details) - Schedule of equity investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofequityinvestmentsTable</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of equity investments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Convertible Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/ConvertibleNotesPayableDetails</Role>
      <ShortName>Convertible Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/ConvertibleNotesPayable</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Bank Loans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BankLoansDetails</Role>
      <ShortName>Bank Loans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BankLoansTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Bank Loans (Details) - Schedule of short-term bank loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofshorttermbankloanTable</Role>
      <ShortName>Bank Loans (Details) - Schedule of short-term bank loan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BankLoansTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Paycheck Protection Program Loan Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails</Role>
      <ShortName>Paycheck Protection Program Loan Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://metuboutique.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/NotesPayable</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Short-Term Loan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ShortTermLoanDetails</Role>
      <ShortName>Short-Term Loan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/ShortTermLoan</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Related Parties Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/RelatedPartiesTransactionsDetails</Role>
      <ShortName>Related Parties Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Related Parties Transactions (Details) - Schedule of related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of related party transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due from related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of amount due from related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due to related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of amount due to related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/EquityDetails</Role>
      <ShortName>Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/EquityTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Equity (Details) - Schedule of converted amount of debt and shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable</Role>
      <ShortName>Equity (Details) - Schedule of converted amount of debt and shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/EquityTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/StockOptionsDetails</Role>
      <ShortName>Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptionsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Stock Options (Details) - Schedule of options issued and outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable</Role>
      <ShortName>Stock Options (Details) - Schedule of options issued and outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptionsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Stock Options (Details) - Schedule of fair value of stock options granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable</Role>
      <ShortName>Stock Options (Details) - Schedule of fair value of stock options granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptionsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Loss per Share (Details) - Schedule of loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleoflosspershareTable</Role>
      <ShortName>Loss per Share (Details) - Schedule of loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LossperShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Lease (Details) - Schedule of operating lease arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable</Role>
      <ShortName>Lease (Details) - Schedule of operating lease arrangements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LeaseTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Lease (Details) - Schedule of supplemental information related to operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable</Role>
      <ShortName>Lease (Details) - Schedule of supplemental information related to operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LeaseTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable</Role>
      <ShortName>Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LeaseTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Business Combination (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/BusinessCombinationDetails</Role>
      <ShortName>Business Combination (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BusinessCombinationTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable</Role>
      <ShortName>Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BusinessCombinationTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SubsequentEvents</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Inventory (Details) - Schedule of inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofinventoryTable0</Role>
      <ShortName>Inventory (Details) - Schedule of inventory</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/InventoryTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0</Role>
      <ShortName>Property and Equipment (Details) - Schedule of property and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Long-Term Investments (Details) - Schedule of ownership percentages of investee</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of ownership percentages of investee</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Long-Term Investments (Details) - Schedule of extent the investee relies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of extent the investee relies</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Long-Term Investments (Details) - Schedule of long-term investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleoflongterminvestmentTable0</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of long-term investment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Long-Term Investments (Details) - Schedule of balance sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofbalancesheetsTable0</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of balance sheets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Long-Term Investments (Details) - Schedule of statements of operation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofstatementsofoperationTable0</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of statements of operation</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>081 - Disclosure - Long-Term Investments (Details) - Schedule of equity investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofequityinvestmentsTable0</Role>
      <ShortName>Long-Term Investments (Details) - Schedule of equity investments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LongTermInvestmentsTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>082 - Disclosure - Bank Loans (Details) - Schedule of short-term bank loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofshorttermbankloanTable0</Role>
      <ShortName>Bank Loans (Details) - Schedule of short-term bank loan</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BankLoansTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>083 - Disclosure - Related Parties Transactions (Details) - Schedule of related party transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of related party transactions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>084 - Disclosure - Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>085 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due from related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of amount due from related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>086 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due to related parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0</Role>
      <ShortName>Related Parties Transactions (Details) - Schedule of amount due to related parties</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/RelatedPartiesTransactionsTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>087 - Disclosure - Equity (Details) - Schedule of converted amount of debt and shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0</Role>
      <ShortName>Equity (Details) - Schedule of converted amount of debt and shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/EquityTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>088 - Disclosure - Stock Options (Details) - Schedule of options issued and outstanding</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0</Role>
      <ShortName>Stock Options (Details) - Schedule of options issued and outstanding</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptionsTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>089 - Disclosure - Stock Options (Details) - Schedule of fair value of stock options granted</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0</Role>
      <ShortName>Stock Options (Details) - Schedule of fair value of stock options granted</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/StockOptionsTables</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>090 - Disclosure - Loss Per Share (Details) - Schedule of loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleoflosspershareTable0</Role>
      <ShortName>Loss Per Share (Details) - Schedule of loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>091 - Disclosure - Lease (Details) - Schedule of operating lease arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0</Role>
      <ShortName>Lease (Details) - Schedule of operating lease arrangements</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LeaseTables</ParentRole>
      <Position>92</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>092 - Disclosure - Lease (Details) - Schedule of supplemental information related to operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0</Role>
      <ShortName>Lease (Details) - Schedule of supplemental information related to operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LeaseTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>093 - Disclosure - Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0</Role>
      <ShortName>Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/LeaseTables</ParentRole>
      <Position>94</Position>
    </Report>
    <Report instance="ea158528-posam1_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>094 - Disclosure - Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0</Role>
      <ShortName>Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://metuboutique.com/role/BusinessCombinationTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="POS AM" original="ea158528-posam1_abvcbio.htm">ea158528-posam1_abvcbio.htm</File>
    <File>abvc-20220331.xsd</File>
    <File>abvc-20220331_cal.xml</File>
    <File>abvc-20220331_def.xml</File>
    <File>abvc-20220331_lab.xml</File>
    <File>abvc-20220331_pre.xml</File>
    <File>ea158528ex-fee_abvcbio.htm</File>
    <File>ea158528ex21-1_abvcbio.htm</File>
    <File>ea158528ex23-2_abvcbio.htm</File>
    <File>ea158528ex4-2_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img_001.jpg</File>
    <File>img_002.jpg</File>
    <File>img_003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="4">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1379">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="11">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>120
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea158528-posam1_abvcbio.htm": {
   "axisCustom": 1,
   "axisStandard": 15,
   "contextCount": 520,
   "dts": {
    "calculationLink": {
     "local": [
      "abvc-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abvc-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ea158528-posam1_abvcbio.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abvc-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 726,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 96,
    "http://metuboutique.com/20220331": 28,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 128
   },
   "keyCustom": 137,
   "keyStandard": 326,
   "memberCustom": 75,
   "memberStandard": 19,
   "nsprefix": "abvc",
   "nsuri": "http://metuboutique.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://metuboutique.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Inventory",
     "role": "http://metuboutique.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Property and Equipment",
     "role": "http://metuboutique.com/role/PropertyandEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:LongTermInvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Long-Term Investments",
     "role": "http://metuboutique.com/role/LongTermInvestments",
     "shortName": "Long-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:LongTermInvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:ConvertibleNotesPayableDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Convertible Notes Payable",
     "role": "http://metuboutique.com/role/ConvertibleNotesPayable",
     "shortName": "Convertible Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:ConvertibleNotesPayableDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:BankLoansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Bank Loans",
     "role": "http://metuboutique.com/role/BankLoans",
     "shortName": "Bank Loans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:BankLoansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:PaycheckProtectionProgramLoanPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Paycheck Protection Program Loan Payable",
     "role": "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable",
     "shortName": "Paycheck Protection Program Loan Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:PaycheckProtectionProgramLoanPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Notes Payable",
     "role": "http://metuboutique.com/role/NotesPayable",
     "shortName": "Notes Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Short-Term Loan",
     "role": "http://metuboutique.com/role/ShortTermLoan",
     "shortName": "Short-Term Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Related Parties Transactions",
     "role": "http://metuboutique.com/role/RelatedPartiesTransactions",
     "shortName": "Related Parties Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Equity",
     "role": "http://metuboutique.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://metuboutique.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:StockOptionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Stock Options",
     "role": "http://metuboutique.com/role/StockOptions",
     "shortName": "Stock Options",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:StockOptionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Loss per Share",
     "role": "http://metuboutique.com/role/LossperShare",
     "shortName": "Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:OperatingLeasesOfLesseeDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Lease",
     "role": "http://metuboutique.com/role/Lease",
     "shortName": "Lease",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:OperatingLeasesOfLesseeDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Business Combination",
     "role": "http://metuboutique.com/role/BusinessCombination",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Subsequent Events",
     "role": "http://metuboutique.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://metuboutique.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Inventory (Tables)",
     "role": "http://metuboutique.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Property and Equipment (Tables)",
     "role": "http://metuboutique.com/role/PropertyandEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Long-Term Investments (Tables)",
     "role": "http://metuboutique.com/role/LongTermInvestmentsTables",
     "shortName": "Long-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Bank Loans (Tables)",
     "role": "http://metuboutique.com/role/BankLoansTables",
     "shortName": "Bank Loans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShortTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Related Parties Transactions (Tables)",
     "role": "http://metuboutique.com/role/RelatedPartiesTransactionsTables",
     "shortName": "Related Parties Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtConversionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Equity (Tables)",
     "role": "http://metuboutique.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtConversionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Stock Options (Tables)",
     "role": "http://metuboutique.com/role/StockOptionsTables",
     "shortName": "Stock Options (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Loss per Share (Tables)",
     "role": "http://metuboutique.com/role/LossperShareTables",
     "shortName": "Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Lease (Tables)",
     "role": "http://metuboutique.com/role/LeaseTables",
     "shortName": "Lease (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Business Combination (Tables)",
     "role": "http://metuboutique.com/role/BusinessCombinationTables",
     "shortName": "Business Combination (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c75",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "abvc:PercentageOfCommonSharesIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Organization and Description of Business (Details)",
     "role": "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c75",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "abvc:PercentageOfCommonSharesIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c76",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c76",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c78",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives",
     "role": "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://metuboutique.com/role/ConsolidatedIncomeStatement",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "abvc:MilestonePaymentsRoyaltyPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Collaborative Agreements (Details)",
     "role": "http://metuboutique.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "abvc:MilestonePaymentsRoyaltyPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Inventory (Details) - Schedule of inventory",
     "role": "http://metuboutique.com/role/ScheduleofinventoryTable",
     "shortName": "Inventory (Details) - Schedule of inventory",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InventoryGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Property and Equipment (Details)",
     "role": "http://metuboutique.com/role/PropertyandEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherDepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment",
     "role": "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
     "shortName": "Property and Equipment (Details) - Schedule of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentOtherNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c162",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Long-Term Investments (Details)",
     "role": "http://metuboutique.com/role/LongTermInvestmentsDetails",
     "shortName": "Long-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "abvc:PurchaseAdditionalShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c112",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Long-Term Investments (Details) - Schedule of ownership percentages of investee",
     "role": "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
     "shortName": "Long-Term Investments (Details) - Schedule of ownership percentages of investee",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfExtentInvesteeReliesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c114",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:RelatedPartyTransactionDescriptionOfTransactions",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Long-Term Investments (Details) - Schedule of extent the investee relies",
     "role": "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
     "shortName": "Long-Term Investments (Details) - Schedule of extent the investee relies",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfLongTermInvestmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:NonmarketableCostMethodInvestmentsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Long-Term Investments (Details) - Schedule of long-term investment",
     "role": "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
     "shortName": "Long-Term Investments (Details) - Schedule of long-term investment",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c133",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Long-Term Investments (Details) - Schedule of balance sheets",
     "role": "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
     "shortName": "Long-Term Investments (Details) - Schedule of balance sheets",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c135",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:NetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Long-Term Investments (Details) - Schedule of statements of operation",
     "role": "http://metuboutique.com/role/ScheduleofstatementsofoperationTable",
     "shortName": "Long-Term Investments (Details) - Schedule of statements of operation",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c135",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:NetSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://metuboutique.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:ShareOfEquityMethodInvesteeLosses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Long-Term Investments (Details) - Schedule of equity investments",
     "role": "http://metuboutique.com/role/ScheduleofequityinvestmentsTable",
     "shortName": "Long-Term Investments (Details) - Schedule of equity investments",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c162",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireNotesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Convertible Notes Payable (Details)",
     "role": "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
     "shortName": "Convertible Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c162",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireNotesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c224",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Bank Loans (Details)",
     "role": "http://metuboutique.com/role/BankLoansDetails",
     "shortName": "Bank Loans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c3",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Bank Loans (Details) - Schedule of short-term bank loan",
     "role": "http://metuboutique.com/role/ScheduleofshorttermbankloanTable",
     "shortName": "Bank Loans (Details) - Schedule of short-term bank loan",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c237",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:LoanFromPaycheckProtectionProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Paycheck Protection Program Loan Payable (Details)",
     "role": "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails",
     "shortName": "Paycheck Protection Program Loan Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c237",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:LoanFromPaycheckProtectionProgram",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c246",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:UnsecuredLoanAgreementsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Notes Payable (Details)",
     "role": "http://metuboutique.com/role/NotesPayableDetails",
     "shortName": "Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c246",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:UnsecuredLoanAgreementsDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c247",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnsecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Short-Term Loan (Details)",
     "role": "http://metuboutique.com/role/ShortTermLoanDetails",
     "shortName": "Short-Term Loan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c247",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnsecuredDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Related Parties Transactions (Details)",
     "role": "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
     "shortName": "Related Parties Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c280",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:RelatedPartyTransactionDescriptionOfTransactions",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Related Parties Transactions (Details) - Schedule of related party transactions",
     "role": "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
     "shortName": "Related Parties Transactions (Details) - Schedule of related party transactions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c294",
      "decimals": null,
      "lang": "en-US",
      "name": "abvc:RelatedPartyTransactionDescriptionOfTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedParties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties",
     "role": "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable",
     "shortName": "Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c49",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Stockholders\u2019 Equity (Deficit) (Unaudited)",
     "role": "http://metuboutique.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity (Deficit) (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c49",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:DueFromtheRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due from related parties",
     "role": "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
     "shortName": "Related Parties Transactions (Details) - Schedule of amount due from related parties",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:DueToRelatedPartyCurrentAndNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due to related parties",
     "role": "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
     "shortName": "Related Parties Transactions (Details) - Schedule of amount due to related parties",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c2",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Equity (Details)",
     "role": "http://metuboutique.com/role/EquityDetails",
     "shortName": "Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c76",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtConversionsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c323",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:DebtConversionConvertedInstrumentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Equity (Details) - Schedule of converted amount of debt and shares",
     "role": "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
     "shortName": "Equity (Details) - Schedule of converted amount of debt and shares",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtConversionsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c323",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:DebtConversionConvertedInstrumentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c355",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Stock Options (Details)",
     "role": "http://metuboutique.com/role/StockOptionsDetails",
     "shortName": "Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c355",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c362",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Stock Options (Details) - Schedule of options issued and outstanding",
     "role": "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
     "shortName": "Stock Options (Details) - Schedule of options issued and outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c362",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c5",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Stock Options (Details) - Schedule of fair value of stock options granted",
     "role": "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable",
     "shortName": "Stock Options (Details) - Schedule of fair value of stock options granted",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Loss per Share (Details) - Schedule of loss per share",
     "role": "http://metuboutique.com/role/ScheduleoflosspershareTable",
     "shortName": "Loss per Share (Details) - Schedule of loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "lang": null,
      "name": "abvc:WeightedaverageSharesOutstandingBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Lease (Details) - Schedule of operating lease arrangements",
     "role": "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable",
     "shortName": "Lease (Details) - Schedule of operating lease arrangements",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfOperatingLeaseArrangementsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Lease (Details) - Schedule of supplemental information related to operating leases",
     "role": "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable",
     "shortName": "Lease (Details) - Schedule of supplemental information related to operating leases",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Organization and Description of Business",
     "role": "http://metuboutique.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:OperatingLeasesFutureMinimumPaymentDueCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases",
     "role": "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable",
     "shortName": "Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c146",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPershares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Business Combination (Details)",
     "role": "http://metuboutique.com/role/BusinessCombinationDetails",
     "shortName": "Business Combination (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c366",
      "decimals": "2",
      "lang": null,
      "name": "abvc:PercentageOfGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c367",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TreasuryStockCommonValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value",
     "role": "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
     "shortName": "Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:TermsOfAgreementDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Subsequent Events (Details)",
     "role": "http://metuboutique.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c5",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:TermsOfAgreementDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c78",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives",
     "role": "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0",
     "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Inventory (Details) - Schedule of inventory",
     "role": "http://metuboutique.com/role/ScheduleofinventoryTable0",
     "shortName": "Inventory (Details) - Schedule of inventory",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c3",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:InventoryWorkInProcess",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Property and Equipment (Details) - Schedule of property and equipment",
     "role": "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0",
     "shortName": "Property and Equipment (Details) - Schedule of property and equipment",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c112",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "076 - Disclosure - Long-Term Investments (Details) - Schedule of ownership percentages of investee",
     "role": "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0",
     "shortName": "Long-Term Investments (Details) - Schedule of ownership percentages of investee",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfExtentInvesteeReliesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c114",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:RelatedPartyTransactionDescriptionOfTransactions",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "077 - Disclosure - Long-Term Investments (Details) - Schedule of extent the investee relies",
     "role": "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0",
     "shortName": "Long-Term Investments (Details) - Schedule of extent the investee relies",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfLongTermInvestmentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:NonmarketableCostMethodInvestmentsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "078 - Disclosure - Long-Term Investments (Details) - Schedule of long-term investment",
     "role": "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0",
     "shortName": "Long-Term Investments (Details) - Schedule of long-term investment",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://metuboutique.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c133",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "079 - Disclosure - Long-Term Investments (Details) - Schedule of balance sheets",
     "role": "http://metuboutique.com/role/ScheduleofbalancesheetsTable0",
     "shortName": "Long-Term Investments (Details) - Schedule of balance sheets",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c136",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080 - Disclosure - Long-Term Investments (Details) - Schedule of statements of operation",
     "role": "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0",
     "shortName": "Long-Term Investments (Details) - Schedule of statements of operation",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "pf0:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c136",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c4",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:ShareOfEquityMethodInvesteeLosses",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081 - Disclosure - Long-Term Investments (Details) - Schedule of equity investments",
     "role": "http://metuboutique.com/role/ScheduleofequityinvestmentsTable0",
     "shortName": "Long-Term Investments (Details) - Schedule of equity investments",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "082 - Disclosure - Bank Loans (Details) - Schedule of short-term bank loan",
     "role": "http://metuboutique.com/role/ScheduleofshorttermbankloanTable0",
     "shortName": "Bank Loans (Details) - Schedule of short-term bank loan",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c280",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "abvc:RelatedPartyTransactionDescriptionOfTransactions",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "083 - Disclosure - Related Parties Transactions (Details) - Schedule of related party transactions",
     "role": "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0",
     "shortName": "Related Parties Transactions (Details) - Schedule of related party transactions",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c497",
      "decimals": null,
      "lang": "en-US",
      "name": "abvc:RelatedPartyTransactionDescriptionOfTransactions",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedParties",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "084 - Disclosure - Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties",
     "role": "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0",
     "shortName": "Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:DueFromtheRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "085 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due from related parties",
     "role": "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0",
     "shortName": "Related Parties Transactions (Details) - Schedule of amount due from related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c502",
      "decimals": "0",
      "lang": null,
      "name": "abvc:DueFromtheRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:DueToRelatedPartyCurrentAndNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "086 - Disclosure - Related Parties Transactions (Details) - Schedule of amount due to related parties",
     "role": "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0",
     "shortName": "Related Parties Transactions (Details) - Schedule of amount due to related parties",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c510",
      "decimals": "0",
      "lang": null,
      "name": "abvc:DueToRelatedPartyCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c323",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtConversionConvertedInstrumentAmount1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "087 - Disclosure - Equity (Details) - Schedule of converted amount of debt and shares",
     "role": "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0",
     "shortName": "Equity (Details) - Schedule of converted amount of debt and shares",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtConversionsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c349",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtConversionConvertedInstrumentAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c364",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "088 - Disclosure - Stock Options (Details) - Schedule of options issued and outstanding",
     "role": "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0",
     "shortName": "Stock Options (Details) - Schedule of options issued and outstanding",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c364",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Collaborative Agreements",
     "role": "http://metuboutique.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c5",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "089 - Disclosure - Stock Options (Details) - Schedule of fair value of stock options granted",
     "role": "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0",
     "shortName": "Stock Options (Details) - Schedule of fair value of stock options granted",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090 - Disclosure - Loss Per Share (Details) - Schedule of loss per share",
     "role": "http://metuboutique.com/role/ScheduleoflosspershareTable0",
     "shortName": "Loss Per Share (Details) - Schedule of loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c5",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091 - Disclosure - Lease (Details) - Schedule of operating lease arrangements",
     "role": "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0",
     "shortName": "Lease (Details) - Schedule of operating lease arrangements",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "092 - Disclosure - Lease (Details) - Schedule of supplemental information related to operating leases",
     "role": "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0",
     "shortName": "Lease (Details) - Schedule of supplemental information related to operating leases",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "abvc:ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c1",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "abvc:OperatingLeasesFutureMinimumPaymentDueCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "093 - Disclosure - Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases",
     "role": "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0",
     "shortName": "Lease (Details) - Schedule of minimum future annual payments under non-cancellable leases",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea158528-posam1_abvcbio.htm",
      "contextRef": "c367",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TreasuryStockCommonValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "094 - Disclosure - Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value",
     "role": "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0",
     "shortName": "Business Combination (Details) - Schedule of assets acquired and liabilities assumed based on fair value",
     "subGroupType": "details",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 105,
   "tag": {
    "abvc_ABVCBioPharmaHKLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ABVCBioPharmaHKLimitedMember",
        "terseLabel": "ABVC BioPharma (HK), Limited [Member]"
       }
      }
     },
     "localname": "ABVCBioPharmaHKLimitedMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_AccountingTreatmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccountingTreatmentDescription",
        "terseLabel": "Accounting treatments"
       }
      }
     },
     "localname": "AccountingTreatmentDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_AccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest",
        "label": "AccruedInterest",
        "terseLabel": "Outstanding principal and accrued interest"
       }
      }
     },
     "localname": "AccruedInterest",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_AdditionCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AdditionCashPayment",
        "terseLabel": "Addition cash payment"
       }
      }
     },
     "localname": "AdditionCashPayment",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_AdditionalSharesOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares of common stock.",
        "label": "AdditionalSharesOfCommonStock",
        "terseLabel": "Additional shares of common stock"
       }
      }
     },
     "localname": "AdditionalSharesOfCommonStock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_AdjustmentsToAdditionalPaidInCapitalInCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital contribution.",
        "label": "AdjustmentsToAdditionalPaidInCapitalInCapitalContribution",
        "terseLabel": "Capital contribution"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalInCapitalContribution",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of adjustments to additional paid in capital shares capital contribution.",
        "label": "AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution",
        "terseLabel": "Capital contribution (in Shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidinCapitalSharesCapitalContribution",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_AdvanceFromCustomers": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance from customers.",
        "label": "AdvanceFromCustomers",
        "terseLabel": "Advance from customers"
       }
      }
     },
     "localname": "AdvanceFromCustomers",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_AdvancesBearInterestDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances bear interest description.",
        "label": "AdvancesBearInterestDescription",
        "terseLabel": "Advances bear interest, description"
       }
      }
     },
     "localname": "AdvancesBearInterestDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_AggregateCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Common Stock Shares.",
        "label": "AggregateCommonStockShares",
        "terseLabel": "Aggregate common stock shares"
       }
      }
     },
     "localname": "AggregateCommonStockShares",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_AggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate principal amount",
        "label": "AggregatePrincipalAmount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "AggregatePrincipalAmount",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_AggregatePrincipalAndAccruedInterestExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "AggregatePrincipalAndAccruedInterestExpense",
        "terseLabel": "Aggregate principal and accrued interest expense"
       }
      }
     },
     "localname": "AggregatePrincipalAndAccruedInterestExpense",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_AggregateWorkingcapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate working capital.",
        "label": "AggregateWorkingcapital",
        "terseLabel": "Aggregate working capital"
       }
      }
     },
     "localname": "AggregateWorkingcapital",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_AgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement related description.",
        "label": "AgreementDescription",
        "terseLabel": "Agreement, description"
       }
      }
     },
     "localname": "AgreementDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_AllocationOfThePurchasePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AllocationOfThePurchasePriceAbstract",
        "terseLabel": "Allocation of the purchase price:"
       }
      }
     },
     "localname": "AllocationOfThePurchasePriceAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_AllocationOfThePurchasePriceAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AllocationOfThePurchasePriceAbstract0",
        "terseLabel": "Allocation of the purchase price:"
       }
      }
     },
     "localname": "AllocationOfThePurchasePriceAbstract0",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_AllowanceForInventoryValuationAndObsolescenceLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for inventory valuation and obsolescence loss.",
        "label": "AllowanceForInventoryValuationAndObsolescenceLoss",
        "terseLabel": "Allowance for inventory valuation and obsolescence loss"
       }
      }
     },
     "localname": "AllowanceForInventoryValuationAndObsolescenceLoss",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofinventoryTable",
      "http://metuboutique.com/role/ScheduleofinventoryTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_AmkeyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AmkeyMember",
        "terseLabel": "Amkey [Member]"
       }
      }
     },
     "localname": "AmkeyMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_AmkeyVenturesLLCAmkeyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AmkeyVenturesLLCAmkeyMember",
        "terseLabel": "Amkey Ventures, LLC (\u201cAmkey\u201d) [Member]"
       }
      }
     },
     "localname": "AmkeyVenturesLLCAmkeyMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ArticlesOfIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ArticlesOfIncorporationMember",
        "terseLabel": "Articles of Incorporation [Member]"
       }
      }
     },
     "localname": "ArticlesOfIncorporationMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_AsiaGeneCorporationtheAsiaGeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AsiaGeneCorporationtheAsiaGeneMember",
        "terseLabel": "AsiaGene Corporation (the \u201cAsiaGene\u201d)\t[Member]"
       }
      }
     },
     "localname": "AsiaGeneCorporationtheAsiaGeneMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_AsiaGeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AsiaGeneMember",
        "terseLabel": "AsiaGene [Member]"
       }
      }
     },
     "localname": "AsiaGeneMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_AsiangeneCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AsiangeneCorporationMember",
        "terseLabel": "AsiaGene Corporation [Member]",
        "verboseLabel": "AsiaGene [Member]"
       }
      }
     },
     "localname": "AsiangeneCorporationMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BHKCoDevelopmentAggreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BHKCoDevelopmentAggreementMember",
        "terseLabel": "BHK Co Development Agreement [Member]",
        "verboseLabel": "BHK Co Development Aggreement [Member]"
       }
      }
     },
     "localname": "BHKCoDevelopmentAggreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BHKCoDevelopmentAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BHKCoDevelopmentAgreementMember",
        "terseLabel": "BHK Co-Development Agreement [Member]"
       }
      }
     },
     "localname": "BHKCoDevelopmentAgreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BankLoansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Loans [Abstract]"
       }
      }
     },
     "localname": "BankLoansAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_BankLoansDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Loans (Details) [Line Items]"
       }
      }
     },
     "localname": "BankLoansDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_BankLoansDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bank Loans (Details) [Table]"
       }
      }
     },
     "localname": "BankLoansDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_BankLoansTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BankLoansTextBlock",
        "terseLabel": "BANK LOANS"
       }
      }
     },
     "localname": "BankLoansTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_BasicLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BasicLossPerShare",
        "terseLabel": "-Basic"
       }
      }
     },
     "localname": "BasicLossPerShare",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "abvc_BeneficialConversionFeature": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for beneficial conversion feature.",
        "label": "BeneficialConversionFeature",
        "terseLabel": "Beneficial Conversion Feature"
       }
      }
     },
     "localname": "BeneficialConversionFeature",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_BioFirstAustraliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioFirstAustraliaMember",
        "terseLabel": "BioFirst (Australia) [Member]"
       }
      }
     },
     "localname": "BioFirstAustraliaMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember",
        "terseLabel": "BioFirst (Australia) Pty Ltd. (the \u201cBioFirst (Australia)\u201d) [Member]"
       }
      }
     },
     "localname": "BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioFirstCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioFirstCorporationMember",
        "terseLabel": "BioFirst Corporation [Member]",
        "verboseLabel": "BioFirst [Member]"
       }
      }
     },
     "localname": "BioFirstCorporationMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioFirstCorporationtheBioFirstMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioFirstCorporationtheBioFirstMember",
        "terseLabel": "BioFirst Corporation (the \"BioFirst\") [Member]"
       }
      }
     },
     "localname": "BioFirstCorporationtheBioFirstMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioFirstMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioFirstMember",
        "terseLabel": "BioFirst [Member]"
       }
      }
     },
     "localname": "BioFirstMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioFirstStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioFirstStockPurchaseAgreementMember",
        "terseLabel": "BioFirst Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "BioFirstStockPurchaseAgreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioHopeKingCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioHopeKingCorporationMember",
        "terseLabel": "BioHopeKing Corporation [Member]"
       }
      }
     },
     "localname": "BioHopeKingCorporationMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioKeyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioKeyMember",
        "terseLabel": "BioKey [Member]"
       }
      }
     },
     "localname": "BioKeyMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioLiteJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioLiteJapanMember",
        "terseLabel": "BioLite Japan [Member]"
       }
      }
     },
     "localname": "BioLiteJapanMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioLiteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioLiteMember",
        "terseLabel": "BioLite [Member]"
       }
      }
     },
     "localname": "BioLiteMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BioLiteTaiwanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BioLiteTaiwanMember",
        "terseLabel": "BioLite Taiwan [Member]"
       }
      }
     },
     "localname": "BioLiteTaiwanMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BorrowingsFromRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "BorrowingsFromRelatedParties",
        "terseLabel": "Borrowings from related parties"
       }
      }
     },
     "localname": "BorrowingsFromRelatedParties",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_BraingenesisBiotechnologyCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BraingenesisBiotechnologyCoLtdMember",
        "terseLabel": "Braingenesis Biotechnology Co., Ltd. [Member]"
       }
      }
     },
     "localname": "BraingenesisBiotechnologyCoLtdMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BuildingsAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BuildingsAndLeaseholdImprovementsMember",
        "terseLabel": "Buildings and leasehold improvements [Member]"
       }
      }
     },
     "localname": "BuildingsAndLeaseholdImprovementsMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BusinessCombinationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination (Details) [Line Items]"
       }
      }
     },
     "localname": "BusinessCombinationDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_BusinessCombinationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination (Details) [Table]"
       }
      }
     },
     "localname": "BusinessCombinationDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_BusinessCombinationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BusinessCombinationMember",
        "terseLabel": "Business Combination [Member]"
       }
      }
     },
     "localname": "BusinessCombinationMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiability",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_CTBCBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CTBCBankMember",
        "terseLabel": "CTBC Bank [Member]"
       }
      }
     },
     "localname": "CTBCBankMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_CathayBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CathayBankMember",
        "terseLabel": "Cathay Bank [Member]"
       }
      }
     },
     "localname": "CathayBankMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_CathayUnitedBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CathayUnitedBankMember",
        "terseLabel": "Cathay United Bank [Member]"
       }
      }
     },
     "localname": "CathayUnitedBankMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_CathayUnitedLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CathayUnitedLoanAgreementMember",
        "terseLabel": "Cathay United Loan Agreement [Member]"
       }
      }
     },
     "localname": "CathayUnitedLoanAgreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_CoDevAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Co-Dev agreement description.",
        "label": "CoDevAgreementDescription",
        "terseLabel": "Co-Dev agreement, description"
       }
      }
     },
     "localname": "CoDevAgreementDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_CodevelopmentagreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CodevelopmentagreementMember",
        "terseLabel": "Co-Dev Agreement [Member]"
       }
      }
     },
     "localname": "CodevelopmentagreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_CollaborativeAgreementsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, description",
        "label": "CollaborativeAgreementsDescription",
        "terseLabel": "Collaborative agreements, description"
       }
      }
     },
     "localname": "CollaborativeAgreementsDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_CollaborativeAgreementsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Agreements (Details) [Line Items]"
       }
      }
     },
     "localname": "CollaborativeAgreementsDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_CollaborativeAgreementsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Agreements (Details) [Table]"
       }
      }
     },
     "localname": "CollaborativeAgreementsDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_CollaborativeAgreementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeAgreementsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_CollaborativeAgreementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Agreements [Table]"
       }
      }
     },
     "localname": "CollaborativeAgreementsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_CommonStockIssuedAfterStockSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued after stock split.",
        "label": "CommonStockIssuedAfterStockSplit",
        "terseLabel": "Common stock issued post-stock split",
        "verboseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "CommonStockIssuedAfterStockSplit",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_CommonStockIssuedBeforeStockSplit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued before stock split.",
        "label": "CommonStockIssuedBeforeStockSplit",
        "terseLabel": "Common stock issued pre-stock split"
       }
      }
     },
     "localname": "CommonStockIssuedBeforeStockSplit",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_CommonStockShareAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares Authorized",
        "label": "CommonStockShareAuthorized",
        "terseLabel": "Ordinary shares authorized"
       }
      }
     },
     "localname": "CommonStockShareAuthorized",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_ConsultingAgreementDesciption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConsultingAgreementDesciption",
        "terseLabel": "Consulting agreement desciption"
       }
      }
     },
     "localname": "ConsultingAgreementDesciption",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_ConsultingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConsultingAgreementMember",
        "terseLabel": "Consulting Agreement [Member]"
       }
      }
     },
     "localname": "ConsultingAgreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ConsultingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "ConsultingFees",
        "terseLabel": "Consulting fees (in Dollars)"
       }
      }
     },
     "localname": "ConsultingFees",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_Consultingagreementdescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consulting agreement description.",
        "label": "Consultingagreementdescription",
        "terseLabel": "Consulting agreement, description"
       }
      }
     },
     "localname": "Consultingagreementdescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_ConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares value is conversion price.",
        "label": "ConversionPrice",
        "terseLabel": "Conversion price (in Dollars per share)"
       }
      }
     },
     "localname": "ConversionPrice",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "abvc_ConvertibleNotesPayableDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable (Details) [Line Items]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_ConvertibleNotesPayableDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable (Details) [Table]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_ConvertibleNotesPayableDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable Disclosure [Abstract]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableDisclosureAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ConvertibleNotesPayableDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of convertible notes payable.",
        "label": "ConvertibleNotesPayableDisclosureTextBlock",
        "terseLabel": "CONVERTIBLE NOTES PAYABLE"
       }
      }
     },
     "localname": "ConvertibleNotesPayableDisclosureTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ConvertiblePromissoryNote": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of convertible promissory note.",
        "label": "ConvertiblePromissoryNote",
        "terseLabel": "Convertible promissory note"
       }
      }
     },
     "localname": "ConvertiblePromissoryNote",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_ConvertiblePromissoryNoteValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible promissory note value.",
        "label": "ConvertiblePromissoryNoteValue",
        "terseLabel": "Convertible promissory note value (in Dollars)"
       }
      }
     },
     "localname": "ConvertiblePromissoryNoteValue",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_CumulativeTransactionAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "CumulativeTransactionAdjustments",
        "terseLabel": "Cumulative transaction adjustments"
       }
      }
     },
     "localname": "CumulativeTransactionAdjustments",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_DebtConversionConvertedInstrumentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "DebtConversionConvertedInstrumentAmount",
        "terseLabel": "Amount of Debt Converted"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_DebtInstrumentAggregateAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "DebtInstrumentAggregateAmount",
        "terseLabel": "Due from Rgene amounted"
       }
      }
     },
     "localname": "DebtInstrumentAggregateAmount",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_DenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DenominatorAbstract",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_DenominatorAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DenominatorAbstract0",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DenominatorAbstract0",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_DescriptionOfPublicOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of public offering .",
        "label": "DescriptionOfPublicOffering",
        "terseLabel": "Description of public offering"
       }
      }
     },
     "localname": "DescriptionOfPublicOffering",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_DueFromtheRelatedPartiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due From Related Parties Current.",
        "label": "DueFromtheRelatedPartiesCurrent",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "DueFromtheRelatedPartiesCurrent",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_DueToEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DueToEmployeeMember",
        "terseLabel": "Due to Employee [Member]"
       }
      }
     },
     "localname": "DueToEmployeeMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_DueToRelatedPartyCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "DueToRelatedPartyCurrentAndNoncurrent",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "DueToRelatedPartyCurrentAndNoncurrent",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_DueToshareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DueToshareholdersMember",
        "terseLabel": "Due to Shareholders [Member]"
       }
      }
     },
     "localname": "DueToshareholdersMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_EquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "EquityDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_EquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity (Details) [Table]"
       }
      }
     },
     "localname": "EquityDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_EquityMethodInvestmentsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityMethodInvestmentsNetAbstract",
        "terseLabel": "Equity Method Investments, net"
       }
      }
     },
     "localname": "EquityMethodInvestmentsNetAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_EquityMethodInvestmentsNetAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityMethodInvestmentsNetAbstract0",
        "terseLabel": "Equity Method Investments, net"
       }
      }
     },
     "localname": "EquityMethodInvestmentsNetAbstract0",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_EugeneJiangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EugeneJiangMember",
        "terseLabel": "Eugene Jiang [Member]"
       }
      }
     },
     "localname": "EugeneJiangMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember",
        "terseLabel": "Euro-Asia Investment &amp; Finance Corp Ltd. (the \u201cEuro-Asia\u201d)\t[Member]"
       }
      }
     },
     "localname": "EuroAsiaInvestmentFinanceCorpLtdtheEuroAsiaMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ExceedingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exceeding amount.",
        "label": "ExceedingAmount",
        "terseLabel": "Exceeding amount"
       }
      }
     },
     "localname": "ExceedingAmount",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_ExercisableAtAPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisableAtAPricePerShare",
        "terseLabel": "Exercisable price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisableAtAPricePerShare",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "abvc_FinancialAmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FinancialAmendmentDescription",
        "terseLabel": "Financial amendment, description"
       }
      }
     },
     "localname": "FinancialAmendmentDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_ForgivenAmountPercentageUsedForPayroll": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ForgivenAmountPercentageUsedForPayroll",
        "terseLabel": "Forgiven amount percentage used for payroll"
       }
      }
     },
     "localname": "ForgivenAmountPercentageUsedForPayroll",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_ForwardStockSplitsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for forward stock splits.",
        "label": "ForwardStockSplitsPolicyTextBlock",
        "terseLabel": "Forward Stock Split"
       }
      }
     },
     "localname": "ForwardStockSplitsPolicyTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_GainLossOnForeignExchangeChanges": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "GainLossOnForeignExchangeChanges",
        "terseLabel": "Gain/Loss on foreign exchange changes"
       }
      }
     },
     "localname": "GainLossOnForeignExchangeChanges",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_GenePharmIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GenePharmIncMember",
        "terseLabel": "GenePharm Inc. [Member]"
       }
      }
     },
     "localname": "GenePharmIncMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_GenePharmInctheGenePharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GenePharmInctheGenePharmMember",
        "terseLabel": "GenePharm Inc. (the \u201cGenePharm\u201d) [Member]"
       }
      }
     },
     "localname": "GenePharmInctheGenePharmMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_GenepharmBiotechCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GenepharmBiotechCorporationMember",
        "terseLabel": "Genepharm Biotech Corporation [Member]"
       }
      }
     },
     "localname": "GenepharmBiotechCorporationMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_GovernmentGrantIncome": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government grant income.",
        "label": "GovernmentGrantIncome",
        "negatedLabel": "Government grant income",
        "terseLabel": "Government grant income"
       }
      }
     },
     "localname": "GovernmentGrantIncome",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_GrantDateTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantDateTerm",
        "terseLabel": "Grant date term"
       }
      }
     },
     "localname": "GrantDateTerm",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "abvc_GrossProfits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "GrossProfits",
        "terseLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfits",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_ImpairmentOfEquityInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of equity investments.",
        "label": "ImpairmentOfEquityInvestments",
        "terseLabel": "Impairment of equity investments"
       }
      }
     },
     "localname": "ImpairmentOfEquityInvestments",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_InterestIncomes": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "InterestIncomes",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomes",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "InterestPortionOfMinimumLeasePaymentsSaleLeasebackTransaction",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable",
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_InterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "InterestRate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "InterestRate",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_InvestmentLoss1": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment loss.",
        "label": "InvestmentLoss1",
        "terseLabel": "Investment loss"
       }
      }
     },
     "localname": "InvestmentLoss1",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_IssuanceOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Common Stock.",
        "label": "IssuanceOfCommonStock",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "IssuanceOfCommonStock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_IssuanceOfStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceOfStockValue",
        "terseLabel": "Common stock newly issued, value"
       }
      }
     },
     "localname": "IssuanceOfStockValue",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_JIANGSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JIANGSMember",
        "terseLabel": "Jiangs [Member]"
       }
      }
     },
     "localname": "JIANGSMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_KameyamaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KameyamaMember",
        "terseLabel": "Kameyama [Member]"
       }
      }
     },
     "localname": "KameyamaMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_KeypointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KeypointMember",
        "terseLabel": "Keypoint [Member]"
       }
      }
     },
     "localname": "KeypointMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_KeypointTechnologyLtdtheKeypointMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KeypointTechnologyLtdtheKeypointMember",
        "terseLabel": "Keypoint Technology Ltd. (the \u201cKeypoint\u2019) [Member]"
       }
      }
     },
     "localname": "KeypointTechnologyLtdtheKeypointMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_KimhoConsultantsCoLtdtheKimhoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KimhoConsultantsCoLtdtheKimhoMember",
        "terseLabel": "Kimho Consultants Co., Ltd. (the \u201cKimho\u201d) [Member]"
       }
      }
     },
     "localname": "KimhoConsultantsCoLtdtheKimhoMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_LBGUSAInctheLBGUSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LBGUSAInctheLBGUSAMember",
        "terseLabel": "LBG USA, Inc. (the \u201cLBG USA\u201d) [Member]"
       }
      }
     },
     "localname": "LBGUSAInctheLBGUSAMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_LBGUSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LBGUSAMember",
        "terseLabel": "LBG USA [Member]"
       }
      }
     },
     "localname": "LBGUSAMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_LabourPensionFundPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LabourPensionFundPercentage",
        "terseLabel": "Labor pension fund percentage"
       }
      }
     },
     "localname": "LabourPensionFundPercentage",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_LbgUsaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LbgUsaIncMember",
        "terseLabel": "LBG USA, Inc.[Member]"
       }
      }
     },
     "localname": "LbgUsaIncMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_LionArtsPromotionInctheLIONMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LionArtsPromotionInctheLIONMember",
        "terseLabel": "Lion Arts Promotion Inc [Member]"
       }
      }
     },
     "localname": "LionArtsPromotionInctheLIONMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_LionArtsPromotionInctheLionArtsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LionArtsPromotionInctheLionArtsMember",
        "terseLabel": "Lion Arts Promotion Inc. (the \u201cLion Arts\u201d) [Member]"
       }
      }
     },
     "localname": "LionArtsPromotionInctheLionArtsMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_LionGeneCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LionGeneCorporationMember",
        "terseLabel": "LionGene Corporation [Member]"
       }
      }
     },
     "localname": "LionGeneCorporationMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_LionGeneCorporationtheLionGeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LionGeneCorporationtheLionGeneMember",
        "terseLabel": "LionGene Corporation (the \u201cLionGene\u201d)\t[Member]"
       }
      }
     },
     "localname": "LionGeneCorporationtheLionGeneMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_LoanAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LoanAgreementDescription",
        "terseLabel": "Loan agreement, description"
       }
      }
     },
     "localname": "LoanAgreementDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LoanAgreementMember",
        "terseLabel": "Loan Agreement [Member]"
       }
      }
     },
     "localname": "LoanAgreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_LoanAgreementTotalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan agreement total amount.",
        "label": "LoanAgreementTotalAmount",
        "terseLabel": "Loan agreement total amount"
       }
      }
     },
     "localname": "LoanAgreementTotalAmount",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_LoanAmout": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LoanAmout",
        "terseLabel": "Loan amount"
       }
      }
     },
     "localname": "LoanAmout",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_LoanFromPaycheckProtectionProgram": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LoanFromPaycheckProtectionProgram",
        "terseLabel": "Loan from paycheck protection program"
       }
      }
     },
     "localname": "LoanFromPaycheckProtectionProgram",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_LoanFromPaycheckProtectionPrograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan from pay check protection program.",
        "label": "LoanFromPaycheckProtectionPrograms",
        "terseLabel": "Loan from paycheck protection programs"
       }
      }
     },
     "localname": "LoanFromPaycheckProtectionPrograms",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_LongTermEquityInvestmentPolicy": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-term equity investment.",
        "label": "LongTermEquityInvestmentPolicy",
        "terseLabel": "Long-term Equity Investment"
       }
      }
     },
     "localname": "LongTermEquityInvestmentPolicy",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_LongTermInvestmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long Term Investment [Abstract]"
       }
      }
     },
     "localname": "LongTermInvestmentAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_LongTermInvestmentNetLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "LongTermInvestmentNetLoss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "LongTermInvestmentNetLoss",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_LongTermInvestmentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LongTermInvestmentTextBlock",
        "terseLabel": "LONG-TERM INVESTMENTS"
       }
      }
     },
     "localname": "LongTermInvestmentTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_LongTermInvestmentsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments (Details) [Line Items]"
       }
      }
     },
     "localname": "LongTermInvestmentsDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments (Details) - Schedule of extent the investee relies [Line Items]"
       }
      }
     },
     "localname": "LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments (Details) - Schedule of extent the investee relies [Table]"
       }
      }
     },
     "localname": "LongTermInvestmentsDetailsScheduleofextenttheinvesteereliesTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments (Details) - Schedule of long-term investment [Line Items]"
       }
      }
     },
     "localname": "LongTermInvestmentsDetailsScheduleoflongterminvestmentLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LongTermInvestmentsDetailsScheduleoflongterminvestmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments (Details) - Schedule of long-term investment [Table]"
       }
      }
     },
     "localname": "LongTermInvestmentsDetailsScheduleoflongterminvestmentTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments (Details) - Schedule of ownership percentages of investee [Line Items]"
       }
      }
     },
     "localname": "LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments (Details) - Schedule of ownership percentages of investee [Table]"
       }
      }
     },
     "localname": "LongTermInvestmentsDetailsScheduleofownershippercentagesofinvesteeTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LongTermInvestmentsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments (Details) [Table]"
       }
      }
     },
     "localname": "LongTermInvestmentsDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LossPerShareAbstract",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "LossPerShareAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_LossPerShareAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LossPerShareAbstract0",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "LossPerShareAbstract0",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_MergerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MergerAgreementMember",
        "terseLabel": "Merger Agreement [Member]"
       }
      }
     },
     "localname": "MergerAgreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_MilestonePaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment, description.",
        "label": "MilestonePaymentDescription",
        "terseLabel": "Milestone payment, description"
       }
      }
     },
     "localname": "MilestonePaymentDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "MilestonePayments",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_MilestonePaymentsRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments royalty percentage.",
        "label": "MilestonePaymentsRoyaltyPercentage",
        "terseLabel": "Milestone payments royalty percentage"
       }
      }
     },
     "localname": "MilestonePaymentsRoyaltyPercentage",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember",
        "terseLabel": "Mr. Tsung-Shann Jiang, Ms. Shu-Ling Jiang, Mr. Chang-Jen Jiang, Ms. Mei-Ling Jiang, and Mr. Eugene Jiang (collectively the \"Jiangs\") [Member]"
       }
      }
     },
     "localname": "MrTsungShannJiangMsShuLingJiangMrChangJenJiangMsMeiLingJiangAndMrEugeneJiangcollectivelyTheJiangsMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_NTMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NTMember",
        "terseLabel": "NT [Member]"
       }
      }
     },
     "localname": "NTMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_NetLoss1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NetLoss1",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetLoss1",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_NetLossAttributableToAbvcAndSubsidiaries": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss attributable to ABVC and subsidiaries.",
        "label": "NetLossAttributableToAbvcAndSubsidiaries",
        "totalLabel": "Net loss attributed to ABVC and subsidiaries"
       }
      }
     },
     "localname": "NetLossAttributableToAbvcAndSubsidiaries",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_NetSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NetSales",
        "terseLabel": "Net sales"
       }
      }
     },
     "localname": "NetSales",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_NonMarketableCostMethodInvestmentsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonMarketableCostMethodInvestmentsNetAbstract",
        "terseLabel": "Non-marketable Cost Method Investments, net"
       }
      }
     },
     "localname": "NonMarketableCostMethodInvestmentsNetAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_NonMarketableCostMethodInvestmentsNetAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonMarketableCostMethodInvestmentsNetAbstract0",
        "terseLabel": "Non-marketable Cost Method Investments, net"
       }
      }
     },
     "localname": "NonMarketableCostMethodInvestmentsNetAbstract0",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_NonRelatedPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NonRelatedPartiesMember",
        "terseLabel": "Non Related Parties [Member]"
       }
      }
     },
     "localname": "NonRelatedPartiesMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_NonmarketableCostMethodInvestmentsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "NonmarketableCostMethodInvestmentsNet",
        "terseLabel": "Sub total"
       }
      }
     },
     "localname": "NonmarketableCostMethodInvestmentsNet",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_NotesPayableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "localname": "NotesPayableLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/NotesPayable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_NotesPayableTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Table]"
       }
      }
     },
     "localname": "NotesPayableTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/NotesPayable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_NumberOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfDirectors",
        "terseLabel": "Number of directors"
       }
      }
     },
     "localname": "NumberOfDirectors",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abvc_NumberOfInvestors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfInvestors",
        "terseLabel": "Number of investors"
       }
      }
     },
     "localname": "NumberOfInvestors",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "abvc_NumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumeratorAbstract",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_NumeratorAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumeratorAbstract0",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NumeratorAbstract0",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_OperatingLeaseLiabilitienoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "OperatingLeaseLiabilitienoncurrent",
        "terseLabel": "Operating lease liabilities (noncurrent)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitienoncurrent",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable",
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_OperatingLeasesFutureMinimumPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeasesFutureMinimumPaymentDue",
        "terseLabel": "Total future minimum lease payments, undiscounted"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDue",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable",
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_OperatingLeasesFutureMinimumPaymentDueCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeasesFutureMinimumPaymentDueCurrent",
        "terseLabel": "2022 (excluding three months ended March 31, 2022)",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueCurrent",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable",
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_OperatingLeasesFutureMinimumPaymentDueInFourYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeasesFutureMinimumPaymentDueInFourYears",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueInFourYears",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable",
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_OperatingLeasesFutureMinimumPaymentDueInThreeYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeasesFutureMinimumPaymentDueInThreeYears",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueInThreeYears",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable",
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_OperatingLeasesFutureMinimumPaymentDueInTwoYears": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeasesFutureMinimumPaymentDueInTwoYears",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueInTwoYears",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable",
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_OperatingLeasesFutureMinimumPaymentDueThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeasesFutureMinimumPaymentDueThereafter",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentDueThereafter",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable",
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_OperatingLeasesOfLesseeDisclosuresTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OperatingLeasesOfLesseeDisclosuresTextBlock",
        "terseLabel": "LEASE"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosuresTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/Lease"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_OperatingSubleaseIncomeRelatedParties": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating sublease income  from related parties.",
        "label": "OperatingSubleaseIncomeRelatedParties",
        "terseLabel": "Operating sublease income \u2013 related parties"
       }
      }
     },
     "localname": "OperatingSubleaseIncomeRelatedParties",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_OrganizationandDescriptionofBusinessDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business (Details) [Line Items]"
       }
      }
     },
     "localname": "OrganizationandDescriptionofBusinessDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_OrganizationandDescriptionofBusinessDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business (Details) [Table]"
       }
      }
     },
     "localname": "OrganizationandDescriptionofBusinessDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_OtherThanTemporaryImpairmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for other than temporary impairment.",
        "label": "OtherThanTemporaryImpairmentPolicyTextBlock",
        "terseLabel": "Other-Than-Temporary Impairment"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentPolicyTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_OutstandingAdvanceFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of outstanding advance from related party.",
        "label": "OutstandingAdvanceFromRelatedParty",
        "terseLabel": "Outstanding advance"
       }
      }
     },
     "localname": "OutstandingAdvanceFromRelatedParty",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_OutstandingPrincipalAndAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "OutstandingPrincipalAndAccruedInterest",
        "terseLabel": "Outstanding principal and accrued interest"
       }
      }
     },
     "localname": "OutstandingPrincipalAndAccruedInterest",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_PAYCHECKPROTECTIONPROGRAMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PAYCHECKPROTECTIONPROGRAMMember",
        "terseLabel": "Paycheck Protection Program [Member]",
        "verboseLabel": "Paycheck protection program [Member]"
       }
      }
     },
     "localname": "PAYCHECKPROTECTIONPROGRAMMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_PaycheckProtectionProgramLoanPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program Loan Payable [Abstract]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanPayableAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_PaycheckProtectionProgramLoanPayableDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program Loan Payable (Details) [Line Items]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanPayableDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_PaycheckProtectionProgramLoanPayableDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Paycheck Protection Program Loan Payable (Details) [Table]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanPayableDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_PaycheckProtectionProgramLoanPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PaycheckProtectionProgramLoanPayableTextBlock",
        "terseLabel": "PAYCHECK PROTECTION PROGRAM LOAN PAYABLE"
       }
      }
     },
     "localname": "PaycheckProtectionProgramLoanPayableTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_PercentageOfCommonSharesIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of common shares issued and outstanding.",
        "label": "PercentageOfCommonSharesIssuedAndOutstanding",
        "terseLabel": "Percentage of common shares issued and outstanding"
       }
      }
     },
     "localname": "PercentageOfCommonSharesIssuedAndOutstanding",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_PercentageOfGoodwill": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PercentageOfGoodwill",
        "terseLabel": "Percentage of goodwill"
       }
      }
     },
     "localname": "PercentageOfGoodwill",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_PercentageOfIssuedShareCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of issued share capital.",
        "label": "PercentageOfIssuedShareCapital",
        "terseLabel": "Percentage of issued share capital"
       }
      }
     },
     "localname": "PercentageOfIssuedShareCapital",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_PercentageOfMonthlyContribution": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of monthly contribution.",
        "label": "PercentageOfMonthlyContribution",
        "terseLabel": "Percentage of monthly contribution"
       }
      }
     },
     "localname": "PercentageOfMonthlyContribution",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_PercentageOfPaymentsUnderCodevelopmentAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of payments under co-development agreement.",
        "label": "PercentageOfPaymentsUnderCodevelopmentAgreement",
        "terseLabel": "Percentage of payments under co-development agreement"
       }
      }
     },
     "localname": "PercentageOfPaymentsUnderCodevelopmentAgreement",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_PlacementAgentAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PlacementAgentAgreementDescription",
        "terseLabel": "Placement agent agreement, description"
       }
      }
     },
     "localname": "PlacementAgentAgreementDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_PrepaymentForLongtermInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment for long-term investments.",
        "label": "PrepaymentForLongtermInvestments",
        "terseLabel": "Prepayment for long-term investments",
        "verboseLabel": "Prepayment for long-term investments (in Dollars)"
       }
      }
     },
     "localname": "PrepaymentForLongtermInvestments",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions",
        "terseLabel": "Present value of future minimum lease payments"
       }
      }
     },
     "localname": "PresentValueOfFutureMinimumLeasePaymentSaleLeasebackTransactions",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable",
      "http://metuboutique.com/role/ScheduleofminimumfutureannualpaymentsundernoncancellableleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_PromissoryNoteDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PromissoryNoteDescription",
        "terseLabel": "Promissory note description"
       }
      }
     },
     "localname": "PromissoryNoteDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_PublicEquityOfferingExceedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "PublicEquityOfferingExceedAmount",
        "terseLabel": "Public equity offering exceed amount"
       }
      }
     },
     "localname": "PublicEquityOfferingExceedAmount",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_PurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase additional shares.",
        "label": "PurchaseAdditionalShares",
        "terseLabel": "Purchase additional shares (in Shares)"
       }
      }
     },
     "localname": "PurchaseAdditionalShares",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_PurchaseConsiderationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PurchaseConsiderationAbstract",
        "terseLabel": "Purchase consideration:"
       }
      }
     },
     "localname": "PurchaseConsiderationAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_PurchaseConsiderationAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PurchaseConsiderationAbstract0",
        "terseLabel": "Purchase consideration:"
       }
      }
     },
     "localname": "PurchaseConsiderationAbstract0",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_ReceivedLoanAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Received loan amount.",
        "label": "ReceivedLoanAmount",
        "terseLabel": "Received loan amount"
       }
      }
     },
     "localname": "ReceivedLoanAmount",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_RegularInterestRateDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regular interest rate description.",
        "label": "RegularInterestRateDescription",
        "terseLabel": "Regular interest rate, description"
       }
      }
     },
     "localname": "RegularInterestRateDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_RelatedPartiesTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "RelatedPartiesTransactionsDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Line Items]"
       }
      }
     },
     "localname": "RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions (Details) - Schedule of accounts receivable due from related parties [Table]"
       }
      }
     },
     "localname": "RelatedPartiesTransactionsDetailsScheduleofaccountsreceivableduefromrelatedpartiesTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions (Details) - Schedule of amount due to related parties [Line Items]"
       }
      }
     },
     "localname": "RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions (Details) - Schedule of amount due to related parties [Table]"
       }
      }
     },
     "localname": "RelatedPartiesTransactionsDetailsScheduleofamountduetorelatedpartiesTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_RelatedPartiesTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties Transactions (Details) [Table]"
       }
      }
     },
     "localname": "RelatedPartiesTransactionsDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_RelatedPartyTransactionDescriptionOfTransactions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents related party descriptions.",
        "label": "RelatedPartyTransactionDescriptionOfTransactions",
        "terseLabel": "Relationship with the Company and its subsidiaries, description"
       }
      }
     },
     "localname": "RelatedPartyTransactionDescriptionOfTransactions",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_RentIncome": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "RentIncome",
        "terseLabel": "Operating sublease income"
       }
      }
     },
     "localname": "RentIncome",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_RestrictedCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Common Shares.",
        "label": "RestrictedCommonShares",
        "terseLabel": "Restricted common shares"
       }
      }
     },
     "localname": "RestrictedCommonShares",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_RgeneCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RgeneCorporationMember",
        "terseLabel": "Rgene Corporation [Member]",
        "verboseLabel": "Rgene [Member]"
       }
      }
     },
     "localname": "RgeneCorporationMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_RgeneCorporationtheRgeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RgeneCorporationtheRgeneMember",
        "terseLabel": "Rgene Corporation (the \u201cRgene\u201d) [Member]"
       }
      }
     },
     "localname": "RgeneCorporationtheRgeneMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_RgeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RgeneMember",
        "terseLabel": "Rgene [Member]"
       }
      }
     },
     "localname": "RgeneMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock",
        "terseLabel": "Schedule of accounts receivable due from related parties"
       }
      }
     },
     "localname": "ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of accounts receivable due from related parties [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfAmountDueFromRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of amount due from related parties [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAmountDueFromRelatedPartiesAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfAmountDueToRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of amount due to related parties [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAmountDueToRelatedPartiesAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assets acquired and liabilities assumed based on fair value [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfAssetsAcquiredAndLiabilitiesAssumedBasedOnFairValueAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of balance sheets [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfBalanceSheetsAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfConvertedAmountOfDebtAndSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of converted amount of debt and shares [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfConvertedAmountOfDebtAndSharesAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfEquityInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of equity investments [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfEquityInvestmentsAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfExtentInvesteeReliesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of extent the investee relies.",
        "label": "ScheduleOfExtentInvesteeReliesTableTextBlock",
        "terseLabel": "Schedule of extent the investee relies"
       }
      }
     },
     "localname": "ScheduleOfExtentInvesteeReliesTableTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ScheduleOfExtentTheInvesteeReliesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of extent the investee relies [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfExtentTheInvesteeReliesAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfFairValueOfStockOptionsGrantedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of stock options granted [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfStockOptionsGrantedAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
        "terseLabel": "Schedule of minimum future annual payments under non-cancellable leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentForOperatingLeasesTableTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ScheduleOfInventoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of inventory [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInventoryAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfLongTermInvestmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of long-term investment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfLongTermInvestmentAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfLongTermInvestmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfLongTermInvestmentTableTextBlock",
        "terseLabel": "Schedule of long-term investment"
       }
      }
     },
     "localname": "ScheduleOfLongTermInvestmentTableTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ScheduleOfLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of loss per share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfLossPerShareAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of minimum future annual payments under non-cancellable leases [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMinimumFutureAnnualPaymentsUnderNonCancellableLeasesAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfOperatingLeaseArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operating lease arrangements [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseArrangementsAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfOperatingLeaseArrangementsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating lease arrangements.",
        "label": "ScheduleOfOperatingLeaseArrangementsTableTextBlock",
        "terseLabel": "Schedule of operating lease arrangements"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseArrangementsTableTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ScheduleOfOptionsIssuedAndOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of options issued and outstanding [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOptionsIssuedAndOutstandingAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfOwnershipPercentagesOfInvesteeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of ownership percentages of investee [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOwnershipPercentagesOfInvesteeAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks",
        "terseLabel": "Schedule of ownership percentages of investee"
       }
      }
     },
     "localname": "ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ScheduleOfPropertyAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of property and equipment estimated useful life.",
        "label": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
        "terseLabel": "Schedule of property and equipment useful lives"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ScheduleOfPropertyAndEquipmentUsefulLivesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property and equipment useful lives [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentUsefulLivesAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfRelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of related party transactions [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Amount due to related party.",
        "label": "ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty",
        "terseLabel": "Schedule of amount due to related parties"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsAmountDueToRelatedParty",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ScheduleOfShortTermBankLoanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of short-term bank loan [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfShortTermBankLoanAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfStatementsOfOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of statements of operation [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStatementsOfOperationAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of supplemental information related to operating leases [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfSupplementalInformationRelatedToOperatingLeasesAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SecuritiesPurchaseAgreementMember",
        "terseLabel": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_SeriesAWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SeriesAWarrantsMember",
        "terseLabel": "Series A Warrants [Member]"
       }
      }
     },
     "localname": "SeriesAWarrantsMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_SeriesBWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SeriesBWarrantsMember",
        "terseLabel": "Series B Warrants [Member]"
       }
      }
     },
     "localname": "SeriesBWarrantsMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrants",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_ShareExchangeAgreementFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareExchangeAgreementFourMember",
        "terseLabel": "Share Exchange Agreement Four [Member]"
       }
      }
     },
     "localname": "ShareExchangeAgreementFourMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ShareExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of arrangement, including but not limited to collaborative arrangements and non-collaborative arrangements.",
        "label": "ShareExchangeAgreementMember",
        "terseLabel": "Share Exchange Agreement [Member]"
       }
      }
     },
     "localname": "ShareExchangeAgreementMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ShareExchangeAgreementOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareExchangeAgreementOneMember",
        "terseLabel": "Share Exchange Agreement One [Member]"
       }
      }
     },
     "localname": "ShareExchangeAgreementOneMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ShareExchangeAgreementThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareExchangeAgreementThreeMember",
        "terseLabel": "Share Exchange Agreement Three [Member]"
       }
      }
     },
     "localname": "ShareExchangeAgreementThreeMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ShareExchangeAgreementTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ShareExchangeAgreementTwoMember",
        "terseLabel": "Share Exchange Agreement Two [Member]"
       }
      }
     },
     "localname": "ShareExchangeAgreementTwoMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_ShareOfEquityMethodInvesteeLosses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of equity method investee losses.",
        "label": "ShareOfEquityMethodInvesteeLosses",
        "terseLabel": "Share of equity method investee losses"
       }
      }
     },
     "localname": "ShareOfEquityMethodInvesteeLosses",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofequityinvestmentsTable",
      "http://metuboutique.com/role/ScheduleofequityinvestmentsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm",
        "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "abvc_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest.",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "abvc_SharesIssued1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued.",
        "label": "SharesIssued1",
        "terseLabel": "Shares issued (in Shares)"
       }
      }
     },
     "localname": "SharesIssued1",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_SharesIssuedPricePerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price per share.",
        "label": "SharesIssuedPricePerShares",
        "terseLabel": "Purchase price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShares",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "abvc_SharesOfferingPricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares offering price percentage.",
        "label": "SharesOfferingPricePercentage",
        "terseLabel": "Shares offering price percentage"
       }
      }
     },
     "localname": "SharesOfferingPricePercentage",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "abvc_StockBasedCompensationForNonemployees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock based compensation for nonemployees.",
        "label": "StockBasedCompensationForNonemployees",
        "terseLabel": "Non-employee stock-based compensation expenses"
       }
      }
     },
     "localname": "StockBasedCompensationForNonemployees",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_StockIssuedDuringPeriodShareBasedCompensationServicesforShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssuedDuringPeriodShareBasedCompensationServicesforShares",
        "terseLabel": "Stock based compensation for services (in Shares)",
        "verboseLabel": "Price per share"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareBasedCompensationServicesforShares",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_StockIssuedDuringPeriodValueShareBasedCompensationServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment services arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "StockIssuedDuringPeriodValueShareBasedCompensationServices",
        "terseLabel": "Stock based compensation for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationServices",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_StockIssuedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "StockIssuedValue",
        "terseLabel": "Issuance of common shares (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedValue",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_StockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Abstract]"
       }
      }
     },
     "localname": "StockOptionsAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "xbrltype": "stringItemType"
    },
    "abvc_StockOptionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options (Details) [Line Items]"
       }
      }
     },
     "localname": "StockOptionsDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options (Details) - Schedule of options issued and outstanding [Line Items]"
       }
      }
     },
     "localname": "StockOptionsDetailsScheduleofoptionsissuedandoutstandingLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options (Details) - Schedule of options issued and outstanding [Table]"
       }
      }
     },
     "localname": "StockOptionsDetailsScheduleofoptionsissuedandoutstandingTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_StockOptionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options (Details) [Table]"
       }
      }
     },
     "localname": "StockOptionsDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_StockOptionsTablesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options (Tables) [Line Items]"
       }
      }
     },
     "localname": "StockOptionsTablesLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_StockOptionsTablesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options (Tables) [Table]"
       }
      }
     },
     "localname": "StockOptionsTablesTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_StockOptionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockOptionsTextBlock",
        "terseLabel": "STOCK OPTIONS"
       }
      }
     },
     "localname": "StockOptionsTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/StockOptions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_StockReverseSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Stock Reverse Split.",
        "label": "StockReverseSplitPolicyTextBlock",
        "terseLabel": "Stock Reverse Split"
       }
      }
     },
     "localname": "StockReverseSplitPolicyTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_StockSubscriptionReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of stock subscription receivable.",
        "label": "StockSubscriptionReceivable",
        "terseLabel": "Stock subscription receivable (in Dollars)"
       }
      }
     },
     "localname": "StockSubscriptionReceivable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_StockSubscriptionReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "StockSubscriptionReceivableMember",
        "terseLabel": "Stock Subscription Receivable"
       }
      }
     },
     "localname": "StockSubscriptionReceivableMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_SubsequentEventsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_SubsequentEventsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "localname": "SubsequentEventsDetailsTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Line Items]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesLineItems",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) - Schedule of property and equipment useful lives [Table]"
       }
      }
     },
     "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofpropertyandequipmentusefullivesTable",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_TermsOfAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of agreement terms.",
        "label": "TermsOfAgreementDescription",
        "terseLabel": "Terms of agreement, description"
       }
      }
     },
     "localname": "TermsOfAgreementDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_TheJiangsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TheJiangsMember",
        "terseLabel": "The Jiangs [Member]"
       }
      }
     },
     "localname": "TheJiangsMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_TotalInterestExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total interest expenses.",
        "label": "TotalInterestExpenses",
        "terseLabel": "Total interest expenses"
       }
      }
     },
     "localname": "TotalInterestExpenses",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_TranslationAdjustmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for translation adjustment.",
        "label": "TranslationAdjustmentPolicyTextBlock",
        "terseLabel": "Translation Adjustment"
       }
      }
     },
     "localname": "TranslationAdjustmentPolicyTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_TwoThousandSixteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandSixteenEquityIncentivePlanMember",
        "terseLabel": "2016 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandSixteenEquityIncentivePlanMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_TypeOfCurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypeOfCurrencyAxis",
        "terseLabel": "Type Of Currency [Axis]"
       }
      }
     },
     "localname": "TypeOfCurrencyAxis",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_TypeOfCurrencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TypeOfCurrency [Domain]"
       }
      }
     },
     "localname": "TypeOfCurrencyDomain",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_UnpaidConsultingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "UnpaidConsultingFees",
        "terseLabel": "Unpaid consulting fees (in Dollars)"
       }
      }
     },
     "localname": "UnpaidConsultingFees",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_UnrestrictedCommonShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UnrestrictedCommonShares",
        "terseLabel": "Unrestricted common shares"
       }
      }
     },
     "localname": "UnrestrictedCommonShares",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_UnsecuredConvertiblePromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UnsecuredConvertiblePromissoryNoteMember",
        "terseLabel": "Unsecured Convertible Promissory Notes [Member]",
        "verboseLabel": "Unsecured convertible promissory note [Member]"
       }
      }
     },
     "localname": "UnsecuredConvertiblePromissoryNoteMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_UnsecuredLoanAgreementsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of unsecured loan agreements.",
        "label": "UnsecuredLoanAgreementsDescription",
        "terseLabel": "Unsecured loan agreement, description"
       }
      }
     },
     "localname": "UnsecuredLoanAgreementsDescription",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/NotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_UpfrontCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payments which are paid during the term of agreement.",
        "label": "UpfrontCashPayment",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "UpfrontCashPayment",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for valuation of deferred tax assets.",
        "label": "ValuationOfDeferredTaxAssetsPolicyTextBlock",
        "terseLabel": "Valuation of Deferred Tax Assets"
       }
      }
     },
     "localname": "ValuationOfDeferredTaxAssetsPolicyTextBlock",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "abvc_ViewTradeSecuritiesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ViewTradeSecuritiesIncMember",
        "terseLabel": "View Trade Securities Inc. [Member]"
       }
      }
     },
     "localname": "ViewTradeSecuritiesIncMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_WallachBethCapitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WallachBethCapitalLLCMember",
        "terseLabel": "WallachBeth Capital LLC [Member]"
       }
      }
     },
     "localname": "WallachBethCapitalLLCMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_WarrantIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant issued.",
        "label": "WarrantIssued",
        "terseLabel": "Warrant issued"
       }
      }
     },
     "localname": "WarrantIssued",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_WarrantTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant term",
        "label": "WarrantTerm",
        "terseLabel": "Warrant term"
       }
      }
     },
     "localname": "WarrantTerm",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "abvc_WarrantsPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsPurchased",
        "terseLabel": "Warrants purchased"
       }
      }
     },
     "localname": "WarrantsPurchased",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "abvc_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageDiscountRateAbstract",
        "terseLabel": "Weighted Average Discount Rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_WeightedAverageDiscountRateAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageDiscountRateAbstract0",
        "terseLabel": "Weighted Average Discount Rate:"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract0",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_WeightedAverageNumberOfSharesDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average shares outstanding .",
        "label": "WeightedAverageNumberOfSharesDiluted",
        "terseLabel": "Weighted-average shares outstanding - Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesDiluted",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "abvc_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageRemainingLeaseTermAbstract",
        "terseLabel": "Weighted Average Remaining Lease Term:"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_WeightedAverageRemainingLeaseTermAbstract0": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WeightedAverageRemainingLeaseTermAbstract0",
        "terseLabel": "Weighted Average Remaining Lease Term:"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract0",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "abvc_WeightedaverageSharesOutstandingBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average shares outstanding.",
        "label": "WeightedaverageSharesOutstandingBasic",
        "terseLabel": "Weighted-average shares outstanding - Basic"
       }
      }
     },
     "localname": "WeightedaverageSharesOutstandingBasic",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "abvc_YoshinobuOdairatheOdairaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "YoshinobuOdairatheOdairaMember",
        "terseLabel": "Yoshinobu Odaira (the \u201cOdaira\u201d) [Member]"
       }
      }
     },
     "localname": "YoshinobuOdairatheOdairaMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_YuanGeneCorporationtheYuanGeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "YuanGeneCorporationtheYuanGeneMember",
        "terseLabel": "YuanGene Corporation (the \u201cYuanGene\u201d) [Member]"
       }
      }
     },
     "localname": "YuanGeneCorporationtheYuanGeneMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_YuanGeneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "YuanGeneMember",
        "terseLabel": "YuanGene [Member]"
       }
      }
     },
     "localname": "YuanGeneMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_YuangeneCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "YuangeneCorporationMember",
        "terseLabel": "YuanGene Corporation [Member]"
       }
      }
     },
     "localname": "YuangeneCorporationMember",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "abvc_principalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "principalAmount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "principalAmount",
     "nsuri": "http://metuboutique.com/20220331",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description",
        "terseLabel": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityListingParValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.",
        "label": "Entity Listing, Par Value Per Share",
        "terseLabel": "Consulting and advisory services value per share (in Dollars per share)"
       }
      }
     },
     "localname": "EntityListingParValuePerShare",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://metuboutique.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CondensedBalanceSheetStatementTable": {
     "auth_ref": [
      "r124",
      "r369",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet Statement [Table]"
       }
      }
     },
     "localname": "CondensedBalanceSheetStatementTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Balance Sheet Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedIncomeStatementTable": {
     "auth_ref": [
      "r124",
      "r369",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Income Statement [Table]"
       }
      }
     },
     "localname": "CondensedIncomeStatementTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Income Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r247",
      "r268",
      "r298",
      "r300",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r514",
      "r515",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r226",
      "r247",
      "r268",
      "r298",
      "r300",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r514",
      "r515",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r247",
      "r268",
      "r293",
      "r298",
      "r300",
      "r329",
      "r330",
      "r331",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r514",
      "r515",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r247",
      "r268",
      "r293",
      "r298",
      "r300",
      "r329",
      "r330",
      "r331",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r514",
      "r515",
      "r533",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r124",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of balance sheets"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "auth_ref": [
      "r124",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Income Statement [Table Text Block]",
        "terseLabel": "Schedule of statements of operation"
       }
      }
     },
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r190",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r45",
      "r434"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r191",
      "r192"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r26",
      "r123",
      "r425",
      "r428",
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable due from related parties"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r26",
      "r123",
      "r425",
      "r428"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable \u2013 related parties, net"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee benefits",
        "verboseLabel": "Due to employee amount"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r15",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r65",
      "r72",
      "r73",
      "r74",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r63",
      "r64",
      "r65",
      "r495",
      "r520",
      "r521"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r27",
      "r434"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r334",
      "r335",
      "r336",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock based compensation for options granted"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r18",
      "r120",
      "r175",
      "r179",
      "r185",
      "r199",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r375",
      "r382",
      "r398",
      "r432",
      "r434",
      "r466",
      "r490"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable",
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r41",
      "r120",
      "r199",
      "r230",
      "r231",
      "r232",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r375",
      "r382",
      "r398",
      "r432",
      "r434"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r297",
      "r299",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r297",
      "r299",
      "r357",
      "r358",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "BUSINESS COMBINATION"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Total assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "negatedLabel": "Total liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "terseLabel": "Total net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedLabel": "Tenant security deposit"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Security deposits"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "terseLabel": "Goodwill as a result of the Merger"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r11",
      "r434",
      "r522",
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r11",
      "r106"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r107",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r99",
      "r106",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Ending",
        "periodStartLabel": "Beginning"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r99",
      "r399"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash financing and investing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r117",
      "r120",
      "r142",
      "r143",
      "r144",
      "r147",
      "r149",
      "r159",
      "r160",
      "r161",
      "r199",
      "r230",
      "r235",
      "r236",
      "r237",
      "r241",
      "r242",
      "r266",
      "r267",
      "r270",
      "r274",
      "r280",
      "r398",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants exercise price (in Dollars per share)",
        "verboseLabel": "Exercise price per share (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Convertible promissory note, shares (in Shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r365",
      "r366",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATIVE AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r227",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r126",
      "r127",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value (in Dollars per share)",
        "verboseLabel": "Common stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r24",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r24",
      "r434"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value, 100,000,000 authorized, 30,307,329 and 28,926,322 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Outstanding amount"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r67",
      "r69",
      "r70",
      "r80",
      "r477",
      "r507"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r164",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r289",
      "r290",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Due to related parties (in Dollars)"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockDescription": {
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Description",
        "terseLabel": "Conversion price, description"
       }
      }
     },
     "localname": "ConversionOfStockDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Aggregate shares of common stock (in Shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r21",
      "r468",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible debenture"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Conversion Price [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes payable \u2013 noncurrent portion"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r21",
      "r468",
      "r492",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible note payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r83",
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Licensing rights"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r84",
      "r120",
      "r199",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r398"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenues"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r109",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "netLabel": "Due to related parties consideration (in Dollars)",
        "terseLabel": "Common shares issued for debt conversion",
        "verboseLabel": "Amount of Debt Converted"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r109",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Number of Shares Issued"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Conversion [Line Items]"
       }
      }
     },
     "localname": "DebtConversionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionTable": {
     "auth_ref": [
      "r109",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table that contains information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion [Table]"
       }
      }
     },
     "localname": "DebtConversionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r246",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in Dollars per share)",
        "verboseLabel": "Common stock price per share (in Dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": {
     "auth_ref": [
      "r53",
      "r281",
      "r282",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for debt instrument.",
        "label": "Debt Instrument, Convertible, Terms of Conversion Feature",
        "terseLabel": "Debt conversion, description"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleTermsOfConversionFeature",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Percentage of common stock shares",
        "verboseLabel": "Offering price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentDecreaseForgiveness": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.",
        "label": "Debt Instrument, Decrease, Forgiveness",
        "terseLabel": "Loan forgiven"
       }
      }
     },
     "localname": "DebtInstrumentDecreaseForgiveness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r20",
      "r21",
      "r281",
      "r467",
      "r468",
      "r483",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument, Description",
        "terseLabel": "Debt Instrument, Description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r244",
      "r259",
      "r260",
      "r410",
      "r412",
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "terseLabel": "Accrued convertible interest",
        "verboseLabel": "Accrued interest expense"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/ShortTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r50",
      "r253",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Bears interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r50",
      "r258",
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Bears interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r50",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateTerms": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.",
        "label": "Debt Instrument, Interest Rate Terms",
        "terseLabel": "Loan agreement, description"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r51",
      "r247",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ShortTermLoanDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentPaymentTerms": {
     "auth_ref": [
      "r52",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.",
        "label": "Debt Instrument, Payment Terms",
        "terseLabel": "Debt instrument payment term description",
        "verboseLabel": "Debt Instrument, Payment Terms of description"
       }
      }
     },
     "localname": "DebtInstrumentPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r104",
      "r121",
      "r348",
      "r353",
      "r354",
      "r355"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of plan assets to benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Funded Percentage",
        "terseLabel": "Benefit percentage"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r104",
      "r216"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r61",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromAffiliateNoncurrent": {
     "auth_ref": [
      "r425",
      "r427",
      "r431",
      "r465",
      "r488",
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables due from an entity that is affiliated with the reporting entity by means of direct or indirect ownership, due after 1 year (or 1 business cycle).",
        "label": "Due from Affiliate, Noncurrent",
        "terseLabel": "Consultant services agreement"
       }
      }
     },
     "localname": "DueFromAffiliateNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromEmployeesNoncurrent": {
     "auth_ref": [
      "r425",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from an Entity employee, not to include stockholders or officers, which are usually due after 1 year (or 1 business cycle).",
        "label": "Due from Employees, Noncurrent",
        "terseLabel": "Due amount"
       }
      }
     },
     "localname": "DueFromEmployeesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromOtherRelatedParties": {
     "auth_ref": [
      "r123",
      "r425",
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount receivable from related parties classified as other.",
        "label": "Due from Other Related Parties",
        "terseLabel": "Due from BHK"
       }
      }
     },
     "localname": "DueFromOtherRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromOtherRelatedPartiesCurrent": {
     "auth_ref": [
      "r123",
      "r425"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount receivable from related parties classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Due from Other Related Parties, Current",
        "terseLabel": "Due from related parties"
       }
      }
     },
     "localname": "DueFromOtherRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r6",
      "r25",
      "r123",
      "r233",
      "r235",
      "r236",
      "r240",
      "r241",
      "r242",
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Due from rgene"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToOtherRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r123",
      "r425",
      "r473",
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable to related parties classified as other.",
        "label": "Due to Other Related Parties",
        "terseLabel": "Amount received"
       }
      }
     },
     "localname": "DueToOtherRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r45",
      "r123",
      "r233",
      "r235",
      "r236",
      "r240",
      "r241",
      "r242",
      "r425"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Due to related parties",
        "verboseLabel": "Outstanding balance and accrued interest"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r81",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r139",
      "r142",
      "r147",
      "r148",
      "r149",
      "r153",
      "r154",
      "r395",
      "r396",
      "r478",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic and diluted (in Dollars per share)",
        "verboseLabel": "-Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleoflosspershareTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r81",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r142",
      "r147",
      "r148",
      "r149",
      "r153",
      "r154",
      "r395",
      "r396",
      "r478",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "-Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable",
      "http://metuboutique.com/role/ScheduleoflosspershareTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/LossperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Employee stock-based compensation expenses",
        "verboseLabel": "Stock-based compensation expenses (in Dollars)"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails",
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits.",
        "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash",
        "terseLabel": "Employee benefits amount"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r72",
      "r73",
      "r74",
      "r126",
      "r127",
      "r128",
      "r130",
      "r136",
      "r138",
      "r158",
      "r201",
      "r280",
      "r284",
      "r334",
      "r335",
      "r336",
      "r350",
      "r351",
      "r394",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r421",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "netLabel": "Percentage of common shares issued and outstanding",
        "terseLabel": "Ownership percentage",
        "verboseLabel": "Interest rate percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r12",
      "r176",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule of equity investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/LongTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r196",
      "r509"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "terseLabel": "Gain/Loss on investment in equity securities",
        "verboseLabel": "Share of losses from investments accounted for using the equity method"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of excess stock shares permitted to be issued.",
        "label": "Excess Stock, Shares Authorized",
        "terseLabel": "Common Stock authorized (in Shares)"
       }
      }
     },
     "localname": "ExcessStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ExcessStockSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders.",
        "label": "Excess Stock, Shares Issued",
        "terseLabel": "Additional shares issued (in Shares)",
        "verboseLabel": "Common shares, issued"
       }
      }
     },
     "localname": "ExcessStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Year"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign-currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r16",
      "r205",
      "r207",
      "r209",
      "r212",
      "r434",
      "r464"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill, net"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r104",
      "r206",
      "r208",
      "r211",
      "r212"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedLabel": "Impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r82",
      "r120",
      "r175",
      "r178",
      "r181",
      "r184",
      "r186",
      "r199",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r398"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Gross profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r104",
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Goodwill write-down value (in Dollars)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r215",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r371",
      "r373"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "abvc_NetLossAttributableToAbvcAndSubsidiaries",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r77",
      "r175",
      "r178",
      "r181",
      "r184",
      "r186",
      "r462",
      "r475",
      "r481",
      "r510"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r78",
      "r104",
      "r173",
      "r197",
      "r474",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Share of losses from investments accounted for using the equity method"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r122",
      "r137",
      "r138",
      "r174",
      "r343",
      "r352",
      "r356",
      "r511"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income tax"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r339",
      "r340",
      "r345",
      "r346",
      "r347",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock options (in Dollars)",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable",
      "http://metuboutique.com/role/ScheduleoflosspershareTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r101",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseDueFromOtherRelatedParties": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables due from related parties classified as other.",
        "label": "Increase (Decrease) Due from Other Related Parties",
        "negatedLabel": "Decrease (increase) in due from related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseDueFromOtherRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase (decrease) in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables, and operating assets classified as other.",
        "label": "Increase (Decrease) in Accounts Receivable and Other Operating Assets",
        "negatedLabel": "Decrease (increase) in prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Increase (decrease) in accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties",
        "terseLabel": "Increase (decrease) in due to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase (decrease) in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Increase (decrease) in advanced from others"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Decrease (increase) in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntercompanyAgreementsDescription": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of product support, consulting, business, or other advisory service agreements entered into between the managing member or general partner and the LLC or LP, affiliate of the managing member or general partner, or affiliate of the LLC or LP. Includes a description of the key provisions of such agreements and the amount of compensation for such services during the accounting period.",
        "label": "Intercompany Agreements, Description",
        "terseLabel": "Consulting service, description"
       }
      }
     },
     "localname": "IntercompanyAgreementsDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestAndDebtExpense": {
     "auth_ref": [
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity.",
        "label": "Interest and Debt Expense",
        "terseLabel": "Interest expenses"
       }
      }
     },
     "localname": "InterestAndDebtExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r75",
      "r172",
      "r408",
      "r411",
      "r480"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense classified as other.",
        "label": "Interest Expense, Other",
        "terseLabel": "Interest expenses"
       }
      }
     },
     "localname": "InterestExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.",
        "label": "Interest Expense, Related Party",
        "terseLabel": "Interest expenses"
       }
      }
     },
     "localname": "InterestExpenseRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r97",
      "r100",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest expense paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofinventoryTable",
      "http://metuboutique.com/role/ScheduleofinventoryTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofinventoryTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r39",
      "r434"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofinventoryTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r37",
      "r114",
      "r156",
      "r202",
      "r203",
      "r204",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofinventoryTable",
      "http://metuboutique.com/role/ScheduleofinventoryTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofinventoryTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentCompanyShareholderServiceFeeExpense": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for shareholder services. Includes, but is not limited to, fee and expense for transfer and dividend disbursing agent.",
        "label": "Investment Company, Shareholder Service Fee Expense",
        "terseLabel": "Service fee amount (in Dollars)"
       }
      }
     },
     "localname": "InvestmentCompanyShareholderServiceFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Investment Interest Rate",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal fees (in Dollars)"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r120",
      "r180",
      "r199",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r376",
      "r382",
      "r383",
      "r398",
      "r432",
      "r433"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable",
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r32",
      "r120",
      "r199",
      "r398",
      "r434",
      "r470",
      "r498"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r49",
      "r120",
      "r199",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r376",
      "r382",
      "r383",
      "r398",
      "r432",
      "r433",
      "r434"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansPayable": {
     "auth_ref": [
      "r21",
      "r468",
      "r486"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Loans Payable",
        "terseLabel": "Paycheck Protection Program Loan Payable"
       }
      }
     },
     "localname": "LoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansReceivableWithFixedRatesOfInterest1": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loan with fixed rate of interest.",
        "label": "Loans Receivable with Fixed Rates of Interest",
        "terseLabel": "Loan interest"
       }
      }
     },
     "localname": "LoansReceivableWithFixedRatesOfInterest1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLineOfCredit": {
     "auth_ref": [
      "r54",
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit, Noncurrent",
        "terseLabel": "Outstanding loan balance"
       }
      }
     },
     "localname": "LongTermLineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r60",
      "r120",
      "r199",
      "r230",
      "r235",
      "r236",
      "r237",
      "r241",
      "r242",
      "r398",
      "r469",
      "r497"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MortgageNotesPayableDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for mortgage notes payable.",
        "label": "Mortgage Notes Payable Disclosure [Text Block]",
        "terseLabel": "NOTES PAYABLE"
       }
      }
     },
     "localname": "MortgageNotesPayableDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/NotesPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r99",
      "r102",
      "r105"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r66",
      "r68",
      "r74",
      "r79",
      "r105",
      "r120",
      "r129",
      "r131",
      "r132",
      "r133",
      "r134",
      "r137",
      "r138",
      "r145",
      "r175",
      "r178",
      "r181",
      "r184",
      "r186",
      "r199",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r396",
      "r398",
      "r476",
      "r506"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r68",
      "r74",
      "r137",
      "r138",
      "r378",
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss for the year"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r139",
      "r140",
      "r146",
      "r149",
      "r175",
      "r178",
      "r181",
      "r184",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to ABVC\u2019s common stockholders (in Dollars)",
        "verboseLabel": "Net loss attributable to ABVC\u2019s common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable",
      "http://metuboutique.com/role/ScheduleoflosspershareTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r284",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoninterestExpenseInvestmentAdvisoryFees": {
     "auth_ref": [
      "r479"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents the company's cost incurred during an accounting period for managing the money in a fund, which will be billed back to the client and is a component of noninterest expenses.",
        "label": "Noninterest Expense Investment Advisory Fees",
        "terseLabel": "Consulting and advisory services (in Dollars)"
       }
      }
     },
     "localname": "NoninterestExpenseInvestmentAdvisoryFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableToBankCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.",
        "label": "Notes Payable to Bank, Current",
        "terseLabel": "Notes payable"
       }
      }
     },
     "localname": "NotesPayableToBankCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Office equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r175",
      "r178",
      "r181",
      "r184",
      "r186"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r416",
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expenses"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable",
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "auth_ref": [
      "r157",
      "r420"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable",
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r415"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities (current)"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable",
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities \u2013 current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r415"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Noncurrent Liabilities",
        "terseLabel": "Operating lease liability \u2013 noncurrent portion",
        "verboseLabel": "Non-current Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoperatingleasearrangementsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable",
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r417",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable",
      "http://metuboutique.com/role/ScheduleofsupplementalinformationrelatedtooperatingleasesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of Business [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r40",
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Current Assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Non-current Assets",
        "verboseLabel": "Noncurrent Assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "auth_ref": [
      "r85",
      "r104",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.",
        "label": "Other Depreciation and Amortization",
        "terseLabel": "Depreciation expenses"
       }
      }
     },
     "localname": "OtherDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r513"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Government grant income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r434"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Current Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash income and expenses"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNotesPayable": {
     "auth_ref": [
      "r21",
      "r468",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes payable classified as other.",
        "label": "Other Notes Payable",
        "terseLabel": "Balance due amount"
       }
      }
     },
     "localname": "OtherNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/NotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNotesPayableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 9.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Other Notes Payable, Current",
        "terseLabel": "Convertible notes payable \u2013 related parties, current portion"
       }
      }
     },
     "localname": "OtherNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Other Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-Term Borrowings",
        "terseLabel": "Short-term loan"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForParticipationLiabilities": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments related to participation costs.",
        "label": "Payments for Participation Liabilities",
        "terseLabel": "Company cash payments"
       }
      }
     },
     "localname": "PaymentsForParticipationLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment for offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.",
        "label": "Payments to Acquire Long-Term Investments",
        "negatedLabel": "Prepayment for equity investment"
       }
      }
     },
     "localname": "PaymentsToAcquireLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Payments to Acquire Notes Receivable",
        "terseLabel": "Convertible promissory note received"
       }
      }
     },
     "localname": "PaymentsToAcquireNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r89",
      "r424"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.",
        "label": "Payments to Fund Long-Term Loans to Related Parties",
        "negatedLabel": "Loan to related parties"
       }
      }
     },
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy": {
     "auth_ref": [
      "r295",
      "r296",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]",
        "terseLabel": "Post-retirement and post-employment benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r323",
      "r325",
      "r326",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r23",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r23",
      "r434"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expense and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Prepaid expenses \u2013 noncurrent"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.",
        "label": "Principal Amount Outstanding of Loans Held-in-portfolio",
        "terseLabel": "Outstanding loan"
       }
      }
     },
     "localname": "PrincipalAmountOutstandingOfLoansHeldInPortfolio",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromBankDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from bank borrowing during the year.",
        "label": "Proceeds from Bank Debt",
        "terseLabel": "Proceeds from short-term loan"
       }
      }
     },
     "localname": "ProceedsFromBankDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from Contributions from Affiliates",
        "terseLabel": "Aggregated capital contributions (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from convertible notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Issuance of common stock",
        "verboseLabel": "Issuance of common stock for debt (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from long-term loans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Issuance of Other Long-Term Debt",
        "terseLabel": "Proceeds from long-term loan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherShortTermDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from short-term debt classified as other.",
        "label": "Proceeds from Other Short-Term Debt",
        "terseLabel": "Proceeds from (repayments of) short term borrowings from third parties"
       }
      }
     },
     "localname": "ProceedsFromOtherShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Proceeds from borrowings from related parties"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "auth_ref": [],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "terseLabel": "Net proceeds from short-term borrowing from related parties"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfInvestmentProjects": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of investment projects held by an entity in hopes of getting a future return or interest from it.",
        "label": "Proceeds from Sale of Investment Projects",
        "terseLabel": "Net proceeds from sale of investment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfInvestmentProjects",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Gross proceeds from exercise of warrants (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.",
        "label": "Professional and Contract Services Expense",
        "terseLabel": "Consulting and advisory services amount (in Dollars)"
       }
      }
     },
     "localname": "ProfessionalAndContractServicesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r527",
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Consulting fees (in Dollars)"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r66",
      "r68",
      "r74",
      "r98",
      "r120",
      "r129",
      "r137",
      "r138",
      "r175",
      "r178",
      "r181",
      "r184",
      "r186",
      "r199",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r373",
      "r377",
      "r379",
      "r385",
      "r386",
      "r396",
      "r398",
      "r481"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "abvc_NetLossAttributableToAbvcAndSubsidiaries",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r221",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r14",
      "r217"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r219",
      "r434",
      "r482",
      "r500"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r219",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/PropertyandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentusefullivesTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r512"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherOperatingIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Investment loss"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r294",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r294",
      "r424",
      "r425",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/PaycheckProtectionProgramLoanPayableDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofaccountsreceivableduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduetorelatedpartiesTable0",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable",
      "http://metuboutique.com/role/ScheduleoflongterminvestmentTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the terms and manner of settlement of the related party transaction.",
        "label": "Related Party Transaction, Terms and Manner of Settlement",
        "terseLabel": "Description of payment settlement"
       }
      }
     },
     "localname": "RelatedPartyTransactionTermsAndMannerOfSettlement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r294",
      "r424",
      "r428",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable",
      "http://metuboutique.com/role/ScheduleofextenttheinvesteereliesTable0",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable",
      "http://metuboutique.com/role/ScheduleofownershippercentagesofinvesteeTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r422",
      "r423",
      "r425",
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTIES TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Repayment of convertible notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term bank loans"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Repayment of notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfOtherShortTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing within one year or the operating cycle, if longer.",
        "label": "Repayments of Other Short-Term Debt",
        "negatedLabel": "Repayment of short-term bank loan"
       }
      }
     },
     "localname": "RepaymentsOfOtherShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSubordinatedShortTermDebt": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer.",
        "label": "Repayments of Subordinated Short-Term Debt",
        "negatedLabel": "Repayment of short-term loan"
       }
      }
     },
     "localname": "RepaymentsOfSubordinatedShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r338",
      "r447",
      "r535"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r11",
      "r106",
      "r112",
      "r463",
      "r494"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r11",
      "r106",
      "r112"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r28",
      "r284",
      "r434",
      "r496",
      "r519",
      "r521"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r126",
      "r127",
      "r128",
      "r130",
      "r136",
      "r138",
      "r201",
      "r334",
      "r335",
      "r336",
      "r350",
      "r351",
      "r394",
      "r516",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r76",
      "r120",
      "r170",
      "r171",
      "r177",
      "r182",
      "r183",
      "r187",
      "r188",
      "r189",
      "r199",
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r242",
      "r398",
      "r481"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "verboseLabel": "Net sales"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleofstatementsofoperationTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "auth_ref": [
      "r374",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.",
        "label": "Sale of Stock, Description of Transaction",
        "terseLabel": "Sale of common stock, description",
        "verboseLabel": "Equity offering, description"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/LongTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Purchase agreement relating to offer and sale of shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share (in Dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable",
      "http://metuboutique.com/role/ScheduleofamountduefromrelatedpartiesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of amount due from related parties"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of supplemental information related to operating leases"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/LeaseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtConversionsTextBlock": {
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information on an original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. The information may be presented entirely or partially in this block of text or in the associated elements.",
        "label": "Schedule of Debt Conversions [Table Text Block]",
        "terseLabel": "Schedule of converted amount of debt and shares"
       }
      }
     },
     "localname": "ScheduleOfDebtConversionsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/LossperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r36",
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable",
      "http://metuboutique.com/role/ScheduleofpropertyandequipmentTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Schedule of assets acquired and liabilities assumed based on fair value"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r426",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable",
      "http://metuboutique.com/role/ScheduleofrelatedpartytransactionsTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r306",
      "r321",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of options issued and outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of short-term bank loan"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SecurityDepositLiability": {
     "auth_ref": [
      "r501"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.",
        "label": "Security Deposit Liability",
        "terseLabel": "Tenant security deposit"
       }
      }
     },
     "localname": "SecurityDepositLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://metuboutique.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock based compensation for non employees"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow",
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable",
      "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable",
      "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable",
      "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of Underlying Shares, Outstanding",
        "periodStartLabel": "Number of Underlying Shares, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Options available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Underlying Shares, Exercisable",
        "verboseLabel": "Number of Underlying Shares, Exercisable (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Number of Underlying Shares, Forfeited",
        "verboseLabel": "Number of Underlying Shares, Forfeited (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "netLabel": "Stock options aggregate",
        "terseLabel": "Number of Underlying Shares, Granted",
        "verboseLabel": "Number of Underlying Shares, Granted (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Underlying Shares, Outstanding (in Shares)",
        "periodStartLabel": "Number of Underlying Shares, Outstanding (in Shares)",
        "terseLabel": "Company granted stock option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0",
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price Per Share, Outstanding",
        "periodStartLabel": "Weighted-Average Exercise Price Per Share, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r326"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest",
        "verboseLabel": "Aggregate Intrinsic Value, Vested and expected to vest (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Underlying Shares, Vested and expected to vest",
        "verboseLabel": "Number of Underlying Shares, Vested and expected to vest (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price Per Share, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Shares per price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable",
      "http://metuboutique.com/role/ScheduleoffairvalueofstockoptionsgrantedTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "verboseLabel": "Aggregate Intrinsic Value, Exercisable (in Dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Contractual Life Remaining in Years, Outstanding",
        "verboseLabel": "Outstanding as of December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable",
      "http://metuboutique.com/role/ScheduleofoptionsissuedandoutstandingTable0"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested grant date exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "(in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "netLabel": "Aggregated shares of common stock",
        "terseLabel": "Shares issued (in Shares)",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "netLabel": "Common stock per share (in Dollars per share)",
        "terseLabel": "Share price per unit (in Dollars per share)",
        "verboseLabel": "Number of investors (in Dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r42",
      "r502"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short-Term Bank Loans and Notes Payable",
        "terseLabel": "Short-term bank loans"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r19",
      "r434",
      "r467",
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtInterestRateIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument.",
        "label": "Short-Term Debt, Interest Rate Increase",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "ShortTermDebtInterestRateIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for short-term debt.",
        "label": "Short-Term Debt [Text Block]",
        "terseLabel": "SHORT-TERM LOAN"
       }
      }
     },
     "localname": "ShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BankLoansDetails",
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable",
      "http://metuboutique.com/role/ScheduleofshorttermbankloanTable0"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r40",
      "r471",
      "r472",
      "r489"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term Investment"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShorttermDebtAverageOutstandingAmount": {
     "auth_ref": [
      "r537",
      "r538"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period.",
        "label": "Short-Term Debt, Average Outstanding Amount",
        "terseLabel": "Balance of outstanding loans"
       }
      }
     },
     "localname": "ShorttermDebtAverageOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r113",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r117",
      "r120",
      "r142",
      "r143",
      "r144",
      "r147",
      "r149",
      "r159",
      "r160",
      "r161",
      "r199",
      "r230",
      "r235",
      "r236",
      "r237",
      "r241",
      "r242",
      "r266",
      "r267",
      "r270",
      "r274",
      "r280",
      "r398",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r57",
      "r72",
      "r73",
      "r74",
      "r126",
      "r127",
      "r128",
      "r130",
      "r136",
      "r138",
      "r158",
      "r201",
      "r280",
      "r284",
      "r334",
      "r335",
      "r336",
      "r350",
      "r351",
      "r394",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r421",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r126",
      "r127",
      "r128",
      "r158",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r56",
      "r251",
      "r280",
      "r281",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Debt conversion (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "auth_ref": [
      "r23",
      "r24",
      "r280",
      "r281",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "terseLabel": "Issuance of common shares for debt conversion (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "auth_ref": [
      "r23",
      "r24",
      "r280",
      "r284",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "terseLabel": "Granted options to purchase an aggregate shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common shares for consulting service (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r280",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common shares for cash (in Shares)",
        "verboseLabel": "Issuance of common shares, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockSplits": {
     "auth_ref": [
      "r23",
      "r24",
      "r280",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of a stock split.",
        "label": "Stock Issued During Period, Shares, Stock Splits",
        "terseLabel": "Common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/BusinessCombinationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r57",
      "r280",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Debt conversion"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r57",
      "r280",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Issuance of common shares for debt conversion"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common shares for consulting service"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r23",
      "r24",
      "r280",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common shares for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/StockOptionsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r24",
      "r30",
      "r31",
      "r120",
      "r193",
      "r199",
      "r398",
      "r434"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r73",
      "r120",
      "r126",
      "r127",
      "r128",
      "r130",
      "r136",
      "r199",
      "r201",
      "r284",
      "r334",
      "r335",
      "r336",
      "r350",
      "r351",
      "r371",
      "r372",
      "r384",
      "r394",
      "r398",
      "r400",
      "r401",
      "r405",
      "r421",
      "r517",
      "r518"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet",
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in number of shares issued and outstanding as a result of capital structure change to a stock dividend, stock split or reserve split occurring after the balance sheet date but prior to the later of the issuance of financial statements or the effective date of registration statement.",
        "label": "Stockholders' Equity Note, Changes in Capital Structure, Subsequent Changes to Number of Common Shares",
        "terseLabel": "Common stock issued to professional investors"
       }
      }
     },
     "localname": "StockholdersEquityNoteChangesInCapitalStructureSubsequentChangesToNumberOfCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r267",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r284",
      "r288",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.",
        "label": "Stockholders' Equity Note, Stock Split",
        "terseLabel": "Common stock issued post-stock split"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "auth_ref": [
      "r23",
      "r24",
      "r30",
      "r265"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "negatedLabel": "Stock subscription receivable"
       }
      }
     },
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "terseLabel": "Stockholders\u2019 Equity",
        "verboseLabel": "Shareholders\u2019 Deficit"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable",
      "http://metuboutique.com/role/ScheduleofbalancesheetsTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse split ratio"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r406",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r406",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r406",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r435",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flows",
        "verboseLabel": "Cash paid during the year for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r10",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, par value (in Dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityValueExcludingAdditionalPaidInCapital": {
     "auth_ref": [
      "r10",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of the par value of temporary equity outstanding. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Par Value",
        "terseLabel": "Common stock, par value (in Dollars)"
       }
      }
     },
     "localname": "TemporaryEquityValueExcludingAdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r59",
      "r286",
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable",
      "http://metuboutique.com/role/ScheduleofassetsacquiredandliabilitiesassumedbasedonfairvalueTable0"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r55",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r55",
      "r286",
      "r287"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/CollaborativeAgreementsDetails",
      "http://metuboutique.com/role/EquityDetails",
      "http://metuboutique.com/role/OrganizationandDescriptionofBusinessDetails",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable",
      "http://metuboutique.com/role/ScheduleofconvertedamountofdebtandsharesTable0"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://metuboutique.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Gain/Loss on investment in equity securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebt": {
     "auth_ref": [
      "r21",
      "r468",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Unsecured Debt",
        "terseLabel": "Unsecured loan amount"
       }
      }
     },
     "localname": "UnsecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ShortTermLoanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r162",
      "r163",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/EquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConvertibleNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r141",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ScheduleoflosspershareTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r139",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic and diluted (in Shares)",
        "verboseLabel": "Weighted-average shares outstanding - Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement",
      "http://metuboutique.com/role/ScheduleoflosspershareTable0"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageRateForeignDeposit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate calculated at point in time for foreign deposit liability.",
        "label": "Weighted Average Rate, Interest-Bearing Foreign Deposits, Point in Time",
        "terseLabel": "Bear interest rate"
       }
      }
     },
     "localname": "WeightedAverageRateForeignDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://metuboutique.com/role/RelatedPartiesTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235172"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235116"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235144"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5291-111683"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1),20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=d3e56071-112765"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=6473203&loc=d3e55336-107963"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(3))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r539": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>121
<FILENAME>0001213900-22-032864-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-032864-xbrl.zip
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M62(V8R&M-0=0^1=X'VDX F3G;),7W3OQUS+@@H3",7;NRILR&;_@RG6DNIT
MS0QK5N-@GP_EY&,YY<$Z/=&P*?-*5EB2/S),?^.4GG7K[%U@31)>X;-Y4PDJ
M/QAWA,;A7'9W\OZ=I&O/@'',S\W2_U\[_)5^,,W^;N,X+F_5>']'#M#Y1[3S
M3V2@1'GBY1.C!V2W>=(6';N]5W]RRZ\C^G0V"B+Y[NH93O&[X32WVSA2%X,X
MI5$ZG@#W'Z.8\"=1<G3=\#\U?H0WW]W&T7HU@).-T+D# 5XT+Y$.%O*OJB$$
M-#/PIW&>5MPN_8^([\V&<WXJ'G8Q&6M?(0[%N?@N%XEY1]-"V#B0VU\H.C]E
M[^BX;'-WI6!D_3>S[= XP2^'@)C1<4)WHZ5@"M#,L$PVCO#JJZU.;>YVQ:7@
ME;Z5694:)W[EA1?,K(Y7E9L5!8?JOYGYTO 'K.Y90&9TO(#]E KF&!N;W =[
M#?<!Y+4T+'P=!TLN3 6W*C\8.=/P,A0!F]UZUL:QJ3*_FS^#URY[#5]#Q</9
M:45;=Z?2$&C\#/.DX7*H^CT[:]K*_ZGB1.DY;"_O-=P*LF^WR=_%(:HRO;2M
MC$;87L,KH'*/=IRZEWC_0Y*X0=@^[+_H!R]T=P[^%ZD=\@6=J;"N#T_%X78]
MS1J[1F* @=,=KW->>U/BIR&AX_G*140*KPY_]S@-P^ Z][Q6F=VNJV'?;'@N
M[L)JT2U')?K-RZZJ)3(G@^9(;)UPM,\?46F^H:E9U1L>$EU&":S8'>.J6AU4
MO/$:_:TU,MRN/&WX1TK^>HTF!D!N2L<RG2-?I6A0.Y/_Y&G#?Z)SYG=[Y]I[
M9]L-<Z5[, \;CA<3#ZTVQ6XM;7%IH])+H!EL^3Q5>&V4=S:P3G;,JJHDO8D(
MBZ?!G N[)ZB?D#C;Z>*$$$@Y;7J:U;3I!X*Y6M/2)0BGA*+8206.3F'-,D!N
M$TYS,B7%I#$2!O!1!NP".B6>-MQ+[3B>O=GAKU[RV,E>WFW"5MP.^70G?+:#
MY61#C-:UAGG<<#RUX[%XZ:9XJ[-Z;;><VS!WE!6_BF7M*XBOBH8P2QL^IG8L
MS=_GQ/K":ATOJ[R,EW5X^&9;%,."> IT,-A6MO$P&N:N7BSWY.+5W=YKL??*
MF_F@%L.DVW75C8WGV8;3J.66FT4/E-[;<;9E(0"U+Q!L:K2=GS4<3-K2 -U]
M3IM0-A6S&C_"*^JSA@NI',G6,:/--BCRE(4Q..(S&/()!+= =6/3"OFLF1*D
M8%=]UY,)U-),%6]SPBZ+>MUJ$$I/;HM^H G[K.%!LBT-T6ELRR(1*C[J]CB(
M8PWOD/VNUC&%UFM'*$,15 W,ID<S<ZA:3:+3F+7BM56<,K>&5[^&3P8.U^Y4
MR]I"8=E$SOD\+I)Z(+W&4('[F-;%5@5#M 9,CL&1()P$KC'2<;W&=3>+L(D9
M\4AP+=CFIV3,Z*S$6H,7O=40)IEH^'#N)!,%)&>%R>&@'(&J(C"=P]U:4&9B
M1ML+AZF;\5#3</O<32(DCE9"T$F 1@(2>@?^JSL9;;3G+?.SS.Q/:+<"M$[F
M4IERU5] L^VY-I>KBW-HHX)>YAHE?B;/=.R34>)&?BPR?D ]M.EI5L:&@ZG.
MQIK:+=]:*"!_)EXLPY&R5W>,MTOC4QY[%;\;#*SGS4HUU52^[L1D'W64S5D0
MQRG7J\CG3<5'^\2'),&0(U,WDTGTO.%0TO"P'F:4_YZ]6>I@Z=T=PXT,'[L!
MNW;#5-Y2\QG/)W3"+1"^QD$\M^EI7GZ;_BHKOHN7._+MV36WZ%/(0HZ@8[Y%
MQ)%,T(V7";K:6*-Z.Z,^*P*-JJF\V@BCO%FLJ738\;"^8LN@CF@2BCQ=EW'A
MGQ!CP(*I%WR)^KP9<Y0E"6M7Z?QMCGR=4WY?QV+S16LZGV>?279#\5E<-I-(
M\B-?0JO,!/E^IZ&,RMZ,4@+%H0S"*:%8'F+Y>;8F,MV!UDY49ASW+)V-TX0S
MPHVBU WG[D(J6AKYA$4T\D2XGTA-"XE97NX^GE%HFK%/H-#D2)P,BI-A<0HP
MCD3C<#B;)3R ['2"0]4U"Y0Q-OIF\$:QWW!UJ4L6='>2;9R6<4R2V/6^I0&3
MIZTP<$=!& B_'_\MG1%??/#9I]'21 ?=F7<=SL#Z9J 5R/JZ=U.B<@I8\F17
M N;DR!P)S>$#K4X$G;K;U@=6ET!0MP&=H?O-:DKU8L'_23F9K_^^N>G\\\O'
MS\_^]<_?O'EZ>Q4]>^G_M7\]N5I$EX?IS;M]]G+_P^Z?E\-%'.Y?>W]MA^^3
MK61 WO^UO_?U=L<[3;9_/S[>'7S8NKX]Z%]M7_L#-OKYS#LXV_;^VCH\_S7Y
M]N++\.?K7]XMDOGB&?D6^M]FX9_75Q_CG\?C#]O3S^_3:.N4NO[O%V?//W[^
M]<NG.?LUBI[M>^/0FV\/!Y.3W_\Z^')#Z?7GL_CX_*CWE'WZQ$97S_M'+VYF
MU-W^]G,XOQC>OONZY_W<#]Z_BQ=?/K"OI\/AQS\GOPZO!K?3O<GD%_+B,/SM
MY;?KK?G7GT].K_P7'Y[1/^>_#O:_B W9V_K]E]\^C+[=G%R]?SZ.GM[L'5ZR
M%WOSKUL]LO><_?G[U7C_9.SW?_NYSSY?O?F7TQ]<;&Z^O:>%TJ:LP_8:)2&V
MC4;.OJ*(=E<5XGNO@IJZ 3I1J+<R.K7V&\[,KL# HV2KMU'F%3,A3C;<DUVR
M^F/YM<Q9S#IV6W4U,'[-1,DN_?D>1 #*9=;Q'NYCN$G<7S.7LDN!7OM"0IG4
MK&.VMKF)SVNF579IT/>7!JWCK:JEB:UKIE-VJ=#WF JMXRO4PW2<>J'X,%J7
M#OTX>[$RPUF["VM:@TZD%W9?.^^RH1\ABU.KO9K6,&.[),Y'9"B8P*+CJZ&3
MT>7QHN'HZA)?4">^Z 2AW1AFN6BXPKKD%R3"8LABT0J(L1^\%S0\:EWNRW<6
M &4:BY']FEZP6^W%'7-=N]27[Y%WH9,!JZX&06AXVKJTB\>*%Y6ZI0W5USK5
MC?W@=;]9'[\+\'\,?EN$Z>M8;M75H.<-EUP7W_^8[O1:W+[>D=YH"&KS2X4C
M+HZ=\RZ\_Y'#^_6KM:&;R=7ZLNF,ZT+\<87X:WUT=QH+UO>&!Z^+\/].DG+G
MB'R=N*PQ("PSS>\"= '^/U[4N-81<.?QC%M/PV?818Y_;SDZI%XJ]+ 7^4=1
MP@_J)ZM%/1,0L(6)Y=O2GLQ'*/_9$U%V<CBG--Y_ )]>;]W&K]SY7&R>^</L
M4131C))B3E_SI\%L3EGB1.Z,Q'/7(TMNWMS</+D=L? )99.MW>WMO:T@$H=G
MCVPX,5>:F7M*/3D<T$7\;[/HMRD>;>[L;N[M/+F-_8VMMW=!(8@6"M@61='O
M+BCXDC62PZ7Q9L+G.N;C[NZJ$<2\O7Q]N=/$=>>RSQ8)DW@YS*9X=+>Y\!.V
M)<80HVYO;N]L[N[H\9AZRO_'2R 6TE&>X&?R?WYBS9&B@V#%L]5;K;D0B^O=
MUFS@O4HL6(Y1Y8$MZ3'QGDSH]58<>#8@ZLW%'Y47YR\EF>DKW_IFH]B;SL9%
M['"O].FS2QFU?RJ"]GNC.&&NQSD@2'JS(=X9O.+/N(U\DI"96!\V'#=O]68C
M82G_?]:*CQM0?RC[^2G+U^4HR,RDHFV<\LY!DHI?WS&:SHN7!'SXTC[?'G))
M\G74+V/@,=+9!%<6YC8,Q4@=B+.J,%52FQ\%PT,>@,VLBF=%?/;Y*CP[DP(1
MM(N'R-:((6ZN!CN2@<K#*2GZ7\@H98QTFZ":>8U9B*U0FDD\R")7!S)P%2-U
M:H!FP@;+B$VN 46\)D8"8: 6VV-V_UF*<\1(I1[DUEOMLJ/[G,KRA(^'4GNH
M.M%=?HX$#U%-2#:VS;+^?-$=#T$V( %YM/EN!1YB6Z&U6&=*U>H7Y6 ;/!2W
MP&HCR'EJ=7RQ#!T\3,DQH[-JW7Z,]+>%;C4=,GSFQYD""[B KBL&&M(?B&HM
M6#L[OU]$364#GHT/R4AX:.4E/4K*+1&#Y)=*R"(B487*2G+S3B<R HI/Q=DJ
M_@D1>:W@6M%][ ;LL[B6$=;U:O+>9>$_&$FW1&RGNR*BAI_UI>!C)%:)SU*@
M\YM_>2'<*T6*8*33 JV%V34H1424;K+RU7U(JV]!.1%W)<%*)CYFM__'\O*_
M)^_^S_.K_TMQ\_^)1OW5O3_>25J+#CM#1MYO]_+K;;[ GJXNMWO9W?:!*R\9
ME\L1QHE:APRMOO'9_>BRKR01V/HT3CZ29$K]DL/B$T'D_6L'%Y".S"^#FU@+
MC'J^<G'@[Z<,#SE-2/K3UR&)Z$S$K6 B0 5*RX O))A,A0W#C7-W0C)K'*4A
M:HT44"><IE=;@ZLV$Q=DYO+-*=^>A=,,#VGV4'5^U]H(PF,KSH\7W#1!2Z82
M).2X3)DWY1/2%WDX/KK+$!B>=FGIA6$>;G$V'DY),<HY"SQ$K+-"J1/.5OO\
M]O<GMB5>'=GF'1\!K38@ 9ULF $(2%)@@EP."D,  1%*5/:[G7;?1T":/52=
M9JE, 02$J6%9;MGZ31\!92VPZH\!%ML_/E+5*'4\!6T !,09\ 'KBXT!@(!
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M9S-^ *+C03") GYB<*,D7TC%38HP+OFBF5<^AC]PGTJK*Q1E&O$M"@](IE8
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MT #UF=^[0?)0BE-'"A"5U>0DOIB-!S>TUB1+@16D;)*&+BO6CPN^I>,ZC!L
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MU,0A;ZZQ=ZL:2Z6R2P=<4SF;=A_@32@K&:_X!B7 V5Q'1S*LJ@%'=$R$I_=
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MS<1,UPHV=@[(UGA@261YP7!55KG2,D?C-AE D$KH4"'GTB)(+D"/^H&+%D6
M7$ULK%%!3*CA:8,^--E(&8U*27/=R3:@@LB\FS\]5[@DXJ9)2;!0F><+L\2M
M@L7/-W#>FT_X&8,;C4+ERFS_LQ!@/A<N  3R*RUX*+F?G(IH,8(<?AH_18J&
MFA\3(%CB4Z-_P^J'G"XQ#5/#HHE'X<'RLI]4C[S2*':A,JDO1R7;;%P5UA7]
MNO0*/BDBY69DF54M1R-<8TWY!MWJ>Q.*7D.)0\K9VQ<@89%L%=>_Y JRN-=<
MYGG?6<<&?>I>\Z?I+H?0</]OSJCQTYE%[8J4K$C(7!U;P=FA6D^Q7?DV7PV[
MN $O_8QF=R?14>@&.#*I(!?31\(22PNGOD:9&:EHQK(&</HV2\!65@83'#MW
MIW-]/0;RZT&B));K70)J@[JIHA@L,'3.NU<V^H,D27Y7_/^X,"^;5C94L1=J
M9ZXT:DY"RW67SVI%"43*;5U#8=B;F> 2S/[;@"L]'.7';0EX6[X)"1 J\07R
M2+25;LS>Q4C+SE/*>M-E%B??0TP%FE]+%[Q['^3,C(A&N<K5'X6YU=NI(*W\
MZ_C2% )[!^3,K]T7+ 0._B;O,X%TI$<_OO3*@%6-SEN$>@WY-KE<QD#OUM(8
MQS&O$6L:[3Y"O%('UX3J[GY*0MMBOS212&YYPOJ5N6@$,'0K@K"V5ME^]"^W
MD/4X'CRB]R6^*L,LD4JILI*3C[.=FY, ?YZF,I^&)@<7RMI$"4%NH86M1ZFG
MR<,LB]LZD*% 0<G-LUDDV2U_9 T->'/A7815RY@._)OL%6L_!GBG8K8X@CWE
M'DDY$P_/,^8R0?J#3003?JS=LM8 BY[*HMKXR5%:\*I(XDX<Y=J+!-VYY&@T
MM9Y*);4&Y @]"U]R.!Z. D[]<'1P'0##+01J:Q9H]I9A&?V[GT"7[C8(01;1
M)XS1^$HAG0"E<ML4/FA3-Y#NH)K^ZI@8<*]]EZU,<>!B>@&B2EV#8)FMI$*X
M[.(#6^D5Y$*0VVR?0I2&3[BS!=\AU TJ</4R^5VRPRBEA6.K;!J[=J#A31+W
M)AC%)V'K(.^,/@5(#A]]9U O1^YK$VI0S\&MBP*6XM8U"''87<#-GN].#H4^
M731>4>=IC+YY3AV'4(D5@]%HWIU'EZ KW8U+!BQD#B"3]H)\RGA1SSUX6=Z8
MRN!2-#F*'6!+[4B &6Y-858+:H'A?)=A_5X7H%/%=A0+6]!3JQ3V%,^NU/MK
M_+"^N^ 4ZW$5J9AQ; K-A2B4?.&Y'XO=6ZQ83PN(W;&M)6N\XCZ)[H6;/=VX
MCQ%&W3U'(X)9F5V$_*#!R]L5:S$";'=L+XI);O%@=A=E@VY)I"NR$SKC^A^K
MU8#IFG4M'1VUWD<<TE9['[$4\CL49<G>-7MN>.XMQNS6!U7INDBH;;>N6!HE
M%Q/ZIT?;Z<Z:ME![5KF?B6'NC-7%T,JO-\RJ2X77F7-AMMF+Y'/'K2248''*
M7<<$L.UV'9.8C*O[RZPZA5$;%V97#"PR+HNHX$O9UX8*R?YAY0$CS0)ND2BQ
ML:G/>U?4H!'\P/?-!X!-9(3+GN9WV'GMM5MT,;_J]8 N6_<;%C[O!2 ?7:WT
MH!"NCTOHT?4/@4F'T0GW6_Q#8-*Z*O7 9B92L^<7LPDS$2)Y-50A8>[18?XS
M3HGB8]M<1#6I^E!A@G6I^,RM^1]02P,$%     @ 98O.5'!=RG/K=0  /-@'
M !4   !A8G9C+3(P,C(P,S,Q7V1E9BYX;6SMO5MSXT:R+OJ^?T7O/B_GQ$1/
MMSUK+IX8GQT4);5EJR4M26TOKQT['!!8)#$- C0NZJ9__:XJ$"1 UAV9*$#-
MA[5&5@N965_6)2LK+__Z7U]6\:MGDN51FGS_^IL_OWO]BB1A.HN2Q?>O/SZ\
MF3Q,KZY>_Z___]6K__&O__GFS:OW)"%94)#9JZ?-JVFZ6C^$T:O'+$CR>9JM
M7OV_Q>K_>_7FU;(HUO]\^_;SY\]_#NG?Y&&4D3PMLY#D[!>OWKRA!&N2TXPP
M@O]\]5B25S^6R:MO_N/5M]_\\YN__?/=NU<?'Z>OOGWW[;?5)__C7W&4?'H*
M<O**RIWDW[]N</KRE,5_3K/%VV_?O?O+V_H/7U=_^<\O[!>MO__\%_[7WWSW
MW7=O^;_N_C2/1'](R7[S]K\^7#^$2[(*WD1)7@1)R!CDT3]S_LOK- P*CJ16
MKE?2OV#_]:;^LS?L5V^^^?;-7[[Y\Y=\MA.1_LVLV+%I$OCKV^H?7S.\7KWZ
M5Y;&Y)[,7_$A_K/8K,GWK_-HM8Z9Y/QWRXS,OW\=/#V';QC4[_Y2\?I_V&]^
MRWZ;IDF>QM&,*>DLB-F8'Y:$%*]?,=(?[Z]V8JQ(43ZE91']7A*FY[?L#]Y*
MOW_+)P&ND+_=!1E)BB4IHC"(\ZXR'Y+#&L(578,K\E#0GU>4GXO8AR2HJ.!B
M3H-\>1FGGUWDVWW[%FJB/BRI<I9I/*/;V<7O951L'BF1;]/L+Z;R*2A4F@:1
M\S9;!$GT!]\I@F1V3O(PB];LO]+Y69E'"<F-)ZH1+4#9'\K5*L@VZ?PA6B31
MG*Z"I)B$85HF!3TR[JARPX@82V](C<L/-'GC.'A*Z0D6/9/)(B-\;5AL"^+/
MX02\2IXIQ33;F(JT_P!R+[K+TC7)B@V=4FP=K&TV(>&W8(O\.DT6CR1;L7'G
MA97V1)\";^#4DBJBIYC<I 7)[X)-\,2^-MX<A9_#3:ZS(/ETG5);S52D_0>@
MDRO84&LI_$0G2D%"ME?1GQ99L&*L+$$SH@6X_[DH]E";0(==FA5L-K.!FI]O
MS8_@)M8]B=F13HVC@N[7_#H0<&48SS0%!4#M56>ZJ4S;OX8\/8LT_'2[MD*F
M]0W4[+E.\YQNTMS>,=\^&]^ "4+X'<U0 O['8$=);1_1:^Q3E' 3RGAC%'P*
MN44^E$\YH1R3XN+9YH@[^@YP\AX;9F<;_I/Q@E)0Z-U$?62[,;"ANJ4).1%V
MYIV=O(>?@:T9D7%G)YJ" N D$-AZ=F+*"<#M/[5U92?9X6=@\LC/8#L!M72@
M#H_M%=U*N-8W8,98XXRVW%B.OX0SRYHGMNWL/_H24"QVC%O*T_@$<)<0'..6
M:U%* ,ZK1>\WLS(FZ7R]WSE)O7.6.9F7<1P];T\?XWEG1Q7R>-YQCEJ'E+WD
M!]^#VE]*> "1WHL.+'?Z.2%9OHS6E&5(&04+DE>0Y04ACB,P(8HP%O*EH,R*
M):DY922.G">\DAK<+K=G&%-3HJ"F1+0S)1PEEQ'"$/JI>O7(V:N'*]("&ABB
MYO4;!YV+;(7MMV%[D16T4/9 PLV1Z,#(=)C48CI@!LX>(.9"8I/PB9JA,35#
M78$6TX$7.*NLT36U1C?%H2UJ+[>:',X9%%0WS3PC(8F>&:-92>99NFH(X[X?
M6E%'&N"*20 Z*!U%^(FV8TE-$M AB.DAG+-A]0)!9A7K=#XC3P6U5G)V#7 =
MA@E1#/NGNE-%>5Y2ULF,2LCB-5A@BZOQHZ,(/Z7F090]!W')#R9Z4=R*L*#[
M#@74<1PF1!$4$E=7RGQWI72Q?PY)P$.^/?231<RNG$%&45F0+B>SCB"*69&7
M:_H9XQ+0#UEH%C=DMOM(D;:%<AV:$Q=XE5%[.%J5JWE9E!D)DJ0,XG6PX1"7
M]*J5)6D2,CN4O=W'I-.(W5DAG#=Y3LWJ(*267\8WI#@*GJ(X8D<$_;=R168L
M@FR6)KL5[WH2N7)"F=LF#HMW.'Z0=PAJ;'LQ' 0_)-"3YPD2YX;D/APA#J,P
MHHIS8U2X+QP&HB:'8^Y+_!@.TDLIX0A^[-!PD%E$!$=<N3/#06P5,?A=4>S/
M<)G?$D(HCBBA3\,%:PDA#*&5#@T'V37T$$XG&P>&PX#LR&.,3^/+<!F3EB3&
M5%-[-+H,0T(0Y0 V<&@X#,6(*HZ!I/%KN%A'6I(8T\O L>$P%B.J*(HY<G<X
M&4A'-#"@US@YG*:0AB+"TX:#.\/E<'=B@Z$U9V^&PZ@[\$(YBAQ=&BZ'E#,K
MJ"ENDB1T3HH@,D^0LR$)J#^C,$S+H=@1!;/O)+E$EL)KJ*#&?5J*JB(!%]=^
M%+5I*:6" N A+\GUL5:^D@I\H*JE?$?? 2)HDOAC.T$M2,+M:1WT+U,ZV';;
M3!>RW55%W_80JFPIIIX0G*:KT&-+ =L? 1ZEC<!C6]4*/H6<=H*@6MN-1TX!
M--&DG6QC;7>(/P?0\7D:ENSHFM"CEEHQQ>9J?\\P%4])8WM>!UEH*J2DW$5=
MK8+5N?@KEWT64:ZL',F;&9D'95R\?K5ETY1Y1R-*BK?TD[?;OWE[_'D_LJ:K
M($J<1:V^WL]-#&&7&_9653Z1-SO&=O**"#36/0K ')@W*[)Z(IDENJU/=XL*
M0\H@CNUD8Q_L)*+SE-Z-V;*ZIKQ;4O''N1F9U7*QCUVKK6S9489Q&K:XQ*QJ
M39K53.A]@L3?OR[S-XL@6/^VJR!R.[^D>VD21D%\E^9<X,E37F3TO#S&+:^'
M3Z^_3QR#+;VW;*-Z2^(BKW_#MRZ.HQ7+:EE;#V?";^-(@A\0WYH[+1U/LK:T
M=$K40FQGA^W4WG[-//EN6BM2.3QI-B/9]Z_?T;_ED_Z?89SF9/;]ZR(K]]'<
MCEJ8EAFKIH.JC$,>NVG3NTK$,^\8_"-4D'3 "O#0PYW]#S,RGX.862&38AID
MV29*%C\S3Q2P3LQX-H;D24N2F=E4EB%\6N6YJ.Z>4+FB<%M%J6\EVG(?A3JM
M(=TJ]AM0Q6[]COG][JWYAA1;Z:&W1Q6KO5DW:*6IX=IJZ%OYO@FCHK8/H2]M
MB;EZ-#DZ:$V"X%:!?P$^^,Y+<DDEORV6).M#=WI^(UEN!L!M5?8?L&MN5\[B
MAD KIT5Z%"=5&XPMX'\%/89VSMM6E378.YZ(Q<X!,F@%B-'9*N)OBLW*2A?<
MR7B7D>TK^66:76^#7:5*D7@JM40&/>T-<=C"_W?@LX(SCF877]8DR0DU"_GF
MUQ(:>&&8<!S'.C'";JNW?T M&Z&4F)Z%L1S>8MR_@SVHZS?^NSBH7@[JAW[X
M@UO):@@Z42\-%4[:JZ7KHKBM0\MX/9W[:+$L;N<?Z=ID @/K1\W+^SU%I1T-
M3-I[I8MJWJ?I['/$'A) M; C._05L1^_P:W/;?8+2P>#HBVK,#Q8U(60:.]P
M3I=N,B?TZ-F6I7\,OE3"P9\+"D9#]OVK\-'>\2!LVYLT"7LP:!ML!KTRY.!H
M+WI.-VY"Z?- GS5[I8.^;!]0'\#]07G!/@1#?[ESOR*@W T&O=74XS:X>CD=
ML_OP=FK9\F"Q5DL-I.=>8[9>)[_KN[PYJ":7AXYJQ7VW5S#RMZIL)[5$=RYO
M^YU>J;;1P;B/4@=,?+H3];-4]!)UB!+*H_W.;;P+BZ<SJ=U/ L?#+N7G]TYH
MIRH#]/0[GY//A#DM]]S3+$L_1\D"VFZ0LO%H)=MI2 Z4_B'>23--[3^F;%[@
M;'-R/EY-"3OM*, R<;@XGD&4P.Q83OAC2,)G1/I1@*5_4W=X69S,GEEL,'O/
MGY9YD:ZH*6/TFBC\< 1 *T:-\H;>=B+7,FYPEH"&V0C48PH;]#-[([;E,>TI
M&DC&:!#7&[,X("E6!N_P'>RPYBF&M))D;,9EAPF!PG?XX.A$>K*/0R&*,QWX
M^9W?BW!NDRW2 [GAVWMB6OB@/;,?^*]WAQBN5W_/9AA;E;5VY+#A1')+3 VT
MAS ]O\'L:M:Z,\!2>\UT2F+:E\"HW[(176HZ;H,PX*QUI\40^@(J$!K/8ABI
M4EK8& 0 ."D ]4%.\.PV0CU(GM<4]T_'4(PJ_(,+AY&T)^+@425ZX(60H#S,
M3-/5*DW0D#\B[V]#,CD+#K$PL)*=G,.S&1]Y$-\%T>PJF0;KJ B@PQ]E7/P:
M6GHU2-$Q>$IQ+?-PN"LR&X#5J*D+^S7R]: O,E:\O3HS#6XQ=D#J'U_<$L0+
M.A(RNPBRA+W!3<*P7)7<87=.(0O!(\P,& [ZM#$!#"4NML&(.^[H!KS.R)*5
MUWDF53 H:\9[0XK;^6/P!?[IS(J[3\>/P:YIBR667?V8T5MPF6W0; H!@Z$?
M:2),3!YS@$XS]"-K\ H088+V6O,A2M*,%XTK2$9RZ./FB/PX+_G'*)DH!&9!
MT/TP+F>\PG'&X2J*+'HJBRI A#GNTJ2@(%!J"R0M @DUE-=M>X<WD%(\!7+C
M^>S$['P:'UAQVV;9A/]ZVRX2N"^ZV$_QP-_N N;#7Y(B"H,X/]42%+FH*$:W
M&6<WX^;-'8N&I+BA.O*D3/U:(Z[+Q111?=A\=WUR5OFD+);TC/YCOXY0]'C$
M;)19*CH L7)31'RO>/.A'I2V9>3/ H745HT:FI]1Q/1VWQZJ!WTUN;T,I;7P
M0TN?;SP-]'34F7 <Y3YI!"76JWN#.?(1I^(T1F->B1Q*$/D11Y133<9EG#:D
M%#.<I_LC=GBGF9+5"U&6Z"Q3Y_W[N!Q7CPF[0;]V6]T'5)!NP#(N'4R!>_),
MDA(\:FM'UN]<UJBE_6Q8 X&5R#U-<[JFMGS ]Y,F[=& ?@ )UJ7R?9;F^5V6
MSL$?RYN4_=U +!!O08$<C+VMN(/5HD/.Q^M-PD(9"J100JP?"']N>$\2RC>>
M)+/)C#5S93Q9T\FM%-!N6S.FH]FS3$'$NO3=$]9$.62-#<[IQAFGO-HDCN[4
MO#R& 5D=[$J\3 )''(N$4"/XC+4#9L$KE-FV9QOLXA(S\7DEMUE*$H@,@DE
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M6VF7^U83P\I>4++J$ME'"D:/+O;GB$)YMOF8L]":G7MW0DW-YZJ*#5*HG[T
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M77Q3UY"IWQ5@HMSFGFV*Y-#,W/(I)_0W27'QO(M8<;PY'9!"ZZPI8>-<Q^B
M(-H-3\K'<W-#M=K:+4"E4 UJES_.:SC;\)^Z^#=&G#IS%N01/:4/"&\A0=OF
MS9B.*77&%$><OEN7]#P)XBJ5'%A7+=(^7R'L]-%&!*66]L><W,XO\B):!05X
M(80#XA[C=>UP/P0%J9+V+EP>=Z.2LAF-/N1  5?*YK>_RS3['&2SJIG4.HZ*
M7*D?R6583V4,)X,I(- EK_<NSWO"JHD0SM=%#UHBPS\.#,% :I9R&409+^_S
M@3=HX=$X?=A7YGS]O1A9'N?F2.I+VCIJD[6%GB0S]C_LP>HYB-E%!U>39CR'
MOPXM,00M4ZOF?4^HM%%8D)E*ME[4:BB*5Y\ A+I-(3<I=.N6LYV$E$_&77'W
M4?YIFI%95+"?H/6LX#2B1:O"2UN[UBT(B5JM)6E4*,7=9O7\QF!Q6J!G4NX5
M-/\55W_&;$>T=YI#:5#MU?6:O5I3PXLQO<W.HWR=YD%\.V=YC]?1,YE-\IQ@
M6T!.(HQG;W5#6%\*UCV;M^Y95^>TB@P@34*OA,0(%I\1$@:56.T#"ECKUL=E
MD#R2U3K-@FRSGQDN=W<;>F,XV^Q!,JJ4ZK0KOD_3V><HCNFF?)440;)@^;)]
M[(46C,>S ]J@J2^/ZFANYH2.CUU%SJGM%*?\G+WXPJIQ$Y0+H G'$6R75@#J
M*ZRZ+L@[UNR:5WGD.\1=2B4E1;1U$U'[*;])DW7U1V<DH5@BW>L["#*&31@"
M[WH6R'T[KI?Z??'\;:[%E,J%[9\SY#J:]R)C&&L]@GEGJ@(!?+:PPJS[6NB7
M)"C*S"R)5_7]\(]$/00UZN"M@JI"Y8_!%^P'50F;T2P0.5#U4[<N@,]N1;!7
MCVW1XG,R)UE&9I2Y@;4I62$V],9P)MF#5.L)WEUR&)V/NY9TW,;RMJ=%K588
M;.,;>M*MHJH8&WN"2+F\)&'2HML,IHR'?V2YH%GK$\A_LGLC3C,2+9)I29=_
M$K83<Y,9_\^XBM9&?GUWEF,\ZNZ =:U]A5_&^I!L,-PW]7 Y'8T(#7UCM8"D
M5@9TY,L-^=R0-4L3^F-857[N(P#&FOT8+!UW;&LMJSPOO6:6F/2QX,6-[(OY
MF6,ZN)C\*E@M7))9&9/;>?T V'S[JR-K9Q]S,B_CZVA>%8&R#.SKR&,,JP4&
MS('E9.VB>1N+HUO\]#A+S._UNB-?F2*%:C5TS],R9>O5=6]9>=X<RZ%5?!75
MH6\N#-@(EA=5CK[W0)Q!>/I@2\\/>&4("LZ[GA@#K#N_W[%N/R<DRY?1^HYD
M+$0Q6+"2 Q4;<G"8&[:@=J3MKU*M1<%Z9^#,2N6X:O&"3?"B9GY/XMKZ=[5J
M#0CZJ@_JI"T3@/1E0CMH2-#IH(M^M.3&T/W!!AV#+$@[_>19T1!@FM+S(:$$
MSP)Z2(7D84F(@R5,B3;.>/I?^_/=GM_ 5>@ H#YA$D"#U?/BKBMI'TI4LQSZ
MP>:&HTG2I=L3((\9_4"*93IK6E]8;X Z=@-?AN:PF:5H]MYLI)-9[:WGR/'=
MOY_:UCIVWF:KLG6).5H#<Q?**UWOINU77>MZKU 9CY[<B8;LQU?UVAYAW*OF
M]NW@GH0D>N8M%TIR24=YL%*Z7&Z<6/A\^;?1*PB<)ATMNBWGK5PY;ZY1[>O)
M[#)*J&T?)8N]N/@KVUX2C_[1;BO< 723>W&'U2X=SXH)2N?J8]K\$\N%;DM]
MI&O<&D2#PD)]&D'5U:*3P?-"^A?L5,JLUGUP.5Y92SU#CYN=0\L" P '5>RR
M5?A^=U%U*R;5(G-MU=E-];VC07=$T;S/F^Q;1.-:W._- %9Q"X/F@+OW?G/;
M3,Y)1D_S(GHF5PE=,27CP0J"3+Y$T*40E:P0M;:D7V9A^43>T-]6R6Q&6FQ-
MQ>;^H<8,IS+HGB>+R68[VR/]ZIQOCVAZ$K#"O+K6VGDS:PWKL(F9?L**E24"
MKG]E_?:N;W4AZXK,@S(N\)7%@#/MH>AF&5:K_T/+UH T!EOT_38"U&\F1SV>
MVN@ NW=$KMD@(V=!SO)6]ZFLK3Y!]/[R7%\)^G!U.PHT@)9*"K,$$GF#Y0DU
M*>Z"#7^+VE5EW8JVRR"<Y'FY:HR^SPG203@_KF&H"=-%*Z:Q%3X:>;E=NF2)
MD6/IY]4(7#H@S:KDAZQ(2!27!<O1[66!V4DQFEY@SC /RD?!^T1UCMH>?,.P
M1NAEJT/6),N"9$'V(;JNST[&9+W.;TWW,!>4#-_<.^QBK#SM99Q^?BC7Z\JM
M$L3-AF;][&)V4@Q4RYW!10USO2Q9E94/%*Q5N;KGHFPMD\LT.^ALUVFQ=F T
MZ.Y_,%#J+;H^([V.N[=U3;X3D!Q;=\#F\R"O,OP'F5W-J':C>517+9V$OY=1
M1O\KF5U'P5,41RP8@%ORO9E^,-)Y?*4RF2NR@!L0Q0PMM:D>8#I?[]/_2)V3
M5?),WCAZKMWP]E.\VLB,4M3/21%$<6XLDN6S&;(,KN$5*&)9O-\A\D=RN4G>
M__J98_O#&5-Q$.^0L"FN9QOFG$9XCS3AB&=^&[Y*XB]2HQS9IA)PWLSDZ;E8
M[YPF'!&O7T:OG1:KPBS7V>;M$TF-X"^@AHKT^ Z*IT;35U';E+9[YJ<QW70U
MN6I[6DA:&-1>>H >K*-C1]S\E=I$.<TW:1_;G7#&M<!$>G<^H&^V-5DBZF'?
M,<73:/>PQ7/K+ *;H6UZ7ARBDF57(WHP8FA/-F<1?($%M45OD*"V1PQ]R%7I
M@F44S]B+&W.A,!\FBR.^6M$M_[EZI!#A+4OG-*0UQ+HYXO ?.XBPWF\^!.&2
MWH6S5LDWE" M%2>?X5J6:C,"#BV2[G9.+2N"JR@Q#W_E7!T5)($*.IE**^6^
M;&)?%[,&1W]U*7KTVUFIP'1I]N^ICUIE*ZU+NAX\+>[*%%I535!][QQAN"-U
M27'+*0/6S K:WRAAXJU6@H$FV@TSQ!AAG?L[?O?!YP]!0;(HB-%4TN+A*V#7
M41]M?(!C<+EDDSA./[-Z2I=IMF.[C^E,9K=/.1UA'A+Z-RQNTF@EVU/U5>S-
M4#.N6!D<^)T6T/OL2"5P*Z<B/G#-R"#1IC@/YD&\\0H.:OL=F2O8IM]UZ]VZ
M6\R*W.X^?H4&#$;1L,6S:(_>G^W5*XXQT0'I*SOU]"@L>1>T70,(C[RG9][3
M,^_IF7?$S[R[6&!J9Z"XZ1J$O8:Q.[KGFKA@5#,[/3Z /SZ KXW3XP/BXP-<
M&>W3XP/PXX.NZ!><P8#AG- P&^9AY/9PT'9D $49U5PG85BN2EX3[IRL,Q)&
MW(E%?X[)UILU6:59$?W!?R\5$EB]8&(-<E]5S@,XC?3^RGA;+$EV0WKKN[3C
MYS?3#GB][U$TV:G]^"_3NBG->M^4IGH\W#6E >M?=/P^J^8N\7<:-SQRY^<8
MHM1=!/.4'"A>O:;?(,R)W?T##'QO:36RJJ]GF^:_(#A2+1BC'<-F<>' *ZRY
MC=N@C^5Q;7)"<; *&'BO$F@_[65J0W6C'C,"]YI*M./12PJM&PS?:.5]RBCU
M!4E('N5G45J0<)FD<;K83-/K0N@RE7GG3 CY\R#(=XB](\X("N@MC+-^3[FN
MET&VVO*=IMDZS0)9J4:)"O14AM.40Z(# R! <SDJQ4?I#_0J\A/5OAOP2@*#
MQUP]?.T=V@7NRRC+"V>L)5][=7F9X2P;M\$]UQKF>[:5N6$L^70H32$D^,H&
MW'/_/$&[6F!SQYROIRA/I.NJ ^[PA\4^>OXQ(P'G?$[R,(MXQ4^CY:4A,:0N
MEG!N!AUN@RJDM1\N_[@HEJ0>8;;O:.S4H,($8PE3>+^>EI'#[MB5.:PK3\D$
MZY+H[L0SU;R5]TX-=&>WW<EEY\UE9[*$\'QU)T_=R5-W\M2=/'4G3]W)4W?R
MU)T\=2=/W<E3-RQ/7<5-?,(WO ^W\^;);P:\+5&/36]0+I[VJ)IE;??OXHDI
M/ 6%)]K!@^O=.>8'[]A1\<#TZ<BPQ!O74#TY!EJV<N)(D1V2_Z8_A\U8/#2:
M!6'@G.G+&]/<Q+$=,\>\>O "V#MH3&[] M@\Z K542/6UA"]-DX*0VFZ^M6Z
M;*3;"(+WYN2^@= 'A"?GY,KIL!ZZ>75.;ATWS#MX>$XN'ANLG;T]UBC?4.)!
M]HG:X-3$GJ9Y<1@CE-^0PJH2HQW%84?NV-Q(+9'$,9^H$"NM$*9J-*#DK4JE
MT[QMZLH$)I3G,'$HGO4R,R#CJ_H>],HR00PK;UG"&_CJ*./BT0-N/DWU<::F
MSIC^'=E/0<R*<N9+0@JW"$76DV":4@$2.IRSBMP#(_=0T .?CWX:5*WM)3YK
MIT8-UBS=^DNHV1C74^PTF$;YQ%[\U5TT6G>I,,)M:-F_7XTKVG)FGSS.)X_S
MR>/\8CW.6[^&@S_'?_4\-Q<.9OE"[KJP]=6,S!W?&B->RQQ6TZ=JZ3TMLPR^
M8): @9\+1U>+2X58'^JY29,06T,-'OTO$P0%-3%#ZG3 N5U'P5,44Y (YBH2
M<'D!2TF$G6E],7MM4:,]8,F.O*)KS7J#M[:T_$:N03V>:&G>#T4:?F)%>4F6
M5RXA/I^ -2CC,FZ]2;';:NNO.FWU[T7+=R-,YVDU[=*D4=#/W>UTE5!VI"=7
MFIZ9[;5011[<>2:DWU?-/3>M';G+Q!@!.,I.;K*.;C+5[(5SD)W\8R?_V,D_
M=O*/G?QC)_^8.M"%VM5!3,S2?W9_/(";@95M=#!4^.Q@WB?@+DOGT6%,@RR.
MM_F!C^B?CF"V!PS><402_T)5:-S_5/ZUEUBYCG@KL #."ZZWJDI&QN*2#J"?
M^!TSGN-:+I9X&OB2_%0CXP+OP\QV43[6RWK?7+$"H3%\QU;E<CJ.L84/RR#;
MT6TJB7 %&AZ7>BH>X](LM+#;A Q@,<V=\>!<6Z99P4(EGX+D4YP&B<L$WCD7
M&3&V'Y^3)[0FOQ(FSCOZ7N4MRKC=? 6L$&>]M(6O6F'BMKTBE+S%FK6%V:!T
MYQ7S0+HM.33CE4_;E@+%2 %?0J7<4/QE,B[>Z\LIIZ52*^8.,EC-@'O'5+KQ
MZ!7KJAE#3YBU;34-BF6P^4CQ8,][R2<+'X[D4Y_Y:)KEOS.=9*/&R36>/IY-
M;;%M?^+1UV@,Z<$@$3*%*ZTYS=(VED.'\FB<6'E .XG.TBQ+/[/FPUC;<8/#
M4&:SVO 406-8S[/_ZU16>;+7S)-=-(IM[<,5 -^UL&Y86G8 =RVS*J^XES ;
M&7S<SDS5+KZG62%\2A;R% 4!LC( 4XA.242G((E^M74*DG"I#U,L28?0"26A
ML<0!F*&"<Y6LN4Q*]B@01\%=L;DN9@W^NW]Q4(\YU=$%OU@ AN%F.2Q]0_D[
MA<S(28RHYI(.#.C;+F?Z:QDD[X_XUK^UT(,1H;'L96:H@&?'<-Z3/ J.>=>_
MM="($:&Q:,0,%9P"Z1<E6X8_1D&RL(#_^*OQE"03C%B;D&(-ZT]DLT[I4!YW
M!2ZK$ZC^O076AJ3&5/70%)VM7OX&Z%"^YI@4+')NE3(1KY*0<JY_;:$7,TKC
M61>&R&QU\G>XM?)KFB^C)'TJ;V=!1+>_):E^L#F@U21&9"CIP-C"_P]00XD=
M,W>L"FRE\MU_6I;%59 8D09T8&PU\!VH!B[*+&4'_CX([#)*6.(ELPFJS;'^
M$ZMCVI;J:"YY#H#5ESS8*HC79^\_/DRV>R7_V>8,D7T\&CW(AU_##=L)CQU'
MQ[9R_5O+XUM+:"PW"#-4:HW(;]GV=FZT6J;3-,G+N A8(':ZM>38[VV,7 ,Z
M(SI#C&"IU0%\QWY<5I<;&UOV\)L107TTW!I6X(OR9/6);'ZFYTR9D?SZ>LK_
MV\9CH?A^/)<$)0HU\HK"#B[>[^NH(#\&Z\"R4/WA9V.Z((M&7:.KN T[S.JS
MGZ>4&3=P@Q]^NHY6+#[.9EJK"(P)<C42-?CR:Z_+"\%7W)S0)?#$$333A]+^
M0[B",$Q+:AYD)"31,PNSF)6$X=.([=JU=.\ZQ1BA!BY'A<P-A3G2C.EL!.?O
M8J_"RV/>XQ"+=W\%I?N:4J+%#JNN[D%HIP@TQ\Z)R$L0-$#M%*%VBE#K55NG
M"#6KQPK'!XH17D]$HX9=$J>B/L#.(EOGT,A@%+E^X.K/U#)-MB; _<X$:-L/
MP#NTEIT/5UV?9K<Y[F8QDQXNU2LFN/(BW64BWJ0%R2?)[#JE&MBC([D6@TU(
M+=L.&8&[?) 6,\Z)<JS>5:-DL>>*FRME)P6>U21-EK*="N*D*4NP3VE3@TF;
M<EHFI]*RISOIZ4[Z0N^D7^NU"2G5Z>NMT N:@02:'S9"GXDNW4MQ6W7!^H=T
M37ZB!H!;JW<E@9&AKD!"GU?D&(%I'74YNM@;87BE/,KI%&K3-=0&,HZI0^+/
MV(XV^RP>>SC/2\**^+(TTI9;2M@938*OCH8_P\S%P6 &BTGA=8\N.ZIM2>0+
M;JB'C+_$JP<0X*'GV#FFS%D&G) 6-;<^BQ[A30^GP!6-&B <?R>_7P_!*D;+
MZ>0&/+D!3V[ %^H&%)0)ZE8Q:7SI. H(H"O"G7Q<!CXNR&*\'>JTC.T.*RF^
MHHIO<2Y/Y%"(:&QP.E07.N4]NN4]*M,>7?PLCVG.NLYL&SE;@"O[=DS;JW3\
M""Y"SJLIWM9K,TEFLM[Q*N2UE$81RF9_]3:$<9B>,'JW?R89E;P:>#J?D:<B
M2&9\"KJZP^JISPJ@3SF#7)1B!W23D''I$(+4)HD1?2;B@'6Z2N/*-/II7G"$
MB/A):F)=#6[GDXPNXP7G@^ A$O- <M ;1X0IIF535Q* L ID-QCEU9X7['_3
MW&Q%1WGW>%5+[GB'D)$C2#EY6_'0MJ@.1+W@CB(G!7OU'6'IV,R/!%:A\.KV
M!J ZX9Z*7S/<<9?25BMLH(03HR8HM=2MZM00KIX0VI" @K!"7J2;M:L*](Y7
MR' WYA]+%L[+0/&YQZB+CAI088+A\&).-7<5R+\>]3)0@*)WD'U]/L>N<,N\
MD*!^L=8U:UI[2*Z2G-+D]ASWE9AYQ@QI>?2L&W@![&"!/8'%8@K8\U[E^56>
MEV3V#:J[1LO<WYGB[-+1 VITJO?OP4QY#:X\XF(&R8S^:<X\F%&R<$F_Y5/]
MH4C#3[=KL8M8P5#BXI3L#=VY.#ZRN#(VC]/KQ@%I^8CC\L!TO=LH.\+K+?'V
MG,Q)EI'9-%VM"3V(*]QWI_,O4;&\HH(^1[,RB/GF<!;D[,UCPX_SLTWE^!"2
M@7?18DN+9R:910*"+-+V?H^L7IRPM(O?RZC8<%&:QN->5'IR%1FU&G.Y?"CQ
MAH""^0U.[&G=-^<BI%+1ZJK!"0GN% >>>U[=Y:.>?H:QG4[3;[6.TPTAC8,
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M*$XU&1?OM>B4TU*I%7,O&JQFP%UH*MUX=)UUU8RAN\S:NIH&Q3+8?*1XL ?
MY).%HT?RJ<_,-<WRWQE/LE'CY-%,'\^FMMBV/_'HD#2&]&"0"#G%E=:<9FD;
MRZ%#>31.K :'.XG.TBQ+/[/NQ%C;<8/#4&:SVO 406/HG^S_0I55[NXU<W<7
MC<)<S7Z%@,]?6'<L+3N VY9935C<:YB-##[N9Z9J%]_4K! ^)11Y"I8 61F
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M ^3@XAQC^XDKF>=GFZ.Y/?D<9+.M"7"[/^%O2H19 "]?_]=@>'L>47LH;A)
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M]+FS'WZ:IN?DF<0IK\?NDOF@HS'>' @M.L"Q)]MM>+;G&#CH0TE@W#D0:FS
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M(4R=D-G#PB_]71SE@2M[*U<\6.A-IL'KS!G8PR]' .S18#%Z;)YZZYUZZT&
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M-!?/55>TW:. _:.4F);=<X"6B)LA*R%KD6:C(H!X]99DVQA"O7_74HX?X@G
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M7T/=TB;J]W<"#147&H9.U&#$KP6M*Q"!U2*>]@#_"]R.)E(QZO$<)PDK&0*
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MVMS.]<VD+3@1,5@\VW/]\R"CKYK2%V[9)S%1+A,XC,LGCR F(+U<-6_=9>\
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M_H^6RW@.8CKN+7%-LVA%!J9_6"1A]Q=<RY%Q/06'/DSW">8!?"[E2-2:;,I
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MSJH79,A%Q0-$,DG+T-7;A&B?./H%AZ^#**'4EDE;LW!LO*A&&\LDUX>-@B,
M/[3M2]J8OG72UJRDM54QV_%1W@2VO>9C:8J7QYC.BE@FD;].B96>4#*O::Y:
M>>],*SM$W-,=7& F((0T;<N\/ (-VMICQH9T\9M#>GB.CC-L0$9$\4;E:G]D
MBSTD=MA4/F;E5RC%:0Q!>!PO)B'(#O"!LO8HJ4OUE(!A=7HJ:]'K RI*(?(:
M6S[U <\L'-347JQ6M!;#=*$/K2'=VP@Z;('G_W4!]BCA"[!7_44A#T]&J(FX
MY:77@<6QUV@Z0RR2D'T&RRVKCY(\+O(<CVZ_#N%DM-H'XP(78-<,SUM:4C1J
M52?3HR'>IGGDZQ;[B. QA;ML20?<@#\<^FR'F\*FLE>"1T>]9& ?GK\^>V:@
M#G=X-L\/VV- !E[%2HWVH MU'Q/2P<4++OQ8LU"Y'$-FK[1$5<?]W!2H0)QR
M%7FX!$/*?U>5J^_3Q>KG793AFRPE:K;8WY E+8CFI2<N6]ID9*09#.Q#">JS
M!U5H)DP]41#29WWKMKZ-4G-I=RHSFZV)[1L:AZ/0:O>TFOIT852M(=W[23IL
M@?7!ZYKT+(^A"J**7@.:"1 E0I9"$%H2>^^(?[I]V@>!9"/YT'D2?@"8-3W*
M]!GX12 ?&-,0) \MU>Q'L]YN2N>NBBGES%J<W(P3#NHG]T"/N1$<9O80'ZI>
MK$,!<QH]8](,#7(K$%PUZTR'GG9UN.4>;+4><"EC2</(:S=7WP]N:$A1NJ<*
M]])A>+K8)6&]55^E04)^-6F(Q61DWVA3<@B C[85E+6>"_BT12[&HMZJ#(;F
M<MTDPM(TX-,TGTS5"8?R"SX12Y"JX]R)=+W&[ 69%>W@,WZG(T81OL")6P.*
M-Q_O=@]I%D8)%<.4SZGIC>G;E0 YTW$JP-<B/3L42A%#KH5\-2R=#'X FAR=
M$YQ/<)X,#N,A, SQH@,JYIV2_7+?/2CV#"F1X" 4]68\( 3,TYW\!4C%8%Y2
M7>0\&6JIAR!YUWO8UC>T])YWU%@'V^07GO2$S]N"PWA64!I/V';PU+Y@V\#)
M=^1")4$(2&.^55L^G<4LMS=X\S!ZV*Q/WWV]B1X/\F?$[F9P+0<42^<A.^&\
M1KXSJG$17\B'* >67V#T][+M/WSZ.O;+?#R@2B%_SZY-R1%]?K)"A%(J?JIE
MREB2WK'D.Z);8<*AE\IR.I+J%H]3+H'M=@^4BYU$:<O'<OY"DI0= %=M'T0[
M'44)JKKY-B*U!-FM&JR:_B!/I0BB!(?G09;0UZXGP1,PB'M+0,P(!*'5JGPP
M"(?H#*^C553XW*ODDNK:BN L+8,AW%(P+X:6P<SP$T[RZ!FW;W.=X8SH._K
MTM]V01RM]RRQ]#L</N+S#ZMX%Y8%--,$LYLDY!>T2 )QB.@[3!KO>DVC[&8U
M-]<5/V8U>XT/L;P3T^$271[>6_.BUN>TD,)M9$X,#DPHZM0CF$0KB$9P;O@(
MF%#5E#AT7GV7E(#Q"$UN@#'C<-=0*7%GWI<.0]"+H<39XOJ@NI/7\+VI6M/3
M,E:W5+/'((E^8;6^3],D3^,H9/]8).$-&80H0/;/Y?HB2H)D%07Q'?D-9E&Z
MLRA?Q2G!-[[''XH3,M*[D1$X.GL>ZN2-/0?H(NWMZ\7UY?\N[B^7UVAQ?8;.
MSN].;R]OV+^7%^CD[=WE]?G=G6_7<"K$=6[B3K'DUK7XHL<D(IX5S74O[Z@Q
M8R(FOA;.I_IP- ?U4I56BS4HE/;VS9O%[4\4T'>7KZ\O+RY/%]?W:'%ZNGQ[
M?7]Y_1K=+*\N3R_/O>/<3.R=PF7Z"V3Y -+J"8>[&"_7]4T,_A+&>5Y$&VI!
MO\WQ>A=?16M\SXQ=,52A\.W ,=P'=X<Q#.&UHDI/Y[85W;*Z04T9[1A%%!-O
MQ.?+2.-@H@T4C["<MAH7O%_4CC9VKI[&B!Y,#PVV -PV D*TD>>P@X$\.TE[
MFK.WA=DI,<>#AS1C@81%EI'U8Q;$]&:QR<@^MG@#_J!CZN75U>)D>4O,V1_.
MT>+U[?GYF_/K^SNO;IN%P+MGK&:K,J#R9'5C>7HD2H?R 3T90]"][^L?"+26
MMS]Y!9>.T+H7>Q03M89/NW4W8YR6EZ%D=N!PET5W6!^U[C5YT[ "^^4$?#@G
MAB+NN"<F:V%?]:HB31ST*"<#TI*;XU>M$ [B_LA6S @ IKH->J2-_%9!D0E)
MJ*SZ$[2^'UM1O W>OR&&:A8%\63XZ(SA^O12R 64#1J\1YNZC?<[JQ()"<'1
MFZ!E?=-%'*?OZ?V<BS1KB-.*WG4,</F0DTGD*TS:],LQ Q$-<ZK.SM+L^(-.
MHFLZ[,Y6LUVAYYI4>4F:(]8MWNPZ<F$M[2968;=R0PKI56.\SL:O!7Y W/EY
M;G=\L-12U>@%2G#AN["22!I"!=5.:4CI)"@L,;VW9C2T<^28< ?=-KU=WIS?
MWO_$#L#.__;V\H9&#;S>-+60ME802^KVC8Q,YWB<(PJ'A_H]7['7EJX6_J9'
MW12[HV*P.<7H9?OGC1!?+]!CYO\9#3UY:F&LN]^."JZR6#<>O3RA<CP?05$E
M5X8PZ]IL\T+9H6"U@-99![M#]?K"8EL%Q^S 7-;?\9L/$E:@FC++Z]=']^>W
M;Q -IM_='YS5N(6(KC@:_T\U7XO-[> ,?/D^(2O^%&UO,)%44@2/."_CIWF!
M#XZ^]:(1MK0=[G!#^-2PL=*:'MJV!-N*6MCCLR,#!2](HC!?/,NX:OE2XAM<
M/*5A^ST(AA]YX]0?UW7\59LS*#%3@%.?'JFQA/D=U&PQQE<V&C>UC5@4OII>
MOU>8!046"<V+P>-.;,>CVJA-Y8MB-*&]$IFJ38O^D\P1>ZZX#%OOBKP@/T3)
MHV\+UIU 7UE;,&W^*;W)PL8XP\W=;[UC$SD)U_:(G!WX<E[5"15U+T\%$PW$
MTIYOJ.=L:"T<6"?G'PI,;\J5UL@MCFFB\I"<80V";@_73%C3L%TQ(X*(U]E8
MJ[0>9^2M^+6U0 6VJN8*61[N<M4\]_=9D.3!BJ*8 _1RS?U>SYLR)NH\/=V4
M0[!<5,P.-9D]^CXJGA@&Z677("G#/%&1L^?@HS *Z$LA+U#8CN%1Y]G*O0&H
MU0K:%<!I/@5!9&&(6E22<QPHTN=,0R>VQ<L$[TWX4X6Z(A0H0JU%L37-KM/D
M39"]P^PB.BU$>V@,YM>X6#SD14;PK(4S,XJN#3<C[N#+P$>;A@BB5%!)!G%T
MO,:W[67; -!\I6RL/S+*1CF*+NXT*#E6;5I,05IM]X"*M%N&R0.$],7#0T=S
MUK9J2^RX&NLJ#3)N'00U0]!-J_*-)94:<HT??3DUX-%< ON\.6  )Y%HMR:_
M@A>H0(H_G:,I(G4(R[*<?IX5G.%UFB8A?=PF/ EBFM=Y]X2QQ>450I0##/E7
M"Q;S\=SM7\:\:1CG#V5GE-/>?JXI6XN8@LYN3>Q5%4LH*-\;KB['C*RE! /X
M4%!]-J +G=5S6HN#Y[1\5" !9=.I(2*>F7VEG98>+><S-2BX,5P?F JYD'AD
M*P :OL'1%Q. CX-9>CGU!-D1G7"V+0X7_:-<\<,#2_/O\BH*'J(XHN]#3:BN
M!:-XT]E]7A2*F^O@7WO#\NH!!IBH_>UH6LKO*8U#LLRE"3O%2YS0*%X*-HEY
MD14[KUK_YM=??_'JJS^BLI=GS:X07.>*LV3&H]OQ&LI=PH](O=_1M(<#$1P6
M=_Z(17!L89<#]G]9$K:I_>;"190/Z3"J;L.?AJ>8-X7T6)+F%F?!P<GA#)Q&
M+;E+_$;U(ED?Z^#B+H@/'S:%(N=U8^?'T?7(D%F/"Y33O_M,9SA<RC;*S3-O
M=<+++J;<9.DZ.@P_ I+J='!\E,&/#<B+-:&WUM9^ZO^#B]K(K#<)VP^L?RA+
MX*!=! #N[?H\%.1$\DG&![?#9G KXV#Q)7<R^.E9%PVI*\!?$)[<'"?HC>FC
MYHP&7]!^3PW,,F>#N.,YHA+F'S)'09EQB$-60V*7L\S))\SND!5[M&'C>"ZW
M90"%;C$ W74;]0;&9)6"E<.YAZ:*)9T$RQ)H'":]HDU7IAKG8STSTSP]C7Z]
MRW6?/F:PUK0]U53<E_!5L:129QWUU&;FEEK.8S*'ML3:)#2MI;"R?8D3](RS
M(B(N#_^<L+)Z"8 C W*.[69]SL BIM<_G-_>7YY<G:/KY?WY';I9_+0@__+I
M%9F+KP&5X8+86N@G0?+NBCY=:P8D03?G&JC/ P"-D\7U]^AJN;CV>TL:7NI&
MZ,"4K%]#:((IG5>BIR\J"@SGWKI1L:038U.\&^ZUHJA<KN)*HI*5L+2B&XHG
M:9:E[^D3@6-#2S""\VI% B8TD\.\@ 062@<7P*1L-Q2R3Q&DK=[=9&378I<[
MR$^/6;"A>JW:Q,SV&C.*KD-#1MQ!I5\6/YU^=W[Z/;JY)9;+*7M%B/SX^G;Q
MANU;?5/&]=YE)=5F6S-?(TM%](9@^3%X-+.5!RLGW5&=*RQ-QJ @IMB*]J#*
M#,7*JS>3)1B0V.+&OIJ-565D2WVWO+TOZQ517>852 ;FTNA&$G ETL'#?B8C
M^\AY,> /NFE[?K6X/S\CRNKV_I(HK?M;XNPMV$9ZYS/=SD+FW7>WS19FA%<H
MH"$=O4:A.;R7S"Q#)C5<RZPDA+:4$BHX4O-XK\(,#&)OTV"QACZP5Y7>N,4K
M'#VSC7Z'Z;D1Q\+06AE60WB[*&[#K09LJP/'G."W)HS"'2Y/)GE,'Y38\'BQ
M? @T!)?-K1=V@(E9C9FW@W9'&UDG*X=S;W:J6)(7%#*#JP>]JRM@7L]J+8EM
M5.\0[CESHEA\>I&$U6N^R6,[]O3V@3DG[J.$]LSJZ-X-):FA;KT:#M: $=L0
M=@MI&\&L='GQ=/ M"2^K !:#BH:K:V(ZS,SO@K.)&)K=66>60RU,R)A=L*^2
M<'"?\DT,C4M3ZM[L2D-&S=1:D<[4AK04OL!\M%F_ =JL2ZWZ'H@&A:[&PCI-
M@Y)C4&HQ-<-3.G/9\(I.<\I# MJ]*T%T\YT^5JD_KNN;UMJ<0;5G_O;V\M[O
ML[?&0I5?$I/-W[Z:0ZLF:>B]3(/*6<1H<N\"'-"C$P'QI+&IKLH4,EJ-N=Q>
MR>]"0HZ5GBS+-<\CSJ@2M-@KD*Z,]7;9(7I:K^!EDA?9CN8$EWNTWH:I2<MM
M\2Q-KJ!@2H,D2@<UW;W::(9":W=2@Z6P5VC*45C^<'[)"J>_&EFY&0[N>E,U
M8P]*5-AM'G!&,5FV1F5SS_E7=F+G59W%XEC6>69[^W);2+99R'L5]G0:WA"R
M &V/]\O3[]'RQMO)L'JY6W\1G-<(Y[P,.B=!CD-:CQH3%Y2.PP^Y(#[I,['R
M')W\6C/DW \8S++.>TME?_5K&IZSCX>!",I/'K"L _P.X;"++",R8H4'3O9M
MDYM@S^R#]T$65DR])@V+_#*YP5F4AJ.G?HW*G)?\B5&GH#0%WB;$48WW]#)L
MN4V^0(R"=[M@&IQU<]=&7VDOA7A&GX:P/)L&8M!G45+][O/_H,=BV4=,RM=[
MXFK\28C>P6)[4K-7!X^/&7X,"NS+%_Z8,?)JRIT[-V+G1QP]/I&O?D%T5/"(
MSS_@;!7E^":+6HBZVM9'Y-Q'FKBSV0'F0-WEJ.J#ZDZ(]4*$<*G7!<;!'#_<
M\8%L]%6/+"_KVX;#E,]%FJUQ5.QHZ&2>UKJ(PX_19!?,P\9NK\AP'^<<OTU[
MU(VYLT)+_C$:\,!<C*WX!C]"._X_6#)>?X^FFH"GC\E>,V7_(S3:#*<XW'+K
M;P\S=;LFPO:H)IR-](;8<0]J]?0 L+IL ^('+-[B31 EY/>G:<+>0MH%,;W+
M^<44ZL#Q#!S6-_ X39560+5:X#JBJVB-44,2D;W^)QQDQ !8"HY.?"D(/X#O
MZ0@/XAP[S477 G4_59&%RI%"05XFT*PPLUJ_?/4"$=WRRO.QWK\U.H\''*H/
M-+.K#96>999NS,RB$7W^G!^YCST#FR@$1\3[)C(%VL;T',4+[N6MIDFF8AR"
MX*A\*D$(?T :] 35B!S-*? P$M<?8Y19<V[# PVB'> C_W)'CR^,*"O+RYH#
M[4=VAJ5I.>IER+IDR$\9<$>ST_V"M6("PH_9K>?E#:_=RN4NI6==R7@@HYRT
M+PE749)'JQ^">(?'OF\Q(:,?8>0/G@UTO:C.H4)->\0Z0!_L1Q@H46-QS'B(
M0@0?85!./B.1:Z:'*N:8G:5Q3/:'6:1Y?B(8\QA:^X$^PA$NDO#\PQ:OR(_W
M*?T5%R.<9<1-FVT/)=#=S,PF0%?29G=E<$6=%A.A#[%\[!FYIC@>TV4S$MD$
M_H>#&)_)%(U#?Q)80O<*_@/1*>7G*>U4S>1'%$\<.)F/[0!IV'2'1QYUMK9/
M4F>XCD^.(&C;*_@.0S$'08\9!"Y?.2Z"XG1NH\8MM:S<3SF(V?%@/0G3WRUS
M0$%Q'G@3[.BZXA^' :$QCT_$=E#/U#Q$^N_G >OCWH&5H"G2CS(-9M"4#6.R
M*H^Y%Z/]#YZ]"G=(-HZ@Z@O/(%_UA8Y83BS/=YNJ+I+KXD0#F//[:,T84] H
M7+0.H@P]4VRPMU,[!1(>^_57YE*_:#CF5+6,!JZZ^R.4"R))]I%SC-U&^;N+
M#%,M@ E>BUNB$>9B6&KS.\,[=4/G!#V+1IJB-6E+_,>R,<H^YOHDII <98\T
MDH'KJW BYII-O!_I\9?>HF;T8TIO4<X&J@'>F+/T.7%JR^[QQYQMH V_4;(-
M]%9]4(K96 JB9NLL>HY"G(1SWRB%_'[D&Z5H3L!W63=!^PC''V>9$5,43K8W
M@LON^MQ5QMP/:4S(Q%&Q_UB^S ../Y[,'_U)J3;-YZ;U#!) W2!R\J]4(($!
MX9SS(*-G)OD-SA@K4T5FX'$\6)$@,P">KY9W=^CF_!;=?;>X/?=L^BDEQB-0
M/E-KPZN)EAS2)TB.5HN$;"7QCMIX;H)]9ESX<%OL6-6(WL5IGJ,MSLK78>;Q
M.(P5*,31.//E,L4T.X^^WFUP1O^X>,C9V;%6ND6_E^.GU'H,P$FX9;MO?;Z=
M!BYRDQ8@GL^ W>T:%Y?)*MW@*_*9+)Z#*&: 2<EVO*D*U%?O8S%@C:R@3$=W
M[[T9<@C!"Q>E'@J*(HL>=@6[FU&D:''RP^EO?OWU%Z^^^F..5HQF><!0$07N
M;WA07I9 X966S5J.G!FA<:ILP:4P?]I6Y/^&4CZVVY/.<))NHL1X5Q+U<_U>
M68\#*(K3MOS6CX>H6FKNY3'QI"R31P^2U\HK!5S2JI'(M8DY-'V-&%/E6P95
MOB4S<G/^81V?L#&588,EHV4Q#,)U!@B  036C@):<DJ.[5XMINPQA8X0H^ O
M.]=(?CU8J9=E@$E=[G[WP8=;3&<1Q1$+:EVG24A\ME41D>V0AJJ2'(O#7Z=I
M?J#5!AO:X_#D/$ ["MM0C*"3QP/=D_9AA(T*(-XT&V\Y_=R)'(U_D<'>P<-_
M(*!>PB';;K6OEU<8JY2RO I9V1AT8D).G^S4X6C0CEO1F(\Y)Y4>9,K!ZV)7
M&XMZF77LT\@E$'9T;?Z+F(".6+S'L97KW<@<G):-SF!&&4]12[S]7HY-\!X#
M@%R/#BQI#]\UN,*-0,63&?%45:C[1S]3Y38&[T>J\BWAZ%#;S^ <5:#A=29G
MI]>76WK006A>86*"Y,OU%<YS3 CGJSC-Z5L.9H]ZF]!S7G'0@#EH=SA?W)U[
M52(6 FO4B^G\K<+%[9EI=SC^)1'9<3QTI=R<K&LKPYQ%K>>\*U(HIK10P!'S
M>&O;6LCMU6N[U;),!>R.<4MMY>7Z;4[SFG"QV*19$?W"'*_**QMYAS0>WL?6
M:<HD@-[E 6(S2N@H71_M*'PIK=QO$IXM%OB=V&JMK&]B747! \VTBW N=KX&
M U0T@O,XI( ):!^^7)Q<7EW>7Y[?^8XA263# P::VP#COHO!>H#]I*JK'<6_
MAFIXT51$<2L"]-EJEV5DB_$>A58($=8YW=F/8?VW$$T(W^7Z6!C]0C)N#_[5
M#-E INWMI7Z H<0 JQ]<C &%:1I+[C3(GR[B]/W=;KN-F0D7Q+QWX28+UXP+
MKUFX1JQJ> LY1P=%R3K--LP*01F.@ZH8QH%'D?N^03@,/>)T7?-UM4U![WY=
M$YPI"P;PO_5*#GP/52@N#6"_"7>PE. -MGL*.X*!1O^ORMFC/U;W;/)I[35H
M4/\8@E@#<$4_:;0-HA 1K8:"3;HC;8F.6\6[D"BV*$'%$T8;0HE\X920*'K"
M[>=S\D%5T)!8@;)%M#,*H7)VC#Z]+#TD)5!"S><Q,LR6XBRY>4VV+;C(2"!*
MXUMO9J*Q#*%S9,7"C*0:E8..78S">'C_ZE+-I-Z&[-O>LY4\K ,U5V84;4B-
M2+KST"NO0_2@D([GK&@13[KJK^Z+:.<9Y4++Y 7I/' =1CE[D QV@XEX#V,N
MT^HZT?"STW4")C\!72>1O+:N@U;&\@'$QG^^V!7$BGY#U.AFM[EE[G-E65ZD
MV<$Q\J##W $#N7^P< 2N-6(XFY(L6K-!4) DM*KWMC+LT8Z^$X*2-#E:!02
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M>D-K)L?[4_*?+'K8T6-WXR"CB(;3F[<*9K1BC)NR'UIQ'?W=P=44D3#*"*V
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M1UP6XM:J+\+C0EYNV^=I@J14!3A7VR?B=I@>0BS6ZRB.B+*[)JSML@R/7UP
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M&[WAV(OO1#7@?O]8B7_OI8QX]7HN+0#_!G5>!@J%Z[KHQB9J\"R$ "^K3('
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M&[\"8Q)O-(P^_3**0%2,B]::OA6GT3:;=>9?G[V'=;JJ.2 :G6+Q\6679B6
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M-0570JQ5W5TSFT3]8KG99-M,[@PG']KI"= A&2R@?]4OP<.9D7B:K)I$(H+
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M/L+/#-$J1>N([$K$F-M#+>B6%KAC%( NJ@LBO*(=45*7!'0)8G@6SED_>X%
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M,%#D"9+/)<I=!$(,5J$$U<Z-L25\8;"0=G!VW'U)',. >BDD.X0W QH&-(N
MV"%7'LPP(+L-&+Q5%,<S3/1; LA*($H8TS#AM020#:); QH&M'? LW ZZ00P
M#!:D!][&^CIB&29KZ@1I0]7:(QI]EB$!:.4 5@AH&"Q%":H=!ZDCKF'B'76"
MM*%>"H$-@[4H0;4BF$:XP\A!:L"PP?J.((>1"G5 M/"T81#.,#G<C=#8D)IQ
M-,-@U3UP63F*#$,:)H>4,2HH%5<I$KI$B8?5"^1T0 +*3RD-4W,I>D#!_#M)
M+9$F\1U0K.9]:I+:!@(NK[V1M:E)90L$P$->4NNC+?Q6*/")JIKT-;X#Y*!*
MX8^N@FJ A+-I/>0O$SJ8N2V7"^E:5=&W Z0J:Y+9#0A.TEGJL2:!U8\ C])2
MXK&N: 6?0JJ=(*E6U_#((8 6FE2+;;3]#O'G #*^)'[*CJX9/6JI%Y,<;D[W
M#%7R6F'DY_4^0C&[Q[#?W5*"*J3REX456A7$,JBFK2*.VD61!L2OX E8+PT2
M%6BH.X2"?WV5QE]O/&__V[$!PF)]354A]+$7W),8,Y)G3W$2T>U>92>C,*8D
M\F8;U'M_XATW<GAO&9_?HB")B]]PSG.N:Z',.*B]G!F_3%@BO 8\M]8U.<^B
M*KU>Y!=DT!\K0FZV+,G_XNV>M]'XVM_BX*@?+!1I)K>$R!E$(GJY_-=7[UC#
M&KJ,-8KH)>PV8ZJ43$YC@J(8\;\\&0U#><W3B*W7JMCJ.(X*YD!X8BUMBJG!
M%\?28CU)J+UC_\/.77H79X9YELR]*#K0R^#/['(.+#TUG,6AX%*>$BTNBU61
M@6!B-A'R [W71=C/6] ,+6Y=[!,1O#93<Q7XQHD*Y.&=^.'XI'>'DGR5T,:Y
M#=7;LE\S9O&V,RR7Y;?]K3:,,*N7NJ'D*L;JU(GJ(5\)#W-1?^?H@+Y,T35=
MX2+9HF@(*7?CF\P65F!=+MS_<+./CST+[A"T&"N@)W*B5MF1B^8O3H[+8RRO
MTG0+]LXL0E&V$V,6E9@_N<C^"F JM:1V'Z'\9?6:1+=Y@J14<I+H5B>0D>^B
M;B;DXOF;HY.,$XA75Y_W*(P1=9BY8:ZL"WB+J6"<RHY3XEXNX;\/O0&%J[$9
M\YF.$R*6T/<&$B*)%_1T.(H'Z?O R\+<Q:LTO /2BFH<TFO?;FV<@KK*F\AP
M421+\0XQ#WBS31;KC]0DL#4!"[$=UP@N>FTB[& 4V!7>1(CO"5F]X"  EM<1
M[/@WV(D#4!=L$SD(>^N"BD36@G?$HA$R!>RF;!0$R?%E'=Z7WN=L$?"G5@NB
M<;\NM7$(["8-X???D= ?P-DOH1GY;I.S!^PZ;10!090.GH>S9V_0T,&/&O11
MW,): QYU=L!=ILTO6E9N6",W=,7*>UQU:Q<I,\?AE-%.;P<\/ZPR1<-2XH,R
M6L<;RC2719VM8*^I_17 ;JY+"R*7.U5W TBD;#,?IM?;:IYD;/<IM8;$;82Y
M6Z-%[Z=U/CE-=#D^2QSS\*EN5@=8V'G#D>)S?1'7$ZH"_^#LKE'PBP6]3U22
M*"(O.-Q >T)2-$[O$GJRE+,*+GG%2(9E?5H2IFEVC*P<CV/G2$^.+>P"3$TQ
M/2NCE&)LK ?^N)3@F90D6]@%EX>B)\G9ZIF5'+ TF7D:)V1'H2F]E@L_G(0T
MQ$MVFFU2?:DHEG&PLYDZD$U"AJJ,<Y604LI 6Y*!LO9DB$9R253+UY-R"RK<
M9NQTEH]A2QM3AF9J3J>058"I*3#A&NMAFHG=_5K<$D?9*OP":N?B7@$]FK"+
M?B"MPB&762FU]Y'C46SWW>B$9BPV4EN$<L:YK3&1N%;6GF^[\8W(G&I+68&;
M8)=YHS+04U^5(OO#8MBT"]M(7%9M*7=RT=4U7[ X>^[/9,57X4Z/@$#]?=E(
M5%:?D06/Q9.4F.11&."^;YCHE&'DB[!12BW"X%1XW2(2,L7I(^&<['8DM":C
M!GB7YE#ES*IS S"SPNA18;7B:2)><._AU4TX]_:8&E3H)P4)%M=.9K? I/R!
MNB^8]1RJFVWF^+!^3T63S%*A-?2=4 NWX_BVPH50CY4&UX;O,ZF':,,BK;T]
ME0?6Q2M$JRLO"MD#\\SWTUW*H[B7:(U]\.11!80C/Q156.8TX;Y$$ _ITE."
MTK!%88R?499CS@9FWZ%DL5YZG^'?>[6PNPW@*9AL76X"9NP;B7\9(2].HX,U
M)TF 8/PGKX@K!C<.J?F%.7BMGZX3D)2(*SU>$"L7>A,I?< AB7A#2;H_40Q]
M(#; 3S4"T^038,\"H/U%[760KGB?](BS-4DB_)0F67X6B^B2,*$44&@;2_(&
M(FH\J1[ZKR9 8AEY%8F](*T8G5M'RE;12*^K<57,K 7PVWH/X/SW0[4&_NV>
M<W*+$NQ[07SN%"P.-5(N+2*.;L5]M7N6#4TY9S4D*T7JVF<RW5NJ/(4KV^DO
M>4Y2/$N3+74F_CCM.2L2;R";:.5=%PM=U]N)Z+OAT]8&$&^.R*5;#2G7@F\N
M(\8BNA:GH7D#"+6,[;5(ML)!EXU52L]* QW$*A@G:IN5F.DZMZ1$I.4#N W3
M-&\PK;QS6IK2H,S*F2O#,E6O6<HUMPDJ#;+L';BMJ%Z-6$7'+4Q'&"=1ANPI
MZLB=K\S[6E?@6 HER+#T>LI^1F$*GAQY!.M:\3L$4WVB+ECANB/'G,1TH^;T
M@)NI,NP)B:?&%->W\_<1B>/[B*S!DSW*D%W>TC1D4V$&6.BY7Q5'WE[.UAPU
M.1['5RX-L;7PRFEMAI2NW]X-*46SJC#^WO8>A11P, M7LQ6;BLZ LNG-.1KH
M)P8UI!,R]JIL=!T">*!,I Q@P[ NZ<D4$-XQVXZ4VW$YS?_3\K):.09U]3?K
MI447>N'%:,72U2@]^2Q5V+TJ1N(VBJ.S,R5, FP\ 7)DV#XH7,?=6G6U]9#O
M=;^!]-!.>:"VA%7",!7[*.2.RTR^.Q*2*DW%1!8[CG4WO@GY,0K,<SW!IAA+
M<+/;>SAB"[*P(R5(W-I09<T637&HL\O IDK2HLW\4"]@;R>G 0;O/1S&C#0+
ML;TV7$[MK)%$.WCGLL=(YWK +\1JUE=G+47J:09-K==>_9OQAU0:J^S12 C"
M'R[HL7,5K4,?OWRD?"FV-X#AUI75 Z4U(UUI4Y3^?/S\+J^M8/'@L?JC+_V8
M/@6L#4U&4;7AGA+OU2"-_A*OR)!"8,-."F.G+CMT%^$UB1#>A%>?_:T7;M"<
M_W\U074"&;V,NME0B,=-<#ZK,,B;>%%UN7Z^PX4+5= .?-PHH9S(4YD:^PH1
M0P2V01W/H=S-"1QQ"KPJQ A0UFS<QE7D8?2/L)4@3V3C59A1",99N)H1LQ!J
M#?R(OPYDCG>:0$D;8FOA%%PLNT_F%[/:O+\Z"2F9*:4T)YF$\05:TX/\.*80
MQ5>?J9)2NG'H18<;JKGQ(#6T-BF=B VP*JS"IO2.TO?21$ITOCTN4(C@LY-D
M6,81E+>Z#YN:)&"VZ[) EH-EP04O 9Z.9U;F1K$[ 0K?[1P3;>7[5_3/P6OC
M04ARO>V;"J]G[U6X[J1W(W5N&-U5^F9/SSXK^$^?8KS"7J0:OE(&YGAOBZ6I
MSHH>;S6]W\G;^ESED9QLRH!_6$9>&%.;Q1@;KOA_!1F;5_].LR<H2WW&+!'I
MTOUKMP"VI (X4<ZTL*F^)$LJTX;);3"U7?*M'.J1WMS;4!0M$(M"5EL=KV5H
MG+[0M\M,SAJX1%\(D5UX,?8MRRO#X;25<H>BMDDNYQ!@)96)W'ZA]GV;H-7L
MF?I[&W27[IY0M%@W2ADYM9;VH1D-X_:K#?GJM*Y;BV:7.N#:">^U:8RU!/::
MY:28>.[%V^N O'QEVE'\6*-=0+)5O-:*JH=72ATL!H\:CV=,^7AQ^!BSO+IC
M^'Y&O>OGK&V=I>1A?0+&TR%%*O7*:Z,!BYT.GZ $6TOTK\)V?6:::W]-P(+4
M?S>R.]U\8S:GU">ACP-4H7!)W.YX*R0ZO2+I6@0[0G*9]GR)*$8?VRB_JX!V
M&[ZPN;DJ0X8KW'3=V^+++;(<2MX=%9H&.YKZ[T^D[UGR,8QJ:6Z+\%1R >T9
M=&%S&5<92A$Z.6X0Q :H67I/J#Z%O,XF\K0RX,5?OF912G@%.0+)^*V+/9;2
ME=E,#Y7C<7QK&VH+MS#:("(.5+=RLB%LG=\H;=WZ-Z]<?@T6N9YO=)FC'"9)
MK O;:S;9RAQWW#&#TL6F.Z%+E/UO:8'Y@$5[70Q5$8^FMZW215R'HX#Y S#"
MG_D^2>F>L#:T4@FEXSQBS0W1+GP11^&Z!( )_CY">P^OBNXPW..P+GHA4M?Q
M6V@%$'/6X!H.V"A"14UGX:I:=3&+8P1^0^]#B>MF/I;MA%0 <!=V$.6Y3!'+
MJ^6TMA55@^M*"V+G];V NM'&7_=3D)MK9;>>D'Y@7P&JN%Z5.:@P$?"2#WM:
MW'N'07W$ M]K\Q$:_ 0,%(!)/$HI"961@]7CJ?1O0RB$#CFORC3HB@(PP@ 5
M8BCBF3SG/AE2<5I0ORHE:6.QZ]G"36JIB\.B< /ZCF*<K\EME' 5KM&DW=1
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M#8,H@"(ICD,N$(JARG37DP_F)/0I/1'G[P../\TI?IRPGZ UH@73I Q!&\?
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M:@S/!89?9('AQ0\_S<DE>D8!X?VD3>I NF",NB*DDP%N$N'F9'6BR3,02BL
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M6\?O\#H:4_19E@M1TI=RP/6H*%G+.IHO4H9Y!:=^U ]H@QD?PX0UX^NE/T*
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MN8?F)*5'Y6%.5A!WSG;XDW#PE!@%]M[2$D7\YUM&%^N^R/[K_P)02P,$%
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M"]4O#X?PZ$O1[4PS<1' #,2)NA+G\41&+?Z@)?HJ"88/Z5<X@R?XOZ^G7SO
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M0>1+<38,AL,(KPI]HZ^6<Z/0HBGJ_?MX'S'''2T+\>CC?O\(I@C7,XY#QC2
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MW(>?Y8B\_]D\W8<WR)&$__IW;'\W5^,>7(T-L<!_HE'2W))[=4MNS_5/+O2
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MYL682T5OJ'UM":;[,8*[\R<J+;?DM%/B^BF:C64&P F>MD5YR )M9?G]PX(
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M[F:+NABUN=4]>J6[?Y5>J!^L+&6N@Y>.<$@?;YL%S@'I/Z9N2LZ@(/93;AV
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M6=$U2XT^TA#B-^LC5;9H50Y?A7*&A3X)4%J1_=<RP=Z)G!%#1.T$Z00TZ'A
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M4'Y*"Y-CIX$VY34QT".Z)??$L;T&.C^4O)DM#?2'S1X'"L'^L!HH(:HQF:1
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MSIA HD4;"QX=+S@2N>9Q 89)38,0!I5B7F *UQ&EQ+5AW. EOL]' $37#G.
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M-[(4C=%YG4=Y<JE@G+FPT]?2%T_'&GME5L:J@MAJ!Z4-[FB%@3?.45TN=L(
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M-Q9F#U_AW@EM9=RK*-*8"!E.?\B0O#4E[EDD!!5;K4>/8I%I^(VLKT?\'SZ
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M&&<*XCV[$((SQQG9'Q_N1=GVG^((BS.:Q3KNP#0<%$.VOCLO44<P.![<H%B
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M>H;Q'A1PC[DB'&-(F0USRDUC']PU>*8,>=:4&4XDVE18!)+%SDOC.KA\TEJ
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M@:908T[EJ_A^K[2I*BJ','3F0E1@>Y5-V(52NN;X[8(H"# <$L:84YY-,<H
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MO(D))U&$TMU;^!<*,R*K1X'<+D+$092(&J.T-&I,D\!T8T*K,$S=Y2.>M($
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MMO[R>-?-[T^#!#',03!H-NNRI<]R?%=,XP]/S,DQ6G,]F69#1HU[9UI./G[
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M(@.%UXM">'.D#Y1\Q660:6M3A7LZ;$C!I$TQ!TV2:K5%.04=LT?QE&EK]8M
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MHE-"--=:R!BH+E?<:=MOAD$C;?ETU8,0B(6D5"<%D=#YZX%W)$RX(-LZP+;
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M/.54]J=M6:C>TA(,#MS@P9!F[/:L/A#Q.[KWV$.F0H[,L&#8IV(,RX7QT+I
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M?!0?/_DA/GKV3+??TR?^]FLZFQ8;(A& '1%6@DIPYS)NU8K@'/ *_!'M>;J
MT1=5L]Z?85)ARG@_^TCMGO8)-AS#$F!Q),<B>$?_B73JB[?_S='!LT=1BB02
M57A'NS/W5MSJE.Y,[X'?',$!W:9NI3MWD#.2SG*<K>HV90WL .Q4ZWVB.&%Y
MCT@F#T;.W@G-YIOC@\=/Z)(!,1:1/1K0# _+DMB16;U4:<R*S]NGGK1X>^L*
MRS59(G%4*':!.MF2"1L:W8*C\A*W#]W$O<&L!@9\TY#,EA&%UG1BT'*>MPR^
MJK5GM,B!5:J^ZHQZJC.ZB=;<:KN[N["4+"!_3M.[*RK5;WZ3;DT[K]./T229
M?IQ7H%;2_6F9E]7?HO_SXL6K5Z]?]XO;-Y?%9P4VHOQ;M']X<,15[;( ^UC1
MCK7N\O&7O72\B5V&9T__NLT72P8H-U[U#_2K2N;_H.3JZ]SJ-#J2^0!'+0-\
M_M>O?5@\P+6^2Z.^+F_RI4KG=N?US=>:TH9M0=2XVYS0TX/C)[LO7)979)M'
M[!T[2;>Y@N\^P\\8"@?>FL3LD.;\:FKERT8IF@)#M'=[[COTFL:A;O\ VNDU
MO95S9U=<NZTFFKU8]&<$P794;*XQ'"=;MH5WT@ >/,N.?]CU5ST.]>X,=3S+
M1A]J&S[4YZ6,!O(R.RHQXU#'H>[J4&\Y_'A_3*ZG3W;M58].V;8!$@$\APFV
M),]\3[3!.-1QJ+LRU,%@P6/2^&G98D.;W3RZMC<1.;N>'#S=M7=]E_GQ;Q?=
MC)BGHB4V5D32#J-NB<L/BS_W)B8 %5^#>T-JTTF"=!1PJT>'\:/#9_&CX^>;
M'N/?>2C[=; -[HF[@X[ZPDK*XP=<2?ETK*3\8S)\,RZKHZ/[4?CXYN3]/U]]
MB%Z?O8_.?GD?O3A[\^;L;73^X>S%/^-(>23.HY.W+__TTLA;F?_[5S^??'CU
M,CK_Q\G[5_\X^_GEJ_?1Z5M8CC<G8SWH-D]1E#5F+SYU%,BXO ?1>88:2LIL
M'C&->;S719#'V&U60I;?'!P>'GF^GT_E^X)_<XZ_42K?&(_9W]NRX7,6KWZ;
MU&GR>_1"6 ]X;+5'C%ROEY,RWY.[GOSTKQ=RMZV<L?=9$.X"Z6T(4:_QU3)_
M/Y5_$=4S&$_8](4J'.#J:)*E)",)EP(JR790B!OAW;V+;)$%%QGOIR;)3<70
M7]=:GNA0<F+O;E<Q_3\V/B""6;A[5M=$\L&=%9@'MC#80C2I8 F\AP@#B%^R
M>' _W^(V<?$>VOWF?MMU'=QX,?HAMNNCGIOB>+0&EP8]1/PP3X=":/^W32IT
M(EXAA?E&'S*XC5M,_^IIB4M5_-=?CO]R\Z%?,T0]H?^!V^JG+/W/2?7]?T??
M?O/='QGHW9G6SZ D8%;1'YG60 3XYG'=:C[Y]OCP<7S\Z(?X^,F3[_K2]WFQ
MW,%PL"N*N-T0[J/O'QU]?S5>TT)TAWM7;I25/_B[+K)9W_^C@V?'MS/./V,V
MQP='PY"5FS[O,T3Y5@3U-H7SZ)BD\^@JZ?RLE_'%%SOA>S(L?#>Z\RT/[=%P
M.'-;XO,G:<+;%+#GWS\ZO%/R=7SP^/".RM?QP?'MRM?.2<_3NR8]3PX.AY/Q
M?[[TP-"^0+ ?MG9Z=-=.O\<'3^ZJ=GK\18KS/FLG,9X.[X[X/+F[XG-\\.P+
M-.?#5D]L/-TA^7K\16?,5Y*OIZ-Z&C">[I#T/+J[TG/T17;=P]9.C^[>Z7=G
MC?.C@Q]&[31@/!T]OSOB\VQ3H/#/%Y_CT;?[,N/I+LG7T1T^_Y[ :QKU4\]Z
MNDOB<_SL[HK/T='!\]%^^A+[Z2Y)V*-G7V2E?)T3\.G!T1\Y K>%YMXBWO(K
M(-'^P3S ##\[(1SU_[2%B8X8?79,+1(721K2'.\]>W+$@#.O5V-EIF65;F#M
MOU=4E7\"8O"E-BGB-_4/M^R]3J#4V[%HLB8WTH**FTT2\[5K=I34V@7"=M>:
MK+ES%/9WPELS,WM9U0?1VW*@3Y*/QR=";&K61:S8V*4KW@N[;[F&WUPDT.\[
M1;V]ANZ^N?'6"$&\R[,"R3UWG:^2MEF4%7S-+4<M-SQ#3;%G5X.]TU"C4S-6
M;/9^, */=P=#_HI?X8MRN3)%3<C0Z!V\Q2[2^0[,_WZ^U=M!$?/$NE!B; R8
M8[-?V++V[4HMUDLX<ZA.3,JQX+\( <:.?2OI&3CUA82V>O0M-R:A8K""3H>6
MFO]Y%Q*C_YP[^WTGBH-[3E"/ Y8_K]D>D7D,JYTX2N;SRLP3Q,(GM4"EMTNO
M?1=>X ,$$'^>7W<CN#&IL2G(RKRLUH-NQAW Y;[5XDP&YKI]P'\WU,22FV'P
M)]@BA?_E]4CA#[P"2_F >^K$_)?VUN"_T-"CBM[ZCRS-W5G(7^D*D^[+]$#0
MDKD)5XK_8F[S<=%@T<ZU4I>GQP:\2"):\?Q/VW%(E]9VQ2TK_H@M>_ZW*FL1
M5\]0M ^QAX.\$#Q*OF");CG4M 7"$5&^3Q\/XI'%]AHX5LEUOV#_3E3".EJH
MXS^P4'\*&EL( 8[B'XZ?Q$<_/+Z-9_Z1&7WS!9,Y/G@V')+:*9R\3B9^_NQY
M?/STC[V9/Y01V,(F^IR-0T&+FVZ>6PENRM+OW[&8Z[T;UMU7_OWA?\#6AU]M
M4:_6R[?PSH?U[><HV3]=$*_6F%\W+7&'2&;^7'?XW(#G_^H3J'(*,@:Q*JQK
M/SKZD4OFH[.5"V!AX  W)GZ2Y%%*=<Q@6DVPJAE##VSHT\'Q8#JXW8B"YM$#
MIJ!Y-E+0W([NZ5#0'-\7"IJW)W]_]>;5VP^DB)[]>!Z]/#U_\<OY^>G96V2>
M@?^=_/R_YZ?GO"YGKZ/7IV]/WKXX/?DY>G'V]N7I![F07>'WK\Y_^?G#>037
MG;U[]9YX7,['?,JNS.H_LPZ%!T;<6Z+(D+:]2;ZNLSJJ%]23>(*M3A/,^<Y-
ML\# .(;<\7":94523#,XN.HF:3AZ;ON95B:G$#AX.X:"!28A/C:3U^82;F,X
M^QKTH)2NQ=Z IC#Z)&.VD,ND2O?SLOS([8;M$RLSR^'GW&VZBL"9JI#+PWS"
MFPJ/"&6&L^*BS.%PKK+Z(P^T+:0G.$8S#V#)',M-0ORG2;6.WL(,HO=F#H_'
M9[R6D?PL(SD/YWY:I-BM<QV]3)I$&&WXG/?G)7VR@^?'WL"H@S$'^?#?Y32C
MQ:2EAQ_6QEN @^B$:4LJ4[>Y]PJ:C)H@P[/,!8UO2B^4.]5&B+FHX.7EZVA6
ME4OX15D;'2.W-::7O'GAD?Q<'HH/ >&#6R53[JSNDBY\X]HTPA##X399Y_<P
MY>@U_TA7"\=_I9C\Y_?9J&QVY/0Y R_U(C.7XP&Q+=S.:]RM&?8?!^U!.B*F
M[8X^!V[!1<(QIKDI#'8-3O?J=H+Y@R8C)0&ZH#6\Y_$N2)\Y)>?C G,.N/F0
MYSFMVCE^9O)RA=O] !4?JY5%!7IR"7-:U)%!GIP.22;=@].SJHK6H/WW^-J!
M)*X_>COJZ)OC)_'3IX<Q_./IH_CHR2'W87_TY$G\[/DSU LREU@3P.!YY6OD
M?\H*I]5 ]20YL5&]@"%7H&KV7KII1?^1+%<_P@2*%E572V?4635/BNS?[+U]
MJR?"RS=GRG>&K>%QM>H1*'2G9P7ZYR?L=FWJ.AH5T:[-"CD!HY^R\MTBP5XK
MI\7T(!98QF5"ZJ^L5B4K"] &_]/"IC\^/'JBN#ZRS!@WDB=@Q!BB*4RB:9X5
MI/) *8(O.LG*%3UA:EJ*IU+0GHR9$FPAIC3T-"'>434D&UNA"H49@56%5_%8
MJ5,[3!'#_:23,)K3U \FGK/;LWJ#[Q8UR- [9'QJ$N4EG!I@I((5NV;0<IZ!
M+*#QC62%9'[C7V0B@XF-_>Y(=.#L6Z]0=O#<8K#KIT4VR5"D9^82"3BS%#X$
MBWW:D!M3B-R)0.IXX+Q:)GE-E(<+LR1QA"=6,'KV$=Z9:I&L:MH8R[(&8SQ9
MEBT<X)_@ ,P-[8QZE<'YIWO,D+>D]Z=-@?D)6"+\K^RQ25)]9(9' Z.OU;%!
MZ&UY&35H*1!<%_8K^H,5D3.:AC-?/R5KG&&35 VCLZ*C'YX_1\0X#80L&=#:
M:UP*/'(S''"P('AOO(JR:85 4<K"Z#AHIG4[1;+'69O+VL&M=<O*2P/?KUR:
M"&P,M%1DK'%43W'UX!+X#694LEF&J"Y$'"-\H+*+4NMZ@).R1N+4#%SKC[G1
MM7R59]'/&?I::(M1Q*Z!/V#8:3L5!!G95N!J-ZID<M-^A%>9T"S_4:;SC^@)
MB_@<1&?LC9L\W_]8(-VEO$IZ"=Z<8;<DK.]T]NB9&7H>3V-_AID%? 4?DD]E
MCFJR9._=VE#ODBE,?@K+PV_U8=)B[NBL/GCVM>B-FFS_5;8"307;!3;C%,XI
M$!>02C22R=?'4\Z>;5D]A3U6(?P1A+7C-31FNBC*O)QG!-Q$@]R03P 2VV1-
MRY$,V2,G=9;LJT!59@[?@7ZJS+X>S+$*N:@UV,:IR6D;@"T 'Y^"33\SB,EL
MVE0!F2C^,)<T(OPHS ,FY7D6$ORL_4V-=RQI&Z'_ .X1?<J["72)[Y? GZ("
MUK*/.*;4@,9!94\'!#A%=8,&"2HHF,ET38^0P=H^!$.C(GY;3 +]WL(P\,=,
M/QN=86P_87^,HW*7JNB2:%Z6*6[B-$OQJ:A&9FU%,_(M%HIUY8W4V1"&"M%F
M\"!V<N+HIRK[5T:AJ1S>9X''$XZ2GMI_W58ME%4&PLRQ)WKA6#Z"3YO :\6X
M6XD38RUG;U@["PR/4;P(B8*)B9?\.%BE%>A_K.K(I>%0-D\P1*0B]$M!1R19
M>"#X)QAR@]FPJOR09)<)B-1I 888G0!HCTWQS)7"HPLCIQB]PXW":A)$ ,\D
M@C6%7S25E38P'2L<^F4))Z &YGQQ69;T& J?\04BO*=N_@U&X$93<#?*M%YP
M9!E-M4!2IF4!\DWGYVK#&Z;FQF#F%+ _%MF*Q8'\&SF-MXH/OPN+M4U\^):%
MWX.;7P<B[Q7CVLVR :EV>(# FK]<R;?+U]QND>]__)_G3Y\]__&F1;ZWY3C!
M!GA)1\;?4-KWCYX='L71OS*P^.=M#2+R[/&/N#4NLH9J I=H'U>@6&&+O<LN
M$(H$.KY-L7[+*7GXSIX.I][I ,\HT@H&^ +<I'D<O7D)5RX.7A[ (-=I8=;1
MJ[4!0[JFE@3>J>&O4G1#C$P@:7TYVYQD'B7_ODO^2[!Q1-Z?_'_VOK0Y;NMH
M][M^!2IEWR*K0'J&FR@[KZLH4HH96\LKRL[-1\P,R$&$ 2982/'^^MM/=Y\-
MP%"4+2<:<C[$$4G@X"Q]>N^G1P=$A\F_2(4ZXRX#-;*#SLB^0K9)M/7J[&P[
MMGI!'+T^?2$ZUS"%U]^#MBO8>&?I\Z2!%IM$KXC$6?$Y@3;UDFS9*:DU_V^2
M5G()A!))5T)!U0RZ$QUVC8Q3<T=/.?(3T^!I<;7S/B%;U5T?D[\DPY!RM4RS
MZ#>RX=$E(?H;^^MS>ZTV=VESE_ZLNW1(/'N&:/-)T\ 4*XN=LY1,)3+"?KI=
MIHCM9->@:W?!3LY^^MP;]G,*Y>S5]'E;%6G3J SA"_9+5LR2Z.UE=GE9X+Z(
M=!'J]*X58DTPXLJJ()/D I>R0J8$6=#1UJ^G%R]I1G1'RY*]Q,;#N+DYFYOS
MY]R<(VA=H10B0Y]4JE/Q8KY-&O82VWORW3UNRO=$PG2JT7EU Y^Q5;9"<7&:
MSN!/O<B*).N(FVCK].+5Z?:&[#=D_^>0_=/1/@3&-8@<B5DE1 3.G^[!J[1)
MD,J438GZBRG<[O1/N0^?(2ZLR?%B-_HI+6;995+A+GR=E^!>F=4'CSBS^O@A
M9U9OF.:&:=Y'RR9=X210!-XLTR+Z)9FDQAG3E-$+-(H4S*64-%R.;T!#?F'B
M'J38/O_EQ?^-#D8'T1L8B+]D_VZS&1SD$X[2L OTK)P2(_Y(([\J"X[$)$MV
M]AB51!Z[X$2-\]_ N=^E)L/W.=VVNNDJ,1M]8G,U_F0WYMYHM!='IWE2UWQ%
MD!)9ME?SZ' \^IF#<)+E$.5)6TSG]"A9@BG[,DL@/K .D-"G3=3TEFX'HFZ:
M!;&LRBMHZ;^'E->R=N_NA-=?ET!L<PD-2+K(T\;+H[>!-8ZVQ$_\2!RCP-5I
M^B%*3 C&5N0E=$(5G<>*_"_SF.(*T3<1<S4?.^?H\VV,E(Y%UDC76UHGF&ET
MLESF&L-]LO7Z[&1;<F']R*L+B#)@BM:$T^<U;OWR[,0+9^+'6OJCFI5)A0,'
M67E]B.A?9A6QQ%Z UZS\"5$7I^B"2(T?/N8WV0?/"3;(%D9P2P'UYFF^Y(\@
MKQ;%"LCZY^AI/4^6DM]3T7$@#)R7LN9H)IFT?<?^)F/VJU[5B4AAIA=SN[JI
M"A.34IO9V*?F<V7ESRE=B"2ZF9?()"EO(.E!4!DQ/$1U)&D">>-7Q @YC2R!
M)/.:!IO<:J^&A#22M^?1E&YI,D75BLE:6%;I#D#"VERH3M-!XLC_I9<($4MU
MD]SR1=K,RUGX9S())UF>N<R2.#I_??8=7>#O3O ?9O!\W]F'4INFPG[V>!CZ
MM74V=;2ET6$K+DRT^'R[PQS"$3?I 6NQJC?$H]-)U:)F[!BE#>-G06E#C/OQ
M2]:DC+/*5(V49EM@H']U/=7-=>H^1;\,'N(Q3Z:D7M=<20YU8[D;<\49N*_>
MQIWN;>S<;_N)5RDX=7313J*Q^Q H5#[^)WUKSU97;$UI#%//@?J^M*H$=3:1
MM"1]^2T21]/:OF>$M-2<6#8U99-#Y6!; ?JID?0NXD5:@!>=D,:5VF0IKLYG
MWSQ/;\O[J/[*/N]V:,8IDW^GJXL%2WG+F"C!_Z:D@_H[D6 SL3QSDMY&7V<)
M8U5QX9W!P1KDR:>":RL0 YJZUH52[G^ P9E-#5\\-(-).DT6I C<E"M.-NO-
M"1ENW8L0*BZ"%4>?<5B)&&,\.H@/#X_CIT^?>JL-5K:UK+*R,@M$8G7%M9#X
M6TT:%XH\^8/;JS:!.,)\:*%2E9AP/B+G\(D\T6)'7A/)E.ABYR#:NLS(Z"L$
M%6]_?W]G;^]H[_APVR3[ZIY)CC+BO4! AN_1J*QY<L-XQ)4B/=C=.M3=>I@,
M\F&NRM!2KR1%* HT2.=M+XDM2GF=7B>S!'0@A2M/^>R/%-+T<#2*1_(_<Q<<
MX&@,]2R"!R:-OAGMTC/CW<@3'\P1/J2WX2TU>=]FPL]_.Q^60/B+Y:G,)(?*
M;;"8Y\"!K.=D26#;H_.:V*8@>5^DRT;*_ 3S?7QD+AN^L.*[8NEX(D=_DW+V
MI7P\X_Q9G1,G<<IT[!TBX_S([H8QGE CP CBIFS!R ;@D8L":!*>)4,5]A'2
MG8EZ"JD)V&AA:[&J#FLW],PYNW/1N]2^SU)3/T(L&@6STZ2J4-\!EFQ+9J]]
M8C%,W-SFK(*)LZ&,M5C5>6%U,^)'3V/'C *.&'(.==NHDKA*HU(NP_$I9D=0
M5>5I:']3MO.^B]*/TSE;N8E5-GW-THS&B*?16_?>"_->3^G<Q6.>0NNX^ST&
MB;L*$EO]W$RA$+?29PZ(>-Y,[X7%W>]N$M<BU*JC+ZMRFJ8D,KBB@'M)H%J;
M/VXW;H4NZ&NTC19Z+U*%SEVBIF/.-9^BW:IKU5Y:0:;0=PJ#<+SJ6V)W&(=&
M;U&[$?LH47BBB!LLZH,=&]PP3FN](EH/21+?(4J&^A_09M N)7JZ_VV?"$73
MUJ(6GUQ)?2<;C0%9A% %5N,>DZQ2)O[@7+$1DLK>WXR'QC@>)CM4NZ>GVI66
M))]!<2/]LUM.[7+;=J/SP)M'=X]60M,):L!PXP,O6^#=$@X[@]&535IC(C$,
M1#;UBJR+%G5IZJ+7N* 46UW1<Z:X8M?8<_"E9S.(^$?F7AQWW(O[GW NX@CI
M]=(5?D'_040@*.I+N.:7U'U47$7_*K.B67G"PM9KC"5@4<R-)EEI1[R-.S&7
MN'_&3DW;<)2U6-5?)S\&0O.=NF<NX)C9P&ZLRZK>%(KG,][SO=C/N7_7!)XR
M5.4B4GA#YC_LXRFQ*M5F\BQMP643XG\I*UT6ZAJUH-OJ%8-VS#1B77CLO%,]
MCHTL]@B"_>Z,CP,U.2 KZZ<PKCT\Z+5F"?I]=?R4!IS(NB-G?J>%\%5F?QE[
M%4EAU!=96]:">R=#O;BT5PVJ*'7\ZV %HK#)[MJ]8@PXMXK>2\Q7&21VTDC?
M Q<^7N$A#I1!WR5] 2\ES?GI\>[>Z*GGFJ(O9K56V;;-A@VOR:KX_MY&^P,A
MJ B>ZQG /) @Q$7FK!,Q2;/D#JO>+?&LIG3_9IZ889SWL#07?IB$1;%,IS Q
M)$ADM<P!9ZE<E7"4IBP_F&^4LG(3<WAH!_N' ),/'W%:[[.'G-;[,&AXO5?%
M#2DYR'("E$%.OT1BZ%L;NV:->*,#K\NJWA32L'AO*)%CE12=I37-IR\6'6F\
M.?/UU?N0S/! _"<[U+ @'9*?#^V8'B;Q=5WZ/OV$A&@HCJAE/SX,P\5TZDM+
M2[7Q8H<DY >2Z7F.)8^=[WP7>3G_TLZ:?B!;R"F<"^?9+DG]FK;B&[M.P^;.
MP5+4A:\8.TDAQ;,@78LM-%/:M1A#;*<IEC8@UDIN)WW)H-])3I^AM4BHEO7$
MSK=X?E52?(C(5O622%::?*$=U8NYCX.KZ3L^PHOI-2<UVZ']^6+]?TG_S;D^
M0CV/,UIKF:LW%)#K,K]V:9RQ .\3E+AD.JU@OD[(&FP+[G5MOA-T]![8?MX2
M#G_:2,AUR4:[3DS3K>Y,-E*3<C=Z@9.4F)?/W.2IK%;O8<[X4X[?)4BXN@56
MN0WC:-,3G;.&ICBF!F0_^X4P0",&<XE^L5/_(_6GWBQ-$_"VV@'U!,0(<P=#
M:+_ #0/](@G])TR0(6AT'!7EH$1\TI6(+I=#_#8AS-LFO_RK7A5IRN=<;EN;
M .R)<W-)J\^-EKPNJ^IXBO=&,;>,F+ O$PHQIP0#MB]T;,Z(PVO^YZ<<3R>>
MX^G<=SS%@BW(I)1VO;YAKJPOU0?$N)<JP+K'GLN\HT^,72)>+ D*R#Z+H^2R
M8:GDNERDC/0+C%J2/MYD]GJ9?'W5[.YI\>ILINQ0LH)H+)P7UVT%H#-I!,*2
M52@2QN/>K$1I<@?2RV)%8'A997FDA[T1AFNQ*N*X?\U^?'UR<7;RO]$O60W]
M3AJH;-CL>JSJC<W(.#0=,VY20;F%%V+93O)L2ER & HXD6^6O-%?>FX'V:-Q
MK(Q-?FP+J+G^FT!8K5TJ+ILR;*OA#QSQ$U)B"\U7KMD<\^VH3YE),;]O53_M
M9C[L^/B'MCKW PPV3RR81AB]@Y'AFM%+BE@*I%T,\,W1[K[N@\=T]6DN\"93
MB_@>FPG993/OF@@FB @3@<U6R6;PEO7\KF4]M\N*_19(8<.MP'RSSP?5,$('
M?\X6C2&4ON@>_<"_ZGS0U/.&2^'DW=JY(DPZ9C+#;;-%.].DGN?(T_4&+:\9
MU9A-V5E:3ZML(O'4*LV*L"HEK!XR-R<(E6;<;NP3!2+C:.LE"D1>E[M2'7)X
M.![O@<S5D9$;#Z+ON$,+:)-G8W/P<%TD%2BDFQ>G[D(;J7PLO"':@LQ?<*^=
M@#S>&#?*.W\!MGN9NXU6BZ#/T)Y-\P1J2J@':,ZB?M+U?/OLK3D^&!UX10;J
M6>T9\T-?/S +]G=F9_SJQ4M[C?I7Z!.[$.S8W1LEQ,-LDMAQI10\PT4BAK)W
MZ"X+GHDC"1])50@2)TSK/?AQ%(G<D!P*NPM&JPYR5Z^JLJY=RBP<=D?Q\=-#
ML'&9C25:[*4KS45Q.2K#%WSE,[DQ$S+!7$&Y\X?@5:NNP]F6&T9?\,.ODWJ6
M_#LZ31CN$08 D YLBAEC+=&FB;_*EL#007X W[A=3,K<QHN?_V8(V3O7?3G7
MC7JY%CC/JE["5#C5Y'8BA=.VSI;1:[94_@QE\VM8^<-4-CV).)PZY)GR?\!\
M9S$N]#+TGLU'C@HN/RU]EN%Z0DD=F:\T#3H:^ MAK.[$GWDBZ2/L %?9!P,7
M*DS+F;RIT72#G? %#UV#$WGZE3P-BG>B0@(F=GD#&2\N36ZNB];M*8V3Y=@H
M__#TUQFWA8!>U,"+KV&!E^>OWYVX5##-PV4VSKX+;V 1=:AXXU]FTC3PEGBY
M%;:[*A*\.&>M<9048"!P6&2RU:Q$6A*II*"J2K6T&0@E%B0EJU3E#(;%%%U]
M3-A9M+,ENQ$X#CJY93\.#37H%Y9Y3UA,%WXOU1[MF2V)HR%B^X%FJ0)QX-.]
MS=E(L;58U1#7F[(,4V\;78_1Z-GXY1C%I8,\4FK01;\1"JB9@!X-!=PK#>WH
M\::A'8PV:6A?.PVO]ZI("?D[%^;\1K3<5EX-W\;9NRZK>E-$;Z9-"9ES-.#@
MD!H; W]W1DJ'KV@.JRQ# Y#H"E_\I9UFLR1;D&#;I9^:&8/Z_#U9]N$7MMQ0
MYBV,=8?7Q>;0A!.Y\+3I<#9^]3[/(?IY]^=[S8C>ROFMMSH:!M[NEF:ON"8]
ME=Z_/TZ;=]^0AK*D4EY#A\^S!;<E,_B!6VZZ2JS9CS\GD[:>9Q^RZ.<D(W,"
M2NQVKP+3-LD>2P+BL=@S39 8Q=%S.W7$^L82T".1F!6P+@:00_A,]N/1P;/>
M8ROJ8#I[\L:\Y:+U;F?.%^@4)^7) 51/^C&=MGY:CU>%;DE/JJO'\>%HW%^#
M^A@MR! _B]_0\P?'W><U!<PWUP(2P(M2Q'BM1$"_1%DGNQOI,6Y85T;&4R=V
M"_+MY%'I2L?P==@N!H9(?<)@$R;X@DS)1Q[I3X(F+U:*N%-7E%<BM(ZZV'BH
M>?LLNV+'W$(P1F6BLM&7 &VLVD+JA=AC5ZA_,0XK<*7L%)X]8_BV2V(Z"X;D
MM3@9A8+^V36C2*JIN[ S<@EBQCO"R3%OH+.@K>5^N97=E)3]](O$9 %F8OOS
M_T\4-H$-NR'?@Z4HV>A.,7Z#;C6)5#HI;B$#F &H9ZDY8-9N%DC+:9HM)<6.
MSJ1(84F#P*Z "U-(U$%?J WT$R?3<7(2OT[V_*-1_]=[5=V<VQ .3FZCM,25
M\!F3TR40PT(T#<.>Y"+;IPX/3"IAAWWB>Y;_P0=2E!)<G:4FS\4FG=#?T579
M9)N8P3T&*E]%@U!BBH>'O8]M'8Z_W>ZQ4O^M@V<'_;<.GGU+O/T$1>++5?L4
M2U#-<;!]+_U'4"J43<2=Z/'8/HC[5(IWIN.\P93WPC_SHK-D$0;QY//Z8/2B
M!8Y ]/>,^\$-.AH52_QTGF3$_(7SG<ZSE&9L./4;8)KCJ-$!*-QJ\Z%7=/FS
M.?&SZ$U!4CV3X*89W*ZOLP_ORZHEBBRC+8!S0)7 %B?=YYT69*?=P_?8CI6K
M,>6H9*Q3L#DW9S.N;)DC<=,RUF(F]!*)5!\SC%X77R/[/!150&Y,)D8OX\;@
M BO@8=Y,TN8&+))>7(".O(&E7?J2;YA)2>[H'[_H>"MT,TYB@H6\D Y1$HTR
MK)]V;LJG$O3A];3I#;M>BU6=U)P?U^= H<HG=$JZ"S _ZM2@:20:=;"ZF-/A
M#+B7HTDA*<?+9$RXMXG)@<::7+%)"RB.1;LP2(_:U!W^;L4<$:W0L3OZ+.?4
M>)-&-V?X#]$\6-2099Z8YLGFQ7GZ74W_RQK'$DGW1M6]/U*--@2X4J3:+<M:
MHC#,Z@=%41Q^@\6./YSCO@N$:9N4@[OSK/X.O*-RQ4]=]L)<K4X;=O*3]6'2
M-UR0QUQ.YCL\.COJTQT;%8'.1S._N"/^\B[%-M.SKY*FZ5B4O#L]\D@X'L_9
M*PQO_H$;;:=3:83-_.LVZ@S+NU1$Z!$'W-K.P6F4 Z,DLQP>82*43$P)+FWH
M\NTX.B1[[K;6?%(+#WLKV\!9HOSF@K_.!=4=BG&RS)=A+9$[=P>_3-@*!P)!
M7>;7AI+J94O<#MO"!ZV_,&$@?5:B)'14XY',DF4\3_7N?>!4!NY2WMX:DG/K
M'YI\5^G Y4%"#R<F27OVRTP@AN!JS2Y5W] ))Y?(;Y"JHV0Z39<-)QKI9X$I
M%MM_Z1761 K<22).I4V-H_%CO(B-0%B+5;VPK=H[=]PT+1 _3;J3+I9,)%SA
M%,+,<8#4)E>CGPNX$IF#7=HDBKDIVWP&RBYO^IS2[Y4 1NO TDC&(,X  22X
M:=:/=!EZE>J6?1ZW'(WL?!]E73< 08@[ILIJ_4TH'AFC/*'>1M2:JN-8LYK'
M0XX4YN=^,PC>2I3B<?,)XEEMC7*]%5?>F,987\@H!/_OT\QA<R?78E4#6H!F
M!-0^L:,Z;Z*D-$%]YF4R%9"T7JWCW]_^,]H?Q0='XN?<"O$0?[TXVWNZA[]L
M,T2;E.Y)U2%=V.H#EWAJWAI=>]:)^@B:GD+94\[8B&&C_:I-D)N:*M_H3%Q(
MGW]IEYRX=\B8GD[98WF5WX:. SB_)G ELUJB*F1_7]@!QMO2+C$=[,SX('ZV
M=Q@?#.[,>/] =T9TC(H;@;(_C\Q[PSH7";W3+L+OW<]<[)F'4FNB.32N$MAA
M/ GT3!/EW,9KO'OX;:AYV^M/'[K,D.V<07%E3W?=PBA'PR_1$E!=2TIFN6$-
M7Z1"\XX[L<(M\ 3^7SR%5UHIR2++9P(O>7H)Y8JOC<0!1 GM6?+&ZY-R,JP+
M@B *)AZ5I71\@'QJLJ+ECQ7I5<FPA'CB26_0T#^D+F2F6!&O\K(J_).42/<R
M)$.D-2>5+?(BW7=AO??])3#M/Z$;/*?-R9TG*ZB%ZWBQDFQA#11_:YFS]+PW
M-2A=E'2NG;>?5H\&3S#VSP4\)1%,1U+K6?M'_IF@5^)QLH)YQ$\>D($=PPS!
MHH0?A<E_FPK<KWI5(2_'16+MN"B+'23,3+/&^>[P2P0ST?ALFB=MK8:9C[^P
M)Y@+:L"&'@B5P4$\:(J"3>8%B.CXCVMPDJF>9%-#EAYKJ-/R.BVX#L0$6%E?
M5-^-6JBL:B[G=+'S!6.63K68 '8DK10M*(NTK>1O],,E\EI($,-K(RHPA_5(
M7@*GKY7L25HFZ)NY104/$L>E!D24MIYG2%?C L]+L S?O_EHI-.]<L&>/N)<
ML/$F%^PKZT'Y57)E3L) -7U&YOFBD#QC3I\7(9]^A*M+&%11VJ=NN7 M >\2
M9L1QZ5!H,Q]'0Q16S<'OW-_:@NOH2-?&!U!L!/O"  SUC8L#@ ])8-&5 ;J*
M=0^L)G>?@3#PA]^S!>D#ULLQ&R\F= E=+;=Z!YT,:UZ0&VX-,K3Y+<F-1\-\
MUWM5OK;.:$;?C \-&L,-785:0YL-&;Z#.32]W+'54=/.!T2%8<TW96\[5ZTP
M<:$J#@&.34+'FJPJ9*C"!:W5"-XW'HGB&AMN1S_DF60F+3(!54NDR:W_JO(W
M]\R$)K<%8&N)A C7)<ONBMBJFHRE]Q?K[SB*%C3FW*%H2Z0H]CBHVL&<Y&9G
MVPD4.9,X*=RT E@M6NP6L*N1:'5K/^?9C9>]V!KRQO0;TX2=QB:CQ7TA*-!5
MVY-3$SF?2E[&*SWO>95J]A[ZXA6!<WDP=,A>]KIC6H#WV[F(N#$O\?>-)WN6
M7B9MWM1:^MJ8_+&>6SH># 0Y-\)#NR /]=IGM90PVXQ;3=Q"HJW]'=]%]QL_
M.1!W/BR?9N-O8:5(GA97S7R7)(.-$:TJ?QQ 0A*G:0#8;IR\'EJ\-.BQF:K#
M[C=G?+:SK+$$WJDE[#X,6_AV8&@?AYYLURR]=H&DK.[(6*YS2XLY!UD'I^1<
M0^HFYGAMLN3F'I$!-Y3FY40,K-GB[A8+NH(FK;5@Y5# ,$P&+$V]H&V3SFPE
MZ<>2 ,M]8K F,HP:S^*OKKFG^6W=I N;)W[Z^L("* A2QY2[DGP7S5/B:?QO
M>,G853%<[_7<'.V9/=KNKG45D[G"*2Y+J!29(&MXN^.5*@(_@_O=<V*)BT1"
M1MWNU!Q I#=!H&#\,P!'F@\#6IVCD_#H,9N[@>="3  WJ&PJS8^'27L4Z'VI
M7"Z))P(CAOT;JH17 FC0#%%-=^D,_RB1#$F;1BIVW>TP[A*(/5&T8;QKL2I.
MP,&UB]Z^?;LI-UJ75;TQ\#'C P/AYU](D\5.RE=>)D4_(OO->.^ (XX.ZN-M
M<CN=I],/T=L*#9]8/M(_KZK$,6"B$<> 9Z3%9;449VBT!) IVGF$EG.!J@R7
MCWNB+PQTH+AX?F+'95?M"ZC:_P"K>9X4'[RXJQ/9%7'6ZZPB*7&2S>+H';C8
MI7"Y%Z0$E N25PK0@];G89'0*:NT]%M7NT1KD\VR\5$(>/H?602I*?V0J"T&
MNFPY%RDKT'<Q-UO+Y3Z*[&NYI8:54<:AR6NU8K0LD]NJ9#.EYCBIY:\%61E5
M@^YLC"8C/<IF$0E?\<!XN23.,AG9>+"9M9D6)Z6Y(H?N]T54\N*A0EUQM'L6
M)(TC"Z<$J!%*/TA"I=HV/:3"X1I^$[LF$=TR\*$E7L&,V>.U33@<8;> \\=,
MM'F\.Z+%+3F9NV@[N>,6P9J%M#V1K& KA?[@6TM^A91[=IFW-?_9G)TB,OL'
MPD)Z)F9+PNWST%W=#Z)82TI/H;-CNY$#WE1$.+DT%]'?NK4IW,Z6<S=SXSK4
M0?F4?*I<RAV-23G3W#H#F5 @0X-84&)T76S2)&'$29H^1MI(Z;58U1NO!^XS
M@R<B'1-EP?=@^/M[\?[^>,/P-PS_#S%\2X=/E87=E^7;%P40YVA-F?XE#-C/
MXOJ>PP&8F42CRT839"PVT$8.;.3 _>3 RW12\3UZZM/.9RC^HX-X?/3T:Y4#
MIPE=M-N-$/BZA4"7".\M!.R+1X]<"+PFWBY($8<;&? U9CD=/^(LI[U-EM,F
MRVG02?S.%(R_8Y3'3=.7M5F5MA?>VQ_JC$BRE30&0$!+[0WQ%X2MWG*!W?EY
M-,TSB=?533N[58A/5HU.GO^V,SX<';!B\2KY%_WWC$M4N!;W+*N9ZUD]\M69
M;:5HX%X&1Z[GI.AHOO_;L].=\8&1D(DD%R\9*&O*84D6^5>DC68J[LVD +33
MJ#Q.=X)BU 64D+28"0Z$P:_OK;>I,L65\:*=^6V4+;Q0;7V[6-(Y2G>LL[-'
M(T?7>U7O!P]<R/!&D&SIW$F-8_RM6=E.\G2'5*B"?N+:_DFY@_0BJ-)X8@%$
MIAT1SD(W7C;.T8C4/\#B+DD!X^HM#A;3^ZA_1FU^.1,L*@36H>*G("5!J.?8
MN(&^-;<!8VON$HI99Z@1W=H_'D6+*TX9FF=7<_WM7O0Q,G]AC+/*#*;KL":=
M[=$TYXH@WM$$)>0"19Q]I FE'U!\9V:QXC/WO'<3],)<E(5\&<D5/"!=,#^Y
M8+R_N[<C+S#"EX!!B67[BD[@JERDU>T.D>FSIS_4I%1?^3SHG8Q\@5Z3T=:K
MD[-W%VBN@6+">HI(.$U"L@7IZ9WWY<Y[3D78.G__'ED&27Y;9XB>TYF08D&Z
M^+7J^T<[V PY':GCE>**+3PA,$+F+P+-K";NA&B.R"CES"5['G3NSP:6:>P)
M/:BKJFR7N]'SV^@MZ9(PV,MIF4=;;]_Z<[6GHVPTD1.:I4N /\A\:&NGMYJ;
MR:1F:77%D5[!D*2C.!@Z"M[68%>#I0JB3(],9<C1P)"=G4FBX]TC?4@/OK,C
MOEDXYZ8A4[+F9UY5F[<N ,:U>6*&,ER@Q_<]4;)AZFNQJC>^>_69!B5]3<>
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MT5<*=6$MELQ?6%<)XO9:%R7^<"GCDW-^EUZ96OLS^4W9_\N%_H5W2_[M&:U
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M(Q#CSVT91[]DT<4\I76=XC;'T5L&/)UCI;]D]!_\,WI_BY^QCE^R%H_BH9_
M#CQVLS?Z)+\Q^>JK&0_;3A[C^0R^X[,K[VH+7[%/U/?E O,57&#O^%E\L'_\
M1;C YX^UX0)KL2H4<3 0TM7MUP,3LCFTNU=%JAQR3X0;H6RZK:*)Z<I;ZW$"
MQC]O9^GW#VWUGSA3Q?PC#6V)LI#BZG_^,OH+_TPO3,W/?\[*;[)9,\=XHV__
M F_^7YO*?(G%Y33)S<;00"MV2J( S<R\J8..=O<.LX(V\KMF=O<SX;AY>MFU
M6?_@]C\[>OK,[?_ ;/YD CB97:M=K1)PF5US+Q+I-K"4LG5%9GXZ&G=[;/2
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M#4SXOK&E+]D'RE;7]MN@V5YMWQS$>P<'\<'A'J[P5576M8EM>FUJR BNIIG
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MFG'1R&S*9FS "*O0%M:..R[* MEH0GRD&0LYPVQ*\9KCPPQ24Z*F"UQ!VBV
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ML2O#U/9AH22V.P UQ5>13##2;FME07054@(25XUQ]0(=*G?U5"'D-"424@%
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MNG!GP+3XTEA#EEHH&<S6$[>3M*M)7(/B!W?Y3<R@<M88N+ E'#*!$;YUW&#
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MRCQ.8=P:I:6Z3G&O4@X&>H-L.8C!MU'7[:#XM(-JFP]!)>R@AHSZG7M !)A
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M=[64(GQE%7"'0". FVL,*PQKGL(?YC!Q1"L2K =X$R[@DO078"K*A!(Z,U9
M_T\.E.'+M(Q-YQ.:F)Z^WTI[ 7N>SN0,QOC<-(YA4; _"K$FWL97>4+3+ES
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M6/,<-=L+_2K=&\[[%-:[?!^4+Q5ZOKY$ZDMDJRG?R4MDT&J7U4Z"T@2Y%$U
M6IZ#/.&T72E[#U'ZWG%'_ Q""PZ1<Y;<!)%1"IM%K?!$^!BZN0@B+RAIE<[^
MR<6'DX/Z2-='NC[2]SW2PU87]<)K/, ^G$NJ,43FAC/^060>F'_ 37"R*5$/
M_\EGW;74JSL/^''D)T#<VZ;S7D1^<.4E>,Z_PP'_D5E(.^I#0SWV*@[#^(8Q
M?LF3R#&2-:ISBFD#OE-2F;?$N;@*"ES+\%J&/P$9KD3D*86[M#0'!>U/,'"2
M:8Y)/,/>*SRE8-8GF/8S7SIIGDQ%LK2,^HLL]S&WJ1S;FGE!"/]PUTKUTQR,
MN C#@I_CO[W(6X!AJNROS][<RV;!./8#V[";Y6F*ENL47DV]+^KI"_B"-_7@
M__NUA5:+@NV@?'=$06VA/>LC79F853@M]9'>R2--U#VP]YZ\X)@8D,33A/*&
M;_?<$PT_WFM-9&R!YYKH^%'>:_KX/]"/:FOXWN?PCP76&^833+&_RD,5^I*=
M3#QSN,A0EDE?-T$8@E4LOF#*)"?@N)CDCS(?.QO*Q/?%S$OFWD3D=!FH_&]7
M%@A0A,WZPADE+"XK,M9O28++D7S=E$(F-?YQX;P[/7;5T;F$'VP4,\H]PPRY
M:1ZB)(!/YMDL7MLX;2NX;*-BP^$S+C9LU\6&VR)3GFP)PJ\?SL'VL(J3ZA*$
M7>%)NK?BFPA+O29HGEP%PG=P0XO59O OA+;$6ZI04>#*_/54)9RSG]@7(>IE
M3CK'Q&CX$VBNJLJ(,^&YUYS NRG(4DQA1?.4VGN5LEDI,5SE\,/8^F)DH VD
M55&'&>L6X7 ]!NC_<H[/S_"2!!4)KKLKN*4;^!UOD>:$5HAOJ%[!.2P]U46!
MF*0'/,YCOQ&,WRE_035?B8=Y_4NK&@^6 Q6QC"YR987SS>UEA>? &/WB3?%7
M=&,X?IRBK(-EF?/B''^4U_/9QU-L7S8/:+3FT^3#ISDKY$\^)Q:+QE%*)2.D
M1R+WICEUMI.%-<7Z"KA]$:?*"Y>L+(;>&/N^Q.C)O<(:#<E05*=##T^H%)/&
MA<>0I_CWC,^IGN/RU)O8N8&?P."A[N$4 E)T(A1-(JB*ADL[-;!(I]4ZDK@S
M."3^%;O*8S=)UD>+HD,6?^ 0_YU' E\?<2FEKEI1"+JWO.UA9"K%0AFL>["/
M.+ZCBY*X&!*/#)XA+E@M"Q1L8QERB\NOBR#Q[/Z$ZG.Q/5]"\>AMB0I<G[G;
M9W4626PH>?#(*..X99&S/+@=1.8E&!M9@-7%K2;MXJJY%U M\3Q/X=*+YWQ"
MU$]  [T8,(C-Q2R>YA'H0?S."1Q:'X[=2=QT?L]\,.XQECI-L,B*^K%B)_<D
M#O%P96)."+_(SGBN@&T1(3>Z#I*8D:.O$*D)B^_03S,)?%GP/)F).7)VBJ5(
M 8/@N 8DE^%^;NSYJ>JF"]D2#(E42^1@^$C(2"_62R&>#9(,BL&2I(G\+!6/
MWP 5SG7@P6)1:: ?8)GZF&I7FLY?"F(K(?F#2[_4*R=A>0U96@*@E7R-\2=T
MXJ(]#/P1@\F;ZNW497(H<W!R]'$LM_*<%'B*:MXBOH %*AW70 "F.5#E-<C)
M"1O."T0*5E8U2635+S2S]QA_FJ<BQ"^*KXQV2%,IL4;U#!12(W \.>KB2,EK
M1\*/^[*Y*4Y-*DVI]!X$$] UN&@<V&"*&H*0'%CZ.*I?24#595A;3BY!F&$<
M+E-O,IEY"3*,ZPA9L$C(8IG7F(8Y+!7+_73E>:X\NA&@+/GQ),=M0DD_GX,,
M;\ L,L%52*0UH7J7ST'BPA\6@@K*FVI:N#?R3L/IQE3E+M4D>AFV$/O4.>3(
M,Z+8XEI3R)X"R_MY*)L5&W\(7(QYQ"NPRM]X] ._(2'-GI:X>YI"_(W%G[1]
M*\<-N6HL1&3J5A.!M:$@$V,0?YD V4H095B>"FP:$"A&$J.Z0ODJ2ZM?L)($
M6*SLD2S,,'HU\1(_B*^]E$ZB!+Y@@P>4$3RIU*<X2+\@S\*?DTQ5(3>==UPN
MZ^IZ8SI/DEH< M\=WS%/?HE$R-456C(("I&!G)G"[R*%/<:'TDF7,.TYY;.W
M.9N=*U1E)2Q>'S&A:\0++T_1+X@0;(C81B'"A0X1QNBH]GRL.:<Z9.WU5.1)
M>48ZHEY_(I5(B4%K5#Y$ICN5E/@!XJ_AD6::?,2S@+70[O0+PEK]C=:?N^<0
M;:J,J$2 Q*C3)(AH1I!QD<A!9B[@#J)MG<=1/%EFID,T5TCR=+D\<KX$^>0O
MTT7HX0T+:QGY8'?"/IZ!4A C6)Q2,N5JA,OY8A9_0>P%9Y_D(>Z?\ .*HARH
MBF61A"*'I^"A%"$AN?28GH:'JOE3[B?6*L/5)*3)IQG*9AJW?! J#&A8&&)7
ML'_18L WL=@X1)F<\AT-E]!,A%3M#T_3!8+Y'4!C'E)I_D0L<%H*.Y/.&I.M
MGL KE!8??H)% "(%-@6/X-K=HE[QM>"]0_":.YN.')E^R!*,%MH@F$-;U7.\
M*?R>;VD\2!B<C(0");+57QEWD,I?*0@"4_TB,@9FE.7M*",MP"6MU9+_R*U0
MWEDY59$0;1+>AB"!VI29 /5G2<M38 5N$N94:TF=KLC%I18!Y7/ NFB%08$I
M&+,@LG$#J.[_ZP2#B4+CS:,J$S#T$0RN@:U?=ILM4%["$)<:].YL9BOVRF6
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MKR3>)".M-IL)!]19+YO#]YSXRIE[?\.O9>_.X%HX?I!2WX%=F.+N;,8?%[M
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M-H=)A2F90R4@D$FF/*B^,Q&ILL DDL!Z\N8#"=L;X]6)@CI\QE%0VVT45'N
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M?^3>X1H1P5IQ!=3^WB68UNJ=),E:,8:=-:()MA-./U,M:!OP[!@*IW_/1_V
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M"12#I;&!><G4=+8C/G.XK[%18'G^25*9]EWRZ9-08>*L!:\<!!!F;?B2<\/
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M\L+9/C2SZ"YN##3S,<GRN2-3R83:>^5E',:G[5PO%W"P\PV2Y0TTYT2S:1Z
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MM%$ >D21T^))7: ( Y^BUUCI( W$*B3PWI]%K.O*$%IQE:'*1DDZ8N6" +0
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M@,N[ ]5<RAL9%[BLD.B[=WBPYQ,OF=#MR/QY:-GR\V3+"Z;K+XDISQD9M4S
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M29$^F]K=JEVOLJP@N>2)T2B5(_0SP)[O[NSZO8.^U4%!?H J'(R!"E@[)<J
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M_)WNSD)@OGJ:QX;_[K((_V^E!,$W@'%_NIJGFF^EE,JE'-6/8.#OPNM]D=F
MP?UNW^_U]^]ZLFG$!X*FW^E_&9(?'N/0?^OVN4&:#XPLT(*VM^<.[W?:N6\[
MB:MW_&R\Y*:.)'E)H20/C+V#O<-V'Q_YI/XA8Z<AZ?$X*1X8M;O^WGZ[S<L]
MKKB!6^\*Y7U0(GE@G&VU>_?(1Y1#,4"8;GU APR7V']8Y.[YW;U5T8:>RB$]
M3U(U4=Z5^"0F2?[0QW2'>QRV._@=CFH]:FJS_W)SYZ%-F!V_M]/W=W9[*[+I
MO7[GX &LF.7NU3%&J6_]2]J=VG[H;=KU=W=V5V2+GL^Y_"/)QBI.!H5W$0J5
MBH>F_;UM?[][#R/^&6SS,HU2Z?TNE?<N>V@;I>=W>^WN/?8AO1H7D55PO<W=
M!W?Z^8?= _^@NRKLN+_3N0<HWU%B_EJ@M+S.)&P/',:']NR!J-S=6Y&]6;]3
M^(5[JZ_9]R,*^FL([',#^KS-MTF1YA)TJ<W>SDL;W5C'R=V76-^PBJ^X"6Q4
M4_W#_0-_>WO.6%KFU-]WC=N'\XSE7I-^1U[S!_":7_ *Z#A)IPFG<'L/;T7!
M:3K<\P_W[F&Z/(Y,V.W<PXJO[5.EO/BZAU-](>#'2:FX+"*YY:95F/GOM0Q3
MXW[WAQ>5EUV G 09&JSAEM^ 2\#-9WW,P=@0<E,!=Q[81^Q%\#6(P^@: .W.
ME@0+B&7#(6X]6K?3WU5Q$T]:'F7=1VH_ $%C=. &Q?3W?JBT!]B@ _SS4IL#
MZ(BR)<58M93#6\B];;\#[7!8Q 9;2!3+O;>_[?<.#K^FWDL^!GUM-*;T3">H
M/_:.,L5"U_>V_?V=[;L'W;C?H&]4\E:E6>Y[_?Y2H+P<$82ZW,A&BL558,#^
MKM_;WR[CU/EMUE2;8JC; [=.!Z[_G0[<2:HCCAVOOGO\>O[>_JY_>'"P.$-D
M 1DW*;B^=[#[A5.G1]^HC@Z'[+W"LCG];?\ *_I73P$=F>I$_1U_KS?W8'E8
M>]M[H KOUA]XCVKX49H#RGJ]77^CX6?#0+;GA\>?IFGBG=EX\K)LD#W'?F^O
M!]RGWQ[EIWF4M[_?4=ZHW_?0&3[</EQT>G6E(5.3X!Y"[GZ5UVK'MRK2[%&
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M2(+B(9!"Q.ZT)9% 559F5IZ_#&CFC]BP>F=A!^_&KMH.7/ $\P?W]3D?*#*
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M<5T4F\@F2%H6T+E.@EQPUHVC^J_OXO2*OG[,OQUGM96(UC@VF\?5&&<Y(!1
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MH#;ARBE2GSU^&8HJ"IIL/B'4<'B2?!_/*8(\=\I'$;TVC ":^^-^=>.V%3[
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MZ'F!H14M1_4N8Y\J%6%:ZL\4AXZP0V8\AK[Q9'D3<I/X-U7W1S_M'>3Q@2/
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M.Q/:R0;V5'[#8$_U NRI"">^*)SHN,[A&D.*-"3%2LNFFGP<B67 &U4  BC
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M%L:W$Z-R,8#_X/)!R1*0TTQ^"6LRNXQJE5!?R4&FPN%QQ[:C9<B!C_GEDJ0
MWD1"88[#[M#N&6,7_G>"U&(_QV(JD7AH@ACD=OF\X@.7#&1CN)8>I1[>C'+,
M5@M:><.UH(VB%C3O3*S1X;,%EN#?WEO_*%7*\.J/UNFN7_]?+W]O?36^M>[O
M+^^*BWMG=H71)>HY$($EBO=%5U"7\7I #-"(F=LVC:JD<K%0W(X(ER0G9N)U
MC[^?&%]"9#/CW@J[L!(0=;^'P<S_LD;C3\97V_CZ]?S(.+?@6AV:QC=[:/W[
MWZ[XZQ6SA_#W6Y-V\G?7^Q']BZ[3'@\HX(T?.CX;JBP4>$:8F'<PM/6DLK)D
M:SS#GFB:?4K!&^T0'OEF+M1T7539#UUT^;^WEW?WA19:8E>T>FP<3%W_O4"R
M1YN'"BNB85!4)ZEB.ZVS/\_?G=GN[2/(M65BD=R117^Y8#U&L8YJV30J<.V1
M:0O_*(FB%BSJ&/KL&2U=;@S'-0VE=DG=6&&?FK1 Q_QQ?OX7V,F$X@T+FACG
MKC<^,LD$QU)M6-<[;L^3 A/FMP[[;7LCJF'Q68!*)'@4AKCMR2B+-1XS"Y6#
MMCY>@&WRZ;P>B[9 ,7%P=]#V(GU('@%_TCN>L!99E:AK3*9R<"W")V!>0'D5
M;:7T*MPYJBGCGECJ=.:YO-/.1>K&X-%CS!@!9SS"2VA&\3?+@Q>+(ZE0"$?D
MW_MBC[0]&BO*J3ZM(?=:H!(*LKH?"O*O+Y=WE\;?;[X;YZUKXZI]?6%\NX'?
MM*^O;NZ^46BF4)Z[LJN_&,FHI<7D!4@EZ8R!3=E;A_JL_A5:'K#3D/])#M?E
M7_1-K=Y$#]"2P20B'&"QN6.MHT5\=<8W10@'7,L^CW'C=_LRW0F/4SGA6ZZ9
M[YA,5M^YV(H58 .Y<65T E!=@7%]= G*_2_+?X1=!EA4<W$$2ZJ4ZK63(P-[
M'K T"*/,S _XVWRE7OMN+^0*$2X.- :U(?48NZ$2(6M"NM88,*;T)CQGPJGJ
M!_PMN"^W2R4[^G9=&1?2LL[XB_3-P2IZ5A2KHB7 ?@^;I=(A_'!8JE9+//V+
M?QK!R_"%&)%_9EWLKZ"![3$^(D[KLY[(:OQ&=B^\@;T_?0R"\6\?/SX_/Q^!
M?7_TX#X90A HI(61,WJZX@6X>G]R-M&WJ%TKZ4?.80UX8DC&T40Y&G$BM39[
MKH-=_90FTGAKWR1S/_7-?<(PL_7Y2O+0X\R"DG$%+&)T#LNJ8 _9H9]4+J(0
M+I8?<F)AV<2358C6%5%B4:*;6",WI;P^&6;JG3SKA8RL]\]'\=PC Y0K&9[6
MT'?%BMG/1[MK"P% G[8O<F?RH>D+5169[*>P%=-6>H1TPD38E&!-N-XI</G6
M#4]2H),4Z"0;6RLW?<B$B$RF-/V@#YKD;1EI6L8D-8-M&CWPL!]89E-J_U"%
M"K$MQ'9C:Q7&O1!<U?6#ACA%=409D!1I\!;P$F=^S[.[,E">L&ESCK:SVT;$
M7]R<%(T3H/T2;DSDMF1S<L'K\E=[FBBD4JT> YJTQ(?\(AP)]X:YMSFMPT6@
MTE,Z? !*4Q90B')H\ +)"=3*#^CS'B^5L+KN$Y:"#0(YBG2HT!W(Z)0Y#U.:
MEF@B4]==Z(F @7+OI?U>+AW^H4<14O[^/Z:J'$[^M8E?IC@F$*_/O4A562<_
MS(UL;@2+:C"]=D-.4BY7#ZP/^+%R_:#_01+A4K;C8>V$?J0@PXQ()>]-A-MS
MJ;$/(;1<!PX)"\DQL\2;]2TB'$4.X%"!4ECBYB?]U\B),>-K#EPSQDXQ]A#>
M-L6+30[-B3XX;VOBIT"U)C1YRZ0#D:<M0&]BD=KN1.,4VR&2QKV*-^8T[&Q@
MMBBBVY7CW^$B.E0G:85T_$Z**NAD55VVTCG9K?1L(X3+,],3=@@UL[!XCA_J
MABKHS*B$SDS4T&&7)GE<3U&8!BY+RQZ)2SN^%KD06JA^)@>B60L[>SC8$[<1
M03MSC"C,ZSG4B>/0#=GGR -V--UF,/-L^(CRJ:,16X:UX)TQ"!%G<H OD:U1
MENB_]4.;>NA%-3T\XP-1%0CG!=)BA9W+=ZM7I[]9-%@YXC)6-^U4Z4B4?#5E
MDZXIZ_6G.0%W+RLZ^/#F "]A%>/S61 ,^6IC:\*^K[ZH[N\"H_.^=P[NB808
M8X<8#3:) _7@.RA70)MX9/( @ZE3YX>X*A]*L_ !3#//B1P%3-L.J;6N'X-=
M(G ]/\Q+G><+(3JK;[@L\[@HR]Q=1W4C)AY:;__[[OX&T^ZMZ_-VZVN1=M]$
MS=(- >QHM3%7JF:I$T]B7KL!\]^1?4 H*K)7B:I_0 ^G%AEQKTRK,S*RU!DA
M4H,J-*(XT@/L\XJR8N3LO;LZ_+^URO]33CKOGCQZ(]4V6\"BEY='#R?GCGU8
MF?R7#"A/126))C8=\F_&8>FHS,.E8HF'0S8(,(@J?IT2758K.,$%S%5S*4%1
MN?I?YWXJ<2=VDW?B],+X1Z.U_;H%Y8<72DS%Z5'1S9 ^*[GG$7<6Z=+HI3U&
MVYDZ)CB6!Y!TIX\<Z'J_&?]Y?GYY>74UG8'8U-X_6\8C>$)_>_^? _\?I5)Y
MG4=\?@.WVW7G\L* ?W5NOK8O6O?PPUGK*UQUET;GR^7E?<=H=3"Z\:UU=_XE
MJCT\^'[=^G[1AH]_,%K7%\;%Y?GEM[/+NZA@]$#^77&/=;J1(UPC(O=AI6#U
MW+!Z90NLWKF'_WR[O+XG'K^YO;PCNZX3XV^,V-U_N83_O[N\-+[=7-]_Z1B7
M\+R+I%2@)"#S[Q++5PN6SPW+U[;)\LCQG?N;\S^^W'R]N+SKB'06J/*K]GG[
M?@FVUX1EESB_7G!^;CB_L8N<7RXXO^#\53F_NG4SY[S5^6)<?;WYZRV9.;6"
MY7/#\O5U'NWUS?UEQ[B_,6;P?A2XU:1@1_5VHV#B/#!Q=]V!F+O+VYL[,DLP
MWW"+2A>LE+O+W]N=^\L[8.+;[V=?V^=&Z_S\YOOU??OZ=V#KNV_&P>UYZ^;,
M:(,Z/JXV=XJ5J\V"E_/"R^N.M"P()4['"M,BB*5=XN9:J>#FO'#SN@WJ#-%"
M:3K__;)U)VWF?>3R<L'E>>'R=8<*,SB+;X7+BR10;KA\K9[B[&#@^9?6]>_@
M1;:O,\4%YPE *28 G-Q2-G9*"HJ\4&ZD8*W!<3U>,C]*LE/LFA[?B[7N;;:"
M;;K<-DNU;>V3<3,F((/?\/6B7VH_2G"O#E]2A%LN:G"G6&YV8:V&>*7J@]8
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MC3MW9#DF_X5I=)AG#SX9(\M[L.%-^-%2_.4]AK=(]/KQ5M[VV3Z]?V2&U<-
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M.6X 3X5+R[ <PX;//7C6T!A;7O#.'6!%G,^H9P]CB(C'9@QLQW)Z-GP(;L2
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M7+"A]0S&G GO?X!K$[]K=&VP\7J/CCMT'R;O M<8A,.!/1R";3UB@3%B?4R
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M=!R3UD:(B&6<ZT)2:KD854)<(BZ^(9SEJ6<&I::I@ 2PG2VH["N&7M[UUM'
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MF/P**X .@S-P1PYH8_)FIM4"0S?!OA;/33^1?(XR.87QS*AM )LW0;KIT %
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MC;&P&"ISJ'@)A>HJT]XZ5EU5"P3:-?H;$VX06B!?(9H0V6LL=DY*A6;&6/C
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M=&AC1@2D+#P'JB0P7XKR24F?0A<(AB$9OJ+#W?D2?L$9L%R3W*E] WV)<T-
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MXXO5? )#I*6<8C:1I#(IM(W,'U30PZ, =S313U&3X10KFJH,#2;W4#D:\JJ
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M_JOL5[D5),G#N=55@BL(*1K!&'DN]7A"*R1"!#+.7<27VY'%SG##8_+&E#C
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M3^W5-92H@SY<Z*<*,KT^?D%5*_Q,HR4K+SY25P6'09]T=USQ@I4?(PY:!1Q
MG[Y+OI-^7;<TY2U&^593\E93\E93<C3!NQ=64U(#1KE6^0/H_7J;Q0]'O*4-
M<!FJ;.EDH U'Q7F!ARLG.:9JDG;(O%3*[6BD#5.@)X[$M;T7VBVU3Y,A[-/^
MDNU_T&J2IH1=K4)"'P^U_J2X,/#').XJ>Z5KL\%0FTS'QU9-<H!BDK*0L,9+
M!7.>#5X$F#./ L=**SY;*WO1>0I.44)# X"H^K45NC::3K3AM$[AP*%S&FK
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MZ/>\^(N8"P$5!\]*<GC0%W+X1EHBR=@GX%!\16[RC -GQ0/R"^367/@KV_A
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M;(-3'?WT0:$UXJ]3*231,>.'$K9E$$([!/<^3[_<Q &H67ODEFM*4CQH[$8
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M01A';W>_'O%Z,#ORT/)VW$C>=HBB_.OMQX 3?PF9K]C,5D-)Q^\ F#0ZIC:
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MP&'8RO^^]4J>\BU,\LX#,V*)%.9Z/ZO>W>U[,-XU8S#5C-'H0TDZJ'N,HAL
MYDAN.*YV%/B8/R#J2L795CZ?Y/;F.CJG_1C 3^KEEAR=EROYTK_[>,8(DS1N
M1*JBY%+Q%WD$"0!J06!>_CUP\GL@ T)'5/^],YW?X.MDHG6UX]W7X;V?[S ?
M=FV;']0K6/3%=ME+/47YR;V?J-[P1)'1J@R'#8Y2+.D7]1A.^N 7^=L=K"+S
M%M.W>S]PH^&!7T?/2F*^OPBY\R-?;S'-S%,5#^S]8 <-#_:TW#E)!_[B[^?<
MM\W<PQ0/[/TPA^W=TE=Q+<]VQ&H)/WAOAQ3O%5#UD+ZX'HRK7GD6Z*H",U2@
M.;_XR_6'];QQ;5C5C;6X=V *=RDZD'B(5\GO[X*-&Y[=30QX.UBM[:LR,0;]
MOAY<# ^FP/,?U3VZ0 XX]\""PK(\EQ@BH9!'&J>(A_;.%B>=*2\O_KK]VP6+
MV'%O=^KE$LC2C)P8^VCOQS5M>%R?.8!]RV?5\4F@N+P"0GM(WIS@J[T?Q:SI
M4<2:4GRB)@/R 8'M]Q]$YXXW/4! ?K'LQNSOX-?L;.>Y)Z@6PN$^6OZ6PM'_
MG_D 0WXA9S13)I.2+OCAOH]^UM1ITQW3[%J8??I-_>MZKJ5(,/;-WH_BS=O2
ML>Z2:\V)!_9^[%WZ7([AZ+NV).R'>Q=6[&!AAHDAOE.WIZ48$_C<W@^WJ=_E
M!]9)T4@B*\C?VVDT=9S\*3H2G4@=B;0P3ZB2@XP,>G+S:BF-H,XN@SX7T<9/
M8=\G\47P 14;1?P%IOK LE=@K,S.3RS.\.NM]_>/*CL!_L>??D^]OM^=7.!K
M^5I3MR"P8Y_LE96JY D+^)?RTPK7EC8UF(9L2>,[\3,<':<=G9;O.KW4G]#)
M\6EJO-W??[N$*5)P<.TL ;8(=O(?EA-=1?8&^_8MD9@X[F6Z$93^0MB7/RU;
M.DYZ7^*0XR\[=K?$_ %,"_6?\! B?@#KOS@-X(+IN[US_::^O[F3[I:-VUE/
M]Z[4[LUU F0-1I$I+=Y(W7WQHD-<K7^8&_2%[NE4FWH%FRAC\T__/#WV:PA3
M1"HC6]Y4W__^QP>XB_8# D/M[8R:^@##FQ>UIE*Y<OZ!_)VREHXEO["U-H2#
M_JLNFIV\%<VVUH:P3N[AL$'>8H=XNK_Z((G$T/3$$E$!:-4_4ZT ]H$"_L(:
MG_H<.)#R&D_B6:^__AU'>WG-F>N<R:C!>0X[!'M(.2>L&R7\H7B2,DS&1SS$
M90B*A]G%I*<'*<P;>+F[9!6G"_SYZ\T]'C<X\U&MW&/2!L+$8WZZWX*S_;RS
M$$Q3FA"<ZTM,0T[J>$D!&<G4E9Y,9-BFI_3".I ]$09EUB_3Y/*[CT%Y3;4W
M[W.*<KE/Q5F65<1;/:)*R=AUMZ6,BH8%4_'9IDXM)9/[1:Y6;V>UW5K=G--,
MQC^EF5+16'1F#4!N9K]4*9!\P=\RQIS%GO9P=XK #F8U6LV*FA,ASD..'V7U
M.66Z0T,SC&11:T[%1'(?TLG[Z#:X00_;(]K@.@X1EHQ=QDM1]G"K[KY>IR=;
M\]TWM,$DB3N1MYBT11]FPP["#]K8L&YY?H:()$]X*9F5RXZ*B[;*'GBUD<J0
MQ*#?H,B\/DE,4UN3EU(.RN[5CW9.#<"3CO"<FKC@XR\<4FC<W29K,DMHP\,Z
M1 $_4I?N#C:R9)%E0NEH.FPI=G\8W62D#6:SRE0S3%7\RU^YUWW4#6#-7LI1
M'S!&5 P7=5CGX*2!<[!#O/RR#O[/&4[BU^33GS8XP@YAS5D#G!)N?.ZR5][<
M^+E'-6MPS-.6($0$PR<H2X14]>?.DN7:P[F%8N#-C?\JW?ALU#=?_ILO_T?R
MY;^+NBN/U)]<RZ-)@5H>C05Q&]7>3W<>MM++5N*'4VTT';\"7WTMYV?#O9UI
MNE[L0.G632^RU0_K>*[;3:KVWNO::#P UC!XH9[Z&C#:#8EU/-6&@^*@TB']
M],EWIV$^'?+@C-%XWP<W'?2!S23;S+P$.A_T:WBNFC)E79OJQ1*O._]U*A7_
M[FZL/]!NEHHM#\J!C+VK(KJA:_KHA3)L8^_:!791G$V,%\:P>:7X89G.WK61
M\:2I8#W45NU=#VF^5:WSYFJ%4YVI%N/]<^11>L.%ET"ZQGC_'+F5[3I(JHLH
M-O[1LRCJMGYL8(>.2[@ WG)=(J>T=QNJPU-J.=,E'1?B+?FEA>279B1D:!-]
MI U*:"]OJ2\'3GUIRBN,Z1CX1;''Y<4GOC0MCNXLCJ[W&P329U4#VN4W.A+?
MSHR#O_N8)PZV[H8>B,<'C.'F>RRI)E;:_>[C>_U#D#4#M).E9Z>GZ"1&2^L6
MJN6T"PW07K!3E[E\1/0^ZCN7VJ*;19Y81TD6*<$VH@SB7>J-JL9[HZI_!7W$
ML(58D&82;6DG=1%C+>'D!JXZZZ]&?<G4]_"N:(_62$/7#^E=4W/W0>[)RJ;
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M^=L+]/=AR_K[%^O68TR4J9>C1 R,NV73"CZB[>Q__T-TX4C&S2(ZKA3TC@T
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M=)^5#6KB5R+<E7E\1<J7[#= *09':05>/N#46Q-K7CE2/_:*CVR#6/Z2M.T
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M9*O#?@5O5X.W*T.Q8'EG3O0_S[X$%REYB0IV(;)C^1O%:(A8(NLM3X1,N?C
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MR#9>M;U)4'''I%NHJB?9,/+3$HP8-P:^. MW),<[.- UO02Y[],/R#O=4P\
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M%NQ8;.U/]O9>$AJ8G.;B^&RK*.6-,LB6F$+VMP+>'.DR:50[?'HAV[<K3+R
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M2;B='HO),&69B)GP^A2!UR?[%<"J]Y#G;(48@/GY9688 ($2UJ?C\ORUM'U
MC%":'&Q$X 93D/LLT/&$^*-,D_\RO_Y$A= W[@9TD^DH+(<.CUW]_]E[M^:V
MD21A]'U^!=8[O6''@60"O-M>1U 7=_,;6](GJ6=BSLL$2!9%3(, &P E:Q[.
M;S^9655 @01(\ Y2V-AI2Q18J,K,RON%X_U<%$,?T&">]_,/K;'MO'Y:MOA<
M3$!>$.'SC"SP7%V0:Y4WW06Y>8)=D.D_%C&\WK] BF-(R_JZ/C6GD&].I&0Y
MA3;<Q$J$\<4>/X&" 4(3))_?!]DY?@*H5,__/7EZ]_'K@3>W[;>OAI_=\Z!-
M>>C" Z0!?IN'^M+[>G]]=WO_J-U^T[HW5]=WU_"?FT?M_OK7[L/C]?WUE7;W
M^\7W[J76N;R\_?WFL7OSJ_:M>_^#>_\."(P]BIGC)MQ'KLM>>)9/?4DBAQWI
M**0QCSP'!!JJ0J=V^,[%WR\Q,'T'QQQ;.CK*SOFYE:8TIW;H K"J'=S.VXGM
M4MQ.-L915/!OD0K^$*G@IW;^T\3J/Q@WMZSIP!8MK,CN(2,2K;6$J=6S'#*'
M@A%CO']2Y@5/=)UZCUE3F)'RS)Q7:3/-A%7!6/H@[$$YME"V<#=H1?BAHHM@
M*I](G]B;8OPE^CKIZ"J; )-E;H >>A$I?@]V7O!!YPX'P8!%=%<&1-\/V-#N
MVR$\%77'X/%=]%3C1K@;&7YR->GM%V%LN477"^?.[[,A\WT>0[?HZQ(D2^U:
M":AS +3F37TX)]U*/:?A/A$]'K%UE/.JDX\-S'5L7^;CH_#G">PST*-D&+X$
ME7LH350BQVVX$%DQ-**&6S;^$S?=PB?PHUS Y:E-Z*)"])!-'G?Y0I\7;':"
MP7Z>)^  K.'O;!+&O:]^=XG,B4UQ J:(@'5^FM?[-$]U804VIQ,AE$[M@*>)
MML>\OCOT '.N,<$68G'.3%HF#KS9>J)OGFNWP!%GOF63AY_]1,Z'[$9RS%B/
M22ZW?'M1MB'R7Y*;P;GV#^YHM+3)M.?8?94O#6U_K,8QHI3,._ZHY*6=^"NW
MF 6*85EA-KQ/L*T/VGLA+^XN.[<7L? $7HJ;$-[,@?3+ O.<( <%OD_O%DQ>
M>MGE^U,\GL0QSQ_.M2'#/FZ.&GUSK)?(S:I9DPD<A9S!_M01)<-PYJEC11T?
M\;F'^/OXQ/7/_LARGV@/8SL(R"4LEJ2SG9_:'3C-F_T/NM:#*:6CQ=<BBZ0P
M-6\ =!V1!<>US$V._BK=\N2C?V':Q+$X?8#^@%H )SU\%=*RUZ, <91'1WUO
MICZ]VNIA5N#+B%$4()^NA%=IB+.%8).1@H14*A_1HP4'4PJ"@%8',@G^?^C#
MKI*-5*,LO_ANHN*MPZ<^CZ?  9G[!+R,_BB.J%.2#1U1*$_4VMWEJ92A[SD:
MYA4J)_#9!-N:8X"T@QT:?/JF@I07-L<E!.@LT5*5,(!\"%^9]W5:#R",1Y3Z
MVV3J3SR>"RK8+SXUSX'9<,A58^KOFL'E5SDU41S\B HN E7P?M<#HZ0_DJ\O
M"&O9H@>[")S@5KW\HI6N(&6NHWM]-L!)==SX"1 Q).OMX(\@\Z9%^<3++NV2
M*ZFKW&-V/SP0B,K#@(M&+Q#[.M<>D'"4AZ.SL9_6F$9=ZTC.%H W"%%#L&$K
M[-D>4+ ',^3\@9Q9:(UY\Q3<2AQP#*2%LO2,7,T10.:)#=%N>, W>E.J<30-
M1)MA;$E@@X6+*12P;7M,-M'8&C"M]ZKH593/]L)X,>+,*RBI&?XB#$M+-1)S
MG.0?&.AU;/8LF+S"I@#:"#_* 8DX>B_2_!7CMR WN502%I_J$A6_/A! A\39
M#RN$FUZZ"8_B5*C)]"7^N#HRYOBC1+2I:_.FYG"9O1=2+^2?+>"@9 7)7$M9
M$S*A#-Y8M\FGE E5$,LMU/=Z_JS5D_BSL'3XN_ O-FR."5,#%GQO?Q >.Q)+
MLKT5K*HR:'I4G(W+*+%NOG24]S:\Q7:?/>=9:,EDA]GDIP([R'% _2-)$DQ[
M_^8JD8Y[0/^EPWX"7@=/@F\2/J(3"IZ;@:"!Q[CN:3E8:$AZ'M8.OJH\5/-R
M2A]="ZT_F,N+3G#. .-"]45FVH"XZ+VJFQ.2(F-W1#&ZX/;X;,! 9Z6$<KZS
M(-I:^@(H"UQ5W,WC3<EK?Q5X+F7&4832[I5<,:!P2G<\NR '#%H(S TX]5]Z
M 3<\>'OV6Y&&SC-O3PTHIREB.EA>&, E[W%O/9^,4LO-8Y-9O[)L12W-(4Z
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MO;45<!Y.'&6GP/C,"J;^*W>\GE!FQ<Y$H(18'FNYK:_4;BAWAL6'-X.H#1A
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MCP_:[3?X[?;R;[_=?K^ZOG_XG_]NF4;SLW;]?W_O/OY3>W]U_:U[V7W\<)I
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MIY*>2GHJZO9*>BKIJ<CTM"1"M6YI;FS'/<8FG)+ZE<-Z-S%):[5"W/W3?VJ
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MSDOVC".NF?N&(=&H<9C/)MC?#F@:-$34_ (]+<LA"L&@?T/H/,FHA5!_.,'
MY1E1J >5T%B? V6G9W--"+4=_JRBD.*O-E9I P9X#H 5WSD+'3\^K"H"]V$\
M.8_41O[UF7W#:CP33BR$Y?-P?G+3B/V?B:@+C_")((T@FG-M?G=\6V(OPR7
ME+XA_NW((3:_U$#F$)ZC;AF0# \=D8I@@1H>\K4<&Y0 QP[M>&VUO-AG0X<7
M=PLHQ<I]:K>XI"-U!G@OJ*7WL";+(S]=*KX$V%!?&LAZ*.6E?2\(M9X5V,'\
M N=:%^A@,"!GGAY9_ O;VXD@(@++8=E^ ;YWFWHXLD4P7.3JCM/QE ,IP%X
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M[QZH1AN,.  Y'(^;UK"1,R+HU^3ML-UGSWG&9QP/2!NCVUG41L5T(76[EYV
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M5VI7:)B?$Z)/N4I)RSL:=\EK34FJC7QOBCFT,P\&#%N"Z;+1&&_VX@X^8C,
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M\T1#LZB9V6P/,]180>/C:76H=Z&D15$2M8D7G=!F.S]D^F'C5.^96M$%*EO
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M(I'5X;V!%F)Z.ZD!FN<^6XO@&;6[C2*S7U+M3PC[;^R%H3FP4=,WTS5]7J1
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MD99/5N#*HVIFAMY;X 3'R3?K9^2;E=#4A8H-UTX7K=,X@^4S\\,@D#8X;H%
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M([YN,./8F-$=C1O,.$W,,#I9J+'!V]T==Z(MJJ19<RM$XT?;GWK.B@+5.X0
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MZ,>#40^TX^1!$3.FJ/C/.'-4;WB1DC'LX^_2F$=;S74_J*3?=ZG*X50'HU-
M=QC'2T_J ^>;L'/1W%E:2ZR) AQC9("@0^Q+$Y)1H2]DHZXP.L=/;8;4X&1I
MG#0*X"0@<&TK=GYQWG^P%A863-W<VQ@^<]Y7Q)]3.-;1\<<L@C_&UA*,Z ["
MN@O0LV;VTK=G_!+I#J.E%^%KTBLY5O/.SX46+.HC4=M]Y;;LRM9R% LN9_NG
MFUJ.II9CC[4<Y4*2.T#NS4G]YVO/0SWXS/=MG&]<DW1RHULB?5\8KE?H1V '
MYL??$+S6S4Y?'PR2UNB+3]GO=2J$GXK V-#-\5@?F<E>R,=+T]^+5/GJ+J?9
M]':\W/P=$5-XO U1QOY8[_5?1#[^KN@C#]A,O=_KZ)V\E4/'S*+9"^4(,?79
ML2;.P@D<^\70CG*D'-)HW!GKPT[.@J:73C]%0&?HX]% [_9RU@[45[*\,!)9
MV:SMT&?;\FUQMN<\/+,+3#.O3O&2*:4\!(==W1CG3#5Y<2*' E88Q;(]GSMF
M><CS-)#"Z):HJ!1(H1Z.'8H8Z@;)8YKZ:#QZ&=14(6.K,. ,?3CJZ%USI_G/
M1VF5=C+Y74:WB*O5K+6K_B:P ILBE>Y<<QDKQVSQQF>_"T0J,L[&Z%;WV5]2
M4HN\TYVX[3>N>=*>^YIV81KLWE7];\Q0N< ,%>:C3KJN#^^P?C'WM8?0PO<:
M4JE5[&0'Z+HY=O+5!L" UE>GL$D%F^&;_6B#<-M8Z:</QCMNME,'L%:R*'*
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MX(9;!K1@!\;EA"G[#$<$M@@JDS9=6 [QE!_(^26&U"U<6 Y=9H;)F)Y/VY#
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M+&T.OZ!J)U%QM/*P+I[^H@X36_*@1['F=3OI0W(QG[/$E'S-[8RVD4QF?\T
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M"H<_$MN6HW VHUUM&;=BO[(Y(_&1ZW*^F<6U)#:H)>]$=+-,$0$U /[&7XQ
MWZ9U9PX3H7E5"CU$0HSX@0PIJJ//+6VR]H&4?']3]6A&O:@(@()RA_QX8@=/
M=FRZ#>EUN!M%$>?N=M9Y?^, N\C@.OL?4%F#A"XIANZ0N3>SGOG \ZA1B*F2
MS@S0!84+SH)_=!<4I$4V0G-^:-K?QN%X6R[_H-:]D6DRBD!(-&RV=<0=GE :
M2L*MN-&(PQ*&" [?K1>6%YGRKHX[O!7#G>0U9C1QC]U<QL@Z]4#\U9K4S+ZI
M!XM, _?7#WA2#%&%T^Y>OY73!I4J3C E:&BU?\_VBE__"P<0W02PMT#[W5U[
M:.2H.[D$R?2/?+-85$R7D"=@\ZTF(-$>PN[TM@56*YM92*0L8X"&B%?%1V>Q
M\?$9(P@QQQL8OV=OG.K.=Y8QW3Z"*7(,(!]LMW(]NKCH=#T^9A"3Q%*6$#/M
MQ#P[[3(Z_YN/C_?E("UYPOA@>79'$4#.,9M=WFH?1QCB&?'I5 Q)F<7=6'PE
M58<\K<IK/,_G,IU5$;(C641YEIXB['1&WUBFX8&$\M= C#?WUA)^Z%@\HQ^_
M^=5VO3N:F:Z'G-*BJ5F V4[H5'F.,)Y?^8>2]X0>CF?IX/"E:25GKL<X2HSW
M4BH,D:!O/V(QPH()= >8"8C3-7Z@Q]0DD.&P\:EM$[_9)C1+."Q)VER(-Y16
ME^@ZPF&>G%?2C1+;")V!\/%\C4<G'HGG]X$\_+ECS]H9M\E'TIZKWJWS>\>>
M:Q=TI\BIKN9S9\IFF0HOUF\NE7?HP*>F[124@&OP<%*@%5N>\]Z):WDS_&,&
M1YD&KN?SQ?^PG\FS+LUH<ZS6 F5,4L94"M()R>5.,PBM"&I8/DZ%% 4HHLE!
MPEF(/$%X92UL0F_/<A,!(N8$!++]X))B[H=^.S^<T$K#&&$+@@H:WUUY3IZC
MS7Z=)PH!)\>.80B4S6PZ8<00&>E %SBJ=_'<<I_0S>RO)[XS<W")Z$.Z&)D:
M8=X^F[KXG&%GW8BOD[86IIB2RUYAY^'<YQ3&+0144F],OL7?=F[M#7Z/IQ<"
M!PG-]?CV6-8D%JT)3QSC+-$?ATFM=T3"LQ <DMMR81+6OQ&W ^V/);S=PZ\<
MN#D *:BRU&-E#DSEP45&'6JAP)EL-OJ"CL7?KRM I&&K4:$XL9?PFD"LP<(;
M&_/Z>N-")A#-W/7@O=%23,E^U<CFQJ F91GCME$L+WD@+!GXDD/8A4&7EH!W
M!G!<,/3G4]?E8VF;1-V?I& XO7!6PESN]4ND]13VE6Q1/DJXY MOH9O9Q32M
M"4OHYQ:POXW 'D3R%OPHX[DX:!.:K+:NVXNL^Y6+^@-)+-NCQC'BB5?U=SOJ
MX&S5[88Q2(</1>3YJ5$?T_8X?O^@&4D;?$FD86W;[$'S]K/0AWG]5%='I"/9
M]AF>E=I0?W:7=XABG^&FK^;G=,\E2,!*K^-OU-FX.KM50ZUQR]%R\>5^!?=S
MX<#M2#=ZW5+QY7Z%S*K"%=9=?3Q.F4_^$J=7[K\V-5^)]>B[+K'N-R76IX[&
M)::Z7EO/TWM[^O>U!]8T\1#X%UBP#RA\^ #F%!&T8>!KH17K*\E^F;S'J-79
MO\]_NSC_0[O^=G5[<7Y[>?45__GKM[,O-"(6?W#VX?,%3HI-WEI-C[Z_>;'E
ML%'$9\KB<FTO0GHX>/9OPIU1+>6C3/4>L0"$]R>PKC(O9%-Z7T_OI9D/H3M0
MK*J%RVI\7>T-=\I=7U^'D>K9@[-T?)G-@6OP7G0W ;4%NWE ]]H'D2MRQA]@
M&5E1'^:',[DNV8\7%BBS_T*-EKG4SJ93$.J4W^ORR_#<I?7H>&M8V)GIVC=[
MX=ASYE2\ ("[#\"D0Z_E--[:'%0T_%2\5M?@;.P^(WD?\/]W<-ET +C:]4IL
M ,,[2<\)A3CBH7N'3],%6/L4&EJCE8^KKZQGSX5UIJZ/_E0UEO[@>L$=2%<?
MM4F,#^+2Z\!9.(%C^VWM-_<)XVLZ)IXO; 17$:PS\V/=)PX!9F6':>5_PB'@
MNVMVA$U)YH,DWKT.1PRSU04 'X"<M7OK$5VK\&D<4HU9NP].WZW$Z6L<V=F8
MK(35RODK\&6=!+J-1*PBFC47SUJ;D2,\*FHT^,$ZD:\F7(V4H&53J@M_C#E]
M39Y+EVRAG[,69;R/6A02 [.\A2@ITDDM1$G$(50O]Y.CI#"%3!DD,V5ML8MB
M89_%QMPF^'IC?A/ E'+CZ%\8L7]RR2< C\X#+DAG'.1L+Y$K;VN16&*0=@2/
MYQV1TYDR")Y9^Y=(5Q>9H88'I)_*^IB$_*%8XA)'C8L<J<@9U(!0OF/PSOL(
M+8QEDLVJI%G)';- /'>.J_F6,LK&<M?$2ZV@K8%9' ;R,%$L61G$A*B'96Z@
M>S0B81\BH5=))-38E:IF?(^5DC$,:%?5_,OT):BL^7=-O=M-=I/-J?E7U?+W
MI<V_''T]7?E 5-DD9R-) H/.ZX1X+*E?:Z7U&$DU0^X.SZO)R =90L&@FB[3
MZY^^+G,:N@OE/A=27HK+YA?NG#NFA.Y7DM#U'H,GZQR&D8R*'3GHRC2ER2>F
M-\TP[?1T8S \JIQ64E(:(<V$-(C6PXO2.'KG%J7RP<$N1*D9[7+4B-*CBM)&
MB.Y!B XJ"=$:CV3X9?)>\N9/(3O&@&J#:'M M&$E1*MQ!W956S-3U35_/7EP
M JI9 [XK^)TV<Z=K7F= B??8*6BU6CA3KK" *&+BVR<N2XJ SBX>1&O4Y2#S
MM]05\*$0\YDDD321XK?(HSF6K>87:>&;4FZS0KC;4^C,W;61^VBS+&6%9Y3P
M/:%")-4IKM7<?#BC.]9 /4.%!L'MKU=4,LS[.KD@).7=Q<KY696$: %'0 DS
MK[EKP3B5SB\OF=.-*G&Z>L\&4#"NNYG5X:<[8G5J(4$Y/J>ND(/)[:S383%F
MDF4@[X&9?,4A:339N+^;=/KM+8*2*+NS!E$5R+%DS[5RQ]T=*9[YU+#%7R^"
MA&L(DX-G$8.>NR$"A2ZH@O .L,!CM<IDO6.)#C:-$/XD4<R6V[-4@G!(._A5
M;H2J$B]I&YM'*(S&R;Z.VBQ?B\3",N587=-*I^=^X7X@K'7U.?)_=/SIPO6!
M6>1.S!5<+>=R-6ZM-@'VV]:^7MU>W*BYMR^V<5JYK%MBM,5QJ[8:S^8(YB#"
MP_Y<\NZQ9.K((O)('/-2!@.SAFOP;A/PS[58+]Z#C%)3T-\7=APA%RAR/M4)
M&O;J]?%/PU3<BKSC<U=4.29Z*AN=@3["SU'A>G*]OW%U8!!.@#[$M;=R_62O
MH&@UJ"'*AH)8$:*H/\2B4/(L\_II$#OH']\\NC=,5Q;+8/H-N=<=7P4)DUEL
M+LH6A:^\NG>%Q?<J(60+K5*&;84RT@);XY>];201XR3Q4KP<9:0[J&_CA6UT
MJ.R#C/1^6G';=CA7Z!%>;(>&J9N=WO=1?Y=09/*5RXV_ZW*Y05,N=RK2?X?E
M<C<X"!$3J=$_4%C]3G^ZQFH5:-M&6[OY[>K;;>OVXANK>7O1H9D*^O96W*DM
MJ-30B3':U'UMJSYLH?[GS5HKRZ/.20438BHTHI=Z/U[/)ATKNT>'&!;!$AEP
MY]&.GMOS&"(=ZKN%]A]!+S6-X9+W:]F<OI#L5:^:&:BQ4-+"A,^LQ.94RRV9
MH=%!*#N:5GFVOL-T%C$,+#FL$HLB^6_245'M1(4[IB&2U'!*SEU1<IED3RI:
M.8[FQ@[7YKLV!^K*X?A'B4J!"[;;]OZ3O4&%X7+4>H2U@D*3XU^P@4]HAB(^
M^5=S@5[&)CH!#7F8HL1G6XOQS*F#&";Q]!]&*WPOXIP[M@9W-LFH\'8-O=M)
M,ZRV&NJU,%1.4F7\9B\HC0P%VJT'9,6 [E=PXQ98LKY*!2J79EO[=O'Y[/;B
MHW9]]NWV\N)&N_UV]O7FC#HMW#2:YI; >!G<$]T4RN%M;2_AEN+<"];R$<[L
MV#+6-I59FR"&G^ZQ+Z\"#Y[\B!%;V4O?QX;M2VO)VJ)B&BFK,\2?4A 8.P7[
M/[]8W-U-6D<9#.Q6P%YS<Z"@O\6XG][;L_7"OIIGO?LVWOHFH-D(4WNQ6&&M
M[?*.)#;^#>"<BK\+X\63,PON\:>=U^]>H8OGE\ KNLHK[AH*9M(A%?6^3>+>
M-X8<Q>-I"WL.:/IH \F!TB(^!:26!^EV7N]8L*"WCDI[ =W S'1Q>(((.$2$
M2C!+P&&7IV3 E <U=WK.&&FF'&675[KI @>CUVD.V!U?*I$=TMF]LU*F.2KM
MGAU@P;*G-3#X^%7#_W@EZ>6=-@'@W7DN6'>MJ;MPO9\U[V[RQNST=+,[TLU^
M_VV2IG9.,9R/M/ G( #:AMEWEOQI!^Q.?%V+?[Q+\(OIEEA[LW)3&N>('X@V
M-H>EL,.2546B29?8FYH'C[JQ%LZI\D>)8%_-5;FT2^A<,(Y*O@_LF$ZU0.(O
M"AI3(_(I-97W[T$ANG<7,S8IXM]K:_DK?"UA&Y]@4Y5$OP<"?'.VQEJYA6.]
MU:[A)CX'LW8J):J_;*AR'U39.QFJ1%508S,=@!P%!KS33II:OVN!^NT.0)LI
M3>G;AFCW0;3QP7_'(]J;*+TIRNP[8;B<)N&^8+(4L,ND3/&#ACCW09R#DR'.
M\WRTIA!M(R?W09!GOF-M)$CQ@X8@]T&0PY,A2$5:-N+Q6-1XL2:UE08>-H2V
M2T(;G0RA?7(]V*%V[=F^,Q/S^,2TSD;([8.L_K"?5ZX#H+ZUI_=+./Y=BE]'
M_(BW5VT$W4[I+SX,\7CT=QL;CBN1P_$UE?_*-KL/+I8RM!MY5AS6GU&;//,"
M']N7 1SQ3QI?K!*>_%&C8NZ!\L:=DZ&\;(=,(_;VXFQQ_7MGZ4[6VM4,^)T5
MH3KV44-R^R YXV1([B,?]GXH>GO!U(0V[35PL(>D!)-?->2T#W(R3X><O+;V
MJ^UZ=[;VV;9U[8-K>3--);(/COLW3H)W6/V*JFA*+-F?*OE=B[N+M>>VT%T)
M!/IH^P$51?V']0!;^D3)I,S)F;3\Y(,-^>Z#?$\GN>8("N@+IK?/'W[5_KPY
MTU,L.O9-0T[[(*<F*Z81D57\,1NC?>('#>GN@W3KD1MSTN3[@HGS#^?AWH5K
M6&(W0PO+G<[=MIX2J,#?-02Z#P(]G?R8QE=Z6.+;)3;6G9I2NS6FW-:K]QL;
M6/3&E;-;9%%GZI;RG^C K2:_>&WMUE\#&@,9+Y<LGJB'32T*Y;U1?@ E+.M1
MEQ+E#5Q<B9^+#HJ_P2*X.EEE^!OQA?R ^M]&T@\L[8%U+H"U)N33@G_,N%O+
MYWXMTNZ52E7MQ70"K>U)OOCM'V[NUZW/>.$<RU*13P:SGYRYG>J=%&'P=_D1
M0F+52P#E"T(*0  UD0%O&S_#>P6$B2&$[R[;6MHCQ*TX@K#Y60_6?[LT\6LS
ML_JA09[ZG@0Q =@"<(_?[644?[*9BN],2* )X2+N^H<H<F1<=;UD^Z:KKM=)
MD!=\L1U%>-!-PZ=1D1*_YD3[HL; SYEK__"W_:S]!>OC&#^P[#^?:V]$FCU^
MUQCU^S#J3R?U]VR9GED?#RL_W;N:;WN/-DVGP!;GG)$R:1H7I7]@P!E$:>,9
MV%-E..DJOULK)3^[H<P=4.;I) 57\7F???CK/!?I_43]BH[7?#RQN0*=I@[;
M7BO1,'!3H_1AY[MNE#YL&J7OC$+VW%RM5Z&Y6K>^K0$C*]&[9CB=BZ#Z,W7S
M!1:+K8FG4^Q3[?.Y[M3<K15O*B@Y;6B#U!0LI];ZKU\!.WOUQ<XTK,-1.C0P
M,=[1$@[K.SY^(F?%8RM*<G[(?I<K>),[8T-XIOAXTZAR]]@ZJ("M_5*-*DE)
M#;M4<KP)FWQ_7-N? &>4#0'&5.M9J7:BS.U(BK>LS+(MXOI_FN)2S.@2.))A
M7+2>;.?N/L =+&;IOP;S$A'L/U^9KS*?3&^%*)IOLU6[AEYE&W7:=(IE?YHW
M'JXMU4A4J7<+TSS*.[9F3]URZOXX+RR/-*=T[L[NSIT;[\KYCSCK&PY>I_E+
MBF%IM'0G%02"T[[>>+?R5\D]O7K_XZ9'QK%'/(2J%$,9XTS005)VT(%0:T+Y
M%!5,&V8<]$S=-)/S3(I#) \D3PC>_4Z%B1\G!N\"U+E9+I2A-\I6B6Q_TR47
MPINB=VIT1\>X4U/O#I/3#<L??Z_P4YQ!+=^>MIQ_6O?.#"[U9XW]%XR&:= R
M#+#R6ERA+[R1/8N+;)2-";5BF$QAN?PR<R/HMPGH@ARTV')Y:*7;,8Y!*VD3
M5XNH*86@]@*OK7^<:S-TT]CCQ>U)@(DM]-)XP496<(MCP\IJ_+TR2 8/:3-W
M#7>2HHOGUXBJKIU+53V.XM37N^-Q.1SLI5HX!8FYN?DJD[FKW'Q7[W5SJLP[
MN?D7$<3=O1=V6,$+.ZAOS"!O1.MC1ARA"6+M"R%'%1!R6%^$/&,3?INXU<DC
MZ+@"@HYV-&!-"-ZO;F#[-*KV;#EC/5( (T)QW,2MZA$"JN6FF[A5$[=JXE8%
M_>BG'#XIY6JGI J>.0$Z2-0 /%]['H DVP[LC74CKQ/J)46J>IW>P4%MZF/#
M>$%!*C'8X@3C+/T*<9:C1]SZG1+.P(JXJ9N]G*AYFC&J?!@;UN"?PCT;W</S
MH,$HO]OO^%22F]X'AXFK[@\CU5F8IX&=W2-PH;&ACXQ!7;!S,P\OX=:O!KWN
ML NL<Q>T??I<_#=W9?^!OC>E#=]I7+QA'ER'-\R>/AZ:+X%LNF42]JI"KZOW
M1]W#DLWNB8)WC#V1:SR\=348UD:KV2PW:@JYTY<9:@WZ*5RU.3B\I.AW]$[>
M9+'3)I3>\."$LCOH[3DUJU2BIFA?]KTD_74[@X,CD#[89\+?=W!I_4[_A5W:
MT;.ZFSS.8^=Q5L5/<S0 '!TU69PUR^*LJ+:/!TCS)Y'!&4E32B8I54^_3&MC
M\VV]L%MJ]Y.TW713DJ;H,Q%AZ[^.^IG5]">EDPTMEA)9%P=CKN=$<Y;$'M6S
M[#XURNA4R(T:%\U1*IG&EL2/\#8ZG=?8$SM;%F8WRDH)GW:HCQFB;MJ7JI"+
MH/SN4N?>&)%.A%F">1_IC)23*+*,M*ZA:YC\0@U&,1M$#S,=*4="LRC_T9X!
MA+4?MX2M2LLX>Q)<+OW 6^-DL;.[.\^^ S1EJ9>%<Q3H+)NWVBM3V%-IJ^DQ
M?MVS_94-_WZT%\]M[4_,;Z:$T<#V'F3VZ,+%GN3P)AO?J8>?36S+PZ12^+7M
M!YH5:,9KS#75'N"P]]H;U]/L_UD[C["G98 7:)CL>VL)9WPKN\K"R=?4?G@&
M1]&>+#^!()VVEH$YK(%QXO=LE^XZ\ /X'CWR;,?6@L;%X3NV7-&@0NW5S;WK
M!0A#O*XSX!7 ::_"O6R[K6Y7[YOE$&M0H5ZGZJ[!(ADE2V-YV_'IU ,)$B++
M]ALH3\]G[&67_%T;=-2N/NPDR6*O%)Q_<Z!!F\,DS6I1HKU::K];(*J]9TV2
MA/ JWEK.DT6M2>%=!'Q7LRAEG VBH5ZDSA2[D0KR!I$'I,NG$@#!/=T[TWLB
M)BN6B<[X\_9[K("1J8UW<E@>HU&R=@S?2^=X!JX%()G92;9AM*-B$17+4*W<
MHA'N06TR*JA-H'/M36]2L\"C>E&E5J-19:EB>_6(.K53Y<G,5)XJ;7F7>P2F
M\,5ZULPAHK4QUB.=_"/L("K<?4;^(H..:.;KK?8CW#2ZF/68//\1!-4 9:VK
M/=AVH#FX@.O]C?)V:JV<P%IH2]N>^<?3+6BQ7 K&K?CU/7P_L>TE,-J5Y2"<
MM/EZL0#.Y^'!) ^!(Q#/R%)-%*6VLC)2H1BSHE@OJ8>4B(+L2@]!G$P1FR75
MD-Z@K&LWMZ0O">*R<8+<^QJ,4DR&J/JA<L*CBTNSBK@T&G&Y'W'9K86X_.H^
M,NYM"B5:?F*8"C^77![9.OOAILH]HSM(*+41$UY0X3? V%N4C*_>QT>$R5S,
MC8(;1;4%:($REZOJ()1^[/69X/[1Z'$13JS%'/&_5&K.)<BEF'QR0"9.N/6.
M]:<*$)D$-%4@RH\B4$3=A'T<W8@%:Y,J B^2S-I#Z?W_V7O7Y;:1I$WXOZ\"
MZ\^](6] - &>W?TZ0I;E&4V[+8^E[O[FUP1(%B5,@P '!\G:J]_,K"J@ ((D
M"( 226$W>EY9(H$ZY/GP)&RJW^HINKZ5#=T^=:B [OB9E!UHI]S<?R$7=I^,
MB@IA@K(%%X7U8#XD1:$CWGD((\_2V:2A]T__U*IPN@>A</X1.3)BTU[CGUD9
M0<^E8EYY/FF #:&8WA.'R#M]0^\.EX-8J&@6O@<R' [!1X2-J?;]?UOSQ<^?
M8,4!GUT96C_@;[,(Y8(#QAJW$\=6P)7-Q(.5 HE["SH7FND!C]?8#S:)0OX9
M.F2S2U[P0-5=B(W@V[>V"T]^U )&+F2LS/"KUVP1"D4A-/UJA;3AT%-RMK.5
MG+T 'S=\_(V%=QX(@WMX*6[VZL%E?G!G+[XQ'[MM0?C&=W!J*I>P@,V '=]:
MEEZ* M6U<12FMSR0&O-IZ++;'SPM7?8'^G"P7%N=LG]<X&:@T?^ ))6V#[!M
M8KD\]1&5KLHL=T3FBJI"/"/;G?@,^% ,OH7-X :BQ<2;H_TD3JVHL2CXRRS)
M7YF3V3_^*AH@LN35*/;[DEE:TDHR^Q40<*O:J"O:IPH%.2H )5>-(ZWH6ZH>
M =EE#*13)09BOI@8R)IBBUV8I+V#,$D_L[%/B41A,?66,HDB')'7YJ:=H P3
M0R\__OU7.?)R.?N8,MN4V'_F ?#PTT_*)\_D)\63=3#;F(9(1UKG;6MM%,;$
M9/Z641A476G[,@"C(+BSN"*C47%3K==^UVO#O\,'3!C@JF7B08[&S60^9.)#
MV;<\8SL(4*K[S&'WF)S-OATU+[RA<+PCKZ@&5U@@YCVHH"U$TO8*=ND7AGU<
MT2I81$4,*A1JE%MK?F-><;U0NCYQZYE^&U^PY4 ^XT4/Y!L>\T"^;6AQ]V9,
ME8%Z1J<Q8W9CQO0/S(S)+7_ ]+XUO<?@_E3#Z%* BE7T*9,CF\U\@)>W\ *V
MWL;H#LQT!)>_(OC(+%^:%\K$6VY@B'4$5.ZP(8R4K@$PG][-78X%_)1QU<DY
M]?F4/5C_E,&-3<O8*]F,C#@GF90)"GF\9?/VJH_(WYLI0GO<KFFYD!%3MD^C
M[L7NMW=;99(E#CEIU,(NU,+@(-0"%L0-\_(MR)Y?HHD]M>QYUEO]PC""A.(*
M93@X8B=?KB[?8DD8ANI\:DNPM(6'?[-!5?P'6Y7A*EV>1IAIJ0;_35[J]K4"
M'V4V!#<$2],U9DWN"!WZD0==I>BD2+0(,$[5"H$-4K1TE9%\V9]<FPIENGT;
M>QR43QTE!@&,P<\KRA1TI6XYOF:I\_$DDNV+U\9^>ZQJ4".W,QKNV719V>!_
M%?6P\D**Z+.R2?E=+/C%9\2'!R&@KR:AER[,62\M1RG"0;3S.$28,K17&O^J
M2$R)!&RM1[$CL2?6>P752YO3!4WIVN6<S%E\4.VX:Z&R5-JV(GE0PKJN*3&3
MCWQ00"J954*%.UETB9CA,TRE>;Z9"D:58>"(MGNHPRVVF4,#@JJ90O-4!%EE
M+I)QP(.1E#DTR_363*'9'P*M,B?)&)2:0T/V5S*$9M6;.0F!Q+KQ4O9\,X)F
MGZ>Y'.2B"Z-7/?>-[],HEF8$3>5][Q@UK<X1-'$=ZBJHZJR\W:<Q*4:G1(&*
MQ+5*JQ\!)W#F3K]Z[F0C%'Q;'PX*0IH=UUR:9SIPLZ/WN\L-!)4.O)FL4/]D
MA2IW;'1,O=NM ^I\OZ9_#)YF^L=SX%8__8RE]2TVSR6=NGK;*"B=#HAPAX<Z
MMN9?D>7N#UEVVJ7;FJJ1Y4@WVT<R=J "&/8^G.">BW&L0?N';;FWP7[<=Z==
M8<Y*)1-DJ ]Z1S& H/=<0L?HZ_T<O+H#TR BH4+M'7?@WC-_7UC#*(T96O5>
MA[K1J6,*X[.?8:]=8;1)M3/LZV;_H"=95AKB(;B*S1>.]\CR)Q\?Z%B(PD;U
M:+U1W4S6R&=9XYE<NX&I#XJ:@#L>L-&,SWCV,0K/%!GKC#IZUUP&56Y&:#SA
MW5<8H5$IMC0<ZMWN"QFDT8S1*%*>,:I2VS%LYF@<SQR-:QOK='ES8YQ1RN]L
M5,N?U]8Q+S<DQC7*6V$OUX5W(ZN1<R%O[)W@ BJX "G176A*>'YJ>%<P@566
MNB*INJ8:^=FQ\,TJ(X2,9H90_;)O-0S^KDM1-TJ77(RUE'1,]__EMX'4#ZA5
MLC%N17I\5_A9Y5:YJ;F!=(^*J2?USGZ)F2HC-\P=CMQXL6)F-7SXLXN9>$Q&
MO:*EU+2'<DR[HGYA5Q,>=BA9UEBU=I!JZ@TVP4GV#@)G W:5A=G8)SE:91:#
MN<-9#"]6CJY&Q7YV.2JK=NJ6HX,GPR[(+Q>I63 -!HU@JBZ8J@"DFCL$2'VQ
M@FDU-NH3QM#"N!"J2@1M^[9[&>,2?97J,@H/OC4'):H:JH2/5A1+%<(%>>JE
MYA<E98=HWMRQ@.,M9".?Q2#(!Z,]%,U ..M7/6P_\ZJ7"V*4.+.^$DYNG]1)
M%:!*<X= E2]6G:S&J'PJ=3),P8O%0%5J22%8NO=L1[D:DE@$]KR!^XWRW/\G
M)96!;S@."@*2??9\^*7[B<$"[7 MUR_C/!<15JD<2?\)E]MI]<V<&HP2$QY4
MS;_P@5[L!4YK*SG28><#J%<4?A;0\Z4#6,77EE]0F57L\DD:^[%@;L 0?0*7
MZC*^:AHY$BK:_P$^OF%S%9"/Y'(N^&J*P9J9ICX8Y RTWGP-%>;2E5NID3^X
MOLCH;855=I6%+*^H=P@=^F(5]6K4T!TK:E"P8*OBC6G_L%Q$BLY#!;VSIHF&
M)77JN2RN8-ZLG?.\/)#X3L1!(+/R/G8 [2!YR18^8'E.%S+W0KST(W/9S XW
MNU:E', *(R?+KG-%(:\ )BHLAWB\+@_ K]@4N&>>465LF@&7 1T$M1AOL.A
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MQ^4+T<>ULAUB'=N$P4*D%GCP4?>YFNN%J''(XHF7#ZIWBFB0C](V\^!'$5)
MZ2LC0)=?OY^M+NQ;M;6T\.7+CLBTLS2#Y[Z'<<Y>"<12QC/)ZV3+)!)M.^'J
M)^":55CAL5F>N&0@\/3NL*>;/7/%D_*4F_IT'A.6222NQL!0Z8\Z>M_L;6$
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M7<W2K!RH0'E;P1<KF,/\W(L0Q6N:';X:GYB3QNNEV>5YN6,YSQQ1AQ&/V%
MB3&'@RLZ%;^N.K^><MSY#YEX>#HN\?'J!^9M8',V_4R*HE_&_KL/&EX=_RF6
MP(4FO=,S<V:]'^BI?*4*4/Y6>33<>^(_<Q^JOI.)9]YOHEM8/"SVUH=+FY["
M"7C^>\V_'9^8[:YN=H9@>_?>+M.V8*1!_Z=E-.UMJ?P+Z3H?[!!PG>8>":U+
M=Y)[%I*!?UI+!O&G\J"^WZS[RBCS%1^/-Q9B*U1CMP245'U&RFB@#_O+V;OM
M#Z;(@98_]LW?V[^S5\,;^3<0=U-W]-%P.<1=Z9BV8.'URJ<L4]+LPO.D"36U
MFW47NM7M;WWEO0K9\AI\ G.HMT?+8RO*'\21GF1QYND;NM%;'F:V_8'L6.E5
MY2DEG[MW/%4ASUJ=ITQ]U(;_C(("=-^Y:I=G69RKND97'[270^X[9:OZF28>
M1KZ'3%,AKUZ=:8Q^?K;Y(%EFER=9G&5,4Q_VEFO%CDX1Q8.I]Y"GGC7@.S+U
M_NA(6&J7![F58V1V]U@)98(JV_$1UBCSL<;% S=K;WE3'&E+QWJ[QQ4CJ^ZS
MZCS=&+7U0<X @&TB9UN=87.)NY,-@[9N%#7ZR]SELZEAN<ANGDQ9+U(P,5HV
MMMTM0YGP)6WJ16.'Y<24BP=0JSZ[$.'N:SJX$,5V<Z/V6TJ#O:&"';[@^4EA
MB]C5J*^W>R5E6"F*B(6:'#7XG!W'J2;HYTQ25QB,=="3L00HCV&J_6QCB4 Y
M+8! B>-@O468@T:95T"R$J%2YVV("GAD+EPD8@*D6_Z+0D9VS-[^8T9NGD_?
M,2M,KUXJO2T('6FN1H[<"'/9,2N Z91=L *IM:IFN*GTJ5V(E@?_-@X;_9NJ
MQ8?K6H*7NX'_L.$--SZBJ2D >" 36W$#.GZ$/J$B"#+LB&=:_#<Y&VP!9A)_
M//P9F_N0-#+M=+$8MJ;W=N#Y[Y1.;UJ4J#(F68PX@.ZMIT[R9O>\W'!M([\Y
M3(^#D>LZNZ7_R4-J6]F9L*I?'2'TE /DH6R.=F9/4!>E>Z&RV@M.17Q%3AF@
MA\JNNO5?%N-<F#^Q Q7$K9]M5\=_VQXITAYUPH@N%FR9=[ [0WF( !18[F//
M+\9?&LH>%.P4KU#N4*IO8ZT(SN+WX"4D=)W3KX&]%W2$> / R',J&>;:?W,)
M:J="NKIX5X;1Z>7NF0,PQO3&QUQ@6;6*<42,S"N@M7D41A:.YTC('F3)''$?
M6)I+L#PXAB; .FZDD$:_U:[?RJ/4&P<,4R^%\RLAG"41XI&N$-2%9%&G4F_V
M]K)HU0B(+5K(MJIXK[(_VA35M!=P*_)&^<6:B";R*%?VBOK7)!0SEQ4&SJ<2
M;>(;]E2E%;RPTEA[3VI?,U#DGXA7/;G[R$ KB!%SVI<OY[$-I?P]0:^[A/U;
MK@";Q>TKGWI5&#E(I?CU_?;<9INF%LL[,*816%O8 C.U@8$)K(MWZW$,A5<(
M [1DFJ4FB5TMW:7ZEH>BED&G;*?;]]CH$DS);['\!6>- @$BSMP@Z0 ")S"(
M6S*?T94[0@"][HL&T#,: +W# - SRH_., YX=L:9$WBYYKZ^Y.$J$8)D_@6"
MEB," GK_CXI"XQV:7',E7R2H6:&[T$$F4#DFHP>/"?:=YSJ/I%8Q0T'W2R]#
M+%O;A0>#T;$2>JX  DVG1,*9E-.?W-TJ8'28JZ*%R1S"V/-<]OVW6?YVO8]B
M!Q?BG603?F(\3%[ -C1;.9.>$1$ (?\X["]UE6+ ?TU<@F,(<$-2F2N:'P#J
MI*<MGP9L\GX:^1@!R;N<&WBF8L3&D0\>,:&(>./<[MZY+8__;1PP '@&JX;?
M22Y@S7JPQS5N@A5#APCYZ9,)JWZ!DF@9F5H<PPN#H5F$DC%WPO'I&V13":@2
M :/H;V_Y;_;!(W=5%%?G@;ZI')\AYL86E\*IG1K/UH%NMI:[?]1)-ASVAT!
M:>"/A/<29W1GW</UXNB.;<"]&I&Y Y%9'L39.& 4YT+P7EEIR>&!D'DE+-$T
MSBKAB?CV..(XL048N4(&_)N8 O49S(IS];WXB[/9S'9PQ/J:\/Y [QL]O9,W
MMT2B(1=(XG=*Y,1)ZO(^\*O9I4#^RE\I: [V^D,W)S H$<.">+X=B,][S"C$
M^<,X%!I8#ML*62LSG<N;<7[==)V#\M:Q&E,D ;Q%-4:N::Q&3LGBG?DLSMJ
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M.,M+<93?X21C0_;45"S91>2SUQ^,EK$,J+3]H?YT6+?5/]#;:K<ZP]INJ];
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M+N%MZV@9JYZVU<T,TRG,6N;ALE:VHU[IGD_Y&[+SFLQA#Z'E;;"1 G0F*)E
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M&1$P#7%8XE,>B?U&O::7E]K$L5U,(&BA#\P7D,N.'.:P$+6&P2^"O-3LC6)
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M.WSPDB1VDJK(//Y2_D%]AS"'!)==)D4\2>A'K7#.9^N (3:"Q],.2X\R=,/
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MS"_HAHBA(')%.IC[._XFR: GMCG^@0PAT=2)D#8N2ZK(-X==\>.X<6R9CKT
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MQ[(2@YWGG'Q(^Z7@C/GIQ/:!3(',2"*1)%30H,A.$3Z6EU.P\UX[L=_*1+_
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M+V/2ZP(3Y#,;^^2&4[6IT==.C+>_O+/JXX1#H_-.RS@(NGDA)&YT!L,15N+
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MT.NYL7YXKC=_!)<W!$V">@0G<,ZM^+Y:=!=EKF)/>>G\[,OQ7-:YY4PBAQL
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M (+59[=V$/H6V%:(< X".Q)W"X\%B;WPO7M[&@MO^N.#;X/\"30KI-]-'"]
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M)>S>2PHKNHY#CQ.B"CN>K7XRKR?LTI,+YD%'J%;_G*Z3VJXYS+8A9-/K).X
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MZ>N6^3 C*'?=+\B@-//0\HV [61/(%>1#^B^#>PP4GN+8NZ-!@/%7NJ2V\N
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MR4H#0@^0Z.J>PCG3;11 3>RH@O >:BXJ )?LB[+[O%% LK\C4T2TP'65HEE
M\KLS4T2<;[KN%.N:XV$\3;CI)(A.;_FV9FS"31)/T -R'&3T\&1*OF/Y02C
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MJ]2*0[_X]."AEYGA.O6I7_]**_4.?E]$&QX[EGYI:8"&8QM;>#0/Z[9<<CH
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M2#<8.T=^2M3W:?'?>VS,R/^-O8GUZ?\ 4$L#!!0    ( &6+SE0LJ//"9P@
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M-8UZN5PJEPE"FPMH-9;E\G&UB7CF L\H5!N-1JEZ])KL]-N8*X:4-/>!LA%
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MN7#8T;W7VV[A:OH&,;M2U#>/_P)02P,$%     @ 98O.5/#6?-.. 0  CP4
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MV4)C:I/]NVR3BLC&_U0Q7:CYADT7\0]02P,$%     @ 98O.5,[#!E2@+0
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MV;XI4:,T,M')YKM?>'T**FQOB:R;^Q2;\<=[<@;O=)VKP@^<@C>"2,P 6+2
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M';NIKK7;K?F0>8G*T_/N%6[%;'G66V<NE5Q]'\.XBFN2XY@AB%E<4BOMW<J
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M=QQ@G$+:Z(KV\X#:K8)03!<HL -G2DJBQ5*]S .^2ZH];[I'!@-09:&74=8
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MS&]\6#X6A<G0#C6AU_H<8-R$975P28PD:*_F;B!^"'.<*LE@!A%'\S7\C)E
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M$]J1@NPD=-?]!3('K'S_)<"$^@VL?=_1*P#+"SIY]$SSX1U@U^5V88O> S8
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M5WK[:Y-L=L"CEH%<G[S"K"9Z?%^*YQMSM/$9L#],X 8_I>!8,TK8=B+71;8
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MTU;#.O./N/;LQ\+;(4P'8=,7KA!NFV<#J0%W%6*FZ%7$Z@?ZD5CY2EW7<*%
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MCTVNCJ V<?9K3^G2-U1M*LDC!=1TUWG$\P\0J-XL6> ;23OPP.KY,0;6A]Q
M+(WKE*COCY<S><8X/9-%S29Y%=)!(*'6Y+:!4*5RYFEWA*RH+GCN_)G:.LE7
M/(,CN"*\-)I'33Y/CA\O>XJ-H!69\\F 2L%QL2]9V-%/6$^JL-$8.TB\TSE'
M_.S\U7X%WTT8HN,=R3 N1#[I]=W="_&-4"E9DT$.>9:93"\@"N-]A%YEZ;FW
M')CN?"U2)ID@\K%BS6 ]8.>T\5^=QSL:").Q$R0:;JV=3NSENE2+G46;22DU
M";<I=C;?0_5G&1<C5\)$\"C'^R9##)^?.?/V:N]&(GR?9%V[[M[%:@YW1*/W
M8:YF#BY](RZM6>74UM 44AC25-W]7E:D*>IZ]Q<S$'W6>A 1T%G\0EFG'6!$
M1P8..;#[\>W@@*PM)>_/WY.?'[]G5.Q&KY<'WN'/!MQT792CU)@$ K32$=1B
M(KHS5=?$'P%0/UKY8G87NKO$[JNZ@'5N^,'&IZ(OMJW\.;;&Y3<_WWFO,(6]
M^*6T-X8%B4S)J_:%E))]6)Q5CV^^2]=058:F!OR+>7_^1 G,/^C1@1$7F[O.
MQ$%T+_-[QW\G8,H^',AO:L[,S"0_;+0P1JXR;;8P:EH!S\*P7PD1B^JY;F$D
M3#'?A,*ZU[I7,>DR!$'ZT,N!&_%]M+A9PZ]M3F/+>HS& 3JS%^I$%O1<EVY*
MP2@FO>D =O.!+071YO$?=,@??&J><R>4\'Y9.I1:Q83#TO-;%CT^U7C+PLBJ
M(:3TE$1HF3ZT!+R[YJS^8#H<B_%BYLKQJJ:F]H'#-?1]TL,\9).%41J*=5^R
M,#;_ROP U>RIIU35$QQ\PVZ4T1*_<@RD6-<[MEST^XN+R5Y^^6=/=\9BTL)"
M=6]_EGF_GC<P H:-=9+PC^7TK6^1GG8+PR/C@_0T1BCY!7PS2W+<PB#'<J"%
MK5HB^8\7X]\\R^>W=';VF7U;R^'MH@*!K*W+;\"@E/8ZPE%E7+8PGJPT;WF$
MMJAI'KL'_12R8Q*^%Q_P189#;SE#".,D,RJ29ILEZ%[KN_D I7Q2HO$Y<;O?
M%4F,\MW5H3(&5@\KCG#\[,?K7W.GCYOZ031DY/PG7OUW!V0YP?Z_M 6>N#%:
M&IO#RVX(?JVZUG9]:IWL]5=%;47?3V<W/WED/U\QZZ[!8S(VES,92H2YA*IB
M=J3Q)-@9;AI/-W2+UII_O@0V[B;=M5>[%)+CKJJ4 F?0<A7$;2/$R;\\UG6=
M$,\ (>[^.E^;S20SU2^-$Z(;G$_D/M2%N<Q)3([07;NO2G;DM7N%+6C<GQ6R
M)__@M?/KZ@^J=[A"+-LLQ#Z@W8>P<]V)'>Y$K?&A^0ZZ"VVX9;P 1<+>*@98
MNA5T$I)ROD,??T2K)F]._(VP\PLOZR?.]]W>=K*=24Y?G#8O/^G;L"GIQ]X,
M_GV%-.<O1^^03VD5\.13COCGU>AN?@)DYE[I&&HZ6$.BV@G8&/'$W[@36_'1
MW#&B\<2<Y%]$0?1C@I]^X+)L.7ID^@EF0Y.>.KA!R+/64OW4YVBEA3'^$AE]
M3%JA@1DPC.OQBMH%(K6:E$!!(B=$F^.N"D2IJ44^"=1AG4*G<6UH<_TY9>"S
M\[\EN_OOO\++"?L$&?/TTO;'SDD1]>\6G/OLZ=01?U1R/F\*M]\P\]Z+]5=>
M=*^MW?<XXK \YV'BP"UKD4.H@J9G?+ P@I!A4)+#U,9Z8[B.,+6M9WE;&)QW
MZ%_<M?CF/R/9KITRE\CQ[!+>Q\AS@I$WR!IY\?_JF/ZSY;C_,J:1O[@:OOF?
M:?TGB$CZ5,EHZZ?9M W$X].V SD_8E4R*I/_5KSY?W,TS%W_UGT+8[OP%'WL
M)J9=@'[XZK_$I.O>R"N^\<K+!6:_+TK,>:)/ZY=</2'+VC')?";?X?FU]NV<
ME:@CH_F7(^M6G(A/_ 0/6(AT<Z5ZC/UXX8]>51-Z![!DZ@9WOG[Z^8&ZSA#L
M8!SL0-L+<XS#_:63B@HF"K*+^XL*@ULDU#"PV[E,$L<?0=M?NQW5"W83[>69
MC+7[_+UKW[S,(H(3PR]AH?=.VZT9NUK;-.O756Z/?)X,V_-DGG'>Z==U1],B
MF_ _!JK3@J []\6#L\C+/4=/6!CF[YC6/2'!\CTET<D"1\\'7VSXF^SJ'S,7
M=KU0GPH+?)HMK=G9ZC=JF,Y 5(0UK-H6:]S2PUEI/ )XB(H'S8\C=\S36]RC
M I)9OD26@&SW_ZPNB.?Z;,_TO[5%<L(65G^_LNBG"2=[YC#+K?LY^CO]P\,$
MNYF=4MVWQ^JK.K9<HI^P)D[S6_ZS:%W;N\CV.O6[1^Y73O@)2%\T..SVIK[7
ME;&>ZJ<]'9I/%<4+A]YNJ]S0<C[E6FW&IRFGWZU8R]UTYDPWYV?5U"<]G"\J
MOM%5S6@M>9N9>1Z]3]WX2QJJP_XJ-,R;_AFQJ__DDE[T?R&G'RR,FPW_/SO]
MM]GI_\%,_@>NL?M423  IF?3@V#3?TO\%S:-_H]U&FF7.&#5:WG4)S!^9C+[
M@B99&%+^!P[^C+KU?SNF_]>01M[=6VYA<'$KV7X(^+^MYK!<SAH+8_EFE'!%
MJ.OHR^_BZ%CL3;>%X=4M^XO,6/^7%[S5M_'/H1C/[\+^$Q[9_&?T3;%.= [N
M-U_B3@('H4QM7FR^R_'%=.E!IIE1X6M]C'NJ#Y2L,^='[!VUWZF@ &1,3<UX
M4>/6'[)G?.$0'_KAZB.K'7U]N6==*#G^9>T#VY]43=G9IFWOT=]">WQQ/ET@
M_)"P_]S;%\?)6N-/\75N;[;?7+MXZN7Q.1%UO3]06;:G;\R:NGU3X<.2_G=]
M[Z:+*@QI+-M=5<C3M@^D%LF7E1TE3=I""==Q5&SQ7(X@J^):NC!LIHQ[=N/F
M%WW[V49.]ZJ)CP_6#EXQ/<JN^!'S+ -=/F/]13S9PEC4UYL=L)"5?^=5TC=W
MNC3'LV;(7\1M2 VH/9![[F620N6<<,;-\7;(+Z?[=\C?BC?\/>QV24 $,IQ4
M4>?_^X/\;\G>WHK]/3K._STZA-+_UX?'O_6\#3;M!YOV1HD1"/7+O[+ICV)
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M\7=Z!JQ[.VL]@W&6B+/!J7%<Q G6R1UW]CQ.R7@^HNQIRM*'+E=N@4>GTD)
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MM454/50.:#T3@4CWK@39<:X;!LQ[ %#&7DQUC%I&\!KR6J4&20_4"%<<44(
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MM7O/'H$]@O_AVK4[[+\!XGOV'CVU[]!Y>T'/0(ECIQ_ME[R0_J:F0^CXF:N
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M!SDM=#D1XZXMC S7NU6TLZT'D?I3=KW^40^AH*8:1]J )ZPX9VM#A;\-ZS0
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M[[_,.ZXEO/CLX_O!$]F![X)^,>3)X3O$.8+;CMC<2[X\9=QU[IL0C(Q-8%A
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M7'FDRMX2W_R3(V^ =5)/G.>HDZ*.4T3N@+']6$B3]P&Z&3@_-UNX;8.3!PD
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MRF&<_9BI[**2(/"=D- NK!W[FN,/GIG+13LA9;!G6"E*:F@1:O-\9UFU=N5
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M,-TW,6KTS[[[]K^)'"F^IMWOY[>-66J$D:'O1;TN ,B>'<C;_:WVS)7(@&-
M=M?ZT!_%F*]?I]6S+[.O-; 4K/1<G% 1R1'837,YE4Z&"?TD\^ZJZ8<SA_VW
MGF!B2)F6NF_L6R75=2JO$IWJ+ZF[IEJ'<B?N,)7_MHU^<SH&=R7&ER_T294U
M?'OEK#_T:ST,J;OF?)>74EE=B?&L;WW[+NXWC7<"<Q>#ONVR@D%K>[HE:*.)
MB3GJ*S]BLRX5ITX9[$'?S1G)P0ZKI<\X7F$F!TD"@>G19Q<6[?9927%.<I3
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MX8SRJW*\8S]5:Z6$AR#^^8V)WH'4^'31]^$0P^MP>=P_H UK1H7CSL3(^^Y
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MY?U2C-P6.'J&!^I.>)4EQCCD2,!*,:)G,X_PAW5Y[^0]B?K&4(LN1TM+?GI
M_#*],[G1JYQYW0:MXXXRV+F&MK_WE@_U\W-?+]80"&5VM^&E-&82LD\U<=%
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M;,J>&550RM+_1+ EMN_#JH>;KHND?X#/=!8Z1BQA(?N@9:>95WIZV6>VUR4
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M:6\N:'1M4$L! A0#%     @ 98O.5,8\WR+J    NP(  !H
M ( !QQX' &5A,34X-3(X97@R,2TQ7V%B=F-B:6\N:'1M4$L! A0#%     @
M98O.5,&'SS<3!   @!0  !H              ( !Z1\' &5A,34X-3(X97@R
M,RTR7V%B=F-B:6\N:'1M4$L! A0#%     @ 98O.5/#6?-.. 0  CP4  !D
M             ( !-"0' &5A,34X-3(X97@T+3)?86)V8V)I;RYH=&U02P$"
M% ,4    " !EB\Y4SL,&5* M   ;+P  "P              @ 'Y)0< :6UG
M7S P,2YJ<&=02P$"% ,4    " !EB\Y4_?6&@5":  !2QP  "P
M    @ '"4P< :6UG7S P,BYJ<&=02P$"% ,4    " !EB\Y45;EQ-S!A   $
M8P  "P              @ $[[@< :6UG7S P,RYJ<&=02P4&      T #0!>
) P  E$\(

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
